<SEC-DOCUMENT>0001558370-22-002668.txt : 20220302
<SEC-HEADER>0001558370-22-002668.hdr.sgml : 20220302
<ACCEPTANCE-DATETIME>20220302161226
ACCESSION NUMBER:		0001558370-22-002668
CONFORMED SUBMISSION TYPE:	10-K
PUBLIC DOCUMENT COUNT:		80
CONFORMED PERIOD OF REPORT:	20211231
FILED AS OF DATE:		20220302
DATE AS OF CHANGE:		20220302

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Annovis Bio, Inc.
		CENTRAL INDEX KEY:			0001477845
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				262540421
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-39202
		FILM NUMBER:		22703559

	BUSINESS ADDRESS:	
		STREET 1:		1055 WESTLAKES DRIVE, SUITE 300
		CITY:			BERWYN
		STATE:			PA
		ZIP:			19312
		BUSINESS PHONE:		610-727-3913

	MAIL ADDRESS:	
		STREET 1:		1055 WESTLAKES DRIVE, SUITE 300
		CITY:			BERWYN
		STATE:			PA
		ZIP:			19312

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	QR Pharma, Inc.
		DATE OF NAME CHANGE:	20091202
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-K
<SEQUENCE>1
<FILENAME>anvs-20211231x10k.htm
<DESCRIPTION>10-K
<TEXT>
<XBRL>
<?xml version='1.0' encoding='UTF-8'?>

      <!-- iXBRL document created with: Toppan Merrill Bridge iXBRL 9.6.8042.36810 -->
      <!-- Based on: iXBRL 1.1 -->
      <!-- Created on: 3/2/2022 8:59:35 PM -->
      <!-- iXBRL Library version: 1.0.8042.36816 -->
      <!-- iXBRL Service Job ID: db77ead6-eb5e-48bd-b659-c882012c1e04 -->

  <html xmlns:us-gaap="http://fasb.org/us-gaap/2021-01-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:srt="http://fasb.org/srt/2021-01-31" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:dei="http://xbrl.sec.gov/dei/2021q4" xmlns:anvs="http://annovisbio.com/20211231" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns="http://www.w3.org/1999/xhtml" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xs="http://www.w3.org/2001/XMLSchema-instance" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:xbrldi="http://xbrl.org/2006/xbrldi"><head><meta content="text/html" http-equiv="content-type" /><title></title></head><body><div style="margin-top:30pt;"></div><div style="display:none;"><ix:header><ix:hidden><ix:nonFraction unitRef="Unit_Standard_USD_NFG_pVdyhEyJarLQmedkXA" xs:nil="true" contextRef="As_Of_12_31_2021_slf_IrTrZku1VVWbbttE4g" name="us-gaap:CommitmentsAndContingencies" id="Hidden_wQgsFEt9qEqLJPdOnLL8zg"></ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_USD_NFG_pVdyhEyJarLQmedkXA" xs:nil="true" contextRef="As_Of_12_31_2020_K1oKCNbpv0CLR8EJWu1PSw" name="us-gaap:CommitmentsAndContingencies" id="Hidden_3yd7vgu1lkuzk37_El_YbQ"></ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_USD_NFG_pVdyhEyJarLQmedkXA" xs:nil="true" contextRef="As_Of_12_31_2021_slf_IrTrZku1VVWbbttE4g" name="us-gaap:PreferredStockValue" id="Hidden_1cHKNqogd0-a4Lt10S2ySQ"></ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_USD_NFG_pVdyhEyJarLQmedkXA" xs:nil="true" contextRef="As_Of_12_31_2020_K1oKCNbpv0CLR8EJWu1PSw" name="us-gaap:PreferredStockValue" id="Hidden__Eya0bxY0UCpLBlvPZA65Q"></ix:nonFraction><ix:nonFraction unitRef="Unit_Divide_USD_shares_ZtgwQidioUWlbMoOaTBzxg" sign="-" contextRef="Duration_1_1_2021_To_12_31_2021_uhkxAiZ6fUeekYGgaMhCqA" decimals="2" name="us-gaap:EarningsPerShareDiluted" id="Hidden_XAUjswUORUOJZosgVNCkDg">1.90</ix:nonFraction><ix:nonFraction unitRef="Unit_Divide_USD_shares_ZtgwQidioUWlbMoOaTBzxg" sign="-" contextRef="Duration_1_1_2020_To_12_31_2020_3DdHOulAJk6Q0Zn4Vsxq5A" decimals="2" name="us-gaap:EarningsPerShareDiluted" id="Hidden_M0jLGMYCbkOJklwUB6rq2g">0.87</ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_shares__cOSbKjBTUyHt70_t1aAVw" contextRef="Duration_1_1_2021_To_12_31_2021_uhkxAiZ6fUeekYGgaMhCqA" decimals="0" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" id="Hidden_ZHMTv2uqVEe3kJ7tG2treA">7626278</ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_shares__cOSbKjBTUyHt70_t1aAVw" contextRef="Duration_1_1_2020_To_12_31_2020_3DdHOulAJk6Q0Zn4Vsxq5A" decimals="0" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" id="Hidden_pTn8WPESjEOeWlQt5m_k9w">6308961</ix:nonFraction><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_uhkxAiZ6fUeekYGgaMhCqA" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" id="Hidden_EQY9UVLtMU6NuqPU1k6Bhg">P8Y4M24D</ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_uhkxAiZ6fUeekYGgaMhCqA" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" id="Hidden_LZM2INVDtkezbYWBS4I2FA">P7Y10M24D</ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_vlN0t7QzKEiNBpiYEjJwDw" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="Hidden_HsUzDjUJtkSAIzhEqWrcUA">P5Y3M18D</ix:nonNumeric><ix:nonFraction unitRef="Unit_Standard_shares__cOSbKjBTUyHt70_t1aAVw" contextRef="Duration_1_1_2021_To_12_31_2021_uhkxAiZ6fUeekYGgaMhCqA" decimals="0" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" id="Hidden_m5NWwkFcQUGtfXm9EhhhFQ">7626278</ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_shares__cOSbKjBTUyHt70_t1aAVw" contextRef="Duration_1_1_2020_To_12_31_2020_3DdHOulAJk6Q0Zn4Vsxq5A" decimals="0" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" id="Hidden_MPeGiLY0WkaN3LWJIoLmiw">6308961</ix:nonFraction><ix:nonFraction unitRef="Unit_Divide_USD_shares_ZtgwQidioUWlbMoOaTBzxg" sign="-" contextRef="Duration_1_1_2021_To_12_31_2021_uhkxAiZ6fUeekYGgaMhCqA" decimals="2" name="us-gaap:EarningsPerShareDiluted" id="Hidden_rSR452tyXk6abBubxNbgsA">1.90</ix:nonFraction><ix:nonFraction unitRef="Unit_Divide_USD_shares_ZtgwQidioUWlbMoOaTBzxg" sign="-" contextRef="Duration_1_1_2020_To_12_31_2020_3DdHOulAJk6Q0Zn4Vsxq5A" decimals="2" name="us-gaap:EarningsPerShareDiluted" id="Hidden_OqBcgGW4EE6_WaDvT8_C5g">0.87</ix:nonFraction><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_uhkxAiZ6fUeekYGgaMhCqA" name="dei:EntityCentralIndexKey" id="Tc_5lLhPSKAD0yopEdGS5BBDw_2_1">0001477845</ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_uhkxAiZ6fUeekYGgaMhCqA" name="dei:DocumentFiscalYearFocus" id="Tc_U2OEu0rr8k-yQZVh15YcjA_3_1">2021</ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_uhkxAiZ6fUeekYGgaMhCqA" name="dei:DocumentFiscalPeriodFocus" id="Tc_2bVdWMX9Rk-EEbr8W__P_Q_4_1">FY</ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_uhkxAiZ6fUeekYGgaMhCqA" name="dei:AmendmentFlag" id="Tc_dbnNVViIb0C6gMId2SaesQ_5_1">false</ix:nonNumeric><ix:nonFraction unitRef="Unit_Standard_shares__cOSbKjBTUyHt70_t1aAVw" contextRef="As_Of_12_31_2020_K1oKCNbpv0CLR8EJWu1PSw" decimals="INF" name="us-gaap:PreferredStockSharesOutstanding" id="Hidden_0E0ZYGeWXkmnptW3JEaf-A">0</ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_shares__cOSbKjBTUyHt70_t1aAVw" contextRef="As_Of_12_31_2021_slf_IrTrZku1VVWbbttE4g" decimals="INF" name="us-gaap:PreferredStockSharesOutstanding" id="Hidden_ceU6MrutgEu_MrBuHg6Uxg">0</ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_USD_NFG_pVdyhEyJarLQmedkXA" contextRef="As_Of_12_31_2021_slf_IrTrZku1VVWbbttE4g" decimals="0" name="us-gaap:IncomeTaxExaminationPenaltiesAndInterestAccrued" id="Hidden_1sZl5MdDJ0KYV2BjEn0mRA">0</ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_shares__cOSbKjBTUyHt70_t1aAVw" contextRef="As_Of_12_31_2020_K1oKCNbpv0CLR8EJWu1PSw" decimals="INF" name="us-gaap:CommonStockSharesIssued" id="Hidden_i8ALY5d87EqQSL0ZvpxgYA">6891608</ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_shares__cOSbKjBTUyHt70_t1aAVw" contextRef="As_Of_12_31_2021_slf_IrTrZku1VVWbbttE4g" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" id="Hidden_HhN3VcDM_kSkl4xTtOaA_A">8100570</ix:nonFraction><ix:nonFraction unitRef="Unit_Divide_USD_shares_ZtgwQidioUWlbMoOaTBzxg" contextRef="As_Of_1_31_2020_kBrHfmPKTE-0UUCmwNXokA" decimals="INF" name="us-gaap:PreferredStockParOrStatedValuePerShare" id="Hidden_W_s6TWSI0kqP0maAGvG-9A">0.0001</ix:nonFraction><ix:nonNumeric contextRef="As_Of_1_31_2020_us-gaap_ClassOfWarrantOrRightAxis_anvs_UnderwritersWarrantsMember_p2Rmy9kgMES4LjCsl9nsqg" name="us-gaap:WarrantsAndRightsOutstandingTerm" id="Hidden_7Pmc5xg25E6fTLpFgVmdTA">P5Y</ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_LAmAyrWmJUC3qRHISSAjmA" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" id="Hidden_5ZJE1WrWLEmz4ZW1wESADw">P10Y</ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_vlN0t7QzKEiNBpiYEjJwDw" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" id="Hidden_zR4qh4oXwUersK0sixk6RQ">P10Y</ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_vlN0t7QzKEiNBpiYEjJwDw" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" id="Hidden_bR4c2uBj-EKLsqDtSgFQaA">P1Y3M18D</ix:nonNumeric><ix:nonFraction unitRef="Unit_Standard_USD_NFG_pVdyhEyJarLQmedkXA" contextRef="As_Of_12_31_2021_us-gaap_GranteeStatusAxis_us-gaap_ShareBasedPaymentArrangementNonemployeeMember_D0px0fClyEe8jZWjjaEH_w" decimals="0" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" id="Hidden_FE1dYrMu70-J5dbAohVyjw">0</ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_USD_NFG_pVdyhEyJarLQmedkXA" contextRef="Duration_1_1_2020_To_12_31_2020_3DdHOulAJk6Q0Zn4Vsxq5A" decimals="0" name="us-gaap:FederalIncomeTaxExpenseBenefitContinuingOperations" id="Hidden_SW8i4KjZHE2PDZm4AjxY8Q">0</ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_USD_NFG_pVdyhEyJarLQmedkXA" contextRef="Duration_1_1_2021_To_12_31_2021_uhkxAiZ6fUeekYGgaMhCqA" decimals="0" name="us-gaap:FederalIncomeTaxExpenseBenefitContinuingOperations" id="Hidden_6_Xqz9nGk0aFTo4spVd-HQ">0</ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_USD_NFG_pVdyhEyJarLQmedkXA" contextRef="Duration_1_1_2021_To_12_31_2021_uhkxAiZ6fUeekYGgaMhCqA" decimals="0" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" id="Hidden_wLzrCC9kDk6BKVi6RIiXmQ">0</ix:nonFraction></ix:hidden><ix:references><link:schemaRef xlink:type="simple" xlink:href="anvs-20211231.xsd"></link:schemaRef></ix:references><ix:resources><xbrli:context id="As_Of_12_31_2020_us-gaap_StatementClassOfStockAxis_anvs_SeriesaRedeemableConvertiblePreferredStockMember_54xJpWZU6E-sSdAV-pOOiA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001477845</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">anvs:SeriesaRedeemableConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2020_us-gaap_StatementClassOfStockAxis_anvs_Series1RedeemableConvertiblePreferredStockMember_hROazqn7SUCQmc794Mq69Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001477845</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">anvs:Series1RedeemableConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2019_us-gaap_StatementClassOfStockAxis_anvs_SeriesaRedeemableConvertiblePreferredStockMember_odVgKOmG90OBa7U96NG4jw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001477845</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">anvs:SeriesaRedeemableConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2019_us-gaap_StatementClassOfStockAxis_anvs_Series1RedeemableConvertiblePreferredStockMember_pzCzknp_UUqMQod8oici_A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001477845</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">anvs:Series1RedeemableConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_us-gaap_IncomeTaxAuthorityAxis_us-gaap_DomesticCountryMember_us-gaap_TaxCreditCarryforwardAxis_us-gaap_ResearchMember_Asd8fgY1d0GxTm44XLZlKg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001477845</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:ResearchMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_us-gaap_GranteeStatusAxis_us-gaap_ShareBasedPaymentArrangementNonemployeeMember_-b4g7yTNB0aLjzC-gDHmiA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001477845</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementNonemployeeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_vHHC9xto40u1e1f1OxZXDA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001477845</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_Roe1SnnNfUKvOnVm7PJZ8w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001477845</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_m87TYAU_iECC8Uth9G-F3g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001477845</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_aLSsuRjKkUqU5e2EQUdxog"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001477845</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_q8XP9K1S6UO9eBjFQKFqmA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001477845</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_8FIUzd9InkOQst0tn_3nZg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001477845</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_xiqgw4dbRkGQtr2BjCvyAw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001477845</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_hBUW9O6ICE63RL-ah82T6g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001477845</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_d1y_dVMmq02lOk2EI5_rBA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001477845</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_5_26_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_us-gaap_SubsidiarySaleOfStockAxis_anvs_SecondaryPublicOfferingMember_VQlutMc_ZkWzfLztqs-8Cg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001477845</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">anvs:SecondaryPublicOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-05-26</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_1_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember_rLszk1iR-U-miS0THNh94A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001477845</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-01-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_us-gaap_AwardDateAxis_anvs_AwardsGrantedIn2021Member_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_VestingAxis_anvs_ShareBasedPaymentArrangementVestingPeriodTwoYearsMember_7fink69gjUCJNwXqPwAp0Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001477845</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">anvs:AwardsGrantedIn2021Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VestingAxis">anvs:ShareBasedPaymentArrangementVestingPeriodTwoYearsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_us-gaap_AwardDateAxis_anvs_AwardsGrantedIn2021Member_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_VestingAxis_anvs_ShareBasedPaymentArrangementVestingPeriodOneYearMember_DimQ7qACMU6TfxILGAwOCw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001477845</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">anvs:AwardsGrantedIn2021Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VestingAxis">anvs:ShareBasedPaymentArrangementVestingPeriodOneYearMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_us-gaap_AwardDateAxis_anvs_AwardsGrantedIn2021Member_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_VestingAxis_anvs_ShareBasedPaymentArrangementVestingPeriodImmediateVestingMember_1D0-tOBHgkGoY1R3CgsSig"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001477845</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">anvs:AwardsGrantedIn2021Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VestingAxis">anvs:ShareBasedPaymentArrangementVestingPeriodImmediateVestingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_us-gaap_AwardDateAxis_anvs_AwardsGrantedIn2021Member_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_VestingAxis_anvs_ShareBasedPaymentArrangementVestingPeriodEqualQuarterlyInstallmentsOverTwoYearsMember_ZOvd1oon0k2qQBob-40BxQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001477845</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">anvs:AwardsGrantedIn2021Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VestingAxis">anvs:ShareBasedPaymentArrangementVestingPeriodEqualQuarterlyInstallmentsOverTwoYearsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2020_us-gaap_AwardDateAxis_anvs_AwardsGrantedIn2020Member_us-gaap_VestingAxis_anvs_ShareBasedPaymentArrangementVestingPeriodOneYearMember_5-6tsJ5Re0SiRVbMTy7QsA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001477845</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">anvs:AwardsGrantedIn2020Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VestingAxis">anvs:ShareBasedPaymentArrangementVestingPeriodOneYearMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_3_2022_To_1_3_2022_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_rxWBqkfQFkesGFeOew63wA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001477845</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2022-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_us-gaap_PlanNameAxis_anvs_EquityIncentivePlan2019Member_UCOHxKW5skOhwhVeKdLFlA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001477845</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">anvs:EquityIncentivePlan2019Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_1_31_2020_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_anvs_EquityIncentivePlan2018Member_c20l7lAf-kqshSDL7zNsjg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001477845</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">anvs:EquityIncentivePlan2018Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-01-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_1_2021_us-gaap_PlanNameAxis_anvs_EquityIncentivePlan2019Member__w3AH-0HNU6nl5M5tn5tng"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001477845</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">anvs:EquityIncentivePlan2019Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_5_31_2021_us-gaap_PlanNameAxis_anvs_EquityIncentivePlan2019Member_KtS-YX7JjU6pl2kOUpEkTw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001477845</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">anvs:EquityIncentivePlan2019Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-05-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_anvs_EquityIncentivePlan2019Member_GgeIFB678UmRgQVDyMstNg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001477845</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">anvs:EquityIncentivePlan2019Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2020_To_12_31_2020_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_LAmAyrWmJUC3qRHISSAjmA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001477845</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_us-gaap_AwardDateAxis_anvs_AwardsGrantedIn2021Member_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_VestingAxis_anvs_ShareBasedPaymentArrangementVestingPeriodEqualQuarterlyInstallmentsOverTwoYearsMember_KPZ_nNTrBk-ED74SOGLcGQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001477845</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">anvs:AwardsGrantedIn2021Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VestingAxis">anvs:ShareBasedPaymentArrangementVestingPeriodEqualQuarterlyInstallmentsOverTwoYearsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2020_To_12_31_2020_us-gaap_AwardDateAxis_anvs_AwardsGrantedIn2020Member_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_VestingAxis_anvs_ShareBasedPaymentArrangementVestingPeriodOneYearMember__Fh8QWUir0eZugsK0WNqcA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001477845</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">anvs:AwardsGrantedIn2020Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VestingAxis">anvs:ShareBasedPaymentArrangementVestingPeriodOneYearMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_PpS2s9PnUUSL1x-_RPEPIQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001477845</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_obnngQDtKEWjaZKdmxph6g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001477845</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2020_To_12_31_2020_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_Fq09egBe_kOjLnI9UQwMsA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001477845</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2020_To_12_31_2020_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_r5vqCaRQJk29U3pXOnvzDg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001477845</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_5_26_2021_To_5_26_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_us-gaap_SubsidiarySaleOfStockAxis_anvs_SecondaryPublicOfferingMember_hxxkehfNkEWWBXStlPA61w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001477845</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">anvs:SecondaryPublicOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-05-26</xbrli:startDate><xbrli:endDate>2021-05-26</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_us-gaap_IncomeTaxAuthorityAxis_us-gaap_DomesticCountryMember_us-gaap_TaxPeriodAxis_anvs_GeneratedIn2017AndPriorMember_bcLUgZK7ak-slt0qx5nwVQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001477845</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">anvs:GeneratedIn2017AndPriorMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_us-gaap_IncomeTaxAuthorityAxis_us-gaap_StateAndLocalJurisdictionMember_5e7zQwkrykWomLKNapiciw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001477845</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_us-gaap_IncomeTaxAuthorityAxis_us-gaap_DomesticCountryMember_HgR3pC70rUmeM4G-ZKbaTg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001477845</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_ryg7L-2WUkOqbAJ4DvlylQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001477845</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_Yj7CnNrKbk2eFi8MMsgZvQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001477845</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2020_To_12_31_2020_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember_dBs7AChUNEK9AUDzdDKJTQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001477845</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2019_To_12_31_2019_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember_RsyiGRhnhk-vxd5-a-DqHg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001477845</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_us-gaap_TypeOfArrangementAxis_anvs_NationalInstituteOnAgingOfNationalInstitutesOfHealthMember_VVmuZtlTeEaVeNDy9uhHaQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001477845</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">anvs:NationalInstituteOnAgingOfNationalInstitutesOfHealthMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2020_us-gaap_TypeOfArrangementAxis_anvs_NationalInstituteOnAgingOfNationalInstitutesOfHealthMember_SIhJO7d5SUmK7j4WVeRGBw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001477845</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">anvs:NationalInstituteOnAgingOfNationalInstitutesOfHealthMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_us-gaap_GranteeStatusAxis_us-gaap_ShareBasedPaymentArrangementNonemployeeMember_D0px0fClyEe8jZWjjaEH_w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001477845</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementNonemployeeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_MkIC0676s0mFrsozz2b5Ow"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001477845</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_vlN0t7QzKEiNBpiYEjJwDw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001477845</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_31_2019_oVmx4yeGk0q3UZkY6l4F-g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001477845</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2019-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_31_2019_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember_us-gaap_RelatedPartyTransactionAxis_anvs_RelatedPartyTransactionIssuanceOfConvertiblePromissoryNotesMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_srt_DirectorMember_4brYU2SNtkC-xZaYEMvK_g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001477845</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">anvs:RelatedPartyTransactionIssuanceOfConvertiblePromissoryNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:DirectorMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_31_2019_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember_YwRIubASaUOYMPLJxHrjxQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001477845</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_us-gaap_ClassOfWarrantOrRightAxis_anvs_UnderwritersWarrantsMember_i9g6mnyCNEylYBl9fs3ugQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001477845</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">anvs:UnderwritersWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2020_us-gaap_ClassOfWarrantOrRightAxis_anvs_UnderwritersWarrantsMember_fVGxQCgHYU-B8YaMWCH07g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001477845</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">anvs:UnderwritersWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2019_S7jX8DT5zEOORR0B4HM-aw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001477845</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_hJjGSBmgGE6iOTr6RBMr5Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001477845</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2020_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_RGBQ6zcqa0CUSFXphddjkA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001477845</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_4-P5H-hF4ESmAJ-kqpCyXw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001477845</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2020_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_ivytLr2eEUunO9BaEWMghQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001477845</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_WarrantMember_GH_2bhJhrkKLRik7_QHn1g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001477845</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockOptionMember_ErimM70Lx0GlzbzdZjfaBQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001477845</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2020_To_12_31_2020_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_WarrantMember_BM2Bi1ZZ70OsQ-maVuCszA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001477845</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2020_To_12_31_2020_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockOptionMember_Ot-TYiGbdkWL1GALWHvnMQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001477845</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2021_MBhTAFV7OEyNVlFF1KbEtw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001477845</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_2_28_2022_KZhnsPfZ-kWXAPyRRcTcqw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001477845</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-02-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_31_2020_To_1_31_2020_us-gaap_StatementClassOfStockAxis_anvs_SeriesaRedeemableConvertiblePreferredStockMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember_ptCGvvBnuEitWVCSkdK7Vw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001477845</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">anvs:SeriesaRedeemableConvertiblePreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-31</xbrli:startDate><xbrli:endDate>2020-01-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_31_2020_To_1_31_2020_us-gaap_StatementClassOfStockAxis_anvs_Series1RedeemableConvertiblePreferredStockMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember_fNVfPPJXjUyuAgQutr0kWQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001477845</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">anvs:Series1RedeemableConvertiblePreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-31</xbrli:startDate><xbrli:endDate>2020-01-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementClassOfStockAxis_anvs_SeriesaRedeemableConvertiblePreferredStockMember_deK8dFWBmk-HMa7S_4aJ1w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001477845</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">anvs:SeriesaRedeemableConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementClassOfStockAxis_anvs_Series1RedeemableConvertiblePreferredStockMember_-LeysnJLjE-x0FvXPGEzVg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001477845</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">anvs:Series1RedeemableConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_Nwz3m5oS6kGLY8WW_bxwDQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001477845</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_JVwGb5QRK0mEvKeM6mX7xg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001477845</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_zHbo2vwCLUiM30jKyAcCgw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001477845</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_31_2020_To_1_31_2020_us-gaap_RelatedPartyTransactionAxis_anvs_RelatedPartyTransactionConversionOfPromissoryNotesToCommonStockMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_srt_DirectorMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_IfkwjFJuWk-TFaP8kqYr2g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001477845</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">anvs:RelatedPartyTransactionConversionOfPromissoryNotesToCommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:DirectorMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-31</xbrli:startDate><xbrli:endDate>2020-01-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_FOnigPlx6UaoZMNa-ktVRg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001477845</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2020_To_12_31_2020_us-gaap_GranteeStatusAxis_us-gaap_ShareBasedPaymentArrangementNonemployeeMember__Y5EzHRV8U2VQ42ne0t5eg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001477845</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementNonemployeeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_3_1_2019_To_3_31_2019_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember_us-gaap_RelatedPartyTransactionAxis_anvs_RelatedPartyTransactionIssuanceOfConvertiblePromissoryNotesMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_srt_DirectorMember_uRDbbwJWlUih1vnjYEeJyA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001477845</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">anvs:RelatedPartyTransactionIssuanceOfConvertiblePromissoryNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:DirectorMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-03-01</xbrli:startDate><xbrli:endDate>2019-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_1_31_2020_us-gaap_StatementClassOfStockAxis_anvs_SeriesaRedeemableConvertiblePreferredStockMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember_WSa7shXqeUSwpAKpQQl-KQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001477845</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">anvs:SeriesaRedeemableConvertiblePreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-01-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_1_31_2020_us-gaap_StatementClassOfStockAxis_anvs_Series1RedeemableConvertiblePreferredStockMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember_O74MBLhVpkagypo4IVPp_Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001477845</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">anvs:Series1RedeemableConvertiblePreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-01-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_1_31_2020_us-gaap_ClassOfWarrantOrRightAxis_anvs_UnderwritersWarrantsMember_p2Rmy9kgMES4LjCsl9nsqg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001477845</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">anvs:UnderwritersWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-01-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_srt_TitleOfIndividualAxis_srt_ExecutiveOfficerMember_2QVIbrzh10W_0LPuXlLcug"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001477845</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ExecutiveOfficerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_anvs_LicenseAgreementTermsAmendedMay2012Member_DCsom2ZXYkiSKjzS68vh2Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001477845</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">anvs:LicenseAgreementTermsAmendedMay2012Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_5_1_2012_To_5_31_2012_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_anvs_LicenseAgreementTermsAmendedMay2012Member_P0aUOpgGN0mwPRsuYBHIew"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001477845</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">anvs:LicenseAgreementTermsAmendedMay2012Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2012-05-01</xbrli:startDate><xbrli:endDate>2012-05-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_us-gaap_TypeOfArrangementAxis_anvs_NationalInstituteOnAgingOfNationalInstitutesOfHealthMember_CduWTDd6hEGUS67lAWkVHw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001477845</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">anvs:NationalInstituteOnAgingOfNationalInstitutesOfHealthMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2020_To_12_31_2020_us-gaap_TypeOfArrangementAxis_anvs_NationalInstituteOnAgingOfNationalInstitutesOfHealthMember_1CkP6VBQfUS9FAKN4vz1Tg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001477845</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">anvs:NationalInstituteOnAgingOfNationalInstitutesOfHealthMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2019_us-gaap_TypeOfArrangementAxis_anvs_NationalInstituteOnAgingOfNationalInstitutesOfHealthMember_RQt1O7nidUO5QNweDycD_A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001477845</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">anvs:NationalInstituteOnAgingOfNationalInstitutesOfHealthMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_uhkxAiZ6fUeekYGgaMhCqA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001477845</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_anvs_LicenseAgreementTermsAmendedMay2012Member_fjPgMKMghE-GlCKw7d5yzw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001477845</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">anvs:LicenseAgreementTermsAmendedMay2012Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_us-gaap_ClassOfWarrantOrRightAxis_anvs_UnderwritersWarrantsMember_lIkEDjt6I02rJoRPhXJAxw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001477845</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">anvs:UnderwritersWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_31_2020_To_1_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember_sRjzEwCZI0yVkxtZkXzw0w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001477845</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-31</xbrli:startDate><xbrli:endDate>2020-01-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2020_To_12_31_2020_3DdHOulAJk6Q0Zn4Vsxq5A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001477845</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_1_31_2020_kBrHfmPKTE-0UUCmwNXokA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001477845</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-01-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_slf_IrTrZku1VVWbbttE4g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001477845</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2020_K1oKCNbpv0CLR8EJWu1PSw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001477845</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="Unit_Standard_USD_NFG_pVdyhEyJarLQmedkXA"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit><xbrli:unit id="Unit_Standard_shares__cOSbKjBTUyHt70_t1aAVw"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:unit id="Unit_Standard_pure_n7tAfGlk1kyqYH5N2uCURw"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit><xbrli:unit id="Unit_Standard_item_Y7Ur8tqCgUit9H-TWiK9OA"><xbrli:measure>anvs:item</xbrli:measure></xbrli:unit><xbrli:unit id="Unit_Standard_Vote_pwF70c76VEGREHjsKw9EwA"><xbrli:measure>anvs:Vote</xbrli:measure></xbrli:unit><xbrli:unit id="Unit_Divide_USD_shares_ZtgwQidioUWlbMoOaTBzxg"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:unit id="Unit_Standard_director_8dNZ3yZCzEGn3lXzcsOwSg"><xbrli:measure>anvs:director</xbrli:measure></xbrli:unit><xbrli:unit id="Unit_Standard_lawsuit_cWy34Dwcxk6mE22LYui79g"><xbrli:measure>anvs:lawsuit</xbrli:measure></xbrli:unit></ix:resources></ix:header></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;min-height:13.8pt;"><a id="_81b3bb27_6fef_45d3_b9a0_f4c413fe9368"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:2pt;padding-bottom:1pt;padding-top:1pt;text-align:center;text-indent:0pt;border-bottom:1.0pt solid #000000;border-top:3.0pt solid #000000;margin:0pt;"><span style="font-size:2pt;font-weight:bold;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><span style="font-size:3pt;font-weight:bold;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><b style="font-weight:bold;">UNITED STATES</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><b style="font-weight:bold;">SECURITIES AND EXCHANGE COMMISSION</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;text-indent:0pt;margin:0pt 0pt 3pt 0pt;"><b style="font-weight:bold;">Washington, D.C. 20549</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><b style="font-weight:bold;">Form&#160;</b><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_uhkxAiZ6fUeekYGgaMhCqA" name="dei:DocumentType" id="Narr_HDdaz2ew50y0_zzkNcP24w"><b style="font-weight:bold;">10-K</b></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="font-size:5pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><a id="_560de5c3_833a_4b71_ad6c_b1899e914aec"></a><a id="Tc_6_8Gze2x40u-t5fO5FuoXw_0_1"></a><a id="Tc_GHqdTaKeE0esnox8FsIk4Q_2_0"></a><a id="Tc_BT-18BvzlUq1C8ghiq8arA_4_1"></a><a id="Tc_481q0qcZN0ypcHbS6ha0Qw_6_0"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:top;width:6.86%;margin:0pt;padding:0pt 3.59pt 0pt 3.59pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><ix:nonNumeric format="ixt-sec:boolballotbox" contextRef="Duration_1_1_2021_To_12_31_2021_uhkxAiZ6fUeekYGgaMhCqA" name="dei:DocumentAnnualReport" id="Tc_S6qGzHb03USvT2UjWPh4RA_0_0"><span style="font-family:'Segoe UI Symbol';font-size:8pt;">&#9746;</span></ix:nonNumeric></p></td><td style="vertical-align:top;width:93.13%;margin:0pt;padding:0pt 3.59pt 0pt 3.59pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-indent:0pt;margin:0pt;"><b style="font-weight:bold;">ANNUAL REPORT PURSUANT TO SECTION&#160;13 OR 15(d)&#160;OF THE SECURITIES EXCHANGE ACT OF&#160;1934</b></p></td></tr><tr><td style="vertical-align:top;width:6.86%;margin:0pt;padding:0pt 3.59pt 0pt 3.59pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;text-indent:0pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:93.13%;margin:0pt;padding:0pt 3.59pt 0pt 3.59pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;text-indent:0pt;margin:0pt;">&#160;</p></td></tr><tr><td colspan="2" style="vertical-align:top;width:100%;margin:0pt;padding:0pt 3.59pt 0pt 3.59pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><b style="font-size:8pt;font-weight:bold;">For the fiscal&#160;year ended </b><ix:nonNumeric format="ixt:datemonthdayyearen" contextRef="Duration_1_1_2021_To_12_31_2021_uhkxAiZ6fUeekYGgaMhCqA" name="dei:DocumentPeriodEndDate" id="Narr_9e7y3i3ymU-YJJivR4lESw"><ix:nonNumeric format="ixt:datemonthdayen" contextRef="Duration_1_1_2021_To_12_31_2021_uhkxAiZ6fUeekYGgaMhCqA" name="dei:CurrentFiscalYearEndDate" id="Narr_D5l79WULX0SXqq-lQVzymg"><b style="font-size:8pt;font-weight:bold;">December&#160;31</b></ix:nonNumeric><b style="font-size:8pt;font-weight:bold;">, 2021</b></ix:nonNumeric></p></td></tr><tr><td colspan="2" style="vertical-align:top;width:100%;margin:0pt;padding:0pt 3.59pt 0pt 3.59pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;text-indent:0pt;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:top;width:6.86%;margin:0pt;padding:0pt 3.59pt 0pt 3.59pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><ix:nonNumeric format="ixt-sec:boolballotbox" contextRef="Duration_1_1_2021_To_12_31_2021_uhkxAiZ6fUeekYGgaMhCqA" name="dei:DocumentTransitionReport" id="Tc_hxF4xcUMkEOm63oc3yI6yA_4_0"><span style="font-family:'Segoe UI Symbol';font-size:8pt;">&#9744;</span></ix:nonNumeric></p></td><td style="vertical-align:top;width:93.13%;margin:0pt;padding:0pt 3.59pt 0pt 3.59pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-indent:0pt;margin:0pt;"><b style="font-weight:bold;">TRANSITION REPORT PURSUANT TO SECTION&#160;13 OR 15(d)&#160;OF THE SECURITIES EXCHANGE ACT OF&#160;1934</b></p></td></tr><tr><td style="vertical-align:top;width:6.86%;margin:0pt;padding:0pt 3.59pt 0pt 3.59pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;text-indent:0pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:93.13%;margin:0pt;padding:0pt 3.59pt 0pt 3.59pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;text-indent:0pt;margin:0pt;">&#160;</p></td></tr><tr><td colspan="2" style="vertical-align:top;width:100%;margin:0pt;padding:0pt 3.59pt 0pt 3.59pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;text-indent:0pt;margin:0pt;"><b style="font-weight:bold;">For the transition period from&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;to&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt 0pt 3pt 0pt;"><b style="font-size:8pt;font-weight:bold;">Commission file number&#160;</b><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_uhkxAiZ6fUeekYGgaMhCqA" name="dei:EntityFileNumber" id="Narr_vaKo0rX23UWysXTf2-_J3Q"><b style="font-size:8pt;font-weight:bold;">001-39202</b></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;text-indent:0pt;margin:0pt;"><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_uhkxAiZ6fUeekYGgaMhCqA" name="dei:EntityRegistrantName" id="Narr_nUnfIag1hE-HbQyKmlWGWg"><b style="font-weight:bold;">Annovis Bio,&#160;Inc.</b></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;text-indent:0pt;margin:0pt;">(Exact name of registrant as specified in its charter)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="font-size:5pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt 3.59pt 0pt 3.59pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:middle;width:50%;margin:0pt;padding:0pt 3.59pt 0pt 3.59pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"></div></div></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt 3.59pt 0pt 3.59pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><ix:nonNumeric format="ixt-sec:stateprovnameen" contextRef="Duration_1_1_2021_To_12_31_2021_uhkxAiZ6fUeekYGgaMhCqA" name="dei:EntityIncorporationStateCountryCode" id="Narr_AjTnWNDYZUKlK4A6Kl25PQ"><b style="font-size:8pt;font-weight:bold;">Delaware</b></ix:nonNumeric><span style="font-size:8pt;"><br /></span><span style="font-size:8pt;">(State or other jurisdiction of</span><span style="font-size:8pt;"><br /></span><span style="font-size:8pt;">incorporation or organization)</span></p></td><td style="vertical-align:middle;width:50%;margin:0pt;padding:0pt 3.59pt 0pt 3.59pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_uhkxAiZ6fUeekYGgaMhCqA" name="dei:EntityTaxIdentificationNumber" id="Narr_Yiavf1KzIU2PZDomd1kUCQ"><b style="font-size:8pt;font-weight:bold;">26-2540421</b></ix:nonNumeric><span style="font-size:8pt;"><br /></span><span style="font-size:8pt;">(I.R.S. Employer</span><span style="font-size:8pt;"><br /></span><span style="font-size:8pt;">Identification No.)</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_uhkxAiZ6fUeekYGgaMhCqA" name="dei:EntityAddressAddressLine1" id="Narr_meRkmEZvAECvhcAuV83xpA"><b style="font-size:8pt;font-weight:bold;">1055 Westlakes Drive, Suite&#160;300</b></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_uhkxAiZ6fUeekYGgaMhCqA" name="dei:EntityAddressCityOrTown" id="Narr_CYhVNAvCpEe7saMO6ppr2w"><b style="font-size:8pt;font-weight:bold;">Berwyn</b></ix:nonNumeric><b style="font-size:8pt;font-weight:bold;">, </b><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_uhkxAiZ6fUeekYGgaMhCqA" name="dei:EntityAddressStateOrProvince" id="Narr_Rb8EPljSH0utcHNGTQ7WRA"><b style="font-size:8pt;font-weight:bold;">PA</b></ix:nonNumeric><b style="font-size:8pt;font-weight:bold;"> </b><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_uhkxAiZ6fUeekYGgaMhCqA" name="dei:EntityAddressPostalZipCode" id="Narr_rjCTKvykt0yYLgFh_tzTcg"><b style="font-size:8pt;font-weight:bold;">19312</b></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;text-indent:0pt;margin:0pt;">(Address of principal executive offices including zip code)</p><div style="font-family:'Times New Roman','Times','serif';font-size:12.0pt;margin-bottom:0pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1pt;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto;"></div></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><b style="font-size:8pt;font-weight:bold;">(</b><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_uhkxAiZ6fUeekYGgaMhCqA" name="dei:CityAreaCode" id="Narr_iZ4Fm6SQok2NdTPGfmb9EA"><b style="font-size:8pt;font-weight:bold;">610</b></ix:nonNumeric><b style="font-size:8pt;font-weight:bold;">)&#160;</b><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_uhkxAiZ6fUeekYGgaMhCqA" name="dei:LocalPhoneNumber" id="Narr_y79riXUlfUK3N8T_ENq_eA"><b style="font-size:8pt;font-weight:bold;">727-3913</b></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;text-indent:0pt;margin:0pt;">(Registrant&#8217;s telephone number, including area code)</p><div style="font-family:'Times New Roman','Times','serif';font-size:12.0pt;margin-bottom:0pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1pt;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto;"></div></div><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;text-indent:0pt;margin:0pt;">Securities registered pursuant to Section&#160;12(b)&#160;of the Act:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="font-size:5pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><a id="_1b4e4fcb_93fd_4b50_845d_0ea62902d24d"></a><a id="Tc_QP3V5dzYD0yGHq5at7gqhA_1_0"></a><a id="Tc_kkw09WV-qUCsnAxdr13Olg_1_2"></a><a id="Tc_YQlNggfYPEygSwxaK55q8w_1_4"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:33.95%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:top;width:27.96%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:bottom;width:33.95%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td></tr><tr><td style="vertical-align:bottom;width:33.95%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;text-indent:0pt;margin:0pt;"><b style="font-weight:bold;">Title of Each Class</b></p></td><td style="vertical-align:bottom;width:2.06%;border-bottom:1.0pt solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;text-indent:0pt;margin:0pt;">&#160;&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:top;width:27.96%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;text-indent:0pt;margin:0pt;"><b style="font-weight:bold;">Trading Symbol</b></p></td><td style="vertical-align:top;width:2.06%;border-bottom:1.0pt solid #ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;text-indent:0pt;margin:0pt;">&#160;&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;width:33.95%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;text-indent:0pt;margin:0pt;"><b style="font-weight:bold;">Name of Each Exchange on Which Registered</b></p></td></tr><tr><td style="vertical-align:bottom;width:33.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_uhkxAiZ6fUeekYGgaMhCqA" name="dei:Security12bTitle" id="Tc_ZpVu2MXQ9EqR_ROepFerTw_2_0"><span style="font-size:8pt;">Common Stock, par value $0.0001 per share</span></ix:nonNumeric></p></td><td style="vertical-align:bottom;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;text-indent:0pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:27.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_uhkxAiZ6fUeekYGgaMhCqA" name="dei:TradingSymbol" id="Tc_RJvDVzOfwE-V6xL5giPSKQ_2_2"><span style="font-size:8pt;">ANVS</span></ix:nonNumeric></p></td><td style="vertical-align:top;width:2.06%;border-bottom:1.0pt solid #ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;text-indent:0pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:33.95%;border-bottom:1.0pt solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><ix:nonNumeric format="ixt-sec:exchnameen" contextRef="Duration_1_1_2021_To_12_31_2021_uhkxAiZ6fUeekYGgaMhCqA" name="dei:SecurityExchangeName" id="Tc_blbFmRJNGU-BGImm9sGfaA_2_4"><span style="font-size:8pt;">New York Stock Exchange</span></ix:nonNumeric></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-indent:36pt;margin:0pt 0pt 3pt 0pt;">Securities registered pursuant to Section&#160;12(g)&#160;of the Act: None.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 3pt 0pt;"><span style="font-size:8pt;">Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule&#160;405 of the Securities Act. Yes&#160;</span><span style="font-family:'Segoe UI Symbol';font-size:8pt;">&#9744;</span><span style="font-size:8pt;"> &#160;</span><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_uhkxAiZ6fUeekYGgaMhCqA" name="dei:EntityWellKnownSeasonedIssuer" id="Narr_j0fNBFCD4EKpNzckBQbUjQ"><span style="font-size:8pt;">No</span></ix:nonNumeric><span style="font-size:8pt;">&#160;</span><span style="font-family:'Segoe UI Symbol';font-size:8pt;">&#9746;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 3pt 0pt;"><span style="font-size:8pt;">Indicate by check mark if the registrant is not required to file reports pursuant to Section&#160;13 or Section&#160;15(d)&#160;of the Exchange Act. Yes&#160;</span><span style="font-family:'Segoe UI Symbol';font-size:8pt;">&#9744;</span><span style="font-size:8pt;"> &#160;</span><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_uhkxAiZ6fUeekYGgaMhCqA" name="dei:EntityVoluntaryFilers" id="Narr_KSIjwBz_gk60wigyxVmjxg"><span style="font-size:8pt;">No</span></ix:nonNumeric><span style="font-size:8pt;">&#160;</span><span style="font-family:'Segoe UI Symbol';font-size:8pt;">&#9746;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 3pt 0pt;"><span style="font-size:8pt;">Indicate by check mark whether the registrant (1)&#160;has filed all reports required to be filed by Section&#160;13 or 15(d)&#160;of the Securities Exchange Act of 1934 during the preceding 12&#160;months (or for such shorter period that the registrant was required to file such reports), and (2)&#160;has been subject to such filing requirements for the past 90&#160;days. </span><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_uhkxAiZ6fUeekYGgaMhCqA" name="dei:EntityCurrentReportingStatus" id="Narr_sMyl1K7cY0CWbtGuhaFExA"><span style="font-size:8pt;">Yes</span></ix:nonNumeric><span style="font-size:8pt;">&#160;</span><span style="font-family:'Segoe UI Symbol';font-size:8pt;">&#9746;</span><span style="font-size:8pt;"> &#160;No&#160;</span><span style="font-family:'Segoe UI Symbol';font-size:8pt;">&#9744;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 3pt 0pt;"><span style="font-size:8pt;">Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule&#160;405 of Regulation S-T (&#167; 232.405 of this chapter) during the preceding 12&#160;months (or for such shorter period that the registrant was required to submit such files). </span><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_uhkxAiZ6fUeekYGgaMhCqA" name="dei:EntityInteractiveDataCurrent" id="Narr_4gCxBjIRsk2QH-EqQLAs9w"><span style="font-size:8pt;">Yes</span></ix:nonNumeric><span style="font-size:8pt;"> </span><span style="font-family:'Segoe UI Symbol';font-size:8pt;">&#9746;</span><span style="font-size:8pt;"> &#160;No&#160;</span><span style="font-family:'Segoe UI Symbol';font-size:8pt;">&#9744;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-indent:36pt;margin:0pt;">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting company&#8221; and &quot;emerging growth company&quot; in Rule&#160;12b-2 of the Exchange Act.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="font-size:5pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:top;width:26%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:21.99%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:21.99%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:30%;margin:0pt;padding:0pt;"></td></tr><tr><td style="vertical-align:top;width:26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;text-indent:0pt;margin:0pt;">Large&#160;accelerated&#160;filer&#160;<span style="font-family:'Segoe UI Symbol';">&#9744;</span></p></td><td style="vertical-align:top;width:21.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;text-indent:0pt;margin:0pt;">Accelerated filer&#160;<span style="font-family:'Segoe UI Symbol';">&#9744;</span></p></td><td style="vertical-align:top;width:21.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><ix:nonNumeric format="ixt-sec:entityfilercategoryen" contextRef="Duration_1_1_2021_To_12_31_2021_uhkxAiZ6fUeekYGgaMhCqA" name="dei:EntityFilerCategory" id="Narr_S-5onUCI6E63_TaWKRJ0dA"><span style="font-size:8pt;">Non-accelerated filer</span></ix:nonNumeric><span style="font-size:8pt;">&#160;</span><span style="font-family:'Segoe UI Symbol';font-size:8pt;">&#9746;</span></p></td><td style="vertical-align:top;width:30%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><span style="font-size:8pt;">Smaller reporting company&#160;</span><ix:nonNumeric format="ixt-sec:boolballotbox" contextRef="Duration_1_1_2021_To_12_31_2021_uhkxAiZ6fUeekYGgaMhCqA" name="dei:EntitySmallBusiness" id="Narr_0-1EqJw-_0KxfWvIT_f3OQ"><span style="font-family:'Segoe UI Symbol';font-size:8pt;">&#9746;</span></ix:nonNumeric></p></td></tr><tr><td style="vertical-align:top;width:26%;margin:0pt;padding:3pt 0pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><span style="font-size:8pt;">Emerging growth company </span><ix:nonNumeric format="ixt-sec:boolballotbox" contextRef="Duration_1_1_2021_To_12_31_2021_uhkxAiZ6fUeekYGgaMhCqA" name="dei:EntityEmergingGrowthCompany" id="Narr_hOlruehqiE6wvmICNoWKXg"><span style="font-family:'Segoe UI Symbol';font-size:8pt;">&#9746;</span></ix:nonNumeric></p></td><td style="vertical-align:top;width:21.99%;margin:0pt;padding:3pt 0pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;text-indent:0pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:21.99%;margin:0pt;padding:3pt 0pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;text-indent:0pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:30%;margin:0pt;padding:3pt 0pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;text-indent:0pt;margin:0pt;">&#160;</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:3pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 3pt 0pt;"><span style="font-size:8pt;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section&#160;13(a)&#160;of the Exchange Act. </span><ix:nonNumeric format="ixt-sec:boolballotbox" contextRef="Duration_1_1_2021_To_12_31_2021_uhkxAiZ6fUeekYGgaMhCqA" name="dei:EntityExTransitionPeriod" id="Narr_bJJkrh3Z5E2vlEW8UGBP_Q"><span style="font-family:'Segoe UI Symbol';font-size:8pt;">&#9746;</span></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 3pt 0pt;"><span style="font-size:8pt;">Indicate by check mark whether the registrant is a shell company (as defined in Rule&#160;12b-2 of the Exchange Act). Yes&#160;</span><ix:nonNumeric format="ixt-sec:boolballotbox" contextRef="Duration_1_1_2021_To_12_31_2021_uhkxAiZ6fUeekYGgaMhCqA" name="dei:EntityShellCompany" id="Narr_E0b_6t0K_U2VW43Vko6qrg"><span style="font-family:'Segoe UI Symbol';font-size:8pt;">&#9744;</span></ix:nonNumeric><span style="font-size:8pt;">&#160;No&#160;</span><span style="font-family:'Segoe UI Symbol';font-size:8pt;">&#9746;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 3pt 0pt;"><span style="font-size:8pt;">Indicate by check mark whether the registrant has filed a report on and attestation to its management&#8217;s assessment of the effectiveness of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or issued its audit report.</span><span style="font-family:'Segoe UI Symbol';font-size:8pt;"> </span><ix:nonNumeric format="ixt-sec:boolballotbox" contextRef="Duration_1_1_2021_To_12_31_2021_uhkxAiZ6fUeekYGgaMhCqA" name="dei:IcfrAuditorAttestationFlag" id="Narr_IbGT3TPouE2iXjcYmWkzUw"><span style="font-family:'Segoe UI Symbol';font-size:8pt;">&#9744;</span></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-indent:36pt;margin:0pt 0pt 3pt 0pt;">As of June&#160;30, 2021, the last business day of the registrant&#8217;s most recently completed second fiscal quarter, the aggregate market value of the registrant&#8217;s common stock held by non-affiliates of the registrant was $<ix:nonFraction unitRef="Unit_Standard_USD_NFG_pVdyhEyJarLQmedkXA" format="ixt:numdotdecimal" scale="0" contextRef="As_Of_6_30_2021_MBhTAFV7OEyNVlFF1KbEtw" decimals="0" name="dei:EntityPublicFloat" id="Narr_mZ--xOq0zUS-6VOxprMwRQ">481,819,080</ix:nonFraction> based on the closing sale price as reported on the NYSE American. </p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-indent:36pt;margin:0pt 0pt 3pt 0pt;">The number of shares of the issuer&#8217;s common stock outstanding as of March 1, 2022, was <ix:nonFraction unitRef="Unit_Standard_shares__cOSbKjBTUyHt70_t1aAVw" format="ixt:numdotdecimal" scale="0" contextRef="As_Of_2_28_2022_KZhnsPfZ-kWXAPyRRcTcqw" decimals="INF" name="dei:EntityCommonStockSharesOutstanding" id="Narr_AeVyz_B6FUa5uepulnuL_w">8,163,923</ix:nonFraction>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;text-indent:0pt;margin:0pt 0pt 5pt 0pt;"><b style="font-weight:bold;">Documents Incorporated by Reference</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-indent:36pt;margin:0pt;">Certain portions, as expressly described in this report, of the registrant&#8217;s proxy statement for the 2022 Annual Meeting of the Stockholders to be held June&#160;2, 2022 are incorporated by reference into Part&#160;III of this Annual Report on Form&#160;10-K.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="font-size:5pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:1pt;padding-top:1pt;text-indent:36pt;border-bottom:3.0pt solid #000000;border-top:1.0pt solid #000000;margin:0pt 0pt 3pt 0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:2pt;visibility:hidden;">&#8203;</span></p><p style="display:none;font-family:'Times New Roman','Times','serif';line-height:0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_e0e80f82_1752_4bb2_bd2f_52f9c312ee04"></a><a id="TOC"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">TABLE OF CONTENTS</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:3pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;table-layout:auto;width:101.12%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:8.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:86.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:5.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td colspan="2" style="vertical-align:bottom;width:94.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:5.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Page</b></p></td></tr><tr><td colspan="2" style="vertical-align:bottom;width:94.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#CautionaryNoteRegardingForwardLookingSta"><span style="font-style:normal;font-weight:normal;">Cautionary Note Regarding Forward-Looking Statements.</span></a></p></td><td style="vertical-align:bottom;width:5.41%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">2</p></td></tr><tr><td colspan="2" style="vertical-align:bottom;width:94.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:5.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td colspan="2" style="vertical-align:bottom;width:94.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#SummaryofRiskFactors_151760"><span style="font-style:normal;font-weight:normal;">Summary of Risk Factors.</span></a></p></td><td style="vertical-align:bottom;width:5.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">3</p></td></tr><tr><td colspan="2" style="vertical-align:bottom;width:94.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:5.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td colspan="2" style="vertical-align:bottom;width:94.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#PARTI_289954"><b style="font-style:normal;font-weight:bold;">Part I.</b></a></p></td><td style="vertical-align:bottom;width:5.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">4</p></td></tr><tr><td style="vertical-align:bottom;width:8.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:86.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:5.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:8.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item1Business_749608"><span style="font-style:normal;font-weight:normal;">Item 1.</span></a></p></td><td style="vertical-align:bottom;width:86.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item1Business_749608"><span style="font-style:normal;font-weight:normal;">Business.</span></a></p></td><td style="vertical-align:bottom;width:5.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">4</p></td></tr><tr><td style="vertical-align:bottom;width:8.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:86.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:5.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:8.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item1ARiskFactors_448269"><span style="font-style:normal;font-weight:normal;">Item1A.</span></a></p></td><td style="vertical-align:bottom;width:86.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item1ARiskFactors_448269"><span style="font-style:normal;font-weight:normal;">Risk Factors.</span></a></p></td><td style="vertical-align:bottom;width:5.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">27</p></td></tr><tr><td style="vertical-align:bottom;width:8.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:86.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:5.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:8.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item1BUnresolvedStaffComments_556571"><span style="font-style:normal;font-weight:normal;">Item1B.</span></a></p></td><td style="vertical-align:bottom;width:86.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item1BUnresolvedStaffComments_556571"><span style="font-style:normal;font-weight:normal;">Unresolved Staff Comments.</span></a></p></td><td style="vertical-align:bottom;width:5.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">64</p></td></tr><tr><td style="vertical-align:bottom;width:8.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:86.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:5.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:8.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item2Properties_424245"><span style="font-style:normal;font-weight:normal;">Item 2.</span></a></p></td><td style="vertical-align:bottom;width:86.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item2Properties_424245"><span style="font-style:normal;font-weight:normal;">Properties.</span></a></p></td><td style="vertical-align:bottom;width:5.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">64</p></td></tr><tr><td style="vertical-align:bottom;width:8.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:86.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:5.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:8.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item3LegalProceedings_59244"><span style="font-style:normal;font-weight:normal;">Item 3.</span></a></p></td><td style="vertical-align:bottom;width:86.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item3LegalProceedings_59244"><span style="font-style:normal;font-weight:normal;">Legal Proceedings.</span></a></p></td><td style="vertical-align:bottom;width:5.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">64</p></td></tr><tr><td style="vertical-align:bottom;width:8.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:86.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:5.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:8.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item4MineSafetyDisclosures_448345"><span style="font-style:normal;font-weight:normal;">Item 4.</span></a></p></td><td style="vertical-align:bottom;width:86.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item4MineSafetyDisclosures_448345"><span style="font-style:normal;font-weight:normal;">Mine Safety Disclosures.</span></a></p></td><td style="vertical-align:bottom;width:5.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">64</p></td></tr><tr><td colspan="2" style="vertical-align:bottom;width:94.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:5.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td colspan="2" style="vertical-align:bottom;width:94.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#PARTII_847922"><b style="font-style:normal;font-weight:bold;">Part II.</b></a></p></td><td style="vertical-align:bottom;width:5.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">65</p></td></tr><tr><td style="vertical-align:bottom;width:8.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:86.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:5.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:8.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item5MarketforRegistrantsCommonEquityRel"><span style="font-style:normal;font-weight:normal;">Item 5.</span></a></p></td><td style="vertical-align:bottom;width:86.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item5MarketforRegistrantsCommonEquityRel"><span style="font-style:normal;font-weight:normal;">Market for Registrant&#8217;s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities.</span></a></p></td><td style="vertical-align:bottom;width:5.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">65</p></td></tr><tr><td style="vertical-align:bottom;width:8.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:86.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:5.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:8.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item6SelectedFinancialData_944064"><span style="font-style:normal;font-weight:normal;">Item 6.</span></a></p></td><td style="vertical-align:bottom;width:86.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item6SelectedFinancialData_944064"><span style="font-style:normal;font-weight:normal;">Selected Financial Data.</span></a></p></td><td style="vertical-align:bottom;width:5.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">65</p></td></tr><tr><td style="vertical-align:bottom;width:8.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:86.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:5.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:8.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item7ManagementsDiscussionandAnalysisofF"><span style="font-style:normal;font-weight:normal;">Item 7.</span></a></p></td><td style="vertical-align:bottom;width:86.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item7ManagementsDiscussionandAnalysisofF"><span style="font-style:normal;font-weight:normal;">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations.</span></a></p></td><td style="vertical-align:bottom;width:5.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">65</p></td></tr><tr><td style="vertical-align:bottom;width:8.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:86.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:5.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:8.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item7AQuantitativeandQualitativeDisclosu"><span style="font-style:normal;font-weight:normal;">Item 7A.</span></a></p></td><td style="vertical-align:bottom;width:86.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item7AQuantitativeandQualitativeDisclosu"><span style="font-style:normal;font-weight:normal;">Quantitative and Qualitative Disclosures About Market Risk.</span></a></p></td><td style="vertical-align:bottom;width:5.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">72</p></td></tr><tr><td style="vertical-align:bottom;width:8.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:86.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:5.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:8.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item8FinancialStatementsandSupplementary"><span style="font-style:normal;font-weight:normal;">Item 8.</span></a></p></td><td style="vertical-align:bottom;width:86.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item8FinancialStatementsandSupplementary"><span style="font-style:normal;font-weight:normal;">Financial Statements and Supplementary Data.</span></a></p></td><td style="vertical-align:bottom;width:5.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">72</p></td></tr><tr><td style="vertical-align:bottom;width:8.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:86.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:5.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:8.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item9ChangesinandDisagreementswithAccoun"><span style="font-style:normal;font-weight:normal;">Item 9.</span></a></p></td><td style="vertical-align:bottom;width:86.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item9ChangesinandDisagreementswithAccoun"><span style="font-style:normal;font-weight:normal;">Changes in and Disagreements with Accountants on Accounting and Financial Disclosure.</span></a></p></td><td style="vertical-align:bottom;width:5.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">72</p></td></tr><tr><td style="vertical-align:bottom;width:8.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:86.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:5.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:8.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item9AControlsandProcedures_371514"><span style="font-style:normal;font-weight:normal;">Item 9A.</span></a></p></td><td style="vertical-align:bottom;width:86.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item9AControlsandProcedures_371514"><span style="font-style:normal;font-weight:normal;">Controls and Procedures.</span></a></p></td><td style="vertical-align:bottom;width:5.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">72</p></td></tr><tr><td style="vertical-align:bottom;width:8.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:86.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:5.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:8.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item9BOtherInformation_404053"><span style="font-style:normal;font-weight:normal;">Item 9B.</span></a></p></td><td style="vertical-align:bottom;width:86.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item9BOtherInformation_404053"><span style="font-style:normal;font-weight:normal;">Other Information.</span></a></p></td><td style="vertical-align:bottom;width:5.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">73</p></td></tr><tr><td colspan="2" style="vertical-align:bottom;width:94.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:5.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td colspan="2" style="vertical-align:bottom;width:94.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#PARTIII_953652"><b style="font-style:normal;font-weight:bold;">Part III.</b></a></p></td><td style="vertical-align:bottom;width:5.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">73</p></td></tr><tr><td style="vertical-align:bottom;width:8.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:86.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:5.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:8.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item10DirectorsandExecutiveOfficersandCo"><span style="font-style:normal;font-weight:normal;">Item 10.</span></a></p></td><td style="vertical-align:bottom;width:86.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item10DirectorsandExecutiveOfficersandCo"><span style="font-style:normal;font-weight:normal;">Directors, Executive Officers and Corporate Governance.</span></a></p></td><td style="vertical-align:bottom;width:5.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">73</p></td></tr><tr><td style="vertical-align:bottom;width:8.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:86.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:5.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:8.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item11ExecutiveCompensation_144002"><span style="font-style:normal;font-weight:normal;">Item 11.</span></a></p></td><td style="vertical-align:bottom;width:86.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item11ExecutiveCompensation_144002"><span style="font-style:normal;font-weight:normal;">Executive Compensation.</span></a></p></td><td style="vertical-align:bottom;width:5.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">73</p></td></tr><tr><td style="vertical-align:bottom;width:8.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:86.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:5.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:8.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item12SecurityOwnershipofCertainBenefici"><span style="font-style:normal;font-weight:normal;">Item 12.</span></a></p></td><td style="vertical-align:bottom;width:86.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item12SecurityOwnershipofCertainBenefici"><span style="font-style:normal;font-weight:normal;">Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters.</span></a></p></td><td style="vertical-align:bottom;width:5.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">73</p></td></tr><tr><td style="vertical-align:bottom;width:8.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:86.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:5.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:8.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item13CertainRelationshipsandRelatedTran"><span style="font-style:normal;font-weight:normal;">Item 13.</span></a></p></td><td style="vertical-align:bottom;width:86.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item13CertainRelationshipsandRelatedTran"><span style="font-style:normal;font-weight:normal;">Certain Relationships and Related Transactions and Director Independence.</span></a></p></td><td style="vertical-align:bottom;width:5.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">73</p></td></tr><tr><td style="vertical-align:bottom;width:8.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:86.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:5.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:8.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item14PrincipalAccountantsFeesandService"><span style="font-style:normal;font-weight:normal;">Item 14.</span></a></p></td><td style="vertical-align:bottom;width:86.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item14PrincipalAccountantsFeesandService"><span style="font-style:normal;font-weight:normal;">Principal Accountants Fees and Services.</span></a></p></td><td style="vertical-align:bottom;width:5.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">73</p></td></tr><tr><td colspan="2" style="vertical-align:bottom;width:94.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:5.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td colspan="2" style="vertical-align:bottom;width:94.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#PARTIV_494222"><b style="font-style:normal;font-weight:bold;">Part IV.</b></a></p></td><td style="vertical-align:bottom;width:5.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">73</p></td></tr><tr><td style="vertical-align:bottom;width:8.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:86.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:5.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:8.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item15ExhibitsandFinancialStatementSched"><span style="font-style:normal;font-weight:normal;">Item 15.</span></a></p></td><td style="vertical-align:bottom;width:86.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item15ExhibitsandFinancialStatementSched"><span style="font-style:normal;font-weight:normal;">Exhibits and Financial Statement Schedules.</span></a></p></td><td style="vertical-align:bottom;width:5.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">73</p></td></tr><tr><td style="vertical-align:bottom;width:8.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:86.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:5.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:8.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item16Form10KSummary_558755"><span style="font-style:normal;font-weight:normal;">Item 16.</span></a></p></td><td style="vertical-align:bottom;width:86.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item16Form10KSummary_558755"><span style="font-style:normal;font-weight:normal;">Form 10-K Summary.</span></a></p></td><td style="vertical-align:bottom;width:5.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">75</p></td></tr><tr><td colspan="2" style="vertical-align:bottom;width:94.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:5.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td colspan="2" style="vertical-align:bottom;width:94.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#SIGNATURES_225846"><span style="font-style:normal;font-weight:normal;">Signatures.</span></a></p></td><td style="vertical-align:bottom;width:5.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">76</p></td></tr><tr><td colspan="2" style="vertical-align:bottom;width:94.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:5.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td colspan="2" style="vertical-align:bottom;width:94.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#IndextoFinancialStatements"><span style="font-style:normal;font-weight:normal;">Index to Financial Statements.</span></a></p></td><td style="vertical-align:bottom;width:5.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">F-1</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">1</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_6b9a0943_493d_42ab_ae84_4fcf8dc079e5"></a><a id="CautionaryNoteRegardingForwardLookingSta"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Cautionary Note&#160;Regarding Forward-Looking Statements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">This Annual Report on Form&#160;10-K contains forward-looking statements, within the meaning of the U.S. Private Securities Litigation Reform Act of 1995, that involve substantial risks and uncertainties. In some cases, you can identify forward-looking statements by the words &#8220;anticipate,&#8221; &#8220;believe,&#8221; &#8220;continue,&#8221; &#8220;could,&#8221; &#8220;estimate,&#8221; &#8220;expect,&#8221; &#8220;intend,&#8221; &#8220;may,&#8221; &#8220;might,&#8221; &#8220;objective,&#8221; &#8220;ongoing,&#8221; &#8220;plan,&#8221; &#8220;predict,&#8221; &#8220;project,&#8221; &#8220;potential,&#8221; &#8220;should,&#8221; &#8220;will,&#8221; or &#8220;would,&#8221; and or the negative of these terms, or other comparable terminology intended to identify statements about the future. These statements involve known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance or achievements to be materially different from the information expressed or implied by these forward-looking statements. Although we believe that we have a reasonable basis for each forward-looking statement contained in this Annual Report on Form&#160;10-K, we caution you that these statements are based on a combination of facts and factors currently known by us and our expectations of the future, about which we cannot be certain.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The forward-looking statements in this Annual Report on Form&#160;10-K include, among other things, statements about:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our business strategies;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the timing of regulatory submissions;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our ability to obtain and maintain regulatory approval of our existing product candidates and any other product candidates we may develop, and the labeling under any approval we may obtain;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">risks relating to the timing and costs of clinical trials and the timing and costs of other expenses;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">risks related to market acceptance of products;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">risks associated with our reliance on third-party organizations;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our competitive position;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">assumptions regarding the size of the available market, product pricing and timing of commercialization of our product candidates;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our intellectual property position and our ability to maintain and protect our intellectual property rights;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our results of operations, financial condition, liquidity, prospects, and growth strategies;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our cash needs and financing plans;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the industry in which we operate; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the trends that may affect the industry or us.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">You should refer to Part&#160;I,&#160;Item&#160;1A &#8220;Risk Factors&#8221; of this Annual Report on Form&#160;10-K for a discussion of important factors that may cause our actual results to differ materially from those expressed or implied by our forward-looking statements. As a result of the risks, uncertainties and assumptions described under &#8220;Risk Factors&#8221; and elsewhere, we cannot assure you that the forward-looking statements in this Annual Report on Form&#160;10-K will prove to be accurate. Furthermore, if our forward-looking statements prove to be inaccurate, the inaccuracy may be material. In light of the significant uncertainties in these forward-looking statements, you should not regard these statements as a representation or warranty by us or any other person that we will achieve our objectives and plans in any specified time frame or at all.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">2</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">You should not rely upon forward-looking statements as predictions of future events. Although we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee that the future results, levels of activity, performance, or events and circumstances reflected in the forward-looking statements will be achieved or occur. We undertake no obligation to update publicly any forward-looking statements for any reason after the date of this report to conform these statements to new information, actual results or changes in our expectations, except as required by law.</p><a id="SummaryofRiskFactors_151760"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Summary of Risk Factors.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The following is a summary of the principal risks described below in Part I, Item 1A &#8220;Risk Factors&#8221; in this Annual Report on Form 10-K. We believe that the risks described in the &#8220;Risk Factors&#8221; section are material to investors, but other factors not presently known to us or that we currently believe are immaterial may also adversely affect us. The following summary should not be considered an exhaustive summary of the material risks facing us, and it should be read in conjunction with the &#8220;Risk Factors&#8221; section and the other information contained in this Annual Report on Form 10-K .</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">We have incurred significant net losses since inception and anticipate that we will continue to incur net losses for the foreseeable future and may never achieve or maintain profitability.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">We will require additional capital to fund our operations, and if we fail to obtain necessary funding, we may not be able to complete the development and commercialization of our product candidates.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">We are heavily dependent on the success of Buntanetap, our lead product candidate, which was formerly called ANVS401, which is still under clinical development, and if it does not receive regulatory approval or is not successfully commercialized, our business may be harmed.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">We have concentrated our research and development efforts on the treatment of Alzheimer&#8217;s disease and Parkinson&#8217;s disease, both of which have seen limited success in drug development.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Clinical trials are expensive, time-consuming, difficult to design and implement, and involve an uncertain outcome.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Results of preclinical studies and early clinical trials may not be indicative of results obtained in later trials or later phases of trials.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">We face significant competition from other biotechnology and pharmaceutical companies and our operating results will suffer if we fail to compete effectively.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">The successful commercialization of Buntanetap and any other product candidates we develop will depend in part on market acceptance; the extent to which governmental authorities and health insurers establish adequate coverage, reimbursement levels, and pricing policies; and our sales, marketing and distribution capabilities. </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">We currently rely on third-parties for the production of clinical supply of Buntanetap and for the conduct, supervision and monitoring of our clinical trials. If those third parties do not successfully carry out their contractual duties, or if they perform in an unsatisfactory manner, it may harm our business.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Enacted and future healthcare and other legislation may increase the difficulty and cost for us to obtain marketing approval of and commercialize our product candidates, if approved, increase the liabilities to which we may become subject, and affect the prices we may set or the manner in which we conduct and plan to conduct our business.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">If we are unable to obtain, maintain and defend patent protection for our technology and products or if the scope of the patent protection obtained is not sufficiently broad, we may not be able to compete effectively in our target markets.</span></td></tr></table><div style="margin-top:10pt;"></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">3</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_730db6dd_a6eb_41ff_9f93_1b895d41fe0b"></a><a id="PARTI_289954"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">PART I</b></p><a id="Item1Business_749608"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.37;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">Item 1. Business.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.37;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">Our Company</b></p><a id="_Hlk64273646"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="white-space:pre-wrap;">Annovis Bio, Inc. is a clinical stage, drug platform company addressing neurodegeneration, such as Alzheimer&#8217;s disease (&#8220;AD&#8221;) and Parkinson&#8217;s disease (&#8220;PD&#8221;). We are developing our lead compound, Buntanetap, formerly called ANVS401, for AD, PD and other chronic neurodegenerative diseases, including AD in Down syndrome (&#8220;AD-DS&#8221;). Buntanetap is a small, once a day, orally administered, brain penetrant compound.  In several studies, Buntanetap inhibited the synthesis of neurotoxic proteins&#8212;APP/A&#946; (&#8220;APP&#8221;), tau/phospho-tau (&#8220;tau&#8221;) and &#945;-Synuclein (&#8220;&#945;SYN&#8221;)&#8212;that are the main cause of neurodegeneration. High levels of neurotoxic proteins lead to impaired axonal transport, which is responsible for the communication between and within nerve cells. When that communication is impaired, the immune system is activated and attacks the nerve cells, eventually killing them. We have shown in our clinical and pre-clinical studies that Buntanetap lowered neurotoxic protein levels leading to improved axonal transport, reduced inflammation, lower nerve cell death and improved function.</span></p><a id="_Hlk64273790"></a><a id="_Hlk64273755"></a><a id="_Hlk64273716"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="white-space:pre-wrap;">We recently completed two Phase 2a clinical trials. In 2021 we completed a Phase 2a clinical trial in 14 AD and 54 PD patients (the &#8220;AD/PD Trial&#8221;) which began treating patients in August 2020.  In collaboration with the Alzheimer&#8217;s Disease Cooperative Study (&#8220;ADCS&#8221;) we conducted a trial in 16 early AD patients (the &#8220;ADCS Trial&#8221;). Both clinical trials were double-blind, placebo-controlled studies. We designed the two Phase 2a studies by applying our understanding of the underlying disease states in neurodegeneration and measured not just target, but also pathway validation in the spinal fluid of these patients. In addition to meeting its primary and secondary endpoints, our AD/PD Trial </span>met exploratory endpoints of measures of biomarkers and improvements in cognition in AD patients and function in PD patients. Since the completion of the AD/PD Trial, we submitted data to the <span style="white-space:pre-wrap;">U.S. Food and Drug Administration (&#8220;FDA&#8221;) and requested direction to further pursue the development of Buntanetap in PD patients. Following that guidance, we plan to initiate a Phase 3 study in early PD patients in the first half of 2022, and to initiate a Phase 3 study in advanced PD patients following an interim analysis of data from the Phase 3 study in early PD patients.  We also plan to continue the development of Buntanetap for AD after we have received FDA feedback on our AD program.  By the end of 2024, we expect to have conducted the foregoing three pivotal studies for Buntanetap, and to have filed one new drug application (&#8220;NDA&#8221;) with the FDA.</span></p><a id="_Hlk64273808"></a><a id="_Hlk64273772"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We believe that we are the only company developing a drug for AD and PD that inhibits more than one neurotoxic protein and has a mechanism of action designed to restore nerve cell axonal and synaptic activity. By improving axonal transport in the brain, we expect to treat memory loss and dementia associated with AD as well as body and brain function in PD. We believe that Buntanetap has the potential to be the first drug to interfere with the underlying mechanism of neurodegeneration. The industry has encountered challenges in targeting specifically one or the other neurotoxic protein, be it APP, tau or &#945;SYN, indicating that targeting one neurotoxic protein alone does not change the course of neurodegeneration. Our goal is to develop a disease modifying drug (&#8220;DMD&#8221;) for patients with neurodegeneration by leveraging our clinical and pre-clinical data in inhibiting at least the three most relevant neurotoxic proteins. AD and PD are two of the largest medical needs of the aging U.S. population, and two potentially large markets, once a DMD has been developed and approved. We desire to demonstrate Buntanetap&#8217;s efficacy in both indications. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Mechanism of Action</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Our lead compound, Buntanetap, is an oral translational inhibitor of neurotoxic aggregating proteins (&#8220;TINAP&#8221;). It inhibits the translation of APP, tau and &#945;SYN. To understand how it inhibits translation, we undertook two complementary approaches: a macro approach to examine all proteins in the cell whose translation is affected by Buntanetap and a micro approach to study the mechanism of action using molecular biology to understand and validate the binding and function.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">4</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;min-height:273pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">First, the non-biased proteomics approach was applied to explore what proteins in the total protein universe were specifically downregulated by Buntanetap. The results demonstrated that, in addition to the proteins already known to be reduced by Buntanetap, other neurotoxic aggregating proteins - huntingtin protein (&#8220;HTT&#8221;) and TDP43 - were downregulated as well.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">A detailed analysis of the reduction of these protein levels was conducted in five different laboratories using multiple methodologies. It revealed that the mRNAs of these proteins have a special region, an atypical stem loop, that is preserved and responsible for their translation. When this region is bound to an RNA binding protein, the mRNA is not translated. When this region is free, the mRNA is translated. In neurodegenerative conditions, the mRNA coding for these neurotoxic proteins is over-translated, produces high levels of these proteins and causes them to become toxic. Buntanetap specifically increases the affinity between this special region and the RNA binding protein, thereby preventing the mRNA from being released and translated. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">This leads to lower translation, lower levels of neurotoxic proteins, and less toxicity in the brain. By preventing the overexpression of these neurotoxic proteins, Buntanetap reverses the downstream toxic cascade that leads to neurodegeneration and reinstates homeostasis. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">This rigorous approach to understanding the mode of action shows that while Buntanetap does lower the levels of more than one neurotoxic protein, it is exquisitely specific for the atypical stem loops in the mRNAs of these proteins.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The following illustration shows the mechanism of action of Buntanetap:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><img src="anvs-20211231x10k003.jpg" alt="Graphical user interface, application, Teams&#10;&#10;Description automatically generated" style="display:inline-block;height:272.25pt;left:0%;padding-bottom:0.75pt;position:relative;top:0pt;width:417pt;" /></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 18pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The special region in the mRNA is a 5&#8217;UTR iron responsive element (&#8220;IRE&#8221;) present in all mRNAs of neurotoxic aggregating proteins. The RNA binding protein is the Iron Regulatory Protein -1 (&#8220;IRP1&#8221;) that specifically binds the IREs of neurotoxic aggregating proteins.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">5</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;min-height:263.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.37;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">The Toxic Cascade Leading to Nerve Cell Death and Loss of Function</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The toxic cascade in neurodegeneration begins with high levels of neurotoxic proteins which lead to impaired axonal transport, inflammation, death of nerve cells and loss of cognition and motor function. Buntanetap and ANVS405 have a mechanism of action we believe to be unique that allows them to inhibit the over-translation of and reduce the levels of APP, tau and &#945;SYN, which play a central role in the pathogenesis of both AD and PD. That leads us to believe that Buntanetap is a promising drug for the treatment of both AD and PD. Our approach is innovative in that we do not have a single therapeutic target for a single disease; instead, we are developing one drug that targets the mRNAs of multiple neurotoxic proteins, applicable to multiple diseases.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.37;margin:0pt 0pt 10pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.37;margin:0pt 0pt 10pt 0pt;"><img src="anvs-20211231x10k004.jpg" alt="Graphical user interface, text, application&#10;&#10;Description automatically generated" style="display:inline-block;height:263.25pt;left:0%;padding-bottom:0pt;position:relative;top:0pt;width:467.58pt;" /></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In our AD/PD Trial, we showed that Buntanetap reduced levels of neurotoxic proteins, improved axonal transport and synaptic function, reduced inflammation, improved the health of nerve cells and improved cognition and function in AD and PD patients.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="white-space:pre-wrap;">In animals we have seen that by reducing the levels of multiple neurotoxic proteins, Buntanetap reversed the toxic cascade. We have been able to reverse the entire toxic cascade in animals and recover function, be it in the brain, the body, or the eyes.  </span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">6</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;min-height:191.06pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.37;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">Pipeline</b></p><a id="_Hlk64273925"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Our pipeline consists of: Buntanetap for chronic neurodegeneration - including AD and PD; ANVS405 to treat acute neurodegeneration &#8211; including traumatic brain injury (&#8220;TBI&#8221;) and stroke; and ANVS301 for advanced AD. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><img src="anvs-20211231x10k005.jpg" alt="Graphic" style="display:inline-block;height:191.06pt;left:0%;padding-bottom:0pt;position:relative;top:0pt;width:382.1pt;" /></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.37;margin:0pt 0pt 10pt 0pt;"><span style="font-style:italic;font-weight:bold;">Buntanetap</span></p><a id="_Hlk64273969"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Our lead compound, Buntanetap, is an orally administered drug being developed for chronic indications such as AD and PD because in preclinical studies it improved axonal transport in these diseases by inhibiting the overproduction of neurotoxic proteins that kill nerve cells. The compound was tested in three Phase 1 clinical studies that showed it to be well tolerated. This safety data is applicable to the clinical development of Buntanetap for AD, PD and other chronic neurodegenerative disorders. We have completed two Phase 2a clinical trials for Buntanetap.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.37;margin:0pt 0pt 10pt 0pt;"><span style="font-style:italic;font-weight:bold;">ANVS405</span></p><a id="_Hlk64274024"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">For acute indications, we are developing ANVS405, focused on protecting the brain after TBI and/or stroke. ANVS405 is the same compound as Buntanetap but it is given intravenously in cases of acute head and brain trauma. ANVS405 was given to rats as an injectable after TBI to ensure that it would reach the brain in less than 15 minutes rather than 1.5 hours. TBI rats that were treated with ANVS405 after the insult exhibited enhanced memory and learning and lower microglia activation, a measure of inflammation. The program has been funded by a grant from the U.S. Army which has been completed, and we plan to seek additional grant funding to further the development of ANVS405 for acute indications of brain and nerve trauma. We plan to conduct a follow-on study to evaluate the effect of ANVS405 administered to TBI rats at various intervals post-injury to determine how long after a TBI we can effectively treat a patient. We would then seek further funding to conduct the toxicology and pharmacokinetics (&#8220;PK&#8221;) studies in animals, file the initial new drug application (&#8220;IND&#8221;), conduct the safety and PK studies in humans and continue with Phase 2 and Phase 3 efficacy studies.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.37;margin:0pt 0pt 10pt 0pt;"><span style="font-style:italic;font-weight:bold;">ANVS301</span></p><a id="_Hlk64274065"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We are developing our compound ANVS301 to increase cognitive capability in later stages of AD and dementia. ANVS301 improved memory and learning in very old rats by lowering the number of errors from six to three and shortening run times from approximately 75 to approximately 28 seconds. ANVS301 is in a Phase 1 clinical trial that is being conducted and financed by the National Institutes of Health (&#8220;NIH&#8221;). The single ascending dose study is nearly complete and we, in collaboration with the NIH, are preparing to move into the multiple ascending dose study. When the single and multiple ascending dose safety studies are complete, we will review the data and decide whether to pursue the indication of advanced AD.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">7</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;min-height:147pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.37;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">Clinical Trials</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.37;margin:0pt 0pt 10pt 0pt;"><span style="font-style:italic;font-weight:bold;">Phase 2 AD/PD Trial</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="white-space:pre-wrap;">In 2021, we completed a Phase 2a clinical trial of Buntanetap in 14 AD and 54 PD patients (the &#8220;AD/PD Trial&#8221;) which was conducted in 12 sites in the U.S.  The AD/PD Trial was a double-blind placebo-controlled study which treated mild to moderate AD and PD patients for approximately 25 days.  The study was designed to assess the safety, tolerability, and PK of Buntanetap.  The study met its primary and secondary endpoints.  The study also met exploratory endpoints of measures of biomarkers and improvements in cognition in AD patients and function in PD patients.  </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="white-space:pre-wrap;">The study was conducted in two parts.  The first part of the trial was in 14 AD patients and 14 PD patients.  Patients were randomly assigned to receive either 80 mg of Buntanetap or placebo once per day.  The second part of the trial was a dose response analysis in 40 PD patients in which patients were randomly assigned to receive 5 mg, 10 mg, 20 mg, or 40 mg of Buntanetap once per day. In all patients, we measured levels of neurotoxic proteins, neurotransmitters, neurotrophic factors, inflammation, and nerve cell death as well as cognitive and functional improvements.  </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Safety and PK</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="white-space:pre-wrap;">Safety results show that Buntanetap was safe and well-tolerated in all dose groups.  No series adverse events were reported. PK parameters for Buntanetap in plasma of AD and PD patients were similar to those seen in Phase 1 in our single ascending dose (&#8220;SAD&#8221;) and multiple ascending dose (&#8220;MAD&#8221;) studies in healthy volunteers and in a proof-of-concept study in mild-cognitive impaired (&#8220;MCI&#8221;) patients.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Reduction of Neurotoxic Proteins</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Buntanetap administration for 25 days lowered secreted APP &#945; and &#946; as well as total-tau and phosphorylated-tau levels in AD patients and alpha-synuclein levels in PD patients. APP and its downstream products and tau are the neurotoxic proteins involved in AD while &#945;SYN is the primary neurotoxic culprit of PD.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Changes in Biomarkers After 25 Days Treatment with Buntanetap</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><img src="anvs-20211231x10k006.jpg" alt="A picture containing chart&#10;&#10;Description automatically generated" style="display:inline-block;height:147pt;left:0%;padding-bottom:0pt;position:relative;top:0pt;width:450.75pt;" /></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">* All values are in comparison to placebo based on all data points.</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Cerebrospinal fluid (&#8220;CSF&#8221;) was extracted before starting the study at baseline and at time 0 to 6 hours at the end of the study in both placebo and Buntanetap treated patients. The values from time 0 to 6 hours were pooled to lower variability and the placebo values were deducted from the treated values. In all but one case we saw that the levels in Buntanetap treated patients were lower than in placebo patients.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">8</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;min-height:164.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Inflammation</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Buntanetap reduced inflammation in both AD and PD patients, shown by Complement C3, YKL-40, GFAP and sTREM2.</p><a id="_Hlk94000917"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:center;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Changes in Inflammatory Markers after 25 Days Treatment with Buntanetap</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><img src="anvs-20211231x10k007.jpg" alt="Diagram&#10;&#10;Description automatically generated" style="display:inline-block;height:153.75pt;left:0%;padding-bottom:0pt;position:relative;top:0pt;width:437.25pt;" /></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">*All values are in comparison to placebo based on all data points.</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Again, CSF was extracted at baseline and for 6 hours after the study and the values of the placebo patients were subtracted from the Buntanetap treated patients. We see that inflammatory markers are generally reduced in both patient populations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="text-decoration-line:underline;text-decoration-style:solid;">Axonal and Synaptic Function</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Buntanetap reduced neurofilament light (&#8220;NFL&#8221;) levels in both AD and PD patients, suggesting an improvement in axonal integrity. Buntanetap also reduced neurogranin (&#8220;NG&#8221;) levels in both AD and PD, suggesting more intact synaptic functions. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:center;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Changes in Synaptic Markers after 25 Days Treatment with Buntanetap</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><img src="anvs-20211231x10k008.jpg" alt="Diagram&#10;&#10;Description automatically generated" style="display:inline-block;height:164.25pt;left:0%;padding-bottom:0pt;position:relative;top:0pt;width:438.75pt;" /></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">*All values are in comparison to placebo based on all data points.</i></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">9</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;min-height:195pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The same CSF as above was used to measure neurofilament light and neurogranin before and after treatment and to compare Buntanetap patients to placebo. In both patient populations neurofilament light and neurogranin are lower in treated than in placebo patients.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">These results confirm that Buntanetap reduces neurotoxic proteins, thus rescues axonal transport, reduces inflammation, and protects synaptic functions.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Cognition in AD Patients</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We performed ADAS-Cogs and WAIS coding tests to evaluate Buntanetap&#8217;s effects on AD patients&#8217; cognition.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 18pt;"><span style="margin-bottom:6pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:36pt;margin:0pt 0pt 12pt 18pt;"><img src="anvs-20211231x10k009.jpg" alt="Chart&#10;&#10;Description automatically generated" style="display:inline-block;height:195pt;width:142.5pt;" /></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="font-family:'Century Gothic';">* P&lt;0.05</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">ADAS-Cog11 was performed at the beginning of the study at baseline and at the end at 25 days in the Buntanetap-treated and the placebo groups. Since the study was not powered for efficacy, we were surprised to see that ADAS-Cog11 improved by 4.4 points, a statistically significant improvement of 30%. At 25 days the treated group is 3.3 points better than placebo, an improvement of 22%.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><img src="anvs-20211231x10k010.jpg" alt="Chart, bar chart&#10;&#10;Description automatically generated" style="display:inline-block;height:177pt;width:153.75pt;" /></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">10</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;min-height:219pt;"><a id="_Hlk94014177"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="font-family:'Century Gothic';">* P&lt;0.05</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The WAIS coding test measures speed in movement and thinking. Treated AD patients show a 6.6 point or 23% statistically significant improvement from baseline and a 4.9 point or 16% improvement from placebo.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Motor Function in PD Patients</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In Parkinson&#8217;s disease we pooled the original 14 PD with the additional 40 PD patients and looked at the MDS-UPDRS and WAIS coding tests to evaluate Buntanetap&#8217;s effects on PD patients&#8217; mobility and functionality. We dosed the 54 PD patients once per day either 5mg, 10mg, 20mg, 40mg or 80mg Buntanetap treatment or placebo. We found a statistically significant improvement in Part II, III and IV individually. Specifically, Part III of the MDS-UPDRS measures the motor functions and has long been used as a standard to assess drugs&#8217; effects on patients&#8217; mobility.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><img src="anvs-20211231x10k011.jpg" alt="Chart&#10;&#10;Description automatically generated with medium confidence" style="display:inline-block;height:162pt;width:192pt;" /></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="font-family:'Century Gothic';">**p&lt;0.01</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We combined the two best doses 10 and 20 mgs and all doses and saw an improvement of 3.7 (21%) for 10 and 20 mg and of 2.43 (13.4%) for all doses combined compared to baseline.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><img src="anvs-20211231x10k012.jpg" alt="Diagram&#10;&#10;Description automatically generated" style="display:inline-block;height:219pt;width:204.75pt;" /></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="font-family:'Century Gothic';">* p&lt;0.05 ** P&lt;0.01 *** P&lt;0.001</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">11</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 18pt;">In the WAIS coding test, PD patients show a statistically significant improvement both from baseline (17.1% for 10+20mg; 13.5% for all doses combined) and from placebo (27.1% for 10+20mg; 23.4% for all doses combined).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.37;margin:0pt 0pt 10pt 0pt;"><span style="font-style:italic;font-weight:bold;">ADCS Trial</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We recently completed a double-blind, placebo-controlled Phase 2a study in early AD patients in conjunction with the ADCS. We treated patients for four weeks with Buntanetap and measured target and pathway engagement in the spinal fluid. This means that we measured levels of neurotoxic proteins, neurotransmitters, neurotrophic factors, inflammation and nerve cell death as well of cognitive improvement. Since Buntanetap is a translation inhibitor, we also measured the rate of synthesis and degradation of A&#946; to show that our drug changes the speed of translation. <span style="font-style:italic;font-weight:bold;"> </span><span style="white-space:pre-wrap;">Under an agreement with UC San Diego, where ADCS is located, we contracted to provide study supplies and PK analysis at our cost but the remaining costs of the ADCS Trial are paid for by the NIH.  The study ended after 16 patients were enrolled and treated. It was conducted in six sites in the U.S., including the University of California San Diego, Johns Hopkins, Indiana University, Washington University, Cleveland Clinic, and Columbia University. Data from this trial is expected in the first half of 2022.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.37;margin:0pt 0pt 10pt 0pt;"><span style="font-style:italic;font-weight:bold;">Phase 1 Studies </span></p><a id="_Hlk64274141"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Three phase 1 clinical studies have been completed with Buntanetap. Clinical studies with single and repeated daily oral administration of Buntanetap tartrate showed Buntanetap to be well tolerated up to doses of 80 mg once a day or 60 mg four times a day. A single dose of 160 mg was associated with an increased incidence of nausea and vomiting; therefore, higher doses were not tested. Buntanetap is not an AChE inhibitor, but its N1 dimethyl metabolite has some AChE inhibitor activity and may be responsible for these observations. The only consistent adverse events (&#8220;AEs&#8221;) seen were dizziness/fainting and headaches. These effects were seen to varying degrees at all doses of Buntanetap and in the placebo group. There were no serious AEs in any of the clinical studies. In the repeat dose studies, treatment with 60 mg four times a day was not associated with any side effects not also seen in placebo.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.37;margin:0pt 0pt 10pt 0pt;"><span style="font-style:italic;font-weight:bold;">Proof-of-Concept Study in Humans</span></p><a id="_Hlk64274250"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In the human proof-of-concept (&#8220;POC&#8221;) study, four patients with MCI were treated for 10 days with Buntanetap with a dose of 60 mg four times a day (240 mg/day), which we knew from a previous safety study to be a well-tolerated level. CSF and plasma were drawn over 12 hours on Day 0 before any administration of Buntanetap and on Day 11 after the last administration of Buntanetap. During each 12-hour period, a total of nine CSF samples were taken and levels of Buntanetap and metabolites were measured in plasma and CSF at all time points.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.37;margin:0pt 0pt 10pt 0pt;"><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Pharmacokinetics</span></p><a id="_Hlk64274281"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Buntanetap&#8217;s PK in plasma corresponded to what we had seen in the previous clinical safety studies: a half-life of five hours. In CSF, however, Buntanetap showed a much longer half-life of over 12 hours. We conducted an identical experiment in rats, where it is possible to measure the PK of Buntanetap in plasma, CSF and brain. By taking the human plasma/CSF and rat plasma/CSF/brain levels, we were able to extrapolate to the human brain levels and calculate them to be eight times higher than plasma levels. This is consistent with the data we have in mice, where in several studies, Buntanetap levels were found to be approximately six to eight times higher in brain than in plasma.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Buntanetap&#8217;s extended presence in the brain is matched by an extended effect, reducing levels of APP, tau and &#945;SYN for the whole 12-hour period tested. The extended effect of Buntanetap in the four human patients was consistent with the preclinical data in rodent brains.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">The persistence of Buntanetap in the CSF and brain and the extended pharmacodynamic effect observed make Buntanetap a good candidate for once-a-day dosing. Extrapolated brain levels of Buntanetap at 60 mg four times a day were far in excess of levels we believe are required to down-regulate APP and &#945;SYN. The doses of Buntanetap needed to lower the levels of neurotoxic proteins are similar for the toxic proteins, suggesting similar dosing in AD and PD. We further compared Buntanetap brain levels of mice that showed improved memory, learning and colonic motility and </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">12</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">calculated that the optimum brain levels measured were between 150 and 500 nM. Using three different extrapolation/comparison calculations we calculated that a daily dose of 5mg to 60 mg should achieve potentially desired brain levels in humans.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.37;margin:0pt 0pt 10pt 0pt;"><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Pharmacodynamics</span></p><a id="_Hlk64274343"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Buntanetap pharmacodynamics was performed on the same 18 CSF samples taken from each person as above. Since we had data for four patients with 18 time points each, it was possible to conduct statistical analysis of the data using a repeated measure mixed model analysis of variance. The p-value represents the probability that the difference between compared groups is due to chance rather than drug effect, and when that probability is less than 5%, or p&lt;0.05, the result is considered statistically significant. FDA evidentiary standards for drug approval require that the trial design must permit a valid comparison with a control group to permit a quantitative assessment of the effect of the drug, which may include demonstration of statistical significance.</p><a id="_Hlk64274462"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.37;margin:0pt 0pt 10pt 0pt;"><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Comparison with Healthy Volunteers</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We also compared the levels found in four healthy volunteers with the levels seen in the four MCI patients before and after 10 days of Buntanetap administration. The heathy volunteers did not go through the entire study as did the MCI patients. They gave one CSF sample taken by lumbar puncture in the morning and that sample was only used to measure sAPP&#945;, sAPP&#946; and tau.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">To make the comparison as accurate as possible, we used a single measurement from the same time point in each of the mornings of Day 0 and Day 11 for each MCI patient because this was similar to the timing for the healthy volunteers. In this very limited comparison, we were able to show that all four patients experienced a decrease in sAPP&#945;, sAPP&#946; and tau. These reductions brought the average levels of sAPP&#945;, sAPP&#946; and tau in the treated MCI patients close to the average levels we measured in healthy volunteers.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We used the same 18 samples collected from the CSF of the mildly cognitive impaired patients and measured four inflammatory factors and one control factor. In accordance with our hypothesis the levels of inflammatory markers were significantly reduced. We also measured Factor FH, a complement regulatory protein, as our control factor. As we had expected, Factor FH was not downregulated by Buntanetap.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.37;margin:0pt 0pt 10pt 0pt;"><span style="font-style:italic;font-weight:bold;">Axonal Transport in Human Nerve Cells</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">When the information highway of a nerve cell slows down, the nerve cell is unable to properly communicate with other nerve cells, internal organs and the periphery and it gets sick and dies.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The transfer of information in a nerve cell is called axonal transport and when transport and synaptic transmission are impaired, the cell releases lower levels of neurotransmitters, leading to impaired nerve cell health. The sick cell is then attacked by the immune system, which is activated when it detects a sick cell, and it eventually kills the cell. Impairment in axonal transport, therefore, leads to inflammation and eventually to nerve cell death.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">13</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;min-height:255pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.37;margin:0pt 0pt 10pt 0pt;"><img src="anvs-20211231x10k013.jpg" alt="Graphic" style="display:inline-block;height:255pt;width:468pt;" /></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.37;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">Preclinical Animal Studies </b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">By inhibiting the overexpression of neurotoxic proteins, Buntanetap improved or prevented the symptoms associated with chronic as well as acute neurodegeneration in several animal models. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.37;margin:0pt 0pt 10pt 0pt;"><span style="font-style:italic;font-weight:bold;">APP/PS1 Transgenic Mouse Model of AD</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">APP/PS1 AD transgenic (&#8220;tg&#8221;) mice were treated for one month with Buntanetap, before behavioral evaluation. Buntanetap improved spatial-working memory in a 2-day radial arm water maze test in this mouse AD model at a 25 mg/kg oral dose and showed a dose response at 10 mg/kg oral dose. In the same study Buntanetap improved synaptic function and long-term potentiation in hippocampal slices at both doses in a dose-dependent fashion. Buntanetap treatment did not affect wild-type mice.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.37;margin:0pt 0pt 10pt 0pt;"><span style="font-style:italic;font-weight:bold;">Trisomic Mouse Model of AD-DS</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">DS trisomic mice display several abnormal behaviors reminiscent of AD, including memory loss. They have elevated levels of APP that has been shown in mice to contribute to deficient memory and learning, cognitive impairment as well as dementia. DS trisomic mice are used as a model for AD, because they exhibit similar deficits as seen in AD. Thus, we considered whether Buntanetap could re-establish healthy behavior in these mice like that seen in wild-type mice. We measured the rate of spontaneous alternations in a Y-maze and found that the alternation rate is significantly lower in DS trisomic mice versus wild-type mice reflecting impaired working memory. While Buntanetap treatment increased alternation rate in DS trisomic mice it had no obvious effects in wild-type mice. We also found an effect on the exploratory activity reflected by the number of arm entries, again reflecting impaired working memory. All DS trisomic mice treated with Buntanetap displayed improved working memory to a variable extent. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.37;margin:0pt 0pt 10pt 0pt;"><span style="font-style:italic;font-weight:bold;">SNCAA53T and SNCAA30P Mouse Models of PD</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">We used these PD tg mice as models of early gastrointestinal dysfunction, which is common in PD patients and precedes the onset of motor symptoms by many years to decades. Untreated PD tg mice resemble pre-Parkinson&#8217;s patients, showing symptoms of constipation by three months of age. Here we assessed the colonic motility by measuring the time required to expel a glass bead inserted into the colon at four and seven months of age. Buntanetap statistically </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">14</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">significantly (p=0.034 at four months and p=0.0001 at seven months) decreased the bead expulsion time between Buntanetap treated and placebo treated mice; thus, it improved the colonic motility of PD tg mice. Furthermore, even after we stopped treatment for nine weeks, the constipation was still reduced. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.37;margin:0pt 0pt 10pt 0pt;"><span style="font-style:italic;font-weight:bold;">TBI in Rats</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">TBI causes severe cognitive and neurological impairment, which can incapacitate the patient, reduce quality of life, and increase the risk of morbidity and mortality. TBI is known to increase the risk for neurodegenerative disorders such as AD and PD. Several studies have analyzed changes in the brain after TBI and identified up-regulation of neurotoxic proteins, such as APP, tau, and &#945;SYN.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In our study (manuscript in preparation), rats were subjected to either fluid percussion injury (&#8220;FPI&#8221;) or sham operation to one side of the brain. Three different ANVS405 doses or saline were given intraperitoneally to rats subjected to FPI for four weeks, with the first dose administered one hour post-injury. At the termination of the treatment, all the rats were first tested for their performance in the water maze, and then they were sacrificed for brain staining of living cells and determination of microglia activation. 10 mg/kg ANVS405 improved memory and learning as measured by water maze performance. Furthermore, sections of the brain were stained with tyrosine hydroxylase (&#8220;TH&#8221;), wherein TH stains only live cells. The amounts of TH immunoreactivity in the whole striatum of the brain slices were measured. The rats treated with all three doses of ANVS405 showed higher TH staining in the ipsilateral area of the brain than the vehicle treated animals. Thus, ANVS405 protects the striatum following FPI in rats. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Because FPI can induce microglial activation, we next checked whether ANVS405 would reverse this pathology. In our study, we found that ANVS405 increased the number of resting microglia and reduced the number of activated microglia.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.37;margin:0pt 0pt 10pt 0pt;"><span style="font-style:italic;font-weight:bold;">Stroke Mice</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Buntanetap was tested in a stroke model, in which mice were challenged with MCAo-induced stroke (middle carotid artery occlusion induced stoke) and after four weeks, the number of surviving neurons was quantified. After four weeks the locomotor function, behavior, and cognition of these mice were also evaluated.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Buntanetap in combination with pifithrin-&#945; (PFT-&#945;) given to mice after the induced stroke improved mice locomotor activity and cognitive function. While both treatments yielded improvements in locomotor and cognitive function, the combined Buntanetap/PFT-&#945; treatment proved able to enhance stroke-induced endogenous neurogenesis and improve the functional recovery in stroke animals. The combined treatment also significantly improved cognitive function more than the single treatment with PFT-&#945; </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.37;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">Markets</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">With a potential market for neurodegenerative diseases estimated at more than $100 billion annually, most pharma companies have a program studying some aspect of nerve and brain degeneration. None of these approaches have resulted in a drug that improves cognition. Some newer approaches target tau, whose expression is more closely associated with cognitive decline. Similarly, for PD, several companies are trying to inhibit &#945;SYN. So far, neither drugs attacking tau nor &#945;SYN have shown positive results. Hence there is an enormous need for a different disease-modifying strategy. There is more than one neurotoxic protein in the brain of AD and of PD patients, and the same neurotoxic proteins are involved in the pathogenesis of AD and PD. A significant portion of AD patients&#8217; brains display mixed PD pathology and vice versa. Therefore, just attacking one of these proteins may result in no or lower efficacy than attacking them all. We are unaware of any other person or entity that is working on inhibiting more than one neurotoxic protein and tackling more than one neurodegenerative disorder at the same time. To prove that this approach is possible, we are studying the effects of Buntanetap on the levels of several neurotoxic proteins and other surrogate markers, in parallel, in AD and PD patients. </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">15</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;min-height:175.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.37;margin:0pt 0pt 10pt 0pt;"><span style="font-style:italic;font-weight:bold;">Alzheimer&#8217;s Disease Market</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">AD is a neurodegenerative disorder with cognitive, functional, and behavioral alterations. AD is age related, and its incidence is increasing with the aging of the population. It is estimated that currently 44 million victims of AD dementia exist in the world and by 2050, more than 100 million people worldwide will be living with AD. Nearly eightfold as many people have preclinical AD as have symptomatic AD and are at risk for progressing to manifest disease. Disease modifying treatments (&#8220;DMTs&#8220;) that will prevent or delay the onset or slow the progression of AD are urgently needed. Similarly, medications to effectively improve cognition or ameliorate neuropsychiatric symptoms of patients in the symptomatic phases of AD are needed to improve memory and behavior.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.37;text-align:center;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">Increase in Incidence of AD with the Aging of the Population</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.37;text-align:center;margin:0pt 0pt 10pt 0pt;"><img src="anvs-20211231x10k014.jpg" alt="Graphic" style="display:inline-block;height:174.75pt;left:0%;padding-bottom:0.75pt;position:relative;top:0pt;width:284.25pt;" /></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.37;text-indent:36pt;margin:0pt 0pt 10pt 0pt;">AD is becoming increasingly common as the global population ages and as the health systems in developing countries improve. There is a significant need to identify drugs that prevent, delay the onset, slow the progression, or improve the symptoms of AD.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.37;margin:0pt 0pt 10pt 0pt;"><span style="font-style:italic;font-weight:bold;">Parkinson&#8217;s Disease Market</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">PD is also a progressive neurodegenerative disorder with movement and non-movement symptoms, functional, behavioral and cognitive alterations. PD, like AD, is age related and is becoming markedly more common with the aging of the world&#8217;s population. PD affects about 1% of the population over the age of 60, while in individuals over the age of 85, this prevalence reaches 5%, highlighting the impact that advancing age has on the risk of developing this condition.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">PD affects about 10 million people worldwide of which over one million are in the US. There are 60,000 new cases of PD diagnosed each year in the US. The incidence is expected to double by 2040.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The National Parkinson&#8217;s Foundation estimates that the economic burden of PD is at least $25 billion a year in the United States.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">To date, there are no available treatments capable of curing PD, with current therapies seeking only to ameliorate dopamine-related motor symptoms of the disease. No treatments to date address non-motor symptoms. There is a clear and unmet medical need for new DMTs that can slow or prevent PD progression.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">16</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.37;margin:0pt 0pt 10pt 0pt;"><span style="font-style:italic;font-weight:bold;">Alzheimer&#8217;s Disease Associated with Down Syndrome&#8212;AD-DS Market</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">DS or trisomy 21 is one of the most common causes of intellectual disability and recent national prevalence estimates suggest that 13.65 per 10,000 live births are infants with DS leading to 5,429, on average, annual DS births in the United States. Worldwide the occurrence of DS is about four to five times that.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">DS life expectancy has increased dramatically; for children with DS born in 2010, median life expectancy is estimated to be 65 years. However, along with this longer lifespan comes the prospect of a considerable increase in the risk of developing dementia associated with AD, with a prevalence of nearly 80% for those with DS who are older than 65 years. In comparison, non-DS individuals have a risk of 40 to 50% by the time they are 90 years old.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Just like in sporadic AD there is a prodromal or asymptomatic phase in DS when AD pathology progressively accumulates (30 - 40 years) but clinical signs of dementia may be delayed by up to a decade. This provides a therapeutic window or an opportunity for prevention that is unique to adults with Down syndrome. AD-DS is an orphan indication with similar symptoms to sporadic AD, but in a much younger population with accelerated disease progression.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In the U.S., AD-DS is an orphan indication because about 50,000 DS people have AD and about 120,000 are at risk to develop AD in the next 5 to 10 years.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;line-height:1.37;margin:0pt 0pt 10pt 0pt;">Mixed Pathologies Market</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In addition to the unmet need of AD and PD patients, approximately 50% of patients exhibit mixed pathologies, with some pathologies resembling AD and some resembling PD. These patients&#8217; needs are not addressed at all by the drugs presently in development for AD or PD, because these drugs target only one or the other neurotoxic protein.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Dementia is increasingly being recognized in cases of PD; such cases are termed PD dementia (&#8220;PDD&#8221;). The spread of fibrillar &#945;SYN pathology from the brainstem to limbic and neocortical structures seems to be the strongest neuropathological correlate of emerging dementia in PD. Up to 50% of patients with PDD develop sufficient numbers of A&#946; plaques and tau-containing neurofibrillary tangles for a secondary diagnosis of Alzheimer&#8217;s disease, and these pathologies may act synergistically with &#945;SYN pathology to confer a worse prognosis.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Another study looking at the incidence of mixed pathologies diagnosed community-dwelling older persons. Those with dementia most often have multiple brain pathologies, which greatly increases the odds of dementia. Specifically, in people with dementia, over 50% had multiple diagnoses (AD, PD/Lewy body dementia, PDD or infarcts). After accounting for age, persons with multiple diagnoses were almost three times more likely to exhibit dementia compared to those with one pathologic diagnosis.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">A therapy that only addresses A&#946;, tau or &#945;SYN will not help people with mixed pathologies. Since Buntanetap inhibits more than one neurotoxic protein, it is possible that by halting the cascade of toxic proteins, it might stop or slow AD, PD and mixed pathology diseases at all stages of development.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.37;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">Approaches and Competition</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.37;margin:0pt 0pt 10pt 0pt;"><span style="font-style:italic;font-weight:bold;">Alzheimer&#8217;s Disease in Orphan Indications</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="white-space:pre-wrap;">There are two orphan indications that represent AD: one is AD-DS and the other is early onset familial AD (&#8220;EOFAD&#8221;).  To date very little work has been done in these indications but several studies in AD-DS or EOFAD are planned, ongoing or completed but results have either not been published or have been negative.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.37;margin:0pt 0pt 10pt 0pt;"><span style="font-style:italic;font-weight:bold;">Alzheimer&#8217;s Disease Approaches</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">Drug development for AD has proven to be very difficult. Drugs which have been approved for the treatment of AD include cholinesterase inhibitors (tacrine, donepezil, rivastigmine, galantamine) and an N-methyl-D-aspartate </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">17</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">receptor antagonist (memantine). Many failures in AD drug development have occurred, with both small molecules and immunotherapies failing to show a drug/placebo difference or having unacceptable toxicity.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Most clinical trials conducted have addressed amyloid targets. Since A&#946; accumulates for years before the symptoms of AD are visible, some pharmaceutical companies are testing their drugs earlier, including cognitively normal people or those who have genetic profiles that place them at high risk for developing AD. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">An increasing number of agents are directed at tau-related targets. Neurofibrillary tangles are one of two major pathological hallmarks of AD. Correlation studies conducted by Braak and Braak demonstrate that neurofibrillary tangle burden more closely correlates with cognitive decline than amyloid plaque load. Several phase 3 studies conducted with tau approaches have failed. There are still several anti-tau approaches in the clinic. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In summary, at present there are no disease-modifying agents on the market. The first large effort to develop a DMD for AD has targeted A&#946;42, but all A&#946;42 approaches to date have failed. The first companies testing tau have shown negative results. Many companies have pulled out of AD research and are waiting to see what approach might have a better outcome. Since the AD brain contains several neurotoxic proteins&#8212;amyloid precursor protein and its toxic fragments A&#946;42 and IC99, a well as tau and &#945;SYN&#8212;a DMD drug needs to target more than just one toxic protein to be efficacious. We believe that Buntanetap is the only drug that satisfies this criterion.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">A concerning observation derived from a review of the AD pipeline is the lack of agents targeting the moderate to advanced stages of AD. With over 15 million people affected by AD dementia worldwide, there is an urgent need to develop more effective symptomatic treatments for moderate to advanced stage disease. The paucity of agents directed at this population represents a significant weakness of the AD drug development pipeline.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.37;margin:0pt 0pt 10pt 0pt;"><span style="font-style:italic;font-weight:bold;">Parkinson&#8217;s Disease Approaches</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="white-space:pre-wrap;">Levodopa (&#8220;L-DOPA&#8221;) was introduced for use in treating PD more than 40 years ago and remains the mainstay of therapy for improving the symptoms of the disease. Unlike dopamine, which cannot cross the blood&#8212;brain barrier, L-DOPA is effectively absorbed into the brain, where it metabolizes into dopamine. It is typically administered five times a day and works well in controlling symptoms for one to five years. Unfortunately, the effects of L-DOPA in any patient diminish with time.  There are several other drugs available to treat PD, which also seek to modulate dopamine levels. Combination drug therapy is common in PD. For instance, the use of other drug classes such as the catechol-O-methyltransferase inhibitors and the monoamine oxidase (MAO) inhibitors allow patients to reduce L-DOPA dosing levels. </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The market for PD drugs is estimated at $2 to $3 billion worldwide, despite high-volume generics. The most important current therapy for PD, L-DOPA, is prescribed as a generic. While volume growth in the category is expected to remain healthy, dollar growth will likely remain relatively flat as some of the category&#8217;s larger brands contend with generic inroads. The size of the current market reflects the absence of innovative branded therapies more than it does the medical need.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">So far, all products are at early stages of clinical development and no products have yet shown efficacy in PD patients. Although several drugs have shown potential neuroprotective ability in preclinical studies, demonstrating these effects in clinical studies remains a challenge. Beyond drug therapies, a few cell and gene therapy approaches are also being explored. Progress across these newer technology platforms has been slow. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.37;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">Intellectual Property</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We strive to protect and enhance the proprietary technologies, inventions and improvements that we believe are important to our business, including seeking, maintaining and defending patent rights, whether developed internally or licensed from third parties. Our policy is to seek to protect our proprietary position by, among other methods, pursuing and obtaining patent protection in the United States and in jurisdictions outside of the United States related to our proprietary technology, inventions, improvements, platforms and our product candidates that are important to the development and implementation of our business.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">18</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Annovis has filed four families of patents and patent applications to prolong the patent life of Buntanetap. The pending patent applications were invented and filed by Annovis and include claims directed to:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">a </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">method</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> of treating neurodegenerative diseases such as AD and PD;</span></td></tr></table><div style="margin-top:12pt;"></div><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">a method of treating and/or preventing acute brain and nerve injuries; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">a method of prevention and treatment of disease states due to metal dis-homeostasis such as AD or PD as well as other acute or chronic neurodegenerative diseases; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">a method of treating viral and bacterial infections of the brain, including COVID-19.</span></td></tr></table><div style="margin-top:10pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">As of March 1, 2022, our portfolio of patents comprised two issued U.S. patents and 29 issued foreign patents, plus 12 pending patent applications in various jurisdictions.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="white-space:pre-wrap;">The patents have expiration dates between 2031 and 2041. In August 2019, the U.S. Patent and Trademark Office (&#8220;USPTO&#8221;) granted the first of our Annovis patents covering PD and associated diseases. In March 2020, the European Patent Office (&#8220;EPO&#8221;) granted our patent for a method of treating AD.  In December 2020, the EPO approved our first patent for a method of treating acute nerve and brain injuries by administering ANVS405 after the injury.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Furthermore, we rely upon trade secrets and know-how and continuing technological innovation to develop and maintain our competitive position. We seek to protect our proprietary information, in part, using confidentiality agreements with our collaborators, employees and consultants and invention assignment agreements with our employees. We also have confidentiality agreements or invention assignment agreements with our collaborators and selected consultants. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="white-space:pre-wrap;">In November 2008 we entered into an exclusive world-wide agreement, as amended in November 2011 and May 2012, with a subsidiary of Horizon Therapeutics, PLC, which is the successor to Raptor Pharmaceuticals, Inc. and TorreyPines Therapeutics, Inc.  The agreement, among other matters, covered three classes of licensed patents with expiration dates between 2022 and 2026.  In 2021, we determined that such licensed patents were not necessary to continue our Buntanetap program, and in July 2021, we gave notice to the licensor of the termination of the license agreement which was effective October 14, 2021.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.37;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">Sales and Marketing</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Once Buntanetap is approved for AD or PD, we plan to enter into sales and marketing agreements with one or several pharmaceutical companies to sell to neurologists, geriatric specialists and to primary care physicians.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.37;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">Manufacturing</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Buntanetap is a small molecule that is manufactured using a four-step patented process. We rely on third-party contractors for manufacturing clinical supplies and plan to do so for commercial amounts also. Presently we are working with a US supplier for the manufacture of a new, large batch of good manufacturing practice (&#8220;cGMP&#8221;) active pharmaceutical ingredient and with a local supplier for the storage stability, encapsulating, blister packing, blinding and distribution of the capsules or pills to the clinical sites. This material will allow us to enter large and long-term advanced clinical studies.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.37;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">Government Regulation</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">The FDA and comparable regulatory authorities in state and local jurisdictions and in other countries impose substantial and burdensome requirements upon companies involved in the clinical development, manufacture, marketing and distribution of drugs, such as those we are developing. These agencies and other federal, state and local entities regulate, among other things, the research and development, testing, manufacture, quality control, safety, effectiveness, </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">19</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">labeling, storage, record keeping, approval, advertising and promotion, distribution, post-approval monitoring and reporting, sampling and export and import of our product candidates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.37;margin:0pt 0pt 10pt 0pt;"><span style="font-style:italic;font-weight:bold;">U.S. Government Regulation of Drug Products</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In the United States, the FDA regulates drugs under the Federal Food, Drug, and Cosmetic Act (&#8220;FDCA&#8221;) and its implementing regulations. Failure to comply with the applicable U.S. requirements at any time during the product development process, approval process or after approval, may subject an applicant to a variety of administrative or judicial sanctions, such as the FDA&#8217;s refusal to approve pending NDAs, withdrawal of an approval, imposition of a clinical hold, issuance of warning letters, product recalls, product seizures, total or partial suspension of production or distribution, injunctions, fines, refusals of government contracts, restitution, disgorgement or civil or criminal penalties.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The process required by the FDA before a drug may be marketed in the United States generally involves the following:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Completion of preclinical laboratory tests, animal studies and formulation studies in compliance with the FDA&#8217;s good laboratory practice regulations.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Submission to the FDA of an IND, which must become effective before human clinical trials may begin.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Approval by an independent institutional review board (&#8220;IRB&#8221;), at each clinical site before each trial may be initiated.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Performance of adequate and well-controlled human clinical trials in accordance with good clinical practice (&#8220;GCP&#8221;), requirements to establish the safety and efficacy of the proposed drug product for each indication.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Submission to the FDA of an NDA.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Satisfactory completion of an FDA advisory committee review, if applicable.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Satisfactory completion of an FDA inspection of the manufacturing facility or facilities at which the product is produced to assess compliance with cGMP requirements and to assure that the facilities, methods and controls are adequate to preserve the drug&#8217;s identity, strength, quality and purity.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Satisfactory completion of FDA audits of clinical trial sites to assure compliance with GCPs and the integrity of the clinical data.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Payment of user fees and securing FDA approval of the NDA.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Compliance with any post-approval requirements, including the potential requirement to implement a Risk Evaluation and Mitigation Strategy (&#8220;REMS&#8221;) and the potential requirement to conduct post-approval studies.</span></td></tr></table><div style="margin-top:10pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.37;margin:0pt 0pt 10pt 0pt;"><span style="font-style:italic;font-weight:bold;">Preclinical Studies</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Preclinical studies include laboratory evaluation of product chemistry, toxicity and formulation, as well as animal studies to assess potential safety and efficacy. An IND sponsor must submit the results of the preclinical tests, together with manufacturing information, analytical data and any available clinical data or literature, among other things, to the FDA as part of an IND. Some preclinical testing may continue even after the IND is submitted. An IND automatically becomes effective 30 days after receipt by the FDA, unless before that time the FDA raises concerns or questions related to one or more proposed clinical trials and places the clinical trial on a clinical hold. In such a case, the IND sponsor and the FDA must resolve any outstanding concerns before the clinical trial can begin. As a result, submission of an IND may not result in the FDA allowing clinical trials to initiate.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">20</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.37;margin:0pt 0pt 10pt 0pt;"><span style="font-style:italic;font-weight:bold;">Clinical Trials</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Clinical trials involve the administration of the investigational new drug to human subjects under the supervision of qualified investigators in accordance with GCP requirements, which include the requirement that all research subjects provide their informed consent in writing for their participation in any clinical trial. Clinical trials are conducted under protocols detailing, among other things, the objectives of the trial, the parameters to be used in monitoring safety, and the effectiveness criteria to be evaluated. A protocol for each clinical trial and any subsequent protocol amendments must be submitted to the FDA as part of the IND. In addition, an IRB at each institution participating in the clinical trial must review and approve the plan for any clinical trial before it initiates at that institution. Information about certain clinical trials must be submitted within specific timeframes to the NIH for public dissemination on www.clinicaltrials.gov.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.37;text-indent:36pt;margin:0pt 0pt 10pt 0pt;">Human clinical trials are typically conducted in three sequential phases, which may overlap or be combined:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Phase 1: The drug is initially introduced into healthy human subjects or patients with the target disease or condition and tested for safety, dosage tolerance, absorption, metabolism, distribution, excretion and, if possible, to gain an early indication of its effectiveness.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Phase 2: The drug is administered to a limited patient population to identify possible adverse effects and safety risks, to preliminarily evaluate the efficacy of the product for specific targeted diseases and to determine dosage tolerance and optimal dosage.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Phase 3: The drug is administered to an expanded patient population, generally at geographically dispersed clinical trial sites, in well-controlled clinical trials to generate enough data to statistically evaluate the efficacy and safety of the product for approval, to establish the overall risk-benefit profile of the product, and to provide adequate information for the labeling of the product.</span></td></tr></table><div style="margin-top:10pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Progress reports detailing the results of the clinical trials must be submitted at least annually to the FDA and more frequently if serious adverse events occur. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.37;margin:0pt 0pt 10pt 0pt;"><span style="font-style:italic;font-weight:bold;">Special FDA Expedited Review and Approval Programs</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The FDA has various programs, including fast track designation, accelerated approval, priority review, and breakthrough therapy designation, which are intended to expedite or simplify the process for the development and FDA review of drugs that are intended for the treatment of serious or life-threatening diseases or conditions and demonstrate the potential to address unmet medical needs. The purpose of these programs is to provide important new drugs to patients earlier than under standard FDA review procedures.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">To be eligible for a fast-track designation, the FDA must determine, based on the request of a sponsor, that a product is intended to treat a serious or life-threatening disease or condition and demonstrates the potential to address an unmet medical need. The FDA will determine that a product will fill an unmet medical need if it will provide a therapy where none exists or provide a therapy that may be potentially superior to existing therapy based on efficacy or safety factors. The FDA may review sections of the NDA for a fast-track product on a rolling basis before the complete application is submitted, if the sponsor provides a schedule for the submission of the sections of the NDA, the FDA agrees to accept sections of the NDA and determines that the schedule is acceptable, and the sponsor pays any required user fees upon submission of the first section of the NDA.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The FDA may give a priority review designation to drugs that offer major advances in treatment or provide a treatment where no adequate therapy exists. A priority review means that the goal for the FDA to review an application is six months, rather than the standard review of ten months under current PDUFA guidelines. Under the current PDUFA agreement, these six- and ten-month review periods are measured from the &#8220;filing&#8221; date rather than the receipt date for NDAs for new molecular entities, which typically adds approximately two months to the timeline for review and decision from the date of submission. Most products that are eligible for fast-track designation are also likely to be considered appropriate to receive a priority review.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">21</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In addition, products tested for their safety and effectiveness in treating serious or life-threatening illnesses and that provide meaningful therapeutic benefit over existing treatments may be eligible for accelerated approval and may be approved on the basis of adequate and well-controlled clinical trials establishing that the drug product has an effect on a surrogate endpoint that is reasonably likely to predict clinical benefit, or on a clinical endpoint that can be measured earlier than irreversible morbidity or mortality (&#8220;IMM&#8221;) that is reasonably likely to predict an effect on IMM or other clinical benefit, taking into account the severity, rarity or prevalence of the condition and the availability or lack of alternative treatments. As a condition of approval, the FDA may require a sponsor of a drug receiving accelerated approval to perform post-marketing studies to verify and describe the predicted effect on IMM or other clinical endpoint, and the drug may be subject to accelerated withdrawal procedures.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Moreover, under the provisions of the Food and Drug Administration Safety and Innovation Act passed in July 2012, a sponsor can request designation of a product candidate as a &#8220;breakthrough therapy.&#8221; A breakthrough therapy is defined as a drug that is intended, alone or in combination with one or more other drugs, to treat a serious or life-threatening disease or condition, and preliminary clinical evidence indicates that the drug may demonstrate substantial improvement over existing therapies on one or more clinically significant endpoints, such as substantial treatment effects observed early in clinical development. Drugs designated as breakthrough therapies are also eligible for accelerated approval. The FDA must take certain actions, such as holding timely meetings and providing advice, intended to expedite the development and review of an application for approval of a breakthrough therapy. At the completion of our two Phase 2 trials, one in PD and one in AD, Annovis will petition the FDA to classify Buntanetap as a breakthrough therapy.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Even if a product qualifies for one or more of these programs, the FDA may later decide that the product no longer meets the conditions for qualification or decide that the time period for FDA review or approval will not be shortened. We may explore some of these opportunities for our product candidates as appropriate.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.37;margin:0pt 0pt 10pt 0pt;"><span style="font-style:italic;font-weight:bold;">Orphan Drug Designation and Exclusivity</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Under the Orphan Drug Act, the FDA may designate a drug product as an &#8220;orphan drug&#8221; if it is intended to treat a rare disease or condition (generally meaning that it affects fewer than 200,000 individuals in the United States, or more in cases in which there is no reasonable expectation that the cost of developing and making a drug product available in the United States for treatment of the disease or condition will be recovered from sales of the product). A company must request orphan product designation before submitting an NDA. If the request is granted, the FDA will disclose the identity of the therapeutic agent and its potential use. Orphan product designation does not convey any advantage in or shorten the duration of the regulatory review and approval process.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">If a product with orphan status receives the first FDA approval for a disease or condition, the product generally will be receiving orphan product exclusivity. Orphan product exclusivity means that the FDA may not approve any other applications for the same product for the same indication for seven years, except in certain limited circumstances. If a drug or drug product designated as an orphan product ultimately receives marketing approval for an indication broader than what was designated in its orphan product application, it may not be entitled to exclusivity. Orphan exclusivity will not bar approval of another product under certain circumstances, including if a subsequent product with the same active ingredient for the same indication is shown to be clinically superior to the approved product on the basis of greater efficacy or safety, or providing a major contribution to patient care, or if the company with orphan drug exclusivity is not able to meet market demand. Further, the FDA may approve more than one product for the same orphan indication or disease, if the products contain different active ingredients. Moreover, competitors may receive approval of different products for the indication for which the orphan product has exclusivity or obtain approval for the same product but for a different indication for which the orphan product has exclusivity.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.37;margin:0pt 0pt 10pt 0pt;"><span style="font-style:italic;font-weight:bold;">Marketing Approval and Post-Approval Requirements</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">Assuming successful completion of the required clinical testing, the results of the preclinical and clinical studies, together with detailed information relating to the product&#8217;s chemistry, manufacture, controls and proposed labeling, among other things, are submitted to the FDA as part of an NDA requesting approval to market the product for one or more indications. In most cases, the submission of an NDA is subject to a substantial application user fee. Under </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">22</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">the Prescription Drug User Fee Act (&#8220;PDUFA&#8221;) guidelines that are currently in effect, the FDA has a goal of ten months from the date of &#8220;filing&#8221; of a standard NDA, for a new molecular entity to review and act on the submission. This review typically takes twelve months from the date the NDA is submitted to FDA because the FDA has approximately two months to make a &#8220;filing&#8221; decision.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The FDA also may require submission of a REMS plan to ensure that the benefits of the drug outweigh its risks. The REMS plan could include medication guides, physician communication plans, assessment plans, and/or elements to assure safe use, such as restricted distribution methods, patient registries, or other risk minimization tools.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The FDA conducts a preliminary review of all NDAs within the first 60 days after submission, before accepting them for filing, to determine whether they are sufficiently complete to permit substantive review. Once the submission is accepted for filing, the FDA begins an in-depth substantive review. The FDA reviews an NDA to determine, among other things, whether the drug is safe and effective and whether the facility in which it is manufactured, processed, packaged or held meets standards designed to assure the product&#8217;s continued safety, quality and purity.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Before approving an NDA, the FDA typically will inspect the facility or facilities where the product is manufactured. Additionally, before approving an NDA, the FDA may inspect one or more clinical trial sites to assure compliance with GCP requirements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The FDA may refer an application for a novel drug to an advisory committee. While the FDA is not bound by the recommendations of an advisory committee, it considers such recommendations carefully when making decisions.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">After evaluating the NDA and all related information, including the advisory committee recommendation, if any, and inspection reports regarding the manufacturing facilities and clinical trial sites, the FDA may issue an approval letter, or, in some cases, a complete response letter. A complete response letter generally contains a statement of specific conditions that must be met in order to secure final approval of the NDA and may require additional clinical or preclinical testing for the FDA to reconsider the application. If and when those conditions have been met to the FDA&#8217;s satisfaction, the FDA will typically issue an approval letter. An approval letter authorizes commercial marketing of the drug with specific prescribing information for specific indications.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Even if the FDA approves a product, it may limit the approved indications for use of the product, require that contraindications, warnings or precautions be included in the product labeling, require that post-approval studies, including Phase 4 clinical trials, be conducted to further assess a drug&#8217;s safety after approval, require testing and surveillance programs to monitor the product after commercialization, or impose other conditions, including distribution and use restrictions or other risk management mechanisms under a REMS. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Once an approval of a drug or medical device is granted, the FDA may withdraw the approval if compliance with regulatory requirements and standards is not maintained or if problems occur after the product reaches the market. Later discovery of previously unknown problems with a product, including adverse events of unanticipated severity or frequency, or with manufacturing processes, or failure to comply with regulatory requirements, may result in mandatory revisions to the approved labeling to add new safety information; imposition of post-market studies or clinical trials to assess new safety risks; or imposition of distribution or other restrictions under a REMS program. Other potential consequences include, among other things:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Restrictions on the marketing or manufacturing of the product, complete withdrawal of the product from the market or product recalls.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Fines, warning letters or holds on post-approval clinical trials.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Refusal of the FDA to approve pending NDAs or supplements to approved NDAs, or suspension or revocation of product approvals.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Product seizure or detention, or refusal to permit the import or export of products.</span></td></tr></table></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">23</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Injunctions or the imposition of civil or criminal penalties.</span></td></tr></table><div style="margin-top:10pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The FDA strictly regulates marketing, labeling, advertising and promotion of products that are placed on the market. Drugs or devices may be promoted only for the approved indications and in accordance with the provisions of the approved label. The FDA and other agencies actively enforce the laws and regulations prohibiting the promotion of off-label uses, and a company that is found to have improperly promoted off-label uses may be subject to significant liability.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.37;margin:0pt 0pt 10pt 0pt;"><span style="font-style:italic;font-weight:bold;">U.S. Coverage and Reimbursement</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Significant uncertainty exists as to the coverage and reimbursement status of our lead product candidate, Buntanetap, or any other for which we may seek regulatory approval. Sales in the U.S. will depend in part on the availability of adequate financial coverage and reimbursement from third-party payors, which include government health programs such as Medicare, Medicaid, TRICARE and the Veterans Administration, as well as managed care organizations and private health insurers. Prices at which we or our customers seek reimbursement for our product candidates can be subject to challenge, reduction or denial by payors.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The process for determining whether a payor will provide coverage for a product is typically separate from the process for setting the reimbursement rate that the payor will pay for the product. Third-party payors may limit coverage to specific products on an approved list or formulary, which might not include all the FDA-approved products for a particular indication. Also, third-party payors may refuse to include a branded drug on their formularies or otherwise restrict patient access to a branded drug when a less costly generic equivalent or another alternative is available. Medicare Part D, Medicare&#8217;s outpatient prescription drug benefit, contains protections to ensure coverage and reimbursement for oral oncology products, and all Part D prescription drug plans are required to cover substantially all oral anti-cancer agents. However, a payor&#8217;s decision to provide coverage for a product does not imply that an adequate reimbursement rate will be available. Private payors often rely on the lead of the governmental payors in rendering coverage and reimbursement determinations. Sales of Buntanetap or any other product candidates will therefore depend substantially on the extent to which the costs of our products will be paid by third-party payors. Achieving favorable coverage and reimbursement from the Centers for Medicare and Medicaid Services (&#8220;CMS&#8221;) and/or the Medicare Administrative Contractors is typically a significant gating issue for successful introduction of a new product.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Third-party payors are increasingly challenging the price and examining the medical necessity and cost-effectiveness of medical products and services, in addition to their safety and efficacy. In order to obtain coverage and reimbursement for any product that might be approved for marketing, we may need to conduct studies in order to demonstrate the medical necessity and cost-effectiveness of any products, which would be in addition to the costs expended to obtain regulatory approvals. Third-party payors may not consider our product candidates to be medically necessary or cost-effective compared to other available therapies, or the rebate percentages required to secure favorable coverage may not yield an adequate margin over cost or may not enable us to maintain price levels sufficient to realize an appropriate return on our investment in drug development.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.37;margin:0pt 0pt 10pt 0pt;"><span style="font-style:italic;font-weight:bold;">U.S. Healthcare Fraud and Abuse Laws and Compliance Requirements</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We are subject to various federal and state laws targeting fraud and abuse in the healthcare industry. These laws may impact, among other things, our proposed sales and marketing programs. In addition, we may be subject to patient privacy regulation by both the federal government and the states in which we conduct our business. The laws that may affect our operations include:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the federal Anti-Kickback Statute, which prohibits, among other things, persons from soliciting, receiving, offering or paying remuneration, directly or indirectly, in cash or in kind, to induce or reward, or in return for, either the referral of an individual for, or the purchase, order or recommendation of, an item or service reimbursable under a federal healthcare program, such as the Medicare and Medicaid programs. The term &#8220;remuneration&#8221; has been broadly interpreted to include anything of value;</span></td></tr></table></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">24</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">federal false claims and civil monetary penalties laws, including the federal civil False Claims Act, which prohibits anyone from, among other things, knowingly presenting, or causing to be presented, for payment to federal programs (including Medicare and Medicaid) claims for items or services that are false or fraudulent;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">provisions of the U.S. federal Health Insurance Portability and Accountability Act of 1996 (&#8220;HIPAA&#8221;), which created new federal criminal statutes that prohibit, among other things, knowingly and willfully executing a scheme to defraud any healthcare benefit program or making false statements in connection with the delivery of or payment for healthcare benefits, items or services. In addition, HIPAA, as amended by the Health Information Technology for Economic and Clinical Health Act and its implementing regulations, impose certain requirements relating to the privacy, security and transmission of individually identifiable health information; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the federal Physician Payment Sunshine Act requirements, under the Patient Protection and Affordable Care Act, which require manufacturers of certain drugs and biologics to track and report to CMS payments and other transfers of value they make to U.S. physicians and teaching hospitals as well as physician ownership and investment interests in the manufacturer.</span></td></tr></table><div style="margin-top:10pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.37;margin:0pt 0pt 10pt 0pt;"><span style="font-style:italic;font-weight:bold;">Regulation Outside the United States</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">To the extent that any of our product candidates, once approved, are sold in a foreign country, we may be subject to similar foreign laws and regulations, which may include, for instance, applicable post-marketing requirements, including safety surveillance, anti-fraud and abuse laws and implementation of corporate compliance programs and reporting of payments or other transfers of value to healthcare professionals.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">To market our future products in the European Economic Area (&#8220;EEA&#8221;), which is comprised of the 28 Member States of the EU plus Norway, Iceland and Liechtenstein, and many other foreign jurisdictions, we must obtain separate regulatory approvals. More concretely, in the EEA, medicinal products can only be commercialized after obtaining a Marketing Authorization (&#8220;MA&#8221;). There are two types of MAs:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">The Community MA, which is issued by the European Commission through the Centralized Procedure, based on the opinion of the Committee for Medicinal Products for Human Use of the European Medicines Agency (&#8220;EMA&#8221;) and which is valid throughout the entire territory of the EEA. The Centralized Procedure is mandatory for certain types of products, such as biotechnology medicinal products, orphan medicinal products and medicinal products indicated for the treatment of AIDS, cancer, neurodegenerative disorders, diabetes, auto-immune and viral diseases. The Centralized Procedure is optional for products containing a new active substance not yet authorized in the EEA, or for products that constitute a significant therapeutic, scientific or technical innovation or which are in the interest of public health in the EU; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">National MAs, which are issued by the competent authorities of the Member States of the EEA and only cover their respective territory, are available for products not falling within the mandatory scope of the Centralized Procedure. Where a product has already been authorized for marketing in a Member State of the EEA, this National MA can be recognized in another Member State through the Mutual Recognition Procedure. If the product has not received a National MA in any Member State at the time of application, it can be approved simultaneously in various Member States through the Decentralized Procedure.</span></td></tr></table><div style="margin-top:10pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Under the above-described procedures, before granting the MA, the EMA or the competent authorities of the Member States of the EEA assess the risk-benefit balance of the product based on scientific criteria concerning its quality, safety and efficacy.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.37;margin:0pt 0pt 10pt 0pt;"><span style="font-style:italic;font-weight:bold;">Data and Marketing Exclusivity</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">In the EEA, new products authorized for marketing, or reference products, qualify for eight years of data exclusivity and an additional two years of market exclusivity upon marketing authorization. The data exclusivity period </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">25</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">prevents generic or biosimilar applicants from relying on the pre-clinical and clinical trial data contained in the dossier of the reference product when applying for a generic or biosimilar marketing authorization in the EU during a period of eight years from the date on which the reference product was first authorized in the EU. The market exclusivity period prevents a successful generic or biosimilar applicant from commercializing its product in the EU until 10 years have elapsed from the initial authorization of the reference product in the EU. The 10-year market exclusivity period can be extended to a maximum of eleven years if, during the first eight years of those 10 years, the marketing authorization holder obtains an authorization for one or more new therapeutic indications which, during the scientific evaluation prior to their authorization, are held to bring a significant clinical benefit in comparison with existing therapies.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.37;margin:0pt 0pt 10pt 0pt;"><span style="font-style:italic;font-weight:bold;">Orphan Drug Designation</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In the EEA, a medicinal product can be designated as an orphan drug if its sponsor can establish that the product is intended for the diagnosis, prevention or treatment of a life-threatening or chronically debilitating condition affecting not more than five in ten thousand persons in the EU when the application is made, or that the product is intended for the diagnosis, prevention or treatment of a life-threatening, seriously debilitating or serious and chronic condition in the EU and that without incentives it is unlikely that the marketing of the drug in the EU would generate sufficient return to justify the necessary investment in development. For either of these conditions, the applicant must demonstrate that there exists no satisfactory method of diagnosis, prevention or treatment of the condition in question that has been authorized in the EU or, if such method exists, the drug will be of significant benefit to those affected by that condition.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In the EEA, an application for designation as an orphan product can be made any time prior to the filing of an application for approval to market the product. Marketing authorization for an orphan drug leads to a ten-year period of market exclusivity. During this market exclusivity period, the EMA or the member state competent authorities, cannot accept another application for a marketing authorization, or grant a marketing authorization, for a similar medicinal product for the same indication. The period of market exclusivity is extended by two years for medicines that have also complied with an agreed PIP.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">This period may, however, be reduced to six years if, at the end of the fifth year, it is established that the product no longer meets the criteria for orphan drug designation, for example because the product is sufficiently profitable not to justify market exclusivity. Market exclusivity can be revoked only in very selected cases, such as consent from the marketing authorization holder, inability to supply sufficient quantities of the product, demonstration of &#8220;clinical superiority&#8221; by a similar medicinal product, or, after a review by the Committee for Orphan Medicinal Products, requested by a member state in the fifth year of the marketing exclusivity period (if the designation criteria are believed to no longer apply). Medicinal products designated as orphan drugs are eligible for incentives made available by the EU and its Member States to support research into, and the development and availability of, orphan drugs.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.37;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">Human Capital Resources</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="white-space:pre-wrap;">As of February 28, 2022, we had four executives comprising three full-time employees and one consultant. We also contract with consultants and third parties for the conduct of certain clinical development, accounting and administrative activities.  We expect to hire additional employees as we advance in planned Phase 3 clinical trials.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.37;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">Corporate Information</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We were incorporated in Delaware in 2008. Our principal executive offices are located at 1055 Westlakes Drive, Suite 300, Berwyn, PA 19312 and our telephone number is (610)727 3913. Our website address is www.annovisbio.com. The inclusion of our website address is, in each case, intended to be an inactive textual reference only and not an active hyperlink to our website. The information contained in, or that can be accessed through, our website is not part of this Annual Report on Form 10-K.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">26</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_28e9c962_d843_4913_92da_2705db2e161f"></a><a id="Item1ARiskFactors_448269"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Item&#160;1A. Risk Factors</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Risks Related to Our Financial Position and Need for Additional Capital</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">We have incurred losses since inception and anticipate that we will continue to incur losses for the foreseeable future. We are not currently profitable, and we may never achieve or sustain profitability.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We are a clinical stage biopharmaceutical company with a limited operating history and have incurred losses since our formation. We incurred net losses of $14,487.1 thousand and $5,462.0 thousand for the&#160;years ended December 31, 2021 and 2020, respectively. As of December 31, 2021, we had an accumulated deficit of $28,726.2 thousand. We have not commercialized any products and have never generated revenue from the commercialization of any product. To date, we have devoted most of our financial resources to research and development, including our preclinical and clinical work, and to intellectual property.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We expect to incur significant additional operating losses for the next several&#160;years, at least, as we advance Buntanetap and any other product candidates through clinical development, complete clinical trials, seek regulatory approval and commercialize the drug or any other product candidates, if approved. The costs of advancing product candidates into each clinical phase tend to increase substantially over the duration of the clinical development process. Therefore, the total costs to advance any of our product candidates to marketing approval in even a single jurisdiction will be substantial. Because of the numerous risks and uncertainties associated with pharmaceutical product development, we are unable to accurately predict the timing or amount of increased expenses or when, or if, we will be able to begin generating revenue from the commercialization of any products or achieve or maintain profitability. Our expenses will also increase substantially if and as we:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">commence our Phase&#160;3 trials in AD and PD, or conduct clinical trials for any other product candidates;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">are required by the FDA to complete multiple Phase&#160;3 trials to support an NDA for Buntanetap in AD or in PD;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">establish a sales, marketing and distribution infrastructure to commercialize our drug, if approved, and for any other product candidates for which we may obtain marketing approval;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">maintain, expand and protect our intellectual property portfolio;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">hire additional clinical, scientific and commercial personnel;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">add operational, financial and management information systems and personnel, including personnel to support our product development and future commercialization efforts, as well as to support our requirements as a public reporting company; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">acquire or in-license or invent other product candidates or technologies.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">Furthermore, our ability to successfully develop, commercialize and license any product candidates and generate product revenue is subject to substantial additional risks and uncertainties, as described under &#8220;&#8212;Risks Related to Development, Clinical Testing, Manufacturing and Regulatory Approval&#8221; and &#8220;&#8212;Risks Related to Commercialization.&#8221; As a result, we expect to continue to incur net losses and negative cash flows for the foreseeable future. These net losses and negative cash flows have had, and will continue to have, an adverse effect on our stockholders&#8217; equity and working capital. The amount of our future net losses will depend, in part, on the rate of future growth of our expenses and our ability to generate revenues. If we are unable to develop and commercialize one or more product candidates, either alone or through collaborations, or if revenues from any product that receives marketing approval are insufficient, we will not achieve profitability. Even if we do achieve profitability, we may not be able to sustain profitability or meet outside expectations for our profitability. If we are unable to achieve or sustain profitability </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">27</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">or to meet outside expectations for our profitability, the value of our common stock will be materially and adversely affected.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">We will require additional capital to fund our operations, and if we fail to obtain necessary financing, we may not be able to complete the development and commercialization of Buntanetap.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Our operations have consumed substantial amounts of cash since inception. We expect to continue to spend substantial amounts to advance the clinical development of Buntanetap and launch and commercialize Buntanetap, if we receive regulatory approval. We will require additional capital for the further development and potential commercialization of Buntanetap and may also need to raise additional funds sooner to pursue a more accelerated development of Buntanetap. If we are unable to raise capital when needed or on attractive terms, we could be forced to delay, reduce or eliminate our research and development programs or any future commercialization efforts.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We believe that our current cash and cash equivalents and funding from existing grants will enable us to fund our operating expenses and capital expenditure requirements until at least March 31, 2023. We have based this estimate on assumptions that may prove to be wrong, and we could deploy our available capital resources sooner than we currently expect. Our future funding requirements, both near and long-term, will depend on many factors, including, but not limited to the:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">initiation, progress, timing, costs and results of preclinical studies and clinical trials, including patient enrollment in such trials, for Buntanetap or any other future product candidates;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">clinical development plans we establish for Buntanetap and any other future product candidates;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">obligation to make royalty and non-royalty sublicense receipt payments to third-party licensors, if any, under our licensing agreements;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">number and characteristics of product candidates that we discover or in-license and develop;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">outcome, timing and cost of regulatory review by the FDA and comparable foreign regulatory authorities, including the potential for the FDA or comparable foreign regulatory authorities to require that we perform more studies than those that we currently expect;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">costs of filing, prosecuting, defending and enforcing any patent claims and maintaining and enforcing other intellectual property rights;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">effects of competing technological and market developments;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">costs and timing of the implementation of commercial-scale manufacturing activities; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">costs and timing of establishing sales, marketing and distribution capabilities for any product candidates for which we may receive regulatory approval.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">If we are unable to expand our operations or otherwise capitalize on our business opportunities due to a lack of capital, our ability to become profitable will be compromised.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Raising additional capital may cause dilution to our stockholders, restrict our operations or require us to relinquish rights to our technologies or product candidates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">Until such time, if ever, as we can generate substantial revenue, we may finance our cash needs through a combination of equity offerings, debt financings, marketing and distribution arrangements and other collaborations, strategic alliances and licensing arrangements or other sources. We do not currently have any committed external source </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">28</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">of funds. In addition, we may seek additional capital due to favorable market conditions or strategic considerations, even if we believe that we have sufficient funds for our current or future operating plans.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">To the extent that we raise additional capital through the sale of equity or convertible debt securities, your ownership interest will be diluted, and the terms of these securities may include liquidation or other preferences that adversely affect your rights as a common stockholder. Debt financing and preferred equity financing, if available, may involve agreements that include covenants limiting or restricting our ability to take specific actions, such as incurring additional debt, making capital expenditures or declaring dividends. If we raise additional funds through collaborations, strategic alliances or marketing, distribution or licensing arrangements with third parties, we may be required to relinquish valuable rights to our technologies, intellectual property, future revenue streams or product candidates or grant licenses on terms that may not be favorable to us. If we are unable to raise additional funds through equity or debt financings when needed, we may be required to delay, limit, reduce or terminate product candidate development or future commercialization efforts.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">We have a limited operating history.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We were established and began operations in 2008. Our operations to date have been primarily focused on conducting preclinical and clinical studies. We have not yet demonstrated the ability to successfully complete a large-scale, pivotal clinical trial, obtain marketing approval, manufacture a commercial scale product, arrange for a third party to do so on our behalf, or conduct sales and marketing activities necessary for successful product commercialization. In addition, as a business with a limited operating history, we may encounter unforeseen expenses, difficulties, complications, delays and other known and unknown factors. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">As we continue to build our business, we expect our financial condition and operating results may fluctuate significantly from quarter to quarter and&#160;year to&#160;year due to a variety of factors, many of which are beyond our control. Accordingly, you should not rely upon the results of any particular quarterly or annual period as indications of future operating performance.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Our ability to use our net operating loss carryforwards to offset future taxable income may be subject to certain limitations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In general, under Section&#160;382 of the U.S. Internal Revenue Code of 1986, as amended (the &#8220;Code&#8221;), a corporation that undergoes an &#8220;ownership change&#8221; is subject to limitations on its ability to use its pre-change net operating loss carryforwards (&#8220;NOLs&#8221;) to offset future taxable income. Due to previous ownership changes, our ability to use our NOLs could be limited by Section&#160;382 of the Code. Future changes in our stock ownership, some of which are outside of our control, could result in an ownership change under Section&#160;382 of the Code. Furthermore, our ability to use NOLs of companies that we may acquire in the future may be subject to limitations. For these reasons, we may not be able to use a material portion of the NOLs, even if we attain profitability.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Risks Related to Development, Clinical Testing, Manufacturing and Regulatory Approval</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">We are heavily dependent on the success of Buntanetap, our most advanced product candidate, which is still under clinical development, and if this drug does not receive regulatory approval or is not successfully commercialized, our business may be harmed.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">We do not have any products that have gained regulatory approval. Currently, our lead clinical stage product candidate is Buntanetap. As a result, our business is dependent on our ability to successfully complete clinical development of, obtain regulatory approval for, and, if approved, successfully commercialize Buntanetap in a timely manner. We cannot commercialize Buntanetap in the United States without first obtaining regulatory approval from the FDA; similarly, we cannot commercialize Buntanetap outside of the United States without obtaining regulatory approval from comparable foreign regulatory authorities. Before obtaining regulatory approvals for the commercial sale of Buntanetap for a target indication, we must demonstrate with substantial evidence gathered in preclinical studies and clinical trials, generally including two adequate and well-controlled clinical trials, and, with respect to approval in the United States, to the satisfaction of the FDA, that Buntanetap is safe and effective for use for that target indication and </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">29</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">that the manufacturing facilities, processes and controls are adequate. Even if Buntanetap were to successfully obtain approval from the FDA and comparable foreign regulatory authorities, any approval might contain significant limitations related to use restrictions for specified age groups, warnings, precautions or contraindications, or may be subject to burdensome post-approval study or risk management requirements. If we are unable to obtain regulatory approval for Buntanetap in one or more jurisdictions, or any approval contains significant limitations, we may not be able to obtain sufficient funding or generate sufficient revenue to continue the development of any other product candidate that we may in-license, develop or acquire in the future. Furthermore, even if we obtain regulatory approval for Buntanetap, we will still need to develop a commercial organization, establish commercially viable pricing and obtain approval for adequate reimbursement from third-party and government payors. If we are unable to successfully commercialize Buntanetap, we may not be able to earn sufficient revenue to continue our business</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Disruptions associated with widespread health emergencies could harm our ability to complete or could materially delay our clinical trials.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">The emergence of widespread health emergencies or pandemics, such as COVID-19, could lead to quarantines, business shutdowns, labor shortages, disruptions to the healthcare system, and overall economic instability. If the suppliers, CROs, hospitals, clinical trial sites, regulators, consultants and other third parties with whom we conduct business were to experience shutdowns or other business disruptions, our ability to enroll patients and conduct our clinical trials in the manner and on the timelines presently planned could be materially and negatively impacted. In March 2020, the clinical trial sites participating in our Phase 2a trial in AD patients in collaboration with the ADCS temporarily suspended enrollment of new patients because of the ongoing COVID-<span style="white-space:pre-wrap;">19 pandemic. The trial sites have reopened and patient recruitment and treatment have resumed. In addition, due to restrictions related to COVID-19 during 2020, we experienced delays in opening clinical trial sites for our AD/PD Trial.  Although we currently believe our clinical trials will be completed on time, the extent to which the COVID-19 pandemic could have a material impact on our clinical trials is dependent on the spread of the disease and government and healthcare system responses to such spread, which are presently highly uncertain.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="white-space:pre-wrap;"> Clinical trials are expensive, time-consuming and difficult to design and implement, and involve an uncertain outcome.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Clinical testing is expensive and can take many&#160;years to complete, and its outcome is inherently uncertain. Failure can occur at any time during the clinical trial process. Because the results of preclinical studies and early clinical trials are not necessarily predictive of future results, Buntanetap and our other compounds may not have favorable results in later preclinical and clinical studies or receive regulatory approval. We may experience delays in initiating and completing any clinical trials that we intend to conduct, and we do not know whether planned clinical trials will begin on time, need to be redesigned, enroll patients on time or be completed on schedule, or at all. Clinical trials can be delayed for a variety of reasons, including delays related to:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the FDA or comparable foreign regulatory authorities disagreeing as to the design or implementation of our clinical studies;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">obtaining regulatory approval to commence a trial;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">reaching an agreement on acceptable terms with prospective contract research organizations (&#8220;CROs&#8221;), and clinical trial sites, the terms of which can be subject to extensive negotiation and may vary significantly among different CROs and trial sites;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">obtaining Institutional Review Board (&#8220;IRB&#8221;) approval at each site, or Independent Ethics Committee (&#8220;IEC&#8221;) approval at sites outside the United States;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">recruiting suitable patients to participate in a trial in a timely manner and in sufficient numbers;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">having patients complete a trial or return for post-treatment follow-up;</span></td></tr></table></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">30</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">imposition of a clinical hold by regulatory authorities, including as a result of unforeseen safety issues or side effects or failure of trial sites to adhere to regulatory requirements or follow trial protocols;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">clinical sites deviating from trial protocol or dropping out of a trial;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">addressing patient safety concerns that arise during the course of a trial;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">adding a sufficient number of clinical trial sites; or</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">manufacturing sufficient quantities of product candidate for use in clinical trials.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We could also encounter delays if a clinical trial is suspended or terminated by us, the IRBs or IECs of the institutions in which such trials are being conducted, the Data Safety Monitoring Board (&#8220;DSMB&#8221;), for such trial or the FDA or other regulatory authorities. Such authorities may impose such a suspension or termination due to a number of factors, including failure to conduct the clinical trial in accordance with regulatory requirements or our clinical protocols, inspection of the clinical trial operations or trial site by the FDA or other regulatory authorities resulting in the imposition of a clinical hold, unforeseen safety issues or adverse side effects, failure to demonstrate a benefit from using a drug, changes in governmental regulations or administrative actions or lack of adequate funding to continue the clinical trial. Furthermore, we rely on CROs and clinical trial sites to ensure the proper and timely conduct of our clinical trials and, while we have agreements governing their committed activities, we have limited influence over their actual performance, as described in &#8220;&#8212;Risks Related to Our Dependence on Third Parties.&#8221;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">The regulatory approval processes of the FDA and comparable foreign authorities are lengthy, time consuming and inherently unpredictable, and if we are ultimately unable to obtain regulatory approval for Buntanetap or any other product candidates, our business will be substantially harmed.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The time required to obtain approval by the FDA and comparable foreign authorities is unpredictable but typically takes many&#160;years following the commencement of clinical trials and depends upon numerous factors, including the substantial discretion of the regulatory authorities. In addition, approval policies, regulations or the type and amount of clinical data necessary to gain approval may change during the course of a product candidate&#8217;s clinical development and may vary among jurisdictions. We have not obtained regulatory approval for any product candidate and it is possible that we will never obtain regulatory approval for Buntanetap or any other product candidate. We are not permitted to market any of our product candidates in the United States until we receive regulatory approval of an NDA from the FDA. Approval from the FDA and comparable foreign authorities may be delayed or denied for a variety of reasons, including:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">we may be unable to demonstrate to the satisfaction of the FDA or comparable foreign regulatory authorities that a product candidate is safe and effective for its proposed indication;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">serious and unexpected drug-related side effects experienced by participants in our clinical trials or by individuals using drugs similar to our product candidates, or other products containing the active ingredient in our product candidates;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">negative or ambiguous results from our clinical trials or results that may not meet the level of statistical significance required by the FDA or comparable foreign regulatory authorities for approval;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">we may be unable to demonstrate that a product candidate&#8217;s clinical and other benefits outweigh its safety risks;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the FDA or comparable foreign regulatory authorities may disagree with our interpretation of data from preclinical studies or clinical trials;</span></td></tr></table></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">31</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the data collected from clinical trials of our product candidates may not be acceptable or sufficient to support the submission of an NDA or other submission or to obtain regulatory approval in the United States or elsewhere, and we may be required to conduct additional clinical trials;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the FDA or comparable foreign authorities may disagree regarding the formulation, labeling and/or the specifications of our product candidates;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the FDA or comparable foreign regulatory authorities may fail to approve or find deficiencies with the manufacturing processes or facilities of third-party manufacturers with which we contract for clinical and commercial supplies; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the approval policies or regulations of the FDA or comparable foreign regulatory authorities may significantly change in a manner rendering our clinical data insufficient for approval.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Prior to obtaining approval to commercialize a product candidate in the United States or abroad, we must demonstrate with substantial evidence from well-controlled clinical trials, and to the satisfaction of the FDA or foreign regulatory agencies, that such product candidates are safe and effective for their intended uses. Results from preclinical studies and clinical trials can be interpreted in different ways. Even if we believe the preclinical or clinical data for our product candidates are promising, such data may not be sufficient to support approval by the FDA and other regulatory authorities. For diseases like AD and PD, the FDA has stated that one single Phase&#160;3 trial is adequate for approval, if it demonstrates robust and unquestionable efficacy. However, the circumstances under which a single adequate and controlled study can be used as the sole basis of demonstrating efficacy of a drug are exceptional.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The FDA or any foreign regulatory bodies can delay, limit or deny approval of our product candidates or require us to conduct additional preclinical or clinical testing or abandon a program for many reasons, including:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the FDA or comparable foreign regulatory authorities may disagree with the design or implementation of our clinical trials;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the FDA or comparable foreign regulatory authorities may disagree with our safety interpretation of our drug;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the FDA or comparable foreign regulatory authorities may disagree with our efficacy interpretation of our drug;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the FDA or comparable foreign regulatory authorities may regard our CMC package as inadequate.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Of the large number of drugs in development, only a small&#160;percentage successfully complete the regulatory approval processes and are commercialized. This lengthy approval process, as well as the unpredictability of future clinical trial results, may result in our failing to obtain regulatory approval to market Buntanetap or another product candidate, which would significantly harm our business, results of operations and prospects.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In addition, the FDA or the applicable foreign regulatory agency also may approve a product candidate for a more limited indication or patient population than we originally requested, and the FDA or applicable foreign regulatory agency may approve a product candidate with a label that does not include the labeling claims necessary or desirable for the successful commercialization of that product candidate. Any of the foregoing scenarios could materially harm the commercial prospects for our product candidates.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">32</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">We have concentrated our research and development efforts on the treatment of AD and PD, diseases that have seen limited success in drug development. Further, Buntanetap is based on a new approach to treating AD and PD, which makes it difficult to predict the time and cost of development and subsequent obtaining of regulatory approval.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Efforts by biopharmaceutical and pharmaceutical companies in treating AD and PD have seen limited success in drug development, and there are no FDA-approved disease modifying therapeutic options available for patients with AD and PD. We cannot be certain that our approach will lead to the development of approvable or marketable products. The only drugs approved by the FDA to treat AD and PD to date address the diseases&#8217; symptoms. No new treatments have been approved for AD since 2003. Since 2003, over 500 clinical studies have been completed and no compound has shown efficacy. AD drug candidates have the highest failure rate of 100%, compared to 50% to 80% for all other drug candidates. As a result, the FDA has a limited set of products to rely on in evaluating Buntanetap. This could result in a longer than expected regulatory review process, increased expected development costs or the delay or prevention of commercialization of Buntanetap for the treatment of AD and PD.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Enrollment and retention of patients in clinical trials is an expensive and time-consuming process and could be made more difficult or rendered impossible by multiple factors outside our control.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The timely completion of clinical trials in accordance with their protocols depends, among other things, on our ability to enroll a sufficient number of patients who remain in the study until its conclusion. We may encounter delays in enrolling, or be unable to enroll, a sufficient number of patients to complete any of our clinical trials, and even once enrolled, we may be unable to retain a sufficient number of patients to complete any of our trials. Patient enrollment and retention in clinical trials depends on many factors, including:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the patient eligibility criteria defined in the protocol;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the size of the patient population required for analysis of the trial&#8217;s primary endpoints;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the nature of the trial protocol;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the existing body of safety and efficacy data with respect to the product candidate;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the proximity of patients to clinical sites;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our ability to recruit clinical trial investigators with the appropriate competencies and experience;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">clinicians&#8217; and patients&#8217; perceptions as to the potential advantages of the product candidate being studied in relation to other available therapies, including any new drugs that may be approved for the indications we are investigating;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">competing clinical trials being conducted by other companies or institutions;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our ability to maintain patient consents; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the risk that patients enrolled in clinical trials will drop out of the trials before completion.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Results of preclinical studies, early clinical trials or analyses may not be indicative of results obtained in later trials.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">The results of preclinical studies, early clinical trials or analyses of our product candidates may not be predictive of the results of later-stage clinical trials. Product candidates in later stages of clinical trials may fail to show the desired safety and efficacy traits despite having progressed through preclinical studies and initial clinical trials. A number of companies in the biopharmaceutical industry have suffered significant setbacks in advanced clinical trials due to lack of efficacy or adverse safety profiles, notwithstanding promising results in earlier trials. In addition, conclusions based on promising data from analyses of clinical results may be shown to be incorrect when implemented in </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">33</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">prospective clinical trials. Even if our clinical trials for Buntanetap are completed as planned, we cannot be certain that their results will support the safety and efficacy sufficient to obtain regulatory approval.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Interim &#8220;top-line&#8221; and preliminary data from our clinical trials that we announce or publish from time to time may change as more patient data become available and are subject to audit and verification procedures that could result in material changes in the final data.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">From time to time, we may publish interim &#8220;top-line&#8221; or preliminary data from our clinical studies. Interim data from clinical trials that we may complete are subject to the risk that one or more of the clinical outcomes may materially change as patient enrollment continues and more patient data become available. Preliminary or &#8220;top-line&#8221; data also remain subject to audit and verification procedures that may result in the final data being materially different from the preliminary data we previously published. As a result, interim and preliminary data should be viewed with caution until the final data are available. Adverse differences between preliminary or interim data and final data could significantly harm our business prospects.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Our product candidates may cause serious adverse events or undesirable side effects, which may delay or prevent marketing approval, or, if approved, require them to be taken off the market, require them to include safety warnings or otherwise limit their sales.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Serious adverse events or undesirable side effects caused by Buntanetap or any other product candidates could cause us or regulatory authorities to interrupt, delay or halt clinical trials and could result in a more restrictive label or the delay or denial of regulatory approval by the FDA or other comparable foreign authorities. Results of any clinical trial we conduct could reveal a high and unacceptable severity and prevalence of side effects or unexpected characteristics. Patients treated with Buntanetap to date, at high doses have experienced adverse events that include nausea and vomiting.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">If unacceptable side effects arise in the development of our product candidates, we, the FDA or the IRBs at the institutions in which our studies are conducted, or the DSMB, if constituted for our clinical trials, could recommend a suspension or termination of our clinical trials, or the FDA or comparable foreign regulatory authorities could order us to cease further development of or deny approval of a product candidate for any or all targeted indications. In addition, drug-related side effects could affect patient recruitment or the ability of enrolled patients to complete a trial or result in potential product liability claims. In addition, these side effects may not be appropriately recognized or managed by the treating medical staff. We expect to have to train medical personnel using our product candidates to understand the side effect profiles for our clinical trials and upon any commercialization of any of our product candidates. Inadequate training in recognizing or managing the potential side effects of our product candidates could result in patient injury or death. Any of these occurrences may harm our business, financial condition and prospects significantly.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Additionally, if one or more of our product candidates receives marketing approval, and we or others later identify undesirable side effects caused by such products, a number of potentially significant negative consequences could result, including:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">regulatory authorities may withdraw approvals of such product;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">regulatory authorities may require additional warnings on the label, such as a &#8220;black box&#8221; warning or contraindication;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">additional restrictions may be imposed on the marketing of the particular product or the manufacturing processes for the product or any component thereof;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">we may be required to implement a REMS or create a medication guide outlining the risks of such side effects for distribution to patients;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">we could be sued and held liable for harm caused to patients;</span></td></tr></table></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">34</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the product may become less competitive; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our reputation may suffer.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Any of these events could prevent us from achieving or maintaining market acceptance of a product candidate, if approved, and could significantly harm our business, results of operations and prospects.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">The market opportunities for Buntanetap, if approved, may be smaller than we anticipate.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We expect to initially seek approval for Buntanetap for AD and PD in the US. Our estimates of market potential have been derived from a variety of sources, including scientific literature, patient foundations and market research, and may prove to be incorrect. Even if we obtain significant market share for any product candidate, if approved, if the potential target populations are small, we may never achieve profitability without obtaining marketing approval for additional indications.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">We have never obtained marketing approval for a product candidate and we may be unable to obtain, or may be delayed in obtaining, marketing approval for any of our product candidates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We have never obtained marketing approval for a product candidate. It is possible that the FDA may refuse to accept for substantive review any NDAs that we submit for our product candidates or may conclude after review of our data that our application is insufficient to obtain marketing approval of our product candidates. If the FDA does not accept or approve our NDAs for our product candidates, it may require that we conduct additional clinical, preclinical or manufacturing validation studies and submit that data before it will reconsider our applications. Depending on the extent of these or any other FDA-required studies, approval of any NDA that we submit may be delayed or may require us to expend more resources than we have available. It is also possible that additional studies, if performed and completed, may not be considered sufficient by the FDA to approve our NDAs.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Any delay in obtaining, or an inability to obtain, marketing approvals would prevent us from commercializing our product candidates, generating revenues and achieving and sustaining profitability. If any of these outcomes occur, we may be forced to abandon our development efforts for our product candidates, which could significantly harm our business.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Even if we obtain FDA approval for Buntanetap or any other product candidates in the United States, we may never obtain approval for or commercialize Buntanetap or any other product candidates in any other jurisdiction, which would limit our ability to realize their full market potential.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In order to market any products in any particular jurisdiction, we must establish and comply with numerous and varying regulatory requirements on a country-by-country basis regarding safety and efficacy. Approval by the FDA in the United States does not ensure approval by regulatory authorities in other countries or jurisdictions. However, the failure to obtain approval in one jurisdiction may negatively impact our ability to obtain approval elsewhere. In addition, clinical trials conducted in one country may not be accepted by regulatory authorities in other countries, and regulatory approval in one country does not guarantee regulatory approval in any other country.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Approval processes vary among countries and can involve additional product testing and validation and additional administrative review periods. Seeking foreign regulatory approval could result in difficulties and increased costs for us and require additional preclinical studies or clinical trials which could be costly and time consuming. Regulatory requirements can vary widely from country to country and could delay or prevent the introduction of our products in those countries. We do not have any product candidates approved for sale in any jurisdiction, including in international markets, and we do not have experience in obtaining regulatory approval in international markets. If we fail to comply with regulatory requirements in international markets or to obtain and maintain required approvals, or if regulatory approvals in international markets are delayed, our target market will be reduced and our ability to realize the full market potential of any product we develop will be unrealized.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">35</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Even if we obtain regulatory approval for Buntanetap or any product candidates, we will still face extensive and ongoing regulatory requirements and obligations and any product candidates, if approved, may face future development and regulatory difficulties.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Any product candidate for which we obtain marketing approval, along with the manufacturing processes, post-approval clinical data, labeling, packaging, distribution, adverse event reporting, storage, recordkeeping, export, import, advertising and promotional activities for such product, among other things, will be subject to extensive and ongoing requirements of and review by the FDA and other regulatory authorities. These requirements include submissions of safety and other post-marketing information and reports, establishment registration and drug listing requirements, continued compliance with cGMP requirements relating to manufacturing, quality control, quality assurance and corresponding maintenance of records and documents, requirements regarding the distribution of samples to physicians and recordkeeping and GCP requirements for any clinical trials that we conduct post-approval.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Even if marketing approval of a product candidate is granted, the approval may be subject to limitations on the indicated uses for which the product candidate may be marketed or to the conditions of approval, including a requirement to implement a REMS.&#160;If any of our product candidates receive marketing approval, the accompanying label may limit the approved indicated use of the product candidate, which could limit sales of the product candidate. The FDA may also impose requirements for costly post-marketing studies or clinical trials and surveillance to monitor the safety or efficacy of a product. The FDA closely regulates the post-approval marketing and promotion of drugs to ensure drugs are marketed only for the approved indications and in accordance with the provisions of the approved labeling. The FDA imposes stringent restrictions on manufacturers&#8217; communications regarding off-label use, and if we market our products for uses beyond their approved indications, we may be subject to enforcement action for off-label marketing. Violations of the FDCA relating to the promotion of prescription drugs may lead to FDA enforcement actions and investigations alleging violations of federal and state healthcare fraud and abuse laws, as well as state consumer protection laws.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In addition, later discovery of previously unknown adverse events or other problems with our products, manufacturers or manufacturing processes or failure to comply with regulatory requirements, may yield various results, including:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">restrictions on manufacturing such products;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">restrictions on the labeling or marketing of products;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">restrictions on product distribution or use;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">requirements to conduct post-marketing studies or clinical trials;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">warning letters or untitled letters;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">withdrawal of the products from the market;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">refusal to approve pending applications or supplements to approved applications that we submit;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">recall of products;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">fines, restitution or disgorgement of profits or revenues;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">suspension or withdrawal of marketing approvals;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">refusal to permit the import or export of our products;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">product seizure; or</span></td></tr></table></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">36</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">injunctions or the imposition of civil or criminal penalties.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Further, the FDA&#8217;s policies may change, and additional government regulations may be enacted that could prevent, limit or delay regulatory approval of our product candidates. If we are slow or unable to adapt to changes in existing requirements or the adoption of new requirements or policies, or if we are not able to maintain regulatory compliance, we may lose any marketing approval that we may have obtained, which would adversely affect our business, prospects and ability to achieve or sustain profitability.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We also cannot predict the likelihood, nature or extent of government regulation that may arise from future legislation or administrative or executive action, either in the United States or abroad. For example, certain policies of the current presidential administration may impact our business and industry. Namely, the current presidential administration has taken several executive actions, including the issuance of a number of Executive Orders, that could impose significant burdens on, or otherwise materially delay, the FDA&#8217;s ability to engage in routine regulatory and oversight activities such as implementing statutes through rulemaking, issuance of guidance, and review and approval of marketing applications. It is difficult to predict how these executive actions will be implemented, and the extent to which they will impact the FDA&#8217;s ability to exercise its regulatory authority. If these executive actions impose constraints on FDA&#8217;s ability to engage in oversight and implementation activities in the normal course, our business may be negatively impacted.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">We may seek a Breakthrough Therapy designation for Buntanetap from the FDA at the end of the two Phase&#160;2a studies in AD and PD, respectively. However, we might not receive such designation, and even if we do, such designation may not lead to a faster development or regulatory review or approval process.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We may seek a Breakthrough Therapy designation for Buntanetap or one or more of our other product candidates. A Breakthrough Therapy is defined as a drug that is intended, alone or in combination with one or more other drugs, to treat a serious condition, and preliminary clinical evidence indicates that the drug may demonstrate substantial improvement over existing therapies on one or more clinically significant endpoints, such as substantial treatment effects observed early in clinical development. For drugs that have been designated as breakthrough therapies, interaction and communication between the FDA and the sponsor of the trial can help to identify the most efficient path for clinical development while minimizing the number of patients placed in ineffective control regimens. Drugs designated as breakthrough therapies by the FDA may also be eligible for priority review if supported by clinical data at the time the NDA is submitted to the FDA.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Designation as a Breakthrough Therapy is within the discretion of the FDA. Accordingly, even if we believe that one of our product candidates meets the criteria for designation as a Breakthrough Therapy, the FDA may disagree and instead determine not to make such designation. Even if we receive Breakthrough Therapy designation, the receipt of such designation for a product candidate may not result in a faster development or regulatory review or approval process compared to drugs considered for approval under conventional FDA procedures and does not assure ultimate approval by the FDA. In addition, even if one or more of our product candidates qualify as breakthrough therapies, the FDA may later decide that the product candidates no longer meet the conditions for qualification or decide that the time period for FDA review or approval will not be shortened.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Potential product liability lawsuits against us could cause us to incur substantial liabilities and limit commercialization of any products that we may develop.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The use of Buntanetap or any other product candidates we may develop in clinical trials and the sale of any products for which we obtain marketing approval exposes us to the risk of product liability claims. Product liability claims might be brought against us by patients, healthcare providers, pharmaceutical companies or others selling or otherwise coming into contact with our products. On occasion, large judgments have been awarded in class action lawsuits based on drugs that had unanticipated adverse effects. If we cannot successfully defend against product liability claims, we could incur substantial liability and costs. In addition, regardless of merit or eventual outcome, product liability claims may result in:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">impairment of our business reputation and significant negative media attention;</span></td></tr></table></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">37</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">withdrawal of participants from our clinical trials;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">significant costs to defend the litigation;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">distraction of management&#8217;s attention from our primary business;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">substantial monetary awards to patients or other claimants;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">inability to commercialize Buntanetap or any other product candidate;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">product recalls, withdrawals or labeling, marketing or promotional restrictions;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">decreased market demand for any product; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">loss of revenue.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The product liability insurance coverage we acquire in the future may not be sufficient to reimburse us for any expenses or losses we may suffer. In connection with our Phase&#160;2a clinical studies, we carry insurance for product liability claims in the United States. We intend to acquire insurance coverage to include larger clinical studies, different countries and sale of commercial products; however, we may be unable to obtain product liability insurance on commercially reasonable terms or in adequate amounts. A successful product liability claim, or series of claims, brought against us could cause our share price to decline and, if judgments exceed our insurance coverage, could adversely affect the results of our operations and business, including preventing or limiting the commercialization of any product candidates we develop.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Risks Related to Commercialization</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">We face significant competition from other biotechnology and pharmaceutical companies and our operating results will suffer if we fail to compete effectively.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The biopharmaceutical and pharmaceutical industries are highly competitive and subject to significant and rapid technological change. Our success is highly dependent on our ability to acquire, develop, and obtain marketing approval for new products on a cost-effective basis and to market them successfully. If Buntanetap is approved, we will face intense competition from a variety of businesses, including large, fully integrated pharmaceutical companies, specialty pharmaceutical companies and biopharmaceutical companies in the United States and other jurisdictions. These organizations may have significantly greater resources than we do and may conduct similar research; seek patent protection; and establish collaborative arrangements for research, development, manufacturing and marketing of products that may compete with us.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Our competitors may, among other things:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">have significantly greater name recognition, financial, manufacturing, marketing, drug development, technical, and human resources than we do, and future mergers and acquisitions in the biotechnology and pharmaceutical industries may result in even more resources being concentrated in our competitors;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">develop and commercialize products that are safer, more effective, less expensive, more convenient, or easier to administer, or have fewer or less severe effects;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">obtain quicker regulatory approval;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">implement more effective approaches to sales and marketing; or</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">form more advantageous strategic alliances.</span></td></tr></table><div style="margin-top:12pt;"></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">38</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Smaller and other early-stage companies may also prove to be significant competitors, particularly through collaborative arrangements with large and established companies. These third parties compete with us in recruiting and retaining qualified scientific and management personnel; establishing clinical trial sites and patient registration; and in acquiring technologies complementary to, or necessary for, our programs. Our commercial opportunity could be reduced or eliminated if our competitors develop and commercialize products that are more effective, have fewer or less severe side effects, or are more convenient or are less expensive than Buntanetap. Our competitors may also obtain FDA or other regulatory approval for their product candidates more rapidly than we may obtain approval for Buntanetap, which could result in our competitors establishing or strengthening their market position before we are able to enter the market.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">The successful commercialization of Buntanetap and any other product candidates we develop will depend in part on the extent to which governmental authorities and health insurers establish adequate coverage, reimbursement levels, and pricing policies. Failure to obtain or maintain coverage and adequate reimbursement for our product candidates, if approved, could limit our ability to market those products and decrease our ability to generate revenue.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The availability and adequacy of coverage and reimbursement by governmental healthcare programs such as Medicare and Medicaid, private health insurers and other third-party payors are essential for most patients to be able to afford prescription medications such as Buntanetap, if approved. Our ability to achieve acceptable levels of coverage and reimbursement for products by governmental authorities, private health insurers and other organizations will have an effect on our ability to successfully commercialize our drug and any other product candidates we develop. Assuming we obtain coverage for our product candidates by a third-party payor, the resulting reimbursement payment rates may not be adequate or may require co-payments that patients find unacceptably high. We cannot be sure that coverage and reimbursement in the United States or elsewhere will be available for our product candidates or any product that we may develop, and any reimbursement that may become available may be decreased or eliminated in the future.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Third-party payors increasingly are challenging prices charged for pharmaceutical products and services, and many third-party payors may refuse to provide coverage and reimbursement for particular drugs or biologics when an equivalent generic drug, biosimilar, or a less expensive therapy is available. It is possible that a third-party payor may consider our product candidates as substitutable and offer to reimburse patients only for the less expensive product. Even if we show improved efficacy or improved convenience of administration with our product candidates, pricing of existing drugs may limit the amount we will be able to charge for our product candidates. These payors may deny or revoke the reimbursement status of a given product or establish prices for new or existing marketed products at levels that are too low to enable us to realize an appropriate return on our investment in our product candidates. If reimbursement is not available or is available only at limited levels, we may not be able to successfully commercialize our product candidates and may not be able to obtain a satisfactory financial return on our product candidates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">There is significant uncertainty related to the insurance coverage and reimbursement of newly approved products. In the United States, third-party payors, including private and governmental payors, such as the Medicare and Medicaid programs, play an important role in determining the extent to which new drugs and biologics will be covered. The Medicare and Medicaid programs increasingly are used as models in the United States for how private payors and other governmental payors develop their coverage and reimbursement policies for drugs and biologics. Some third-party payors may require pre-approval of coverage for new or innovative devices or drug therapies before they will reimburse healthcare providers who use such therapies. It is difficult to predict at this time what third-party payors will decide with respect to the coverage and reimbursement for our product candidates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">No uniform policy for coverage and reimbursement for products exists among third-party payors in the United States. Therefore, coverage and reimbursement for products can differ significantly from payor to payor. As a result, the coverage determination process is often a time-consuming and costly process that will require us to provide scientific and clinical support for the use of our product candidates to each payor separately, with no assurance that coverage and adequate reimbursement will be applied consistently or obtained in the first instance. Furthermore, rules&#160;and regulations regarding reimbursement change frequently, in some cases at short notice, and we believe that changes in these rules&#160;and regulations are likely.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">We may also be subject to extensive governmental price controls and other market regulations outside of the United States, and we believe the increasing emphasis on cost-containment initiatives in other countries have and will </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">39</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">continue to put pressure on the pricing and usage of medical products. In many countries, the prices of medical products are subject to varying price control mechanisms as part of national health systems. Other countries allow companies to fix their own prices for medical products but monitor and control company profits.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Additional foreign price controls or other changes in pricing regulation could restrict the amount that we are able to charge for our product candidates. Accordingly, in markets outside the United States, the reimbursement for our product candidates may be reduced compared with the United States and may be insufficient to generate commercially reasonable revenue and profits.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Moreover, increasing efforts by governmental and third-party payors in the United States to cap or reduce healthcare costs may cause such organizations to limit both coverage and the level of reimbursement for newly approved products and, as a result, they may not cover or provide adequate payment for our product candidates. We expect to experience pricing pressures in connection with the sale of our product candidates due to the trend toward managed health care, the increasing influence of health maintenance organizations and additional legislative changes. The downward pressure on healthcare costs in general, particularly prescription drugs and biologics and surgical procedures and other treatments, has become intense. As a result, increasingly high barriers are being erected to the entry of new products.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Even if Buntanetap or any product candidate we develop receives marketing approval, it may fail to achieve market acceptance by physicians, patients, third-party payors or others in the medical community necessary for commercial success.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">If Buntanetap or any product candidate we develop receives marketing approval, it may nonetheless fail to gain sufficient market acceptance by physicians, patients, third-party payors and others in the medical community. If it does not achieve an adequate level of acceptance, we may not generate significant product revenues or become profitable. The degree of market acceptance of our product candidates, if approved, will depend on a number of factors, including but not limited to:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the efficacy and potential advantages compared to alternative treatments;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">effectiveness of sales and marketing efforts;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the cost of treatment in relation to alternative treatments, including any similar generic treatments;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our ability to offer our products for sale at competitive prices;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the convenience and ease of administration compared to alternative treatments;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the willingness of the target patient population to try new therapies and of physicians to prescribe these therapies;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the strength of marketing and distribution support;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the availability of third-party coverage and adequate reimbursement;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the prevalence and severity of any side effects; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">any restrictions on the use of our product together with other medications.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Because we expect sales of our product candidates, if approved, to generate substantially all of our revenues for the foreseeable future, the failure of our product candidates to find market acceptance would harm our business and could require us to seek additional financing.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">40</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">If we are unable to establish sales, marketing and distribution capabilities, we may not be successful in commercializing Buntanetap, if approved.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We do not have any infrastructure for the sales, marketing or distribution of Buntanetap, and the cost of establishing and maintaining such an organization may exceed the cost-effectiveness of doing so. In order to market and successfully commercialize our drug or any product candidate we develop, if approved, we must build our sales, distribution, marketing, managerial and other non-technical capabilities or collaborate with third parties to perform these services. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We do not anticipate having the resources in the foreseeable future to allocate to the sales and marketing of our product candidates, if approved, in certain markets overseas. Therefore, our future success will depend, in part, on our ability to enter into and maintain collaborative relationships for such capabilities, the collaborator&#8217;s strategic interest in a product and such collaborator&#8217;s ability to successfully market and sell the product. We intend to pursue collaborative arrangements regarding the sale and marketing of Buntanetap, if approved, for certain markets overseas; however, we cannot assure you that we will be able to establish or maintain such collaborative arrangements, or if able to do so, that they will have effective sales forces. To the extent that we depend on third parties for marketing and distribution, any revenues we receive will depend upon the efforts of such third parties, and there can be no assurance that such efforts will be successful.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">If we are unable to build our own sales force or negotiate a collaborative relationship for the commercialization of Buntanetap, we may be forced to delay the potential commercialization of the drug or reduce the scope of our sales or marketing activities. If we need to increase our expenditures to fund commercialization activities for Buntanetap we will need to obtain additional capital, which may not be available to us on acceptable terms, or at all. We may also have to enter into collaborative arrangements for Buntanetap at an earlier stage than otherwise would be ideal and we may be required to relinquish rights to it or otherwise agree to terms unfavorable to us. Any of these occurrences may have an adverse effect on our business, operating results and prospects.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">If we are unable to establish adequate sales, marketing and distribution capabilities, we will not be successful in commercializing our product candidates and may never become profitable. We will be competing with many companies that currently have extensive and well-funded marketing and sales operations. Without an internal team or the support of a third party to perform marketing and sales functions, we may be unable to compete successfully against these more established companies.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">A variety of risks associated with operating internationally could materially adversely affect our business.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We currently have no international operations, but our business strategy includes potentially expanding internationally if any of our product candidates receive regulatory approval. Doing business internationally involves a number of risks, including but not limited to:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">multiple, conflicting and changing laws and regulations, such as privacy regulations, tax laws, export and import restrictions, employment laws, regulatory requirements and other governmental approvals, permits and licenses;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">failure by us to obtain and maintain regulatory approvals for the use of our products in various countries;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">additional potentially relevant third-party patent rights;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">complexities and difficulties in obtaining protection and enforcing our intellectual property;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">difficulties in staffing and managing foreign operations;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">complexities associated with managing multiple payor reimbursement regimes, government payors or patient self-pay systems;</span></td></tr></table></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">41</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">limits in our ability to penetrate international markets;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">financial risks, such as longer payment cycles, difficulty collecting accounts receivable, the impact of local and regional financial crises on demand and payment for our products and exposure to foreign currency exchange rate fluctuations;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">natural disasters, political and economic instability, including wars, terrorism and political unrest, outbreak of disease, boycotts, curtailment of trade and other business restrictions;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">certain expenses including, among others, expenses for travel, translation and insurance; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">regulatory and compliance risks that relate to maintaining accurate information and control over sales and activities that may fall within the purview of the U.S. Foreign Corrupt Practices Act, its books and records provisions, or its anti-bribery provisions.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Any of these factors could significantly harm any future international expansion and operations and, consequently, our results of operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Risks Related to Our Dependence on Third Parties</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Our employees and independent contractors, including principal investigators, CROs, consultants, vendors, and any third parties we may engage in connection with development and commercialization, may engage in misconduct or other improper activities, including noncompliance with regulatory standards and requirements, which could have a material adverse effect on our business.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Our employees and independent contractors, including principal investigators, consultants, vendors and any third parties we may engage in connection with development and commercialization of our product candidates, could engage in misconduct, including intentional, reckless or negligent conduct or unauthorized activities that violate: the laws and regulations of the FDA or other similar regulatory requirements of other authorities, including those laws that require the reporting of true, complete and accurate information to such authorities; manufacturing standards; data privacy, security, fraud and abuse and other healthcare laws and regulations; or laws that require the reporting of true, complete and accurate financial information and data. Specifically, sales, marketing and business arrangements in the healthcare industry are subject to extensive laws and regulations intended to prevent fraud, misconduct, kickbacks, self-dealing and other abusive practices. These laws and regulations may restrict or prohibit a wide range of pricing, discounting, marketing and promotion, sales commission, customer incentive programs and other business arrangements. Activities subject to these laws could also involve the improper use or misrepresentation of information obtained in the course of clinical trials, creation of fraudulent data in preclinical studies or clinical trials or illegal misappropriation of drug product, which could result in regulatory sanctions and cause serious harm to our reputation. It is not always possible to identify and deter misconduct by employees and other third parties, and the precautions we take to detect and prevent this activity may not be effective in controlling unknown or unmanaged risks or losses or in protecting us from governmental investigations or other actions or lawsuits stemming from a failure to comply with such laws or regulations. Additionally, we are subject to the risk that a person or government could allege such fraud or other misconduct, even if none occurred. If any such actions are instituted against us and we are not successful in defending ourselves or asserting our rights, those actions could have a significant impact on our business and results of operations, including the imposition of significant civil, criminal and administrative penalties, damages, monetary fines, disgorgements, possible exclusion from participation in Medicare, Medicaid, other U.S. federal healthcare programs or healthcare programs in other jurisdictions, individual imprisonment, other sanctions, contractual damages, reputational harm, diminished profits and future earnings, and curtailment of our operations.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">42</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">We currently rely on a third-party contract manufacturing organization (&#8220;CMO&#8221;), for the production of clinical supply of Buntanetap and intend to rely on CMOs for the production of commercial supply of Buntanetap, if approved. Our dependence on CMOs may impair the development and commercialization of the drug, which would adversely impact our business and financial position.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We have limited personnel with experience in manufacturing, and we do not own facilities for manufacturing. Instead, we rely on and expect to continue to rely on CMOs for the supply of cGMP grade clinical trial materials and commercial quantities of Buntanetap and any product candidates we develop, if approved. Reliance on CMOs may expose us to more risk than if we were to manufacture our product candidates ourselves. We intend to have manufactured a sufficient clinical supply of Buntanetap drug substance to enable us to complete our clinical trials, and we have also engaged a CMO to provide clinical and commercial supply of the drug product.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The facilities used to manufacture our product candidates must be inspected by the FDA and comparable foreign authorities. While we provide oversight of manufacturing activities, we do not and will not control the execution of manufacturing activities by, and are or will be essentially dependent on, our CMOs for compliance with cGMP requirements for the manufacture of our product candidates. As a result, we are subject to the risk that our product candidates may have manufacturing defects that we have limited ability to prevent. If a CMO cannot successfully manufacture material that conforms to our specifications and the regulatory requirements, we will not be able to secure or maintain regulatory approval for the use of our product candidates in clinical trials, or for commercial distribution of our product candidates, if approved. In addition, we have limited control over the ability of our CMOs to maintain adequate quality control, quality assurance and qualified personnel. If the FDA or comparable foreign regulatory authority finds deficiencies with or does not approve these facilities for the manufacture of our product candidates or if it withdraws any such approval or finds deficiencies in the future, we may need to find alternative manufacturing facilities, which would delay our development program and significantly impact our ability to develop, obtain regulatory approval for or commercialize our product candidates, if approved. In addition, any failure to achieve and maintain compliance with these laws, regulations and standards could subject us to the risk that we may have to suspend the manufacture of our product candidates or that obtained approvals could be revoked. Furthermore, CMOs may breach existing agreements they have with us because of factors beyond our control. They may also terminate or refuse to renew their agreement at a time that is costly or otherwise inconvenient for us. If we were unable to find an adequate CMO or another acceptable solution in time, our clinical trials could be delayed, or our commercial activities could be harmed.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We rely on and will continue to rely on CMOs to purchase from third-party suppliers the raw materials necessary to produce our product candidates. We do not and will not have control over the process or timing of the acquisition of these raw materials by our CMOs. Supplies of raw material could be interrupted from time to time and we cannot be certain that alternative supplies could be obtained within a reasonable timeframe, at an acceptable cost, or at all. In addition, a disruption in the supply of raw materials could delay the commercial launch of our product candidates, if approved, or result in a shortage in supply, which would impair our ability to generate revenues from the sale of our product candidates. Growth in the costs and expenses of raw materials may also impair our ability to cost effectively manufacture our product candidates. There are a limited number of suppliers for the raw materials that we may use to manufacture our product candidates and we may need to assess alternative suppliers to prevent a possible disruption of the manufacture of our product candidates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Finding new CMOs or third-party suppliers involves additional cost and requires our management&#8217;s time and focus. In addition, there is typically a transition period when a new CMO commences work. Although we generally have not, and do not intend to, begin a clinical trial unless we believe we have on hand, or will be able to obtain, a sufficient supply of our product candidates to complete the clinical trial, any significant delay in the supply of our product candidates or the raw materials needed to produce our product candidates, could considerably delay conducting our clinical trials and potential regulatory approval of our product candidates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">As part of their manufacture of our product candidates, our CMOs and third-party suppliers are expected to comply with and respect the proprietary rights of others. If a CMO or third-party supplier fails to acquire the proper licenses or otherwise infringes the proprietary rights of others in the course of providing services to us, we may have to find alternative CMOs or third-party suppliers or defend against claims of infringement, either of which would </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">43</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">significantly impact our ability to develop, obtain regulatory approval for or commercialize our product candidates, if approved.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">We intend to rely on third parties to conduct, supervise and monitor our clinical trials. If those third parties do not successfully carry out their contractual duties, or if they perform in an unsatisfactory manner, it may harm our business.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We rely, and will continue to rely, on CROs, CRO-contracted vendors and clinical trial sites to ensure the proper and timely conduct of our clinical trials, including our two Phase&#160;2a trials of Buntanetap. Our reliance on CROs for clinical development activities limits our control over these activities, but we remain responsible for ensuring that each of our trials is conducted in accordance with the applicable protocol and legal, regulatory and scientific standards.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We and our CROs will be required to comply with the Good Laboratory Practice requirements for our preclinical studies and GCP requirements for our clinical trials, which are regulations and guidelines enforced by the FDA and are also required by comparable foreign regulatory authorities. Regulatory authorities enforce GCP requirements through periodic inspections of trial sponsors, principal investigators and clinical trial sites. If we or our CROs fail to comply with GCP requirements, the clinical data generated in our clinical trials may be deemed unreliable and the FDA or comparable foreign regulatory authorities may require us to perform additional clinical trials before approving our marketing applications. We cannot assure you that upon inspection by a given regulatory authority, such regulatory authority will determine that any of our clinical trials comply with GCP requirements. In addition, our clinical trials must be conducted with product produced under cGMP requirements. Accordingly, if our CROs fail to comply with these requirements, we may be required to repeat clinical trials, which would delay the regulatory approval process.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Our CROs are not our employees, and we do not control whether or not they devote sufficient time and resources to our clinical trials. Our CROs may also have relationships with other commercial entities, including our competitors, for whom they may also be conducting clinical trials, or other drug development activities, which could harm our competitive position. We face the risk of potential unauthorized disclosure or misappropriation of our intellectual property by CROs, which may reduce our trade secret protection and allow our potential competitors to access and exploit our proprietary technology. If our CROs do not successfully carry out their contractual duties or obligations, fail to meet expected deadlines, or if the quality or accuracy of the clinical data they obtain is compromised due to the failure to adhere to our clinical protocols or regulatory requirements or for any other reason, our clinical trials may be extended, delayed or terminated, and we may not be able to obtain regulatory approval for, or successfully commercialize any product candidate that we develop. As a result, our financial results and the commercial prospects for any product candidate that we develop would be harmed, our costs could increase, and our ability to generate revenue could be delayed.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">If our relationship with any CROs terminate, we may not be able to enter into arrangements with alternative CROs or do so on commercially reasonable terms. Switching or adding additional CROs involves substantial cost and requires management&#8217;s time and focus. In addition, there is a natural transition period when a new CRO commences work. As a result, delays occur, which can materially impact our ability to meet our desired clinical development timelines. Though we intend to carefully manage our relationships with our CROs, there can be no assurance that we will not encounter challenges or delays in the future or that these delays or challenges will not have an adverse impact on our business, financial condition and prospects.</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the number and type of our collaborations could adversely affect our attractiveness to future collaborators or acquirers; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the loss of, or a disruption in our relationship with, any one or more collaborators could harm our business.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">If any collaborations do not result in the successful development and commercialization of products or if one of our collaborators terminates its agreement with us, we may not receive any future research and development funding or milestone or royalty payments under such collaborations. If we do not receive the funding we expect under these agreements, our continued development of our product candidates could be delayed, and we may need additional resources to develop additional product candidates. All of the risks relating to product development, regulatory approval </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">44</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">and commercialization described in this Annual Report on Form&#160;10-K also apply to the activities of any collaborators and there can be no assurance that our collaborations will produce positive results or successful products on a timely basis or at all.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In addition, subject to its contractual obligations to us, if one of our collaborators is involved in a business combination or otherwise changes its business priorities, the collaborator might deemphasize or terminate the development or commercialization of our product candidates. If a collaborator terminates its agreement with us, we may find it more difficult to attract new collaborators and the perception of our business and our stock price could be adversely affected.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We may in the future collaborate with additional pharmaceutical and biotechnology companies for development and potential commercialization of therapeutic products. We face significant competition in seeking appropriate collaborators. Our ability to reach a definitive agreement for a collaboration will depend, among other things, upon our assessment of the collaborator&#8217;s resources and expertise, the terms and conditions of the proposed collaboration and the proposed collaborator&#8217;s evaluation of a number of factors. If we are unable to reach agreements with suitable collaborators on a timely basis, on acceptable terms, or at all, we may have to curtail the development of a product candidate, reduce or delay its development program or one or more of our other development programs, delay its potential commercialization or reduce the scope of any sales or marketing activities, or increase our expenditures and undertake development or commercialization activities at our own expense. If we elect to fund and undertake development or commercialization activities on our own, we may need to obtain additional expertise and additional capital, which may not be available to us on acceptable terms or at all. If we fail to enter into collaborations and do not have sufficient funds or expertise to undertake the necessary development and commercialization activities, we may not be able to further develop our product candidates or bring them to market or continue to develop our programs, and our business may be materially and adversely affected.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Risks Related to Healthcare Laws and Other Legal Compliance Matters</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Enacted and future healthcare legislation may increase the difficulty and cost for us to obtain marketing approval of and commercialize our product candidates, if approved, and may affect the prices we may set.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In the United States and other jurisdictions, there have been, and we expect there will continue to be, a number of legislative and regulatory changes and proposed changes to the healthcare system that could affect our future results of operations. In particular, there have been and continue to be a number of initiatives at the U.S. federal and state levels that seek to reduce healthcare costs and improve the quality of healthcare. For example, in March&#160;2010, the Patient Protection and Affordable Care Act, as amended by the Health Care and Education Reconciliation Act (collectively the &#8220;ACA&#8221;) was enacted, which substantially changed the way healthcare is financed by both governmental and private insurers. Among the provisions of the ACA, those of greatest importance to the pharmaceutical and biotechnology industries include the following:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">an annual, non-deductible fee payable by any entity that manufactures or imports certain branded prescription drugs and biologic agents (other than those designated as orphan drugs), which is apportioned among these entities according to their market share in certain government healthcare programs;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">a new Medicare Part&#160;D coverage gap discount program, in which manufacturers must agree to offer point-of-sale discounts off negotiated prices of applicable brand drugs to eligible beneficiaries during their coverage gap period, as a condition for the manufacturer&#8217;s outpatient drugs to be covered under Medicare Part&#160;D;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">new requirements to report certain financial arrangements with physicians and teaching hospitals, including reporting &#8220;transfers of value&#8221; made or distributed to prescribers and other healthcare providers and reporting investment interests held by physicians and their immediate family members;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">an increase in the statutory minimum rebates a manufacturer must pay under the Medicaid Drug Rebate Program;</span></td></tr></table></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">45</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">a new methodology by which rebates owed by manufacturers under the Medicaid Drug Rebate Program are calculated for drugs and biologics that are inhaled, infused, instilled, implanted, or injected;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">extension of a manufacturer&#8217;s Medicaid rebate liability to covered drugs dispensed to individuals who are enrolled in Medicaid managed care organizations;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">expansion of eligibility criteria for Medicaid programs thereby potentially increasing a manufacturer&#8217;s Medicaid rebate liability;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">a new Patient-Centered Outcomes Research Institute to oversee, identify priorities in, and conduct comparative clinical effectiveness research, along with funding for such research;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">establishment of a Center for Medicare Innovation at the CMS to test innovative payment and service delivery models to lower Medicare and Medicaid spending, potentially including prescription drug spending;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">expansion of the entities eligible for discounts under the Public Health Service program; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">a licensure framework for follow on biologic products.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Since its enactment, there have been judicial and Congressional challenges to certain aspects of the ACA, and we expect there may be additional challenges and amendments to the ACA in the future. It is uncertain the extent to which any such changes may impact our business or financial condition.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Other legislative changes have been proposed and adopted in the United States since the ACA was enacted. For example, the Budget Control Act of 2011, resulted in aggregate reductions of Medicare payments to providers of 2% per fiscal&#160;year. These reductions went into effect in April&#160;2013 and, due to subsequent legislative amendments to the statute, will remain in effect through 2027 unless additional action is taken by Congress. In January&#160;2013, the American Taxpayer Relief Act of 2012 was signed into law, which, among other things, further reduced Medicare payments to several types of providers, including hospitals, imaging centers and cancer treatment centers, and increased the statute of limitations period for the government to recover overpayments to providers from three to five&#160;years. Additionally, the orphan drug tax credit was reduced as part of a broader tax reform. These new laws or any other similar laws introduced in the future may result in additional reductions in Medicare and other health care funding, which could negatively affect our customers and accordingly, our financial operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In addition, there has been increasing legislative and enforcement interest in the United States with respect to specialty drug pricing practices. Specifically, there have been Congressional inquiries and proposed federal and state legislation designed to bring more transparency to drug pricing, reduce the cost of prescription drugs under Medicare, review the relationship between pricing and manufacturer patient programs and reform government program reimbursement methodologies for drugs. Moreover, payment methodologies may be subject to changes in healthcare legislation and regulatory initiatives. We expect that additional U.S. federal healthcare reform measures will be adopted in the future, any of which could limit the amounts that the U.S. federal government will pay for healthcare products and services, which could result in reduced demand for our product candidates or additional pricing pressures.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Individual states in the United States have also become increasingly aggressive in passing legislation and implementing regulations designed to control pharmaceutical and biological product pricing, including price or patient reimbursement constraints, discounts, restrictions on certain product access and marketing cost disclosure and transparency measures, and, in some cases, designed to encourage importation from other countries and bulk purchasing. Legally mandated price controls on payment amounts by third-party payors or other restrictions could harm our business, results of operations, financial condition and prospects. In addition, regional healthcare authorities and individual hospitals are increasingly using bidding procedures to determine what pharmaceutical products and which suppliers will be included in their prescription drug and other healthcare programs. This could reduce the ultimate demand for our product candidates or put pressure on our product pricing.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">46</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In markets outside of the United States, reimbursement and healthcare payment systems vary significantly by country, and many countries have instituted price ceilings on specific products and therapies. We cannot predict the likelihood, nature, or extent of government regulation that may arise from future legislation or administrative action in the United States or any other jurisdiction. If we or any third parties we may engage are slow or unable to adapt to changes in existing requirements or the adoption of new requirements or policies, or if we or such third parties are not able to maintain regulatory compliance, our product candidates may lose any regulatory approval that may have been obtained and we may not achieve or sustain profitability.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Our business operations and current and future relationships with investigators, healthcare professionals, consultants, third-party payors, patient organizations, and customers will be subject to applicable healthcare regulatory laws, which could expose us to penalties.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Our business operations and current and future arrangements with investigators, healthcare professionals, consultants, third-party payors, patient organizations, and customers, may expose us to broadly applicable fraud and abuse and other healthcare laws and regulations. These laws may constrain the business or financial arrangements and relationships through which we conduct our operations, including how we research, market, sell and distribute our product candidates, if approved. Such laws include:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the U.S. federal Anti-Kickback Statute, which prohibits, among other things, persons or entities from knowingly and willfully soliciting, offering, receiving, or providing any remuneration (including any kickback, bribe, or certain rebate), directly or indirectly, overtly or covertly, in cash or in kind, to induce or reward, or in return for, either the referral of an individual for, or the purchase, lease, order, or recommendation of, any good, facility, item, or service, for which payment may be made, in whole or in part, under U.S. federal and state healthcare programs such as Medicare and Medicaid. A person or entity does not need to have actual knowledge of the statute or specific intent to violate it in order to have committed a violation. The U.S. federal Anti-Kickback Statute has been interpreted to apply to arrangements between pharmaceutical manufacturers on the one hand and prescribers, purchasers and formulary managers on the other hand;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the U.S. federal false claims and civil monetary penalties laws, including the civil False Claims Act (&#8220;FCA&#8221;) which, among other things, impose criminal and civil penalties, including through civil whistleblower or </span><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;">qui tam</i><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> actions, against individuals or entities for knowingly presenting, or causing to be presented, to the U.S. federal government, claims for payment or approval that are false or fraudulent, knowingly making, using or causing to be made or used, a false record or statement material to a false or fraudulent claim, or from knowingly making a false statement to avoid, decrease or conceal an obligation to pay money to the U.S. federal government. In addition, the government may assert that a claim including items and services resulting from a violation of the U.S. federal Anti-Kickback Statute constitutes a false or fraudulent claim for purposes of the FCA. A claim includes &#8220;any request or demand&#8221; for money or property presented to the federal government. In addition, manufacturers can be held liable under the FCA even when they do not submit claims directly to government payors if they are deemed to &#8220;cause&#8221; the submission of false or fraudulent claims;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">HIPAA, which imposes criminal and civil liability for, among other things, knowingly and willfully executing, or attempting to execute, a scheme to defraud any healthcare benefit program or obtain, by means of false or fraudulent pretenses, representations, or promises, any of the money or property owned by, or under the custody or control of, any healthcare benefit program, regardless of the payor (e.g.,&#160;public or private) and knowingly and willfully falsifying, concealing or covering up a material fact or making any materially false statement, in connection with the delivery of, or payment for, healthcare benefits, items or services. Similar to the U.S. federal Anti-Kickback Statute, a person or entity does not need to have actual knowledge of the statute or specific intent to violate it in order to have committed a violation;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">HIPAA, as amended by the Health Information Technology for Economic and Clinical Health Act of 2009 (&#8220;HITECH&#8221;) and their respective implementing regulations, which impose, among other things, specified requirements relating to the privacy, security and transmission of individually identifiable health </span></td></tr></table></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">47</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"></td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">information without appropriate authorization by covered entities subject to the rule, such as health plans, healthcare clearinghouses and healthcare providers as well as their business associates that perform certain services involving the use or disclosure of individually identifiable health information. HITECH also created new tiers of civil monetary penalties, amended HIPAA to make civil and criminal penalties directly applicable to business associates and gave state attorneys general new authority to file civil actions for damages or injunctions in federal courts to enforce the federal HIPAA laws and seek attorneys&#8217; fees and costs associated with pursuing federal civil actions;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the FDCA, which prohibits, among other things, the adulteration or misbranding of drugs, biologics and medical devices;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the U.S. federal legislation commonly referred to as the Physician Payments Sunshine Act, enacted as part of the ACA, and its implementing regulations, which requires certain manufacturers of drugs, devices, biologics, and medical supplies that are reimbursable under Medicare, Medicaid, or the Children&#8217;s Health Insurance Program to report annually to the government information related to certain payments and other transfers of value to physicians and teaching hospitals, as well as ownership and investment interests held by the physicians described above and their immediate family members; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">analogous U.S. state laws and regulations, including: state anti-kickback and false claims laws, which may apply to our business practices, including but not limited to, research, distribution, sales, and marketing arrangements and claims involving healthcare items or services reimbursed by any third-party payor, including private insurers; state laws that require pharmaceutical companies to comply with the pharmaceutical industry&#8217;s voluntary compliance guidelines and the relevant compliance guidance promulgated by the U.S. federal government, or otherwise restrict payments that may be made to healthcare providers and other potential referral sources; state laws and regulations that require drug manufacturers to file reports relating to pricing and marketing information, which requires tracking gifts and other remuneration and items of value provided to healthcare professionals and entities; and state laws governing the privacy and security of health information in certain circumstances, many of which differ from each other in significant ways and often are not preempted by HIPAA, thus complicating compliance efforts.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Because of the breadth of these laws and the narrowness of the statutory exceptions and regulatory safe harbors available under such laws, it is possible that some of our business activities, including our consulting agreements and other relationships with physicians and other healthcare providers, some of whom receive stock or stock options as compensation for their services, could be subject to challenge under one or more of such laws. Ensuring that our current and future internal operations and business arrangements with third parties comply with applicable healthcare laws and regulations will involve substantial costs. It is possible that governmental authorities will conclude that our business practices do not comply with current or future statutes, regulations, agency guidance or case law involving applicable fraud and abuse or other healthcare laws and regulations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">If our operations are found to be in violation of any of the laws described above or any other governmental laws and regulations that may apply to us, we may be subject to the imposition of civil, criminal and administrative penalties, damages, disgorgement, monetary fines, possible exclusion from participation in Medicare, Medicaid and other federal healthcare programs, individual imprisonment, contractual damages, reputational harm, diminished profits and future earnings, additional reporting requirements or oversight if we become subject to a corporate integrity agreement or similar agreement to resolve allegations of non-compliance with these laws, and curtailment or restructuring of our operations, any of which could adversely affect our ability to operate our business and our results of operations. If any of the physicians or other providers or entities with whom we expect to do business are found to not be in compliance with applicable laws, they may be subject to criminal, civil or administrative sanctions, including exclusions from government funded healthcare programs and imprisonment, which could affect our ability to operate our business. Further, defending against any such actions can be costly, time-consuming and may require significant personnel resources. Therefore, even if we are successful in defending against any such actions that may be brought against us, our business may be impaired.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">48</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Any clinical trial programs we conduct or research collaborations we enter into in the EEA may subject us to the General Data Protection Regulation.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">If we conduct clinical trial programs or enter into research collaborations in the EEA, we may be subject to the General Data Protection regulation (&#8220;GDPR&#8221;). The GDPR applies extraterritorially and implements stringent operational requirements for processors and controllers of personal data, including, for example, high standards for obtaining consent from individuals to process their personal data, robust disclosures to individuals, a comprehensive individual data rights regime, data export restrictions governing transfers of data from the European Union (&#8220;EU&#8221;) to other jurisdictions, short timelines for data breach notifications, limitations on retention of information, increased requirements pertaining to health data, other special categories of personal data and coded data and additional obligations if we contract third-party processors in connection with the processing of personal data. The GDPR provides that EU member states may establish their own laws and regulations limiting the processing of personal data, including genetic, biometric or health data, which could limit our ability to use and share personal data or could cause our costs to increase. If our or our partners&#8217; or service providers&#8217; privacy or data security measures fail to comply with the GDPR requirements, we may be subject to litigation, regulatory investigations, enforcement notices requiring us to change the way we use personal data and/or fines of up to 20&#160;million Euros or up to 4% of the total worldwide annual turnover of the preceding financial&#160;year, whichever is higher, as well as compensation claims by affected individuals, negative publicity, reputational harm and a potential loss of business and goodwill.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">We are subject to environmental, health and safety laws and regulations, and we may become exposed to liability and substantial expenses in connection with environmental compliance or remediation activities.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Our operations, including our development, testing and manufacturing activities, are subject to numerous environmental, health and safety laws and regulations. These laws and regulations govern, among other things, the controlled use, handling, release and disposal of and the maintenance of a registry for, hazardous materials and biological materials, such as chemical solvents, human cells, carcinogenic compounds, mutagenic compounds and compounds that have a toxic effect on reproduction, laboratory procedures and exposure to blood-borne pathogens. If we fail to comply with such laws and regulations, we could be subject to fines or other sanctions.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">As with other companies engaged in activities similar to ours, we face a risk of environmental liability inherent in our current and historical activities, including liability relating to releases of or exposure to hazardous or biological materials. Environmental, health and safety laws and regulations are becoming more stringent. We may be required to incur substantial expenses in connection with future environmental compliance or remediation activities, in which case, the production efforts of our third-party manufacturers or our development efforts may be interrupted or delayed.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Recent U.S. tax legislation may materially adversely affect our financial condition, results of operations and cash flows.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="white-space:pre-wrap;">On March 27, 2020, the Coronavirus Aid, Relief, and Economic Security Act (&#8220;CARES Act&#8221;) was enacted in response to the COVID-19 pandemic. The CARES Act, among other things, permits NOL carryovers and carrybacks to offset 100% of taxable income for taxable years beginning before 2021. Previously, NOLs generated after December 31, 2017 were limited to 80% of taxable income in future years.  In addition, the CARES Act allows NOLs incurred in 2018, 2019 and 2020 to be carried back to each of the five preceding taxable years to generate a refund of previously paid income taxes. The NOL carryback provision of the CARES Act had no impact on us due to our tax losses generated during all prior years.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">U.S. tax legislation enacted in 2017 has significantly changed the U.S. federal income taxation of U.S. corporations, including by reducing the U.S. corporate income tax rate, limiting interest deductions, and revising the rules&#160;governing NOLs. The legislation could be subject to potential amendments and technical corrections, as well as interpretations and implementing regulations by the U.S. Treasury and Internal Revenue Service, any of which could lessen or increase certain adverse impacts of the legislation. In addition, it is unclear how these U.S. federal income tax changes will affect state and local taxation, which often uses federal taxable income as a starting point for computing state and local tax liabilities.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">49</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">While some of the changes made by the tax legislation may adversely affect us in one or more reporting periods and prospectively, other changes may be beneficial.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Risks Related to Our Intellectual Property</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">If we are unable to maintain patent protection for our technology or if the scope of the patent protection obtained is not sufficiently broad, we may not be able to compete effectively in our markets.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We rely upon a combination of patents, trade secret protection and confidentiality agreements to protect the intellectual property related to our drug development programs and product candidates. Our success depends in large part on our ability to obtain, maintain and defend patent protection in the United States and other countries with respect to Buntanetap and any future product candidates. The patent prosecution process is expensive and time-consuming, and we may not be able to file and prosecute all necessary or desirable patent applications at a reasonable cost or in a timely manner. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">If we are unable to obtain additional patent protection to prolong the patent life of our compounds, we may not be able to continue development of our compounds.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We seek to protect and prolong our proprietary position by filing patent applications in the United States and abroad related to our development programs and product candidates. If the patent applications we own with respect to our development programs and product candidates fail to issue, if their breadth or strength of protection is threatened, or if they fail to provide meaningful exclusivity for Buntanetap or any future product candidate, it could dissuade companies from collaborating with us to develop product candidates, and threaten our ability to commercialize future product candidates. Any such outcome could have a materially adverse effect on our business and our company could cease to exist.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Annovis has filed four families of patent applications to prolong the patent life of Buntanetap. Unless these applications are approved by the U.S. and international patent offices, the patent life of using Buntanetap is limited. The first patent application family we filed, which would be expected to expire in 2031, covers the use of Buntanetap at much lower doses and expands its use to the treatment of AD, PD and other neurodegenerative disorders such as Huntington&#8217;s disease, prion diseases, amyotrophic lateral sclerosis, tauopathies and frontotemporal dementia, based on our preclinical research. In August&#160;<span style="white-space:pre-wrap;">2019, the U.S. Patent and Trademark Office (&#8220;USPTO&#8221;) granted the first of our Annovis patents from this family covering PD and Lewy body diseases and in March 2020, the European Patent Office (&#8220;EPO&#8221;) approved another patent in this family covering AD.  The second patent application family covers ANVS405&#8217;s use in acute brain and nerve trauma and would be expected to expire in 2036, before any patent term adjustments or extensions. In December 2020, the EPO approved our first patent from this family for a method of treating acute nerve and brain injuries by administering ANVS405 after the injury. The third patent application family relates to the use of the mechanism of action of Buntanetap and ANVS405 to prevent and treat neurodegenerative diseases and would be expected to expire in 2038, before any patent term adjustments or extensions. In May 2020, we filed a patent application with the USPTO concerning a method of inhibiting, preventing, or treating neurological injuries due to viral, bacterial, fungal, protozoan, or parasitic infections in humans and in animals via administration of Buntanetap or related compounds which would be expected to expire in 2041, before any patent term adjustments or extensions.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">While the issuance of our new patents gives us some comfort that the patent life relating to methods of using Buntanetap may be prolonged to 2031, the fact that only a portion of the family claims has so far been allowed could result in very limited patent coverage. It is possible that we will fail to identify further patentable aspects of our research and development output before it is too late to obtain patent protection. The patent applications that we own may fail to result in issued patents with claims that provide further coverage of Buntanetap or any other product candidate in the United States or in other foreign countries.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">50</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Our patents may be challenged in courts or in patent offices which could result in the invalidation, narrowing or unenforceability of our patents and our patent portfolio may not provide us with sufficient rights to exclude others from commercializing products similar or identical to ours.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">There is no assurance that all the potentially relevant prior art relating to our patents and patent applications has been found, which can invalidate a patent or prevent a patent from issuing from a pending patent application. Even if patents do successfully issue and even if such patents further cover Buntanetap or any future product candidate, third parties may challenge their validity, enforceability or scope, which may result in such patents being narrowed, invalidated, or held unenforceable. Any successful opposition to these patents or any other patents owned by or licensed to us could deprive us of rights necessary for the successful commercialization of any product candidates that we may develop. Further, if we encounter delays in regulatory approvals, the period during which we could market a product candidate under patent protection could be reduced.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The patent position of biotechnology and pharmaceutical companies generally is highly uncertain, involves complex legal and factual questions and has in recent&#160;years been the subject of much litigation. In addition, the laws of foreign countries may not protect our rights to the same extent as the laws of the United States. For example, European patent law restricts the patentability of methods of treatment of the human body more than U.S. law does. However, in certain instances, the laws of the United States are more restrictive than those of foreign countries. For example, a recent series of Supreme Court Cases has narrowed the types of subject matter considered eligible for patenting. Accordingly, certain diagnostic methods are considered ineligible for patenting because they are directed to a &#8220;law of nature.&#8221; Further, publications of discoveries in scientific literature often lag the actual discoveries, and patent applications in the United States and other jurisdictions are typically not published until 18&#160;months after filing, or in some cases not at all. Therefore, we cannot know with certainty whether we were the first to make the inventions claimed in our owned or licensed patents or pending patent applications, or that we were the first to file for patent protection of such inventions. As a result, the issuance, scope, validity, enforceability and commercial value of our patent rights are highly uncertain. Our pending and future patent applications may not result in patents being issued which protect our technology or products, in whole or in part, or which effectively prevent others from commercializing competitive technologies and products. Changes in either the patent laws or interpretation of the patent laws in the United States and other countries may diminish the value of our patents or narrow the scope of our patent protection.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The issuance of a patent is not conclusive as to its inventorship, scope, validity or enforceability, and our owned and licensed patents may be challenged in the courts or patent offices in the United States and abroad. Such challenges may result in patent claims being narrowed, invalidated, held unenforceable, in whole or in part, or reduced in term. Such a result could limit our ability to stop others from using or commercializing similar or identical technology and products. Moreover, patents have a limited lifespan. In the United States, the natural expiration of a patent is generally 20&#160;years after it is filed. While various extensions may be available, the life of a patent is limited. Without patent protection for our current or future product candidates, we may be open to competition from generic versions of such products. Given the amount of time required for the development, testing and regulatory review of new product candidates, patents protecting such candidates might expire before or shortly after such candidates are commercialized. As a result, our owned and licensed patent portfolio may not provide us with sufficient rights to exclude others from commercializing products similar or identical to ours.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">We may become subject to third parties&#8217; claims alleging infringement of their patents and proprietary rights, or we may need to become involved in lawsuits to protect or enforce our patents, which could be costly, time consuming, delay or prevent the development and commercialization of our product candidates or put our patents and other proprietary rights at risk.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">Our commercial success depends, in part, upon our ability to develop, manufacture, market and sell our product candidates without alleged or actual infringement, misappropriation or other violation of the patents and proprietary rights of third parties. Litigation relating to infringement or misappropriation of patent and other intellectual property rights in the pharmaceutical and biotechnology industries is common, including patent infringement lawsuits, interferences, oppositions and reexamination proceedings before the USPTO and corresponding foreign patent offices. The various markets in which we plan to operate are subject to frequent and extensive litigation regarding patents and other intellectual property rights. In addition, many companies in intellectual property-dependent industries, including </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">51</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">the biotechnology and pharmaceutical industries, have employed intellectual property litigation as a means to gain an advantage over their competitors. Numerous U.S., EU and foreign issued patents and pending patent applications, which are owned by third parties, exist in the fields in which we are developing product candidates. Some claimants may have substantially greater resources than we do and may be able to sustain the costs of complex intellectual property litigation to a greater degree and for longer periods of time than we could. In addition, patent holding companies that focus solely on extracting royalties and settlements by enforcing patent rights may target us. As the biotechnology and pharmaceutical industries expand and more patents are issued, the risk increases that our product candidates may be subject to claims of infringement of the intellectual property rights of third parties.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We may be subject to third-party claims including infringement, interference or derivation proceedings, post-grant review and <i style="font-style:italic;">inter partes</i> review before the USPTO or similar adversarial proceedings or litigation in other jurisdictions. Even if we believe third party infringement claims are without merit, a court of competent jurisdiction could hold that these third-party patents are valid, enforceable and infringed, and the holders of any such patents may be able to block our ability to commercialize the applicable product candidate unless we obtained a license under the applicable patents, or until such patents expire or are finally determined to be invalid or unenforceable. Proceedings challenging our patents or those that we license may also result in our patent claims being invalidated or narrowed in scope. Similarly, if our patents or patent applications are challenged during interference or derivation proceedings, a court may hold that a third-party is entitled to certain patent ownership rights instead of us. Further, if any third-party patents were held by a court of competent jurisdiction to cover aspects of our compositions, formulations, methods of manufacture, or methods of treatment, prevention or use, the holders of any such patents may be able to block our ability to develop and commercialize the applicable product candidate unless we obtained a license or until such patent expires or is finally determined to be invalid or unenforceable. In addition, defending such claims would cause us to incur substantial expenses and, if successful, could cause us to pay substantial damages, if we are found to be infringing a third party&#8217;s patent rights. If we are found to have infringed such rights willfully, the damages may be enhanced and may include attorneys&#8217; fees. Further, if a patent infringement suit is brought against us or our third-party service providers, our development, manufacturing or sales activities relating to the product or product candidate that is the subject of the suit may be delayed or terminated. As a result of patent infringement claims, or in order to avoid potential infringement claims, we may choose to seek, or be required to seek, a license from the third party, which may require us to pay license fees or royalties or both. These licenses may not be available on acceptable terms, or at all. Even if a license can be obtained on acceptable terms, the rights may be nonexclusive, which could give our competitors access to the same intellectual property rights. If we are unable to enter into a license on acceptable terms, we could be prevented from commercializing one or more of our product candidates, forced to modify such product candidates, or to cease some aspect of our business operations, which could harm our business significantly. Modifying our product candidates to design around third-party intellectual property rights may result in significant cost or delay to us and could prove to be technically infeasible. Any of these events, even if we were ultimately to prevail, could require us to divert substantial financial and management resources that we would otherwise be able to devote to our business. In addition, if the breadth or strength of protection provided the patents and patent applications we own or in-license is threatened, it could dissuade companies from collaborating with us to license, develop or commercialize current or future product candidates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">If we were to initiate legal proceedings against a third party to enforce a patent covering one of our product candidates, the defendant could counterclaim that our patent is invalid or unenforceable. In patent litigation in the United States and in Europe, defendant counterclaims alleging invalidity or unenforceability are commonplace. Grounds for a validity challenge could be an alleged failure to meet any of several statutory requirements, for example, lack of eligibility, lack of novelty, obviousness or non-enablement. Third parties might allege unenforceability of our patents because someone connected with prosecution of the patent withheld relevant information, or made a misleading statement, during prosecution. The outcome of proceedings involving assertions of invalidity and unenforceability during patent litigation is unpredictable. With respect to the validity of patents, for example, we cannot be certain that there is no invalidating prior art of which we and the patent examiner were unaware during prosecution. If a defendant were to prevail on a legal assertion of invalidity or unenforceability, we would lose at least part, and perhaps all, of the patent protection on our product candidates. Furthermore, our patents and other intellectual property rights also will not protect our technology if competitors design around our protected technology without infringing on our patents or other intellectual property rights.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">52</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Furthermore, because of the substantial amount of discovery required in connection with intellectual property litigation, there is a risk that some of our confidential information could be compromised by disclosure during this type of litigation. There could also be public announcements of the results of hearings, motions or other interim proceedings or developments. If securities analysts or investors view these announcements in a negative light, the price of our common stock could be adversely affected.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Finally, even if resolved in our favor, litigation or other legal proceedings relating to intellectual property claims may cause us to incur significant expenses and could distract our technical and management personnel from their normal responsibilities. In addition, there could be public announcements of the results of hearings, motions or other interim proceedings or developments and if securities analysts or investors view these announcements in a negative light, the price of our common stock could be adversely affected. Such litigation or proceedings could substantially increase our operating losses and reduce our resources available for development activities. We may not have sufficient financial or other resources to adequately conduct such litigation or proceedings. Some of our competitors may be able to sustain the costs of such litigation or proceedings more effectively than we can because of their substantially greater financial resources. Uncertainties resulting from the initiation and continuation of patent litigation or other proceedings could have an adverse effect on our ability to compete in the marketplace.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">We may not identify relevant third-party patents or may incorrectly interpret the relevance, scope or expiration of a third-party patent, which might adversely affect our ability to develop, manufacture and market our product candidates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We cannot guarantee that any of our or our licensors&#8217; patent searches or analyses, including but not limited to the identification of relevant patents, the scope of patent claims or the expiration of relevant patents, are complete or thorough, nor can we be certain that we have identified each and every third-party patent and pending application in the United States, Europe and elsewhere that is relevant to or necessary for the commercialization of our product candidates in any jurisdiction. For example, in the United States, applications filed before November&#160;29, 2000 and certain applications filed after that date that will not be filed outside the United States remain confidential until patents issue. Patent applications in the United States, EU and elsewhere are published approximately 18&#160;months after the earliest filing for which priority is claimed, with such earliest filing date being commonly referred to as the priority date. Therefore, patent applications covering our future product candidates, or their manufacture or use may currently be unpublished. Additionally, pending patent applications that have been published can, subject to certain limitations, be later amended in a manner that could cover our product candidates or the use of our product candidates. The scope of a patent claim is determined by an interpretation of the law, the written disclosure in a patent and the patent&#8217;s prosecution history. Our interpretation of the relevance or the scope of a patent or a pending application may be incorrect, which may negatively impact our ability to market our product candidates. We may incorrectly determine that our product candidates are not covered by a third-party patent or may incorrectly predict whether a third party&#8217;s pending application will issue with claims of relevant scope. Our determination of the expiration date of any patent in the United States, the EU or elsewhere that we consider relevant may be incorrect, which may negatively impact our ability to develop and market our product candidates. Our failure to identify and correctly interpret relevant patents may negatively impact our ability to develop and market our product candidates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">From time to time we may identify patents or applications in the same general area as our products and product candidates. We may determine these third-party patents are irrelevant to our business based on various factors including our interpretation of the scope of the patent claims and our interpretation of when the patent expires. If the patents are asserted against us, however, a court may disagree with our determinations. Further, while we may determine that the scope of claims that will issue from a patent application does not present a risk, it is difficult to accurately predict the scope of claims that will issue from a patent application, our determination may be incorrect, and the issuing patent may be asserted against us. We cannot guarantee that we will be able to successfully settle or otherwise resolve such infringement claims. If we fail in any such dispute, in addition to being forced to pay monetary damages, we may be temporarily or permanently prohibited from commercializing our product candidates. We might, if possible, also be forced to redesign our product candidates so that we no longer infringe on the third-party intellectual property rights. Any of these events, even if we were ultimately to prevail, could require us to divert substantial financial and management resources that we would otherwise be able to devote to our business.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">53</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Changes in patent laws or patent jurisprudence could diminish the value of patents in general, thereby impairing our ability to protect our product candidates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">As is the case with other biopharmaceutical and pharmaceutical companies, our success is heavily dependent on intellectual property, particularly patents. Obtaining and enforcing patents in the biopharmaceutical and pharmaceutical industries involve both technological complexity and legal complexity. Therefore, obtaining and enforcing biopharmaceutical and pharmaceutical patents is costly, time-consuming and inherently uncertain. In addition, the America Invents Act (&#8220;AIA&#8221;) which was passed in September&#160;2011, resulted in significant changes to the U.S. patent system.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">An important change introduced by the AIA is that, as of March&#160;16, 2013, the United States transitioned to a &#8220;first-to-file&#8221; system for deciding which party should be granted a patent when two or more patent applications are filed by different parties claiming the same invention. A third party that files&#160;a patent application in the USPTO after that date but before us could therefore be awarded a patent covering an invention of ours even if we made the invention before it was made by the third party. This will require us to be cognizant going forward of the time from invention to filing of a patent application, but circumstances could prevent us from promptly filing patent applications on our inventions.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Among some of the other changes introduced by the AIA are changes that limit where a patentee may file&#160;a patent infringement suit and provide opportunities for third parties to challenge any issued patent with the USPTO. This applies to all of our U.S. patents, even those issued before March&#160;16, 2013. Because of a lower evidentiary standard in USPTO proceedings compared to the evidentiary standard in U.S. federal courts necessary to invalidate a patent claim, a third party could potentially provide evidence in a USPTO proceeding sufficient for the USPTO to hold a claim invalid even though the same evidence would be insufficient to invalidate the claim if first presented in a district court action.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Accordingly, a third party may attempt to use the USPTO procedures to invalidate our patent claims that would not have been invalidated if first challenged by the third party as a defendant in a district court action. It is not clear what, if any, impact the AIA will have on the operation of our business. However, the AIA and its implementation could increase the uncertainties and costs surrounding the prosecution of our or our licensors&#8217; patent applications and the enforcement or defense of our or our licensors&#8217; issued patents.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Additionally, the U.S. Supreme Court has ruled on several patent cases in recent&#160;years either narrowing the scope of patent protection available in certain circumstances or weakening the rights of patent owners in certain situations. In addition to increasing uncertainty with regard to our ability to obtain patents in the future, this combination of events has created uncertainty with respect to the value of patents, once obtained. Depending on decisions by Congress, the federal courts and the USPTO, the laws and regulations governing patents could change in unpredictable ways that could weaken our ability to obtain new patents or to enforce our existing patents and patents that we might obtain in the future. Similarly, the complexity and uncertainty of European patent laws has also increased in recent&#160;years. In addition, the European patent system is relatively stringent in the type of amendments that are allowed during prosecution. Complying with these laws and regulations could limit our ability to obtain new patents in the future that may be important for our business.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Obtaining and maintaining our patent protection depends on compliance with various procedural, document submission, fee payment and other requirements imposed by governmental patent agencies, and our patent protection could be reduced or eliminated for non-compliance with these requirements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">Periodic maintenance and annuity fees on any issued patent are due to be paid to the USPTO and European and other patent agencies over the lifetime of a patent. In addition, the USPTO and European and other patent agencies require compliance with a number of procedural, documentary, fee payment and other similar provisions during the patent application process. While an inadvertent failure to make payment of such fees or to comply with such provisions can in many cases be cured by payment of a late fee or by other means in accordance with the applicable rules, there are situations in which such noncompliance will result in the abandonment or lapse of the patent or patent application, and the partial or complete loss of patent rights in the relevant jurisdiction. Non-compliance events that could result in abandonment or lapse of a patent or patent application include failure to respond to official actions within prescribed time limits, non-payment of fees and failure to properly legalize and submit formal documents within prescribed time </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">54</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">limits. If we or our licensors fail to maintain the patents and patent applications covering our product candidates or if we or our licensors otherwise allow our patents or patent applications to be abandoned or lapse, our competitors might be able to enter the market, which would hurt our competitive position and could impair our ability to successfully commercialize our product candidates in any indication for which they are approved.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">We enjoy only limited geographical protection with respect to certain patents and we may not be able to protect our intellectual property rights throughout the world.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Filing, prosecuting and defending patents covering our product candidates in all countries throughout the world would be prohibitively expensive. Competitors may use our and our licensors&#8217; technologies in jurisdictions where we have not obtained patent protection to develop their own products and, further, may export otherwise infringing products to territories where we and our licensors have patent protection, but enforcement is not as strong as that in the United States or the EU. These products may compete with our product candidates, and our and our licensors&#8217; patents or other intellectual property rights may not be effective or sufficient to prevent them from competing.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In addition, we may decide to abandon national and regional patent applications before grant. The grant proceeding of each national or regional patent is an independent proceeding which may lead to situations in which applications might in some jurisdictions be refused by the relevant patent offices, while granted by others. For example, unlike other countries, China has a heightened requirement for patentability, and specifically requires a detailed description of medical uses of a claimed drug. Furthermore, generic drug manufacturers or other competitors may challenge the scope, validity or enforceability of our or our licensors&#8217; patents, requiring us or our licensors to engage in complex, lengthy and costly litigation or other proceedings. Generic drug manufacturers may develop, seek approval for and launch generic versions of our products. It is also quite common that depending on the country, the scope of patent protection may vary for the same product candidate or technology.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The laws of some jurisdictions do not protect intellectual property rights to the same extent as the laws or rules&#160;and regulations in the United States and the EU, and many companies have encountered significant difficulties in protecting and defending such rights in such jurisdictions. The legal systems of certain countries, particularly certain developing countries, do not favor the enforcement of patents, trade secrets and other intellectual property protection, which could make it difficult for us to stop the infringement of our patents or marketing of competing products in violation of our proprietary rights generally. Proceedings to enforce our patent rights in other jurisdictions, whether or not successful, could result in substantial costs and divert our efforts and attention from other aspects of our business, could put our patents at risk of being invalidated or interpreted narrowly and our patent applications at risk of not issuing, and could provoke third parties to assert claims against us. We may not prevail in any lawsuits that we initiate, and the damages or other remedies awarded, if any, may not be commercially meaningful. Accordingly, our efforts to enforce our intellectual property rights around the world may be inadequate to obtain a significant commercial advantage from the intellectual property that we develop or license. Furthermore, while we intend to protect our intellectual property rights in our expected significant markets, we cannot ensure that we will be able to initiate or maintain similar efforts in all jurisdictions in which we may wish to market our product candidates. Accordingly, our efforts to protect our intellectual property rights in such countries may be inadequate, which may have an adverse effect on our ability to successfully commercialize our product candidates in all of our expected significant foreign markets. If we or our licensors encounter difficulties in protecting, or are otherwise precluded from effectively protecting, the intellectual property rights important for our business in such jurisdictions, the value of these rights may be diminished, and we may face additional competition from others in those jurisdictions.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Some countries also have compulsory licensing laws under which a patent owner may be compelled to grant licenses to third parties. In addition, some countries limit the enforceability of patents against government agencies or government contractors. In these countries, the patent owner may have limited remedies, which could materially diminish the value of such patent. If we or any of our licensors is forced to grant a license to third parties with respect to any patents relevant to our business, our competitive position may be impaired.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">55</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">If we do not obtain patent term extension in the United States under the Hatch-Waxman Act and in foreign countries under similar legislation, thereby potentially extending the term of marketing exclusivity for our product candidates, our business may be materially harmed.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Patents have a limited lifespan. In the United States, if all maintenance fees are timely paid, the natural expiration of a patent is generally 20&#160;years from its earliest U.S. non-provisional filing date. Various extensions may be available, but the life of a patent, and the protection it affords, is limited. Even if patents covering our product candidates are obtained, once the patent life has expired for a product, we may be open to competition from competitive medications, including generic medications. Given the amount of time required for the development, testing and regulatory review of new product candidates, patents protecting such candidates might expire before or shortly after such candidates are commercialized. As a result, our owned and licensed patent portfolio may not provide us with sufficient rights to exclude others from commercializing products similar or identical to ours.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Depending upon the timing, duration and conditions of FDA marketing approval of our product candidates, we may be able to extend the term of a patent covering each product candidate under the Drug Price Competition and Patent Term Restoration Act of 1984, referred to as the Hatch-Waxman Amendments and similar legislation in the EU. The Hatch-Waxman Amendments permit a patent term extension of up to five&#160;years for a patent covering an approved product as compensation for effective patent term lost during product development and the FDA regulatory review process. The total patent term including the extension cannot exceed 14&#160;years following regulatory approval. However, we may not receive an extension if we fail to apply within applicable deadlines, fail to apply prior to expiration of relevant patents or otherwise fail to satisfy applicable requirements. Moreover, the length of the extension could be less than we request. If we are unable to obtain patent term extension or the term of any such extension is less than we request, the period during which we can enforce our patent rights for that product will be shortened and our competitors may obtain approval to market competing products sooner. As a result, our revenue from applicable products could be reduced, possibly materially.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Further, under certain circumstances, patent terms covering our products or product candidates may be extended for time spent during the pendency of the patent application in the USPTO, referred to as Patent Term Adjustment (&#8220;PTA&#8221;). The laws and regulations underlying how the USPTO calculates the PTA is subject to change and any such PTA granted by the USPTO could be challenged by a third-party. If we do not prevail under such a challenge, the PTA may be reduced or eliminated, resulting in a shorter patent term, which may negatively impact our ability to exclude competitors. Because PTA added to the term of patents covering pharmaceutical products has particular value, our business may be adversely affected if the PTA is successfully challenged by a third party and our ability to exclude competitors is reduced or eliminated.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Intellectual property rights do not address all potential threats to our competitive advantage.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The degree of future protection afforded by our intellectual property rights is uncertain because intellectual property rights have limitations, and may not adequately protect our business, or permit us to maintain our competitive advantage. The following examples are illustrative:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">others may be able to make products that are similar to Buntanetap or our future product candidates but that are not covered by the claims of the patents that we own or license from others;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">others may independently develop similar or alternative technologies or otherwise circumvent any of our technologies without infringing our intellectual property rights;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">we or any of our collaborators might not have been the first to conceive and reduce to practice the inventions covered by the patents or patent applications that we own, license or will own or license;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">we or any of our collaborators might not have been the first to file patent applications covering certain of the patents or patent applications that we or they own or have obtained a license, or will own or will have obtained a license;</span></td></tr></table></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">56</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">it is possible that our pending patent applications will not lead to issued patents;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">issued patents that we own may not provide us with any competitive advantage, or may be held invalid or unenforceable, as a result of legal challenges by our competitors;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our competitors might conduct research and development activities in countries where we do not have patent rights, or in countries where research and development safe harbor laws exist, and then use the information learned from such activities to develop competitive products for sale in our major commercial markets;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">ownership of our patents or patent applications may be challenged by third parties; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the patents of third parties or pending or future applications of third parties, if issued, may have an adverse effect on our business.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Our reliance on third parties requires us to share our trade secrets, which increases the possibility that our trade secrets will be misappropriated or disclosed, and confidentiality agreements with employees and third parties may not adequately prevent disclosure of trade secrets and protect other proprietary information.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We consider proprietary trade secrets or confidential know-how and unpatented know-how to be important to our business. We may rely on trade secrets or confidential know-how to protect our technology, especially where patent protection is believed by us to be of limited value. Because we expect to rely on third parties to manufacture Buntanetap and any future product candidates, and we expect to collaborate with third parties on the development of Buntanetap and any future product candidates, we must, at times, share trade secrets with them. We also conduct joint research and development programs that may require us to share trade secrets under the terms of our research and development partnerships or similar agreements. However, trade secrets or confidential know-how can be difficult to maintain as confidential.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">To protect this type of information against disclosure or appropriation by competitors, our policy is to require our employees, consultants, contractors and advisors to enter into confidentiality agreements and, if applicable, material transfer agreements, consulting agreements or other similar agreements with us prior to beginning research or disclosing proprietary information. These agreements typically limit the rights of the third parties to use or disclose our confidential information, including our trade secrets. However, current or former employees, consultants, contractors and advisers may unintentionally or willfully disclose our confidential information to competitors, and confidentiality agreements may not provide an adequate remedy in the event of unauthorized disclosure of confidential information. The need to share trade secrets and other confidential information increases the risk that such trade secrets become known by our competitors, are inadvertently incorporated into the technology of others, or are disclosed or used in violation of these agreements. Given that our proprietary position is based, in part, on our know-how and trade secrets, a competitor&#8217;s discovery of our trade secrets or other unauthorized use or disclosure would impair our competitive position and may have an adverse effect on our business and results of operations. Enforcing a claim that a third party obtained illegally and is using trade secrets or confidential know-how is expensive, time consuming and unpredictable. The enforceability of confidentiality agreements may vary from jurisdiction to jurisdiction.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In addition, these agreements typically restrict the ability of our advisors, employees, third-party contractors and consultants to publish data potentially relating to our trade secrets, although our agreements may contain certain limited publication rights. Despite our efforts to protect our trade secrets, our competitors may discover our trade secrets, either through breach of our agreements with third parties, independent development or publication of information by any of our third-party collaborators. A competitor&#8217;s discovery of our trade secrets would impair our competitive position and have an adverse impact on our business.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">57</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">If our trademarks and trade names are not adequately protected, then we may not be able to build name recognition in our markets of interest and our business may be adversely affected.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Our unregistered trademarks or trade names may be challenged, infringed, circumvented or declared generic or determined to be infringing on other marks. We may not be able to protect our rights to these trademarks and trade names, which we need to build name recognition among potential collaborators or customers in our markets of interest. At times, competitors may adopt trade names or trademarks similar to ours, thereby impeding our ability to build brand identity and possibly leading to market confusion. In addition, there could be potential trade name or trademark infringement claims brought by owners of other registered trademarks or trademarks that incorporate variations of our unregistered trademarks or trade names. Over the long term, if we are unable to successfully register our trademarks and trade names and establish name recognition based on our trademarks and trade names, then we may not be able to compete effectively, and our business may be adversely affected. Our efforts to enforce or protect our proprietary rights related to trademarks, trade secrets, domain names, copyrights or other intellectual property may be ineffective and could result in substantial costs and diversion of resources and could adversely impact our financial condition or results of operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">We may need to license certain intellectual property from third parties, and such licenses may not be available or may not be available on commercially reasonable terms.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">A third party may hold intellectual property, including patent rights that are important or necessary to the development or commercialization of Buntanetap or our future product candidates. It may be necessary for us to use the patented or proprietary technology of third parties to commercialize Buntanetap or our product candidates, in which case we would be required to obtain a license from these third parties. Such a license may not be available on commercially reasonable terms, or at all, which could materially harm our business. At this time, we are unaware of any intellectual property that interferes with ours or is complementary and needed to commercialize Buntanetap.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">We may be subject to claims that our employees, consultants or independent contractors have wrongfully used or disclosed confidential information of their former employers or other third parties.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We employ individuals who were previously employed at other biotechnology or pharmaceutical companies. Although we seek to protect our ownership of intellectual property rights by ensuring that our agreements with our employees, collaborators and other third parties with whom we do business include provisions requiring such parties to assign rights in inventions to us, we may be subject to claims that we or our employees, consultants or independent contractors have inadvertently or otherwise used or disclosed confidential information of our employees&#8217; former employers or other third parties. We may also be subject to claims that former employers or other third parties have an ownership interest in our patents. Litigation may be necessary to defend against these claims. There is no guarantee of success in defending these claims, and if we fail in defending any such claims, in addition to paying monetary damages, we may lose valuable intellectual property rights, such as exclusive ownership or right to use. Even if we are successful, litigation could result in substantial cost and be a distraction to our management and other employees.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Our proprietary information may be lost, or we may suffer security breaches.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In the ordinary course of our business, we collect and store sensitive data, including intellectual property, clinical trial data, proprietary business information, personal data and personally identifiable information of our clinical trial subjects and employees, in our data centers and on our networks. The secure processing, maintenance and transmission of this information is critical to our operations. Despite our security measures, our information technology and infrastructure may be vulnerable to attacks by hackers or breached due to employee error, malfeasance or other disruptions. Although, to our knowledge, we have not experienced any such material security breach to date, any such breach could compromise our networks and the information stored there could be accessed, publicly disclosed, lost or stolen. Any such access, disclosure or other loss of information could result in legal claims or proceedings, liability under laws that protect the privacy of personal information, significant regulatory penalties, disruption of our operations, damage to our reputation and cause a loss of confidence in us and our ability to conduct clinical trials, which could adversely affect our reputation and delay our clinical development of our product candidates.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">58</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Risks Related to Our Employees, Managing Our Growth and Our Operations</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Our future success depends on our ability to retain our key personnel and to attract, retain and motivate qualified personnel.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We are highly dependent on the development, regulatory, commercialization and business development expertise of Maria L. Maccecchini,&#160;PhD, as well as the other principal members of our management, scientific and clinical teams. Although we have employment agreements, offer letters or consulting agreements with our executive officers, these agreements do not prevent them from terminating their services at any time.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">If we lose one or more of our executive officers or key employees, our ability to implement our business strategy successfully could be seriously harmed. Furthermore, replacing executive officers and key employees may be difficult and may take an extended period of time because of the limited number of individuals in our industry with the breadth of skills and experience required to successfully develop product candidates, gain regulatory approval, and commercialize new products. Competition to hire from this limited pool is intense, and we may be unable to hire, train, retain or motivate these additional key personnel on acceptable terms given the competition among numerous pharmaceutical and biotechnology companies for similar personnel. We also experience competition for the hiring of scientific and clinical personnel from universities and research institutions. In addition, we rely on consultants and advisors, including scientific and clinical advisors, to assist us in formulating our research and development and commercialization strategy. Our consultants and advisors may be engaged by entities other than us and may have commitments under consulting or advisory contracts with other entities that may limit their availability to us. If we are unable to continue to attract and retain highly qualified personnel, our ability to develop and commercialize product candidates will be limited.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">We expect to expand our development, regulatory, and sales and marketing capabilities, and as a result, we may encounter difficulties in managing our growth, which could disrupt our operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We expect to experience significant growth in the number of our employees and the scope of our operations, particularly in the areas of development, regulatory affairs and sales and marketing. To manage our anticipated future growth, we must continue to implement and improve our managerial, operational and financial systems, expand our facilities or acquire new facilities and continue to recruit and train additional qualified personnel. Due to our limited financial resources and the limited experience of our management team in managing a company with such anticipated growth, we may not be able to effectively manage the expansion of our operations or recruit and train additional qualified personnel. The expansion of our operations may lead to significant costs and may divert our management and business development resources. Any inability to manage growth could delay the execution of our business plans or disrupt our operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">We may engage in acquisitions that could disrupt our business, cause dilution to our stockholders or reduce our financial resources.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In the future, we may enter into transactions to acquire other businesses, products or technologies. If we do identify suitable candidates, we may not be able to make such acquisitions on favorable terms, or at all. Any acquisitions we make may not strengthen our competitive position, and these transactions may be viewed negatively by customers or investors. We may decide to incur debt in connection with an acquisition or issue our common stock or other equity securities to the stockholders of the acquired company, which would reduce the&#160;percentage ownership of our existing stockholders. We could incur losses resulting from undiscovered liabilities of the acquired business that are not covered by the indemnification we may obtain from the seller. In addition, we may not be able to successfully integrate the acquired personnel, technologies and operations into our existing business in an effective, timely and nondisruptive manner. Acquisitions may also divert management attention from day-to-day responsibilities, increase our expenses and reduce our cash available for operations and other uses. We cannot predict the number, timing or size of future acquisitions or the effect that any such transactions might have on our operating results.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">59</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Our business and operations would suffer in the event of system failures.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Our computer systems, as well as those of our CROs and other contractors and consultants, are vulnerable to damage from computer viruses, unauthorized access, natural disasters (including hurricanes), terrorism, war and telecommunication and electrical failures. If such an event were to occur and cause interruptions in our operations, it could result in a material disruption of our development programs. For example, the loss of preclinical or clinical trial data from completed, ongoing or planned trials could result in delays in our regulatory approval efforts and significantly increase our costs to recover or reproduce the data. To the extent that any disruption or security breach were to result in a loss of or damage to our data or applications, or inappropriate disclosure of personal, confidential or proprietary information, we could incur liability and the further development of Buntanetap or any other product candidate could be delayed.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Risks Related to Our Common Stock</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">The market price of our common stock may be volatile and fluctuate substantially, which could result in substantial losses for purchasers of our common stock.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The market price of our common stock is highly volatile and may be subject to wide fluctuations in response to a variety of factors, including the following:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">delays or unanticipated developments in the completion of our planned clinical trials;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">any delay in submitting an NDA and any adverse development or perceived adverse development with respect to the FDA&#8217;s review of that NDA;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">failure to successfully develop and commercialize Buntanetap or any future product candidates;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">inability to obtain additional funding;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">regulatory or legal developments in the United States and other countries applicable to Buntanetap or any other product candidates;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">adverse regulatory decisions;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">changes in the structure of healthcare payment systems;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">inability to obtain adequate product supply for Buntanetap or any other product candidates, or the inability to do so at acceptable prices;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">introduction of new products, services or technologies by our competitors;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">failure to meet or exceed financial projections we provide to the public;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">failure to meet or exceed the estimates and projections of the investment community;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">changes in the market valuations of companies similar to ours;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">market conditions in the pharmaceutical and biotechnology sectors, and the issuance of new or changed securities analysts&#8217; reports or recommendations;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">announcements of significant acquisitions, strategic collaborations, joint ventures or capital commitments by us or our competitors;</span></td></tr></table></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">60</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">significant lawsuits, including patent or shareholder litigation, and disputes or other developments relating to our proprietary rights, including patents, litigation matters and our ability to obtain patent protection for our technologies;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">additions or departures of key scientific or management personnel;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">sales of our common stock by us or our shareholders in the future;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">trading volume of our common stock;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">general economic, industry and market conditions, including but not limited to the impact of the COVID-19 pandemic; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the other factors described in this &#8220;Risk Factors&#8221; section.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In addition, the stock markets have experienced extreme price and volume fluctuations that have affected and continue to affect the market prices of equity securities of many companies. These fluctuations have often been unrelated or disproportionate to the operating performance of those companies. Broad market and industry factors, as well as general economic, political, regulatory and market conditions, may negatively affect the market price of our common stock, regardless of our actual operating performance. The market price of our common stock may decline, and you may lose some or all of your investment.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">We could be subject to securities class action litigation.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In the past, securities class action litigation has often been brought against companies following a decline in the market price of their securities. This risk is especially relevant for us because biotechnology companies have experienced significant share price volatility in recent&#160;<span style="white-space:pre-wrap;">years. During the year ended December 31, 2021, two securities class action complaints were filed against us and our executive officers following disclosure of interim results from the AD/PD Trial.  Both complaints were voluntarily dismissed without prejudice by the plaintiffs. If we again face such litigation in the future, it could result in substantial costs and a diversion of management&#8217;s attention and resources, which could harm our business.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Our directors, executive officers and certain shareholders own a significant&#160;percentage of our common stock and, if they choose to act together, will be able to exert significant control over matters subject to shareholder approval.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Our directors, executive officers, and shareholders affiliated with our directors and executive officers own approximately 31.2% of the current voting power of our outstanding common stock. Therefore, they have the ability to substantially influence us through their ownership position. For example, these holders may be able to control elections of directors, amendments of our organizational documents, or approval of any merger, sale of assets, or other major corporate transaction. The interests of these holders may not always coincide with our corporate interests or the interests of other shareholders, and they may act in a manner with which you may not agree or that may not be in the best interests of our other shareholders. So long as they continue to own a significant amount of our equity, these holders will be able to strongly influence or effectively control our decisions.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">If securities or industry analysts do not publish research or reports about our business, or if they issue an adverse or misleading opinion regarding our common stock, our stock price and trading volume could decline.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The trading market for our common stock depends, in part, on the research and reports that securities or industry analysts may publish about us or our business. We do not have any control over these analysts. If our financial performance fails to meet analyst estimates or one or more of the analysts who cover us downgrade our common stock or change their opinion of our common stock, our share price would likely decline. If one or more of these analysts cease coverage of us or fail to regularly publish reports on us, we could lose visibility in the financial markets, which could cause our share price or trading volume to decline.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">61</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Because we do not anticipate paying any cash dividends on our common stock in the foreseeable future, capital appreciation, if any, will be your sole source of gain.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We have never declared or paid any cash dividends on our common stock. We currently anticipate that we will retain future earnings for the development, operation and expansion of our business and do not anticipate declaring or paying any cash dividends for the foreseeable future. As a result, capital appreciation, if any, of our common stock would be your sole source of gain on an investment in our common stock for the foreseeable future. See &#8220;Dividend Policy&#8221; for additional information.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">We incur increased costs as a result of operating as a public company, and our management is required to devote substantial time to compliance initiatives and corporate governance practices.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">As a public company, and particularly after we no longer qualify as an emerging growth company, we incur significant legal, accounting and other expenses. The Sarbanes-Oxley Act of 2002 (&#8220;SOX&#8221;), the Dodd-Frank Wall Street Reform and Consumer Protection Act, the listing requirements of the New York Stock Exchange, and other applicable securities rules&#160;and regulations impose various requirements on U.S. reporting public companies, including the establishment and maintenance of effective disclosure and financial controls and corporate governance practices. Our management and other personnel devote a substantial amount of time to these compliance initiatives. Moreover, these rules&#160;and regulations increase our legal and financial compliance costs and make some activities more time-consuming and costly. For example, these rules&#160;and regulations may make it more expensive for us to obtain director and officer liability insurance, which in turn could make it more difficult for us to attract and retain qualified senior management personnel or members for our board of directors. In addition, these rules&#160;and regulations are often subject to varying interpretations, and, as a result, their application in practice may evolve over time as new guidance is provided by regulatory and governing bodies. This could result in continuing uncertainty regarding compliance matters and higher costs necessitated by ongoing revisions to disclosure and governance practices. Pursuant to Section&#160;404 of SOX, we are required to furnish a report by our senior management on our internal control over financial reporting. While we remain an emerging growth company, we will not be required to include an attestation report on internal control over financial reporting issued by our independent registered public accounting firm. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">To comply with Section&#160;404, we are required to engage in a process to document and evaluate our internal control over financial reporting, which is both costly and challenging. In this regard, we need to continue to dedicate internal resources, engage outside consultants and adopt a detailed work plan to assess and document the adequacy of internal control over financial reporting, continue steps to improve control processes as appropriate, validate through testing that controls are functioning as documented and maintain a continuous reporting and improvement process for internal control over financial reporting. Despite our efforts, there is a risk that we will not be able to conclude, within the prescribed timeframe or at all, that our internal control over financial reporting is effective as required by Section&#160;404. If we identify one or more material weaknesses, it could result in an adverse reaction in the financial markets due to a loss of confidence in the reliability of our financial statements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">We are an &#8220;emerging growth company,&#8221; and the reduced reporting requirements applicable to emerging growth companies may make our common stock less attractive to investors.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We are an &#8220;emerging growth company,&#8221; as defined in the Jumpstart Our Business Startups Act (&#8220;JOBS Act&#8221;). For as long as we continue to be an emerging growth company, we may take advantage of exemptions from various reporting requirements that are applicable to other public companies that are not emerging growth companies, including exemption from compliance with the auditor attestation requirements of Section&#160;404, reduced disclosure obligations regarding executive compensation and exemptions from the requirements of holding a nonbinding advisory vote on executive compensation and shareholder approval of any golden parachute payments not previously approved. We will remain an emerging growth company until the earlier of (1)&#160;the last day of the fiscal&#160;year (a)&#160;following the fifth anniversary of the closing of our initial public offering (&#8220;IPO&#8221;) on January 31, 2020, (b)&#160;in which we have total annual gross revenue of at least $1.07&#160;billion or (c)&#160;in which we are deemed to be a large accelerated filer, which means the market value of our common stock held by non-affiliates exceeds $700&#160;million as of the end of our prior second fiscal quarter, and (2)&#160;the date on which we have issued more than $1.0&#160;billion in non-convertible debt during the prior three-year period.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">62</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In addition, under the JOBS Act, emerging growth companies can delay adopting new or revised accounting standards until such time as those standards apply to private companies. We have irrevocably elected not to avail ourselves of this exemption from new or revised accounting standards and, therefore, we will be subject to the same new or revised accounting standards as other public companies that are not emerging growth companies.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We cannot predict if investors will find our common stock less attractive because we may rely on these exemptions. If some investors find our common stock less attractive as a result, there may be a less active trading market for our common stock and our share price may be more volatile.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Provisions in our restated certificate of incorporation and amended and restated bylaws and under Delaware law could make an acquisition of our company, which may be beneficial to our stockholders, more difficult and may prevent attempts by our stockholders to replace or remove our current management.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Provisions in our restated certificate of incorporation and our amended and restated bylaws that became effective upon the closing of our IPO may discourage, delay or prevent a merger, acquisition or other change in control of our company that stockholders may consider favorable, including transactions in which our stockholders might otherwise receive a premium for their shares. These provisions could also limit the price that investors might be willing to pay in the future for shares of our common stock, thereby depressing the market price of our common stock. In addition, because our board of directors is responsible for appointing the members of our management team, these provisions may frustrate or prevent any attempts by our stockholders to replace or remove our current management by making it more difficult for stockholders to replace members of our board of directors. Among other things, these provisions include those establishing:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Advance notice bylaw provisions for proposals from stockholders for presentation at annual meetings; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Forum selection bylaw provisions.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Because we are incorporated in Delaware, we are governed by the provisions of Section&#160;203 of the General Corporation Law of the State of Delaware, which prohibits a person who owns in excess of 15% of our outstanding voting stock from merging or combining with us for a period of three&#160;years after the date of the transaction in which the person acquired in excess of 15% of our outstanding voting stock, unless the merger or combination is approved in a prescribed manner.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Furthermore, our restated certificate of incorporation that became effective upon the closing of our IPO specifies that, unless we consent in writing to the selection of an alternative forum, the Court of Chancery of the State of Delaware will be the sole and exclusive forum for most legal actions involving actions brought against us by stockholders. We believe this provision benefits us by providing increased consistency in the application of Delaware law by chancellors particularly experienced in resolving corporate disputes, efficient administration of cases on a more expedited schedule relative to other forums and protection against the burdens of multi-forum litigation. However, the provision may have the effect of discouraging lawsuits against our directors and officers. The enforceability of similar choice of forum provisions in other companies&#8217; certificates of incorporation has been challenged in legal proceedings, and it is possible that, in connection with any applicable action brought against us, a court could find the choice of forum provisions contained in our restated certificate of incorporation to be inapplicable or unenforceable in such action.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Our bylaws designate the Court of Chancery of the State of Delaware as the sole and exclusive forum for certain types of actions and proceedings that may be initiated by our stockholders, which could limit our stockholders&#8217; ability to obtain a favorable judicial forum for disputes with us or our directors, officers or employees.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">Our bylaws provide that, unless we consent in writing to the selection of an alternative forum, the Court of Chancery of the State of Delaware is the exclusive forum for certain types of actions and proceedings that may be initiated by our stockholders with respect to our company and our directors. This choice of forum provision may limit a stockholder&#8217;s ability to bring a claim in a judicial forum that the stockholder believes is favorable for disputes with us or our directors, which may discourage meritorious claims from being asserted against us and our directors. Alternatively, if a court were to find this provision of our charter inapplicable to, or unenforceable in respect of, one or more of the </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">63</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">specified types of actions or proceedings, we may incur additional costs associated with resolving such matters in other jurisdictions, which could adversely affect our business, financial condition or results of operations. We adopted this provision because we believe it makes it less likely that we will be forced to incur the expense of defending duplicative actions in multiple forums and less likely that plaintiffs&#8217; attorneys will be able to employ such litigation to coerce us into otherwise unjustified</p><a id="_caea4368_11ca_410b_a47c_a734afe00d65"></a><a id="Item1BUnresolvedStaffComments_556571"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Item&#160;1B. Unresolved Staff Comments.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">None.</p><a id="_66ccab4b_0e28_41f0_8c44_7a7c032c01ec"></a><a id="Item2Properties_424245"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Item&#160;2. Properties.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Our offices are in Berwyn, Pennsylvania, where we have leased and have access to 1,500&#160;square feet of office space pursuant to a short-term lease agreement. We believe that our facilities are adequate to meet our current needs.</p><a id="_9a7abefa_2899_4edd_9dc5_5635730092d7"></a><a id="Item3LegalProceedings_59244"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Item&#160;3. Legal Proceedings.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">From time to time, we may become subject to litigation and claims arising in the ordinary course of business. We are not currently a party to any material legal proceedings, and we are not aware of any pending or threatened legal proceedings against us that we believe could have a material adverse effect on our business, operating results or financial condition.</p><a id="_f7268958_74a0_4c05_8ff3_68f3ebc5688b"></a><a id="Item4MineSafetyDisclosures_448345"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Item&#160;4. Mine Safety Disclosures.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Not applicable.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">64</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_e4d1616c_6c0a_4c92_b121_eee9e4cdebc4"></a><a id="PARTII_847922"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 12pt 0pt;">PART&#160;II</p><a id="Item5MarketforRegistrantsCommonEquityRel"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Item&#160;5. Market for Registrant&#8217;s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Market Information</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="white-space:pre-wrap;">Our common stock is listed on the New York Stock Exchange under the symbol &#8220;ANVS&#8221;.  Our common stock began trading on the New York Stock Exchange on November 18, 2021.  From January 29, 2020, the date of our initial public offering, to November 17, 2021, our common stock traded on the NYSE American.  Prior to January 29, 2020, there was no public market for our stock.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Holders of Record</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">As of February 28, 2022, there were approximately 18 holders of record of shares of our common stock. This number does not reflect the beneficial holders of our common stock who hold shares in street name through brokerage accounts or other nominees.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Dividend Policy</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We have never declared or paid any cash dividends on our common stock. We currently intend to retain all available funds and any future earnings to support our operations and finance the growth and development of our business. We do not intend to pay cash dividends on our common stock for the foreseeable future.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Securities Authorized for Issuance Under Equity Compensation Plans</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The information called for by this item regarding equity compensation plans is incorporated by reference to Part&#160;III,&#160;Item&#160;12 of this Annual Report on Form&#160;10-K.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Issuer Purchases of Equity Securities</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">None.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Recent Sales of Unregistered Securities</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">We did not issue any equity securities during the year ended December 31, 2021 that were not registered under the Securities Act and that have not otherwise been described in a Quarterly Report on Form 10-Q or a Current Report on Form 8-K.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_0966ff53_6d68_4b30_91cc_301f3bbece07"></a><a id="Item6SelectedFinancialData_944064"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Item&#160;6. Selected Financial Data</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">This item is not required for smaller reporting companies.</p><a id="_561d0307_27d4_4754_9d37_e8e2843d33e4"></a><a id="Item7ManagementsDiscussionandAnalysisofF"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Item&#160;7. Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">You should read the following discussion and analysis of our financial condition and results of operations together with our financial statements and the related notes appearing at the end of this Annual Report on Form&#160;10-K. Some of the information contained in this discussion and analysis or set forth elsewhere in this Annual Report on Form&#160;10-K, including information with respect to our plans and strategy for our business and related financing, includes forward-looking statements that involve risks and uncertainties. You should read &#8220;Cautionary Note&#160;Regarding Forward-Looking Statements&#8221; and Item&#160;1A. Risk Factors of this Annual Report on Form&#160;10-K for a discussion of important factors that could cause actual results to differ materially from the results described in or implied by the forward-looking statements contained in the following discussion and analysis.</i></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">65</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Overview</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Company Overview</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We are a clinical stage, drug platform company addressing Alzheimer&#8217;s disease (&#8220;AD&#8221;), Parkinson&#8217;s disease (&#8220;PD&#8221;) and other chronic neurodegenerative diseases such as AD in Down Syndrome (&#8220;AD-DS&#8221;). Our lead compound, Buntanetap, is a small molecule administered orally that attacks neurodegeneration by entering the brain and inhibiting the translation of neurotoxic proteins&#8212;amyloid precursor protein APP/A&#946; (&#8220;APP&#8221;), tau/phospho-tau (&#8220;tau&#8221;) and &#945;-Synuclein (&#8220;&#945;SYN&#8221;)&#8212;thereby improving axonal transport. Human studies in four mildly cognitive impaired patients have shown that Buntanetap lowered the levels of neurotoxic proteins and inflammatory factors. In preclinical studies, lower neurotoxic protein levels led to improved axonal transport, reduced inflammation, lower nerve cell death and improved function.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">AD is a substantial market affecting over 30&#160;million people worldwide and is expected to grow to over 100&#160;million by 2050. While the market for neurodegeneration is over $100&#160;billion, to date there are no disease modifying drugs for any neurodegenerative condition. Enormous efforts have gone into developing better drugs to treat neurodegeneration and the outcomes have been sobering. The results of clinical trials in AD, the two AD orphan indications AD-DS and early onset familial AD or in PD have not supported the development of successful disease modifying therapies.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Buntanetap is a small lipophilic molecule that is orally available and readily enters the brain, as demonstrated by preclinical pharmacokinetics analyses showing brain concentrations approximately six to eight times higher than plasma concentrations. Buntanetap has a mechanism of action that we believe to be unique, in that it inhibited the over-translation of and, therefore, reduced the levels of several neurotoxic proteins both <i style="font-style:italic;">in vitro</i> and <i style="font-style:italic;">in vivo</i> including APP, tau and &#945;SYN.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">By targeting multiple neurotoxic proteins, Buntanetap resembles a combination therapy approach, with the added convenience of being a single drug with a single drug target. Therefore, we have worked to understand how Buntanetap is able to inhibit the translation of more than one neurotoxic protein.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="white-space:pre-wrap;">We recently completed two Phase 2a clinical trials. In 2021 we completed a Phase 2a clinical trial in 14 AD and 54 PD patients (the &#8220;AD/PD Trial&#8221;) which began treating patients in August 2020.  In collaboration with the Alzheimer&#8217;s Disease Cooperative Study (&#8220;ADCS&#8221;) we conducted a trial in 16 early AD patients (the &#8220;ADCS Trial&#8221;). Both clinical trials were double-blind, placebo-controlled studies. We designed the two Phase 2a studies by applying our understanding of the underlying disease states in neurodegeneration and measured not just target, but also pathway validation in the spinal fluid of these patients. We measured as many factors as possible associated with the toxic cascade which begins with high levels of neurotoxic proteins which lead to impaired axonal transport, inflammation, the death of nerve cells and loss of cognition and motor function. By showing both target and pathway validation in two patient populations, we believe that our opportunity for successful Phase 3 studies is better than if we merely demonstrated target validation in one patient population.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We have never been profitable and have incurred net losses since inception. Our accumulated deficit at December&#160;31, 2021 was $28,726.2 thousand. We expect to incur losses for the foreseeable future, and we expect these losses to increase as we continue our development of, and seek regulatory approvals for, our product candidates. Because of the numerous risks and uncertainties associated with product development, we are unable to predict the timing or amount of increased expenses or when, or if, we will be able to achieve or maintain profitability.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Financial Operations Overview</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The following discussion sets forth certain components of our statements of operations as well as factors that impact those items.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">66</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Research and Development Expenses</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Our research and development expenses consist of expenses incurred in development and clinical studies relating to our product candidates, including:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">expenses associated with clinical development;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">personnel-related expenses, such as salaries, benefits, travel and other related expenses, including stock-based compensation; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">payments to third-party contract research organizations (&#8220;CROs&#8221;), contractor laboratories and independent contractors.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We expense all research and development costs as incurred. Clinical development expenses for our product candidates are a significant component of our current research and development expenses. Product candidates in later stage clinical development generally have higher research and development expenses than those in earlier stages of development, primarily due to increased size and duration of the clinical trials. We track and record information regarding external research and development expenses for each study or trial that we conduct. From time to time, we use third-party CROs, contractor laboratories and independent contractors in clinical studies. We recognize the expenses associated with third parties performing these services for us in our clinical studies based on the&#160;percentage of each study completed at the end of each reporting period.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="white-space:pre-wrap;">Our research and development expenses in 2021 and 2020 primarily related to the AD/PD Trial which began treating patients in August 2020.  In addition, we completed two long-term animal toxicology studies &#8212; a six-month study in rats and a nine-month study in dogs &#8212; which began in November&#160;2019 and were substantially complete as of December 31, 2020. We expect that our research and development expenses in 2022 and for the next several&#160;years will be higher than in 2021 as a result of costs associated with the initiation of our planned Phase 3 trials. These expenditures are subject to numerous uncertainties regarding timing and cost to completion. Completion of our clinical development and clinical trials may take several&#160;years or more and the length of time generally varies according to the type, complexity, novelty and intended use of our product candidates. The cost of clinical trials may vary significantly over the life of a project as a result of differences arising during clinical development, including, among others:</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the number of sites included in the clinical trials;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the length of time required to enroll suitable patients;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the size of patient populations participating in the clinical trials;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the duration of patient follow-ups;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the development stage of the product candidates; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the efficacy and safety profile of the product candidates.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Due to the stage of our research and development, we are unable to determine the duration or completion costs of our development of Buntanetap. As a result of the difficulties of forecasting research and development costs of Buntanetap as well as the other uncertainties discussed above, we are unable to determine when and to what extent we will generate revenues from the commercialization and sale of approved product candidates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">General and Administrative Expenses</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">General and administrative expenses consist primarily of salaries, benefits and other related costs, including stock-based compensation, for personnel serving in our executive, finance, accounting, and administrative functions. Our </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">67</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">general and administrative expenses also include professional fees for legal services, including patent-related expenses, consulting, tax and accounting services, insurance, rent and general corporate expenses. We expect that our general and administrative expenses will increase with the continued development and potential commercialization of our product candidates. We expect that our general and administrative expenses in 2022 and for the next several&#160;years will be higher than in 2021 as we increase our employee count.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Grant Income</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Grants received are recognized as grant income in the statements of operations as and when they are earned for the specific research and development projects for which these grants are designated. In September&#160;2019, as modified in September 2020, we received a Notice of Award for a $1.9 million grant from the National Institute on Aging of the NIH to cover the costs of long-term toxicology studies on Buntanetap in rats and dogs. The costs of the studies and the grant income were substantially completed as of December 31, 2020.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Income Taxes</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">As of December 31, 2021, the Company had U.S. federal net operating loss (&#8220;NOL&#8221;) carryforwards of $21,844,192, which may be available to offset future income tax liabilities. Federal NOL carryforwards generated in 2017 and prior of $2,764,240 will expire beginning 2032. The remaining federal NOL carryforwards generated beginning in 2018, do not expire. Following the enactment of the Coronavirus Aid, Relief, and Economic Security Act in March 2020, NOL carryforwards generated from 2018 through 2020 are permitted to offset 100% of taxable income in future&#160;years. NOL carryforwards generated beginning in 2021 are permitted to offset 80% of taxable income in future&#160;years.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">NOL and tax credit carryforwards are subject to review and possible adjustment by the Internal Revenue Service (the &#8220;IRS&#8221;) and may become subject to an annual limitation in the event of certain cumulative changes in the ownership interest of significant shareholders over a three-year period in excess of 50% as defined under Sections&#160;382 and 383 in the Internal Revenue Code. This could substantially limit the amount of tax attributes that can be utilized annually to offset future taxable income or tax liabilities. The amount of the annual limitation is determined based on our value immediately prior to the ownership change. Subsequent ownership changes may further affect the limitation in future&#160;years.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Critical Accounting Policies and Use of Estimates</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We have based our management&#8217;s discussion and analysis of financial condition and results of operations on our financial statements, which have been prepared in accordance with accounting principles generally accepted in the United States of America. The preparation of these financial statements requires us to make estimates that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements as well as the reported revenues and expenses during the reporting periods. On an ongoing basis, we evaluate our estimates and judgments, including those related to clinical development expenses, stock-based compensation and grant income. We base our estimates on historical experience and on various other factors that we believe to be appropriate under the circumstances. Actual results may differ from these estimates under different assumptions or conditions.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">While our significant accounting policies are more fully discussed in Note&#160;2 to our audited financial statements appearing at the end of this Annual Report on Form&#160;10-K, we believe that the following accounting policies are critical to the process of making significant judgments and estimates in the preparation of our financial statements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Research and Development Expenses</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">We rely on third parties to conduct our clinical studies and to provide services, including data management, statistical analysis and electronic compilation. At the end of each reporting period, we compare the payments made to each service provider to the estimated progress towards completion of the related project. Factors that we consider in preparing these estimates include the number of patients enrolled in studies, milestones achieved and other criteria </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">68</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">related to the efforts of our vendors. These estimates are subject to change as additional information becomes available. Depending on the timing of payments to vendors and estimated services provided, we record net prepaid or accrued expenses related to these costs.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Stock-Based Compensation</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We account for grants of stock options to employees and non-employees based on their grant date fair value and recognize compensation expense over the vesting periods. We estimate the fair value of stock options as of the date of grant using the Black-Scholes option pricing model. The Black-Scholes model requires us to make assumptions and judgments about the variables used in the calculations, including the expected term, the expected volatility of our common stock, the risk-free interest rate and the expected dividend rate. Given the lack of a public market for our common stock prior to the IPO, the expected stock price volatility is based on a weighted approach that incorporates the historic daily volatility of our common stock since the IPO and the historic daily volatility of similar companies that have been publicly traded for a period commensurate with the expected term of the option.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Grant Income</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Grants received are recognized as grant income in the statements of operations as and when they are earned for the specific research and development projects for which these grants are designated. Grants payments received in excess of grant income earned are recognized as deferred grant on the balance sheet and grant income earned in excess of grant payments received is recognized as grant receivable on the balance sheets.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Results of Operations</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">Operating expenses and other income (expense) were comprised of the following:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:72.9%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.14%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.14%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:72.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:23.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year Ended </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:72.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:23.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:72.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">&#160;</p></td></tr><tr style="height:0pt;visibility:hidden;"><td colspan="8" style="padding:0pt;"></td></tr><tr><td style="vertical-align:bottom;width:72.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:23.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(in&#160;thousands)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:72.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Operating expenses:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:72.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Research and development</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 8,479.0</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 3,054.0</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:72.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">General and administrative</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 6,058.2</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 3,586.2</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:72.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Other income (expense):</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:72.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Change in fair value of derivative liability</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (26.5)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:72.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Interest income, net</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 13.3</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 47.2</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:72.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Grant income</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 36.8</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 1,157.4</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Years ended December 31, 2021 and 2020</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Research and Development Expenses</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Research and development expenses increased by $5,425.0 thousand for the&#160;year ended December 31, 2021 compared to the&#160;year ended December 31, 2020. The increase was primarily the result of an increase of $3,559.8 thousand in expenses related to our clinical trials, including production of material, an increase in stock-based compensation expense of $1,878.0 thousand, and an increase of $599.5 thousand in other personnel expenses, partially offset by a decrease of $725.8 thousand in expenses related to our long-term toxicology studies.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">General and Administrative Expenses</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">General and administrative expenses increased by $2,472.0 thousand for the&#160;year ended December 31, 2021 compared to the&#160;year ended December 31, 2020. The increase was primarily the result of increases of $954.7 thousand in stock-based compensation expense, $458.4 thousand in other personnel expenses, an increase of $560.4 thousand in professional fees and recruiting expenses, and an increase of $259.5 thousand in conference and meeting expenses.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">69</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Change in Fair Value of Derivative Liability</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The derivative liability represents an embedded derivative in our convertible promissory notes which were issued in March&#160;<span style="white-space:pre-wrap;">2019. At each balance sheet date, we estimated the fair value of the derivative liability and recognized any change in our statements of operations. The fair value of the derivative liability was adjusted to $132.5 thousand immediately prior to the closing of our IPO on January 31, 2020.  Effective upon the closing of the IPO, the derivative liability was eliminated, and the amount was reclassified to additional paid-in capital on the balance sheet.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Interest Income, Net</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Interest income, net decreased $33.9 thousand for the&#160;year ended December 31, 2021 compared to the&#160;<span style="white-space:pre-wrap;">year ended December 31, 2020. The decrease was primarily the result of lower interest rates compared to the prior year.  </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Grant Income</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Grant income decreased $1,120.6 thousand for the&#160;year ended December 31, 2021 compared to the&#160;year ended December 31, 2020. The decrease was the result of income recognized related to a grant from the NIH to reimburse the costs of our long-term toxicology studies in rats and dogs, which studies began in November&#160;2019 and were substantially completed as of December 31, 2020.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Liquidity and Capital Resources</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Since our inception in 2008, we have devoted most of our cash resources to research and development and general and administrative activities. We have financed our operations primarily with the proceeds from the sale of common stock, convertible preferred stock and convertible promissory notes. To date, we have not generated any revenues from the sale of products, and we do not anticipate generating any revenues from the sales of products for the foreseeable future. We have incurred losses and generated negative cash flows from operations since inception. As of December 31, 2021, our principal source of liquidity was our cash, which totaled $45,686.0 thousand.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Equity Financings</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We closed our IPO on January&#160;31, 2020, raising gross proceeds of $13,800.0 thousand and net proceeds of $12,034.4 thousand, after deducting underwriting discounts and issuance costs.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We closed an equity offering on May 26, 2021, raising gross proceeds of $50,000.0 thousand and net proceeds of $46,648.4 thousand, after deducting underwriting discounts and issuance costs.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Debt Financings</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In March 2019 we issued $530.0 thousand principal amount of convertible promissory notes. Upon the closing of our IPO on January&#160;31, 2020, the outstanding convertible promissory notes plus accrued interest converted into 118,470 shares of our common stock at a 20% discount to the public offering price.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Future Capital Requirements</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We expect that current cash and cash equivalents will be sufficient to fund our operations and capital requirements for at least the next 12&#160;months. We believe that these available funds will be sufficient to complete a Phase&#160;3 clinical trial for Buntanetap in PD and conduct a second Phase&#160;3 study in AD or PD for this product candidate. However, it is difficult to predict our spending for our product candidates prior to obtaining FDA approval. Moreover, changing circumstances may cause us to expend cash significantly faster than we currently anticipate, and we may need to spend more cash than currently expected because of circumstances beyond our control.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">To the extent that our capital resources are insufficient to meet our future operating and capital requirements, we will need to finance our cash needs through public or private equity offerings, debt financings, collaboration and </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">70</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">licensing arrangements or other financing alternatives. We have no committed external sources of funds. Additional equity or debt financing or collaboration and licensing arrangements may not be available on acceptable terms, if at all.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Cash Flows</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">The following table summarizes our cash flows from operating, investing and financing activities.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:72.92%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.17%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:72.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:22.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Year Ended </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:72.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:22.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:72.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style="height:0pt;visibility:hidden;"><td colspan="8" style="padding:0pt;"></td></tr><tr><td style="vertical-align:bottom;width:72.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:22.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">(in&#160;thousands)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:72.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Statement of Cash Flows Data:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:72.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total net cash provided by (used in):</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:72.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Operating activities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> (9,132.1)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> (3,970.8)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:72.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Financing activities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 46,743.5</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 12,043.6</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:72.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Increase in cash and cash equivalents</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.17%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 37,611.4</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.34%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 8,072.8</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Years ended December 31, 2021 and 2020</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Operating Activities</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">For the&#160;year ended December 31, 2021, cash used in operations was $9,132.1 thousand compared to $3,970.8 thousand for the&#160;year ended December 31, 2020. The increase in cash used in operations was primarily the result of the costs associated with our AD/PD Trial and higher personnel expenses.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We expect cash used in operating activities to increase in 2022 as compared to 2021 due to an expected increase in our operating losses associated with ongoing development of our product candidates and planned increases in our personnel count. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Financing Activities</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Cash provided by financing activities was $46,743.5 thousand during the&#160;year ended December 31, 2021, attributable to net proceeds from our equity offering of approximately $46,648.4 thousand and proceeds from the exercise of stock options of $95.1 thousand. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Cash provided by financing activities was $12,043.6 thousand during the year ended December 31, 2020, attributable to net proceeds from our IPO of $12,034.4 thousand, after deducting underwriting discounts and issuance costs, and proceeds from the exercise of stock options of $9.2 thousand.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Recent Accounting Pronouncements</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In December&#160;2019, the FASB issued ASU No.&#160;2019-12,&#160;Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes. The amendments in ASU 2019-12 simplify the accounting for income taxes by removing certain exceptions to the general principles in Topic 740 and clarifying and amending existing guidance. The new standard is effective for fiscal&#160;years, and interim periods within those fiscal&#160;years, beginning after December&#160;15, 2020, with early adoption permitted. The adoption of this standard did not have an impact on our financial statements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Significant Contractual Obligations and Commitments</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 18pt;">We lease our office facilities under a&#160;month-to-month operating lease.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Off-Balance Sheet Arrangements</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We do not have any off-balance sheet arrangements, as defined by applicable SEC regulations.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">71</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">JOBS Act</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Section&#160;107 of the JOBS Act also provides that an &#8220;emerging growth company&#8221; can take advantage of the extended transition period provided in Section&#160;7(a)(2)(B)&#160;of the Securities Act for complying with new or revised accounting standards. In other words, an &#8220;emerging growth company&#8221; can delay the adoption of new or revised accounting standards until those standards would otherwise apply to private companies. We have irrevocably elected not to avail ourselves of this exemption from new or revised accounting standards and, therefore, we will be subject to the same new or revised accounting standards as other public companies that are not emerging growth companies.</p><a id="_25871daa_0268_4827_8c9f_74c34110ad22"></a><a id="Item7AQuantitativeandQualitativeDisclosu"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Item&#160;7A. Quantitative and Qualitative Disclosures About Market Risk.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">This item is not required for smaller reporting companies.</p><a id="_260a0f72_6759_4ecd_bdb6_7aed897bf19b"></a><a id="Item8FinancialStatementsandSupplementary"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Item&#160;8. Financial Statements and Supplementary Data.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Our financial statements, accompanying notes and Report of Independent Registered Public Accounting Firm are included in this Annual Report on Form&#160;10-K beginning on page&#160;F-1, which are incorporated in this Item&#160;8 by reference.</p><a id="_0dde3af7_b648_4a11_9772_1f15ba0d846a"></a><a id="Item9ChangesinandDisagreementswithAccoun"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Item&#160;9. Changes in and Disagreements with Accountants on Accounting and Financial Disclosure.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">None.</p><a id="_ddf0d448_01e9_44a9_993e_b4ec8cf22356"></a><a id="Item9AControlsandProcedures_371514"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Item&#160;9A. Controls and Procedures.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Evaluation of Disclosure Controls and Procedures.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Our management, with the participation of our Chief Executive Officer and Chief Financial Officer, has evaluated the effectiveness of our disclosure controls and procedures (as such term is defined in Rules&#160;13a-15(e)&#160;and 15d-15(e)&#160;under the Exchange Act) as of the end of the period covered by this Annual Report on Form&#160;10-K. Management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving their objectives and management necessarily applies its judgment in evaluating the cost benefit relationship of possible controls and procedures. Based on such evaluation, our Chief Executive Officer and Chief Financial Officer have concluded that, as of the end of the period covered by this report, our disclosure controls and procedures were effective to ensure that the information required to be disclosed by us in the reports that it files or submits under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in SEC rules&#160;and forms, and that information required to be disclosed in the reports we file or submit under the Exchange Act is accumulated and communicated to our management, including our Chief Executive Officer and Chief Financial Officer, as our principal financial and accounting officer, to allow timely decisions regarding required disclosures.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Management&#8217;s Report on Internal Control Over Financial Reporting</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Management is responsible for establishing and maintaining adequate internal control over financial reporting as defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act. Our internal control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles. Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Management utilized the criteria established in the Internal Control &#8211; Integrated Framework (2013)&#160;issued by the Committee of Sponsoring Organizations of the Treadway Commission (COSO) to conduct an assessment of the effectiveness of our internal control over financial reporting as of December 31, 2021. Based on the assessment, management has concluded that, as of December 31, 2021, our internal control over financial reporting was effective.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">72</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">As an emerging growth company, management&#8217;s assessment of internal control over financial reporting was not subject to attestation by our independent registered public accounting firm.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Changes in Internal Control Over Financial Reporting</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">There was no change in our internal control over financial reporting identified in connection with the evaluation required by Rule&#160;13a-15(d)&#160;and 15d-15(d)&#160;of the Exchange Act that occurred during the quarter ended December&#160;31, 2021 that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.</p><a id="_45816286_8bdd_41df_8517_f60c669b73fe"></a><a id="Item9BOtherInformation_404053"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Item&#160;9B. Other Information.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="font-weight:normal;">None.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_ebd857dc_85c5_4e20_819f_b382c5cff697"></a><a id="PARTIII_953652"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">PART&#160;III</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><a id="Item10DirectorsandExecutiveOfficersandCo"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Item&#160;10. Directors and Executive Officers and Corporate Governance.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We incorporate the information required by this Item&#160;10 by reference to the definitive proxy statement for our 2022 annual meeting of shareholders, to be filed with the SEC.</p><a id="_56171543_18b2_419b_87c7_043a7276d941"></a><a id="Item11ExecutiveCompensation_144002"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Item&#160;11. Executive Compensation.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We incorporate the information required by this Item&#160;11 by reference to the definitive proxy statement for our 2022 annual meeting of shareholders, to be filed with the SEC.</p><a id="_f6490945_6111_42e5_b5ac_a2e5139f5f56"></a><a id="Item12SecurityOwnershipofCertainBenefici"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Item&#160;12. Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We incorporate the information required by this Item&#160;12 by reference to the definitive proxy statement for our 2022 annual meeting of shareholders, to be filed with the SEC.</p><a id="_6f050778_a849_49e4_9848_db7343aaecf0"></a><a id="Item13CertainRelationshipsandRelatedTran"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Item&#160;13. Certain Relationships and Related Transactions and Director Independence.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We incorporate the information required by this Item&#160;13 by reference to the definitive proxy statement for our 2022 annual meeting of shareholders, to be filed with the SEC.</p><a id="_0d3e426f_f3ec_4021_8e52_8b33d6f74037"></a><a id="Item14PrincipalAccountantsFeesandService"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Item&#160;14. Principal Accountants Fees and Services.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We incorporate the information required by this Item&#160;14 by reference to the definitive proxy statement for our 2022 annual meeting of shareholders, to be filed with the SEC.</p><a id="_a8c77673_44b4_4688_b95f_a170ae7c1872"></a><a id="PARTIV_494222"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 12pt 0pt;">PART&#160;IV</p><a id="Item15ExhibitsandFinancialStatementSched"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Item&#160;15. Exhibits and Financial Statement Schedules.</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(a)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Documents filed as part of this report:</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:54pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">1.</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Financial Statements. The financial statements as set forth under Item&#160;8 of this Annual Report on Form&#160;10-K are incorporated herein.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:54pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">2.</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Financial Statement Schedules. All financial statement schedules have been omitted because they are not applicable, not required, or the information is shown in the financial statements or related notes.</span></td></tr></table></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">73</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:54pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">3.</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Exhibits. See (b)&#160;below.</span></td></tr></table><div style="margin-top:12pt;"></div><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(b)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Exhibits</span></td></tr></table><div style="margin-top:12pt;"></div><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;table-layout:auto;width:100%;"><tr style="height:1pt;"><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:12.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></th><th style="font-weight:normal;text-align:left;vertical-align:top;width:1.84%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:86.1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></th></tr><tr><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:12.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Exhibit</b><br /><b style="font-weight:bold;">Number</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:top;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:86.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Description of Exhibit</b></p></th></tr><tr><td style="vertical-align:bottom;width:12.05%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:86.1%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:12.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0pt 7pt;">3.1</p></td><td style="vertical-align:top;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:86.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1477845/000110465920011925/tm206971d1_ex3-1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Amended and Restated Certificate of Incorporation of the Registrant. (Incorporated by reference to Exhibit&#160;3.1 to Form&#160;8-K filed February&#160;6, 2020.)</span></a></p></td></tr><tr><td style="vertical-align:bottom;width:12.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:86.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:12.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0pt 7pt;">3.2</p></td><td style="vertical-align:top;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:86.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1477845/000110465920011925/tm206971d1_ex3-2.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Amended and Restated Bylaws of the Registrant. (Incorporated by reference to Exhibit&#160;3.2 to Form&#160;8-K filed February&#160;6, 2020.)</span></a></p></td></tr><tr><td style="vertical-align:bottom;width:12.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:86.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:12.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0pt 7pt;">4.1</p></td><td style="vertical-align:top;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:86.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1477845/000104746919005362/a2239691zex-4_1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Specimen Certificate evidencing shares of the Registrant&#8217;s common stock. (Incorporated by reference to Exhibit&#160;4.1 to Amendment No.&#160;3 to Form&#160;S-1 filed September&#160;20, 2019.)</span></a></p></td></tr><tr><td style="vertical-align:bottom;width:12.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:86.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:12.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0pt 7pt;">4.2</p></td><td style="vertical-align:top;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:86.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1477845/000110465920038326/tm2013055d1_ex4-2.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Form&#160;of Warrant to purchase common stock issued to ThinkEquity, a division of Fordham Financial Management,&#160;Inc. in connection with the closing of the IPO. (Incorporated by reference to Exhibit&#160;4.2 to Form 10-K filed March 25, 2020.)</span></a></p></td></tr><tr><td style="vertical-align:bottom;width:12.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:86.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:12.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0pt 7pt;">4.3</p></td><td style="vertical-align:top;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:86.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1477845/000110465920038326/tm2013055d1_ex4-3.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Description of Registrant&#8217;s Securities. (Incorporated by reference to Exhibit&#160;4.3 to Form 10-K filed March 25, 2020.)</span></a></p></td></tr><tr><td style="vertical-align:bottom;width:12.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:86.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:12.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0pt 7pt;">10.1+</p></td><td style="vertical-align:top;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:86.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1477845/000110465920038326/tm2013055d1_ex10-1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Second Amended and Restated Employment Agreement dated as of March&#160;24, 2020 between the Registrant and Maria Maccecchini. (Incorporated by reference to Exhibit&#160;10.1 to Form 10-K filed March 25, 2020.)</span></a></p></td></tr><tr><td style="vertical-align:bottom;width:12.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:86.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:12.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0pt 7pt;">10.2+</p></td><td style="vertical-align:top;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:86.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1477845/000104746919003982/a2239177zex-10_2.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Annovis Bio,&#160;Inc. 2018 Equity Incentive Plan. (Incorporated by reference to Exhibit&#160;10.2 to Form&#160;S-1 filed July&#160;3, 2019.)</span></a></p></td></tr><tr><td style="vertical-align:top;width:12.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:86.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:12.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0pt 7pt;">10.3</p></td><td style="vertical-align:top;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:86.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1477845/000104746919004651/a2239387zex-10_5.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Registration Rights Agreement dated as of December&#160;19, 2014 among the Registrant and the signatories thereto. (Incorporated by reference to Exhibit&#160;10.5 to Amendment No.&#160;1 to Form&#160;S-1 filed August&#160;8, 2019.)</span></a></p></td></tr><tr><td style="vertical-align:bottom;width:12.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:86.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:12.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0pt 7pt;">10.4</p></td><td style="vertical-align:top;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:86.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1477845/000104746919003982/a2239177zex-10_7.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Investigator-Initiated Clinical Trial Agreement dated June&#160;27, 2016 between The Regents of the University of California and the Registrant. (Incorporated by reference to Exhibit&#160;10.7 to Form&#160;S-1 filed July&#160;3, 2019.)</span></a></p></td></tr><tr><td style="vertical-align:top;width:12.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:86.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:12.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">10.5+</p></td><td style="vertical-align:top;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:86.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1477845/000104746919004651/a2239387zex-10_8.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Annovis Bio,&#160;Inc. 2019 Equity Incentive Plan. (Incorporated by reference to Appendix A to the Proxy Statement on Schedule 14A filed on April 19, 2021.)</span></a></p></td></tr><tr><td style="vertical-align:top;width:12.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:86.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:12.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">10.6+</p></td><td style="vertical-align:top;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:86.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1477845/000110465920038326/tm2013055d1_ex10-9.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Employment Agreement dated as of March&#160;24, 2020 between the Registrant and Jeffrey McGroarty. (Incorporated by reference to Exhibit&#160;10.9 to Form 10-K filed March 25, 2020.)</span></a></p></td></tr><tr><td style="vertical-align:top;width:12.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:86.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:12.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0pt 7pt;">23.1</p></td><td style="vertical-align:top;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:86.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="anvs-20211231xex23d1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Consent of WithumSmith+Brown, PC.</span></a></p></td></tr><tr><td style="vertical-align:top;width:12.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:86.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:12.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0pt 7pt;">24.1</p></td><td style="vertical-align:top;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:86.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Power_of_Attorney"><span style="font-style:normal;font-weight:normal;">Power of Attorney</span></a>. (Included on signature page to this Annual Report on Form&#160;10-K.)</p></td></tr><tr><td style="vertical-align:top;width:12.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:86.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:12.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0pt 7pt;">31.1</p></td><td style="vertical-align:top;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:86.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="anvs-20211231xex31d1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Certification Pursuant to Section&#160;302 of the Sarbanes-Oxley Act of 2002.</span></a></p></td></tr><tr><td style="vertical-align:top;width:12.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:86.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:12.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0pt 7pt;">31.2</p></td><td style="vertical-align:top;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:86.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="anvs-20211231xex31d2.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Certification Pursuant to Section&#160;302 of the Sarbanes-Oxley Act of 2002.</span></a></p></td></tr><tr><td style="vertical-align:top;width:12.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:86.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:12.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0pt 7pt;">32.1</p></td><td style="vertical-align:top;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:86.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="anvs-20211231xex32d1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Certification Pursuant to Section&#160;906 of the Sarbanes-Oxley Act of 2002.</span></a></p></td></tr><tr><td style="vertical-align:top;width:12.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:86.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">74</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;min-height:13.8pt;"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;table-layout:auto;width:100%;"><tr style="height:1pt;"><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:12.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></th><th style="font-weight:normal;text-align:left;vertical-align:top;width:1.84%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:86.1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></th></tr><tr><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:12.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Exhibit</b><br /><b style="font-weight:bold;">Number</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:top;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:86.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Description of Exhibit</b></p></th></tr><tr><td style="vertical-align:top;width:12.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0pt 7pt;">32.2</p></td><td style="vertical-align:top;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:86.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="anvs-20211231xex32d2.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Certification Pursuant to Section&#160;906 of the Sarbanes-Oxley Act of 2002.</span></a></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:12.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:bottom;width:1.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:top;width:86.09%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td></tr><tr><td style="vertical-align:top;width:12.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">101.INS</p></td><td style="vertical-align:bottom;width:1.85%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:86.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">XBRL Instance Document &#8211; the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document.</p></td></tr><tr><td style="vertical-align:top;width:12.05%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;width:1.85%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:86.09%;margin:0pt;padding:0pt;"></td></tr><tr><td style="vertical-align:top;width:12.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">101.SCH</p></td><td style="vertical-align:bottom;width:1.85%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:86.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">XBRL Taxonomy Extension Schema Document</p></td></tr><tr><td style="vertical-align:top;width:12.05%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;width:1.85%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:86.09%;margin:0pt;padding:0pt;"></td></tr><tr><td style="vertical-align:top;width:12.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">101.CAL</p></td><td style="vertical-align:bottom;width:1.85%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:86.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">XBRL Taxonomy Extension Calculation Linkbase Document</p></td></tr><tr><td style="vertical-align:top;width:12.05%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;width:1.85%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:86.09%;margin:0pt;padding:0pt;"></td></tr><tr><td style="vertical-align:top;width:12.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">101.DEF</p></td><td style="vertical-align:bottom;width:1.85%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:86.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">XBRL Taxonomy Extension Definition Linkbase Document</p></td></tr><tr><td style="vertical-align:top;width:12.05%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;width:1.85%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:86.09%;margin:0pt;padding:0pt;"></td></tr><tr><td style="vertical-align:top;width:12.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">101.LAB</p></td><td style="vertical-align:bottom;width:1.85%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:86.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">XBRL Taxonomy Extension Labels Linkbase Document</p></td></tr><tr><td style="vertical-align:top;width:12.05%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;width:1.85%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:86.09%;margin:0pt;padding:0pt;"></td></tr><tr><td style="vertical-align:top;width:12.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">101.PRE</p></td><td style="vertical-align:bottom;width:1.85%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:86.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">XBRL Taxonomy Extension Presentation Linkbase Document</p></td></tr><tr><td style="vertical-align:top;width:12.05%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;width:1.85%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:86.09%;margin:0pt;padding:0pt;"></td></tr><tr><td style="vertical-align:top;width:12.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">104</p></td><td style="vertical-align:bottom;width:1.85%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:86.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Cover Page Interactive Data File &#8211; the cover page interactive data file does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document.</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><div style="font-family:'Times New Roman','Times','serif';font-size:12.0pt;margin-bottom:0pt;margin-top:0pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1pt;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto 0 0;"></div></div><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">+</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">Indicates management contract or compensatory plan.</p></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(c)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Financial Statement Schedules</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">None.</p><a id="_ededa54a_39b7_403a_b499_3050e009d066"></a><a id="Item16Form10KSummary_558755"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Item&#160;16. Form&#160;10-K Summary.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">None.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="display:none;font-family:'Times New Roman','Times','serif';line-height:0pt;margin:0pt;"><span style="font-size:0pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">75</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_cff75dc5_fd4e_4b39_9729_1192d8bd6845"></a><a id="IndextoFinancialStatements"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">ANNOVIS BIO,&#160;INC.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Table of Contents</b></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;table-layout:auto;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:88.39%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;width:3.54%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:8.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:88.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:3.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;width:8.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:1pt;text-align:center;border-bottom:1px solid #000000;margin:0pt;"><b style="font-weight:bold;">Page(s)</b></p></td></tr><tr><td style="vertical-align:bottom;width:88.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#REPORTOFINDEPENDENTREGISTEREDPUBLICACCOU"><span style="font-style:normal;font-weight:normal;">Report of Independent Registered Public Accounting Firm</span></a></p></td><td style="vertical-align:top;width:3.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:8.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">F-2</p></td></tr><tr><td style="vertical-align:bottom;width:88.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#BalanceSheets_148726"><span style="font-style:normal;font-weight:normal;">Balance Sheets as of December 31, 2021 and 2020</span></a></p></td><td style="vertical-align:top;width:3.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:8.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">F-3</p></td></tr><tr><td style="vertical-align:bottom;width:88.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#StatementsofOperations_7171"><span style="font-style:normal;font-weight:normal;">Statements of Operations for the&#160;Years ended December 31, 2021 and 2020</span></a></p></td><td style="vertical-align:top;width:3.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:8.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">F-4</p></td></tr><tr><td style="vertical-align:bottom;width:88.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#StockholdersEquityDeficit_933195"><span style="font-style:normal;font-weight:normal;">Statements of Redeemable Convertible Preferred Stock and Stockholders&#8217; Equity (Deficit) for the&#160;Years ended December 31, 2021 and 2020</span></a></p></td><td style="vertical-align:top;width:3.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:8.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">F-5</p></td></tr><tr><td style="vertical-align:bottom;width:88.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#StatementsofCashFlows_169542"><span style="font-style:normal;font-weight:normal;">Statements of Cash Flows for the&#160;Years ended December 31, 2021 and 2020</span></a></p></td><td style="vertical-align:top;width:3.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:8.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">F-6</p></td></tr><tr><td style="vertical-align:bottom;width:88.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#NotestoFinancialStatements_177435"><span style="font-style:normal;font-weight:normal;">Notes&#160;to Financial Statements</span></a></p></td><td style="vertical-align:top;width:3.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:8.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">F-7</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-1</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_7c7be6e0_fc78_4c98_9294_6286e3919302"></a><a id="REPORTOFINDEPENDENTREGISTEREDPUBLICACCOU"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 12pt 0pt;">REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;">To the Stockholders and the Board of Directors of Annovis Bio,&#160;Inc.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Opinion on the Financial Statements</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We have audited the accompanying balance sheets of Annovis Bio,&#160;Inc. (the &#8220;Company&#8221;), as of December 31, 2021 and 2020, and the related statements of operations, statements of redeemable convertible preferred stock and stockholders&#8217; equity (deficit) and cash flows for each of the two&#160;years in the period ended December&#160;31, 2021 and the related notes (collectively referred to as the &#8220;financial statements&#8221;). In our opinion, the financial statements present fairly, in all material respects, the financial position of the Company as of December 31, 2021 and 2020, and the results of its operations and its cash flows for each of the two&#160;years in the period ended December&#160;31, 2021, in conformity with accounting principles generally accepted in the United States of America.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Basis for Opinion</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">These financial statements are the responsibility of the Company&#8217;s management. Our responsibility is to express an opinion on the Company&#8217;s financial statements based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (&#8220;PCAOB&#8221;) and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules&#160;and regulations of the Securities and Exchange Commission and the PCAOB.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audits to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. The Company is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part of our audits we are required to obtain an understanding of internal control over financial reporting but not for the purpose of expressing an opinion on the effectiveness of the Company&#8217;s internal control over financial reporting. Accordingly, we express no such opinion.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Our audits included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audits provide a reasonable basis for our opinion.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;">/s/ <ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_uhkxAiZ6fUeekYGgaMhCqA" name="dei:AuditorName" id="Narr_7dU9uXZymkWN95A6LJ2Gmw">WithumSmith+Brown, PC</ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;">We have served as the Company&#8217;s auditor since 2019.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_uhkxAiZ6fUeekYGgaMhCqA" name="dei:AuditorLocation" id="Narr_fhOrXnPF-0ybEcRVO8-hSQ">East Brunswick, New Jersey</ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;">March 2, 2022</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;">PCAOB ID Number <ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_uhkxAiZ6fUeekYGgaMhCqA" name="dei:AuditorFirmId" id="Narr_jc8ZWysILEKZvqbQaiT1xw">100</ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-2</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_718012d2_0d59_4fe6_b4d9_00e14983f7f8"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 12pt 0pt;">ANNOVIS BIO,&#160;INC.</p><a id="BalanceSheets_148726"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><b style="font-weight:bold;">Balance Sheets</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_6c5307e4_e7b3_4da2_9c91_7be2f777aa9f"></a><a id="Tc_4_6uNY9uiky3Klbyl5ao3w_1_2"></a><a id="Tc_c0Txx3xMFUSkmIkWUqIg8w_2_2"></a><a id="Tc_zNTPxZv4yUG4Jod--PtZZA_2_5"></a><a id="Tc_EE0QuhQRt0yK-FGOmKxWYg_4_0"></a><a id="Tc_-4sbuko7_EWdoQMmUBfhfQ_5_0"></a><a id="Tc_x6syRIV8BEKPC-n0aoJEjQ_6_0"></a><a id="Tc_xlEC0WNFbUWHRVds3cXK_A_6_2"></a><a id="Tc_hJxRaWMx5USx28YTB2ncWQ_6_5"></a><a id="Tc_49vedpWyBEu0qps-CLnr7Q_7_0"></a><a id="Tc_FHFssyAvLEOuSAQyOgrYTw_8_0"></a><a id="Tc_Dk6BN0WWWU-gDQhpYl6cAg_9_0"></a><a id="Tc_IVxT6CxyrUOTyMp9y5Jt1g_9_2"></a><a id="Tc_YKttsERYXEeio0T2BYyR_Q_9_5"></a><a id="Tc_LMj2a3Cy0EehsV89OXbgpw_10_0"></a><a id="Tc_pzpe8l35YU6anURwcjwuyQ_11_0"></a><a id="Tc_yt5tnERji0uAoieM1JfZBQ_12_0"></a><a id="Tc__tjbPsbYskOSxefcxfKLGA_12_2"></a><a id="Tc_li6e50teRkqhfq8gsTqOAA_12_5"></a><a id="Tc_e5WEouGaeESVIPtYFYsjsg_13_0"></a><a id="Tc_pUrvIrh_IUOHm9J-8bfEFg_14_0"></a><a id="Tc_6jIRbSRUlUCGPeSZHHpOKg_15_0"></a><a id="Tc_BCt0elEobU6x0e4yCEcF8g_16_0"></a><a id="Tc_Cgl9HrHzLEyBDde7fBGMHg_17_0"></a><a id="Tc_HiD4FM_TdUKDFUagDEyiUw_18_0"></a><a id="_6d558747_ea69_4a32_bf17_e8e414c7e7b5"></a><a id="_6d558747_ea69_4a32_bf17_e8e414c7e7b5_2"></a><a id="_6d558747_ea69_4a32_bf17_e8e414c7e7b5_3"></a><a id="Tc_5LYdJ0Yk-EmgoFZTP0WWtA_19_0"></a><a id="Tc_-0U5eVzzRECQNOdJnCOcvA_20_0"></a><a id="Tc_nFCX1Pg7-Umxk9EN6BGFcQ_21_0"></a><a id="Tc_vTAcWsvRpEWTtGI3lcQz2A_22_0"></a><a id="Tc_eKON9YfmfEevcw1Q3tywDA_23_0"></a><a id="Tc_vRShV8z700aYBR35U-V8vQ_23_2"></a><a id="Tc_3YKxVo6TUk6yW9x_37BuXw_23_5"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:69.43%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.7%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:69.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:28.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">As of December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:69.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td></tr><tr><td style="vertical-align:bottom;width:69.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:69.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Assets</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:69.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Current assets:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:69.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Cash and cash equivalents</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_NFG_pVdyhEyJarLQmedkXA" contextRef="As_Of_12_31_2021_slf_IrTrZku1VVWbbttE4g" decimals="0" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="0" id="Tc_cyl-kTsRJ02faZftH6sJwA_6_3">45,686,014</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_NFG_pVdyhEyJarLQmedkXA" contextRef="As_Of_12_31_2020_K1oKCNbpv0CLR8EJWu1PSw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="0" id="Tc_0gjS2DH8fUCPKBFnzZfyLQ_6_6">8,074,658</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:69.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Prepaid expenses and other current assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_NFG_pVdyhEyJarLQmedkXA" contextRef="As_Of_12_31_2021_slf_IrTrZku1VVWbbttE4g" decimals="0" format="ixt:numdotdecimal" name="anvs:PrepaidExpenseSecurityDepositsAndOtherAssetsCurrent" scale="0" id="Tc_3zq-VcTAFkiairIiyNUqZg_7_3">315,464</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_NFG_pVdyhEyJarLQmedkXA" contextRef="As_Of_12_31_2020_K1oKCNbpv0CLR8EJWu1PSw" decimals="0" format="ixt:numdotdecimal" name="anvs:PrepaidExpenseSecurityDepositsAndOtherAssetsCurrent" scale="0" id="Tc_lg7MdPDJKE6VBXn0N5d5Bg_7_6">44,676</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:69.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Total current assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.7%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_NFG_pVdyhEyJarLQmedkXA" contextRef="As_Of_12_31_2021_slf_IrTrZku1VVWbbttE4g" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AssetsCurrent" scale="0" id="Tc_U8vEFdQEzkq1biuAofjTdA_8_3">46,001,478</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_NFG_pVdyhEyJarLQmedkXA" contextRef="As_Of_12_31_2020_K1oKCNbpv0CLR8EJWu1PSw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AssetsCurrent" scale="0" id="Tc_iXCfV_UN10qzKUlIiVH1GA_8_6">8,119,334</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:69.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Total assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.7%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_NFG_pVdyhEyJarLQmedkXA" contextRef="As_Of_12_31_2021_slf_IrTrZku1VVWbbttE4g" decimals="0" format="ixt:numdotdecimal" name="us-gaap:Assets" scale="0" id="Tc_zhY1sllw2E6W6EKBVRIXtg_9_3">46,001,478</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_NFG_pVdyhEyJarLQmedkXA" contextRef="As_Of_12_31_2020_K1oKCNbpv0CLR8EJWu1PSw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:Assets" scale="0" id="Tc_3-zJKVLgzUGFwDj2CpXhww_9_6">8,119,334</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:69.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Liabilities, Redeemable Convertible Preferred Stock and Stockholders&#8217; Equity </b> <b style="font-weight:bold;">(Deficit)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:69.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Current liabilities:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:69.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Accounts payable</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_NFG_pVdyhEyJarLQmedkXA" contextRef="As_Of_12_31_2021_slf_IrTrZku1VVWbbttE4g" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AccountsPayableCurrent" scale="0" id="Tc_qd8L-OyZ_EGog4NSJ-LO_Q_12_3">688,074</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_NFG_pVdyhEyJarLQmedkXA" contextRef="As_Of_12_31_2020_K1oKCNbpv0CLR8EJWu1PSw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AccountsPayableCurrent" scale="0" id="Tc_mvrRSADvI06ueq74TIh0XQ_12_6">341,856</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:69.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Accrued expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_NFG_pVdyhEyJarLQmedkXA" contextRef="As_Of_12_31_2021_slf_IrTrZku1VVWbbttE4g" decimals="0" format="ixt:numdotdecimal" name="anvs:AccruedLiabilitiesAndInterestAndEmployeeRelatedLiabilitiesCurrent" scale="0" id="Tc_4moMmyOzyES0J5WTcW1JCg_13_3">818,440</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_NFG_pVdyhEyJarLQmedkXA" contextRef="As_Of_12_31_2020_K1oKCNbpv0CLR8EJWu1PSw" decimals="0" format="ixt:numdotdecimal" name="anvs:AccruedLiabilitiesAndInterestAndEmployeeRelatedLiabilitiesCurrent" scale="0" id="Tc_U_mwi_9AZUSZ9zNWt_bHtA_13_6">236,524</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:69.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Total current liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.7%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_NFG_pVdyhEyJarLQmedkXA" contextRef="As_Of_12_31_2021_slf_IrTrZku1VVWbbttE4g" decimals="0" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesCurrent" scale="0" id="Tc_hjKPKBO_g0WeeTw3hvWPSQ_14_3">1,506,514</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_NFG_pVdyhEyJarLQmedkXA" contextRef="As_Of_12_31_2020_K1oKCNbpv0CLR8EJWu1PSw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesCurrent" scale="0" id="Tc_TTlwAoBVoEqcOv1NanpGog_14_6">578,380</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:69.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Total liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_NFG_pVdyhEyJarLQmedkXA" contextRef="As_Of_12_31_2021_slf_IrTrZku1VVWbbttE4g" decimals="0" format="ixt:numdotdecimal" name="us-gaap:Liabilities" scale="0" id="Tc_pyKaoptbzEeq-TIYBXXdIA_15_3">1,506,514</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_NFG_pVdyhEyJarLQmedkXA" contextRef="As_Of_12_31_2020_K1oKCNbpv0CLR8EJWu1PSw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:Liabilities" scale="0" id="Tc_9KpxThwHHk6Lgwam-Mj5Ig_15_6">578,380</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:69.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Commitments and contingencies (Note 8)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:69.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Stockholders&#8217; equity (deficit):</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:69.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Preferred stock - $<ix:nonFraction unitRef="Unit_Divide_USD_shares_ZtgwQidioUWlbMoOaTBzxg" contextRef="As_Of_12_31_2020_K1oKCNbpv0CLR8EJWu1PSw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="Narr_jwCJY0w28EmzE3UOM99n5w"><ix:nonFraction unitRef="Unit_Divide_USD_shares_ZtgwQidioUWlbMoOaTBzxg" contextRef="As_Of_12_31_2021_slf_IrTrZku1VVWbbttE4g" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="Narr_3vkuyOY_SUWImRBJml-g0w">0.0001</ix:nonFraction></ix:nonFraction> par value, <ix:nonFraction unitRef="Unit_Standard_shares__cOSbKjBTUyHt70_t1aAVw" contextRef="As_Of_12_31_2020_K1oKCNbpv0CLR8EJWu1PSw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:PreferredStockSharesAuthorized" scale="0" id="Narr_2oDAD-GPkE6f42Agq2_9IQ"><ix:nonFraction unitRef="Unit_Standard_shares__cOSbKjBTUyHt70_t1aAVw" contextRef="As_Of_12_31_2021_slf_IrTrZku1VVWbbttE4g" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:PreferredStockSharesAuthorized" scale="0" id="Narr_r1Q439MbZUqPDXcax8-ZoQ">2,000,000</ix:nonFraction></ix:nonFraction> shares authorized and <ix:nonFraction unitRef="Unit_Standard_shares__cOSbKjBTUyHt70_t1aAVw" contextRef="As_Of_12_31_2020_K1oKCNbpv0CLR8EJWu1PSw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:PreferredStockSharesIssued" scale="0" id="Narr_DOoUROqCcUq10agcdK9RqA"><ix:nonFraction unitRef="Unit_Standard_shares__cOSbKjBTUyHt70_t1aAVw" contextRef="As_Of_12_31_2021_slf_IrTrZku1VVWbbttE4g" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:PreferredStockSharesIssued" scale="0" id="Narr_XVgwZnD7tkCj1eFXEtQVwA">0</ix:nonFraction></ix:nonFraction> shares issued and outstanding</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="-sec-ix-hidden:Hidden_1cHKNqogd0-a4Lt10S2ySQ;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> &#8212;</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="-sec-ix-hidden:Hidden__Eya0bxY0UCpLBlvPZA65Q;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> &#8212;</span></span></p></td></tr><tr><td style="vertical-align:bottom;width:69.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Common stock - $<ix:nonFraction unitRef="Unit_Divide_USD_shares_ZtgwQidioUWlbMoOaTBzxg" contextRef="As_Of_12_31_2020_K1oKCNbpv0CLR8EJWu1PSw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="Narr_CGO-iDj7YEq7Zmotg27WOg"><ix:nonFraction unitRef="Unit_Divide_USD_shares_ZtgwQidioUWlbMoOaTBzxg" contextRef="As_Of_12_31_2021_slf_IrTrZku1VVWbbttE4g" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="Narr_GoVkRp49skGAAS5AZkF_QA">0.0001</ix:nonFraction></ix:nonFraction> par value, <ix:nonFraction unitRef="Unit_Standard_shares__cOSbKjBTUyHt70_t1aAVw" contextRef="As_Of_12_31_2020_K1oKCNbpv0CLR8EJWu1PSw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesAuthorized" scale="0" id="Narr_jpdu4PjVy02wEPGWpxTHGA"><ix:nonFraction unitRef="Unit_Standard_shares__cOSbKjBTUyHt70_t1aAVw" contextRef="As_Of_12_31_2021_slf_IrTrZku1VVWbbttE4g" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesAuthorized" scale="0" id="Narr_CmRy69EITkuzwnkz8o9qNw">35,000,000</ix:nonFraction></ix:nonFraction> shares authorized and <ix:nonFraction unitRef="Unit_Standard_shares__cOSbKjBTUyHt70_t1aAVw" contextRef="As_Of_12_31_2021_slf_IrTrZku1VVWbbttE4g" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesIssued" scale="0" id="Narr_XsHSyh3C506n8IqYBPWcRA">8,100,570</ix:nonFraction> and <ix:nonFraction unitRef="Unit_Standard_shares__cOSbKjBTUyHt70_t1aAVw" contextRef="As_Of_12_31_2020_K1oKCNbpv0CLR8EJWu1PSw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" id="Narr_1OYXaccn4EqC85sy7M1thg">6,891,608</ix:nonFraction> shares <span style="-sec-ix-hidden:Hidden_i8ALY5d87EqQSL0ZvpxgYA;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">issued</span></span> and <span style="-sec-ix-hidden:Hidden_HhN3VcDM_kSkl4xTtOaA_A;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">outstanding</span></span> at December&#160;31,&#160;2021 and 2020, respectively</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_NFG_pVdyhEyJarLQmedkXA" contextRef="As_Of_12_31_2021_slf_IrTrZku1VVWbbttE4g" decimals="0" format="ixt:numdotdecimal" name="us-gaap:CommonStockValue" scale="0" id="Tc_47JC3vHBrUqSZcQ4rgfTtA_19_3">810</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_NFG_pVdyhEyJarLQmedkXA" contextRef="As_Of_12_31_2020_K1oKCNbpv0CLR8EJWu1PSw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:CommonStockValue" scale="0" id="Tc_ubzJRdRzLEe-EAb0tE5kCg_19_6">689</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:69.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Additional paid-in capital</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_NFG_pVdyhEyJarLQmedkXA" contextRef="As_Of_12_31_2021_slf_IrTrZku1VVWbbttE4g" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AdditionalPaidInCapital" scale="0" id="Tc_wVp0tD6720-IrLev2Qq37g_20_3">73,220,361</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_NFG_pVdyhEyJarLQmedkXA" contextRef="As_Of_12_31_2020_K1oKCNbpv0CLR8EJWu1PSw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AdditionalPaidInCapital" scale="0" id="Tc_1qdHzI17mkCVE1XCtJZXOA_20_6">21,779,340</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:69.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Accumulated deficit</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_NFG_pVdyhEyJarLQmedkXA" contextRef="As_Of_12_31_2021_slf_IrTrZku1VVWbbttE4g" decimals="0" format="ixt:numdotdecimal" name="us-gaap:RetainedEarningsAccumulatedDeficit" sign="-" scale="0" id="Tc_ke5KZROy306499I0HJkkgQ_21_3">28,726,207</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_NFG_pVdyhEyJarLQmedkXA" contextRef="As_Of_12_31_2020_K1oKCNbpv0CLR8EJWu1PSw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:RetainedEarningsAccumulatedDeficit" sign="-" scale="0" id="Tc_tQXMmXuYO0GmXzI9WgGpBQ_21_6">14,239,075</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:69.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Total stockholders&#8217; equity </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.7%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_NFG_pVdyhEyJarLQmedkXA" contextRef="As_Of_12_31_2021_slf_IrTrZku1VVWbbttE4g" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="0" id="Tc_38zSegv7zkmCkhM3buv9ug_22_3">44,494,964</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_NFG_pVdyhEyJarLQmedkXA" contextRef="As_Of_12_31_2020_K1oKCNbpv0CLR8EJWu1PSw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="0" id="Tc_X159wrpkk0KRl3v96kXL_A_22_6">7,540,954</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:69.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Total liabilities and stockholders&#8217; equity</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.7%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_NFG_pVdyhEyJarLQmedkXA" contextRef="As_Of_12_31_2021_slf_IrTrZku1VVWbbttE4g" decimals="0" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesAndStockholdersEquity" scale="0" id="Tc_DalKhHope0CRvVHT4H6vHA_23_3">46,001,478</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_NFG_pVdyhEyJarLQmedkXA" contextRef="As_Of_12_31_2020_K1oKCNbpv0CLR8EJWu1PSw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesAndStockholdersEquity" scale="0" id="Tc_XiPIj5whJ0arXpPbFhWvwg_23_6">8,119,334</ix:nonFraction></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">See accompanying notes to financial statements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-3</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_22774bf9_8021_4bc9_b7c9_e04f86e184ae"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 12pt 0pt;">ANNOVIS BIO,&#160;INC.</p><a id="StatementsofOperations_7171"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Statements of Operations</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_d4963940_5a91_40ff_8386_48669054e401"></a><a id="Tc_k_ko_MS9hk628zfG7xCbtg_1_3"></a><a id="Tc_ozuQ9qJAf0yBucmXedvp-w_3_3"></a><a id="Tc_BQlmT1UF5UGvKIqZbFo-_A_3_6"></a><a id="Tc_ZRSpcQFziE6hiBEYgmHdQg_4_0"></a><a id="Tc_nA2I3IWoR0W8uiED8GKNnA_5_0"></a><a id="Tc_Dx2e0mY7B0C0yZVm5WeBqQ_5_3"></a><a id="Tc_INzLDMmvakiRbxLWiB44XA_5_6"></a><a id="Tc_pumd_myM50qAKnhsooHK6w_6_0"></a><a id="Tc_cbQ9Jz9-OEOa-uS2vfyVfg_7_0"></a><a id="Tc_QiSGLpkurUinKuud1Nn4KQ_9_0"></a><a id="Tc_YfIAaixKjUm00zdcBY6zOg_10_0"></a><a id="Tc_tPxSIAfMdUa4dY322anuWA_11_0"></a><a id="Tc_9RhwxJJ6E0Sof_01FCC6GA_11_4"></a><a id="Tc_PJf6VsQSOk-C56IyIOZPJQ_12_0"></a><a id="Tc_HCWRzBOTr0qGsswx7OhQVg_13_0"></a><a id="Tc_4ib0MqNQc0K6XBfqnc3y2Q_14_0"></a><a id="Tc_TSKNx97VnEOrhM9lrORGWg_16_0"></a><a id="Tc_dTWeUFY2PU2ixn6Jr4erog_17_0"></a><a id="Tc_iaOrZaw1pkmeTYiVLUPk4w_17_4"></a><a id="Tc_Jb5hu6w6Fke6N-4JNUoDZQ_17_7"></a><a id="Tc_7GzHWDMJYEGnnRRzyo-HAA_18_0"></a><a id="Tc_N_X7XyayUk-bRxP0Ais6Fg_18_3"></a><a id="Tc_0vD-UHcSEkeqf62BUTuDJA_18_6"></a><a id="Tc_lSLoo3-wLkufAufNvlIUEQ_19_0"></a><a id="Tc_LdSb79UnRkK9ZCBoLZZB6Q_19_3"></a><a id="Tc_on_PmhAb8kGF_mRmi0nMbQ_19_6"></a><a id="Tc_XuRlC2YGUkSaYvTUdcUVCQ_20_0"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:69.75%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.6%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:69.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:26.21%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year Ended December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:69.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:69.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;</b><b style="font-family:'Calibri','Helvetica','sans-serif';font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td></tr><tr><td style="vertical-align:bottom;width:69.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Operating expenses:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:69.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Research and development</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_NFG_pVdyhEyJarLQmedkXA" contextRef="Duration_1_1_2021_To_12_31_2021_uhkxAiZ6fUeekYGgaMhCqA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="0" id="Tc_Mbjz93pXHkO640RsF0PQag_5_4">8,479,031</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_NFG_pVdyhEyJarLQmedkXA" contextRef="Duration_1_1_2020_To_12_31_2020_3DdHOulAJk6Q0Zn4Vsxq5A" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="0" id="Tc_Xq4EAv7pp0aHW-G7-zGjwA_5_7">3,054,025</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:69.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">General and administrative</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.6%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_NFG_pVdyhEyJarLQmedkXA" contextRef="Duration_1_1_2021_To_12_31_2021_uhkxAiZ6fUeekYGgaMhCqA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:GeneralAndAdministrativeExpense" scale="0" id="Tc_OeAFmPTmJkmvzvuoRtG18w_6_4">6,058,190</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_NFG_pVdyhEyJarLQmedkXA" contextRef="Duration_1_1_2020_To_12_31_2020_3DdHOulAJk6Q0Zn4Vsxq5A" decimals="0" format="ixt:numdotdecimal" name="us-gaap:GeneralAndAdministrativeExpense" scale="0" id="Tc_2nVLRzefkkeVZagwIjGbvA_6_7">3,586,196</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:69.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Total operating expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_NFG_pVdyhEyJarLQmedkXA" contextRef="Duration_1_1_2021_To_12_31_2021_uhkxAiZ6fUeekYGgaMhCqA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OperatingExpenses" scale="0" id="Tc_Qkv20WXmWkansRpC6OUUcw_7_4">14,537,221</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_NFG_pVdyhEyJarLQmedkXA" contextRef="Duration_1_1_2020_To_12_31_2020_3DdHOulAJk6Q0Zn4Vsxq5A" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OperatingExpenses" scale="0" id="Tc_7HeSgb4pU0KKGahsHbNFBQ_7_7">6,640,221</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:69.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:69.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Operating loss</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_NFG_pVdyhEyJarLQmedkXA" contextRef="Duration_1_1_2021_To_12_31_2021_uhkxAiZ6fUeekYGgaMhCqA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OperatingIncomeLoss" sign="-" scale="0" id="Tc_Hy3fa98TBUSv8UGW0JSVow_9_4">14,537,221</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_NFG_pVdyhEyJarLQmedkXA" contextRef="Duration_1_1_2020_To_12_31_2020_3DdHOulAJk6Q0Zn4Vsxq5A" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OperatingIncomeLoss" sign="-" scale="0" id="Tc_XNDvFW6pQUebOARWh_xy5w_9_7">6,640,221</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:69.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Other income (expense):</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:69.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Change in fair value of derivative liability</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_NFG_pVdyhEyJarLQmedkXA" contextRef="Duration_1_1_2020_To_12_31_2020_3DdHOulAJk6Q0Zn4Vsxq5A" decimals="0" format="ixt:numdotdecimal" name="us-gaap:UnrealizedGainLossOnDerivatives" sign="-" scale="0" id="Tc_pr5R8eTY-0O1uaEJK0jS1w_11_7">26,500</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:69.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Interest income, net</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_NFG_pVdyhEyJarLQmedkXA" contextRef="Duration_1_1_2021_To_12_31_2021_uhkxAiZ6fUeekYGgaMhCqA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:InterestIncomeExpenseNonoperatingNet" scale="0" id="Tc_RndsHhKQ9UGLRGYEFAGODA_12_4">13,335</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_NFG_pVdyhEyJarLQmedkXA" contextRef="Duration_1_1_2020_To_12_31_2020_3DdHOulAJk6Q0Zn4Vsxq5A" decimals="0" format="ixt:numdotdecimal" name="us-gaap:InterestIncomeExpenseNonoperatingNet" scale="0" id="Tc_k7AgRZ6_0E64pRsw_LmoQg_12_7">47,225</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:69.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Grant income</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_NFG_pVdyhEyJarLQmedkXA" contextRef="Duration_1_1_2021_To_12_31_2021_uhkxAiZ6fUeekYGgaMhCqA" decimals="0" format="ixt:numdotdecimal" name="anvs:IncomeFromGrants" scale="0" id="Tc_VYtWUmxKaEiRiRKdFXD2aA_13_4">36,754</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_NFG_pVdyhEyJarLQmedkXA" contextRef="Duration_1_1_2020_To_12_31_2020_3DdHOulAJk6Q0Zn4Vsxq5A" decimals="0" format="ixt:numdotdecimal" name="anvs:IncomeFromGrants" scale="0" id="Tc_9Th5dhhkrEWTNhgnGrUm7g_13_7">1,157,449</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:69.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Total other income (expense) </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.6%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_NFG_pVdyhEyJarLQmedkXA" contextRef="Duration_1_1_2021_To_12_31_2021_uhkxAiZ6fUeekYGgaMhCqA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:NonoperatingIncomeExpense" scale="0" id="Tc_qu79wLByLUCruHwi7Ruczw_14_4">50,089</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_NFG_pVdyhEyJarLQmedkXA" contextRef="Duration_1_1_2020_To_12_31_2020_3DdHOulAJk6Q0Zn4Vsxq5A" decimals="0" format="ixt:numdotdecimal" name="us-gaap:NonoperatingIncomeExpense" scale="0" id="Tc_SxOQ28qonEONqyn-tC_aeg_14_7">1,178,174</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:69.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:69.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Loss before income taxes</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_NFG_pVdyhEyJarLQmedkXA" contextRef="Duration_1_1_2021_To_12_31_2021_uhkxAiZ6fUeekYGgaMhCqA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" sign="-" scale="0" id="Tc_VRmK3IMYcEOcGJq6qId9bA_16_4">14,487,132</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_NFG_pVdyhEyJarLQmedkXA" contextRef="Duration_1_1_2020_To_12_31_2020_3DdHOulAJk6Q0Zn4Vsxq5A" decimals="0" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" sign="-" scale="0" id="Tc_bpRKLjyZhk2dnXA3MK5rhw_16_7">5,462,047</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:69.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Income tax expense (benefit)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:69.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Net loss</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.6%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_NFG_pVdyhEyJarLQmedkXA" contextRef="Duration_1_1_2021_To_12_31_2021_uhkxAiZ6fUeekYGgaMhCqA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" sign="-" scale="0" id="Tc_tOg408dx8kSpV1_EG7LFkQ_18_4">14,487,132</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_NFG_pVdyhEyJarLQmedkXA" contextRef="Duration_1_1_2020_To_12_31_2020_3DdHOulAJk6Q0Zn4Vsxq5A" decimals="0" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" sign="-" scale="0" id="Tc_ylWfBux2RESK1pTChZPfXg_18_7">5,462,047</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:69.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Basic and diluted loss per common share</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.6%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Divide_USD_shares_ZtgwQidioUWlbMoOaTBzxg" contextRef="Duration_1_1_2021_To_12_31_2021_uhkxAiZ6fUeekYGgaMhCqA" decimals="2" format="ixt:numdotdecimal" name="us-gaap:EarningsPerShareBasic" sign="-" scale="0" id="Tc_8PsVXD2LKkGb_mHV_RCMow_19_4">1.90</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Divide_USD_shares_ZtgwQidioUWlbMoOaTBzxg" contextRef="Duration_1_1_2020_To_12_31_2020_3DdHOulAJk6Q0Zn4Vsxq5A" decimals="2" format="ixt:numdotdecimal" name="us-gaap:EarningsPerShareBasic" sign="-" scale="0" id="Tc_0pfIDxtlK0KReBCFh8HMaA_19_7">0.87</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:69.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Weighted average number of common shares outstanding, basic and diluted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.6%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares__cOSbKjBTUyHt70_t1aAVw" contextRef="Duration_1_1_2021_To_12_31_2021_uhkxAiZ6fUeekYGgaMhCqA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" id="Tc_v-_HaYc_KUOxYbWnKG_iSg_20_4">7,626,278</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares__cOSbKjBTUyHt70_t1aAVw" contextRef="Duration_1_1_2020_To_12_31_2020_3DdHOulAJk6Q0Zn4Vsxq5A" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" id="Tc_iACgygUeLEinVxzTqSbehg_20_7">6,308,961</ix:nonFraction></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">See accompanying notes to financial statements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-4</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_d0c83ce9_c293_483d_87f2_30ac3e28f9be"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 12pt 0pt;">ANNOVIS BIO,&#160;INC.</p><a id="StockholdersEquityDeficit_933195"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><b style="font-weight:bold;">Statements of Redeemable Convertible Preferred Stock and Stockholders&#8217; Equity (Deficit)</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><b style="font-weight:bold;">For the Years Ended December 31, 2021 and 2020 </b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_eed35834_721c_46ca_810a_d8274a4740b2"></a><a id="Tc_42SkX2IFKUilnuNUhjmehQ_1_2"></a><a id="Tc_Nq1PjSYyLUelj0Tz2O0pmQ_1_13"></a><a id="Tc_ObG58dwiZk2pbQBw_RxQXA_2_24"></a><a id="Tc_n_jKaLHtGkWsWLAW2dKGzg_3_18"></a><a id="Tc_C_235SEkf0acTOXU-xH6qw_3_24"></a><a id="Tc_Dc07XkfjqkSpDohhdNv0Yw_4_2"></a><a id="Tc_v63SDjHb-kygv-CSnxDvoQ_4_7"></a><a id="Tc_h2hm1tE0jEG85nn87jKACQ_4_13"></a><a id="Tc_e7eA1HU_Xk65K0km4zj73w_4_18"></a><a id="Tc_7Hs82T2OLUypbzQnD5ToaA_4_21"></a><a id="Tc_VnSZbI-58EyiQ99gkrBRjg_4_24"></a><a id="Tc_p6tZUzQ-xU6irqx57sK5fQ_5_2"></a><a id="Tc_Hov_sG_cZEKwugPcKwuLZQ_5_4"></a><a id="Tc_Uq2U0QzxOkixrJ_1qpXRGA_5_7"></a><a id="Tc_1IzVr8rcdkuJcntRmctwGg_5_9"></a><a id="Tc_fHSmcnTp30qZAO_p0d-K3A_5_13"></a><a id="Tc_ORIFt6neV0-SDK2veD3zLA_5_15"></a><a id="Tc_C_59acfaPUGV4XcWgnpZ8Q_5_18"></a><a id="Tc_bPWaKSTKm02gkiuaig67Eg_5_21"></a><a id="Tc_vvqYc8gTikmiig4Uc2tQIQ_5_24"></a><a id="Tc_g-juu3LCNk2CeWma68xoLw_6_0"></a><a id="Tc_RGm6S7YZI0S_6-2ovGuNtw_6_4"></a><a id="Tc_qGsPBSCJA0-SoWSvRph35w_6_9"></a><a id="Tc_jeD6N3TC_ECTUu4HBPifLA_6_15"></a><a id="Tc_A4BZb-rwmkC5AxiUbrbuqA_6_18"></a><a id="Tc_Simmz0_KDUyK2PuDKK8GNA_6_21"></a><a id="Tc_uthBOtt650Gu94sUGYWxzw_6_24"></a><a id="Tc_PyRcY3nWW0G5hAnuZa7mGQ_7_0"></a><a id="Tc_mE1uwQxXI06h-ClmWRmelw_7_22"></a><a id="Tc_NK3ThZ_GV0iDE6_Gs3QuUA_8_0"></a><a id="Tc_M0wlXMupKUGI0cDWxQyLmw_8_2"></a><a id="Tc_Te-bZHqBDUywciIbdVOhig_8_5"></a><a id="Tc_9znkqGvqXkiPoh0JD4kVpw_8_7"></a><a id="Tc_jFM4LOy5QUeZU6FN0iFcDA_8_10"></a><a id="Tc_lS30DYs_wEqUp5kxqzDetw_8_22"></a><a id="Tc_GsHAT9R7NU2SYy3g1MOV4A_9_0"></a><a id="Tc_IrldIITYrk2kjEz6vfUnwQ_9_2"></a><a id="Tc_5PLAaZYn10SIykF0Zj8REg_9_5"></a><a id="Tc_a9uYreZxX0iikirbyIr_rA_9_7"></a><a id="Tc_vGqwMuhEak-1rL8GoAY0cQ_9_10"></a><a id="Tc_b5okkQIIXkKwI2QPuGDDrQ_9_22"></a><a id="Tc_4fi4RErkm0O278UEEzwx1A_10_0"></a><a id="Tc_f2RTBDUuTUSzHv7HJD32jQ_10_2"></a><a id="Tc_YtHgHx4aPkuOCFOwlSJAlg_10_5"></a><a id="Tc_Rdk38V1Ye0-koOkvJ8tIRA_10_7"></a><a id="Tc_BtPuB1JQKESaFX3BILVq5g_10_10"></a><a id="Tc_MIGdsvLU90uN8FpSN7YIBg_10_22"></a><a id="Tc_WukU1sNMoEO4Oopx7e-AFQ_11_0"></a><a id="Tc_DNQtJpPu7kKYcSlEPEwFbg_11_2"></a><a id="Tc_u8emeo_q10yMEKfF2yaY-g_11_5"></a><a id="Tc_OrtuVdBTEEKtNk98S0h7KQ_11_7"></a><a id="Tc_7rj7MeCC2k6EdnunxAYb3g_11_10"></a><a id="Tc_bp62wLWDFkqNQFFZi_iQiQ_11_22"></a><a id="Tc_yO9wxThQe0qqvD9EcTJsCg_12_0"></a><a id="Tc_0oalakZqzUqL5sNjfkezDQ_12_2"></a><a id="Tc_nMw9gFP5I0G4GXWlkD51yQ_12_5"></a><a id="Tc_ohuWJItkY0a27O56wVbcqQ_12_7"></a><a id="Tc_CH7IqeZTQ0WsSVlQI82gXA_12_10"></a><a id="Tc_x7pFK3dtQU25p_jiOFoypw_12_13"></a><a id="Tc_l70MN1LzYUi4SW56b14rXA_12_16"></a><a id="Tc_f3Y24gnU_ky3HuXv1Um_1Q_12_22"></a><a id="Tc_xa_1f_CQGE6bfohPdLasDA_13_0"></a><a id="Tc_E6H6DWKqsUOB9u7DNKRTKg_13_2"></a><a id="Tc_W4rBuAQmuUam1lDOmaoWrA_13_5"></a><a id="Tc_sRgqyrCB9EmDUZtRE9dU8w_13_7"></a><a id="Tc_SMfnf1x_vEiw8RpWpuaK7A_13_10"></a><a id="Tc_iSSRbC5kSEqvH76gSZd10w_13_13"></a><a id="Tc_ipgbxhCCCEqrtYZKU6Vikw_13_16"></a><a id="Tc_9-UEhoiLTEueld4Dx3_mlw_13_19"></a><a id="Tc_dr6InxZ25EqD0jJiABLcAg_14_0"></a><a id="Tc_nhnHIjoAd0KGD5URK4e4OA_15_0"></a><a id="Tc_KZTJ5sKLDUKh4qsz6ysTCw_15_2"></a><a id="Tc_VF-kMOEcTk6NT-iFrjZl0w_15_5"></a><a id="Tc_mnmA1KpkIkCNqD9wNRpzZg_15_7"></a><a id="Tc_2URSGkWDf0SG3LZMHpnh6Q_15_10"></a><a id="Tc_r6-kx42olUiC_LTiIm8weA_15_22"></a><a id="Tc_F6CiXCfSJkSzjodSny2EFg_16_0"></a><a id="Tc_7pODtz04qkCSQWIVh3gtAg_16_2"></a><a id="Tc_nINgDJHybESDJ2ZJWCUvtA_16_5"></a><a id="Tc_6WsdSSo-1kWymP7Sw_K3pg_16_7"></a><a id="Tc_uG9UAfnOzkmGCXrHtqCr0Q_16_10"></a><a id="Tc_S4_e12V5tk-h6MWAThUbeg_16_22"></a><a id="Tc_3re8su3LrUSTLBUm1AaXYg_17_0"></a><a id="Tc_-stg4IEyFE-QwkAmmiknTg_17_2"></a><a id="Tc_zfmPh8Hmcki-4OusWsGPGw_17_5"></a><a id="Tc_znYcXu6T9k6CZ641IMVxRg_17_7"></a><a id="Tc_-cjXUVWysUOcAOCOIbpHuw_17_10"></a><a id="Tc_216ir4o7zU-p3OPdj_-OmA_17_22"></a><a id="Tc_EnnEPp5dTk-ti3Xq3KzdjQ_17_25"></a><a id="Tc_1l0W77hevUOBVf68yflt9Q_18_0"></a><a id="Tc_rvZOSpvc40qJcBEvdnLhdA_18_2"></a><a id="Tc_xNDlxKigNE2wEhxVyKIxhg_18_5"></a><a id="Tc_JNURgNPESE2YIvXPa0gqYQ_18_7"></a><a id="Tc_IKDAXgeSQUC5egbzvwQVgA_18_10"></a><a id="Tc_59Ho5ngQgUOTcfCJgU1ANw_18_13"></a><a id="Tc_F2aZM300NUqL8nZSOVym9A_18_16"></a><a id="Tc_BI81AGSjXkSes4meUIRF3g_18_22"></a><a id="Tc_dlqN288-Q0ylY-nW0iFKew_19_0"></a><a id="Tc_zIxqg1UotkmHwKWHczcHuA_19_2"></a><a id="Tc_wOVxi6MiTECallWkPxAS2w_19_5"></a><a id="Tc_iCjYGzmcME6I6f4Cx862xA_19_7"></a><a id="Tc_9Q6NV0NYsU6aH3Jvzix_3Q_19_10"></a><a id="Tc_K-j7y-gWpkuuei3C6ySBLw_19_13"></a><a id="Tc_mMzc9ebe0kizdwNMbETSbg_19_16"></a><a id="Tc_C-uPZeYfqUCEA-Xkj-pMrA_19_19"></a><a id="Tc_8JMlwqWbPkeZDTwwIB1oTg_20_0"></a><a id="Tc_UMNqkEKZU0ygyVcUpk27Bw_20_2"></a><a id="Tc_v1pGV1K1pkG-fEHm4NKAZA_20_4"></a><a id="Tc_KziIIZconEmrEzxGjOZ9PA_20_5"></a><a id="Tc_E5a2aXWPvESbHk8jPFCFJw_20_7"></a><a id="Tc_LYIlGb6LMUqjDuM5E9RKvQ_20_9"></a><a id="Tc_2_o-DVUhlkiiTb58Ls_WAw_20_10"></a><a id="Tc_HbWZ2AJOD0KzoNLMPKSzxA_20_15"></a><a id="Tc_mFhwYh7V6kWzNG1LEcgutA_20_18"></a><a id="Tc_0a5jqj3hsE2OgB5NZ2J60Q_20_21"></a><a id="Tc_lo0qi5qJgkOioFnNvNN-JQ_20_24"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:102.14%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:13.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.93%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.8%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.93%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.72%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.8%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.72%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.46%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.84%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:4.81%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.8%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.8%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.74%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.8%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.74%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:13.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="9" style="vertical-align:bottom;white-space:nowrap;width:34.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Redeemable Convertible Preferred Stock</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;border-right:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;border-left:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="13" style="vertical-align:bottom;white-space:nowrap;width:47.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Stockholders&#8217; Equity (Deficit)</b></p></td></tr><tr><td style="vertical-align:bottom;width:13.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;border-right:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;border-left:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Total</b> </p></td></tr><tr><td style="vertical-align:bottom;width:13.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;border-right:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;border-left:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Additional</b> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Stockholders&#8217; </b></p></td></tr><tr><td style="vertical-align:bottom;width:13.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="4" style="vertical-align:bottom;white-space:nowrap;width:18.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Series A</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="4" style="vertical-align:bottom;white-space:nowrap;width:14.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Series A-1</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;border-right:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;border-left:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="4" style="vertical-align:bottom;white-space:nowrap;width:14.73%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Common Stock</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Paid-In</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Accumulated</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Equity</b></p></td></tr><tr><td style="vertical-align:bottom;width:13.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.93%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Shares</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Amount</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Shares</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Amount</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;border-right:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;border-left:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Shares</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:5.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Amount</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.07%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Capital</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Deficit</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(Deficit)</b></p></td></tr><tr><td style="vertical-align:bottom;width:13.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Balance, December&#160;31,&#160;2019</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares__cOSbKjBTUyHt70_t1aAVw" contextRef="As_Of_12_31_2019_us-gaap_StatementClassOfStockAxis_anvs_SeriesaRedeemableConvertiblePreferredStockMember_odVgKOmG90OBa7U96NG4jw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:TemporaryEquitySharesIssued" scale="0" id="Tc_crn0lsa1UEe5UH_4Hbs3Hw_6_2">5,133,159</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_NFG_pVdyhEyJarLQmedkXA" contextRef="As_Of_12_31_2019_us-gaap_StatementClassOfStockAxis_anvs_SeriesaRedeemableConvertiblePreferredStockMember_odVgKOmG90OBa7U96NG4jw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:TemporaryEquityCarryingAmountAttributableToParent" scale="0" id="Tc_pmJi0xJq90yiFPfvJSjXhQ_6_5">6,509,303</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares__cOSbKjBTUyHt70_t1aAVw" contextRef="As_Of_12_31_2019_us-gaap_StatementClassOfStockAxis_anvs_Series1RedeemableConvertiblePreferredStockMember_pzCzknp_UUqMQod8oici_A" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:TemporaryEquitySharesIssued" scale="0" id="Tc_9HGaqxB-I0iOPzjNbiqLWQ_6_7">630,722</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_NFG_pVdyhEyJarLQmedkXA" contextRef="As_Of_12_31_2019_us-gaap_StatementClassOfStockAxis_anvs_Series1RedeemableConvertiblePreferredStockMember_pzCzknp_UUqMQod8oici_A" decimals="0" format="ixt:numdotdecimal" name="us-gaap:TemporaryEquityCarryingAmountAttributableToParent" scale="0" id="Tc_Xv4o6_MxBUCTYH79JctN7Q_6_10">567,649</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;background:#cceeff;border-right:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;background:#cceeff;border-left:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares__cOSbKjBTUyHt70_t1aAVw" contextRef="As_Of_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_d1y_dVMmq02lOk2EI5_rBA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SharesIssued" scale="0" id="Tc_BmJ2ES4RZUaaaWea0B-FzA_6_13">282,614</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_NFG_pVdyhEyJarLQmedkXA" contextRef="As_Of_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_d1y_dVMmq02lOk2EI5_rBA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="0" id="Tc_gWwKeIX3LUG5X-d0bOVyiw_6_16">28</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_NFG_pVdyhEyJarLQmedkXA" contextRef="As_Of_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_8FIUzd9InkOQst0tn_3nZg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="0" id="Tc_M-78okxZ20GjqAkaYQt8WA_6_19">200,600</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_NFG_pVdyhEyJarLQmedkXA" contextRef="As_Of_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_q8XP9K1S6UO9eBjFQKFqmA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" sign="-" scale="0" id="Tc_yiumKFVfyUekM1pzvkP17Q_6_22">8,777,028</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_NFG_pVdyhEyJarLQmedkXA" contextRef="As_Of_12_31_2019_S7jX8DT5zEOORR0B4HM-aw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" sign="-" scale="0" id="Tc_Jt90k6eYw0u6i0RVHSSNVg_6_25">8,576,400</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:13.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0pt 6pt;">Conversion of redeemable convertible preferred stock to common stock upon completion of initial public offering</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_shares__cOSbKjBTUyHt70_t1aAVw" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementClassOfStockAxis_anvs_SeriesaRedeemableConvertiblePreferredStockMember_deK8dFWBmk-HMa7S_4aJ1w" decimals="INF" format="ixt:numdotdecimal" name="anvs:TemporaryEquitySharesConversionOfPreferredStockToCommonStock" scale="0" id="Tc_pjs2aqHcR0WT7iBvvpOGpQ_7_2">5,133,159</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_NFG_pVdyhEyJarLQmedkXA" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementClassOfStockAxis_anvs_SeriesaRedeemableConvertiblePreferredStockMember_deK8dFWBmk-HMa7S_4aJ1w" decimals="0" format="ixt:numdotdecimal" name="anvs:TemporaryEquityConversionOfPreferredStockToCommonStock" scale="0" id="Tc_8mXEcpQHQUuAJ2PObODnIw_7_5">6,509,303</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_shares__cOSbKjBTUyHt70_t1aAVw" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementClassOfStockAxis_anvs_Series1RedeemableConvertiblePreferredStockMember_-LeysnJLjE-x0FvXPGEzVg" decimals="INF" format="ixt:numdotdecimal" name="anvs:TemporaryEquitySharesConversionOfPreferredStockToCommonStock" scale="0" id="Tc_na3SnAVhLkiiKXgTG5-gjg_7_7">630,722</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_NFG_pVdyhEyJarLQmedkXA" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementClassOfStockAxis_anvs_Series1RedeemableConvertiblePreferredStockMember_-LeysnJLjE-x0FvXPGEzVg" decimals="0" format="ixt:numdotdecimal" name="anvs:TemporaryEquityConversionOfPreferredStockToCommonStock" scale="0" id="Tc_gJrric6iFEiRMbQYRJ1hEg_7_10">567,649</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;border-right:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;border-left:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares__cOSbKjBTUyHt70_t1aAVw" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_FOnigPlx6UaoZMNa-ktVRg" decimals="INF" format="ixt:numdotdecimal" name="anvs:StockIssuedDuringPeriodSharesConversionOfConvertibleSecuritiesPreferredStock" scale="0" id="Tc_ozKz8hxrKEeWmHbbfYpenw_7_13">4,117,089</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_NFG_pVdyhEyJarLQmedkXA" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_FOnigPlx6UaoZMNa-ktVRg" decimals="0" format="ixt:numdotdecimal" name="anvs:StockIssuedDuringPeriodValueConversionOfConvertibleSecuritiesPreferredStock" scale="0" id="Tc_8hEgfiFBn02PCg_NvpgRPA_7_16">412</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_NFG_pVdyhEyJarLQmedkXA" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_JVwGb5QRK0mEvKeM6mX7xg" decimals="0" format="ixt:numdotdecimal" name="anvs:StockIssuedDuringPeriodValueConversionOfConvertibleSecuritiesPreferredStock" scale="0" id="Tc_1bjZ3seAUEKtPJ6WFkaoaA_7_19">7,076,540</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_NFG_pVdyhEyJarLQmedkXA" contextRef="Duration_1_1_2020_To_12_31_2020_3DdHOulAJk6Q0Zn4Vsxq5A" decimals="0" format="ixt:numdotdecimal" name="anvs:StockIssuedDuringPeriodValueConversionOfConvertibleSecuritiesPreferredStock" scale="0" id="Tc_GssEpakqOEW0lN3GsVxfaw_7_25">7,076,952</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:13.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0pt 6pt;">Conversion of convertible promissory notes, including embedded derivative, to common stock upon completion of initial public offering</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;background:#cceeff;border-right:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;background:#cceeff;border-left:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares__cOSbKjBTUyHt70_t1aAVw" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_FOnigPlx6UaoZMNa-ktVRg" decimals="INF" format="ixt:numdotdecimal" name="anvs:StockIssuedDuringPeriodSharesConversionOfConvertibleNotes" scale="0" id="Tc_4BAnqhkSs0ayfWaIxKdzSQ_8_13">118,470</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_NFG_pVdyhEyJarLQmedkXA" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_FOnigPlx6UaoZMNa-ktVRg" decimals="0" format="ixt:numdotdecimal" name="anvs:StockIssuedDuringPeriodValueConversionOfConvertibleSecuritiesConvertiblePromissoryNotes" scale="0" id="Tc_XNLR3gieY0-bni74ewRaZg_8_16">12</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_NFG_pVdyhEyJarLQmedkXA" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_JVwGb5QRK0mEvKeM6mX7xg" decimals="0" format="ixt:numdotdecimal" name="anvs:StockIssuedDuringPeriodValueConversionOfConvertibleSecuritiesConvertiblePromissoryNotes" scale="0" id="Tc_ZzFjBi2emEmxBMcnlnwh6g_8_19">672,512</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_NFG_pVdyhEyJarLQmedkXA" contextRef="Duration_1_1_2020_To_12_31_2020_3DdHOulAJk6Q0Zn4Vsxq5A" decimals="0" format="ixt:numdotdecimal" name="anvs:StockIssuedDuringPeriodValueConversionOfConvertibleSecuritiesConvertiblePromissoryNotes" scale="0" id="Tc_7zmLsZbfH0GhCDh5eUZpjA_8_25">672,524</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:13.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0pt 6pt;">Issuance of common stock in initial public offering, net of issuance costs</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;border-right:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;border-left:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares__cOSbKjBTUyHt70_t1aAVw" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_FOnigPlx6UaoZMNa-ktVRg" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" id="Tc_gx1UC0fNFUm4YYlFtXJM5w_9_13">2,300,000</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_NFG_pVdyhEyJarLQmedkXA" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_FOnigPlx6UaoZMNa-ktVRg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="0" id="Tc_itwMy_HfIka5ZVqrybF9BQ_9_16">230</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_NFG_pVdyhEyJarLQmedkXA" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_JVwGb5QRK0mEvKeM6mX7xg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="0" id="Tc_4HUT-PIazU2FcnLcodt4vw_9_19">11,955,565</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_NFG_pVdyhEyJarLQmedkXA" contextRef="Duration_1_1_2020_To_12_31_2020_3DdHOulAJk6Q0Zn4Vsxq5A" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="0" id="Tc_bYSzNeF9v0q5r6GfVn448w_9_25">11,955,795</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:13.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0pt 6pt;">Exercise of stock options</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;background:#cceeff;border-right:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;background:#cceeff;border-left:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares__cOSbKjBTUyHt70_t1aAVw" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_FOnigPlx6UaoZMNa-ktVRg" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="0" id="Tc_ibjWlpFDKkOASFtOQlh5ww_10_13">48,435</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_NFG_pVdyhEyJarLQmedkXA" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_FOnigPlx6UaoZMNa-ktVRg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="0" id="Tc_OsdfAfnvHUS_R6NkbhPOeQ_10_16">5</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_NFG_pVdyhEyJarLQmedkXA" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_JVwGb5QRK0mEvKeM6mX7xg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="0" id="Tc_Q7XPZ9K5iE-dopCigoK2Rg_10_19">9,212</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_NFG_pVdyhEyJarLQmedkXA" contextRef="Duration_1_1_2020_To_12_31_2020_3DdHOulAJk6Q0Zn4Vsxq5A" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="0" id="Tc_m5iRsDUBVU2624TyVeS14A_10_25">9,217</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:13.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0pt 6pt;">Issuance of common stock to consultants and advisors</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;border-right:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;border-left:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares__cOSbKjBTUyHt70_t1aAVw" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_FOnigPlx6UaoZMNa-ktVRg" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesIssuedForServices" scale="0" id="Tc_r0DlDJ2YHEuy8eaHycj7eg_11_13">25,000</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_NFG_pVdyhEyJarLQmedkXA" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_FOnigPlx6UaoZMNa-ktVRg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" scale="0" id="Tc_KBNNgkO1n0GiYa0gy3agig_11_16">2</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_NFG_pVdyhEyJarLQmedkXA" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_JVwGb5QRK0mEvKeM6mX7xg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" scale="0" id="Tc_PI57DSMrXE6sPV8bOgKHCg_11_19">122,748</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_NFG_pVdyhEyJarLQmedkXA" contextRef="Duration_1_1_2020_To_12_31_2020_3DdHOulAJk6Q0Zn4Vsxq5A" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" scale="0" id="Tc__MmluatONkieN2F_wBHeMw_11_25">122,750</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:13.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0pt 6pt;">Stock-based compensation expense</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;background:#cceeff;border-right:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;background:#cceeff;border-left:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_NFG_pVdyhEyJarLQmedkXA" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_JVwGb5QRK0mEvKeM6mX7xg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" scale="0" id="Tc_WW7IuyYO-UKIt3f1jkImHg_12_19">1,742,163</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_NFG_pVdyhEyJarLQmedkXA" contextRef="Duration_1_1_2020_To_12_31_2020_3DdHOulAJk6Q0Zn4Vsxq5A" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" scale="0" id="Tc_XZUVzoohIU6h5OOLKqIFGA_12_25">1,742,163</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:13.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0pt 6pt;">Net loss</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.93%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.93%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;border-right:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;border-left:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_NFG_pVdyhEyJarLQmedkXA" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_Yj7CnNrKbk2eFi8MMsgZvQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" sign="-" scale="0" id="Tc_S_Zh-lDslkybFC7-WZV8dQ_13_22">5,462,047</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_NFG_pVdyhEyJarLQmedkXA" contextRef="Duration_1_1_2020_To_12_31_2020_3DdHOulAJk6Q0Zn4Vsxq5A" decimals="0" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" sign="-" scale="0" id="Tc_W88J1qoKDESziI2y5430gg_13_25">5,462,047</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:13.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Balance, December&#160;31,&#160;2020</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares__cOSbKjBTUyHt70_t1aAVw" contextRef="As_Of_12_31_2020_us-gaap_StatementClassOfStockAxis_anvs_SeriesaRedeemableConvertiblePreferredStockMember_54xJpWZU6E-sSdAV-pOOiA" decimals="INF" format="ixt:zerodash" name="us-gaap:TemporaryEquitySharesIssued" scale="0" id="Tc_j1BIqEQmykKWGfoMqUwQHQ_14_2">&#8212;</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_NFG_pVdyhEyJarLQmedkXA" contextRef="As_Of_12_31_2020_us-gaap_StatementClassOfStockAxis_anvs_SeriesaRedeemableConvertiblePreferredStockMember_54xJpWZU6E-sSdAV-pOOiA" decimals="0" format="ixt:zerodash" name="us-gaap:TemporaryEquityCarryingAmountAttributableToParent" scale="0" id="Tc_J9YF3EIF-USZ6ZDb1BTPYA_14_5">&#8212;</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares__cOSbKjBTUyHt70_t1aAVw" contextRef="As_Of_12_31_2020_us-gaap_StatementClassOfStockAxis_anvs_Series1RedeemableConvertiblePreferredStockMember_hROazqn7SUCQmc794Mq69Q" decimals="INF" format="ixt:zerodash" name="us-gaap:TemporaryEquitySharesIssued" scale="0" id="Tc_69E5XSZcLEmPZLb3x7Z-IA_14_7">&#8212;</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_NFG_pVdyhEyJarLQmedkXA" contextRef="As_Of_12_31_2020_us-gaap_StatementClassOfStockAxis_anvs_Series1RedeemableConvertiblePreferredStockMember_hROazqn7SUCQmc794Mq69Q" decimals="0" format="ixt:zerodash" name="us-gaap:TemporaryEquityCarryingAmountAttributableToParent" scale="0" id="Tc_Fdxv78zYPUKFvBfxyZX8xg_14_10">&#8212;</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;background:#cceeff;border-right:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;background:#cceeff;border-left:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares__cOSbKjBTUyHt70_t1aAVw" contextRef="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_hBUW9O6ICE63RL-ah82T6g" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SharesIssued" scale="0" id="Tc_j44c9GrlckaipkxqjzSryQ_14_13">6,891,608</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_NFG_pVdyhEyJarLQmedkXA" contextRef="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_hBUW9O6ICE63RL-ah82T6g" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="0" id="Tc_YOYhdT5kZkyP89I7M5LuDg_14_16">689</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_NFG_pVdyhEyJarLQmedkXA" contextRef="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_aLSsuRjKkUqU5e2EQUdxog" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="0" id="Tc_yOZSiS8qMkuTfZIMLcdJZA_14_19">21,779,340</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_NFG_pVdyhEyJarLQmedkXA" contextRef="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_m87TYAU_iECC8Uth9G-F3g" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" sign="-" scale="0" id="Tc_oPHEaBVuOECgTyrXuq5hdA_14_22">14,239,075</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_NFG_pVdyhEyJarLQmedkXA" contextRef="As_Of_12_31_2020_K1oKCNbpv0CLR8EJWu1PSw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="0" id="Tc_Wm9EhEPu9UuvgPaReoWzNw_14_25">7,540,954</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:13.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0pt 6pt;">Issuance of common stock, net of issuance costs</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;border-right:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;border-left:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares__cOSbKjBTUyHt70_t1aAVw" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_zHbo2vwCLUiM30jKyAcCgw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" id="Tc_2Hekyg9390uRzmNT1CLrKQ_15_13">1,000,000</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_NFG_pVdyhEyJarLQmedkXA" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_zHbo2vwCLUiM30jKyAcCgw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="0" id="Tc_rus-5Gwf6kOOYznumaafjw_15_16">100</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_NFG_pVdyhEyJarLQmedkXA" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_Nwz3m5oS6kGLY8WW_bxwDQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="0" id="Tc_LHaRazFbJU-pe4eZxKA30Q_15_19">46,648,313</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_NFG_pVdyhEyJarLQmedkXA" contextRef="Duration_1_1_2021_To_12_31_2021_uhkxAiZ6fUeekYGgaMhCqA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="0" id="Tc_fclz53uUv0KXU_H9vROX5w_15_25">46,648,413</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:13.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0pt 6pt;">Exercise of stock options</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;background:#cceeff;border-right:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;background:#cceeff;border-left:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares__cOSbKjBTUyHt70_t1aAVw" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_zHbo2vwCLUiM30jKyAcCgw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="0" id="Tc_4AzdzD3VlE-ItfvHvtdSvQ_16_13">155,038</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_NFG_pVdyhEyJarLQmedkXA" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_zHbo2vwCLUiM30jKyAcCgw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="0" id="Tc_vHDTPmHQaECbFwi2uBjkUw_16_16">16</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_NFG_pVdyhEyJarLQmedkXA" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_Nwz3m5oS6kGLY8WW_bxwDQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="0" id="Tc_NwoFLSp9g0SpMEoL94VuiQ_16_19">95,086</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_NFG_pVdyhEyJarLQmedkXA" contextRef="Duration_1_1_2021_To_12_31_2021_uhkxAiZ6fUeekYGgaMhCqA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="0" id="Tc_QUZPEDpA4kWY6_edO3swhQ_16_25">95,102</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:13.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0pt 6pt;">Cashless exercise of warrants</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;border-right:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;border-left:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares__cOSbKjBTUyHt70_t1aAVw" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_zHbo2vwCLUiM30jKyAcCgw" decimals="INF" format="ixt:numdotdecimal" name="anvs:StockIssuedDuringPeriodSharesWarrantsExercised" scale="0" id="Tc_DJUxhTxneEG8pblEeeeosw_17_13">53,924</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_NFG_pVdyhEyJarLQmedkXA" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_zHbo2vwCLUiM30jKyAcCgw" decimals="0" format="ixt:numdotdecimal" name="anvs:StockIssuedDuringPeriodValueWarrantsExercised" scale="0" id="Tc_Vpx4eCDNHUOOXkUFBgAntA_17_16">5</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_NFG_pVdyhEyJarLQmedkXA" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_Nwz3m5oS6kGLY8WW_bxwDQ" decimals="0" format="ixt:numdotdecimal" name="anvs:StockIssuedDuringPeriodValueWarrantsExercised" sign="-" scale="0" id="Tc_xrCkR3US8k60_tMPSoYUJQ_17_19">5</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:13.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0pt 6pt;">Stock-based compensation expense</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;background:#cceeff;border-right:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;background:#cceeff;border-left:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_NFG_pVdyhEyJarLQmedkXA" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_Nwz3m5oS6kGLY8WW_bxwDQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" scale="0" id="Tc_gbtcf35dRkWAzlO1jrRp9g_18_19">4,697,627</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_NFG_pVdyhEyJarLQmedkXA" contextRef="Duration_1_1_2021_To_12_31_2021_uhkxAiZ6fUeekYGgaMhCqA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" scale="0" id="Tc_2O68M5CO8ku8_YK1BPAnyw_18_25">4,697,627</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:13.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0pt 6pt;">Net loss</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.93%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.93%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;border-right:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;border-left:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_NFG_pVdyhEyJarLQmedkXA" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_ryg7L-2WUkOqbAJ4DvlylQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" sign="-" scale="0" id="Tc_Lcytg_OwZU2ragf8p7cVqg_19_22">14,487,132</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_NFG_pVdyhEyJarLQmedkXA" contextRef="Duration_1_1_2021_To_12_31_2021_uhkxAiZ6fUeekYGgaMhCqA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" sign="-" scale="0" id="Tc_VLekNJ13u0-AJEw9X58VLg_19_25">14,487,132</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:13.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Balance, December&#160;31,&#160;2021</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.93%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.8%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.93%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.72%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.8%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.72%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;background:#cceeff;border-right:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;background:#cceeff;border-left:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.46%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares__cOSbKjBTUyHt70_t1aAVw" contextRef="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_xiqgw4dbRkGQtr2BjCvyAw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SharesIssued" scale="0" id="Tc_X5Vwzpqt1k67WR49M0joGA_20_13">8,100,570</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.84%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.81%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_NFG_pVdyhEyJarLQmedkXA" contextRef="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_xiqgw4dbRkGQtr2BjCvyAw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="0" id="Tc_Di9n34EJikqTYfNyK92_ew_20_16">810</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.8%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.27%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_NFG_pVdyhEyJarLQmedkXA" contextRef="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_Roe1SnnNfUKvOnVm7PJZ8w" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="0" id="Tc_08T3fyqIUU6yC1wM6aPElA_20_19">73,220,361</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.8%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.74%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_NFG_pVdyhEyJarLQmedkXA" contextRef="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_vHHC9xto40u1e1f1OxZXDA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" sign="-" scale="0" id="Tc_4UdKxYv5pk6g14N6-52m5g_20_22">28,726,207</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.8%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.74%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_NFG_pVdyhEyJarLQmedkXA" contextRef="As_Of_12_31_2021_slf_IrTrZku1VVWbbttE4g" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="0" id="Tc__tSn7Utn5kCEsUI92WEsWw_20_25">44,494,964</ix:nonFraction></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">See accompanying notes to financial statements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-5</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_a0080f74_38e5_40f2_a889_3c1c15aa2a4f"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 12pt 0pt;">ANNOVIS BIO,&#160;INC.</p><a id="StatementsofCashFlows_169542"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><b style="font-weight:bold;">Statements of Cash Flows</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_b49e932b_6cb7_4b05_8b25_82bc55b98382"></a><a id="Tc__RJPl2wRqkyJzbZSGX6hnA_1_2"></a><a id="Tc_UbsAtoiK-0ua2z4dhrOEgA_2_2"></a><a id="Tc_VfqZMX3oME-xaINTbW4S3w_2_5"></a><a id="Tc_ijDq3dkOX0KISJ1tmNIY5Q_3_0"></a><a id="Tc_qqOOEn0uUkm5_5RFZTCxXg_4_0"></a><a id="Tc_cDtH73yeZUyGrp69PbfC-A_4_2"></a><a id="Tc_nUmX9zd0cUaDjxa8JKbZeQ_4_5"></a><a id="Tc_WWQUYjhSX0iQIInrN-cGhw_5_0"></a><a id="Tc_TRNhLwMGPUO65vZbSW_Bog_6_0"></a><a id="Tc_BcO7lN-uJUKhaJrZC5jLBA_6_3"></a><a id="Tc_APZp9dLelU24dY-bN5CedA_7_0"></a><a id="Tc_ZqmUdQZxYESeVyBF6O_AtQ_7_3"></a><a id="Tc_DwCv5p-_fUmdOPVrpCXhqQ_8_0"></a><a id="Tc_iRLpqX7Ax06fOxsVruM0vw_9_0"></a><a id="Tc_H_WiBcX5tE-X4ZFYFqJCJw_9_3"></a><a id="Tc_-rVV_9jN10OTACmpqRxQKQ_10_0"></a><a id="Tc_xDmyLL5_tEaQ4AmSDSjsNw_11_0"></a><a id="Tc_0_fVHwbTukmyjz5GAkkV5Q_11_3"></a><a id="Tc_7W-Kf1_d0kakZnzrl2sziA_12_0"></a><a id="Tc_LpZz2TxLUk2OiEwgiuOi5g_13_0"></a><a id="Tc_SKme-j47dEy6zh1sdHlOLQ_14_0"></a><a id="Tc_Lk-xjRZHCki6wl1I4hotsg_15_0"></a><a id="Tc__Om9ns6SbES1l59jMrSgYA_16_0"></a><a id="Tc_5UN4lX4KA0aWgW-VUnK9fw_17_0"></a><a id="Tc_Hjd2lzADT0eMfhTYeJ4Uwg_18_0"></a><a id="Tc_YwtcM7w0_Uem1Rst_MQtmw_19_0"></a><a id="Tc_NA40dAZR8U2C76ELLDGIWg_20_0"></a><a id="Tc_GXwBFQ1Oc0uA19ULSiKcFA_21_0"></a><a id="Tc_aR_2QlFt6EW-nEO2U3bQNg_22_0"></a><a id="Tc_JZjYHmoZ4ESWrSa8Mxa9sw_22_2"></a><a id="Tc_pSGlUkvowkKA_KT1XI6WQA_22_5"></a><a id="Tc_EVDGl6WM5Uqdwc2sJ9pBeQ_23_0"></a><a id="Tc_EYPSG_qx6U6sBtJceA09Bg_24_0"></a><a id="Tc_p23p28dDOkS8vewDGYqc3Q_24_2"></a><a id="Tc_cpC_lVixAkGM-wo2xoq9FA_24_3"></a><a id="Tc_BSfqqiFH2kyPLQDzCsjXuA_24_5"></a><a id="Tc_RgpSNs6PMEaovGmeh0aGdg_25_0"></a><a id="Tc_MmhhSmKkTUWh3xcl3jt3FQ_25_2"></a><a id="Tc_m3tjkNqfJEmnRc4NAKWHpw_25_3"></a><a id="Tc_mm3_LPlEGECzrVJ8Qy47bg_25_5"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:71.51%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.87%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:71.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:26.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year Ended December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:71.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.93%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td></tr><tr><td style="vertical-align:bottom;width:71.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Cash flows from operating activities:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:71.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Net loss</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_NFG_pVdyhEyJarLQmedkXA" contextRef="Duration_1_1_2021_To_12_31_2021_uhkxAiZ6fUeekYGgaMhCqA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" sign="-" scale="0" id="Tc_XxsXNPtbsECN-dS-w8tgBw_4_3">14,487,132</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_NFG_pVdyhEyJarLQmedkXA" contextRef="Duration_1_1_2020_To_12_31_2020_3DdHOulAJk6Q0Zn4Vsxq5A" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" sign="-" scale="0" id="Tc_WywI_Osr6kut7ktf57bY_Q_4_6">5,462,047</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:71.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Adjustments to reconcile net loss to net cash used in operating activities:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:71.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Amortization of deferred financing fees</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_NFG_pVdyhEyJarLQmedkXA" contextRef="Duration_1_1_2020_To_12_31_2020_3DdHOulAJk6Q0Zn4Vsxq5A" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AmortizationOfFinancingCosts" scale="0" id="Tc_mi_trP8vgU-w7XJxcLePow_6_6">129</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:71.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Amortization of debt discount</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_NFG_pVdyhEyJarLQmedkXA" contextRef="Duration_1_1_2020_To_12_31_2020_3DdHOulAJk6Q0Zn4Vsxq5A" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AmortizationOfDebtDiscountPremium" scale="0" id="Tc_gPpMF3oKWUGsM68cQtp5-w_7_6">396</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:71.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Stock-based compensation expense, including stock issued to consultants and advisors</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_NFG_pVdyhEyJarLQmedkXA" contextRef="Duration_1_1_2021_To_12_31_2021_uhkxAiZ6fUeekYGgaMhCqA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensation" scale="0" id="Tc_utofmZP3Bk6-LvENNjEAJA_8_3">4,697,627</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_NFG_pVdyhEyJarLQmedkXA" contextRef="Duration_1_1_2020_To_12_31_2020_3DdHOulAJk6Q0Zn4Vsxq5A" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensation" scale="0" id="Tc_ywd_3OIhOES9MDiJHmYyoQ_8_6">1,864,913</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:71.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Change in fair value of derivative liability</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_NFG_pVdyhEyJarLQmedkXA" contextRef="Duration_1_1_2020_To_12_31_2020_3DdHOulAJk6Q0Zn4Vsxq5A" decimals="0" format="ixt:numdotdecimal" name="us-gaap:UnrealizedGainLossOnDerivatives" sign="-" scale="0" id="Tc_lnfAmg0y4EOZdbOP7GTwOg_9_6">26,500</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:71.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Changes in operating assets and liabilities:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:71.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;">Grant receivable</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_NFG_pVdyhEyJarLQmedkXA" contextRef="Duration_1_1_2020_To_12_31_2020_3DdHOulAJk6Q0Zn4Vsxq5A" decimals="0" format="ixt:numdotdecimal" name="anvs:IncreaseDecreaseInGrantsReceivable" sign="-" scale="0" id="Tc_72jKXPkccU6DG2eKwcWBfg_11_6">735,075</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:71.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;">Prepaid expenses and other current assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_NFG_pVdyhEyJarLQmedkXA" contextRef="Duration_1_1_2021_To_12_31_2021_uhkxAiZ6fUeekYGgaMhCqA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" scale="0" id="Tc_Z2Qr0aGOmU-lJv6tcHuR6A_12_3">270,788</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_NFG_pVdyhEyJarLQmedkXA" contextRef="Duration_1_1_2020_To_12_31_2020_3DdHOulAJk6Q0Zn4Vsxq5A" decimals="0" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" scale="0" id="Tc_1vli_YsKw02A102y8XRajw_12_6">34,097</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:71.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;">Accounts payable</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_NFG_pVdyhEyJarLQmedkXA" contextRef="Duration_1_1_2021_To_12_31_2021_uhkxAiZ6fUeekYGgaMhCqA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInAccountsPayable" scale="0" id="Tc_QPAqqnsx2kC4qF4kuML43w_13_3">346,218</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_NFG_pVdyhEyJarLQmedkXA" contextRef="Duration_1_1_2020_To_12_31_2020_3DdHOulAJk6Q0Zn4Vsxq5A" decimals="0" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInAccountsPayable" sign="-" scale="0" id="Tc_t2eL_coHOEKSfKquIVWryg_13_6">695,660</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:71.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;">Accrued expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.87%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_NFG_pVdyhEyJarLQmedkXA" contextRef="Duration_1_1_2021_To_12_31_2021_uhkxAiZ6fUeekYGgaMhCqA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInAccruedLiabilities" scale="0" id="Tc_SowV2zf94kK3yDZZr7Lt3w_14_3">581,916</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_NFG_pVdyhEyJarLQmedkXA" contextRef="Duration_1_1_2020_To_12_31_2020_3DdHOulAJk6Q0Zn4Vsxq5A" decimals="0" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInAccruedLiabilities" sign="-" scale="0" id="Tc_SnZaJCi7w0q1xICPA9rwdQ_14_6">406,032</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:71.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 24pt;">Net cash used in operating activities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.87%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_NFG_pVdyhEyJarLQmedkXA" contextRef="Duration_1_1_2021_To_12_31_2021_uhkxAiZ6fUeekYGgaMhCqA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" sign="-" scale="0" id="Tc_qnA8DT-QRUWUZ4OlPYjWqA_15_3">9,132,159</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_NFG_pVdyhEyJarLQmedkXA" contextRef="Duration_1_1_2020_To_12_31_2020_3DdHOulAJk6Q0Zn4Vsxq5A" decimals="0" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" sign="-" scale="0" id="Tc_0EDyyfAXGECiILSeEkTR7A_15_6">3,970,823</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:71.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Cash flows from financing activities:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:71.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Proceeds from issuance of common stock, net of issuance costs</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_NFG_pVdyhEyJarLQmedkXA" contextRef="Duration_1_1_2021_To_12_31_2021_uhkxAiZ6fUeekYGgaMhCqA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromIssuanceOfCommonStock" scale="0" id="Tc_KKKxM4eUjUupYae1QA9oOA_17_3">46,648,413</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_NFG_pVdyhEyJarLQmedkXA" contextRef="Duration_1_1_2020_To_12_31_2020_3DdHOulAJk6Q0Zn4Vsxq5A" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromIssuanceOfCommonStock" scale="0" id="Tc_OudJY-SUk0ShMAvNSsJNpg_17_6">12,034,406</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:71.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Proceeds from exercise of stock options</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.87%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_NFG_pVdyhEyJarLQmedkXA" contextRef="Duration_1_1_2021_To_12_31_2021_uhkxAiZ6fUeekYGgaMhCqA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromStockOptionsExercised" scale="0" id="Tc_LUK94WBeSUiuCxTfNeTzZA_18_3">95,102</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_NFG_pVdyhEyJarLQmedkXA" contextRef="Duration_1_1_2020_To_12_31_2020_3DdHOulAJk6Q0Zn4Vsxq5A" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromStockOptionsExercised" scale="0" id="Tc_OmxMpbS5S0ufqzKpv9uYJA_18_6">9,217</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:71.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 24pt;">Net cash provided by financing activities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.87%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_NFG_pVdyhEyJarLQmedkXA" contextRef="Duration_1_1_2021_To_12_31_2021_uhkxAiZ6fUeekYGgaMhCqA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="0" id="Tc_kdAWcz8eOUisguYPjGd3Bg_19_3">46,743,515</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_NFG_pVdyhEyJarLQmedkXA" contextRef="Duration_1_1_2020_To_12_31_2020_3DdHOulAJk6Q0Zn4Vsxq5A" decimals="0" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="0" id="Tc_km4hjCjvyU2KqJatP0TltQ_19_6">12,043,623</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:71.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 24pt;">Net increase in cash and cash equivalents</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_NFG_pVdyhEyJarLQmedkXA" contextRef="Duration_1_1_2021_To_12_31_2021_uhkxAiZ6fUeekYGgaMhCqA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" scale="0" id="Tc_-st175dXpEeUcf5zlBXq4Q_20_3">37,611,356</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_NFG_pVdyhEyJarLQmedkXA" contextRef="Duration_1_1_2020_To_12_31_2020_3DdHOulAJk6Q0Zn4Vsxq5A" decimals="0" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" scale="0" id="Tc_SnYo6NCH2UqUDSWTgsFosw_20_6">8,072,800</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:71.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Cash and cash equivalents, beginning of year</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.87%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_NFG_pVdyhEyJarLQmedkXA" contextRef="As_Of_12_31_2020_K1oKCNbpv0CLR8EJWu1PSw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="0" id="Tc_fNjsR7Vk8Eu2rkrinmxRgw_21_3">8,074,658</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_NFG_pVdyhEyJarLQmedkXA" contextRef="As_Of_12_31_2019_S7jX8DT5zEOORR0B4HM-aw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="0" id="Tc_pq8MudX8E0-1bPHtDDI_yA_21_6">1,858</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:71.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Cash and cash equivalents, end of year</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.87%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_NFG_pVdyhEyJarLQmedkXA" contextRef="As_Of_12_31_2021_slf_IrTrZku1VVWbbttE4g" decimals="0" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="0" id="Tc_DqN6doehrkKynVCSX4IjDQ_22_3">45,686,014</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_NFG_pVdyhEyJarLQmedkXA" contextRef="As_Of_12_31_2020_K1oKCNbpv0CLR8EJWu1PSw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="0" id="Tc_uooZ3TjZ3kqxlma3PNL_xg_22_6">8,074,658</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:71.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Supplemental disclosure of non-cash financing activities:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:71.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Conversion of redeemable convertible preferred stock to common stock</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_NFG_pVdyhEyJarLQmedkXA" contextRef="Duration_1_1_2020_To_12_31_2020_3DdHOulAJk6Q0Zn4Vsxq5A" decimals="0" format="ixt:numdotdecimal" name="anvs:ConversionOfRedeemableConvertiblePreferredStockToCommonStock" scale="0" id="Tc_kQ8kVee7eEiUlnLXV6igqg_24_6">7,076,952</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:71.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Conversion of convertible promissory notes, including embedded derivative, to common stock</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_NFG_pVdyhEyJarLQmedkXA" contextRef="Duration_1_1_2020_To_12_31_2020_3DdHOulAJk6Q0Zn4Vsxq5A" decimals="0" format="ixt:numdotdecimal" name="anvs:ConversionOfConvertiblePromissoryNotesIncludingEmbeddedDerivativeToCommonStock" scale="0" id="Tc_ZAt7U6B6f0KFqClSEV21SQ_25_6">672,524</ix:nonFraction></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt 0pt 12pt 0pt;">See accompanying notes to financial statements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-6</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_2129281e_881d_47af_b00e_0ce533ada03b"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Annovis Bio,&#160;Inc.</b></p><a id="NotestoFinancialStatements_177435"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Notes&#160;to Financial Statements</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">December&#160;31, 2021 and 2020</b></p><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_uhkxAiZ6fUeekYGgaMhCqA" name="us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" id="Tb_VxLX6s5EQEyHmB9RT_I91Q" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">(1)&#160;Nature of Business and Liquidity</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Annovis Bio,&#160;Inc. (the &#8220;Company&#8221; or &#8220;Annovis&#8221;) was incorporated on April&#160;29, 2008, under the laws of the State of Delaware. Annovis is a clinical-stage drug platform company addressing neurodegeneration such as Alzheimer&#8217;s disease (&#8220;AD&#8221;), Parkinson&#8217;s disease (&#8220;PD&#8221;) and Down syndrome patients with AD (&#8220;DS-AD&#8221;). The toxic cascade in neurodegeneration begins with high levels of neurotoxic proteins which lead to impaired axonal transport, inflammation, death of nerve cells and loss of cognition and motor function. The Company&#8217;s lead compound, Buntanetap, is a small molecule administered orally that attacks neurodegeneration by entering the brain and inhibiting the translation of multiple neurotoxic proteins thereby impeding the toxic cascade.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Since its founding, the Company has been engaged in organizational activities, including raising capital, and research and development activities. The Company has <span style="-sec-ix-hidden:Hidden_wLzrCC9kDk6BKVi6RIiXmQ;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">not</span></span> generated substantial revenues and has not yet achieved profitable operations, nor has it ever generated positive cash flows from operations. There is no assurance that profitable operations, if achieved, could be sustained on a continuing basis. The Company is subject to those risks associated with any clinical stage pharmaceutical company that has substantial expenditures for research and development. There can be no assurance that the Company&#8217;s research and development projects will be successful, that products developed will obtain necessary regulatory approval, or that any approved product will be commercially viable. In addition, the Company operates in an environment of rapid technological change and is largely dependent on the services of its employees and consultants. Further, the Company&#8217;s future operations are dependent on the success of the Company&#8217;s efforts to raise additional capital.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company has a history of incurring net losses and anticipates incurring additional losses until such time, if ever, that it can generate significant revenue from its product candidates currently in development. The Company&#8217;s primary source of capital has been the issuance of equity securities.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company closed its initial public offering (the &#8220;IPO&#8221;) on January&#160;31, 2020, pursuant to which it sold a total of <ix:nonFraction unitRef="Unit_Standard_shares__cOSbKjBTUyHt70_t1aAVw" contextRef="Duration_1_31_2020_To_1_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember_sRjzEwCZI0yVkxtZkXzw0w" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" id="Narr_Ln63qVFnCkeyAqtmRQYwOA">2,300,000</ix:nonFraction> shares of common stock at an initial offering price of $<ix:nonFraction unitRef="Unit_Divide_USD_shares_ZtgwQidioUWlbMoOaTBzxg" contextRef="As_Of_1_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember_rLszk1iR-U-miS0THNh94A" decimals="2" format="ixt:numdotdecimal" name="us-gaap:SharePrice" scale="0" id="Narr__7H6AV-XfUGPTYUjJBzzkg">6.00</ix:nonFraction> per share for total gross proceeds of approximately&#160;$<ix:nonFraction unitRef="Unit_Standard_USD_NFG_pVdyhEyJarLQmedkXA" contextRef="Duration_1_31_2020_To_1_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember_sRjzEwCZI0yVkxtZkXzw0w" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromIssuanceOfCommonStock" scale="6" id="Narr_qkKOmRuPl06lLgbb-PxIwA">13.8</ix:nonFraction> million. The net proceeds of the IPO were approximately $<ix:nonFraction unitRef="Unit_Standard_USD_NFG_pVdyhEyJarLQmedkXA" contextRef="Duration_1_31_2020_To_1_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember_sRjzEwCZI0yVkxtZkXzw0w" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" scale="6" id="Narr_90S1qGChik6l75QAcXU-qw">12.0</ix:nonFraction> million after deducting underwriting discounts and issuance costs paid by&#160;the Company. In conjunction with the IPO, the Company granted the underwriters <ix:nonFraction unitRef="Unit_Standard_shares__cOSbKjBTUyHt70_t1aAVw" contextRef="As_Of_1_31_2020_us-gaap_ClassOfWarrantOrRightAxis_anvs_UnderwritersWarrantsMember_p2Rmy9kgMES4LjCsl9nsqg" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" scale="0" id="Narr_OdL1d1oC0U2RZxT4RlJcsw">100,000</ix:nonFraction> warrants to purchase shares of Company common stock at an exercise price of $<ix:nonFraction unitRef="Unit_Divide_USD_shares_ZtgwQidioUWlbMoOaTBzxg" contextRef="As_Of_1_31_2020_us-gaap_ClassOfWarrantOrRightAxis_anvs_UnderwritersWarrantsMember_p2Rmy9kgMES4LjCsl9nsqg" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="Narr_stenrccGPkCUCf9kUB1WYA">7.50</ix:nonFraction> per share, which is <ix:nonFraction unitRef="Unit_Standard_pure_n7tAfGlk1kyqYH5N2uCURw" contextRef="As_Of_1_31_2020_us-gaap_ClassOfWarrantOrRightAxis_anvs_UnderwritersWarrantsMember_p2Rmy9kgMES4LjCsl9nsqg" decimals="2" format="ixt:numdotdecimal" name="anvs:PercentageOfExercisePriceToShareOfferingPrice" scale="-2" id="Narr_9WYL0GUViUy0pr4cmYyjxg">125</ix:nonFraction>% of the initial public offering price. Upon the closing of the IPO, outstanding redeemable convertible preferred stock and convertible promissory notes&#160;converted into shares of Company common stock totaling <ix:nonFraction unitRef="Unit_Standard_shares__cOSbKjBTUyHt70_t1aAVw" contextRef="Duration_1_31_2020_To_1_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember_sRjzEwCZI0yVkxtZkXzw0w" decimals="INF" format="ixt:numdotdecimal" name="anvs:StockIssuedDuringPeriodSharesConversionOfConvertibleSecuritiesPreferredStock" scale="0" id="Narr_-2T-n3uT4UKdTG4pK0D2Hg">4,117,089</ix:nonFraction> and <ix:nonFraction unitRef="Unit_Standard_shares__cOSbKjBTUyHt70_t1aAVw" contextRef="Duration_1_31_2020_To_1_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember_sRjzEwCZI0yVkxtZkXzw0w" decimals="INF" format="ixt:numdotdecimal" name="anvs:StockIssuedDuringPeriodSharesConversionOfConvertibleNotes" scale="0" id="Narr_vQELTN72wESKFtuu0IH8Ug">118,470</ix:nonFraction><span style="white-space:pre-wrap;">, respectively.  On May 26, 2021, the Company closed an underwritten public offering of </span><ix:nonFraction unitRef="Unit_Standard_shares__cOSbKjBTUyHt70_t1aAVw" contextRef="Duration_5_26_2021_To_5_26_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_us-gaap_SubsidiarySaleOfStockAxis_anvs_SecondaryPublicOfferingMember_hxxkehfNkEWWBXStlPA61w" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" id="Narr_cWiYQYscAEWthQUNNlIkxg">1,000,000</ix:nonFraction> shares of its common stock at an offering price of $<ix:nonFraction unitRef="Unit_Divide_USD_shares_ZtgwQidioUWlbMoOaTBzxg" contextRef="As_Of_5_26_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_us-gaap_SubsidiarySaleOfStockAxis_anvs_SecondaryPublicOfferingMember_VQlutMc_ZkWzfLztqs-8Cg" decimals="2" format="ixt:numdotdecimal" name="us-gaap:SharePrice" scale="0" id="Narr_2lBWGydoXUe3vHGMKipL5A">50.00</ix:nonFraction> per share, for gross proceeds of $<ix:nonFraction unitRef="Unit_Standard_USD_NFG_pVdyhEyJarLQmedkXA" contextRef="Duration_5_26_2021_To_5_26_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_us-gaap_SubsidiarySaleOfStockAxis_anvs_SecondaryPublicOfferingMember_hxxkehfNkEWWBXStlPA61w" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromIssuanceOfCommonStock" scale="6" id="Narr_ZByga6QmvU2zwUZevIyqSw">50.0</ix:nonFraction><span style="white-space:pre-wrap;"> million.  The net proceeds of the offering were approximately </span>$<ix:nonFraction unitRef="Unit_Standard_USD_NFG_pVdyhEyJarLQmedkXA" contextRef="Duration_5_26_2021_To_5_26_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_us-gaap_SubsidiarySaleOfStockAxis_anvs_SecondaryPublicOfferingMember_hxxkehfNkEWWBXStlPA61w" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" scale="6" id="Narr_ylxtS1151kC-g4xxSrO8tQ">46.6</ix:nonFraction><span style="white-space:pre-wrap;"> million, after deducting underwriting discounts and issuance costs paid by the Company.  The Company&#8217;s common stock trades on the New York Stock Exchange under the ticker symbol &#8220;ANVS&#8221;.  </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">As of the date these financial statements are issued, management believes that the current cash and cash equivalents are sufficient to fund operations and capital requirements for at least the next 12&#160;months including one potential short-term clinical trial in AD and one potential short term clinical trial in PD. To fund additional planned Phase 3 trials, however, the Company will need to raise additional capital. There is no assurance that such financing will be available when needed or on acceptable terms.</p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_uhkxAiZ6fUeekYGgaMhCqA" name="us-gaap:SignificantAccountingPoliciesTextBlock" id="Tb_AqM9X4FYQUmVAZPtBW3VZg" continuedAt="Tb_AqM9X4FYQUmVAZPtBW3VZg_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">(2)&#160;Summary of Significant Accounting Policies</p><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_uhkxAiZ6fUeekYGgaMhCqA" name="us-gaap:BasisOfAccounting" id="Tb_bQiz5cmJGEmlaEu9cy6mew" continuedAt="Tb_bQiz5cmJGEmlaEu9cy6mew_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;">(a)&#160;Basis of Presentation</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">The accompanying financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America (&#8220;U.S.&#160;GAAP&#8221;). Any reference in these notes to applicable guidance is meant </p></ix:nonNumeric></ix:nonNumeric></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-7</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb_AqM9X4FYQUmVAZPtBW3VZg_cont1" continuedAt="Tb_AqM9X4FYQUmVAZPtBW3VZg_cont2"><ix:continuation id="Tb_bQiz5cmJGEmlaEu9cy6mew_cont1"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">to refer to U.S.&#160;GAAP as found in the Accounting Standards Codification (&#8220;ASC&#8221;) and Accounting Standards Update (&#8220;ASU&#8221;) of the Financial Accounting Standards Board (&#8220;FASB&#8221;).</p></ix:continuation><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_uhkxAiZ6fUeekYGgaMhCqA" name="us-gaap:UseOfEstimates" id="Tb_9Pw8vdHFwU6QJMbHf3gi3g" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;">(b)&#160;Use of Estimates</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The preparation of financial statements in conformity with U.S.&#160;GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, including disclosure of contingent assets and liabilities, at the date of the financial statements, and the reported amounts of revenues and expenses during the reporting period. Due to the uncertainty of factors surrounding the estimates or judgments used in the preparation of the financial statements, actual results may materially vary from these estimates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Significant items subject to such estimates and assumptions include progress towards completion of research and development projects, stock-based compensation expense, grant income and contingent liabilities. Future events and their effects cannot be predicted with certainty; accordingly, accounting estimates require the exercise of judgment. Accounting estimates used in the preparation of these financial statements change as new events occur, as more experience is acquired, as additional information is obtained and as the operating environment changes.</p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_uhkxAiZ6fUeekYGgaMhCqA" name="us-gaap:EarningsPerSharePolicyTextBlock" id="Tb_Jt8FadyEVUuQI7R7nh_FGg" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;">(c)&#160;Basic and Diluted Net Income (Loss) per Share</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Basic net income (loss) per share is determined using the weighted average number of shares of common stock outstanding during each period. Diluted net income (loss) per share includes the effect, if any, from the potential exercise or conversion of securities, such as redeemable convertible preferred stock, convertible promissory notes and stock options, which would result in the issuance of incremental shares of common stock. The computation of diluted net income (loss) per shares does not include the conversion of securities that would have an anti-dilutive effect.</p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_uhkxAiZ6fUeekYGgaMhCqA" name="us-gaap:CashAndCashEquivalentsPolicyTextBlock" id="Tb_V2kQLYpxV0uWkDEabM27vQ" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;">(d)&#160;Cash and Cash Equivalents</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company considers all highly liquid investments with original maturities of three&#160;months or less to be cash equivalents. At times, the Company&#8217;s cash balances may exceed the current insured amounts under the Federal Deposit Insurance Corporation. </p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_uhkxAiZ6fUeekYGgaMhCqA" name="anvs:IssuanceCostsAssociatedWithEquityIssuancesPolicyTextBlock" id="Tb_eKEpF3dQVEWuY49TCqBLng" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;">(e)&#160;Issuance Costs Associated with Equity Issuances</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Issuance costs incurred in connection with the Company&#8217;s equity issuances, which primarily consisted of direct incremental legal, printing, listing and accounting fees, are offset against proceeds received in the issuances and charged to additional paid-in capital in the period the equity issuance is completed. </p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_uhkxAiZ6fUeekYGgaMhCqA" name="us-gaap:FairValueOfFinancialInstrumentsPolicy" id="Tb_16LXHoP6oUqYL2NswSNneg" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;">(f)&#160;Fair Value of Financial Instruments</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company&#8217;s financial instruments include cash and cash equivalents, accounts payable and accrued expenses. Cash and cash equivalents are reported at fair value. The recorded carrying amount of accounts payable and accrued expenses reflect their fair value due to their short-term nature.</p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_uhkxAiZ6fUeekYGgaMhCqA" name="us-gaap:ResearchDevelopmentAndComputerSoftwarePolicyTextBlock" id="Tb_4nxInUdjlkCj7A4m5JSqWg" continuedAt="Tb_4nxInUdjlkCj7A4m5JSqWg_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;">(g)&#160;Research and Development</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Research and development costs are expensed as incurred and are primarily comprised of personnel-related expenses and external research and development expenses incurred under arrangements with third parties, such as contract research organizations and consultants. At the end of each reporting period, the Company compares the payments made to each service provider to the estimated progress towards completion of the related project. Factors that the Company considers in preparing these estimates include the number of patients enrolled in studies, milestones achieved, and other criteria related to the efforts of its vendors. These estimates will be subject to change as additional information becomes available. Depending on the timing of payments to vendors and estimated services provided, the Company will record net prepaid or accrued expenses related to these costs.</p></ix:nonNumeric></ix:continuation></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-8</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb_AqM9X4FYQUmVAZPtBW3VZg_cont2" continuedAt="Tb_AqM9X4FYQUmVAZPtBW3VZg_cont3"><ix:continuation id="Tb_4nxInUdjlkCj7A4m5JSqWg_cont1"></ix:continuation><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_uhkxAiZ6fUeekYGgaMhCqA" name="anvs:GrantIncomePolicyTextBlock" id="Tb_YDr5ocI2DECeBRtNwfqbzg" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;">(h)&#160;Grant Income</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Grants received are recognized as grant income in the statements of operations as and when they are earned for the specific research and development projects for which these grants are designated. Grants payments received in excess of grant income earned are recognized as deferred grant on the balance sheet and grant income earned in excess of grant payments received is recognized as grant receivable on the balance sheets.</p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_uhkxAiZ6fUeekYGgaMhCqA" name="us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy" id="Tb_GbHSWycpnUiclK4ZKnn1Ug" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;">(i)&#160;Stock-Based Compensation</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Stock-based compensation cost is measured at the grant date based on the fair value of the award and is recognized as expense on a straight-line basis over the requisite service period, which is generally the vesting period. Forfeitures are recognized in compensation expense in the period when they occur.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company uses the Black-Scholes option pricing model to value its option awards which requires the use of subjective assumptions, including the expected life of the option and expected share price volatility. The assumptions used in calculating the fair value of stock-based awards represent management&#8217;s best estimates and involve inherent uncertainties and the application of management&#8217;s judgment. As a result, if factors change and management uses different assumptions, stock-based compensation expense could be materially different for future awards.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Upon exercise of stock options, the Company issues shares first from treasury stock, if available, then from authorized but unissued shares.</p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_uhkxAiZ6fUeekYGgaMhCqA" name="us-gaap:IncomeTaxPolicyTextBlock" id="Tb_HX387abS00Kqb97WxVaM-A" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;">(j)&#160;Income Taxes</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company provides for income taxes using the asset and liability approach. Deferred tax assets and liabilities are recorded based on the differences between the financial statement and tax bases of assets and liabilities and the tax rates in effect when these differences are expected to reverse. Deferred tax assets are reduced by a valuation allowance if, based on the weight of available evidence, it is more likely than not that some or all of the deferred tax assets will not be realized. As of December 31, 2021 and 2020, the Company had a full valuation allowance against its deferred tax assets.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company is subject to the provisions of ASC 740,&#160;Income Taxes, which prescribes a more likely-than-not threshold for the financial statement recognition of uncertain tax positions. ASC 740 clarifies the accounting for income taxes by prescribing a minimum recognition threshold and measurement attribute for the financial statement recognition and measurement of a tax position taken or expected to be taken in a tax return. There are currently no open federal or state tax audits. The Company has not recorded any liability for uncertain tax positions at December&#160;31, 2021 or December&#160;31, 2020.</p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_uhkxAiZ6fUeekYGgaMhCqA" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" id="Tb_Q3SCjC5O7kWlCT_HBWd-WA" continuedAt="Tb_Q3SCjC5O7kWlCT_HBWd-WA_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;">(k)&#160;Recent Accounting Pronouncements</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In December&#160;2019, the FASB issued ASU No.&#160;2019-12,&#160;Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes. The amendments in ASU 2019-12 simplify the accounting for income taxes by removing certain exceptions to the general principles in Topic 740 and clarifying and amending existing guidance. The new standard is effective for fiscal&#160;years, and interim periods within those fiscal&#160;years, beginning after December&#160;15, 2020, with early adoption permitted. The adoption of this standard did not have an impact on the Company&#8217;s financial statements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="white-space:pre-wrap;">In November 2021, the FASB issued ASU No. 2021-10, Government Assistance (Topic 832): Disclosures by Business Entities about Government Assistance. The amendments in ASU 2021-10 require annual disclosures about transactions with a government that are accounted for by applying a grant or contribution accounting model by analogy.  The new disclosure requirements include information about the nature of the transactions and the related accounting policy used to account for the transactions; the line items on the balance sheet and income statement that are affected by the transactions, and the amounts applicable to each financial statement line item; and significant terms and conditions of the transactions, including commitments and contingencies.  The guidance is effective for fiscal years beginning after </span></p></ix:nonNumeric></ix:continuation></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-9</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb_AqM9X4FYQUmVAZPtBW3VZg_cont3"><ix:continuation id="Tb_Q3SCjC5O7kWlCT_HBWd-WA_cont1"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="white-space:pre-wrap;">December 15, 2021, with early adoption permitted, and may be adopted prospectively or retrospectively.  The Company does not believe the adoption of this standard will have a significant impact on its financial statements.</span></p></ix:continuation><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="font-size:2pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></ix:continuation><a id="_7751c273_da10_4c97_843e_a4dca186eb03"></a><a id="Tc_hoHS9Pr9C0O7ZkldewMz7w_1_5"></a><a id="Tc_3vNV2S5EQE-s50mP31crSg_2_5"></a><a id="Tc_JL760gaDpkug5aBe4j1mNA_3_2"></a><a id="Tc_OfHteypfe0e5x-plKpIhDQ_3_5"></a><a id="Tc_iJ_3tyWk_0W6mjegwytkvg_3_8"></a><a id="Tc_u9kXQQtLOkavgV3lqdvMhw_3_11"></a><a id="Tc_jO58RQmH2kOoK6BvQFQXAg_4_0"></a><a id="Tc_HSXQG1JL1UqstSN2Qd8btQ_4_2"></a><a id="Tc_snmJyTTaKkKoywo-SFTtJQ_4_5"></a><a id="Tc_4w7f4HJry0SY23L_vG2low_4_8"></a><a id="Tc_eXJA2H8Fek2Igs9-vQnuAg_4_9"></a><a id="Tc_T3x69u_aTEaIsdxdFS_bLA_4_11"></a><a id="Tc_Vw-1zEUW_0Kxo3kHbVf4Ww_4_12"></a><a id="_b3030a14_ed0e_4b05_8ce0_2007a6c6ff0a"></a><a id="Tc_HEk9bbS_gUqpR9LU6oFBvg_1_5"></a><a id="Tc_MCqwRItjzE6EiZJJ2r8zEg_2_5"></a><a id="Tc_61I2lxQLMUiCzVE3YopvTg_3_2"></a><a id="Tc_dkByMPLBBECSex7oA0HxMw_3_5"></a><a id="Tc_8XA0pDBPpkuDOvNrokCndg_3_8"></a><a id="Tc_FzsEYz0MxEW2AoBe9YSvVQ_3_11"></a><a id="Tc_cQSS9rmJkE6Hw6ZWFAZQgw_4_0"></a><a id="Tc_eYxa81caGkS8OOzAqlhlfg_4_2"></a><a id="Tc_gUCMjFHGHkS9y_kdaXETrw_4_5"></a><a id="Tc_IN__8SdgA0KwmeQRBhboGA_4_8"></a><a id="Tc_oYn_Noax10G2Ck51o4r9Vg_4_9"></a><a id="Tc_OBJ-SxLu50qCtE0ag9JzOw_4_11"></a><a id="Tc_YRxHLXrmoEWyblesu_wuHA_4_12"></a><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_uhkxAiZ6fUeekYGgaMhCqA" name="us-gaap:FairValueDisclosuresTextBlock" id="Tb_NeHd9Fd_gUGwSf-zMmdptA" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">(3)&#160;Fair Value Measurements</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company measures certain assets and liabilities at fair value in accordance with ASC 820, Fair Value Measurements and Disclosures. ASC 820 defines fair value as the price that would be received to sell an asset or paid to transfer a liability (the exit price) in an orderly transaction between market participants at the measurement date. The guidance in ASC 820 outlines a valuation framework and creates a fair value hierarchy that serves to increase the consistency and comparability of fair value measurements and the related disclosures. In determining fair value, the Company maximizes the use of quoted prices and observable inputs. Observable inputs are inputs that market participants would use in pricing the asset or liability based on market data obtained from independent sources. The fair value hierarchy is broken down into three levels based on the source of inputs as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 36pt;">Level&#160;1&#8212;Valuations based on unadjusted quoted prices in active markets for identical assets or liabilities.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 36pt;">Level&#160;2&#8212;Valuations based on observable inputs and quoted prices in active markets for similar assets and liabilities.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 36pt;">Level&#160;3&#8212;Valuations based on unobservable inputs and models that are supported by little or no market activity.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">The following table provides the carrying value and fair value of certain financial assets and liabilities of the Company measured at fair value on a recurring basis as of December 31, 2021 and December&#160;31, 2020:</p><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_uhkxAiZ6fUeekYGgaMhCqA" name="us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" id="Tb_gqMxTLer50mSiXU8Zc3Ylg" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:45.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.02%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.82%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.61%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.6%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:45.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:36.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Fair Value Measurement at </b></p></td></tr><tr><td style="vertical-align:bottom;width:45.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:36.21%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;2021</b></p></td></tr><tr><td style="vertical-align:bottom;width:45.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Carrying Value</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Level 1</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Level 2</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Level 3</b></p></td></tr><tr><td style="vertical-align:bottom;width:45.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Cash and cash equivalents</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_NFG_pVdyhEyJarLQmedkXA" contextRef="As_Of_12_31_2021_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_4-P5H-hF4ESmAJ-kqpCyXw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="0" id="Tc_dlWr81TKKUGSBVCIbSSiew_4_3">45,686,014</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_NFG_pVdyhEyJarLQmedkXA" contextRef="As_Of_12_31_2021_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_hJjGSBmgGE6iOTr6RBMr5Q" decimals="0" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="0" id="Tc_s9Lct84R-EaQNtA7s05CMw_4_6">45,686,014</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:45.56%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.97%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.74%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.96%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.93%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:45.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:36.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;white-space:pre-wrap;">Fair Value Measurement at  </b></p></td></tr><tr><td style="vertical-align:bottom;width:45.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:36.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;2020</b></p></td></tr><tr><td style="vertical-align:bottom;width:45.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Carrying Value</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Level 1</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Level 2</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Level 3</b></p></td></tr><tr><td style="vertical-align:bottom;width:45.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Cash and cash equivalents</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_NFG_pVdyhEyJarLQmedkXA" contextRef="As_Of_12_31_2020_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_ivytLr2eEUunO9BaEWMghQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="0" id="Tc_Yf4DuM2ySU-aF9LXYBgj6g_4_3">8,074,658</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_NFG_pVdyhEyJarLQmedkXA" contextRef="As_Of_12_31_2020_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_RGBQ6zcqa0CUSFXphddjkA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="0" id="Tc_dhhIRNV6HUWsaJVirR0GYg_4_6">8,074,658</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_uhkxAiZ6fUeekYGgaMhCqA" name="anvs:OtherNonoperatingIncomeGrantIncomeTextBlock" id="Tb_3TLp-cI38Uqqo7sbwSBvwA" continuedAt="Tb_3TLp-cI38Uqqo7sbwSBvwA_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">(4)&#160;Grant Income</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In September&#160;2019, as modified in September 2020, the Company received a Notice of Award for a $<ix:nonFraction unitRef="Unit_Standard_USD_NFG_pVdyhEyJarLQmedkXA" contextRef="As_Of_9_30_2019_us-gaap_TypeOfArrangementAxis_anvs_NationalInstituteOnAgingOfNationalInstitutesOfHealthMember_RQt1O7nidUO5QNweDycD_A" decimals="-5" format="ixt:numdotdecimal" name="anvs:GrantsReceivableNoticeOfAwardAmount" scale="6" id="Narr_UAiUX05rkES2zOXQigK5qg">1.9</ix:nonFraction>&#160;million grant from the National Institute on Aging of the National Institutes of Health&#160;(the &#8220;NIH&#8221;) to cover costs of long-term chronic toxicology studies of Buntanetap in rats and dogs. The Company began the long-term chronic toxicology studies in November&#160;<span style="white-space:pre-wrap;">2019.   The Company recognized grant income of </span>$<ix:nonFraction unitRef="Unit_Standard_USD_NFG_pVdyhEyJarLQmedkXA" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_TypeOfArrangementAxis_anvs_NationalInstituteOnAgingOfNationalInstitutesOfHealthMember_CduWTDd6hEGUS67lAWkVHw" decimals="0" format="ixt:numdotdecimal" name="anvs:IncomeFromGrants" scale="0" id="Narr_GJil8_aJSkyaqeSfE5WOpw">36,754</ix:nonFraction> and $<ix:nonFraction unitRef="Unit_Standard_USD_NFG_pVdyhEyJarLQmedkXA" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_TypeOfArrangementAxis_anvs_NationalInstituteOnAgingOfNationalInstitutesOfHealthMember_1CkP6VBQfUS9FAKN4vz1Tg" decimals="0" format="ixt:numdotdecimal" name="anvs:IncomeFromGrants" scale="0" id="Narr_y8yf1Bczc0avY0P3p2UYuQ">1,157,449</ix:nonFraction> for the&#160;years ended December 31, 2021 and 2020, respectively, in connection with the NIH grant. The Company received payments under the grant of $<ix:nonFraction unitRef="Unit_Standard_USD_NFG_pVdyhEyJarLQmedkXA" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_TypeOfArrangementAxis_anvs_NationalInstituteOnAgingOfNationalInstitutesOfHealthMember_CduWTDd6hEGUS67lAWkVHw" decimals="0" format="ixt:numdotdecimal" name="anvs:ProceedsFromGrants" scale="0" id="Narr_SadTnRRQpE2abvOIVFMTwg">36,754</ix:nonFraction> and $<ix:nonFraction unitRef="Unit_Standard_USD_NFG_pVdyhEyJarLQmedkXA" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_TypeOfArrangementAxis_anvs_NationalInstituteOnAgingOfNationalInstitutesOfHealthMember_1CkP6VBQfUS9FAKN4vz1Tg" decimals="0" format="ixt:numdotdecimal" name="anvs:ProceedsFromGrants" scale="0" id="Narr_j5bV7InThEG_fVZXMduabg">1,892,524</ix:nonFraction> during the&#160;years ended December 31, 2021 and 2020, respectively and recorded a grant receivable of $<ix:nonFraction unitRef="Unit_Standard_USD_NFG_pVdyhEyJarLQmedkXA" contextRef="As_Of_12_31_2020_us-gaap_TypeOfArrangementAxis_anvs_NationalInstituteOnAgingOfNationalInstitutesOfHealthMember_SIhJO7d5SUmK7j4WVeRGBw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:GrantsReceivableCurrent" scale="0" id="Narr_XarV6R_zXkmS5FPjlPpPoA"><ix:nonFraction unitRef="Unit_Standard_USD_NFG_pVdyhEyJarLQmedkXA" contextRef="As_Of_12_31_2021_us-gaap_TypeOfArrangementAxis_anvs_NationalInstituteOnAgingOfNationalInstitutesOfHealthMember_VVmuZtlTeEaVeNDy9uhHaQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:GrantsReceivableCurrent" scale="0" id="Narr_i1HQuZaUPku7xJjoJ3k6uw">0</ix:nonFraction></ix:nonFraction> as of December 31, 2021 and 2020, and had <ix:nonFraction unitRef="Unit_Standard_USD_NFG_pVdyhEyJarLQmedkXA" contextRef="Duration_1_1_2020_To_12_31_2020_3DdHOulAJk6Q0Zn4Vsxq5A" decimals="0" format="ixt-sec:numwordsen" name="anvs:UnreimbursedEligibleCostsIncurredDuringPeriod" scale="0" id="Narr_6k0t8OoMDkuh_oz2Gf7X1w"><ix:nonFraction unitRef="Unit_Standard_USD_NFG_pVdyhEyJarLQmedkXA" contextRef="Duration_1_1_2021_To_12_31_2021_uhkxAiZ6fUeekYGgaMhCqA" decimals="0" format="ixt-sec:numwordsen" name="anvs:UnreimbursedEligibleCostsIncurredDuringPeriod" scale="0" id="Narr_oVFcJHiw0E-6rthrTagewg">no</ix:nonFraction></ix:nonFraction> unreimbursed, eligible costs incurred under the grant. As of December 31, 2021, there were <ix:nonFraction unitRef="Unit_Standard_USD_NFG_pVdyhEyJarLQmedkXA" contextRef="As_Of_12_31_2020_K1oKCNbpv0CLR8EJWu1PSw" decimals="0" format="ixt-sec:numwordsen" name="anvs:GrantAwardRemainingAmountAvailable" scale="0" id="Narr_aVDWBg0Wlk22jXWXe1nq8Q"><ix:nonFraction unitRef="Unit_Standard_USD_NFG_pVdyhEyJarLQmedkXA" contextRef="As_Of_12_31_2021_slf_IrTrZku1VVWbbttE4g" decimals="0" format="ixt-sec:numwordsen" name="anvs:GrantAwardRemainingAmountAvailable" scale="0" id="Narr_HkBANK377U6VccDVvq5ZAw">no</ix:nonFraction></ix:nonFraction> remaining funds available under the grant.</p></ix:nonNumeric></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-10</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb_3TLp-cI38Uqqo7sbwSBvwA_cont1"></ix:continuation><a id="Tc_DjA5v3qXfkWImLPPXy2MkQ_1_2"></a><a id="Tc_9aeMAAliSESW7OcHkYTS-A_2_2"></a><a id="Tc_dWDj4bLCFUOviCcYT9j-UA_2_5"></a><a id="Tc_PH22QZgflU-yaexQNZJCww_3_0"></a><a id="Tc_sBsaTEZYrkSDf0U4m18WgA_3_2"></a><a id="Tc_bcepSOWDKU2fUT7uv2xuFw_3_5"></a><a id="Tc_rsL2ENLpx0a8dHdxpSgXXQ_3_6"></a><a id="Tc_n3ots7bnbUKppl5FW5RCTw_4_0"></a><a id="Tc_WdeUFXOXgkW6XW6hGse_Vw_5_0"></a><a id="Tc_yynixfamLEOpmeMUQTYHFg_6_0"></a><a id="Tc_IGEJE3g_MEuFLCvmwxqGBA_7_2"></a><a id="Tc_SYd-ynQ29Uy7JstUQosE3A_7_5"></a><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_uhkxAiZ6fUeekYGgaMhCqA" name="anvs:DeferredCostsCapitalizedPrepaidExpensesAndOtherAssetsDisclosureTextBlock" id="Tb_9NF3T8VFvUmV1Bh_cywsaw" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">(5)&#160;Prepaid Expenses and Other Current Assets</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">Prepaid expenses and other current assets consisted of the following:</p><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_uhkxAiZ6fUeekYGgaMhCqA" name="us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" id="Tb_qCxte0QwqEK2ePQ8GedJSA" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:74.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:74.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:23.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">As of December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:74.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.95%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td></tr><tr><td style="vertical-align:bottom;width:74.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Prepaid clinical trial expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_NFG_pVdyhEyJarLQmedkXA" contextRef="As_Of_12_31_2021_slf_IrTrZku1VVWbbttE4g" decimals="0" format="ixt:numdotdecimal" name="anvs:PrepaidResearchAndDevelopmentExpenseCurrent" scale="0" id="Tc_hvJ6dNdQY0WH2XXKIXs7cw_3_3">232,752</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:74.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Prepaid insurance</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_NFG_pVdyhEyJarLQmedkXA" contextRef="As_Of_12_31_2021_slf_IrTrZku1VVWbbttE4g" decimals="0" format="ixt:numdotdecimal" name="us-gaap:PrepaidInsurance" scale="0" id="Tc_1lg7a9CKf02mpQEl3OgdsA_4_3">29,111</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_NFG_pVdyhEyJarLQmedkXA" contextRef="As_Of_12_31_2020_K1oKCNbpv0CLR8EJWu1PSw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:PrepaidInsurance" scale="0" id="Tc_mt42xJXbc0O9jzIMEpC7_w_4_6">26,542</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:74.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Prepaid expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_NFG_pVdyhEyJarLQmedkXA" contextRef="As_Of_12_31_2021_slf_IrTrZku1VVWbbttE4g" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OtherPrepaidExpenseCurrent" scale="0" id="Tc_9YvzT_2XMkGThOUeL7E2BA_5_3">43,736</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_NFG_pVdyhEyJarLQmedkXA" contextRef="As_Of_12_31_2020_K1oKCNbpv0CLR8EJWu1PSw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OtherPrepaidExpenseCurrent" scale="0" id="Tc__kfZkqirkEu4xEw4_PJcEw_5_6">11,690</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:74.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Security deposits</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_NFG_pVdyhEyJarLQmedkXA" contextRef="As_Of_12_31_2021_slf_IrTrZku1VVWbbttE4g" decimals="0" format="ixt:numdotdecimal" name="us-gaap:SecurityDeposit" scale="0" id="Tc_TsJrs7N49kmN8jYVFZzyeQ_6_3">9,865</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_NFG_pVdyhEyJarLQmedkXA" contextRef="As_Of_12_31_2020_K1oKCNbpv0CLR8EJWu1PSw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:SecurityDeposit" scale="0" id="Tc_GHkwo2iot0y1kgpCoy2MfQ_6_6">6,444</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:74.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.78%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_NFG_pVdyhEyJarLQmedkXA" contextRef="As_Of_12_31_2021_slf_IrTrZku1VVWbbttE4g" decimals="0" format="ixt:numdotdecimal" name="anvs:PrepaidExpenseSecurityDepositsAndOtherAssetsCurrent" scale="0" id="Tc_3yksOgtaskq8ycnf3-EbAQ_7_3">315,464</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.49%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_NFG_pVdyhEyJarLQmedkXA" contextRef="As_Of_12_31_2020_K1oKCNbpv0CLR8EJWu1PSw" decimals="0" format="ixt:numdotdecimal" name="anvs:PrepaidExpenseSecurityDepositsAndOtherAssetsCurrent" scale="0" id="Tc_SWOK1zsLg0SVEkvUgZV6Kg_7_6">44,676</ix:nonFraction></p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="Tc_UWUDuNxVw0yiWWE56JpqEw_1_2"></a><a id="Tc_7h7sKa3AjkGxXxIQnETubw_2_2"></a><a id="Tc_0csL-OLV3Eyu2pA9prsd4g_2_5"></a><a id="Tc_yBXI6CTAWkuP_z1LbaTOnw_3_0"></a><a id="Tc_ePYFzY0XSE2pL8oi7w3Mcw_3_2"></a><a id="Tc_C_QMRy2vgEmKkQRFXPN3Nw_3_5"></a><a id="Tc_aFhn8Ob6gEuqmxOrDqWAiA_4_0"></a><a id="Tc_O4zjw2Kv9k-HGPFBRES61g_5_0"></a><a id="Tc_Wmk1n5J9GkqnvYRtKwh7DQ_5_3"></a><a id="Tc_0fdCgpvd0UatvvEIWHu1AQ_6_2"></a><a id="Tc_0IFTA_W6VkuY6Uriin5f0Q_6_5"></a><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_uhkxAiZ6fUeekYGgaMhCqA" name="us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" id="Tb_dpKy2FNQGkSIxXBG097TEQ" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">(6)&#160;Accrued Expenses</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">Accrued expenses consisted of the following:</p><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_uhkxAiZ6fUeekYGgaMhCqA" name="us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock" id="Tb_V_FbGkcaJEaaJfpLhJth5Q" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:73.83%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.8%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:73.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:24.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">As of December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2020</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Payroll and related benefits</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_NFG_pVdyhEyJarLQmedkXA" contextRef="As_Of_12_31_2021_slf_IrTrZku1VVWbbttE4g" decimals="0" format="ixt:numdotdecimal" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" scale="0" id="Tc_jqT-wLe4W0GIQnUs1EUZTg_3_3">712,768</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_NFG_pVdyhEyJarLQmedkXA" contextRef="As_Of_12_31_2020_K1oKCNbpv0CLR8EJWu1PSw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" scale="0" id="Tc_dLW5dsNBOUyjr5geYP1uuA_3_6">16,493</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:73.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Accrued professional and clinical fees</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_NFG_pVdyhEyJarLQmedkXA" contextRef="As_Of_12_31_2021_slf_IrTrZku1VVWbbttE4g" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AccruedProfessionalFeesCurrent" scale="0" id="Tc_uFt1JSaDe0KceCk1CZTYqw_4_3">105,672</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_NFG_pVdyhEyJarLQmedkXA" contextRef="As_Of_12_31_2020_K1oKCNbpv0CLR8EJWu1PSw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AccruedProfessionalFeesCurrent" scale="0" id="Tc_wqJzGBNA60OMeIqHChmffg_4_6">216,198</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:73.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Accrued license payments</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.8%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.86%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_NFG_pVdyhEyJarLQmedkXA" contextRef="As_Of_12_31_2020_K1oKCNbpv0CLR8EJWu1PSw" decimals="0" format="ixt:numdotdecimal" name="anvs:AccruedLicensePaymentsCurrent" scale="0" id="Tc_8t3XbgaAuUi6uxUK51NsGA_5_6">3,833</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:73.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.8%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_NFG_pVdyhEyJarLQmedkXA" contextRef="As_Of_12_31_2021_slf_IrTrZku1VVWbbttE4g" decimals="0" format="ixt:numdotdecimal" name="anvs:AccruedLiabilitiesAndInterestAndEmployeeRelatedLiabilitiesCurrent" scale="0" id="Tc_GH7Nrr9fdUi4un4MkrlQLQ_6_3">818,440</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.86%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_NFG_pVdyhEyJarLQmedkXA" contextRef="As_Of_12_31_2020_K1oKCNbpv0CLR8EJWu1PSw" decimals="0" format="ixt:numdotdecimal" name="anvs:AccruedLiabilitiesAndInterestAndEmployeeRelatedLiabilitiesCurrent" scale="0" id="Tc_8h-_Px0qg0uWaeJQLUHKoQ_6_6">236,524</ix:nonFraction></p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 36pt;">See Note&#160;8 for further detail on the accrued license payments.</p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_uhkxAiZ6fUeekYGgaMhCqA" name="us-gaap:DebtDisclosureTextBlock" id="Tb_z4YT9sqPYUalcInjD8Fp1g" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">(7)&#160;Convertible Promissory Notes</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In March&#160;2019, the Company issued convertible promissory notes (the &#8220;Notes&#8221;) to various investors in the aggregate principal amount of $<ix:nonFraction unitRef="Unit_Standard_USD_NFG_pVdyhEyJarLQmedkXA" contextRef="As_Of_3_31_2019_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember_YwRIubASaUOYMPLJxHrjxQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentFaceAmount" scale="0" id="Narr_D_ysZ2GdsUG2VNpQTPTDaQ">530,000</ix:nonFraction>. Interest accrued at <ix:nonFraction unitRef="Unit_Standard_pure_n7tAfGlk1kyqYH5N2uCURw" contextRef="As_Of_3_31_2019_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember_YwRIubASaUOYMPLJxHrjxQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="Narr_mQv4ISL0HkewxWfTmDHeSQ">8</ix:nonFraction>% compounded annually on all Notes. The maturity date was the earlier of a Liquidity Event or upon the written demand of the holders of a majority of the outstanding principal amount of the Notes&#160;made any time after December&#160;31, 2023. A Liquidity Event was defined as (i)&#160;the date of the closing of a merger or reorganization of the Company with another entity; (ii)&#160;the sale of substantially all of the assets of the Company in which the Company&#8217;s stockholders own less than 50% of the equity securities after the event; or (iii)&#160;a liquidation of the Company.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company incurred costs of $<ix:nonFraction unitRef="Unit_Standard_USD_NFG_pVdyhEyJarLQmedkXA" contextRef="As_Of_3_31_2019_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember_YwRIubASaUOYMPLJxHrjxQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DeferredFinanceCostsGross" scale="0" id="Narr_Qf0jdhMmZk-9GJdLmbsXqQ">8,622</ix:nonFraction> in connection with the issuance of the Notes. In addition, on issuance, the Company recognized a discount associated with the Notes&#160;of $<ix:nonFraction unitRef="Unit_Standard_USD_NFG_pVdyhEyJarLQmedkXA" contextRef="As_Of_3_31_2019_oVmx4yeGk0q3UZkY6l4F-g" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentUnamortizedDiscount" scale="0" id="Narr_RmZ355dDckeVLuuORASmNA">26,500</ix:nonFraction> related to the fair value of an embedded derivative reflecting the share-settlement provision upon the closing of a Qualified Financing. Unamortized deferred financing fees and debt discount were deducted from the face amount of the Notes&#160;on the balance sheets. The Company amortized the deferred financing fees and debt discount over the term of the Notes&#160;as additional interest expense using the effective interest method. The effective interest rate on the Notes&#160;was&#160;<ix:nonFraction unitRef="Unit_Standard_pure_n7tAfGlk1kyqYH5N2uCURw" contextRef="As_Of_3_31_2019_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember_YwRIubASaUOYMPLJxHrjxQ" decimals="3" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" scale="-2" id="Narr_5hD7iFR6GECn9kh4bfz7Kw">9.8</ix:nonFraction>%. The Company made <ix:nonFraction unitRef="Unit_Standard_USD_NFG_pVdyhEyJarLQmedkXA" contextRef="Duration_1_1_2019_To_12_31_2019_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember_RsyiGRhnhk-vxd5-a-DqHg" decimals="0" format="ixt-sec:numwordsen" name="us-gaap:InterestPaidNet" scale="0" id="Narr_uOzA8MXLiE-G9jM1Nsey3w"><ix:nonFraction unitRef="Unit_Standard_USD_NFG_pVdyhEyJarLQmedkXA" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember_dBs7AChUNEK9AUDzdDKJTQ" decimals="0" format="ixt-sec:numwordsen" name="us-gaap:InterestPaidNet" scale="0" id="Narr_MstguZX9SUK3Osuo1JiXeA">no</ix:nonFraction></ix:nonFraction> cash payments for interest.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">On January&#160;<span style="white-space:pre-wrap;">31, 2020, the Company closed its IPO.  In accordance with the terms of the Notes, the outstanding Notes&#160;plus accrued interest converted into </span><ix:nonFraction unitRef="Unit_Standard_shares__cOSbKjBTUyHt70_t1aAVw" contextRef="Duration_1_31_2020_To_1_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember_sRjzEwCZI0yVkxtZkXzw0w" decimals="INF" format="ixt:numdotdecimal" name="anvs:StockIssuedDuringPeriodSharesConversionOfConvertibleNotes" scale="0" id="Narr_7jeCAK9chke8gOux80hYRQ">118,470</ix:nonFraction> shares of Company common stock at a <ix:nonFraction unitRef="Unit_Standard_pure_n7tAfGlk1kyqYH5N2uCURw" contextRef="Duration_1_31_2020_To_1_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember_sRjzEwCZI0yVkxtZkXzw0w" decimals="2" format="ixt:numdotdecimal" name="anvs:ConversionOfConvertibleSecuritiesConvertiblePromissoryNotesPercentageOfDiscountToInitialPublicOfferingPrice" scale="-2" id="Narr_kppkYR5HdEmjy2Xy45EU6Q">20</ix:nonFraction>% discount to the initial offering price of shares issued in the IPO. </p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_uhkxAiZ6fUeekYGgaMhCqA" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" id="Tb_ZWzvDZQUVEyq1QRUdGxKyA" continuedAt="Tb_ZWzvDZQUVEyq1QRUdGxKyA_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">(8)&#160;Commitments and Contingencies</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;">(a)&#160;Leases</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company leases its office facilities under a&#160;month-to-month operating lease. Total rental expense was $<ix:nonFraction unitRef="Unit_Standard_USD_NFG_pVdyhEyJarLQmedkXA" contextRef="Duration_1_1_2021_To_12_31_2021_uhkxAiZ6fUeekYGgaMhCqA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseExpense" scale="0" id="Narr__kDnnj3YSUi8shYISGFY8g">51,760</ix:nonFraction> and $<ix:nonFraction unitRef="Unit_Standard_USD_NFG_pVdyhEyJarLQmedkXA" contextRef="Duration_1_1_2020_To_12_31_2020_3DdHOulAJk6Q0Zn4Vsxq5A" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseExpense" scale="0" id="Narr_JFJebxA2okWZUzllcogHmQ">41,603</ix:nonFraction> for the&#160;years ended December 31, 2021 and 2020, respectively.</p></ix:nonNumeric></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-11</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb_ZWzvDZQUVEyq1QRUdGxKyA_cont1"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;">(b)&#160;License Agreement</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company previously licensed the rights to certain chemical compounds, know-how and intellectual property rights that may be suitable for the development of human therapeutics from a subsidiary of Horizon Therapeutics, PLC (the &#8220;Licensor&#8221;). Under the license agreement, the Company paid a minimum annual fee of $<ix:nonFraction unitRef="Unit_Standard_USD_NFG_pVdyhEyJarLQmedkXA" contextRef="Duration_5_1_2012_To_5_31_2012_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_anvs_LicenseAgreementTermsAmendedMay2012Member_P0aUOpgGN0mwPRsuYBHIew" decimals="0" format="ixt:numdotdecimal" name="anvs:LicenseAgreementMinimumAnnualCommitment" scale="0" id="Narr_TTBkMvKNGUib7eFnqAO5gQ">46,000</ix:nonFraction> and was required to make milestone payments upon attainment of certain milestone events, royalties based on net sales of products covered by the patent-related rights and a portion of any sublicense income received by the Company. The Licensor also granted the Company a buy-out option which was exercisable at any time during the term of the agreement at increasing amounts based on the achievement of certain milestones. The Company had the right to terminate the agreement at any time by giving <ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_anvs_LicenseAgreementTermsAmendedMay2012Member_DCsom2ZXYkiSKjzS68vh2Q" format="ixt-sec:durwordsen" name="anvs:LicenseAgreementPeriodOfAdvanceNoticeOfTermination" id="Narr_VIOA19Pax0yGAA34uNUIRw">90&#160;days</ix:nonNumeric> advance notice subject to the payment of any amounts due under the agreement at that time. Expenses related to the license agreement were recognized in general and administrative expense in the statements of operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="white-space:pre-wrap;"> In July 2021, the Company gave notice to the Licensor of its termination of the license agreement and the license agreement was terminated effective October 14, 2021. The Company has paid to the Licensor the prorated annual fees through the termination date.  </span><ix:nonFraction unitRef="Unit_Standard_USD_NFG_pVdyhEyJarLQmedkXA" contextRef="As_Of_12_31_2021_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_anvs_LicenseAgreementTermsAmendedMay2012Member_fjPgMKMghE-GlCKw7d5yzw" decimals="INF" format="ixt-sec:numwordsen" name="anvs:CumulativeNumberOfMilestonesAchieved" scale="0" id="Narr__falpFyNMEW5n53Zi6fhQg">No</ix:nonFraction> milestones had been achieved as of the termination date.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;">(c)&#160;Employment Agreements</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company has agreements with its executive officers that provide for severance payments to the employee upon termination of the agreement by the Company for any reason other than for cause, death or disability or by the employee for good reason The maximum aggregate severance payments under the agreements were approximately&#160;$<ix:nonFraction unitRef="Unit_Standard_USD_NFG_pVdyhEyJarLQmedkXA" contextRef="As_Of_12_31_2021_srt_TitleOfIndividualAxis_srt_ExecutiveOfficerMember_2QVIbrzh10W_0LPuXlLcug" decimals="0" format="ixt:numdotdecimal" name="anvs:MaximumAggregateSeverancePayments" scale="0" id="Narr_FQIlRIDyOkeV3d6FFj2nrQ">930,000</ix:nonFraction>&#160;at December&#160;31,&#160;2021. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;">(d)&#160;Litigation</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company is subject, from time to time, to claims by third parties under various legal disputes. The defense of such claims, or any adverse outcome relating to any such claims, could have a material adverse effect on the Company&#8217;s liquidity, financial condition and cash flows. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">During the year ended December 31, 2021, <ix:nonFraction unitRef="Unit_Standard_lawsuit_cWy34Dwcxk6mE22LYui79g" contextRef="Duration_1_1_2021_To_12_31_2021_uhkxAiZ6fUeekYGgaMhCqA" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:LossContingencyNewClaimsFiledNumber" scale="0" id="Narr_NqUZ5_zWqUKJm4vS2RFbww">two</ix:nonFraction><span style="white-space:pre-wrap;"> securities class action complaints were filed against the Company and its executive officers following disclosure of interim results from the AD/PD Trial.  Both complaints were voluntarily dismissed without prejudice by the plaintiffs.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">At December&#160;31, 2021, the Company did not have any pending legal actions.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;">(e)&#160;Risks and Uncertainties</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The extent to which the COVID-19 pandemic could have a material impact on the Company&#8217;s current or future clinical trials is dependent on the spread of the disease and government and healthcare system responses to such spread, which are presently highly uncertain. Management continues to evaluate the potential impact. The financial statements do not include any adjustments that might result from the outcome of this uncertainty.</p></ix:continuation><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_uhkxAiZ6fUeekYGgaMhCqA" name="us-gaap:StockholdersEquityNoteDisclosureTextBlock" id="Tb_dsSIzFWFokKSa9y7sCmQNA" continuedAt="Tb_dsSIzFWFokKSa9y7sCmQNA_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">(9)&#160;Redeemable Convertible Preferred Stock and Stockholders&#8217; Equity</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;">(a) Overview</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company closed its IPO on January&#160;31, 2020, issuing <ix:nonFraction unitRef="Unit_Standard_shares__cOSbKjBTUyHt70_t1aAVw" contextRef="Duration_1_31_2020_To_1_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember_sRjzEwCZI0yVkxtZkXzw0w" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" id="Narr_8y7K_P8vFkmpjfvF_2wbgg">2,300,000</ix:nonFraction> shares of common stock. In connection with the closing of the Company&#8217;s IPO, the then-outstanding <ix:nonFraction unitRef="Unit_Standard_shares__cOSbKjBTUyHt70_t1aAVw" contextRef="Duration_1_31_2020_To_1_31_2020_us-gaap_StatementClassOfStockAxis_anvs_SeriesaRedeemableConvertiblePreferredStockMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember_ptCGvvBnuEitWVCSkdK7Vw" decimals="INF" format="ixt:numdotdecimal" name="anvs:TemporaryEquitySharesConversionOfPreferredStockToCommonStock" scale="0" id="Narr_H9fcTAODIk2Lb5AvcFyiFg">5,133,159</ix:nonFraction> shares of Series&#160;A and <ix:nonFraction unitRef="Unit_Standard_shares__cOSbKjBTUyHt70_t1aAVw" contextRef="Duration_1_31_2020_To_1_31_2020_us-gaap_StatementClassOfStockAxis_anvs_Series1RedeemableConvertiblePreferredStockMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember_fNVfPPJXjUyuAgQutr0kWQ" decimals="INF" format="ixt:numdotdecimal" name="anvs:TemporaryEquitySharesConversionOfPreferredStockToCommonStock" scale="0" id="Narr_E0ueD8m2ekGNvtqccdjgbQ">630,722</ix:nonFraction> shares of Series&#160;A-1 redeemable convertible preferred stock converted into an aggregate of <ix:nonFraction unitRef="Unit_Standard_shares__cOSbKjBTUyHt70_t1aAVw" contextRef="Duration_1_31_2020_To_1_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember_sRjzEwCZI0yVkxtZkXzw0w" decimals="INF" format="ixt:numdotdecimal" name="anvs:StockIssuedDuringPeriodSharesConversionOfConvertibleSecuritiesPreferredStock" scale="0" id="Narr_E_mvPYt27k2OotMSoAfrBA">4,117,089</ix:nonFraction> shares of Company common stock. Each share of redeemable convertible preferred stock was converted into the number of shares of common stock determined by dividing the original issue price by the applicable conversion price. The Series&#160;A-1 conversion price was $<ix:nonFraction unitRef="Unit_Divide_USD_shares_ZtgwQidioUWlbMoOaTBzxg" contextRef="As_Of_1_31_2020_us-gaap_StatementClassOfStockAxis_anvs_Series1RedeemableConvertiblePreferredStockMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember_O74MBLhVpkagypo4IVPp_Q" decimals="2" format="ixt:numdotdecimal" name="anvs:RedeemableConvertiblePreferredStockConvertibleConversionPrice" scale="0" id="Narr_NXA9wN3SekyhTpCkythKeA">1.26</ix:nonFraction>, and the Series&#160;A conversion price was $<ix:nonFraction unitRef="Unit_Divide_USD_shares_ZtgwQidioUWlbMoOaTBzxg" contextRef="As_Of_1_31_2020_us-gaap_StatementClassOfStockAxis_anvs_SeriesaRedeemableConvertiblePreferredStockMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember_WSa7shXqeUSwpAKpQQl-KQ" decimals="2" format="ixt:numdotdecimal" name="anvs:RedeemableConvertiblePreferredStockConvertibleConversionPrice" scale="0" id="Narr_nA1yHaGcYUyUZFfByxf8Ew">0.70</ix:nonFraction>.</p></ix:nonNumeric></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-12</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb_dsSIzFWFokKSa9y7sCmQNA_cont1"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company&#8217;s Amended and Restated Certificate of Incorporation was adopted on January&#160;31, 2020 to authorize the issuance of <ix:nonFraction unitRef="Unit_Standard_item_Y7Ur8tqCgUit9H-TWiK9OA" contextRef="As_Of_1_31_2020_kBrHfmPKTE-0UUCmwNXokA" decimals="INF" format="ixt-sec:numwordsen" name="anvs:NumberOfClassesOfStockDesignated" scale="0" id="Narr_tN-HsCvQsUmUrYpztoEUAA">two</ix:nonFraction> classes of stock to be designated, respectively, common stock and preferred stock. The total number of shares which the Company is authorized to issue is <ix:nonFraction unitRef="Unit_Standard_shares__cOSbKjBTUyHt70_t1aAVw" contextRef="As_Of_1_31_2020_kBrHfmPKTE-0UUCmwNXokA" decimals="INF" format="ixt:numdotdecimal" name="anvs:CommonStockAndPreferredStockSharesAuthorized" scale="0" id="Narr_ymG2GICYjEmymFA4vAApqg">37,000,000</ix:nonFraction>, each with a <span style="-sec-ix-hidden:Hidden_W_s6TWSI0kqP0maAGvG-9A;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">par value</span></span> of $<ix:nonFraction unitRef="Unit_Divide_USD_shares_ZtgwQidioUWlbMoOaTBzxg" contextRef="As_Of_1_31_2020_kBrHfmPKTE-0UUCmwNXokA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="Narr_4vNc22ZujEC70pMaC_LjWA">0.0001</ix:nonFraction> per share. Of these shares, <ix:nonFraction unitRef="Unit_Standard_shares__cOSbKjBTUyHt70_t1aAVw" contextRef="As_Of_1_31_2020_kBrHfmPKTE-0UUCmwNXokA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesAuthorized" scale="0" id="Narr_RWPIwzi1d0Svhcbt3029VA">35,000,000</ix:nonFraction> shall be common stock and <ix:nonFraction unitRef="Unit_Standard_shares__cOSbKjBTUyHt70_t1aAVw" contextRef="As_Of_1_31_2020_kBrHfmPKTE-0UUCmwNXokA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:PreferredStockSharesAuthorized" scale="0" id="Narr_qhIn0eO4MkSPS4XmreLcqQ">2,000,000</ix:nonFraction> shall be preferred stock.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;">(b) Common Stock</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;padding-left:36pt;text-indent:-36pt;margin:0pt 0pt 12pt 0pt;"><span style="font-weight:normal;">1.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Dividends</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Subject to the rights of holders of all classes of Company stock outstanding having rights that are senior to or equivalent to holders of common stock, the holders of the common stock are entitled to receive dividends when and as declared by the Board.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;padding-left:36pt;text-indent:-36pt;margin:0pt 0pt 12pt 0pt;"><span style="font-weight:normal;">2.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Liquidation</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Subject to the rights of holders of all classes of stock outstanding having rights that are senior to or equivalent to holders of common stock as to liquidation, upon the liquidation, dissolution or winding up of the Company, the assets of the Company will be distributed to the holders of common stock.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;padding-left:36pt;text-indent:-36pt;margin:0pt 0pt 12pt 0pt;"><span style="font-weight:normal;">3.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Voting</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The holders of common stock are entitled to <ix:nonFraction unitRef="Unit_Standard_Vote_pwF70c76VEGREHjsKw9EwA" contextRef="As_Of_12_31_2021_slf_IrTrZku1VVWbbttE4g" decimals="0" format="ixt-sec:numwordsen" name="anvs:NumberOfVotesForEachShareOfCommonStock" scale="0" id="Narr_7aoFRSMyzUuj0nj_dupdXg">one</ix:nonFraction> vote for each share of common stock held. There is no cumulative voting.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;">(c)&#160;Preferred Stock</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Preferred stock may be issued from time to time by the Board in one or more series.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;">(d)&#160;Warrants</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">In conjunction with the IPO, the Company granted the underwriters <ix:nonFraction unitRef="Unit_Standard_shares__cOSbKjBTUyHt70_t1aAVw" contextRef="As_Of_1_31_2020_us-gaap_ClassOfWarrantOrRightAxis_anvs_UnderwritersWarrantsMember_p2Rmy9kgMES4LjCsl9nsqg" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" scale="0" id="Narr_-lWad8kgIkuOETux-C7awg">100,000</ix:nonFraction> warrants to purchase shares of Company common stock at an exercise price of $<ix:nonFraction unitRef="Unit_Divide_USD_shares_ZtgwQidioUWlbMoOaTBzxg" contextRef="As_Of_1_31_2020_us-gaap_ClassOfWarrantOrRightAxis_anvs_UnderwritersWarrantsMember_p2Rmy9kgMES4LjCsl9nsqg" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="Narr_1f8BgVxlr0q0E-mv8lAC2g">7.50</ix:nonFraction> per share, which is <ix:nonFraction unitRef="Unit_Standard_pure_n7tAfGlk1kyqYH5N2uCURw" contextRef="As_Of_1_31_2020_us-gaap_ClassOfWarrantOrRightAxis_anvs_UnderwritersWarrantsMember_p2Rmy9kgMES4LjCsl9nsqg" decimals="2" format="ixt:numdotdecimal" name="anvs:PercentageOfExercisePriceToShareOfferingPrice" scale="-2" id="Narr_qCnLKIUwfkqkEXauSj7A_w">125</ix:nonFraction>% of the initial public offering price. The warrants have a <span style="-sec-ix-hidden:Hidden_7Pmc5xg25E6fTLpFgVmdTA;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">five</span></span>-year term and were exercisable as of January&#160;29, 2021. During the year ended December 31, 2021, <ix:nonFraction unitRef="Unit_Standard_shares__cOSbKjBTUyHt70_t1aAVw" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_ClassOfWarrantOrRightAxis_anvs_UnderwritersWarrantsMember_lIkEDjt6I02rJoRPhXJAxw" decimals="INF" format="ixt:numdotdecimal" name="anvs:ConversionOfWarrantsNumberOfWarrantsConverted" scale="0" id="Narr_RV0cJz9MfUaMv8My7IkF0g">97,600</ix:nonFraction><span style="white-space:pre-wrap;"> of the warrants were tendered to the Company by the holders pursuant to cashless exercises.  Warrants outstanding as of December 31, 2021 and 2020, were </span><ix:nonFraction unitRef="Unit_Standard_shares__cOSbKjBTUyHt70_t1aAVw" contextRef="As_Of_12_31_2021_us-gaap_ClassOfWarrantOrRightAxis_anvs_UnderwritersWarrantsMember_i9g6mnyCNEylYBl9fs3ugQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ClassOfWarrantOrRightOutstanding" scale="0" id="Narr_RssR8JpHbEaeIyOcS4riww">2,400</ix:nonFraction> and <ix:nonFraction unitRef="Unit_Standard_shares__cOSbKjBTUyHt70_t1aAVw" contextRef="As_Of_12_31_2020_us-gaap_ClassOfWarrantOrRightAxis_anvs_UnderwritersWarrantsMember_fVGxQCgHYU-B8YaMWCH07g" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ClassOfWarrantOrRightOutstanding" scale="0" id="Narr_gXHVLogv0EK_shUGJbYO-w">100,000</ix:nonFraction><span style="white-space:pre-wrap;">, respectively.  The Company accounts for the warrants as a component of stockholders&#8217; equity.  </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></ix:continuation><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_uhkxAiZ6fUeekYGgaMhCqA" name="us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" id="Tb_fvoTYB_aN0Wq8DCKL6RTtg" continuedAt="Tb_fvoTYB_aN0Wq8DCKL6RTtg_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">(10)&#160;Stock-Based Compensation</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Effective upon the closing of the Company&#8217;s IPO on January&#160;31, 2020, the Company&#8217;s 2019 Equity Incentive Plan (the &#8220;2019 Plan&#8221;) became effective, succeeding the Company&#8217;s previous equity incentive plan. <ix:nonFraction unitRef="Unit_Standard_shares__cOSbKjBTUyHt70_t1aAVw" contextRef="As_Of_1_31_2020_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_anvs_EquityIncentivePlan2018Member_c20l7lAf-kqshSDL7zNsjg" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" scale="0" id="Narr_TQxOZr2jsk2HOLP1ITL-Rg">No</ix:nonFraction> new options may be issued under the previous plan, although shares subject to grants which are cancelled or forfeited will again be available under the 2019 Plan. Effective June 1, 2021, the 2019 Plan was amended to increase the number of shares authorized to be issued from <ix:nonFraction unitRef="Unit_Standard_shares__cOSbKjBTUyHt70_t1aAVw" contextRef="As_Of_5_31_2021_us-gaap_PlanNameAxis_anvs_EquityIncentivePlan2019Member_KtS-YX7JjU6pl2kOUpEkTw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" scale="0" id="Narr_e-FXdry9UE6jG9C0T2taBA">1,000,000</ix:nonFraction> to <ix:nonFraction unitRef="Unit_Standard_shares__cOSbKjBTUyHt70_t1aAVw" contextRef="As_Of_6_1_2021_us-gaap_PlanNameAxis_anvs_EquityIncentivePlan2019Member__w3AH-0HNU6nl5M5tn5tng" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" scale="0" id="Narr_mUxGHM0yckiwLc9OWdACJA">2,000,000</ix:nonFraction>. As of December 31, 2021, <ix:nonFraction unitRef="Unit_Standard_shares__cOSbKjBTUyHt70_t1aAVw" contextRef="As_Of_12_31_2021_us-gaap_PlanNameAxis_anvs_EquityIncentivePlan2019Member_UCOHxKW5skOhwhVeKdLFlA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" scale="0" id="Narr_cmYVy4aolkq1wfDCnatzpw">630,569</ix:nonFraction> shares were available for future grants.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The 2019 Plan provides for grants to employees, members of the Board, consultants and advisors to the Company, in the form of stock options, stock awards and other equity-based awards. The amount and terms of grants are determined by the Board. Stock options have a maximum term of <ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_anvs_EquityIncentivePlan2019Member_GgeIFB678UmRgQVDyMstNg" format="ixt-sec:durwordsen" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" id="Narr_V8PZpAhcQEGNiPNKFQQFww">10 years</ix:nonNumeric> after date of grant and are exercisable in cash or as otherwise determined by the Board. </p><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_uhkxAiZ6fUeekYGgaMhCqA" name="us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" id="Tb_YjdcRAhs-k-N6gjX-3MA5Q" continuedAt="Tb_YjdcRAhs-k-N6gjX-3MA5Q_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Stock-based compensation expense in the statements of operations, including the fair value of stock awards to consultants and advisors for services rendered, for the&#160;years ended December 31, 2021 and 2020 was as follows:</p></ix:nonNumeric></ix:nonNumeric></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-13</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_90d1056b_eb46_44f5_9eca_fcc5d79a7f59"></a><a id="Tc_6cRvnV4yj0S2_-OWZ5_Ypw_1_2"></a><a id="Tc_H1jrB77B0U-dQD9Me8fM7A_2_2"></a><a id="Tc_dY5qrnxqSUaPxkRzHSZxpg_3_2"></a><a id="Tc_hO7mzSklHE--rulZAKVltA_3_5"></a><a id="Tc_lero9dYfd0q3-8X3XMQUyQ_5_0"></a><a id="Tc_u9LrfFIZrUqkWv4RK_G2pg_5_2"></a><a id="Tc_WzCrsvs6pkWuoQi9cCqJkA_5_5"></a><a id="Tc_TbixQ88cF0e9GUtutfuyrQ_6_0"></a><a id="Tc_FCD90B7qfkm7kQN2halXLQ_7_2"></a><a id="Tc_60a8W1HTQ06_GHLhVr6Qtg_7_5"></a><a id="Tc_pBICVnfAMk-4amtw3vriHw_1_7"></a><a id="Tc_19if310ttUqBXTNAXurW2g_2_7"></a><a id="Tc_WITqzDT4VEiJG-MHvbVeeQ_3_7"></a><a id="Tc_a7JRCS3aLUiP2zSgM1y2MA_4_4"></a><a id="Tc_wFSpJt8iykGolibGu9K-Eg_4_7"></a><a id="Tc_82mnFS2a-E2izedwVeUohA_4_9"></a><a id="Tc_ZTSIZy5ExUGLqMv6UBvpEA_5_2"></a><a id="Tc_NGrovGnVd0y77lNKa2EYOQ_5_4"></a><a id="Tc_Lh-qVODrjUOzksF7GxZW6g_5_7"></a><a id="Tc_gfGzS72t6EOM4EgZcj933g_5_9"></a><a id="Tc_xjXg3EaO30uLhLLboWw6GQ_6_2"></a><a id="Tc_UdnV-NKLlEuH3z69AqTfsw_6_4"></a><a id="Tc_agPDpk2cukKJyfKVxD9VaQ_6_7"></a><a id="Tc_rrCuHA5C-029YjKhRl0g7Q_6_9"></a><a id="Tc_H63ZlIMgwEWG8myykkqVzg_7_0"></a><a id="Tc_9vz4euGg9EWWB8xellZWkg_8_0"></a><a id="Tc_-rbOx0I_5k2_lHhQNwWQvw_9_0"></a><a id="Tc_2ttDD3EWQkC71h0jhujmDA_10_0"></a><a id="Tc_kb3YJoysREC4hNKJi61i-Q_11_0"></a><a id="Tc_To7x-LZKKECn9d3SWnCxJg_12_0"></a><a id="Tc_KtIw4VIq5E2sMtf5nSVbNA_13_0"></a><a id="Tc_aRhiSRWUxkmmbsDbJ-F6oQ_14_0"></a><a id="Tc_vGnWkXAE3k-MAo6xj4U7MA_15_0"></a><a id="_075f73d6_a67d_4b57_bce0_0a58f283e6f5"></a><a id="_075f73d6_a67d_4b57_bce0_0a58f283e6f5_2"></a><a id="_075f73d6_a67d_4b57_bce0_0a58f283e6f5_3"></a><ix:continuation id="Tb_fvoTYB_aN0Wq8DCKL6RTtg_cont1" continuedAt="Tb_fvoTYB_aN0Wq8DCKL6RTtg_cont2"><ix:continuation id="Tb_YjdcRAhs-k-N6gjX-3MA5Q_cont1"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:73%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:24.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Year Ended </b></p></td></tr><tr><td style="vertical-align:bottom;width:73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:24.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.85%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.95%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2020</b></p></td></tr><tr><td style="vertical-align:bottom;width:73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Research and development</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_NFG_pVdyhEyJarLQmedkXA" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_PpS2s9PnUUSL1x-_RPEPIQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensation" scale="0" id="Tc_Jzy0J_ayPEa5wxxJeHJJ_w_5_3">2,016,745</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_NFG_pVdyhEyJarLQmedkXA" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_Fq09egBe_kOjLnI9UQwMsA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensation" scale="0" id="Tc_VZyix7uJFUCidgtwSXhCgA_5_6">138,704</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">General and administrative</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_NFG_pVdyhEyJarLQmedkXA" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_obnngQDtKEWjaZKdmxph6g" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensation" scale="0" id="Tc_RDaosi8fwU-nXirFdc9RNA_6_3">2,680,882</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_NFG_pVdyhEyJarLQmedkXA" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_r5vqCaRQJk29U3pXOnvzDg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensation" scale="0" id="Tc_dMpc33ZTZE2HNqh8VU-PdA_6_6">1,726,209</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_NFG_pVdyhEyJarLQmedkXA" contextRef="Duration_1_1_2021_To_12_31_2021_uhkxAiZ6fUeekYGgaMhCqA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensation" scale="0" id="Tc_sCXjCitrUk2b0cNmHbYMiw_7_3">4,697,627</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_NFG_pVdyhEyJarLQmedkXA" contextRef="Duration_1_1_2020_To_12_31_2020_3DdHOulAJk6Q0Zn4Vsxq5A" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensation" scale="0" id="Tc_0NabRXBD7UyEmphM8S3UQw_7_6">1,864,913</ix:nonFraction></p></td></tr></table></ix:continuation><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">Stock option activity for the years ended December 31, 2021, and 2020, was as follows:</p><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_uhkxAiZ6fUeekYGgaMhCqA" name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" id="Tb_lJ_xcdtgsEabH4zoOGjByw" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:54.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.63%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.52%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.43%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:54.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Weighted</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:54.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Average</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:54.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Remaining</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:54.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Weighted</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Contractual</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Aggregate</b></p></td></tr><tr><td style="vertical-align:bottom;width:54.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Number of</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Average</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Term</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Intrinsic</b></p></td></tr><tr><td style="vertical-align:bottom;width:54.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Shares</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Exercise Price</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">(Years)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Value</b></p></td></tr><tr><td style="vertical-align:bottom;width:54.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Outstanding at December&#160;31,&#160;2019</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares__cOSbKjBTUyHt70_t1aAVw" contextRef="As_Of_12_31_2019_S7jX8DT5zEOORR0B4HM-aw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" id="Tc_2W294jPMIkav4ZwH2TPrEQ_7_2">352,282</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">$ <ix:nonFraction unitRef="Unit_Divide_USD_shares_ZtgwQidioUWlbMoOaTBzxg" contextRef="As_Of_12_31_2019_S7jX8DT5zEOORR0B4HM-aw" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="Tc_3SH2r8hU-kytrxxiU-dThA_7_5">0.19</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:54.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Granted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares__cOSbKjBTUyHt70_t1aAVw" contextRef="Duration_1_1_2020_To_12_31_2020_3DdHOulAJk6Q0Zn4Vsxq5A" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" scale="0" id="Tc_axM_G8gA6Eqs-goQGaamfw_8_2">810,000</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_ZtgwQidioUWlbMoOaTBzxg" contextRef="Duration_1_1_2020_To_12_31_2020_3DdHOulAJk6Q0Zn4Vsxq5A" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" id="Tc_l7xQmtOn_kuZmy8mGjKdzA_8_5">3.46</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:54.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Exercised</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_shares__cOSbKjBTUyHt70_t1aAVw" contextRef="Duration_1_1_2020_To_12_31_2020_3DdHOulAJk6Q0Zn4Vsxq5A" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="0" id="Tc_5aKzDRWjUU2ukZr0Y9FHDw_9_2">48,435</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_ZtgwQidioUWlbMoOaTBzxg" contextRef="Duration_1_1_2020_To_12_31_2020_3DdHOulAJk6Q0Zn4Vsxq5A" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" scale="0" id="Tc_s2qcb-mLJ0aV585sqM0FIQ_9_5">0.19</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:54.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Forfeited</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_shares__cOSbKjBTUyHt70_t1aAVw" contextRef="Duration_1_1_2020_To_12_31_2020_3DdHOulAJk6Q0Zn4Vsxq5A" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" scale="0" id="Tc_kFj33-F6YEWSpNYlUIka6Q_10_2">2,381</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_ZtgwQidioUWlbMoOaTBzxg" contextRef="Duration_1_1_2020_To_12_31_2020_3DdHOulAJk6Q0Zn4Vsxq5A" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" scale="0" id="Tc_q1v37hbgxE263oRFp9JO7g_10_5">0.14</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:54.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Outstanding at December&#160;31,&#160;2020</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares__cOSbKjBTUyHt70_t1aAVw" contextRef="As_Of_12_31_2020_K1oKCNbpv0CLR8EJWu1PSw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" id="Tc_5mNmZJCRmkug6iEHmsKbbQ_11_2">1,111,466</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_ZtgwQidioUWlbMoOaTBzxg" contextRef="As_Of_12_31_2020_K1oKCNbpv0CLR8EJWu1PSw" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="Tc_6Z8KQx9aKESyqjesr1yrTw_11_5">2.57</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:54.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Granted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares__cOSbKjBTUyHt70_t1aAVw" contextRef="Duration_1_1_2021_To_12_31_2021_uhkxAiZ6fUeekYGgaMhCqA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" scale="0" id="Tc_yIipyX75CU2AYT97FnGpBw_12_2">538,095</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_ZtgwQidioUWlbMoOaTBzxg" contextRef="Duration_1_1_2021_To_12_31_2021_uhkxAiZ6fUeekYGgaMhCqA" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" id="Tc_pky3vL5b-k6m6Hq0v-t9Qw_12_5">33.78</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:54.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Exercised</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_shares__cOSbKjBTUyHt70_t1aAVw" contextRef="Duration_1_1_2021_To_12_31_2021_uhkxAiZ6fUeekYGgaMhCqA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="0" id="Tc_yJ2lrAlUtEiVWJXvpgJSAw_13_2">159,813</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_ZtgwQidioUWlbMoOaTBzxg" contextRef="Duration_1_1_2021_To_12_31_2021_uhkxAiZ6fUeekYGgaMhCqA" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" scale="0" id="Tc_6FML1xA5gkuoHgNOhXrxxw_13_5">2.83</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:54.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Outstanding at December&#160;31,&#160;2021</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares__cOSbKjBTUyHt70_t1aAVw" contextRef="As_Of_12_31_2021_slf_IrTrZku1VVWbbttE4g" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" id="Tc_gwyWDxDRkEe1F2i7gFFMGA_14_2">1,489,748</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_ZtgwQidioUWlbMoOaTBzxg" contextRef="As_Of_12_31_2021_slf_IrTrZku1VVWbbttE4g" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="Tc_0MRG0g6HPUeQGABk5fA0CA_14_5">13.82</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="-sec-ix-hidden:Hidden_EQY9UVLtMU6NuqPU1k6Bhg;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> 8.4</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">$ <ix:nonFraction unitRef="Unit_Standard_USD_NFG_pVdyhEyJarLQmedkXA" contextRef="As_Of_12_31_2021_slf_IrTrZku1VVWbbttE4g" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" scale="0" id="Tc_oFBHmVYgjkCBwhVJZQgMNQ_14_9">14,325,377</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:54.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Exercisable at December&#160;31,&#160;2021</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares__cOSbKjBTUyHt70_t1aAVw" contextRef="As_Of_12_31_2021_slf_IrTrZku1VVWbbttE4g" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" scale="0" id="Tc_Xz6VLr8kY0mYiRPx0ObBrw_15_2">1,105,568</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_ZtgwQidioUWlbMoOaTBzxg" contextRef="As_Of_12_31_2021_slf_IrTrZku1VVWbbttE4g" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" scale="0" id="Tc_ysg9XsdQZEGb7ISZo9ywBA_15_5">5.87</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="-sec-ix-hidden:Hidden_LZM2INVDtkezbYWBS4I2FA;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> 7.9</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">$ <ix:nonFraction unitRef="Unit_Standard_USD_NFG_pVdyhEyJarLQmedkXA" contextRef="As_Of_12_31_2021_slf_IrTrZku1VVWbbttE4g" decimals="0" format="ixt:numdotdecimal" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" scale="0" id="Tc_SPdYxX2qdUO87DhuMO5MzA_15_9">14,325,377</ix:nonFraction></p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The aggregate intrinsic value of options exercised during the years ended December 31, 2021 and 2020 was $<ix:nonFraction unitRef="Unit_Standard_USD_NFG_pVdyhEyJarLQmedkXA" contextRef="Duration_1_1_2021_To_12_31_2021_uhkxAiZ6fUeekYGgaMhCqA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" scale="0" id="Narr_C4Z_cEhoXkOY6DuHHkjpog">11,163,998</ix:nonFraction> and $<ix:nonFraction unitRef="Unit_Standard_USD_NFG_pVdyhEyJarLQmedkXA" contextRef="Duration_1_1_2020_To_12_31_2020_3DdHOulAJk6Q0Zn4Vsxq5A" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" scale="0" id="Narr_pykSx5HoqUqY0vd1h-cT4Q">196,976</ix:nonFraction>, respectively. As of December 31, 2021 there was $<ix:nonFraction unitRef="Unit_Standard_USD_NFG_pVdyhEyJarLQmedkXA" contextRef="As_Of_12_31_2021_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_MkIC0676s0mFrsozz2b5Ow" decimals="0" format="ixt:numdotdecimal" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" scale="0" id="Narr_EYst8uzj30WJ-b0sz5QjOA">9,933,691</ix:nonFraction> unrecognized compensation expense related to unvested options. That cost is expected to be recognized over a weighted-average period of <span style="-sec-ix-hidden:Hidden_bR4c2uBj-EKLsqDtSgFQaA;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">1.4</span></span> years.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">During the years ended December 31, 2021 and 2020, the Company issued <ix:nonFraction unitRef="Unit_Standard_shares__cOSbKjBTUyHt70_t1aAVw" contextRef="Duration_1_1_2021_To_12_31_2021_uhkxAiZ6fUeekYGgaMhCqA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" scale="0" id="Narr__Ma8LdSlOUSzE143Hb5g9g">538,095</ix:nonFraction> and <ix:nonFraction unitRef="Unit_Standard_shares__cOSbKjBTUyHt70_t1aAVw" contextRef="Duration_1_1_2020_To_12_31_2020_3DdHOulAJk6Q0Zn4Vsxq5A" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" scale="0" id="Narr_2HGdIf80F0uCTFVrAXvF4w">810,000</ix:nonFraction> options, respectively. Under the grant agreements for the 2021 stock option grants, <ix:nonFraction unitRef="Unit_Standard_shares__cOSbKjBTUyHt70_t1aAVw" contextRef="As_Of_12_31_2021_us-gaap_AwardDateAxis_anvs_AwardsGrantedIn2021Member_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_VestingAxis_anvs_ShareBasedPaymentArrangementVestingPeriodImmediateVestingMember_1D0-tOBHgkGoY1R3CgsSig" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" scale="0" id="Narr_Y2Hptnl5b0GV9panSwdI1Q">143,391</ix:nonFraction> of the options vested immediately, <ix:nonFraction unitRef="Unit_Standard_shares__cOSbKjBTUyHt70_t1aAVw" contextRef="As_Of_12_31_2021_us-gaap_AwardDateAxis_anvs_AwardsGrantedIn2021Member_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_VestingAxis_anvs_ShareBasedPaymentArrangementVestingPeriodOneYearMember_DimQ7qACMU6TfxILGAwOCw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" scale="0" id="Narr_kclcN27raUe3WvKiePfvMA">155,253</ix:nonFraction> of the options vest on March 31, 2022, <ix:nonFraction unitRef="Unit_Standard_shares__cOSbKjBTUyHt70_t1aAVw" contextRef="As_Of_12_31_2021_us-gaap_AwardDateAxis_anvs_AwardsGrantedIn2021Member_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_VestingAxis_anvs_ShareBasedPaymentArrangementVestingPeriodTwoYearsMember_7fink69gjUCJNwXqPwAp0Q" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" scale="0" id="Narr_ny-Ls3NAfESrqLWU-3qFpw">155,251</ix:nonFraction> of the options vest on March 31, 2023 and <ix:nonFraction unitRef="Unit_Standard_shares__cOSbKjBTUyHt70_t1aAVw" contextRef="As_Of_12_31_2021_us-gaap_AwardDateAxis_anvs_AwardsGrantedIn2021Member_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_VestingAxis_anvs_ShareBasedPaymentArrangementVestingPeriodEqualQuarterlyInstallmentsOverTwoYearsMember_ZOvd1oon0k2qQBob-40BxQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" scale="0" id="Narr_kkaO5BM3R0m-XZbAckXAmA">84,200</ix:nonFraction> of the options vest in substantially equal quarterly installments over <ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_AwardDateAxis_anvs_AwardsGrantedIn2021Member_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_VestingAxis_anvs_ShareBasedPaymentArrangementVestingPeriodEqualQuarterlyInstallmentsOverTwoYearsMember_KPZ_nNTrBk-ED74SOGLcGQ" format="ixt-sec:durwordsen" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="Narr_BupSt7erZUilELlCPkGX2A">two years</ix:nonNumeric><span style="white-space:pre-wrap;"> from the date of grant.  Under the grant agreements for the 2020 stock option grants, <ix:nonFraction unitRef="Unit_Standard_shares__cOSbKjBTUyHt70_t1aAVw" contextRef="As_Of_12_31_2020_us-gaap_AwardDateAxis_anvs_AwardsGrantedIn2020Member_us-gaap_VestingAxis_anvs_ShareBasedPaymentArrangementVestingPeriodOneYearMember_5-6tsJ5Re0SiRVbMTy7QsA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" scale="0" id="Narr_swKB6RyZ_0O2fJw1fTtQow">50,000</ix:nonFraction> of the options vested after </span><ix:nonNumeric contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_AwardDateAxis_anvs_AwardsGrantedIn2020Member_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_VestingAxis_anvs_ShareBasedPaymentArrangementVestingPeriodOneYearMember__Fh8QWUir0eZugsK0WNqcA" format="ixt-sec:durwordsen" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="Narr_uzWbROPCk06Z0L8djynTHg"><span style="white-space:pre-wrap;">one year</span></ix:nonNumeric><span style="white-space:pre-wrap;"> and the remainder of the options were vested and exercisable upon grant. All of the options have a 10-year term.  </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">The weighted average grant date fair value of options issued during the&#160;years ended December 31, 2021 and 2020 was $<ix:nonFraction unitRef="Unit_Divide_USD_shares_ZtgwQidioUWlbMoOaTBzxg" contextRef="Duration_1_1_2021_To_12_31_2021_uhkxAiZ6fUeekYGgaMhCqA" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="Narr_UjxHS9UIXESIPxTg6v605Q">27.13</ix:nonFraction> per share and $<ix:nonFraction unitRef="Unit_Divide_USD_shares_ZtgwQidioUWlbMoOaTBzxg" contextRef="Duration_1_1_2020_To_12_31_2020_3DdHOulAJk6Q0Zn4Vsxq5A" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="Narr_25kk2X3i20WAdTKNtG1RUw">2.19</ix:nonFraction><span style="white-space:pre-wrap;"> per share, respectively.  The fair value was estimated using the Black Sholes option pricing model.  The expected life of options was estimated using the simplified method, as the Company has limited historical information to develop reasonable expectations about future exercise patterns and post-vesting employment. The risk-free rate was based on the interest rate payable on U.S. Treasury securities at the time of grant for a period that is commensurate with the expected term of the option.  Given the lack of a public market for the Company&#8217;s common stock prior to the IPO, the expected stock price volatility was based on a weighted approach that incorporates the historic daily volatility of the Company&#8217;s common stock since the IPO and the historic daily volatility of similar companies that have been publicly traded for a period commensurate with the expected term of the option.  The expected dividend yield is </span><ix:nonFraction unitRef="Unit_Standard_pure_n7tAfGlk1kyqYH5N2uCURw" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_LAmAyrWmJUC3qRHISSAjmA" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="-2" id="Narr_MydXeq6SXkS6BVpdkXMHMA"><ix:nonFraction unitRef="Unit_Standard_pure_n7tAfGlk1kyqYH5N2uCURw" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_vlN0t7QzKEiNBpiYEjJwDw" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="-2" id="Narr_sGQBhjfOh0iDNGVVAqREaw">0</ix:nonFraction></ix:nonFraction>% because the Company has not historically paid and does not expect for the </p></ix:continuation></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-14</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="Tc_cbNq5xzIlkmfHsybAC_NZQ_1_2"></a><a id="Tc_TocXWKX3V0irfQsFaZSbhw_1_5"></a><a id="Tc_2eCTVKOL1Uu8yB3fet8m4A_2_2"></a><a id="Tc_-l6ar3P-pkCBOM3BKWFRNg_2_5"></a><a id="Tc_cdQVbL1Hw0WoI8egRhoKig_3_0"></a><a id="Tc_N2VYzoDsXEabaLOheG1-WA_3_3"></a><a id="Tc__7JsvfClWkWWcSICXcZ1oQ_3_6"></a><a id="Tc_Kqn_KhKrM0eN4k9783YfXg_4_0"></a><a id="Tc_AP6eswqh80qFR4Vpt3-mgg_5_0"></a><a id="Tc_gqFwTLwv6EuxdGXER0-DwQ_5_3"></a><a id="Tc_WZihU8UvlkC9wfkIP4lt9g_5_6"></a><a id="Tc_d9WnthCd_0WZyBW9qRIxdA_6_0"></a><ix:continuation id="Tb_fvoTYB_aN0Wq8DCKL6RTtg_cont2"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">foreseeable future to pay a dividend on its common stock. The weighted average assumptions used in the valuation of options granted were as follows:</p><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_uhkxAiZ6fUeekYGgaMhCqA" name="us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" id="Tb_d_sAhpKvZ0mL1UcpIdNr5A" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:58.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:16.66%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:16.66%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:58.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year Ended </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year Ended </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:58.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:58.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Risk-free interest rate</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_n7tAfGlk1kyqYH5N2uCURw" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_vlN0t7QzKEiNBpiYEjJwDw" decimals="4" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="Tc_geziVtxzaE-8FsydTZDEnQ_3_2">1.17</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_n7tAfGlk1kyqYH5N2uCURw" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_LAmAyrWmJUC3qRHISSAjmA" decimals="4" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="Tc_WW0a5E0HkUWxl_M_lq55Wg_3_5">0.38</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:58.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Expected life</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="-sec-ix-hidden:Hidden_HsUzDjUJtkSAIzhEqWrcUA;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> 5.3</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><ix:nonNumeric contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_LAmAyrWmJUC3qRHISSAjmA" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="Tc_Lk8iUjg2EkSlgdJ4snKWUw_4_5"> 5.0</ix:nonNumeric></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:58.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Expected volatility</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_n7tAfGlk1kyqYH5N2uCURw" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_vlN0t7QzKEiNBpiYEjJwDw" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="Tc_u4P2NLCjyUaVf5d8HbfzfA_5_2">113</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_n7tAfGlk1kyqYH5N2uCURw" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_LAmAyrWmJUC3qRHISSAjmA" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="Tc_Xa5b2Ft_tUukRNjGc5nfVQ_5_5">80</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:58.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Expected dividend yield</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_n7tAfGlk1kyqYH5N2uCURw" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_vlN0t7QzKEiNBpiYEjJwDw" decimals="2" format="ixt:zerodash" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="-2" id="Tc_q1L5WpMRiE2g75T6awlueQ_6_2">&#8212;</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_n7tAfGlk1kyqYH5N2uCURw" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_LAmAyrWmJUC3qRHISSAjmA" decimals="2" format="ixt:zerodash" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="-2" id="Tc_oePj9uO1JkCtg3Iel5X5bw_6_5">&#8212;</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">During the year ended December 31, 2020, the Company granted stock awards totaling <ix:nonFraction unitRef="Unit_Standard_shares__cOSbKjBTUyHt70_t1aAVw" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_GranteeStatusAxis_us-gaap_ShareBasedPaymentArrangementNonemployeeMember__Y5EzHRV8U2VQ42ne0t5eg" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesIssuedForServices" scale="0" id="Narr_r_yHlDyAhk6MEV5wFaFTyA">25,000</ix:nonFraction><span style="white-space:pre-wrap;"> shares to consultants and advisors for services rendered which vested upon grant.  These awards had a weighted-average grant date fair value of </span>$<ix:nonFraction unitRef="Unit_Divide_USD_shares_ZtgwQidioUWlbMoOaTBzxg" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_GranteeStatusAxis_us-gaap_ShareBasedPaymentArrangementNonemployeeMember__Y5EzHRV8U2VQ42ne0t5eg" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="Narr_BGF2iwytV0yi1qcsmI9EnQ">4.91</ix:nonFraction> per share and an aggregate fair value of $<ix:nonFraction unitRef="Unit_Standard_USD_NFG_pVdyhEyJarLQmedkXA" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_GranteeStatusAxis_us-gaap_ShareBasedPaymentArrangementNonemployeeMember__Y5EzHRV8U2VQ42ne0t5eg" decimals="0" format="ixt:numdotdecimal" name="anvs:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedInPeriodFairValue" scale="0" id="Narr_e2kUQ3ZOq0m0-B4RxDgmLg">122,750</ix:nonFraction><span style="white-space:pre-wrap;">, which was recognized in stock-based compensation expense upon grant.  </span><ix:nonFraction unitRef="Unit_Standard_shares__cOSbKjBTUyHt70_t1aAVw" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_GranteeStatusAxis_us-gaap_ShareBasedPaymentArrangementNonemployeeMember_-b4g7yTNB0aLjzC-gDHmiA" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:StockIssuedDuringPeriodSharesIssuedForServices" scale="0" id="Narr_o4Pg39cMJU6tcgvNfiqzAQ">No</ix:nonFraction> stock awards were issued during the year ended December 31, 2021. As of December 31, 2021, there were <ix:nonFraction unitRef="Unit_Standard_shares__cOSbKjBTUyHt70_t1aAVw" contextRef="As_Of_12_31_2021_slf_IrTrZku1VVWbbttE4g" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" scale="0" id="Narr_r48Krne4yU2qi3EakAA6ng">no</ix:nonFraction> unvested stock awards and there was <span style="-sec-ix-hidden:Hidden_FE1dYrMu70-J5dbAohVyjw;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">no</span></span> unrecognized compensation expense related to stock awards.</p></ix:continuation><a id="Tc_2cnbTNsmgkW8Wz5NdBhtaw_1_2"></a><a id="Tc_JoCc-geDEUGacgaVA-pKog_2_2"></a><a id="Tc_p6MhiU7EMkuniOt2BrKM1w_3_2"></a><a id="Tc_kVtcr_OV8kugNj7Yf7PW3w_3_5"></a><a id="Tc_CWU830CRxkaEDWYcHwFQlg_4_0"></a><a id="Tc_8NF_uvfde0yDLs62eWJuhA_5_0"></a><a id="Tc_bB5s7MrcL0Cxt5KUYTwLDA_5_2"></a><a id="Tc_KmRnKM3gmUmS31CqDhjvWw_5_5"></a><a id="Tc_YuFN-mLLUEWrErsuzFbf9Q_6_0"></a><a id="Tc_cdwQnp40NUq-uHdcCxz3cA_7_0"></a><a id="Tc_4PywMutVoUeEmUQqR4R6VQ_8_0"></a><a id="Tc_x8i9yoe6CE6UPObDgozviw_8_2"></a><a id="Tc_sPev02ujRUKQLqUuWwMh0A_8_5"></a><a id="Tc_7DrEPjeNo0uLWYD83yrHQw_1_1"></a><a id="Tc_iQqYiSZ8sE20B4Oqhj3cHQ_2_1"></a><a id="Tc_sArQTxyaNUalhso7efFcvg_2_3"></a><a id="Tc_oOKdQoDTqkCYg55X5YW7EQ_3_0"></a><a id="Tc_4pSokXZK9k64GJvmlkNdug_4_0"></a><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_uhkxAiZ6fUeekYGgaMhCqA" name="us-gaap:EarningsPerShareTextBlock" id="Tb_i7hWTDacBUeu04a3o0khyQ" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">(11) Net Loss Per Share</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company has reported a net loss for the&#160;years ended December 31, 2021 and 2020, and the basic and diluted net loss per share attributable to common stockholders are the same for both&#160;years because all redeemable convertible preferred stock, convertible promissory notes, warrants and stock options have been excluded from the computation of diluted weighted-average shares outstanding because such securities would have an antidilutive impact.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">The following table sets forth the computation of basic and diluted net loss per share:</p><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_uhkxAiZ6fUeekYGgaMhCqA" name="us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" id="Tb_GATS2saxC0aLjPKtFj2nnw" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:66.67%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.96%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.67%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:66.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;"> </b><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:31.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year Ended </b></p></td></tr><tr><td style="vertical-align:bottom;width:66.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:31.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:66.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td></tr><tr><td style="vertical-align:bottom;width:66.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Numerator</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:66.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Net loss</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.96%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_NFG_pVdyhEyJarLQmedkXA" contextRef="Duration_1_1_2021_To_12_31_2021_uhkxAiZ6fUeekYGgaMhCqA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" sign="-" scale="0" id="Tc_X0ocdAT2lk-tk4NaSpEJQg_5_3">14,487,132</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.67%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_NFG_pVdyhEyJarLQmedkXA" contextRef="Duration_1_1_2020_To_12_31_2020_3DdHOulAJk6Q0Zn4Vsxq5A" decimals="0" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" sign="-" scale="0" id="Tc_GvAdbLnRvUKrqZH6vgkbnQ_5_6">5,462,047</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:66.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Denominator</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:66.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Weighted-average common shares outstanding, basic and diluted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares__cOSbKjBTUyHt70_t1aAVw" contextRef="Duration_1_1_2021_To_12_31_2021_uhkxAiZ6fUeekYGgaMhCqA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" id="Tc_eepf9vkV_kCwfHNOnNgIXw_7_3">7,626,278</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares__cOSbKjBTUyHt70_t1aAVw" contextRef="Duration_1_1_2020_To_12_31_2020_3DdHOulAJk6Q0Zn4Vsxq5A" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" id="Tc_zuyuPBZraEOA-2UY6bpsFg_7_6">6,308,961</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:66.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Net loss per share, basic and diluted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Divide_USD_shares_ZtgwQidioUWlbMoOaTBzxg" contextRef="Duration_1_1_2021_To_12_31_2021_uhkxAiZ6fUeekYGgaMhCqA" decimals="2" format="ixt:numdotdecimal" name="us-gaap:EarningsPerShareBasic" sign="-" scale="0" id="Tc_DuQnnDwtUEqrqFt_IvLBNA_8_3">1.90</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Divide_USD_shares_ZtgwQidioUWlbMoOaTBzxg" contextRef="Duration_1_1_2020_To_12_31_2020_3DdHOulAJk6Q0Zn4Vsxq5A" decimals="2" format="ixt:numdotdecimal" name="us-gaap:EarningsPerShareBasic" sign="-" scale="0" id="Tc_zQOYSdGJ-Ue7zHUK1aue0w_8_6">0.87</ix:nonFraction>)</p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">Potential common shares that are excluded from the computation of diluted weighted-average shares outstanding are as follows:</p><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_uhkxAiZ6fUeekYGgaMhCqA" name="us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" id="Tb_3aqrIV1dMEiBdahJB1DHug" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:74.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.71%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.71%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:74.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:25.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:74.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.71%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.71%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td></tr><tr><td style="vertical-align:bottom;width:74.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Stock options</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares__cOSbKjBTUyHt70_t1aAVw" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockOptionMember_ErimM70Lx0GlzbzdZjfaBQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="Tc_4kXM4wHa0UCxsFCCXkIh0g_3_1">1,489,748</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares__cOSbKjBTUyHt70_t1aAVw" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockOptionMember_Ot-TYiGbdkWL1GALWHvnMQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="Tc_5PuGOz0IEkmAUDrwPbORRg_3_3">1,111,466</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:74.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Warrants</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares__cOSbKjBTUyHt70_t1aAVw" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_WarrantMember_GH_2bhJhrkKLRik7_QHn1g" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="Tc_9iSP_wANn0CLF9XXi7FUwg_4_1">2,400</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares__cOSbKjBTUyHt70_t1aAVw" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_WarrantMember_BM2Bi1ZZ70OsQ-maVuCszA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="Tc__9EEuNvu-UOUSzknaiGtNA_4_3">100,000</ix:nonFraction></p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_dc22ecab_c6bc_46a5_9a4d_1b51576b8d6d"></a><a id="_dc22ecab_c6bc_46a5_9a4d_1b51576b8d6d_2"></a><a id="_dc22ecab_c6bc_46a5_9a4d_1b51576b8d6d_3"></a><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_uhkxAiZ6fUeekYGgaMhCqA" name="us-gaap:IncomeTaxDisclosureTextBlock" id="Tb_GSA3zuFAzUWg7KJiizVqJA" continuedAt="Tb_GSA3zuFAzUWg7KJiizVqJA_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">(12) Income Taxes</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The federal and state provision (benefit) for income taxes was&#160;$<ix:nonFraction unitRef="Unit_Standard_USD_NFG_pVdyhEyJarLQmedkXA" contextRef="Duration_1_1_2020_To_12_31_2020_3DdHOulAJk6Q0Zn4Vsxq5A" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StateAndLocalIncomeTaxExpenseBenefitContinuingOperations" scale="0" id="Narr_LVHqh8rbbkuctlhNPQKl9A"><ix:nonFraction unitRef="Unit_Standard_USD_NFG_pVdyhEyJarLQmedkXA" contextRef="Duration_1_1_2021_To_12_31_2021_uhkxAiZ6fUeekYGgaMhCqA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StateAndLocalIncomeTaxExpenseBenefitContinuingOperations" scale="0" id="Narr_ytnXIDhzVEGhTcCs0nem9A">0</ix:nonFraction></ix:nonFraction>&#160;for the&#160;years ended December 31, 2021 and 2020.</p></ix:nonNumeric></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-15</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="Tc_o360dDBMi0aJuK_fVxDhtQ_1_2"></a><a id="Tc_gzaCbmV1VUqWspOTARa9ZA_2_2"></a><a id="Tc_iQgWg-o18ku6dFejnMyGEw_3_2"></a><a id="Tc_XySHigcSqEubRbxp5eZmKA_3_4"></a><a id="Tc_9bDrHbNWrEiRLTfBJobDbQ_4_0"></a><a id="Tc_ybHwqLExckGTzvU964P3CQ_4_3"></a><a id="Tc_gr6miABd50e3LCSpjIrV2g_4_5"></a><a id="Tc_ljG7ZZB5wkC3L6cZbwznFA_5_0"></a><a id="Tc_up4N8TQr30islt7M-HxUrw_5_3"></a><a id="Tc_QlsZdPyG10CIVzx7udFClQ_5_5"></a><a id="Tc_tA5S6xY6IUqBI13mpc354w_6_0"></a><a id="Tc_MJ5B-L-8q0y5qqkeCqPREQ_6_3"></a><a id="Tc_b0YzwTzgZkqcRLz9AlwsMA_6_5"></a><a id="Tc_JeUsb5yDQ0eZfkQbol5BEw_7_0"></a><a id="Tc_bOkN1eb3kECc3vOP5vZo3A_7_3"></a><a id="Tc_wDQ1xIJwMkuDO8QFs98cBw_7_5"></a><a id="Tc_eWCKiezemUmdw1v2dUDClw_8_0"></a><a id="Tc_3m_Gkjhsq0OziXj0VX9LwQ_8_3"></a><a id="Tc__SEXEw2350WePlm8aorWNw_8_4"></a><a id="Tc_NAMDcUmC6EyD0FbqqRUoMw_8_5"></a><a id="Tc_K1efkKYMcE-P7OtqTMUDIA_9_0"></a><a id="Tc_YdeSx-PlOk6iZg7uMKIxDA_9_3"></a><a id="Tc_TJsp0XGdtEaULXuEG6TtuQ_9_5"></a><a id="Tc_HCMSlahrKEuzJE8HaxHXvQ_10_0"></a><a id="Tc_E-TFcgG2bUCUqaiYJaflbQ_10_3"></a><a id="Tc_ee2jMN1rZUmRPIQTQttf2Q_10_5"></a><a id="Tc_CU9Fo2zGIUOQxKmkco6_SA_1_2"></a><a id="Tc_POiVQnkigkmePi4dsJYDFw_2_2"></a><a id="Tc_lfyiWIiYoUqf0lmX7sv02g_2_5"></a><a id="Tc_mLjlfwyu70GH_4cldkcn7g_3_0"></a><a id="Tc_qAGAnT_M5kGMplwzPM2kRw_3_2"></a><a id="Tc_JI1OLnw0DE-ON3G_uinpGA_3_5"></a><a id="Tc_Fh79_XXX-keFf0plL460Ig_4_0"></a><a id="Tc_yGg2Mg0K_kOoSmfdJP0YCA_4_6"></a><a id="Tc_sDzruh9DpES3DajTLcBupw_5_0"></a><a id="Tc_ZTt0SJ_FFU-wTEkZ56yT9w_6_0"></a><a id="Tc_sNlkF4dVKUazn2gt_WbY0Q_7_0"></a><a id="Tc_U1yQCagMI0erZnN5QTz7sg_8_0"></a><a id="Tc_60yHd2xGOkqu7HxLovgG2w_9_0"></a><a id="Tc_JAZ9KKAQbEew7mKHCi691g_9_2"></a><a id="Tc_6XyYlxNY80OS2J-oFaBxTw_9_5"></a><ix:continuation id="Tb_GSA3zuFAzUWg7KJiizVqJA_cont1" continuedAt="Tb_GSA3zuFAzUWg7KJiizVqJA_cont2"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">A reconciliation of income tax provision (benefit) computed at the statutory federal income tax rate to income taxes as reflected in the financial statements for the&#160;years ended December 31, 2021 and 2020 is as follows:</p><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_uhkxAiZ6fUeekYGgaMhCqA" name="us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" id="Tb_c3wm2TluZkqys_W2yir7rw" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:75.45%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.38%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.43%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.38%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:75.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;"> </b><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:20.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year Ended </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:75.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:20.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:75.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:75.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Federal income tax benefit at statutory rate</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_n7tAfGlk1kyqYH5N2uCURw" contextRef="Duration_1_1_2021_To_12_31_2021_uhkxAiZ6fUeekYGgaMhCqA" decimals="3" format="ixt:numdotdecimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" scale="-2" id="Tc_sGmGeimvKki8qFGyQ0HISg_4_2">21.0</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_n7tAfGlk1kyqYH5N2uCURw" contextRef="Duration_1_1_2020_To_12_31_2020_3DdHOulAJk6Q0Zn4Vsxq5A" decimals="3" format="ixt:numdotdecimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" scale="-2" id="Tc_YP9MNm2U1kS1auM8eXC1Jg_4_4">21.0</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:75.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">State and local tax, net of federal benefit</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_n7tAfGlk1kyqYH5N2uCURw" contextRef="Duration_1_1_2021_To_12_31_2021_uhkxAiZ6fUeekYGgaMhCqA" decimals="3" format="ixt:numdotdecimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" scale="-2" id="Tc_HVlQnlC4YkyndPwVUbAGXQ_5_2">13.7</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_n7tAfGlk1kyqYH5N2uCURw" contextRef="Duration_1_1_2020_To_12_31_2020_3DdHOulAJk6Q0Zn4Vsxq5A" decimals="3" format="ixt:numdotdecimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" scale="-2" id="Tc_uLFQ90Uivkik2ocVY_Q9Ug_5_4">7.6</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:75.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Permanent differences</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_n7tAfGlk1kyqYH5N2uCURw" contextRef="Duration_1_1_2021_To_12_31_2021_uhkxAiZ6fUeekYGgaMhCqA" decimals="3" format="ixt:numdotdecimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpense" scale="-2" id="Tc_5l2oVodiO0-sEsi8Cvun0w_6_2">0.1</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_pure_n7tAfGlk1kyqYH5N2uCURw" contextRef="Duration_1_1_2020_To_12_31_2020_3DdHOulAJk6Q0Zn4Vsxq5A" decimals="3" format="ixt:numdotdecimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpense" sign="-" scale="-2" id="Tc_Ll9mTimbmkmVT0vtK8fWgg_6_4">0.8</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:75.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Research and development credit</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_n7tAfGlk1kyqYH5N2uCURw" contextRef="Duration_1_1_2021_To_12_31_2021_uhkxAiZ6fUeekYGgaMhCqA" decimals="3" format="ixt:numdotdecimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment" scale="-2" id="Tc_J_GTsCkXMEKdzYwob1Mrkw_7_2">2.4</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_n7tAfGlk1kyqYH5N2uCURw" contextRef="Duration_1_1_2020_To_12_31_2020_3DdHOulAJk6Q0Zn4Vsxq5A" decimals="3" format="ixt:numdotdecimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment" scale="-2" id="Tc_XwhxnbcGvky3c3b2HjEj_A_7_4">1.9</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:75.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Stock-based compensation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_n7tAfGlk1kyqYH5N2uCURw" contextRef="Duration_1_1_2021_To_12_31_2021_uhkxAiZ6fUeekYGgaMhCqA" decimals="3" format="ixt:numdotdecimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" scale="-2" id="Tc_n7bWHASCCESvMrBt5ncc3w_8_2">15.7</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:75.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Change in valuation allowance</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_pure_n7tAfGlk1kyqYH5N2uCURw" contextRef="Duration_1_1_2021_To_12_31_2021_uhkxAiZ6fUeekYGgaMhCqA" decimals="3" format="ixt:numdotdecimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" sign="-" scale="-2" id="Tc_6OnX7TyLpEOQ40w4lU-TPQ_9_2">52.9</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_pure_n7tAfGlk1kyqYH5N2uCURw" contextRef="Duration_1_1_2020_To_12_31_2020_3DdHOulAJk6Q0Zn4Vsxq5A" decimals="3" format="ixt:numdotdecimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" sign="-" scale="-2" id="Tc_PWYEcU1eoUSWWAD1LbNS6A_9_4">29.7</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:75.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Effective income tax rate</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.38%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_n7tAfGlk1kyqYH5N2uCURw" contextRef="Duration_1_1_2021_To_12_31_2021_uhkxAiZ6fUeekYGgaMhCqA" decimals="3" format="ixt:numdotdecimal" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" scale="-2" id="Tc_Fm4Su2Fo60SYCasOcYzrlA_10_2">0.0</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.38%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_n7tAfGlk1kyqYH5N2uCURw" contextRef="Duration_1_1_2020_To_12_31_2020_3DdHOulAJk6Q0Zn4Vsxq5A" decimals="3" format="ixt:numdotdecimal" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" scale="-2" id="Tc_X26vHx85PkaYUgFkgW2PBA_10_4">0.0</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">Deferred taxes are recognized for temporary differences between the basis of assets and liabilities for financial statement and income tax purposes. The significant components of the Company&#8217;s deferred tax assets are comprised of the following:</p><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_uhkxAiZ6fUeekYGgaMhCqA" name="us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" id="Tb_8wVigjioNUubegvzuNQv8A" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:66.67%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.96%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.67%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:66.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;"> </b><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:31.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">As&#160;of&#160;December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:66.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td></tr><tr><td style="vertical-align:bottom;width:66.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Net operating loss carryforwards</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_NFG_pVdyhEyJarLQmedkXA" contextRef="As_Of_12_31_2021_slf_IrTrZku1VVWbbttE4g" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" scale="0" id="Tc_44kjSsqsjU-rXybbOWLCUA_3_3">6,512,249</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_NFG_pVdyhEyJarLQmedkXA" contextRef="As_Of_12_31_2020_K1oKCNbpv0CLR8EJWu1PSw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" scale="0" id="Tc__PfBcGIskUu333GqjhX22A_3_6">2,460,773</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:66.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Capitalized research and development</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_NFG_pVdyhEyJarLQmedkXA" contextRef="As_Of_12_31_2021_slf_IrTrZku1VVWbbttE4g" decimals="0" format="ixt:numdotdecimal" name="anvs:DeferredTaxAssetsTaxCreditCarryforwardsCapitalizedResearchAndDevelopment" scale="0" id="Tc_aozjY7nEjE-p-8WX5X-cIw_4_3">2,002,431</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:66.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Stock-based compensation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_NFG_pVdyhEyJarLQmedkXA" contextRef="As_Of_12_31_2021_slf_IrTrZku1VVWbbttE4g" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" scale="0" id="Tc_S_FUCU6_1k2eNeo7OjXU8Q_5_3">1,759,129</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_NFG_pVdyhEyJarLQmedkXA" contextRef="As_Of_12_31_2020_K1oKCNbpv0CLR8EJWu1PSw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" scale="0" id="Tc_Dpf7B4gt9ES5dXdG8Q1y9Q_5_6">547,628</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:66.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Research and development tax credit carryforwards</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_NFG_pVdyhEyJarLQmedkXA" contextRef="As_Of_12_31_2021_slf_IrTrZku1VVWbbttE4g" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch" scale="0" id="Tc_nspLmk8L9U2XZUEMmupCuA_6_3">648,077</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.67%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_NFG_pVdyhEyJarLQmedkXA" contextRef="As_Of_12_31_2020_K1oKCNbpv0CLR8EJWu1PSw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch" scale="0" id="Tc_dgjQMFeKHkWRC3wzOntsWw_6_6">241,414</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:66.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total deferred tax assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_NFG_pVdyhEyJarLQmedkXA" contextRef="As_Of_12_31_2021_slf_IrTrZku1VVWbbttE4g" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsGross" scale="0" id="Tc_jeoGMATvNkK4LeEEzW7qpA_7_3">10,921,886</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_NFG_pVdyhEyJarLQmedkXA" contextRef="As_Of_12_31_2020_K1oKCNbpv0CLR8EJWu1PSw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsGross" scale="0" id="Tc_Wm3ZkOI70UOMVzIweZb3lw_7_6">3,249,815</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:66.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Less valuation allowance</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_NFG_pVdyhEyJarLQmedkXA" contextRef="As_Of_12_31_2021_slf_IrTrZku1VVWbbttE4g" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsValuationAllowance" scale="0" id="Tc_z_XsxwfYbESYkb15Pubolg_8_3">10,921,886</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.67%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_NFG_pVdyhEyJarLQmedkXA" contextRef="As_Of_12_31_2020_K1oKCNbpv0CLR8EJWu1PSw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsValuationAllowance" scale="0" id="Tc_-g1LAdLGhUGTNvMbcFrLPA_8_6">3,249,815</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:66.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Net deferred taxes</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.96%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_NFG_pVdyhEyJarLQmedkXA" contextRef="As_Of_12_31_2021_slf_IrTrZku1VVWbbttE4g" decimals="0" format="ixt:zerodash" name="us-gaap:DeferredTaxAssetsNet" scale="0" id="Tc_ybBiaIi8QUm4Iw7FJQGYbg_9_3">&#8212;</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.67%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_NFG_pVdyhEyJarLQmedkXA" contextRef="As_Of_12_31_2020_K1oKCNbpv0CLR8EJWu1PSw" decimals="0" format="ixt:zerodash" name="us-gaap:DeferredTaxAssetsNet" scale="0" id="Tc_T65wZKpWjEKh7Wng4j1X-g_9_6">&#8212;</ix:nonFraction></p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">As of December 31, 2021, the Company had U.S. federal net operating loss (&#8220;NOL&#8221;) carryforwards of $<ix:nonFraction unitRef="Unit_Standard_USD_NFG_pVdyhEyJarLQmedkXA" contextRef="As_Of_12_31_2021_us-gaap_IncomeTaxAuthorityAxis_us-gaap_DomesticCountryMember_HgR3pC70rUmeM4G-ZKbaTg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OperatingLossCarryforwards" scale="0" id="Narr_PIeE-hMCQ0aYMaIsAIBhFA">21,844,192</ix:nonFraction>, which may be available to offset future income tax liabilities. Federal NOL carryforwards generated in 2017 and prior of $<ix:nonFraction unitRef="Unit_Standard_USD_NFG_pVdyhEyJarLQmedkXA" contextRef="As_Of_12_31_2021_us-gaap_IncomeTaxAuthorityAxis_us-gaap_DomesticCountryMember_us-gaap_TaxPeriodAxis_anvs_GeneratedIn2017AndPriorMember_bcLUgZK7ak-slt0qx5nwVQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OperatingLossCarryforwards" scale="0" id="Narr_fNnuqWjHCUqlvkF_LTEdtQ">2,764,240</ix:nonFraction> will expire beginning in 2032. The remaining federal NOL carryforwards generated in 2018 and later do not expire. As of December 31, 2021, the Company also had U.S. state NOL carryforwards of $<ix:nonFraction unitRef="Unit_Standard_USD_NFG_pVdyhEyJarLQmedkXA" contextRef="As_Of_12_31_2021_us-gaap_IncomeTaxAuthorityAxis_us-gaap_StateAndLocalJurisdictionMember_5e7zQwkrykWomLKNapiciw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OperatingLossCarryforwards" scale="0" id="Narr_m9Yh2l9jkUSj49jKGxklTQ">24,391,076</ix:nonFraction> which may be available to offset future income tax liabilities and will expire beginning in 2028.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company has recorded a full valuation allowance against its net deferred tax assets as of December 31, 2021 and 2020 because the Company has determined that is it more likely than not that these assets will not be fully realized due to historic net operating losses incurred. The Company experienced a net change in valuation allowance of $<ix:nonFraction unitRef="Unit_Standard_USD_NFG_pVdyhEyJarLQmedkXA" contextRef="Duration_1_1_2021_To_12_31_2021_uhkxAiZ6fUeekYGgaMhCqA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount" scale="0" id="Narr_N2N63CSYZUaMfpACaO_yxA">7,672,071</ix:nonFraction> and $<ix:nonFraction unitRef="Unit_Standard_USD_NFG_pVdyhEyJarLQmedkXA" contextRef="Duration_1_1_2020_To_12_31_2020_3DdHOulAJk6Q0Zn4Vsxq5A" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount" scale="0" id="Narr_p69uUogxbkOZ0Xa3CkWCbQ">1,619,516</ix:nonFraction> in the&#160;years ended December 31, 2021 and 2020, respectively.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">As of December 31, 2021, the Company had federal research and development tax credit carryforwards of $<ix:nonFraction unitRef="Unit_Standard_USD_NFG_pVdyhEyJarLQmedkXA" contextRef="As_Of_12_31_2021_us-gaap_IncomeTaxAuthorityAxis_us-gaap_DomesticCountryMember_us-gaap_TaxCreditCarryforwardAxis_us-gaap_ResearchMember_Asd8fgY1d0GxTm44XLZlKg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:TaxCreditCarryforwardAmount" scale="0" id="Narr_etXDZ4cA1kmYOhcro_Pdqw">648,077</ix:nonFraction> available to reduce future tax liabilities which expire beginning in 2028.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Under the provisions of the Internal Revenue Code, the NOL and tax credit carryforwards are subject to review and possible adjustment by the Internal Revenue Service and state tax authorities. NOL and tax credit carryforwards may become subject to an annual limitation in the event of certain cumulative changes in the ownership interest of significant stockholders over a three-year period in excess of 50%, as defined under Sections&#160;382 and 383 of the Internal Revenue Code as well as similar state provisions. This could limit the amount of tax attributes that can be utilized annually to offset future taxable income or tax liabilities. The amount of the annual limitation is determined based on the value of the Company immediately prior to the ownership change. Subsequent ownership changes may further affect the limitation in future&#160;years. The Company has completed financings since its inception which may have resulted in a change in control as defined by Sections&#160;382 and 383 of the Internal Revenue Code, or could result in a change in control in the future. </p></ix:continuation></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-16</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb_GSA3zuFAzUWg7KJiizVqJA_cont2"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company files tax returns as prescribed by the tax laws of the jurisdictions in which it operates. In the normal course of business, the Company is subject to examination by federal and state jurisdictions, where applicable. The Company&#8217;s tax&#160;years from 2018 to the present remain open for review. All open&#160;years may be examined to the extent that tax credits or NOL carryforwards are used in future periods. The Company will recognize interest and penalties related to uncertain tax positions in income tax expense. As of December 31, 2021, the Company had <span style="-sec-ix-hidden:Hidden_1sZl5MdDJ0KYV2BjEn0mRA;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">no</span></span> accrued interest or penalties related to uncertain tax positions and <ix:nonFraction unitRef="Unit_Standard_USD_NFG_pVdyhEyJarLQmedkXA" contextRef="Duration_1_1_2021_To_12_31_2021_uhkxAiZ6fUeekYGgaMhCqA" decimals="0" format="ixt-sec:numwordsen" name="us-gaap:IncomeTaxExaminationPenaltiesAndInterestExpense" scale="0" id="Narr_EtE6ZmNGck6j61BkSA3tZQ">no</ix:nonFraction> amounts have been recognized in the Company&#8217;s statements of operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="white-space:pre-wrap;">On March 27, 2020, the Coronavirus Aid, Relief, and Economic Security Act (&#8220;CARES Act&#8221;) was enacted in response to the COVID-19 pandemic. The CARES Act, among other things, permits NOL carryovers and carrybacks to offset 100% of taxable income for taxable years beginning before 2021. Previously, NOLs generated after December 31, 2017 were limited to 80% of taxable income in future years.  In addition, the CARES Act allows NOLs incurred in 2018, 2019 and 2020 to be carried back to each of the five preceding taxable years to generate a refund of previously paid income taxes. The NOL carryback provision of the CARES Act had no impact on the Company due to its tax losses generated during all prior years.</span></p></ix:continuation><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_uhkxAiZ6fUeekYGgaMhCqA" name="us-gaap:RelatedPartyTransactionsDisclosureTextBlock" id="Tb_mdf9jgV_fkOQoQIKMHyzvQ" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">(13) Related-Party Transactions</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">As discussed in Note&#160;7, in March&#160;2019 the Company issued Notes&#160;in the aggregate principal amount of $<ix:nonFraction unitRef="Unit_Standard_USD_NFG_pVdyhEyJarLQmedkXA" contextRef="As_Of_3_31_2019_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember_YwRIubASaUOYMPLJxHrjxQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentFaceAmount" scale="0" id="Narr_17b3TEJrIE-o3V0kC97K4w">530,000</ix:nonFraction>. <ix:nonFraction unitRef="Unit_Standard_director_8dNZ3yZCzEGn3lXzcsOwSg" contextRef="Duration_3_1_2019_To_3_31_2019_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember_us-gaap_RelatedPartyTransactionAxis_anvs_RelatedPartyTransactionIssuanceOfConvertiblePromissoryNotesMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_srt_DirectorMember_uRDbbwJWlUih1vnjYEeJyA" decimals="INF" format="ixt-sec:numwordsen" name="anvs:RelatedPartyTransactionNumberOfCompanyDirectors" scale="0" id="Narr_g0mcmq5Rb02qtiKdKH9mTQ">Three</ix:nonFraction> of the Company&#8217;s directors purchased an aggregate of $<ix:nonFraction unitRef="Unit_Standard_USD_NFG_pVdyhEyJarLQmedkXA" contextRef="As_Of_3_31_2019_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember_us-gaap_RelatedPartyTransactionAxis_anvs_RelatedPartyTransactionIssuanceOfConvertiblePromissoryNotesMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_srt_DirectorMember_4brYU2SNtkC-xZaYEMvK_g" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentFaceAmount" scale="0" id="Narr_jpTUlYsoG0iFh8ef4OWIHQ">305,000</ix:nonFraction> of the Notes. On January&#160;31, 2020, the Company closed its IPO and the outstanding Notes&#160;plus accrued interest held by directors converted into <ix:nonFraction unitRef="Unit_Standard_shares__cOSbKjBTUyHt70_t1aAVw" contextRef="Duration_1_31_2020_To_1_31_2020_us-gaap_RelatedPartyTransactionAxis_anvs_RelatedPartyTransactionConversionOfPromissoryNotesToCommonStockMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_srt_DirectorMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_IfkwjFJuWk-TFaP8kqYr2g" decimals="0" format="ixt:numdotdecimal" name="anvs:StockIssuedDuringPeriodSharesConversionOfConvertibleNotes" scale="0" id="Narr_9rpACz2JrE6chCKXwJvOfg">71,429</ix:nonFraction> shares of the Company&#8217;s common stock.</p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_uhkxAiZ6fUeekYGgaMhCqA" name="us-gaap:SubsequentEventsTextBlock" id="Tb_TG3YsRT2Jk-9qeZfYLiFcw" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">(14) Subsequent Events</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">On January 3, 2022, the Company granted options to purchase an aggregate of <ix:nonFraction unitRef="Unit_Standard_shares__cOSbKjBTUyHt70_t1aAVw" contextRef="Duration_1_3_2022_To_1_3_2022_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_rxWBqkfQFkesGFeOew63wA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" scale="0" id="Narr_Ib0PuxjNg0eJWaK5suro4A">188,294</ix:nonFraction> shares of common stock at an exercise price of $<ix:nonFraction unitRef="Unit_Divide_USD_shares_ZtgwQidioUWlbMoOaTBzxg" contextRef="Duration_1_3_2022_To_1_3_2022_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_rxWBqkfQFkesGFeOew63wA" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" id="Narr_kssufqq9wkGIJPK1zlkssw">19.78</ix:nonFraction> per share to employees, members of the board of directors and consultants to the Company.</p></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="display:none;font-family:'Times New Roman','Times','serif';line-height:0pt;margin:0pt;"><span style="font-size:0pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-17</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_64e96e7e_71cc_4b04_90fb_442ff9723bcb"></a><a id="SIGNATURES_225846"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 12pt 0pt;">SIGNATURES</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In accordance with the requirements Section&#160;13 or 15(d) of the Securities Exchange Act of 1934, the registrant duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:49.82%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:top;width:2.97%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:top;width:5.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:bottom;width:41.69%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td></tr><tr><td style="vertical-align:top;width:49.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td colspan="3" style="vertical-align:top;width:50.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">ANNOVIS BIO,&#160;INC.</p></td></tr><tr><td style="vertical-align:top;width:49.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td colspan="3" style="vertical-align:top;width:50.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:top;width:49.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:2.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">By:</p></td><td colspan="2" style="vertical-align:top;width:47.19%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">/s/ MARIA MACCECCHINI</p></td></tr><tr><td style="vertical-align:top;width:49.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:2.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:5.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Name:</p></td><td style="vertical-align:bottom;width:41.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Maria Maccecchini</p></td></tr><tr><td style="vertical-align:top;width:49.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:2.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:5.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Title:</p></td><td style="vertical-align:bottom;width:41.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><i style="font-style:italic;">President and Chief Executive Officer</i></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="Power_of_Attorney"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 12pt 0pt;">SIGNATURES</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the registrant and in the capacities and on the dates indicated. Each of the undersigned hereby constitute and appoint Maria Maccecchini and Jeffrey McGroarty, and each of them, his or her true and lawful attorneys-in-fact and agents, with full and several power of substitution and resubstitution, for him or her and in his or her name, place and stead in any and all capacities, to sign one or more amendments to this Annual Report on Form&#160;10-K, each in such form as they or any one of them may approve, and to file the same with all exhibits thereto and other documents in connection therewith with the Securities and Exchange Commission, granting unto said attorneys-in-fact and agents, and each of them, full power and authority to do and perform each and every act and thing requisite and necessary to be done so that this Annual Report and any amendments shall comply with the Securities Exchange Act of 1934, as amended, and the applicable rules and regulations adopted or issued pursuant thereto, as fully and to all intents and purposes as he or she might or could do in person, hereby ratifying and confirming all that said attorneys-in-fact and agents, or any of them or their substitute or resubstitute, may lawfully do or cause to be done by virtue hereof.</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:45.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:middle;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"></div></div></td><td style="vertical-align:middle;width:31.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"></div></div></td><td style="vertical-align:middle;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"></div></div></td><td style="vertical-align:middle;width:18.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"></div></div></td></tr><tr><td style="vertical-align:top;width:45.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">Signature</p></td><td style="vertical-align:middle;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:middle;width:31.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">Title</p></td><td style="vertical-align:middle;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:middle;width:18.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">Date</p></td></tr><tr><td style="vertical-align:top;width:45.86%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">&#160;</p></td><td style="vertical-align:middle;width:2.06%;margin:0pt;padding:0pt;"></td><td style="vertical-align:middle;width:31.64%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:middle;width:2.06%;margin:0pt;padding:0pt;"></td><td style="vertical-align:middle;width:18.37%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:top;width:45.86%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">/s/ MARIA MACCECCHINI</p></td><td style="vertical-align:middle;width:2.06%;margin:0pt;padding:0pt;"></td><td style="vertical-align:middle;white-space:nowrap;width:31.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">President and Chief Executive Officer</p></td><td style="vertical-align:middle;width:2.06%;margin:0pt;padding:0pt;"></td><td style="vertical-align:middle;width:18.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">March&#160;2, 2022</p></td></tr><tr><td style="vertical-align:top;width:45.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">Maria Maccecchini</p></td><td style="vertical-align:middle;width:2.06%;margin:0pt;padding:0pt;"></td><td style="vertical-align:middle;width:31.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">(principal executive officer)</p></td><td style="vertical-align:middle;width:2.06%;margin:0pt;padding:0pt;"></td><td style="vertical-align:middle;width:18.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:top;width:45.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">&#160;</p></td><td style="vertical-align:middle;width:2.06%;margin:0pt;padding:0pt;"></td><td style="vertical-align:middle;width:31.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:middle;width:2.06%;margin:0pt;padding:0pt;"></td><td style="vertical-align:middle;width:18.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:top;width:45.86%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">/s/ JEFFREY MCGROARTY</p></td><td style="vertical-align:middle;width:2.06%;margin:0pt;padding:0pt;"></td><td style="vertical-align:middle;width:31.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Chief Financial Officer (principal </p></td><td style="vertical-align:middle;width:2.06%;margin:0pt;padding:0pt;"></td><td style="vertical-align:middle;width:18.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">March&#160;2, 2022</p></td></tr><tr><td style="vertical-align:top;width:45.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">Jeffrey McGroarty</p></td><td style="vertical-align:middle;width:2.06%;margin:0pt;padding:0pt;"></td><td style="vertical-align:middle;width:31.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">financial and accounting officer)</p></td><td style="vertical-align:middle;width:2.06%;margin:0pt;padding:0pt;"></td><td style="vertical-align:middle;width:18.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:top;width:45.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">&#160;</p></td><td style="vertical-align:middle;width:2.06%;margin:0pt;padding:0pt;"></td><td style="vertical-align:middle;width:31.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:middle;width:2.06%;margin:0pt;padding:0pt;"></td><td style="vertical-align:middle;width:18.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:top;width:45.86%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">/s/ MICHAEL HOFFMAN</p></td><td style="vertical-align:middle;width:2.06%;margin:0pt;padding:0pt;"></td><td style="vertical-align:middle;width:31.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Chairman of the Board and Director</p></td><td style="vertical-align:middle;width:2.06%;margin:0pt;padding:0pt;"></td><td style="vertical-align:middle;width:18.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">March&#160;2, 2022</p></td></tr><tr><td style="vertical-align:top;width:45.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">Michael Hoffman</p></td><td style="vertical-align:middle;width:2.06%;margin:0pt;padding:0pt;"></td><td style="vertical-align:middle;width:31.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:middle;width:2.06%;margin:0pt;padding:0pt;"></td><td style="vertical-align:middle;width:18.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:top;width:45.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">&#160;</p></td><td style="vertical-align:middle;width:2.06%;margin:0pt;padding:0pt;"></td><td style="vertical-align:middle;width:31.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:middle;width:2.06%;margin:0pt;padding:0pt;"></td><td style="vertical-align:middle;width:18.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:top;width:45.86%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">/s/ CLAUDINE BRUCK</p></td><td style="vertical-align:middle;width:2.06%;margin:0pt;padding:0pt;"></td><td style="vertical-align:middle;width:31.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Director</p></td><td style="vertical-align:middle;width:2.06%;margin:0pt;padding:0pt;"></td><td style="vertical-align:middle;width:18.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">March&#160;2, 2022</p></td></tr><tr><td style="vertical-align:top;width:45.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">Claudine Bruck</p></td><td style="vertical-align:middle;width:2.06%;margin:0pt;padding:0pt;"></td><td style="vertical-align:middle;width:31.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:middle;width:2.06%;margin:0pt;padding:0pt;"></td><td style="vertical-align:middle;width:18.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:top;width:45.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">&#160;</p></td><td style="vertical-align:middle;width:2.06%;margin:0pt;padding:0pt;"></td><td style="vertical-align:middle;width:31.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:middle;width:2.06%;margin:0pt;padding:0pt;"></td><td style="vertical-align:middle;width:18.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:top;width:45.86%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">/s/ REID MCCARTHY</p></td><td style="vertical-align:middle;width:2.06%;margin:0pt;padding:0pt;"></td><td style="vertical-align:middle;width:31.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Director</p></td><td style="vertical-align:middle;width:2.06%;margin:0pt;padding:0pt;"></td><td style="vertical-align:middle;width:18.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">March&#160;2, 2022</p></td></tr><tr><td style="vertical-align:top;width:45.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">Reid McCarthy</p></td><td style="vertical-align:middle;width:2.06%;margin:0pt;padding:0pt;"></td><td style="vertical-align:middle;width:31.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:middle;width:2.06%;margin:0pt;padding:0pt;"></td><td style="vertical-align:middle;width:18.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:top;width:45.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">&#160;</p></td><td style="vertical-align:middle;width:2.06%;margin:0pt;padding:0pt;"></td><td style="vertical-align:middle;width:31.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:middle;width:2.06%;margin:0pt;padding:0pt;"></td><td style="vertical-align:middle;width:18.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:top;width:45.86%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">/s/ MARK WHITE</p></td><td style="vertical-align:middle;width:2.06%;margin:0pt;padding:0pt;"></td><td style="vertical-align:middle;width:31.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Director</p></td><td style="vertical-align:middle;width:2.06%;margin:0pt;padding:0pt;"></td><td style="vertical-align:middle;white-space:nowrap;width:18.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">March&#160;2, 2022</p></td></tr><tr><td style="vertical-align:top;width:45.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">Mark White</p></td><td style="vertical-align:middle;width:2.06%;margin:0pt;padding:0pt;"></td><td style="vertical-align:middle;width:31.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:middle;width:2.06%;margin:0pt;padding:0pt;"></td><td style="vertical-align:middle;width:18.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">&#160;</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">76</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;margin-left:10.35%;margin-right:10.35%;margin-top:30pt;page-break-after:avoid;width:79.3%;border:0;"></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.1
<SEQUENCE>2
<FILENAME>anvs-20211231xex23d1.htm
<DESCRIPTION>EX-23.1
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  9.11.0.85--><!--Created on: 3/2/2022 09:00:11 PM (UTC)--><!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-size:12pt;font-weight:bold;">Exhibit 23.1</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><b style="color:#0057b8;font-weight:bold;">CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;min-height:16.0pt;text-align:justify;margin:0pt;">We hereby consent to the incorporation by reference in the Registration Statements on Form&#160;S-3 (Registration No.&#160;333-252625) and Form&#160;S-8 (Registration No.&#160;333-236457) of Annovis Bio,&#160;Inc. of our report dated March&#160;2, 2022, relating to the financial statements of the Company as of and for the&#160;years ended December&#160;31, 2021 and 2020, which appear in this Form&#160;10-K.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;min-height:16.0pt;text-align:justify;margin:0pt;"><font style="margin-bottom:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;min-height:16.0pt;text-align:justify;margin:0pt;"><font style="margin-bottom:12pt;visibility:hidden;">&#8203;</font></p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;min-height:16.0pt;margin:0pt;">/s/ WithumSmith+Brown, PC</p></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;min-height:16.0pt;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;min-height:16.0pt;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;min-height:16.0pt;margin:0pt;">East Brunswick, New Jersey</p></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;min-height:16.0pt;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;min-height:16.0pt;margin:0pt;">March&#160;2, 2022</p></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"></td></tr></table></div><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:10.35%;margin-right:10.35%;margin-top:30pt;page-break-after:avoid;width:79.3%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>3
<FILENAME>anvs-20211231xex31d1.htm
<DESCRIPTION>EX-31.1
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  9.11.0.85--><!--Created on: 3/2/2022 09:00:14 PM (UTC)--><!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Exhibit 31.1</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">CERTIFICATION PURSUANT TO EXCHANGE ACT RULES 13a-14(a) AND 15d-14(a),</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">AS ADOPTED PURSUANT TO</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">I, Maria Maccecchini, certify that:</p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">1.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">I have reviewed this Annual Report on Form 10-K of Annovis Bio, Inc.;</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">2.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">3.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">4.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">The registrant&#39;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:54pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">(a)</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant is made known to us by others within the entity, particularly during the period in which this report is being prepared;</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:54pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">(b)</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:54pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">(c)</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">Evaluated the effectiveness of the registrant&#39;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:54pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">(d)</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">Disclosed in this report any change in the registrant&#39;s internal control over financial reporting that occurred during the registrant&#39;s most recent fiscal quarter (the registrant&#39;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#39;s internal control over financial reporting; and</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">5.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">The registrant&#39;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#39;s auditors and the audit committee of the registrant&#39;s board of directors (or persons performing the equivalent functions):</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:54pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">(a)</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#39;s ability to record, process, summarize and report financial information; and</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:54pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;">(b)</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#39;s internal control over financial reporting.</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 0pt 54pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 0pt 54pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p><div><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;" align="center"><tr style="height:1pt;"><td style="vertical-align:top;width:5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">2</p></div></div></td><td style="vertical-align:top;width:45%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr style="height:11.25pt;"><td style="vertical-align:top;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Date:</p></td><td style="vertical-align:top;width:45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">March 2, 2022</p></td><td style="vertical-align:top;width:50%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">/s/ Maria Maccecchini</p></td></tr><tr><td colspan="2" style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:50%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Maria Maccecchini</p></td></tr><tr><td colspan="2" style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">President and Chief Executive Officer</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:avoid;width:88.24%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>4
<FILENAME>anvs-20211231xex31d2.htm
<DESCRIPTION>EX-31.2
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  9.11.0.85--><!--Created on: 3/2/2022 09:00:17 PM (UTC)--><!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Exhibit 31.2</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">CERTIFICATION PURSUANT TO EXCHANGE ACT RULES 13a-14(a) AND 15d-14(a),</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">AS ADOPTED PURSUANT TO</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">I, Jeffrey McGroarty, certify that:</p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">1.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">I have reviewed this Annual Report on Form 10-K of Annovis Bio, Inc.;</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">2.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">3.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">4.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">The registrant&#39;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:54pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">(a)</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant is made known to us by others within the entity, particularly during the period in which this report is being prepared;</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:54pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">(b)</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:54pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">(c)</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">Evaluated the effectiveness of the registrant&#39;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:54pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">(d)</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">Disclosed in this report any change in the registrant&#39;s internal control over financial reporting that occurred during the registrant&#39;s most recent fiscal quarter (the registrant&#39;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#39;s internal control over financial reporting; and</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">5.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">The registrant&#39;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#39;s auditors and the audit committee of the registrant&#39;s board of directors (or persons performing the equivalent functions):</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:54pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">(a)</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#39;s ability to record, process, summarize and report financial information; and</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:54pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;">(b)</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#39;s internal control over financial reporting.</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 0pt 54pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 0pt 54pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p><div><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;" align="center"><tr style="height:1pt;"><td style="vertical-align:top;width:5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:45%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr><td style="vertical-align:top;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Date:</p></td><td style="vertical-align:top;width:45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">March 2, 2022</p></td><td style="vertical-align:top;width:50%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">/s/ Jeffrey McGroarty</p></td></tr><tr><td colspan="2" style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:50%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Jeffrey McGroarty</p></td></tr><tr><td colspan="2" style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Chief Financial Officer</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:avoid;width:88.24%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>5
<FILENAME>anvs-20211231xex32d1.htm
<DESCRIPTION>EX-32.1
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  9.11.0.85--><!--Created on: 3/2/2022 09:00:19 PM (UTC)--><!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Exhibit 32.1</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">In connection with the Annual Report of Annovis Bio, Inc. (the &#8220;Company&#8221;) on Form 10-K for the year ended December 31, 2021 as filed with the Securities and Exchange Commission on the date hereof (the &#8220;Report&#8221;), I, Maria Maccecchini, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:</p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">1.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;">2.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;">The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 0pt 18pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 0pt 18pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 0pt 18pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p><div><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;" align="center"><tr style="height:1pt;"><td style="vertical-align:top;width:5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:45%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr><td style="vertical-align:top;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Date:</p></td><td style="vertical-align:top;width:45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">March 2, 2022</p></td><td style="vertical-align:top;width:50%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">/s/ Maria Maccecchini</p></td></tr><tr><td colspan="2" style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:50%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Maria Maccecchini</p></td></tr><tr><td colspan="2" style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">President and Chief Executive Officer</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:avoid;width:88.24%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.2
<SEQUENCE>6
<FILENAME>anvs-20211231xex32d2.htm
<DESCRIPTION>EX-32.2
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  9.11.0.85--><!--Created on: 3/2/2022 09:00:22 PM (UTC)--><!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Exhibit 32.2</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">In connection with the Annual Report of Annovis Bio, Inc. (the &#8220;Company&#8221;) on Form 10-K for the year ended December 31, 2021 as filed with the Securities and Exchange Commission on the date hereof (the &#8220;Report&#8221;), I, Jeffrey McGroarty, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:</p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">1.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;">2.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;">The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 0pt 18pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 0pt 18pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 0pt 18pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p><div><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;" align="center"><tr style="height:1pt;"><td style="vertical-align:top;width:4.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:45.84%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr><td style="vertical-align:top;width:4.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Date:</p></td><td style="vertical-align:top;width:45.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">March 2, 2022</p></td><td style="vertical-align:top;width:50%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">/s/ Jeffrey McGroarty</p></td></tr><tr><td colspan="2" style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:50%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Jeffrey McGroarty</p></td></tr><tr><td colspan="2" style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Chief Financial Officer</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:avoid;width:88.24%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>7
<FILENAME>anvs-20211231x10k003.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 anvs-20211231x10k003.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" (A T(# 2(  A$! Q$!_\0
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M3P_K\4=MKENF\&/_ %5Y%T\V+^J]5-=10 4444 %%%% !1110 4444 %%%%
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M;?4=/G2>UN$#QR+T(_H>Q':K=:FP4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444$X&: //OBUXV;
MPGX:^SV4NW5=0S%;D=8U_CD_ ' ]R/2OE_I_]>NI^(?B5_%7C6^O@^;6)C;V
MH[")"1G_ ($<M^-4O"7A6_\ &&O1:78@J#\T\Y7*P1]V/OV [G\:YJC<Y<J.
M.JW.?*CK?@]X(/B3Q -7O(LZ7IL@;##B:8<JON%X8_@.]?3':L[0M$L?#NBV
MVE:=%Y=M;IM4'JQ[L3W).23[UHUO&/*K'5"*BK(^.O&6BMX>\9:MIA7"17+-
M%_US8[D_0X_"L.O?_CGX--_IL7B>RBS<62^7=A1R\.<AO^ G/X$^E> 5S58V
MD<=:/+(])^$/CI_#6O+I%[+_ ,2G4) OS'B"8\!AZ!N ?P/K7TQ7PZ0""#T/
M%?5WPL\2/XF\"6<]P^^\MLVMP3U+)T;\5*GZDUK2E=69O0G=69VE%%%;&X44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M444R0HHHH *1ONTM(WW: /)? W_(FZ?]9O\ T=)6[<3QVMM+<3,%BB0N['L
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MX#7'6DNH:#K_ (UU/^T)+I[.-6,;Q@"5F7Y"V#_!G\16=.@I1>NMK_BDOZ]
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M ,%]Q_\ $4 =C2-]VN._X6=X>[+JI'J-+N.?_'*#\3?#Y&-FJ_\ @KN/_B*
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ML=4-.M1I']E"/_0O)\CRL\;,8Q5&#PQIEO-I<J+.7TQ&CM2TQ.U6Z@^M8?\
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M]WJ4UV@CM5;".%P"=W7@UC6G&2T-*<6GJ>J45Q__  GD_P#T)OBC_P  U_\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% %<7UHT4L@NH3'"2)6$@PA'4$YX_&BVO[.\+"UNX
M)RO)$4BMC\C7F5E_R)OCS_K]N/Z50\'11ZEXCT8Z3I1T^33H0VH3-+@SJRC'
MR]\]?QKD^LN\5;?_ #/H/[&A[.K-S?N>EOA3UUOJW96OJ>KR:QID,K12ZC:)
M(IPRM.H(/N,U<5E= ZL&5AD$'((KQV*.U?Q=XE^T>%I]:(O#AHAGRNO!^O\
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M?3;<7%XH'EQ,"0QR.P([9IJ2:N:4Z\*E/VL=C.T#Q?8^(;VZM;6&='MQEC(
M ><<8-=#7B7@&]U>#Q+*+*R659I%6[)4GRD+\D<\=_6NU\4>/9--U/\ LC1[
M07FH9 ;(+*I/\( Y)_E41G[MV<>'QR=#VE7O;;\CN**\Q@^(.O:1>Q1>)=)\
MJ"4\.L91@/49)!QZ5Z5!-'<P1SPN'BD4,C#H0>AJHR3V.NAB:=:_+NNCW*6M
M:U:Z#IS7UX)#"K!3Y:Y.2<4VVUVTNM _MF,2?9?+:3E?FPN<\?A6#\3?^1-F
M_P"NT?\ Z%4.B?\ ))3_ ->4W_LU+F?-8QE7FJ\J?11O\QR?%+PZS '[8H/<
MP]/R-=3INJV6KV2W=C<+-"W&Y>Q]"#R#7C7A6[\)P:+>1Z_$LERS_NL1,7V[
M>S#@<^]=)\)8YQ#JDF&%JS($ST+#.?TQG\*F,VVKG+A,;5J3C&;3YK[;JW<V
M9OB?H$$\D3K>;D8J<1#J#CUK4T#QCIGB2YE@L1<!XDWMYJ!1C./6O*="OM"L
M?$&I/KUK]HA9G$:^7OPV_P"OI7HOA75O"MS<W1T2R^SR1P[Y6\G9E<_6B,VW
MJPPN+JU9+FG'TZG8T5Y8?B%XEU"6XN])TF-]/MV^;,;.<?[1!_'CI7HNCWL^
MH:3;7=S:/:32IN:%SDK_ )ZU:DGL=U'%4ZS:A?[B]15>]O(-/LIKNY<)#"I=
MV] *\W;Q]XEUB>5O#^C;[6(\LT32-^)! 'T%#DD.OB:=%I2W?1:L]0KC?$'Q
M#LM"U=M.%G-<RQ@>848*%)&<>_%)X2\<_P!NW+Z;J%L+74D!PHR%?'48/((]
M*\_&H:ZOQ"GO(M.235=[?Z.4) ^7'3.?N\]:B4]%8X\3COW<947N[;7_  [G
MMUM.+FUAG4%5E17 /49&:EJ*V:1[6%YD"2LBEU'8XY%1:E?1:;IMQ>S'$<,9
M<^^!TK4]*]HW9B7OCG1K#7/[)F>;[0'5&94!12<=3GWKI:^?#I5[J^D:GXD<
MD^7<#?QUW'+'\,K^=>T>$M6_MKPU9W;-F4)Y<O\ OKP?SZ_C6<)MO4\_!8R=
M:;C-6OJO0J:UXZTC0=1-C>"Y,P4-^[C!&#^-2:-XWT/7+E;:UN62X;[L<R%2
MWT[&N!\9R647Q,MGU$*;-5B,P92PV\YX'6L_5GT:]\7:8/"D3*=Z9**R@ONX
M(!Y&.]2YM,YYX^K&I+563M;JSU;Q!XHT_P -) U^)B)B0OE)NZ>O(]:S++XD
M>';V=8?M$L#,< SQ[5S]1D#\:P/B]_Q[Z5G^_)_(5SGBBZ\)SZ-:)HT(&H K
MYC1QL@QCG.>O/I3E-ILO$XVK3JS46K1MH]WZ'MX((R#D&BLOPY'<1>&].2ZW
M"9;= P;J#CO6I6J/5A+FBF4=9U6'1-*GU"X1WBA ++&!DY('&?K4>A:U;Z_I
M:7]LDB1.Q4+( #P<=JYGXFW6I1: 8+6U62SE!^TRE23& 1MP<\9/UJA\,M0U
M%-+>&YMDCTJ%'D2Y((RV[D$YQZ]JCF]ZQQRQ36+]CTMVZ_Y'H]%>83?$'7]6
MU*6'PWI:S6\1ZM&79AZG! 4'TIDGQ+UJ/4+6QETN"VGW!+A9D;.2>JC(QQZY
MH]I$3S&AYV[VT/4J*XOQ1XNO]$\2Z=IMM#;/#<A=[2*Q89;'&"*U/&.N7/A[
M0&OK1(GE$BKB4$K@GV(I\RU\C=XFFN?^[N=!169X=U&;5M L[^=466>/<P0$
M*#D],U+J^JV^BZ7/?W1Q%$N<#JQ[ >Y-.^ES55(N'/TM<O45Y;;^._%VIRO=
MZ;HB2V2'&U8F;_Q[(R?I5[P_\0K_ %OQ7#IQLX(+63((8,9%(7)&<XZ@]JGV
MB.2.849-)7U=EIN>B45YMJWQ$U/3?%5WI<=A!<11MLB5%82,Q QSGU/I5>/X
MAZ_I>KQ0>(-,C@@E()41LC*I.,C).:/:1!YC03L[Z.VQZC2$X!/I6!XK\4V_
MAG3%N"@FGE.V&+.-Q]2?05QUMXX\7)#_ &A>:&)-,;YF:.%EPOJ#D_F13<TG
M8TJXRE2GR/?R5[>IUWAOQA:>);BZAM[>:(VX!8R8YR<<8KHZ\J^$K!]1U5AT
M**?_ !XUZK2@VU=BP5:5:BISWU"BBBK.L**** "BBB@ HHHH **** "BBB@#
MCK?P?=0Z%XCL#=0E]5N))8V .$#=C_\ 6HM_!]U8:GHFHV=U"D]K;+:7H*G;
M<( !Q[_7T'I78T5E[&!W_P!IXC77??3>ZM^7^9PH\+>)K#6]5O=)U6QACOYS
M*RRP%R.N.WO7:VZRK;1+.ZO,$ =E& 6QR0/K4M%5"FH;&6(Q=3$)<Z6G5))[
M6U?4X'_A7UP-":!+V*/4HM0:]M;E5.$R1\I_+^5;KZ#=S^+M.UR6:$"WLV@E
MC4'ESG)'MSWKH:*E48+;^K&L\RQ%2_,^_3^;<XP^!5M_'D7B*QECBC(=I8&4
M\R%2,C'8D@G\:;I/P[TQ+>677+>#4-0GF>66;Y@.3T S7:T4E0IWO8;S7%N*
MCSM:)76CLKV5]^ISOACPY+X;N-2ABEC.FSS>=;0C.Z+/4<]NGY52\5^%M2\2
M2FW-UIXL7VX,EJ6F@P>2C \Y]ZZ^BJ=*+CR="(X^O&O]83]_O9??Z^9S#>%"
M?$]KJ!E1[.'3S9-$^2[#D9)Z=*P$^'-]:.;:ROM-^P[LJ]SIL<LZ*3TW$?-^
M->C45+H0?0TIYKBJ>B?1+5)[7MOUU9S,_A=CXBT+4+=X(K?38Y$:)8]N[<N,
M@+P.>:?I_AV>S\1:]J33QM'J2H$0 Y3:N.:Z.BJ]E&]_G^%C%XZLX\K?2WRY
MN;\S#\(Z'-X=\.P:;/,DLD;.2Z @'+$]ZIS>$1>>(]8O;N1'L]0M%MC$N0ZX
MQSGIVKJ**/91Y5'H@^NUE5G53]Z>_P!]_EJC@CX(UVXLH]%O?$(DT2,@;$@Q
M,Z Y"EO\]*T=4\)72ZK'JWAZ_33[L0BWD22/?')&!@9'J,#\A7645/L(6-GF
MF)<KW772RL[[W5K._F<!J7AN32/"/B34+^\-[JE[;L9I]NU0 .%4=A573/"V
MO:QX8TZRE\0 :--;QNT8A'F[< [-W<>]>D,JNI5@"#U!%  50J@ #@ 4GAXW
M\C59O74+:<U[WLM+*RLK:6MI8CMK>*TM8;:%=L42!$7T &!4M%%;GE-MN["B
MBB@04444 ><?%W_D&:;_ -=F_P#0:T/%O_)+1_U[V_\ [+6SXG\+6_BBWMX;
MBXEA$+E@8P#G(QWJ;4_#\.I^'!HTD\B1!$3S% W?+C\.U9N+NSSYX>HYU6E\
M2LON/%IM%-IX;TKQ!%$)8WD9)T<97<&.W(]"!C\/>O9%O[74O!<EW9JJ026;
ME44 !/E(*X'H>*;:^$[.W\*OX?>22:W8,-[ ;@2<Y'N#3=$\*1Z)I%WID=]/
M-!<!L;P,H2,'&/\ /%*,7$SPV%J4'9+1K7R9P?PX\-:3KEE>2ZC:"=XI5"Y=
MA@8]C7JME8VNG6J6UG!'!"G1$&!63X7\+6_A>WGAM[B683.&)D &,#':MZJA
M&R.C!8=4:24DE+J>?ZGH?CJ;5+J6RUE([5Y6,2&8C:N>!]VNYL4GBL+>.Y??
M<+$HD?.=S <G\ZGHIJ-C6E05.3DFW?NSROQU_P E'T3_ +8_^C#7JE<WK/@^
MVUG7K35I;J:.2VV;44#!VMNYKI*44TV9X>E*%2I*6S>AD^)_^17U3_KUD_\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MDDF<]&C&%&E57Q.7ZL]2HHHKH/H@HHHH **** "BBB@ HHHH **** "BBB@
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@#D/BA_R3G6/^N:_^AK4?PH_
MY)IH_P!)?_1KU)\4/^2<ZQ_US7_T-:C^%'_)--'^DO\ Z->LO^7OR'T.1B_Y
M.1G_ .N/_ML*]AKQZ+_DY&?_ *X_^VPKV&BE]KU8,****U$%%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MNZ9T86M.;E"IO%] HHHJSK"BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH ***#TH **\Z\"W]Y=:OXI2XNII5AF(C#N2$^9^F>G2N0
MT=M?N_#=_K47BF> V;G]Q+,W[S !X)/OC&*OD)YCW2BO,]:\1:AJ'PE@U7SG
M@O&D5'DB)0DAB">/7%8KWWB#PM#HNJ?\)&;^&\V%[21RQ (!(P2?7&>.:% .
M8]FHI <@&J.LV=W?Z5/:V5Y]CFE&T3A=Q4=\<CG'>H*+]%>;_#2XOCK.O6=Y
M?SW8M76-6E<GHS#(!/&<5Z13DK.PD[H****0PHHHH **** "BBB@ HHHH **
M** "BBB@ HHHH Y#XH?\DYUC_KFO_H:U'\*/^2::/])?_1KU)\4/^2<ZQ_US
M7_T-:C^%'_)--'^DO_HUZR_Y>_(?0Y&+_DY&?_KC_P"VPKV&O'HO^3D9_P#K
MC_[;"O8:*7VO5@PHHHK404444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %!Z444 >9?#W_D->+O^NQ_
M]">O.K;1LZ NNLC36\-[Y%S$#CY<*0<]LY(_*O>]+\-:;H]Q?3VB2*]ZVZ8L
MY.3DGCTZFH;'PAH^GZ-=Z3# YL[HDRH[EB20!U[=!6JFD[F?+<YCQT;$_"^$
MZ8JK9$PF%5Z!2?Y^OO4GA3X=Z'#;:;J\@GN)WACG"2L-BL5!S@#G!]:Z$^#M
M)/A[^PV6=K$/Y@0RG(.<\'TS6S:6T=E9P6L((BAC6- 3DX P.?PJ>;2R*Y=;
MLYSQ$/&/]H)_8!LA:>6-WG8W;\G/]*Z"P^U?V=;_ &[9]K\M?.V?=WXYQ[9J
MS14W'8\V^'7_ "-OBO\ Z^!_Z&]>DUDZ5X<T[1KV]N[-)%FO&WS%G+ G)/'I
MU-:U.3N[@E9!1114C"BBB@ HHHH **** "BBB@ HHHH **** "BBB@#RSXQ^
M);G3=(?1FT[?;:C%A+H28VLK D%<?3OWJ/X->)KJ_P!*CT%-.VVVGQLTEV9.
MI9RRKMQUY/?M77^/_#(\4^$[JS1 ;J,>=;'_ *:+T'XC(_&H_AWX8_X1?PG;
MVTJ;;R?]]<Y'(<C[OX# _.L.67M;]!]#BHO^3D9_^N/_ +;"O8:\>B_Y.1G_
M .N/_ML*]AJJ7VO5@PHHHK404444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%,EEC@B>65U2-%+,S
M' 4#J30 ^BN%B^(5W):C6/\ A%M0/AUB2E_&ZO(4_P">I@'S!#UR,G'.*['3
M]0L]5L(;ZPN8[BUF7='+&V584 6:*** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH \>B_Y.1G_ .N/_ML*]AKQZ+_DY&?_
M *X_^VXKV&LJ7VO5C84445J(**** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M#JFESB6WDXYX9&'56'8CTJXS4MBX34]C4HHHJBPHHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ JKJ5DNHZ;<V;221B:-DWQL59<CJ".A%6J
M* /E2'1]>?Q[_8_VJY&K?:/(:?S&W8Z%LYSC;S]*^H[&T2QL(+1'=UAC"!I&
MW,V!U)[FLY?#&GKXL;Q&(_\ 36MQ;GCCK][ZXX^E;-8TJ7)<;84445L(****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MJ231R"L'4,IR#76_#_QM<^"?$"W.YWTV<A+V ?Q+_? _O+U]QD5R]R -0NP
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MV'_?!_QH]@^X>U1ZUO7^\/SHWK_>'YUY+_P@GA3_ *%^P_[X/^-'_"">%/\
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MQ7UW48AB$QF$:"0C!<*,D?6IE'F5B)PYU9G@D'P;N].^'NL7U[;?:_$$MO\
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M% !1110 4444 %%%% !1110 'I7S/K^K?V_XFU/5@<QSSE(/^N*?(GYX+?\
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MLM52%+V 2B&59H_F(*N.A!!%>U1KPC2Y&M]_T.5[G#VMS!:ZM\0$GGCB8_.
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 5X!\0O#C>'/%<LL:8T_5':> CHDW62/\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MM5BWG,LK'=)*WJ['DG_(K6HHK@.D**** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ K(\2_\@1_^NL7_HQ:** -
M>BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
7"BBB@ HHHH **** "BBB@ HHHH __]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>8
<FILENAME>anvs-20211231x10k004.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 anvs-20211231x10k004.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" (/ Z@# 2(  A$! Q$!_\0
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M79FSZLHHHKJ)"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M;G?N.^*[);99#MMO+0+PI !Z4YU+/0FC3>[(I(;M0LXL;<1N.D9P:Y#6MBW
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M[;*NGSW(N9;4 88C^'/H36WJ^C6NL:2^GS#9&0-C+U0CH1]* .>\5.MGXO\
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M\<&)2*R=04>=&P[UM6DT]"*:NM2V&#0\U57,<_3)Y_*C>XC8_P (J.XDV@2
M_*16T9)JY#5G8X7Q!*8KR1?+#2.QVMUQ7.7-G=RO\R!6]!7H&K:*UW<PFV"@
M2#+$GICFL.6SF;]TV$.?QJK\KT$E<SM-FBTN)C*#+*?3HM:$6K0.5\K,<I&
M0F:9#8+;"0-EG/J*2*WABGW&'+MT4]ZPDTW?J:J^Q;2WN!+E)6W..3BN<_LM
MY;Z2/>TC!NI&*[JT\F[L"%;R) <$ _,,5ER6<ES%<_O,RIR&'!Q5TFUH*HD]
M2O%I36\1FE=R%X"YZ46\Z)+C*JN<\]JJ1W]V_P BR;QT932(Z^:%"%I!]X=:
MQE&3>IHFDM#4>X5V9E4$GICO[U5>YA8F-PP'\1H=)UD6)(MH/0@U=AL8XDWS
MJ&E;L>U9Z0U92O+1&9Y4)F+11.\?;VKM/AK#(/'>G-L*HJR=1_LFLA7CA4!%
M"!>P'>ND\#G'Q TPQ#:)!(9 ?]P]/2M:-3FJ(FK#E@SW:BBBO:/-"BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M6DSEI)6Q(_(0]Q31"K.Y95V>@.<5=]00R(0R0L9Y&"CD8YS[58CLY]0$5O:
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M;+R,9E+'"1^Q-4L/-NWS)>(@E?SM\SL**X_2O%=W/>RZ9J=G]DU%8RZ+G*R
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MC<D5U.KQ2QI*CKM>//!]:X:^@,TIEV@CN!VKCG$WBRNLL9_=AE.?[QP*I-*
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M7,O(****YSH"BBB@ JZOW1]*I5=7[H^E3(J(M>!_M$1A[G2,_P!UJ]\KY_\
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M/3\*SNW+0JUD9?CNVC%W"Z !ID(;WKS;48([>Y@A3@NQW'KS7>ZYJ']KZB9
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MWVPGNW0X9P.V:O:AX-DO]1U>Z:9%:Z*O;L.L;+WJQJ7AR]OK>PNX[M8-9LU
M$PY5_8TW7IM15]E]SL)4*B<G;=_>KF1K.BKX.6WU?2+JX55E6.6&20LL@)JO
M>^'[.?X@V5J9KH07D#W$BB4CYNO'M6L/#VN:Q=P-X@NX#:P,'$$'1R.YK5GT
M667QA9:PKJ(;>W:(IW)-3[?EWE=V>OY%^PYMHV5UI^9@+9-XM\27]O>7,R6&
MG$1)!&^W<?4TZWMI/"GB^QTVWN99M.U)6_<RMN,9'<5H:CX>U&#5Y-5T&YCA
MFF&)H9?N/[TNE>'M0_M?^V=:NDN+U$*P1I]R.E[2/+\7NVV\_P#A];C]G+F^
M'WK[^7_#:6.:U>6^T+5YO#]E= 0:DX9'=^8<]<5JZM:II&M>%+.!Y/*B=P<L
M?GXY)]:L'P6;V"_FU*<2:A<MNCE7_EEC[N*L-H&HW5SH5Q=SQ-+I['S2/^6@
MQ@4W5AIKM>_F[;_H2J4U?3>UO)7V_4R=+TD>,KJ]U'5;F<PQS-%#!&Y55 ]:
MZ;0]!&A">..]N)[=SF..5MWE_C61)X>UG2M1N+GP_=0B&X;>]O/T#>HK7T*Q
MU6U6:75;X7$TIR$086/V%95IWB^67N]C6C#EDN:+YNYS7Q#:,7^D+.;C[.S'
MS%MR0Y'MBJ$:WT'@+6BYNDM/,!M//8^8%SWKL-8T6;4=9TN]CD54M'+,#U-6
M?$6FR:QHES8Q.J/*!AFZ#FKA7BH0A]_EJ3/#RE.<_N\]#@O!MPRZM)<:8UXU
ME!:%KM;E\C>!GBM'0_#Z>+;%M9U>[N7DN&/E)'(5$:YXXK8TWPU-I>L"YAD3
M[+- (KJ'^\P&-PJFGA[Q!HLLT6@WL'V*5BPCGZQD^E7.M&4FX2L]-?S,X491
MBE.-UKI^6A1L;1[D:WX7O[J>:&P"S03!R'QC(!-9VG6$=O\ #:[U-)IS<S@J
MY:0D8#=O2NQT3PXVF6EZ]Q<?:-0O0?.F/TX ]JK0^%[F/P.VAF9//)8[^W)S
M2]O&]D]+K_@O[Q_5Y6NUK9_\!?<<_P"'([%;6XD@M=3CN#9L6DG8E#QVK.NS
M?2^&O#XLYG%T96*'<>2*[+3=)\016LEG?WMO);& Q(J+@@XP*@M_"=U%;:-&
M9XR;&4NY_O?2K]O!2;;Z^O1D>PFXI)=/3JC,?7?[9UCPS)N:.X21X[F+.,..
MN14 L8[;QBZZW<7<$\D^^VN4D(1QV6MZ\\'+)XPMM;M)%C0-NFC]6]1574?#
M&O:G<BVNK^"73Q<"99&'[Q<'H*4:M/11=E;YK4<J575R5W?Y/3^O0[4]:*0#
M"@#H!BEKS#U HHHH **** "BBB@ HHHH *NK]T?2J575^Z/I4R*B+7@'[1;
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M:BL?]7-^%2UM#8SEN%%%%42%%%% !1110 4444 %%%% !1110 4444 %%%%
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M6/\ JYOPJ6MH;&<MPHHHJB0HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M7$L@*<2PNV RBNWTOPQ)IZ^( TZM_:DK2+@?<R,<US]S\+H[C2O#<?VE5O\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M#99>3*UCZG"EU&8V7@]#Z&M4(2N>U5+R!"F,X-453J2IS4X.S1PYWVD[1L>
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M6]U>MA8K=\1[0/E##OS3;KP)K.MQLVK21&>+2EM('5O^6P.=U&H:&QHOCO\
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MI]:\?#2WUOR-.^TQ:4J;Y/-VAW;^'IQ6=9^#[L_#:_\ #DMLD5U#(S6LP/\
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MP#HVL:;J.J7%Y9+IUA<;3%9+)O"R?Q,/0'TH [NBBBF(**** "BBB@ HHHH
M*NK]T?2J575^Z/I4R*B+7E?Q9F>&[L3'C)1A7JE>3_%YO+N]/D_NHQZ4EN4>
M6R2"*T;>JF1CDGTJQ:L8+(C?DN.@K/FF%S!)E<$<@@59A8M;QD^E.3LCU<DP
MJQ&,BI;+5_+_ ()+&C22!5&2:U88U6:-2P 49-5+"/<[,7V #D^U6K<0^:"N
MYF8=,]J*<=+G;Q-C'4KK#Q>D=_5_Y(V].*+*P49#=,]:[;PT4AU:$DJ-PQQZ
MURFG%TB61HUSCCCM6C:7!1Q*O#JV1BKDCYI.QU_B*/9J2R,,JZC'X5DN@(X
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M:U?!MQ$WBJTBB4@8?^5"2N!ZU4=Q_P >[_2I*CN/^/=_I6Y)AT445F4%%%%
M!1110 4444 'Y4?@*** "BBB@ HHHH **** "BBB@ _ ?E1110 4?@*** "B
MBB@ _ ?E1^ HHH **** "BBB@ HHHH **** "BBB@"[8_P"KF_"I:BL?]7-^
M%2UM#8SEN%%%%42%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !5U?NCZ52JZOW1]*F141
M:\C^,I"RV!9PH*L,=S7KE>,_&XG[5I8'<-211YLTY2U6VCC5CC+-]:G3/EKG
M&<=JQB[JY!R >#6YE2B;/N@ 4I['T?##2Q<E_=_5#'DVDKN(!&,"MC3$AAB\
MV4,TN/EXX K!DVFZ"L<#&:V[<DP824;>P/6M(['CYFV\95;_ )G^9TMI=F2V
M+,!TX-3PR_)C/-9T(*Z=P:FM9U4KGD#J:HX#7MKF6WE$D<K(PZ$5LKXNU1(P
M T3D=W6N9>YRQQP.PK2L-(U+4R#;V[!#_&XP*5EU*3:=T+JGB7Q#=0LJ7D$*
M'J(T(/YURHTZ^OBVZ[D<GEA&IKTZ#PA:6T7G:K=+M'49VK4-[XDT#2[.6TT^
M$.[H5RBX'(QG/>HLGL=M+'U:.L%%/_"K_D>=0:%IZ@-)))(>X/ K2,-O BB"
M,(OL.M01D&/..*E,IS&Q&0.U4H)&>(Q^)Q/\:;:_#[@G'SH>/EK,G@$CL7D'
M)[U/<7!,G'K48@$BES\QSG%.QRCK9(TB((7:>YK-GCWS;MSJF>BGC%7Y/+C
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M^=6E\1Z2[!5O8\F40_\  R,@?E7E]C#!)X?\+L\4;DZO(N64'(W-Q6A_9?\
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MJ?AJ_C^%<$<UE/<:A<W:W=[#%]\DMD@?A7:>!H[6/066STZ_L(_..8KXY<G
MYZGBA /\2>,]-\+WNG6M\)&>^DV(4Z)[M[4_6O%^FZ#KFEZ7>[U;421%+QL4
M^_UKB/$?A7Q)XO\ $.K75N]O:VL<7V6#[3'N+@<EE].>]$V@W_BJZ\,1ZO8R
MQ^593P7,A'^KD PK9]R,B@+'5:CX^L-.M=5G:SN9?[.N$MW5,9D9NFVK7A_Q
MA::]>RV#6EU87\:"0V]TN&*'^(>HKS--!\26OA77X[^RFN;Q=2@=#&O,Z(?O
M#\*[+1AJ/B3QM;:_-I-SIEC8V9MT%S@23,3SP.PHNPLCO*NK]T?2J575^Z/I
M2D.(M>*?'5RESI6.N&KVNO$_CJNZZTKZ-211Y/*/F5 22<$UM0',0'3%9$(8
MR;NO:KOF-$5JFKJQV9=B_JN)C5Z+?TZD\Z?O$<>F#6A9QB0(02I/4U5!$D>1
MT(JY9N4C5"O&:*;TL>AQ!AN3$+$0UC/6_G_6IN,X6S"!B?K6MX?TJ'59=DU_
M%;*#C#=3]*PF^:,8Z5/#G ]:T9\^>O67AC2],M_.2W-W*HR&;DGZ5B:MXQO[
M<^5!9&U&< R+S7,:;XBU/2\>3<LR#^!^174VGC/3=3C$&KVBKG@MC<M19]1W
M.2O;ZXOBSW5U)(W;<:R)1DCG@5Z3<^#])U6(S:7=!"1D!3N'Y=JY+5?".JZ;
MN=X/-B'_ "TCY%4FA69E0N3&1Z5+N+(,=J@M\",@]<U80!1CUJA$(4,2>]*X
M$8+;]H'I2#<%<X[U']G>7DY- $5VZ1A9(SA^O/2L^]O_ #K!_,C0 >G6M2]M
M2]NB 8.>IKG]0A:!7&T.F>@H&C,@UJ^241PN6'8-R!70Z3XI4786XC6&-5*D
M#HQKC1<2Q3F2-=I':JSM(YSN.XG)J-44>B7S12J]Y#-%"Q'RA3R:*\_MYWCG
M0R@R*/X2<9HIW%8]2UZT2>>Y<$ ^8?QK+T[3FA1BI4EN@-+JFH//J]S$B_*L
MK#BI(;M+:()M._//>O-<X\QT\KM866PD!W33+GL0.GM227+V\)A@5G9A@D]:
MN13EP"5P#Z]ZE)1&WHHSCTJDT]A._4SK2Q9,2-]['S9[5E7=R9;KRHP 1W-=
M1%,TZF-HPJ]#6?\ V+:"8MYC[CW]*4EI[HT];LYYHW\P%V#-G I9K)C*KHRA
MTP0<5T,WA\A0\<@;N,UG-I\[22,Z,&'  [TM4]0NF=+X>^)^IZ<\=IJ<*7%N
M!@2*-K#\N*Z+5_\ A"?B/"EO?W!BN0/DW2;&7^E>820,24P<CL15*ZTX$K)N
M(*]JN-1[,7*C9\1_ W5[%#/HEPE]".0GW7Q_6N$ET+5K2-DNH[F&>-L&.3(_
M(UV.F>-_$7AB4?9;[[1;*,^1<'(/T[UZ'H/Q'T#Q=9&#7=,%K+]UMZ[D_/M5
MV3V%JCYUO8)]P>08<C\ZZCPK%'!8O.<[_2MOXF>&--TO6+=]!G#V]Q&9"@?=
M@Y[5S-A.UI"MN<ABW(-)Z M3J]/B%O!++)_K93GZ#TJY93>=*5!)/2LF_OOL
M<21(?WC#IZ5=\/1R*AEF!WMS4,#<MX-KY[BL;7S-*! A*C.XD5OB5(DRQ S5
M&9H)"[8!;'%+0:.8TZ:YLYD65R5?I7?>"9C)XTL<_P!U_P#T&N>>SC>)&*C/
M:ND\"6^SQ9:MZ*_\JE+WD.^A['4=Q_Q[O]*DJ.X_X]W^E=IB8=%%%9E!1110
M 4444 %%%% !1110 5FZS=:/9V\3ZS]F\EY!''Y\88%CT R*TJ\[^)]G+K4^
MCZ-$6!D=Y\KV*#(_6F!V-Q<Z*^H6^C7*VCW+IYD-M)&&^4=P","JFH^)?#-A
M,-,O[RT4\#R&0,H^HQ@5Y;I%S?ZAXBTCQ9=(\12[32\$'@!2-WYUN:/J?AW1
M--U?3_$D*IJQGE,BS0EGN Q.TH<<\8HL([/5?$/A72Q;V6I36:)* \$30AD(
M[%1C%6-0\4:%HQBCO+^& NH*(!T7MP.@KSU=.FAT7P,E_;'S3J3$+(N66(\J
MI_"M*TOM%\/^*=?7Q0J133S;[>6>(LLD795.#^5%@.LO]9\-:;;P:S=RV2)<
M-MBNO+#,Y] 0,UHZ?=V&J0KJ%B\4RRC F0#)'IGK7C-_9ZA)X9LY-/@:&"YU
MQY=-AGC^ZFTXRIZ FO1OAO#%#X5CVNQF:9VN%9=NR3/( ]* -&/Q;H,VH3:>
MFH(US#N$D>T_+@9.>U.M-3\/(UI)9FTC:_W>0T404RXZ\@5Q'A?1;RYO/%-]
M'>,D(O)X_LOE#YSLZ[NM9WAZZAOKSPCI]L6>ZTY9S=Q["##Q_%18#T;^U_#=
MU:2:P9+.6*W?RWN6C!9&!QC.,BGZSK^@Z="B:O=6X28;ECE7?N'KMKQ:2RU#
M2O!\VH6L;RV6I7LD-W%_SS<2_*X'TXKMK6\TK0O&6H3>* L?VB"(V=U<1EH_
M+"C*@X.#FG8#IY_%7A.PTR%Y+RSCL9\A L?R-[8 Q5ZVUC0]1<F&:WD:UC$N
M60#RD(X(STXKBO$LNBZIX,CN='LPML=109,&W<=PR0/0UF^(;&[GU/Q5%8PN
MRK!:-)%$,&2('+*/PS2L!WVG>(O#&IW:V-C<V<DR,62,(!SZKQU^E6X-8T9_
M[1:WG@S:$_;-JX*G_:]:X'6=4\/:Y;:/9>%XE?4UN(V1882K6ZC[V\XXXK!O
M;+4+"/Q7XAT]7EVW<EK>V_:2(J,,/=3_ #IV ]FM/L-WIT;6L<+V4R[E54 1
ME/M3[>RM+3=]EM+>#=][RH@F?K@5F>$!CP;HW&/]$3@_2MJD,8(HEE:58T$C
M<,X4;C]33#:6Q<N;:$L6WEC&,EO7Z^]344@(FMK=W9W@B9G&UF* EAZ'U%-M
M[*SM"3:VEO 6ZF*()G\A4]% !1110 4444 7;'_5S?A4M16/^KF_"I:VAL9R
MW"BBBJ)"BBB@ HHHH **** "BBB@ KG_ !!XNL_#FJ:1870;=J4IC1@>$QW/
MYUT%>:^.O#.H^(_%+/%9RM!9Z8S6TV/E-P3D >_'ZT,$=1;>,M/N?%E_X?!*
MS640EDD)^7'4_E64?B5;L&NXM(U"71E?:VH!/DZXR!U(]ZY30/!^MK=6%_J-
MI<)>:I!<1:B^.82PPI:M*"?Q78^%1X._X1:66=(?LJ7Z,/L[)T#D^N.U*X['
M077CMX?$MCH]MI%S<I>J)(+B-AM9.[?04V[^(44=W<KI^DWVH6MHQ2YNH%^1
M".N/7%5+3PY?:9XL\)JL4DUK8:?)!-<J/E5B.AJCIDGB3P797>@0>&KC5(WF
MD>UO(&&PASG]YZ8S0!L:M\1+6S&F-IUC/J0U"%YD$. 55/O9SZ5T>E:S;ZQH
M<.K6I8P2QF10W48ZBO)M7^'.MS6^@V,?G++%;W,DT\#82.1CN"$^AZ5Z;X<A
M>/P;:0'3GL)4MRC6K#E6Q@_F:$#L8=E\1_MFF:CJ9TFXCLK.-Y!,7!\S:<$
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M8<IKO.\ZX4!5]12,C1$8<$&JWVE40"-ASZT&X1ANZL."!5MI[[DI/H:D%RN
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M:&QG+<****HD**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M9YO^>;?E6Y11RA<P_L\W_/-ORH^SS?\ /-ORK<HHY0N8?V>;_GFWY4?9YO\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%(652 2 3P/>EH *\V^*#8GL1CL:])K@_B% DLUF6Z@'%735Y$5':)YN
MA4 @+R!G-5WNFC'R_E6R=/5S\IXJ-=&!8EB,&NOE.;F,^VO9 -[$BM*WU!Y
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M5XW,$\'D,0H8=<]Z$VA-*Y'/I#RW.^-E,1Y!![5TO@/1GM?&EE<+(&0*X/\
MWS7&FXN+601*Y(Z UTOPZNI_^$[LX79@&5\@G_9HC)<RT&T[;GO%%%%=IS!1
M110 4444 %%%% !5'6-2BTG2;B^E.%B0D#U/85>K@O&EU>:IK=GHFG6OVL6Y
M%U=Q[L @'Y5)_6@#2\#Z_=ZQ8SP:HGE:A ^70]=C<J?RJIK'B^?0_&JV<\9?
M37@5I7 _U))QN/M69<7VK:7XJL];OM(%C9R 6MRRR;@03\I/TK6>WAO/B1<P
M3HLD,NF!64\@@M0!TNIW)70;RYMY!D6SO&ZG_9)!KE)]2U2/P/I&MQSNTD(2
M2Y'_ #T0]:JW<\W@^TOM(O79])N+>465PW/E,5/[MOZ5T/A:WCNO NGV\JY2
M2U",/8T ;<-U%-9)=JP\ID\P-[8S7"MX@U0^'M:\012'R7E\NT!Y5$!P7_K6
M<=5NK+0KCP>C'^TS<_9(?7R6.=WX#->A6VG65CH\.F,L9MQ&(=C]'X_K0!S^
MDZ-K=I<V=];:^U_;3 &XCN.5*D9RF.E=7<7$5K;R7$[A(HU+,QZ "N)>*Y\"
M:K:BWE:;0;R81&!SDV[MTVG^[[5%XOUF.\UJ#19TN4TY")+J1(F(D]$&.WK0
M!<\(>*9]>U#7KF96BL[=D^SHPQ\FTG=^-1V%GJ_BN&357U>XL87<BUA@Q@*#
M@%O7-9>AZO976O>)K:U25?M4:+ OE$ !4/!]*ZSP2ZOX1L I'RJ5(]""<T )
MX6U6[O(KRPU$J;^PE\F5UZ.,95OQ%9UB^HV?Q"DL9]2EN;:6V,RQL  AST%3
M>'<2^,?$DR<QB2.,D=-P7FFO_P E2C_[!_\ [-0!UU8WBNZFLO"NI7-O(8YH
MX&9&'8ULU@>-O^1+U;_KW:@!FH:M/8>!_P"T@VZX%LK GNQ%7/#>LQZ[H-K?
MIPSKAU[JPZ@US^OOGP3I-L.MR\$?\LT^WDC\)^*9K64B/3=0C,T3'A4E4?,/
MQ'/X4 6/%/B@Z-JVDV$/,ES,/,_V4]Z=X[NKNWT.V^Q73VTLUY%$94ZA6)S7
M,WMM+J/AW4_$UPI$LLR/;@_PQ(W&/KUK9\>EKSPIIIBE,32WMN5D7JN>] $>
MIV.O^&]-DU:+7Y+M;8!Y(+B,8=>XR.]/\07E]J>H^'K:QOYK%+]6=V0<_=R!
M5H^"I+WRUU;6[V^MU8,8&(56(]<=:H>,[*XN?$?A^UL+IK.;$HCE0?=PO2@!
M]Z=:\)W%E<RZNVH6D]PL$L4R ,-QP"I%:GB+6[V.^MM$T94.HW(+M(_*PQCJ
MQKG_  MIG]JZB?\ A(+^ZNM4TZ3/V>9L(I[.!WK45UM/BE,UQA1=V2K QZ$J
M>0* '?\ "(ZML\S_ (2B^^U=<X&S/^[Z5/H.LW\]W=Z#K 6/4X$W+-'PLR'H
MXKJ*X]W6\^*,)M_F%G9,L[#L6/ - %OPCJ=S/'>Z;J$A>^L9BC,W5E/*M^5-
MUW4;J;Q#IFC6$IC=V\ZX9>T8[?C5/7W7PYXML==)V6=T/LMX>P/56-2^#8VU
M*YU#Q',#F]DV6^>T*\#\^M &?'::MK_B36HH]=N;.&TE1$CC (Y7/>M*6UU/
MPQH6I7K:G<:E*L1:-95'RD=^*R+#01K'BOQ&YU"\M?+GC&+>3:&^7O74Z9HD
M.C)-YNH7-RDN%(NI-P'L* ,#2-*UV2WL=8L_$+79GVO-#-S$5/4+CH17<UP>
MHVD_@6Z74],<MHTTH%S9,<B,L?O)Z<]J[I'$B*Z]&&10 K,$4LQP ,DUQ'AW
MQ?<:EXJNK6X398W&38N>C[>&Q5_QUJ5Q;:.NGV"E[_4&\F% <''<_E7+:G;^
M((-%L/(\/B!M*998Y5F!.!]X8[Y% '8^*WU&RLXM3T]V/V1]\T Z21]_QJAJ
MWB"35_[-TS0I\3WX$LDR_P#+&$=3]>U:TGB&Q/A;^V68-;/#OQZDC[OUSQ7&
M>"(G\/Z\Z:A:K!_:Z^;:M_<[^7[>M '5^(M:N=+CL]-TY!/J=V?+AW]% '+M
M]*I+X2U>5/-N/$UZ+H\GR@ @/L/2DU-ELOB/IES<G;!-;/#&QZ!\YQ784 <K
MH>L:C::RV@:X4DN=GF6]R@P)D]QV(JCIGC.2+Q;?Z3J2E;;S_*MKDCY0^,["
M?Y5/K;K>>/=%M;<YFME>68C^%2, &JNCZ3:ZU=>*[&\3=&]X,'NIV\$>A% &
MWXSO;BP\.R7%K*8Y1(@##T+<UN0,6MXV)Y*@G\J\RU[4[NQT.;P]K#%KF.2/
M[-<'I.@8?J*[3Q!J_P#8WAA[E>9V18X5[L[< "@##;QC./'0M-G_ !*,_9C-
MV\_KC-;WBZ[GL?"U]<VTACF1,JP[<UPHTKQ$?"1THZ OGEO/^T><-WFYSNQ6
MU?ZQ_;7PNNKAQMN$C\J=#U613@@T =EI\C2Z=;2.<LT:DGU.*LU4TO\ Y!5I
M_P!<E_E5N@#AO'=KJEC87FLV>MW,"QJNVW4#;UQ4D]KJ>A^$[^^?6;B[E> /
M&9 !Y9QVJY\1/^1'U#_=7^8I_BC_ )$&Y_Z]1_(4 9EMH>O_ -D1WT/B:<S>
M2)0DL8*DXS@^U=#X7U:36_#UK?3($E<$.%Z;@<$C\J\_AL-2BN['3=:UZ]&E
M7\"B!XR%!;',;'M7H5P]EX6\..8D$=M:1?(OJ>WYF@#G/$/C"XT[Q9:6]NA?
M3[4J-1D'1/,X7\NOXUT7B6]FLO"]_>VK@2QP%XV]^U<+IEKX@DT*_BG\/BX;
M5"TLLK3 $Y^[^7%7(-2N+KX9ZM8WRE+^PA:"93UXZ'\J .B\(>)T\1:<!,A@
MU"%1]H@;@C/1AZ@^M*;ZY_X3U;+S3]F-F7V=MV>M9<VASS:-I>MZ21'JMK;(
M!V$Z8Y1OZ57T36H-;\=QW,8,<BV)6:)N#&X;D&@".TCUCQ3?ZM/'KDUA/9W+
M0Q6D8&% Z%AWS6SXCNM5T[P#=3RSHFHQQ &6'IG<!D4W7_#YGE.O:%.+?4T7
M)9#\EPH_A8=_K6?KVK_V]\++V\V&*1XPKK_=8, : )#HGB"TTL7]OXEFDE2+
MS0D\8VMQG!JW)XQ,?A"SU1;;S+Z\Q%!;C^.4\?E4$'@Z[OM/ACO_ !#?S6SQ
MKNA4A0PQTR*9XGM[?2+_ ,+2A!'I]I<^6?2/(PI- $T7AC7;V,7&I>(;F*Y?
MDQVN%1/8>M)9:GJGA[6[?2=;G%U:W9*VE[C!WC^!_>NP!! (.0>AKC?';+<W
M.A:=#\UW)?QRJHZJJ\LWTH 371J6H>,[;2[75)K*(VS2DQ@')!IIEUCPSKNE
MVUUJ9U"SU"4PD2( \;8R",=15/Q39:C?>-HH]*OFL[M;%V1U'WN>AJ;P9IT&
MISKJFI7EU=ZM9DQ/%<-_J&[X']: *WB'3]9L-8L(HO$=V$O[DIMVC]V.O%=M
MH]A<:=8"WN;Z6\D!)\V08)K \7?\AWPW_P!??]*ZZ@ HHHH XSXBZI/HVGZ=
M?P$AXKM21_>&#D5U&F:A!JNFV]];L&BF0,/;VKB?B[_R+5K_ -?(_D:P_A9X
MD^SW+Z+</^[E.Z'/9NXKT5AO:815([J_W'FO$^SQCIRV=OO/7:\W^)TK1W%B
M%[@UZ17FGQ1.+BQ^AKBI?$=]3X3CH;A^,DU;2Y(ZFL=9MM2"<GO72YV,%"YK
MO?D#@U6DO6/):L]I_>H&G)^E3SE<A<DNW8_>J%IB3G-5#(30,TN=CY$6?-8G
MAJ4NVWJ:A4U)FCG8^1";G/\ $:<K,#]XT9%(QXI<[#E0]Y"1]ZH_M,T8^5S4
M39S3"2*%-AR*Q;CU.X0Y+4]M8D*\FLUMWI43Y[BK]K8ATR6>_:1B2:K_ &GG
M-0M&2<U&8F[4_:B]FC1CNU!SFGR7"OS@5E%66F&9E-5SW#D+LA5CR**SVN"3
MS14\PTCG/$<8?Q!J(..9V_G69'$48QN 6'0@]JV_$85]=U!L@'SVK*4%"K%<
M$]Z\M,[;$2YAG4%J:V_<6RQ&>]2.N^0MU/2I$4J &7(/3/:AR'8C#D[%W?*3
MR/2K*KMAED'//%4B"LQ"KD5;$I6WV@ GH0:!$)F<L"3C=VJ2.#SGVC)(&3BF
M2(JPYX.*2UF"H44G<QI#+J6JPMN;#-V]JU$G2.1,$L>X(K$MVD1VW'<N><U:
M0'SAM;//'-2]1IEG[5Y5P7)*A3D8K:T^^66#[H.36%*ZIEG90QR"".HJE9Z@
M;*4D#*MPU)JZLAIV9V<T>8"\>,^HJG;NSRX?%.M;E)8SY<@<+@DU/&("6RFY
MO4'I6:NC1V8]S*AVJY4=C2LA51M)+$9Y]:E01RQ[2#D=C2N9)(AA>%/7TJMR
M=AR7"R6QBFB#-C@]*J-(+?\ =2?-O/ !Z"I)IA'"/ERQX-9KR$3KOBW+CIGG
M'M3M?06RN76+^6'W$J. W7\ZZKX<7/G^/=.$@!<+)AAW&VN6BNB (V55B1<8
M[D5U'PT@;_A/+)UP8PLG/<?+2C'WD4Y>Z?0-%%%=IRA1110 4444 %%%% !6
M/HV@KI5U?W<DYN+J]E\QY&&,#LH]A6Q10!3U;38-7TNXL+@?NYD*D]Q[BLO2
M_#;6&J0W\MZT\L=H+4Y7&X _>/O7044 4]5TNTUG3IK&]B$D$JX(/;W'O1I6
MGII6EV]A&Y=($V*QZD5<HH QY/#=E)XHBUXK_I4<)B'''U^M3:YHT6MV!MI)
M9(G5@\<L9PR,.AK2HH Y*'PC?W5_:SZYK+7T-HP>&%8]@+#HS>M=644]5'Y4
MZB@#)T_0X[#6-3OQ)O-\R$IMQLV@C^M93>%M2LKB<Z+K)L[:=B[PO%O"$]2O
M/%=729&<9Y]* ,[1-&M]#L/LT+,[,Q>65SEI'/4FHVT16\3KK7G'<(/)\O''
M7.<UK$@#).** "J.LZ:-8T>ZT]I#&+B,H7 SC-7=Z[MNX;L9QGFHS<P!BIGC
M##J-XS0!DW7AY;JWTJ%IR$L'5^GW]HQ3_$?AVT\2Z:+.Z)4+(KJZ]5(/]1D5
MKA@PRI!'J*6@#/O](AO=#ETI?W4+Q>4N!]T8XJE?^'%O]$L-.>Y9?LDD4F_;
M][9_C6V\B1C+NJ@_WCBAG1%W,RA?4GB@!PX%95_HJWVMZ=J1F*FRWX3'WMPQ
M6HK!@"I!![BD$B,Y0.I8=5!Y% &/J7A];O6+35;:<VUW <,RC(E3NIJ;6]!M
M-=MECN-R2QMNBFC.'C;U!K1::)&VO(BGT+ 4Y65AE2"/4&@#DCX=\3E/(_X2
MDB#IN^SCS,?7-;6B:#9Z#:M%;;GDD.Z6:0Y>1O4FKYN8%)!FC!'8L*<)HBF\
M2IM'\6X8IV8KHHZ[HUOK^CW&FW/^KF&,]U/J*M65I%864-I NV*% BCV%2+-
M$YPDB,?9@:>2 ,DX%(9R<_A/45U>]OM.UV2S%VP=XUB#<@8JPGAF[N=.NK/5
M]7EO4FQL8+L,9'<8K?\ M5O_ ,]XO^^Q3S)&(_,+J$_O$\?G3LQ71R'_  AV
MI7CP0:OKLEYI\#!A (MI<CIN.>:[  *  , <"FQRQRKNCD5QZJ<T\D 9/ I#
M,=M"67Q.NLSSF0Q0^5!%CB//4_4UKD!E*D9!&"*C^U6__/>+_OL4[SHAMS(G
MS=/F'-.S%='*0^!DC>.!KYVTR*Z:Y2T*\9)R!GT!K8U_0H==T];<R&"6)Q)!
M,@YC8="*U'=(QEV51ZDXI&EC10S2*JGH2< TK#N9^I:);:QI:V>H9D( (E7Y
M6##^(>AK$'ASQ+"GV>#Q0P@'"F2W#2 ?7-=4+B!B LT9)Z ,*D) &3P*+!<Q
M]"\.VVAK(ZR27%W,<S7,IR[G^@]J?I.B+I5[J5RLQD-[,)2",;>,8K0^U6__
M #WB_P"^Q4BLK*&4@@]P:=F*Z,K7_#UEXAM%ANT^:-@\<@ZJ14>H>'UU+4=,
MN)YR8+$EQ!CAWQ@$_2M4W5N'V&>(-_=+C-2YXSVI6'<*Y>Z\'1S+K4<-VT,.
MI@%HPN1&_=A]:Z9)(Y,['5L==IS2-+&KA&=0QZ GDT6"YS%EX<UVTD@#>)99
M(8L QF$#<!VKJJ:)$9R@=2PZ@'FE9E12SL%4=23B@#-\0:.NO:+<:<TIB$P
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MSKVS[CUK76>)SA948^S U)TH R=6T1=4OM.N6F*&SE\T*!G=QTK6J+[3;_\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 5Y5\73B?3_H:]5KR+XS/LN-.^C4GL
M-'FSN!Q5&X;KBD:<FJ\LFZB*"6PP#<U7+>/!JO$,G-:$"\UJV06X4J[$<560
M5,IQBLGJ6BXIS2U&C<4\FHL,:W6HFJ0TTBBPR&HWZ5+CM4;<<4!8KL<5&34K
GBH2:D0QC3&-*QXIAIC&G!J%T!J4G!IA-%PL5S%CFBI'HJKDV/__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>9
<FILENAME>anvs-20211231x10k005.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 anvs-20211231x10k005.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" &  O\# 2(  A$! Q$!_\0
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MM_W[%']@:3_T#K;_ +]B@#0W#U'YT;AZC\ZS_P"P-)_Z!UM_W[%']@:3_P!
MZV_[]B@#0W#U'YU%$P\R;D?>]?854_L#2?\ H'6W_?L5%%H6DF27.G6W#?\
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M* "BBB@ HHHH **** "BBB@ HHHH **** (K;_4CZG^9J6HK;_4CZG^9J6@
MHHHH **** "J-AK.GZI)=)9723-:R&*8+GY&]/TJ'Q'J$VEZ!>75M"\UPL9$
M4:*6+.>%X'N:X;PUI>J^%]>LA<:9Y-O>P&WN9(IS-OF&6$C84;<DD=Z .QLO
M&.@:A>):6VHHTSL4171T#D=0I8 $_2MRO*+=I-0\&VOAZWLKQM4^V%P6MG1;
M<"8MO+L !QZ'O7JXZ4 %%%% !1110 5EWW_(<TO_ 'I?_0#6I67??\AS2_\
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MK_>/I1];\A_ZOO\ Y^?A_P $]RHKPW>_]]O^^C2%W_OM_P!]&CZWY#_U>?\
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M+EA_WV.S8[9]*W: ,"BO>BK))NY^25IJI4E.,>5-[+H%%%%49A1110 4444
M%5+_ /U ^M6ZJ7_^H'UH MT444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110!%;?ZD?4_S-2U%;?ZD?4_S-2T %%%% !1110 V1_+C9R,A03BN2
MTOQ]!J$9>73;JV#VTEU 796$R)][&#P?K75SJ7@D51DE2!^5<;X>\(KI?@J6
M+^SHHM8GM9(Y6!!9B=V!NSCTZ<4 7M*\9I?3V45YI=WIXOU#6DLQ5DEXR!E2
M<''.#745P>FZ7KFH0^';&^TO^S[;2&CEDE>=7:5T3: H7.!DY.:[R@ HHHH
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M>V_NH?\ 9S_Y^R^\[OR?!W_3I_WVW^-)Y/@[UM/^^V_QKA*2CVW]U#_LY_\
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M ,^MS_WZ7_&C_A.-$_Y];G_OTO\ C7GIIM'UB92R;#>?WGH?_"<:)_SZW/\
MWZ7_ !H_X3G1/^?6Y_[]+_C7G9IM+ZS,?]C8;S^\]%_X3K1/^?6Y_P"_2_XT
MG_"=Z'_SZW7_ 'Y7_&O.3331]9F4LEPOG]YZ.?'NA?\ /K=?]^5_^*J)/'NA
MJ\F;6ZY;(_<KZ?[U>=&H_P")OK2^LU"ED>%\_O/3/^%@:#_SZ77_ 'Y3_P"*
MII^(6@?\^EW_ -^4_P#BJ\S-1FE]:J%K(L)Y_>>G_P#"P] '_+I=_P#?E/\
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M %%%% !67??\AS2_]Z7_ - -:E9=]_R'-+_WI?\ T T :E%%% "'H:\LO/\
MC^G_ .NC?S->J'I7GUSX>U62ZF=;1BK.Q!W+TS]:Y\0FTK'L934A"4N=I;;F
M(:0UK?\ "-ZO_P ^;?\ ?:_XTG_"-ZO_ ,^;?]]+_C7-R2['M_6:/\Z^]&32
M5K?\(UJ__/DW_?:_XTG_  C6L?\ /DW_ 'VO^-+DEV*6)H?SK[T9%)6O_P (
MSK'_ #Y-_P!]K_C2?\(SK'_/DW_?:_XT<DNP_K5#^=?>C'-)6P?#&L_\^3?]
M]K_C2?\ ",:S_P ^+?\ ?:_XTN278KZU0_G7WHQ?^6A_W:#6M_PC&L^:1]B;
M.W^^OK]:<?"^M?\ /BW_ 'VO^-')+L-8JA_.OO1C4TUM?\(MK7_/BW_?:_XT
MT^%M;_Y\6_[[7_&ER2[%+%4/YU]Z,:D-;/\ PBNM_P#/@W_?:_XTG_"*:W_S
MX-_WVO\ C1[.?8?UO#_SK[T8QIM;1\*:Y_SX-_WVO^-)_P (GKG_ #X-_P!]
MK_C2]G/L4L7A_P"=?>C%--K;_P"$3US_ )\&_P"^U_QI/^$2UW_GP;_OM?\
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M\*XLU&:7UBIW-%E&"_D_%_YG;'XEW(_YAD/_ ']/^%-/Q-NA_P PR'_OZ?\
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M+)#(H9'4Y!!J6O4/A&FG9A1110(**** "BBB@ J)/^/B3Z"I:B3_ (^)/H*
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M"LO9R.]8RCW.<-,:NE_X1J/_ )^G_P"^!33X8C/_ "]/_P!\"E[*1:QU#O\
M@SFCUIAZUT__  BT?_/V_P#WP*0^%8S_ ,O;_P#? I>REV*6/H=_P9RQIIKJ
M?^$3C_Y_'_[X%)_PB4?_ #^/_P!\"E[*?8M9AA_YOP9R1_UI_P!W^M(:ZG_A
M$HS<%?MC_=_N#UI__"'Q?\_K_P#?L4O8S[%+,</_ #?@SD#3378'P;$?^7V3
M_OV*;_PA<7_/])_W[%'L9]BUF6&_F_!G'&F'K79GP5%_S_2?]^Q2?\(1%_S_
M $G_ '[%+V,^Q2S/"_S?@SBC337:_P#"#1?\_P#)_P!^Q_C2?\(+%_S_ ,G_
M '['^-+V$^Q:S3"_S?@SASTIIKN?^$#A_P"@A)_W['^--_X0&'_H(2?]^A_C
M2]A4[%+-<)_-^#_R.%-1FN]/@"$_\Q&3_OT/\::?A["?^8C+_P!^A_C2^KU.
MQ:S?"?S?@_\ (X%NM1?Q-]?Z5Z$?AW"?^8E+_P!^A_C42?#R%GD']I2C#8_U
M0]/K2^KU.Q:SC!_S?@_\C@#49KT0_#> _P#,3E_[]#_&D/PU@/\ S%)?^_0_
MQI?5JG8T6=8+^?\ !_Y'G!IAKT@_#. _\Q27_OR/\::?AC ?^8K-_P!^1_C2
M^K5>Q:SO _S_ (/_ "/-3UJ,]*]-/PNMS_S%9O\ OR/\::?A9;G_ )BTW_?D
M?XTOJM7L6L]P/\_X/_(\P:F&O4#\*K<_\Q:;_OR/\::?A1;G_F+S?]^1_C2^
MJU>QHL^P'\_X/_(\L-,;I7JA^$MN?^8Q-_WX7_&D/PCMC_S&)O\ OPO^-3]4
MJ]BUQ!E_\_X/_(\H;K49[UZR?A#;'_F,S_\ ?A?\::?@_;'_ )C,_P#WX7_&
MCZI6[%KB'+_Y_P '_D>2FHVKUT_!VV/_ #&I_P#OPO\ C43?!VV\U4_MJ?D'
M_E@O^-3]3K=BUQ'EW\_X/_(\C:N[\!> 9->F34=11DTU#E5/!F/I]/>NJLO@
M_IT%Y%+<ZE-<Q(V6A,04/[$@UZ-%%'!$D42*D: *JJ,  =JWH8)\UZAY>;<3
M0=+V>">KW>UO2_4(HHX(DBB14C0!551@ >E/HHKTSX=N^K"BBB@ HHHH ***
M* "HD_X^)/H*EJ)/^/B3Z"@"6BBB@ HHHH **** "BBB@ JI?_Z@?6K=5+__
M % ^M %NBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** (K;_4
MCZG^9J6HK;_4CZG^9J6@ HHHH **** .;\5ZA>0RZ7IMG<&T;4;GR6N0 6C7
M!)VYXW'&!3?^$;N+6.X5?$>KO!)"<I+,&<,.0ROC*_3IS6SJFE66LV36E_ )
M8B0P&2"I'0@CD'W%4=.\+6&G7+W(DO+FY9#&)KJY>5E0]5&3P* //XY]5;PQ
MX;D34=8N9]2NF\U8KP+(P 8!59L #@'FO2="BGAT>!+A+Q)1G<MY,LLHY/WF
M7@UGR^#-,DTK3]/26\ACL&+P/#<%9%)S_$.>YK9L+,6%E';+//,$S^\N)#(Y
MY[L>M %FBBB@ HHHH *R[[_D.:7_ +TO_H!K4K+OO^0YI?\ O2_^@&@#4HHH
MH *YF^O+E+V95GD50W #=*Z:N2U'_C_G_P!ZLZNQVX&*<W?L,-_=_P#/S+_W
MU33J%Y_S]2_]]5":8:PNSU53AV1,=1O?^?J;_OJFG4;W_G[F_P"^J@---3=E
MJG#LB<ZE??\ /W-_WU3#J=]_S^3?]]U >E,-+F?<M4H?RK[BP=4O_P#G\F_[
M[IIU34/^?V?_ +[JL:8:7,^YHJ5/^5?<3G5-0\XG[;/G;_?]Z#JVH_\ /[/_
M -]U4/\ K3_N_P!:0TN9]RE2I_RK[BT=7U'_ )_KC_ONF'6-2_Y_KC_ONJII
MAI<S[FBHT_Y5]Q;.L:E_S_W'_?=,.LZG_P _]Q_WW54U&:7,^Y:HT_Y5]Q<.
MM:I_T$+G_OLTPZWJG_00N?\ OX:J&F&ES2[EJC2_E7W%PZYJO_01N?\ OX::
M=<U7_H(W/_?PU2-,-+FEW+5"E_*ON1=.NZM_T$KK_OX:8=>U?_H)77_?PU2-
M,-+FEW-%0I?RK[D73K^K_P#03NO^_AJ(:_JX9\:G=#)_YZ'TJFU1?Q-]:GGE
MW-%AZ7\B^Y&@?$.L_P#04N_^_AIA\1:U_P!!6[_[^FJ#5&:7/+N:+#T?Y%]R
M- ^(];_Z"MY_W]-,/B36_P#H+7G_ ']-9S4PU//+N:K#4?Y%]R- ^)=<_P"@
MO>?]_33#XFUW_H+WO_?TUG-49I<\NYHL-1_D7W(TCXGU[_H,7O\ W]-,/BC7
MO^@Q>_\ ?TUFM4;4N>7<T6%H?R+[D:1\4Z__ -!F^_[_ !IA\5>(/^@U??\
M?XUF&HVZ5//+N:+"T/Y%]R-0^*_$.?\ D-7W_?XTP^+/$/\ T&[_ /[_ !K*
M;K49[TN>7<T6%H?R+[D:Q\6^(O\ H-W_ /W^-1MXM\1;@?[;O\C_ *;&LHU&
MU3[2?=FBPF'_ .?:^Y&_9>.O$=C>Q7!U6YN%0Y,4TA96'H17N/AGQ-9>)M,6
MZM6VR#B6$GYHV_P]Z^:VK3\/:UJ&AZO#<Z<6,I(4Q#D2#^Z1WK>ABI4Y>]JC
MR\VR*CBZ5Z249K;HGY/_ #/INBJ]C-+<V,$T\#6\KH&>)CDH?2K%>TM3\TDG
M%M,****!!1110 4444 %1)_Q\2?05+42?\?$GT% $M%%% !1110 4444 %%%
M% !52_\ ]0/K5NJE_P#Z@?6@"W1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% $5M_J1]3_,U+45M_J1]3_,U+0 4444 %%%% !1110 4444
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M=7:^%]"L;E+FUTFTBF0Y5TB (^E:U;4,&J;YI:L\O-N(Y8NG[&@G&+W[OR]
MHHHKN/EPHHHH **** "BBB@ J)/^/B3Z"I:B3_CXD^@H EHHHH **** "BBB
M@ HHHH *J7_^H'UJW52__P!0/K0!;HHHH **** "BBB@ HHHH **,U!]MM=^
MS[3#O_N^8,T#2;V)Z***!!1110 4444 %%%% $5M_J1]3_,U+45M_J1]3_,U
M+0 4444 %%%% !1110 4444 %%%% !1110 5EWW_ "'-+_WI?_0#6I67??\
M(<TO_>E_] - &I1110 4444 %%%% !1110 4444 %%%% $0_X^C_ +G]:EJ(
M?\?1_P!S^M2T %%%% !1110 4444 %%%% !1110 5%%_K)O]_P#H*EJ*+_63
M?[_]!0!+1110 4444 %%%% !1110 4444 %%%% !4+_\?,?T-35"_P#Q\Q_0
MT 34444 %%%% !1110 4444 %%%% !42?\?$GT%2U$G_ !\2?04 2T444 %%
M%% !1110 4444 %5+_\ U ^M6ZJ7_P#J!]: +=%%% !117-?$#7Y/#/@75M5
M@D$=Q%"1 Q .)&(5>#UY- '2T5YK\%O&5_XO\*W3ZM=?:=0M;DH\A55)0@%>
M  /[P_"ND\>^*V\%^$[C6UM!=F%T7RC)LSN8#K@^M '351U745TRS,HB>>9B
M$A@3[TCGH!_CV )KD;CXDPCX5#QM:V0F 12UJ9<;7WA&7=CL<]N:LVWB][_X
M:+XSCTM6N$LY+E;7S<X"DY ;'HOI05!Q4DY*Z!_">JZ^QF\0ZO+&C<BRLFVQ
MH/0G^(U#+\*?#[QD1O>1MV82@_S%5/#GQ2BUWX<ZMXK?3Q VG>8&MA-NW%5#
M#YL<9SCI6G\.?&L_CKP]-J\VG+8QK.T**)O,W8 )/08ZXI61W+-,5'^'+E79
M:+^O4PYM+\5>!B;O3[QM4TQ.9(),DJOT[?4?E7>Z)K-KKVE0ZA:$^7(.5/5&
M'4'WKR+6OCXZ:K>6V@>&Y=2M+,GSKAG8 @'!;"J<+[FNA^$OB"R\0-K-UIEO
M);6<DB2?9W.?)D(.X CJ.A'M1L75Q$<71E*HDJD=;K2ZO;7SUW/3**QO%/B2
MS\)>';K6KY7>"W RD>-SDD  9[Y-6=#U5=;T.RU1+>6W2[A698I<;E5N1G'M
M3/,-"BN2\0?$#3]#U@:/#8:EJNI^7YKVVG0>8T2=BW( K1\,>*]-\66$EU8>
M<C0R&*>WN(RDL+C^%E[&@#<HKA;[XGV-KKNH:1;Z%KM_/8.$G:RM!(JDC(YW
M5TN@:V-?TTW@TZ_L/WA3R;Z'RY.,<XR>.: -"V_U(^I_F:EJ*V_U(^I_F:EH
M **** "BBB@ HS574;2"^T^>VN4WPNI#+N*Y_$$&O)8]/W^#/#2VT1EGOM1(
ME22XD42D>8 &8$D# '3TH ]DHKR[1[NX;_A%K::>=I[;4[BVGWR%AN52< Y^
M91D8)KU'M0 4444 %%%% !67??\ (<TO_>E_] -:E9=]_P AS2_]Z7_T T :
ME%%% !5234K6*1HWD(93@_*:MUR]_P#\?TW^]43DUL=&'I1J2:D;7]KV?_/0
M_P#?!H_M>S_YZ'_O@USE%9^T9U_4Z?F='_;%E_ST/_?!I/[8LO\ GHW_ 'P:
MYNDH]HQ_4J?=G2_VS9?\]&_[X-)_;-E_SU;_ +X-<T:0T>U8_J-/NSIO[:L?
M^>K?]\&C^VK'_GJW_?!KES2&E[60_J-+NSI!K-C]H+>:V-O]P^M2?VW8?\]6
M_P"^#7*?\M/PI31[60_J%+NSJO[<L/\ GJW_ 'P:/[<L/^>K?]\'_"N4-)1[
M60_J%+NSJ_[=T\?\M6_[X/\ A2?V]I__ #V;_OVW^%<FU,-+VTBEE]+N_P"O
MD=?_ ,)!IW_/9O\ OVW^%)_PD.F_\]F_[]M_A7'FF&CVTBEEM'N_Z^1V7_"1
M:;_SV;_OVW^%)_PD>F?\]V_[]M_A7%GH:8:7MI%++*/=_P!?([;_ (272_\
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MN)=7OO#/@RVR7U.]628#J(U./RY)_P" UW6A>*]*U+7=3\-V,4\<^CA$EWH
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MRO>OLC,8RH/EB0%CV!4J?^!"M+3-6L-9M?M6G745S"&*%XSD CM_+\ZX_2/
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M]MS_ //*/\S2?VY/_P \H_S-'M(C^JU>QNT5@_V[/_SQC_,TG]NS_P#/&/\
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MMO\ 4CZG^9J6@#EO%6DZKK>HZ9;V31V]M;N;J2XE02+YB\(NS()ZD_@*Y_\
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MHHHJC(**** "BBB@ HHHH *B3_CXD^@J6HD_X^)/H* ):*** "BBB@ HHHH
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M2?\ 'Q)]!4M1)_Q\2?04 2T444 %%%% !1110 4444 %5+__ % ^M6ZJ7_\
MJ!]: +=%%% !7,ZQX/CUCQ':ZR^H7$4EJ(?)B3[GR2;VW#/S;N![8S7344 <
MSX<\(_V#>RW4M^UTWE&WA7RA&(HS(TA'4[B2W7CH.*S+;X=&$(KZP\BQR0F(
M?9P"J1K*JJ>>3^^//^STYKN:* .1T[P0VG:W8WZZHSPVH!\@P ;G%N("V[/
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F-V(%/HH **** "BBB@ HHHH **** "H;F$S1[5(!SGFIJ* /_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>10
<FILENAME>anvs-20211231x10k006.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 anvs-20211231x10k006.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" $F X8# 2(  A$! Q$!_\0
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M%% !137D2-=SNJC.,L<4Z@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M6MO ]_;O+YK1:K.A?^]@(,_I71^)OAOX:\7ZG'J&L6DLMS'$(59+AT^4$G&
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MVT<+3/UD*J!N/UQ0!?HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@#$UGQAX=\/W,=MJVLV=G/(,
MK'+* V/4CL/<URGQ%^(<WAN;0K31[O2!-J<FYKB^<F*.'C#G:?ND]_:N2>_\
M.^%O&?B\>.]+:XN+^X,ME/+:&<3VY&%C0X.".!V_2LK2-$O+2V^&D.JV3)YF
MJ7+1P3IN:.!MI16S]2<'UH ]O\2:Q-H?A+4M7CCCEFM+1YPA)VL57./7%<9I
M/Q676?A=J?B:VMH1J6FQG[1:,QVJV>#Z[2.1]".U=+\0U)^''B%5&3_9TP
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M-)CH<'OQGMCC9^)^GW7BOQ$MEH-D]WJ6C6!.L7,4AC$R<'[/D?>8_,<>^.U
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M65<^$[F::UE$MNTF 9I&!!C?S%<M'QZ+L'3@#Z5UU% !36C1\;D5L>HS3J*
M(_(A_P">2?\ ?(H\B'_GDG_?(J2B@"/R(?\ GDG_ 'R*/(A_YY)_WR*DHH C
M\B'_ )Y)_P!\BCR(?^>2?]\BI** (_(A_P">2?\ ?(H\B'_GDG_?(J2B@"/R
M(?\ GDG_ 'R*/(A_YY)_WR*DHH C\B'_ )Y)_P!\BCR(?^>2?]\BI** (_(A
M_P">2?\ ?(H\B'_GDG_?(J3-&: (_(A_YY)_WR*/(A_YY)_WR*DS1F@"/R(?
M^>2?]\BCR(?^>2?]\BI** (_(A_YY)_WR*/(A_YY)_WR*DHH C\B'_GDG_?(
MH\B'_GDG_?(J2B@"/R(?^>2?]\BCR(?^>2?]\BI** (_(A_YY)_WR*/(A_YY
M)_WR*DHH C\B'_GDG_?(H\B'_GDG_?(J2B@"/R(?^>2?]\BCR(?^>2?]\BI*
M* (_(A_YY)_WR*/(A_YY)_WR*DHH C\B'_GDG_?(H\B'_GDG_?(J2B@"/R(?
M^>2?]\BCR(?^>2?]\BI** (_(A_YY)_WR*/(A_YY)_WR*DHH C\B'_GDG_?(
MH\B'_GDG_?(J2B@"/R(?^>2?]\BCR(?^>2?]\BI** (_(A_YY)_WR*/(A_YY
M)_WR*DHH C\B'_GDG_?(H\B'_GDG_?(J2B@"/R(?^>2?]\BCR(?^>2?]\BI*
M* (_(A_YY)_WR*/(A_YY)_WR*DHH C\B'_GDG_?(H\B'_GDG_?(J2B@"/R(?
M^>2?]\BCR(?^>2?]\BI** (_(A_YY)_WR*/(A_YY)_WR*DHH C\B'_GDG_?(
MIZJJC"@ >@%+10 4444 %%%% !1110 4444 8/B/6HM(-NJ+$+R<,D4TJ$I$
MO&YF(&<=/E'4X^HA2*U?P@^F:=<FXDN+2<1.1@RMSN/MEF_6NDHIW%8X/4&_
MMVVQIUO,WV;3)(YD,3*=Q:,B+!'+81N/\:T/*A\2ZQ<3VTDR6RVL:?: A4B9
M9?,7 8<E<<_7%=913Y@L>?2O?:4L5W:228E$WD/) 7:9MX8*0!\OFLSMVX5?
M2O0!D@9&#Z4M%)NX)6&NK-C:Y7\*;L?_ )ZG\A4E%(9'L?\ YZG\A1L?_GJ?
MR%244 1['_YZG\A1L?\ YZG\A4E% $>Q_P#GJ?R%&Q_^>I_(5)10!'L?_GJ?
MR%&Q_P#GJ?R%244 1['_ .>I_(4;'_YZG\A4E% $>Q_^>I_(4;'_ .>I_(5)
M10!'L?\ YZG\A1L?_GJ?R%244 1['_YZG\A1L?\ YZG\A4E% $>Q_P#GJ?R%
M&Q_^>I_(5)10!'L?_GJ?R%&Q_P#GJ?R%244 1['_ .>I_(4;'_YZG\A4E% $
M>Q_^>I_(4;'_ .>I_(5)10!'L?\ YZG\A1L?_GJ?R%244 1['_YZG\A1L?\
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MX?\ OW_]>O)^HXKM^)S>RJ'.?:[G_GXE_P"^S1]KN?\ GXE_[[-='_PB"_\
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M*_ZZG_T%JYJNE^'_ /R/6E?]=3_Z"U9UOX<O1DS^%GT4.E% Z45\V>:%%%%
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M17K'E$7VF/\ V_\ O@_X50UJXC;0M0 W<VTG\!_NGVK4JAKG_(!U'_KVD_\
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M\!_!.[#_  !1117:;!72> 5W>.=*!)_UIZ''\+5S==+\/_\ D>M*_P"NI_\
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M .O4E% $>R7_ )Z#_OG_ .O1LE_YZ#_OG_Z]244 1A9.[C_OFBI** "BBB@
MJ&XNK>T0/<3QPJ3@&1@H)_&GS.8H7D6-I"JDA$QEO89XKCM2,FH^(8C<^7I\
M9L&*"^B23!#_ #X&[;TVYYSB@#L\C&<C'K4,-Y;7$32PW$4D:$AF1P0,=<FN
M:EF:7X<9BC\DFR!,:,3B/H2,\XVYQ[51U@60N[H60A%A]FMOM?DX";?/'7''
MW-WX>U '8KJ%FUH;I;J$VXZRB0;1^/2IA-$2@$BDN,H,_>'J/6N2DTZ/4-5U
M./3C;K%$]K-M*YA:5=^0P'^SLS]!5"QU"31I+3:D<\:0+'&SL5+1>8$S&/5F
M.[']T(* ._HHICF08V*K>N6Q_2@!]%1;I_\ GFG_ 'W_ /6HW3_\\T_[[_\
MK4 2T5%NG_YYI_WW_P#6HW3_ //-/^^__K4 2T5%NG_YYI_WW_\ 6HW3_P#/
M-/\ OO\ ^M0!+146Z?\ YYI_WW_]:C=/_P \T_[[_P#K4 2T5%NG_P">:?\
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M?PF:]%%%>L>4%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M?]]5)@>E&!Z4 1_:8?\ GJG_ 'U1]IA_YZI_WU4F!Z48'I0!']IA_P">J?\
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M'_8>O$Z]O^+X \(V_P#U^I_Z ]>(5[> _@G=A_@"BBBNTV"ND\ L%\<Z46(
M\T\G_=:N;KI?A_\ \CUI7_74_P#H+5G6_AR]&3/X6?0HN8<?ZU/^^J/M,/\
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M?4>E#^'M0U&)TU.YMP8[-K6!H QY)4F1@>ARB\<]^:O66F7<FH3WVJ_9GD>
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M+O;[HV8SSVJS;:I:79MQ;R^9Y\1F3:#]S@9/IR<<^] %RBBB@ HHHH ****
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M"+RG_P">\GZ?X4>4_P#SWD_3_"I:* (O*?\ Y[R?I_A1Y3_\]Y/T_P *EHH
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MD;R>#[JR0&.YO(KN2VA88;8S,5X[<,OYUU=%5<5C@M1=-;ML:9$[BVTN2.9
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M#E27#HKDY&=JG&?7UJ/3M9DLI;5=1:XF,$(B9T.Y5.\(TC'/S?-A >?NL>]
M':444QW9<;8V;Z$4 /HJ+S7_ .>#_F/\:/-?_G@_YC_&@"6BHO-?_G@_YC_&
MCS7_ .>#_F/\: ):*B\U_P#G@_YC_&CS7_YX/^8_QH EHJ+S7_YX/^8_QH\U
M_P#G@_YC_&@"6BHO-?\ YX/^8_QH\U_^>#_F/\: ):*B\U_^>#_F/\:/-?\
MYX/^8_QH EHJ+S7_ .>#_F/\:/-?_G@_YC_&@"6BHO-?_G@_YC_&CS7_ .>#
M_F/\: ):*B\U_P#G@_YC_&CS7_YX/^8_QH EHJ+S7_YX/^8_QH\U_P#G@_YC
M_&@"6BHO-?\ YX/^8_QH\U_^>#_F/\: ):*B\U_^>#_F/\:/-?\ YX/^8_QH
M EHJ+S7_ .>#_F/\:/-?_G@_YC_&@"6BHO-?_G@_YC_&CS7_ .>#_F/\: ):
M*B\U_P#G@_YC_&CS7_YX/^8_QH EHJ+S7_YX/^8_QH\U_P#G@_YC_&@"6BHO
M-?\ YX/^8_QH\U_^>#_F/\: ):*B\U_^>#_F/\:/-?\ YX/^8_QH EHJ+S7_
M .>#_F/\:/-?_G@_YC_&@"6BHO-?_G@_YC_&CS7_ .>#_F/\: ):*B\U_P#G
M@_YC_&CS7_YX/^8_QH EHJ+S7_YX/^8_QH\U_P#G@_YC_&@"6BHO-?\ YX/^
M8_QH\U_^>#_F/\: ):*B\U_^>#_F/\:/-?\ YX/^8_QH EHJ+S7_ .>#_F/\
M:/-?_G@_YC_&@"6BHO-?_G@_YC_&CS7_ .>#_F/\: ):*B\U_P#G@_YC_&CS
M7_YX/^8_QH EHJ+S7_YX/^8_QH\U_P#G@_YC_&@"6BHO-?\ YX/^8_QJ1267
M)4J?0T +1110 4444 %%%% !116+=7R:OI%U_9E^8C&"'E1,L!@D@9Z'WYH
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MJV+%-\9Z,.H/H:T* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MC7I->6W7PDO9=+N='@\2M%I+WWVZ&V-H"58L&*LV[D=<=.?RKU*@"GJ5V]G
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M'!ZD%P,>U>E2P13A1+$D@5@P#J#@CH>>]24 <KX)T.]T1_$?VR)(UO=:N+N
M*P.8GV[3QTZ'BNJHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
L@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH __]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>11
<FILENAME>anvs-20211231x10k007.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 anvs-20211231x10k007.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" $T VL# 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#W^BBB@ HH
MHH **** "BBB@ HK(\37>L66ASSZ%:6US?KC8ES)LC [DGJ>.U97PZ\4W?C#
MP9;:S?0P0SRO(K)""% 5L#J2: .LHKRBT^*ESK'Q>MO#FF1PMHN9(GN"A+2R
M(I+;&SC .!T/ZBO5^U !17EMW\69+;XJQ^&Q:0G1Q,EI+>$-N6=E) SG;C.!
MCV-:_P 0?%NN^'K_ $*PT&TL;BZU2=H0+LL%! &.01CK0!W=%>=^'/'VM#Q7
M'X8\8:+%INH7$9DM)K>7?#/CJ!R<'\?RXKI/&VNW'AKP?J.L6D<4D]K%O1)<
M[2<CK@@T =!17EWACXB>))O$ND:3XFTBQ@36;8W%E/92D\;=WS*2<<?2NLN_
MB!X2L=3DTZZ\06,5W%G?&TGW<=03TS[=: .EHKS7Q?\ %*RT>Z\-MINH6,EI
MJ-P#/(ZL<6^2"XQC'((_I6SX8\1W^HZ[XB2_OM*?3[)T,'V9SOC0J3F3/ XY
M_.@#L:*YW2O'GA;6]1.GZ;KMG<W?.(D?EL?W<_>_#-,U'X@^$](NKBUO]=L[
M>XMF"2Q.QW*2,@8QD\>E '2T5YWX^^)5MX=TK1KO2[^QE&H7"X9\NK0?Q,,'
MMQ70W'CWPK:7=K:W&NV4<UTBR0JSXW*WW3GH,^^* .CHH!!&0:\_\5^.M6A\
M2Q^%O"6F17^LF/S9Y+ABL-NG8MCJ?Q].N: /0**X'P_K7Q M]<BT[Q/H%G-;
M3(S"_P!-<[(R!G#!C_A^-8FA>/O&GB/Q)<G3-(TN;2+:]-I-;F<I<Q*#CS&R
M>!^'M0!ZS17E^M^./%__  GE_P"'?#]CHLJ6L*3%[Z1HR0??< >M5?$?Q#\1
MZ=<WD5O)H5K-IT,!EM;LNSW<D@Y\G##Y0>!UR: /6J*\UTW7/'.I^,8='EGT
M6*WMD6?4)+*&1S&#]V,F0X#'T X'->E4 %%>8W_CGQ3X@\07VD>!=+LI8M/;
MR[G4+]R(]_\ =4#K^M7-/\3^,[?2M:3Q#H,%K=6%LTT-[ ^ZWF..  3G/^>*
M /0J*X'P=\3=%U?2-)BU36=/CUN[CR]NC;?F)( [@'IP371ZYXO\/>&Y(H]8
MU:ULY)?N)(WS$>N!SCWH VZ*P(?&WAJXL;R]AUFTEM;+'VB5'W+'GIDC^E,T
M[QYX5U;4TTVPUVRN+QQE8D?);C/!Z$^W6@#HJ*P-6\;^&="U!+#5-:L[6Z<
MB.1^0#Z^GXU9L?$VB:EIL^HV>IVTME;LRRSA\(A'7)- &M16!HOC;PUXBNGM
M=)UFTN[A!DQH_P V/4 ]1]*WZ "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBD) ZF@!:**:DB2%@CJQ4X.#G% #
MJ*0D#J:7(H **,@T4 %%("#T-+0 44A(4$D@ =S33-$'1#(@9QE1N&6^GK0
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M4:W8L7^SW"7;86( X)4<$D>OK6UIOP]\4)HOC&+5+JQGO];^:.2)B$W=\C'
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M%% !1110 4444 %%%% !0>E%!Z4 >2Z;XSN]'\1_$6\U">ZO++2GA:&V\SA
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M_"C-Q_<B_P"^S_A0!*JJB!$4*JC  Z 4M0YN/[D7_?9_PHS<?W(O^^S_ (4
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M7/\ G['_ '[7_"D_X3'7/^?L?]^U_P *[OJ-7NCE^NT_,]4HKRO_ (3'7/\
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M.D*A!)%L!WE3D'/;GK0!T-,DF2,@,2,^Q-/HH A^U0_WC_WR?\*/M4/]X_\
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M:Z.N<\!?\B3I?_7,_P#H1KHZ].'PHZX[(****H84444 %%%% !1110 4444
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M;_OH?XTJR2%@#"P'KN%2T4 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M\\)?R'^-344 0^>?^>$OY#_&CSS_ ,\)?R'^-344 0^>?^>$OY#_ !H\\_\
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MB';<?WXO^^#_ (T;;C^_%_WP?\:FHJAD.VX_OQ?]\'_&C;<?WXO^^#_C4U%
M$.VX_OQ?]\'_ !I5$VX;GC([X4_XU+10 4444 %%%1+<PO<26ZRH9HU#.@/*
M@YP2.V<&@"6BL^RUW2]1N3;V=[#-* 251L\#K4E]JMAIOE_;;R&W\PX7S' S
M0!<HJE>:OIU@T2W=[!"9?N"1P-WO]/>GOJ5E'?1V3W42W4B[DB+C<P]A^!_*
M@"U14<4\4^_RI%?8Q1MISAAU%24 %%%% !1110 4444 %%%% !1110 4444
M%9/B7_D7;W_KF:UJ9+#'/$T4T:R1L,,K#(-5!\LDR9KFBT>(]Z*]A_L+2?\
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M5[34K;R%GPVQR\4NV)#GYPZYYXP!P:[6B@ ICQ+(06W<>C$?RI]% $/V:/\
MV_\ OXW^-'V:/_;_ ._C?XU-10!#]FC_ -O_ +^-_C1]FC_V_P#OXW^-344
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M:FHH A^S1_[?_?QO\:/LT?\ M_\ ?QO\:FHH A^S1_[?_?QO\:/LT?\ M_\
M?QO\:FHH A^S1_[?_?QO\:/LT?\ M_\ ?QO\:FHH A^S1_[?_?QO\:/LT?\
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M-'ZO_P!_&_QH^S1^K_\ ?QO\:FHH A^S1^K_ /?QO\:/LT?J_P#W\;_&IJ*
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M-14/VJ#_ )ZK^='VJ#_GJOYT 345#]J@_P">J_G1]J@_YZK^= $U%0_:H/\
MGJOYT?:H/^>J_G0!-14/VJ#_ )ZK^='VJ#_GJOYT 345#]J@_P">J_G1]J@_
MYZK^= $U%0_:H/\ GJOYT?:H/^>J_G0!-14/VJ#_ )ZK^='VJ#_GJOYT 345
M#]J@_P">J_G1]J@_YZK^= $U%0_:H/\ GJOYT?:H/^>J_G0!-14/VJ#_ )ZK
M^='VJ#_GJOYT 345#]J@_P">J_G1]J@_YZK^= $U%0_:H/\ GJOYT?:H/^>J
M_G0!-14/VJ#_ )ZK^='VJ#_GJOYT 345#]J@_P">J_G1]J@_YZK^= $U%0_:
MH/\ GJOYT?:H/^>J_G0!-14/VJ#_ )ZK^='VJ#_GJOYT 345#]J@_P">J_G1
M]J@_YZK^= $U%0_:H/\ GJOYT?:H/^>J_G0!-14/VJ#_ )ZK^='VJ#_GJOYT
M 344Q)HY"0CAL>E/H **** "BBB@ HHHH ***K7NH6FFPB:\N$AC)QN<X&:
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M ,=_QH\Y_P#GA+_X[_C0!-14/G/_ ,\)?_'?\:/.?_GA+_X[_C0!-14/G/\
M\\)?_'?\:/.?_GA+_P"._P"- $U%0^<__/"7_P =_P :/.?_ )X2_P#CO^-
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M[:QM9+F[GC@@C&YY)&"JH]230!-17*Z9\2?!VL:@+"PU^TEN2<*A)3<?12P
M;\*LZCXZ\,:3K,>D7^M6L%_)@"%B>,],G&!^)% '0T4 @C(.0:* "BBB@ HH
MHH **** "BBB@#%D\-P/J$UZE]J$,LQ!<13X!QT&,=/:G2^&[":[:=C<;78/
M)")B(Y&'1F7N:V** *%UI,%Y#)%.\S*[AU(D(,9'0H1TJ >';$61M\SEC)YO
MGF4^;O\ [V[KFM:B@"A;Z3;6UA)9QF7;+DR.TA+N3U)8\YJ&3P[I\MW!<&-U
M,(4!%<A6V_=W#OBM6FR/Y<;/C.T$T .HKCV\?6RN5^PS<''WQ6QJWB73=#T1
M=5U*4PV[;0H"EV9FZ* .236<*L*FD63&<9;&Q17EWC/QCJUSX47Q%X1U>.VM
MH)/*N(;JQ/F%RV,8<<8K.\3^)O%F@1^'K*Y\4Z;9SWD;R7%]-:*(O51C''IQ
M6A1[%17BEW\2/$4OPZL-42]L[*ZDU'[(]]Y.870$CS &' J]=^--9TOX;:KJ
MD?BC3-<U!9TAMY[*!=L;-_"5Z$]: /7:*\<\3?%6_M/ASH6K:8R?VG?,/.'E
M!MH3_6?+VY_*NDU_6/%^I/IUOX96"SMY;/[5<:G=0[XE..$';- '?T5RWP^\
M0WWB;PE;ZCJ,,<=R7>-VB&$DVG&Y?8XK>U._73-/ENW0NL8R5!P3S32;=D)M
M)79;HKD[3QS;W=W%;K92J9&"@EQQFHO&OBC4]+NM.T7P_:PSZSJ3$1&X)$4*
M#J[8Z_2JG3E3TDB85(SUBSL:*X+1QX_T[6X(M8U70M2L),^<44P2PGMM'\7X
MUS>N^,M=3XC:EI$?B[2M&LK8Q>7'>6ZL9=P&0IQG_P#74%GL-%>9_$OQMK/A
M]]-L?#P2>^,9O+H;%;_1TQN//3/-3^//&5Y9> M,UO1+^&T-[<0K]HEC#HB.
M#DD'/ _I0!Z+17G_ ,,_%FI^(FU:TU"\LM26QE5(]0LXRD<P(STZ9'M7>RR"
M*%Y",A5+8^E)M)78)7T'T5A#Q+$3C[/)_P!]"J7CS4-:TCP[_;&BN";)UFN;
M<QAO.A_C )Z$#G(KEPV.P^*O[&5[;[FM2C.G\:L=517FFC^--6\2VWB/7].E
M$6AV=JZV(>$9EE5"6<DC. >,=*I^!/&GB/QU<Z=]DF6&PL85.J7;0+FXG(YC
M0'@ =R*ZS(]7HKCO!&OZCK6H^)H;Z99$L=4>VMPJ!=L8 P#CK]:YJ\^(VI7G
MQ3TO1])"C0C</:SW!0,)Y50LP5CT"\=* /5J*\9F\?>,&M+CQC#)IX\-V]]]
MF-B8CYK1!]A??_>SVZ5['%()8DD'1E##\: 'T5RWBOQM;^%;BWBFLY9S,I8%
M' Q@X[T>%/&UOXJN+B*&SE@,*AB7<'.<^GTJ.>/-RWU%S*]CJ:*X[7_B?X4\
M-ZFVG7^H,;J/_6I!"TOE#_:*C ^G6K>J^/\ PSH^BVNK7.J1FUNQFV,2EVF_
MW5 S_A5C.FHKCXOB?X4G\.W.N1:@S6EJZQW"^4PDB+' W(>1]:I+\9?!#I<L
MNK-F#&%\A]TN>GEC&6_"@#O:*Y-_B1X83PO;^(S?L=,GG%N)1$V4<YX9>HQ@
MU5L/B7X=\1P:C;:-J+?;H+:25$EA:-F 4_,NX<CI0!VU%><:%\1=/TCX>Z)J
M7B?4V>]O8R5"Q[Y92"<D*H[>O2MN/XD>&)_"]WX@AOFDLK-E6X"Q-YD3$@ %
M",]30!UE%<$GQD\#O]IQJYS H8 P.#-DX_=C'S<^GUZ5IP_$;PO-X5/B3^TU
M33@YB+.C!_,_N;,9+>WX]* .JHKD]$^(_AG7X+Q[&]?S+.%IYH)86CD$8&2P
M4CD?2J>E_%KP?K.HV]A9ZC(9[A28P\#J"P&2F2,;L=OZT =Q17FGPM\<OXJU
M#Q%;SWEQ<&&_>2U$L.P);G 1>!USG@\U:UWQ)XEU?Q=<^%_"(L[9K&-)+_4;
MM2XB+C*HBCJ<>OZ4 >@T5QFBMX_L%U"#64TK4Q';E[.Y@8PM++V1U(P![]O?
MMSW@CQ?XHO?'=SH&K7NG:@(K=I+P6D)C^PRAL>7N.-_ID9^M 'JE%%% !111
M0 5QGQ!_X]K+_?;^0KLZCEMX9P!-$D@'3>H./SK*M3]I!Q)G'FC8\[\"?\AY
M_P#K@W\Q67XHUS7M'^(@N+W6KJWT 7%O#$UB(I8XBP^9+B,_,"W.&[#H#V]6
MBM+>%MT4$2-C&50 _I6+=>"/#-[KR:Y<:+:2:DK!A.R<EAT)'0D<<D9X%*A2
M]E#E;%3AR1L<MI%M OQN\0@01 )IENRX0<'=U'O7E_A2SO-1U[0-,U2>WMM&
MFU6XNK26.W!EDGBD)\II.JYSQ7T5%HNG0ZS<:O':JM_<1+%+-DY9%Z#KBL\^
M"O#IT^&P_LN+[-!<_:XE#,"DV<[P<Y!S[UL6>5V4.N2?$3Q<=*U/0+2(:A'Y
MBZG'N=OD'W*I:]>3V'Q.U?QTKO\ 9-&U&VL)E7D&%HRLA^H)'YUZK?\ PU\'
MZGJDNIWNAP37DK^8\K.^6;UP&QVK1;PEH3V&HV+Z;$UMJ4QGNXR6(E<XRQYS
MV'3% 'C_ ,/X;B/Q];:K?22HWBVQNYBF<% ),J ?]P _C6I8Z9X=U+Q3HFB>
M'OLT.E^'+OSI[YY%\R>?DB)#U?D_,>G 'I7IMUX4T.\%B)]/C;[!"T%KAF7R
MD9=C*,'H5XK'L_A9X)T^]@O+70+>.X@<21N'D)5@<@\MZT =C7%_$'_CWLO]
M]OY5VE1RV\,X FBCD Z;U!Q^=:4:GLYJ1G5A[2#B>=^ _P#D.2?]<6_F*HZK
M)I</QM5_% A\DZ<HTEKO'DB3=\^,\;_K[>U>H16EO VZ*"*-L8RJ ']*IZUX
M?TGQ%:?9=7T^WO(0<A9DSM/J#U!^E57J^UGS6)H4O9PY3S7P]XHGG^)RZ</"
M6BV]S-"_FWUE=)*ZPKR"VP<9.."<\BJGPWT_Q'+K&JWEI<:2FCQZY<^>DUN6
MN#AN=KXXXQCFO3]"\+:'X9A>+1M,M[-9/OF-?F;ZL>3^=3Z?H6F:5;75O8VB
MP174KS3*K'YW?[S=>]8FQ\[>*_$-KK/BC7-=6'47O[&>*/2)H+=GB18FRY+
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MP^\*ZEJXU:\T>*:^!4^<[OG*]/XL=JV-2T;3]82!+^V6=8)5FC#,1M<=#P:
M/$YI]%;2?B0=6-L-1DEW1K/@2X*9CV@\^G3OBO7_  ?Y_P#PANC?:,^=]BBW
M;NOW14>I^"/#.LZK'J>HZ+:7-['C$KIR<=,]F_'-;P 4    = * .8^(7_(E
M7_\ NC^8KQ7PQ_R-&F=/^/E/YU]'RPQ3QF.:-)$/574$'\#59-*TZ-U=+"U5
MU.0RPJ"#^58U*7-)2N9RA=W.%^(&O:I%XBT7P[9:Q'H5OJ =Y=2= 2-O1%W<
M FLZ37=7\*^$?$$\7BZT\236>WRB44R6V[J9-I.0.M>BZUH&D^(K+['J]A!>
M09R%E7.#Z@]0?I4.D>%-!T*PEL=,TJUM[:7B5%3/F?[Q.2?QK8T/+H];UWP]
M?:%=+XXC\0C5IDCFL=D? 89W1[3E<?A60^K>.(O"=SXJB\62E;75'MXK-X%9
M67S-OS'J>O2O7M*\!^%M#OGO=-T.SMKEL_O$3D9Z[<_=_#%3GPAH)T:32#IL
M?V"2;SVAW-@R9W;LYSU% '"Z5=^)]$\<2:5J7B&35(;S3'NQOA">3(!G"8Z"
MN.LO$?B-/ Z>*3\0TDN[9R!I<B1GS,-C8W.XL?I7N-WH%A<7;:@MLG]H+;-;
MQS$GY5(QCTQ^%<EX0^%FC:3I6GMK.DZ=<ZO:[B;A%+ G<2#R!DCW% '&:AXI
MU'1-0\7Z[90A;V2SLR%*Y$1<#)P?3/>I/"GB#QE%XCTQ&O=2U.UNS_I<=[]E
M 53_ !Q^7(6X],5Z\/#VD_;+VZ-A"TU\@CN2XW"51T!!X_2J&C^ _"V@WS7N
MEZ'9VUR<_O53++G^[G.W\,4 >1OJOC8^&M7\2P>+)E33]5DAALWA5E=0^,,W
M4CI@5NQ:QXK\+^*DCO\ 6WUF.^TJ6^^SM"$6-U7(5 .@YKT8>$-!&DW.EC38
MQ97,QGFAW-AY"<ENN>M6FT'3'U.VU%K-#=VL1AAD).40\$8SB@#P?2O&/CBZ
M2SUFWU+4+JXN91FS=;46K*3RJCS-X./;-;VJ7?B_5O$7BO[%XENM+M],@CG2
MV6-7^;:#MR>@ZYQUKT6+X>>$8=7_ +4C\/V*WF[?YGE\!O4+T!]\5I#PYI N
M=0N!9)YNHKMNFR?WHQC!Y_E0!XY:C5?$'Q#\$ZI/K-Q%-=Z<TS+&@VKM^\![
M-WKK?B[Y0M] .I;CH0U%/[0QG;LQQN]LUV-MX5T2SN;"Y@T^-)M/B,-JP9OW
M2'J!S_.M.ZM;>]MI+:Z@CG@D&UXY%#*P]"#0!R5[/\.VBTY;I]!9#(GV,#RS
M\W\.W;_^JN ^(3:#?6E_J.B7^G1_9+H'5K"6+RI[MU(P [#=],<&O3-+^'GA
M+1M0^WZ?H%E#<@Y60(6*G_9R2!^%2WG@;POJ&LKJ]WHEG-?J0?.9.21T)'0G
MW(H UM+G6YTFSG2(PK)"CB,]4! XJW0  , 8%% !1110 4444 %%%% !1110
M 4444 %%%% !3)4,D3H.K*13Z* //G\!7[2,WVJVY.?XO\*U?&&BW.H^#QIT
M.DVVK2*4W02W!@SCNC]F'8UUE%8TJ$*;;B1&G&.QY,OA'Q=<?"V\T>^#3WLE
MRKVUO-=+*\408':TIP&(K1\8^!;GQ3JVA1SVB26$-I)%<.SK^Z8KA2!G)P?2
MO2**V+/'M5\*^+KSX?:3I,VBV]Y>Z7?*1&\\8CN(5Z$Y.!D=0:M2^'/$&M:?
MI=I-X0T[0XH]42XN(K.>(J409#';C)SQCFO5Z* /'+3X7:HGB/Q&\ZJ=+:WG
M32H]ZD!I<D\=N<<FC6=,^(LWA#1O#UGH:M!';HFHNM_'&TV.L8;.0#W(KV.B
M@#!\'KJ,7AV"#4M%@TB2']VEI!,)55!T^85?UJQDU+29[2)E5Y  "W0<U?HI
MQ;B[H4DFK,X2P\#WUI?P7#7-N5C<,0-V3C\*L>-_#&JZG=:;KGAZXABUG3&)
MC2X_U<R-U1L=*[.BM*M:51WD13I1IJT3Q:/X<ZQXI\9VVMZ[X=T[1O)G$]Q+
M#>//)<L.@ W%5&1Z9KK-/\%K+\0_$&K:MI%G<6=PL/V.2=(Y2"HYP#DKV]*[
MVBLC0\HNOA[XC\1>+-8UFYUFXT-)/]%MH[8))YEN!CGGC/I5(^!/$W_"$6OA
MJXM4O([#68Y(I))(\36H;))!/'7&TU[)10!6LK&TTZV6WL[6"VA7I'#&$4?@
M.*EGC,MO)&" 64@$U)12E%233ZC3L[G,CPU<@@^=%^O^%;M[ TVFW$"J&9X6
M0 ]"2I%6:*XL%EU#!W]BK7\S6MB)U;<_0X3PUX:U/3?A1+H5Q;+'J#6T\8B#
MJ1N;=CD''<5S_A/P3X@\%76BWVFV2M'=6Z0:U8B= %<#B923@GUQUKUNBNXQ
M/*M'T;QEIGB'Q#8KHL0TG6+V:4ZB+Q!)"KK@,$!R2.#68OPDU[2-=\,_V?XA
MO;K3[&Y>63<J1_9@1D[1NRV_D'ZU[110!XM-X%\9K87/@V&UL&\.W%_]H.H&
M?#K$7WE-G7=G\*]FBC$4*1CHJA1^%/HH XCQUX+O?%-U:RVMS;Q"%"I$N[G)
MSV%)X%\%7OA:ZNY;JYMY1,BJHBW<8)ZY ]:[BBL_9QYN;J3RJ]SRK^PO&OA/
M6-<'A_2-,UBRU>Y:Y$MS.(WB+#E7!^\H]!_6K>M^&?%*WGA[Q'I]II-SJVG6
M[03Z>"8X6#=XF/W2/>O2J*T*/%M6\!^+/$%AX@U6_P!/LH-2U0VT::?;S JJ
M1N"2[G@MC_/-=E+X8NS\4]*UM+*(6%MI36[2@J"LF[@ =>G<5V]% 'A'B3P]
MJN@_#];2>V@BN)_%*36Z2,'C*LQV;@N>/4>E=$OASQAXE\2P:OKNFZ?IB:;9
MSPV\=M.)&N7D0KR>R\\ ]*]+OM.LM3BCCOK2&Y2.19465 P5UZ,,]QZU:Z4
M>&W/PR\2Q:3X:O[:%GU#3K-K6>RBU VS\NS!DE4X[\BK+_#C7)? /B-3IS)K
MFJF)?)DU0W)=4D##>[X&X#/<U[310!PMQX6NW^(OAS5DL8OL-AISP2294>6_
M\( Z^O3UKCK[X8:]>Z)J"QQI!=0^()M1M8?M.P31, !AT^XW''I7M=% 'C_A
M_P !ZY+<:EJ>KZ=<6][]@FMK03ZT]V[%T(P<_*%Y]>#5NV\#ZQ#X;\ 6GV"-
M;C2+U9KP"1/W:\[CG/S<XZ9KU6B@#C/ .@:EH=QXF?48!$M]K$UU;XD#;XV
MP>#QTZ'FL_7/#_BC1/&-WXG\)1VEZ-0C1+[3KF3R][(,*Z/T!QQS^O;T.B@#
MA+)?B-JMCJKWS:9HDLD&VPAA_?O%*#G<['*D'IC!_#'.1H?ASQ;JOCK2M?\
M$6EZ;I;:9#)')+:2AI+]F7;EMO1>^#_^KU*B@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
4@ HHHH **** "BBB@ HHHH __]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>12
<FILENAME>anvs-20211231x10k008.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 anvs-20211231x10k008.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" %) VX# 2(  A$! Q$!_\0
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M?INF67'RX?TS_P#JKCOAQ=:SJ?BN8ZGXOU"+5K:5Q?:-=H"CI_"8@3P/<<T
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ML4 %%%% !1110 4444 %%13W,%ML\^>.+>VU=[A=Q]!GJ:EH **** "BBB@
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M18O#WAVQTB!B\=K"(PQ&-Q[G\3FM2J6JZO8:)I\E_J5RMO:QXWR,"0,G Z4
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M<ZKIFFZ-8B!EAM7D\^1I.S%E/2N5C\/^./$/C31;W6M"L=.FTN8M-JUO.O\
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MPH\,:]8WRPZ;:6FH763]M$19E<\EL9&30!O>#IHI_!>C/#(DB?8HAN1@1D*
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M'??;?L_]EW7VC9Y>[S.,8SD8_6K?BOPQ:>+= FTJZ=X@Y#QRQ_>C<'(8?0T
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MB\GRL>7L7&<YYS]!0!QR_%+6;WP/H5Q86%J=?U>Z>SC5R?)1D.&<\YQT./\
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M/1O$,0:?3KEF*;<=06Z8/IFN4N=7U/Q3\.K3Q6RHVL>';TEIH.5G13AROU%
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MX1\/Z#<R76EZ/9VEQ*,/)#$%)]L]A["I)/"V@RPW<,FDV;17DGFW"&(8E?\
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M4C6_F-(V=V" /E\Q\GH.%7&*[R,L8U+C:Q R/0TZB@!CJ[ ;'"GW&:9Y<_\
MSV7_ +X_^O4U% $/ES_\]E_[X_\ KT>7/_SV7_OC_P"O4U% $/ES_P#/9?\
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M26[1Z%! \9OXKF0SJI&]?O\ F%NX'U]JT+ZYLD\0B>\F@%N]BZPO(PV$[AN
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MZX?^S&N$KNI4H2@FT:QBFCO_ /A:-W_T#(?^_I_PH_X6C=_] R'_ +^G_"N
MHK3V%/L/E1W_ /PM&[_Z!D/_ ']/^%'_  M&[_Z!D/\ W]/^%<!11["GV#E1
MW_\ PM&[_P"@9#_W]/\ A1_PM&[_ .@9#_W]/^%<!11["GV#E1W_ /PM&[_Z
M!D/_ ']/^%3V7Q)NKR_MK;^SH5\Z58]WF$XR0,]*\YJ]HO\ R'M._P"OF/\
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MI?\ OJC[/_TVE_[ZJ:B@"'[/_P!-I?\ OJC[/_TVE_[ZJ:B@"'[/_P!-I?\
MOJI0, #)..YI:* "BBB@ HHHH **** "BBB@ JG=M?K-%]F2V:#_ );&5F#
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MGO0!T%%9%AK9OG@B%L5F9I!,N_(BV,5)SCG+<#I^E:] !1110 4444 %%%%
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M5H!%>0PVIM[-[>-A+O$DC;?FX'"_+WYY]JNV]A=:E?S76K64,49MOLPMS()
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MDG_?(J2B@"/R(?\ GDG_ 'R*/(A_YY)_WR*DHH C\B'_ )Y)_P!\BG@   #
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M@":BH?M4/]_]#1]JA_O_ *&@":BH?M4/]_\ 0T?:H?[_ .AH FH/2H?M4/\
M?_0T?:H<??\ T- '#3?Z^3_>-,I\QS,Y_P!HTROR*I\3/J8[!1114C"BBB@
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MZ4 =;15#2;\7UJ7>:%I@?GCB8$Q9Z*W/7'6K] !149N(0<&6,$?[0I/M$/\
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M7,2+]JG23,GFR+MS*)/O@Y'&< <<C K:1%C144851@#T%.HH **** "BBB@
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M(T+5(KZ!HS<F:Z3YI04*@9)^[D#*@@C(]*UZ "BHC<Q D%CD>QI/M4/]X_\
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MIR=X"<I.?-==K?J<N*Q2KI*UK!1117N'&%%%% !1110 4444 %%%% !1110
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MY)_W\_\ K4 2T5%NG_YY)_W\_P#K4;I_^>2?]_/_ *U $M%1;I_^>2?]_/\
MZU&Z?_GDG_?S_P"M0!+146Z?_GDG_?S_ .M1NG_YY)_W\_\ K4 2T5%NG_YY
M)_W\_P#K4;I_^>2?]_/_ *U $M%1;I_^>2?]_/\ ZU&Z?_GDG_?S_P"M0!+1
M46Z?_GDG_?S_ .M1NG_YY)_W\_\ K4 2T5%NG_YY)_W\_P#K4;I_^>2?]_/_
M *U $M%1;I_^>2?]_/\ ZU&Z?_GDG_?S_P"M0!+146Z?_GDG_?S_ .M1NG_Y
MY)_W\_\ K4 2T5%NG_YY)_W\_P#K4;I_^>2?]_/_ *U $M%1;I_^>2?]_/\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MNCCYZ*:]8KF/$_@+0O%]S;W&K13O+;J4C:*X:/ /7[IKH;2UBLK.&UA#"*)
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M:&19HSE296(_*MX3@H--:E)JQYU\0+[6M-^*UEJ.CEI/L.EFXN+8$_OH0^'
M'3.#G\*CT_Q@8[?Q_P"(](E%P%6*6W.=P4E0.GMGI[5Z9)X8MY?&*>(VGD,R
MV9M/)P-A4MG/KFL_P_\ #S1_#LNM+;*TEIJKEI;60 H@(Y4>W-8$GG6JZ#X<
MT+1M.UC7/$7B235[Y//74K.5WVG@G &5"\]#7K_AW5+76= LK^RFFFMYH@R2
M3KM=QZD>IKBQ\(;-%-E%XDU^/16/S:6EWB(C^[G&=OM7H-I:06%G#:6L:Q00
MH$C1>BJ. * )J*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#_
!V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>13
<FILENAME>anvs-20211231x10k009.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 anvs-20211231x10k009.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" && 1T# 2(  A$! Q$!_\0
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M*<MO2WB+-AOO8)4']174ZI\-9K?X7?\ "&>&KN*W\UQ]IN;G.9 3N<_*.I(
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M'/"7PQTO2[B[OK7[%="6#5(+<R&.X.27< \*>GM@=QR 5/$5]\2?!$V@I?\
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M(YHO_0+MO^^3_C1_PCFB_P#0+MO^^3_C3]DN_P"'_!#F9V&:*X__ (1S1?\
MH%VW_?)_QJWX5MX;2[UF"WC6*%+E-J+T&8E)Q2E325TP4G<Z6BBBLBPHHHH
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M=%*R+]I/N5/[.M_[I_[ZH_LZW_NG_OJK=%%D'M9]RI_9UO\ W3_WU1_9UO\
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M\&M_P1][5_\ KY7_ -%+4XK^&QT_B.MHHHKRSI"BBB@ HHHH **** "BBB@
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M7$JQ1@@%F.!R<#]:FK&U?1[F_MF2.\^8!RJR("N3P.F.G..O6MA00H!.3W-
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M25#BI_$7_(=TC_KG<?R2H\5V4_@1B]V,Q1BG8HQ5B&XJQX6_X_=:_P"OE/\
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G **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH __9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>14
<FILENAME>anvs-20211231x10k010.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 anvs-20211231x10k010.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" %B 30# 2(  A$! Q$!_\0
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M\J&XCN/W\J^9D+Y.-P;)ZG_Z]?3592^&-"34O[171[$7N[=YX@7?N]<XZ^]
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M2#)8T 2T5BZ;X@6\NO(N+=[5I.;?S#_K%_H?:MJG*+B[,2:>P4444AA1110
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M5[N'RY-,BZY5A=8*GL0=O6HDHO1L$WNCL:*S-$;5/L(35HHUG0X#H^[>.Q/
MYK3KE:L[&J=PHHHI#"BBB@ HHHH **** "BBB@ HHHH **** "BBB@!&.U2?
M09KS;_A<6G_] R?_ +^#_"O2)/\ 5O\ 0U\JUE5FXVL=^!H0J\W.MK'L7_"X
MM/\ ^@9/_P!_!_A1_P +BT__ *!D_P#W\'^%>.T5C[61W_4:';\3V+_A<6G_
M /0,G_[^#_"C_A<6G_\ 0,G_ ._@_P *\=HH]K(/J-#M^)[KH'Q)L]?U>+3H
MK&6)Y,X9G! Q^%=O7S_\-_\ D=K+Z-_*OH"MZ<G)79YF,I1I348=@HHHK0Y
MHHHH **** "BBB@#B[4_Z1?_ /7W)_2K.:J6Q_TG4/\ K[D_I5C-=Z6A@/S1
MFH\TN:=@+OA?[^I?]=Q_*NAKG?"WWM2_Z[_TKHJXZOQLUAL%%%%9E%*^U 6;
MQ1@1F20,P\R38H5<9).#ZBK@.0#5>[L(+W'G \(R9!Q\K?>'XX%6%4*H4#
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M]$_[Z% EC8X#J3Z T[8O]T?E0%4= *V//%HHHH **** "BBB@#AH#_I6H?\
M7W)_2K&:JPG%WJ'_ %]R?TJ;->DEHCG),T9J/-&:+ :?A7KJ/_7?^E=%7.>%
M/^8C_P!=_P"E='7#6^-FT/A"BBBLR@HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** &R?ZM_H:^5:^JI/]6_T-?*M<]?H>KEGVOE^H4445@>J%%%%
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MW.-1U'_KZ?\ I5>^(^P7&Z0QCRVRX_AXZU-*?^)EJ/\ U]/_ $J&X4202(Q
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MT-?*M?54G^K?Z&OE6N>OT/5RS[7R_4****P/5"BBB@#K/AO_ ,CM9?1OY5]
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MU"X;4D=H(88]S_*<8(KH/"_BNR\56L\EM%/;SVTGE7%M<)MDC;W% &]1110
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544 %%%% !1110 4444 %%%% '__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>15
<FILENAME>anvs-20211231x10k011.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 anvs-20211231x10k011.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" %$ 8 # 2(  A$! Q$!_\0
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M:=AB:><^)T_Z]6_]"%=-7,:<<^)T_P"O5O\ T(5T]<];XBH;!1116184444
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MT[ 2Z2<^)U_Z]6_]"%=77)Z.<^)E_P"O5O\ T(5UE<E?XC2&P4445B6%%%%
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MIS5+4"[H1SXF'_7JW_H0KL:XW0#GQ-_VZG_T(5V5<.(^,VI[!1116!84444
M%8U_IUU<3,P*R[XPBL>#$=V<C_/:MFB@#,6TF_M5;M8PF]0)22#G Z"M)@2I
M .#ZTM% $>R3_GK_ ..T;)/^>O\ X[4E% $>R3_GK_X[1LD_YZ_^.U)10!'L
MD_YZ_P#CM&R3_GK_ ..U)10!'LD_YZ_^.T;)/^>O_CM244 1[)/^>O\ X[1L
MD_YZ_P#CM244 1[)/^>O_CM&R3_GK_X[4E% '+WP(O9@3D[NM5ZLW_\ Q_S?
M[U5J^/K?Q9>K/GZGQOU"BBBLR HHHH Z.P1S8Q$28&.F*L[)/^>O_CM0Z=_Q
MX0_2K5?7X?\ A1]$>_2^"/H1[)/^>O\ X[1LD_YZ_P#CM245J:'&>,587-KN
M;=\C=L=ZYFNH\:?\?5I_N-_.N7KP<7_&D92W"BBBN8D**** .G\&JS37>UMO
MRKVSW-==LD_YZ_\ CM<GX*_U]Y_NK_,UV%>[@OX*_KJ:QV&*K@_,^X?2GT45
MU%!1110!P%V<:[JO_7P/_0%K%\5137'AN\BMUE:0KPD6=S<\CCUK8O#C7M5_
MZ^!_Z M9'B&6YBT.Y>T+"4+U49(&>2/?%>K%?NUZ'+]HP-)AT=;VU,7A2YMI
M@PQ*T)PA]2:[;->=Z5J^^2*PL+RXN)?[1# ODGR<'=N/I7H.:*>JT'(T/#QS
MXF_[=3_Z$*[2N*\.'/B;_MV/_H0KM:XL3_$-:?PA1117.:!1110 444C$A25
M&3C@4 +16:#+_;:,WF!6@(8=5!S6BV=IVXS[T +14>)O[R?E1B;^\GY4 245
M'B;^\GY48F_O)^5 $E%1XF_O)^5&)O[R?E0!)14>)O[R?E1B;^\GY4 245'B
M;^\GY48F_O)^5 $E%1XF_O)^5&)O[R?E0!SE_P#\?\W^]5:K%]G[;-GKN[57
MKX^M_%EZL^?J?&_4****S("BBB@#IM._X\(?I5JJ5@)?L,6TKC'>K.)O[R?E
M7U^'_A1]$>_2^"/H245'B;^\GY48F_O)^5:FAR7C3_CZM/\ <;^=<O73>,=_
MVFUWD'Y&Z?6N9KP<7_&D92W"BBBN8D**** .I\%?Z^\_W5_F:["N-\&[_.N]
MA ^5>OU-==B;^\GY5[N"_@+^NIK'8DHIBB3/S%2/:GUU%!1110!YY?'&OZK_
M -? _P#0%K(U^\N;+1+JXM0IE1<@L,A1W/X5K:@?^)_JO_7P/_0%K"\36TM[
MX?N[>!&>1EX0'&[GI]*]>/\ #5NQR?:,G2XG^VP3+XFMY@Y!,21(-_MQS77Y
MKC=+2-;FV_XI2.W(('G*$^0^OK77YITUH$F:GAHY\2G_ *]C_P"A"NWKA_#/
M_(RG_KV/_H0KN*\_%?Q#>E\(4445SF@4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110!S%_\ \?\ -_O56JS?_P#'_-_O56KX^M_%EZL^?J?&
M_4****S("BBB@#IM._X\(?I5JJNG?\>$/TJU7U^'_A1]$>_2^"/H%%%%:FAQ
MWC3_ (^K3_<;^=<O74>-/^/JT_W&_G7+UX.+_C2,I;A1117,2%%%% '4^"O]
M?>?[J_S-=A7'^"O]?>?[J_S-=A7NX+^ OZZFL=@HHHKJ*"BBB@#SG4?^1@U7
M_KX'_H"UB>(!<OHERMKN\TK_  ?>(SSCWQ6UJ7_(P:K_ -? _P#0%K)U?[-_
M9<_VR9X8-OS.C$$?0BO9@OW:]#C?Q'':5=>9,EAI\=V-NH"7,BD;8P#G)->@
M UP^D7>KG5(4T[[1=:86Q)+>1A"J_P"R>IKMQ12V'(UO"_\ R,I_Z]C_ .A"
MNYKA?"__ ",I_P"O8_\ H0KNJ\_%?Q#>E\(4445S&@4444 %9E[<2)=6#;FB
M4S%73KN7:>?SQ6G2$ ]0#0!F+._]KC!9XY5& #C9QU(K38D*2!D^E&!G.!2T
M 1;Y/^>?ZT;Y/^>?ZU+10!%OD_YY_K1OD_YY_K4M% $6^3_GG^M&^3_GG^M2
MT4 1;Y/^>?ZT;Y/^>?ZU+10!%OD_YY_K1OD_YY_K4M% $6^3_GG^M&^3_GG^
MM2T4 <O?$F]F)&#NZ57JS?\ _'_-_O56KX^M_%EZL^?J?&_4****S("BBB@#
MHK!W%C$ F1CKFK.^3_GG^M1:=_QX0_2K5?7X?^%'T1[]+X(^A%OD_P">?ZT;
MY/\ GG^M2T5J:'&>,2QN;7<N/D;^=<S74>-/^/JT_P!QOYUR]>#B_P"-(REN
M%%%%<Q(4444 =/X-9A-=[5S\J_S-=;OD_P">?ZURG@K_ %]Y_NK_ #-=A7NX
M+^"OZZFL=AB,Y/S)@4^BBNHH**** /.=1_Y&#5?^O@?^@+6%XCGEM="N9H0"
MX P2,A>>N/:M[4!GQ!JO_7P/_0%K%\0K=-HER+-2\^,JH&=W/3\:]B/\->AR
M/XCG4D?3;S3VMM;DOS<3+&\+D'*D'+#'3%=F!7*Z2\,=Y"R^&9K65^&EP,)Z
M_A76 4Z;T"1I>%_^1E/_ %['_P!"%=U7#>&!CQ*?^O8_^A"NYKS\5_$-Z7PA
M1117,:!1110 444C':I."<#.!0 M%9XO7;5(H$=2C(6=",,GI5]CM4G!/L*
M%HJ+S6_YYM1YK?\ /-J ):*B\UO^>;4>:W_/-J ):*B\UO\ GFU'FM_SS:@"
M6BHO-;_GFU'FM_SS:@"6BHO-;_GFU'FM_P \VH EHJ+S6_YYM1YK?\\VH YV
M_P#^/^;_ 'JK58OCF]F.,?-TJO7Q];^++U9\_4^-^H4445F0%%%% '3:=_QX
M0_2K54K"0BQB&QCQU%6/-;_GFU?7X?\ A1]$>_2^"/H2T5%YK?\ /-J/-;_G
MFU:FAR?C3_CZM/\ <;^=<O73>,6+7-KE2OR-U^M<S7@XO^-(REN%%%%<Q(44
M44 =3X*_U]Y_NK_,UV%<;X-8K-=X4M\J]/J:ZWS6_P">;5[N"_@+^NIK'8EH
MIBN6."A'UI]=104444 >>7XSK^J_]? _] 6L/Q/+/!X>NY+>0QR!?OKU SSC
MWQ6]>C_B?:K_ -? _P#0%K(\07,UEH=U<01J\B+P'&0.>I^E>M%_NUZ'+]HX
MC[=H^F7>G7&EZI>-(\P$XF=F4QX.[<#T/2O0+2ZAOK9+FV</$^=K#OSBN:T^
MWN)+N!WUK3YXV()B2)<L/05UJ1JBA44*HZ #%%.X2-#PT,>)3_U['_T(5V]<
M3X<&/$O_ &['_P!"%=M7#BOXAM2^$****YS0**** "BBB@!GDQ"4R^6GF'^+
M'/YT^BB@ HHHH **** "BBB@ HHHH **** "BBB@#F+_ /X_YO\ >JM5F_\
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M62-Y9F4H"!@5G_\ "+:?_P _$GY5U%%8RP]*3YI+45D<O_PBVG_\_$GY4?\
M"+:?_P _$GY5U%)N7=MW#=C.,\U/U6C_ "ARHYC_ (1;3_\ GXD_*C_A%M/_
M .?B3\JZ?<NXKN&X#.,\XI:/JM'^4.5&/I6FVFDO*T4K-Y@ .1Z5J?:(O[WZ
M&I**VA",%RQV':PQ94<X4Y/TI]%%4 4444 <)<#.N:M_U\C_ - 2C%.F&=;U
M;_KY'_H"4[;7IQ?NHYGN1[:-M/VTN*JX$V@C'B8?]>I_]"%=C7(:&,>)A_UZ
MM_Z$*Z^N'$?&;4]@HHHK L**** "BBB@ HJJ]ZJ7\=J4YD!*L#Z>U620HR2
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M44 -V)_<7\J-B?W%_*G44 -V)_<7\J-B?W%_*G44 -V)_<7\J-B?W%_*G44
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
&**** /_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>16
<FILENAME>anvs-20211231x10k012.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 anvs-20211231x10k012.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" &V 9H# 2(  A$! Q$!_\0
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M5TU% ',^;XQ_Y]=)_P"_S_X4>;XQ_P"?72?^_P _^%=-10!S/F^,?^?72?\
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MC! %M.8P<^N.M9W_  @]I_T%=9_\#6KIZ* .8_X0>T_Z"NL_^!K4?\(/:?\
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M@;0V,AN_49^M &U103@9J'[2O]R3_O@T 345#]I7^Y)_WP:/M*_W)/\ O@T
M345#]I7^Y)_WP:/M*_W)/^^#0!-14/VE?[DG_?!H^TK_ ')/^^#0!-14/VE?
M[DG_ 'P:/M*_W)/^^#0!-14/VE?[DG_?!H^TK_<D_P"^#0!-14/VE?[DG_?!
MH^TK_<D_[X- $KL$1G8X"C)KC?\ A:OA#_H*#_OVW^%=1=7"FTF^23[C?P'T
MKX[S7HX#"0Q'-S/:QRXBM*E:W4^FI/BCX.EC:-]3!5@01Y;=#^%<-:+\+;36
MC?)>KY*QQ"*'RG!C=&+;]_4ELX.>U>.Y/K1D^M>A_9-'NSF^N3[(]P\7:K\.
M_%NZ:?5!%>E8XUN#"S[$60.0%/'.,$^AK<T;QSX T"R:STV]$%N9&D\L*Y +
M'G&>@]J^<\GUHR?6C^R:/=A]<GV1]._\+5\(?]!0?]^V_P *ZZUN8KVTANH&
MW0S1K(C>JD9!_(U\:Y-?6GAFX5?"FCC:_%C!T4_\\UK@Q^#AAXIQ;U.G#UY5
M&TS;HJ'[2O\ <D_[X-'VE?[DG_?!KS3J)J*A^TK_ ')/^^#1]I7^Y)_WP: )
MJ*A^TK_<D_[X-87B/QKI'AFUEDO9&,T<)G%NH_>.@8*2 >N,T ='16+%XKT:
M;3;O4$O$-K9DK<2#D1, "03ZC(JCIOC_ $/4]3FL(KC;,MQ]GB#8_?G8'RF.
MHVD4 =117+ZIX^T32M2AL)9]\[W*V\JK@>060N"^>@V@FMJQU:SU*RAO;.0S
M6TR[HY$4D,/:@"]14/VE?[DG_?!H^TK_ ')/^^#0!-14/VE?[DG_ 'P:E5MR
M@@$9]10 M%%% !1110!Q5U_R->K_ .Y;_P#H+4_-179QXKU;_<M__06I^:]&
M'PHYWN.S1FFYHS3L!&A_XJ70?^OF7_T1)7<5PT9SXET'_KYE_P#1$E=S7+B/
MB7H:4]F%%%%<YH%%%% !52VTRTM)C+#%M8@@<DA03D@>G-6Z* "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@"&Z_X])O]QOY5\:FOLJZ_X])O]QOY5\:F
MO;R?:?R_4\_'?9^84445[1PA1110 5]=>%_^13T;_KQ@_P#1:U\BU]=>%_\
MD4]&_P"O&#_T6M>/F_P1.W!?$S6HHHKPCT0HHHH *\]^)_@*[\9V!:UN%,D$
M)$-L55=\A88)D/( !/'?BN8^,WBK7- U[3H=+U*:UCDM2[JF,$[R,\BO-/\
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MT?:(?^>BT_RT_NK^5'EI_=7\J &?:(?^>BT?:(?^>BT_RT_NK^5'EI_=7\J
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MDU"='2W8Y9$1 @W>YQ40^+8;V.DLC_Q5&A_]=Y?_ $0]>A5YW8'_ (JG0_\
MKO+_ .B'KT2N;%_&O0TI;,****Y34**** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH ANO^/2;_<;^5?&IK[*NO^/2;_<;^5?&IKV\GVG\OU//
MQWV?F%%%%>T<(4444 %?77A?_D4]&_Z\8/\ T6M?(M?77A?_ )%/1O\ KQ@_
M]%K7CYO\$3MP7Q,UJ***\(]$**** /G[X_?\C+I?_7F?_0S7D=>N?'[_ )&7
M2_\ KS/_ *&:\CKLI_"CFG\044459 4444 >R?L__P#(6UK_ *X1?^A&O>:\
M&_9__P"0MK7_ %PB_P#0C7O-<E7XCII_"%%%%9EA1110 4444 >>ZQ_R-NI_
M]<[?_P!!:H,U-K)_XJW4_P#KG;_^@M5;/->Q1^!>AR2W9P\,-SK&H:F=1\17
M.GS07;Q+:Q.J!(Q]P\]<CG-=+H-DEC;RHFJ3:@&<'?*X8KQTXKA+=_#"ZMK
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M]GYA1117M'"%%%% !7UUX7_Y%/1O^O&#_P!%K7R+7UUX7(_X1/1N1_QXP?\
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M+6"=X6GN^#*ZG#8 '3-;7AF_2\BO+=]/CL+RTF$5S F-NXKD,".H(-3!Z_\
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M0J5054 G)]:@H6BBB@ HHHH X#51GQ9JG_7.W_\ 06J+%3ZF,^+-4_ZYV_\
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MB%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MKB%'_%2:#_U\R_\ HB2NWKFQ'Q+T-*>S"BBBN<T"BBB@ HHHH **** "N?\
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M #P/_?0H\V7_ )X'_OH4 3T5!YLO_/ _]]"CS9?^>!_[Z% $]%0>;+_SP/\
MWT*/-E_YX'_OH4 3T5!YLO\ SP/_ 'T*/-E_YX'_ +Z% $]%0>;+_P \#_WT
M*/-E_P">!_[Z% $]%0>;+_SP/_?0H\V7_G@?^^A0!/14'FR_\\#_ -]"CS9?
M^>!_[Z% $]%0>;+_ ,\#_P!]"CS9?^>!_P"^A0!/14'FR_\ / _]]"CS9?\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% '* 9\5:S_NVW_H+5<Q51/^1IUK_=
MMO\ T%JNUU=%\OR,AN*,4ZB@90N!_P 5#X?_ .OJ7_T1)765RES_ ,C#X?\
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MX-344 0_:4_NR?\ ?!H^TI_=D_[X-344 0_:4_NR?]\&C[2G]V3_ +X-344
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M6(R3S-*RQKT12QX4>@H YGQ%X\\1Z=K?B2WTS1["YLM"@AN;B6:=D8HR%V
M'+<''0<=\T6_Q'U6TN7EUS18+>QFTB75K06\Y>3RXP"4?( W$,.G ]ZZRY\)
M:7=2Z[)*DI;6X$@O,2'YE5"@Q_=X)Z4RZ\(Z=,;:5(P9[33WT^#SLO'Y;  A
MUR-P^4=Z .7T[QOXI_M_PW9ZOHVFV]KKID>*2"Y:1D01[PI! &[IR,BO2*\G
M\(_"K4=)\66.KZE<V2P:=YGV:&U>9\[E*@?O&.U0"3@?G7K% !03@45#=6ZW
M=I-;.SJLJ,A9&VL 1C(/8T >%Z7X_MI?BU_:YUL-;7U\^DBPRV(X  (IO3F1
M3GV:M+4+JX'B.]43RA1XVLHP Y^Z81E?I[5Z1+X,T27PI'X;-KMT^.-(T",0
MZ[2""&Z[LC.:9)X)T>6Z>X=)C(^HQ:FQ\T\SQKM4_3':@#F_'6F0:Y\0_".E
M7C7'V2:"^:1(9GC)*JA7E2#P:SM.\5ZAX7BU;0H3)K$T.M1Z9I;W,W4R1[]D
MC]<)@CUZ"NV\2>#-+\475E<WS7<<UF'$,EM<-$0'QNY7_=%,_P"$"\.#PU_8
M L!]A\SSOOMYGF_\]-^=V_WS0!S=U\0=>TRPUNUO]#@?7-+CAF*6DC2PO#(V
M/,Z;OEP<CK^%5]0^*LT.D:'_ &>FGWE]JBRR"=?.^S1JAP20%,F>VW'![UU-
MCX"T;3=.N[6S-Y%)>,KSW:W<GVAROW<R9SQZ=*9-\._#TND6>GBWFC%F[R07
M$4[I,KN<NWF Y);OZT <M=?%34HO"L&I_P!CBW=;YK2[N)HY6MX0%R)0 H<H
MW !QP<Y]_2M.NUO],M;M7BD$\2R!X6W(<C.5/<5BS>"-*DT"+1EEU"*UC+$F
M.]D#R;L[@[9RP.3P:W;*RM].L;>RM(EBMK>-8HHUZ*JC 'Y4 3T444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
144 %%%% !1110 4444 ?_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>17
<FILENAME>anvs-20211231x10k013.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 anvs-20211231x10k013.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" &! L,# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH *HZK;27FD7EI$0))H'C4D\9((Y_.KU-R!Q^5
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MUK6[K7&5[2:.]3;9R7-S)_HP"\J(MNTY.3G/&>AQ7IF1@8Y!].:7'3G%49'
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MS1"SNY7@DRA+AO+9EP0><E<8QDYK<J.2"*9XWDB1VB;?&6&2IP1D>AP2/QH
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M1+;WE[)!'"4)?R4#[I2<\<KG&.A ZGC3T7P_%I:R23F&YO))Y)FN!#L.78G
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MC<#="I_>'J_3[Q]:7]?E_P $/Z_K\#B=&UC5+O5_/T][:>359YSYLD1 2W@
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M"58;A^!!J%6GW_K7_(]-Y9!TE4CKI?Y]%\_T-#_A6.@_\]+[_O\ _P#UJ/\
MA6.@_P#/2^_[_P#_ -:H/^$RUB+2H-?GT^T&D32[-BNQG5<D;B>AZ=*M#Q-K
M%SXLO-'L+*VEB@:)O-8E=L9 +$\\GGC%/VL]KF+RVHKW2TOU71I/[KC/^%8Z
M#_STOO\ O_\ _6H_X5EH/_/2^_[_ /\ ]:J4_C77D@U6ZAT^R>UTV\:*5RS
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M+*1F#R;LG(KT2N.N?^2J6/\ V#Y/YBKC.4KIOH3*,5:R.Q%%(.E+6)H%%%%
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MD'04M @HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ KSKQEC_A8OA7C/[BZ_DM>BUYUXS./B+X7/_3O=?R6DREL
MR\R'?E220<#Z53ND"LK%]L@Z>E7\,5W9QV'M5*0;8EW#.YL-[4R21F_=@9RX
M/I4:Y5CN).T9SZU))&"BM&=OR@'/K3 "7R2VP<$8ZT +DE %PQP 17)0Q+#X
M^O\ @[7M4;;G )W$9]^U=;N(4;=N3R?>N81-_CN5SQ_H7RC_ (%0!T\*HB $
M\#.U0*>555P'!)!ZCI4<3 (I(.:>P+;0J_-GK0 PL%/*CCD<4P@$< 9/&?2I
M7+'DXSC!IJY7>A (!!_6@!C*S[BZ 8QMQWII@S+'(26 &#4@^61EW;AU..U$
MA0R@@D=L4 0M9HZR1ESM8Y)!YI(888E6) Q4=R2WZT\ Y.#TZBE5"B*2",]O
M6@!F Y& <#@FHGW;@C*&4CY<?SJ?=A#N7;\U1NRA(POR@=CUZT -10H ?D>X
MZ&E9@P)?!V]P.@I\4@9>4./0]:655V,I.!@Y- %.&.WN()258C.#_"1]*?:1
M/;\>>&CSP&&<#ZTMM*C(RL>?2I5\HYP#D9('O0 &-@RG&[Y>,\4DH/EA@ QZ
M8]*D0NR_,P^OI2,#O!9P%XZ"@"-QO4[<*",@#M678VFIQ:G/)=:@+BU?:880
M@!B]<GOFM7:Q5G4CFF.%W;BW;)QZT -?8X//(.6'<8K*O8\QND<6XCGYGV@_
MC6K)N9@?+PP.<#OQWK!\1OLTJ[E+E2B;ORH NZ;/J4MNHU"PBML$KL20. !T
MY]Q6BT@,9>4[-N"03C;FJ6ESM-I5JX&[?$"23WJ_L:56WD-O!R",=* ,JPUK
M3]5NYH[!VF5.&E0$IGT!]:=J#HNSD\,,@<DKWQ5F#3[:QC2&UA2W0N24C'!8
M\DUBZMH5L^M0:F))_M,:[5C#_)U]/6@#H5V[5V@DA<C)_2JC3+-;S 6\@=20
M X(W8]#5M0?+X7(&,-GOZ56U9+HJ)4N42"/)<!<\=: ,6\DE72EC:,P3,I/W
MN![9K.\)^8%G0.T@!'S$Y(]15FZ?[3HL3*&_>1DH7JIX:N91;7;0VP:5 -R@
MXWL* .@E$@#EG!(!QG@ 5A:M>V=JL45Q=0PS3\+O."3[5MM))/$S2P%#@$CZ
M]JP=7T^WN&7[5;QRNG,3.O*D<<?E0 O@L;?BMH0!_BN#@#I^X>O5?B/_ ,BW
M;?\ 81MO_1@KR[P> OQ2\/8'>XR?^V#UZC\1_P#D6[;_ +"-M_Z,% '8#I10
M.E% !1110 5S^NWUP^MZ5H=M(\/VSS)KB9#AEAC RJGL6+*,]0,XP<5T%4[W
M3+:^E@FE5A/;DF*6-RK)D8(!'8CJ.GY4=0..U?6G\.>([Z33XC-:6NGHUQ;F
M5@K3O(%B X;YR-W09/&>U=/HVKSZI<ZC%-:+ +298@1)NW$H&(/ P1N (&?K
M4JZ%IJPK%]F!43K<DL[%GE!R&8DY8C ZYZ#T%36.FVNG?:/LL;*;B9IY"7+9
M=CDGD\?0<4+:S_K^M?P!G/67BB]N]?OK%+>!D6218#YA"JD6 \CG;W=MH'^R
M?3-1#QM<7%N+BUTV$PC3#J$LDMT5$8R0%^X<YVL0?0=!6O'X4TB$,(X)%W^8
M'(G?+J[;F4G/()YQ]?4U7L/#?_$QU&YU"*'RYI(U@AAE8HL,:@(K+@#@[CCD
M?-[4+;^OZ[,?4U[2YN+H02FV6.WE@60EG^=7.#M*X].^?PK(\2:=_:,UK':W
M%S'J*R(\313LJPH&!9V4'!R,CD'/ ]:W(;:."6>1#(6F8.^Z1F . . 3A1@=
M!BJ/_"/:?_:;:B?M9N&8.0;V8QD@8!\O?LX[<<4^MQ+8YS4M2ET;Q/)JTDCG
M2KC=8O%DE?-5-ZN!V).^/Z[:UKR\;PGX.^U&+[3-!&@9&D8&61B!@'#'))XX
MK1_L33S8BR: R6XF$^V21G/F!]^<L2?O<U8N[*WOEB6YC\Q8I5F0$D .IRIX
MZX//-);6_K^M_P  >]S @\5S2WTMDVGA;DW8M8$$V0Q\L2,7.WY=H/.,\\5&
MOB^XFN+2UM=-2XN)Y[F A9R%!AX+ [?NDX!)QC/?OJKX;TQ',D<4B2F=[CS%
MF<,'<$-@YX!!Z=*L6VCZ?9S136]LL;PPF",@GY4)W$8SW(!)ZFC^OZ^8'+P>
M.;V2[@MY-&C!DNIK8LET67,:9=P2@RH;Y2>,=L]*MQ^,R^A'4/L*^9#8B]N8
MS,0L:D$HH;;RS8X&!QU[9U?^$:TD0^4+4A?(EMP1(V0DAW/SGJ3SGK[U6F\&
M:'.LB/:R&.6..-T%Q(%8)]TD;L$CUZT= ZD.FR2:GXKENY(O)-G8QQ/&&SME
MD^=E)XSM4)S_ +1]:KZKXSET^_U&W33TECL9+>-I3.5!,I'R_</S $''/')(
M[]#9:7::?-=36T962ZD$DI+ELL %[GC@#I5:Z\-Z3>(R7%KO1[G[4ZF1L/)M
MVY;GD8XQT]J'Y?U_6H+S,^'Q5)/93ZC'8C^SX[-[H3O(5&!RJGY>I&3QG;CG
MDU';^*;\2Z:^H:5%9VFH)^[D:Y)='$32$,NP8&%/.<^PZ5IQ>&],BTQ].\J6
M2U=!&4EN)'P@Z*"6R%Z<"KEWIUI?/;-=0+*;67SH=W17P1G'T)IZ?U_7]6 P
M[3Q1<WLD<,&F[[A)(XKI!(?W3, 7YV]%!SEL9(P!FM6\U-H=0BT^VA$UW)$T
MVUFVJB*0,DXZDD #OSTQ2PZ+8V^H37L22K),_F.GG/Y9?&-VS.W/ YQVI;O1
M[.]O8[R595N(T,>^*9X]R$Y*G:1D9&>:7;^OZU RXO$UQ<W(MK?3B\\4D<5T
MGF9\IB 7&X#&$!ZDC)&!S6):#^T?[/"]=5U22_X/W;>+[I'H&VQY]=Y]:ZM/
M#^G1W-Q.D<JFX.Z2,3.(RV,;@F=H. .<=JA'A72%A@B6W<)!:M:1XF<%8FQD
M9SUX'/6FN_\ 7]72#R_K^M0T'6IM9-RS6J0) YB9?,)=) 2&1E(&" %.>00P
MQZUBZ[XIECL=>A%HBFSC:+#L2Y=]JQ'9CYE<L<$$_=(Z].IM-.MK+SS"K!YV
MWRNS$LYP%!)/L /PJG%X:TJ+RS]G:0Q>5L:25F($9)09)Y ))Y[TK)[_ -=Q
MIVU,?2O$#VJ)HRV),\,R6-N#,6WD1!V9SCY=HZXW<\9-31^+_G@,UFODR7%Q
M:F2.0L3+%GA1MY#;2!SUXYZUICPYIB,72*1)?/>X\Q9G#!WR&P<YP0<8Z5.N
MC:>B62+:H%LF+VX'1&(()]SACR?6AN^I-K:(JZ%K;ZW;PW*VPC@DM8IL[\E7
M;)*$8[#!Z]^E5I/$Y:YLEM;-9H+N\-I'(TVTMM#%W"[3E1L;OS],&MBPT^UT
MRSCM+.$10)]U16=:>%-'LKFVN(;>026K2- 6G=A'O^\ "< >W2GI<;*FLSJW
MB6T^[LTVTFOIB6VC)&Q 3@\'YS_P$>E9@\7W.FV,<?\ 9K22#2SJ<OG7;,8M
MS9",VSZ@=^,8QR.EN_#^FWTM])<0LSWUN+:<B1ANC&>!@\?>/(IL_AS2KB">
M&2V.VX6)9<2N"PC.4&0<@ ^G7)SUI=/Z\_\ @?</K_7E_P '[RC_ ,)2\EP8
MK>R\PP2)'=9<CRB0&?G;C"*<Y)&2,#FH;CQ@T/D2+8(;>:TFO5>2<HRPQ@$,
MR[3C<6&/KZ\5J#PYI@FNI/)DVW63+%YS^6Q*[2=F=N< <X[56C\&Z(BD&VED
MS;BU)DN)&)B!R%)+9Q_3BC^OP_S$M!]EKLYT635M4LA8VJP),!YA=^5R05VC
M!SP!U/H.E9NJ>,KG3!>^9I2%[6UCG*?:3G=(^Q(R A^8X/3/X]:Z/4-.MM4T
M^:QNXR]O*NUE#%3ZC!'(.15&+POI$-Q).+9VEDDCE=Y)G8L\?W"<GDCW]O2G
MI?R!;%*V\4RS7D]F]@%N1<BV@039WGRQ(Q8[?EV@\XSSP,FCPI(]_<ZOJ[K&
M!<71@B\ILJR1?)N!P.K;S^57&\*Z0TGF>1*'\^2X++/("6?[P)!^Z?[O3VJQ
M;:'I]GHK:1;PM'9,K*8UD8'#9SALY'4]#Q20& ?&ET4C9-+1VDO5LA#]H(E6
M3+;@R[>"JJ&]"&ZXYJ*T\?&2&.YN]-$-L8;F9W28N=L3A05&T;@Q(P>.3T[U
MT2^']-6X%P8&:<.S^:TC%BS)L)SGKM&,]JA/A71BH0V?R+:+9JGF-A8@<@ 9
MZ_[77WH_K\/\P_K^OD4Y_%C65U):WEEBY,4+Q112;B6E<HJ,<#!R,YZ8SZ<P
M:AXFO@+BQM+>W&HK?162GS24RZ!R0=O)5<DC';/M6RV@Z>\;AXF:1Y$F:8R,
M9"Z_=.[.>.PZ=>.:/^$?TS?;/Y!W6T[7"-YC9,C @LQS\Q()ZYH7G_6W_! Y
MK3];D'BN\DAM!+'>:@-/#[RH BC+,RC'S8;?D\=ADG@=Q6;#H&FP36DL5N5:
MT,AA_>,0ID.7)YY)/<YK2HZ!U"BBB@ HHHH *\[\9X'Q%\+D_P#/O=?R6O1*
M\\\8@'XC>%@?^>%T#^2TF4MG_74OC.W:1UY%5+@!RFYN<YS5_:RG'\6.#VQ5
M*4QW+L%/"G!R,4$CG4B-"6!8?-CUIK/((EX//'TI63RX@6&X#'\Z4 MN4D!3
MC%,!I&'=P,=<"N:A?S?&<O[LJ8[09]\MQBNKX4%#R<<FN4@E(\>7A1@56V"A
M/^!&@#I%#-%C^,^U2 ' '<=?KZTL2NR9;ACR.*D 5!V.??J: (6V@[,$DC.3
M0@.-S %N^10ZL'\UCCV]!2M^\!"?+CJ#W- $2QA,N.#GH.E+(K  H@;!R13\
M!SQUIC'<"5&3CF@".)?F8G&3C-/9V\TK@X'2DAV[!E< DBG$,Q!'>@",KYCX
M."">:CF$9;GHK'::E*[ >=Q[8[4QXT<X(.0,CGC- #8P& Y)8CMZT2?NT"X[
M]7Y J1$VQKQRAZYI)"N2&!8YS@^E $"0J4,CX)#8)4=:D55+'Y=N*(P4@5A\
MHSGCGFI2R"(YZMP: (L8=PJ_*>QI,_,?E!QQD]C4C;=^>?3BEQO9>@';WH B
M\M3+@M\HXJ+:H93LR1U_"II0QDV@#C.?I2 @MD#(/4^E #'$KC"D!CG/O65J
MULI$RNHD5D^ZPR,^XK79OD^7ICK69K%Q;PVK/<NT42D$L#SGI0!;MHC]DAB5
M%0C'&W _ 5,Y^;'5@.GK2QL$6-B<KM!!I<&1R 0 ?6@!@R_.SMR1QS5.]7<\
M1*A07 'UJZNU?W;$L<<'VJAJ!'F1JX8 .-NT]\T 7(T(7&,KG.WL3BH)T_T>
M0,APR'(SP35H-M #H><Y([4V50\ Y##;D+TH YBY4#38=R'8"3C/0#L*A\,(
MB0RRQKMWN&);T[U>N[=Y; E?W*JQ90_/'I47A^-TC=C*DG&6&/Y4 :,ZLX Y
M&6Y]ZR+W>64'#C'!(_.MJ?YLMT7@8]*Q-2#QD&+H.,GN.] %/P6Q;XH: ",X
M>Y'_ ) >O4_B1_R+=M_V$;;_ -&"O+O!J;?BGH&#U:XQ_P!^&KU'XD?\BW;?
M]A&V_P#1@H SO$NOZM:ZGJK6FK6EE#ID"2BVF4$W)(R<DG(4_=&.]2^#O$>I
MZIJ,EO>ZA8WJ2VZ72M:KC[/N)'E-R<D8[X/6LSQ?*TOB&[OA'I(70HDG\N\A
MWRSY^;"MGY!V'!YJ]X%U&:2^NH)(],(O(EOP^GKMV;B1LD]6XZ_I0,] '7O2
MTU1R?YTZ@05@Z_XBDT:]L[:*T2<W$<TCLTI3RDC7)8_*?ER0"??H>E;U4+[1
M=/U)Y7N[?S6EMVMG.]AF,G)7@\9(&<<\4F-'.6?CJ6>*)Y]*:)I;6WE2(29<
MRS,51"-HP#@G/H,D"K<WBJ6WN)X9;.)A;7T%I/(DQVKYNW!'R\D%@"./7VK2
ME\.:7+<37#6[>=,\;EQ(P*M'C85Y^7&.W7OFI'T'39;!K&2U5[=Y1,ZL22[A
M@VYB>2<@=?2JTO\ U_7?\"3.D\3M&8X?LP-U-YKQ(C,X:%&VJ_"Y);(P .YY
MP,UES^.+^WG:"30QYD<UK!(J7.XB28 L@^7!90<XSC')(KIKO1;*\O8+N194
MGA0QJ\,SQY0X)4[2,C(!P:;'H.F13),EJ Z3M<J=S<2%=A;&?[O [#MBDO/^
MM?\ +\1O^OZ_K0QK?QBTZ>6;-1=-).$1':0&.)MA887));@ #G!YP,U _C2_
MCEN(6T9%FMS:I(OVDD"6;&8\A,%AN'3/')([[$/A32+?[-Y$4\1MU9$:.YD5
MBK')#$-EAD \YJ9_#VEN #;8 NA=X#L,R@;03SR,8&.G XH7G_7]+\0?6Q7T
MK5KB\N-8N;CRH]/M9V@A93G(0?.QX]21_P !JH/%IVVDK6BQQ7EI-=P;Y"&6
M., AG&/E!##UQ[]MFRTBRT^SEM+>'$$SN\BNQ;<7)+=3T))XK+O/#$4D!L;:
M*-;6: 6\TTLSM*L((_=H"#\I&1U'KS1Y?UL/K<CT&.\3PZNM7-LDFL7$!F=3
M*0"&^=4)QP , <'&*CC\9I+%8R+;*5OH(GAQ(?\ 6,I=E;"G&U0#QDG(&.17
M4;%V; ,+C&!Z5E'PSI0LK*TBMV@BL3FW,$K1LG&#\RD$Y!.?6F[78EMKN4%\
M27_VRPM)M,6">\W&,2R%0X5\'''#;/WFTX/;L<);ZZQU>\1(&>:6\^Q6R?:&
M*/Y:;G?&,(!D@X!R16K'H.GQ72W"Q.767SE#RLRB39LW $]=O'XD]>:@'A?2
ME">7#+&\=Q)<+(D[JX=R2_S YP<GCI0!CZGJ6W6;.XU. 6ZZ5;SWLX1MYQDQ
MQ]/[PW-CU ]*LW'BF[M;66[GTT1V:/$OV@NVQ-Y(8GY<E5^7+#(^;KP36E+X
M:TF=KMI;8N;J!;>;,C?,BYP.O!R2<CGWI'\-:=+&$E%S*/*:%C)<R,71L;E8
MEN0<#Z<XQDT@)+C56L=)M[J[@"W4QCC6WC?=F5R %#=QD]?0$U7;6KJ&]^PS
M640NFW2+B?\ =^2H7,C-C(Y;:!C)QG@=+]_I=IJ-HEM<1GRXW5XS&Y1D9?NE
M2,$$52N?"VDWDHDGBF9_):!C]ID'F(W)#_-\WXYH?]?UZ_@!D6?C#4=2-M'9
M:/"T]Q8_;0&NR$12^U-S;. P!(XSQC'>EC\7:C+X;EUX:/"ME'$\N6NB"ZJQ
M&5&SD%1N!.,_J=ZTT+3K&*6.WMRBRPI Y\QB2B@A1DG(P">GKFHK[2C/IJ:-
M!! FEO ;>7,C!T3  5!CG(R,DC'!YIZ7T_K?_@ O,H7NKW$VJVEBMN/+DO"$
MECNF0E(TWLQ 7D;OD(SCG\*H6GCN:XMH;I])/D26US<XBE+N4B. 5!49#9&"
M<=>F!D]%)H.FRS6\K0'=;0/;Q;9&4*C8W# /7Y1SUJGJ'AN$VX.G1)%.MNEF
MH:5U MP>4!&=I()&[!-+^OZ_#\07F)H^O7FJ:K+;?9+4VL4$<CW,-R7 =\GR
MP-F"0!DG(ZCCFLBWU2>W\3WM^EI%):W=^FFH_FD-^[0EF"[<'#;@3GHOM6[H
M.EWFEB:*:Z=[7"K;P/,9C$ #GYRH)!XX.<8Z\\30Z!IT 94A;:3(0ID8A#(2
M7*\\$DGD<\TWOI_7]; MK/\ K^GJ9-AXMN+K2H]4FTT16DQ\NWVS%GFD,FU
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M'';(HSE1@[<L.G4T "@91_F#G@J:9=R1P(SM(5"@9/6G%0P&&.\$]J24!@N
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M,6CR23W]])<207UXBQ+)%@F"-<[57((SDDGCJ?84+I_7]?\  !]EY&Q1112
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "O._&7_ "47PK_UPNOY+7HE>>>,!N^(WA8?
M].]W_):3*6S_ *ZFC@G(R%'( J&3 ("@\=:M.@&Y3R<56F21I $/S$9YID@
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MEXATVP@LK6?7DMX$"1K_ &1&< >Y&:V-&MM?UO6%TR;Q!J5E,8VE7[1I<*Y
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M:)9)=70D\IYDA 5<G<S;1_.@#3HI!T%+0 4444 %%%% !1110 4444 %%%%
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MT/E7 _U#UW/Q'_Y%NV_["-M_Z,% '8#I10.E% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7G7C3GXB>%_\
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MCKL;(/4&GR0LZX#,F.PI@#&=<# ':@"4@CKUIHZD5(<GMS4:^:"2P!!]* %
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M/\10(Z2BHH'+H"RD''(]*EH **** "BBB@ HHHH **** "O.O&A_XN)X7/\
MT[W7\EKT6O.O&G_)1/"__7O=?R6DREL_ZZFB"02,_2D)8XS3L<YI/O-]*9(T
MD^M'/K2[1SQ1@'% #3G'6F@MZTIQ@\&@$%0 * $R:;@YIQ&*":0#>::WW:?@
MY^M-QC[U,!-Q]:,]#CFE5>>:7C- #"S[P%^Z>M!+ Y%. ZFC&!]: &@D')I#
MG\*>5[4WI]* (W4[3@$_2N,:!H/$,MS9G[+<2, 5O?\ 5N/5?>NV9=W&[GVK
M$U+PV-6O(Y;J\E>U3G[,, ;NQSUH V5+;06QGOCIFEY(-"1^7&J#&P# &:RK
MY]:6Y LK>VDB/WMYYH T]QR.::Z+(NUQN^E"!O+7> &_BQVH+",$_,<]A0 \
M?*H'0=J"".<UEPZ_;237$=Q!/:1P?>GN%(0CU!J];WEO>0K):W"3PG[KH<@T
M +("ZD$D9':H[8;6V!]Y'5C4[>N1^-5[>,BYE.05- $Y/J:A1Y6F=67" <'U
MJ?9C@<BD()&,8H 8&!7D].U174*W5L\3YPXQ]*F6),'CC-(Z[1E%/XT 5DC\
MF)41ON# SWI]LTJQGSB,@]!3B,CGK2J,J<]J (+N."ZM6,A*J.C#^$^M%BA2
MV4"8R+C[S=33;IXS:2Q+M4GUI]G&R64:%E) _AH E*YY]*Y;4+&74O%=O\\1
MBM_WA1_YBNI==ZE>5R.M9%CISV^JS2SOYCE<1N3T7TH LQ;F^(WA//\ SUNL
M?]^&KJ/B1_R+=K_V$;;_ -&"N4@G5_B;X7B4_,DMSG_OPU=9\2/^1;MO^PC;
M?^C!0!DO?:WIWBO6M362ZNM,M[I(IK(+N(C,2?/&,?PDDD#J,]ZUO#.H_P!H
MZUJ\ME<7%QII2%T:92 LQW[U7(S@ )QV)-9UY?QOXFU*UU7Q!-I$,;+]GAC:
M. 2J5!+EV7+<Y'7M6CX6U%[C5=1M8-4?5=.B2)HKMPI(D._?'N4 -C"GOC=U
MI+8I[G7CK2T@SGVI:9(5BZEH=OJ>HZ?>7/F>;8.98-KX4.1C)XYXS^=;58FK
MZTNFR6UN(S-<7+D1Q+G(11EG)[*,C)]QU)Q28T,A\/V,$UK*C3[[:2:5<R9R
MTC%F)]<DFB^\.V5]?7%W,T_FSVIM&"R8'EDDG'H>?TKG_#^LR7T^GEI;PF]E
MNKY%$H*I"KE8U8$$E2"N,8YIW_"9W]_IUK-IND%9;FZ2WC\Z3H?G,@(ZAE5&
MR#ZB@#3O/!>E7\L\TR3;YHXHLK)C8(CE"OH0>:V8K)$LC TDS%E*L[/EN1Z_
MX5A:=XRCU+[(D=LT37,LZJ'<8$<1(:7Z$C ^M9&L>(]2UC0;)K.SN[.34)[<
M6[QR_.Z$&1\;<$81",GCYO:@>QO3>$-+FLGLS#((FMHK4[9.1'&2R@?B>?7\
M*?/X5LI;A[AGN$F:=)Q(LO*.J[ 1D?W>#^-8\7Q"MVM#_H<GV\22Q"U5A(3Y
M9(+;AG(S@#N2<#H<+K7B*?4]/>RT\36\TLMO:R3K)M:WED==R C^)5)SC_ZU
M C2A\(V5N\$D,MVAA>4@K*>DC!G4^Q(!]>.M+%X.TV&VBMPDS1)9FR*F8X,3
M=0??_"MV-E@MQOD(5%^9G/ZDUR__  G43V%YJ$-E)):00^<L@;B7YMJJ"1P6
M&"!UP><4 : T!HM)^Q07MXARBB5Y?G55.<#&./\ )S4VJZ!;ZS/9373SJ;.8
M3P^4^,.. 3QSUK/F\4W\=REJ="F-S(LLD47G(69$* -U^4'>>OI2#Q@KWMC!
M;632P7MS);Q3K(,$1H2[X[J"",]_RH&6)O"6EW$5TD\+S2783S9WE)D;8P91
MGL 0" ./:I7\+Z=<VU[#<0-(+T@W#LWS28Z D=O88_6L73?%<FH0:=>7<;6T
M,JW-Z/*E&P01@*#)QD@[P>,<@&MS2]8N[^=%?2YK>W>W$\<KD8))/RG'0X .
M.>M "GPW8M->3F)EDO(3"[*=I5#NR!Z'YCS]*?9Z%:6%U'+;B53':QVBJ'^7
M8A8K^/S']*S)?&UO*TYTRW-]'!/';2.D@4>:\FP*I/4Y()QQBJ[>/8UU,VAT
MYUC%^UDT_FKC*H79OH #GTHV"]S1N="CBOEU6-);J\@=Y+>*:;:JLR[#@X.
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MTHQ@9I!2 3<?2CJ"30I-'K3 0#YN*3J>*=TSBFCC/- "!L@[J0$ Y%+QC!I
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MNV_["-M_Z,%<O"$/Q&\)2*<YDNN?^W=JZCXC_P#(MVW_ &$;;_T8* .O XH
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M/>KBKM7%+10(**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MZ<U[+7#_  S'_$HOO^OP_P#HM*T@ERMM7)E>Z2=CB_\ A'OBF?\ EX;\K?\
MQH_X1[XI_P#/RWY6_P#C7<>+=?\ $OA]GNX(-,?3S(L<1D#F3)'?# =0:V],
MO[^&/R_$,VFP7<C$PI!(1O0#).&.21SG':I4XO[*_'_,Z982I&FJG-=/L]?/
MITZGEG_"._%+_GY;\K?_ !H_X1[XI?\ /RWY6_\ C7L4FIV$,$4\M];)%+CR
MY&E4*^?0YYI\]]:6L(FN+J"&(]'DD"J?Q-/FC_*OQ_S,/9S[L\9_X1WXI?\
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M9YNO\RM^!R?B*P73_%+?:IDL]+-JL5K))8?:HT  !0#^$YSS[U)<N-*T30+
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ME:Q7\!VLZVVJ:A+%)$E_>O-$D@P=F>#CWS^E1^ >FO?]A27^E7/^%@>%^?\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MB[[A9%?[!9_\^=O_ -^A_A1]@LO^?2W_ ._0_P *GI3VHN^X617_ +/L\_\
M'K;_ /?H?X4'3[/_ )]8/^_0_P *L8I*+L+$'V"S_P"?6#_OT/\ "C[!9_\
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M"3(X8MN.?N@ 'L>?<5:U#6K^"XL66^"6\]TD"X@#&3:"TK=S@[=J@#.?7(H
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M&KK/B1_R+=M_V$;;_P!&"N4MACXC>$_^NEU_Z(:NK^(__(N6W_81MO\ T8*
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M>_2I5UO2GF\I=2M#)N9=HF4G*C<PZ]@03Z9J1-4T]X7F6]M_+1PC/Y@ #'!
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MM9W,TT&^XM6MF_NDYJM8Z_8ZCJ-S96YF\ZW.)-\94?@>]:7^<TO?(&#W..M
M!D>M1QSP3;O*GCD*\$(X)!]\5*5!/3.1S5*RTC3].>5[.U6%Y6+2,#]XGJ:
M+E)BE-1SQ&:)D$C1Y'WEZB@"0J1C(QGUHXJCI^EO8-([7]S<ASG$Q^[]*O4
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MI)%)"R2A<X&6QGJ ,FG?K_6NH6Z'.Z]X:U#6]9G=I(%L988;<GS&$@C$F^4
M =6 49SVJSJ>DZF-5AN-*CLA!#:21Q+*Q413-C#[0I#<#'48Y]:UH-9TNY)$
M&HVLA$(G.V53B,]'//W3ZTJZQIKE M_;$O((E'FC+.1D*!W."#]#FE;2W]:Z
M?UYA?6_]?U^AQW_"$:@-+:/S;=KE--CL(/WK!5R<SN3M^\<\'';MFH_$-C>Z
M=%/=[K2TDNX?L"1I*2KR,PCAD (^5E1FW$=O4"NUDUC38H3,]_;+&&9"QD&
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M@Y )SSSWJU)XB\-S2S223J6GA\F0[C\R9)Q^I_.@#I;&8W-A;3L IDB5R .
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M[->39N'!N9#N"$G8=N W3G&!SQBI/^$7U-8[Z M:-;W&HQW[(I*F495GC/'
MRIQUSGG'-=G10M/Z]/\ ) ]?Z]?\V<E-X3N;^_%S>S1F.:^6[N858XVQIMBC
M''(SAF)QGTK0\.6&HZ7:);W<5L3*TL\\L<I)\UWW8 *C(P3SQC &.];M%"T!
MZA1110 5YKX\Y\?>&.1_J+K^2UZ57+^*/ NE^+GMGU)[J-[;/EO;3F-AGJ,C
MMP*3&F<?KNAV>OV*VEX&,:N'POJ,_P"-<]_PK#0,?ZN7\Z[/_A2WAOO?:W_X
M,&H_X4MX;_Y_M;_\#VIB.,_X5AH']R7\Z#\,- _N2_G79_\ "EO#?_/]K?\
MX'M1_P *6\-_\_VM_P#@P:@#B_\ A6.@?W)?SI#\,= _N2_G7:_\*6\.?\_V
MM_\ @>U'_"EO#G_/]K?_ ('M0!Q?_"L=!Q_JY?SKI=&TBVT33DL;0,(D)(R.
M>3FK_P#PI;PW_P _VM_^![4?\*6\-_\ /]K?_@P:@ _/\J/S_*D_X4MX;_Y_
MM;_\#VI?^%+>&_\ G^UO_P #VH */\]*3_A2WAO_ )_M;_\  ]J/^%+>&_\
MG^UO_P #VH 4_C32<#H:=_PI;PW_ ,_VM_\ @>U)_P *6\-_\_VM?^![4  Y
M['\J  #D9_*E_P"%+>&_^?[6_P#P/:C_ (4MX;_Y_M;_ / ]J $()I<<<YH_
MX4MX;_Y_M;_\#VH_X4MX;_Y_M;_\#VH *,4G_"EO#?\ S_:W_P"![4?\*6\-
M_P#/]K?_ ('M0 ?G^5+CZ_E1_P *6\.?\_VM_P#@>U'_  I;PW_S_:W_ .![
M4 &/K^5&/K^5'_"EO#?_ #_:W_X'M1_PI;PW_P _VM_^![4 'Y_E11_PI7PW
M_P _VM_^![4G_"EO#G_/]K?_ ('M0 ZC\_RIO_"EO#G_ #_:W_X'M2_\*6\.
M?\_VM_\ @>U "X-&#2?\*6\.?\_VM_\ @>U'_"EO#G_/]K?_ ('M0 O.>_Y4
M?G^5)_PI;PY_S_:W_P"![4?\*6\.?\_VM_\ @>U "X^OY4F/K^5)_P *6\.?
M\_VM_P#@>U'_  I;PW_S_:W_ .![4 &/2H"%\TX!W8[58_X4MX;_ .?[6_\
MP/:D_P"%+>&\_P#'[K7_ ('M0!FP_P#)1_">/^>EU_Z(:NH^(^?^$<ML#_F(
M6W;_ *:"H=$^%NAZ!K$&J6LVH2W, 81_:+MG"[A@G'T)_.NU9 PY /IF@!1T
M%+110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
-44 %%%% !1110!__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>18
<FILENAME>anvs-20211231x10k014.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 anvs-20211231x10k014.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" #I 7L# 2(  A$! Q$!_\0
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MB@ HHHH **** "BBFK(C#*NI'3(- #J*3(/>C<I7=D8]<T +12 @C(.0:6@
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M%8GV#Q%_T'+;_P  1_\ %4?8/$7_ $'+;_P!'_Q5&@&W16)]@\1?]!RV_P#
M$?\ Q5'V#Q%_T'+;_P  1_\ %4: ;=%8GV#Q%_T'+;_P!'_Q5'V#Q%_T'+;_
M , 1_P#%4: ;=%8GV#Q%_P!!RV_\ 1_\51]@\1?]!RV_\ 1_\51H!MT5B?8/
M$7_0<MO_  !'_P 51]@\1?\ 0<MO_ $?_%4: ;=%8GV#Q%_T'+;_ , 1_P#%
M4?8/$7_0<MO_  !'_P 51H!MT5B?8/$7_0<MO_ $?_%4?8/$7_0<MO\ P!'_
M ,51H!MT5B?8/$7_ $'+;_P!'_Q5'V#Q%_T'+;_P!'_Q5&@&W16)]@\1?]!R
MV_\  $?_ !5'V#Q%_P!!RV_\ 1_\51H!MTU_N-]*Q?L/B+_H.6W_ ( C_P"*
MI&L?$6TYUNVZ?\^(_P#BJ:W!GB2#Y%^@I<4Y1\JX]*7%?5K8\9C,48I^*,4[
M@1L/E/TKZ"LO^/"W_P"N2_R%> ,/E.?2O9K6Q\0&TA*:U;!?+7 ^Q9P,?[U>
M5FGPQ.S";LZ9?NBEJ*V61;:)9I!)*$ =PNT,<<G':I:XEL=9E>)2J^&-4+V1
MOE^RR9M1G,WRGY>.>?;FO-OA( VM7<K&%Y?LVQ_L\LS1Q8\L 8D)P2."2<GR
MZ]$\4WGV70+Q(K^&RO)X9([6660(/,VDC!/TS^%<'\+;F_N];NY[S5GNF>VP
M8#J(N1&%*JG /7AR3WW"F!ZMBF20Q3*%EC1U!# ,H(!'0T^B@!*Y/P7_ *G7
M/^PQ<?\ LM=;7)^"_P#4ZY_V&+C_ -EK.I\(T=-^-'XT45S%!^-'XT44 'XT
M?C110 ?C1^-%% !^-'XT44 'XT?C110 ?C1^-%% !^-'XT44 'XT?C110 ?C
M1^-%% !^-'XT44 'XT?C110 ?C1^-%% !^-'XT44 'XT?C110 ?C1^-%% !^
M--;[C?0TZFM]UOI36XF?/R+\B_2EVT]!\B_2EQ7U:>AX[(]M&VI,48H$1,/E
M/TKWRS_X\;?_ *Y+_(5X.P^4_2O>+/\ X\K?_KDO_H->7F?PQ.S";LN+]T4M
M(OW12UQK8ZSB?B3K<.C:?I0GDL8([N^%N]W>0B5;92C$N%/!.!C\:S? .I:3
M)XBN+#2M5TK5$-H9FGL[)()(R' VMMX8'.?;%=WJUQ966F7%[J"*UK;1M,Y9
M-^ !DX'K6!X6\7Z)XAU&XMM*L9H&CB#F9HD5'^[N4%6.2NY<]N>,TP.K+*HR
MQ  [FFO)'$ 9'5 2 "QQSZ5R7C33]-U.:UANQ%>7D<,TEII=S,(H+EL %F)4
M\J.1Z9_&N2\/0Z7XCNM$M]>;[981>&UEMQ?@ ,^\K-)@D@E55/FR< YSSF@#
MUVN3\%_ZG7/^PQ<?^RU'X,N=5E^'.DS6R0W=UY>U&NYFC#Q!R$8L%8\H%/3G
M-97A&?Q*(=8\G3M(;.JSE]]_*N&^7(&(3D>_'TK.I\(T=_16%]H\5_\ 0+T3
M_P &4O\ \8H^T>*_^@7HG_@RE_\ C%<]AF[16%]H\5_] O1/_!E+_P#&*/M'
MBO\ Z!>B?^#*7_XQ18#=HK"^T>*_^@7HG_@RE_\ C%'VCQ7_ - O1/\ P92_
M_&*+ ;M%87VCQ7_T"]$_\&4O_P 8H^T>*_\ H%Z)_P"#*7_XQ18#=HK"^T>*
M_P#H%Z)_X,I?_C%'VCQ7_P! O1/_  92_P#QBBP&[16%]H\5_P#0+T3_ ,&4
MO_QBC[1XK_Z!>B?^#*7_ .,46 W:*POM'BO_ *!>B?\ @RE_^,4?:/%?_0+T
M3_P92_\ QBBP&[16%]H\5_\ 0+T3_P &4O\ \8H^T>*_^@7HG_@RE_\ C%%@
M-VBL+[1XK_Z!>B?^#*7_ .,4?:/%?_0+T3_P92__ !BBP&[16%]H\5_] O1/
M_!E+_P#&*/M'BO\ Z!>B?^#*7_XQ18#=HK"^T>*_^@7HG_@RE_\ C%'VCQ7_
M - O1/\ P92__&*+ ;M%87VCQ7_T"]$_\&4O_P 8H^T>*_\ H%Z)_P"#*7_X
MQ18#=HK"^T>*_P#H%Z)_X,I?_C%'VCQ7_P! O1/_  92_P#QBBP&[16%]H\5
M_P#0+T3_ ,&4O_QBC[1XK_Z!>B?^#*7_ .,46 W:*POM'BO_ *!>B?\ @RE_
M^,4?:/%?_0+T3_P92_\ QBBP&[16%]H\5_\ 0+T3_P &4O\ \8H^T>*_^@7H
MG_@RE_\ C%%@-VD;[K?2L/[1XK_Z!>B?^#*7_P",4C7'BO!_XE>B8Q_T$9?_
M (Q32U!GD*#Y%^E.Q2J!M&.F*7%?4IZ'CC<48IV*,47 C8?*?I7NMI_QY0?]
M<U_E7AQ'RFO5K>?Q3]EA":9HQ38NTG4902,=_P!S7EYGJHG7A-V=.OW12U%;
M&9K:(W"(DY0&18V+*&QR 2 2,]\#Z5+7(MCK,#Q?]NCT&>ZLKF&);9'EGBEM
MUE6XC"G,?) &>.:QO 6L^#=4C0>&[6UM;M;8--!%;F,QJ3DJ>!_$:ZG6H[N;
M1+Z*PF6&\>!Q#*W1'QP3^-<%\,YM:DU&\CU.3]W%&>&U%+EG8E.1M)( VMR<
M?>'I3 [[4]&TS6H%@U33K2^A5MRI<PK(%/J 1P:CU'P_HVKV\-OJ6E6-Y# <
MPQSVZNL?3[H(XZ <5I44 -CC2)%2-51% 5548  Z "N5\%_ZG7/^PQ<?^RUU
ME<GX+_U.N?\ 88N/_9:SJ?"-'34445SE!1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !36^ZWTI
MU(WW6^E"W$SPI!\B_2G8I5'R+]*=@5]0MCR!F*,4_ HP*8$;#Y3]*]OM?^/.
M#_KFO\J\38?*?I7MEK_QYP?]<U_E7EYEM$ZL+NRVOW12TB_=%+7*MCK,;Q9&
M\OA'68TBDE9K.4"./.YCM/ P"<_2N!^$BO'<21R:3IMG(MF@9[;2KBUD8@C(
M=Y%"M^'?FNY\76NG2:#<7NIQ7,L-A')<;+>=XF;"$$94C/!/7ZUQGPOGT^34
M;@P:5)97$D#$C^UY+U0@*''S' /SCD#L13 ]0S1FN<\5?VB$@DBUD:/I<2O)
M?7<>PRX ^55WJR@9Z\9X %<UI5[XG\37.FZ7?:G=:-<1:2E[=/;0QK++*\C*
MFX.K!1MC)*@#EL=J /2*Y3P7_J=<_P"PQ<?^RU)X;\0:A?\ @C3]5FL)K^^=
M3'-':&-"[JY1F'F,J@94G&>]87A+6=0BBU@)X7U:;=JL['9+:#83M^4[IAR/
M;(]S6=1>Z-'?T5A?V_J?_0GZW_W^LO\ Y(H_M_4_^A/UO_O]9?\ R16%BC=H
MK"_M_4_^A/UO_O\ 67_R11_;^I_]"?K?_?ZR_P#DBBP&[16%_;^I_P#0GZW_
M -_K+_Y(H_M_4_\ H3];_P"_UE_\D46 W:*PO[?U/_H3];_[_67_ ,D4?V_J
M?_0GZW_W^LO_ )(HL!NT5A?V_J?_ $)^M_\ ?ZR_^2*/[?U/_H3];_[_ %E_
M\D46 W:*PO[?U/\ Z$_6_P#O]9?_ "11_;^I_P#0GZW_ -_K+_Y(HL!NT5A?
MV_J?_0GZW_W^LO\ Y(H_M_4_^A/UO_O]9?\ R118#=HK"_M_4_\ H3];_P"_
MUE_\D4?V_J?_ $)^M_\ ?ZR_^2*+ ;M%87]OZG_T)^M_]_K+_P"2*/[?U/\
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M&6B:1K,-];W&HO;VTIFMM/EN"]M!(<_,J'@$9./2N>_X6?J__/C8_P#?+_\
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M0=&MM,M6=HH%(W2'+,222Q]R23^-8G@P_N=<Z_\ (8N/_9:ZRN3\%_ZG7/\
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M*_MH_P#0P3_^!;_XT?VT?^AAG_\  M_\:ZOJ']]&/UG^Z>[X.:,&O"/[:/\
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MQ 3?IUG_ -=S_P"@FN!\FNE\2^-?"^LVD$5AKEG</')O94?H,8S7-_VKI?\
MS_0?]]5V8*7+12?F<^(3=03R:/)I?[5TO_G^@_[ZH_M72_\ G^@_[ZKJ]HNY
MCRL;Y/M77^ (]FHW9_Z8C_T*N2_M72_^?Z#_ +ZK;\->+?#FC74TM_K%I;HZ
M;59WZG-<^*E>C)(UHI\Z/4>U>9^)5SXCO?\ ?7_T$5O_ /"SO!'_ $,VG_\
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L"0Q'J,&NEHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>19
<FILENAME>anvs-20211231.xsd
<DESCRIPTION>EX-101.SCH
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--XBRL document created with Toppan Merrill Bridge  9.6.8042.36810 -->
<!--Based on XBRL 2.1-->
<!--Created on: 3/2/2022 8:59:47 PM-->
<!--Modified on: 3/2/2022 8:59:47 PM-->
<xsd:schema targetNamespace="http://annovisbio.com/20211231" attributeFormDefault="unqualified" elementFormDefault="qualified" xmlns:xsd="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:negated="http://www.xbrl.org/2009/role/negated" xmlns:xl="http://www.xbrl.org/2003/XLink" xmlns:us-gaap="http://fasb.org/us-gaap/2021-01-31" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:country="http://xbrl.sec.gov/country/2021" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:srt-types="http://fasb.org/srt-types/2021-01-31" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21" xmlns:anvs="http://annovisbio.com/20211231" xmlns:enum2="http://xbrl.org/2020/extensible-enumerations-2.0" xmlns:currency="http://xbrl.sec.gov/currency/2021" xmlns:us-roles="http://fasb.org/us-roles/2021-01-31" xmlns:sic="http://xbrl.sec.gov/sic/2021" xmlns:us-types="http://fasb.org/us-types/2021-01-31" xmlns:srt-roles="http://fasb.org/srt-roles/2021-01-31" xmlns:stpr="http://xbrl.sec.gov/stpr/2021" xmlns:exch="http://xbrl.sec.gov/exch/2021" xmlns:naics="http://xbrl.sec.gov/naics/2021" xmlns:attributeFormDefault="unqualified" xmlns:srt="http://fasb.org/srt/2021-01-31" xmlns:deprecated="http://www.xbrl.org/2009/role/deprecated" xmlns:net="http://www.xbrl.org/2009/role/net" xmlns:dei="http://xbrl.sec.gov/dei/2021q4">
  <xsd:annotation>
    <xsd:appinfo>
      <link:roleType roleURI="http://annovisbio.com/role/DisclosureStandardAndCustomAxisDomainDefaults" id="DisclosureStandardAndCustomAxisDomainDefaults">
        <link:definition>99900 - Disclosure - Standard And Custom Axis Domain Defaults</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://annovisbio.com/role/StatementBalanceSheets" id="StatementBalanceSheets">
        <link:definition>00100 - Statement - Balance Sheets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://annovisbio.com/role/StatementStatementsOfOperations" id="StatementStatementsOfOperations">
        <link:definition>00200 - Statement - Statements of Operations</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://annovisbio.com/role/StatementStatementsOfCashFlows" id="StatementStatementsOfCashFlows">
        <link:definition>00400 - Statement - Statements of Cash Flows</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://annovisbio.com/role/DisclosurePrepaidExpensesAndOtherCurrentAssetsDetails" id="DisclosurePrepaidExpensesAndOtherCurrentAssetsDetails">
        <link:definition>40501 - Disclosure - Prepaid Expenses and Other Current Assets (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://annovisbio.com/role/DisclosureAccruedExpensesDetails" id="DisclosureAccruedExpensesDetails">
        <link:definition>40601 - Disclosure - Accrued Expenses (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://annovisbio.com/role/DisclosureIncomeTaxesReconciliationOfIncomeTaxProvisionBenefitDetails" id="DisclosureIncomeTaxesReconciliationOfIncomeTaxProvisionBenefitDetails">
        <link:definition>41201 - Disclosure - Income Taxes - Reconciliation of income tax provision (benefit) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://annovisbio.com/role/DisclosureIncomeTaxesDeferredTaxesDetails" id="DisclosureIncomeTaxesDeferredTaxesDetails">
        <link:definition>41202 - Disclosure - Income Taxes - Deferred taxes (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://annovisbio.com/role/DocumentDocumentAndEntityInformation" id="DocumentDocumentAndEntityInformation">
        <link:definition>00090 - Document - Document and Entity Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://annovisbio.com/role/StatementBalanceSheetsParenthetical" id="StatementBalanceSheetsParenthetical">
        <link:definition>00105 - Statement - Balance Sheets (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://annovisbio.com/role/StatementStatementsOfChangesInRedeemableConvertiblePreferredStock" id="StatementStatementsOfChangesInRedeemableConvertiblePreferredStock">
        <link:definition>00300 - Statement - Statements of Changes in Redeemable Convertible Preferred Stock</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://annovisbio.com/role/StatementStatementsOfChangesInStockholdersEquityDeficit" id="StatementStatementsOfChangesInStockholdersEquityDeficit">
        <link:definition>00301 - Statement - Statements of Changes in Stockholders' Equity (Deficit)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://annovisbio.com/role/DisclosureNatureOfBusinessAndLiquidity" id="DisclosureNatureOfBusinessAndLiquidity">
        <link:definition>10101 - Disclosure - Nature of Business and Liquidity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://annovisbio.com/role/DisclosureSummaryOfSignificantAccountingPolicies" id="DisclosureSummaryOfSignificantAccountingPolicies">
        <link:definition>10201 - Disclosure - Summary of Significant Accounting Policies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://annovisbio.com/role/DisclosureFairValueMeasurements" id="DisclosureFairValueMeasurements">
        <link:definition>10301 - Disclosure - Fair Value Measurements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://annovisbio.com/role/DisclosurePrepaidExpensesAndOtherCurrentAssets" id="DisclosurePrepaidExpensesAndOtherCurrentAssets">
        <link:definition>10501 - Disclosure - Prepaid Expenses and Other Current Assets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://annovisbio.com/role/DisclosureAccruedExpenses" id="DisclosureAccruedExpenses">
        <link:definition>10601 - Disclosure - Accrued Expenses</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://annovisbio.com/role/DisclosureConvertiblePromissoryNotes" id="DisclosureConvertiblePromissoryNotes">
        <link:definition>10701 - Disclosure - Convertible Promissory Notes</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://annovisbio.com/role/DisclosureCommitmentsAndContingencies" id="DisclosureCommitmentsAndContingencies">
        <link:definition>10801 - Disclosure - Commitments and Contingencies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://annovisbio.com/role/DisclosureRedeemableConvertiblePreferredStockAndStockholdersEquity" id="DisclosureRedeemableConvertiblePreferredStockAndStockholdersEquity">
        <link:definition>10901 - Disclosure - Redeemable Convertible Preferred Stock and Stockholders' Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://annovisbio.com/role/DisclosureStockBasedCompensation" id="DisclosureStockBasedCompensation">
        <link:definition>11001 - Disclosure - Stock-Based Compensation</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://annovisbio.com/role/DisclosureNetLossPerShare" id="DisclosureNetLossPerShare">
        <link:definition>11101 - Disclosure - Net Loss Per Share</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://annovisbio.com/role/DisclosureIncomeTaxes" id="DisclosureIncomeTaxes">
        <link:definition>11201 - Disclosure - Income Taxes</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://annovisbio.com/role/DisclosureRelatedPartyTransactions" id="DisclosureRelatedPartyTransactions">
        <link:definition>11301 - Disclosure - Related-Party Transactions</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://annovisbio.com/role/DisclosureSubsequentEvents" id="DisclosureSubsequentEvents">
        <link:definition>11401 - Disclosure - Subsequent Events</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://annovisbio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" id="DisclosureSummaryOfSignificantAccountingPoliciesPolicies">
        <link:definition>20202 - Disclosure - Summary of Significant Accounting Policies (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://annovisbio.com/role/DisclosureFairValueMeasurementsTables" id="DisclosureFairValueMeasurementsTables">
        <link:definition>30303 - Disclosure - Fair Value Measurements (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://annovisbio.com/role/DisclosurePrepaidExpensesAndOtherCurrentAssetsTables" id="DisclosurePrepaidExpensesAndOtherCurrentAssetsTables">
        <link:definition>30503 - Disclosure - Prepaid Expenses and Other Current Assets (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://annovisbio.com/role/DisclosureAccruedExpensesTables" id="DisclosureAccruedExpensesTables">
        <link:definition>30603 - Disclosure - Accrued Expenses (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://annovisbio.com/role/DisclosureStockBasedCompensationTables" id="DisclosureStockBasedCompensationTables">
        <link:definition>31003 - Disclosure - Stock-Based Compensation (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://annovisbio.com/role/DisclosureNetLossPerShareTables" id="DisclosureNetLossPerShareTables">
        <link:definition>31103 - Disclosure - Net Loss Per Share (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://annovisbio.com/role/DisclosureIncomeTaxesTables" id="DisclosureIncomeTaxesTables">
        <link:definition>31203 - Disclosure - Income Taxes (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://annovisbio.com/role/DisclosureNatureOfBusinessAndLiquidityDetails" id="DisclosureNatureOfBusinessAndLiquidityDetails">
        <link:definition>40101 - Disclosure - Nature of Business and Liquidity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://annovisbio.com/role/DisclosureFairValueMeasurementsDetails" id="DisclosureFairValueMeasurementsDetails">
        <link:definition>40301 - Disclosure - Fair Value Measurements (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://annovisbio.com/role/DisclosureGrantIncomeDetails" id="DisclosureGrantIncomeDetails">
        <link:definition>40401 - Disclosure - Grant Income (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://annovisbio.com/role/DisclosureConvertiblePromissoryNotesDetails" id="DisclosureConvertiblePromissoryNotesDetails">
        <link:definition>40701 - Disclosure - Convertible Promissory Notes (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://annovisbio.com/role/DisclosureCommitmentsAndContingenciesLeasesDetails" id="DisclosureCommitmentsAndContingenciesLeasesDetails">
        <link:definition>40801 - Disclosure - Commitments and Contingencies - Leases (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://annovisbio.com/role/DisclosureCommitmentsAndContingenciesLicenseAgreementDetails" id="DisclosureCommitmentsAndContingenciesLicenseAgreementDetails">
        <link:definition>40802 - Disclosure - Commitments and Contingencies - License Agreement (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://annovisbio.com/role/DisclosureCommitmentsAndContingenciesEmploymentAgreementsDetails" id="DisclosureCommitmentsAndContingenciesEmploymentAgreementsDetails">
        <link:definition>40803 - Disclosure - Commitments and Contingencies - Employment Agreements (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://annovisbio.com/role/DisclosureRedeemableConvertiblePreferredStockAndStockholdersEquityCommonAndPreferredStockDetails" id="DisclosureRedeemableConvertiblePreferredStockAndStockholdersEquityCommonAndPreferredStockDetails">
        <link:definition>40901 - Disclosure - Redeemable Convertible Preferred Stock and Stockholders' Equity - Common and Preferred Stock (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://annovisbio.com/role/DisclosureRedeemableConvertiblePreferredStockAndStockholdersEquityWarrantsDetails" id="DisclosureRedeemableConvertiblePreferredStockAndStockholdersEquityWarrantsDetails">
        <link:definition>40902 - Disclosure - Redeemable Convertible Preferred Stock and Stockholders' Equity - Warrants (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://annovisbio.com/role/DisclosureStockBasedCompensationSummaryOfPlansDetails" id="DisclosureStockBasedCompensationSummaryOfPlansDetails">
        <link:definition>41001 - Disclosure - Stock-Based Compensation - Summary of plans (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://annovisbio.com/role/DisclosureStockBasedCompensationShareBasedCompensationExpenseDetails" id="DisclosureStockBasedCompensationShareBasedCompensationExpenseDetails">
        <link:definition>41002 - Disclosure - Stock-Based Compensation - Share-based compensation expense (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://annovisbio.com/role/DisclosureStockBasedCompensationStockOptionActivityDetails" id="DisclosureStockBasedCompensationStockOptionActivityDetails">
        <link:definition>41003 - Disclosure - Stock-Based Compensation - Stock option activity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://annovisbio.com/role/DisclosureStockBasedCompensationAdditionalDisclosuresDetails" id="DisclosureStockBasedCompensationAdditionalDisclosuresDetails">
        <link:definition>41004 - Disclosure - Stock-Based Compensation - Additional disclosures (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://annovisbio.com/role/DisclosureNetLossPerShareBasicAndDilutedNetLossPerShareDetails" id="DisclosureNetLossPerShareBasicAndDilutedNetLossPerShareDetails">
        <link:definition>41101 - Disclosure - Net Loss Per Share - Basic and diluted net loss per share (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://annovisbio.com/role/DisclosureNetLossPerSharePotentialSharesExcludedFromCalculationDetails" id="DisclosureNetLossPerSharePotentialSharesExcludedFromCalculationDetails">
        <link:definition>41102 - Disclosure - Net Loss Per Share - Potential shares excluded from calculation (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://annovisbio.com/role/DisclosureIncomeTaxesAdditionalDisclosuresDetails" id="DisclosureIncomeTaxesAdditionalDisclosuresDetails">
        <link:definition>41203 - Disclosure - Income Taxes - Additional disclosures (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://annovisbio.com/role/DisclosureRelatedPartyTransactionsDetails" id="DisclosureRelatedPartyTransactionsDetails">
        <link:definition>41301 - Disclosure - Related-Party Transactions (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://annovisbio.com/role/DisclosureSubsequentEventsDetails" id="DisclosureSubsequentEventsDetails">
        <link:definition>41401 - Disclosure - Subsequent Events (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://annovisbio.com/role/DisclosureGrantIncome" id="DisclosureGrantIncome">
        <link:definition>10401 - Disclosure - Grant Income</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:linkbaseRef xlink:type="simple" xlink:href="anvs-20211231_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
      <link:linkbaseRef xlink:type="simple" xlink:href="anvs-20211231_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
      <link:linkbaseRef xlink:type="simple" xlink:href="anvs-20211231_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
      <link:linkbaseRef xlink:type="simple" xlink:href="anvs-20211231_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Calculation Links, all" />
    </xsd:appinfo>
  </xsd:annotation>
  <xsd:import namespace="http://xbrl.sec.gov/dei/2021q4" schemaLocation="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd" />
  <xsd:import namespace="http://www.xbrl.org/dtr/type/2020-01-21" schemaLocation="https://www.xbrl.org/dtr/type/2020-01-21/types.xsd" />
  <xsd:import namespace="http://www.xbrl.org/2009/role/negated" schemaLocation="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd" />
  <xsd:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
  <xsd:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" />
  <xsd:import namespace="http://fasb.org/us-roles/2021-01-31" schemaLocation="https://xbrl.fasb.org/us-gaap/2021/elts/us-roles-2021-01-31.xsd" />
  <xsd:import namespace="http://fasb.org/us-gaap/2021-01-31" schemaLocation="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd" />
  <xsd:import namespace="http://fasb.org/srt/2021-01-31" schemaLocation="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd" />
  <xsd:element id="anvs_IncomeFromGrants" name="IncomeFromGrants" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="credit" />
  <xsd:element id="anvs_Series1RedeemableConvertiblePreferredStockMember" name="Series1RedeemableConvertiblePreferredStockMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="anvs_SeriesaRedeemableConvertiblePreferredStockMember" name="SeriesaRedeemableConvertiblePreferredStockMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="anvs_StockIssuedDuringPeriodValueConversionOfConvertibleSecuritiesPreferredStock" name="StockIssuedDuringPeriodValueConversionOfConvertibleSecuritiesPreferredStock" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="credit" />
  <xsd:element id="anvs_StockIssuedDuringPeriodSharesConversionOfConvertibleSecuritiesPreferredStock" name="StockIssuedDuringPeriodSharesConversionOfConvertibleSecuritiesPreferredStock" nillable="true" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <xsd:element id="anvs_StockIssuedDuringPeriodValueConversionOfConvertibleSecuritiesConvertiblePromissoryNotes" name="StockIssuedDuringPeriodValueConversionOfConvertibleSecuritiesConvertiblePromissoryNotes" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="credit" />
  <xsd:element id="anvs_TemporaryEquityConversionOfPreferredStockToCommonStock" name="TemporaryEquityConversionOfPreferredStockToCommonStock" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="debit" />
  <xsd:element id="anvs_TemporaryEquitySharesConversionOfPreferredStockToCommonStock" name="TemporaryEquitySharesConversionOfPreferredStockToCommonStock" nillable="true" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <xsd:element id="anvs_RedeemableConvertiblePreferredStockConvertibleConversionPrice" name="RedeemableConvertiblePreferredStockConvertibleConversionPrice" nillable="true" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" />
  <xsd:element id="anvs_NumberOfClassesOfStockDesignated" name="NumberOfClassesOfStockDesignated" nillable="true" type="xbrli:integerItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" />
  <xsd:element id="anvs_CommonStockAndPreferredStockSharesAuthorized" name="CommonStockAndPreferredStockSharesAuthorized" nillable="true" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" />
  <xsd:element id="anvs_NumberOfVotesForEachShareOfCommonStock" name="NumberOfVotesForEachShareOfCommonStock" nillable="true" type="xbrli:integerItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" />
  <xsd:element id="anvs_UnderwritersWarrantsMember" name="UnderwritersWarrantsMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="anvs_PercentageOfExercisePriceToShareOfferingPrice" name="PercentageOfExercisePriceToShareOfferingPrice" nillable="true" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" />
  <xsd:element id="anvs_GrantIncomePolicyTextBlock" name="GrantIncomePolicyTextBlock" nillable="true" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <xsd:element id="anvs_IncreaseDecreaseInGrantsReceivable" name="IncreaseDecreaseInGrantsReceivable" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="credit" />
  <xsd:element id="anvs_DeferredCostsCapitalizedPrepaidExpensesAndOtherAssetsDisclosureTextBlock" name="DeferredCostsCapitalizedPrepaidExpensesAndOtherAssetsDisclosureTextBlock" nillable="true" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <xsd:element id="anvs_AccruedLiabilitiesAndInterestAndEmployeeRelatedLiabilitiesCurrent" name="AccruedLiabilitiesAndInterestAndEmployeeRelatedLiabilitiesCurrent" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="credit" />
  <xsd:element id="anvs_AccruedLicensePaymentsCurrent" name="AccruedLicensePaymentsCurrent" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="credit" />
  <xsd:element id="anvs_PrepaidResearchAndDevelopmentExpenseCurrent" name="PrepaidResearchAndDevelopmentExpenseCurrent" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="debit" />
  <xsd:element id="anvs_PrepaidExpenseSecurityDepositsAndOtherAssetsCurrent" name="PrepaidExpenseSecurityDepositsAndOtherAssetsCurrent" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="debit" />
  <xsd:element id="anvs_RelatedPartyTransactionNumberOfCompanyDirectors" name="RelatedPartyTransactionNumberOfCompanyDirectors" nillable="true" type="xbrli:integerItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <xsd:element id="anvs_RelatedPartyTransactionIssuanceOfConvertiblePromissoryNotesMember" name="RelatedPartyTransactionIssuanceOfConvertiblePromissoryNotesMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="anvs_RelatedPartyTransactionConversionOfPromissoryNotesToCommonStockMember" name="RelatedPartyTransactionConversionOfPromissoryNotesToCommonStockMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="anvs_EarningsPerShareBasicAndDilutedNumeratorAbstract" name="EarningsPerShareBasicAndDilutedNumeratorAbstract" nillable="true" type="xbrli:stringItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="anvs_EarningsPerShareBasicAndDilutedDenominatorAbstract" name="EarningsPerShareBasicAndDilutedDenominatorAbstract" nillable="true" type="xbrli:stringItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="anvs_ConversionOfConvertibleSecuritiesConvertiblePromissoryNotesPercentageOfDiscountToInitialPublicOfferingPrice" name="ConversionOfConvertibleSecuritiesConvertiblePromissoryNotesPercentageOfDiscountToInitialPublicOfferingPrice" nillable="true" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <xsd:element id="anvs_ProceedsFromGrants" name="ProceedsFromGrants" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="debit" />
  <xsd:element id="anvs_NationalInstituteOnAgingOfNationalInstitutesOfHealthMember" name="NationalInstituteOnAgingOfNationalInstitutesOfHealthMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="anvs_GrantsReceivableNoticeOfAwardAmount" name="GrantsReceivableNoticeOfAwardAmount" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="debit" />
  <xsd:element id="anvs_NatureOfBusinessAndLiquidityAbstract" name="NatureOfBusinessAndLiquidityAbstract" nillable="true" type="xbrli:stringItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="anvs_InitialPublicOfferingAndOverAllotmentOptionMember" name="InitialPublicOfferingAndOverAllotmentOptionMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="anvs_LicenseAgreementMinimumAnnualCommitment" name="LicenseAgreementMinimumAnnualCommitment" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="credit" />
  <xsd:element id="anvs_LicenseAgreementTermsAmendedMay2012Member" name="LicenseAgreementTermsAmendedMay2012Member" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="anvs_CumulativeNumberOfMilestonesAchieved" name="CumulativeNumberOfMilestonesAchieved" nillable="true" type="xbrli:integerItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" />
  <xsd:element id="anvs_MaximumAggregateSeverancePayments" name="MaximumAggregateSeverancePayments" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="credit" />
  <xsd:element id="anvs_LicenseAgreementPeriodOfAdvanceNoticeOfTermination" name="LicenseAgreementPeriodOfAdvanceNoticeOfTermination" nillable="true" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <xsd:element id="anvs_EquityIncentivePlan2019Member" name="EquityIncentivePlan2019Member" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="anvs_ConversionOfRedeemableConvertiblePreferredStockToCommonStock" name="ConversionOfRedeemableConvertiblePreferredStockToCommonStock" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="debit" />
  <xsd:element id="anvs_ConversionOfConvertiblePromissoryNotesIncludingEmbeddedDerivativeToCommonStock" name="ConversionOfConvertiblePromissoryNotesIncludingEmbeddedDerivativeToCommonStock" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="debit" />
  <xsd:element id="anvs_CommonStockAndPreferredStockMember" name="CommonStockAndPreferredStockMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="anvs_StockPurchaseAgreementAxis" name="StockPurchaseAgreementAxis" nillable="true" type="xbrli:stringItemType" substitutionGroup="xbrldt:dimensionItem" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="anvs_StockPurchaseAgreementDomain" name="StockPurchaseAgreementDomain" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="anvs_EquityIncentivePlan2018Member" name="EquityIncentivePlan2018Member" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="anvs_GeneratedIn2017AndPriorMember" name="GeneratedIn2017AndPriorMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="anvs_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedInPeriodFairValue" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedInPeriodFairValue" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="debit" />
  <xsd:element id="anvs_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract" nillable="true" type="xbrli:stringItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="anvs_ShareBasedPaymentArrangementVestingPeriodOneYearMember" name="ShareBasedPaymentArrangementVestingPeriodOneYearMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="anvs_GrantAwardRemainingAmountAvailable" name="GrantAwardRemainingAmountAvailable" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="debit" />
  <xsd:element id="anvs_StockIssuedDuringPeriodValueWarrantsExercised" name="StockIssuedDuringPeriodValueWarrantsExercised" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="credit" />
  <xsd:element id="anvs_StockIssuedDuringPeriodSharesWarrantsExercised" name="StockIssuedDuringPeriodSharesWarrantsExercised" nillable="true" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <xsd:element id="anvs_StockIssuedDuringPeriodSharesConversionOfConvertibleNotes" name="StockIssuedDuringPeriodSharesConversionOfConvertibleNotes" nillable="true" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <xsd:element id="anvs_ConversionOfWarrantsNumberOfWarrantsConverted" name="ConversionOfWarrantsNumberOfWarrantsConverted" nillable="true" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <xsd:element id="anvs_SecondaryPublicOfferingMember" name="SecondaryPublicOfferingMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="anvs_IssuanceCostsAssociatedWithEquityIssuancesPolicyTextBlock" name="IssuanceCostsAssociatedWithEquityIssuancesPolicyTextBlock" nillable="true" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <xsd:element name="UnreimbursedEligibleCostsIncurredDuringPeriod" id="anvs_UnreimbursedEligibleCostsIncurredDuringPeriod" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="debit" />
  <xsd:element name="AwardsGrantedIn2021Member" id="anvs_AwardsGrantedIn2021Member" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="AwardsGrantedIn2020Member" id="anvs_AwardsGrantedIn2020Member" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="ShareBasedPaymentArrangementVestingPeriodImmediateVestingMember" id="anvs_ShareBasedPaymentArrangementVestingPeriodImmediateVestingMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="ShareBasedPaymentArrangementVestingPeriodTwoYearsMember" id="anvs_ShareBasedPaymentArrangementVestingPeriodTwoYearsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="ShareBasedPaymentArrangementVestingPeriodEqualQuarterlyInstallmentsOverTwoYearsMember" id="anvs_ShareBasedPaymentArrangementVestingPeriodEqualQuarterlyInstallmentsOverTwoYearsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="NonOperatingIncomeGrantIncomeAbstract" id="anvs_NonOperatingIncomeGrantIncomeAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="OtherNonoperatingIncomeGrantIncomeTextBlock" id="anvs_OtherNonoperatingIncomeGrantIncomeTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="DeferredTaxAssetsTaxCreditCarryforwardsCapitalizedResearchAndDevelopment" id="anvs_DeferredTaxAssetsTaxCreditCarryforwardsCapitalizedResearchAndDevelopment" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" xbrli:balance="debit" />
</xsd:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>20
<FILENAME>anvs-20211231_cal.xml
<DESCRIPTION>EX-101.CAL
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--XBRL document created with Toppan Merrill Bridge  9.6.8042.36810 -->
<!--Based on XBRL 2.1-->
<!--Created on: 3/2/2022 8:59:47 PM-->
<!--Modified on: 3/2/2022 8:59:47 PM-->
<link:linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance">
  <roleRef xlink:type="simple" xlink:href="anvs-20211231.xsd#StatementBalanceSheets" roleURI="http://annovisbio.com/role/StatementBalanceSheets" />
  <roleRef xlink:type="simple" xlink:href="anvs-20211231.xsd#StatementStatementsOfOperations" roleURI="http://annovisbio.com/role/StatementStatementsOfOperations" />
  <roleRef xlink:type="simple" xlink:href="anvs-20211231.xsd#StatementStatementsOfCashFlows" roleURI="http://annovisbio.com/role/StatementStatementsOfCashFlows" />
  <roleRef xlink:type="simple" xlink:href="anvs-20211231.xsd#DisclosurePrepaidExpensesAndOtherCurrentAssetsDetails" roleURI="http://annovisbio.com/role/DisclosurePrepaidExpensesAndOtherCurrentAssetsDetails" />
  <roleRef xlink:type="simple" xlink:href="anvs-20211231.xsd#DisclosureAccruedExpensesDetails" roleURI="http://annovisbio.com/role/DisclosureAccruedExpensesDetails" />
  <roleRef xlink:type="simple" xlink:href="anvs-20211231.xsd#DisclosureIncomeTaxesReconciliationOfIncomeTaxProvisionBenefitDetails" roleURI="http://annovisbio.com/role/DisclosureIncomeTaxesReconciliationOfIncomeTaxProvisionBenefitDetails" />
  <roleRef xlink:type="simple" xlink:href="anvs-20211231.xsd#DisclosureIncomeTaxesDeferredTaxesDetails" roleURI="http://annovisbio.com/role/DisclosureIncomeTaxesDeferredTaxesDetails" />
  <calculationLink xlink:role="http://annovisbio.com/role/StatementBalanceSheets" xlink:type="extended" xlink:title="00100 - Statement - Balance Sheets">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent_637818515858305957" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_AssetsCurrent_637818515858305957" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_637818515858305957" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent_637818515858305957" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_637818515858305957" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="anvs-20211231.xsd#anvs_PrepaidExpenseSecurityDepositsAndOtherAssetsCurrent" xlink:label="anvs_PrepaidExpenseSecurityDepositsAndOtherAssetsCurrent_637818515858305957" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent_637818515858305957" xlink:to="anvs_PrepaidExpenseSecurityDepositsAndOtherAssetsCurrent_637818515858305957" order="2" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities_637818515858315928" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_Liabilities_637818515858315928" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent_637818515858315928" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities_637818515858315928" xlink:to="us-gaap_LiabilitiesCurrent_637818515858315928" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent_637818515858315928" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent_637818515858315928" xlink:to="us-gaap_AccountsPayableCurrent_637818515858315928" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="anvs-20211231.xsd#anvs_AccruedLiabilitiesAndInterestAndEmployeeRelatedLiabilitiesCurrent" xlink:label="anvs_AccruedLiabilitiesAndInterestAndEmployeeRelatedLiabilitiesCurrent_637818515858315928" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent_637818515858315928" xlink:to="anvs_AccruedLiabilitiesAndInterestAndEmployeeRelatedLiabilitiesCurrent_637818515858315928" order="2" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies_637818515858315928" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_CommitmentsAndContingencies_637818515858315928" order="2" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity_637818515858315928" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_StockholdersEquity_637818515858315928" order="3" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue_637818515858315928" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity_637818515858315928" xlink:to="us-gaap_PreferredStockValue_637818515858315928" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue_637818515858315928" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity_637818515858315928" xlink:to="us-gaap_CommonStockValue_637818515858315928" order="2" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="us-gaap_AdditionalPaidInCapital_637818515858325880" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity_637818515858315928" xlink:to="us-gaap_AdditionalPaidInCapital_637818515858325880" order="3" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_637818515858325880" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity_637818515858315928" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_637818515858325880" order="4" use="optional" weight="1" priority="2" />
  </calculationLink>
  <calculationLink xlink:role="http://annovisbio.com/role/StatementStatementsOfOperations" xlink:type="extended" xlink:title="00200 - Statement - Statements of Operations">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_637818515858325880" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_637818515858325880" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss_637818515858325880" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_637818515858325880" xlink:to="us-gaap_OperatingIncomeLoss_637818515858325880" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses_637818515858325880" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss_637818515858325880" xlink:to="us-gaap_OperatingExpenses_637818515858325880" order="1" use="optional" weight="-1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense_637818515858325880" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses_637818515858325880" xlink:to="us-gaap_ResearchAndDevelopmentExpense_637818515858325880" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense_637818515858325880" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses_637818515858325880" xlink:to="us-gaap_GeneralAndAdministrativeExpense_637818515858325880" order="2" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="us-gaap_NonoperatingIncomeExpense_637818515858336010" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_637818515858325880" xlink:to="us-gaap_NonoperatingIncomeExpense_637818515858336010" order="2" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrealizedGainLossOnDerivatives" xlink:label="us-gaap_UnrealizedGainLossOnDerivatives_637818515858336010" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NonoperatingIncomeExpense_637818515858336010" xlink:to="us-gaap_UnrealizedGainLossOnDerivatives_637818515858336010" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestIncomeExpenseNonoperatingNet" xlink:label="us-gaap_InterestIncomeExpenseNonoperatingNet_637818515858336010" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NonoperatingIncomeExpense_637818515858336010" xlink:to="us-gaap_InterestIncomeExpenseNonoperatingNet_637818515858336010" order="2" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="anvs-20211231.xsd#anvs_IncomeFromGrants" xlink:label="anvs_IncomeFromGrants_637818515858336010" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NonoperatingIncomeExpense_637818515858336010" xlink:to="anvs_IncomeFromGrants_637818515858336010" order="3" use="optional" weight="1" priority="3" />
  </calculationLink>
  <calculationLink xlink:role="http://annovisbio.com/role/StatementStatementsOfCashFlows" xlink:type="extended" xlink:title="00400 - Statement - Statements of Cash Flows">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_637818515858336010" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_637818515858336010" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProfitLoss" xlink:label="us-gaap_ProfitLoss_637818515858336010" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_637818515858336010" xlink:to="us-gaap_ProfitLoss_637818515858336010" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AmortizationOfFinancingCosts" xlink:label="us-gaap_AmortizationOfFinancingCosts_637818515858336010" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_637818515858336010" xlink:to="us-gaap_AmortizationOfFinancingCosts_637818515858336010" order="2" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AmortizationOfDebtDiscountPremium" xlink:label="us-gaap_AmortizationOfDebtDiscountPremium_637818515858336010" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_637818515858336010" xlink:to="us-gaap_AmortizationOfDebtDiscountPremium_637818515858336010" order="3" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation_637818515858345879" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_637818515858336010" xlink:to="us-gaap_ShareBasedCompensation_637818515858345879" order="4" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrealizedGainLossOnDerivatives" xlink:label="us-gaap_UnrealizedGainLossOnDerivatives_637818515858345879" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_637818515858336010" xlink:to="us-gaap_UnrealizedGainLossOnDerivatives_637818515858345879" order="5" use="optional" weight="-1" priority="3" />
    <loc xlink:type="locator" xlink:href="anvs-20211231.xsd#anvs_IncreaseDecreaseInGrantsReceivable" xlink:label="anvs_IncreaseDecreaseInGrantsReceivable_637818515858345879" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_637818515858336010" xlink:to="anvs_IncreaseDecreaseInGrantsReceivable_637818515858345879" order="6" use="optional" weight="-1" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_637818515858345879" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_637818515858336010" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_637818515858345879" order="7" use="optional" weight="-1" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_637818515858345879" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_637818515858336010" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable_637818515858345879" order="8" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities_637818515858345879" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_637818515858336010" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilities_637818515858345879" order="9" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_637818515858345879" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_637818515858345879" order="2" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_637818515858345879" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities_637818515858345879" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_637818515858345879" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="us-gaap_ProceedsFromStockOptionsExercised_637818515858345879" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities_637818515858345879" xlink:to="us-gaap_ProceedsFromStockOptionsExercised_637818515858345879" order="2" use="optional" weight="1" priority="2" />
  </calculationLink>
  <calculationLink xlink:role="http://annovisbio.com/role/DisclosurePrepaidExpensesAndOtherCurrentAssetsDetails" xlink:type="extended" xlink:title="40501 - Disclosure - Prepaid Expenses and Other Current Assets (Details)">
    <loc xlink:type="locator" xlink:href="anvs-20211231.xsd#anvs_PrepaidExpenseSecurityDepositsAndOtherAssetsCurrent" xlink:label="anvs_PrepaidExpenseSecurityDepositsAndOtherAssetsCurrent" />
    <loc xlink:type="locator" xlink:href="anvs-20211231.xsd#anvs_PrepaidResearchAndDevelopmentExpenseCurrent" xlink:label="anvs_PrepaidResearchAndDevelopmentExpenseCurrent_637818515858355879" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="anvs_PrepaidExpenseSecurityDepositsAndOtherAssetsCurrent" xlink:to="anvs_PrepaidResearchAndDevelopmentExpenseCurrent_637818515858355879" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidInsurance" xlink:label="us-gaap_PrepaidInsurance_637818515858355879" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="anvs_PrepaidExpenseSecurityDepositsAndOtherAssetsCurrent" xlink:to="us-gaap_PrepaidInsurance_637818515858355879" order="2" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherPrepaidExpenseCurrent" xlink:label="us-gaap_OtherPrepaidExpenseCurrent_637818515858355879" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="anvs_PrepaidExpenseSecurityDepositsAndOtherAssetsCurrent" xlink:to="us-gaap_OtherPrepaidExpenseCurrent_637818515858355879" order="3" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SecurityDeposit" xlink:label="us-gaap_SecurityDeposit_637818515858355879" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="anvs_PrepaidExpenseSecurityDepositsAndOtherAssetsCurrent" xlink:to="us-gaap_SecurityDeposit_637818515858355879" order="4" use="optional" weight="1" priority="2" />
  </calculationLink>
  <calculationLink xlink:role="http://annovisbio.com/role/DisclosureAccruedExpensesDetails" xlink:type="extended" xlink:title="40601 - Disclosure - Accrued Expenses (Details)">
    <loc xlink:type="locator" xlink:href="anvs-20211231.xsd#anvs_AccruedLiabilitiesAndInterestAndEmployeeRelatedLiabilitiesCurrent" xlink:label="anvs_AccruedLiabilitiesAndInterestAndEmployeeRelatedLiabilitiesCurrent" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent_637818515858355879" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="anvs_AccruedLiabilitiesAndInterestAndEmployeeRelatedLiabilitiesCurrent" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrent_637818515858355879" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:label="us-gaap_AccruedProfessionalFeesCurrent_637818515858355879" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="anvs_AccruedLiabilitiesAndInterestAndEmployeeRelatedLiabilitiesCurrent" xlink:to="us-gaap_AccruedProfessionalFeesCurrent_637818515858355879" order="2" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="anvs-20211231.xsd#anvs_AccruedLicensePaymentsCurrent" xlink:label="anvs_AccruedLicensePaymentsCurrent_637818515858365905" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="anvs_AccruedLiabilitiesAndInterestAndEmployeeRelatedLiabilitiesCurrent" xlink:to="anvs_AccruedLicensePaymentsCurrent_637818515858365905" order="3" use="optional" weight="1" priority="2" />
  </calculationLink>
  <calculationLink xlink:role="http://annovisbio.com/role/DisclosureIncomeTaxesReconciliationOfIncomeTaxProvisionBenefitDetails" xlink:type="extended" xlink:title="41201 - Disclosure - Income Taxes - Reconciliation of income tax provision (benefit) (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_637818515858365905" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_637818515858365905" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_637818515858365905" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_637818515858365905" order="2" use="optional" weight="1" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense_637818515858365905" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense_637818515858365905" order="3" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost_637818515858365905" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost_637818515858365905" order="4" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment_637818515858365905" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment_637818515858365905" order="5" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_637818515858365905" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_637818515858365905" order="6" use="optional" weight="1" priority="2" />
  </calculationLink>
  <calculationLink xlink:role="http://annovisbio.com/role/DisclosureIncomeTaxesDeferredTaxesDetails" xlink:type="extended" xlink:title="41202 - Disclosure - Income Taxes - Deferred taxes (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="us-gaap_DeferredTaxAssetsNet" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_637818515858365905" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsNet" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance_637818515858365905" order="1" use="optional" weight="-1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="us-gaap_DeferredTaxAssetsGross_637818515858375895" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsNet" xlink:to="us-gaap_DeferredTaxAssetsGross_637818515858375895" order="2" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_637818515858375895" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross_637818515858375895" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_637818515858375895" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="anvs-20211231.xsd#anvs_DeferredTaxAssetsTaxCreditCarryforwardsCapitalizedResearchAndDevelopment" xlink:label="anvs_DeferredTaxAssetsTaxCreditCarryforwardsCapitalizedResearchAndDevelopment_637818515858375895" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross_637818515858375895" xlink:to="anvs_DeferredTaxAssetsTaxCreditCarryforwardsCapitalizedResearchAndDevelopment_637818515858375895" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_637818515858375895" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross_637818515858375895" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_637818515858375895" order="3" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_637818515858375895" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross_637818515858375895" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_637818515858375895" order="4" use="optional" weight="1" priority="2" />
  </calculationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>21
<FILENAME>anvs-20211231_def.xml
<DESCRIPTION>EX-101.DEF
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--XBRL document created with Toppan Merrill Bridge  9.6.8042.36810 -->
<!--Based on XBRL 2.1-->
<!--Created on: 3/2/2022 8:59:47 PM-->
<!--Modified on: 3/2/2022 8:59:47 PM-->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt">
  <roleRef xlink:type="simple" xlink:href="anvs-20211231.xsd#StatementStatementsOfChangesInRedeemableConvertiblePreferredStock" roleURI="http://annovisbio.com/role/StatementStatementsOfChangesInRedeemableConvertiblePreferredStock" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="anvs-20211231.xsd#StatementStatementsOfChangesInStockholdersEquityDeficit" roleURI="http://annovisbio.com/role/StatementStatementsOfChangesInStockholdersEquityDeficit" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="anvs-20211231.xsd#DisclosureNatureOfBusinessAndLiquidityDetails" roleURI="http://annovisbio.com/role/DisclosureNatureOfBusinessAndLiquidityDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="anvs-20211231.xsd#DisclosureFairValueMeasurementsDetails" roleURI="http://annovisbio.com/role/DisclosureFairValueMeasurementsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="anvs-20211231.xsd#DisclosureGrantIncomeDetails" roleURI="http://annovisbio.com/role/DisclosureGrantIncomeDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="anvs-20211231.xsd#DisclosureConvertiblePromissoryNotesDetails" roleURI="http://annovisbio.com/role/DisclosureConvertiblePromissoryNotesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="anvs-20211231.xsd#DisclosureCommitmentsAndContingenciesLicenseAgreementDetails" roleURI="http://annovisbio.com/role/DisclosureCommitmentsAndContingenciesLicenseAgreementDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="anvs-20211231.xsd#DisclosureCommitmentsAndContingenciesEmploymentAgreementsDetails" roleURI="http://annovisbio.com/role/DisclosureCommitmentsAndContingenciesEmploymentAgreementsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="anvs-20211231.xsd#DisclosureRedeemableConvertiblePreferredStockAndStockholdersEquityCommonAndPreferredStockDetails" roleURI="http://annovisbio.com/role/DisclosureRedeemableConvertiblePreferredStockAndStockholdersEquityCommonAndPreferredStockDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="anvs-20211231.xsd#DisclosureRedeemableConvertiblePreferredStockAndStockholdersEquityWarrantsDetails" roleURI="http://annovisbio.com/role/DisclosureRedeemableConvertiblePreferredStockAndStockholdersEquityWarrantsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="anvs-20211231.xsd#DisclosureStockBasedCompensationSummaryOfPlansDetails" roleURI="http://annovisbio.com/role/DisclosureStockBasedCompensationSummaryOfPlansDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="anvs-20211231.xsd#DisclosureStockBasedCompensationShareBasedCompensationExpenseDetails" roleURI="http://annovisbio.com/role/DisclosureStockBasedCompensationShareBasedCompensationExpenseDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="anvs-20211231.xsd#DisclosureStockBasedCompensationAdditionalDisclosuresDetails" roleURI="http://annovisbio.com/role/DisclosureStockBasedCompensationAdditionalDisclosuresDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="anvs-20211231.xsd#DisclosureNetLossPerSharePotentialSharesExcludedFromCalculationDetails" roleURI="http://annovisbio.com/role/DisclosureNetLossPerSharePotentialSharesExcludedFromCalculationDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="anvs-20211231.xsd#DisclosureIncomeTaxesAdditionalDisclosuresDetails" roleURI="http://annovisbio.com/role/DisclosureIncomeTaxesAdditionalDisclosuresDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="anvs-20211231.xsd#DisclosureRelatedPartyTransactionsDetails" roleURI="http://annovisbio.com/role/DisclosureRelatedPartyTransactionsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="anvs-20211231.xsd#DisclosureSubsequentEventsDetails" roleURI="http://annovisbio.com/role/DisclosureSubsequentEventsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <link:arcroleRef arcroleURI="http://www.esma.europa.eu/xbrl/esef/arcrole/wider-narrower" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/arcrole/esma-arcrole-2018-11-21.xsd#wider-narrower" />
  <link:roleRef roleURI="http://annovisbio.com/role/DisclosureStandardAndCustomAxisDomainDefaults" xlink:href="anvs-20211231.xsd#DisclosureStandardAndCustomAxisDomainDefaults" xlink:type="simple" />
  <roleRef xlink:type="simple" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-roles-2021-01-31.xsd#eedm" roleURI="http://fasb.org/us-gaap/role/eedm/ExtensibleEnumerationLists" xmlns="http://www.xbrl.org/2003/linkbase" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" />
  <definitionLink xlink:role="http://fasb.org/us-gaap/role/eedm/ExtensibleEnumerationLists" xlink:type="extended" xlink:title="Extensible Enumeration Domain Members" xmlns="http://www.xbrl.org/2003/linkbase" />
  <link:definitionLink xlink:role="http://annovisbio.com/role/DisclosureStandardAndCustomAxisDomainDefaults" xlink:type="extended" xlink:title="99900 - Disclosure - Standard And Custom Axis Domain Defaults">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis_1" xlink:title="us-gaap_StatementClassOfStockAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain_1" xlink:title="us-gaap_ClassOfStockDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_StatementClassOfStockAxis_1" xlink:to="us-gaap_ClassOfStockDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_StatementClassOfStockAxis_1 To us-gaap_ClassOfStockDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementScenarioAxis" xlink:label="srt_StatementScenarioAxis_1" xlink:title="srt_StatementScenarioAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="srt_ScenarioUnspecifiedDomain_1" xlink:title="srt_ScenarioUnspecifiedDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="srt_StatementScenarioAxis_1" xlink:to="srt_ScenarioUnspecifiedDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:srt_StatementScenarioAxis_1 To srt_ScenarioUnspecifiedDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis_1" xlink:title="us-gaap_StatementEquityComponentsAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain_1" xlink:title="us-gaap_EquityComponentDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_StatementEquityComponentsAxis_1" xlink:to="us-gaap_EquityComponentDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_StatementEquityComponentsAxis_1 To us-gaap_EquityComponentDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis_1" xlink:title="dei_LegalEntityAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain_1" xlink:title="dei_EntityDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="dei_LegalEntityAxis_1" xlink:to="dei_EntityDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:dei_LegalEntityAxis_1 To dei_EntityDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_1" xlink:title="us-gaap_SubsidiarySaleOfStockAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_1" xlink:title="us-gaap_SaleOfStockNameOfTransactionDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_SubsidiarySaleOfStockAxis_1" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_SubsidiarySaleOfStockAxis_1 To us-gaap_SaleOfStockNameOfTransactionDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis_1" xlink:title="us-gaap_ClassOfWarrantOrRightAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain_1" xlink:title="us-gaap_ClassOfWarrantOrRightDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_ClassOfWarrantOrRightAxis_1" xlink:to="us-gaap_ClassOfWarrantOrRightDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_ClassOfWarrantOrRightAxis_1 To us-gaap_ClassOfWarrantOrRightDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis_1" xlink:title="us-gaap_FairValueByMeasurementFrequencyAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain_1" xlink:title="us-gaap_FairValueMeasurementFrequencyDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis_1" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_FairValueByMeasurementFrequencyAxis_1 To us-gaap_FairValueMeasurementFrequencyDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis_1" xlink:title="us-gaap_FairValueByFairValueHierarchyLevelAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_1" xlink:title="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis_1" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_FairValueByFairValueHierarchyLevelAxis_1 To us-gaap_FairValueMeasurementsFairValueHierarchyDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis_1" xlink:title="us-gaap_TypeOfArrangementAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_1" xlink:title="us-gaap_ArrangementsAndNonarrangementTransactionsMember_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_TypeOfArrangementAxis_1" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_TypeOfArrangementAxis_1 To us-gaap_ArrangementsAndNonarrangementTransactionsMember_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="us-gaap_LongtermDebtTypeAxis_1" xlink:title="us-gaap_LongtermDebtTypeAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="us-gaap_LongtermDebtTypeDomain_1" xlink:title="us-gaap_LongtermDebtTypeDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_LongtermDebtTypeAxis_1" xlink:to="us-gaap_LongtermDebtTypeDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_LongtermDebtTypeAxis_1 To us-gaap_LongtermDebtTypeDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_1" xlink:title="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_1" xlink:title="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_1" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_1 To us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis_1" xlink:title="srt_CounterpartyNameAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain_1" xlink:title="srt_RepurchaseAgreementCounterpartyNameDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="srt_CounterpartyNameAxis_1" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:srt_CounterpartyNameAxis_1 To srt_RepurchaseAgreementCounterpartyNameDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualAxis" xlink:label="srt_TitleOfIndividualAxis_1" xlink:title="srt_TitleOfIndividualAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain_1" xlink:title="srt_TitleOfIndividualWithRelationshipToEntityDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="srt_TitleOfIndividualAxis_1" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:srt_TitleOfIndividualAxis_1 To srt_TitleOfIndividualWithRelationshipToEntityDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="anvs-20211231.xsd#anvs_StockPurchaseAgreementAxis" xlink:label="anvs_StockPurchaseAgreementAxis_1" xlink:title="anvs_StockPurchaseAgreementAxis_1" />
    <link:loc xlink:type="locator" xlink:href="anvs-20211231.xsd#anvs_StockPurchaseAgreementDomain" xlink:label="anvs_StockPurchaseAgreementDomain_1" xlink:title="anvs_StockPurchaseAgreementDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="anvs_StockPurchaseAgreementAxis_1" xlink:to="anvs_StockPurchaseAgreementDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:anvs_StockPurchaseAgreementAxis_1 To anvs_StockPurchaseAgreementDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis_1" xlink:title="us-gaap_PlanNameAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain_1" xlink:title="us-gaap_PlanNameDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_PlanNameAxis_1" xlink:to="us-gaap_PlanNameDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_PlanNameAxis_1 To us-gaap_PlanNameDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis_1" xlink:title="us-gaap_AwardTypeAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1" xlink:title="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_AwardTypeAxis_1" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_AwardTypeAxis_1 To us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_1" xlink:title="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_1" xlink:title="us-gaap_AntidilutiveSecuritiesNameDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_1" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_1 To us-gaap_AntidilutiveSecuritiesNameDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_1" xlink:title="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain_1" xlink:title="us-gaap_RelatedPartyDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_1" xlink:to="us-gaap_RelatedPartyDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_1 To us-gaap_RelatedPartyDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionAxis" xlink:label="us-gaap_RelatedPartyTransactionAxis_1" xlink:title="us-gaap_RelatedPartyTransactionAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="us-gaap_RelatedPartyTransactionDomain_1" xlink:title="us-gaap_RelatedPartyTransactionDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_RelatedPartyTransactionAxis_1" xlink:to="us-gaap_RelatedPartyTransactionDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_RelatedPartyTransactionAxis_1 To us-gaap_RelatedPartyTransactionDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis_1" xlink:title="us-gaap_SubsequentEventTypeAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain_1" xlink:title="us-gaap_SubsequentEventTypeDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_SubsequentEventTypeAxis_1" xlink:to="us-gaap_SubsequentEventTypeDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_SubsequentEventTypeAxis_1 To us-gaap_SubsequentEventTypeDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GranteeStatusAxis" xlink:label="us-gaap_GranteeStatusAxis_1" xlink:title="us-gaap_GranteeStatusAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GranteeStatusDomain" xlink:label="us-gaap_GranteeStatusDomain_1" xlink:title="us-gaap_GranteeStatusDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_GranteeStatusAxis_1" xlink:to="us-gaap_GranteeStatusDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_GranteeStatusAxis_1 To us-gaap_GranteeStatusDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VestingAxis" xlink:label="us-gaap_VestingAxis_1" xlink:title="us-gaap_VestingAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VestingDomain" xlink:label="us-gaap_VestingDomain_1" xlink:title="us-gaap_VestingDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_VestingAxis_1" xlink:to="us-gaap_VestingDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_VestingAxis_1 To us-gaap_VestingDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis_1" xlink:title="us-gaap_IncomeStatementLocationAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain_1" xlink:title="us-gaap_IncomeStatementLocationDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_IncomeStatementLocationAxis_1" xlink:to="us-gaap_IncomeStatementLocationDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_IncomeStatementLocationAxis_1 To us-gaap_IncomeStatementLocationDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="us-gaap_IncomeTaxAuthorityAxis_1" xlink:title="us-gaap_IncomeTaxAuthorityAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain_1" xlink:title="us-gaap_IncomeTaxAuthorityDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_IncomeTaxAuthorityAxis_1" xlink:to="us-gaap_IncomeTaxAuthorityDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_IncomeTaxAuthorityAxis_1 To us-gaap_IncomeTaxAuthorityDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxPeriodAxis" xlink:label="us-gaap_TaxPeriodAxis_1" xlink:title="us-gaap_TaxPeriodAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxPeriodDomain" xlink:label="us-gaap_TaxPeriodDomain_1" xlink:title="us-gaap_TaxPeriodDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_TaxPeriodAxis_1" xlink:to="us-gaap_TaxPeriodDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_TaxPeriodAxis_1 To us-gaap_TaxPeriodDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxCreditCarryforwardAxis" xlink:label="us-gaap_TaxCreditCarryforwardAxis_1" xlink:title="us-gaap_TaxCreditCarryforwardAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxCreditCarryforwardNameDomain" xlink:label="us-gaap_TaxCreditCarryforwardNameDomain_1" xlink:title="us-gaap_TaxCreditCarryforwardNameDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_TaxCreditCarryforwardAxis_1" xlink:to="us-gaap_TaxCreditCarryforwardNameDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_TaxCreditCarryforwardAxis_1 To us-gaap_TaxCreditCarryforwardNameDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardDateAxis" xlink:label="us-gaap_AwardDateAxis_1" xlink:title="us-gaap_AwardDateAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardDateDomain" xlink:label="us-gaap_AwardDateDomain_1" xlink:title="us-gaap_AwardDateDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_AwardDateAxis_1" xlink:to="us-gaap_AwardDateDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_AwardDateAxis_1 To us-gaap_AwardDateDomain_1" order="1" />
  </link:definitionLink>
  <definitionLink xlink:role="http://annovisbio.com/role/StatementStatementsOfChangesInRedeemableConvertiblePreferredStock" xlink:type="extended" xlink:title="00300 - Statement - Statements of Changes in Redeemable Convertible Preferred Stock" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RedeemableConvertiblePreferredStockMember" xlink:label="us-gaap_RedeemableConvertiblePreferredStockMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_RedeemableConvertiblePreferredStockMember" use="optional" />
    <loc xlink:type="locator" xlink:href="anvs-20211231.xsd#anvs_SeriesaRedeemableConvertiblePreferredStockMember" xlink:label="anvs_SeriesaRedeemableConvertiblePreferredStockMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_RedeemableConvertiblePreferredStockMember" xlink:to="anvs_SeriesaRedeemableConvertiblePreferredStockMember" use="optional" />
    <loc xlink:type="locator" xlink:href="anvs-20211231.xsd#anvs_Series1RedeemableConvertiblePreferredStockMember" xlink:label="anvs_Series1RedeemableConvertiblePreferredStockMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_RedeemableConvertiblePreferredStockMember" xlink:to="anvs_Series1RedeemableConvertiblePreferredStockMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInTemporaryEquityRollForward" xlink:label="us-gaap_IncreaseDecreaseInTemporaryEquityRollForward" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_IncreaseDecreaseInTemporaryEquityRollForward" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_IncreaseDecreaseInTemporaryEquityRollForward" xlink:to="us-gaap_TemporaryEquityCarryingAmountAttributableToParent" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquitySharesIssued" xlink:label="us-gaap_TemporaryEquitySharesIssued" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_IncreaseDecreaseInTemporaryEquityRollForward" xlink:to="us-gaap_TemporaryEquitySharesIssued" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="anvs-20211231.xsd#anvs_TemporaryEquityConversionOfPreferredStockToCommonStock" xlink:label="anvs_TemporaryEquityConversionOfPreferredStockToCommonStock" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_IncreaseDecreaseInTemporaryEquityRollForward" xlink:to="anvs_TemporaryEquityConversionOfPreferredStockToCommonStock" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="anvs-20211231.xsd#anvs_TemporaryEquitySharesConversionOfPreferredStockToCommonStock" xlink:label="anvs_TemporaryEquitySharesConversionOfPreferredStockToCommonStock" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="anvs_TemporaryEquityConversionOfPreferredStockToCommonStock" xlink:to="anvs_TemporaryEquitySharesConversionOfPreferredStockToCommonStock" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://annovisbio.com/role/StatementStatementsOfChangesInStockholdersEquityDeficit" xlink:type="extended" xlink:title="00301 - Statement - Statements of Changes in Stockholders' Equity (Deficit)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AdditionalPaidInCapitalMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_RetainedEarningsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:label="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="us-gaap_StockholdersEquity" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesIssued" xlink:label="us-gaap_SharesIssued" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="us-gaap_SharesIssued" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="anvs-20211231.xsd#anvs_StockIssuedDuringPeriodValueConversionOfConvertibleSecuritiesPreferredStock" xlink:label="anvs_StockIssuedDuringPeriodValueConversionOfConvertibleSecuritiesPreferredStock" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="anvs_StockIssuedDuringPeriodValueConversionOfConvertibleSecuritiesPreferredStock" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="anvs-20211231.xsd#anvs_StockIssuedDuringPeriodSharesConversionOfConvertibleSecuritiesPreferredStock" xlink:label="anvs_StockIssuedDuringPeriodSharesConversionOfConvertibleSecuritiesPreferredStock" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="anvs_StockIssuedDuringPeriodValueConversionOfConvertibleSecuritiesPreferredStock" xlink:to="anvs_StockIssuedDuringPeriodSharesConversionOfConvertibleSecuritiesPreferredStock" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="anvs-20211231.xsd#anvs_StockIssuedDuringPeriodValueConversionOfConvertibleSecuritiesConvertiblePromissoryNotes" xlink:label="anvs_StockIssuedDuringPeriodValueConversionOfConvertibleSecuritiesConvertiblePromissoryNotes" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="anvs_StockIssuedDuringPeriodValueConversionOfConvertibleSecuritiesConvertiblePromissoryNotes" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="anvs-20211231.xsd#anvs_StockIssuedDuringPeriodSharesConversionOfConvertibleNotes" xlink:label="anvs_StockIssuedDuringPeriodSharesConversionOfConvertibleNotes" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="anvs_StockIssuedDuringPeriodValueConversionOfConvertibleSecuritiesConvertiblePromissoryNotes" xlink:to="anvs_StockIssuedDuringPeriodSharesConversionOfConvertibleNotes" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="anvs-20211231.xsd#anvs_StockIssuedDuringPeriodValueWarrantsExercised" xlink:label="anvs_StockIssuedDuringPeriodValueWarrantsExercised" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="anvs_StockIssuedDuringPeriodValueWarrantsExercised" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="anvs-20211231.xsd#anvs_StockIssuedDuringPeriodSharesWarrantsExercised" xlink:label="anvs_StockIssuedDuringPeriodSharesWarrantsExercised" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="anvs_StockIssuedDuringPeriodValueWarrantsExercised" xlink:to="anvs_StockIssuedDuringPeriodSharesWarrantsExercised" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:label="us-gaap_StockIssuedDuringPeriodValueIssuedForServices" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="us-gaap_StockIssuedDuringPeriodValueIssuedForServices" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:label="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:to="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="10" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="us-gaap_NetIncomeLoss" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://annovisbio.com/role/DisclosureNatureOfBusinessAndLiquidityDetails" xlink:type="extended" xlink:title="40101 - Disclosure - Nature of Business and Liquidity (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="us-gaap_ScheduleOfStockByClassTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_StatementEquityComponentsAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="anvs-20211231.xsd#anvs_InitialPublicOfferingAndOverAllotmentOptionMember" xlink:label="anvs_InitialPublicOfferingAndOverAllotmentOptionMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="anvs_InitialPublicOfferingAndOverAllotmentOptionMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IPOMember" xlink:label="us-gaap_IPOMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="anvs_InitialPublicOfferingAndOverAllotmentOptionMember" xlink:to="us-gaap_IPOMember" use="optional" />
    <loc xlink:type="locator" xlink:href="anvs-20211231.xsd#anvs_SecondaryPublicOfferingMember" xlink:label="anvs_SecondaryPublicOfferingMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="anvs_SecondaryPublicOfferingMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="3" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_ClassOfWarrantOrRightAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="anvs-20211231.xsd#anvs_UnderwritersWarrantsMember" xlink:label="anvs_UnderwritersWarrantsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="anvs_UnderwritersWarrantsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockLineItems" xlink:label="us-gaap_ClassOfStockLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ScheduleOfStockByClassTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="anvs-20211231.xsd#anvs_NatureOfBusinessAndLiquidityAbstract" xlink:label="anvs_NatureOfBusinessAndLiquidityAbstract" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="anvs_NatureOfBusinessAndLiquidityAbstract" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="anvs_NatureOfBusinessAndLiquidityAbstract" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="anvs_NatureOfBusinessAndLiquidityAbstract" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharePrice" xlink:label="us-gaap_SharePrice" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="anvs_NatureOfBusinessAndLiquidityAbstract" xlink:to="us-gaap_SharePrice" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="anvs_NatureOfBusinessAndLiquidityAbstract" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:label="us-gaap_SaleOfStockConsiderationReceivedOnTransaction" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="anvs_NatureOfBusinessAndLiquidityAbstract" xlink:to="us-gaap_SaleOfStockConsiderationReceivedOnTransaction" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="anvs_NatureOfBusinessAndLiquidityAbstract" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="anvs_NatureOfBusinessAndLiquidityAbstract" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="anvs-20211231.xsd#anvs_PercentageOfExercisePriceToShareOfferingPrice" xlink:label="anvs_PercentageOfExercisePriceToShareOfferingPrice" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="anvs_NatureOfBusinessAndLiquidityAbstract" xlink:to="anvs_PercentageOfExercisePriceToShareOfferingPrice" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="anvs-20211231.xsd#anvs_StockIssuedDuringPeriodSharesConversionOfConvertibleSecuritiesPreferredStock" xlink:label="anvs_StockIssuedDuringPeriodSharesConversionOfConvertibleSecuritiesPreferredStock" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="anvs_NatureOfBusinessAndLiquidityAbstract" xlink:to="anvs_StockIssuedDuringPeriodSharesConversionOfConvertibleSecuritiesPreferredStock" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="anvs-20211231.xsd#anvs_StockIssuedDuringPeriodSharesConversionOfConvertibleNotes" xlink:label="anvs_StockIssuedDuringPeriodSharesConversionOfConvertibleNotes" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="10" xlink:from="anvs_NatureOfBusinessAndLiquidityAbstract" xlink:to="anvs_StockIssuedDuringPeriodSharesConversionOfConvertibleNotes" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://annovisbio.com/role/DisclosureFairValueMeasurementsDetails" xlink:type="extended" xlink:title="40301 - Disclosure - Fair Value Measurements (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:to="us-gaap_FairValueByMeasurementFrequencyAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="us-gaap_FairValueMeasurementsRecurringMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="us-gaap_FairValueMeasurementsRecurringMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="us-gaap_FairValueInputsLevel1Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel1Member" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="us-gaap_CashAndCashEquivalentsFairValueDisclosure" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://annovisbio.com/role/DisclosureGrantIncomeDetails" xlink:type="extended" xlink:title="40401 - Disclosure - Grant Income (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_TypeOfArrangementAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="anvs-20211231.xsd#anvs_NationalInstituteOnAgingOfNationalInstitutesOfHealthMember" xlink:label="anvs_NationalInstituteOnAgingOfNationalInstitutesOfHealthMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="anvs_NationalInstituteOnAgingOfNationalInstitutesOfHealthMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="anvs-20211231.xsd#anvs_GrantsReceivableNoticeOfAwardAmount" xlink:label="anvs_GrantsReceivableNoticeOfAwardAmount" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="anvs_GrantsReceivableNoticeOfAwardAmount" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="anvs-20211231.xsd#anvs_IncomeFromGrants" xlink:label="anvs_IncomeFromGrants" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="anvs_IncomeFromGrants" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="anvs-20211231.xsd#anvs_ProceedsFromGrants" xlink:label="anvs_ProceedsFromGrants" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="anvs_ProceedsFromGrants" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GrantsReceivableCurrent" xlink:label="us-gaap_GrantsReceivableCurrent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_GrantsReceivableCurrent" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="anvs-20211231.xsd#anvs_UnreimbursedEligibleCostsIncurredDuringPeriod" xlink:label="anvs_UnreimbursedEligibleCostsIncurredDuringPeriod" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="anvs_UnreimbursedEligibleCostsIncurredDuringPeriod" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="anvs-20211231.xsd#anvs_GrantAwardRemainingAmountAvailable" xlink:label="anvs_GrantAwardRemainingAmountAvailable" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="anvs_GrantAwardRemainingAmountAvailable" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://annovisbio.com/role/DisclosureConvertiblePromissoryNotesDetails" xlink:type="extended" xlink:title="40701 - Disclosure - Convertible Promissory Notes (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentTable" xlink:label="us-gaap_DebtInstrumentTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="us-gaap_LongtermDebtTypeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_LongtermDebtTypeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="us-gaap_LongtermDebtTypeDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_LongtermDebtTypeAxis" xlink:to="us-gaap_LongtermDebtTypeDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConvertibleDebtMember" xlink:label="us-gaap_ConvertibleDebtMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_LongtermDebtTypeDomain" xlink:to="us-gaap_ConvertibleDebtMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_StatementEquityComponentsAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="3" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IPOMember" xlink:label="us-gaap_IPOMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_IPOMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="us-gaap_DebtInstrumentLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="us-gaap_DebtInstrumentFaceAmount" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentFaceAmount" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentInterestRateStatedPercentage" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredFinanceCostsGross" xlink:label="us-gaap_DeferredFinanceCostsGross" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DeferredFinanceCostsGross" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentUnamortizedDiscount" xlink:label="us-gaap_DebtInstrumentUnamortizedDiscount" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentUnamortizedDiscount" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:label="us-gaap_DebtInstrumentInterestRateEffectivePercentage" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentInterestRateEffectivePercentage" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestPaidNet" xlink:label="us-gaap_InterestPaidNet" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_InterestPaidNet" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="anvs-20211231.xsd#anvs_StockIssuedDuringPeriodSharesConversionOfConvertibleNotes" xlink:label="anvs_StockIssuedDuringPeriodSharesConversionOfConvertibleNotes" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="anvs_StockIssuedDuringPeriodSharesConversionOfConvertibleNotes" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="anvs-20211231.xsd#anvs_ConversionOfConvertibleSecuritiesConvertiblePromissoryNotesPercentageOfDiscountToInitialPublicOfferingPrice" xlink:label="anvs_ConversionOfConvertibleSecuritiesConvertiblePromissoryNotesPercentageOfDiscountToInitialPublicOfferingPrice" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="anvs_ConversionOfConvertibleSecuritiesConvertiblePromissoryNotesPercentageOfDiscountToInitialPublicOfferingPrice" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://annovisbio.com/role/DisclosureCommitmentsAndContingenciesLicenseAgreementDetails" xlink:type="extended" xlink:title="40802 - Disclosure - Commitments and Contingencies - License Agreement (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherCommitmentsTable" xlink:label="us-gaap_OtherCommitmentsTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_OtherCommitmentsTable" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="anvs-20211231.xsd#anvs_LicenseAgreementTermsAmendedMay2012Member" xlink:label="anvs_LicenseAgreementTermsAmendedMay2012Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:to="anvs_LicenseAgreementTermsAmendedMay2012Member" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherCommitmentsLineItems" xlink:label="us-gaap_OtherCommitmentsLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="us-gaap_OtherCommitmentsTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="anvs-20211231.xsd#anvs_LicenseAgreementMinimumAnnualCommitment" xlink:label="anvs_LicenseAgreementMinimumAnnualCommitment" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="anvs_LicenseAgreementMinimumAnnualCommitment" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="anvs-20211231.xsd#anvs_AccruedLicensePaymentsCurrent" xlink:label="anvs_AccruedLicensePaymentsCurrent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="anvs_AccruedLicensePaymentsCurrent" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="anvs-20211231.xsd#anvs_CumulativeNumberOfMilestonesAchieved" xlink:label="anvs_CumulativeNumberOfMilestonesAchieved" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="anvs_CumulativeNumberOfMilestonesAchieved" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="anvs-20211231.xsd#anvs_LicenseAgreementPeriodOfAdvanceNoticeOfTermination" xlink:label="anvs_LicenseAgreementPeriodOfAdvanceNoticeOfTermination" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="anvs_LicenseAgreementPeriodOfAdvanceNoticeOfTermination" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://annovisbio.com/role/DisclosureCommitmentsAndContingenciesEmploymentAgreementsDetails" xlink:type="extended" xlink:title="40803 - Disclosure - Commitments and Contingencies - Employment Agreements (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfDeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTitleOfIndividualAndByTypeOfDeferredCompensationTable" xlink:label="us-gaap_ScheduleOfDeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTitleOfIndividualAndByTypeOfDeferredCompensationTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualAxis" xlink:label="srt_TitleOfIndividualAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfDeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTitleOfIndividualAndByTypeOfDeferredCompensationTable" xlink:to="srt_TitleOfIndividualAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ExecutiveOfficerMember" xlink:label="srt_ExecutiveOfficerMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="srt_ExecutiveOfficerMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsLineItems" xlink:label="us-gaap_DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsLineItems" xlink:to="us-gaap_ScheduleOfDeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTitleOfIndividualAndByTypeOfDeferredCompensationTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredCompensationArrangementsAbstract" xlink:label="us-gaap_DeferredCompensationArrangementsAbstract" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsLineItems" xlink:to="us-gaap_DeferredCompensationArrangementsAbstract" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="anvs-20211231.xsd#anvs_MaximumAggregateSeverancePayments" xlink:label="anvs_MaximumAggregateSeverancePayments" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_DeferredCompensationArrangementsAbstract" xlink:to="anvs_MaximumAggregateSeverancePayments" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LossContingencyInformationAboutLitigationMattersAbstract" xlink:label="us-gaap_LossContingencyInformationAboutLitigationMattersAbstract" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsLineItems" xlink:to="us-gaap_LossContingencyInformationAboutLitigationMattersAbstract" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LossContingencyNewClaimsFiledNumber" xlink:label="us-gaap_LossContingencyNewClaimsFiledNumber" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_LossContingencyInformationAboutLitigationMattersAbstract" xlink:to="us-gaap_LossContingencyNewClaimsFiledNumber" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://annovisbio.com/role/DisclosureRedeemableConvertiblePreferredStockAndStockholdersEquityCommonAndPreferredStockDetails" xlink:type="extended" xlink:title="40901 - Disclosure - Redeemable Convertible Preferred Stock and Stockholders' Equity - Common and Preferred Stock (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="us-gaap_ScheduleOfStockByClassTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_StatementEquityComponentsAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="anvs-20211231.xsd#anvs_CommonStockAndPreferredStockMember" xlink:label="anvs_CommonStockAndPreferredStockMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_EquityComponentDomain" xlink:to="anvs_CommonStockAndPreferredStockMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="anvs_CommonStockAndPreferredStockMember" xlink:to="us-gaap_CommonStockMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_StatementClassOfStockAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="anvs-20211231.xsd#anvs_SeriesaRedeemableConvertiblePreferredStockMember" xlink:label="anvs_SeriesaRedeemableConvertiblePreferredStockMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="anvs_SeriesaRedeemableConvertiblePreferredStockMember" use="optional" />
    <loc xlink:type="locator" xlink:href="anvs-20211231.xsd#anvs_Series1RedeemableConvertiblePreferredStockMember" xlink:label="anvs_Series1RedeemableConvertiblePreferredStockMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="anvs_Series1RedeemableConvertiblePreferredStockMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="3" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="anvs-20211231.xsd#anvs_InitialPublicOfferingAndOverAllotmentOptionMember" xlink:label="anvs_InitialPublicOfferingAndOverAllotmentOptionMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="anvs_InitialPublicOfferingAndOverAllotmentOptionMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IPOMember" xlink:label="us-gaap_IPOMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="anvs_InitialPublicOfferingAndOverAllotmentOptionMember" xlink:to="us-gaap_IPOMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockLineItems" xlink:label="us-gaap_ClassOfStockLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ScheduleOfStockByClassTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="anvs-20211231.xsd#anvs_TemporaryEquitySharesConversionOfPreferredStockToCommonStock" xlink:label="anvs_TemporaryEquitySharesConversionOfPreferredStockToCommonStock" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="anvs_TemporaryEquitySharesConversionOfPreferredStockToCommonStock" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="anvs-20211231.xsd#anvs_StockIssuedDuringPeriodSharesConversionOfConvertibleSecuritiesPreferredStock" xlink:label="anvs_StockIssuedDuringPeriodSharesConversionOfConvertibleSecuritiesPreferredStock" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="anvs_StockIssuedDuringPeriodSharesConversionOfConvertibleSecuritiesPreferredStock" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="anvs-20211231.xsd#anvs_RedeemableConvertiblePreferredStockConvertibleConversionPrice" xlink:label="anvs_RedeemableConvertiblePreferredStockConvertibleConversionPrice" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="anvs_RedeemableConvertiblePreferredStockConvertibleConversionPrice" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="anvs-20211231.xsd#anvs_NumberOfClassesOfStockDesignated" xlink:label="anvs_NumberOfClassesOfStockDesignated" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="anvs_NumberOfClassesOfStockDesignated" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="anvs-20211231.xsd#anvs_CommonStockAndPreferredStockSharesAuthorized" xlink:label="anvs_CommonStockAndPreferredStockSharesAuthorized" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="anvs_CommonStockAndPreferredStockSharesAuthorized" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="10" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_CommonStockSharesAuthorized" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="11" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_PreferredStockSharesAuthorized" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="anvs-20211231.xsd#anvs_NumberOfVotesForEachShareOfCommonStock" xlink:label="anvs_NumberOfVotesForEachShareOfCommonStock" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="12" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="anvs_NumberOfVotesForEachShareOfCommonStock" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="us-gaap_PreferredStockSharesIssued" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="13" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_PreferredStockSharesIssued" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="14" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_PreferredStockSharesOutstanding" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://annovisbio.com/role/DisclosureRedeemableConvertiblePreferredStockAndStockholdersEquityWarrantsDetails" xlink:type="extended" xlink:title="40902 - Disclosure - Redeemable Convertible Preferred Stock and Stockholders' Equity - Warrants (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightTable" xlink:label="us-gaap_ClassOfWarrantOrRightTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ClassOfWarrantOrRightTable" xlink:to="us-gaap_ClassOfWarrantOrRightAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="anvs-20211231.xsd#anvs_UnderwritersWarrantsMember" xlink:label="anvs_UnderwritersWarrantsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="anvs_UnderwritersWarrantsMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightLineItems" xlink:label="us-gaap_ClassOfWarrantOrRightLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="anvs-20211231.xsd#anvs_PercentageOfExercisePriceToShareOfferingPrice" xlink:label="anvs_PercentageOfExercisePriceToShareOfferingPrice" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="anvs_PercentageOfExercisePriceToShareOfferingPrice" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WarrantsAndRightsOutstandingTerm" xlink:label="us-gaap_WarrantsAndRightsOutstandingTerm" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_WarrantsAndRightsOutstandingTerm" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="anvs-20211231.xsd#anvs_StockIssuedDuringPeriodSharesWarrantsExercised" xlink:label="anvs_StockIssuedDuringPeriodSharesWarrantsExercised" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="anvs_StockIssuedDuringPeriodSharesWarrantsExercised" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="anvs-20211231.xsd#anvs_ConversionOfWarrantsNumberOfWarrantsConverted" xlink:label="anvs_ConversionOfWarrantsNumberOfWarrantsConverted" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="anvs_ConversionOfWarrantsNumberOfWarrantsConverted" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://annovisbio.com/role/DisclosureStockBasedCompensationSummaryOfPlansDetails" xlink:type="extended" xlink:title="41001 - Disclosure - Stock-Based Compensation - Summary of plans (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_PlanNameAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="anvs-20211231.xsd#anvs_EquityIncentivePlan2019Member" xlink:label="anvs_EquityIncentivePlan2019Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_PlanNameDomain" xlink:to="anvs_EquityIncentivePlan2019Member" use="optional" />
    <loc xlink:type="locator" xlink:href="anvs-20211231.xsd#anvs_EquityIncentivePlan2018Member" xlink:label="anvs_EquityIncentivePlan2018Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_PlanNameDomain" xlink:to="anvs_EquityIncentivePlan2018Member" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://annovisbio.com/role/DisclosureStockBasedCompensationShareBasedCompensationExpenseDetails" xlink:type="extended" xlink:title="41002 - Disclosure - Stock-Based Compensation - Share-based compensation expense (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_IncomeStatementLocationAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensation" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://annovisbio.com/role/DisclosureStockBasedCompensationAdditionalDisclosuresDetails" xlink:type="extended" xlink:title="41004 - Disclosure - Stock-Based Compensation - Additional disclosures (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardDateAxis" xlink:label="us-gaap_AwardDateAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardDateAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardDateDomain" xlink:label="us-gaap_AwardDateDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_AwardDateAxis" xlink:to="us-gaap_AwardDateDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="anvs-20211231.xsd#anvs_AwardsGrantedIn2021Member" xlink:label="anvs_AwardsGrantedIn2021Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_AwardDateDomain" xlink:to="anvs_AwardsGrantedIn2021Member" use="optional" />
    <loc xlink:type="locator" xlink:href="anvs-20211231.xsd#anvs_AwardsGrantedIn2020Member" xlink:label="anvs_AwardsGrantedIn2020Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_AwardDateDomain" xlink:to="anvs_AwardsGrantedIn2020Member" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GranteeStatusAxis" xlink:label="us-gaap_GranteeStatusAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="3" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_GranteeStatusAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GranteeStatusDomain" xlink:label="us-gaap_GranteeStatusDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_GranteeStatusAxis" xlink:to="us-gaap_GranteeStatusDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedPaymentArrangementNonemployeeMember" xlink:label="us-gaap_ShareBasedPaymentArrangementNonemployeeMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_GranteeStatusDomain" xlink:to="us-gaap_ShareBasedPaymentArrangementNonemployeeMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VestingAxis" xlink:label="us-gaap_VestingAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="4" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_VestingAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VestingDomain" xlink:label="us-gaap_VestingDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_VestingAxis" xlink:to="us-gaap_VestingDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="anvs-20211231.xsd#anvs_ShareBasedPaymentArrangementVestingPeriodImmediateVestingMember" xlink:label="anvs_ShareBasedPaymentArrangementVestingPeriodImmediateVestingMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_VestingDomain" xlink:to="anvs_ShareBasedPaymentArrangementVestingPeriodImmediateVestingMember" use="optional" />
    <loc xlink:type="locator" xlink:href="anvs-20211231.xsd#anvs_ShareBasedPaymentArrangementVestingPeriodOneYearMember" xlink:label="anvs_ShareBasedPaymentArrangementVestingPeriodOneYearMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_VestingDomain" xlink:to="anvs_ShareBasedPaymentArrangementVestingPeriodOneYearMember" use="optional" />
    <loc xlink:type="locator" xlink:href="anvs-20211231.xsd#anvs_ShareBasedPaymentArrangementVestingPeriodTwoYearsMember" xlink:label="anvs_ShareBasedPaymentArrangementVestingPeriodTwoYearsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_VestingDomain" xlink:to="anvs_ShareBasedPaymentArrangementVestingPeriodTwoYearsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="anvs-20211231.xsd#anvs_ShareBasedPaymentArrangementVestingPeriodEqualQuarterlyInstallmentsOverTwoYearsMember" xlink:label="anvs_ShareBasedPaymentArrangementVestingPeriodEqualQuarterlyInstallmentsOverTwoYearsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_VestingDomain" xlink:to="anvs_ShareBasedPaymentArrangementVestingPeriodEqualQuarterlyInstallmentsOverTwoYearsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:label="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="anvs-20211231.xsd#anvs_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedInPeriodFairValue" xlink:label="anvs_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedInPeriodFairValue" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="10" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="anvs_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedInPeriodFairValue" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="11" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="12" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="13" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://annovisbio.com/role/DisclosureNetLossPerSharePotentialSharesExcludedFromCalculationDetails" xlink:type="extended" xlink:title="41102 - Disclosure - Net Loss Per Share - Potential shares excluded from calculation (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WarrantMember" xlink:label="us-gaap_WarrantMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_WarrantMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://annovisbio.com/role/DisclosureIncomeTaxesAdditionalDisclosuresDetails" xlink:type="extended" xlink:title="41203 - Disclosure - Income Taxes - Additional disclosures (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLossCarryforwardsTable" xlink:label="us-gaap_OperatingLossCarryforwardsTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_OperatingLossCarryforwardsTable" xlink:to="us-gaap_StatementEquityComponentsAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="us-gaap_IncomeTaxAuthorityAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_OperatingLossCarryforwardsTable" xlink:to="us-gaap_IncomeTaxAuthorityAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DomesticCountryMember" xlink:label="us-gaap_DomesticCountryMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_DomesticCountryMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:label="us-gaap_StateAndLocalJurisdictionMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_StateAndLocalJurisdictionMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxPeriodAxis" xlink:label="us-gaap_TaxPeriodAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="3" xlink:from="us-gaap_OperatingLossCarryforwardsTable" xlink:to="us-gaap_TaxPeriodAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxPeriodDomain" xlink:label="us-gaap_TaxPeriodDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_TaxPeriodAxis" xlink:to="us-gaap_TaxPeriodDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="anvs-20211231.xsd#anvs_GeneratedIn2017AndPriorMember" xlink:label="anvs_GeneratedIn2017AndPriorMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_TaxPeriodDomain" xlink:to="anvs_GeneratedIn2017AndPriorMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxCreditCarryforwardAxis" xlink:label="us-gaap_TaxCreditCarryforwardAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="4" xlink:from="us-gaap_OperatingLossCarryforwardsTable" xlink:to="us-gaap_TaxCreditCarryforwardAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxCreditCarryforwardNameDomain" xlink:label="us-gaap_TaxCreditCarryforwardNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_TaxCreditCarryforwardAxis" xlink:to="us-gaap_TaxCreditCarryforwardNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchMember" xlink:label="us-gaap_ResearchMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_TaxCreditCarryforwardNameDomain" xlink:to="us-gaap_ResearchMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLossCarryforwardsLineItems" xlink:label="us-gaap_OperatingLossCarryforwardsLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="us-gaap_OperatingLossCarryforwardsTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="us-gaap_OperatingLossCarryforwards" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="us-gaap_OperatingLossCarryforwards" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxCreditCarryforwardAmount" xlink:label="us-gaap_TaxCreditCarryforwardAmount" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="us-gaap_TaxCreditCarryforwardAmount" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued" xlink:label="us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense" xlink:label="us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://annovisbio.com/role/DisclosureRelatedPartyTransactionsDetails" xlink:type="extended" xlink:title="41301 - Disclosure - Related-Party Transactions (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_DirectorMember" xlink:label="srt_DirectorMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="srt_DirectorMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionAxis" xlink:label="us-gaap_RelatedPartyTransactionAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_RelatedPartyTransactionAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="us-gaap_RelatedPartyTransactionDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="us-gaap_RelatedPartyTransactionDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="anvs-20211231.xsd#anvs_RelatedPartyTransactionIssuanceOfConvertiblePromissoryNotesMember" xlink:label="anvs_RelatedPartyTransactionIssuanceOfConvertiblePromissoryNotesMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="anvs_RelatedPartyTransactionIssuanceOfConvertiblePromissoryNotesMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="anvs-20211231.xsd#anvs_RelatedPartyTransactionConversionOfPromissoryNotesToCommonStockMember" xlink:label="anvs_RelatedPartyTransactionConversionOfPromissoryNotesToCommonStockMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="anvs_RelatedPartyTransactionConversionOfPromissoryNotesToCommonStockMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="us-gaap_LongtermDebtTypeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="3" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_LongtermDebtTypeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="us-gaap_LongtermDebtTypeDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_LongtermDebtTypeAxis" xlink:to="us-gaap_LongtermDebtTypeDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConvertibleDebtMember" xlink:label="us-gaap_ConvertibleDebtMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_LongtermDebtTypeDomain" xlink:to="us-gaap_ConvertibleDebtMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="4" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_StatementEquityComponentsAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="us-gaap_RelatedPartyTransactionLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="us-gaap_DebtInstrumentFaceAmount" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_DebtInstrumentFaceAmount" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="anvs-20211231.xsd#anvs_RelatedPartyTransactionNumberOfCompanyDirectors" xlink:label="anvs_RelatedPartyTransactionNumberOfCompanyDirectors" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="anvs_RelatedPartyTransactionNumberOfCompanyDirectors" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="anvs-20211231.xsd#anvs_StockIssuedDuringPeriodSharesConversionOfConvertibleNotes" xlink:label="anvs_StockIssuedDuringPeriodSharesConversionOfConvertibleNotes" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="anvs_StockIssuedDuringPeriodSharesConversionOfConvertibleNotes" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://annovisbio.com/role/DisclosureSubsequentEventsDetails" xlink:type="extended" xlink:title="41401 - Disclosure - Subsequent Events (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTable" xlink:label="us-gaap_SubsequentEventTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_SubsequentEventTypeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventLineItems" xlink:label="us-gaap_SubsequentEventLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_SubsequentEventTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" priority="1" use="optional" />
  </definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>22
<FILENAME>anvs-20211231_lab.xml
<DESCRIPTION>EX-101.LAB
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--XBRL document created with Toppan Merrill Bridge  9.6.8042.36810 -->
<!--Based on XBRL 2.1-->
<!--Created on: 3/2/2022 8:59:47 PM-->
<!--Modified on: 3/2/2022 8:59:47 PM-->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrldt="http://xbrl.org/2005/xbrldt">
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel" xmlns="http://www.xbrl.org/2003/linkbase" />
  <link:labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CoverAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document and Entity Information</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentInformationTable" xlink:label="dei_DocumentInformationTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentInformationTable" xlink:to="dei_DocumentInformationTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentInformationTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document Information [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentInformationLineItems" xlink:label="dei_DocumentInformationLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentInformationLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentInformationLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document Information [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_DocumentInformationLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document and Entity Information</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityRegistrantName_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Registrant Name</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentType" xlink:label="dei_DocumentType" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentType_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document Type</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentAnnualReport" xlink:label="dei_DocumentAnnualReport" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAnnualReport" xlink:to="dei_DocumentAnnualReport_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAnnualReport_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document Annual Report</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Current Fiscal Year End Date</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodEndDate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document Period End Date</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentTransitionReport" xlink:to="dei_DocumentTransitionReport_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentTransitionReport_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document Transition Report</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFileNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity File Number</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Incorporation, State or Country Code</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Tax Identification Number</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Address, Address Line One</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCityOrTown_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Address, City or Town</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressStateOrProvince_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Address, State or Province</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressPostalZipCode_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Address, Postal Zip Code</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CityAreaCode_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">City Area Code</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_LocalPhoneNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Local Phone Number</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12bTitle_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Title of 12(b) Security</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_TradingSymbol_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Trading Symbol</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityExchangeName_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Security Exchange Name</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCurrentReportingStatus_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Current Reporting Status</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityWellKnownSeasonedIssuer" xlink:to="dei_EntityWellKnownSeasonedIssuer_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Well Known Seasoned Issuer</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityVoluntaryFilers" xlink:to="dei_EntityVoluntaryFilers_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityVoluntaryFilers_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Voluntary Filers</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityInteractiveDataCurrent" xlink:to="dei_EntityInteractiveDataCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Interactive Data Current</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFilerCategory_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Filer Category</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntitySmallBusiness" xlink:to="dei_EntitySmallBusiness_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntitySmallBusiness_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Small Business</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Emerging Growth Company</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityExTransitionPeriod" xlink:label="dei_EntityExTransitionPeriod" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityExTransitionPeriod" xlink:to="dei_EntityExTransitionPeriod_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityExTransitionPeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Ex Transition Period</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityShellCompany" xlink:to="dei_EntityShellCompany_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityShellCompany_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Shell Company</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPublicFloat" xlink:to="dei_EntityPublicFloat_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPublicFloat_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Public Float</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_IcfrAuditorAttestationFlag" xlink:label="dei_IcfrAuditorAttestationFlag" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_IcfrAuditorAttestationFlag" xlink:to="dei_IcfrAuditorAttestationFlag_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_IcfrAuditorAttestationFlag_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">ICFR Auditor Attestation Flag</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Common Stock, Shares Outstanding</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCentralIndexKey_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Central Index Key</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalYearFocus_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document Fiscal Year Focus</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document Fiscal Period Focus</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentFlag_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amendment Flag</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AuditorName" xlink:label="dei_AuditorName" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorName" xlink:to="dei_AuditorName_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditorName_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Auditor Name</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AuditorLocation" xlink:label="dei_AuditorLocation" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorLocation" xlink:to="dei_AuditorLocation_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditorLocation_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Auditor Location</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AuditorFirmId" xlink:label="dei_AuditorFirmId" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorFirmId" xlink:to="dei_AuditorFirmId_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditorFirmId_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Auditor Firm ID</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementOfFinancialPositionAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfFinancialPositionAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Balance Sheets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Statement [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Statement [Line Items]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Assets [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AssetsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrentAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Assets, Current [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Current assets:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash and Cash Equivalents, at Carrying Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash and cash equivalents</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash and cash equivalents, Carrying Value</label>
    <loc xlink:type="locator" xlink:href="anvs-20211231.xsd#anvs_PrepaidExpenseSecurityDepositsAndOtherAssetsCurrent" xlink:label="anvs_PrepaidExpenseSecurityDepositsAndOtherAssetsCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="anvs_PrepaidExpenseSecurityDepositsAndOtherAssetsCurrent" xlink:to="anvs_PrepaidExpenseSecurityDepositsAndOtherAssetsCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="anvs_PrepaidExpenseSecurityDepositsAndOtherAssetsCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer. Includes security deposits.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="anvs_PrepaidExpenseSecurityDepositsAndOtherAssetsCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Prepaid Expense, Security Deposits, and Other Assets, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="anvs_PrepaidExpenseSecurityDepositsAndOtherAssetsCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Prepaid expenses and other current assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="anvs_PrepaidExpenseSecurityDepositsAndOtherAssetsCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total prepaid expenses and other current assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Assets, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_AssetsCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total current assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Assets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_Assets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Liabilities and Equity [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Liabilities, Redeemable Convertible Preferred Stock and Stockholders' Equity (Deficit)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Liabilities, Current [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Current liabilities:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableCurrent" xlink:to="us-gaap_AccountsPayableCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accounts Payable, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accounts payable</label>
    <loc xlink:type="locator" xlink:href="anvs-20211231.xsd#anvs_AccruedLiabilitiesAndInterestAndEmployeeRelatedLiabilitiesCurrent" xlink:label="anvs_AccruedLiabilitiesAndInterestAndEmployeeRelatedLiabilitiesCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="anvs_AccruedLiabilitiesAndInterestAndEmployeeRelatedLiabilitiesCurrent" xlink:to="anvs_AccruedLiabilitiesAndInterestAndEmployeeRelatedLiabilitiesCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="anvs_AccruedLiabilitiesAndInterestAndEmployeeRelatedLiabilitiesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Includes accrued interest and obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="anvs_AccruedLiabilitiesAndInterestAndEmployeeRelatedLiabilitiesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accrued Liabilities and Interest, and Employee-Related Liabilities, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="anvs_AccruedLiabilitiesAndInterestAndEmployeeRelatedLiabilitiesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accrued expenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="anvs_AccruedLiabilitiesAndInterestAndEmployeeRelatedLiabilitiesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total accrued expenses</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Liabilities, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total current liabilities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_Liabilities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Liabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_Liabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total liabilities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingencies" xlink:to="us-gaap_CommitmentsAndContingencies_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingencies_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Commitments and Contingencies.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommitmentsAndContingencies_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Commitments and contingencies (Note 8)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stockholders' Equity Attributable to Parent [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stockholders' equity (deficit):</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockValue" xlink:to="us-gaap_PreferredStockValue_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Preferred Stock, Value, Issued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_PreferredStockValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Preferred stock - $0.0001 par value, 2,000,000 shares authorized and 0 shares issued and outstanding</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockValue" xlink:to="us-gaap_CommonStockValue_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common Stock, Value, Issued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CommonStockValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common stock - $0.0001 par value, 35,000,000 shares authorized and 8,100,570 and 6,891,608 shares issued and outstanding at December 31, 2021 and 2020, respectively</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="us-gaap_AdditionalPaidInCapital" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapital" xlink:to="us-gaap_AdditionalPaidInCapital_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdditionalPaidInCapital_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Additional Paid in Capital</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AdditionalPaidInCapital_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Additional paid-in capital</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Retained Earnings (Accumulated Deficit)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accumulated deficit</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquity_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stockholders' Equity Attributable to Parent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_StockholdersEquity_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Balance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_StockholdersEquity_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Balance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_StockholdersEquity_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total stockholders' equity</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Liabilities and Equity</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total liabilities and stockholders' equity</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Preferred Stock, Par or Stated Value Per Share</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Preferred stock, par value (dollars per share)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesAuthorized" xlink:to="us-gaap_PreferredStockSharesAuthorized_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesAuthorized_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Preferred Stock, Shares Authorized</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PreferredStockSharesAuthorized_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Preferred stock, shares authorized</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_PreferredStockSharesAuthorized_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of preferred shares authorized</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="us-gaap_PreferredStockSharesIssued" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesIssued" xlink:to="us-gaap_PreferredStockSharesIssued_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesIssued_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Preferred Stock, Shares Issued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PreferredStockSharesIssued_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Preferred stock, shares issued</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesOutstanding" xlink:to="us-gaap_PreferredStockSharesOutstanding_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Preferred Stock, Shares Outstanding</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Preferred stock, shares outstanding</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common Stock, Par or Stated Value Per Share</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common stock, par value (dollars per share)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesAuthorized" xlink:to="us-gaap_CommonStockSharesAuthorized_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common Stock, Shares Authorized</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common stock, shares authorized</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of common shares authorized</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesIssued" xlink:to="us-gaap_CommonStockSharesIssued_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common Stock, Shares, Issued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common stock, shares issued</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesOutstanding" xlink:to="us-gaap_CommonStockSharesOutstanding_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common Stock, Shares, Outstanding</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common stock, shares outstanding</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:label="us-gaap_IncomeStatementAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeStatementAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Statements of Operations</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="us-gaap_OperatingExpensesAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpensesAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingExpensesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Expenses [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingExpensesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating expenses:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="us-gaap_ResearchAndDevelopmentExpense_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Research and Development Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Research and development</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpense" xlink:to="us-gaap_GeneralAndAdministrativeExpense_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">General and Administrative Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">General and administrative</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_OperatingExpenses_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingExpenses_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Expenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OperatingExpenses_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total operating expenses</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Income (Loss)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating loss</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_NonoperatingIncomeExpenseAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Nonoperating Income (Expense) [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other income (expense):</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrealizedGainLossOnDerivatives" xlink:label="us-gaap_UnrealizedGainLossOnDerivatives" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnrealizedGainLossOnDerivatives" xlink:to="us-gaap_UnrealizedGainLossOnDerivatives_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_UnrealizedGainLossOnDerivatives_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Unrealized Gain (Loss) on Derivatives</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_UnrealizedGainLossOnDerivatives_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Change in fair value of derivative liability</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_UnrealizedGainLossOnDerivatives_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Change in fair value of derivative liability</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestIncomeExpenseNonoperatingNet" xlink:label="us-gaap_InterestIncomeExpenseNonoperatingNet" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestIncomeExpenseNonoperatingNet" xlink:to="us-gaap_InterestIncomeExpenseNonoperatingNet_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestIncomeExpenseNonoperatingNet_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Interest Income (Expense), Nonoperating, Net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InterestIncomeExpenseNonoperatingNet_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Interest income, net</label>
    <loc xlink:type="locator" xlink:href="anvs-20211231.xsd#anvs_IncomeFromGrants" xlink:label="anvs_IncomeFromGrants" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="anvs_IncomeFromGrants" xlink:to="anvs_IncomeFromGrants_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="anvs_IncomeFromGrants_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income from non-repayable sum of money awarded to an entity to carry out a specific purpose as provided in grant agreements. Outside the scope of Topic 606.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="anvs_IncomeFromGrants_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income from Grants</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="anvs_IncomeFromGrants_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Grant income</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="us-gaap_NonoperatingIncomeExpense" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_NonoperatingIncomeExpense_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NonoperatingIncomeExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Nonoperating Income (Expense)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NonoperatingIncomeExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total other income (expense)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Loss before income taxes</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetIncomeLoss_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net Income (Loss) Attributable to Parent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetIncomeLoss_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net loss</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetIncomeLoss_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net loss</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasic" xlink:to="us-gaap_EarningsPerShareBasic_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareBasic_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Earnings Per Share, Basic</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EarningsPerShareBasic_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Basic loss per common share</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_EarningsPerShareBasic_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net loss per share, basic</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="us-gaap_EarningsPerShareDiluted" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareDiluted" xlink:to="us-gaap_EarningsPerShareDiluted_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareDiluted_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Earnings Per Share, Diluted</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EarningsPerShareDiluted_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Diluted loss per common share</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_EarningsPerShareDiluted_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net loss per share, diluted</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted Average Number of Shares Outstanding, Basic</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted average number of common shares outstanding, basic</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted-average common shares outstanding, basic</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted Average Number of Shares Outstanding, Diluted</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted average number of common shares outstanding, diluted</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted-average common shares outstanding, diluted</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementOfStockholdersEquityAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Statements of Redeemable Convertible Preferred Stock and Stockholders' Equity (Deficit)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_StatementClassOfStockAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementClassOfStockAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Class of Stock [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_ClassOfStockDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfStockDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Class of Stock [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RedeemableConvertiblePreferredStockMember" xlink:label="us-gaap_RedeemableConvertiblePreferredStockMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RedeemableConvertiblePreferredStockMember" xlink:to="us-gaap_RedeemableConvertiblePreferredStockMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RedeemableConvertiblePreferredStockMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Redeemable convertible preferred stock</label>
    <loc xlink:type="locator" xlink:href="anvs-20211231.xsd#anvs_SeriesaRedeemableConvertiblePreferredStockMember" xlink:label="anvs_SeriesaRedeemableConvertiblePreferredStockMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="anvs_SeriesaRedeemableConvertiblePreferredStockMember" xlink:to="anvs_SeriesaRedeemableConvertiblePreferredStockMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="anvs_SeriesaRedeemableConvertiblePreferredStockMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Series A Redeemable convertible preferred stock.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="anvs_SeriesaRedeemableConvertiblePreferredStockMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Series A Redeemable convertible preferred stock</label>
    <loc xlink:type="locator" xlink:href="anvs-20211231.xsd#anvs_Series1RedeemableConvertiblePreferredStockMember" xlink:label="anvs_Series1RedeemableConvertiblePreferredStockMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="anvs_Series1RedeemableConvertiblePreferredStockMember" xlink:to="anvs_Series1RedeemableConvertiblePreferredStockMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="anvs_Series1RedeemableConvertiblePreferredStockMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Series A-1 Redeemable convertible preferred stock.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="anvs_Series1RedeemableConvertiblePreferredStockMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Series A-1 Redeemable convertible preferred stock</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInTemporaryEquityRollForward" xlink:label="us-gaap_IncreaseDecreaseInTemporaryEquityRollForward" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInTemporaryEquityRollForward" xlink:to="us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Increase (Decrease) in Temporary Equity [Roll Forward]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Changes in Redeemable Convertible Preferred Stock</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:to="us-gaap_TemporaryEquityCarryingAmountAttributableToParent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Temporary Equity, Carrying Amount, Attributable to Parent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Balance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Balance</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquitySharesIssued" xlink:label="us-gaap_TemporaryEquitySharesIssued" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquitySharesIssued" xlink:to="us-gaap_TemporaryEquitySharesIssued_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TemporaryEquitySharesIssued_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Temporary Equity, Shares Issued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_TemporaryEquitySharesIssued_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Balance, shares</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_TemporaryEquitySharesIssued_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Balance, shares</label>
    <loc xlink:type="locator" xlink:href="anvs-20211231.xsd#anvs_TemporaryEquityConversionOfPreferredStockToCommonStock" xlink:label="anvs_TemporaryEquityConversionOfPreferredStockToCommonStock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="anvs_TemporaryEquityConversionOfPreferredStockToCommonStock" xlink:to="anvs_TemporaryEquityConversionOfPreferredStockToCommonStock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="anvs_TemporaryEquityConversionOfPreferredStockToCommonStock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Conversion of redeemable convertible preferred stock to common stock.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="anvs_TemporaryEquityConversionOfPreferredStockToCommonStock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Temporary Equity, Conversion of Preferred Stock to Common Stock</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="anvs_TemporaryEquityConversionOfPreferredStockToCommonStock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Conversion of redeemable convertible preferred stock to common stock upon completion of initial public offering</label>
    <loc xlink:type="locator" xlink:href="anvs-20211231.xsd#anvs_TemporaryEquitySharesConversionOfPreferredStockToCommonStock" xlink:label="anvs_TemporaryEquitySharesConversionOfPreferredStockToCommonStock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="anvs_TemporaryEquitySharesConversionOfPreferredStockToCommonStock" xlink:to="anvs_TemporaryEquitySharesConversionOfPreferredStockToCommonStock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="anvs_TemporaryEquitySharesConversionOfPreferredStockToCommonStock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Conversion of redeemable convertible preferred stock to common stock, shares.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="anvs_TemporaryEquitySharesConversionOfPreferredStockToCommonStock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Temporary Equity, Shares, Conversion of Preferred Stock to Common Stock</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="anvs_TemporaryEquitySharesConversionOfPreferredStockToCommonStock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Conversion of redeemable convertible preferred stock to common stock upon completion of initial public offering, shares</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="anvs_TemporaryEquitySharesConversionOfPreferredStockToCommonStock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Conversion of redeemable convertible preferred stock to common stock, shares</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_StatementEquityComponentsAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementEquityComponentsAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Equity Components [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_EquityComponentDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EquityComponentDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Equity Component [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockMember" xlink:to="us-gaap_CommonStockMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common Stock</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalMember" xlink:to="us-gaap_AdditionalPaidInCapitalMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Additional Paid-In Capital</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsMember" xlink:to="us-gaap_RetainedEarningsMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RetainedEarningsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accumulated Deficit</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:label="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Increase (Decrease) in Stockholders' Equity [Roll Forward]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Changes in Stockholders' Equity</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesIssued" xlink:label="us-gaap_SharesIssued" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesIssued" xlink:to="us-gaap_SharesIssued_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharesIssued_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Shares, Issued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_SharesIssued_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Balance, shares</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_SharesIssued_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Balance, shares</label>
    <loc xlink:type="locator" xlink:href="anvs-20211231.xsd#anvs_StockIssuedDuringPeriodValueConversionOfConvertibleSecuritiesPreferredStock" xlink:label="anvs_StockIssuedDuringPeriodValueConversionOfConvertibleSecuritiesPreferredStock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="anvs_StockIssuedDuringPeriodValueConversionOfConvertibleSecuritiesPreferredStock" xlink:to="anvs_StockIssuedDuringPeriodValueConversionOfConvertibleSecuritiesPreferredStock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="anvs_StockIssuedDuringPeriodValueConversionOfConvertibleSecuritiesPreferredStock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The value of stock issued during the period upon the conversion of convertible preferred stock.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="anvs_StockIssuedDuringPeriodValueConversionOfConvertibleSecuritiesPreferredStock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock Issued During Period, Value, Conversion Of Convertible Securities, Preferred Stock</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="anvs_StockIssuedDuringPeriodValueConversionOfConvertibleSecuritiesPreferredStock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Conversion of redeemable convertible preferred stock to common stock upon completion of initial public offering</label>
    <loc xlink:type="locator" xlink:href="anvs-20211231.xsd#anvs_StockIssuedDuringPeriodSharesConversionOfConvertibleSecuritiesPreferredStock" xlink:label="anvs_StockIssuedDuringPeriodSharesConversionOfConvertibleSecuritiesPreferredStock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="anvs_StockIssuedDuringPeriodSharesConversionOfConvertibleSecuritiesPreferredStock" xlink:to="anvs_StockIssuedDuringPeriodSharesConversionOfConvertibleSecuritiesPreferredStock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="anvs_StockIssuedDuringPeriodSharesConversionOfConvertibleSecuritiesPreferredStock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of shares issued during the period as a result of the conversion of convertible preferred stock.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="anvs_StockIssuedDuringPeriodSharesConversionOfConvertibleSecuritiesPreferredStock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock Issued During Period, Shares, Conversion Of Convertible Securities, Preferred Stock</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="anvs_StockIssuedDuringPeriodSharesConversionOfConvertibleSecuritiesPreferredStock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Conversion of redeemable convertible preferred stock to common stock upon completion of initial public offering, shares</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="anvs_StockIssuedDuringPeriodSharesConversionOfConvertibleSecuritiesPreferredStock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of shares issued for the conversion of redeemable convertible preferred stock</label>
    <loc xlink:type="locator" xlink:href="anvs-20211231.xsd#anvs_StockIssuedDuringPeriodValueConversionOfConvertibleSecuritiesConvertiblePromissoryNotes" xlink:label="anvs_StockIssuedDuringPeriodValueConversionOfConvertibleSecuritiesConvertiblePromissoryNotes" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="anvs_StockIssuedDuringPeriodValueConversionOfConvertibleSecuritiesConvertiblePromissoryNotes" xlink:to="anvs_StockIssuedDuringPeriodValueConversionOfConvertibleSecuritiesConvertiblePromissoryNotes_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="anvs_StockIssuedDuringPeriodValueConversionOfConvertibleSecuritiesConvertiblePromissoryNotes_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The value of stock issued during the period upon the conversion of convertible promissory notes.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="anvs_StockIssuedDuringPeriodValueConversionOfConvertibleSecuritiesConvertiblePromissoryNotes_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock Issued During Period, Value, Conversion Of Convertible Securities, Convertible Promissory Notes</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="anvs_StockIssuedDuringPeriodValueConversionOfConvertibleSecuritiesConvertiblePromissoryNotes_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Conversion of convertible promissory notes, including embedded derivative, to common stock upon completion of initial public offering</label>
    <loc xlink:type="locator" xlink:href="anvs-20211231.xsd#anvs_StockIssuedDuringPeriodSharesConversionOfConvertibleNotes" xlink:label="anvs_StockIssuedDuringPeriodSharesConversionOfConvertibleNotes" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="anvs_StockIssuedDuringPeriodSharesConversionOfConvertibleNotes" xlink:to="anvs_StockIssuedDuringPeriodSharesConversionOfConvertibleNotes_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="anvs_StockIssuedDuringPeriodSharesConversionOfConvertibleNotes_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of shares issued during the period as a result of the conversion of convertible notes.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="anvs_StockIssuedDuringPeriodSharesConversionOfConvertibleNotes_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock Issued During Period, Shares, Conversion of Convertible Notes</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="anvs_StockIssuedDuringPeriodSharesConversionOfConvertibleNotes_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Conversion of convertible promissory notes, including embedded derivative, to common stock upon completion of initial public offering, shares</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="anvs_StockIssuedDuringPeriodSharesConversionOfConvertibleNotes_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of common shares issued upon conversion of notes</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock Issued During Period, Value, New Issues</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Issuance of common stock, net of issuance costs</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock Issued During Period, Shares, New Issues</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Issuance of common stock, net of issuance costs (in shares)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Issuance of common stock</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock Issued During Period, Value, Stock Options Exercised</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Exercise of stock options</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Exercised</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Exercise of stock options, shares</label>
    <loc xlink:type="locator" xlink:href="anvs-20211231.xsd#anvs_StockIssuedDuringPeriodValueWarrantsExercised" xlink:label="anvs_StockIssuedDuringPeriodValueWarrantsExercised" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="anvs_StockIssuedDuringPeriodValueWarrantsExercised" xlink:to="anvs_StockIssuedDuringPeriodValueWarrantsExercised_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="anvs_StockIssuedDuringPeriodValueWarrantsExercised_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Value of stock issued as a result of the exercise of warrants.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="anvs_StockIssuedDuringPeriodValueWarrantsExercised_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock Issued During Period, Value, Warrants Exercised</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="anvs_StockIssuedDuringPeriodValueWarrantsExercised_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cashless exercise of warrants</label>
    <loc xlink:type="locator" xlink:href="anvs-20211231.xsd#anvs_StockIssuedDuringPeriodSharesWarrantsExercised" xlink:label="anvs_StockIssuedDuringPeriodSharesWarrantsExercised" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="anvs_StockIssuedDuringPeriodSharesWarrantsExercised" xlink:to="anvs_StockIssuedDuringPeriodSharesWarrantsExercised_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="anvs_StockIssuedDuringPeriodSharesWarrantsExercised_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Shares of stock issued as a result of the exercise of warrants.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="anvs_StockIssuedDuringPeriodSharesWarrantsExercised_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock Issued During Period, Shares, Warrants Exercised</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="anvs_StockIssuedDuringPeriodSharesWarrantsExercised_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cashless exercise of warrants, shares</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="anvs_StockIssuedDuringPeriodSharesWarrantsExercised_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Shares issued upon exercise of warrants</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:label="us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:to="us-gaap_StockIssuedDuringPeriodValueIssuedForServices_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueIssuedForServices_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock Issued During Period, Value, Issued for Services</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodValueIssuedForServices_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Issuance of common stock to consultants and advisors</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:label="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:to="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock Issued During Period, Shares, Issued for Services</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Issuance of common stock to consultants and advisors, shares</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of shares issued to consultants and advisors</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">APIC, Share-based Payment Arrangement, Option, Increase for Cost Recognition</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock based compensation expense</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="us-gaap_StatementOfCashFlowsAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_StatementOfCashFlowsAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfCashFlowsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Statements of Cash Flows</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net Cash Provided by (Used in) Operating Activities [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash flows from operating activities:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProfitLoss" xlink:label="us-gaap_ProfitLoss" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProfitLoss" xlink:to="us-gaap_ProfitLoss_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProfitLoss_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net Income (Loss), Including Portion Attributable to Noncontrolling Interest</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProfitLoss_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net loss</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Adjustments, Noncash Items, to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Adjustments to reconcile net loss to net cash used in operating activities:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AmortizationOfFinancingCosts" xlink:label="us-gaap_AmortizationOfFinancingCosts" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AmortizationOfFinancingCosts" xlink:to="us-gaap_AmortizationOfFinancingCosts_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AmortizationOfFinancingCosts_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amortization of Debt Issuance Costs</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AmortizationOfFinancingCosts_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amortization of deferred financing fees</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AmortizationOfDebtDiscountPremium" xlink:label="us-gaap_AmortizationOfDebtDiscountPremium" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AmortizationOfDebtDiscountPremium" xlink:to="us-gaap_AmortizationOfDebtDiscountPremium_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AmortizationOfDebtDiscountPremium_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amortization of Debt Discount (Premium)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AmortizationOfDebtDiscountPremium_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amortization of debt discount</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensation_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Payment Arrangement, Noncash Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensation_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock-based compensation expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensation_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock-based compensation expense, including stock issued to consultants and advisors</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Increase (Decrease) in Operating Capital [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Changes in operating assets and liabilities:</label>
    <loc xlink:type="locator" xlink:href="anvs-20211231.xsd#anvs_IncreaseDecreaseInGrantsReceivable" xlink:label="anvs_IncreaseDecreaseInGrantsReceivable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="anvs_IncreaseDecreaseInGrantsReceivable" xlink:to="anvs_IncreaseDecreaseInGrantsReceivable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="anvs_IncreaseDecreaseInGrantsReceivable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The increase (decrease) during the reporting period in grants receivable.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="anvs_IncreaseDecreaseInGrantsReceivable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Increase (Decrease) in Grants Receivable</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="anvs_IncreaseDecreaseInGrantsReceivable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Grant receivable</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Increase (Decrease) in Prepaid Expense and Other Assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Prepaid expenses and other current assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayable" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Increase (Decrease) in Accounts Payable</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accounts payable</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Increase (Decrease) in Accrued Liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accrued expenses</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net Cash Provided by (Used in) Operating Activities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net cash used in operating activities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net Cash Provided by (Used in) Financing Activities [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash flows from financing activities:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Proceeds from Issuance of Common Stock</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Proceeds from issuance of common stock, net of issuance costs</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Gross proceeds from issuance of common shares</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="us-gaap_ProceedsFromStockOptionsExercised" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromStockOptionsExercised" xlink:to="us-gaap_ProceedsFromStockOptionsExercised_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromStockOptionsExercised_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Proceeds from Stock Options Exercised</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromStockOptionsExercised_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Proceeds from exercise of stock options</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net Cash Provided by (Used in) Financing Activities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net cash provided by financing activities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net increase in cash and cash equivalents</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash and cash equivalents, end of year</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash and cash equivalents, beginning of year</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SupplementalCashFlowElementsAbstract" xlink:label="us-gaap_SupplementalCashFlowElementsAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SupplementalCashFlowElementsAbstract" xlink:to="us-gaap_SupplementalCashFlowElementsAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SupplementalCashFlowElementsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Supplemental Cash Flow Elements [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SupplementalCashFlowElementsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Supplemental disclosure of non-cash financing activities:</label>
    <loc xlink:type="locator" xlink:href="anvs-20211231.xsd#anvs_ConversionOfRedeemableConvertiblePreferredStockToCommonStock" xlink:label="anvs_ConversionOfRedeemableConvertiblePreferredStockToCommonStock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="anvs_ConversionOfRedeemableConvertiblePreferredStockToCommonStock" xlink:to="anvs_ConversionOfRedeemableConvertiblePreferredStockToCommonStock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="anvs_ConversionOfRedeemableConvertiblePreferredStockToCommonStock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The increase (decrease) during the reporting period in the conversion of redeemable convertible preferred stock to common stock.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="anvs_ConversionOfRedeemableConvertiblePreferredStockToCommonStock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Conversion of Redeemable Convertible Preferred Stock to Common Stock</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="anvs_ConversionOfRedeemableConvertiblePreferredStockToCommonStock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Conversion of redeemable convertible preferred stock to common stock</label>
    <loc xlink:type="locator" xlink:href="anvs-20211231.xsd#anvs_ConversionOfConvertiblePromissoryNotesIncludingEmbeddedDerivativeToCommonStock" xlink:label="anvs_ConversionOfConvertiblePromissoryNotesIncludingEmbeddedDerivativeToCommonStock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="anvs_ConversionOfConvertiblePromissoryNotesIncludingEmbeddedDerivativeToCommonStock" xlink:to="anvs_ConversionOfConvertiblePromissoryNotesIncludingEmbeddedDerivativeToCommonStock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="anvs_ConversionOfConvertiblePromissoryNotesIncludingEmbeddedDerivativeToCommonStock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The increase (decrease) during the reporting period in the conversion of convertible promissory notes, including embedded derivative, to common stock</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="anvs_ConversionOfConvertiblePromissoryNotesIncludingEmbeddedDerivativeToCommonStock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Conversion of Convertible Promissory Notes, Including Embedded Derivative, to Common Stock</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="anvs_ConversionOfConvertiblePromissoryNotesIncludingEmbeddedDerivativeToCommonStock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Conversion of convertible promissory notes, including embedded derivative, to common stock</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Nature of Business and Liquidity</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Nature of Business and Liquidity</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_AccountingPoliciesAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountingPoliciesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Summary of Significant Accounting Policies</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Significant Accounting Policies [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Summary of Significant Accounting Policies</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueDisclosuresAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueDisclosuresAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value Measurements</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:label="us-gaap_FairValueDisclosuresTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueDisclosuresTextBlock" xlink:to="us-gaap_FairValueDisclosuresTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueDisclosuresTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value Disclosures [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueDisclosuresTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value Measurements</label>
    <loc xlink:type="locator" xlink:href="anvs-20211231.xsd#anvs_NonOperatingIncomeGrantIncomeAbstract" xlink:label="anvs_NonOperatingIncomeGrantIncomeAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="anvs_NonOperatingIncomeGrantIncomeAbstract" xlink:to="anvs_NonOperatingIncomeGrantIncomeAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="anvs_NonOperatingIncomeGrantIncomeAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">No definition available.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="anvs_NonOperatingIncomeGrantIncomeAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Grant Income</label>
    <loc xlink:type="locator" xlink:href="anvs-20211231.xsd#anvs_OtherNonoperatingIncomeGrantIncomeTextBlock" xlink:label="anvs_OtherNonoperatingIncomeGrantIncomeTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="anvs_OtherNonoperatingIncomeGrantIncomeTextBlock" xlink:to="anvs_OtherNonoperatingIncomeGrantIncomeTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="anvs_OtherNonoperatingIncomeGrantIncomeTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The entire disclosure for the grant income classified as other non-operating income.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="anvs_OtherNonoperatingIncomeGrantIncomeTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other Nonoperating Income, Grant Income [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="anvs_OtherNonoperatingIncomeGrantIncomeTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Grant Income</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" xlink:label="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" xlink:to="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Prepaid Expenses and Other Current Assets</label>
    <loc xlink:type="locator" xlink:href="anvs-20211231.xsd#anvs_DeferredCostsCapitalizedPrepaidExpensesAndOtherAssetsDisclosureTextBlock" xlink:label="anvs_DeferredCostsCapitalizedPrepaidExpensesAndOtherAssetsDisclosureTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="anvs_DeferredCostsCapitalizedPrepaidExpensesAndOtherAssetsDisclosureTextBlock" xlink:to="anvs_DeferredCostsCapitalizedPrepaidExpensesAndOtherAssetsDisclosureTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="anvs_DeferredCostsCapitalizedPrepaidExpensesAndOtherAssetsDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The entire disclosure of the amounts paid in advance for capitalized costs that will be expensed with the passage of time or the occurrence of a triggering event, and will be charged against earnings within one year or the normal operating cycle, if longer; the aggregate carrying amount of current assets, not separately presented elsewhere in the balance sheet; and other deferred costs.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="anvs_DeferredCostsCapitalizedPrepaidExpensesAndOtherAssetsDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Costs, Capitalized, Prepaid Expenses, and Other Assets Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="anvs_DeferredCostsCapitalizedPrepaidExpensesAndOtherAssetsDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Prepaid Expenses and Other Current Assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract" xlink:label="us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract" xlink:to="us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accrued Expenses</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accounts Payable and Accrued Liabilities Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accrued Expenses</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="us-gaap_DebtDisclosureAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_DebtDisclosureAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtDisclosureAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Convertible Promissory Notes.</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtDisclosureTextBlock" xlink:label="us-gaap_DebtDisclosureTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtDisclosureTextBlock" xlink:to="us-gaap_DebtDisclosureTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Convertible Promissory Notes</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Commitments and Contingencies</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Commitments and Contingencies Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Commitments and Contingencies</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="us-gaap_StockholdersEquityNoteAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="us-gaap_StockholdersEquityNoteAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityNoteAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Redeemable Convertible Preferred Stock and Stockholders' Equity</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stockholders' Equity Note Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Redeemable Convertible Preferred Stock and Stockholders' Equity</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock-Based Compensation</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Payment Arrangement [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock-Based Compensation</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net Loss Per Share</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareTextBlock" xlink:label="us-gaap_EarningsPerShareTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareTextBlock" xlink:to="us-gaap_EarningsPerShareTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Earnings Per Share [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EarningsPerShareTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net Loss Per Share</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxDisclosureAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxDisclosureAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income Taxes</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income Tax Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income Taxes</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="us-gaap_RelatedPartyTransactionsAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsAbstract" xlink:to="us-gaap_RelatedPartyTransactionsAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Related-Party Transactions</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:to="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Related Party Transactions Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Related-Party Transactions</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="us-gaap_SubsequentEventsAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventsAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Subsequent Events</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="us-gaap_SubsequentEventsTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsTextBlock" xlink:to="us-gaap_SubsequentEventsTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventsTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Subsequent Events [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_SubsequentEventsTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Subsequent Events</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BasisOfAccounting" xlink:label="us-gaap_BasisOfAccounting" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BasisOfAccounting" xlink:to="us-gaap_BasisOfAccounting_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BasisOfAccounting_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Basis of Accounting [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_BasisOfAccounting_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Basis of Presentation</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UseOfEstimates" xlink:label="us-gaap_UseOfEstimates" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UseOfEstimates" xlink:to="us-gaap_UseOfEstimates_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_UseOfEstimates_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Use of Estimates, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_UseOfEstimates_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Use of Estimates</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Earnings Per Share, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Basic and Diluted Net Income (Loss) per Share</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash and Cash Equivalents, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash and Cash Equivalents</label>
    <loc xlink:type="locator" xlink:href="anvs-20211231.xsd#anvs_IssuanceCostsAssociatedWithEquityIssuancesPolicyTextBlock" xlink:label="anvs_IssuanceCostsAssociatedWithEquityIssuancesPolicyTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="anvs_IssuanceCostsAssociatedWithEquityIssuancesPolicyTextBlock" xlink:to="anvs_IssuanceCostsAssociatedWithEquityIssuancesPolicyTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="anvs_IssuanceCostsAssociatedWithEquityIssuancesPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Disclosure of accounting policy for issuance costs associated with equity issuances.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="anvs_IssuanceCostsAssociatedWithEquityIssuancesPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Issuance Costs Associated with Equity Issuances [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="anvs_IssuanceCostsAssociatedWithEquityIssuancesPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Issuance Costs Associated with Equity Issuances</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:label="us-gaap_FairValueOfFinancialInstrumentsPolicy" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:to="us-gaap_FairValueOfFinancialInstrumentsPolicy_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueOfFinancialInstrumentsPolicy_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value of Financial Instruments, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueOfFinancialInstrumentsPolicy_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value of Financial Instruments</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchDevelopmentAndComputerSoftwarePolicyTextBlock" xlink:label="us-gaap_ResearchDevelopmentAndComputerSoftwarePolicyTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchDevelopmentAndComputerSoftwarePolicyTextBlock" xlink:to="us-gaap_ResearchDevelopmentAndComputerSoftwarePolicyTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchDevelopmentAndComputerSoftwarePolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Research, Development, and Computer Software, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ResearchDevelopmentAndComputerSoftwarePolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Research and Development</label>
    <loc xlink:type="locator" xlink:href="anvs-20211231.xsd#anvs_GrantIncomePolicyTextBlock" xlink:label="anvs_GrantIncomePolicyTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="anvs_GrantIncomePolicyTextBlock" xlink:to="anvs_GrantIncomePolicyTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="anvs_GrantIncomePolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Disclosure of accounting policy for grant income.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="anvs_GrantIncomePolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Grant Income [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="anvs_GrantIncomePolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Grant Income</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:to="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Payment Arrangement [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock-Based Compensation</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="us-gaap_IncomeTaxPolicyTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxPolicyTextBlock" xlink:to="us-gaap_IncomeTaxPolicyTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income Tax, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income Taxes</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">New Accounting Pronouncements, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Recent Accounting Pronouncements</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:label="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:to="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of carrying value and fair value of financial assets and liabilities measured at fair value on a recurring basis</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" xlink:label="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" xlink:to="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of prepaid expenses and other current assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Accrued Liabilities [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of accrued expenses</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock-Based Compensation</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of stock-based compensation expense</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Payment Arrangement, Option, Activity [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of stock option activity</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of weighted average assumptions used to determine fair value of options</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net Loss Per Share</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:to="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of basic and diluted net loss per share</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of shares excluded from the computation of diluted weighted-average shares outstanding</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:to="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Reconciliation of income tax provision (benefit) computed at the statutory federal income tax rate to income taxes as reflected in the financial statements</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Deferred Tax Assets and Liabilities [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of significant components of deferred tax assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="us-gaap_ScheduleOfStockByClassTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_ScheduleOfStockByClassTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfStockByClassTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Stock by Class [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SubsidiarySaleOfStockAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Sale of Stock [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Sale of Stock [Domain]</label>
    <loc xlink:type="locator" xlink:href="anvs-20211231.xsd#anvs_InitialPublicOfferingAndOverAllotmentOptionMember" xlink:label="anvs_InitialPublicOfferingAndOverAllotmentOptionMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="anvs_InitialPublicOfferingAndOverAllotmentOptionMember" xlink:to="anvs_InitialPublicOfferingAndOverAllotmentOptionMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="anvs_InitialPublicOfferingAndOverAllotmentOptionMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">First sale of stock by a private company to the public and right given to the underwriter to sell additional shares over the initial allotment.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="anvs_InitialPublicOfferingAndOverAllotmentOptionMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">IPO and Over-Allotment Option</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IPOMember" xlink:label="us-gaap_IPOMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IPOMember" xlink:to="us-gaap_IPOMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IPOMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">IPO</label>
    <loc xlink:type="locator" xlink:href="anvs-20211231.xsd#anvs_SecondaryPublicOfferingMember" xlink:label="anvs_SecondaryPublicOfferingMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="anvs_SecondaryPublicOfferingMember" xlink:to="anvs_SecondaryPublicOfferingMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="anvs_SecondaryPublicOfferingMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Secondary sale of stock.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="anvs_SecondaryPublicOfferingMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Secondary Public Offering</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Class of Warrant or Right [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="us-gaap_ClassOfWarrantOrRightDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Class of Warrant or Right [Domain]</label>
    <loc xlink:type="locator" xlink:href="anvs-20211231.xsd#anvs_UnderwritersWarrantsMember" xlink:label="anvs_UnderwritersWarrantsMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="anvs_UnderwritersWarrantsMember" xlink:to="anvs_UnderwritersWarrantsMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="anvs_UnderwritersWarrantsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information pertaining to Underwriters warrants.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="anvs_UnderwritersWarrantsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Underwriters warrants</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockLineItems" xlink:label="us-gaap_ClassOfStockLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ClassOfStockLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfStockLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Class of Stock [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ClassOfStockLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Redeemable Convertible Preferred Stock and Stockholders' Equity</label>
    <loc xlink:type="locator" xlink:href="anvs-20211231.xsd#anvs_NatureOfBusinessAndLiquidityAbstract" xlink:label="anvs_NatureOfBusinessAndLiquidityAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="anvs_NatureOfBusinessAndLiquidityAbstract" xlink:to="anvs_NatureOfBusinessAndLiquidityAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="anvs_NatureOfBusinessAndLiquidityAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">No definition available.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="anvs_NatureOfBusinessAndLiquidityAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Nature of Business and Liquidity [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="anvs_NatureOfBusinessAndLiquidityAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Nature of Business and Liquidity</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Revenue from Contract with Customer, Excluding Assessed Tax</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Revenue</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharePrice" xlink:label="us-gaap_SharePrice" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharePrice" xlink:to="us-gaap_SharePrice_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share price</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:label="us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:to="us-gaap_SaleOfStockConsiderationReceivedOnTransaction_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SaleOfStockConsiderationReceivedOnTransaction_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Sale of Stock, Consideration Received on Transaction</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SaleOfStockConsiderationReceivedOnTransaction_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net proceeds from issuance of common shares</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Class of Warrant or Right, Number of Securities Called by Warrants or Rights</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of warrants issued</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Class of Warrant or Right, Exercise Price of Warrants or Rights</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Exercise price</label>
    <loc xlink:type="locator" xlink:href="anvs-20211231.xsd#anvs_PercentageOfExercisePriceToShareOfferingPrice" xlink:label="anvs_PercentageOfExercisePriceToShareOfferingPrice" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="anvs_PercentageOfExercisePriceToShareOfferingPrice" xlink:to="anvs_PercentageOfExercisePriceToShareOfferingPrice_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="anvs_PercentageOfExercisePriceToShareOfferingPrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Percentage of exercise price to the share offering price.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="anvs_PercentageOfExercisePriceToShareOfferingPrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Percentage of Exercise Price to the Share Offering Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="anvs_PercentageOfExercisePriceToShareOfferingPrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Percentage of exercise price to the share offering price</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value Measurement Inputs and Valuation Techniques [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueByMeasurementFrequencyAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Measurement Frequency [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Measurement Frequency [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="us-gaap_FairValueMeasurementsRecurringMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementsRecurringMember" xlink:to="us-gaap_FairValueMeasurementsRecurringMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueMeasurementsRecurringMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Recurring</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value Hierarchy and NAV [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value Hierarchy and NAV [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="us-gaap_FairValueInputsLevel1Member" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel1Member" xlink:to="us-gaap_FairValueInputsLevel1Member_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueInputsLevel1Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Level 1</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value Measurement Inputs and Valuation Techniques [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value Measurements</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:to="us-gaap_CashAndCashEquivalentsFairValueDisclosure_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash and Cash Equivalents, Fair Value Disclosure</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash and cash equivalents, Fair Value</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Collaborative Arrangement and Arrangement Other than Collaborative [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_TypeOfArrangementAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TypeOfArrangementAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Collaborative Arrangement and Arrangement Other than Collaborative [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Collaborative Arrangement and Arrangement Other than Collaborative [Domain]</label>
    <loc xlink:type="locator" xlink:href="anvs-20211231.xsd#anvs_NationalInstituteOnAgingOfNationalInstitutesOfHealthMember" xlink:label="anvs_NationalInstituteOnAgingOfNationalInstitutesOfHealthMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="anvs_NationalInstituteOnAgingOfNationalInstitutesOfHealthMember" xlink:to="anvs_NationalInstituteOnAgingOfNationalInstitutesOfHealthMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="anvs_NationalInstituteOnAgingOfNationalInstitutesOfHealthMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information pertaining to the National Institute on Aging of the National Institutes of Health.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="anvs_NationalInstituteOnAgingOfNationalInstitutesOfHealthMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">NIH</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Grant Income</label>
    <loc xlink:type="locator" xlink:href="anvs-20211231.xsd#anvs_GrantsReceivableNoticeOfAwardAmount" xlink:label="anvs_GrantsReceivableNoticeOfAwardAmount" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="anvs_GrantsReceivableNoticeOfAwardAmount" xlink:to="anvs_GrantsReceivableNoticeOfAwardAmount_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="anvs_GrantsReceivableNoticeOfAwardAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The amount of grant awarded.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="anvs_GrantsReceivableNoticeOfAwardAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Grants Receivable, Notice of Award Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="anvs_GrantsReceivableNoticeOfAwardAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Notice of Award, grant amount</label>
    <loc xlink:type="locator" xlink:href="anvs-20211231.xsd#anvs_ProceedsFromGrants" xlink:label="anvs_ProceedsFromGrants" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="anvs_ProceedsFromGrants" xlink:to="anvs_ProceedsFromGrants_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="anvs_ProceedsFromGrants_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The cash inflow from grants.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="anvs_ProceedsFromGrants_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Proceeds from Grants</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GrantsReceivableCurrent" xlink:label="us-gaap_GrantsReceivableCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GrantsReceivableCurrent" xlink:to="us-gaap_GrantsReceivableCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GrantsReceivableCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Grants Receivable, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_GrantsReceivableCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Grant receivable</label>
    <loc xlink:type="locator" xlink:href="anvs-20211231.xsd#anvs_UnreimbursedEligibleCostsIncurredDuringPeriod" xlink:label="anvs_UnreimbursedEligibleCostsIncurredDuringPeriod" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="anvs_UnreimbursedEligibleCostsIncurredDuringPeriod" xlink:to="anvs_UnreimbursedEligibleCostsIncurredDuringPeriod_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="anvs_UnreimbursedEligibleCostsIncurredDuringPeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The amount of unreimbursed eligible costs incurred during the period.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="anvs_UnreimbursedEligibleCostsIncurredDuringPeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Unreimbursed Eligible Costs Incurred During the Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="anvs_UnreimbursedEligibleCostsIncurredDuringPeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Unreimbursed, eligible costs incurred under the grant</label>
    <loc xlink:type="locator" xlink:href="anvs-20211231.xsd#anvs_GrantAwardRemainingAmountAvailable" xlink:label="anvs_GrantAwardRemainingAmountAvailable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="anvs_GrantAwardRemainingAmountAvailable" xlink:to="anvs_GrantAwardRemainingAmountAvailable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="anvs_GrantAwardRemainingAmountAvailable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The remining balance of funds available under a grant award.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="anvs_GrantAwardRemainingAmountAvailable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Grant Award, Remaining Amount Available</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="anvs_GrantAwardRemainingAmountAvailable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Remining funds available</label>
    <loc xlink:type="locator" xlink:href="anvs-20211231.xsd#anvs_PrepaidResearchAndDevelopmentExpenseCurrent" xlink:label="anvs_PrepaidResearchAndDevelopmentExpenseCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="anvs_PrepaidResearchAndDevelopmentExpenseCurrent" xlink:to="anvs_PrepaidResearchAndDevelopmentExpenseCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="anvs_PrepaidResearchAndDevelopmentExpenseCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount of asset related to consideration paid in advance for research and development expense that provides economic benefits within a future period of one year or the normal operating cycle, if longer.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="anvs_PrepaidResearchAndDevelopmentExpenseCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Prepaid Research and Development Expense, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="anvs_PrepaidResearchAndDevelopmentExpenseCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Prepaid clinical trial expenses</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidInsurance" xlink:label="us-gaap_PrepaidInsurance" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidInsurance" xlink:to="us-gaap_PrepaidInsurance_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PrepaidInsurance_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Prepaid Insurance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_PrepaidInsurance_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Prepaid insurance</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherPrepaidExpenseCurrent" xlink:label="us-gaap_OtherPrepaidExpenseCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherPrepaidExpenseCurrent" xlink:to="us-gaap_OtherPrepaidExpenseCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherPrepaidExpenseCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other Prepaid Expense, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherPrepaidExpenseCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Prepaid expenses</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SecurityDeposit" xlink:label="us-gaap_SecurityDeposit" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SecurityDeposit" xlink:to="us-gaap_SecurityDeposit_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SecurityDeposit_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Security Deposit</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SecurityDeposit_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Security deposit</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Employee-related Liabilities, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Payroll and related benefits</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:label="us-gaap_AccruedProfessionalFeesCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedProfessionalFeesCurrent" xlink:to="us-gaap_AccruedProfessionalFeesCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccruedProfessionalFeesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accrued Professional Fees, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccruedProfessionalFeesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accrued professional and clinical fees</label>
    <loc xlink:type="locator" xlink:href="anvs-20211231.xsd#anvs_AccruedLicensePaymentsCurrent" xlink:label="anvs_AccruedLicensePaymentsCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="anvs_AccruedLicensePaymentsCurrent" xlink:to="anvs_AccruedLicensePaymentsCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="anvs_AccruedLicensePaymentsCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Carrying value as of the balance sheet date of obligations incurred through that date and payable for accrued license payments.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="anvs_AccruedLicensePaymentsCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accrued License Payments, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="anvs_AccruedLicensePaymentsCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accrued license payments</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentTable" xlink:label="us-gaap_DebtInstrumentTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_DebtInstrumentTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Long-term Debt Instruments [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="us-gaap_LongtermDebtTypeAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongtermDebtTypeAxis" xlink:to="us-gaap_LongtermDebtTypeAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LongtermDebtTypeAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Long-term Debt, Type [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="us-gaap_LongtermDebtTypeDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongtermDebtTypeDomain" xlink:to="us-gaap_LongtermDebtTypeDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LongtermDebtTypeDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Long-term Debt, Type [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConvertibleDebtMember" xlink:label="us-gaap_ConvertibleDebtMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConvertibleDebtMember" xlink:to="us-gaap_ConvertibleDebtMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConvertibleDebtMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Convertible promissory notes</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="us-gaap_DebtInstrumentLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt Instrument [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtInstrumentLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Convertible Promissory Notes</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="us-gaap_DebtInstrumentFaceAmount" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentFaceAmount" xlink:to="us-gaap_DebtInstrumentFaceAmount_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentFaceAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt Instrument, Face Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtInstrumentFaceAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Aggregate principal amount</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:to="us-gaap_DebtInstrumentInterestRateStatedPercentage_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt Instrument, Interest Rate, Stated Percentage</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stated interest rate</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredFinanceCostsGross" xlink:label="us-gaap_DeferredFinanceCostsGross" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredFinanceCostsGross" xlink:to="us-gaap_DeferredFinanceCostsGross_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredFinanceCostsGross_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt Issuance Costs, Gross</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredFinanceCostsGross_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt issuance costs incurred</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentUnamortizedDiscount" xlink:label="us-gaap_DebtInstrumentUnamortizedDiscount" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentUnamortizedDiscount" xlink:to="us-gaap_DebtInstrumentUnamortizedDiscount_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentUnamortizedDiscount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt Instrument, Unamortized Discount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtInstrumentUnamortizedDiscount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt discount</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:label="us-gaap_DebtInstrumentInterestRateEffectivePercentage" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:to="us-gaap_DebtInstrumentInterestRateEffectivePercentage_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentInterestRateEffectivePercentage_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt Instrument, Interest Rate, Effective Percentage</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtInstrumentInterestRateEffectivePercentage_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Effective interest rate</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestPaidNet" xlink:label="us-gaap_InterestPaidNet" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestPaidNet" xlink:to="us-gaap_InterestPaidNet_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestPaidNet_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Interest Paid, Excluding Capitalized Interest, Operating Activities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InterestPaidNet_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash payments for interest</label>
    <loc xlink:type="locator" xlink:href="anvs-20211231.xsd#anvs_ConversionOfConvertibleSecuritiesConvertiblePromissoryNotesPercentageOfDiscountToInitialPublicOfferingPrice" xlink:label="anvs_ConversionOfConvertibleSecuritiesConvertiblePromissoryNotesPercentageOfDiscountToInitialPublicOfferingPrice" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="anvs_ConversionOfConvertibleSecuritiesConvertiblePromissoryNotesPercentageOfDiscountToInitialPublicOfferingPrice" xlink:to="anvs_ConversionOfConvertibleSecuritiesConvertiblePromissoryNotesPercentageOfDiscountToInitialPublicOfferingPrice_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="anvs_ConversionOfConvertibleSecuritiesConvertiblePromissoryNotesPercentageOfDiscountToInitialPublicOfferingPrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">In the conversion of promissory notes to common shares, the percentage discount to the initial offering price of shares issued in the IPO.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="anvs_ConversionOfConvertibleSecuritiesConvertiblePromissoryNotesPercentageOfDiscountToInitialPublicOfferingPrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Conversion Of Convertible Securities, Convertible Promissory Notes, Percentage of Discount To Initial Public Offering Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="anvs_ConversionOfConvertibleSecuritiesConvertiblePromissoryNotesPercentageOfDiscountToInitialPublicOfferingPrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Percentage of discount to the initial offering price of shares issued in the IPO</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeLeaseDescriptionTable" xlink:label="us-gaap_LesseeLeaseDescriptionTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="us-gaap_LesseeLeaseDescriptionTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeLeaseDescriptionTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lessee, Lease, Description [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeLeaseDescriptionLineItems" xlink:label="us-gaap_LesseeLeaseDescriptionLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeLeaseDescriptionLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeLeaseDescriptionLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lessee, Lease, Description [Line Items]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseCostAbstract" xlink:label="us-gaap_LeaseCostAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseCostAbstract" xlink:to="us-gaap_LeaseCostAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LeaseCostAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lease, Cost [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LeaseCostAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Leases</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseExpense" xlink:label="us-gaap_OperatingLeaseExpense" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseExpense" xlink:to="us-gaap_OperatingLeaseExpense_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Lease, Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeaseExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Rental expense</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherCommitmentsTable" xlink:label="us-gaap_OtherCommitmentsTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherCommitmentsTable" xlink:to="us-gaap_OtherCommitmentsTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherCommitmentsTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other Commitments [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Research and Development Arrangement, Contract to Perform for Others, Type [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Research and Development Arrangement, Contract to Perform for Others, Type [Domain]</label>
    <loc xlink:type="locator" xlink:href="anvs-20211231.xsd#anvs_LicenseAgreementTermsAmendedMay2012Member" xlink:label="anvs_LicenseAgreementTermsAmendedMay2012Member" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="anvs_LicenseAgreementTermsAmendedMay2012Member" xlink:to="anvs_LicenseAgreementTermsAmendedMay2012Member_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="anvs_LicenseAgreementTermsAmendedMay2012Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Terms of the license agreements, as amended May 2012, under research and development arrangements accounted for as a contract to perform research and development for others.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="anvs_LicenseAgreementTermsAmendedMay2012Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amended License Agreement</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherCommitmentsLineItems" xlink:label="us-gaap_OtherCommitmentsLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="us-gaap_OtherCommitmentsLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherCommitmentsLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other Commitments [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherCommitmentsLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Commitments and Contingencies</label>
    <loc xlink:type="locator" xlink:href="anvs-20211231.xsd#anvs_LicenseAgreementMinimumAnnualCommitment" xlink:label="anvs_LicenseAgreementMinimumAnnualCommitment" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="anvs_LicenseAgreementMinimumAnnualCommitment" xlink:to="anvs_LicenseAgreementMinimumAnnualCommitment_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="anvs_LicenseAgreementMinimumAnnualCommitment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The minimum amount of annual commitment under the terms of a license agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="anvs_LicenseAgreementMinimumAnnualCommitment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">License Agreement, Minimum Annual Commitment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="anvs_LicenseAgreementMinimumAnnualCommitment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Minimum annual commitment</label>
    <loc xlink:type="locator" xlink:href="anvs-20211231.xsd#anvs_CumulativeNumberOfMilestonesAchieved" xlink:label="anvs_CumulativeNumberOfMilestonesAchieved" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="anvs_CumulativeNumberOfMilestonesAchieved" xlink:to="anvs_CumulativeNumberOfMilestonesAchieved_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="anvs_CumulativeNumberOfMilestonesAchieved_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The cumulative number of milestones achieved.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="anvs_CumulativeNumberOfMilestonesAchieved_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cumulative Number of Milestones Achieved</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="anvs_CumulativeNumberOfMilestonesAchieved_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of milestones achieved</label>
    <loc xlink:type="locator" xlink:href="anvs-20211231.xsd#anvs_LicenseAgreementPeriodOfAdvanceNoticeOfTermination" xlink:label="anvs_LicenseAgreementPeriodOfAdvanceNoticeOfTermination" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="anvs_LicenseAgreementPeriodOfAdvanceNoticeOfTermination" xlink:to="anvs_LicenseAgreementPeriodOfAdvanceNoticeOfTermination_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="anvs_LicenseAgreementPeriodOfAdvanceNoticeOfTermination_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The period of advance notice required to terminate the license agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="anvs_LicenseAgreementPeriodOfAdvanceNoticeOfTermination_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">License Agreement, Period of Advance Notice of Termination</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="anvs_LicenseAgreementPeriodOfAdvanceNoticeOfTermination_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Period for advance notice of termination</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfDeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTitleOfIndividualAndByTypeOfDeferredCompensationTable" xlink:label="us-gaap_ScheduleOfDeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTitleOfIndividualAndByTypeOfDeferredCompensationTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfDeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTitleOfIndividualAndByTypeOfDeferredCompensationTable" xlink:to="us-gaap_ScheduleOfDeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTitleOfIndividualAndByTypeOfDeferredCompensationTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfDeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTitleOfIndividualAndByTypeOfDeferredCompensationTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Deferred Compensation Arrangement with Individual, Excluding Share-based Payments and Postretirement Benefits, by Title of Individual and by Type of Deferred Compensation [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualAxis" xlink:label="srt_TitleOfIndividualAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_TitleOfIndividualAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Title of Individual [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Title of Individual [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ExecutiveOfficerMember" xlink:label="srt_ExecutiveOfficerMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ExecutiveOfficerMember" xlink:to="srt_ExecutiveOfficerMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_ExecutiveOfficerMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Executive Officers</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsLineItems" xlink:label="us-gaap_DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsLineItems" xlink:to="us-gaap_DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Compensation Arrangement with Individual, Excluding Share-based Payments and Postretirement Benefits [Line Items]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredCompensationArrangementsAbstract" xlink:label="us-gaap_DeferredCompensationArrangementsAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredCompensationArrangementsAbstract" xlink:to="us-gaap_DeferredCompensationArrangementsAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredCompensationArrangementsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Compensation Arrangements [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredCompensationArrangementsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Employment Agreements</label>
    <loc xlink:type="locator" xlink:href="anvs-20211231.xsd#anvs_MaximumAggregateSeverancePayments" xlink:label="anvs_MaximumAggregateSeverancePayments" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="anvs_MaximumAggregateSeverancePayments" xlink:to="anvs_MaximumAggregateSeverancePayments_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="anvs_MaximumAggregateSeverancePayments_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The maximum aggregate severance payments payable to executive officers under the terms of employment agreements.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="anvs_MaximumAggregateSeverancePayments_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Maximum Aggregate Severance Payments</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="anvs_MaximumAggregateSeverancePayments_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Maximum aggregate severance payments</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LossContingencyInformationAboutLitigationMattersAbstract" xlink:label="us-gaap_LossContingencyInformationAboutLitigationMattersAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LossContingencyInformationAboutLitigationMattersAbstract" xlink:to="us-gaap_LossContingencyInformationAboutLitigationMattersAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LossContingencyInformationAboutLitigationMattersAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Loss Contingency, Information about Litigation Matters [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LossContingencyInformationAboutLitigationMattersAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Litigation</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LossContingencyNewClaimsFiledNumber" xlink:label="us-gaap_LossContingencyNewClaimsFiledNumber" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LossContingencyNewClaimsFiledNumber" xlink:to="us-gaap_LossContingencyNewClaimsFiledNumber_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LossContingencyNewClaimsFiledNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Loss Contingency, New Claims Filed, Number</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LossContingencyNewClaimsFiledNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of new claims filed</label>
    <loc xlink:type="locator" xlink:href="anvs-20211231.xsd#anvs_CommonStockAndPreferredStockMember" xlink:label="anvs_CommonStockAndPreferredStockMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="anvs_CommonStockAndPreferredStockMember" xlink:to="anvs_CommonStockAndPreferredStockMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="anvs_CommonStockAndPreferredStockMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Pertaining to both common stock and preferred stock.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="anvs_CommonStockAndPreferredStockMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common Stock And Preferred Stock [Member]</label>
    <loc xlink:type="locator" xlink:href="anvs-20211231.xsd#anvs_RedeemableConvertiblePreferredStockConvertibleConversionPrice" xlink:label="anvs_RedeemableConvertiblePreferredStockConvertibleConversionPrice" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="anvs_RedeemableConvertiblePreferredStockConvertibleConversionPrice" xlink:to="anvs_RedeemableConvertiblePreferredStockConvertibleConversionPrice_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="anvs_RedeemableConvertiblePreferredStockConvertibleConversionPrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The price per share of the conversion price of redeemable convertible preferred stock.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="anvs_RedeemableConvertiblePreferredStockConvertibleConversionPrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Redeemable Convertible Preferred Stock, Convertible, Conversion Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="anvs_RedeemableConvertiblePreferredStockConvertibleConversionPrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Conversion price</label>
    <loc xlink:type="locator" xlink:href="anvs-20211231.xsd#anvs_NumberOfClassesOfStockDesignated" xlink:label="anvs_NumberOfClassesOfStockDesignated" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="anvs_NumberOfClassesOfStockDesignated" xlink:to="anvs_NumberOfClassesOfStockDesignated_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="anvs_NumberOfClassesOfStockDesignated_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of classes of stock designated.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="anvs_NumberOfClassesOfStockDesignated_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of classes of stock designated</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="anvs_NumberOfClassesOfStockDesignated_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of classes of stock designated</label>
    <loc xlink:type="locator" xlink:href="anvs-20211231.xsd#anvs_CommonStockAndPreferredStockSharesAuthorized" xlink:label="anvs_CommonStockAndPreferredStockSharesAuthorized" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="anvs_CommonStockAndPreferredStockSharesAuthorized" xlink:to="anvs_CommonStockAndPreferredStockSharesAuthorized_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="anvs_CommonStockAndPreferredStockSharesAuthorized_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The maximum number of shares permitted to be issued by an entity's charter and bylaws.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="anvs_CommonStockAndPreferredStockSharesAuthorized_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common Stock And Preferred Stock, Shares Authorized</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="anvs_CommonStockAndPreferredStockSharesAuthorized_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of common and preferred shares authorized</label>
    <loc xlink:type="locator" xlink:href="anvs-20211231.xsd#anvs_NumberOfVotesForEachShareOfCommonStock" xlink:label="anvs_NumberOfVotesForEachShareOfCommonStock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="anvs_NumberOfVotesForEachShareOfCommonStock" xlink:to="anvs_NumberOfVotesForEachShareOfCommonStock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="anvs_NumberOfVotesForEachShareOfCommonStock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of vote for each share of common stock.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="anvs_NumberOfVotesForEachShareOfCommonStock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of Votes for Each Share of Common Stock</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="anvs_NumberOfVotesForEachShareOfCommonStock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of vote for each share of common stock</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightTable" xlink:label="us-gaap_ClassOfWarrantOrRightTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightTable" xlink:to="us-gaap_ClassOfWarrantOrRightTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Class of Warrant or Right [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightLineItems" xlink:label="us-gaap_ClassOfWarrantOrRightLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Class of Warrant or Right [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ClassOfWarrantOrRightLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Warrants</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WarrantsAndRightsOutstandingTerm" xlink:label="us-gaap_WarrantsAndRightsOutstandingTerm" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantsAndRightsOutstandingTerm" xlink:to="us-gaap_WarrantsAndRightsOutstandingTerm_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WarrantsAndRightsOutstandingTerm_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Warrants and Rights Outstanding, Term</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_WarrantsAndRightsOutstandingTerm_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Warrant term</label>
    <loc xlink:type="locator" xlink:href="anvs-20211231.xsd#anvs_ConversionOfWarrantsNumberOfWarrantsConverted" xlink:label="anvs_ConversionOfWarrantsNumberOfWarrantsConverted" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="anvs_ConversionOfWarrantsNumberOfWarrantsConverted" xlink:to="anvs_ConversionOfWarrantsNumberOfWarrantsConverted_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="anvs_ConversionOfWarrantsNumberOfWarrantsConverted_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The number of warrants converted in a noncash (or part noncash) transaction.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="anvs_ConversionOfWarrantsNumberOfWarrantsConverted_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Conversion of Warrants, Number of Warrants Converted</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="anvs_ConversionOfWarrantsNumberOfWarrantsConverted_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of warrants converted in a non-cash transaction</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightOutstanding" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Class of Warrant or Right, Outstanding</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Warrants outstanding</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PlanNameAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Plan Name [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameDomain" xlink:to="us-gaap_PlanNameDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PlanNameDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Plan Name [Domain]</label>
    <loc xlink:type="locator" xlink:href="anvs-20211231.xsd#anvs_EquityIncentivePlan2019Member" xlink:label="anvs_EquityIncentivePlan2019Member" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="anvs_EquityIncentivePlan2019Member" xlink:to="anvs_EquityIncentivePlan2019Member_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="anvs_EquityIncentivePlan2019Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information pertaining to the Company's 2019 Equity Incentive Plan.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="anvs_EquityIncentivePlan2019Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">2019 Plan</label>
    <loc xlink:type="locator" xlink:href="anvs-20211231.xsd#anvs_EquityIncentivePlan2018Member" xlink:label="anvs_EquityIncentivePlan2018Member" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="anvs_EquityIncentivePlan2018Member" xlink:to="anvs_EquityIncentivePlan2018Member_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="anvs_EquityIncentivePlan2018Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Pertaining to the 2018 Equity Incentive Plan.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="anvs_EquityIncentivePlan2018Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">2018 Plan</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_AwardTypeAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AwardTypeAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Award Type [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Award Type [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeStockOptionMember" xlink:to="us-gaap_EmployeeStockOptionMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeStockOptionMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock Options</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Shares authorized</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Outstanding at end of the period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Outstanding at beginning of the period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Options outstanding</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Shares available for future grants</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Term of award</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementLocationAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income Statement Location [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_IncomeStatementLocationDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementLocationDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income Statement Location [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Research and development</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpenseMember" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">General and administrative</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of Shares</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Granted</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Options granted</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Forfeited</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Exercisable at end of period</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted Average Exercise Price</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Outstanding at end of the period (in dollars per share)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Outstanding at beginning of the period (in dollars per share)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Granted (in dollars per share)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Exercise price</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Exercised (in dollars per share)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Forfeited (in dollars per share)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Exercisable at end of period (in dollars per share)</label>
    <loc xlink:type="locator" xlink:href="anvs-20211231.xsd#anvs_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract" xlink:label="anvs_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="anvs_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract" xlink:to="anvs_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="anvs_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">No definition available.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="anvs_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-Based Compensation Arrangement By Share-Based Payment Award, Options, Weighted-Average Remaining Contractual Term [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="anvs_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted Average Remaining Contractual Term</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Outstanding at end of the period (in years)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Exercisable at end of period (in years)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Aggregate intrinsic value of options outstanding</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Aggregate intrinsic value of options exercisable</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardDateAxis" xlink:label="us-gaap_AwardDateAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AwardDateAxis" xlink:to="us-gaap_AwardDateAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AwardDateAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Award Date [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardDateDomain" xlink:label="us-gaap_AwardDateDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AwardDateDomain" xlink:to="us-gaap_AwardDateDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AwardDateDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Award Date [Domain]</label>
    <loc xlink:type="locator" xlink:href="anvs-20211231.xsd#anvs_AwardsGrantedIn2021Member" xlink:label="anvs_AwardsGrantedIn2021Member" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="anvs_AwardsGrantedIn2021Member" xlink:to="anvs_AwardsGrantedIn2021Member_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="anvs_AwardsGrantedIn2021Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information pertaining to awards granted in 2021.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="anvs_AwardsGrantedIn2021Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Awards granted in 2021</label>
    <loc xlink:type="locator" xlink:href="anvs-20211231.xsd#anvs_AwardsGrantedIn2020Member" xlink:label="anvs_AwardsGrantedIn2020Member" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="anvs_AwardsGrantedIn2020Member" xlink:to="anvs_AwardsGrantedIn2020Member_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="anvs_AwardsGrantedIn2020Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information pertaining to awards granted in 2020.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="anvs_AwardsGrantedIn2020Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Awards granted in 2020</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GranteeStatusAxis" xlink:label="us-gaap_GranteeStatusAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GranteeStatusAxis" xlink:to="us-gaap_GranteeStatusAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GranteeStatusAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Grantee Status [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GranteeStatusDomain" xlink:label="us-gaap_GranteeStatusDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GranteeStatusDomain" xlink:to="us-gaap_GranteeStatusDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GranteeStatusDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Grantee Status [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedPaymentArrangementNonemployeeMember" xlink:label="us-gaap_ShareBasedPaymentArrangementNonemployeeMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedPaymentArrangementNonemployeeMember" xlink:to="us-gaap_ShareBasedPaymentArrangementNonemployeeMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedPaymentArrangementNonemployeeMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Consultants and advisors</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VestingAxis" xlink:label="us-gaap_VestingAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_VestingAxis" xlink:to="us-gaap_VestingAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_VestingAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Vesting [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VestingDomain" xlink:label="us-gaap_VestingDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_VestingDomain" xlink:to="us-gaap_VestingDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_VestingDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Vesting [Domain]</label>
    <loc xlink:type="locator" xlink:href="anvs-20211231.xsd#anvs_ShareBasedPaymentArrangementVestingPeriodImmediateVestingMember" xlink:label="anvs_ShareBasedPaymentArrangementVestingPeriodImmediateVestingMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="anvs_ShareBasedPaymentArrangementVestingPeriodImmediateVestingMember" xlink:to="anvs_ShareBasedPaymentArrangementVestingPeriodImmediateVestingMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="anvs_ShareBasedPaymentArrangementVestingPeriodImmediateVestingMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Immediate vesting of awards under share-based payment arrangement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="anvs_ShareBasedPaymentArrangementVestingPeriodImmediateVestingMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Immediate Vesting</label>
    <loc xlink:type="locator" xlink:href="anvs-20211231.xsd#anvs_ShareBasedPaymentArrangementVestingPeriodOneYearMember" xlink:label="anvs_ShareBasedPaymentArrangementVestingPeriodOneYearMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="anvs_ShareBasedPaymentArrangementVestingPeriodOneYearMember" xlink:to="anvs_ShareBasedPaymentArrangementVestingPeriodOneYearMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="anvs_ShareBasedPaymentArrangementVestingPeriodOneYearMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">One year vesting period of award under share-based payment arrangement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="anvs_ShareBasedPaymentArrangementVestingPeriodOneYearMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Vests one year from grant date</label>
    <loc xlink:type="locator" xlink:href="anvs-20211231.xsd#anvs_ShareBasedPaymentArrangementVestingPeriodTwoYearsMember" xlink:label="anvs_ShareBasedPaymentArrangementVestingPeriodTwoYearsMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="anvs_ShareBasedPaymentArrangementVestingPeriodTwoYearsMember" xlink:to="anvs_ShareBasedPaymentArrangementVestingPeriodTwoYearsMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="anvs_ShareBasedPaymentArrangementVestingPeriodTwoYearsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Two year vesting period of award under share-based payment arrangement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="anvs_ShareBasedPaymentArrangementVestingPeriodTwoYearsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Vests two years from grant date</label>
    <loc xlink:type="locator" xlink:href="anvs-20211231.xsd#anvs_ShareBasedPaymentArrangementVestingPeriodEqualQuarterlyInstallmentsOverTwoYearsMember" xlink:label="anvs_ShareBasedPaymentArrangementVestingPeriodEqualQuarterlyInstallmentsOverTwoYearsMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="anvs_ShareBasedPaymentArrangementVestingPeriodEqualQuarterlyInstallmentsOverTwoYearsMember" xlink:to="anvs_ShareBasedPaymentArrangementVestingPeriodEqualQuarterlyInstallmentsOverTwoYearsMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="anvs_ShareBasedPaymentArrangementVestingPeriodEqualQuarterlyInstallmentsOverTwoYearsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Vesting period of equal quarterly installments over two years for award under share-based payment arrangement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="anvs_ShareBasedPaymentArrangementVestingPeriodEqualQuarterlyInstallmentsOverTwoYearsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Vests in equal Quarterly installments over two years</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Aggregate intrinsic value of options exercised</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Unrecognized compensation expense</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted-average recognition period</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Vested options</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Vesting period</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted average grant date fair value</label>
    <loc xlink:type="locator" xlink:href="anvs-20211231.xsd#anvs_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedInPeriodFairValue" xlink:label="anvs_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedInPeriodFairValue" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="anvs_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedInPeriodFairValue" xlink:to="anvs_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedInPeriodFairValue_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="anvs_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedInPeriodFairValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair value of share-based awards granted.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="anvs_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedInPeriodFairValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Granted in Period, Fair Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="anvs_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedInPeriodFairValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair value of stock awards granted</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Options, Nonvested, Number of Shares</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Unvested awards outstanding</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions and Methodology [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Estimated fair value of options</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Risk-free interest rate</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Expected life</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Expected volatility</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Expected dividend yield</label>
    <loc xlink:type="locator" xlink:href="anvs-20211231.xsd#anvs_EarningsPerShareBasicAndDilutedNumeratorAbstract" xlink:label="anvs_EarningsPerShareBasicAndDilutedNumeratorAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="anvs_EarningsPerShareBasicAndDilutedNumeratorAbstract" xlink:to="anvs_EarningsPerShareBasicAndDilutedNumeratorAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="anvs_EarningsPerShareBasicAndDilutedNumeratorAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">No definition available.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="anvs_EarningsPerShareBasicAndDilutedNumeratorAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Earnings Per Share, Basic and Diluted, Numerator [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="anvs_EarningsPerShareBasicAndDilutedNumeratorAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Numerator</label>
    <loc xlink:type="locator" xlink:href="anvs-20211231.xsd#anvs_EarningsPerShareBasicAndDilutedDenominatorAbstract" xlink:label="anvs_EarningsPerShareBasicAndDilutedDenominatorAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="anvs_EarningsPerShareBasicAndDilutedDenominatorAbstract" xlink:to="anvs_EarningsPerShareBasicAndDilutedDenominatorAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="anvs_EarningsPerShareBasicAndDilutedDenominatorAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">No definition available.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="anvs_EarningsPerShareBasicAndDilutedDenominatorAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Earnings Per Share, Basic and Diluted, Denominator [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="anvs_EarningsPerShareBasicAndDilutedDenominatorAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Denominator</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Antidilutive Securities [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Antidilutive Securities, Name [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WarrantMember" xlink:label="us-gaap_WarrantMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantMember" xlink:to="us-gaap_WarrantMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WarrantMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Warrants</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Antidilutive securities excluded from computation of earnings per share</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExpenseBenefitContinuingOperationsByJurisdictionAbstract" xlink:label="us-gaap_IncomeTaxExpenseBenefitContinuingOperationsByJurisdictionAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxExpenseBenefitContinuingOperationsByJurisdictionAbstract" xlink:to="us-gaap_IncomeTaxExpenseBenefitContinuingOperationsByJurisdictionAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxExpenseBenefitContinuingOperationsByJurisdictionAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Federal and state provision (benefit) for income taxes</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperations" xlink:label="us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperations" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperations" xlink:to="us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperations_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperations_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Federal Income Tax Expense (Benefit), Continuing Operations</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperations_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Federal provision (benefit) for income taxes</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StateAndLocalIncomeTaxExpenseBenefitContinuingOperations" xlink:label="us-gaap_StateAndLocalIncomeTaxExpenseBenefitContinuingOperations" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StateAndLocalIncomeTaxExpenseBenefitContinuingOperations" xlink:to="us-gaap_StateAndLocalIncomeTaxExpenseBenefitContinuingOperations_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StateAndLocalIncomeTaxExpenseBenefitContinuingOperations_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">State and Local Income Tax Expense (Benefit), Continuing Operations</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StateAndLocalIncomeTaxExpenseBenefitContinuingOperations_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">State provision (benefit) for income taxes</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Effective Income Tax Rate Reconciliation, Percent [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Reconciliation of income tax benefit computed at the statutory federal income tax rate to income taxes as reflected in the financial statements</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Federal income tax benefits at statutory rate</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Percent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">State and local tax, net of federal benefit</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Effective Income Tax Rate Reconciliation, Nondeductible Expense, Percent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Permanent differences</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Effective Income Tax Rate Reconciliation, Nondeductible Expense, Research and Development, Percent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Research and development credit</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-based Payment Arrangement, Percent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock-based compensation</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Change in valuation allowance</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Effective Income Tax Rate Reconciliation, Percent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Effective income tax rate</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsNetOfValuationAllowanceAbstract" xlink:label="us-gaap_DeferredTaxAssetsNetOfValuationAllowanceAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsNetOfValuationAllowanceAbstract" xlink:to="us-gaap_DeferredTaxAssetsNetOfValuationAllowanceAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsNetOfValuationAllowanceAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Tax Assets, Net of Valuation Allowance [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredTaxAssetsNetOfValuationAllowanceAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred taxes</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Tax Assets, Operating Loss Carryforwards</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net operating loss carryforwards</label>
    <loc xlink:type="locator" xlink:href="anvs-20211231.xsd#anvs_DeferredTaxAssetsTaxCreditCarryforwardsCapitalizedResearchAndDevelopment" xlink:label="anvs_DeferredTaxAssetsTaxCreditCarryforwardsCapitalizedResearchAndDevelopment" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="anvs_DeferredTaxAssetsTaxCreditCarryforwardsCapitalizedResearchAndDevelopment" xlink:to="anvs_DeferredTaxAssetsTaxCreditCarryforwardsCapitalizedResearchAndDevelopment_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="anvs_DeferredTaxAssetsTaxCreditCarryforwardsCapitalizedResearchAndDevelopment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount before allocation of valuation allowances of deferred tax asset attributable to capitalized research and development.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="anvs_DeferredTaxAssetsTaxCreditCarryforwardsCapitalizedResearchAndDevelopment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Tax Assets, Tax Credit Carryforwards, Capitalized Research and Development</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="anvs_DeferredTaxAssetsTaxCreditCarryforwardsCapitalizedResearchAndDevelopment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Capitalized research and development</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based compensation</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Tax Assets, Tax Credit Carryforwards, Research</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Research and development tax credit carryforwards</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="us-gaap_DeferredTaxAssetsGross" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsGross_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsGross_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Tax Assets, Gross</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_DeferredTaxAssetsGross_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total deferred tax assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Tax Assets, Valuation Allowance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Less valuation allowance</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="us-gaap_DeferredTaxAssetsNet" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsNet" xlink:to="us-gaap_DeferredTaxAssetsNet_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsNet_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Tax Assets, Net of Valuation Allowance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_DeferredTaxAssetsNet_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net deferred taxes</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLossCarryforwardsTable" xlink:label="us-gaap_OperatingLossCarryforwardsTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLossCarryforwardsTable" xlink:to="us-gaap_OperatingLossCarryforwardsTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLossCarryforwardsTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Loss Carryforwards [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="us-gaap_IncomeTaxAuthorityAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxAuthorityAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income Tax Authority [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_IncomeTaxAuthorityDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxAuthorityDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income Tax Authority [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DomesticCountryMember" xlink:label="us-gaap_DomesticCountryMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DomesticCountryMember" xlink:to="us-gaap_DomesticCountryMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DomesticCountryMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">U.S. federal</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:label="us-gaap_StateAndLocalJurisdictionMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StateAndLocalJurisdictionMember" xlink:to="us-gaap_StateAndLocalJurisdictionMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StateAndLocalJurisdictionMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">State</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxPeriodAxis" xlink:label="us-gaap_TaxPeriodAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TaxPeriodAxis" xlink:to="us-gaap_TaxPeriodAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TaxPeriodAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Tax Period [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxPeriodDomain" xlink:label="us-gaap_TaxPeriodDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TaxPeriodDomain" xlink:to="us-gaap_TaxPeriodDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TaxPeriodDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Tax Period [Domain]</label>
    <loc xlink:type="locator" xlink:href="anvs-20211231.xsd#anvs_GeneratedIn2017AndPriorMember" xlink:label="anvs_GeneratedIn2017AndPriorMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="anvs_GeneratedIn2017AndPriorMember" xlink:to="anvs_GeneratedIn2017AndPriorMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="anvs_GeneratedIn2017AndPriorMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information pertaining to tax years 2017 and prior.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="anvs_GeneratedIn2017AndPriorMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Generated in 2017 and prior</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxCreditCarryforwardAxis" xlink:label="us-gaap_TaxCreditCarryforwardAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TaxCreditCarryforwardAxis" xlink:to="us-gaap_TaxCreditCarryforwardAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TaxCreditCarryforwardAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Tax Credit Carryforward [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxCreditCarryforwardNameDomain" xlink:label="us-gaap_TaxCreditCarryforwardNameDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TaxCreditCarryforwardNameDomain" xlink:to="us-gaap_TaxCreditCarryforwardNameDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TaxCreditCarryforwardNameDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Tax Credit Carryforward, Name [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchMember" xlink:label="us-gaap_ResearchMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchMember" xlink:to="us-gaap_ResearchMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Research Tax Credit Carryforward</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLossCarryforwardsLineItems" xlink:label="us-gaap_OperatingLossCarryforwardsLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="us-gaap_OperatingLossCarryforwardsLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLossCarryforwardsLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Loss Carryforwards [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLossCarryforwardsLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income taxes</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="us-gaap_OperatingLossCarryforwards" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLossCarryforwards" xlink:to="us-gaap_OperatingLossCarryforwards_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLossCarryforwards_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Loss Carryforwards</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLossCarryforwards_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net operating loss carryforwards</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:to="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net change in valuation allowance</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxCreditCarryforwardAmount" xlink:label="us-gaap_TaxCreditCarryforwardAmount" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TaxCreditCarryforwardAmount" xlink:to="us-gaap_TaxCreditCarryforwardAmount_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TaxCreditCarryforwardAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Tax Credit Carryforward, Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_TaxCreditCarryforwardAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Tax credit carryforward</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued" xlink:label="us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued" xlink:to="us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income Tax Examination, Penalties and Interest Accrued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accrued interest or penalties</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense" xlink:label="us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense" xlink:to="us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income Tax Examination, Penalties and Interest Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Recognized income tax interest and penalties</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Related Party Transactions, by Related Party [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Related Party [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="us-gaap_RelatedPartyDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Related Party [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_DirectorMember" xlink:label="srt_DirectorMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_DirectorMember" xlink:to="srt_DirectorMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_DirectorMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Directors</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionAxis" xlink:label="us-gaap_RelatedPartyTransactionAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="us-gaap_RelatedPartyTransactionAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Related Party Transaction [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="us-gaap_RelatedPartyTransactionDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="us-gaap_RelatedPartyTransactionDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Related Party Transaction [Domain]</label>
    <loc xlink:type="locator" xlink:href="anvs-20211231.xsd#anvs_RelatedPartyTransactionIssuanceOfConvertiblePromissoryNotesMember" xlink:label="anvs_RelatedPartyTransactionIssuanceOfConvertiblePromissoryNotesMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="anvs_RelatedPartyTransactionIssuanceOfConvertiblePromissoryNotesMember" xlink:to="anvs_RelatedPartyTransactionIssuanceOfConvertiblePromissoryNotesMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="anvs_RelatedPartyTransactionIssuanceOfConvertiblePromissoryNotesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information pertaining to Convertible promissory notes issued by the Company and purchased by related parties.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="anvs_RelatedPartyTransactionIssuanceOfConvertiblePromissoryNotesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Issuance of convertible promissory notes to related parties</label>
    <loc xlink:type="locator" xlink:href="anvs-20211231.xsd#anvs_RelatedPartyTransactionConversionOfPromissoryNotesToCommonStockMember" xlink:label="anvs_RelatedPartyTransactionConversionOfPromissoryNotesToCommonStockMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="anvs_RelatedPartyTransactionConversionOfPromissoryNotesToCommonStockMember" xlink:to="anvs_RelatedPartyTransactionConversionOfPromissoryNotesToCommonStockMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="anvs_RelatedPartyTransactionConversionOfPromissoryNotesToCommonStockMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information pertaining to the conversion of promissory notes to common stock as a result of the Company's closing of an initial public offering.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="anvs_RelatedPartyTransactionConversionOfPromissoryNotesToCommonStockMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Conversion of promissory notes to common stock</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="us-gaap_RelatedPartyTransactionLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_RelatedPartyTransactionLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Related Party Transaction [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RelatedPartyTransactionLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Related-Party Transactions</label>
    <loc xlink:type="locator" xlink:href="anvs-20211231.xsd#anvs_RelatedPartyTransactionNumberOfCompanyDirectors" xlink:label="anvs_RelatedPartyTransactionNumberOfCompanyDirectors" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="anvs_RelatedPartyTransactionNumberOfCompanyDirectors" xlink:to="anvs_RelatedPartyTransactionNumberOfCompanyDirectors_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="anvs_RelatedPartyTransactionNumberOfCompanyDirectors_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The number of Company directors who purchased convertible promissory notes issued by the Company.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="anvs_RelatedPartyTransactionNumberOfCompanyDirectors_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Related Party Transaction, Number Of Company Directors</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="anvs_RelatedPartyTransactionNumberOfCompanyDirectors_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of directors who purchased convertible promissory notes issued by the Company</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTable" xlink:label="us-gaap_SubsequentEventTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_SubsequentEventTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Subsequent Event [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventTypeAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Subsequent Event Type [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventTypeDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventTypeDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Subsequent Event Type [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventMember" xlink:to="us-gaap_SubsequentEventMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Subsequent events</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventLineItems" xlink:label="us-gaap_SubsequentEventLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_SubsequentEventLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Subsequent Event [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_SubsequentEventLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Subsequent Events</label>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>23
<FILENAME>anvs-20211231_pre.xml
<DESCRIPTION>EX-101.PRE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--XBRL document created with Toppan Merrill Bridge  9.6.8042.36810 -->
<!--Based on XBRL 2.1-->
<!--Created on: 3/2/2022 8:59:47 PM-->
<!--Modified on: 3/2/2022 8:59:47 PM-->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance">
  <roleRef xlink:type="simple" xlink:href="anvs-20211231.xsd#DocumentDocumentAndEntityInformation" roleURI="http://annovisbio.com/role/DocumentDocumentAndEntityInformation" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="anvs-20211231.xsd#StatementBalanceSheets" roleURI="http://annovisbio.com/role/StatementBalanceSheets" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="anvs-20211231.xsd#StatementBalanceSheetsParenthetical" roleURI="http://annovisbio.com/role/StatementBalanceSheetsParenthetical" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="anvs-20211231.xsd#StatementStatementsOfOperations" roleURI="http://annovisbio.com/role/StatementStatementsOfOperations" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="anvs-20211231.xsd#StatementStatementsOfChangesInRedeemableConvertiblePreferredStock" roleURI="http://annovisbio.com/role/StatementStatementsOfChangesInRedeemableConvertiblePreferredStock" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="anvs-20211231.xsd#StatementStatementsOfChangesInStockholdersEquityDeficit" roleURI="http://annovisbio.com/role/StatementStatementsOfChangesInStockholdersEquityDeficit" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="anvs-20211231.xsd#StatementStatementsOfCashFlows" roleURI="http://annovisbio.com/role/StatementStatementsOfCashFlows" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="anvs-20211231.xsd#DisclosureNatureOfBusinessAndLiquidity" roleURI="http://annovisbio.com/role/DisclosureNatureOfBusinessAndLiquidity" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="anvs-20211231.xsd#DisclosureSummaryOfSignificantAccountingPolicies" roleURI="http://annovisbio.com/role/DisclosureSummaryOfSignificantAccountingPolicies" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="anvs-20211231.xsd#DisclosureFairValueMeasurements" roleURI="http://annovisbio.com/role/DisclosureFairValueMeasurements" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="anvs-20211231.xsd#DisclosureGrantIncome" roleURI="http://annovisbio.com/role/DisclosureGrantIncome" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="anvs-20211231.xsd#DisclosurePrepaidExpensesAndOtherCurrentAssets" roleURI="http://annovisbio.com/role/DisclosurePrepaidExpensesAndOtherCurrentAssets" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="anvs-20211231.xsd#DisclosureAccruedExpenses" roleURI="http://annovisbio.com/role/DisclosureAccruedExpenses" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="anvs-20211231.xsd#DisclosureConvertiblePromissoryNotes" roleURI="http://annovisbio.com/role/DisclosureConvertiblePromissoryNotes" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="anvs-20211231.xsd#DisclosureCommitmentsAndContingencies" roleURI="http://annovisbio.com/role/DisclosureCommitmentsAndContingencies" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="anvs-20211231.xsd#DisclosureRedeemableConvertiblePreferredStockAndStockholdersEquity" roleURI="http://annovisbio.com/role/DisclosureRedeemableConvertiblePreferredStockAndStockholdersEquity" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="anvs-20211231.xsd#DisclosureStockBasedCompensation" roleURI="http://annovisbio.com/role/DisclosureStockBasedCompensation" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="anvs-20211231.xsd#DisclosureNetLossPerShare" roleURI="http://annovisbio.com/role/DisclosureNetLossPerShare" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="anvs-20211231.xsd#DisclosureIncomeTaxes" roleURI="http://annovisbio.com/role/DisclosureIncomeTaxes" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="anvs-20211231.xsd#DisclosureRelatedPartyTransactions" roleURI="http://annovisbio.com/role/DisclosureRelatedPartyTransactions" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="anvs-20211231.xsd#DisclosureSubsequentEvents" roleURI="http://annovisbio.com/role/DisclosureSubsequentEvents" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="anvs-20211231.xsd#DisclosureSummaryOfSignificantAccountingPoliciesPolicies" roleURI="http://annovisbio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="anvs-20211231.xsd#DisclosureFairValueMeasurementsTables" roleURI="http://annovisbio.com/role/DisclosureFairValueMeasurementsTables" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="anvs-20211231.xsd#DisclosurePrepaidExpensesAndOtherCurrentAssetsTables" roleURI="http://annovisbio.com/role/DisclosurePrepaidExpensesAndOtherCurrentAssetsTables" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="anvs-20211231.xsd#DisclosureAccruedExpensesTables" roleURI="http://annovisbio.com/role/DisclosureAccruedExpensesTables" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="anvs-20211231.xsd#DisclosureStockBasedCompensationTables" roleURI="http://annovisbio.com/role/DisclosureStockBasedCompensationTables" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="anvs-20211231.xsd#DisclosureNetLossPerShareTables" roleURI="http://annovisbio.com/role/DisclosureNetLossPerShareTables" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="anvs-20211231.xsd#DisclosureIncomeTaxesTables" roleURI="http://annovisbio.com/role/DisclosureIncomeTaxesTables" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="anvs-20211231.xsd#DisclosureNatureOfBusinessAndLiquidityDetails" roleURI="http://annovisbio.com/role/DisclosureNatureOfBusinessAndLiquidityDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="anvs-20211231.xsd#DisclosureFairValueMeasurementsDetails" roleURI="http://annovisbio.com/role/DisclosureFairValueMeasurementsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="anvs-20211231.xsd#DisclosureGrantIncomeDetails" roleURI="http://annovisbio.com/role/DisclosureGrantIncomeDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="anvs-20211231.xsd#DisclosurePrepaidExpensesAndOtherCurrentAssetsDetails" roleURI="http://annovisbio.com/role/DisclosurePrepaidExpensesAndOtherCurrentAssetsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="anvs-20211231.xsd#DisclosureAccruedExpensesDetails" roleURI="http://annovisbio.com/role/DisclosureAccruedExpensesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="anvs-20211231.xsd#DisclosureConvertiblePromissoryNotesDetails" roleURI="http://annovisbio.com/role/DisclosureConvertiblePromissoryNotesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="anvs-20211231.xsd#DisclosureCommitmentsAndContingenciesLeasesDetails" roleURI="http://annovisbio.com/role/DisclosureCommitmentsAndContingenciesLeasesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="anvs-20211231.xsd#DisclosureCommitmentsAndContingenciesLicenseAgreementDetails" roleURI="http://annovisbio.com/role/DisclosureCommitmentsAndContingenciesLicenseAgreementDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="anvs-20211231.xsd#DisclosureCommitmentsAndContingenciesEmploymentAgreementsDetails" roleURI="http://annovisbio.com/role/DisclosureCommitmentsAndContingenciesEmploymentAgreementsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="anvs-20211231.xsd#DisclosureRedeemableConvertiblePreferredStockAndStockholdersEquityCommonAndPreferredStockDetails" roleURI="http://annovisbio.com/role/DisclosureRedeemableConvertiblePreferredStockAndStockholdersEquityCommonAndPreferredStockDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="anvs-20211231.xsd#DisclosureRedeemableConvertiblePreferredStockAndStockholdersEquityWarrantsDetails" roleURI="http://annovisbio.com/role/DisclosureRedeemableConvertiblePreferredStockAndStockholdersEquityWarrantsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="anvs-20211231.xsd#DisclosureStockBasedCompensationSummaryOfPlansDetails" roleURI="http://annovisbio.com/role/DisclosureStockBasedCompensationSummaryOfPlansDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="anvs-20211231.xsd#DisclosureStockBasedCompensationShareBasedCompensationExpenseDetails" roleURI="http://annovisbio.com/role/DisclosureStockBasedCompensationShareBasedCompensationExpenseDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="anvs-20211231.xsd#DisclosureStockBasedCompensationStockOptionActivityDetails" roleURI="http://annovisbio.com/role/DisclosureStockBasedCompensationStockOptionActivityDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="anvs-20211231.xsd#DisclosureStockBasedCompensationAdditionalDisclosuresDetails" roleURI="http://annovisbio.com/role/DisclosureStockBasedCompensationAdditionalDisclosuresDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="anvs-20211231.xsd#DisclosureNetLossPerShareBasicAndDilutedNetLossPerShareDetails" roleURI="http://annovisbio.com/role/DisclosureNetLossPerShareBasicAndDilutedNetLossPerShareDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="anvs-20211231.xsd#DisclosureNetLossPerSharePotentialSharesExcludedFromCalculationDetails" roleURI="http://annovisbio.com/role/DisclosureNetLossPerSharePotentialSharesExcludedFromCalculationDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="anvs-20211231.xsd#DisclosureIncomeTaxesReconciliationOfIncomeTaxProvisionBenefitDetails" roleURI="http://annovisbio.com/role/DisclosureIncomeTaxesReconciliationOfIncomeTaxProvisionBenefitDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="anvs-20211231.xsd#DisclosureIncomeTaxesDeferredTaxesDetails" roleURI="http://annovisbio.com/role/DisclosureIncomeTaxesDeferredTaxesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="anvs-20211231.xsd#DisclosureIncomeTaxesAdditionalDisclosuresDetails" roleURI="http://annovisbio.com/role/DisclosureIncomeTaxesAdditionalDisclosuresDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="anvs-20211231.xsd#DisclosureRelatedPartyTransactionsDetails" roleURI="http://annovisbio.com/role/DisclosureRelatedPartyTransactionsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="anvs-20211231.xsd#DisclosureSubsequentEventsDetails" roleURI="http://annovisbio.com/role/DisclosureSubsequentEventsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <presentationLink xlink:role="http://annovisbio.com/role/DocumentDocumentAndEntityInformation" xlink:type="extended" xlink:title="00090 - Document - Document and Entity Information" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName_637818515858915901" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityRegistrantName_637818515858915901" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentType" xlink:label="dei_DocumentType_637818515858915901" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentType_637818515858915901" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentAnnualReport" xlink:label="dei_DocumentAnnualReport_637818515858915901" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentAnnualReport_637818515858915901" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate_637818515858915901" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_CurrentFiscalYearEndDate_637818515858915901" order="4" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate_637818515858915901" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentPeriodEndDate_637818515858915901" order="5" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport_637818515858915901" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentTransitionReport_637818515858915901" order="6" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber_637818515858915901" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityFileNumber_637818515858915901" order="7" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode_637818515858915901" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityIncorporationStateCountryCode_637818515858915901" order="8" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber_637818515858925876" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityTaxIdentificationNumber_637818515858925876" order="9" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1_637818515858925876" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressAddressLine1_637818515858925876" order="10" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown_637818515858925876" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressCityOrTown_637818515858925876" order="11" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince_637818515858925876" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressStateOrProvince_637818515858925876" order="12" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode_637818515858925876" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressPostalZipCode_637818515858925876" order="13" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode_637818515858925876" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_CityAreaCode_637818515858925876" order="14" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber_637818515858925876" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_LocalPhoneNumber_637818515858925876" order="15" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle_637818515858925876" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_Security12bTitle_637818515858925876" order="16" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol_637818515858925876" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_TradingSymbol_637818515858925876" order="17" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName_637818515858925876" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_SecurityExchangeName_637818515858925876" order="18" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus_637818515858935680" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCurrentReportingStatus_637818515858935680" order="19" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer_637818515858935680" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityWellKnownSeasonedIssuer_637818515858935680" order="20" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers_637818515858935680" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityVoluntaryFilers_637818515858935680" order="21" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent_637818515858935680" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityInteractiveDataCurrent_637818515858935680" order="22" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory_637818515858935680" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityFilerCategory_637818515858935680" order="23" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness_637818515858935680" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntitySmallBusiness_637818515858935680" order="24" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany_637818515858935680" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityEmergingGrowthCompany_637818515858935680" order="25" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityExTransitionPeriod" xlink:label="dei_EntityExTransitionPeriod_637818515858935680" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityExTransitionPeriod_637818515858935680" order="26" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany_637818515858935680" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityShellCompany_637818515858935680" order="27" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat_637818515858945912" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityPublicFloat_637818515858945912" order="28" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_IcfrAuditorAttestationFlag" xlink:label="dei_IcfrAuditorAttestationFlag_637818515858945912" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_IcfrAuditorAttestationFlag_637818515858945912" order="29" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding_637818515858945912" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCommonStockSharesOutstanding_637818515858945912" order="30" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey_637818515858945912" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCentralIndexKey_637818515858945912" order="31" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus_637818515858945912" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentFiscalYearFocus_637818515858945912" order="32" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus_637818515858945912" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentFiscalPeriodFocus_637818515858945912" order="33" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag_637818515858945912" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AmendmentFlag_637818515858945912" order="34" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AuditorName" xlink:label="dei_AuditorName_637818515858955870" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AuditorName_637818515858955870" order="35" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AuditorLocation" xlink:label="dei_AuditorLocation_637818515858955870" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AuditorLocation_637818515858955870" order="36" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AuditorFirmId" xlink:label="dei_AuditorFirmId_637818515858955870" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AuditorFirmId_637818515858955870" order="37" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </presentationLink>
  <presentationLink xlink:role="http://annovisbio.com/role/StatementBalanceSheets" xlink:type="extended" xlink:title="00100 - Statement - Balance Sheets" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract_637818515858955870" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_AssetsAbstract_637818515858955870" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract_637818515858955870" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract_637818515858955870" xlink:to="us-gaap_AssetsCurrentAbstract_637818515858955870" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_637818515858955870" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract_637818515858955870" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_637818515858955870" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="anvs-20211231.xsd#anvs_PrepaidExpenseSecurityDepositsAndOtherAssetsCurrent" xlink:label="anvs_PrepaidExpenseSecurityDepositsAndOtherAssetsCurrent_637818515858955870" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract_637818515858955870" xlink:to="anvs_PrepaidExpenseSecurityDepositsAndOtherAssetsCurrent_637818515858955870" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent_637818515858955870" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract_637818515858955870" xlink:to="us-gaap_AssetsCurrent_637818515858955870" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets_637818515858965872" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract_637818515858955870" xlink:to="us-gaap_Assets_637818515858965872" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_637818515858965872" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract_637818515858965872" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract_637818515858965872" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract_637818515858965872" xlink:to="us-gaap_LiabilitiesCurrentAbstract_637818515858965872" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent_637818515858965872" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract_637818515858965872" xlink:to="us-gaap_AccountsPayableCurrent_637818515858965872" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="anvs-20211231.xsd#anvs_AccruedLiabilitiesAndInterestAndEmployeeRelatedLiabilitiesCurrent" xlink:label="anvs_AccruedLiabilitiesAndInterestAndEmployeeRelatedLiabilitiesCurrent_637818515858965872" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract_637818515858965872" xlink:to="anvs_AccruedLiabilitiesAndInterestAndEmployeeRelatedLiabilitiesCurrent_637818515858965872" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent_637818515858965872" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract_637818515858965872" xlink:to="us-gaap_LiabilitiesCurrent_637818515858965872" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities_637818515858965872" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract_637818515858965872" xlink:to="us-gaap_Liabilities_637818515858965872" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies_637818515858965872" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract_637818515858965872" xlink:to="us-gaap_CommitmentsAndContingencies_637818515858965872" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract_637818515858965872" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract_637818515858965872" xlink:to="us-gaap_StockholdersEquityAbstract_637818515858965872" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue_637818515858965872" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract_637818515858965872" xlink:to="us-gaap_PreferredStockValue_637818515858965872" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue_637818515858965872" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract_637818515858965872" xlink:to="us-gaap_CommonStockValue_637818515858965872" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="us-gaap_AdditionalPaidInCapital_637818515858965872" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract_637818515858965872" xlink:to="us-gaap_AdditionalPaidInCapital_637818515858965872" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_637818515858975871" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract_637818515858965872" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_637818515858975871" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity_637818515858975871" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract_637818515858965872" xlink:to="us-gaap_StockholdersEquity_637818515858975871" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_637818515858975871" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract_637818515858965872" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_637818515858975871" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="4" />
  </presentationLink>
  <presentationLink xlink:role="http://annovisbio.com/role/StatementBalanceSheetsParenthetical" xlink:type="extended" xlink:title="00105 - Statement - Balance Sheets (Parenthetical)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_637818515858975871" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare_637818515858975871" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized_637818515858975871" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_PreferredStockSharesAuthorized_637818515858975871" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="us-gaap_PreferredStockSharesIssued_637818515858975871" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_PreferredStockSharesIssued_637818515858975871" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding_637818515858975871" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_PreferredStockSharesOutstanding_637818515858975871" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_637818515858975871" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_637818515858975871" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized_637818515858985870" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesAuthorized_637818515858985870" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued_637818515858985870" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesIssued_637818515858985870" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding_637818515858985870" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesOutstanding_637818515858985870" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://annovisbio.com/role/StatementStatementsOfOperations" xlink:type="extended" xlink:title="00200 - Statement - Statements of Operations" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:label="us-gaap_IncomeStatementAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="us-gaap_OperatingExpensesAbstract_637818515858985870" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_OperatingExpensesAbstract_637818515858985870" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense_637818515858985870" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract_637818515858985870" xlink:to="us-gaap_ResearchAndDevelopmentExpense_637818515858985870" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense_637818515858985870" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract_637818515858985870" xlink:to="us-gaap_GeneralAndAdministrativeExpense_637818515858985870" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses_637818515858985870" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract_637818515858985870" xlink:to="us-gaap_OperatingExpenses_637818515858985870" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss_637818515858985870" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_OperatingIncomeLoss_637818515858985870" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract_637818515858985870" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_NonoperatingIncomeExpenseAbstract_637818515858985870" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrealizedGainLossOnDerivatives" xlink:label="us-gaap_UnrealizedGainLossOnDerivatives_637818515858985870" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract_637818515858985870" xlink:to="us-gaap_UnrealizedGainLossOnDerivatives_637818515858985870" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestIncomeExpenseNonoperatingNet" xlink:label="us-gaap_InterestIncomeExpenseNonoperatingNet_637818515858985870" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract_637818515858985870" xlink:to="us-gaap_InterestIncomeExpenseNonoperatingNet_637818515858985870" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="anvs-20211231.xsd#anvs_IncomeFromGrants" xlink:label="anvs_IncomeFromGrants_637818515858995994" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract_637818515858985870" xlink:to="anvs_IncomeFromGrants_637818515858995994" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="us-gaap_NonoperatingIncomeExpense_637818515858995994" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract_637818515858985870" xlink:to="us-gaap_NonoperatingIncomeExpense_637818515858995994" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_637818515858995994" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_637818515858995994" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss_637818515858995994" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_NetIncomeLoss_637818515858995994" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic_637818515858995994" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_EarningsPerShareBasic_637818515858995994" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="us-gaap_EarningsPerShareDiluted_637818515858995994" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_EarningsPerShareDiluted_637818515858995994" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_637818515858995994" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_637818515858995994" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_637818515858995994" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_637818515858995994" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://annovisbio.com/role/StatementStatementsOfChangesInRedeemableConvertiblePreferredStock" xlink:type="extended" xlink:title="00300 - Statement - Statements of Changes in Redeemable Convertible Preferred Stock" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable_637818515858995994" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementTable_637818515858995994" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis_637818515858995994" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_637818515858995994" xlink:to="us-gaap_StatementClassOfStockAxis_637818515858995994" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain_637818515859005873" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis_637818515858995994" xlink:to="us-gaap_ClassOfStockDomain_637818515859005873" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RedeemableConvertiblePreferredStockMember" xlink:label="us-gaap_RedeemableConvertiblePreferredStockMember_637818515859005873" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain_637818515859005873" xlink:to="us-gaap_RedeemableConvertiblePreferredStockMember_637818515859005873" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="anvs-20211231.xsd#anvs_SeriesaRedeemableConvertiblePreferredStockMember" xlink:label="anvs_SeriesaRedeemableConvertiblePreferredStockMember_637818515859005873" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RedeemableConvertiblePreferredStockMember_637818515859005873" xlink:to="anvs_SeriesaRedeemableConvertiblePreferredStockMember_637818515859005873" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="anvs-20211231.xsd#anvs_Series1RedeemableConvertiblePreferredStockMember" xlink:label="anvs_Series1RedeemableConvertiblePreferredStockMember_637818515859005873" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RedeemableConvertiblePreferredStockMember_637818515859005873" xlink:to="anvs_Series1RedeemableConvertiblePreferredStockMember_637818515859005873" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems_637818515859005873" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_637818515858995994" xlink:to="us-gaap_StatementLineItems_637818515859005873" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInTemporaryEquityRollForward" xlink:label="us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_637818515859005873" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637818515859005873" xlink:to="us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_637818515859005873" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent_637818515859005873" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_637818515859005873" xlink:to="us-gaap_TemporaryEquityCarryingAmountAttributableToParent_637818515859005873" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquitySharesIssued" xlink:label="us-gaap_TemporaryEquitySharesIssued_637818515859005873" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_637818515859005873" xlink:to="us-gaap_TemporaryEquitySharesIssued_637818515859005873" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="anvs-20211231.xsd#anvs_TemporaryEquityConversionOfPreferredStockToCommonStock" xlink:label="anvs_TemporaryEquityConversionOfPreferredStockToCommonStock_637818515859005873" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_637818515859005873" xlink:to="anvs_TemporaryEquityConversionOfPreferredStockToCommonStock_637818515859005873" order="3" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="anvs-20211231.xsd#anvs_TemporaryEquitySharesConversionOfPreferredStockToCommonStock" xlink:label="anvs_TemporaryEquitySharesConversionOfPreferredStockToCommonStock_637818515859005873" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="anvs_TemporaryEquityConversionOfPreferredStockToCommonStock_637818515859005873" xlink:to="anvs_TemporaryEquitySharesConversionOfPreferredStockToCommonStock_637818515859005873" order="1" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent_6378185158590058731" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_637818515859005873" xlink:to="us-gaap_TemporaryEquityCarryingAmountAttributableToParent_6378185158590058731" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquitySharesIssued" xlink:label="us-gaap_TemporaryEquitySharesIssued_6378185158590058731" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_637818515859005873" xlink:to="us-gaap_TemporaryEquitySharesIssued_6378185158590058731" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="4" />
  </presentationLink>
  <presentationLink xlink:role="http://annovisbio.com/role/StatementStatementsOfChangesInStockholdersEquityDeficit" xlink:type="extended" xlink:title="00301 - Statement - Statements of Changes in Stockholders' Equity (Deficit)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable_637818515859015896" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementTable_637818515859015896" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis_637818515859015896" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_637818515859015896" xlink:to="us-gaap_StatementEquityComponentsAxis_637818515859015896" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember_637818515859015896" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis_637818515859015896" xlink:to="us-gaap_CommonStockMember_637818515859015896" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember_637818515859015896" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis_637818515859015896" xlink:to="us-gaap_AdditionalPaidInCapitalMember_637818515859015896" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember_637818515859015896" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis_637818515859015896" xlink:to="us-gaap_RetainedEarningsMember_637818515859015896" order="3" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain_637818515859015896" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis_637818515859015896" xlink:to="us-gaap_EquityComponentDomain_637818515859015896" order="4" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems_637818515859015896" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_637818515859015896" xlink:to="us-gaap_StatementLineItems_637818515859015896" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:label="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_637818515859015896" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637818515859015896" xlink:to="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_637818515859015896" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity_637818515859015896" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_637818515859015896" xlink:to="us-gaap_StockholdersEquity_637818515859015896" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesIssued" xlink:label="us-gaap_SharesIssued_637818515859015896" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_637818515859015896" xlink:to="us-gaap_SharesIssued_637818515859015896" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="anvs-20211231.xsd#anvs_StockIssuedDuringPeriodValueConversionOfConvertibleSecuritiesPreferredStock" xlink:label="anvs_StockIssuedDuringPeriodValueConversionOfConvertibleSecuritiesPreferredStock_637818515859015896" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_637818515859015896" xlink:to="anvs_StockIssuedDuringPeriodValueConversionOfConvertibleSecuritiesPreferredStock_637818515859015896" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="anvs-20211231.xsd#anvs_StockIssuedDuringPeriodSharesConversionOfConvertibleSecuritiesPreferredStock" xlink:label="anvs_StockIssuedDuringPeriodSharesConversionOfConvertibleSecuritiesPreferredStock_637818515859025923" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="anvs_StockIssuedDuringPeriodValueConversionOfConvertibleSecuritiesPreferredStock_637818515859015896" xlink:to="anvs_StockIssuedDuringPeriodSharesConversionOfConvertibleSecuritiesPreferredStock_637818515859025923" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="anvs-20211231.xsd#anvs_StockIssuedDuringPeriodValueConversionOfConvertibleSecuritiesConvertiblePromissoryNotes" xlink:label="anvs_StockIssuedDuringPeriodValueConversionOfConvertibleSecuritiesConvertiblePromissoryNotes_637818515859025923" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_637818515859015896" xlink:to="anvs_StockIssuedDuringPeriodValueConversionOfConvertibleSecuritiesConvertiblePromissoryNotes_637818515859025923" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="anvs-20211231.xsd#anvs_StockIssuedDuringPeriodSharesConversionOfConvertibleNotes" xlink:label="anvs_StockIssuedDuringPeriodSharesConversionOfConvertibleNotes_637818515859025923" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="anvs_StockIssuedDuringPeriodValueConversionOfConvertibleSecuritiesConvertiblePromissoryNotes_637818515859025923" xlink:to="anvs_StockIssuedDuringPeriodSharesConversionOfConvertibleNotes_637818515859025923" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_637818515859025923" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_637818515859015896" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues_637818515859025923" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_637818515859025923" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockIssuedDuringPeriodValueNewIssues_637818515859025923" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_637818515859025923" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_637818515859025923" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_637818515859015896" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_637818515859025923" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_637818515859025923" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_637818515859025923" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_637818515859025923" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="anvs-20211231.xsd#anvs_StockIssuedDuringPeriodValueWarrantsExercised" xlink:label="anvs_StockIssuedDuringPeriodValueWarrantsExercised_637818515859025923" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_637818515859015896" xlink:to="anvs_StockIssuedDuringPeriodValueWarrantsExercised_637818515859025923" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="anvs-20211231.xsd#anvs_StockIssuedDuringPeriodSharesWarrantsExercised" xlink:label="anvs_StockIssuedDuringPeriodSharesWarrantsExercised_637818515859025923" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="anvs_StockIssuedDuringPeriodValueWarrantsExercised_637818515859025923" xlink:to="anvs_StockIssuedDuringPeriodSharesWarrantsExercised_637818515859025923" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:label="us-gaap_StockIssuedDuringPeriodValueIssuedForServices_637818515859025923" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_637818515859015896" xlink:to="us-gaap_StockIssuedDuringPeriodValueIssuedForServices_637818515859025923" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:label="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_637818515859036178" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockIssuedDuringPeriodValueIssuedForServices_637818515859025923" xlink:to="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_637818515859036178" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition_637818515859036178" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_637818515859015896" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition_637818515859036178" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss_637818515859036178" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_637818515859015896" xlink:to="us-gaap_NetIncomeLoss_637818515859036178" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity_637818515859036178" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_637818515859015896" xlink:to="us-gaap_StockholdersEquity_637818515859036178" order="11" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesIssued" xlink:label="us-gaap_SharesIssued_637818515859045604" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_637818515859015896" xlink:to="us-gaap_SharesIssued_637818515859045604" order="12" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="4" />
  </presentationLink>
  <presentationLink xlink:role="http://annovisbio.com/role/StatementStatementsOfCashFlows" xlink:type="extended" xlink:title="00400 - Statement - Statements of Cash Flows" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="us-gaap_StatementOfCashFlowsAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_637818515859045604" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_637818515859045604" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProfitLoss" xlink:label="us-gaap_ProfitLoss_637818515859045604" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_637818515859045604" xlink:to="us-gaap_ProfitLoss_637818515859045604" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_637818515859045604" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_637818515859045604" xlink:to="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_637818515859045604" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AmortizationOfFinancingCosts" xlink:label="us-gaap_AmortizationOfFinancingCosts_637818515859045604" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_637818515859045604" xlink:to="us-gaap_AmortizationOfFinancingCosts_637818515859045604" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AmortizationOfDebtDiscountPremium" xlink:label="us-gaap_AmortizationOfDebtDiscountPremium_637818515859045604" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_637818515859045604" xlink:to="us-gaap_AmortizationOfDebtDiscountPremium_637818515859045604" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation_637818515859045604" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_637818515859045604" xlink:to="us-gaap_ShareBasedCompensation_637818515859045604" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="7" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrealizedGainLossOnDerivatives" xlink:label="us-gaap_UnrealizedGainLossOnDerivatives_637818515859045604" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_637818515859045604" xlink:to="us-gaap_UnrealizedGainLossOnDerivatives_637818515859045604" order="4" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_637818515859045604" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_637818515859045604" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_637818515859045604" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="anvs-20211231.xsd#anvs_IncreaseDecreaseInGrantsReceivable" xlink:label="anvs_IncreaseDecreaseInGrantsReceivable_637818515859045604" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_637818515859045604" xlink:to="anvs_IncreaseDecreaseInGrantsReceivable_637818515859045604" order="1" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_637818515859055897" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_637818515859045604" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_637818515859055897" order="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_637818515859055897" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_637818515859045604" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable_637818515859055897" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities_637818515859055897" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_637818515859045604" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilities_637818515859055897" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_637818515859055897" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_637818515859045604" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_637818515859055897" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_637818515859055897" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_637818515859055897" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_637818515859055897" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_637818515859055897" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_637818515859055897" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="us-gaap_ProceedsFromStockOptionsExercised_637818515859055897" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_637818515859055897" xlink:to="us-gaap_ProceedsFromStockOptionsExercised_637818515859055897" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_637818515859055897" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_637818515859055897" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_637818515859055897" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_637818515859055897" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_637818515859055897" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_637818515859055897" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_637818515859055897" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_637818515859065900" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_637818515859065900" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SupplementalCashFlowElementsAbstract" xlink:label="us-gaap_SupplementalCashFlowElementsAbstract_637818515859065900" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_SupplementalCashFlowElementsAbstract_637818515859065900" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="anvs-20211231.xsd#anvs_ConversionOfRedeemableConvertiblePreferredStockToCommonStock" xlink:label="anvs_ConversionOfRedeemableConvertiblePreferredStockToCommonStock_637818515859065900" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SupplementalCashFlowElementsAbstract_637818515859065900" xlink:to="anvs_ConversionOfRedeemableConvertiblePreferredStockToCommonStock_637818515859065900" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="anvs-20211231.xsd#anvs_ConversionOfConvertiblePromissoryNotesIncludingEmbeddedDerivativeToCommonStock" xlink:label="anvs_ConversionOfConvertiblePromissoryNotesIncludingEmbeddedDerivativeToCommonStock_637818515859065900" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SupplementalCashFlowElementsAbstract_637818515859065900" xlink:to="anvs_ConversionOfConvertiblePromissoryNotesIncludingEmbeddedDerivativeToCommonStock_637818515859065900" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="3" />
  </presentationLink>
  <presentationLink xlink:role="http://annovisbio.com/role/DisclosureNatureOfBusinessAndLiquidity" xlink:type="extended" xlink:title="10101 - Disclosure - Nature of Business and Liquidity" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_637818515859065900" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_637818515859065900" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://annovisbio.com/role/DisclosureSummaryOfSignificantAccountingPolicies" xlink:type="extended" xlink:title="10201 - Disclosure - Summary of Significant Accounting Policies" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock_637818515859065900" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock_637818515859065900" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://annovisbio.com/role/DisclosureFairValueMeasurements" xlink:type="extended" xlink:title="10301 - Disclosure - Fair Value Measurements" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:label="us-gaap_FairValueDisclosuresTextBlock_637818515859065900" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueDisclosuresTextBlock_637818515859065900" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://annovisbio.com/role/DisclosureGrantIncome" xlink:type="extended" xlink:title="10401 - Disclosure - Grant Income" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="anvs-20211231.xsd#anvs_NonOperatingIncomeGrantIncomeAbstract" xlink:label="anvs_NonOperatingIncomeGrantIncomeAbstract" />
    <loc xlink:type="locator" xlink:href="anvs-20211231.xsd#anvs_OtherNonoperatingIncomeGrantIncomeTextBlock" xlink:label="anvs_OtherNonoperatingIncomeGrantIncomeTextBlock_637818515859075902" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="anvs_NonOperatingIncomeGrantIncomeAbstract" xlink:to="anvs_OtherNonoperatingIncomeGrantIncomeTextBlock_637818515859075902" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://annovisbio.com/role/DisclosurePrepaidExpensesAndOtherCurrentAssets" xlink:type="extended" xlink:title="10501 - Disclosure - Prepaid Expenses and Other Current Assets" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" xlink:label="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="anvs-20211231.xsd#anvs_DeferredCostsCapitalizedPrepaidExpensesAndOtherAssetsDisclosureTextBlock" xlink:label="anvs_DeferredCostsCapitalizedPrepaidExpensesAndOtherAssetsDisclosureTextBlock_637818515859075902" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" xlink:to="anvs_DeferredCostsCapitalizedPrepaidExpensesAndOtherAssetsDisclosureTextBlock_637818515859075902" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://annovisbio.com/role/DisclosureAccruedExpenses" xlink:type="extended" xlink:title="10601 - Disclosure - Accrued Expenses" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract" xlink:label="us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_637818515859075902" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_637818515859075902" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://annovisbio.com/role/DisclosureConvertiblePromissoryNotes" xlink:type="extended" xlink:title="10701 - Disclosure - Convertible Promissory Notes" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="us-gaap_DebtDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtDisclosureTextBlock" xlink:label="us-gaap_DebtDisclosureTextBlock_637818515859075902" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_DebtDisclosureTextBlock_637818515859075902" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://annovisbio.com/role/DisclosureCommitmentsAndContingencies" xlink:type="extended" xlink:title="10801 - Disclosure - Commitments and Contingencies" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_637818515859075902" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_637818515859075902" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://annovisbio.com/role/DisclosureRedeemableConvertiblePreferredStockAndStockholdersEquity" xlink:type="extended" xlink:title="10901 - Disclosure - Redeemable Convertible Preferred Stock and Stockholders' Equity" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="us-gaap_StockholdersEquityNoteAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_637818515859086034" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock_637818515859086034" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://annovisbio.com/role/DisclosureStockBasedCompensation" xlink:type="extended" xlink:title="11001 - Disclosure - Stock-Based Compensation" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_637818515859086034" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_637818515859086034" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://annovisbio.com/role/DisclosureNetLossPerShare" xlink:type="extended" xlink:title="11101 - Disclosure - Net Loss Per Share" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareTextBlock" xlink:label="us-gaap_EarningsPerShareTextBlock_637818515859086034" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareTextBlock_637818515859086034" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://annovisbio.com/role/DisclosureIncomeTaxes" xlink:type="extended" xlink:title="11201 - Disclosure - Income Taxes" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_637818515859086034" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock_637818515859086034" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://annovisbio.com/role/DisclosureRelatedPartyTransactions" xlink:type="extended" xlink:title="11301 - Disclosure - Related-Party Transactions" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="us-gaap_RelatedPartyTransactionsAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_637818515859095952" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsAbstract" xlink:to="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_637818515859095952" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://annovisbio.com/role/DisclosureSubsequentEvents" xlink:type="extended" xlink:title="11401 - Disclosure - Subsequent Events" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="us-gaap_SubsequentEventsAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="us-gaap_SubsequentEventsTextBlock_637818515859095952" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventsTextBlock_637818515859095952" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://annovisbio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" xlink:type="extended" xlink:title="20202 - Disclosure - Summary of Significant Accounting Policies (Policies)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BasisOfAccounting" xlink:label="us-gaap_BasisOfAccounting_637818515859095952" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_BasisOfAccounting_637818515859095952" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UseOfEstimates" xlink:label="us-gaap_UseOfEstimates_637818515859095952" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_UseOfEstimates_637818515859095952" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_637818515859095952" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock_637818515859095952" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock_637818515859095952" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock_637818515859095952" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="anvs-20211231.xsd#anvs_IssuanceCostsAssociatedWithEquityIssuancesPolicyTextBlock" xlink:label="anvs_IssuanceCostsAssociatedWithEquityIssuancesPolicyTextBlock_637818515859095952" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="anvs_IssuanceCostsAssociatedWithEquityIssuancesPolicyTextBlock_637818515859095952" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:label="us-gaap_FairValueOfFinancialInstrumentsPolicy_637818515859095952" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_FairValueOfFinancialInstrumentsPolicy_637818515859095952" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchDevelopmentAndComputerSoftwarePolicyTextBlock" xlink:label="us-gaap_ResearchDevelopmentAndComputerSoftwarePolicyTextBlock_637818515859095952" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ResearchDevelopmentAndComputerSoftwarePolicyTextBlock_637818515859095952" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="anvs-20211231.xsd#anvs_GrantIncomePolicyTextBlock" xlink:label="anvs_GrantIncomePolicyTextBlock_637818515859105926" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="anvs_GrantIncomePolicyTextBlock_637818515859105926" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_637818515859105926" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_637818515859105926" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_637818515859105926" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_IncomeTaxPolicyTextBlock_637818515859105926" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_637818515859105926" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_637818515859105926" order="11" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://annovisbio.com/role/DisclosureFairValueMeasurementsTables" xlink:type="extended" xlink:title="30303 - Disclosure - Fair Value Measurements (Tables)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:label="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_637818515859105926" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_637818515859105926" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://annovisbio.com/role/DisclosurePrepaidExpensesAndOtherCurrentAssetsTables" xlink:type="extended" xlink:title="30503 - Disclosure - Prepaid Expenses and Other Current Assets (Tables)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" xlink:label="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" xlink:label="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock_637818515859105926" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" xlink:to="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock_637818515859105926" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://annovisbio.com/role/DisclosureAccruedExpensesTables" xlink:type="extended" xlink:title="30603 - Disclosure - Accrued Expenses (Tables)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract" xlink:label="us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_637818515859105926" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract" xlink:to="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_637818515859105926" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://annovisbio.com/role/DisclosureStockBasedCompensationTables" xlink:type="extended" xlink:title="31003 - Disclosure - Stock-Based Compensation (Tables)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_637250488103173191" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_637818515859115992" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_637250488103173191" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_637818515859115992" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_637818515859115992" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_637250488103173191" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_637818515859115992" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_637818515859115992" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_637250488103173191" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_637818515859115992" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://annovisbio.com/role/DisclosureNetLossPerShareTables" xlink:type="extended" xlink:title="31103 - Disclosure - Net Loss Per Share (Tables)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_637818515859115992" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_637818515859115992" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_637818515859115992" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_637818515859115992" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://annovisbio.com/role/DisclosureIncomeTaxesTables" xlink:type="extended" xlink:title="31203 - Disclosure - Income Taxes (Tables)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract_637250510374017182" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_637818515859115992" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract_637250510374017182" xlink:to="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_637818515859115992" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_637818515859115992" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract_637250510374017182" xlink:to="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_637818515859115992" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://annovisbio.com/role/DisclosureNatureOfBusinessAndLiquidityDetails" xlink:type="extended" xlink:title="40101 - Disclosure - Nature of Business and Liquidity (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="us-gaap_ScheduleOfStockByClassTable_637818515859115992" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_ScheduleOfStockByClassTable_637818515859115992" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis_637818515859125974" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable_637818515859115992" xlink:to="us-gaap_StatementEquityComponentsAxis_637818515859125974" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain_637818515859125974" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis_637818515859125974" xlink:to="us-gaap_EquityComponentDomain_637818515859125974" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember_637818515859125974" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain_637818515859125974" xlink:to="us-gaap_CommonStockMember_637818515859125974" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_637818515859205992" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable_637818515859115992" xlink:to="us-gaap_SubsidiarySaleOfStockAxis_637818515859205992" order="2" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_637818515859205992" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis_637818515859205992" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_637818515859205992" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="anvs-20211231.xsd#anvs_InitialPublicOfferingAndOverAllotmentOptionMember" xlink:label="anvs_InitialPublicOfferingAndOverAllotmentOptionMember_637818515859205992" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain_637818515859205992" xlink:to="anvs_InitialPublicOfferingAndOverAllotmentOptionMember_637818515859205992" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IPOMember" xlink:label="us-gaap_IPOMember_637818515859205992" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="anvs_InitialPublicOfferingAndOverAllotmentOptionMember_637818515859205992" xlink:to="us-gaap_IPOMember_637818515859205992" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="anvs-20211231.xsd#anvs_SecondaryPublicOfferingMember" xlink:label="anvs_SecondaryPublicOfferingMember_637818515859205992" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain_637818515859205992" xlink:to="anvs_SecondaryPublicOfferingMember_637818515859205992" order="2" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis_637818515859205992" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable_637818515859115992" xlink:to="us-gaap_ClassOfWarrantOrRightAxis_637818515859205992" order="3" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain_637818515859205992" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis_637818515859205992" xlink:to="us-gaap_ClassOfWarrantOrRightDomain_637818515859205992" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="anvs-20211231.xsd#anvs_UnderwritersWarrantsMember" xlink:label="anvs_UnderwritersWarrantsMember_637818515859216000" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightDomain_637818515859205992" xlink:to="anvs_UnderwritersWarrantsMember_637818515859216000" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockLineItems" xlink:label="us-gaap_ClassOfStockLineItems_637818515859216000" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable_637818515859115992" xlink:to="us-gaap_ClassOfStockLineItems_637818515859216000" order="4" use="optional" />
    <loc xlink:type="locator" xlink:href="anvs-20211231.xsd#anvs_NatureOfBusinessAndLiquidityAbstract" xlink:label="anvs_NatureOfBusinessAndLiquidityAbstract_637818515859216000" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems_637818515859216000" xlink:to="anvs_NatureOfBusinessAndLiquidityAbstract_637818515859216000" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_637818515859216000" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="anvs_NatureOfBusinessAndLiquidityAbstract_637818515859216000" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_637818515859216000" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_637818515859216000" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="anvs_NatureOfBusinessAndLiquidityAbstract_637818515859216000" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_637818515859216000" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharePrice" xlink:label="us-gaap_SharePrice_637818515859216000" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="anvs_NatureOfBusinessAndLiquidityAbstract_637818515859216000" xlink:to="us-gaap_SharePrice_637818515859216000" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_637818515859216000" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="anvs_NatureOfBusinessAndLiquidityAbstract_637818515859216000" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_637818515859216000" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:label="us-gaap_SaleOfStockConsiderationReceivedOnTransaction_637818515859216000" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="anvs_NatureOfBusinessAndLiquidityAbstract_637818515859216000" xlink:to="us-gaap_SaleOfStockConsiderationReceivedOnTransaction_637818515859216000" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_637818515859216000" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="anvs_NatureOfBusinessAndLiquidityAbstract_637818515859216000" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_637818515859216000" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_637818515859216000" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="anvs_NatureOfBusinessAndLiquidityAbstract_637818515859216000" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_637818515859216000" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="7" />
    <loc xlink:type="locator" xlink:href="anvs-20211231.xsd#anvs_PercentageOfExercisePriceToShareOfferingPrice" xlink:label="anvs_PercentageOfExercisePriceToShareOfferingPrice_637818515859216000" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="anvs_NatureOfBusinessAndLiquidityAbstract_637818515859216000" xlink:to="anvs_PercentageOfExercisePriceToShareOfferingPrice_637818515859216000" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="anvs-20211231.xsd#anvs_StockIssuedDuringPeriodSharesConversionOfConvertibleSecuritiesPreferredStock" xlink:label="anvs_StockIssuedDuringPeriodSharesConversionOfConvertibleSecuritiesPreferredStock_637818515859225989" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="anvs_NatureOfBusinessAndLiquidityAbstract_637818515859216000" xlink:to="anvs_StockIssuedDuringPeriodSharesConversionOfConvertibleSecuritiesPreferredStock_637818515859225989" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="anvs-20211231.xsd#anvs_StockIssuedDuringPeriodSharesConversionOfConvertibleNotes" xlink:label="anvs_StockIssuedDuringPeriodSharesConversionOfConvertibleNotes_637818515859225989" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="anvs_NatureOfBusinessAndLiquidityAbstract_637818515859216000" xlink:to="anvs_StockIssuedDuringPeriodSharesConversionOfConvertibleNotes_637818515859225989" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="6" />
  </presentationLink>
  <presentationLink xlink:role="http://annovisbio.com/role/DisclosureFairValueMeasurementsDetails" xlink:type="extended" xlink:title="40301 - Disclosure - Fair Value Measurements (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract_637538572007802700" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_637818515859225989" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract_637538572007802700" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_637818515859225989" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis_637818515859225989" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_637818515859225989" xlink:to="us-gaap_FairValueByMeasurementFrequencyAxis_637818515859225989" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain_637818515859225989" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis_637818515859225989" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain_637818515859225989" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="us-gaap_FairValueMeasurementsRecurringMember_637818515859225989" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementFrequencyDomain_637818515859225989" xlink:to="us-gaap_FairValueMeasurementsRecurringMember_637818515859225989" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis_637818515859225989" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_637818515859225989" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis_637818515859225989" order="2" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_637818515859225989" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis_637818515859225989" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_637818515859225989" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="us-gaap_FairValueInputsLevel1Member_637818515859225989" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_637818515859225989" xlink:to="us-gaap_FairValueInputsLevel1Member_637818515859225989" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_637818515859225989" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_637818515859225989" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_637818515859225989" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_637818515859235949" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_637818515859225989" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_637818515859235949" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure_637818515859245961" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_637818515859225989" xlink:to="us-gaap_CashAndCashEquivalentsFairValueDisclosure_637818515859245961" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
  </presentationLink>
  <presentationLink xlink:role="http://annovisbio.com/role/DisclosureGrantIncomeDetails" xlink:type="extended" xlink:title="40401 - Disclosure - Grant Income (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="anvs-20211231.xsd#anvs_NonOperatingIncomeGrantIncomeAbstract" xlink:label="anvs_NonOperatingIncomeGrantIncomeAbstract_1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_637818515859245961" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="anvs_NonOperatingIncomeGrantIncomeAbstract_1" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_637818515859245961" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis_637818515859245961" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_637818515859245961" xlink:to="us-gaap_TypeOfArrangementAxis_637818515859245961" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_637818515859245961" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis_637818515859245961" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_637818515859245961" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="anvs-20211231.xsd#anvs_NationalInstituteOnAgingOfNationalInstitutesOfHealthMember" xlink:label="anvs_NationalInstituteOnAgingOfNationalInstitutesOfHealthMember_637818515859245961" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember_637818515859245961" xlink:to="anvs_NationalInstituteOnAgingOfNationalInstitutesOfHealthMember_637818515859245961" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_637818515859256039" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_637818515859245961" xlink:to="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_637818515859256039" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="anvs-20211231.xsd#anvs_GrantsReceivableNoticeOfAwardAmount" xlink:label="anvs_GrantsReceivableNoticeOfAwardAmount_637818515859256039" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_637818515859256039" xlink:to="anvs_GrantsReceivableNoticeOfAwardAmount_637818515859256039" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="anvs-20211231.xsd#anvs_IncomeFromGrants" xlink:label="anvs_IncomeFromGrants_637818515859256039" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_637818515859256039" xlink:to="anvs_IncomeFromGrants_637818515859256039" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="anvs-20211231.xsd#anvs_ProceedsFromGrants" xlink:label="anvs_ProceedsFromGrants_637818515859256039" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_637818515859256039" xlink:to="anvs_ProceedsFromGrants_637818515859256039" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GrantsReceivableCurrent" xlink:label="us-gaap_GrantsReceivableCurrent_637818515859256039" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_637818515859256039" xlink:to="us-gaap_GrantsReceivableCurrent_637818515859256039" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="anvs-20211231.xsd#anvs_UnreimbursedEligibleCostsIncurredDuringPeriod" xlink:label="anvs_UnreimbursedEligibleCostsIncurredDuringPeriod_637818515859256039" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_637818515859256039" xlink:to="anvs_UnreimbursedEligibleCostsIncurredDuringPeriod_637818515859256039" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="anvs-20211231.xsd#anvs_GrantAwardRemainingAmountAvailable" xlink:label="anvs_GrantAwardRemainingAmountAvailable_637818515859256039" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_637818515859256039" xlink:to="anvs_GrantAwardRemainingAmountAvailable_637818515859256039" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://annovisbio.com/role/DisclosurePrepaidExpensesAndOtherCurrentAssetsDetails" xlink:type="extended" xlink:title="40501 - Disclosure - Prepaid Expenses and Other Current Assets (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" xlink:label="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="anvs-20211231.xsd#anvs_PrepaidResearchAndDevelopmentExpenseCurrent" xlink:label="anvs_PrepaidResearchAndDevelopmentExpenseCurrent_637818515859256039" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" xlink:to="anvs_PrepaidResearchAndDevelopmentExpenseCurrent_637818515859256039" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidInsurance" xlink:label="us-gaap_PrepaidInsurance_637818515859256039" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" xlink:to="us-gaap_PrepaidInsurance_637818515859256039" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherPrepaidExpenseCurrent" xlink:label="us-gaap_OtherPrepaidExpenseCurrent_637818515859256039" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" xlink:to="us-gaap_OtherPrepaidExpenseCurrent_637818515859256039" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SecurityDeposit" xlink:label="us-gaap_SecurityDeposit_637818515859256039" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" xlink:to="us-gaap_SecurityDeposit_637818515859256039" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="anvs-20211231.xsd#anvs_PrepaidExpenseSecurityDepositsAndOtherAssetsCurrent" xlink:label="anvs_PrepaidExpenseSecurityDepositsAndOtherAssetsCurrent_637818515859265999" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" xlink:to="anvs_PrepaidExpenseSecurityDepositsAndOtherAssetsCurrent_637818515859265999" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://annovisbio.com/role/DisclosureAccruedExpensesDetails" xlink:type="extended" xlink:title="40601 - Disclosure - Accrued Expenses (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract" xlink:label="us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent_637818515859265999" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrent_637818515859265999" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:label="us-gaap_AccruedProfessionalFeesCurrent_637818515859265999" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract" xlink:to="us-gaap_AccruedProfessionalFeesCurrent_637818515859265999" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="anvs-20211231.xsd#anvs_AccruedLicensePaymentsCurrent" xlink:label="anvs_AccruedLicensePaymentsCurrent_637818515859265999" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract" xlink:to="anvs_AccruedLicensePaymentsCurrent_637818515859265999" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="anvs-20211231.xsd#anvs_AccruedLiabilitiesAndInterestAndEmployeeRelatedLiabilitiesCurrent" xlink:label="anvs_AccruedLiabilitiesAndInterestAndEmployeeRelatedLiabilitiesCurrent_637818515859265999" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract" xlink:to="anvs_AccruedLiabilitiesAndInterestAndEmployeeRelatedLiabilitiesCurrent_637818515859265999" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://annovisbio.com/role/DisclosureConvertiblePromissoryNotesDetails" xlink:type="extended" xlink:title="40701 - Disclosure - Convertible Promissory Notes (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="us-gaap_DebtDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentTable" xlink:label="us-gaap_DebtInstrumentTable_637818515859265999" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_DebtInstrumentTable_637818515859265999" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="us-gaap_LongtermDebtTypeAxis_637818515859265999" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentTable_637818515859265999" xlink:to="us-gaap_LongtermDebtTypeAxis_637818515859265999" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="us-gaap_LongtermDebtTypeDomain_637818515859265999" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongtermDebtTypeAxis_637818515859265999" xlink:to="us-gaap_LongtermDebtTypeDomain_637818515859265999" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConvertibleDebtMember" xlink:label="us-gaap_ConvertibleDebtMember_637818515859265999" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongtermDebtTypeDomain_637818515859265999" xlink:to="us-gaap_ConvertibleDebtMember_637818515859265999" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis_637818515859265999" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentTable_637818515859265999" xlink:to="us-gaap_StatementEquityComponentsAxis_637818515859265999" order="2" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain_637818515859265999" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis_637818515859265999" xlink:to="us-gaap_EquityComponentDomain_637818515859265999" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember_637818515859275978" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain_637818515859265999" xlink:to="us-gaap_CommonStockMember_637818515859275978" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_637818515859275978" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentTable_637818515859265999" xlink:to="us-gaap_SubsidiarySaleOfStockAxis_637818515859275978" order="3" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_637818515859275978" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis_637818515859275978" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_637818515859275978" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IPOMember" xlink:label="us-gaap_IPOMember_637818515859275978" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain_637818515859275978" xlink:to="us-gaap_IPOMember_637818515859275978" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="us-gaap_DebtInstrumentLineItems_637818515859275978" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentTable_637818515859265999" xlink:to="us-gaap_DebtInstrumentLineItems_637818515859275978" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="us-gaap_DebtInstrumentFaceAmount_637818515859275978" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems_637818515859275978" xlink:to="us-gaap_DebtInstrumentFaceAmount_637818515859275978" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage_637818515859275978" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems_637818515859275978" xlink:to="us-gaap_DebtInstrumentInterestRateStatedPercentage_637818515859275978" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredFinanceCostsGross" xlink:label="us-gaap_DeferredFinanceCostsGross_637818515859275978" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems_637818515859275978" xlink:to="us-gaap_DeferredFinanceCostsGross_637818515859275978" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentUnamortizedDiscount" xlink:label="us-gaap_DebtInstrumentUnamortizedDiscount_637818515859275978" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems_637818515859275978" xlink:to="us-gaap_DebtInstrumentUnamortizedDiscount_637818515859275978" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:label="us-gaap_DebtInstrumentInterestRateEffectivePercentage_637818515859275978" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems_637818515859275978" xlink:to="us-gaap_DebtInstrumentInterestRateEffectivePercentage_637818515859275978" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestPaidNet" xlink:label="us-gaap_InterestPaidNet_637818515859275978" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems_637818515859275978" xlink:to="us-gaap_InterestPaidNet_637818515859275978" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="anvs-20211231.xsd#anvs_StockIssuedDuringPeriodSharesConversionOfConvertibleNotes" xlink:label="anvs_StockIssuedDuringPeriodSharesConversionOfConvertibleNotes_637818515859275978" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems_637818515859275978" xlink:to="anvs_StockIssuedDuringPeriodSharesConversionOfConvertibleNotes_637818515859275978" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="anvs-20211231.xsd#anvs_ConversionOfConvertibleSecuritiesConvertiblePromissoryNotesPercentageOfDiscountToInitialPublicOfferingPrice" xlink:label="anvs_ConversionOfConvertibleSecuritiesConvertiblePromissoryNotesPercentageOfDiscountToInitialPublicOfferingPrice_637818515859286162" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems_637818515859275978" xlink:to="anvs_ConversionOfConvertibleSecuritiesConvertiblePromissoryNotesPercentageOfDiscountToInitialPublicOfferingPrice_637818515859286162" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://annovisbio.com/role/DisclosureCommitmentsAndContingenciesLeasesDetails" xlink:type="extended" xlink:title="40801 - Disclosure - Commitments and Contingencies - Leases (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseCostAbstract" xlink:label="us-gaap_LeaseCostAbstract_637818515859286162" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_LeaseCostAbstract_637818515859286162" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseExpense" xlink:label="us-gaap_OperatingLeaseExpense_637818515859286162" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeaseCostAbstract_637818515859286162" xlink:to="us-gaap_OperatingLeaseExpense_637818515859286162" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
  </presentationLink>
  <presentationLink xlink:role="http://annovisbio.com/role/DisclosureCommitmentsAndContingenciesLicenseAgreementDetails" xlink:type="extended" xlink:title="40802 - Disclosure - Commitments and Contingencies - License Agreement (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherCommitmentsTable" xlink:label="us-gaap_OtherCommitmentsTable_637818515859286162" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_1" xlink:to="us-gaap_OtherCommitmentsTable_637818515859286162" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_637818515859286162" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherCommitmentsTable_637818515859286162" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_637818515859286162" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_637818515859295561" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_637818515859286162" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_637818515859295561" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="anvs-20211231.xsd#anvs_LicenseAgreementTermsAmendedMay2012Member" xlink:label="anvs_LicenseAgreementTermsAmendedMay2012Member_637818515859295561" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_637818515859295561" xlink:to="anvs_LicenseAgreementTermsAmendedMay2012Member_637818515859295561" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherCommitmentsLineItems" xlink:label="us-gaap_OtherCommitmentsLineItems_637818515859295561" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherCommitmentsTable_637818515859286162" xlink:to="us-gaap_OtherCommitmentsLineItems_637818515859295561" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="anvs-20211231.xsd#anvs_LicenseAgreementMinimumAnnualCommitment" xlink:label="anvs_LicenseAgreementMinimumAnnualCommitment_637818515859295561" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherCommitmentsLineItems_637818515859295561" xlink:to="anvs_LicenseAgreementMinimumAnnualCommitment_637818515859295561" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="anvs-20211231.xsd#anvs_AccruedLicensePaymentsCurrent" xlink:label="anvs_AccruedLicensePaymentsCurrent_637818515859295561" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherCommitmentsLineItems_637818515859295561" xlink:to="anvs_AccruedLicensePaymentsCurrent_637818515859295561" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="anvs-20211231.xsd#anvs_CumulativeNumberOfMilestonesAchieved" xlink:label="anvs_CumulativeNumberOfMilestonesAchieved_637818515859295561" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherCommitmentsLineItems_637818515859295561" xlink:to="anvs_CumulativeNumberOfMilestonesAchieved_637818515859295561" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="anvs-20211231.xsd#anvs_LicenseAgreementPeriodOfAdvanceNoticeOfTermination" xlink:label="anvs_LicenseAgreementPeriodOfAdvanceNoticeOfTermination_637818515859295561" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherCommitmentsLineItems_637818515859295561" xlink:to="anvs_LicenseAgreementPeriodOfAdvanceNoticeOfTermination_637818515859295561" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://annovisbio.com/role/DisclosureCommitmentsAndContingenciesEmploymentAgreementsDetails" xlink:type="extended" xlink:title="40803 - Disclosure - Commitments and Contingencies - Employment Agreements (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfDeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTitleOfIndividualAndByTypeOfDeferredCompensationTable" xlink:label="us-gaap_ScheduleOfDeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTitleOfIndividualAndByTypeOfDeferredCompensationTable_637818515859295561" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_ScheduleOfDeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTitleOfIndividualAndByTypeOfDeferredCompensationTable_637818515859295561" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualAxis" xlink:label="srt_TitleOfIndividualAxis_637818515859295561" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfDeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTitleOfIndividualAndByTypeOfDeferredCompensationTable_637818515859295561" xlink:to="srt_TitleOfIndividualAxis_637818515859295561" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain_637818515859295561" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualAxis_637818515859295561" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain_637818515859295561" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ExecutiveOfficerMember" xlink:label="srt_ExecutiveOfficerMember_637818515859306228" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain_637818515859295561" xlink:to="srt_ExecutiveOfficerMember_637818515859306228" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsLineItems" xlink:label="us-gaap_DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsLineItems_637818515859306228" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfDeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTitleOfIndividualAndByTypeOfDeferredCompensationTable_637818515859295561" xlink:to="us-gaap_DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsLineItems_637818515859306228" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredCompensationArrangementsAbstract" xlink:label="us-gaap_DeferredCompensationArrangementsAbstract_637818515859306228" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsLineItems_637818515859306228" xlink:to="us-gaap_DeferredCompensationArrangementsAbstract_637818515859306228" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="anvs-20211231.xsd#anvs_MaximumAggregateSeverancePayments" xlink:label="anvs_MaximumAggregateSeverancePayments_637818515859306228" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredCompensationArrangementsAbstract_637818515859306228" xlink:to="anvs_MaximumAggregateSeverancePayments_637818515859306228" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LossContingencyInformationAboutLitigationMattersAbstract" xlink:label="us-gaap_LossContingencyInformationAboutLitigationMattersAbstract_637818515859306228" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsLineItems_637818515859306228" xlink:to="us-gaap_LossContingencyInformationAboutLitigationMattersAbstract_637818515859306228" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LossContingencyNewClaimsFiledNumber" xlink:label="us-gaap_LossContingencyNewClaimsFiledNumber_637818515859306228" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LossContingencyInformationAboutLitigationMattersAbstract_637818515859306228" xlink:to="us-gaap_LossContingencyNewClaimsFiledNumber_637818515859306228" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://annovisbio.com/role/DisclosureRedeemableConvertiblePreferredStockAndStockholdersEquityCommonAndPreferredStockDetails" xlink:type="extended" xlink:title="40901 - Disclosure - Redeemable Convertible Preferred Stock and Stockholders' Equity - Common and Preferred Stock (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="us-gaap_StockholdersEquityNoteAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="us-gaap_ScheduleOfStockByClassTable_637818515859306228" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="us-gaap_ScheduleOfStockByClassTable_637818515859306228" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis_637818515859306228" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable_637818515859306228" xlink:to="us-gaap_StatementEquityComponentsAxis_637818515859306228" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain_637818515859316141" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis_637818515859306228" xlink:to="us-gaap_EquityComponentDomain_637818515859316141" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="anvs-20211231.xsd#anvs_CommonStockAndPreferredStockMember" xlink:label="anvs_CommonStockAndPreferredStockMember_637818515859316141" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain_637818515859316141" xlink:to="anvs_CommonStockAndPreferredStockMember_637818515859316141" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember_637818515859316141" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="anvs_CommonStockAndPreferredStockMember_637818515859316141" xlink:to="us-gaap_CommonStockMember_637818515859316141" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis_637818515859316141" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable_637818515859306228" xlink:to="us-gaap_StatementClassOfStockAxis_637818515859316141" order="2" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain_637818515859316141" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis_637818515859316141" xlink:to="us-gaap_ClassOfStockDomain_637818515859316141" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="anvs-20211231.xsd#anvs_SeriesaRedeemableConvertiblePreferredStockMember" xlink:label="anvs_SeriesaRedeemableConvertiblePreferredStockMember_637818515859316141" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain_637818515859316141" xlink:to="anvs_SeriesaRedeemableConvertiblePreferredStockMember_637818515859316141" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="anvs-20211231.xsd#anvs_Series1RedeemableConvertiblePreferredStockMember" xlink:label="anvs_Series1RedeemableConvertiblePreferredStockMember_637818515859316141" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain_637818515859316141" xlink:to="anvs_Series1RedeemableConvertiblePreferredStockMember_637818515859316141" order="2" use="optional" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_637818515859316141" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable_637818515859306228" xlink:to="us-gaap_SubsidiarySaleOfStockAxis_637818515859316141" order="3" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_637818515859316141" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis_637818515859316141" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_637818515859316141" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="anvs-20211231.xsd#anvs_InitialPublicOfferingAndOverAllotmentOptionMember" xlink:label="anvs_InitialPublicOfferingAndOverAllotmentOptionMember_637818515859316141" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain_637818515859316141" xlink:to="anvs_InitialPublicOfferingAndOverAllotmentOptionMember_637818515859316141" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IPOMember" xlink:label="us-gaap_IPOMember_637818515859325915" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="anvs_InitialPublicOfferingAndOverAllotmentOptionMember_637818515859316141" xlink:to="us-gaap_IPOMember_637818515859325915" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockLineItems" xlink:label="us-gaap_ClassOfStockLineItems_637818515859325915" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable_637818515859306228" xlink:to="us-gaap_ClassOfStockLineItems_637818515859325915" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_637818515859325915" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems_637818515859325915" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_637818515859325915" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="anvs-20211231.xsd#anvs_TemporaryEquitySharesConversionOfPreferredStockToCommonStock" xlink:label="anvs_TemporaryEquitySharesConversionOfPreferredStockToCommonStock_637818515859325915" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems_637818515859325915" xlink:to="anvs_TemporaryEquitySharesConversionOfPreferredStockToCommonStock_637818515859325915" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="7" />
    <loc xlink:type="locator" xlink:href="anvs-20211231.xsd#anvs_StockIssuedDuringPeriodSharesConversionOfConvertibleSecuritiesPreferredStock" xlink:label="anvs_StockIssuedDuringPeriodSharesConversionOfConvertibleSecuritiesPreferredStock_637818515859325915" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems_637818515859325915" xlink:to="anvs_StockIssuedDuringPeriodSharesConversionOfConvertibleSecuritiesPreferredStock_637818515859325915" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="8" />
    <loc xlink:type="locator" xlink:href="anvs-20211231.xsd#anvs_RedeemableConvertiblePreferredStockConvertibleConversionPrice" xlink:label="anvs_RedeemableConvertiblePreferredStockConvertibleConversionPrice_637818515859325915" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems_637818515859325915" xlink:to="anvs_RedeemableConvertiblePreferredStockConvertibleConversionPrice_637818515859325915" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="anvs-20211231.xsd#anvs_NumberOfClassesOfStockDesignated" xlink:label="anvs_NumberOfClassesOfStockDesignated_637818515859325915" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems_637818515859325915" xlink:to="anvs_NumberOfClassesOfStockDesignated_637818515859325915" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="anvs-20211231.xsd#anvs_CommonStockAndPreferredStockSharesAuthorized" xlink:label="anvs_CommonStockAndPreferredStockSharesAuthorized_637818515859325915" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems_637818515859325915" xlink:to="anvs_CommonStockAndPreferredStockSharesAuthorized_637818515859325915" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_637818515859325915" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems_637818515859325915" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_637818515859325915" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_637818515859325915" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems_637818515859325915" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare_637818515859325915" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized_637818515859335973" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems_637818515859325915" xlink:to="us-gaap_CommonStockSharesAuthorized_637818515859335973" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized_637818515859335973" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems_637818515859325915" xlink:to="us-gaap_PreferredStockSharesAuthorized_637818515859335973" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="anvs-20211231.xsd#anvs_NumberOfVotesForEachShareOfCommonStock" xlink:label="anvs_NumberOfVotesForEachShareOfCommonStock_637818515859335973" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems_637818515859325915" xlink:to="anvs_NumberOfVotesForEachShareOfCommonStock_637818515859335973" order="11" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="us-gaap_PreferredStockSharesIssued_637818515859335973" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems_637818515859325915" xlink:to="us-gaap_PreferredStockSharesIssued_637818515859335973" order="12" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding_637818515859335973" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems_637818515859325915" xlink:to="us-gaap_PreferredStockSharesOutstanding_637818515859335973" order="13" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
  </presentationLink>
  <presentationLink xlink:role="http://annovisbio.com/role/DisclosureRedeemableConvertiblePreferredStockAndStockholdersEquityWarrantsDetails" xlink:type="extended" xlink:title="40902 - Disclosure - Redeemable Convertible Preferred Stock and Stockholders' Equity - Warrants (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="us-gaap_StockholdersEquityNoteAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightTable" xlink:label="us-gaap_ClassOfWarrantOrRightTable_637818515859346047" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="us-gaap_ClassOfWarrantOrRightTable_637818515859346047" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis_637818515859346047" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightTable_637818515859346047" xlink:to="us-gaap_ClassOfWarrantOrRightAxis_637818515859346047" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain_637818515859346047" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis_637818515859346047" xlink:to="us-gaap_ClassOfWarrantOrRightDomain_637818515859346047" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="anvs-20211231.xsd#anvs_UnderwritersWarrantsMember" xlink:label="anvs_UnderwritersWarrantsMember_637818515859346047" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightDomain_637818515859346047" xlink:to="anvs_UnderwritersWarrantsMember_637818515859346047" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightLineItems" xlink:label="us-gaap_ClassOfWarrantOrRightLineItems_637818515859346047" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightTable_637818515859346047" xlink:to="us-gaap_ClassOfWarrantOrRightLineItems_637818515859346047" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_637818515859346047" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems_637818515859346047" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_637818515859346047" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_637818515859346047" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems_637818515859346047" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_637818515859346047" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="anvs-20211231.xsd#anvs_PercentageOfExercisePriceToShareOfferingPrice" xlink:label="anvs_PercentageOfExercisePriceToShareOfferingPrice_637818515859346047" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems_637818515859346047" xlink:to="anvs_PercentageOfExercisePriceToShareOfferingPrice_637818515859346047" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WarrantsAndRightsOutstandingTerm" xlink:label="us-gaap_WarrantsAndRightsOutstandingTerm_637818515859346047" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems_637818515859346047" xlink:to="us-gaap_WarrantsAndRightsOutstandingTerm_637818515859346047" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="anvs-20211231.xsd#anvs_StockIssuedDuringPeriodSharesWarrantsExercised" xlink:label="anvs_StockIssuedDuringPeriodSharesWarrantsExercised_637818515859346047" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems_637818515859346047" xlink:to="anvs_StockIssuedDuringPeriodSharesWarrantsExercised_637818515859346047" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="anvs-20211231.xsd#anvs_ConversionOfWarrantsNumberOfWarrantsConverted" xlink:label="anvs_ConversionOfWarrantsNumberOfWarrantsConverted_637818515859355994" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems_637818515859346047" xlink:to="anvs_ConversionOfWarrantsNumberOfWarrantsConverted_637818515859355994" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding_637818515859355994" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems_637818515859346047" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding_637818515859355994" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
  </presentationLink>
  <presentationLink xlink:role="http://annovisbio.com/role/DisclosureStockBasedCompensationSummaryOfPlansDetails" xlink:type="extended" xlink:title="41001 - Disclosure - Stock-Based Compensation - Summary of plans (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_637818515859355994" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_1" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_637818515859355994" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis_637818515859355994" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_637818515859355994" xlink:to="us-gaap_PlanNameAxis_637818515859355994" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain_637818515859355994" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis_637818515859355994" xlink:to="us-gaap_PlanNameDomain_637818515859355994" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="anvs-20211231.xsd#anvs_EquityIncentivePlan2019Member" xlink:label="anvs_EquityIncentivePlan2019Member_637818515859355994" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain_637818515859355994" xlink:to="anvs_EquityIncentivePlan2019Member_637818515859355994" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="anvs-20211231.xsd#anvs_EquityIncentivePlan2018Member" xlink:label="anvs_EquityIncentivePlan2018Member_637818515859355994" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain_637818515859355994" xlink:to="anvs_EquityIncentivePlan2018Member_637818515859355994" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis_637818515859355994" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_637818515859355994" xlink:to="us-gaap_AwardTypeAxis_637818515859355994" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_637818515859355994" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis_637818515859355994" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_637818515859355994" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember_637818515859355994" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_637818515859355994" xlink:to="us-gaap_EmployeeStockOptionMember_637818515859355994" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637818515859355994" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_637818515859355994" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637818515859355994" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_637818515859365901" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637818515859355994" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_637818515859365901" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_637818515859365901" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637818515859355994" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_637818515859365901" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_637818515859365901" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637818515859355994" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_637818515859365901" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_637818515859365901" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637818515859355994" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_637818515859365901" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://annovisbio.com/role/DisclosureStockBasedCompensationShareBasedCompensationExpenseDetails" xlink:type="extended" xlink:title="41002 - Disclosure - Stock-Based Compensation - Share-based compensation expense (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_637818515859365901" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_2" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_637818515859365901" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis_637818515859365901" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_637818515859365901" xlink:to="us-gaap_IncomeStatementLocationAxis_637818515859365901" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain_637818515859365901" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis_637818515859365901" xlink:to="us-gaap_IncomeStatementLocationDomain_637818515859365901" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_637818515859365901" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain_637818515859365901" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember_637818515859365901" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember_637818515859365901" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain_637818515859365901" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember_637818515859365901" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637818515859365901" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_637818515859365901" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637818515859365901" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation_637818515859376209" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637818515859365901" xlink:to="us-gaap_ShareBasedCompensation_637818515859376209" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://annovisbio.com/role/DisclosureStockBasedCompensationStockOptionActivityDetails" xlink:type="extended" xlink:title="41003 - Disclosure - Stock-Based Compensation - Stock option activity (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_637818515859376209" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_3" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_637818515859376209" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_637818515859376209" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_637818515859376209" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_637818515859376209" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_637818515859376209" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_637818515859376209" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_637818515859376209" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_637818515859376209" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_637818515859376209" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_637818515859376209" order="3" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_637818515859376209" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_637818515859376209" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_637818515859376209" order="4" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_6378185158593762091" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_637818515859376209" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_6378185158593762091" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_637818515859376209" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_637818515859376209" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_637818515859376209" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_637818515859376209" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_3" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_637818515859376209" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_637818515859376209" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_637818515859376209" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_637818515859376209" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="7" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_637818515859386011" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_637818515859376209" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_637818515859386011" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_637818515859386011" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_637818515859376209" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_637818515859386011" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_637818515859386011" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_637818515859376209" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_637818515859386011" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_637818515859386011" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_637818515859376209" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_637818515859386011" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="7" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_637818515859386011" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_637818515859376209" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_637818515859386011" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="anvs-20211231.xsd#anvs_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract" xlink:label="anvs_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract_637818515859386011" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_3" xlink:to="anvs_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract_637818515859386011" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_637818515859386011" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="anvs_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract_637818515859386011" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_637818515859386011" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_637818515859386011" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="anvs_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract_637818515859386011" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_637818515859386011" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_637818515859386011" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_3" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_637818515859386011" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_637818515859386011" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_3" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_637818515859386011" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://annovisbio.com/role/DisclosureStockBasedCompensationAdditionalDisclosuresDetails" xlink:type="extended" xlink:title="41004 - Disclosure - Stock-Based Compensation - Additional disclosures (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_637818515859395963" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_4" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_637818515859395963" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis_637818515859395963" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_637818515859395963" xlink:to="us-gaap_AwardTypeAxis_637818515859395963" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_637818515859395963" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis_637818515859395963" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_637818515859395963" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember_637818515859395963" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_637818515859395963" xlink:to="us-gaap_EmployeeStockOptionMember_637818515859395963" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardDateAxis" xlink:label="us-gaap_AwardDateAxis_637818515859395963" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_637818515859395963" xlink:to="us-gaap_AwardDateAxis_637818515859395963" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardDateDomain" xlink:label="us-gaap_AwardDateDomain_637818515859395963" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardDateAxis_637818515859395963" xlink:to="us-gaap_AwardDateDomain_637818515859395963" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="anvs-20211231.xsd#anvs_AwardsGrantedIn2021Member" xlink:label="anvs_AwardsGrantedIn2021Member_637818515859395963" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardDateDomain_637818515859395963" xlink:to="anvs_AwardsGrantedIn2021Member_637818515859395963" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="anvs-20211231.xsd#anvs_AwardsGrantedIn2020Member" xlink:label="anvs_AwardsGrantedIn2020Member_637818515859395963" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardDateDomain_637818515859395963" xlink:to="anvs_AwardsGrantedIn2020Member_637818515859395963" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GranteeStatusAxis" xlink:label="us-gaap_GranteeStatusAxis_637818515859395963" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_637818515859395963" xlink:to="us-gaap_GranteeStatusAxis_637818515859395963" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GranteeStatusDomain" xlink:label="us-gaap_GranteeStatusDomain_637818515859395963" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GranteeStatusAxis_637818515859395963" xlink:to="us-gaap_GranteeStatusDomain_637818515859395963" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedPaymentArrangementNonemployeeMember" xlink:label="us-gaap_ShareBasedPaymentArrangementNonemployeeMember_637818515859406017" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GranteeStatusDomain_637818515859395963" xlink:to="us-gaap_ShareBasedPaymentArrangementNonemployeeMember_637818515859406017" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VestingAxis" xlink:label="us-gaap_VestingAxis_637818515859406017" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_637818515859395963" xlink:to="us-gaap_VestingAxis_637818515859406017" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VestingDomain" xlink:label="us-gaap_VestingDomain_637818515859406017" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VestingAxis_637818515859406017" xlink:to="us-gaap_VestingDomain_637818515859406017" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="anvs-20211231.xsd#anvs_ShareBasedPaymentArrangementVestingPeriodImmediateVestingMember" xlink:label="anvs_ShareBasedPaymentArrangementVestingPeriodImmediateVestingMember_637818515859406017" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VestingDomain_637818515859406017" xlink:to="anvs_ShareBasedPaymentArrangementVestingPeriodImmediateVestingMember_637818515859406017" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="anvs-20211231.xsd#anvs_ShareBasedPaymentArrangementVestingPeriodOneYearMember" xlink:label="anvs_ShareBasedPaymentArrangementVestingPeriodOneYearMember_637818515859406017" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VestingDomain_637818515859406017" xlink:to="anvs_ShareBasedPaymentArrangementVestingPeriodOneYearMember_637818515859406017" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="anvs-20211231.xsd#anvs_ShareBasedPaymentArrangementVestingPeriodTwoYearsMember" xlink:label="anvs_ShareBasedPaymentArrangementVestingPeriodTwoYearsMember_637818515859406017" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VestingDomain_637818515859406017" xlink:to="anvs_ShareBasedPaymentArrangementVestingPeriodTwoYearsMember_637818515859406017" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="anvs-20211231.xsd#anvs_ShareBasedPaymentArrangementVestingPeriodEqualQuarterlyInstallmentsOverTwoYearsMember" xlink:label="anvs_ShareBasedPaymentArrangementVestingPeriodEqualQuarterlyInstallmentsOverTwoYearsMember_637818515859406017" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VestingDomain_637818515859406017" xlink:to="anvs_ShareBasedPaymentArrangementVestingPeriodEqualQuarterlyInstallmentsOverTwoYearsMember_637818515859406017" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637818515859406017" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_637818515859395963" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637818515859406017" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_637818515859406017" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637818515859406017" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_637818515859406017" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:label="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_637818515859406017" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637818515859406017" xlink:to="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_637818515859406017" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_637818515859416009" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637818515859406017" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_637818515859416009" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_637818515859416009" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637818515859406017" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_637818515859416009" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_637818515859416009" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637818515859406017" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_637818515859416009" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_637818515859416009" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637818515859406017" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_637818515859416009" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_637818515859416009" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637818515859406017" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_637818515859416009" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_637818515859416009" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637818515859406017" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_637818515859416009" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="anvs-20211231.xsd#anvs_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedInPeriodFairValue" xlink:label="anvs_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedInPeriodFairValue_637818515859416009" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637818515859406017" xlink:to="anvs_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedInPeriodFairValue_637818515859416009" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_637818515859416009" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637818515859406017" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_637818515859416009" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_637818515859416009" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637818515859406017" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_637818515859416009" order="11" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_637818515859425999" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637818515859406017" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_637818515859425999" order="12" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_637818515859425999" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_637818515859425999" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_637818515859425999" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_637818515859425999" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_637818515859425999" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_637818515859425999" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_637818515859425999" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_637818515859425999" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_637818515859425999" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_637818515859425999" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_637818515859425999" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_637818515859425999" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
  </presentationLink>
  <presentationLink xlink:role="http://annovisbio.com/role/DisclosureNetLossPerShareBasicAndDilutedNetLossPerShareDetails" xlink:type="extended" xlink:title="41101 - Disclosure - Net Loss Per Share - Basic and diluted net loss per share (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract" />
    <loc xlink:type="locator" xlink:href="anvs-20211231.xsd#anvs_EarningsPerShareBasicAndDilutedNumeratorAbstract" xlink:label="anvs_EarningsPerShareBasicAndDilutedNumeratorAbstract_637818515859436049" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="anvs_EarningsPerShareBasicAndDilutedNumeratorAbstract_637818515859436049" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss_637818515859436049" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="anvs_EarningsPerShareBasicAndDilutedNumeratorAbstract_637818515859436049" xlink:to="us-gaap_NetIncomeLoss_637818515859436049" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="anvs-20211231.xsd#anvs_EarningsPerShareBasicAndDilutedDenominatorAbstract" xlink:label="anvs_EarningsPerShareBasicAndDilutedDenominatorAbstract_637818515859436049" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="anvs_EarningsPerShareBasicAndDilutedDenominatorAbstract_637818515859436049" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_637818515859436049" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="anvs_EarningsPerShareBasicAndDilutedDenominatorAbstract_637818515859436049" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_637818515859436049" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_637818515859436049" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="anvs_EarningsPerShareBasicAndDilutedDenominatorAbstract_637818515859436049" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_637818515859436049" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic_637818515859436049" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="anvs_EarningsPerShareBasicAndDilutedDenominatorAbstract_637818515859436049" xlink:to="us-gaap_EarningsPerShareBasic_637818515859436049" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="us-gaap_EarningsPerShareDiluted_637818515859436049" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="anvs_EarningsPerShareBasicAndDilutedDenominatorAbstract_637818515859436049" xlink:to="us-gaap_EarningsPerShareDiluted_637818515859436049" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
  </presentationLink>
  <presentationLink xlink:role="http://annovisbio.com/role/DisclosureNetLossPerSharePotentialSharesExcludedFromCalculationDetails" xlink:type="extended" xlink:title="41102 - Disclosure - Net Loss Per Share - Potential shares excluded from calculation (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_637818515859446372" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_637818515859446372" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_637818515859446372" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_637818515859446372" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_637818515859446372" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_637818515859446372" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_637818515859446372" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain_637818515859446372" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember_637818515859446372" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain_637818515859446372" xlink:to="us-gaap_EmployeeStockOptionMember_637818515859446372" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WarrantMember" xlink:label="us-gaap_WarrantMember_637818515859446372" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain_637818515859446372" xlink:to="us-gaap_WarrantMember_637818515859446372" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_637818515859446372" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_637818515859446372" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_637818515859446372" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_637818515859446372" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_637818515859446372" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_637818515859446372" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
  </presentationLink>
  <presentationLink xlink:role="http://annovisbio.com/role/DisclosureIncomeTaxesReconciliationOfIncomeTaxProvisionBenefitDetails" xlink:type="extended" xlink:title="41201 - Disclosure - Income Taxes - Reconciliation of income tax provision (benefit) (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract_637251282146734479" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExpenseBenefitContinuingOperationsByJurisdictionAbstract" xlink:label="us-gaap_IncomeTaxExpenseBenefitContinuingOperationsByJurisdictionAbstract_637818515859455960" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract_637251282146734479" xlink:to="us-gaap_IncomeTaxExpenseBenefitContinuingOperationsByJurisdictionAbstract_637818515859455960" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperations" xlink:label="us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperations_637818515859455960" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxExpenseBenefitContinuingOperationsByJurisdictionAbstract_637818515859455960" xlink:to="us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperations_637818515859455960" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StateAndLocalIncomeTaxExpenseBenefitContinuingOperations" xlink:label="us-gaap_StateAndLocalIncomeTaxExpenseBenefitContinuingOperations_637818515859455960" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxExpenseBenefitContinuingOperationsByJurisdictionAbstract_637818515859455960" xlink:to="us-gaap_StateAndLocalIncomeTaxExpenseBenefitContinuingOperations_637818515859455960" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_637818515859455960" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract_637251282146734479" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_637818515859455960" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_637818515859455960" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_637818515859455960" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_637818515859455960" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_637818515859455960" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_637818515859455960" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_637818515859455960" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense_637818515859455960" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_637818515859455960" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense_637818515859455960" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment_637818515859455960" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_637818515859455960" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment_637818515859455960" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost_637818515859455960" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_637818515859455960" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost_637818515859455960" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_637818515859455960" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_637818515859455960" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_637818515859455960" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations_637818515859455960" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_637818515859455960" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperations_637818515859455960" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="4" />
  </presentationLink>
  <presentationLink xlink:role="http://annovisbio.com/role/DisclosureIncomeTaxesDeferredTaxesDetails" xlink:type="extended" xlink:title="41202 - Disclosure - Income Taxes - Deferred taxes (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract_637251288811670906" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsNetOfValuationAllowanceAbstract" xlink:label="us-gaap_DeferredTaxAssetsNetOfValuationAllowanceAbstract_637818515859455960" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract_637251288811670906" xlink:to="us-gaap_DeferredTaxAssetsNetOfValuationAllowanceAbstract_637818515859455960" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_637818515859465876" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetOfValuationAllowanceAbstract_637818515859455960" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_637818515859465876" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="anvs-20211231.xsd#anvs_DeferredTaxAssetsTaxCreditCarryforwardsCapitalizedResearchAndDevelopment" xlink:label="anvs_DeferredTaxAssetsTaxCreditCarryforwardsCapitalizedResearchAndDevelopment_637818515859465876" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetOfValuationAllowanceAbstract_637818515859455960" xlink:to="anvs_DeferredTaxAssetsTaxCreditCarryforwardsCapitalizedResearchAndDevelopment_637818515859465876" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_637818515859465876" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetOfValuationAllowanceAbstract_637818515859455960" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_637818515859465876" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_637818515859465876" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetOfValuationAllowanceAbstract_637818515859455960" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_637818515859465876" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="us-gaap_DeferredTaxAssetsGross_637818515859465876" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetOfValuationAllowanceAbstract_637818515859455960" xlink:to="us-gaap_DeferredTaxAssetsGross_637818515859465876" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_637818515859465876" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetOfValuationAllowanceAbstract_637818515859455960" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance_637818515859465876" order="6" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="us-gaap_DeferredTaxAssetsNet_637818515859465876" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetOfValuationAllowanceAbstract_637818515859455960" xlink:to="us-gaap_DeferredTaxAssetsNet_637818515859465876" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="6" />
  </presentationLink>
  <presentationLink xlink:role="http://annovisbio.com/role/DisclosureIncomeTaxesAdditionalDisclosuresDetails" xlink:type="extended" xlink:title="41203 - Disclosure - Income Taxes - Additional disclosures (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract_637251306845174076" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLossCarryforwardsTable" xlink:label="us-gaap_OperatingLossCarryforwardsTable_637818515859465876" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract_637251306845174076" xlink:to="us-gaap_OperatingLossCarryforwardsTable_637818515859465876" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis_637818515859465876" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLossCarryforwardsTable_637818515859465876" xlink:to="us-gaap_StatementEquityComponentsAxis_637818515859465876" order="1" use="optional" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain_637818515859465876" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis_637818515859465876" xlink:to="us-gaap_EquityComponentDomain_637818515859465876" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember_637818515859465876" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain_637818515859465876" xlink:to="us-gaap_CommonStockMember_637818515859465876" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="us-gaap_IncomeTaxAuthorityAxis_637818515859465876" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLossCarryforwardsTable_637818515859465876" xlink:to="us-gaap_IncomeTaxAuthorityAxis_637818515859465876" order="2" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain_637818515859475978" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityAxis_637818515859465876" xlink:to="us-gaap_IncomeTaxAuthorityDomain_637818515859475978" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DomesticCountryMember" xlink:label="us-gaap_DomesticCountryMember_637818515859475978" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityDomain_637818515859475978" xlink:to="us-gaap_DomesticCountryMember_637818515859475978" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:label="us-gaap_StateAndLocalJurisdictionMember_637818515859475978" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityDomain_637818515859475978" xlink:to="us-gaap_StateAndLocalJurisdictionMember_637818515859475978" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxPeriodAxis" xlink:label="us-gaap_TaxPeriodAxis_637818515859475978" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLossCarryforwardsTable_637818515859465876" xlink:to="us-gaap_TaxPeriodAxis_637818515859475978" order="3" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxPeriodDomain" xlink:label="us-gaap_TaxPeriodDomain_637818515859475978" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TaxPeriodAxis_637818515859475978" xlink:to="us-gaap_TaxPeriodDomain_637818515859475978" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="anvs-20211231.xsd#anvs_GeneratedIn2017AndPriorMember" xlink:label="anvs_GeneratedIn2017AndPriorMember_637818515859475978" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TaxPeriodDomain_637818515859475978" xlink:to="anvs_GeneratedIn2017AndPriorMember_637818515859475978" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxCreditCarryforwardAxis" xlink:label="us-gaap_TaxCreditCarryforwardAxis_637818515859475978" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLossCarryforwardsTable_637818515859465876" xlink:to="us-gaap_TaxCreditCarryforwardAxis_637818515859475978" order="4" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxCreditCarryforwardNameDomain" xlink:label="us-gaap_TaxCreditCarryforwardNameDomain_637818515859475978" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TaxCreditCarryforwardAxis_637818515859475978" xlink:to="us-gaap_TaxCreditCarryforwardNameDomain_637818515859475978" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchMember" xlink:label="us-gaap_ResearchMember_637818515859475978" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TaxCreditCarryforwardNameDomain_637818515859475978" xlink:to="us-gaap_ResearchMember_637818515859475978" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLossCarryforwardsLineItems" xlink:label="us-gaap_OperatingLossCarryforwardsLineItems_637818515859475978" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLossCarryforwardsTable_637818515859465876" xlink:to="us-gaap_OperatingLossCarryforwardsLineItems_637818515859475978" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="us-gaap_OperatingLossCarryforwards_637818515859475978" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems_637818515859475978" xlink:to="us-gaap_OperatingLossCarryforwards_637818515859475978" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_637818515859475978" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems_637818515859475978" xlink:to="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_637818515859475978" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxCreditCarryforwardAmount" xlink:label="us-gaap_TaxCreditCarryforwardAmount_637818515859475978" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems_637818515859475978" xlink:to="us-gaap_TaxCreditCarryforwardAmount_637818515859475978" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_637818515859486153" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems_637818515859475978" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_637818515859486153" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="7" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued" xlink:label="us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued_637818515859486153" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems_637818515859475978" xlink:to="us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued_637818515859486153" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense" xlink:label="us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense_637818515859486153" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems_637818515859475978" xlink:to="us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense_637818515859486153" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
  </presentationLink>
  <presentationLink xlink:role="http://annovisbio.com/role/DisclosureRelatedPartyTransactionsDetails" xlink:type="extended" xlink:title="41301 - Disclosure - Related-Party Transactions (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="us-gaap_RelatedPartyTransactionsAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_637818515859486153" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsAbstract" xlink:to="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_637818515859486153" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_637818515859486153" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_637818515859486153" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_637818515859486153" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain_637818515859486153" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_637818515859486153" xlink:to="us-gaap_RelatedPartyDomain_637818515859486153" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_DirectorMember" xlink:label="srt_DirectorMember_637818515859486153" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyDomain_637818515859486153" xlink:to="srt_DirectorMember_637818515859486153" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionAxis" xlink:label="us-gaap_RelatedPartyTransactionAxis_637818515859486153" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_637818515859486153" xlink:to="us-gaap_RelatedPartyTransactionAxis_637818515859486153" order="2" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="us-gaap_RelatedPartyTransactionDomain_637818515859486153" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionAxis_637818515859486153" xlink:to="us-gaap_RelatedPartyTransactionDomain_637818515859486153" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="anvs-20211231.xsd#anvs_RelatedPartyTransactionIssuanceOfConvertiblePromissoryNotesMember" xlink:label="anvs_RelatedPartyTransactionIssuanceOfConvertiblePromissoryNotesMember_637818515859495999" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionDomain_637818515859486153" xlink:to="anvs_RelatedPartyTransactionIssuanceOfConvertiblePromissoryNotesMember_637818515859495999" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="anvs-20211231.xsd#anvs_RelatedPartyTransactionConversionOfPromissoryNotesToCommonStockMember" xlink:label="anvs_RelatedPartyTransactionConversionOfPromissoryNotesToCommonStockMember_637818515859495999" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionDomain_637818515859486153" xlink:to="anvs_RelatedPartyTransactionConversionOfPromissoryNotesToCommonStockMember_637818515859495999" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="us-gaap_LongtermDebtTypeAxis_637818515859495999" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_637818515859486153" xlink:to="us-gaap_LongtermDebtTypeAxis_637818515859495999" order="3" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="us-gaap_LongtermDebtTypeDomain_637818515859495999" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongtermDebtTypeAxis_637818515859495999" xlink:to="us-gaap_LongtermDebtTypeDomain_637818515859495999" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConvertibleDebtMember" xlink:label="us-gaap_ConvertibleDebtMember_637818515859495999" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongtermDebtTypeDomain_637818515859495999" xlink:to="us-gaap_ConvertibleDebtMember_637818515859495999" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis_637818515859495999" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_637818515859486153" xlink:to="us-gaap_StatementEquityComponentsAxis_637818515859495999" order="4" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain_637818515859495999" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis_637818515859495999" xlink:to="us-gaap_EquityComponentDomain_637818515859495999" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember_637818515859495999" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain_637818515859495999" xlink:to="us-gaap_CommonStockMember_637818515859495999" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="us-gaap_RelatedPartyTransactionLineItems_637818515859495999" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_637818515859486153" xlink:to="us-gaap_RelatedPartyTransactionLineItems_637818515859495999" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="us-gaap_DebtInstrumentFaceAmount_637818515859495999" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems_637818515859495999" xlink:to="us-gaap_DebtInstrumentFaceAmount_637818515859495999" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="anvs-20211231.xsd#anvs_RelatedPartyTransactionNumberOfCompanyDirectors" xlink:label="anvs_RelatedPartyTransactionNumberOfCompanyDirectors_637818515859495999" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems_637818515859495999" xlink:to="anvs_RelatedPartyTransactionNumberOfCompanyDirectors_637818515859495999" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="anvs-20211231.xsd#anvs_StockIssuedDuringPeriodSharesConversionOfConvertibleNotes" xlink:label="anvs_StockIssuedDuringPeriodSharesConversionOfConvertibleNotes_637818515859495999" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems_637818515859495999" xlink:to="anvs_StockIssuedDuringPeriodSharesConversionOfConvertibleNotes_637818515859495999" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
  </presentationLink>
  <presentationLink xlink:role="http://annovisbio.com/role/DisclosureSubsequentEventsDetails" xlink:type="extended" xlink:title="41401 - Disclosure - Subsequent Events (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="us-gaap_SubsequentEventsAbstract_637238435853274374" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTable" xlink:label="us-gaap_SubsequentEventTable_637818515859505912" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventsAbstract_637238435853274374" xlink:to="us-gaap_SubsequentEventTable_637818515859505912" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis_637818515859505912" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTable_637818515859505912" xlink:to="us-gaap_SubsequentEventTypeAxis_637818515859505912" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain_637818515859505912" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeAxis_637818515859505912" xlink:to="us-gaap_SubsequentEventTypeDomain_637818515859505912" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember_637818515859505912" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeDomain_637818515859505912" xlink:to="us-gaap_SubsequentEventMember_637818515859505912" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventLineItems" xlink:label="us-gaap_SubsequentEventLineItems_637818515859505912" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTable_637818515859505912" xlink:to="us-gaap_SubsequentEventLineItems_637818515859505912" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="8" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_637818515859505912" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems_637818515859505912" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_637818515859505912" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_637818515859505912" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems_637818515859505912" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_637818515859505912" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
  </presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140032788274824">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Document and Entity Information - USD ($)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Feb. 28, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Document and Entity Information</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">Annovis Bio,&#160;Inc.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-K<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentAnnualReport', window );">Document Annual Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Dec. 31,  2021<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-39202<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">26-2540421<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">1055 Westlakes Drive, Suite&#160;300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Berwyn<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">PA<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">19312<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">610<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">727-3913<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, par value $0.0001 per share<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">ANVS<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NYSE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityWellKnownSeasonedIssuer', window );">Entity Well Known Seasoned Issuer</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityVoluntaryFilers', window );">Entity Voluntary Filers</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Non-accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityExTransitionPeriod', window );">Entity Ex Transition Period</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityPublicFloat', window );">Entity Public Float</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 481,819,080<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_IcfrAuditorAttestationFlag', window );">ICFR Auditor Attestation Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,163,923<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001477845<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2021<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">FY<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AuditorName', window );">Auditor Name</a></td>
<td class="text">WithumSmith+Brown, PC<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AuditorLocation', window );">Auditor Location</a></td>
<td class="text">East Brunswick, New Jersey<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AuditorFirmId', window );">Auditor Firm ID</a></td>
<td class="text">100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorFirmId">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>PCAOB issued Audit Firm Identifier</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorFirmId</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:nonemptySequenceNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorLocation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorLocation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentAnnualReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an annual report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentAnnualReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityExTransitionPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 7A<br> -Section B<br> -Subsection 2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityExTransitionPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityPublicFloat">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityPublicFloat</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityVoluntaryFilers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityVoluntaryFilers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityWellKnownSeasonedIssuer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityWellKnownSeasonedIssuer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_IcfrAuditorAttestationFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_IcfrAuditorAttestationFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140032788515000">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Balance Sheets - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 45,686,014<span></span>
</td>
<td class="nump">$ 8,074,658<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_anvs_PrepaidExpenseSecurityDepositsAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">315,464<span></span>
</td>
<td class="nump">44,676<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">46,001,478<span></span>
</td>
<td class="nump">8,119,334<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">46,001,478<span></span>
</td>
<td class="nump">8,119,334<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">688,074<span></span>
</td>
<td class="nump">341,856<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_anvs_AccruedLiabilitiesAndInterestAndEmployeeRelatedLiabilitiesCurrent', window );">Accrued expenses</a></td>
<td class="nump">818,440<span></span>
</td>
<td class="nump">236,524<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">1,506,514<span></span>
</td>
<td class="nump">578,380<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">1,506,514<span></span>
</td>
<td class="nump">578,380<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and contingencies (Note 8)</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders' equity (deficit):</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock - $0.0001 par value, 2,000,000 shares authorized and 0 shares issued and outstanding</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock - $0.0001 par value, 35,000,000 shares authorized and 8,100,570 and 6,891,608 shares issued and outstanding at December 31, 2021 and 2020, respectively</a></td>
<td class="nump">810<span></span>
</td>
<td class="nump">689<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid-in capital</a></td>
<td class="nump">73,220,361<span></span>
</td>
<td class="nump">21,779,340<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(28,726,207)<span></span>
</td>
<td class="num">(14,239,075)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders' equity</a></td>
<td class="nump">44,494,964<span></span>
</td>
<td class="nump">7,540,954<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and stockholders' equity</a></td>
<td class="nump">$ 46,001,478<span></span>
</td>
<td class="nump">$ 8,119,334<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_anvs_AccruedLiabilitiesAndInterestAndEmployeeRelatedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Includes accrued interest and obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">anvs_AccruedLiabilitiesAndInterestAndEmployeeRelatedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>anvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_anvs_PrepaidExpenseSecurityDepositsAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer. Includes security deposits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">anvs_PrepaidExpenseSecurityDepositsAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>anvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6801-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 15: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.(a),19)<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14326-108349<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 20: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140032794126680">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Balance Sheets (Parenthetical) - $ / shares<br></strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Balance Sheets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value (dollars per share)</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized</a></td>
<td class="nump">2,000,000<span></span>
</td>
<td class="nump">2,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (dollars per share)</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
<td class="nump">35,000,000<span></span>
</td>
<td class="nump">35,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued</a></td>
<td class="nump">8,100,570<span></span>
</td>
<td class="nump">6,891,608<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding</a></td>
<td class="nump">8,100,570<span></span>
</td>
<td class="nump">6,891,608<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140032788432952">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Statements of Operations - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">$ 8,479,031<span></span>
</td>
<td class="nump">$ 3,054,025<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative</a></td>
<td class="nump">6,058,190<span></span>
</td>
<td class="nump">3,586,196<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
<td class="nump">14,537,221<span></span>
</td>
<td class="nump">6,640,221<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Operating loss</a></td>
<td class="num">(14,537,221)<span></span>
</td>
<td class="num">(6,640,221)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpenseAbstract', window );"><strong>Other income (expense):</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrealizedGainLossOnDerivatives', window );">Change in fair value of derivative liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(26,500)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestIncomeExpenseNonoperatingNet', window );">Interest income, net</a></td>
<td class="nump">13,335<span></span>
</td>
<td class="nump">47,225<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_anvs_IncomeFromGrants', window );">Grant income</a></td>
<td class="nump">36,754<span></span>
</td>
<td class="nump">1,157,449<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Total other income (expense)</a></td>
<td class="nump">50,089<span></span>
</td>
<td class="nump">1,178,174<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Loss before income taxes</a></td>
<td class="num">(14,487,132)<span></span>
</td>
<td class="num">(5,462,047)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (14,487,132)<span></span>
</td>
<td class="num">$ (5,462,047)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Basic loss per common share</a></td>
<td class="num">$ (1.90)<span></span>
</td>
<td class="num">$ (0.87)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Diluted loss per common share</a></td>
<td class="num">$ (1.90)<span></span>
</td>
<td class="num">$ (0.87)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted average number of common shares outstanding, basic</a></td>
<td class="nump">7,626,278<span></span>
</td>
<td class="nump">6,308,961<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted average number of common shares outstanding, diluted</a></td>
<td class="nump">7,626,278<span></span>
</td>
<td class="nump">6,308,961<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_anvs_IncomeFromGrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Income from non-repayable sum of money awarded to an entity to carry out a specific purpose as provided in grant agreements. Outside the scope of Topic 606.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">anvs_IncomeFromGrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>anvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1448-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1337-109256<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e4984-109258<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e3842-109258<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1252-109256<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e4984-109258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e3842-109258<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1252-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1337-109256<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 940<br> -SubTopic 20<br> -Section 25<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123384075&amp;loc=d3e41242-110953<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestIncomeExpenseNonoperatingNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net amount of nonoperating interest income (expense).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestIncomeExpenseNonoperatingNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 730<br> -Section 25<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6472174&amp;loc=d3e58812-109433<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrealizedGainLossOnDerivatives">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net change in the difference between the fair value and the carrying value, or in the comparative fair values, of derivative instruments, including options, swaps, futures, and forward contracts, held at each balance sheet date, that was included in earnings for the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrealizedGainLossOnDerivatives</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1448-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140032790831608">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Statements of Changes in Redeemable Convertible Preferred Stock<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($) </div>
<div>shares</div>
</th></tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=anvs_SeriesaRedeemableConvertiblePreferredStockMember', window );">Series A Redeemable convertible preferred stock</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward', window );"><strong>Changes in Redeemable Convertible Preferred Stock</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent', window );">Balance | $</a></td>
<td class="nump">$ 6,509,303<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesIssued', window );">Balance, shares | shares</a></td>
<td class="nump">5,133,159<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_anvs_TemporaryEquityConversionOfPreferredStockToCommonStock', window );">Conversion of redeemable convertible preferred stock to common stock upon completion of initial public offering | $</a></td>
<td class="num">$ (6,509,303)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_anvs_TemporaryEquitySharesConversionOfPreferredStockToCommonStock', window );">Conversion of redeemable convertible preferred stock to common stock upon completion of initial public offering, shares | shares</a></td>
<td class="num">(5,133,159)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent', window );">Balance | $</a></td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesIssued', window );">Balance, shares | shares</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=anvs_Series1RedeemableConvertiblePreferredStockMember', window );">Series A-1 Redeemable convertible preferred stock</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward', window );"><strong>Changes in Redeemable Convertible Preferred Stock</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent', window );">Balance | $</a></td>
<td class="nump">$ 567,649<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesIssued', window );">Balance, shares | shares</a></td>
<td class="nump">630,722<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_anvs_TemporaryEquityConversionOfPreferredStockToCommonStock', window );">Conversion of redeemable convertible preferred stock to common stock upon completion of initial public offering | $</a></td>
<td class="num">$ (567,649)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_anvs_TemporaryEquitySharesConversionOfPreferredStockToCommonStock', window );">Conversion of redeemable convertible preferred stock to common stock upon completion of initial public offering, shares | shares</a></td>
<td class="num">(630,722)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent', window );">Balance | $</a></td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesIssued', window );">Balance, shares | shares</a></td>
<td class="nump">0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_anvs_TemporaryEquityConversionOfPreferredStockToCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Conversion of redeemable convertible preferred stock to common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">anvs_TemporaryEquityConversionOfPreferredStockToCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>anvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_anvs_TemporaryEquitySharesConversionOfPreferredStockToCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Conversion of redeemable convertible preferred stock to common stock, shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">anvs_TemporaryEquitySharesConversionOfPreferredStockToCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>anvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInTemporaryEquityRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, attributable to parent, of an entity's issued and outstanding stock which is not included within permanent equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. Includes stock with a put option held by an ESOP and stock redeemable by a holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityCarryingAmountAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquitySharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of securities classified as temporary equity that have been sold (or granted) to the entity's shareholders. Securities issued include securities outstanding and securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquitySharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=anvs_SeriesaRedeemableConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=anvs_SeriesaRedeemableConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=anvs_Series1RedeemableConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=anvs_Series1RedeemableConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140032788912520">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Statements of Changes in Stockholders' Equity (Deficit) - USD ($)<br></strong></div></th>
<th class="th"><div>Common Stock</div></th>
<th class="th"><div>Additional Paid-In Capital</div></th>
<th class="th"><div>Accumulated Deficit</div></th>
<th class="th"><div>Total</div></th>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2019</a></td>
<td class="nump">$ 28<span></span>
</td>
<td class="nump">$ 200,600<span></span>
</td>
<td class="num">$ (8,777,028)<span></span>
</td>
<td class="num">$ (8,576,400)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Balance, shares at Dec. 31, 2019</a></td>
<td class="nump">282,614<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Changes in Stockholders' Equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_anvs_StockIssuedDuringPeriodValueConversionOfConvertibleSecuritiesPreferredStock', window );">Conversion of redeemable convertible preferred stock to common stock upon completion of initial public offering</a></td>
<td class="nump">$ 412<span></span>
</td>
<td class="nump">7,076,540<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,076,952<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_anvs_StockIssuedDuringPeriodSharesConversionOfConvertibleSecuritiesPreferredStock', window );">Conversion of redeemable convertible preferred stock to common stock upon completion of initial public offering, shares</a></td>
<td class="nump">4,117,089<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_anvs_StockIssuedDuringPeriodValueConversionOfConvertibleSecuritiesConvertiblePromissoryNotes', window );">Conversion of convertible promissory notes, including embedded derivative, to common stock upon completion of initial public offering</a></td>
<td class="nump">$ 12<span></span>
</td>
<td class="nump">672,512<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">672,524<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_anvs_StockIssuedDuringPeriodSharesConversionOfConvertibleNotes', window );">Conversion of convertible promissory notes, including embedded derivative, to common stock upon completion of initial public offering, shares</a></td>
<td class="nump">118,470<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of common stock, net of issuance costs</a></td>
<td class="nump">$ 230<span></span>
</td>
<td class="nump">11,955,565<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,955,795<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock, net of issuance costs (in shares)</a></td>
<td class="nump">2,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Exercise of stock options</a></td>
<td class="nump">$ 5<span></span>
</td>
<td class="nump">9,212<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9,217<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercise of stock options, shares</a></td>
<td class="nump">48,435<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">48,435<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueIssuedForServices', window );">Issuance of common stock to consultants and advisors</a></td>
<td class="nump">$ 2<span></span>
</td>
<td class="nump">122,748<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 122,750<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices', window );">Issuance of common stock to consultants and advisors, shares</a></td>
<td class="nump">25,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition', window );">Stock based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,742,163<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,742,163<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(5,462,047)<span></span>
</td>
<td class="num">(5,462,047)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2020</a></td>
<td class="nump">$ 689<span></span>
</td>
<td class="nump">21,779,340<span></span>
</td>
<td class="num">(14,239,075)<span></span>
</td>
<td class="nump">7,540,954<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Balance, shares at Dec. 31, 2020</a></td>
<td class="nump">6,891,608<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Changes in Stockholders' Equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of common stock, net of issuance costs</a></td>
<td class="nump">$ 100<span></span>
</td>
<td class="nump">46,648,313<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">46,648,413<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock, net of issuance costs (in shares)</a></td>
<td class="nump">1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Exercise of stock options</a></td>
<td class="nump">$ 16<span></span>
</td>
<td class="nump">95,086<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 95,102<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercise of stock options, shares</a></td>
<td class="nump">155,038<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">159,813<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_anvs_StockIssuedDuringPeriodValueWarrantsExercised', window );">Cashless exercise of warrants</a></td>
<td class="nump">$ 5<span></span>
</td>
<td class="num">(5)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_anvs_StockIssuedDuringPeriodSharesWarrantsExercised', window );">Cashless exercise of warrants, shares</a></td>
<td class="nump">53,924<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition', window );">Stock based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,697,627<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,697,627<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(14,487,132)<span></span>
</td>
<td class="num">(14,487,132)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2021</a></td>
<td class="nump">$ 810<span></span>
</td>
<td class="nump">$ 73,220,361<span></span>
</td>
<td class="num">$ (28,726,207)<span></span>
</td>
<td class="nump">$ 44,494,964<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Balance, shares at Dec. 31, 2021</a></td>
<td class="nump">8,100,570<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_anvs_StockIssuedDuringPeriodSharesConversionOfConvertibleNotes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of the conversion of convertible notes.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">anvs_StockIssuedDuringPeriodSharesConversionOfConvertibleNotes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>anvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_anvs_StockIssuedDuringPeriodSharesConversionOfConvertibleSecuritiesPreferredStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of the conversion of convertible preferred stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">anvs_StockIssuedDuringPeriodSharesConversionOfConvertibleSecuritiesPreferredStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>anvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_anvs_StockIssuedDuringPeriodSharesWarrantsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Shares of stock issued as a result of the exercise of warrants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">anvs_StockIssuedDuringPeriodSharesWarrantsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>anvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_anvs_StockIssuedDuringPeriodValueConversionOfConvertibleSecuritiesConvertiblePromissoryNotes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The value of stock issued during the period upon the conversion of convertible promissory notes.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">anvs_StockIssuedDuringPeriodValueConversionOfConvertibleSecuritiesConvertiblePromissoryNotes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>anvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_anvs_StockIssuedDuringPeriodValueConversionOfConvertibleSecuritiesPreferredStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The value of stock issued during the period upon the conversion of convertible preferred stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">anvs_StockIssuedDuringPeriodValueConversionOfConvertibleSecuritiesPreferredStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>anvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_anvs_StockIssuedDuringPeriodValueWarrantsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued as a result of the exercise of warrants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">anvs_StockIssuedDuringPeriodValueWarrantsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>anvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInStockholdersEquityRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of stock issued as of the balance sheet date, including shares that had been issued and were previously outstanding but which are now held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued in lieu of cash for services contributed to the entity. Number of shares includes, but is not limited to, shares issued for services contributed by vendors and founders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesIssuedForServices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueIssuedForServices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued in lieu of cash for services contributed to the entity. Value of the stock issued includes, but is not limited to, services contributed by vendors and founders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueIssuedForServices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued as a result of the exercise of stock options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140032788851224">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Statements of Cash Flows - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Cash flows from operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="num">$ (14,487,132)<span></span>
</td>
<td class="num">$ (5,462,047)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfFinancingCosts', window );">Amortization of deferred financing fees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">129<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfDebtDiscountPremium', window );">Amortization of debt discount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">396<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation expense, including stock issued to consultants and advisors</a></td>
<td class="nump">4,697,627<span></span>
</td>
<td class="nump">1,864,913<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrealizedGainLossOnDerivatives', window );">Change in fair value of derivative liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">26,500<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_anvs_IncreaseDecreaseInGrantsReceivable', window );">Grant receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">735,075<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Prepaid expenses and other current assets</a></td>
<td class="num">(270,788)<span></span>
</td>
<td class="num">(34,097)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayable', window );">Accounts payable</a></td>
<td class="nump">346,218<span></span>
</td>
<td class="num">(695,660)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedLiabilities', window );">Accrued expenses</a></td>
<td class="nump">581,916<span></span>
</td>
<td class="num">(406,032)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="num">(9,132,159)<span></span>
</td>
<td class="num">(3,970,823)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash flows from financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of common stock, net of issuance costs</a></td>
<td class="nump">46,648,413<span></span>
</td>
<td class="nump">12,034,406<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Proceeds from exercise of stock options</a></td>
<td class="nump">95,102<span></span>
</td>
<td class="nump">9,217<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by financing activities</a></td>
<td class="nump">46,743,515<span></span>
</td>
<td class="nump">12,043,623<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Net increase in cash and cash equivalents</a></td>
<td class="nump">37,611,356<span></span>
</td>
<td class="nump">8,072,800<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and cash equivalents, beginning of year</a></td>
<td class="nump">8,074,658<span></span>
</td>
<td class="nump">1,858<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and cash equivalents, end of year</a></td>
<td class="nump">$ 45,686,014<span></span>
</td>
<td class="nump">8,074,658<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowElementsAbstract', window );"><strong>Supplemental disclosure of non-cash financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_anvs_ConversionOfRedeemableConvertiblePreferredStockToCommonStock', window );">Conversion of redeemable convertible preferred stock to common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,076,952<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_anvs_ConversionOfConvertiblePromissoryNotesIncludingEmbeddedDerivativeToCommonStock', window );">Conversion of convertible promissory notes, including embedded derivative, to common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 672,524<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_anvs_ConversionOfConvertiblePromissoryNotesIncludingEmbeddedDerivativeToCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the conversion of convertible promissory notes, including embedded derivative, to common stock</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">anvs_ConversionOfConvertiblePromissoryNotesIncludingEmbeddedDerivativeToCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>anvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_anvs_ConversionOfRedeemableConvertiblePreferredStockToCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the conversion of redeemable convertible preferred stock to common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">anvs_ConversionOfRedeemableConvertiblePreferredStockToCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>anvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_anvs_IncreaseDecreaseInGrantsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in grants receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">anvs_IncreaseDecreaseInGrantsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>anvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfDebtDiscountPremium">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense included in interest expense to amortize debt discount and premium associated with the related debt instruments. Excludes amortization of financing costs. Alternate captions include noncash interest expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1A<br> -URI http://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28541-108399<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495355-112611<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.8)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfDebtDiscountPremium</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfFinancingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense attributable to debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495355-112611<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28555-108399<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfFinancingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123444420&amp;loc=d3e33268-110906<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in prepaid expenses, and assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from exercise of option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=SL79508275-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3000-108585<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4569616-111683<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 23: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 29: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 31: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowElementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowElementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrealizedGainLossOnDerivatives">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net change in the difference between the fair value and the carrying value, or in the comparative fair values, of derivative instruments, including options, swaps, futures, and forward contracts, held at each balance sheet date, that was included in earnings for the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrealizedGainLossOnDerivatives</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140032793959448">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Nature of Business and Liquidity<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Nature of Business and Liquidity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock', window );">Nature of Business and Liquidity</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">(1)&#160;Nature of Business and Liquidity</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Annovis Bio,&#160;Inc. (the &#8220;Company&#8221; or &#8220;Annovis&#8221;) was incorporated on April&#160;29, 2008, under the laws of the State of Delaware. Annovis is a clinical-stage drug platform company addressing neurodegeneration such as Alzheimer&#8217;s disease (&#8220;AD&#8221;), Parkinson&#8217;s disease (&#8220;PD&#8221;) and Down syndrome patients with AD (&#8220;DS-AD&#8221;). The toxic cascade in neurodegeneration begins with high levels of neurotoxic proteins which lead to impaired axonal transport, inflammation, death of nerve cells and loss of cognition and motor function. The Company&#8217;s lead compound, Buntanetap, is a small molecule administered orally that attacks neurodegeneration by entering the brain and inhibiting the translation of multiple neurotoxic proteins thereby impeding the toxic cascade.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Since its founding, the Company has been engaged in organizational activities, including raising capital, and research and development activities. The Company has <span style="-sec-ix-hidden:Hidden_wLzrCC9kDk6BKVi6RIiXmQ;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">not</span></span> generated substantial revenues and has not yet achieved profitable operations, nor has it ever generated positive cash flows from operations. There is no assurance that profitable operations, if achieved, could be sustained on a continuing basis. The Company is subject to those risks associated with any clinical stage pharmaceutical company that has substantial expenditures for research and development. There can be no assurance that the Company&#8217;s research and development projects will be successful, that products developed will obtain necessary regulatory approval, or that any approved product will be commercially viable. In addition, the Company operates in an environment of rapid technological change and is largely dependent on the services of its employees and consultants. Further, the Company&#8217;s future operations are dependent on the success of the Company&#8217;s efforts to raise additional capital.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company has a history of incurring net losses and anticipates incurring additional losses until such time, if ever, that it can generate significant revenue from its product candidates currently in development. The Company&#8217;s primary source of capital has been the issuance of equity securities.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company closed its initial public offering (the &#8220;IPO&#8221;) on January&#160;31, 2020, pursuant to which it sold a total of 2,300,000 shares of common stock at an initial offering price of $6.00 per share for total gross proceeds of approximately&#160;$13.8 million. The net proceeds of the IPO were approximately $12.0 million after deducting underwriting discounts and issuance costs paid by&#160;the Company. In conjunction with the IPO, the Company granted the underwriters 100,000 warrants to purchase shares of Company common stock at an exercise price of $7.50 per share, which is 125% of the initial public offering price. Upon the closing of the IPO, outstanding redeemable convertible preferred stock and convertible promissory notes&#160;converted into shares of Company common stock totaling 4,117,089 and 118,470<span style="white-space:pre-wrap;">, respectively.  On May 26, 2021, the Company closed an underwritten public offering of </span>1,000,000 shares of its common stock at an offering price of $50.00 per share, for gross proceeds of $50.0<span style="white-space:pre-wrap;"> million.  The net proceeds of the offering were approximately </span>$46.6<span style="white-space:pre-wrap;"> million, after deducting underwriting discounts and issuance costs paid by the Company.  The Company&#8217;s common stock trades on the New York Stock Exchange under the ticker symbol &#8220;ANVS&#8221;.  </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">As of the date these financial statements are issued, management believes that the current cash and cash equivalents are sufficient to fund operations and capital requirements for at least the next 12&#160;months including one potential short-term clinical trial in AD and one potential short term clinical trial in PD. To fund additional planned Phase 3 trials, however, the Company will need to raise additional capital. There is no assurance that such financing will be available when needed or on acceptable terms.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -URI http://asc.fasb.org/topic&amp;trid=2122149<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -URI http://asc.fasb.org/topic&amp;trid=2197479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140032793931176">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Summary of Significant Accounting Policies</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">Summary of Significant Accounting Policies</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">(2)&#160;Summary of Significant Accounting Policies</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;">(a)&#160;Basis of Presentation</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">The accompanying financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America (&#8220;U.S.&#160;GAAP&#8221;). Any reference in these notes to applicable guidance is meant </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">to refer to U.S.&#160;GAAP as found in the Accounting Standards Codification (&#8220;ASC&#8221;) and Accounting Standards Update (&#8220;ASU&#8221;) of the Financial Accounting Standards Board (&#8220;FASB&#8221;).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;">(b)&#160;Use of Estimates</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The preparation of financial statements in conformity with U.S.&#160;GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, including disclosure of contingent assets and liabilities, at the date of the financial statements, and the reported amounts of revenues and expenses during the reporting period. Due to the uncertainty of factors surrounding the estimates or judgments used in the preparation of the financial statements, actual results may materially vary from these estimates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Significant items subject to such estimates and assumptions include progress towards completion of research and development projects, stock-based compensation expense, grant income and contingent liabilities. Future events and their effects cannot be predicted with certainty; accordingly, accounting estimates require the exercise of judgment. Accounting estimates used in the preparation of these financial statements change as new events occur, as more experience is acquired, as additional information is obtained and as the operating environment changes.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;">(c)&#160;Basic and Diluted Net Income (Loss) per Share</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Basic net income (loss) per share is determined using the weighted average number of shares of common stock outstanding during each period. Diluted net income (loss) per share includes the effect, if any, from the potential exercise or conversion of securities, such as redeemable convertible preferred stock, convertible promissory notes and stock options, which would result in the issuance of incremental shares of common stock. The computation of diluted net income (loss) per shares does not include the conversion of securities that would have an anti-dilutive effect.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;">(d)&#160;Cash and Cash Equivalents</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company considers all highly liquid investments with original maturities of three&#160;months or less to be cash equivalents. At times, the Company&#8217;s cash balances may exceed the current insured amounts under the Federal Deposit Insurance Corporation. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;">(e)&#160;Issuance Costs Associated with Equity Issuances</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Issuance costs incurred in connection with the Company&#8217;s equity issuances, which primarily consisted of direct incremental legal, printing, listing and accounting fees, are offset against proceeds received in the issuances and charged to additional paid-in capital in the period the equity issuance is completed. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;">(f)&#160;Fair Value of Financial Instruments</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company&#8217;s financial instruments include cash and cash equivalents, accounts payable and accrued expenses. Cash and cash equivalents are reported at fair value. The recorded carrying amount of accounts payable and accrued expenses reflect their fair value due to their short-term nature.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;">(g)&#160;Research and Development</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Research and development costs are expensed as incurred and are primarily comprised of personnel-related expenses and external research and development expenses incurred under arrangements with third parties, such as contract research organizations and consultants. At the end of each reporting period, the Company compares the payments made to each service provider to the estimated progress towards completion of the related project. Factors that the Company considers in preparing these estimates include the number of patients enrolled in studies, milestones achieved, and other criteria related to the efforts of its vendors. These estimates will be subject to change as additional information becomes available. Depending on the timing of payments to vendors and estimated services provided, the Company will record net prepaid or accrued expenses related to these costs.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;">(h)&#160;Grant Income</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Grants received are recognized as grant income in the statements of operations as and when they are earned for the specific research and development projects for which these grants are designated. Grants payments received in excess of grant income earned are recognized as deferred grant on the balance sheet and grant income earned in excess of grant payments received is recognized as grant receivable on the balance sheets.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;">(i)&#160;Stock-Based Compensation</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Stock-based compensation cost is measured at the grant date based on the fair value of the award and is recognized as expense on a straight-line basis over the requisite service period, which is generally the vesting period. Forfeitures are recognized in compensation expense in the period when they occur.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company uses the Black-Scholes option pricing model to value its option awards which requires the use of subjective assumptions, including the expected life of the option and expected share price volatility. The assumptions used in calculating the fair value of stock-based awards represent management&#8217;s best estimates and involve inherent uncertainties and the application of management&#8217;s judgment. As a result, if factors change and management uses different assumptions, stock-based compensation expense could be materially different for future awards.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Upon exercise of stock options, the Company issues shares first from treasury stock, if available, then from authorized but unissued shares.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;">(j)&#160;Income Taxes</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company provides for income taxes using the asset and liability approach. Deferred tax assets and liabilities are recorded based on the differences between the financial statement and tax bases of assets and liabilities and the tax rates in effect when these differences are expected to reverse. Deferred tax assets are reduced by a valuation allowance if, based on the weight of available evidence, it is more likely than not that some or all of the deferred tax assets will not be realized. As of December 31, 2021 and 2020, the Company had a full valuation allowance against its deferred tax assets.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company is subject to the provisions of ASC 740,&#160;Income Taxes, which prescribes a more likely-than-not threshold for the financial statement recognition of uncertain tax positions. ASC 740 clarifies the accounting for income taxes by prescribing a minimum recognition threshold and measurement attribute for the financial statement recognition and measurement of a tax position taken or expected to be taken in a tax return. There are currently no open federal or state tax audits. The Company has not recorded any liability for uncertain tax positions at December&#160;31, 2021 or December&#160;31, 2020.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;">(k)&#160;Recent Accounting Pronouncements</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In December&#160;2019, the FASB issued ASU No.&#160;2019-12,&#160;Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes. The amendments in ASU 2019-12 simplify the accounting for income taxes by removing certain exceptions to the general principles in Topic 740 and clarifying and amending existing guidance. The new standard is effective for fiscal&#160;years, and interim periods within those fiscal&#160;years, beginning after December&#160;15, 2020, with early adoption permitted. The adoption of this standard did not have an impact on the Company&#8217;s financial statements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="white-space:pre-wrap;">In November 2021, the FASB issued ASU No. 2021-10, Government Assistance (Topic 832): Disclosures by Business Entities about Government Assistance. The amendments in ASU 2021-10 require annual disclosures about transactions with a government that are accounted for by applying a grant or contribution accounting model by analogy.  The new disclosure requirements include information about the nature of the transactions and the related accounting policy used to account for the transactions; the line items on the balance sheet and income statement that are affected by the transactions, and the amounts applicable to each financial statement line item; and significant terms and conditions of the transactions, including commitments and contingencies.  The guidance is effective for fiscal years beginning after </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="white-space:pre-wrap;">December 15, 2021, with early adoption permitted, and may be adopted prospectively or retrospectively.  The Company does not believe the adoption of this standard will have a significant impact on its financial statements.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="font-size:2pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123372394&amp;loc=d3e18726-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI http://asc.fasb.org/topic&amp;trid=2122369<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140032793878232">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Measurements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresTextBlock', window );">Fair Value Measurements</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">(3)&#160;Fair Value Measurements</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company measures certain assets and liabilities at fair value in accordance with ASC 820, Fair Value Measurements and Disclosures. ASC 820 defines fair value as the price that would be received to sell an asset or paid to transfer a liability (the exit price) in an orderly transaction between market participants at the measurement date. The guidance in ASC 820 outlines a valuation framework and creates a fair value hierarchy that serves to increase the consistency and comparability of fair value measurements and the related disclosures. In determining fair value, the Company maximizes the use of quoted prices and observable inputs. Observable inputs are inputs that market participants would use in pricing the asset or liability based on market data obtained from independent sources. The fair value hierarchy is broken down into three levels based on the source of inputs as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 36pt;">Level&#160;1&#8212;Valuations based on unadjusted quoted prices in active markets for identical assets or liabilities.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 36pt;">Level&#160;2&#8212;Valuations based on observable inputs and quoted prices in active markets for similar assets and liabilities.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 36pt;">Level&#160;3&#8212;Valuations based on unobservable inputs and models that are supported by little or no market activity.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">The following table provides the carrying value and fair value of certain financial assets and liabilities of the Company measured at fair value on a recurring basis as of December 31, 2021 and December&#160;31, 2020:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:45.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.02%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.82%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.61%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.6%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:45.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:36.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Fair Value Measurement at </b></p></td></tr><tr><td style="vertical-align:bottom;width:45.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:36.21%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;2021</b></p></td></tr><tr><td style="vertical-align:bottom;width:45.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Carrying Value</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Level 1</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Level 2</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Level 3</b></p></td></tr><tr><td style="vertical-align:bottom;width:45.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Cash and cash equivalents</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 45,686,014</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 45,686,014</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:45.56%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.97%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.74%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.96%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.93%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:45.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:36.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;white-space:pre-wrap;">Fair Value Measurement at  </b></p></td></tr><tr><td style="vertical-align:bottom;width:45.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:36.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;2020</b></p></td></tr><tr><td style="vertical-align:bottom;width:45.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Carrying Value</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Level 1</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Level 2</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Level 3</b></p></td></tr><tr><td style="vertical-align:bottom;width:45.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Cash and cash equivalents</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 8,074,658</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 8,074,658</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140032793931176">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Grant Income<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_anvs_NonOperatingIncomeGrantIncomeAbstract', window );"><strong>Grant Income</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_anvs_OtherNonoperatingIncomeGrantIncomeTextBlock', window );">Grant Income</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">(4)&#160;Grant Income</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In September&#160;2019, as modified in September 2020, the Company received a Notice of Award for a $1.9&#160;million grant from the National Institute on Aging of the National Institutes of Health&#160;(the &#8220;NIH&#8221;) to cover costs of long-term chronic toxicology studies of Buntanetap in rats and dogs. The Company began the long-term chronic toxicology studies in November&#160;<span style="white-space:pre-wrap;">2019.   The Company recognized grant income of </span>$36,754 and $1,157,449 for the&#160;years ended December 31, 2021 and 2020, respectively, in connection with the NIH grant. The Company received payments under the grant of $36,754 and $1,892,524 during the&#160;years ended December 31, 2021 and 2020, respectively and recorded a grant receivable of $0 as of December 31, 2021 and 2020, and had no unreimbursed, eligible costs incurred under the grant. As of December 31, 2021, there were no remaining funds available under the grant.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_anvs_NonOperatingIncomeGrantIncomeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">anvs_NonOperatingIncomeGrantIncomeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>anvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_anvs_OtherNonoperatingIncomeGrantIncomeTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the grant income classified as other non-operating income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">anvs_OtherNonoperatingIncomeGrantIncomeTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>anvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140032793848504">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Prepaid Expenses and Other Current Assets<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract', window );"><strong>Prepaid Expenses and Other Current Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_anvs_DeferredCostsCapitalizedPrepaidExpensesAndOtherAssetsDisclosureTextBlock', window );">Prepaid Expenses and Other Current Assets</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">(5)&#160;Prepaid Expenses and Other Current Assets</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">Prepaid expenses and other current assets consisted of the following:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:74.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:74.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:23.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">As of December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:74.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.95%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td></tr><tr><td style="vertical-align:bottom;width:74.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Prepaid clinical trial expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 232,752</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:74.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Prepaid insurance</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 29,111</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 26,542</p></td></tr><tr><td style="vertical-align:bottom;width:74.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Prepaid expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 43,736</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 11,690</p></td></tr><tr><td style="vertical-align:bottom;width:74.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Security deposits</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 9,865</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 6,444</p></td></tr><tr><td style="vertical-align:bottom;width:74.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.78%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 315,464</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.49%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 44,676</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_anvs_DeferredCostsCapitalizedPrepaidExpensesAndOtherAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure of the amounts paid in advance for capitalized costs that will be expensed with the passage of time or the occurrence of a triggering event, and will be charged against earnings within one year or the normal operating cycle, if longer; the aggregate carrying amount of current assets, not separately presented elsewhere in the balance sheet; and other deferred costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">anvs_DeferredCostsCapitalizedPrepaidExpensesAndOtherAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>anvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140032793866792">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accrued Expenses<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract', window );"><strong>Accrued Expenses</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock', window );">Accrued Expenses</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">(6)&#160;Accrued Expenses</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">Accrued expenses consisted of the following:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:73.83%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.8%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:73.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:24.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">As of December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2020</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Payroll and related benefits</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 712,768</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 16,493</p></td></tr><tr><td style="vertical-align:bottom;width:73.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Accrued professional and clinical fees</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 105,672</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 216,198</p></td></tr><tr><td style="vertical-align:bottom;width:73.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Accrued license payments</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.8%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.86%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3,833</p></td></tr><tr><td style="vertical-align:bottom;width:73.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.8%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 818,440</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.86%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 236,524</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 36pt;">See Note&#160;8 for further detail on the accrued license payments.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a),20,24)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140032793917560">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Convertible Promissory Notes<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Convertible Promissory Notes.</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureTextBlock', window );">Convertible Promissory Notes</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">(7)&#160;Convertible Promissory Notes</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In March&#160;2019, the Company issued convertible promissory notes (the &#8220;Notes&#8221;) to various investors in the aggregate principal amount of $530,000. Interest accrued at 8% compounded annually on all Notes. The maturity date was the earlier of a Liquidity Event or upon the written demand of the holders of a majority of the outstanding principal amount of the Notes&#160;made any time after December&#160;31, 2023. A Liquidity Event was defined as (i)&#160;the date of the closing of a merger or reorganization of the Company with another entity; (ii)&#160;the sale of substantially all of the assets of the Company in which the Company&#8217;s stockholders own less than 50% of the equity securities after the event; or (iii)&#160;a liquidation of the Company.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company incurred costs of $8,622 in connection with the issuance of the Notes. In addition, on issuance, the Company recognized a discount associated with the Notes&#160;of $26,500 related to the fair value of an embedded derivative reflecting the share-settlement provision upon the closing of a Qualified Financing. Unamortized deferred financing fees and debt discount were deducted from the face amount of the Notes&#160;on the balance sheets. The Company amortized the deferred financing fees and debt discount over the term of the Notes&#160;as additional interest expense using the effective interest method. The effective interest rate on the Notes&#160;was&#160;9.8%. The Company made no cash payments for interest.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">On January&#160;<span style="white-space:pre-wrap;">31, 2020, the Company closed its IPO.  In accordance with the terms of the Notes, the outstanding Notes&#160;plus accrued interest converted into </span>118,470 shares of Company common stock at a 20% discount to the initial offering price of shares issued in the IPO. </p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -URI http://asc.fasb.org/topic&amp;trid=2208564<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495334-112611<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495371-112611<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495371-112611<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(c))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495334-112611<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495334-112611<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495348-112611<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495371-112611<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140032793855496">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">Commitments and Contingencies</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">(8)&#160;Commitments and Contingencies</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;">(a)&#160;Leases</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company leases its office facilities under a&#160;month-to-month operating lease. Total rental expense was $51,760 and $41,603 for the&#160;years ended December 31, 2021 and 2020, respectively.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;">(b)&#160;License Agreement</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company previously licensed the rights to certain chemical compounds, know-how and intellectual property rights that may be suitable for the development of human therapeutics from a subsidiary of Horizon Therapeutics, PLC (the &#8220;Licensor&#8221;). Under the license agreement, the Company paid a minimum annual fee of $46,000 and was required to make milestone payments upon attainment of certain milestone events, royalties based on net sales of products covered by the patent-related rights and a portion of any sublicense income received by the Company. The Licensor also granted the Company a buy-out option which was exercisable at any time during the term of the agreement at increasing amounts based on the achievement of certain milestones. The Company had the right to terminate the agreement at any time by giving 90&#160;days advance notice subject to the payment of any amounts due under the agreement at that time. Expenses related to the license agreement were recognized in general and administrative expense in the statements of operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="white-space:pre-wrap;"> In July 2021, the Company gave notice to the Licensor of its termination of the license agreement and the license agreement was terminated effective October 14, 2021. The Company has paid to the Licensor the prorated annual fees through the termination date.  </span>No milestones had been achieved as of the termination date.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;">(c)&#160;Employment Agreements</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company has agreements with its executive officers that provide for severance payments to the employee upon termination of the agreement by the Company for any reason other than for cause, death or disability or by the employee for good reason The maximum aggregate severance payments under the agreements were approximately&#160;$930,000&#160;at December&#160;31,&#160;2021. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;">(d)&#160;Litigation</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company is subject, from time to time, to claims by third parties under various legal disputes. The defense of such claims, or any adverse outcome relating to any such claims, could have a material adverse effect on the Company&#8217;s liquidity, financial condition and cash flows. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">During the year ended December 31, 2021, two<span style="white-space:pre-wrap;"> securities class action complaints were filed against the Company and its executive officers following disclosure of interim results from the AD/PD Trial.  Both complaints were voluntarily dismissed without prejudice by the plaintiffs.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">At December&#160;31, 2021, the Company did not have any pending legal actions.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;">(e)&#160;Risks and Uncertainties</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The extent to which the COVID-19 pandemic could have a material impact on the Company&#8217;s current or future clinical trials is dependent on the spread of the disease and government and healthcare system responses to such spread, which are presently highly uncertain. Management continues to evaluate the potential impact. The financial statements do not include any adjustments that might result from the outcome of this uncertainty.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -URI http://asc.fasb.org/topic&amp;trid=2127136<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -URI http://asc.fasb.org/topic&amp;trid=2144648<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 440<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6491277&amp;loc=d3e6429-115629<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123406679&amp;loc=d3e25336-109308<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123406679&amp;loc=d3e25336-109308<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140032793848504">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Redeemable Convertible Preferred Stock and Stockholders' Equity<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteAbstract', window );"><strong>Redeemable Convertible Preferred Stock and Stockholders' Equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">Redeemable Convertible Preferred Stock and Stockholders' Equity</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">(9)&#160;Redeemable Convertible Preferred Stock and Stockholders&#8217; Equity</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;">(a) Overview</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company closed its IPO on January&#160;31, 2020, issuing 2,300,000 shares of common stock. In connection with the closing of the Company&#8217;s IPO, the then-outstanding 5,133,159 shares of Series&#160;A and 630,722 shares of Series&#160;A-1 redeemable convertible preferred stock converted into an aggregate of 4,117,089 shares of Company common stock. Each share of redeemable convertible preferred stock was converted into the number of shares of common stock determined by dividing the original issue price by the applicable conversion price. The Series&#160;A-1 conversion price was $1.26, and the Series&#160;A conversion price was $0.70.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company&#8217;s Amended and Restated Certificate of Incorporation was adopted on January&#160;31, 2020 to authorize the issuance of two classes of stock to be designated, respectively, common stock and preferred stock. The total number of shares which the Company is authorized to issue is 37,000,000, each with a <span style="-sec-ix-hidden:Hidden_W_s6TWSI0kqP0maAGvG-9A;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">par value</span></span> of $0.0001 per share. Of these shares, 35,000,000 shall be common stock and 2,000,000 shall be preferred stock.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;">(b) Common Stock</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;padding-left:36pt;text-indent:-36pt;margin:0pt 0pt 12pt 0pt;"><span style="font-weight:normal;">1.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Dividends</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Subject to the rights of holders of all classes of Company stock outstanding having rights that are senior to or equivalent to holders of common stock, the holders of the common stock are entitled to receive dividends when and as declared by the Board.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;padding-left:36pt;text-indent:-36pt;margin:0pt 0pt 12pt 0pt;"><span style="font-weight:normal;">2.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Liquidation</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Subject to the rights of holders of all classes of stock outstanding having rights that are senior to or equivalent to holders of common stock as to liquidation, upon the liquidation, dissolution or winding up of the Company, the assets of the Company will be distributed to the holders of common stock.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;padding-left:36pt;text-indent:-36pt;margin:0pt 0pt 12pt 0pt;"><span style="font-weight:normal;">3.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Voting</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The holders of common stock are entitled to one vote for each share of common stock held. There is no cumulative voting.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;">(c)&#160;Preferred Stock</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Preferred stock may be issued from time to time by the Board in one or more series.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;">(d)&#160;Warrants</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">In conjunction with the IPO, the Company granted the underwriters 100,000 warrants to purchase shares of Company common stock at an exercise price of $7.50 per share, which is 125% of the initial public offering price. The warrants have a <span style="-sec-ix-hidden:Hidden_7Pmc5xg25E6fTLpFgVmdTA;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">five</span></span>-year term and were exercisable as of January&#160;29, 2021. During the year ended December 31, 2021, 97,600<span style="white-space:pre-wrap;"> of the warrants were tendered to the Company by the holders pursuant to cashless exercises.  Warrants outstanding as of December 31, 2021 and 2020, were </span>2,400 and 100,000<span style="white-space:pre-wrap;">, respectively.  The Company accounts for the warrants as a component of stockholders&#8217; equity.  </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496171-112644<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496171-112644<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496189-112644<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -URI http://asc.fasb.org/topic&amp;trid=2208762<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496189-112644<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496171-112644<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496189-112644<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 16<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496180-112644<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(e)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140032793821544">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Stock-Based Compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">Stock-Based Compensation</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">(10)&#160;Stock-Based Compensation</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Effective upon the closing of the Company&#8217;s IPO on January&#160;31, 2020, the Company&#8217;s 2019 Equity Incentive Plan (the &#8220;2019 Plan&#8221;) became effective, succeeding the Company&#8217;s previous equity incentive plan. No new options may be issued under the previous plan, although shares subject to grants which are cancelled or forfeited will again be available under the 2019 Plan. Effective June 1, 2021, the 2019 Plan was amended to increase the number of shares authorized to be issued from 1,000,000 to 2,000,000. As of December 31, 2021, 630,569 shares were available for future grants.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The 2019 Plan provides for grants to employees, members of the Board, consultants and advisors to the Company, in the form of stock options, stock awards and other equity-based awards. The amount and terms of grants are determined by the Board. Stock options have a maximum term of 10 years after date of grant and are exercisable in cash or as otherwise determined by the Board. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Stock-based compensation expense in the statements of operations, including the fair value of stock awards to consultants and advisors for services rendered, for the&#160;years ended December 31, 2021 and 2020 was as follows:</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:73%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:24.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Year Ended </b></p></td></tr><tr><td style="vertical-align:bottom;width:73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:24.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.85%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.95%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2020</b></p></td></tr><tr><td style="vertical-align:bottom;width:73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Research and development</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,016,745</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 138,704</p></td></tr><tr><td style="vertical-align:bottom;width:73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">General and administrative</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,680,882</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,726,209</p></td></tr><tr><td style="vertical-align:bottom;width:73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 4,697,627</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,864,913</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">Stock option activity for the years ended December 31, 2021, and 2020, was as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:54.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.63%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.52%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.43%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:54.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Weighted</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:54.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Average</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:54.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Remaining</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:54.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Weighted</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Contractual</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Aggregate</b></p></td></tr><tr><td style="vertical-align:bottom;width:54.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Number of</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Average</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Term</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Intrinsic</b></p></td></tr><tr><td style="vertical-align:bottom;width:54.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Shares</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Exercise Price</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">(Years)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Value</b></p></td></tr><tr><td style="vertical-align:bottom;width:54.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Outstanding at December&#160;31,&#160;2019</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 352,282</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">$ 0.19</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:54.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Granted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 810,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3.46</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:54.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Exercised</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (48,435)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 0.19</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:54.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Forfeited</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (2,381)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 0.14</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:54.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Outstanding at December&#160;31,&#160;2020</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,111,466</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2.57</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:54.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Granted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 538,095</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 33.78</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:54.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Exercised</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (159,813)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2.83</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:54.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Outstanding at December&#160;31,&#160;2021</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,489,748</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 13.82</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="-sec-ix-hidden:Hidden_EQY9UVLtMU6NuqPU1k6Bhg;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> 8.4</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">$ 14,325,377</p></td></tr><tr><td style="vertical-align:bottom;width:54.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Exercisable at December&#160;31,&#160;2021</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,105,568</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 5.87</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="-sec-ix-hidden:Hidden_LZM2INVDtkezbYWBS4I2FA;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> 7.9</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">$ 14,325,377</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The aggregate intrinsic value of options exercised during the years ended December 31, 2021 and 2020 was $11,163,998 and $196,976, respectively. As of December 31, 2021 there was $9,933,691 unrecognized compensation expense related to unvested options. That cost is expected to be recognized over a weighted-average period of <span style="-sec-ix-hidden:Hidden_bR4c2uBj-EKLsqDtSgFQaA;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">1.4</span></span> years.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">During the years ended December 31, 2021 and 2020, the Company issued 538,095 and 810,000 options, respectively. Under the grant agreements for the 2021 stock option grants, 143,391 of the options vested immediately, 155,253 of the options vest on March 31, 2022, 155,251 of the options vest on March 31, 2023 and 84,200 of the options vest in substantially equal quarterly installments over two years<span style="white-space:pre-wrap;"> from the date of grant.  Under the grant agreements for the 2020 stock option grants, 50,000 of the options vested after </span><span style="white-space:pre-wrap;">one year</span><span style="white-space:pre-wrap;"> and the remainder of the options were vested and exercisable upon grant. All of the options have a 10-year term.  </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">The weighted average grant date fair value of options issued during the&#160;years ended December 31, 2021 and 2020 was $27.13 per share and $2.19<span style="white-space:pre-wrap;"> per share, respectively.  The fair value was estimated using the Black Sholes option pricing model.  The expected life of options was estimated using the simplified method, as the Company has limited historical information to develop reasonable expectations about future exercise patterns and post-vesting employment. The risk-free rate was based on the interest rate payable on U.S. Treasury securities at the time of grant for a period that is commensurate with the expected term of the option.  Given the lack of a public market for the Company&#8217;s common stock prior to the IPO, the expected stock price volatility was based on a weighted approach that incorporates the historic daily volatility of the Company&#8217;s common stock since the IPO and the historic daily volatility of similar companies that have been publicly traded for a period commensurate with the expected term of the option.  The expected dividend yield is </span>0% because the Company has not historically paid and does not expect for the </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">foreseeable future to pay a dividend on its common stock. The weighted average assumptions used in the valuation of options granted were as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:58.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:16.66%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:16.66%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:58.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year Ended </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year Ended </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:58.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:58.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Risk-free interest rate</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1.17</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 0.38</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:58.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Expected life</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="-sec-ix-hidden:Hidden_HsUzDjUJtkSAIzhEqWrcUA;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> 5.3</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 5.0</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:58.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Expected volatility</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 113</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 80</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:58.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Expected dividend yield</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">During the year ended December 31, 2020, the Company granted stock awards totaling 25,000<span style="white-space:pre-wrap;"> shares to consultants and advisors for services rendered which vested upon grant.  These awards had a weighted-average grant date fair value of </span>$4.91 per share and an aggregate fair value of $122,750<span style="white-space:pre-wrap;">, which was recognized in stock-based compensation expense upon grant.  </span>No stock awards were issued during the year ended December 31, 2021. As of December 31, 2021, there were no unvested stock awards and there was <span style="-sec-ix-hidden:Hidden_FE1dYrMu70-J5dbAohVyjw;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">no</span></span> unrecognized compensation expense related to stock awards.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -URI http://asc.fasb.org/topic&amp;trid=2228938<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140032793933368">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss Per Share<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Net Loss Per Share</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareTextBlock', window );">Net Loss Per Share</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">(11) Net Loss Per Share</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company has reported a net loss for the&#160;years ended December 31, 2021 and 2020, and the basic and diluted net loss per share attributable to common stockholders are the same for both&#160;years because all redeemable convertible preferred stock, convertible promissory notes, warrants and stock options have been excluded from the computation of diluted weighted-average shares outstanding because such securities would have an antidilutive impact.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">The following table sets forth the computation of basic and diluted net loss per share:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:66.67%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.96%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.67%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:66.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;"> </b><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:31.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year Ended </b></p></td></tr><tr><td style="vertical-align:bottom;width:66.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:31.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:66.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td></tr><tr><td style="vertical-align:bottom;width:66.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Numerator</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:66.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Net loss</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.96%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (14,487,132)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.67%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (5,462,047)</p></td></tr><tr><td style="vertical-align:bottom;width:66.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Denominator</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:66.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Weighted-average common shares outstanding, basic and diluted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 7,626,278</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 6,308,961</p></td></tr><tr><td style="vertical-align:bottom;width:66.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Net loss per share, basic and diluted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (1.90)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (0.87)</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">Potential common shares that are excluded from the computation of diluted weighted-average shares outstanding are as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:74.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.71%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.71%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:74.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:25.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:74.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.71%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.71%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td></tr><tr><td style="vertical-align:bottom;width:74.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Stock options</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,489,748</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,111,466</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:74.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Warrants</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,400</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 100,000</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109243012&amp;loc=SL65017193-207537<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -URI http://asc.fasb.org/topic&amp;trid=2144383<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140032874021752">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Taxes</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">Income Taxes</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">(12) Income Taxes</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The federal and state provision (benefit) for income taxes was&#160;$0&#160;for the&#160;years ended December 31, 2021 and 2020.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">A reconciliation of income tax provision (benefit) computed at the statutory federal income tax rate to income taxes as reflected in the financial statements for the&#160;years ended December 31, 2021 and 2020 is as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:75.45%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.38%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.43%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.38%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:75.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;"> </b><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:20.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year Ended </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:75.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:20.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:75.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:75.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Federal income tax benefit at statutory rate</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 21.0</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 21.0</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:75.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">State and local tax, net of federal benefit</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 13.7</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 7.6</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:75.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Permanent differences</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 0.1</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (0.8)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:75.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Research and development credit</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2.4</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1.9</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:75.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Stock-based compensation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 15.7</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:75.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Change in valuation allowance</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (52.9)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (29.7)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:75.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Effective income tax rate</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.38%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 0.0</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.38%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 0.0</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">Deferred taxes are recognized for temporary differences between the basis of assets and liabilities for financial statement and income tax purposes. The significant components of the Company&#8217;s deferred tax assets are comprised of the following:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:66.67%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.96%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.67%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:66.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;"> </b><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:31.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">As&#160;of&#160;December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:66.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td></tr><tr><td style="vertical-align:bottom;width:66.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Net operating loss carryforwards</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 6,512,249</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,460,773</p></td></tr><tr><td style="vertical-align:bottom;width:66.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Capitalized research and development</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,002,431</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:66.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Stock-based compensation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,759,129</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 547,628</p></td></tr><tr><td style="vertical-align:bottom;width:66.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Research and development tax credit carryforwards</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 648,077</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.67%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 241,414</p></td></tr><tr><td style="vertical-align:bottom;width:66.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total deferred tax assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 10,921,886</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3,249,815</p></td></tr><tr><td style="vertical-align:bottom;width:66.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Less valuation allowance</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (10,921,886)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.67%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (3,249,815)</p></td></tr><tr><td style="vertical-align:bottom;width:66.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Net deferred taxes</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.96%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.67%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">As of December 31, 2021, the Company had U.S. federal net operating loss (&#8220;NOL&#8221;) carryforwards of $21,844,192, which may be available to offset future income tax liabilities. Federal NOL carryforwards generated in 2017 and prior of $2,764,240 will expire beginning in 2032. The remaining federal NOL carryforwards generated in 2018 and later do not expire. As of December 31, 2021, the Company also had U.S. state NOL carryforwards of $24,391,076 which may be available to offset future income tax liabilities and will expire beginning in 2028.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company has recorded a full valuation allowance against its net deferred tax assets as of December 31, 2021 and 2020 because the Company has determined that is it more likely than not that these assets will not be fully realized due to historic net operating losses incurred. The Company experienced a net change in valuation allowance of $7,672,071 and $1,619,516 in the&#160;years ended December 31, 2021 and 2020, respectively.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">As of December 31, 2021, the Company had federal research and development tax credit carryforwards of $648,077 available to reduce future tax liabilities which expire beginning in 2028.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Under the provisions of the Internal Revenue Code, the NOL and tax credit carryforwards are subject to review and possible adjustment by the Internal Revenue Service and state tax authorities. NOL and tax credit carryforwards may become subject to an annual limitation in the event of certain cumulative changes in the ownership interest of significant stockholders over a three-year period in excess of 50%, as defined under Sections&#160;382 and 383 of the Internal Revenue Code as well as similar state provisions. This could limit the amount of tax attributes that can be utilized annually to offset future taxable income or tax liabilities. The amount of the annual limitation is determined based on the value of the Company immediately prior to the ownership change. Subsequent ownership changes may further affect the limitation in future&#160;years. The Company has completed financings since its inception which may have resulted in a change in control as defined by Sections&#160;382 and 383 of the Internal Revenue Code, or could result in a change in control in the future. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company files tax returns as prescribed by the tax laws of the jurisdictions in which it operates. In the normal course of business, the Company is subject to examination by federal and state jurisdictions, where applicable. The Company&#8217;s tax&#160;years from 2018 to the present remain open for review. All open&#160;years may be examined to the extent that tax credits or NOL carryforwards are used in future periods. The Company will recognize interest and penalties related to uncertain tax positions in income tax expense. As of December 31, 2021, the Company had <span style="-sec-ix-hidden:Hidden_1sZl5MdDJ0KYV2BjEn0mRA;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">no</span></span> accrued interest or penalties related to uncertain tax positions and no amounts have been recognized in the Company&#8217;s statements of operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="white-space:pre-wrap;">On March 27, 2020, the Coronavirus Aid, Relief, and Economic Security Act (&#8220;CARES Act&#8221;) was enacted in response to the COVID-19 pandemic. The CARES Act, among other things, permits NOL carryovers and carrybacks to offset 100% of taxable income for taxable years beginning before 2021. Previously, NOLs generated after December 31, 2017 were limited to 80% of taxable income in future years.  In addition, the CARES Act allows NOLs incurred in 2018, 2019 and 2020 to be carried back to each of the five preceding taxable years to generate a refund of previously paid income taxes. The NOL carryback provision of the CARES Act had no impact on the Company due to its tax losses generated during all prior years.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32857-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 11.C)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330215-122817<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32809-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.5.Q1)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32705-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 270<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6424409&amp;loc=d3e44925-109338<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -URI http://asc.fasb.org/topic&amp;trid=2144680<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6424122&amp;loc=d3e41874-109331<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140032793967608">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related-Party Transactions<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsAbstract', window );"><strong>Related-Party Transactions</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock', window );">Related-Party Transactions</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">(13) Related-Party Transactions</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">As discussed in Note&#160;7, in March&#160;2019 the Company issued Notes&#160;in the aggregate principal amount of $530,000. Three of the Company&#8217;s directors purchased an aggregate of $305,000 of the Notes. On January&#160;31, 2020, the Company closed its IPO and the outstanding Notes&#160;plus accrued interest held by directors converted into 71,429 shares of the Company&#8217;s common stock.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -URI http://asc.fasb.org/topic&amp;trid=2122745<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39691-107864<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140032793890088">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Subsequent Events<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventsAbstract', window );"><strong>Subsequent Events</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventsTextBlock', window );">Subsequent Events</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">(14) Subsequent Events</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">On January 3, 2022, the Company granted options to purchase an aggregate of 188,294 shares of common stock at an exercise price of $19.78 per share to employees, members of the board of directors and consultants to the Company.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 855<br> -URI http://asc.fasb.org/topic&amp;trid=2122774<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 855<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6842918&amp;loc=SL6314017-165662<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140032788517592">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Summary of Significant Accounting Policies</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BasisOfAccounting', window );">Basis of Presentation</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;">(a)&#160;Basis of Presentation</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">The accompanying financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America (&#8220;U.S.&#160;GAAP&#8221;). Any reference in these notes to applicable guidance is meant </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">to refer to U.S.&#160;GAAP as found in the Accounting Standards Codification (&#8220;ASC&#8221;) and Accounting Standards Update (&#8220;ASU&#8221;) of the Financial Accounting Standards Board (&#8220;FASB&#8221;).</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;">(b)&#160;Use of Estimates</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The preparation of financial statements in conformity with U.S.&#160;GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, including disclosure of contingent assets and liabilities, at the date of the financial statements, and the reported amounts of revenues and expenses during the reporting period. Due to the uncertainty of factors surrounding the estimates or judgments used in the preparation of the financial statements, actual results may materially vary from these estimates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Significant items subject to such estimates and assumptions include progress towards completion of research and development projects, stock-based compensation expense, grant income and contingent liabilities. Future events and their effects cannot be predicted with certainty; accordingly, accounting estimates require the exercise of judgment. Accounting estimates used in the preparation of these financial statements change as new events occur, as more experience is acquired, as additional information is obtained and as the operating environment changes.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Basic and Diluted Net Income (Loss) per Share</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;">(c)&#160;Basic and Diluted Net Income (Loss) per Share</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Basic net income (loss) per share is determined using the weighted average number of shares of common stock outstanding during each period. Diluted net income (loss) per share includes the effect, if any, from the potential exercise or conversion of securities, such as redeemable convertible preferred stock, convertible promissory notes and stock options, which would result in the issuance of incremental shares of common stock. The computation of diluted net income (loss) per shares does not include the conversion of securities that would have an anti-dilutive effect.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock', window );">Cash and Cash Equivalents</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;">(d)&#160;Cash and Cash Equivalents</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company considers all highly liquid investments with original maturities of three&#160;months or less to be cash equivalents. At times, the Company&#8217;s cash balances may exceed the current insured amounts under the Federal Deposit Insurance Corporation. </p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_anvs_IssuanceCostsAssociatedWithEquityIssuancesPolicyTextBlock', window );">Issuance Costs Associated with Equity Issuances</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;">(e)&#160;Issuance Costs Associated with Equity Issuances</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Issuance costs incurred in connection with the Company&#8217;s equity issuances, which primarily consisted of direct incremental legal, printing, listing and accounting fees, are offset against proceeds received in the issuances and charged to additional paid-in capital in the period the equity issuance is completed. </p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueOfFinancialInstrumentsPolicy', window );">Fair Value of Financial Instruments</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;">(f)&#160;Fair Value of Financial Instruments</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company&#8217;s financial instruments include cash and cash equivalents, accounts payable and accrued expenses. Cash and cash equivalents are reported at fair value. The recorded carrying amount of accounts payable and accrued expenses reflect their fair value due to their short-term nature.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchDevelopmentAndComputerSoftwarePolicyTextBlock', window );">Research and Development</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;">(g)&#160;Research and Development</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Research and development costs are expensed as incurred and are primarily comprised of personnel-related expenses and external research and development expenses incurred under arrangements with third parties, such as contract research organizations and consultants. At the end of each reporting period, the Company compares the payments made to each service provider to the estimated progress towards completion of the related project. Factors that the Company considers in preparing these estimates include the number of patients enrolled in studies, milestones achieved, and other criteria related to the efforts of its vendors. These estimates will be subject to change as additional information becomes available. Depending on the timing of payments to vendors and estimated services provided, the Company will record net prepaid or accrued expenses related to these costs.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_anvs_GrantIncomePolicyTextBlock', window );">Grant Income</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;">(h)&#160;Grant Income</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Grants received are recognized as grant income in the statements of operations as and when they are earned for the specific research and development projects for which these grants are designated. Grants payments received in excess of grant income earned are recognized as deferred grant on the balance sheet and grant income earned in excess of grant payments received is recognized as grant receivable on the balance sheets.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy', window );">Stock-Based Compensation</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;">(i)&#160;Stock-Based Compensation</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Stock-based compensation cost is measured at the grant date based on the fair value of the award and is recognized as expense on a straight-line basis over the requisite service period, which is generally the vesting period. Forfeitures are recognized in compensation expense in the period when they occur.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company uses the Black-Scholes option pricing model to value its option awards which requires the use of subjective assumptions, including the expected life of the option and expected share price volatility. The assumptions used in calculating the fair value of stock-based awards represent management&#8217;s best estimates and involve inherent uncertainties and the application of management&#8217;s judgment. As a result, if factors change and management uses different assumptions, stock-based compensation expense could be materially different for future awards.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Upon exercise of stock options, the Company issues shares first from treasury stock, if available, then from authorized but unissued shares.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxPolicyTextBlock', window );">Income Taxes</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;">(j)&#160;Income Taxes</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company provides for income taxes using the asset and liability approach. Deferred tax assets and liabilities are recorded based on the differences between the financial statement and tax bases of assets and liabilities and the tax rates in effect when these differences are expected to reverse. Deferred tax assets are reduced by a valuation allowance if, based on the weight of available evidence, it is more likely than not that some or all of the deferred tax assets will not be realized. As of December 31, 2021 and 2020, the Company had a full valuation allowance against its deferred tax assets.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company is subject to the provisions of ASC 740,&#160;Income Taxes, which prescribes a more likely-than-not threshold for the financial statement recognition of uncertain tax positions. ASC 740 clarifies the accounting for income taxes by prescribing a minimum recognition threshold and measurement attribute for the financial statement recognition and measurement of a tax position taken or expected to be taken in a tax return. There are currently no open federal or state tax audits. The Company has not recorded any liability for uncertain tax positions at December&#160;31, 2021 or December&#160;31, 2020.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recent Accounting Pronouncements</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;">(k)&#160;Recent Accounting Pronouncements</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In December&#160;2019, the FASB issued ASU No.&#160;2019-12,&#160;Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes. The amendments in ASU 2019-12 simplify the accounting for income taxes by removing certain exceptions to the general principles in Topic 740 and clarifying and amending existing guidance. The new standard is effective for fiscal&#160;years, and interim periods within those fiscal&#160;years, beginning after December&#160;15, 2020, with early adoption permitted. The adoption of this standard did not have an impact on the Company&#8217;s financial statements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="white-space:pre-wrap;">In November 2021, the FASB issued ASU No. 2021-10, Government Assistance (Topic 832): Disclosures by Business Entities about Government Assistance. The amendments in ASU 2021-10 require annual disclosures about transactions with a government that are accounted for by applying a grant or contribution accounting model by analogy.  The new disclosure requirements include information about the nature of the transactions and the related accounting policy used to account for the transactions; the line items on the balance sheet and income statement that are affected by the transactions, and the amounts applicable to each financial statement line item; and significant terms and conditions of the transactions, including commitments and contingencies.  The guidance is effective for fiscal years beginning after </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="white-space:pre-wrap;">December 15, 2021, with early adoption permitted, and may be adopted prospectively or retrospectively.  The Company does not believe the adoption of this standard will have a significant impact on its financial statements.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_anvs_GrantIncomePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for grant income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">anvs_GrantIncomePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>anvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_anvs_IssuanceCostsAssociatedWithEquityIssuancesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for issuance costs associated with equity issuances.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">anvs_IssuanceCostsAssociatedWithEquityIssuancesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>anvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccounting">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI http://asc.fasb.org/topic&amp;trid=2122369<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccounting</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4273-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueOfFinancialInstrumentsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for determining the fair value of financial instruments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 60<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=7493716&amp;loc=d3e21868-110260<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13279-108611<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueOfFinancialInstrumentsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e32247-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32847-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32840-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL116659661-227067<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e32280-109318<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32809-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchDevelopmentAndComputerSoftwarePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for its research and development and computer software activities including the accounting treatment for costs incurred for (1) research and development activities, (2) development of computer software for internal use, (3) computer software to be sold, leased or otherwise marketed as a separate product or as part of a product or process and (4) in-process research and development acquired in a purchase business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 50<br> -Section 25<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=16397303&amp;loc=d3e19347-109286<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 40<br> -Section 30<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=118172244&amp;loc=d3e17916-109280<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.15)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchDevelopmentAndComputerSoftwarePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b),(f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6191-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6161-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6143-108592<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6061-108592<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6132-108592<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140032793875960">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Measurements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock', window );">Schedule of carrying value and fair value of financial assets and liabilities measured at fair value on a recurring basis</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:45.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.02%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.82%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.61%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.6%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:45.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:36.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Fair Value Measurement at </b></p></td></tr><tr><td style="vertical-align:bottom;width:45.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:36.21%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;2021</b></p></td></tr><tr><td style="vertical-align:bottom;width:45.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Carrying Value</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Level 1</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Level 2</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Level 3</b></p></td></tr><tr><td style="vertical-align:bottom;width:45.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Cash and cash equivalents</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 45,686,014</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 45,686,014</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:45.56%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.97%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.74%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.96%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.93%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:45.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:36.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;white-space:pre-wrap;">Fair Value Measurement at  </b></p></td></tr><tr><td style="vertical-align:bottom;width:45.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:36.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;2020</b></p></td></tr><tr><td style="vertical-align:bottom;width:45.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Carrying Value</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Level 1</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Level 2</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Level 3</b></p></td></tr><tr><td style="vertical-align:bottom;width:45.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Cash and cash equivalents</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 8,074,658</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 8,074,658</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140032793995432">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Prepaid Expenses and Other Current Assets (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract', window );"><strong>Prepaid Expenses and Other Current Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock', window );">Schedule of prepaid expenses and other current assets</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:74.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:74.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:23.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">As of December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:74.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.95%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td></tr><tr><td style="vertical-align:bottom;width:74.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Prepaid clinical trial expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 232,752</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:74.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Prepaid insurance</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 29,111</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 26,542</p></td></tr><tr><td style="vertical-align:bottom;width:74.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Prepaid expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 43,736</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 11,690</p></td></tr><tr><td style="vertical-align:bottom;width:74.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Security deposits</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 9,865</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 6,444</p></td></tr><tr><td style="vertical-align:bottom;width:74.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.78%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 315,464</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.49%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 44,676</p></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the amounts paid in advance for capitalized costs that will be expensed with the passage of time or the occurrence of a triggering event, and will be charged against earnings within one year or the normal operating cycle, if longer; the aggregate carrying amount of current assets, not separately presented elsewhere in the balance sheet; and other deferred costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140032793851304">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accrued Expenses (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract', window );"><strong>Accrued Expenses</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock', window );">Schedule of accrued expenses</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:73.83%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.8%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:73.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:24.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">As of December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2020</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Payroll and related benefits</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 712,768</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 16,493</p></td></tr><tr><td style="vertical-align:bottom;width:73.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Accrued professional and clinical fees</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 105,672</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 216,198</p></td></tr><tr><td style="vertical-align:bottom;width:73.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Accrued license payments</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.8%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.86%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3,833</p></td></tr><tr><td style="vertical-align:bottom;width:73.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.8%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 818,440</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.86%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 236,524</p></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of accrued liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140032873753256">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Stock-Based Compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock', window );">Schedule of stock-based compensation expense</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Stock-based compensation expense in the statements of operations, including the fair value of stock awards to consultants and advisors for services rendered, for the&#160;years ended December 31, 2021 and 2020 was as follows:</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:73%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:24.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Year Ended </b></p></td></tr><tr><td style="vertical-align:bottom;width:73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:24.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.85%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.95%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2020</b></p></td></tr><tr><td style="vertical-align:bottom;width:73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Research and development</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,016,745</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 138,704</p></td></tr><tr><td style="vertical-align:bottom;width:73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">General and administrative</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,680,882</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,726,209</p></td></tr><tr><td style="vertical-align:bottom;width:73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 4,697,627</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,864,913</p></td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Schedule of stock option activity</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:54.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.63%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.52%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.43%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:54.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Weighted</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:54.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Average</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:54.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Remaining</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:54.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Weighted</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Contractual</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Aggregate</b></p></td></tr><tr><td style="vertical-align:bottom;width:54.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Number of</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Average</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Term</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Intrinsic</b></p></td></tr><tr><td style="vertical-align:bottom;width:54.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Shares</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Exercise Price</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">(Years)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Value</b></p></td></tr><tr><td style="vertical-align:bottom;width:54.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Outstanding at December&#160;31,&#160;2019</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 352,282</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">$ 0.19</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:54.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Granted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 810,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3.46</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:54.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Exercised</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (48,435)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 0.19</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:54.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Forfeited</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (2,381)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 0.14</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:54.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Outstanding at December&#160;31,&#160;2020</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,111,466</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2.57</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:54.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Granted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 538,095</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 33.78</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:54.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Exercised</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (159,813)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2.83</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:54.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Outstanding at December&#160;31,&#160;2021</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,489,748</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 13.82</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="-sec-ix-hidden:Hidden_EQY9UVLtMU6NuqPU1k6Bhg;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> 8.4</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">$ 14,325,377</p></td></tr><tr><td style="vertical-align:bottom;width:54.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Exercisable at December&#160;31,&#160;2021</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,105,568</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 5.87</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="-sec-ix-hidden:Hidden_LZM2INVDtkezbYWBS4I2FA;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> 7.9</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">$ 14,325,377</p></td></tr></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Schedule of weighted average assumptions used to determine fair value of options</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:58.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:16.66%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:16.66%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:58.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year Ended </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year Ended </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:58.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:58.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Risk-free interest rate</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1.17</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 0.38</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:58.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Expected life</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="-sec-ix-hidden:Hidden_HsUzDjUJtkSAIzhEqWrcUA;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> 5.3</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 5.0</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:58.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Expected volatility</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 113</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 80</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:58.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Expected dividend yield</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=122041274&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140032794677064">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss Per Share (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Net Loss Per Share</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock', window );">Schedule of basic and diluted net loss per share</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:66.67%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.96%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.67%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:66.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;"> </b><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:31.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year Ended </b></p></td></tr><tr><td style="vertical-align:bottom;width:66.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:31.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:66.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td></tr><tr><td style="vertical-align:bottom;width:66.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Numerator</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:66.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Net loss</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.96%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (14,487,132)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.67%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (5,462,047)</p></td></tr><tr><td style="vertical-align:bottom;width:66.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Denominator</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:66.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Weighted-average common shares outstanding, basic and diluted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 7,626,278</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 6,308,961</p></td></tr><tr><td style="vertical-align:bottom;width:66.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Net loss per share, basic and diluted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (1.90)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (0.87)</p></td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock', window );">Schedule of shares excluded from the computation of diluted weighted-average shares outstanding</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:74.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.71%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.71%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:74.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:25.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:74.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.71%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.71%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td></tr><tr><td style="vertical-align:bottom;width:74.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Stock options</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,489,748</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,111,466</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:74.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Warrants</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,400</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 100,000</p></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140032873946232">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Taxes</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock', window );">Reconciliation of income tax provision (benefit) computed at the statutory federal income tax rate to income taxes as reflected in the financial statements</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:75.45%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.38%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.43%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.38%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:75.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;"> </b><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:20.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year Ended </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:75.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:20.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:75.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:75.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Federal income tax benefit at statutory rate</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 21.0</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 21.0</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:75.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">State and local tax, net of federal benefit</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 13.7</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 7.6</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:75.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Permanent differences</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 0.1</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (0.8)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:75.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Research and development credit</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2.4</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1.9</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:75.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Stock-based compensation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 15.7</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:75.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Change in valuation allowance</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (52.9)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (29.7)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:75.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Effective income tax rate</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.38%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 0.0</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.38%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 0.0</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock', window );">Schedule of significant components of deferred tax assets</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:66.67%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.96%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.67%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:66.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;"> </b><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:31.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">As&#160;of&#160;December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:66.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td></tr><tr><td style="vertical-align:bottom;width:66.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Net operating loss carryforwards</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 6,512,249</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,460,773</p></td></tr><tr><td style="vertical-align:bottom;width:66.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Capitalized research and development</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,002,431</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:66.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Stock-based compensation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,759,129</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 547,628</p></td></tr><tr><td style="vertical-align:bottom;width:66.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Research and development tax credit carryforwards</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 648,077</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.67%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 241,414</p></td></tr><tr><td style="vertical-align:bottom;width:66.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total deferred tax assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 10,921,886</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3,249,815</p></td></tr><tr><td style="vertical-align:bottom;width:66.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Less valuation allowance</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (10,921,886)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.67%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (3,249,815)</p></td></tr><tr><td style="vertical-align:bottom;width:66.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Net deferred taxes</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.96%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.67%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140032790507192">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Nature of Business and Liquidity (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>May 26, 2021</div></th>
<th class="th"><div>Jan. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_anvs_NatureOfBusinessAndLiquidityAbstract', window );"><strong>Nature of Business and Liquidity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Gross proceeds from issuance of common shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 46,648,413<span></span>
</td>
<td class="nump">$ 12,034,406<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=anvs_UnderwritersWarrantsMember', window );">Underwriters warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_anvs_NatureOfBusinessAndLiquidityAbstract', window );"><strong>Nature of Business and Liquidity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Number of warrants issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7.50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_anvs_PercentageOfExercisePriceToShareOfferingPrice', window );">Percentage of exercise price to the share offering price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">125.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_anvs_NatureOfBusinessAndLiquidityAbstract', window );"><strong>Nature of Business and Liquidity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000,000<span></span>
</td>
<td class="nump">2,300,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_anvs_StockIssuedDuringPeriodSharesConversionOfConvertibleSecuritiesPreferredStock', window );">Number of shares issued for the conversion of redeemable convertible preferred stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,117,089<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_anvs_StockIssuedDuringPeriodSharesConversionOfConvertibleNotes', window );">Number of common shares issued upon conversion of notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">118,470<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock | IPO</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_anvs_NatureOfBusinessAndLiquidityAbstract', window );"><strong>Nature of Business and Liquidity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Share price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Gross proceeds from issuance of common shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 13,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction', window );">Net proceeds from issuance of common shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 12,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_anvs_StockIssuedDuringPeriodSharesConversionOfConvertibleSecuritiesPreferredStock', window );">Number of shares issued for the conversion of redeemable convertible preferred stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,117,089<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_anvs_StockIssuedDuringPeriodSharesConversionOfConvertibleNotes', window );">Number of common shares issued upon conversion of notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">118,470<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock | Secondary Public Offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_anvs_NatureOfBusinessAndLiquidityAbstract', window );"><strong>Nature of Business and Liquidity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock</a></td>
<td class="nump">1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Share price</a></td>
<td class="nump">$ 50.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Gross proceeds from issuance of common shares</a></td>
<td class="nump">$ 50,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction', window );">Net proceeds from issuance of common shares</a></td>
<td class="nump">$ 46,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_anvs_NatureOfBusinessAndLiquidityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">anvs_NatureOfBusinessAndLiquidityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>anvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_anvs_PercentageOfExercisePriceToShareOfferingPrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of exercise price to the share offering price.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">anvs_PercentageOfExercisePriceToShareOfferingPrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>anvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_anvs_StockIssuedDuringPeriodSharesConversionOfConvertibleNotes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of the conversion of convertible notes.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">anvs_StockIssuedDuringPeriodSharesConversionOfConvertibleNotes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>anvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_anvs_StockIssuedDuringPeriodSharesConversionOfConvertibleSecuritiesPreferredStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of the conversion of convertible preferred stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">anvs_StockIssuedDuringPeriodSharesConversionOfConvertibleSecuritiesPreferredStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>anvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash received on stock transaction after deduction of issuance costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockConsiderationReceivedOnTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Price of a single share of a number of saleable stocks of a company.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=anvs_UnderwritersWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=anvs_UnderwritersWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=anvs_SecondaryPublicOfferingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=anvs_SecondaryPublicOfferingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140032790823960">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value Measurements (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents, Carrying Value</a></td>
<td class="nump">$ 45,686,014<span></span>
</td>
<td class="nump">$ 8,074,658<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents, Carrying Value</a></td>
<td class="nump">45,686,014<span></span>
</td>
<td class="nump">8,074,658<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring | Level 1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash and cash equivalents, Fair Value</a></td>
<td class="nump">$ 45,686,014<span></span>
</td>
<td class="nump">$ 8,074,658<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140032794227208">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Grant Income (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Grant Income</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_anvs_IncomeFromGrants', window );">Grant income</a></td>
<td class="nump">$ 36,754<span></span>
</td>
<td class="nump">$ 1,157,449<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_anvs_UnreimbursedEligibleCostsIncurredDuringPeriod', window );">Unreimbursed, eligible costs incurred under the grant</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_anvs_GrantAwardRemainingAmountAvailable', window );">Remining funds available</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=anvs_NationalInstituteOnAgingOfNationalInstitutesOfHealthMember', window );">NIH</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Grant Income</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_anvs_GrantsReceivableNoticeOfAwardAmount', window );">Notice of Award, grant amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,900,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_anvs_IncomeFromGrants', window );">Grant income</a></td>
<td class="nump">36,754<span></span>
</td>
<td class="nump">1,157,449<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_anvs_ProceedsFromGrants', window );">Proceeds from Grants</a></td>
<td class="nump">36,754<span></span>
</td>
<td class="nump">1,892,524<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GrantsReceivableCurrent', window );">Grant receivable</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_anvs_GrantAwardRemainingAmountAvailable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The remining balance of funds available under a grant award.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">anvs_GrantAwardRemainingAmountAvailable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>anvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_anvs_GrantsReceivableNoticeOfAwardAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of grant awarded.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">anvs_GrantsReceivableNoticeOfAwardAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>anvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_anvs_IncomeFromGrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Income from non-repayable sum of money awarded to an entity to carry out a specific purpose as provided in grant agreements. Outside the scope of Topic 606.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">anvs_IncomeFromGrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>anvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_anvs_ProceedsFromGrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from grants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">anvs_ProceedsFromGrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>anvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_anvs_UnreimbursedEligibleCostsIncurredDuringPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of unreimbursed eligible costs incurred during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">anvs_UnreimbursedEligibleCostsIncurredDuringPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>anvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GrantsReceivableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of amounts due under the terms of governmental, corporate, or foundation grants. For classified balance sheets, represents the current amount receivable, that is amounts expected to be collected within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.8)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GrantsReceivableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=anvs_NationalInstituteOnAgingOfNationalInstitutesOfHealthMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=anvs_NationalInstituteOnAgingOfNationalInstitutesOfHealthMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140032788697688">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Prepaid Expenses and Other Current Assets (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract', window );"><strong>Prepaid Expenses and Other Current Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_anvs_PrepaidResearchAndDevelopmentExpenseCurrent', window );">Prepaid clinical trial expenses</a></td>
<td class="nump">$ 232,752<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidInsurance', window );">Prepaid insurance</a></td>
<td class="nump">29,111<span></span>
</td>
<td class="nump">$ 26,542<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherPrepaidExpenseCurrent', window );">Prepaid expenses</a></td>
<td class="nump">43,736<span></span>
</td>
<td class="nump">11,690<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SecurityDeposit', window );">Security deposit</a></td>
<td class="nump">9,865<span></span>
</td>
<td class="nump">6,444<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_anvs_PrepaidExpenseSecurityDepositsAndOtherAssetsCurrent', window );">Total prepaid expenses and other current assets</a></td>
<td class="nump">$ 315,464<span></span>
</td>
<td class="nump">$ 44,676<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_anvs_PrepaidExpenseSecurityDepositsAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer. Includes security deposits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">anvs_PrepaidExpenseSecurityDepositsAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>anvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_anvs_PrepaidResearchAndDevelopmentExpenseCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for research and development expense that provides economic benefits within a future period of one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">anvs_PrepaidResearchAndDevelopmentExpenseCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>anvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherPrepaidExpenseCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for other costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6387103&amp;loc=d3e6435-108320<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6787-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherPrepaidExpenseCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidInsurance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for insurance that provides economic benefits within a future period of one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6387103&amp;loc=d3e6435-108320<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 10<br> -Section 05<br> -Paragraph 5<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123349782&amp;loc=d3e5879-108316<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (g)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6787-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidInsurance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SecurityDeposit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of an asset, typically cash, provided to a counterparty to provide certain assurance of performance by the entity pursuant to the terms of a written or oral agreement, such as a lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.8,17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SecurityDeposit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140032794184344">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Accrued Expenses (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract', window );"><strong>Accrued Expenses</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeRelatedLiabilitiesCurrent', window );">Payroll and related benefits</a></td>
<td class="nump">$ 712,768<span></span>
</td>
<td class="nump">$ 16,493<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedProfessionalFeesCurrent', window );">Accrued professional and clinical fees</a></td>
<td class="nump">105,672<span></span>
</td>
<td class="nump">216,198<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_anvs_AccruedLicensePaymentsCurrent', window );">Accrued license payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,833<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_anvs_AccruedLiabilitiesAndInterestAndEmployeeRelatedLiabilitiesCurrent', window );">Total accrued expenses</a></td>
<td class="nump">$ 818,440<span></span>
</td>
<td class="nump">$ 236,524<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_anvs_AccruedLiabilitiesAndInterestAndEmployeeRelatedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Includes accrued interest and obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">anvs_AccruedLiabilitiesAndInterestAndEmployeeRelatedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>anvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_anvs_AccruedLicensePaymentsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for accrued license payments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">anvs_AccruedLicensePaymentsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>anvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedProfessionalFeesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6911-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6935-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedProfessionalFeesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeRelatedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeRelatedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140032788803064">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Convertible Promissory Notes (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jan. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Mar. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Convertible Promissory Notes</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentUnamortizedDiscount', window );">Debt discount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 26,500<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Convertible Promissory Notes</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_anvs_StockIssuedDuringPeriodSharesConversionOfConvertibleNotes', window );">Number of common shares issued upon conversion of notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">118,470<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock | IPO</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Convertible Promissory Notes</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_anvs_StockIssuedDuringPeriodSharesConversionOfConvertibleNotes', window );">Number of common shares issued upon conversion of notes</a></td>
<td class="nump">118,470<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_anvs_ConversionOfConvertibleSecuritiesConvertiblePromissoryNotesPercentageOfDiscountToInitialPublicOfferingPrice', window );">Percentage of discount to the initial offering price of shares issued in the IPO</a></td>
<td class="nump">20.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleDebtMember', window );">Convertible promissory notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Convertible Promissory Notes</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Aggregate principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 530,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredFinanceCostsGross', window );">Debt issuance costs incurred</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8,622<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage', window );">Effective interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9.80%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestPaidNet', window );">Cash payments for interest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_anvs_ConversionOfConvertibleSecuritiesConvertiblePromissoryNotesPercentageOfDiscountToInitialPublicOfferingPrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>In the conversion of promissory notes to common shares, the percentage discount to the initial offering price of shares issued in the IPO.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">anvs_ConversionOfConvertibleSecuritiesConvertiblePromissoryNotesPercentageOfDiscountToInitialPublicOfferingPrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>anvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_anvs_StockIssuedDuringPeriodSharesConversionOfConvertibleNotes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of the conversion of convertible notes.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">anvs_StockIssuedDuringPeriodSharesConversionOfConvertibleNotes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>anvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28551-108399<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=114775985&amp;loc=d3e28878-108400<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124429444&amp;loc=SL124452920-239629<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69C<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495737-112612<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69B<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495735-112612<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Effective interest rate for the funds borrowed under the debt agreement considering interest compounding and original issue discount or premium.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6036836-161870<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28551-108399<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124429444&amp;loc=SL124452920-239629<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateEffectivePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentUnamortizedDiscount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated amortization, of debt discount.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1A<br> -URI http://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28541-108399<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=114775985&amp;loc=d3e28878-108400<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495340-112611<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentUnamortizedDiscount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredFinanceCostsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before accumulated amortization, of debt issuance costs. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28555-108399<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredFinanceCostsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4297-108586<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 17<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3367-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleDebtMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleDebtMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140032793752248">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies - Leases (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseCostAbstract', window );"><strong>Leases</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseExpense', window );">Rental expense</a></td>
<td class="nump">$ 51,760<span></span>
</td>
<td class="nump">$ 41,603<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCostAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCostAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of operating lease expense. Excludes sublease income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918638-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140032788869160">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies - License Agreement (Details)<br></strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>May 31, 2012 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherCommitmentsLineItems', window );"><strong>Commitments and Contingencies</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_anvs_AccruedLicensePaymentsCurrent', window );">Accrued license payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,833<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=anvs_LicenseAgreementTermsAmendedMay2012Member', window );">Amended License Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherCommitmentsLineItems', window );"><strong>Commitments and Contingencies</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_anvs_LicenseAgreementMinimumAnnualCommitment', window );">Minimum annual commitment</a></td>
<td class="nump">$ 46,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_anvs_CumulativeNumberOfMilestonesAchieved', window );">Number of milestones achieved</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_anvs_LicenseAgreementPeriodOfAdvanceNoticeOfTermination', window );">Period for advance notice of termination</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">90 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_anvs_AccruedLicensePaymentsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for accrued license payments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">anvs_AccruedLicensePaymentsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>anvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_anvs_CumulativeNumberOfMilestonesAchieved">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative number of milestones achieved.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">anvs_CumulativeNumberOfMilestonesAchieved</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>anvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_anvs_LicenseAgreementMinimumAnnualCommitment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The minimum amount of annual commitment under the terms of a license agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">anvs_LicenseAgreementMinimumAnnualCommitment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>anvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_anvs_LicenseAgreementPeriodOfAdvanceNoticeOfTermination">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The period of advance notice required to terminate the license agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">anvs_LicenseAgreementPeriodOfAdvanceNoticeOfTermination</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>anvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherCommitmentsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherCommitmentsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=anvs_LicenseAgreementTermsAmendedMay2012Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=anvs_LicenseAgreementTermsAmendedMay2012Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140032788515752">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies - Employment Agreements (Details)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($) </div>
<div>lawsuit</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingencyInformationAboutLitigationMattersAbstract', window );"><strong>Litigation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingencyNewClaimsFiledNumber', window );">Number of new claims filed | lawsuit</a></td>
<td class="nump">2<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=srt_ExecutiveOfficerMember', window );">Executive Officers</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredCompensationArrangementsAbstract', window );"><strong>Employment Agreements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_anvs_MaximumAggregateSeverancePayments', window );">Maximum aggregate severance payments | $</a></td>
<td class="nump">$ 930,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_anvs_MaximumAggregateSeverancePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum aggregate severance payments payable to executive officers under the terms of employment agreements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">anvs_MaximumAggregateSeverancePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>anvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCompensationArrangementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCompensationArrangementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingencyInformationAboutLitigationMattersAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingencyInformationAboutLitigationMattersAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingencyNewClaimsFiledNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The total number of new claims filed pertaining to a loss contingency during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14435-108349<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingencyNewClaimsFiledNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=srt_ExecutiveOfficerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=srt_ExecutiveOfficerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140032790512648">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Redeemable Convertible Preferred Stock and Stockholders' Equity - Common and Preferred Stock (Details)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Jan. 31, 2020 </div>
<div>item </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>Vote </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>$ / shares </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Redeemable Convertible Preferred Stock and Stockholders' Equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_anvs_NumberOfClassesOfStockDesignated', window );">Number of classes of stock designated | item</a></td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_anvs_CommonStockAndPreferredStockSharesAuthorized', window );">Number of common and preferred shares authorized</a></td>
<td class="nump">37,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (dollars per share) | $ / shares</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value (dollars per share) | $ / shares</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Number of common shares authorized</a></td>
<td class="nump">35,000,000<span></span>
</td>
<td class="nump">35,000,000<span></span>
</td>
<td class="nump">35,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Number of preferred shares authorized</a></td>
<td class="nump">2,000,000<span></span>
</td>
<td class="nump">2,000,000<span></span>
</td>
<td class="nump">2,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_anvs_NumberOfVotesForEachShareOfCommonStock', window );">Number of vote for each share of common stock | Vote</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=anvs_SeriesaRedeemableConvertiblePreferredStockMember', window );">Series A Redeemable convertible preferred stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Redeemable Convertible Preferred Stock and Stockholders' Equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_anvs_TemporaryEquitySharesConversionOfPreferredStockToCommonStock', window );">Conversion of redeemable convertible preferred stock to common stock, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,133,159<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=anvs_SeriesaRedeemableConvertiblePreferredStockMember', window );">Series A Redeemable convertible preferred stock | IPO</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Redeemable Convertible Preferred Stock and Stockholders' Equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_anvs_TemporaryEquitySharesConversionOfPreferredStockToCommonStock', window );">Conversion of redeemable convertible preferred stock to common stock, shares</a></td>
<td class="nump">5,133,159<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_anvs_RedeemableConvertiblePreferredStockConvertibleConversionPrice', window );">Conversion price | $ / shares</a></td>
<td class="nump">$ 0.70<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=anvs_Series1RedeemableConvertiblePreferredStockMember', window );">Series A-1 Redeemable convertible preferred stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Redeemable Convertible Preferred Stock and Stockholders' Equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_anvs_TemporaryEquitySharesConversionOfPreferredStockToCommonStock', window );">Conversion of redeemable convertible preferred stock to common stock, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">630,722<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=anvs_Series1RedeemableConvertiblePreferredStockMember', window );">Series A-1 Redeemable convertible preferred stock | IPO</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Redeemable Convertible Preferred Stock and Stockholders' Equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_anvs_TemporaryEquitySharesConversionOfPreferredStockToCommonStock', window );">Conversion of redeemable convertible preferred stock to common stock, shares</a></td>
<td class="nump">630,722<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_anvs_RedeemableConvertiblePreferredStockConvertibleConversionPrice', window );">Conversion price | $ / shares</a></td>
<td class="nump">$ 1.26<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Redeemable Convertible Preferred Stock and Stockholders' Equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000,000<span></span>
</td>
<td class="nump">2,300,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_anvs_StockIssuedDuringPeriodSharesConversionOfConvertibleSecuritiesPreferredStock', window );">Number of shares issued for the conversion of redeemable convertible preferred stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,117,089<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock | IPO</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Redeemable Convertible Preferred Stock and Stockholders' Equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock</a></td>
<td class="nump">2,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_anvs_StockIssuedDuringPeriodSharesConversionOfConvertibleSecuritiesPreferredStock', window );">Number of shares issued for the conversion of redeemable convertible preferred stock</a></td>
<td class="nump">4,117,089<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_anvs_CommonStockAndPreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">anvs_CommonStockAndPreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>anvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_anvs_NumberOfClassesOfStockDesignated">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of classes of stock designated.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">anvs_NumberOfClassesOfStockDesignated</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>anvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_anvs_NumberOfVotesForEachShareOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of vote for each share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">anvs_NumberOfVotesForEachShareOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>anvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_anvs_RedeemableConvertiblePreferredStockConvertibleConversionPrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The price per share of the conversion price of redeemable convertible preferred stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">anvs_RedeemableConvertiblePreferredStockConvertibleConversionPrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>anvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_anvs_StockIssuedDuringPeriodSharesConversionOfConvertibleSecuritiesPreferredStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of the conversion of convertible preferred stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">anvs_StockIssuedDuringPeriodSharesConversionOfConvertibleSecuritiesPreferredStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>anvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_anvs_TemporaryEquitySharesConversionOfPreferredStockToCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Conversion of redeemable convertible preferred stock to common stock, shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">anvs_TemporaryEquitySharesConversionOfPreferredStockToCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>anvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=anvs_SeriesaRedeemableConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=anvs_SeriesaRedeemableConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=anvs_Series1RedeemableConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=anvs_Series1RedeemableConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140032794225800">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Redeemable Convertible Preferred Stock and Stockholders' Equity - Warrants (Details) - Underwriters warrants - $ / shares<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Jan. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Warrants</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Number of warrants issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7.50<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_anvs_PercentageOfExercisePriceToShareOfferingPrice', window );">Percentage of exercise price to the share offering price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">125.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingTerm', window );">Warrant term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_anvs_ConversionOfWarrantsNumberOfWarrantsConverted', window );">Number of warrants converted in a non-cash transaction</a></td>
<td class="nump">97,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants outstanding</a></td>
<td class="nump">2,400<span></span>
</td>
<td class="nump">100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_anvs_ConversionOfWarrantsNumberOfWarrantsConverted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of warrants converted in a noncash (or part noncash) transaction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">anvs_ConversionOfWarrantsNumberOfWarrantsConverted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>anvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_anvs_PercentageOfExercisePriceToShareOfferingPrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of exercise price to the share offering price.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">anvs_PercentageOfExercisePriceToShareOfferingPrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>anvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstandingTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period between issuance and expiration of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstandingTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=anvs_UnderwritersWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=anvs_UnderwritersWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140032788331960">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Summary of plans (Details) - shares<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Jun. 01, 2021</div></th>
<th class="th"><div>May 31, 2021</div></th>
<th class="th"><div>Jan. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Stock-Based Compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Options outstanding</a></td>
<td class="nump">1,489,748<span></span>
</td>
<td class="nump">1,111,466<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">352,282<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Stock Options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Stock-Based Compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod', window );">Term of award</a></td>
<td class="text">10 years<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=anvs_EquityIncentivePlan2019Member', window );">2019 Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Stock-Based Compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Shares authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,000,000<span></span>
</td>
<td class="nump">1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Shares available for future grants</a></td>
<td class="nump">630,569<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=anvs_EquityIncentivePlan2019Member', window );">2019 Plan | Stock Options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Stock-Based Compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod', window );">Term of award</a></td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=anvs_EquityIncentivePlan2018Member', window );">2018 Plan | Stock Options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Stock-Based Compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Shares available for future grants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares authorized for issuance under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=anvs_EquityIncentivePlan2019Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=anvs_EquityIncentivePlan2019Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=anvs_EquityIncentivePlan2018Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=anvs_EquityIncentivePlan2018Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140032790401896">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Share-based compensation expense (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Stock-Based Compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation expense</a></td>
<td class="nump">$ 4,697,627<span></span>
</td>
<td class="nump">$ 1,864,913<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Stock-Based Compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation expense</a></td>
<td class="nump">2,016,745<span></span>
</td>
<td class="nump">138,704<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember', window );">General and administrative</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Stock-Based Compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation expense</a></td>
<td class="nump">$ 2,680,882<span></span>
</td>
<td class="nump">$ 1,726,209<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140032790735880">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Stock option activity (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward', window );"><strong>Number of Shares</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Outstanding at beginning of the period</a></td>
<td class="nump">1,111,466<span></span>
</td>
<td class="nump">352,282<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Granted</a></td>
<td class="nump">538,095<span></span>
</td>
<td class="nump">810,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercised</a></td>
<td class="num">(159,813)<span></span>
</td>
<td class="num">(48,435)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Forfeited</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2,381)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Outstanding at end of the period</a></td>
<td class="nump">1,489,748<span></span>
</td>
<td class="nump">1,111,466<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Exercisable at end of period</a></td>
<td class="nump">1,105,568<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward', window );"><strong>Weighted Average Exercise Price</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Outstanding at beginning of the period (in dollars per share)</a></td>
<td class="nump">$ 2.57<span></span>
</td>
<td class="nump">$ 0.19<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Granted (in dollars per share)</a></td>
<td class="nump">33.78<span></span>
</td>
<td class="nump">3.46<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Exercised (in dollars per share)</a></td>
<td class="nump">2.83<span></span>
</td>
<td class="nump">0.19<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice', window );">Forfeited (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.14<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Outstanding at end of the period (in dollars per share)</a></td>
<td class="nump">13.82<span></span>
</td>
<td class="nump">$ 2.57<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Exercisable at end of period (in dollars per share)</a></td>
<td class="nump">$ 5.87<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_anvs_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract', window );"><strong>Weighted Average Remaining Contractual Term</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Outstanding at end of the period (in years)</a></td>
<td class="text">8 years 4 months 24 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Exercisable at end of period (in years)</a></td>
<td class="text">7 years 10 months 24 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Aggregate intrinsic value of options outstanding</a></td>
<td class="nump">$ 14,325,377<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1', window );">Aggregate intrinsic value of options exercisable</a></td>
<td class="nump">$ 14,325,377<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_anvs_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">anvs_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>anvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140032790234040">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Additional disclosures (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Stock-Based Compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue', window );">Aggregate intrinsic value of options exercised</a></td>
<td class="nump">$ 11,163,998<span></span>
</td>
<td class="nump">$ 196,976<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Options granted</a></td>
<td class="nump">538,095<span></span>
</td>
<td class="nump">810,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted average grant date fair value</a></td>
<td class="nump">$ 27.13<span></span>
</td>
<td class="nump">$ 2.19<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares', window );">Unvested awards outstanding</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GranteeStatusAxis=us-gaap_ShareBasedPaymentArrangementNonemployeeMember', window );">Consultants and advisors</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Stock-Based Compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices', window );">Number of shares issued to consultants and advisors</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">25,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions', window );">Unrecognized compensation expense</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted average grant date fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4.91<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_anvs_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedInPeriodFairValue', window );">Fair value of stock awards granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 122,750<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardDateAxis=anvs_AwardsGrantedIn2020Member', window );">Awards granted in 2020 | Vests one year from grant date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Stock-Based Compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber', window );">Vested options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Stock Options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Stock-Based Compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions', window );">Unrecognized compensation expense</a></td>
<td class="nump">$ 9,933,691<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Weighted-average recognition period</a></td>
<td class="text">1 year 3 months 18 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod', window );">Term of award</a></td>
<td class="text">10 years<span></span>
</td>
<td class="text">10 years<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract', window );"><strong>Estimated fair value of options</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="nump">1.17%<span></span>
</td>
<td class="nump">0.38%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected life</a></td>
<td class="text">5 years 3 months 18 days<span></span>
</td>
<td class="text">5 years<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility</a></td>
<td class="nump">113.00%<span></span>
</td>
<td class="nump">80.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Expected dividend yield</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Stock Options | Awards granted in 2021 | Immediate Vesting</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Stock-Based Compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber', window );">Vested options</a></td>
<td class="nump">143,391<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Stock Options | Awards granted in 2021 | Vests one year from grant date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Stock-Based Compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber', window );">Vested options</a></td>
<td class="nump">155,253<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Stock Options | Awards granted in 2021 | Vests two years from grant date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Stock-Based Compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber', window );">Vested options</a></td>
<td class="nump">155,251<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Stock Options | Awards granted in 2021 | Vests in equal Quarterly installments over two years</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Stock-Based Compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber', window );">Vested options</a></td>
<td class="nump">84,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period</a></td>
<td class="text">2 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Stock Options | Awards granted in 2020 | Vests one year from grant date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Stock-Based Compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_anvs_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedInPeriodFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of share-based awards granted.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">anvs_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedInPeriodFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>anvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cost to be recognized for option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=122041274&amp;loc=d3e301413-122809<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of non-vested options outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued in lieu of cash for services contributed to the entity. Number of shares includes, but is not limited to, shares issued for services contributed by vendors and founders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesIssuedForServices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GranteeStatusAxis=us-gaap_ShareBasedPaymentArrangementNonemployeeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GranteeStatusAxis=us-gaap_ShareBasedPaymentArrangementNonemployeeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardDateAxis=anvs_AwardsGrantedIn2020Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardDateAxis=anvs_AwardsGrantedIn2020Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VestingAxis=anvs_ShareBasedPaymentArrangementVestingPeriodOneYearMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VestingAxis=anvs_ShareBasedPaymentArrangementVestingPeriodOneYearMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardDateAxis=anvs_AwardsGrantedIn2021Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardDateAxis=anvs_AwardsGrantedIn2021Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VestingAxis=anvs_ShareBasedPaymentArrangementVestingPeriodImmediateVestingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VestingAxis=anvs_ShareBasedPaymentArrangementVestingPeriodImmediateVestingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VestingAxis=anvs_ShareBasedPaymentArrangementVestingPeriodTwoYearsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VestingAxis=anvs_ShareBasedPaymentArrangementVestingPeriodTwoYearsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VestingAxis=anvs_ShareBasedPaymentArrangementVestingPeriodEqualQuarterlyInstallmentsOverTwoYearsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VestingAxis=anvs_ShareBasedPaymentArrangementVestingPeriodEqualQuarterlyInstallmentsOverTwoYearsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140032790401176">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss Per Share - Basic and diluted net loss per share (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_anvs_EarningsPerShareBasicAndDilutedNumeratorAbstract', window );"><strong>Numerator</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (14,487,132)<span></span>
</td>
<td class="num">$ (5,462,047)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_anvs_EarningsPerShareBasicAndDilutedDenominatorAbstract', window );"><strong>Denominator</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted-average common shares outstanding, basic</a></td>
<td class="nump">7,626,278<span></span>
</td>
<td class="nump">6,308,961<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted-average common shares outstanding, diluted</a></td>
<td class="nump">7,626,278<span></span>
</td>
<td class="nump">6,308,961<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Net loss per share, basic</a></td>
<td class="num">$ (1.90)<span></span>
</td>
<td class="num">$ (0.87)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Net loss per share, diluted</a></td>
<td class="num">$ (1.90)<span></span>
</td>
<td class="num">$ (0.87)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_anvs_EarningsPerShareBasicAndDilutedDenominatorAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">anvs_EarningsPerShareBasicAndDilutedDenominatorAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>anvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_anvs_EarningsPerShareBasicAndDilutedNumeratorAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">anvs_EarningsPerShareBasicAndDilutedNumeratorAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>anvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1448-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1337-109256<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e4984-109258<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e3842-109258<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1252-109256<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e4984-109258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e3842-109258<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1252-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1337-109256<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1448-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140032794618920">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss Per Share - Potential shares excluded from calculation (Details) - shares<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember', window );">Stock Options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Net Loss Per Share</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded from computation of earnings per share</a></td>
<td class="nump">1,489,748<span></span>
</td>
<td class="nump">1,111,466<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember', window );">Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Net Loss Per Share</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded from computation of earnings per share</a></td>
<td class="nump">2,400<span></span>
</td>
<td class="nump">100,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140032790240632">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Reconciliation of income tax provision (benefit) (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsByJurisdictionAbstract', window );"><strong>Federal and state provision (benefit) for income taxes</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperations', window );">Federal provision (benefit) for income taxes</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StateAndLocalIncomeTaxExpenseBenefitContinuingOperations', window );">State provision (benefit) for income taxes</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract', window );"><strong>Reconciliation of income tax benefit computed at the statutory federal income tax rate to income taxes as reflected in the financial statements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate', window );">Federal income tax benefits at statutory rate</a></td>
<td class="nump">21.00%<span></span>
</td>
<td class="nump">21.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes', window );">State and local tax, net of federal benefit</a></td>
<td class="nump">13.70%<span></span>
</td>
<td class="nump">7.60%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense', window );">Permanent differences</a></td>
<td class="nump">0.10%<span></span>
</td>
<td class="num">(0.80%)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment', window );">Research and development credit</a></td>
<td class="nump">2.40%<span></span>
</td>
<td class="nump">1.90%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost', window );">Stock-based compensation</a></td>
<td class="nump">15.70%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance', window );">Change in valuation allowance</a></td>
<td class="num">(52.90%)<span></span>
</td>
<td class="num">(29.70%)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations', window );">Effective income tax rate</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of domestic federal statutory tax rate applicable to pretax income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to nondeductible expenses.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to research and development expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to nondeductible expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current and deferred federal income tax expense (benefit) attributable to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32672-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsByJurisdictionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefitContinuingOperationsByJurisdictionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StateAndLocalIncomeTaxExpenseBenefitContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of state and local current and deferred income tax expense (benefit) attributable to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32672-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StateAndLocalIncomeTaxExpenseBenefitContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140032788842408">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Income Taxes - Deferred taxes (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsNetOfValuationAllowanceAbstract', window );"><strong>Deferred taxes</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards', window );">Net operating loss carryforwards</a></td>
<td class="nump">$ 6,512,249<span></span>
</td>
<td class="nump">$ 2,460,773<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_anvs_DeferredTaxAssetsTaxCreditCarryforwardsCapitalizedResearchAndDevelopment', window );">Capitalized research and development</a></td>
<td class="nump">2,002,431<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost', window );">Share-based compensation</a></td>
<td class="nump">1,759,129<span></span>
</td>
<td class="nump">547,628<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch', window );">Research and development tax credit carryforwards</a></td>
<td class="nump">648,077<span></span>
</td>
<td class="nump">241,414<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGross', window );">Total deferred tax assets</a></td>
<td class="nump">10,921,886<span></span>
</td>
<td class="nump">3,249,815<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Less valuation allowance</a></td>
<td class="num">(10,921,886)<span></span>
</td>
<td class="num">(3,249,815)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsNet', window );">Net deferred taxes</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_anvs_DeferredTaxAssetsTaxCreditCarryforwardsCapitalizedResearchAndDevelopment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to capitalized research and development.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">anvs_DeferredTaxAssetsTaxCreditCarryforwardsCapitalizedResearchAndDevelopment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>anvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsNetOfValuationAllowanceAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsNetOfValuationAllowanceAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible research tax credit carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32559-109319<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140032790190328">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Additional disclosures (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Income taxes</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount', window );">Net change in valuation allowance</a></td>
<td class="nump">$ 7,672,071<span></span>
</td>
<td class="nump">$ 1,619,516<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued', window );">Accrued interest or penalties</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense', window );">Recognized income tax interest and penalties</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember', window );">U.S. federal</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Income taxes</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Net operating loss carryforwards</a></td>
<td class="nump">21,844,192<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember', window );">U.S. federal | Research Tax Credit Carryforward</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Income taxes</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAmount', window );">Tax credit carryforward</a></td>
<td class="nump">648,077<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember', window );">U.S. federal | Generated in 2017 and prior</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Income taxes</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Net operating loss carryforwards</a></td>
<td class="nump">2,764,240<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember', window );">State</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Income taxes</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Net operating loss carryforwards</a></td>
<td class="nump">$ 24,391,076<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Income taxes</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock</a></td>
<td class="nump">1,000,000<span></span>
</td>
<td class="nump">2,300,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of estimated penalties and interest accrued as of the balance sheet date arising from income tax examinations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32718-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The sum of the amounts of estimated penalties and interest recognized in the period arising from income tax examinations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32718-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32559-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwardsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwardsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCreditCarryforwardAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of the tax credit carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32559-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCreditCarryforwardAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the valuation allowance for a specified deferred tax asset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCreditCarryforwardAxis=us-gaap_ResearchMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCreditCarryforwardAxis=us-gaap_ResearchMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxPeriodAxis=anvs_GeneratedIn2017AndPriorMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxPeriodAxis=anvs_GeneratedIn2017AndPriorMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140032788836008">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related-Party Transactions (Details)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Jan. 31, 2020 </div>
<div>shares</div>
</th>
<th class="th">
<div>Mar. 31, 2019 </div>
<div>USD ($) </div>
<div>director</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>shares</div>
</th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related-Party Transactions</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_anvs_StockIssuedDuringPeriodSharesConversionOfConvertibleNotes', window );">Number of common shares issued upon conversion of notes | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">118,470<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleDebtMember', window );">Convertible promissory notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related-Party Transactions</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Aggregate principal amount | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 530,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=srt_DirectorMember', window );">Directors | Issuance of convertible promissory notes to related parties | Convertible promissory notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related-Party Transactions</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Aggregate principal amount | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 305,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_anvs_RelatedPartyTransactionNumberOfCompanyDirectors', window );">Number of directors who purchased convertible promissory notes issued by the Company | director</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=srt_DirectorMember', window );">Directors | Conversion of promissory notes to common stock | Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related-Party Transactions</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_anvs_StockIssuedDuringPeriodSharesConversionOfConvertibleNotes', window );">Number of common shares issued upon conversion of notes | shares</a></td>
<td class="nump">71,429<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_anvs_RelatedPartyTransactionNumberOfCompanyDirectors">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of Company directors who purchased convertible promissory notes issued by the Company.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">anvs_RelatedPartyTransactionNumberOfCompanyDirectors</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>anvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_anvs_StockIssuedDuringPeriodSharesConversionOfConvertibleNotes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of the conversion of convertible notes.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">anvs_StockIssuedDuringPeriodSharesConversionOfConvertibleNotes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>anvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28551-108399<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=114775985&amp;loc=d3e28878-108400<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124429444&amp;loc=SL124452920-239629<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69C<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495737-112612<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69B<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495735-112612<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleDebtMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleDebtMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=srt_DirectorMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=srt_DirectorMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=anvs_RelatedPartyTransactionIssuanceOfConvertiblePromissoryNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=anvs_RelatedPartyTransactionIssuanceOfConvertiblePromissoryNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=anvs_RelatedPartyTransactionConversionOfPromissoryNotesToCommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=anvs_RelatedPartyTransactionConversionOfPromissoryNotesToCommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140032790243128">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Subsequent Events (Details) - $ / shares<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jan. 03, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Events</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Options granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">538,095<span></span>
</td>
<td class="nump">810,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Exercise price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 33.78<span></span>
</td>
<td class="nump">$ 3.46<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent events</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Events</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Options granted</a></td>
<td class="nump">188,294<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Exercise price</a></td>
<td class="nump">$ 19.78<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>74
<FILENAME>anvs-20211231x10k_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:anvs="http://annovisbio.com/20211231"
  xmlns:dei="http://xbrl.sec.gov/dei/2021q4"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2021-01-31"
  xmlns:us-gaap="http://fasb.org/us-gaap/2021-01-31"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="anvs-20211231.xsd" xlink:type="simple"/>
    <context id="As_Of_12_31_2020_us-gaap_StatementClassOfStockAxis_anvs_SeriesaRedeemableConvertiblePreferredStockMember_54xJpWZU6E-sSdAV-pOOiA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001477845</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">anvs:SeriesaRedeemableConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2020_us-gaap_StatementClassOfStockAxis_anvs_Series1RedeemableConvertiblePreferredStockMember_hROazqn7SUCQmc794Mq69Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001477845</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">anvs:Series1RedeemableConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2019_us-gaap_StatementClassOfStockAxis_anvs_SeriesaRedeemableConvertiblePreferredStockMember_odVgKOmG90OBa7U96NG4jw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001477845</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">anvs:SeriesaRedeemableConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2019_us-gaap_StatementClassOfStockAxis_anvs_Series1RedeemableConvertiblePreferredStockMember_pzCzknp_UUqMQod8oici_A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001477845</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">anvs:Series1RedeemableConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_us-gaap_IncomeTaxAuthorityAxis_us-gaap_DomesticCountryMember_us-gaap_TaxCreditCarryforwardAxis_us-gaap_ResearchMember_Asd8fgY1d0GxTm44XLZlKg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001477845</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:ResearchMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_us-gaap_GranteeStatusAxis_us-gaap_ShareBasedPaymentArrangementNonemployeeMember_-b4g7yTNB0aLjzC-gDHmiA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001477845</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementNonemployeeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_vHHC9xto40u1e1f1OxZXDA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001477845</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_Roe1SnnNfUKvOnVm7PJZ8w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001477845</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_m87TYAU_iECC8Uth9G-F3g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001477845</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_aLSsuRjKkUqU5e2EQUdxog">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001477845</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_q8XP9K1S6UO9eBjFQKFqmA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001477845</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_8FIUzd9InkOQst0tn_3nZg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001477845</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_xiqgw4dbRkGQtr2BjCvyAw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001477845</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_hBUW9O6ICE63RL-ah82T6g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001477845</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_d1y_dVMmq02lOk2EI5_rBA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001477845</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="As_Of_5_26_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_us-gaap_SubsidiarySaleOfStockAxis_anvs_SecondaryPublicOfferingMember_VQlutMc_ZkWzfLztqs-8Cg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001477845</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">anvs:SecondaryPublicOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-05-26</instant>
        </period>
    </context>
    <context id="As_Of_1_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember_rLszk1iR-U-miS0THNh94A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001477845</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-01-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_us-gaap_AwardDateAxis_anvs_AwardsGrantedIn2021Member_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_VestingAxis_anvs_ShareBasedPaymentArrangementVestingPeriodTwoYearsMember_7fink69gjUCJNwXqPwAp0Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001477845</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">anvs:AwardsGrantedIn2021Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">anvs:ShareBasedPaymentArrangementVestingPeriodTwoYearsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_us-gaap_AwardDateAxis_anvs_AwardsGrantedIn2021Member_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_VestingAxis_anvs_ShareBasedPaymentArrangementVestingPeriodOneYearMember_DimQ7qACMU6TfxILGAwOCw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001477845</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">anvs:AwardsGrantedIn2021Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">anvs:ShareBasedPaymentArrangementVestingPeriodOneYearMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_us-gaap_AwardDateAxis_anvs_AwardsGrantedIn2021Member_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_VestingAxis_anvs_ShareBasedPaymentArrangementVestingPeriodImmediateVestingMember_1D0-tOBHgkGoY1R3CgsSig">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001477845</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">anvs:AwardsGrantedIn2021Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">anvs:ShareBasedPaymentArrangementVestingPeriodImmediateVestingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_us-gaap_AwardDateAxis_anvs_AwardsGrantedIn2021Member_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_VestingAxis_anvs_ShareBasedPaymentArrangementVestingPeriodEqualQuarterlyInstallmentsOverTwoYearsMember_ZOvd1oon0k2qQBob-40BxQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001477845</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">anvs:AwardsGrantedIn2021Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">anvs:ShareBasedPaymentArrangementVestingPeriodEqualQuarterlyInstallmentsOverTwoYearsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2020_us-gaap_AwardDateAxis_anvs_AwardsGrantedIn2020Member_us-gaap_VestingAxis_anvs_ShareBasedPaymentArrangementVestingPeriodOneYearMember_5-6tsJ5Re0SiRVbMTy7QsA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001477845</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">anvs:AwardsGrantedIn2020Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">anvs:ShareBasedPaymentArrangementVestingPeriodOneYearMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="Duration_1_3_2022_To_1_3_2022_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_rxWBqkfQFkesGFeOew63wA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001477845</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-01-03</endDate>
        </period>
    </context>
    <context id="As_Of_12_31_2021_us-gaap_PlanNameAxis_anvs_EquityIncentivePlan2019Member_UCOHxKW5skOhwhVeKdLFlA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001477845</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">anvs:EquityIncentivePlan2019Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_1_31_2020_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_anvs_EquityIncentivePlan2018Member_c20l7lAf-kqshSDL7zNsjg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001477845</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">anvs:EquityIncentivePlan2018Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-01-31</instant>
        </period>
    </context>
    <context id="As_Of_6_1_2021_us-gaap_PlanNameAxis_anvs_EquityIncentivePlan2019Member__w3AH-0HNU6nl5M5tn5tng">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001477845</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">anvs:EquityIncentivePlan2019Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-01</instant>
        </period>
    </context>
    <context id="As_Of_5_31_2021_us-gaap_PlanNameAxis_anvs_EquityIncentivePlan2019Member_KtS-YX7JjU6pl2kOUpEkTw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001477845</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">anvs:EquityIncentivePlan2019Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-05-31</instant>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_anvs_EquityIncentivePlan2019Member_GgeIFB678UmRgQVDyMstNg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001477845</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">anvs:EquityIncentivePlan2019Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2020_To_12_31_2020_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_LAmAyrWmJUC3qRHISSAjmA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001477845</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_us-gaap_AwardDateAxis_anvs_AwardsGrantedIn2021Member_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_VestingAxis_anvs_ShareBasedPaymentArrangementVestingPeriodEqualQuarterlyInstallmentsOverTwoYearsMember_KPZ_nNTrBk-ED74SOGLcGQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001477845</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">anvs:AwardsGrantedIn2021Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">anvs:ShareBasedPaymentArrangementVestingPeriodEqualQuarterlyInstallmentsOverTwoYearsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2020_To_12_31_2020_us-gaap_AwardDateAxis_anvs_AwardsGrantedIn2020Member_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_VestingAxis_anvs_ShareBasedPaymentArrangementVestingPeriodOneYearMember__Fh8QWUir0eZugsK0WNqcA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001477845</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">anvs:AwardsGrantedIn2020Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">anvs:ShareBasedPaymentArrangementVestingPeriodOneYearMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_PpS2s9PnUUSL1x-_RPEPIQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001477845</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_obnngQDtKEWjaZKdmxph6g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001477845</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2020_To_12_31_2020_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_Fq09egBe_kOjLnI9UQwMsA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001477845</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2020_To_12_31_2020_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_r5vqCaRQJk29U3pXOnvzDg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001477845</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="Duration_5_26_2021_To_5_26_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_us-gaap_SubsidiarySaleOfStockAxis_anvs_SecondaryPublicOfferingMember_hxxkehfNkEWWBXStlPA61w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001477845</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">anvs:SecondaryPublicOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-05-26</startDate>
            <endDate>2021-05-26</endDate>
        </period>
    </context>
    <context id="As_Of_12_31_2021_us-gaap_IncomeTaxAuthorityAxis_us-gaap_DomesticCountryMember_us-gaap_TaxPeriodAxis_anvs_GeneratedIn2017AndPriorMember_bcLUgZK7ak-slt0qx5nwVQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001477845</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">anvs:GeneratedIn2017AndPriorMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_us-gaap_IncomeTaxAuthorityAxis_us-gaap_StateAndLocalJurisdictionMember_5e7zQwkrykWomLKNapiciw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001477845</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_us-gaap_IncomeTaxAuthorityAxis_us-gaap_DomesticCountryMember_HgR3pC70rUmeM4G-ZKbaTg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001477845</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_ryg7L-2WUkOqbAJ4DvlylQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001477845</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_Yj7CnNrKbk2eFi8MMsgZvQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001477845</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2020_To_12_31_2020_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember_dBs7AChUNEK9AUDzdDKJTQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001477845</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2019_To_12_31_2019_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember_RsyiGRhnhk-vxd5-a-DqHg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001477845</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="As_Of_12_31_2021_us-gaap_TypeOfArrangementAxis_anvs_NationalInstituteOnAgingOfNationalInstitutesOfHealthMember_VVmuZtlTeEaVeNDy9uhHaQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001477845</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">anvs:NationalInstituteOnAgingOfNationalInstitutesOfHealthMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2020_us-gaap_TypeOfArrangementAxis_anvs_NationalInstituteOnAgingOfNationalInstitutesOfHealthMember_SIhJO7d5SUmK7j4WVeRGBw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001477845</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">anvs:NationalInstituteOnAgingOfNationalInstitutesOfHealthMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_us-gaap_GranteeStatusAxis_us-gaap_ShareBasedPaymentArrangementNonemployeeMember_D0px0fClyEe8jZWjjaEH_w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001477845</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementNonemployeeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_MkIC0676s0mFrsozz2b5Ow">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001477845</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_vlN0t7QzKEiNBpiYEjJwDw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001477845</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="As_Of_3_31_2019_oVmx4yeGk0q3UZkY6l4F-g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001477845</identifier>
        </entity>
        <period>
            <instant>2019-03-31</instant>
        </period>
    </context>
    <context id="As_Of_3_31_2019_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember_us-gaap_RelatedPartyTransactionAxis_anvs_RelatedPartyTransactionIssuanceOfConvertiblePromissoryNotesMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_srt_DirectorMember_4brYU2SNtkC-xZaYEMvK_g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001477845</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">anvs:RelatedPartyTransactionIssuanceOfConvertiblePromissoryNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:DirectorMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-03-31</instant>
        </period>
    </context>
    <context id="As_Of_3_31_2019_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember_YwRIubASaUOYMPLJxHrjxQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001477845</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-03-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_us-gaap_ClassOfWarrantOrRightAxis_anvs_UnderwritersWarrantsMember_i9g6mnyCNEylYBl9fs3ugQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001477845</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">anvs:UnderwritersWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2020_us-gaap_ClassOfWarrantOrRightAxis_anvs_UnderwritersWarrantsMember_fVGxQCgHYU-B8YaMWCH07g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001477845</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">anvs:UnderwritersWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2019_S7jX8DT5zEOORR0B4HM-aw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001477845</identifier>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_hJjGSBmgGE6iOTr6RBMr5Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001477845</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2020_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_RGBQ6zcqa0CUSFXphddjkA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001477845</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_4-P5H-hF4ESmAJ-kqpCyXw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001477845</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2020_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_ivytLr2eEUunO9BaEWMghQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001477845</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_WarrantMember_GH_2bhJhrkKLRik7_QHn1g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001477845</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockOptionMember_ErimM70Lx0GlzbzdZjfaBQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001477845</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2020_To_12_31_2020_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_WarrantMember_BM2Bi1ZZ70OsQ-maVuCszA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001477845</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2020_To_12_31_2020_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockOptionMember_Ot-TYiGbdkWL1GALWHvnMQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001477845</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="As_Of_6_30_2021_MBhTAFV7OEyNVlFF1KbEtw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001477845</identifier>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="As_Of_2_28_2022_KZhnsPfZ-kWXAPyRRcTcqw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001477845</identifier>
        </entity>
        <period>
            <instant>2022-02-28</instant>
        </period>
    </context>
    <context id="Duration_1_31_2020_To_1_31_2020_us-gaap_StatementClassOfStockAxis_anvs_SeriesaRedeemableConvertiblePreferredStockMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember_ptCGvvBnuEitWVCSkdK7Vw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001477845</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">anvs:SeriesaRedeemableConvertiblePreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-31</startDate>
            <endDate>2020-01-31</endDate>
        </period>
    </context>
    <context id="Duration_1_31_2020_To_1_31_2020_us-gaap_StatementClassOfStockAxis_anvs_Series1RedeemableConvertiblePreferredStockMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember_fNVfPPJXjUyuAgQutr0kWQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001477845</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">anvs:Series1RedeemableConvertiblePreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-31</startDate>
            <endDate>2020-01-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementClassOfStockAxis_anvs_SeriesaRedeemableConvertiblePreferredStockMember_deK8dFWBmk-HMa7S_4aJ1w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001477845</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">anvs:SeriesaRedeemableConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementClassOfStockAxis_anvs_Series1RedeemableConvertiblePreferredStockMember_-LeysnJLjE-x0FvXPGEzVg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001477845</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">anvs:Series1RedeemableConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_Nwz3m5oS6kGLY8WW_bxwDQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001477845</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_JVwGb5QRK0mEvKeM6mX7xg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001477845</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_zHbo2vwCLUiM30jKyAcCgw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001477845</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_31_2020_To_1_31_2020_us-gaap_RelatedPartyTransactionAxis_anvs_RelatedPartyTransactionConversionOfPromissoryNotesToCommonStockMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_srt_DirectorMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_IfkwjFJuWk-TFaP8kqYr2g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001477845</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">anvs:RelatedPartyTransactionConversionOfPromissoryNotesToCommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:DirectorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-31</startDate>
            <endDate>2020-01-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_FOnigPlx6UaoZMNa-ktVRg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001477845</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2020_To_12_31_2020_us-gaap_GranteeStatusAxis_us-gaap_ShareBasedPaymentArrangementNonemployeeMember__Y5EzHRV8U2VQ42ne0t5eg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001477845</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementNonemployeeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="Duration_3_1_2019_To_3_31_2019_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember_us-gaap_RelatedPartyTransactionAxis_anvs_RelatedPartyTransactionIssuanceOfConvertiblePromissoryNotesMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_srt_DirectorMember_uRDbbwJWlUih1vnjYEeJyA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001477845</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">anvs:RelatedPartyTransactionIssuanceOfConvertiblePromissoryNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:DirectorMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-03-01</startDate>
            <endDate>2019-03-31</endDate>
        </period>
    </context>
    <context id="As_Of_1_31_2020_us-gaap_StatementClassOfStockAxis_anvs_SeriesaRedeemableConvertiblePreferredStockMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember_WSa7shXqeUSwpAKpQQl-KQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001477845</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">anvs:SeriesaRedeemableConvertiblePreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-01-31</instant>
        </period>
    </context>
    <context id="As_Of_1_31_2020_us-gaap_StatementClassOfStockAxis_anvs_Series1RedeemableConvertiblePreferredStockMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember_O74MBLhVpkagypo4IVPp_Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001477845</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">anvs:Series1RedeemableConvertiblePreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-01-31</instant>
        </period>
    </context>
    <context id="As_Of_1_31_2020_us-gaap_ClassOfWarrantOrRightAxis_anvs_UnderwritersWarrantsMember_p2Rmy9kgMES4LjCsl9nsqg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001477845</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">anvs:UnderwritersWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-01-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_srt_TitleOfIndividualAxis_srt_ExecutiveOfficerMember_2QVIbrzh10W_0LPuXlLcug">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001477845</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ExecutiveOfficerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_anvs_LicenseAgreementTermsAmendedMay2012Member_DCsom2ZXYkiSKjzS68vh2Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001477845</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">anvs:LicenseAgreementTermsAmendedMay2012Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_5_1_2012_To_5_31_2012_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_anvs_LicenseAgreementTermsAmendedMay2012Member_P0aUOpgGN0mwPRsuYBHIew">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001477845</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">anvs:LicenseAgreementTermsAmendedMay2012Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2012-05-01</startDate>
            <endDate>2012-05-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_us-gaap_TypeOfArrangementAxis_anvs_NationalInstituteOnAgingOfNationalInstitutesOfHealthMember_CduWTDd6hEGUS67lAWkVHw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001477845</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">anvs:NationalInstituteOnAgingOfNationalInstitutesOfHealthMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2020_To_12_31_2020_us-gaap_TypeOfArrangementAxis_anvs_NationalInstituteOnAgingOfNationalInstitutesOfHealthMember_1CkP6VBQfUS9FAKN4vz1Tg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001477845</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">anvs:NationalInstituteOnAgingOfNationalInstitutesOfHealthMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="As_Of_9_30_2019_us-gaap_TypeOfArrangementAxis_anvs_NationalInstituteOnAgingOfNationalInstitutesOfHealthMember_RQt1O7nidUO5QNweDycD_A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001477845</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">anvs:NationalInstituteOnAgingOfNationalInstitutesOfHealthMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-09-30</instant>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_uhkxAiZ6fUeekYGgaMhCqA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001477845</identifier>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="As_Of_12_31_2021_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_anvs_LicenseAgreementTermsAmendedMay2012Member_fjPgMKMghE-GlCKw7d5yzw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001477845</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">anvs:LicenseAgreementTermsAmendedMay2012Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_us-gaap_ClassOfWarrantOrRightAxis_anvs_UnderwritersWarrantsMember_lIkEDjt6I02rJoRPhXJAxw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001477845</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">anvs:UnderwritersWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_31_2020_To_1_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember_sRjzEwCZI0yVkxtZkXzw0w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001477845</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-31</startDate>
            <endDate>2020-01-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2020_To_12_31_2020_3DdHOulAJk6Q0Zn4Vsxq5A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001477845</identifier>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="As_Of_1_31_2020_kBrHfmPKTE-0UUCmwNXokA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001477845</identifier>
        </entity>
        <period>
            <instant>2020-01-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_slf_IrTrZku1VVWbbttE4g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001477845</identifier>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2020_K1oKCNbpv0CLR8EJWu1PSw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001477845</identifier>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <unit id="Unit_Standard_USD_NFG_pVdyhEyJarLQmedkXA">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="Unit_Standard_shares__cOSbKjBTUyHt70_t1aAVw">
        <measure>shares</measure>
    </unit>
    <unit id="Unit_Standard_pure_n7tAfGlk1kyqYH5N2uCURw">
        <measure>pure</measure>
    </unit>
    <unit id="Unit_Standard_item_Y7Ur8tqCgUit9H-TWiK9OA">
        <measure>anvs:item</measure>
    </unit>
    <unit id="Unit_Standard_Vote_pwF70c76VEGREHjsKw9EwA">
        <measure>anvs:Vote</measure>
    </unit>
    <unit id="Unit_Divide_USD_shares_ZtgwQidioUWlbMoOaTBzxg">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="Unit_Standard_director_8dNZ3yZCzEGn3lXzcsOwSg">
        <measure>anvs:director</measure>
    </unit>
    <unit id="Unit_Standard_lawsuit_cWy34Dwcxk6mE22LYui79g">
        <measure>anvs:lawsuit</measure>
    </unit>
    <us-gaap:CommitmentsAndContingencies
      contextRef="As_Of_12_31_2021_slf_IrTrZku1VVWbbttE4g"
      id="Hidden_wQgsFEt9qEqLJPdOnLL8zg"
      unitRef="Unit_Standard_USD_NFG_pVdyhEyJarLQmedkXA"
      xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies
      contextRef="As_Of_12_31_2020_K1oKCNbpv0CLR8EJWu1PSw"
      id="Hidden_3yd7vgu1lkuzk37_El_YbQ"
      unitRef="Unit_Standard_USD_NFG_pVdyhEyJarLQmedkXA"
      xsi:nil="true"/>
    <us-gaap:PreferredStockValue
      contextRef="As_Of_12_31_2021_slf_IrTrZku1VVWbbttE4g"
      id="Hidden_1cHKNqogd0-a4Lt10S2ySQ"
      unitRef="Unit_Standard_USD_NFG_pVdyhEyJarLQmedkXA"
      xsi:nil="true"/>
    <us-gaap:PreferredStockValue
      contextRef="As_Of_12_31_2020_K1oKCNbpv0CLR8EJWu1PSw"
      id="Hidden__Eya0bxY0UCpLBlvPZA65Q"
      unitRef="Unit_Standard_USD_NFG_pVdyhEyJarLQmedkXA"
      xsi:nil="true"/>
    <us-gaap:EarningsPerShareDiluted
      contextRef="Duration_1_1_2021_To_12_31_2021_uhkxAiZ6fUeekYGgaMhCqA"
      decimals="2"
      id="Hidden_XAUjswUORUOJZosgVNCkDg"
      unitRef="Unit_Divide_USD_shares_ZtgwQidioUWlbMoOaTBzxg">-1.90</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="Duration_1_1_2020_To_12_31_2020_3DdHOulAJk6Q0Zn4Vsxq5A"
      decimals="2"
      id="Hidden_M0jLGMYCbkOJklwUB6rq2g"
      unitRef="Unit_Divide_USD_shares_ZtgwQidioUWlbMoOaTBzxg">-0.87</us-gaap:EarningsPerShareDiluted>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="Duration_1_1_2021_To_12_31_2021_uhkxAiZ6fUeekYGgaMhCqA"
      decimals="0"
      id="Hidden_ZHMTv2uqVEe3kJ7tG2treA"
      unitRef="Unit_Standard_shares__cOSbKjBTUyHt70_t1aAVw">7626278</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="Duration_1_1_2020_To_12_31_2020_3DdHOulAJk6Q0Zn4Vsxq5A"
      decimals="0"
      id="Hidden_pTn8WPESjEOeWlQt5m_k9w"
      unitRef="Unit_Standard_shares__cOSbKjBTUyHt70_t1aAVw">6308961</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="Duration_1_1_2021_To_12_31_2021_uhkxAiZ6fUeekYGgaMhCqA"
      id="Hidden_EQY9UVLtMU6NuqPU1k6Bhg">P8Y4M24D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
      contextRef="Duration_1_1_2021_To_12_31_2021_uhkxAiZ6fUeekYGgaMhCqA"
      id="Hidden_LZM2INVDtkezbYWBS4I2FA">P7Y10M24D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_vlN0t7QzKEiNBpiYEjJwDw"
      id="Hidden_HsUzDjUJtkSAIzhEqWrcUA">P5Y3M18D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="Duration_1_1_2021_To_12_31_2021_uhkxAiZ6fUeekYGgaMhCqA"
      decimals="0"
      id="Hidden_m5NWwkFcQUGtfXm9EhhhFQ"
      unitRef="Unit_Standard_shares__cOSbKjBTUyHt70_t1aAVw">7626278</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="Duration_1_1_2020_To_12_31_2020_3DdHOulAJk6Q0Zn4Vsxq5A"
      decimals="0"
      id="Hidden_MPeGiLY0WkaN3LWJIoLmiw"
      unitRef="Unit_Standard_shares__cOSbKjBTUyHt70_t1aAVw">6308961</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:EarningsPerShareDiluted
      contextRef="Duration_1_1_2021_To_12_31_2021_uhkxAiZ6fUeekYGgaMhCqA"
      decimals="2"
      id="Hidden_rSR452tyXk6abBubxNbgsA"
      unitRef="Unit_Divide_USD_shares_ZtgwQidioUWlbMoOaTBzxg">-1.90</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="Duration_1_1_2020_To_12_31_2020_3DdHOulAJk6Q0Zn4Vsxq5A"
      decimals="2"
      id="Hidden_OqBcgGW4EE6_WaDvT8_C5g"
      unitRef="Unit_Divide_USD_shares_ZtgwQidioUWlbMoOaTBzxg">-0.87</us-gaap:EarningsPerShareDiluted>
    <dei:EntityCentralIndexKey
      contextRef="Duration_1_1_2021_To_12_31_2021_uhkxAiZ6fUeekYGgaMhCqA"
      id="Tc_5lLhPSKAD0yopEdGS5BBDw_2_1">0001477845</dei:EntityCentralIndexKey>
    <dei:DocumentFiscalYearFocus
      contextRef="Duration_1_1_2021_To_12_31_2021_uhkxAiZ6fUeekYGgaMhCqA"
      id="Tc_U2OEu0rr8k-yQZVh15YcjA_3_1">2021</dei:DocumentFiscalYearFocus>
    <dei:DocumentFiscalPeriodFocus
      contextRef="Duration_1_1_2021_To_12_31_2021_uhkxAiZ6fUeekYGgaMhCqA"
      id="Tc_2bVdWMX9Rk-EEbr8W__P_Q_4_1">FY</dei:DocumentFiscalPeriodFocus>
    <dei:AmendmentFlag
      contextRef="Duration_1_1_2021_To_12_31_2021_uhkxAiZ6fUeekYGgaMhCqA"
      id="Tc_dbnNVViIb0C6gMId2SaesQ_5_1">false</dei:AmendmentFlag>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="As_Of_12_31_2020_K1oKCNbpv0CLR8EJWu1PSw"
      decimals="INF"
      id="Hidden_0E0ZYGeWXkmnptW3JEaf-A"
      unitRef="Unit_Standard_shares__cOSbKjBTUyHt70_t1aAVw">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="As_Of_12_31_2021_slf_IrTrZku1VVWbbttE4g"
      decimals="INF"
      id="Hidden_ceU6MrutgEu_MrBuHg6Uxg"
      unitRef="Unit_Standard_shares__cOSbKjBTUyHt70_t1aAVw">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:IncomeTaxExaminationPenaltiesAndInterestAccrued
      contextRef="As_Of_12_31_2021_slf_IrTrZku1VVWbbttE4g"
      decimals="0"
      id="Hidden_1sZl5MdDJ0KYV2BjEn0mRA"
      unitRef="Unit_Standard_USD_NFG_pVdyhEyJarLQmedkXA">0</us-gaap:IncomeTaxExaminationPenaltiesAndInterestAccrued>
    <us-gaap:CommonStockSharesIssued
      contextRef="As_Of_12_31_2020_K1oKCNbpv0CLR8EJWu1PSw"
      decimals="INF"
      id="Hidden_i8ALY5d87EqQSL0ZvpxgYA"
      unitRef="Unit_Standard_shares__cOSbKjBTUyHt70_t1aAVw">6891608</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="As_Of_12_31_2021_slf_IrTrZku1VVWbbttE4g"
      decimals="INF"
      id="Hidden_HhN3VcDM_kSkl4xTtOaA_A"
      unitRef="Unit_Standard_shares__cOSbKjBTUyHt70_t1aAVw">8100570</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="As_Of_1_31_2020_kBrHfmPKTE-0UUCmwNXokA"
      decimals="INF"
      id="Hidden_W_s6TWSI0kqP0maAGvG-9A"
      unitRef="Unit_Divide_USD_shares_ZtgwQidioUWlbMoOaTBzxg">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:WarrantsAndRightsOutstandingTerm
      contextRef="As_Of_1_31_2020_us-gaap_ClassOfWarrantOrRightAxis_anvs_UnderwritersWarrantsMember_p2Rmy9kgMES4LjCsl9nsqg"
      id="Hidden_7Pmc5xg25E6fTLpFgVmdTA">P5Y</us-gaap:WarrantsAndRightsOutstandingTerm>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod
      contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_LAmAyrWmJUC3qRHISSAjmA"
      id="Hidden_5ZJE1WrWLEmz4ZW1wESADw">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_vlN0t7QzKEiNBpiYEjJwDw"
      id="Hidden_zR4qh4oXwUersK0sixk6RQ">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_vlN0t7QzKEiNBpiYEjJwDw"
      id="Hidden_bR4c2uBj-EKLsqDtSgFQaA">P1Y3M18D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
      contextRef="As_Of_12_31_2021_us-gaap_GranteeStatusAxis_us-gaap_ShareBasedPaymentArrangementNonemployeeMember_D0px0fClyEe8jZWjjaEH_w"
      decimals="0"
      id="Hidden_FE1dYrMu70-J5dbAohVyjw"
      unitRef="Unit_Standard_USD_NFG_pVdyhEyJarLQmedkXA">0</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions>
    <us-gaap:FederalIncomeTaxExpenseBenefitContinuingOperations
      contextRef="Duration_1_1_2020_To_12_31_2020_3DdHOulAJk6Q0Zn4Vsxq5A"
      decimals="0"
      id="Hidden_SW8i4KjZHE2PDZm4AjxY8Q"
      unitRef="Unit_Standard_USD_NFG_pVdyhEyJarLQmedkXA">0</us-gaap:FederalIncomeTaxExpenseBenefitContinuingOperations>
    <us-gaap:FederalIncomeTaxExpenseBenefitContinuingOperations
      contextRef="Duration_1_1_2021_To_12_31_2021_uhkxAiZ6fUeekYGgaMhCqA"
      decimals="0"
      id="Hidden_6_Xqz9nGk0aFTo4spVd-HQ"
      unitRef="Unit_Standard_USD_NFG_pVdyhEyJarLQmedkXA">0</us-gaap:FederalIncomeTaxExpenseBenefitContinuingOperations>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="Duration_1_1_2021_To_12_31_2021_uhkxAiZ6fUeekYGgaMhCqA"
      decimals="0"
      id="Hidden_wLzrCC9kDk6BKVi6RIiXmQ"
      unitRef="Unit_Standard_USD_NFG_pVdyhEyJarLQmedkXA">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <dei:DocumentType
      contextRef="Duration_1_1_2021_To_12_31_2021_uhkxAiZ6fUeekYGgaMhCqA"
      id="Narr_HDdaz2ew50y0_zzkNcP24w">10-K</dei:DocumentType>
    <dei:DocumentAnnualReport
      contextRef="Duration_1_1_2021_To_12_31_2021_uhkxAiZ6fUeekYGgaMhCqA"
      id="Tc_S6qGzHb03USvT2UjWPh4RA_0_0">true</dei:DocumentAnnualReport>
    <dei:DocumentPeriodEndDate
      contextRef="Duration_1_1_2021_To_12_31_2021_uhkxAiZ6fUeekYGgaMhCqA"
      id="Narr_9e7y3i3ymU-YJJivR4lESw">2021-12-31</dei:DocumentPeriodEndDate>
    <dei:CurrentFiscalYearEndDate
      contextRef="Duration_1_1_2021_To_12_31_2021_uhkxAiZ6fUeekYGgaMhCqA"
      id="Narr_D5l79WULX0SXqq-lQVzymg">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:DocumentTransitionReport
      contextRef="Duration_1_1_2021_To_12_31_2021_uhkxAiZ6fUeekYGgaMhCqA"
      id="Tc_hxF4xcUMkEOm63oc3yI6yA_4_0">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber
      contextRef="Duration_1_1_2021_To_12_31_2021_uhkxAiZ6fUeekYGgaMhCqA"
      id="Narr_vaKo0rX23UWysXTf2-_J3Q">001-39202</dei:EntityFileNumber>
    <dei:EntityRegistrantName
      contextRef="Duration_1_1_2021_To_12_31_2021_uhkxAiZ6fUeekYGgaMhCqA"
      id="Narr_nUnfIag1hE-HbQyKmlWGWg">Annovis Bio,&#160;Inc.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="Duration_1_1_2021_To_12_31_2021_uhkxAiZ6fUeekYGgaMhCqA"
      id="Narr_AjTnWNDYZUKlK4A6Kl25PQ">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber
      contextRef="Duration_1_1_2021_To_12_31_2021_uhkxAiZ6fUeekYGgaMhCqA"
      id="Narr_Yiavf1KzIU2PZDomd1kUCQ">26-2540421</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="Duration_1_1_2021_To_12_31_2021_uhkxAiZ6fUeekYGgaMhCqA"
      id="Narr_meRkmEZvAECvhcAuV83xpA">1055 Westlakes Drive, Suite&#160;300</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown
      contextRef="Duration_1_1_2021_To_12_31_2021_uhkxAiZ6fUeekYGgaMhCqA"
      id="Narr_CYhVNAvCpEe7saMO6ppr2w">Berwyn</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="Duration_1_1_2021_To_12_31_2021_uhkxAiZ6fUeekYGgaMhCqA"
      id="Narr_Rb8EPljSH0utcHNGTQ7WRA">PA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="Duration_1_1_2021_To_12_31_2021_uhkxAiZ6fUeekYGgaMhCqA"
      id="Narr_rjCTKvykt0yYLgFh_tzTcg">19312</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="Duration_1_1_2021_To_12_31_2021_uhkxAiZ6fUeekYGgaMhCqA"
      id="Narr_iZ4Fm6SQok2NdTPGfmb9EA">610</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="Duration_1_1_2021_To_12_31_2021_uhkxAiZ6fUeekYGgaMhCqA"
      id="Narr_y79riXUlfUK3N8T_ENq_eA">727-3913</dei:LocalPhoneNumber>
    <dei:Security12bTitle
      contextRef="Duration_1_1_2021_To_12_31_2021_uhkxAiZ6fUeekYGgaMhCqA"
      id="Tc_ZpVu2MXQ9EqR_ROepFerTw_2_0">Common Stock, par value $0.0001 per share</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="Duration_1_1_2021_To_12_31_2021_uhkxAiZ6fUeekYGgaMhCqA"
      id="Tc_RJvDVzOfwE-V6xL5giPSKQ_2_2">ANVS</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="Duration_1_1_2021_To_12_31_2021_uhkxAiZ6fUeekYGgaMhCqA"
      id="Tc_blbFmRJNGU-BGImm9sGfaA_2_4">NYSE</dei:SecurityExchangeName>
    <dei:EntityWellKnownSeasonedIssuer
      contextRef="Duration_1_1_2021_To_12_31_2021_uhkxAiZ6fUeekYGgaMhCqA"
      id="Narr_j0fNBFCD4EKpNzckBQbUjQ">No</dei:EntityWellKnownSeasonedIssuer>
    <dei:EntityVoluntaryFilers
      contextRef="Duration_1_1_2021_To_12_31_2021_uhkxAiZ6fUeekYGgaMhCqA"
      id="Narr_KSIjwBz_gk60wigyxVmjxg">No</dei:EntityVoluntaryFilers>
    <dei:EntityCurrentReportingStatus
      contextRef="Duration_1_1_2021_To_12_31_2021_uhkxAiZ6fUeekYGgaMhCqA"
      id="Narr_sMyl1K7cY0CWbtGuhaFExA">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent
      contextRef="Duration_1_1_2021_To_12_31_2021_uhkxAiZ6fUeekYGgaMhCqA"
      id="Narr_4gCxBjIRsk2QH-EqQLAs9w">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory
      contextRef="Duration_1_1_2021_To_12_31_2021_uhkxAiZ6fUeekYGgaMhCqA"
      id="Narr_S-5onUCI6E63_TaWKRJ0dA">Non-accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness
      contextRef="Duration_1_1_2021_To_12_31_2021_uhkxAiZ6fUeekYGgaMhCqA"
      id="Narr_0-1EqJw-_0KxfWvIT_f3OQ">true</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany
      contextRef="Duration_1_1_2021_To_12_31_2021_uhkxAiZ6fUeekYGgaMhCqA"
      id="Narr_hOlruehqiE6wvmICNoWKXg">true</dei:EntityEmergingGrowthCompany>
    <dei:EntityExTransitionPeriod
      contextRef="Duration_1_1_2021_To_12_31_2021_uhkxAiZ6fUeekYGgaMhCqA"
      id="Narr_bJJkrh3Z5E2vlEW8UGBP_Q">true</dei:EntityExTransitionPeriod>
    <dei:EntityShellCompany
      contextRef="Duration_1_1_2021_To_12_31_2021_uhkxAiZ6fUeekYGgaMhCqA"
      id="Narr_E0b_6t0K_U2VW43Vko6qrg">false</dei:EntityShellCompany>
    <dei:IcfrAuditorAttestationFlag
      contextRef="Duration_1_1_2021_To_12_31_2021_uhkxAiZ6fUeekYGgaMhCqA"
      id="Narr_IbGT3TPouE2iXjcYmWkzUw">false</dei:IcfrAuditorAttestationFlag>
    <dei:EntityPublicFloat
      contextRef="As_Of_6_30_2021_MBhTAFV7OEyNVlFF1KbEtw"
      decimals="0"
      id="Narr_mZ--xOq0zUS-6VOxprMwRQ"
      unitRef="Unit_Standard_USD_NFG_pVdyhEyJarLQmedkXA">481819080</dei:EntityPublicFloat>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="As_Of_2_28_2022_KZhnsPfZ-kWXAPyRRcTcqw"
      decimals="INF"
      id="Narr_AeVyz_B6FUa5uepulnuL_w"
      unitRef="Unit_Standard_shares__cOSbKjBTUyHt70_t1aAVw">8163923</dei:EntityCommonStockSharesOutstanding>
    <dei:AuditorName
      contextRef="Duration_1_1_2021_To_12_31_2021_uhkxAiZ6fUeekYGgaMhCqA"
      id="Narr_7dU9uXZymkWN95A6LJ2Gmw">WithumSmith+Brown, PC</dei:AuditorName>
    <dei:AuditorLocation
      contextRef="Duration_1_1_2021_To_12_31_2021_uhkxAiZ6fUeekYGgaMhCqA"
      id="Narr_fhOrXnPF-0ybEcRVO8-hSQ">East Brunswick, New Jersey</dei:AuditorLocation>
    <dei:AuditorFirmId
      contextRef="Duration_1_1_2021_To_12_31_2021_uhkxAiZ6fUeekYGgaMhCqA"
      id="Narr_jc8ZWysILEKZvqbQaiT1xw">100</dei:AuditorFirmId>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="As_Of_12_31_2021_slf_IrTrZku1VVWbbttE4g"
      decimals="0"
      id="Tc_cyl-kTsRJ02faZftH6sJwA_6_3"
      unitRef="Unit_Standard_USD_NFG_pVdyhEyJarLQmedkXA">45686014</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="As_Of_12_31_2020_K1oKCNbpv0CLR8EJWu1PSw"
      decimals="0"
      id="Tc_0gjS2DH8fUCPKBFnzZfyLQ_6_6"
      unitRef="Unit_Standard_USD_NFG_pVdyhEyJarLQmedkXA">8074658</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <anvs:PrepaidExpenseSecurityDepositsAndOtherAssetsCurrent
      contextRef="As_Of_12_31_2021_slf_IrTrZku1VVWbbttE4g"
      decimals="0"
      id="Tc_3zq-VcTAFkiairIiyNUqZg_7_3"
      unitRef="Unit_Standard_USD_NFG_pVdyhEyJarLQmedkXA">315464</anvs:PrepaidExpenseSecurityDepositsAndOtherAssetsCurrent>
    <anvs:PrepaidExpenseSecurityDepositsAndOtherAssetsCurrent
      contextRef="As_Of_12_31_2020_K1oKCNbpv0CLR8EJWu1PSw"
      decimals="0"
      id="Tc_lg7MdPDJKE6VBXn0N5d5Bg_7_6"
      unitRef="Unit_Standard_USD_NFG_pVdyhEyJarLQmedkXA">44676</anvs:PrepaidExpenseSecurityDepositsAndOtherAssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="As_Of_12_31_2021_slf_IrTrZku1VVWbbttE4g"
      decimals="0"
      id="Tc_U8vEFdQEzkq1biuAofjTdA_8_3"
      unitRef="Unit_Standard_USD_NFG_pVdyhEyJarLQmedkXA">46001478</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="As_Of_12_31_2020_K1oKCNbpv0CLR8EJWu1PSw"
      decimals="0"
      id="Tc_iXCfV_UN10qzKUlIiVH1GA_8_6"
      unitRef="Unit_Standard_USD_NFG_pVdyhEyJarLQmedkXA">8119334</us-gaap:AssetsCurrent>
    <us-gaap:Assets
      contextRef="As_Of_12_31_2021_slf_IrTrZku1VVWbbttE4g"
      decimals="0"
      id="Tc_zhY1sllw2E6W6EKBVRIXtg_9_3"
      unitRef="Unit_Standard_USD_NFG_pVdyhEyJarLQmedkXA">46001478</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="As_Of_12_31_2020_K1oKCNbpv0CLR8EJWu1PSw"
      decimals="0"
      id="Tc_3-zJKVLgzUGFwDj2CpXhww_9_6"
      unitRef="Unit_Standard_USD_NFG_pVdyhEyJarLQmedkXA">8119334</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent
      contextRef="As_Of_12_31_2021_slf_IrTrZku1VVWbbttE4g"
      decimals="0"
      id="Tc_qd8L-OyZ_EGog4NSJ-LO_Q_12_3"
      unitRef="Unit_Standard_USD_NFG_pVdyhEyJarLQmedkXA">688074</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="As_Of_12_31_2020_K1oKCNbpv0CLR8EJWu1PSw"
      decimals="0"
      id="Tc_mvrRSADvI06ueq74TIh0XQ_12_6"
      unitRef="Unit_Standard_USD_NFG_pVdyhEyJarLQmedkXA">341856</us-gaap:AccountsPayableCurrent>
    <anvs:AccruedLiabilitiesAndInterestAndEmployeeRelatedLiabilitiesCurrent
      contextRef="As_Of_12_31_2021_slf_IrTrZku1VVWbbttE4g"
      decimals="0"
      id="Tc_4moMmyOzyES0J5WTcW1JCg_13_3"
      unitRef="Unit_Standard_USD_NFG_pVdyhEyJarLQmedkXA">818440</anvs:AccruedLiabilitiesAndInterestAndEmployeeRelatedLiabilitiesCurrent>
    <anvs:AccruedLiabilitiesAndInterestAndEmployeeRelatedLiabilitiesCurrent
      contextRef="As_Of_12_31_2020_K1oKCNbpv0CLR8EJWu1PSw"
      decimals="0"
      id="Tc_U_mwi_9AZUSZ9zNWt_bHtA_13_6"
      unitRef="Unit_Standard_USD_NFG_pVdyhEyJarLQmedkXA">236524</anvs:AccruedLiabilitiesAndInterestAndEmployeeRelatedLiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="As_Of_12_31_2021_slf_IrTrZku1VVWbbttE4g"
      decimals="0"
      id="Tc_hjKPKBO_g0WeeTw3hvWPSQ_14_3"
      unitRef="Unit_Standard_USD_NFG_pVdyhEyJarLQmedkXA">1506514</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="As_Of_12_31_2020_K1oKCNbpv0CLR8EJWu1PSw"
      decimals="0"
      id="Tc_TTlwAoBVoEqcOv1NanpGog_14_6"
      unitRef="Unit_Standard_USD_NFG_pVdyhEyJarLQmedkXA">578380</us-gaap:LiabilitiesCurrent>
    <us-gaap:Liabilities
      contextRef="As_Of_12_31_2021_slf_IrTrZku1VVWbbttE4g"
      decimals="0"
      id="Tc_pyKaoptbzEeq-TIYBXXdIA_15_3"
      unitRef="Unit_Standard_USD_NFG_pVdyhEyJarLQmedkXA">1506514</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="As_Of_12_31_2020_K1oKCNbpv0CLR8EJWu1PSw"
      decimals="0"
      id="Tc_9KpxThwHHk6Lgwam-Mj5Ig_15_6"
      unitRef="Unit_Standard_USD_NFG_pVdyhEyJarLQmedkXA">578380</us-gaap:Liabilities>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="As_Of_12_31_2020_K1oKCNbpv0CLR8EJWu1PSw"
      decimals="INF"
      id="Narr_jwCJY0w28EmzE3UOM99n5w"
      unitRef="Unit_Divide_USD_shares_ZtgwQidioUWlbMoOaTBzxg">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="As_Of_12_31_2021_slf_IrTrZku1VVWbbttE4g"
      decimals="INF"
      id="Narr_3vkuyOY_SUWImRBJml-g0w"
      unitRef="Unit_Divide_USD_shares_ZtgwQidioUWlbMoOaTBzxg">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="As_Of_12_31_2020_K1oKCNbpv0CLR8EJWu1PSw"
      decimals="INF"
      id="Narr_2oDAD-GPkE6f42Agq2_9IQ"
      unitRef="Unit_Standard_shares__cOSbKjBTUyHt70_t1aAVw">2000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="As_Of_12_31_2021_slf_IrTrZku1VVWbbttE4g"
      decimals="INF"
      id="Narr_r1Q439MbZUqPDXcax8-ZoQ"
      unitRef="Unit_Standard_shares__cOSbKjBTUyHt70_t1aAVw">2000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesIssued
      contextRef="As_Of_12_31_2020_K1oKCNbpv0CLR8EJWu1PSw"
      decimals="INF"
      id="Narr_DOoUROqCcUq10agcdK9RqA"
      unitRef="Unit_Standard_shares__cOSbKjBTUyHt70_t1aAVw">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesIssued
      contextRef="As_Of_12_31_2021_slf_IrTrZku1VVWbbttE4g"
      decimals="INF"
      id="Narr_XVgwZnD7tkCj1eFXEtQVwA"
      unitRef="Unit_Standard_shares__cOSbKjBTUyHt70_t1aAVw">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="As_Of_12_31_2020_K1oKCNbpv0CLR8EJWu1PSw"
      decimals="INF"
      id="Narr_CGO-iDj7YEq7Zmotg27WOg"
      unitRef="Unit_Divide_USD_shares_ZtgwQidioUWlbMoOaTBzxg">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="As_Of_12_31_2021_slf_IrTrZku1VVWbbttE4g"
      decimals="INF"
      id="Narr_GoVkRp49skGAAS5AZkF_QA"
      unitRef="Unit_Divide_USD_shares_ZtgwQidioUWlbMoOaTBzxg">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="As_Of_12_31_2020_K1oKCNbpv0CLR8EJWu1PSw"
      decimals="INF"
      id="Narr_jpdu4PjVy02wEPGWpxTHGA"
      unitRef="Unit_Standard_shares__cOSbKjBTUyHt70_t1aAVw">35000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="As_Of_12_31_2021_slf_IrTrZku1VVWbbttE4g"
      decimals="INF"
      id="Narr_CmRy69EITkuzwnkz8o9qNw"
      unitRef="Unit_Standard_shares__cOSbKjBTUyHt70_t1aAVw">35000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued
      contextRef="As_Of_12_31_2021_slf_IrTrZku1VVWbbttE4g"
      decimals="INF"
      id="Narr_XsHSyh3C506n8IqYBPWcRA"
      unitRef="Unit_Standard_shares__cOSbKjBTUyHt70_t1aAVw">8100570</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="As_Of_12_31_2020_K1oKCNbpv0CLR8EJWu1PSw"
      decimals="INF"
      id="Narr_1OYXaccn4EqC85sy7M1thg"
      unitRef="Unit_Standard_shares__cOSbKjBTUyHt70_t1aAVw">6891608</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockValue
      contextRef="As_Of_12_31_2021_slf_IrTrZku1VVWbbttE4g"
      decimals="0"
      id="Tc_47JC3vHBrUqSZcQ4rgfTtA_19_3"
      unitRef="Unit_Standard_USD_NFG_pVdyhEyJarLQmedkXA">810</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="As_Of_12_31_2020_K1oKCNbpv0CLR8EJWu1PSw"
      decimals="0"
      id="Tc_ubzJRdRzLEe-EAb0tE5kCg_19_6"
      unitRef="Unit_Standard_USD_NFG_pVdyhEyJarLQmedkXA">689</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapital
      contextRef="As_Of_12_31_2021_slf_IrTrZku1VVWbbttE4g"
      decimals="0"
      id="Tc_wVp0tD6720-IrLev2Qq37g_20_3"
      unitRef="Unit_Standard_USD_NFG_pVdyhEyJarLQmedkXA">73220361</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AdditionalPaidInCapital
      contextRef="As_Of_12_31_2020_K1oKCNbpv0CLR8EJWu1PSw"
      decimals="0"
      id="Tc_1qdHzI17mkCVE1XCtJZXOA_20_6"
      unitRef="Unit_Standard_USD_NFG_pVdyhEyJarLQmedkXA">21779340</us-gaap:AdditionalPaidInCapital>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="As_Of_12_31_2021_slf_IrTrZku1VVWbbttE4g"
      decimals="0"
      id="Tc_ke5KZROy306499I0HJkkgQ_21_3"
      unitRef="Unit_Standard_USD_NFG_pVdyhEyJarLQmedkXA">-28726207</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="As_Of_12_31_2020_K1oKCNbpv0CLR8EJWu1PSw"
      decimals="0"
      id="Tc_tQXMmXuYO0GmXzI9WgGpBQ_21_6"
      unitRef="Unit_Standard_USD_NFG_pVdyhEyJarLQmedkXA">-14239075</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2021_slf_IrTrZku1VVWbbttE4g"
      decimals="0"
      id="Tc_38zSegv7zkmCkhM3buv9ug_22_3"
      unitRef="Unit_Standard_USD_NFG_pVdyhEyJarLQmedkXA">44494964</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2020_K1oKCNbpv0CLR8EJWu1PSw"
      decimals="0"
      id="Tc_X159wrpkk0KRl3v96kXL_A_22_6"
      unitRef="Unit_Standard_USD_NFG_pVdyhEyJarLQmedkXA">7540954</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="As_Of_12_31_2021_slf_IrTrZku1VVWbbttE4g"
      decimals="0"
      id="Tc_DalKhHope0CRvVHT4H6vHA_23_3"
      unitRef="Unit_Standard_USD_NFG_pVdyhEyJarLQmedkXA">46001478</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="As_Of_12_31_2020_K1oKCNbpv0CLR8EJWu1PSw"
      decimals="0"
      id="Tc_XiPIj5whJ0arXpPbFhWvwg_23_6"
      unitRef="Unit_Standard_USD_NFG_pVdyhEyJarLQmedkXA">8119334</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="Duration_1_1_2021_To_12_31_2021_uhkxAiZ6fUeekYGgaMhCqA"
      decimals="0"
      id="Tc_Mbjz93pXHkO640RsF0PQag_5_4"
      unitRef="Unit_Standard_USD_NFG_pVdyhEyJarLQmedkXA">8479031</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="Duration_1_1_2020_To_12_31_2020_3DdHOulAJk6Q0Zn4Vsxq5A"
      decimals="0"
      id="Tc_Xq4EAv7pp0aHW-G7-zGjwA_5_7"
      unitRef="Unit_Standard_USD_NFG_pVdyhEyJarLQmedkXA">3054025</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="Duration_1_1_2021_To_12_31_2021_uhkxAiZ6fUeekYGgaMhCqA"
      decimals="0"
      id="Tc_OeAFmPTmJkmvzvuoRtG18w_6_4"
      unitRef="Unit_Standard_USD_NFG_pVdyhEyJarLQmedkXA">6058190</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="Duration_1_1_2020_To_12_31_2020_3DdHOulAJk6Q0Zn4Vsxq5A"
      decimals="0"
      id="Tc_2nVLRzefkkeVZagwIjGbvA_6_7"
      unitRef="Unit_Standard_USD_NFG_pVdyhEyJarLQmedkXA">3586196</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:OperatingExpenses
      contextRef="Duration_1_1_2021_To_12_31_2021_uhkxAiZ6fUeekYGgaMhCqA"
      decimals="0"
      id="Tc_Qkv20WXmWkansRpC6OUUcw_7_4"
      unitRef="Unit_Standard_USD_NFG_pVdyhEyJarLQmedkXA">14537221</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="Duration_1_1_2020_To_12_31_2020_3DdHOulAJk6Q0Zn4Vsxq5A"
      decimals="0"
      id="Tc_7HeSgb4pU0KKGahsHbNFBQ_7_7"
      unitRef="Unit_Standard_USD_NFG_pVdyhEyJarLQmedkXA">6640221</us-gaap:OperatingExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="Duration_1_1_2021_To_12_31_2021_uhkxAiZ6fUeekYGgaMhCqA"
      decimals="0"
      id="Tc_Hy3fa98TBUSv8UGW0JSVow_9_4"
      unitRef="Unit_Standard_USD_NFG_pVdyhEyJarLQmedkXA">-14537221</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="Duration_1_1_2020_To_12_31_2020_3DdHOulAJk6Q0Zn4Vsxq5A"
      decimals="0"
      id="Tc_XNDvFW6pQUebOARWh_xy5w_9_7"
      unitRef="Unit_Standard_USD_NFG_pVdyhEyJarLQmedkXA">-6640221</us-gaap:OperatingIncomeLoss>
    <us-gaap:UnrealizedGainLossOnDerivatives
      contextRef="Duration_1_1_2020_To_12_31_2020_3DdHOulAJk6Q0Zn4Vsxq5A"
      decimals="0"
      id="Tc_pr5R8eTY-0O1uaEJK0jS1w_11_7"
      unitRef="Unit_Standard_USD_NFG_pVdyhEyJarLQmedkXA">-26500</us-gaap:UnrealizedGainLossOnDerivatives>
    <us-gaap:InterestIncomeExpenseNonoperatingNet
      contextRef="Duration_1_1_2021_To_12_31_2021_uhkxAiZ6fUeekYGgaMhCqA"
      decimals="0"
      id="Tc_RndsHhKQ9UGLRGYEFAGODA_12_4"
      unitRef="Unit_Standard_USD_NFG_pVdyhEyJarLQmedkXA">13335</us-gaap:InterestIncomeExpenseNonoperatingNet>
    <us-gaap:InterestIncomeExpenseNonoperatingNet
      contextRef="Duration_1_1_2020_To_12_31_2020_3DdHOulAJk6Q0Zn4Vsxq5A"
      decimals="0"
      id="Tc_k7AgRZ6_0E64pRsw_LmoQg_12_7"
      unitRef="Unit_Standard_USD_NFG_pVdyhEyJarLQmedkXA">47225</us-gaap:InterestIncomeExpenseNonoperatingNet>
    <anvs:IncomeFromGrants
      contextRef="Duration_1_1_2021_To_12_31_2021_uhkxAiZ6fUeekYGgaMhCqA"
      decimals="0"
      id="Tc_VYtWUmxKaEiRiRKdFXD2aA_13_4"
      unitRef="Unit_Standard_USD_NFG_pVdyhEyJarLQmedkXA">36754</anvs:IncomeFromGrants>
    <anvs:IncomeFromGrants
      contextRef="Duration_1_1_2020_To_12_31_2020_3DdHOulAJk6Q0Zn4Vsxq5A"
      decimals="0"
      id="Tc_9Th5dhhkrEWTNhgnGrUm7g_13_7"
      unitRef="Unit_Standard_USD_NFG_pVdyhEyJarLQmedkXA">1157449</anvs:IncomeFromGrants>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="Duration_1_1_2021_To_12_31_2021_uhkxAiZ6fUeekYGgaMhCqA"
      decimals="0"
      id="Tc_qu79wLByLUCruHwi7Ruczw_14_4"
      unitRef="Unit_Standard_USD_NFG_pVdyhEyJarLQmedkXA">50089</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="Duration_1_1_2020_To_12_31_2020_3DdHOulAJk6Q0Zn4Vsxq5A"
      decimals="0"
      id="Tc_SxOQ28qonEONqyn-tC_aeg_14_7"
      unitRef="Unit_Standard_USD_NFG_pVdyhEyJarLQmedkXA">1178174</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="Duration_1_1_2021_To_12_31_2021_uhkxAiZ6fUeekYGgaMhCqA"
      decimals="0"
      id="Tc_VRmK3IMYcEOcGJq6qId9bA_16_4"
      unitRef="Unit_Standard_USD_NFG_pVdyhEyJarLQmedkXA">-14487132</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="Duration_1_1_2020_To_12_31_2020_3DdHOulAJk6Q0Zn4Vsxq5A"
      decimals="0"
      id="Tc_bpRKLjyZhk2dnXA3MK5rhw_16_7"
      unitRef="Unit_Standard_USD_NFG_pVdyhEyJarLQmedkXA">-5462047</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2021_To_12_31_2021_uhkxAiZ6fUeekYGgaMhCqA"
      decimals="0"
      id="Tc_tOg408dx8kSpV1_EG7LFkQ_18_4"
      unitRef="Unit_Standard_USD_NFG_pVdyhEyJarLQmedkXA">-14487132</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2020_To_12_31_2020_3DdHOulAJk6Q0Zn4Vsxq5A"
      decimals="0"
      id="Tc_ylWfBux2RESK1pTChZPfXg_18_7"
      unitRef="Unit_Standard_USD_NFG_pVdyhEyJarLQmedkXA">-5462047</us-gaap:NetIncomeLoss>
    <us-gaap:EarningsPerShareBasic
      contextRef="Duration_1_1_2021_To_12_31_2021_uhkxAiZ6fUeekYGgaMhCqA"
      decimals="2"
      id="Tc_8PsVXD2LKkGb_mHV_RCMow_19_4"
      unitRef="Unit_Divide_USD_shares_ZtgwQidioUWlbMoOaTBzxg">-1.90</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="Duration_1_1_2020_To_12_31_2020_3DdHOulAJk6Q0Zn4Vsxq5A"
      decimals="2"
      id="Tc_0pfIDxtlK0KReBCFh8HMaA_19_7"
      unitRef="Unit_Divide_USD_shares_ZtgwQidioUWlbMoOaTBzxg">-0.87</us-gaap:EarningsPerShareBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="Duration_1_1_2021_To_12_31_2021_uhkxAiZ6fUeekYGgaMhCqA"
      decimals="0"
      id="Tc_v-_HaYc_KUOxYbWnKG_iSg_20_4"
      unitRef="Unit_Standard_shares__cOSbKjBTUyHt70_t1aAVw">7626278</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="Duration_1_1_2020_To_12_31_2020_3DdHOulAJk6Q0Zn4Vsxq5A"
      decimals="0"
      id="Tc_iACgygUeLEinVxzTqSbehg_20_7"
      unitRef="Unit_Standard_shares__cOSbKjBTUyHt70_t1aAVw">6308961</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:TemporaryEquitySharesIssued
      contextRef="As_Of_12_31_2019_us-gaap_StatementClassOfStockAxis_anvs_SeriesaRedeemableConvertiblePreferredStockMember_odVgKOmG90OBa7U96NG4jw"
      decimals="INF"
      id="Tc_crn0lsa1UEe5UH_4Hbs3Hw_6_2"
      unitRef="Unit_Standard_shares__cOSbKjBTUyHt70_t1aAVw">5133159</us-gaap:TemporaryEquitySharesIssued>
    <us-gaap:TemporaryEquityCarryingAmountAttributableToParent
      contextRef="As_Of_12_31_2019_us-gaap_StatementClassOfStockAxis_anvs_SeriesaRedeemableConvertiblePreferredStockMember_odVgKOmG90OBa7U96NG4jw"
      decimals="0"
      id="Tc_pmJi0xJq90yiFPfvJSjXhQ_6_5"
      unitRef="Unit_Standard_USD_NFG_pVdyhEyJarLQmedkXA">6509303</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
    <us-gaap:TemporaryEquitySharesIssued
      contextRef="As_Of_12_31_2019_us-gaap_StatementClassOfStockAxis_anvs_Series1RedeemableConvertiblePreferredStockMember_pzCzknp_UUqMQod8oici_A"
      decimals="INF"
      id="Tc_9HGaqxB-I0iOPzjNbiqLWQ_6_7"
      unitRef="Unit_Standard_shares__cOSbKjBTUyHt70_t1aAVw">630722</us-gaap:TemporaryEquitySharesIssued>
    <us-gaap:TemporaryEquityCarryingAmountAttributableToParent
      contextRef="As_Of_12_31_2019_us-gaap_StatementClassOfStockAxis_anvs_Series1RedeemableConvertiblePreferredStockMember_pzCzknp_UUqMQod8oici_A"
      decimals="0"
      id="Tc_Xv4o6_MxBUCTYH79JctN7Q_6_10"
      unitRef="Unit_Standard_USD_NFG_pVdyhEyJarLQmedkXA">567649</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
    <us-gaap:SharesIssued
      contextRef="As_Of_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_d1y_dVMmq02lOk2EI5_rBA"
      decimals="INF"
      id="Tc_BmJ2ES4RZUaaaWea0B-FzA_6_13"
      unitRef="Unit_Standard_shares__cOSbKjBTUyHt70_t1aAVw">282614</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_d1y_dVMmq02lOk2EI5_rBA"
      decimals="0"
      id="Tc_gWwKeIX3LUG5X-d0bOVyiw_6_16"
      unitRef="Unit_Standard_USD_NFG_pVdyhEyJarLQmedkXA">28</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_8FIUzd9InkOQst0tn_3nZg"
      decimals="0"
      id="Tc_M-78okxZ20GjqAkaYQt8WA_6_19"
      unitRef="Unit_Standard_USD_NFG_pVdyhEyJarLQmedkXA">200600</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_q8XP9K1S6UO9eBjFQKFqmA"
      decimals="0"
      id="Tc_yiumKFVfyUekM1pzvkP17Q_6_22"
      unitRef="Unit_Standard_USD_NFG_pVdyhEyJarLQmedkXA">-8777028</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2019_S7jX8DT5zEOORR0B4HM-aw"
      decimals="0"
      id="Tc_Jt90k6eYw0u6i0RVHSSNVg_6_25"
      unitRef="Unit_Standard_USD_NFG_pVdyhEyJarLQmedkXA">-8576400</us-gaap:StockholdersEquity>
    <anvs:TemporaryEquitySharesConversionOfPreferredStockToCommonStock
      contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementClassOfStockAxis_anvs_SeriesaRedeemableConvertiblePreferredStockMember_deK8dFWBmk-HMa7S_4aJ1w"
      decimals="INF"
      id="Tc_pjs2aqHcR0WT7iBvvpOGpQ_7_2"
      unitRef="Unit_Standard_shares__cOSbKjBTUyHt70_t1aAVw">5133159</anvs:TemporaryEquitySharesConversionOfPreferredStockToCommonStock>
    <anvs:TemporaryEquityConversionOfPreferredStockToCommonStock
      contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementClassOfStockAxis_anvs_SeriesaRedeemableConvertiblePreferredStockMember_deK8dFWBmk-HMa7S_4aJ1w"
      decimals="0"
      id="Tc_8mXEcpQHQUuAJ2PObODnIw_7_5"
      unitRef="Unit_Standard_USD_NFG_pVdyhEyJarLQmedkXA">6509303</anvs:TemporaryEquityConversionOfPreferredStockToCommonStock>
    <anvs:TemporaryEquitySharesConversionOfPreferredStockToCommonStock
      contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementClassOfStockAxis_anvs_Series1RedeemableConvertiblePreferredStockMember_-LeysnJLjE-x0FvXPGEzVg"
      decimals="INF"
      id="Tc_na3SnAVhLkiiKXgTG5-gjg_7_7"
      unitRef="Unit_Standard_shares__cOSbKjBTUyHt70_t1aAVw">630722</anvs:TemporaryEquitySharesConversionOfPreferredStockToCommonStock>
    <anvs:TemporaryEquityConversionOfPreferredStockToCommonStock
      contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementClassOfStockAxis_anvs_Series1RedeemableConvertiblePreferredStockMember_-LeysnJLjE-x0FvXPGEzVg"
      decimals="0"
      id="Tc_gJrric6iFEiRMbQYRJ1hEg_7_10"
      unitRef="Unit_Standard_USD_NFG_pVdyhEyJarLQmedkXA">567649</anvs:TemporaryEquityConversionOfPreferredStockToCommonStock>
    <anvs:StockIssuedDuringPeriodSharesConversionOfConvertibleSecuritiesPreferredStock
      contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_FOnigPlx6UaoZMNa-ktVRg"
      decimals="INF"
      id="Tc_ozKz8hxrKEeWmHbbfYpenw_7_13"
      unitRef="Unit_Standard_shares__cOSbKjBTUyHt70_t1aAVw">4117089</anvs:StockIssuedDuringPeriodSharesConversionOfConvertibleSecuritiesPreferredStock>
    <anvs:StockIssuedDuringPeriodValueConversionOfConvertibleSecuritiesPreferredStock
      contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_FOnigPlx6UaoZMNa-ktVRg"
      decimals="0"
      id="Tc_8hEgfiFBn02PCg_NvpgRPA_7_16"
      unitRef="Unit_Standard_USD_NFG_pVdyhEyJarLQmedkXA">412</anvs:StockIssuedDuringPeriodValueConversionOfConvertibleSecuritiesPreferredStock>
    <anvs:StockIssuedDuringPeriodValueConversionOfConvertibleSecuritiesPreferredStock
      contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_JVwGb5QRK0mEvKeM6mX7xg"
      decimals="0"
      id="Tc_1bjZ3seAUEKtPJ6WFkaoaA_7_19"
      unitRef="Unit_Standard_USD_NFG_pVdyhEyJarLQmedkXA">7076540</anvs:StockIssuedDuringPeriodValueConversionOfConvertibleSecuritiesPreferredStock>
    <anvs:StockIssuedDuringPeriodValueConversionOfConvertibleSecuritiesPreferredStock
      contextRef="Duration_1_1_2020_To_12_31_2020_3DdHOulAJk6Q0Zn4Vsxq5A"
      decimals="0"
      id="Tc_GssEpakqOEW0lN3GsVxfaw_7_25"
      unitRef="Unit_Standard_USD_NFG_pVdyhEyJarLQmedkXA">7076952</anvs:StockIssuedDuringPeriodValueConversionOfConvertibleSecuritiesPreferredStock>
    <anvs:StockIssuedDuringPeriodSharesConversionOfConvertibleNotes
      contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_FOnigPlx6UaoZMNa-ktVRg"
      decimals="INF"
      id="Tc_4BAnqhkSs0ayfWaIxKdzSQ_8_13"
      unitRef="Unit_Standard_shares__cOSbKjBTUyHt70_t1aAVw">118470</anvs:StockIssuedDuringPeriodSharesConversionOfConvertibleNotes>
    <anvs:StockIssuedDuringPeriodValueConversionOfConvertibleSecuritiesConvertiblePromissoryNotes
      contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_FOnigPlx6UaoZMNa-ktVRg"
      decimals="0"
      id="Tc_XNLR3gieY0-bni74ewRaZg_8_16"
      unitRef="Unit_Standard_USD_NFG_pVdyhEyJarLQmedkXA">12</anvs:StockIssuedDuringPeriodValueConversionOfConvertibleSecuritiesConvertiblePromissoryNotes>
    <anvs:StockIssuedDuringPeriodValueConversionOfConvertibleSecuritiesConvertiblePromissoryNotes
      contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_JVwGb5QRK0mEvKeM6mX7xg"
      decimals="0"
      id="Tc_ZzFjBi2emEmxBMcnlnwh6g_8_19"
      unitRef="Unit_Standard_USD_NFG_pVdyhEyJarLQmedkXA">672512</anvs:StockIssuedDuringPeriodValueConversionOfConvertibleSecuritiesConvertiblePromissoryNotes>
    <anvs:StockIssuedDuringPeriodValueConversionOfConvertibleSecuritiesConvertiblePromissoryNotes
      contextRef="Duration_1_1_2020_To_12_31_2020_3DdHOulAJk6Q0Zn4Vsxq5A"
      decimals="0"
      id="Tc_7zmLsZbfH0GhCDh5eUZpjA_8_25"
      unitRef="Unit_Standard_USD_NFG_pVdyhEyJarLQmedkXA">672524</anvs:StockIssuedDuringPeriodValueConversionOfConvertibleSecuritiesConvertiblePromissoryNotes>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_FOnigPlx6UaoZMNa-ktVRg"
      decimals="INF"
      id="Tc_gx1UC0fNFUm4YYlFtXJM5w_9_13"
      unitRef="Unit_Standard_shares__cOSbKjBTUyHt70_t1aAVw">2300000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_FOnigPlx6UaoZMNa-ktVRg"
      decimals="0"
      id="Tc_itwMy_HfIka5ZVqrybF9BQ_9_16"
      unitRef="Unit_Standard_USD_NFG_pVdyhEyJarLQmedkXA">230</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_JVwGb5QRK0mEvKeM6mX7xg"
      decimals="0"
      id="Tc_4HUT-PIazU2FcnLcodt4vw_9_19"
      unitRef="Unit_Standard_USD_NFG_pVdyhEyJarLQmedkXA">11955565</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="Duration_1_1_2020_To_12_31_2020_3DdHOulAJk6Q0Zn4Vsxq5A"
      decimals="0"
      id="Tc_bYSzNeF9v0q5r6GfVn448w_9_25"
      unitRef="Unit_Standard_USD_NFG_pVdyhEyJarLQmedkXA">11955795</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_FOnigPlx6UaoZMNa-ktVRg"
      decimals="INF"
      id="Tc_ibjWlpFDKkOASFtOQlh5ww_10_13"
      unitRef="Unit_Standard_shares__cOSbKjBTUyHt70_t1aAVw">48435</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_FOnigPlx6UaoZMNa-ktVRg"
      decimals="0"
      id="Tc_OsdfAfnvHUS_R6NkbhPOeQ_10_16"
      unitRef="Unit_Standard_USD_NFG_pVdyhEyJarLQmedkXA">5</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_JVwGb5QRK0mEvKeM6mX7xg"
      decimals="0"
      id="Tc_Q7XPZ9K5iE-dopCigoK2Rg_10_19"
      unitRef="Unit_Standard_USD_NFG_pVdyhEyJarLQmedkXA">9212</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="Duration_1_1_2020_To_12_31_2020_3DdHOulAJk6Q0Zn4Vsxq5A"
      decimals="0"
      id="Tc_m5iRsDUBVU2624TyVeS14A_10_25"
      unitRef="Unit_Standard_USD_NFG_pVdyhEyJarLQmedkXA">9217</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodSharesIssuedForServices
      contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_FOnigPlx6UaoZMNa-ktVRg"
      decimals="INF"
      id="Tc_r0DlDJ2YHEuy8eaHycj7eg_11_13"
      unitRef="Unit_Standard_shares__cOSbKjBTUyHt70_t1aAVw">25000</us-gaap:StockIssuedDuringPeriodSharesIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_FOnigPlx6UaoZMNa-ktVRg"
      decimals="0"
      id="Tc_KBNNgkO1n0GiYa0gy3agig_11_16"
      unitRef="Unit_Standard_USD_NFG_pVdyhEyJarLQmedkXA">2</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_JVwGb5QRK0mEvKeM6mX7xg"
      decimals="0"
      id="Tc_PI57DSMrXE6sPV8bOgKHCg_11_19"
      unitRef="Unit_Standard_USD_NFG_pVdyhEyJarLQmedkXA">122748</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="Duration_1_1_2020_To_12_31_2020_3DdHOulAJk6Q0Zn4Vsxq5A"
      decimals="0"
      id="Tc__MmluatONkieN2F_wBHeMw_11_25"
      unitRef="Unit_Standard_USD_NFG_pVdyhEyJarLQmedkXA">122750</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_JVwGb5QRK0mEvKeM6mX7xg"
      decimals="0"
      id="Tc_WW7IuyYO-UKIt3f1jkImHg_12_19"
      unitRef="Unit_Standard_USD_NFG_pVdyhEyJarLQmedkXA">1742163</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="Duration_1_1_2020_To_12_31_2020_3DdHOulAJk6Q0Zn4Vsxq5A"
      decimals="0"
      id="Tc_XZUVzoohIU6h5OOLKqIFGA_12_25"
      unitRef="Unit_Standard_USD_NFG_pVdyhEyJarLQmedkXA">1742163</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_Yj7CnNrKbk2eFi8MMsgZvQ"
      decimals="0"
      id="Tc_S_Zh-lDslkybFC7-WZV8dQ_13_22"
      unitRef="Unit_Standard_USD_NFG_pVdyhEyJarLQmedkXA">-5462047</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2020_To_12_31_2020_3DdHOulAJk6Q0Zn4Vsxq5A"
      decimals="0"
      id="Tc_W88J1qoKDESziI2y5430gg_13_25"
      unitRef="Unit_Standard_USD_NFG_pVdyhEyJarLQmedkXA">-5462047</us-gaap:NetIncomeLoss>
    <us-gaap:TemporaryEquitySharesIssued
      contextRef="As_Of_12_31_2020_us-gaap_StatementClassOfStockAxis_anvs_SeriesaRedeemableConvertiblePreferredStockMember_54xJpWZU6E-sSdAV-pOOiA"
      decimals="INF"
      id="Tc_j1BIqEQmykKWGfoMqUwQHQ_14_2"
      unitRef="Unit_Standard_shares__cOSbKjBTUyHt70_t1aAVw">0</us-gaap:TemporaryEquitySharesIssued>
    <us-gaap:TemporaryEquityCarryingAmountAttributableToParent
      contextRef="As_Of_12_31_2020_us-gaap_StatementClassOfStockAxis_anvs_SeriesaRedeemableConvertiblePreferredStockMember_54xJpWZU6E-sSdAV-pOOiA"
      decimals="0"
      id="Tc_J9YF3EIF-USZ6ZDb1BTPYA_14_5"
      unitRef="Unit_Standard_USD_NFG_pVdyhEyJarLQmedkXA">0</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
    <us-gaap:TemporaryEquitySharesIssued
      contextRef="As_Of_12_31_2020_us-gaap_StatementClassOfStockAxis_anvs_Series1RedeemableConvertiblePreferredStockMember_hROazqn7SUCQmc794Mq69Q"
      decimals="INF"
      id="Tc_69E5XSZcLEmPZLb3x7Z-IA_14_7"
      unitRef="Unit_Standard_shares__cOSbKjBTUyHt70_t1aAVw">0</us-gaap:TemporaryEquitySharesIssued>
    <us-gaap:TemporaryEquityCarryingAmountAttributableToParent
      contextRef="As_Of_12_31_2020_us-gaap_StatementClassOfStockAxis_anvs_Series1RedeemableConvertiblePreferredStockMember_hROazqn7SUCQmc794Mq69Q"
      decimals="0"
      id="Tc_Fdxv78zYPUKFvBfxyZX8xg_14_10"
      unitRef="Unit_Standard_USD_NFG_pVdyhEyJarLQmedkXA">0</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
    <us-gaap:SharesIssued
      contextRef="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_hBUW9O6ICE63RL-ah82T6g"
      decimals="INF"
      id="Tc_j44c9GrlckaipkxqjzSryQ_14_13"
      unitRef="Unit_Standard_shares__cOSbKjBTUyHt70_t1aAVw">6891608</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_hBUW9O6ICE63RL-ah82T6g"
      decimals="0"
      id="Tc_YOYhdT5kZkyP89I7M5LuDg_14_16"
      unitRef="Unit_Standard_USD_NFG_pVdyhEyJarLQmedkXA">689</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_aLSsuRjKkUqU5e2EQUdxog"
      decimals="0"
      id="Tc_yOZSiS8qMkuTfZIMLcdJZA_14_19"
      unitRef="Unit_Standard_USD_NFG_pVdyhEyJarLQmedkXA">21779340</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_m87TYAU_iECC8Uth9G-F3g"
      decimals="0"
      id="Tc_oPHEaBVuOECgTyrXuq5hdA_14_22"
      unitRef="Unit_Standard_USD_NFG_pVdyhEyJarLQmedkXA">-14239075</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2020_K1oKCNbpv0CLR8EJWu1PSw"
      decimals="0"
      id="Tc_Wm9EhEPu9UuvgPaReoWzNw_14_25"
      unitRef="Unit_Standard_USD_NFG_pVdyhEyJarLQmedkXA">7540954</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_zHbo2vwCLUiM30jKyAcCgw"
      decimals="INF"
      id="Tc_2Hekyg9390uRzmNT1CLrKQ_15_13"
      unitRef="Unit_Standard_shares__cOSbKjBTUyHt70_t1aAVw">1000000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_zHbo2vwCLUiM30jKyAcCgw"
      decimals="0"
      id="Tc_rus-5Gwf6kOOYznumaafjw_15_16"
      unitRef="Unit_Standard_USD_NFG_pVdyhEyJarLQmedkXA">100</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_Nwz3m5oS6kGLY8WW_bxwDQ"
      decimals="0"
      id="Tc_LHaRazFbJU-pe4eZxKA30Q_15_19"
      unitRef="Unit_Standard_USD_NFG_pVdyhEyJarLQmedkXA">46648313</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="Duration_1_1_2021_To_12_31_2021_uhkxAiZ6fUeekYGgaMhCqA"
      decimals="0"
      id="Tc_fclz53uUv0KXU_H9vROX5w_15_25"
      unitRef="Unit_Standard_USD_NFG_pVdyhEyJarLQmedkXA">46648413</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_zHbo2vwCLUiM30jKyAcCgw"
      decimals="INF"
      id="Tc_4AzdzD3VlE-ItfvHvtdSvQ_16_13"
      unitRef="Unit_Standard_shares__cOSbKjBTUyHt70_t1aAVw">155038</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_zHbo2vwCLUiM30jKyAcCgw"
      decimals="0"
      id="Tc_vHDTPmHQaECbFwi2uBjkUw_16_16"
      unitRef="Unit_Standard_USD_NFG_pVdyhEyJarLQmedkXA">16</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_Nwz3m5oS6kGLY8WW_bxwDQ"
      decimals="0"
      id="Tc_NwoFLSp9g0SpMEoL94VuiQ_16_19"
      unitRef="Unit_Standard_USD_NFG_pVdyhEyJarLQmedkXA">95086</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="Duration_1_1_2021_To_12_31_2021_uhkxAiZ6fUeekYGgaMhCqA"
      decimals="0"
      id="Tc_QUZPEDpA4kWY6_edO3swhQ_16_25"
      unitRef="Unit_Standard_USD_NFG_pVdyhEyJarLQmedkXA">95102</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <anvs:StockIssuedDuringPeriodSharesWarrantsExercised
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_zHbo2vwCLUiM30jKyAcCgw"
      decimals="INF"
      id="Tc_DJUxhTxneEG8pblEeeeosw_17_13"
      unitRef="Unit_Standard_shares__cOSbKjBTUyHt70_t1aAVw">53924</anvs:StockIssuedDuringPeriodSharesWarrantsExercised>
    <anvs:StockIssuedDuringPeriodValueWarrantsExercised
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_zHbo2vwCLUiM30jKyAcCgw"
      decimals="0"
      id="Tc_Vpx4eCDNHUOOXkUFBgAntA_17_16"
      unitRef="Unit_Standard_USD_NFG_pVdyhEyJarLQmedkXA">5</anvs:StockIssuedDuringPeriodValueWarrantsExercised>
    <anvs:StockIssuedDuringPeriodValueWarrantsExercised
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_Nwz3m5oS6kGLY8WW_bxwDQ"
      decimals="0"
      id="Tc_xrCkR3US8k60_tMPSoYUJQ_17_19"
      unitRef="Unit_Standard_USD_NFG_pVdyhEyJarLQmedkXA">-5</anvs:StockIssuedDuringPeriodValueWarrantsExercised>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_Nwz3m5oS6kGLY8WW_bxwDQ"
      decimals="0"
      id="Tc_gbtcf35dRkWAzlO1jrRp9g_18_19"
      unitRef="Unit_Standard_USD_NFG_pVdyhEyJarLQmedkXA">4697627</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="Duration_1_1_2021_To_12_31_2021_uhkxAiZ6fUeekYGgaMhCqA"
      decimals="0"
      id="Tc_2O68M5CO8ku8_YK1BPAnyw_18_25"
      unitRef="Unit_Standard_USD_NFG_pVdyhEyJarLQmedkXA">4697627</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_ryg7L-2WUkOqbAJ4DvlylQ"
      decimals="0"
      id="Tc_Lcytg_OwZU2ragf8p7cVqg_19_22"
      unitRef="Unit_Standard_USD_NFG_pVdyhEyJarLQmedkXA">-14487132</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2021_To_12_31_2021_uhkxAiZ6fUeekYGgaMhCqA"
      decimals="0"
      id="Tc_VLekNJ13u0-AJEw9X58VLg_19_25"
      unitRef="Unit_Standard_USD_NFG_pVdyhEyJarLQmedkXA">-14487132</us-gaap:NetIncomeLoss>
    <us-gaap:SharesIssued
      contextRef="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_xiqgw4dbRkGQtr2BjCvyAw"
      decimals="INF"
      id="Tc_X5Vwzpqt1k67WR49M0joGA_20_13"
      unitRef="Unit_Standard_shares__cOSbKjBTUyHt70_t1aAVw">8100570</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_xiqgw4dbRkGQtr2BjCvyAw"
      decimals="0"
      id="Tc_Di9n34EJikqTYfNyK92_ew_20_16"
      unitRef="Unit_Standard_USD_NFG_pVdyhEyJarLQmedkXA">810</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_Roe1SnnNfUKvOnVm7PJZ8w"
      decimals="0"
      id="Tc_08T3fyqIUU6yC1wM6aPElA_20_19"
      unitRef="Unit_Standard_USD_NFG_pVdyhEyJarLQmedkXA">73220361</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_vHHC9xto40u1e1f1OxZXDA"
      decimals="0"
      id="Tc_4UdKxYv5pk6g14N6-52m5g_20_22"
      unitRef="Unit_Standard_USD_NFG_pVdyhEyJarLQmedkXA">-28726207</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2021_slf_IrTrZku1VVWbbttE4g"
      decimals="0"
      id="Tc__tSn7Utn5kCEsUI92WEsWw_20_25"
      unitRef="Unit_Standard_USD_NFG_pVdyhEyJarLQmedkXA">44494964</us-gaap:StockholdersEquity>
    <us-gaap:ProfitLoss
      contextRef="Duration_1_1_2021_To_12_31_2021_uhkxAiZ6fUeekYGgaMhCqA"
      decimals="0"
      id="Tc_XxsXNPtbsECN-dS-w8tgBw_4_3"
      unitRef="Unit_Standard_USD_NFG_pVdyhEyJarLQmedkXA">-14487132</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="Duration_1_1_2020_To_12_31_2020_3DdHOulAJk6Q0Zn4Vsxq5A"
      decimals="0"
      id="Tc_WywI_Osr6kut7ktf57bY_Q_4_6"
      unitRef="Unit_Standard_USD_NFG_pVdyhEyJarLQmedkXA">-5462047</us-gaap:ProfitLoss>
    <us-gaap:AmortizationOfFinancingCosts
      contextRef="Duration_1_1_2020_To_12_31_2020_3DdHOulAJk6Q0Zn4Vsxq5A"
      decimals="0"
      id="Tc_mi_trP8vgU-w7XJxcLePow_6_6"
      unitRef="Unit_Standard_USD_NFG_pVdyhEyJarLQmedkXA">129</us-gaap:AmortizationOfFinancingCosts>
    <us-gaap:AmortizationOfDebtDiscountPremium
      contextRef="Duration_1_1_2020_To_12_31_2020_3DdHOulAJk6Q0Zn4Vsxq5A"
      decimals="0"
      id="Tc_gPpMF3oKWUGsM68cQtp5-w_7_6"
      unitRef="Unit_Standard_USD_NFG_pVdyhEyJarLQmedkXA">396</us-gaap:AmortizationOfDebtDiscountPremium>
    <us-gaap:ShareBasedCompensation
      contextRef="Duration_1_1_2021_To_12_31_2021_uhkxAiZ6fUeekYGgaMhCqA"
      decimals="0"
      id="Tc_utofmZP3Bk6-LvENNjEAJA_8_3"
      unitRef="Unit_Standard_USD_NFG_pVdyhEyJarLQmedkXA">4697627</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="Duration_1_1_2020_To_12_31_2020_3DdHOulAJk6Q0Zn4Vsxq5A"
      decimals="0"
      id="Tc_ywd_3OIhOES9MDiJHmYyoQ_8_6"
      unitRef="Unit_Standard_USD_NFG_pVdyhEyJarLQmedkXA">1864913</us-gaap:ShareBasedCompensation>
    <us-gaap:UnrealizedGainLossOnDerivatives
      contextRef="Duration_1_1_2020_To_12_31_2020_3DdHOulAJk6Q0Zn4Vsxq5A"
      decimals="0"
      id="Tc_lnfAmg0y4EOZdbOP7GTwOg_9_6"
      unitRef="Unit_Standard_USD_NFG_pVdyhEyJarLQmedkXA">-26500</us-gaap:UnrealizedGainLossOnDerivatives>
    <anvs:IncreaseDecreaseInGrantsReceivable
      contextRef="Duration_1_1_2020_To_12_31_2020_3DdHOulAJk6Q0Zn4Vsxq5A"
      decimals="0"
      id="Tc_72jKXPkccU6DG2eKwcWBfg_11_6"
      unitRef="Unit_Standard_USD_NFG_pVdyhEyJarLQmedkXA">-735075</anvs:IncreaseDecreaseInGrantsReceivable>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="Duration_1_1_2021_To_12_31_2021_uhkxAiZ6fUeekYGgaMhCqA"
      decimals="0"
      id="Tc_Z2Qr0aGOmU-lJv6tcHuR6A_12_3"
      unitRef="Unit_Standard_USD_NFG_pVdyhEyJarLQmedkXA">270788</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="Duration_1_1_2020_To_12_31_2020_3DdHOulAJk6Q0Zn4Vsxq5A"
      decimals="0"
      id="Tc_1vli_YsKw02A102y8XRajw_12_6"
      unitRef="Unit_Standard_USD_NFG_pVdyhEyJarLQmedkXA">34097</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="Duration_1_1_2021_To_12_31_2021_uhkxAiZ6fUeekYGgaMhCqA"
      decimals="0"
      id="Tc_QPAqqnsx2kC4qF4kuML43w_13_3"
      unitRef="Unit_Standard_USD_NFG_pVdyhEyJarLQmedkXA">346218</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="Duration_1_1_2020_To_12_31_2020_3DdHOulAJk6Q0Zn4Vsxq5A"
      decimals="0"
      id="Tc_t2eL_coHOEKSfKquIVWryg_13_6"
      unitRef="Unit_Standard_USD_NFG_pVdyhEyJarLQmedkXA">-695660</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities
      contextRef="Duration_1_1_2021_To_12_31_2021_uhkxAiZ6fUeekYGgaMhCqA"
      decimals="0"
      id="Tc_SowV2zf94kK3yDZZr7Lt3w_14_3"
      unitRef="Unit_Standard_USD_NFG_pVdyhEyJarLQmedkXA">581916</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities
      contextRef="Duration_1_1_2020_To_12_31_2020_3DdHOulAJk6Q0Zn4Vsxq5A"
      decimals="0"
      id="Tc_SnZaJCi7w0q1xICPA9rwdQ_14_6"
      unitRef="Unit_Standard_USD_NFG_pVdyhEyJarLQmedkXA">-406032</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="Duration_1_1_2021_To_12_31_2021_uhkxAiZ6fUeekYGgaMhCqA"
      decimals="0"
      id="Tc_qnA8DT-QRUWUZ4OlPYjWqA_15_3"
      unitRef="Unit_Standard_USD_NFG_pVdyhEyJarLQmedkXA">-9132159</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="Duration_1_1_2020_To_12_31_2020_3DdHOulAJk6Q0Zn4Vsxq5A"
      decimals="0"
      id="Tc_0EDyyfAXGECiILSeEkTR7A_15_6"
      unitRef="Unit_Standard_USD_NFG_pVdyhEyJarLQmedkXA">-3970823</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="Duration_1_1_2021_To_12_31_2021_uhkxAiZ6fUeekYGgaMhCqA"
      decimals="0"
      id="Tc_KKKxM4eUjUupYae1QA9oOA_17_3"
      unitRef="Unit_Standard_USD_NFG_pVdyhEyJarLQmedkXA">46648413</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="Duration_1_1_2020_To_12_31_2020_3DdHOulAJk6Q0Zn4Vsxq5A"
      decimals="0"
      id="Tc_OudJY-SUk0ShMAvNSsJNpg_17_6"
      unitRef="Unit_Standard_USD_NFG_pVdyhEyJarLQmedkXA">12034406</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="Duration_1_1_2021_To_12_31_2021_uhkxAiZ6fUeekYGgaMhCqA"
      decimals="0"
      id="Tc_LUK94WBeSUiuCxTfNeTzZA_18_3"
      unitRef="Unit_Standard_USD_NFG_pVdyhEyJarLQmedkXA">95102</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="Duration_1_1_2020_To_12_31_2020_3DdHOulAJk6Q0Zn4Vsxq5A"
      decimals="0"
      id="Tc_OmxMpbS5S0ufqzKpv9uYJA_18_6"
      unitRef="Unit_Standard_USD_NFG_pVdyhEyJarLQmedkXA">9217</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="Duration_1_1_2021_To_12_31_2021_uhkxAiZ6fUeekYGgaMhCqA"
      decimals="0"
      id="Tc_kdAWcz8eOUisguYPjGd3Bg_19_3"
      unitRef="Unit_Standard_USD_NFG_pVdyhEyJarLQmedkXA">46743515</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="Duration_1_1_2020_To_12_31_2020_3DdHOulAJk6Q0Zn4Vsxq5A"
      decimals="0"
      id="Tc_km4hjCjvyU2KqJatP0TltQ_19_6"
      unitRef="Unit_Standard_USD_NFG_pVdyhEyJarLQmedkXA">12043623</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="Duration_1_1_2021_To_12_31_2021_uhkxAiZ6fUeekYGgaMhCqA"
      decimals="0"
      id="Tc_-st175dXpEeUcf5zlBXq4Q_20_3"
      unitRef="Unit_Standard_USD_NFG_pVdyhEyJarLQmedkXA">37611356</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="Duration_1_1_2020_To_12_31_2020_3DdHOulAJk6Q0Zn4Vsxq5A"
      decimals="0"
      id="Tc_SnYo6NCH2UqUDSWTgsFosw_20_6"
      unitRef="Unit_Standard_USD_NFG_pVdyhEyJarLQmedkXA">8072800</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="As_Of_12_31_2020_K1oKCNbpv0CLR8EJWu1PSw"
      decimals="0"
      id="Tc_fNjsR7Vk8Eu2rkrinmxRgw_21_3"
      unitRef="Unit_Standard_USD_NFG_pVdyhEyJarLQmedkXA">8074658</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="As_Of_12_31_2019_S7jX8DT5zEOORR0B4HM-aw"
      decimals="0"
      id="Tc_pq8MudX8E0-1bPHtDDI_yA_21_6"
      unitRef="Unit_Standard_USD_NFG_pVdyhEyJarLQmedkXA">1858</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="As_Of_12_31_2021_slf_IrTrZku1VVWbbttE4g"
      decimals="0"
      id="Tc_DqN6doehrkKynVCSX4IjDQ_22_3"
      unitRef="Unit_Standard_USD_NFG_pVdyhEyJarLQmedkXA">45686014</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="As_Of_12_31_2020_K1oKCNbpv0CLR8EJWu1PSw"
      decimals="0"
      id="Tc_uooZ3TjZ3kqxlma3PNL_xg_22_6"
      unitRef="Unit_Standard_USD_NFG_pVdyhEyJarLQmedkXA">8074658</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <anvs:ConversionOfRedeemableConvertiblePreferredStockToCommonStock
      contextRef="Duration_1_1_2020_To_12_31_2020_3DdHOulAJk6Q0Zn4Vsxq5A"
      decimals="0"
      id="Tc_kQ8kVee7eEiUlnLXV6igqg_24_6"
      unitRef="Unit_Standard_USD_NFG_pVdyhEyJarLQmedkXA">7076952</anvs:ConversionOfRedeemableConvertiblePreferredStockToCommonStock>
    <anvs:ConversionOfConvertiblePromissoryNotesIncludingEmbeddedDerivativeToCommonStock
      contextRef="Duration_1_1_2020_To_12_31_2020_3DdHOulAJk6Q0Zn4Vsxq5A"
      decimals="0"
      id="Tc_ZAt7U6B6f0KFqClSEV21SQ_25_6"
      unitRef="Unit_Standard_USD_NFG_pVdyhEyJarLQmedkXA">672524</anvs:ConversionOfConvertiblePromissoryNotesIncludingEmbeddedDerivativeToCommonStock>
    <us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock
      contextRef="Duration_1_1_2021_To_12_31_2021_uhkxAiZ6fUeekYGgaMhCqA"
      id="Tb_VxLX6s5EQEyHmB9RT_I91Q">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;(1)&#160;Nature of Business and Liquidity&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Annovis Bio,&#160;Inc. (the &#x201c;Company&#x201d; or &#x201c;Annovis&#x201d;) was incorporated on April&#160;29, 2008, under the laws of the State of Delaware. Annovis is a clinical-stage drug platform company addressing neurodegeneration such as Alzheimer&#x2019;s disease (&#x201c;AD&#x201d;), Parkinson&#x2019;s disease (&#x201c;PD&#x201d;) and Down syndrome patients with AD (&#x201c;DS-AD&#x201d;). The toxic cascade in neurodegeneration begins with high levels of neurotoxic proteins which lead to impaired axonal transport, inflammation, death of nerve cells and loss of cognition and motor function. The Company&#x2019;s lead compound, Buntanetap, is a small molecule administered orally that attacks neurodegeneration by entering the brain and inhibiting the translation of multiple neurotoxic proteins thereby impeding the toxic cascade.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Since its founding, the Company has been engaged in organizational activities, including raising capital, and research and development activities. The Company has &lt;span style="-sec-ix-hidden:Hidden_wLzrCC9kDk6BKVi6RIiXmQ;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;not&lt;/span&gt;&lt;/span&gt; generated substantial revenues and has not yet achieved profitable operations, nor has it ever generated positive cash flows from operations. There is no assurance that profitable operations, if achieved, could be sustained on a continuing basis. The Company is subject to those risks associated with any clinical stage pharmaceutical company that has substantial expenditures for research and development. There can be no assurance that the Company&#x2019;s research and development projects will be successful, that products developed will obtain necessary regulatory approval, or that any approved product will be commercially viable. In addition, the Company operates in an environment of rapid technological change and is largely dependent on the services of its employees and consultants. Further, the Company&#x2019;s future operations are dependent on the success of the Company&#x2019;s efforts to raise additional capital.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company has a history of incurring net losses and anticipates incurring additional losses until such time, if ever, that it can generate significant revenue from its product candidates currently in development. The Company&#x2019;s primary source of capital has been the issuance of equity securities.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company closed its initial public offering (the &#x201c;IPO&#x201d;) on January&#160;31, 2020, pursuant to which it sold a total of 2,300,000 shares of common stock at an initial offering price of $6.00 per share for total gross proceeds of approximately&#160;$13.8 million. The net proceeds of the IPO were approximately $12.0 million after deducting underwriting discounts and issuance costs paid by&#160;the Company. In conjunction with the IPO, the Company granted the underwriters 100,000 warrants to purchase shares of Company common stock at an exercise price of $7.50 per share, which is 125% of the initial public offering price. Upon the closing of the IPO, outstanding redeemable convertible preferred stock and convertible promissory notes&#160;converted into shares of Company common stock totaling 4,117,089 and 118,470&lt;span style="white-space:pre-wrap;"&gt;, respectively.  On May 26, 2021, the Company closed an underwritten public offering of &lt;/span&gt;1,000,000 shares of its common stock at an offering price of $50.00 per share, for gross proceeds of $50.0&lt;span style="white-space:pre-wrap;"&gt; million.  The net proceeds of the offering were approximately &lt;/span&gt;$46.6&lt;span style="white-space:pre-wrap;"&gt; million, after deducting underwriting discounts and issuance costs paid by the Company.  The Company&#x2019;s common stock trades on the New York Stock Exchange under the ticker symbol &#x201c;ANVS&#x201d;.  &lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;As of the date these financial statements are issued, management believes that the current cash and cash equivalents are sufficient to fund operations and capital requirements for at least the next 12&#160;months including one potential short-term clinical trial in AD and one potential short term clinical trial in PD. To fund additional planned Phase 3 trials, however, the Company will need to raise additional capital. There is no assurance that such financing will be available when needed or on acceptable terms.&lt;/p&gt;</us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="Duration_1_31_2020_To_1_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember_sRjzEwCZI0yVkxtZkXzw0w"
      decimals="INF"
      id="Narr_Ln63qVFnCkeyAqtmRQYwOA"
      unitRef="Unit_Standard_shares__cOSbKjBTUyHt70_t1aAVw">2300000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:SharePrice
      contextRef="As_Of_1_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember_rLszk1iR-U-miS0THNh94A"
      decimals="2"
      id="Narr__7H6AV-XfUGPTYUjJBzzkg"
      unitRef="Unit_Divide_USD_shares_ZtgwQidioUWlbMoOaTBzxg">6.00</us-gaap:SharePrice>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="Duration_1_31_2020_To_1_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember_sRjzEwCZI0yVkxtZkXzw0w"
      decimals="-5"
      id="Narr_qkKOmRuPl06lLgbb-PxIwA"
      unitRef="Unit_Standard_USD_NFG_pVdyhEyJarLQmedkXA">13800000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction
      contextRef="Duration_1_31_2020_To_1_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember_sRjzEwCZI0yVkxtZkXzw0w"
      decimals="-5"
      id="Narr_90S1qGChik6l75QAcXU-qw"
      unitRef="Unit_Standard_USD_NFG_pVdyhEyJarLQmedkXA">12000000.0</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="As_Of_1_31_2020_us-gaap_ClassOfWarrantOrRightAxis_anvs_UnderwritersWarrantsMember_p2Rmy9kgMES4LjCsl9nsqg"
      decimals="INF"
      id="Narr_OdL1d1oC0U2RZxT4RlJcsw"
      unitRef="Unit_Standard_shares__cOSbKjBTUyHt70_t1aAVw">100000</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="As_Of_1_31_2020_us-gaap_ClassOfWarrantOrRightAxis_anvs_UnderwritersWarrantsMember_p2Rmy9kgMES4LjCsl9nsqg"
      decimals="2"
      id="Narr_stenrccGPkCUCf9kUB1WYA"
      unitRef="Unit_Divide_USD_shares_ZtgwQidioUWlbMoOaTBzxg">7.50</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <anvs:PercentageOfExercisePriceToShareOfferingPrice
      contextRef="As_Of_1_31_2020_us-gaap_ClassOfWarrantOrRightAxis_anvs_UnderwritersWarrantsMember_p2Rmy9kgMES4LjCsl9nsqg"
      decimals="2"
      id="Narr_9WYL0GUViUy0pr4cmYyjxg"
      unitRef="Unit_Standard_pure_n7tAfGlk1kyqYH5N2uCURw">1.25</anvs:PercentageOfExercisePriceToShareOfferingPrice>
    <anvs:StockIssuedDuringPeriodSharesConversionOfConvertibleSecuritiesPreferredStock
      contextRef="Duration_1_31_2020_To_1_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember_sRjzEwCZI0yVkxtZkXzw0w"
      decimals="INF"
      id="Narr_-2T-n3uT4UKdTG4pK0D2Hg"
      unitRef="Unit_Standard_shares__cOSbKjBTUyHt70_t1aAVw">4117089</anvs:StockIssuedDuringPeriodSharesConversionOfConvertibleSecuritiesPreferredStock>
    <anvs:StockIssuedDuringPeriodSharesConversionOfConvertibleNotes
      contextRef="Duration_1_31_2020_To_1_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember_sRjzEwCZI0yVkxtZkXzw0w"
      decimals="INF"
      id="Narr_vQELTN72wESKFtuu0IH8Ug"
      unitRef="Unit_Standard_shares__cOSbKjBTUyHt70_t1aAVw">118470</anvs:StockIssuedDuringPeriodSharesConversionOfConvertibleNotes>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="Duration_5_26_2021_To_5_26_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_us-gaap_SubsidiarySaleOfStockAxis_anvs_SecondaryPublicOfferingMember_hxxkehfNkEWWBXStlPA61w"
      decimals="INF"
      id="Narr_cWiYQYscAEWthQUNNlIkxg"
      unitRef="Unit_Standard_shares__cOSbKjBTUyHt70_t1aAVw">1000000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:SharePrice
      contextRef="As_Of_5_26_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_us-gaap_SubsidiarySaleOfStockAxis_anvs_SecondaryPublicOfferingMember_VQlutMc_ZkWzfLztqs-8Cg"
      decimals="2"
      id="Narr_2lBWGydoXUe3vHGMKipL5A"
      unitRef="Unit_Divide_USD_shares_ZtgwQidioUWlbMoOaTBzxg">50.00</us-gaap:SharePrice>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="Duration_5_26_2021_To_5_26_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_us-gaap_SubsidiarySaleOfStockAxis_anvs_SecondaryPublicOfferingMember_hxxkehfNkEWWBXStlPA61w"
      decimals="-5"
      id="Narr_ZByga6QmvU2zwUZevIyqSw"
      unitRef="Unit_Standard_USD_NFG_pVdyhEyJarLQmedkXA">50000000.0</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction
      contextRef="Duration_5_26_2021_To_5_26_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_us-gaap_SubsidiarySaleOfStockAxis_anvs_SecondaryPublicOfferingMember_hxxkehfNkEWWBXStlPA61w"
      decimals="-5"
      id="Narr_ylxtS1151kC-g4xxSrO8tQ"
      unitRef="Unit_Standard_USD_NFG_pVdyhEyJarLQmedkXA">46600000</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <us-gaap:SignificantAccountingPoliciesTextBlock
      contextRef="Duration_1_1_2021_To_12_31_2021_uhkxAiZ6fUeekYGgaMhCqA"
      id="Tb_AqM9X4FYQUmVAZPtBW3VZg">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;(2)&#160;Summary of Significant Accounting Policies&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;"&gt;(a)&#160;Basis of Presentation&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"&gt;The accompanying financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America (&#x201c;U.S.&#160;GAAP&#x201d;). Any reference in these notes to applicable guidance is meant &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;to refer to U.S.&#160;GAAP as found in the Accounting Standards Codification (&#x201c;ASC&#x201d;) and Accounting Standards Update (&#x201c;ASU&#x201d;) of the Financial Accounting Standards Board (&#x201c;FASB&#x201d;).&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;"&gt;(b)&#160;Use of Estimates&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The preparation of financial statements in conformity with U.S.&#160;GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, including disclosure of contingent assets and liabilities, at the date of the financial statements, and the reported amounts of revenues and expenses during the reporting period. Due to the uncertainty of factors surrounding the estimates or judgments used in the preparation of the financial statements, actual results may materially vary from these estimates.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Significant items subject to such estimates and assumptions include progress towards completion of research and development projects, stock-based compensation expense, grant income and contingent liabilities. Future events and their effects cannot be predicted with certainty; accordingly, accounting estimates require the exercise of judgment. Accounting estimates used in the preparation of these financial statements change as new events occur, as more experience is acquired, as additional information is obtained and as the operating environment changes.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;"&gt;(c)&#160;Basic and Diluted Net Income (Loss) per Share&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Basic net income (loss) per share is determined using the weighted average number of shares of common stock outstanding during each period. Diluted net income (loss) per share includes the effect, if any, from the potential exercise or conversion of securities, such as redeemable convertible preferred stock, convertible promissory notes and stock options, which would result in the issuance of incremental shares of common stock. The computation of diluted net income (loss) per shares does not include the conversion of securities that would have an anti-dilutive effect.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;"&gt;(d)&#160;Cash and Cash Equivalents&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company considers all highly liquid investments with original maturities of three&#160;months or less to be cash equivalents. At times, the Company&#x2019;s cash balances may exceed the current insured amounts under the Federal Deposit Insurance Corporation. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;"&gt;(e)&#160;Issuance Costs Associated with Equity Issuances&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Issuance costs incurred in connection with the Company&#x2019;s equity issuances, which primarily consisted of direct incremental legal, printing, listing and accounting fees, are offset against proceeds received in the issuances and charged to additional paid-in capital in the period the equity issuance is completed. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;"&gt;(f)&#160;Fair Value of Financial Instruments&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company&#x2019;s financial instruments include cash and cash equivalents, accounts payable and accrued expenses. Cash and cash equivalents are reported at fair value. The recorded carrying amount of accounts payable and accrued expenses reflect their fair value due to their short-term nature.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;"&gt;(g)&#160;Research and Development&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Research and development costs are expensed as incurred and are primarily comprised of personnel-related expenses and external research and development expenses incurred under arrangements with third parties, such as contract research organizations and consultants. At the end of each reporting period, the Company compares the payments made to each service provider to the estimated progress towards completion of the related project. Factors that the Company considers in preparing these estimates include the number of patients enrolled in studies, milestones achieved, and other criteria related to the efforts of its vendors. These estimates will be subject to change as additional information becomes available. Depending on the timing of payments to vendors and estimated services provided, the Company will record net prepaid or accrued expenses related to these costs.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;"&gt;(h)&#160;Grant Income&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Grants received are recognized as grant income in the statements of operations as and when they are earned for the specific research and development projects for which these grants are designated. Grants payments received in excess of grant income earned are recognized as deferred grant on the balance sheet and grant income earned in excess of grant payments received is recognized as grant receivable on the balance sheets.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;"&gt;(i)&#160;Stock-Based Compensation&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Stock-based compensation cost is measured at the grant date based on the fair value of the award and is recognized as expense on a straight-line basis over the requisite service period, which is generally the vesting period. Forfeitures are recognized in compensation expense in the period when they occur.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company uses the Black-Scholes option pricing model to value its option awards which requires the use of subjective assumptions, including the expected life of the option and expected share price volatility. The assumptions used in calculating the fair value of stock-based awards represent management&#x2019;s best estimates and involve inherent uncertainties and the application of management&#x2019;s judgment. As a result, if factors change and management uses different assumptions, stock-based compensation expense could be materially different for future awards.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Upon exercise of stock options, the Company issues shares first from treasury stock, if available, then from authorized but unissued shares.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;"&gt;(j)&#160;Income Taxes&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company provides for income taxes using the asset and liability approach. Deferred tax assets and liabilities are recorded based on the differences between the financial statement and tax bases of assets and liabilities and the tax rates in effect when these differences are expected to reverse. Deferred tax assets are reduced by a valuation allowance if, based on the weight of available evidence, it is more likely than not that some or all of the deferred tax assets will not be realized. As of December 31, 2021 and 2020, the Company had a full valuation allowance against its deferred tax assets.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company is subject to the provisions of ASC 740,&#160;Income Taxes, which prescribes a more likely-than-not threshold for the financial statement recognition of uncertain tax positions. ASC 740 clarifies the accounting for income taxes by prescribing a minimum recognition threshold and measurement attribute for the financial statement recognition and measurement of a tax position taken or expected to be taken in a tax return. There are currently no open federal or state tax audits. The Company has not recorded any liability for uncertain tax positions at December&#160;31, 2021 or December&#160;31, 2020.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;"&gt;(k)&#160;Recent Accounting Pronouncements&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;In December&#160;2019, the FASB issued ASU No.&#160;2019-12,&#160;Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes. The amendments in ASU 2019-12 simplify the accounting for income taxes by removing certain exceptions to the general principles in Topic 740 and clarifying and amending existing guidance. The new standard is effective for fiscal&#160;years, and interim periods within those fiscal&#160;years, beginning after December&#160;15, 2020, with early adoption permitted. The adoption of this standard did not have an impact on the Company&#x2019;s financial statements.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt;In November 2021, the FASB issued ASU No. 2021-10, Government Assistance (Topic 832): Disclosures by Business Entities about Government Assistance. The amendments in ASU 2021-10 require annual disclosures about transactions with a government that are accounted for by applying a grant or contribution accounting model by analogy.  The new disclosure requirements include information about the nature of the transactions and the related accounting policy used to account for the transactions; the line items on the balance sheet and income statement that are affected by the transactions, and the amounts applicable to each financial statement line item; and significant terms and conditions of the transactions, including commitments and contingencies.  The guidance is effective for fiscal years beginning after &lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt;December 15, 2021, with early adoption permitted, and may be adopted prospectively or retrospectively.  The Company does not believe the adoption of this standard will have a significant impact on its financial statements.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"&gt;&lt;span style="font-size:2pt;margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:SignificantAccountingPoliciesTextBlock>
    <us-gaap:BasisOfAccounting
      contextRef="Duration_1_1_2021_To_12_31_2021_uhkxAiZ6fUeekYGgaMhCqA"
      id="Tb_bQiz5cmJGEmlaEu9cy6mew">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;"&gt;(a)&#160;Basis of Presentation&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"&gt;The accompanying financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America (&#x201c;U.S.&#160;GAAP&#x201d;). Any reference in these notes to applicable guidance is meant &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;to refer to U.S.&#160;GAAP as found in the Accounting Standards Codification (&#x201c;ASC&#x201d;) and Accounting Standards Update (&#x201c;ASU&#x201d;) of the Financial Accounting Standards Board (&#x201c;FASB&#x201d;).&lt;/p&gt;</us-gaap:BasisOfAccounting>
    <us-gaap:UseOfEstimates
      contextRef="Duration_1_1_2021_To_12_31_2021_uhkxAiZ6fUeekYGgaMhCqA"
      id="Tb_9Pw8vdHFwU6QJMbHf3gi3g">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;"&gt;(b)&#160;Use of Estimates&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The preparation of financial statements in conformity with U.S.&#160;GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, including disclosure of contingent assets and liabilities, at the date of the financial statements, and the reported amounts of revenues and expenses during the reporting period. Due to the uncertainty of factors surrounding the estimates or judgments used in the preparation of the financial statements, actual results may materially vary from these estimates.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Significant items subject to such estimates and assumptions include progress towards completion of research and development projects, stock-based compensation expense, grant income and contingent liabilities. Future events and their effects cannot be predicted with certainty; accordingly, accounting estimates require the exercise of judgment. Accounting estimates used in the preparation of these financial statements change as new events occur, as more experience is acquired, as additional information is obtained and as the operating environment changes.&lt;/p&gt;</us-gaap:UseOfEstimates>
    <us-gaap:EarningsPerSharePolicyTextBlock
      contextRef="Duration_1_1_2021_To_12_31_2021_uhkxAiZ6fUeekYGgaMhCqA"
      id="Tb_Jt8FadyEVUuQI7R7nh_FGg">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;"&gt;(c)&#160;Basic and Diluted Net Income (Loss) per Share&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Basic net income (loss) per share is determined using the weighted average number of shares of common stock outstanding during each period. Diluted net income (loss) per share includes the effect, if any, from the potential exercise or conversion of securities, such as redeemable convertible preferred stock, convertible promissory notes and stock options, which would result in the issuance of incremental shares of common stock. The computation of diluted net income (loss) per shares does not include the conversion of securities that would have an anti-dilutive effect.&lt;/p&gt;</us-gaap:EarningsPerSharePolicyTextBlock>
    <us-gaap:CashAndCashEquivalentsPolicyTextBlock
      contextRef="Duration_1_1_2021_To_12_31_2021_uhkxAiZ6fUeekYGgaMhCqA"
      id="Tb_V2kQLYpxV0uWkDEabM27vQ">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;"&gt;(d)&#160;Cash and Cash Equivalents&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company considers all highly liquid investments with original maturities of three&#160;months or less to be cash equivalents. At times, the Company&#x2019;s cash balances may exceed the current insured amounts under the Federal Deposit Insurance Corporation. &lt;/p&gt;</us-gaap:CashAndCashEquivalentsPolicyTextBlock>
    <anvs:IssuanceCostsAssociatedWithEquityIssuancesPolicyTextBlock
      contextRef="Duration_1_1_2021_To_12_31_2021_uhkxAiZ6fUeekYGgaMhCqA"
      id="Tb_eKEpF3dQVEWuY49TCqBLng">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;"&gt;(e)&#160;Issuance Costs Associated with Equity Issuances&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Issuance costs incurred in connection with the Company&#x2019;s equity issuances, which primarily consisted of direct incremental legal, printing, listing and accounting fees, are offset against proceeds received in the issuances and charged to additional paid-in capital in the period the equity issuance is completed. &lt;/p&gt;</anvs:IssuanceCostsAssociatedWithEquityIssuancesPolicyTextBlock>
    <us-gaap:FairValueOfFinancialInstrumentsPolicy
      contextRef="Duration_1_1_2021_To_12_31_2021_uhkxAiZ6fUeekYGgaMhCqA"
      id="Tb_16LXHoP6oUqYL2NswSNneg">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;"&gt;(f)&#160;Fair Value of Financial Instruments&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company&#x2019;s financial instruments include cash and cash equivalents, accounts payable and accrued expenses. Cash and cash equivalents are reported at fair value. The recorded carrying amount of accounts payable and accrued expenses reflect their fair value due to their short-term nature.&lt;/p&gt;</us-gaap:FairValueOfFinancialInstrumentsPolicy>
    <us-gaap:ResearchDevelopmentAndComputerSoftwarePolicyTextBlock
      contextRef="Duration_1_1_2021_To_12_31_2021_uhkxAiZ6fUeekYGgaMhCqA"
      id="Tb_4nxInUdjlkCj7A4m5JSqWg">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;"&gt;(g)&#160;Research and Development&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Research and development costs are expensed as incurred and are primarily comprised of personnel-related expenses and external research and development expenses incurred under arrangements with third parties, such as contract research organizations and consultants. At the end of each reporting period, the Company compares the payments made to each service provider to the estimated progress towards completion of the related project. Factors that the Company considers in preparing these estimates include the number of patients enrolled in studies, milestones achieved, and other criteria related to the efforts of its vendors. These estimates will be subject to change as additional information becomes available. Depending on the timing of payments to vendors and estimated services provided, the Company will record net prepaid or accrued expenses related to these costs.&lt;/p&gt;</us-gaap:ResearchDevelopmentAndComputerSoftwarePolicyTextBlock>
    <anvs:GrantIncomePolicyTextBlock
      contextRef="Duration_1_1_2021_To_12_31_2021_uhkxAiZ6fUeekYGgaMhCqA"
      id="Tb_YDr5ocI2DECeBRtNwfqbzg">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;"&gt;(h)&#160;Grant Income&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Grants received are recognized as grant income in the statements of operations as and when they are earned for the specific research and development projects for which these grants are designated. Grants payments received in excess of grant income earned are recognized as deferred grant on the balance sheet and grant income earned in excess of grant payments received is recognized as grant receivable on the balance sheets.&lt;/p&gt;</anvs:GrantIncomePolicyTextBlock>
    <us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy
      contextRef="Duration_1_1_2021_To_12_31_2021_uhkxAiZ6fUeekYGgaMhCqA"
      id="Tb_GbHSWycpnUiclK4ZKnn1Ug">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;"&gt;(i)&#160;Stock-Based Compensation&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Stock-based compensation cost is measured at the grant date based on the fair value of the award and is recognized as expense on a straight-line basis over the requisite service period, which is generally the vesting period. Forfeitures are recognized in compensation expense in the period when they occur.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company uses the Black-Scholes option pricing model to value its option awards which requires the use of subjective assumptions, including the expected life of the option and expected share price volatility. The assumptions used in calculating the fair value of stock-based awards represent management&#x2019;s best estimates and involve inherent uncertainties and the application of management&#x2019;s judgment. As a result, if factors change and management uses different assumptions, stock-based compensation expense could be materially different for future awards.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Upon exercise of stock options, the Company issues shares first from treasury stock, if available, then from authorized but unissued shares.&lt;/p&gt;</us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy>
    <us-gaap:IncomeTaxPolicyTextBlock
      contextRef="Duration_1_1_2021_To_12_31_2021_uhkxAiZ6fUeekYGgaMhCqA"
      id="Tb_HX387abS00Kqb97WxVaM-A">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;"&gt;(j)&#160;Income Taxes&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company provides for income taxes using the asset and liability approach. Deferred tax assets and liabilities are recorded based on the differences between the financial statement and tax bases of assets and liabilities and the tax rates in effect when these differences are expected to reverse. Deferred tax assets are reduced by a valuation allowance if, based on the weight of available evidence, it is more likely than not that some or all of the deferred tax assets will not be realized. As of December 31, 2021 and 2020, the Company had a full valuation allowance against its deferred tax assets.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company is subject to the provisions of ASC 740,&#160;Income Taxes, which prescribes a more likely-than-not threshold for the financial statement recognition of uncertain tax positions. ASC 740 clarifies the accounting for income taxes by prescribing a minimum recognition threshold and measurement attribute for the financial statement recognition and measurement of a tax position taken or expected to be taken in a tax return. There are currently no open federal or state tax audits. The Company has not recorded any liability for uncertain tax positions at December&#160;31, 2021 or December&#160;31, 2020.&lt;/p&gt;</us-gaap:IncomeTaxPolicyTextBlock>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock
      contextRef="Duration_1_1_2021_To_12_31_2021_uhkxAiZ6fUeekYGgaMhCqA"
      id="Tb_Q3SCjC5O7kWlCT_HBWd-WA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;"&gt;(k)&#160;Recent Accounting Pronouncements&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;In December&#160;2019, the FASB issued ASU No.&#160;2019-12,&#160;Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes. The amendments in ASU 2019-12 simplify the accounting for income taxes by removing certain exceptions to the general principles in Topic 740 and clarifying and amending existing guidance. The new standard is effective for fiscal&#160;years, and interim periods within those fiscal&#160;years, beginning after December&#160;15, 2020, with early adoption permitted. The adoption of this standard did not have an impact on the Company&#x2019;s financial statements.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt;In November 2021, the FASB issued ASU No. 2021-10, Government Assistance (Topic 832): Disclosures by Business Entities about Government Assistance. The amendments in ASU 2021-10 require annual disclosures about transactions with a government that are accounted for by applying a grant or contribution accounting model by analogy.  The new disclosure requirements include information about the nature of the transactions and the related accounting policy used to account for the transactions; the line items on the balance sheet and income statement that are affected by the transactions, and the amounts applicable to each financial statement line item; and significant terms and conditions of the transactions, including commitments and contingencies.  The guidance is effective for fiscal years beginning after &lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt;December 15, 2021, with early adoption permitted, and may be adopted prospectively or retrospectively.  The Company does not believe the adoption of this standard will have a significant impact on its financial statements.&lt;/span&gt;&lt;/p&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:FairValueDisclosuresTextBlock
      contextRef="Duration_1_1_2021_To_12_31_2021_uhkxAiZ6fUeekYGgaMhCqA"
      id="Tb_NeHd9Fd_gUGwSf-zMmdptA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;(3)&#160;Fair Value Measurements&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company measures certain assets and liabilities at fair value in accordance with ASC 820, Fair Value Measurements and Disclosures. ASC 820 defines fair value as the price that would be received to sell an asset or paid to transfer a liability (the exit price) in an orderly transaction between market participants at the measurement date. The guidance in ASC 820 outlines a valuation framework and creates a fair value hierarchy that serves to increase the consistency and comparability of fair value measurements and the related disclosures. In determining fair value, the Company maximizes the use of quoted prices and observable inputs. Observable inputs are inputs that market participants would use in pricing the asset or liability based on market data obtained from independent sources. The fair value hierarchy is broken down into three levels based on the source of inputs as follows:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 36pt;"&gt;Level&#160;1&#x2014;Valuations based on unadjusted quoted prices in active markets for identical assets or liabilities.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 36pt;"&gt;Level&#160;2&#x2014;Valuations based on observable inputs and quoted prices in active markets for similar assets and liabilities.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 36pt;"&gt;Level&#160;3&#x2014;Valuations based on unobservable inputs and models that are supported by little or no market activity.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"&gt;The following table provides the carrying value and fair value of certain financial assets and liabilities of the Company measured at fair value on a recurring basis as of December 31, 2021 and December&#160;31, 2020:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:45.37%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.02%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.82%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.61%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.6%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:45.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:36.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Fair Value Measurement at &lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:45.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:36.21%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:45.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Carrying Value&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Level 1&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Level 2&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Level 3&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:45.37%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Cash and cash equivalents&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 45,686,014&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.02%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 45,686,014&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.3%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.61%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.26%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.3%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.6%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:45.56%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.97%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.74%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.96%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.93%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:45.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:36.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;white-space:pre-wrap;"&gt;Fair Value Measurement at  &lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:45.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:36.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;2020&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:45.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Carrying Value&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Level 1&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Level 2&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Level 3&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:45.56%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Cash and cash equivalents&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.97%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 8,074,658&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.3%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 8,074,658&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.49%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.3%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.96%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.93%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:FairValueDisclosuresTextBlock>
    <us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock
      contextRef="Duration_1_1_2021_To_12_31_2021_uhkxAiZ6fUeekYGgaMhCqA"
      id="Tb_gqMxTLer50mSiXU8Zc3Ylg">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:45.37%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.02%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.82%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.61%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.6%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:45.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:36.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Fair Value Measurement at &lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:45.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:36.21%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:45.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Carrying Value&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Level 1&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Level 2&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Level 3&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:45.37%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Cash and cash equivalents&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 45,686,014&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.02%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 45,686,014&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.3%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.61%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.26%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.3%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.6%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:45.56%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.97%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.74%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.96%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.93%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:45.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:36.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;white-space:pre-wrap;"&gt;Fair Value Measurement at  &lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:45.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:36.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;2020&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:45.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Carrying Value&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Level 1&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Level 2&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Level 3&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:45.56%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Cash and cash equivalents&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.97%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 8,074,658&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.3%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 8,074,658&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.49%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.3%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.96%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.93%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="As_Of_12_31_2021_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_4-P5H-hF4ESmAJ-kqpCyXw"
      decimals="0"
      id="Tc_dlWr81TKKUGSBVCIbSSiew_4_3"
      unitRef="Unit_Standard_USD_NFG_pVdyhEyJarLQmedkXA">45686014</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="As_Of_12_31_2021_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_hJjGSBmgGE6iOTr6RBMr5Q"
      decimals="0"
      id="Tc_s9Lct84R-EaQNtA7s05CMw_4_6"
      unitRef="Unit_Standard_USD_NFG_pVdyhEyJarLQmedkXA">45686014</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="As_Of_12_31_2020_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_ivytLr2eEUunO9BaEWMghQ"
      decimals="0"
      id="Tc_Yf4DuM2ySU-aF9LXYBgj6g_4_3"
      unitRef="Unit_Standard_USD_NFG_pVdyhEyJarLQmedkXA">8074658</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="As_Of_12_31_2020_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_RGBQ6zcqa0CUSFXphddjkA"
      decimals="0"
      id="Tc_dhhIRNV6HUWsaJVirR0GYg_4_6"
      unitRef="Unit_Standard_USD_NFG_pVdyhEyJarLQmedkXA">8074658</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <anvs:OtherNonoperatingIncomeGrantIncomeTextBlock
      contextRef="Duration_1_1_2021_To_12_31_2021_uhkxAiZ6fUeekYGgaMhCqA"
      id="Tb_3TLp-cI38Uqqo7sbwSBvwA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;(4)&#160;Grant Income&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;In September&#160;2019, as modified in September 2020, the Company received a Notice of Award for a $1.9&#160;million grant from the National Institute on Aging of the National Institutes of Health&#160;(the &#x201c;NIH&#x201d;) to cover costs of long-term chronic toxicology studies of Buntanetap in rats and dogs. The Company began the long-term chronic toxicology studies in November&#160;&lt;span style="white-space:pre-wrap;"&gt;2019.   The Company recognized grant income of &lt;/span&gt;$36,754 and $1,157,449 for the&#160;years ended December 31, 2021 and 2020, respectively, in connection with the NIH grant. The Company received payments under the grant of $36,754 and $1,892,524 during the&#160;years ended December 31, 2021 and 2020, respectively and recorded a grant receivable of $0 as of December 31, 2021 and 2020, and had no unreimbursed, eligible costs incurred under the grant. As of December 31, 2021, there were no remaining funds available under the grant.&lt;/p&gt;</anvs:OtherNonoperatingIncomeGrantIncomeTextBlock>
    <anvs:GrantsReceivableNoticeOfAwardAmount
      contextRef="As_Of_9_30_2019_us-gaap_TypeOfArrangementAxis_anvs_NationalInstituteOnAgingOfNationalInstitutesOfHealthMember_RQt1O7nidUO5QNweDycD_A"
      decimals="-5"
      id="Narr_UAiUX05rkES2zOXQigK5qg"
      unitRef="Unit_Standard_USD_NFG_pVdyhEyJarLQmedkXA">1900000</anvs:GrantsReceivableNoticeOfAwardAmount>
    <anvs:IncomeFromGrants
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_TypeOfArrangementAxis_anvs_NationalInstituteOnAgingOfNationalInstitutesOfHealthMember_CduWTDd6hEGUS67lAWkVHw"
      decimals="0"
      id="Narr_GJil8_aJSkyaqeSfE5WOpw"
      unitRef="Unit_Standard_USD_NFG_pVdyhEyJarLQmedkXA">36754</anvs:IncomeFromGrants>
    <anvs:IncomeFromGrants
      contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_TypeOfArrangementAxis_anvs_NationalInstituteOnAgingOfNationalInstitutesOfHealthMember_1CkP6VBQfUS9FAKN4vz1Tg"
      decimals="0"
      id="Narr_y8yf1Bczc0avY0P3p2UYuQ"
      unitRef="Unit_Standard_USD_NFG_pVdyhEyJarLQmedkXA">1157449</anvs:IncomeFromGrants>
    <anvs:ProceedsFromGrants
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_TypeOfArrangementAxis_anvs_NationalInstituteOnAgingOfNationalInstitutesOfHealthMember_CduWTDd6hEGUS67lAWkVHw"
      decimals="0"
      id="Narr_SadTnRRQpE2abvOIVFMTwg"
      unitRef="Unit_Standard_USD_NFG_pVdyhEyJarLQmedkXA">36754</anvs:ProceedsFromGrants>
    <anvs:ProceedsFromGrants
      contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_TypeOfArrangementAxis_anvs_NationalInstituteOnAgingOfNationalInstitutesOfHealthMember_1CkP6VBQfUS9FAKN4vz1Tg"
      decimals="0"
      id="Narr_j5bV7InThEG_fVZXMduabg"
      unitRef="Unit_Standard_USD_NFG_pVdyhEyJarLQmedkXA">1892524</anvs:ProceedsFromGrants>
    <us-gaap:GrantsReceivableCurrent
      contextRef="As_Of_12_31_2020_us-gaap_TypeOfArrangementAxis_anvs_NationalInstituteOnAgingOfNationalInstitutesOfHealthMember_SIhJO7d5SUmK7j4WVeRGBw"
      decimals="0"
      id="Narr_XarV6R_zXkmS5FPjlPpPoA"
      unitRef="Unit_Standard_USD_NFG_pVdyhEyJarLQmedkXA">0</us-gaap:GrantsReceivableCurrent>
    <us-gaap:GrantsReceivableCurrent
      contextRef="As_Of_12_31_2021_us-gaap_TypeOfArrangementAxis_anvs_NationalInstituteOnAgingOfNationalInstitutesOfHealthMember_VVmuZtlTeEaVeNDy9uhHaQ"
      decimals="0"
      id="Narr_i1HQuZaUPku7xJjoJ3k6uw"
      unitRef="Unit_Standard_USD_NFG_pVdyhEyJarLQmedkXA">0</us-gaap:GrantsReceivableCurrent>
    <anvs:UnreimbursedEligibleCostsIncurredDuringPeriod
      contextRef="Duration_1_1_2020_To_12_31_2020_3DdHOulAJk6Q0Zn4Vsxq5A"
      decimals="0"
      id="Narr_6k0t8OoMDkuh_oz2Gf7X1w"
      unitRef="Unit_Standard_USD_NFG_pVdyhEyJarLQmedkXA">0</anvs:UnreimbursedEligibleCostsIncurredDuringPeriod>
    <anvs:UnreimbursedEligibleCostsIncurredDuringPeriod
      contextRef="Duration_1_1_2021_To_12_31_2021_uhkxAiZ6fUeekYGgaMhCqA"
      decimals="0"
      id="Narr_oVFcJHiw0E-6rthrTagewg"
      unitRef="Unit_Standard_USD_NFG_pVdyhEyJarLQmedkXA">0</anvs:UnreimbursedEligibleCostsIncurredDuringPeriod>
    <anvs:GrantAwardRemainingAmountAvailable
      contextRef="As_Of_12_31_2020_K1oKCNbpv0CLR8EJWu1PSw"
      decimals="0"
      id="Narr_aVDWBg0Wlk22jXWXe1nq8Q"
      unitRef="Unit_Standard_USD_NFG_pVdyhEyJarLQmedkXA">0</anvs:GrantAwardRemainingAmountAvailable>
    <anvs:GrantAwardRemainingAmountAvailable
      contextRef="As_Of_12_31_2021_slf_IrTrZku1VVWbbttE4g"
      decimals="0"
      id="Narr_HkBANK377U6VccDVvq5ZAw"
      unitRef="Unit_Standard_USD_NFG_pVdyhEyJarLQmedkXA">0</anvs:GrantAwardRemainingAmountAvailable>
    <anvs:DeferredCostsCapitalizedPrepaidExpensesAndOtherAssetsDisclosureTextBlock
      contextRef="Duration_1_1_2021_To_12_31_2021_uhkxAiZ6fUeekYGgaMhCqA"
      id="Tb_9NF3T8VFvUmV1Bh_cywsaw">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;(5)&#160;Prepaid Expenses and Other Current Assets&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"&gt;Prepaid expenses and other current assets consisted of the following:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:74.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.49%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:74.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:23.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;As of December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:74.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.95%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2020&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:74.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Prepaid clinical trial expenses&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.45%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.78%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 232,752&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.45%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.49%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:74.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Prepaid insurance&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 29,111&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.49%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 26,542&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:74.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Prepaid expenses&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.45%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.78%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 43,736&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.45%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.49%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 11,690&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:74.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Security deposits&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 9,865&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 6,444&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:74.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.45%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.78%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 315,464&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.45%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.49%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 44,676&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</anvs:DeferredCostsCapitalizedPrepaidExpensesAndOtherAssetsDisclosureTextBlock>
    <us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock
      contextRef="Duration_1_1_2021_To_12_31_2021_uhkxAiZ6fUeekYGgaMhCqA"
      id="Tb_qCxte0QwqEK2ePQ8GedJSA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:74.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.49%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:74.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:23.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;As of December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:74.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.95%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2020&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:74.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Prepaid clinical trial expenses&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.45%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.78%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 232,752&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.45%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.49%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:74.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Prepaid insurance&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 29,111&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.49%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 26,542&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:74.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Prepaid expenses&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.45%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.78%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 43,736&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.45%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.49%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 11,690&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:74.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Security deposits&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 9,865&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 6,444&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:74.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.45%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.78%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 315,464&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.45%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.49%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 44,676&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock>
    <anvs:PrepaidResearchAndDevelopmentExpenseCurrent
      contextRef="As_Of_12_31_2021_slf_IrTrZku1VVWbbttE4g"
      decimals="0"
      id="Tc_hvJ6dNdQY0WH2XXKIXs7cw_3_3"
      unitRef="Unit_Standard_USD_NFG_pVdyhEyJarLQmedkXA">232752</anvs:PrepaidResearchAndDevelopmentExpenseCurrent>
    <us-gaap:PrepaidInsurance
      contextRef="As_Of_12_31_2021_slf_IrTrZku1VVWbbttE4g"
      decimals="0"
      id="Tc_1lg7a9CKf02mpQEl3OgdsA_4_3"
      unitRef="Unit_Standard_USD_NFG_pVdyhEyJarLQmedkXA">29111</us-gaap:PrepaidInsurance>
    <us-gaap:PrepaidInsurance
      contextRef="As_Of_12_31_2020_K1oKCNbpv0CLR8EJWu1PSw"
      decimals="0"
      id="Tc_mt42xJXbc0O9jzIMEpC7_w_4_6"
      unitRef="Unit_Standard_USD_NFG_pVdyhEyJarLQmedkXA">26542</us-gaap:PrepaidInsurance>
    <us-gaap:OtherPrepaidExpenseCurrent
      contextRef="As_Of_12_31_2021_slf_IrTrZku1VVWbbttE4g"
      decimals="0"
      id="Tc_9YvzT_2XMkGThOUeL7E2BA_5_3"
      unitRef="Unit_Standard_USD_NFG_pVdyhEyJarLQmedkXA">43736</us-gaap:OtherPrepaidExpenseCurrent>
    <us-gaap:OtherPrepaidExpenseCurrent
      contextRef="As_Of_12_31_2020_K1oKCNbpv0CLR8EJWu1PSw"
      decimals="0"
      id="Tc__kfZkqirkEu4xEw4_PJcEw_5_6"
      unitRef="Unit_Standard_USD_NFG_pVdyhEyJarLQmedkXA">11690</us-gaap:OtherPrepaidExpenseCurrent>
    <us-gaap:SecurityDeposit
      contextRef="As_Of_12_31_2021_slf_IrTrZku1VVWbbttE4g"
      decimals="0"
      id="Tc_TsJrs7N49kmN8jYVFZzyeQ_6_3"
      unitRef="Unit_Standard_USD_NFG_pVdyhEyJarLQmedkXA">9865</us-gaap:SecurityDeposit>
    <us-gaap:SecurityDeposit
      contextRef="As_Of_12_31_2020_K1oKCNbpv0CLR8EJWu1PSw"
      decimals="0"
      id="Tc_GHkwo2iot0y1kgpCoy2MfQ_6_6"
      unitRef="Unit_Standard_USD_NFG_pVdyhEyJarLQmedkXA">6444</us-gaap:SecurityDeposit>
    <anvs:PrepaidExpenseSecurityDepositsAndOtherAssetsCurrent
      contextRef="As_Of_12_31_2021_slf_IrTrZku1VVWbbttE4g"
      decimals="0"
      id="Tc_3yksOgtaskq8ycnf3-EbAQ_7_3"
      unitRef="Unit_Standard_USD_NFG_pVdyhEyJarLQmedkXA">315464</anvs:PrepaidExpenseSecurityDepositsAndOtherAssetsCurrent>
    <anvs:PrepaidExpenseSecurityDepositsAndOtherAssetsCurrent
      contextRef="As_Of_12_31_2020_K1oKCNbpv0CLR8EJWu1PSw"
      decimals="0"
      id="Tc_SWOK1zsLg0SVEkvUgZV6Kg_7_6"
      unitRef="Unit_Standard_USD_NFG_pVdyhEyJarLQmedkXA">44676</anvs:PrepaidExpenseSecurityDepositsAndOtherAssetsCurrent>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock
      contextRef="Duration_1_1_2021_To_12_31_2021_uhkxAiZ6fUeekYGgaMhCqA"
      id="Tb_dpKy2FNQGkSIxXBG097TEQ">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;(6)&#160;Accrued Expenses&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"&gt;Accrued expenses consisted of the following:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:73.83%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.8%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.86%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:24.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;As of December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2020&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.83%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Payroll and related benefits&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.8%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 712,768&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.94%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 16,493&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Accrued professional and clinical fees&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 105,672&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 216,198&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.83%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Accrued license payments&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.8%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.94%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.86%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 3,833&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.8%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 818,440&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.86%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 236,524&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 36pt;"&gt;See Note&#160;8 for further detail on the accrued license payments.&lt;/p&gt;</us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock>
    <us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock
      contextRef="Duration_1_1_2021_To_12_31_2021_uhkxAiZ6fUeekYGgaMhCqA"
      id="Tb_V_FbGkcaJEaaJfpLhJth5Q">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:73.83%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.8%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.86%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:24.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;As of December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2020&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.83%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Payroll and related benefits&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.8%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 712,768&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.94%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 16,493&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Accrued professional and clinical fees&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 105,672&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 216,198&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.83%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Accrued license payments&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.8%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.94%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.86%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 3,833&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.8%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 818,440&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.86%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 236,524&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="As_Of_12_31_2021_slf_IrTrZku1VVWbbttE4g"
      decimals="0"
      id="Tc_jqT-wLe4W0GIQnUs1EUZTg_3_3"
      unitRef="Unit_Standard_USD_NFG_pVdyhEyJarLQmedkXA">712768</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="As_Of_12_31_2020_K1oKCNbpv0CLR8EJWu1PSw"
      decimals="0"
      id="Tc_dLW5dsNBOUyjr5geYP1uuA_3_6"
      unitRef="Unit_Standard_USD_NFG_pVdyhEyJarLQmedkXA">16493</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:AccruedProfessionalFeesCurrent
      contextRef="As_Of_12_31_2021_slf_IrTrZku1VVWbbttE4g"
      decimals="0"
      id="Tc_uFt1JSaDe0KceCk1CZTYqw_4_3"
      unitRef="Unit_Standard_USD_NFG_pVdyhEyJarLQmedkXA">105672</us-gaap:AccruedProfessionalFeesCurrent>
    <us-gaap:AccruedProfessionalFeesCurrent
      contextRef="As_Of_12_31_2020_K1oKCNbpv0CLR8EJWu1PSw"
      decimals="0"
      id="Tc_wqJzGBNA60OMeIqHChmffg_4_6"
      unitRef="Unit_Standard_USD_NFG_pVdyhEyJarLQmedkXA">216198</us-gaap:AccruedProfessionalFeesCurrent>
    <anvs:AccruedLicensePaymentsCurrent
      contextRef="As_Of_12_31_2020_K1oKCNbpv0CLR8EJWu1PSw"
      decimals="0"
      id="Tc_8t3XbgaAuUi6uxUK51NsGA_5_6"
      unitRef="Unit_Standard_USD_NFG_pVdyhEyJarLQmedkXA">3833</anvs:AccruedLicensePaymentsCurrent>
    <anvs:AccruedLiabilitiesAndInterestAndEmployeeRelatedLiabilitiesCurrent
      contextRef="As_Of_12_31_2021_slf_IrTrZku1VVWbbttE4g"
      decimals="0"
      id="Tc_GH7Nrr9fdUi4un4MkrlQLQ_6_3"
      unitRef="Unit_Standard_USD_NFG_pVdyhEyJarLQmedkXA">818440</anvs:AccruedLiabilitiesAndInterestAndEmployeeRelatedLiabilitiesCurrent>
    <anvs:AccruedLiabilitiesAndInterestAndEmployeeRelatedLiabilitiesCurrent
      contextRef="As_Of_12_31_2020_K1oKCNbpv0CLR8EJWu1PSw"
      decimals="0"
      id="Tc_8h-_Px0qg0uWaeJQLUHKoQ_6_6"
      unitRef="Unit_Standard_USD_NFG_pVdyhEyJarLQmedkXA">236524</anvs:AccruedLiabilitiesAndInterestAndEmployeeRelatedLiabilitiesCurrent>
    <us-gaap:DebtDisclosureTextBlock
      contextRef="Duration_1_1_2021_To_12_31_2021_uhkxAiZ6fUeekYGgaMhCqA"
      id="Tb_z4YT9sqPYUalcInjD8Fp1g">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;(7)&#160;Convertible Promissory Notes&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;In March&#160;2019, the Company issued convertible promissory notes (the &#x201c;Notes&#x201d;) to various investors in the aggregate principal amount of $530,000. Interest accrued at 8% compounded annually on all Notes. The maturity date was the earlier of a Liquidity Event or upon the written demand of the holders of a majority of the outstanding principal amount of the Notes&#160;made any time after December&#160;31, 2023. A Liquidity Event was defined as (i)&#160;the date of the closing of a merger or reorganization of the Company with another entity; (ii)&#160;the sale of substantially all of the assets of the Company in which the Company&#x2019;s stockholders own less than 50% of the equity securities after the event; or (iii)&#160;a liquidation of the Company.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company incurred costs of $8,622 in connection with the issuance of the Notes. In addition, on issuance, the Company recognized a discount associated with the Notes&#160;of $26,500 related to the fair value of an embedded derivative reflecting the share-settlement provision upon the closing of a Qualified Financing. Unamortized deferred financing fees and debt discount were deducted from the face amount of the Notes&#160;on the balance sheets. The Company amortized the deferred financing fees and debt discount over the term of the Notes&#160;as additional interest expense using the effective interest method. The effective interest rate on the Notes&#160;was&#160;9.8%. The Company made no cash payments for interest.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;On January&#160;&lt;span style="white-space:pre-wrap;"&gt;31, 2020, the Company closed its IPO.  In accordance with the terms of the Notes, the outstanding Notes&#160;plus accrued interest converted into &lt;/span&gt;118,470 shares of Company common stock at a 20% discount to the initial offering price of shares issued in the IPO. &lt;/p&gt;</us-gaap:DebtDisclosureTextBlock>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="As_Of_3_31_2019_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember_YwRIubASaUOYMPLJxHrjxQ"
      decimals="0"
      id="Narr_D_ysZ2GdsUG2VNpQTPTDaQ"
      unitRef="Unit_Standard_USD_NFG_pVdyhEyJarLQmedkXA">530000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="As_Of_3_31_2019_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember_YwRIubASaUOYMPLJxHrjxQ"
      decimals="INF"
      id="Narr_mQv4ISL0HkewxWfTmDHeSQ"
      unitRef="Unit_Standard_pure_n7tAfGlk1kyqYH5N2uCURw">0.08</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DeferredFinanceCostsGross
      contextRef="As_Of_3_31_2019_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember_YwRIubASaUOYMPLJxHrjxQ"
      decimals="0"
      id="Narr_Qf0jdhMmZk-9GJdLmbsXqQ"
      unitRef="Unit_Standard_USD_NFG_pVdyhEyJarLQmedkXA">8622</us-gaap:DeferredFinanceCostsGross>
    <us-gaap:DebtInstrumentUnamortizedDiscount
      contextRef="As_Of_3_31_2019_oVmx4yeGk0q3UZkY6l4F-g"
      decimals="0"
      id="Narr_RmZ355dDckeVLuuORASmNA"
      unitRef="Unit_Standard_USD_NFG_pVdyhEyJarLQmedkXA">26500</us-gaap:DebtInstrumentUnamortizedDiscount>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage
      contextRef="As_Of_3_31_2019_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember_YwRIubASaUOYMPLJxHrjxQ"
      decimals="3"
      id="Narr_5hD7iFR6GECn9kh4bfz7Kw"
      unitRef="Unit_Standard_pure_n7tAfGlk1kyqYH5N2uCURw">0.098</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:InterestPaidNet
      contextRef="Duration_1_1_2019_To_12_31_2019_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember_RsyiGRhnhk-vxd5-a-DqHg"
      decimals="0"
      id="Narr_uOzA8MXLiE-G9jM1Nsey3w"
      unitRef="Unit_Standard_USD_NFG_pVdyhEyJarLQmedkXA">0</us-gaap:InterestPaidNet>
    <us-gaap:InterestPaidNet
      contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember_dBs7AChUNEK9AUDzdDKJTQ"
      decimals="0"
      id="Narr_MstguZX9SUK3Osuo1JiXeA"
      unitRef="Unit_Standard_USD_NFG_pVdyhEyJarLQmedkXA">0</us-gaap:InterestPaidNet>
    <anvs:StockIssuedDuringPeriodSharesConversionOfConvertibleNotes
      contextRef="Duration_1_31_2020_To_1_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember_sRjzEwCZI0yVkxtZkXzw0w"
      decimals="INF"
      id="Narr_7jeCAK9chke8gOux80hYRQ"
      unitRef="Unit_Standard_shares__cOSbKjBTUyHt70_t1aAVw">118470</anvs:StockIssuedDuringPeriodSharesConversionOfConvertibleNotes>
    <anvs:ConversionOfConvertibleSecuritiesConvertiblePromissoryNotesPercentageOfDiscountToInitialPublicOfferingPrice
      contextRef="Duration_1_31_2020_To_1_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember_sRjzEwCZI0yVkxtZkXzw0w"
      decimals="2"
      id="Narr_kppkYR5HdEmjy2Xy45EU6Q"
      unitRef="Unit_Standard_pure_n7tAfGlk1kyqYH5N2uCURw">0.20</anvs:ConversionOfConvertibleSecuritiesConvertiblePromissoryNotesPercentageOfDiscountToInitialPublicOfferingPrice>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock
      contextRef="Duration_1_1_2021_To_12_31_2021_uhkxAiZ6fUeekYGgaMhCqA"
      id="Tb_ZWzvDZQUVEyq1QRUdGxKyA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;(8)&#160;Commitments and Contingencies&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;"&gt;(a)&#160;Leases&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company leases its office facilities under a&#160;month-to-month operating lease. Total rental expense was $51,760 and $41,603 for the&#160;years ended December 31, 2021 and 2020, respectively.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;"&gt;(b)&#160;License Agreement&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company previously licensed the rights to certain chemical compounds, know-how and intellectual property rights that may be suitable for the development of human therapeutics from a subsidiary of Horizon Therapeutics, PLC (the &#x201c;Licensor&#x201d;). Under the license agreement, the Company paid a minimum annual fee of $46,000 and was required to make milestone payments upon attainment of certain milestone events, royalties based on net sales of products covered by the patent-related rights and a portion of any sublicense income received by the Company. The Licensor also granted the Company a buy-out option which was exercisable at any time during the term of the agreement at increasing amounts based on the achievement of certain milestones. The Company had the right to terminate the agreement at any time by giving 90&#160;days advance notice subject to the payment of any amounts due under the agreement at that time. Expenses related to the license agreement were recognized in general and administrative expense in the statements of operations.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt; In July 2021, the Company gave notice to the Licensor of its termination of the license agreement and the license agreement was terminated effective October 14, 2021. The Company has paid to the Licensor the prorated annual fees through the termination date.  &lt;/span&gt;No milestones had been achieved as of the termination date.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;"&gt;(c)&#160;Employment Agreements&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company has agreements with its executive officers that provide for severance payments to the employee upon termination of the agreement by the Company for any reason other than for cause, death or disability or by the employee for good reason The maximum aggregate severance payments under the agreements were approximately&#160;$930,000&#160;at December&#160;31,&#160;2021. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;"&gt;(d)&#160;Litigation&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company is subject, from time to time, to claims by third parties under various legal disputes. The defense of such claims, or any adverse outcome relating to any such claims, could have a material adverse effect on the Company&#x2019;s liquidity, financial condition and cash flows. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;During the year ended December 31, 2021, two&lt;span style="white-space:pre-wrap;"&gt; securities class action complaints were filed against the Company and its executive officers following disclosure of interim results from the AD/PD Trial.  Both complaints were voluntarily dismissed without prejudice by the plaintiffs.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;At December&#160;31, 2021, the Company did not have any pending legal actions.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;"&gt;(e)&#160;Risks and Uncertainties&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The extent to which the COVID-19 pandemic could have a material impact on the Company&#x2019;s current or future clinical trials is dependent on the spread of the disease and government and healthcare system responses to such spread, which are presently highly uncertain. Management continues to evaluate the potential impact. The financial statements do not include any adjustments that might result from the outcome of this uncertainty.&lt;/p&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <us-gaap:OperatingLeaseExpense
      contextRef="Duration_1_1_2021_To_12_31_2021_uhkxAiZ6fUeekYGgaMhCqA"
      decimals="0"
      id="Narr__kDnnj3YSUi8shYISGFY8g"
      unitRef="Unit_Standard_USD_NFG_pVdyhEyJarLQmedkXA">51760</us-gaap:OperatingLeaseExpense>
    <us-gaap:OperatingLeaseExpense
      contextRef="Duration_1_1_2020_To_12_31_2020_3DdHOulAJk6Q0Zn4Vsxq5A"
      decimals="0"
      id="Narr_JFJebxA2okWZUzllcogHmQ"
      unitRef="Unit_Standard_USD_NFG_pVdyhEyJarLQmedkXA">41603</us-gaap:OperatingLeaseExpense>
    <anvs:LicenseAgreementMinimumAnnualCommitment
      contextRef="Duration_5_1_2012_To_5_31_2012_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_anvs_LicenseAgreementTermsAmendedMay2012Member_P0aUOpgGN0mwPRsuYBHIew"
      decimals="0"
      id="Narr_TTBkMvKNGUib7eFnqAO5gQ"
      unitRef="Unit_Standard_USD_NFG_pVdyhEyJarLQmedkXA">46000</anvs:LicenseAgreementMinimumAnnualCommitment>
    <anvs:LicenseAgreementPeriodOfAdvanceNoticeOfTermination
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_anvs_LicenseAgreementTermsAmendedMay2012Member_DCsom2ZXYkiSKjzS68vh2Q"
      id="Narr_VIOA19Pax0yGAA34uNUIRw">P90D</anvs:LicenseAgreementPeriodOfAdvanceNoticeOfTermination>
    <anvs:CumulativeNumberOfMilestonesAchieved
      contextRef="As_Of_12_31_2021_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_anvs_LicenseAgreementTermsAmendedMay2012Member_fjPgMKMghE-GlCKw7d5yzw"
      decimals="INF"
      id="Narr__falpFyNMEW5n53Zi6fhQg"
      unitRef="Unit_Standard_USD_NFG_pVdyhEyJarLQmedkXA">0</anvs:CumulativeNumberOfMilestonesAchieved>
    <anvs:MaximumAggregateSeverancePayments
      contextRef="As_Of_12_31_2021_srt_TitleOfIndividualAxis_srt_ExecutiveOfficerMember_2QVIbrzh10W_0LPuXlLcug"
      decimals="0"
      id="Narr_FQIlRIDyOkeV3d6FFj2nrQ"
      unitRef="Unit_Standard_USD_NFG_pVdyhEyJarLQmedkXA">930000</anvs:MaximumAggregateSeverancePayments>
    <us-gaap:LossContingencyNewClaimsFiledNumber
      contextRef="Duration_1_1_2021_To_12_31_2021_uhkxAiZ6fUeekYGgaMhCqA"
      decimals="INF"
      id="Narr_NqUZ5_zWqUKJm4vS2RFbww"
      unitRef="Unit_Standard_lawsuit_cWy34Dwcxk6mE22LYui79g">2</us-gaap:LossContingencyNewClaimsFiledNumber>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock
      contextRef="Duration_1_1_2021_To_12_31_2021_uhkxAiZ6fUeekYGgaMhCqA"
      id="Tb_dsSIzFWFokKSa9y7sCmQNA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;(9)&#160;Redeemable Convertible Preferred Stock and Stockholders&#x2019; Equity&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;"&gt;(a) Overview&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company closed its IPO on January&#160;31, 2020, issuing 2,300,000 shares of common stock. In connection with the closing of the Company&#x2019;s IPO, the then-outstanding 5,133,159 shares of Series&#160;A and 630,722 shares of Series&#160;A-1 redeemable convertible preferred stock converted into an aggregate of 4,117,089 shares of Company common stock. Each share of redeemable convertible preferred stock was converted into the number of shares of common stock determined by dividing the original issue price by the applicable conversion price. The Series&#160;A-1 conversion price was $1.26, and the Series&#160;A conversion price was $0.70.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company&#x2019;s Amended and Restated Certificate of Incorporation was adopted on January&#160;31, 2020 to authorize the issuance of two classes of stock to be designated, respectively, common stock and preferred stock. The total number of shares which the Company is authorized to issue is 37,000,000, each with a &lt;span style="-sec-ix-hidden:Hidden_W_s6TWSI0kqP0maAGvG-9A;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;par value&lt;/span&gt;&lt;/span&gt; of $0.0001 per share. Of these shares, 35,000,000 shall be common stock and 2,000,000 shall be preferred stock.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;"&gt;(b) Common Stock&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;padding-left:36pt;text-indent:-36pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-weight:normal;"&gt;1.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Dividends&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Subject to the rights of holders of all classes of Company stock outstanding having rights that are senior to or equivalent to holders of common stock, the holders of the common stock are entitled to receive dividends when and as declared by the Board.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;padding-left:36pt;text-indent:-36pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-weight:normal;"&gt;2.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Liquidation&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Subject to the rights of holders of all classes of stock outstanding having rights that are senior to or equivalent to holders of common stock as to liquidation, upon the liquidation, dissolution or winding up of the Company, the assets of the Company will be distributed to the holders of common stock.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;padding-left:36pt;text-indent:-36pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-weight:normal;"&gt;3.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Voting&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The holders of common stock are entitled to one vote for each share of common stock held. There is no cumulative voting.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;"&gt;(c)&#160;Preferred Stock&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Preferred stock may be issued from time to time by the Board in one or more series.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;"&gt;(d)&#160;Warrants&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"&gt;In conjunction with the IPO, the Company granted the underwriters 100,000 warrants to purchase shares of Company common stock at an exercise price of $7.50 per share, which is 125% of the initial public offering price. The warrants have a &lt;span style="-sec-ix-hidden:Hidden_7Pmc5xg25E6fTLpFgVmdTA;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;five&lt;/span&gt;&lt;/span&gt;-year term and were exercisable as of January&#160;29, 2021. During the year ended December 31, 2021, 97,600&lt;span style="white-space:pre-wrap;"&gt; of the warrants were tendered to the Company by the holders pursuant to cashless exercises.  Warrants outstanding as of December 31, 2021 and 2020, were &lt;/span&gt;2,400 and 100,000&lt;span style="white-space:pre-wrap;"&gt;, respectively.  The Company accounts for the warrants as a component of stockholders&#x2019; equity.  &lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="Duration_1_31_2020_To_1_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember_sRjzEwCZI0yVkxtZkXzw0w"
      decimals="INF"
      id="Narr_8y7K_P8vFkmpjfvF_2wbgg"
      unitRef="Unit_Standard_shares__cOSbKjBTUyHt70_t1aAVw">2300000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <anvs:TemporaryEquitySharesConversionOfPreferredStockToCommonStock
      contextRef="Duration_1_31_2020_To_1_31_2020_us-gaap_StatementClassOfStockAxis_anvs_SeriesaRedeemableConvertiblePreferredStockMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember_ptCGvvBnuEitWVCSkdK7Vw"
      decimals="INF"
      id="Narr_H9fcTAODIk2Lb5AvcFyiFg"
      unitRef="Unit_Standard_shares__cOSbKjBTUyHt70_t1aAVw">5133159</anvs:TemporaryEquitySharesConversionOfPreferredStockToCommonStock>
    <anvs:TemporaryEquitySharesConversionOfPreferredStockToCommonStock
      contextRef="Duration_1_31_2020_To_1_31_2020_us-gaap_StatementClassOfStockAxis_anvs_Series1RedeemableConvertiblePreferredStockMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember_fNVfPPJXjUyuAgQutr0kWQ"
      decimals="INF"
      id="Narr_E0ueD8m2ekGNvtqccdjgbQ"
      unitRef="Unit_Standard_shares__cOSbKjBTUyHt70_t1aAVw">630722</anvs:TemporaryEquitySharesConversionOfPreferredStockToCommonStock>
    <anvs:StockIssuedDuringPeriodSharesConversionOfConvertibleSecuritiesPreferredStock
      contextRef="Duration_1_31_2020_To_1_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember_sRjzEwCZI0yVkxtZkXzw0w"
      decimals="INF"
      id="Narr_E_mvPYt27k2OotMSoAfrBA"
      unitRef="Unit_Standard_shares__cOSbKjBTUyHt70_t1aAVw">4117089</anvs:StockIssuedDuringPeriodSharesConversionOfConvertibleSecuritiesPreferredStock>
    <anvs:RedeemableConvertiblePreferredStockConvertibleConversionPrice
      contextRef="As_Of_1_31_2020_us-gaap_StatementClassOfStockAxis_anvs_Series1RedeemableConvertiblePreferredStockMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember_O74MBLhVpkagypo4IVPp_Q"
      decimals="2"
      id="Narr_NXA9wN3SekyhTpCkythKeA"
      unitRef="Unit_Divide_USD_shares_ZtgwQidioUWlbMoOaTBzxg">1.26</anvs:RedeemableConvertiblePreferredStockConvertibleConversionPrice>
    <anvs:RedeemableConvertiblePreferredStockConvertibleConversionPrice
      contextRef="As_Of_1_31_2020_us-gaap_StatementClassOfStockAxis_anvs_SeriesaRedeemableConvertiblePreferredStockMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember_WSa7shXqeUSwpAKpQQl-KQ"
      decimals="2"
      id="Narr_nA1yHaGcYUyUZFfByxf8Ew"
      unitRef="Unit_Divide_USD_shares_ZtgwQidioUWlbMoOaTBzxg">0.70</anvs:RedeemableConvertiblePreferredStockConvertibleConversionPrice>
    <anvs:NumberOfClassesOfStockDesignated
      contextRef="As_Of_1_31_2020_kBrHfmPKTE-0UUCmwNXokA"
      decimals="INF"
      id="Narr_tN-HsCvQsUmUrYpztoEUAA"
      unitRef="Unit_Standard_item_Y7Ur8tqCgUit9H-TWiK9OA">2</anvs:NumberOfClassesOfStockDesignated>
    <anvs:CommonStockAndPreferredStockSharesAuthorized
      contextRef="As_Of_1_31_2020_kBrHfmPKTE-0UUCmwNXokA"
      decimals="INF"
      id="Narr_ymG2GICYjEmymFA4vAApqg"
      unitRef="Unit_Standard_shares__cOSbKjBTUyHt70_t1aAVw">37000000</anvs:CommonStockAndPreferredStockSharesAuthorized>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="As_Of_1_31_2020_kBrHfmPKTE-0UUCmwNXokA"
      decimals="INF"
      id="Narr_4vNc22ZujEC70pMaC_LjWA"
      unitRef="Unit_Divide_USD_shares_ZtgwQidioUWlbMoOaTBzxg">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="As_Of_1_31_2020_kBrHfmPKTE-0UUCmwNXokA"
      decimals="INF"
      id="Narr_RWPIwzi1d0Svhcbt3029VA"
      unitRef="Unit_Standard_shares__cOSbKjBTUyHt70_t1aAVw">35000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="As_Of_1_31_2020_kBrHfmPKTE-0UUCmwNXokA"
      decimals="INF"
      id="Narr_qhIn0eO4MkSPS4XmreLcqQ"
      unitRef="Unit_Standard_shares__cOSbKjBTUyHt70_t1aAVw">2000000</us-gaap:PreferredStockSharesAuthorized>
    <anvs:NumberOfVotesForEachShareOfCommonStock
      contextRef="As_Of_12_31_2021_slf_IrTrZku1VVWbbttE4g"
      decimals="0"
      id="Narr_7aoFRSMyzUuj0nj_dupdXg"
      unitRef="Unit_Standard_Vote_pwF70c76VEGREHjsKw9EwA">1</anvs:NumberOfVotesForEachShareOfCommonStock>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="As_Of_1_31_2020_us-gaap_ClassOfWarrantOrRightAxis_anvs_UnderwritersWarrantsMember_p2Rmy9kgMES4LjCsl9nsqg"
      decimals="INF"
      id="Narr_-lWad8kgIkuOETux-C7awg"
      unitRef="Unit_Standard_shares__cOSbKjBTUyHt70_t1aAVw">100000</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="As_Of_1_31_2020_us-gaap_ClassOfWarrantOrRightAxis_anvs_UnderwritersWarrantsMember_p2Rmy9kgMES4LjCsl9nsqg"
      decimals="2"
      id="Narr_1f8BgVxlr0q0E-mv8lAC2g"
      unitRef="Unit_Divide_USD_shares_ZtgwQidioUWlbMoOaTBzxg">7.50</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <anvs:PercentageOfExercisePriceToShareOfferingPrice
      contextRef="As_Of_1_31_2020_us-gaap_ClassOfWarrantOrRightAxis_anvs_UnderwritersWarrantsMember_p2Rmy9kgMES4LjCsl9nsqg"
      decimals="2"
      id="Narr_qCnLKIUwfkqkEXauSj7A_w"
      unitRef="Unit_Standard_pure_n7tAfGlk1kyqYH5N2uCURw">1.25</anvs:PercentageOfExercisePriceToShareOfferingPrice>
    <anvs:ConversionOfWarrantsNumberOfWarrantsConverted
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_ClassOfWarrantOrRightAxis_anvs_UnderwritersWarrantsMember_lIkEDjt6I02rJoRPhXJAxw"
      decimals="INF"
      id="Narr_RV0cJz9MfUaMv8My7IkF0g"
      unitRef="Unit_Standard_shares__cOSbKjBTUyHt70_t1aAVw">97600</anvs:ConversionOfWarrantsNumberOfWarrantsConverted>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="As_Of_12_31_2021_us-gaap_ClassOfWarrantOrRightAxis_anvs_UnderwritersWarrantsMember_i9g6mnyCNEylYBl9fs3ugQ"
      decimals="INF"
      id="Narr_RssR8JpHbEaeIyOcS4riww"
      unitRef="Unit_Standard_shares__cOSbKjBTUyHt70_t1aAVw">2400</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="As_Of_12_31_2020_us-gaap_ClassOfWarrantOrRightAxis_anvs_UnderwritersWarrantsMember_fVGxQCgHYU-B8YaMWCH07g"
      decimals="INF"
      id="Narr_gXHVLogv0EK_shUGJbYO-w"
      unitRef="Unit_Standard_shares__cOSbKjBTUyHt70_t1aAVw">100000</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock
      contextRef="Duration_1_1_2021_To_12_31_2021_uhkxAiZ6fUeekYGgaMhCqA"
      id="Tb_fvoTYB_aN0Wq8DCKL6RTtg">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;(10)&#160;Stock-Based Compensation&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Effective upon the closing of the Company&#x2019;s IPO on January&#160;31, 2020, the Company&#x2019;s 2019 Equity Incentive Plan (the &#x201c;2019 Plan&#x201d;) became effective, succeeding the Company&#x2019;s previous equity incentive plan. No new options may be issued under the previous plan, although shares subject to grants which are cancelled or forfeited will again be available under the 2019 Plan. Effective June 1, 2021, the 2019 Plan was amended to increase the number of shares authorized to be issued from 1,000,000 to 2,000,000. As of December 31, 2021, 630,569 shares were available for future grants.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The 2019 Plan provides for grants to employees, members of the Board, consultants and advisors to the Company, in the form of stock options, stock awards and other equity-based awards. The amount and terms of grants are determined by the Board. Stock options have a maximum term of 10 years after date of grant and are exercisable in cash or as otherwise determined by the Board. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Stock-based compensation expense in the statements of operations, including the fair value of stock awards to consultants and advisors for services rendered, for the&#160;years ended December 31, 2021 and 2020 was as follows:&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:73%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:24.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Year Ended &lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:24.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.85%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.95%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2020&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Research and development&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.37%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2,016,745&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.37%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 138,704&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;General and administrative&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2,680,882&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,726,209&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.37%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 4,697,627&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.37%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,864,913&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"&gt;Stock option activity for the years ended December 31, 2021, and 2020, was as follows:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:54.03%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.63%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.52%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.43%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:54.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Weighted&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:54.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Average&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:54.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Remaining&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:54.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Weighted&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Contractual&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Aggregate&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:54.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Number of&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Average&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Term&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Intrinsic&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:54.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Shares&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Exercise Price&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;(Years)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Value&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:54.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Outstanding at December&#160;31,&#160;2019&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.37%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 352,282&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.63%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;$ 0.19&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.52%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.43%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:54.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Granted&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 810,000&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 3.46&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:54.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Exercised&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.37%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (48,435)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.63%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 0.19&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.52%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.43%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:54.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Forfeited&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (2,381)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 0.14&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:54.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Outstanding at December&#160;31,&#160;2020&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.37%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,111,466&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.63%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2.57&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.52%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.43%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:54.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Granted&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 538,095&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 33.78&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:54.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Exercised&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.37%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (159,813)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.63%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2.83&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.52%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.43%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:54.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Outstanding at December&#160;31,&#160;2021&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.37%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,489,748&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 13.82&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;&lt;span style="-sec-ix-hidden:Hidden_EQY9UVLtMU6NuqPU1k6Bhg;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt; 8.4&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;$ 14,325,377&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:54.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Exercisable at December&#160;31,&#160;2021&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.37%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,105,568&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.63%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 5.87&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.52%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;&lt;span style="-sec-ix-hidden:Hidden_LZM2INVDtkezbYWBS4I2FA;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt; 7.9&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.43%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;$ 14,325,377&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The aggregate intrinsic value of options exercised during the years ended December 31, 2021 and 2020 was $11,163,998 and $196,976, respectively. As of December 31, 2021 there was $9,933,691 unrecognized compensation expense related to unvested options. That cost is expected to be recognized over a weighted-average period of &lt;span style="-sec-ix-hidden:Hidden_bR4c2uBj-EKLsqDtSgFQaA;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;1.4&lt;/span&gt;&lt;/span&gt; years.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"&gt;During the years ended December 31, 2021 and 2020, the Company issued 538,095 and 810,000 options, respectively. Under the grant agreements for the 2021 stock option grants, 143,391 of the options vested immediately, 155,253 of the options vest on March 31, 2022, 155,251 of the options vest on March 31, 2023 and 84,200 of the options vest in substantially equal quarterly installments over two years&lt;span style="white-space:pre-wrap;"&gt; from the date of grant.  Under the grant agreements for the 2020 stock option grants, 50,000 of the options vested after &lt;/span&gt;&lt;span style="white-space:pre-wrap;"&gt;one year&lt;/span&gt;&lt;span style="white-space:pre-wrap;"&gt; and the remainder of the options were vested and exercisable upon grant. All of the options have a 10-year term.  &lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"&gt;The weighted average grant date fair value of options issued during the&#160;years ended December 31, 2021 and 2020 was $27.13 per share and $2.19&lt;span style="white-space:pre-wrap;"&gt; per share, respectively.  The fair value was estimated using the Black Sholes option pricing model.  The expected life of options was estimated using the simplified method, as the Company has limited historical information to develop reasonable expectations about future exercise patterns and post-vesting employment. The risk-free rate was based on the interest rate payable on U.S. Treasury securities at the time of grant for a period that is commensurate with the expected term of the option.  Given the lack of a public market for the Company&#x2019;s common stock prior to the IPO, the expected stock price volatility was based on a weighted approach that incorporates the historic daily volatility of the Company&#x2019;s common stock since the IPO and the historic daily volatility of similar companies that have been publicly traded for a period commensurate with the expected term of the option.  The expected dividend yield is &lt;/span&gt;0% because the Company has not historically paid and does not expect for the &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;foreseeable future to pay a dividend on its common stock. The weighted average assumptions used in the valuation of options granted were as follows:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:58.22%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.66%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.66%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.66%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Year Ended &lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.66%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Year Ended &lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;2020&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Risk-free interest rate&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.66%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1.17&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.66%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 0.38&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Expected life&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.66%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;span style="-sec-ix-hidden:Hidden_HsUzDjUJtkSAIzhEqWrcUA;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt; 5.3&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.66%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 5.0&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Expected volatility&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.66%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 113&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.66%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 80&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Expected dividend yield&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.66%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.66%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;During the year ended December 31, 2020, the Company granted stock awards totaling 25,000&lt;span style="white-space:pre-wrap;"&gt; shares to consultants and advisors for services rendered which vested upon grant.  These awards had a weighted-average grant date fair value of &lt;/span&gt;$4.91 per share and an aggregate fair value of $122,750&lt;span style="white-space:pre-wrap;"&gt;, which was recognized in stock-based compensation expense upon grant.  &lt;/span&gt;No stock awards were issued during the year ended December 31, 2021. As of December 31, 2021, there were no unvested stock awards and there was &lt;span style="-sec-ix-hidden:Hidden_FE1dYrMu70-J5dbAohVyjw;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;no&lt;/span&gt;&lt;/span&gt; unrecognized compensation expense related to stock awards.&lt;/p&gt;</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="As_Of_1_31_2020_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_anvs_EquityIncentivePlan2018Member_c20l7lAf-kqshSDL7zNsjg"
      decimals="INF"
      id="Narr_TQxOZr2jsk2HOLP1ITL-Rg"
      unitRef="Unit_Standard_shares__cOSbKjBTUyHt70_t1aAVw">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="As_Of_5_31_2021_us-gaap_PlanNameAxis_anvs_EquityIncentivePlan2019Member_KtS-YX7JjU6pl2kOUpEkTw"
      decimals="INF"
      id="Narr_e-FXdry9UE6jG9C0T2taBA"
      unitRef="Unit_Standard_shares__cOSbKjBTUyHt70_t1aAVw">1000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="As_Of_6_1_2021_us-gaap_PlanNameAxis_anvs_EquityIncentivePlan2019Member__w3AH-0HNU6nl5M5tn5tng"
      decimals="INF"
      id="Narr_mUxGHM0yckiwLc9OWdACJA"
      unitRef="Unit_Standard_shares__cOSbKjBTUyHt70_t1aAVw">2000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="As_Of_12_31_2021_us-gaap_PlanNameAxis_anvs_EquityIncentivePlan2019Member_UCOHxKW5skOhwhVeKdLFlA"
      decimals="INF"
      id="Narr_cmYVy4aolkq1wfDCnatzpw"
      unitRef="Unit_Standard_shares__cOSbKjBTUyHt70_t1aAVw">630569</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_anvs_EquityIncentivePlan2019Member_GgeIFB678UmRgQVDyMstNg"
      id="Narr_V8PZpAhcQEGNiPNKFQQFww">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
    <us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock
      contextRef="Duration_1_1_2021_To_12_31_2021_uhkxAiZ6fUeekYGgaMhCqA"
      id="Tb_YjdcRAhs-k-N6gjX-3MA5Q">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Stock-based compensation expense in the statements of operations, including the fair value of stock awards to consultants and advisors for services rendered, for the&#160;years ended December 31, 2021 and 2020 was as follows:&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:73%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:24.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Year Ended &lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:24.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.85%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.95%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2020&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Research and development&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.37%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2,016,745&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.37%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 138,704&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;General and administrative&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2,680,882&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,726,209&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.37%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 4,697,627&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.37%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,864,913&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock>
    <us-gaap:ShareBasedCompensation
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_PpS2s9PnUUSL1x-_RPEPIQ"
      decimals="0"
      id="Tc_Jzy0J_ayPEa5wxxJeHJJ_w_5_3"
      unitRef="Unit_Standard_USD_NFG_pVdyhEyJarLQmedkXA">2016745</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_Fq09egBe_kOjLnI9UQwMsA"
      decimals="0"
      id="Tc_VZyix7uJFUCidgtwSXhCgA_5_6"
      unitRef="Unit_Standard_USD_NFG_pVdyhEyJarLQmedkXA">138704</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_obnngQDtKEWjaZKdmxph6g"
      decimals="0"
      id="Tc_RDaosi8fwU-nXirFdc9RNA_6_3"
      unitRef="Unit_Standard_USD_NFG_pVdyhEyJarLQmedkXA">2680882</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_r5vqCaRQJk29U3pXOnvzDg"
      decimals="0"
      id="Tc_dMpc33ZTZE2HNqh8VU-PdA_6_6"
      unitRef="Unit_Standard_USD_NFG_pVdyhEyJarLQmedkXA">1726209</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="Duration_1_1_2021_To_12_31_2021_uhkxAiZ6fUeekYGgaMhCqA"
      decimals="0"
      id="Tc_sCXjCitrUk2b0cNmHbYMiw_7_3"
      unitRef="Unit_Standard_USD_NFG_pVdyhEyJarLQmedkXA">4697627</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="Duration_1_1_2020_To_12_31_2020_3DdHOulAJk6Q0Zn4Vsxq5A"
      decimals="0"
      id="Tc_0NabRXBD7UyEmphM8S3UQw_7_6"
      unitRef="Unit_Standard_USD_NFG_pVdyhEyJarLQmedkXA">1864913</us-gaap:ShareBasedCompensation>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock
      contextRef="Duration_1_1_2021_To_12_31_2021_uhkxAiZ6fUeekYGgaMhCqA"
      id="Tb_lJ_xcdtgsEabH4zoOGjByw">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:54.03%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.63%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.52%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.43%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:54.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Weighted&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:54.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Average&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:54.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Remaining&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:54.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Weighted&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Contractual&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Aggregate&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:54.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Number of&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Average&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Term&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Intrinsic&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:54.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Shares&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Exercise Price&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;(Years)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Value&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:54.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Outstanding at December&#160;31,&#160;2019&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.37%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 352,282&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.63%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;$ 0.19&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.52%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.43%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:54.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Granted&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 810,000&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 3.46&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:54.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Exercised&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.37%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (48,435)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.63%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 0.19&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.52%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.43%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:54.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Forfeited&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (2,381)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 0.14&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:54.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Outstanding at December&#160;31,&#160;2020&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.37%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,111,466&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.63%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2.57&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.52%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.43%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:54.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Granted&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 538,095&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 33.78&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:54.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Exercised&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.37%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (159,813)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.63%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2.83&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.52%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.43%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:54.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Outstanding at December&#160;31,&#160;2021&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.37%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,489,748&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 13.82&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;&lt;span style="-sec-ix-hidden:Hidden_EQY9UVLtMU6NuqPU1k6Bhg;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt; 8.4&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;$ 14,325,377&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:54.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Exercisable at December&#160;31,&#160;2021&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.37%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,105,568&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.63%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 5.87&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.52%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;&lt;span style="-sec-ix-hidden:Hidden_LZM2INVDtkezbYWBS4I2FA;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt; 7.9&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.43%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;$ 14,325,377&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="As_Of_12_31_2019_S7jX8DT5zEOORR0B4HM-aw"
      decimals="INF"
      id="Tc_2W294jPMIkav4ZwH2TPrEQ_7_2"
      unitRef="Unit_Standard_shares__cOSbKjBTUyHt70_t1aAVw">352282</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="As_Of_12_31_2019_S7jX8DT5zEOORR0B4HM-aw"
      decimals="2"
      id="Tc_3SH2r8hU-kytrxxiU-dThA_7_5"
      unitRef="Unit_Divide_USD_shares_ZtgwQidioUWlbMoOaTBzxg">0.19</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="Duration_1_1_2020_To_12_31_2020_3DdHOulAJk6Q0Zn4Vsxq5A"
      decimals="INF"
      id="Tc_axM_G8gA6Eqs-goQGaamfw_8_2"
      unitRef="Unit_Standard_shares__cOSbKjBTUyHt70_t1aAVw">810000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="Duration_1_1_2020_To_12_31_2020_3DdHOulAJk6Q0Zn4Vsxq5A"
      decimals="2"
      id="Tc_l7xQmtOn_kuZmy8mGjKdzA_8_5"
      unitRef="Unit_Divide_USD_shares_ZtgwQidioUWlbMoOaTBzxg">3.46</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="Duration_1_1_2020_To_12_31_2020_3DdHOulAJk6Q0Zn4Vsxq5A"
      decimals="INF"
      id="Tc_5aKzDRWjUU2ukZr0Y9FHDw_9_2"
      unitRef="Unit_Standard_shares__cOSbKjBTUyHt70_t1aAVw">48435</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="Duration_1_1_2020_To_12_31_2020_3DdHOulAJk6Q0Zn4Vsxq5A"
      decimals="2"
      id="Tc_s2qcb-mLJ0aV585sqM0FIQ_9_5"
      unitRef="Unit_Divide_USD_shares_ZtgwQidioUWlbMoOaTBzxg">0.19</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="Duration_1_1_2020_To_12_31_2020_3DdHOulAJk6Q0Zn4Vsxq5A"
      decimals="INF"
      id="Tc_kFj33-F6YEWSpNYlUIka6Q_10_2"
      unitRef="Unit_Standard_shares__cOSbKjBTUyHt70_t1aAVw">2381</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
      contextRef="Duration_1_1_2020_To_12_31_2020_3DdHOulAJk6Q0Zn4Vsxq5A"
      decimals="2"
      id="Tc_q1v37hbgxE263oRFp9JO7g_10_5"
      unitRef="Unit_Divide_USD_shares_ZtgwQidioUWlbMoOaTBzxg">0.14</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="As_Of_12_31_2020_K1oKCNbpv0CLR8EJWu1PSw"
      decimals="INF"
      id="Tc_5mNmZJCRmkug6iEHmsKbbQ_11_2"
      unitRef="Unit_Standard_shares__cOSbKjBTUyHt70_t1aAVw">1111466</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="As_Of_12_31_2020_K1oKCNbpv0CLR8EJWu1PSw"
      decimals="2"
      id="Tc_6Z8KQx9aKESyqjesr1yrTw_11_5"
      unitRef="Unit_Divide_USD_shares_ZtgwQidioUWlbMoOaTBzxg">2.57</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="Duration_1_1_2021_To_12_31_2021_uhkxAiZ6fUeekYGgaMhCqA"
      decimals="INF"
      id="Tc_yIipyX75CU2AYT97FnGpBw_12_2"
      unitRef="Unit_Standard_shares__cOSbKjBTUyHt70_t1aAVw">538095</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="Duration_1_1_2021_To_12_31_2021_uhkxAiZ6fUeekYGgaMhCqA"
      decimals="2"
      id="Tc_pky3vL5b-k6m6Hq0v-t9Qw_12_5"
      unitRef="Unit_Divide_USD_shares_ZtgwQidioUWlbMoOaTBzxg">33.78</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="Duration_1_1_2021_To_12_31_2021_uhkxAiZ6fUeekYGgaMhCqA"
      decimals="INF"
      id="Tc_yJ2lrAlUtEiVWJXvpgJSAw_13_2"
      unitRef="Unit_Standard_shares__cOSbKjBTUyHt70_t1aAVw">159813</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="Duration_1_1_2021_To_12_31_2021_uhkxAiZ6fUeekYGgaMhCqA"
      decimals="2"
      id="Tc_6FML1xA5gkuoHgNOhXrxxw_13_5"
      unitRef="Unit_Divide_USD_shares_ZtgwQidioUWlbMoOaTBzxg">2.83</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="As_Of_12_31_2021_slf_IrTrZku1VVWbbttE4g"
      decimals="INF"
      id="Tc_gwyWDxDRkEe1F2i7gFFMGA_14_2"
      unitRef="Unit_Standard_shares__cOSbKjBTUyHt70_t1aAVw">1489748</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="As_Of_12_31_2021_slf_IrTrZku1VVWbbttE4g"
      decimals="2"
      id="Tc_0MRG0g6HPUeQGABk5fA0CA_14_5"
      unitRef="Unit_Divide_USD_shares_ZtgwQidioUWlbMoOaTBzxg">13.82</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="As_Of_12_31_2021_slf_IrTrZku1VVWbbttE4g"
      decimals="0"
      id="Tc_oFBHmVYgjkCBwhVJZQgMNQ_14_9"
      unitRef="Unit_Standard_USD_NFG_pVdyhEyJarLQmedkXA">14325377</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="As_Of_12_31_2021_slf_IrTrZku1VVWbbttE4g"
      decimals="INF"
      id="Tc_Xz6VLr8kY0mYiRPx0ObBrw_15_2"
      unitRef="Unit_Standard_shares__cOSbKjBTUyHt70_t1aAVw">1105568</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="As_Of_12_31_2021_slf_IrTrZku1VVWbbttE4g"
      decimals="2"
      id="Tc_ysg9XsdQZEGb7ISZo9ywBA_15_5"
      unitRef="Unit_Divide_USD_shares_ZtgwQidioUWlbMoOaTBzxg">5.87</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
      contextRef="As_Of_12_31_2021_slf_IrTrZku1VVWbbttE4g"
      decimals="0"
      id="Tc_SPdYxX2qdUO87DhuMO5MzA_15_9"
      unitRef="Unit_Standard_USD_NFG_pVdyhEyJarLQmedkXA">14325377</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
      contextRef="Duration_1_1_2021_To_12_31_2021_uhkxAiZ6fUeekYGgaMhCqA"
      decimals="0"
      id="Narr_C4Z_cEhoXkOY6DuHHkjpog"
      unitRef="Unit_Standard_USD_NFG_pVdyhEyJarLQmedkXA">11163998</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
      contextRef="Duration_1_1_2020_To_12_31_2020_3DdHOulAJk6Q0Zn4Vsxq5A"
      decimals="0"
      id="Narr_pykSx5HoqUqY0vd1h-cT4Q"
      unitRef="Unit_Standard_USD_NFG_pVdyhEyJarLQmedkXA">196976</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
      contextRef="As_Of_12_31_2021_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_MkIC0676s0mFrsozz2b5Ow"
      decimals="0"
      id="Narr_EYst8uzj30WJ-b0sz5QjOA"
      unitRef="Unit_Standard_USD_NFG_pVdyhEyJarLQmedkXA">9933691</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="Duration_1_1_2021_To_12_31_2021_uhkxAiZ6fUeekYGgaMhCqA"
      decimals="INF"
      id="Narr__Ma8LdSlOUSzE143Hb5g9g"
      unitRef="Unit_Standard_shares__cOSbKjBTUyHt70_t1aAVw">538095</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="Duration_1_1_2020_To_12_31_2020_3DdHOulAJk6Q0Zn4Vsxq5A"
      decimals="INF"
      id="Narr_2HGdIf80F0uCTFVrAXvF4w"
      unitRef="Unit_Standard_shares__cOSbKjBTUyHt70_t1aAVw">810000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
      contextRef="As_Of_12_31_2021_us-gaap_AwardDateAxis_anvs_AwardsGrantedIn2021Member_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_VestingAxis_anvs_ShareBasedPaymentArrangementVestingPeriodImmediateVestingMember_1D0-tOBHgkGoY1R3CgsSig"
      decimals="INF"
      id="Narr_Y2Hptnl5b0GV9panSwdI1Q"
      unitRef="Unit_Standard_shares__cOSbKjBTUyHt70_t1aAVw">143391</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
      contextRef="As_Of_12_31_2021_us-gaap_AwardDateAxis_anvs_AwardsGrantedIn2021Member_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_VestingAxis_anvs_ShareBasedPaymentArrangementVestingPeriodOneYearMember_DimQ7qACMU6TfxILGAwOCw"
      decimals="INF"
      id="Narr_kclcN27raUe3WvKiePfvMA"
      unitRef="Unit_Standard_shares__cOSbKjBTUyHt70_t1aAVw">155253</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
      contextRef="As_Of_12_31_2021_us-gaap_AwardDateAxis_anvs_AwardsGrantedIn2021Member_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_VestingAxis_anvs_ShareBasedPaymentArrangementVestingPeriodTwoYearsMember_7fink69gjUCJNwXqPwAp0Q"
      decimals="INF"
      id="Narr_ny-Ls3NAfESrqLWU-3qFpw"
      unitRef="Unit_Standard_shares__cOSbKjBTUyHt70_t1aAVw">155251</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
      contextRef="As_Of_12_31_2021_us-gaap_AwardDateAxis_anvs_AwardsGrantedIn2021Member_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_VestingAxis_anvs_ShareBasedPaymentArrangementVestingPeriodEqualQuarterlyInstallmentsOverTwoYearsMember_ZOvd1oon0k2qQBob-40BxQ"
      decimals="INF"
      id="Narr_kkaO5BM3R0m-XZbAckXAmA"
      unitRef="Unit_Standard_shares__cOSbKjBTUyHt70_t1aAVw">84200</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_AwardDateAxis_anvs_AwardsGrantedIn2021Member_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_VestingAxis_anvs_ShareBasedPaymentArrangementVestingPeriodEqualQuarterlyInstallmentsOverTwoYearsMember_KPZ_nNTrBk-ED74SOGLcGQ"
      id="Narr_BupSt7erZUilELlCPkGX2A">P2Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
      contextRef="As_Of_12_31_2020_us-gaap_AwardDateAxis_anvs_AwardsGrantedIn2020Member_us-gaap_VestingAxis_anvs_ShareBasedPaymentArrangementVestingPeriodOneYearMember_5-6tsJ5Re0SiRVbMTy7QsA"
      decimals="INF"
      id="Narr_swKB6RyZ_0O2fJw1fTtQow"
      unitRef="Unit_Standard_shares__cOSbKjBTUyHt70_t1aAVw">50000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_AwardDateAxis_anvs_AwardsGrantedIn2020Member_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_VestingAxis_anvs_ShareBasedPaymentArrangementVestingPeriodOneYearMember__Fh8QWUir0eZugsK0WNqcA"
      id="Narr_uzWbROPCk06Z0L8djynTHg">P1Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="Duration_1_1_2021_To_12_31_2021_uhkxAiZ6fUeekYGgaMhCqA"
      decimals="2"
      id="Narr_UjxHS9UIXESIPxTg6v605Q"
      unitRef="Unit_Divide_USD_shares_ZtgwQidioUWlbMoOaTBzxg">27.13</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="Duration_1_1_2020_To_12_31_2020_3DdHOulAJk6Q0Zn4Vsxq5A"
      decimals="2"
      id="Narr_25kk2X3i20WAdTKNtG1RUw"
      unitRef="Unit_Divide_USD_shares_ZtgwQidioUWlbMoOaTBzxg">2.19</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_LAmAyrWmJUC3qRHISSAjmA"
      decimals="2"
      id="Narr_MydXeq6SXkS6BVpdkXMHMA"
      unitRef="Unit_Standard_pure_n7tAfGlk1kyqYH5N2uCURw">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_vlN0t7QzKEiNBpiYEjJwDw"
      decimals="2"
      id="Narr_sGQBhjfOh0iDNGVVAqREaw"
      unitRef="Unit_Standard_pure_n7tAfGlk1kyqYH5N2uCURw">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock
      contextRef="Duration_1_1_2021_To_12_31_2021_uhkxAiZ6fUeekYGgaMhCqA"
      id="Tb_d_sAhpKvZ0mL1UcpIdNr5A">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:58.22%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.66%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.66%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.66%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Year Ended &lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.66%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Year Ended &lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;2020&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Risk-free interest rate&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.66%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1.17&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.66%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 0.38&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Expected life&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.66%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;span style="-sec-ix-hidden:Hidden_HsUzDjUJtkSAIzhEqWrcUA;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt; 5.3&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.66%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 5.0&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Expected volatility&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.66%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 113&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.66%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 80&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Expected dividend yield&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.66%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.66%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_vlN0t7QzKEiNBpiYEjJwDw"
      decimals="4"
      id="Tc_geziVtxzaE-8FsydTZDEnQ_3_2"
      unitRef="Unit_Standard_pure_n7tAfGlk1kyqYH5N2uCURw">0.0117</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_LAmAyrWmJUC3qRHISSAjmA"
      decimals="4"
      id="Tc_WW0a5E0HkUWxl_M_lq55Wg_3_5"
      unitRef="Unit_Standard_pure_n7tAfGlk1kyqYH5N2uCURw">0.0038</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_LAmAyrWmJUC3qRHISSAjmA"
      id="Tc_Lk8iUjg2EkSlgdJ4snKWUw_4_5">P5Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_vlN0t7QzKEiNBpiYEjJwDw"
      decimals="2"
      id="Tc_u4P2NLCjyUaVf5d8HbfzfA_5_2"
      unitRef="Unit_Standard_pure_n7tAfGlk1kyqYH5N2uCURw">1.13</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_LAmAyrWmJUC3qRHISSAjmA"
      decimals="2"
      id="Tc_Xa5b2Ft_tUukRNjGc5nfVQ_5_5"
      unitRef="Unit_Standard_pure_n7tAfGlk1kyqYH5N2uCURw">0.80</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_vlN0t7QzKEiNBpiYEjJwDw"
      decimals="2"
      id="Tc_q1L5WpMRiE2g75T6awlueQ_6_2"
      unitRef="Unit_Standard_pure_n7tAfGlk1kyqYH5N2uCURw">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_LAmAyrWmJUC3qRHISSAjmA"
      decimals="2"
      id="Tc_oePj9uO1JkCtg3Iel5X5bw_6_5"
      unitRef="Unit_Standard_pure_n7tAfGlk1kyqYH5N2uCURw">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:StockIssuedDuringPeriodSharesIssuedForServices
      contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_GranteeStatusAxis_us-gaap_ShareBasedPaymentArrangementNonemployeeMember__Y5EzHRV8U2VQ42ne0t5eg"
      decimals="INF"
      id="Narr_r_yHlDyAhk6MEV5wFaFTyA"
      unitRef="Unit_Standard_shares__cOSbKjBTUyHt70_t1aAVw">25000</us-gaap:StockIssuedDuringPeriodSharesIssuedForServices>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_GranteeStatusAxis_us-gaap_ShareBasedPaymentArrangementNonemployeeMember__Y5EzHRV8U2VQ42ne0t5eg"
      decimals="2"
      id="Narr_BGF2iwytV0yi1qcsmI9EnQ"
      unitRef="Unit_Divide_USD_shares_ZtgwQidioUWlbMoOaTBzxg">4.91</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <anvs:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedInPeriodFairValue
      contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_GranteeStatusAxis_us-gaap_ShareBasedPaymentArrangementNonemployeeMember__Y5EzHRV8U2VQ42ne0t5eg"
      decimals="0"
      id="Narr_e2kUQ3ZOq0m0-B4RxDgmLg"
      unitRef="Unit_Standard_USD_NFG_pVdyhEyJarLQmedkXA">122750</anvs:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedInPeriodFairValue>
    <us-gaap:StockIssuedDuringPeriodSharesIssuedForServices
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_GranteeStatusAxis_us-gaap_ShareBasedPaymentArrangementNonemployeeMember_-b4g7yTNB0aLjzC-gDHmiA"
      decimals="INF"
      id="Narr_o4Pg39cMJU6tcgvNfiqzAQ"
      unitRef="Unit_Standard_shares__cOSbKjBTUyHt70_t1aAVw">0</us-gaap:StockIssuedDuringPeriodSharesIssuedForServices>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares
      contextRef="As_Of_12_31_2021_slf_IrTrZku1VVWbbttE4g"
      decimals="INF"
      id="Narr_r48Krne4yU2qi3EakAA6ng"
      unitRef="Unit_Standard_shares__cOSbKjBTUyHt70_t1aAVw">0</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares>
    <us-gaap:EarningsPerShareTextBlock
      contextRef="Duration_1_1_2021_To_12_31_2021_uhkxAiZ6fUeekYGgaMhCqA"
      id="Tb_i7hWTDacBUeu04a3o0khyQ">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;(11) Net Loss Per Share&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company has reported a net loss for the&#160;years ended December 31, 2021 and 2020, and the basic and diluted net loss per share attributable to common stockholders are the same for both&#160;years because all redeemable convertible preferred stock, convertible promissory notes, warrants and stock options have been excluded from the computation of diluted weighted-average shares outstanding because such securities would have an antidilutive impact.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"&gt;The following table sets forth the computation of basic and diluted net loss per share:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:66.67%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.96%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.67%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:66.67%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt; &lt;/b&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:31.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Year Ended &lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:66.67%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:31.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:66.67%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2020&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:66.67%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Numerator&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.96%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.67%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:66.67%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Net loss&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.96%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (14,487,132)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.67%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (5,462,047)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:66.67%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Denominator&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.96%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.67%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:66.67%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Weighted-average common shares outstanding, basic and diluted&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.96%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 7,626,278&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.67%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 6,308,961&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:66.67%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Net loss per share, basic and diluted&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.96%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (1.90)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.67%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (0.87)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"&gt;Potential common shares that are excluded from the computation of diluted weighted-average shares outstanding are as follows:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:74.5%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.71%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.71%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:74.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:25.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:74.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.71%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.71%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2020&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:74.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Stock options&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.71%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,489,748&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.71%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,111,466&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:74.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Warrants&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2,400&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 100,000&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:EarningsPerShareTextBlock>
    <us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock
      contextRef="Duration_1_1_2021_To_12_31_2021_uhkxAiZ6fUeekYGgaMhCqA"
      id="Tb_GATS2saxC0aLjPKtFj2nnw">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:66.67%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.96%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.67%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:66.67%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt; &lt;/b&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:31.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Year Ended &lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:66.67%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:31.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:66.67%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2020&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:66.67%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Numerator&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.96%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.67%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:66.67%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Net loss&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.96%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (14,487,132)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.67%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (5,462,047)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:66.67%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Denominator&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.96%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.67%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:66.67%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Weighted-average common shares outstanding, basic and diluted&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.96%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 7,626,278&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.67%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 6,308,961&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:66.67%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Net loss per share, basic and diluted&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.96%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (1.90)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.67%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (0.87)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2021_To_12_31_2021_uhkxAiZ6fUeekYGgaMhCqA"
      decimals="0"
      id="Tc_X0ocdAT2lk-tk4NaSpEJQg_5_3"
      unitRef="Unit_Standard_USD_NFG_pVdyhEyJarLQmedkXA">-14487132</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2020_To_12_31_2020_3DdHOulAJk6Q0Zn4Vsxq5A"
      decimals="0"
      id="Tc_GvAdbLnRvUKrqZH6vgkbnQ_5_6"
      unitRef="Unit_Standard_USD_NFG_pVdyhEyJarLQmedkXA">-5462047</us-gaap:NetIncomeLoss>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="Duration_1_1_2021_To_12_31_2021_uhkxAiZ6fUeekYGgaMhCqA"
      decimals="INF"
      id="Tc_eepf9vkV_kCwfHNOnNgIXw_7_3"
      unitRef="Unit_Standard_shares__cOSbKjBTUyHt70_t1aAVw">7626278</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="Duration_1_1_2020_To_12_31_2020_3DdHOulAJk6Q0Zn4Vsxq5A"
      decimals="INF"
      id="Tc_zuyuPBZraEOA-2UY6bpsFg_7_6"
      unitRef="Unit_Standard_shares__cOSbKjBTUyHt70_t1aAVw">6308961</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="Duration_1_1_2021_To_12_31_2021_uhkxAiZ6fUeekYGgaMhCqA"
      decimals="2"
      id="Tc_DuQnnDwtUEqrqFt_IvLBNA_8_3"
      unitRef="Unit_Divide_USD_shares_ZtgwQidioUWlbMoOaTBzxg">-1.90</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="Duration_1_1_2020_To_12_31_2020_3DdHOulAJk6Q0Zn4Vsxq5A"
      decimals="2"
      id="Tc_zQOYSdGJ-Ue7zHUK1aue0w_8_6"
      unitRef="Unit_Divide_USD_shares_ZtgwQidioUWlbMoOaTBzxg">-0.87</us-gaap:EarningsPerShareBasic>
    <us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock
      contextRef="Duration_1_1_2021_To_12_31_2021_uhkxAiZ6fUeekYGgaMhCqA"
      id="Tb_3aqrIV1dMEiBdahJB1DHug">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:74.5%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.71%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.71%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:74.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:25.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:74.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.71%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.71%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2020&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:74.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Stock options&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.71%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,489,748&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.71%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,111,466&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:74.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Warrants&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2,400&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 100,000&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockOptionMember_ErimM70Lx0GlzbzdZjfaBQ"
      decimals="INF"
      id="Tc_4kXM4wHa0UCxsFCCXkIh0g_3_1"
      unitRef="Unit_Standard_shares__cOSbKjBTUyHt70_t1aAVw">1489748</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockOptionMember_Ot-TYiGbdkWL1GALWHvnMQ"
      decimals="INF"
      id="Tc_5PuGOz0IEkmAUDrwPbORRg_3_3"
      unitRef="Unit_Standard_shares__cOSbKjBTUyHt70_t1aAVw">1111466</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_WarrantMember_GH_2bhJhrkKLRik7_QHn1g"
      decimals="INF"
      id="Tc_9iSP_wANn0CLF9XXi7FUwg_4_1"
      unitRef="Unit_Standard_shares__cOSbKjBTUyHt70_t1aAVw">2400</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_WarrantMember_BM2Bi1ZZ70OsQ-maVuCszA"
      decimals="INF"
      id="Tc__9EEuNvu-UOUSzknaiGtNA_4_3"
      unitRef="Unit_Standard_shares__cOSbKjBTUyHt70_t1aAVw">100000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:IncomeTaxDisclosureTextBlock
      contextRef="Duration_1_1_2021_To_12_31_2021_uhkxAiZ6fUeekYGgaMhCqA"
      id="Tb_GSA3zuFAzUWg7KJiizVqJA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;(12) Income Taxes&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The federal and state provision (benefit) for income taxes was&#160;$0&#160;for the&#160;years ended December 31, 2021 and 2020.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"&gt;A reconciliation of income tax provision (benefit) computed at the statutory federal income tax rate to income taxes as reflected in the financial statements for the&#160;years ended December 31, 2021 and 2020 is as follows:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:75.45%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.38%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.43%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.38%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt; &lt;/b&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:20.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Year Ended &lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:20.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2020&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75.45%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Federal income tax benefit at statutory rate&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.38%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 21.0&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.43%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.38%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 21.0&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;State and local tax, net of federal benefit&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 13.7&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 7.6&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75.45%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Permanent differences&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.38%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 0.1&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.43%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.38%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (0.8)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Research and development credit&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2.4&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1.9&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75.45%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Stock-based compensation&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.38%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 15.7&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.43%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.38%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Change in valuation allowance&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (52.9)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (29.7)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75.45%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Effective income tax rate&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.38%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 0.0&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.43%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.38%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 0.0&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"&gt;Deferred taxes are recognized for temporary differences between the basis of assets and liabilities for financial statement and income tax purposes. The significant components of the Company&#x2019;s deferred tax assets are comprised of the following:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:66.67%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.96%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.67%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:66.67%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt; &lt;/b&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:31.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;As&#160;of&#160;December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:66.67%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2020&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:66.67%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Net operating loss carryforwards&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.96%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 6,512,249&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.67%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2,460,773&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:66.67%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Capitalized research and development&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.96%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2,002,431&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.67%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:66.67%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Stock-based compensation&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.96%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,759,129&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.67%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 547,628&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:66.67%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Research and development tax credit carryforwards&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 648,077&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.67%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 241,414&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:66.67%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Total deferred tax assets&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.96%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 10,921,886&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.67%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 3,249,815&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:66.67%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Less valuation allowance&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (10,921,886)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.67%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (3,249,815)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:66.67%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Net deferred taxes&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.96%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.67%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;As of December 31, 2021, the Company had U.S. federal net operating loss (&#x201c;NOL&#x201d;) carryforwards of $21,844,192, which may be available to offset future income tax liabilities. Federal NOL carryforwards generated in 2017 and prior of $2,764,240 will expire beginning in 2032. The remaining federal NOL carryforwards generated in 2018 and later do not expire. As of December 31, 2021, the Company also had U.S. state NOL carryforwards of $24,391,076 which may be available to offset future income tax liabilities and will expire beginning in 2028.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company has recorded a full valuation allowance against its net deferred tax assets as of December 31, 2021 and 2020 because the Company has determined that is it more likely than not that these assets will not be fully realized due to historic net operating losses incurred. The Company experienced a net change in valuation allowance of $7,672,071 and $1,619,516 in the&#160;years ended December 31, 2021 and 2020, respectively.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;As of December 31, 2021, the Company had federal research and development tax credit carryforwards of $648,077 available to reduce future tax liabilities which expire beginning in 2028.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Under the provisions of the Internal Revenue Code, the NOL and tax credit carryforwards are subject to review and possible adjustment by the Internal Revenue Service and state tax authorities. NOL and tax credit carryforwards may become subject to an annual limitation in the event of certain cumulative changes in the ownership interest of significant stockholders over a three-year period in excess of 50%, as defined under Sections&#160;382 and 383 of the Internal Revenue Code as well as similar state provisions. This could limit the amount of tax attributes that can be utilized annually to offset future taxable income or tax liabilities. The amount of the annual limitation is determined based on the value of the Company immediately prior to the ownership change. Subsequent ownership changes may further affect the limitation in future&#160;years. The Company has completed financings since its inception which may have resulted in a change in control as defined by Sections&#160;382 and 383 of the Internal Revenue Code, or could result in a change in control in the future. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company files tax returns as prescribed by the tax laws of the jurisdictions in which it operates. In the normal course of business, the Company is subject to examination by federal and state jurisdictions, where applicable. The Company&#x2019;s tax&#160;years from 2018 to the present remain open for review. All open&#160;years may be examined to the extent that tax credits or NOL carryforwards are used in future periods. The Company will recognize interest and penalties related to uncertain tax positions in income tax expense. As of December 31, 2021, the Company had &lt;span style="-sec-ix-hidden:Hidden_1sZl5MdDJ0KYV2BjEn0mRA;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;no&lt;/span&gt;&lt;/span&gt; accrued interest or penalties related to uncertain tax positions and no amounts have been recognized in the Company&#x2019;s statements of operations.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt;On March 27, 2020, the Coronavirus Aid, Relief, and Economic Security Act (&#x201c;CARES Act&#x201d;) was enacted in response to the COVID-19 pandemic. The CARES Act, among other things, permits NOL carryovers and carrybacks to offset 100% of taxable income for taxable years beginning before 2021. Previously, NOLs generated after December 31, 2017 were limited to 80% of taxable income in future years.  In addition, the CARES Act allows NOLs incurred in 2018, 2019 and 2020 to be carried back to each of the five preceding taxable years to generate a refund of previously paid income taxes. The NOL carryback provision of the CARES Act had no impact on the Company due to its tax losses generated during all prior years.&lt;/span&gt;&lt;/p&gt;</us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:StateAndLocalIncomeTaxExpenseBenefitContinuingOperations
      contextRef="Duration_1_1_2020_To_12_31_2020_3DdHOulAJk6Q0Zn4Vsxq5A"
      decimals="0"
      id="Narr_LVHqh8rbbkuctlhNPQKl9A"
      unitRef="Unit_Standard_USD_NFG_pVdyhEyJarLQmedkXA">0</us-gaap:StateAndLocalIncomeTaxExpenseBenefitContinuingOperations>
    <us-gaap:StateAndLocalIncomeTaxExpenseBenefitContinuingOperations
      contextRef="Duration_1_1_2021_To_12_31_2021_uhkxAiZ6fUeekYGgaMhCqA"
      decimals="0"
      id="Narr_ytnXIDhzVEGhTcCs0nem9A"
      unitRef="Unit_Standard_USD_NFG_pVdyhEyJarLQmedkXA">0</us-gaap:StateAndLocalIncomeTaxExpenseBenefitContinuingOperations>
    <us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock
      contextRef="Duration_1_1_2021_To_12_31_2021_uhkxAiZ6fUeekYGgaMhCqA"
      id="Tb_c3wm2TluZkqys_W2yir7rw">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:75.45%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.38%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.43%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.38%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt; &lt;/b&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:20.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Year Ended &lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:20.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2020&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75.45%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Federal income tax benefit at statutory rate&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.38%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 21.0&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.43%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.38%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 21.0&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;State and local tax, net of federal benefit&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 13.7&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 7.6&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75.45%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Permanent differences&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.38%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 0.1&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.43%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.38%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (0.8)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Research and development credit&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2.4&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1.9&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75.45%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Stock-based compensation&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.38%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 15.7&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.43%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.38%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Change in valuation allowance&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (52.9)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (29.7)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75.45%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Effective income tax rate&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.38%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 0.0&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.43%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.38%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 0.0&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="Duration_1_1_2021_To_12_31_2021_uhkxAiZ6fUeekYGgaMhCqA"
      decimals="3"
      id="Tc_sGmGeimvKki8qFGyQ0HISg_4_2"
      unitRef="Unit_Standard_pure_n7tAfGlk1kyqYH5N2uCURw">0.210</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="Duration_1_1_2020_To_12_31_2020_3DdHOulAJk6Q0Zn4Vsxq5A"
      decimals="3"
      id="Tc_YP9MNm2U1kS1auM8eXC1Jg_4_4"
      unitRef="Unit_Standard_pure_n7tAfGlk1kyqYH5N2uCURw">0.210</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
      contextRef="Duration_1_1_2021_To_12_31_2021_uhkxAiZ6fUeekYGgaMhCqA"
      decimals="3"
      id="Tc_HVlQnlC4YkyndPwVUbAGXQ_5_2"
      unitRef="Unit_Standard_pure_n7tAfGlk1kyqYH5N2uCURw">0.137</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
      contextRef="Duration_1_1_2020_To_12_31_2020_3DdHOulAJk6Q0Zn4Vsxq5A"
      decimals="3"
      id="Tc_uLFQ90Uivkik2ocVY_Q9Ug_5_4"
      unitRef="Unit_Standard_pure_n7tAfGlk1kyqYH5N2uCURw">0.076</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpense
      contextRef="Duration_1_1_2021_To_12_31_2021_uhkxAiZ6fUeekYGgaMhCqA"
      decimals="3"
      id="Tc_5l2oVodiO0-sEsi8Cvun0w_6_2"
      unitRef="Unit_Standard_pure_n7tAfGlk1kyqYH5N2uCURw">0.001</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpense>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpense
      contextRef="Duration_1_1_2020_To_12_31_2020_3DdHOulAJk6Q0Zn4Vsxq5A"
      decimals="3"
      id="Tc_Ll9mTimbmkmVT0vtK8fWgg_6_4"
      unitRef="Unit_Standard_pure_n7tAfGlk1kyqYH5N2uCURw">-0.008</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpense>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment
      contextRef="Duration_1_1_2021_To_12_31_2021_uhkxAiZ6fUeekYGgaMhCqA"
      decimals="3"
      id="Tc_J_GTsCkXMEKdzYwob1Mrkw_7_2"
      unitRef="Unit_Standard_pure_n7tAfGlk1kyqYH5N2uCURw">0.024</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment
      contextRef="Duration_1_1_2020_To_12_31_2020_3DdHOulAJk6Q0Zn4Vsxq5A"
      decimals="3"
      id="Tc_XwhxnbcGvky3c3b2HjEj_A_7_4"
      unitRef="Unit_Standard_pure_n7tAfGlk1kyqYH5N2uCURw">0.019</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost
      contextRef="Duration_1_1_2021_To_12_31_2021_uhkxAiZ6fUeekYGgaMhCqA"
      decimals="3"
      id="Tc_n7bWHASCCESvMrBt5ncc3w_8_2"
      unitRef="Unit_Standard_pure_n7tAfGlk1kyqYH5N2uCURw">0.157</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="Duration_1_1_2021_To_12_31_2021_uhkxAiZ6fUeekYGgaMhCqA"
      decimals="3"
      id="Tc_6OnX7TyLpEOQ40w4lU-TPQ_9_2"
      unitRef="Unit_Standard_pure_n7tAfGlk1kyqYH5N2uCURw">-0.529</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="Duration_1_1_2020_To_12_31_2020_3DdHOulAJk6Q0Zn4Vsxq5A"
      decimals="3"
      id="Tc_PWYEcU1eoUSWWAD1LbNS6A_9_4"
      unitRef="Unit_Standard_pure_n7tAfGlk1kyqYH5N2uCURw">-0.297</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="Duration_1_1_2021_To_12_31_2021_uhkxAiZ6fUeekYGgaMhCqA"
      decimals="3"
      id="Tc_Fm4Su2Fo60SYCasOcYzrlA_10_2"
      unitRef="Unit_Standard_pure_n7tAfGlk1kyqYH5N2uCURw">0.000</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="Duration_1_1_2020_To_12_31_2020_3DdHOulAJk6Q0Zn4Vsxq5A"
      decimals="3"
      id="Tc_X26vHx85PkaYUgFkgW2PBA_10_4"
      unitRef="Unit_Standard_pure_n7tAfGlk1kyqYH5N2uCURw">0.000</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock
      contextRef="Duration_1_1_2021_To_12_31_2021_uhkxAiZ6fUeekYGgaMhCqA"
      id="Tb_8wVigjioNUubegvzuNQv8A">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:66.67%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.96%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.67%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:66.67%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt; &lt;/b&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:31.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;As&#160;of&#160;December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:66.67%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2020&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:66.67%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Net operating loss carryforwards&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.96%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 6,512,249&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.67%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2,460,773&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:66.67%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Capitalized research and development&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.96%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2,002,431&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.67%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:66.67%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Stock-based compensation&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.96%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,759,129&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.67%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 547,628&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:66.67%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Research and development tax credit carryforwards&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 648,077&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.67%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 241,414&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:66.67%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Total deferred tax assets&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.96%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 10,921,886&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.67%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 3,249,815&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:66.67%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Less valuation allowance&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (10,921,886)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.67%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (3,249,815)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:66.67%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Net deferred taxes&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.96%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.67%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards
      contextRef="As_Of_12_31_2021_slf_IrTrZku1VVWbbttE4g"
      decimals="0"
      id="Tc_44kjSsqsjU-rXybbOWLCUA_3_3"
      unitRef="Unit_Standard_USD_NFG_pVdyhEyJarLQmedkXA">6512249</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards
      contextRef="As_Of_12_31_2020_K1oKCNbpv0CLR8EJWu1PSw"
      decimals="0"
      id="Tc__PfBcGIskUu333GqjhX22A_3_6"
      unitRef="Unit_Standard_USD_NFG_pVdyhEyJarLQmedkXA">2460773</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <anvs:DeferredTaxAssetsTaxCreditCarryforwardsCapitalizedResearchAndDevelopment
      contextRef="As_Of_12_31_2021_slf_IrTrZku1VVWbbttE4g"
      decimals="0"
      id="Tc_aozjY7nEjE-p-8WX5X-cIw_4_3"
      unitRef="Unit_Standard_USD_NFG_pVdyhEyJarLQmedkXA">2002431</anvs:DeferredTaxAssetsTaxCreditCarryforwardsCapitalizedResearchAndDevelopment>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
      contextRef="As_Of_12_31_2021_slf_IrTrZku1VVWbbttE4g"
      decimals="0"
      id="Tc_S_FUCU6_1k2eNeo7OjXU8Q_5_3"
      unitRef="Unit_Standard_USD_NFG_pVdyhEyJarLQmedkXA">1759129</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
      contextRef="As_Of_12_31_2020_K1oKCNbpv0CLR8EJWu1PSw"
      decimals="0"
      id="Tc_Dpf7B4gt9ES5dXdG8Q1y9Q_5_6"
      unitRef="Unit_Standard_USD_NFG_pVdyhEyJarLQmedkXA">547628</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch
      contextRef="As_Of_12_31_2021_slf_IrTrZku1VVWbbttE4g"
      decimals="0"
      id="Tc_nspLmk8L9U2XZUEMmupCuA_6_3"
      unitRef="Unit_Standard_USD_NFG_pVdyhEyJarLQmedkXA">648077</us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch
      contextRef="As_Of_12_31_2020_K1oKCNbpv0CLR8EJWu1PSw"
      decimals="0"
      id="Tc_dgjQMFeKHkWRC3wzOntsWw_6_6"
      unitRef="Unit_Standard_USD_NFG_pVdyhEyJarLQmedkXA">241414</us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch>
    <us-gaap:DeferredTaxAssetsGross
      contextRef="As_Of_12_31_2021_slf_IrTrZku1VVWbbttE4g"
      decimals="0"
      id="Tc_jeoGMATvNkK4LeEEzW7qpA_7_3"
      unitRef="Unit_Standard_USD_NFG_pVdyhEyJarLQmedkXA">10921886</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsGross
      contextRef="As_Of_12_31_2020_K1oKCNbpv0CLR8EJWu1PSw"
      decimals="0"
      id="Tc_Wm3ZkOI70UOMVzIweZb3lw_7_6"
      unitRef="Unit_Standard_USD_NFG_pVdyhEyJarLQmedkXA">3249815</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="As_Of_12_31_2021_slf_IrTrZku1VVWbbttE4g"
      decimals="0"
      id="Tc_z_XsxwfYbESYkb15Pubolg_8_3"
      unitRef="Unit_Standard_USD_NFG_pVdyhEyJarLQmedkXA">10921886</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="As_Of_12_31_2020_K1oKCNbpv0CLR8EJWu1PSw"
      decimals="0"
      id="Tc_-g1LAdLGhUGTNvMbcFrLPA_8_6"
      unitRef="Unit_Standard_USD_NFG_pVdyhEyJarLQmedkXA">3249815</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsNet
      contextRef="As_Of_12_31_2021_slf_IrTrZku1VVWbbttE4g"
      decimals="0"
      id="Tc_ybBiaIi8QUm4Iw7FJQGYbg_9_3"
      unitRef="Unit_Standard_USD_NFG_pVdyhEyJarLQmedkXA">0</us-gaap:DeferredTaxAssetsNet>
    <us-gaap:DeferredTaxAssetsNet
      contextRef="As_Of_12_31_2020_K1oKCNbpv0CLR8EJWu1PSw"
      decimals="0"
      id="Tc_T65wZKpWjEKh7Wng4j1X-g_9_6"
      unitRef="Unit_Standard_USD_NFG_pVdyhEyJarLQmedkXA">0</us-gaap:DeferredTaxAssetsNet>
    <us-gaap:OperatingLossCarryforwards
      contextRef="As_Of_12_31_2021_us-gaap_IncomeTaxAuthorityAxis_us-gaap_DomesticCountryMember_HgR3pC70rUmeM4G-ZKbaTg"
      decimals="0"
      id="Narr_PIeE-hMCQ0aYMaIsAIBhFA"
      unitRef="Unit_Standard_USD_NFG_pVdyhEyJarLQmedkXA">21844192</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards
      contextRef="As_Of_12_31_2021_us-gaap_IncomeTaxAuthorityAxis_us-gaap_DomesticCountryMember_us-gaap_TaxPeriodAxis_anvs_GeneratedIn2017AndPriorMember_bcLUgZK7ak-slt0qx5nwVQ"
      decimals="0"
      id="Narr_fNnuqWjHCUqlvkF_LTEdtQ"
      unitRef="Unit_Standard_USD_NFG_pVdyhEyJarLQmedkXA">2764240</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards
      contextRef="As_Of_12_31_2021_us-gaap_IncomeTaxAuthorityAxis_us-gaap_StateAndLocalJurisdictionMember_5e7zQwkrykWomLKNapiciw"
      decimals="0"
      id="Narr_m9Yh2l9jkUSj49jKGxklTQ"
      unitRef="Unit_Standard_USD_NFG_pVdyhEyJarLQmedkXA">24391076</us-gaap:OperatingLossCarryforwards>
    <us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount
      contextRef="Duration_1_1_2021_To_12_31_2021_uhkxAiZ6fUeekYGgaMhCqA"
      decimals="0"
      id="Narr_N2N63CSYZUaMfpACaO_yxA"
      unitRef="Unit_Standard_USD_NFG_pVdyhEyJarLQmedkXA">7672071</us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount>
    <us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount
      contextRef="Duration_1_1_2020_To_12_31_2020_3DdHOulAJk6Q0Zn4Vsxq5A"
      decimals="0"
      id="Narr_p69uUogxbkOZ0Xa3CkWCbQ"
      unitRef="Unit_Standard_USD_NFG_pVdyhEyJarLQmedkXA">1619516</us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount>
    <us-gaap:TaxCreditCarryforwardAmount
      contextRef="As_Of_12_31_2021_us-gaap_IncomeTaxAuthorityAxis_us-gaap_DomesticCountryMember_us-gaap_TaxCreditCarryforwardAxis_us-gaap_ResearchMember_Asd8fgY1d0GxTm44XLZlKg"
      decimals="0"
      id="Narr_etXDZ4cA1kmYOhcro_Pdqw"
      unitRef="Unit_Standard_USD_NFG_pVdyhEyJarLQmedkXA">648077</us-gaap:TaxCreditCarryforwardAmount>
    <us-gaap:IncomeTaxExaminationPenaltiesAndInterestExpense
      contextRef="Duration_1_1_2021_To_12_31_2021_uhkxAiZ6fUeekYGgaMhCqA"
      decimals="0"
      id="Narr_EtE6ZmNGck6j61BkSA3tZQ"
      unitRef="Unit_Standard_USD_NFG_pVdyhEyJarLQmedkXA">0</us-gaap:IncomeTaxExaminationPenaltiesAndInterestExpense>
    <us-gaap:RelatedPartyTransactionsDisclosureTextBlock
      contextRef="Duration_1_1_2021_To_12_31_2021_uhkxAiZ6fUeekYGgaMhCqA"
      id="Tb_mdf9jgV_fkOQoQIKMHyzvQ">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;(13) Related-Party Transactions&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;As discussed in Note&#160;7, in March&#160;2019 the Company issued Notes&#160;in the aggregate principal amount of $530,000. Three of the Company&#x2019;s directors purchased an aggregate of $305,000 of the Notes. On January&#160;31, 2020, the Company closed its IPO and the outstanding Notes&#160;plus accrued interest held by directors converted into 71,429 shares of the Company&#x2019;s common stock.&lt;/p&gt;</us-gaap:RelatedPartyTransactionsDisclosureTextBlock>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="As_Of_3_31_2019_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember_YwRIubASaUOYMPLJxHrjxQ"
      decimals="0"
      id="Narr_17b3TEJrIE-o3V0kC97K4w"
      unitRef="Unit_Standard_USD_NFG_pVdyhEyJarLQmedkXA">530000</us-gaap:DebtInstrumentFaceAmount>
    <anvs:RelatedPartyTransactionNumberOfCompanyDirectors
      contextRef="Duration_3_1_2019_To_3_31_2019_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember_us-gaap_RelatedPartyTransactionAxis_anvs_RelatedPartyTransactionIssuanceOfConvertiblePromissoryNotesMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_srt_DirectorMember_uRDbbwJWlUih1vnjYEeJyA"
      decimals="INF"
      id="Narr_g0mcmq5Rb02qtiKdKH9mTQ"
      unitRef="Unit_Standard_director_8dNZ3yZCzEGn3lXzcsOwSg">3</anvs:RelatedPartyTransactionNumberOfCompanyDirectors>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="As_Of_3_31_2019_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember_us-gaap_RelatedPartyTransactionAxis_anvs_RelatedPartyTransactionIssuanceOfConvertiblePromissoryNotesMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_srt_DirectorMember_4brYU2SNtkC-xZaYEMvK_g"
      decimals="0"
      id="Narr_jpTUlYsoG0iFh8ef4OWIHQ"
      unitRef="Unit_Standard_USD_NFG_pVdyhEyJarLQmedkXA">305000</us-gaap:DebtInstrumentFaceAmount>
    <anvs:StockIssuedDuringPeriodSharesConversionOfConvertibleNotes
      contextRef="Duration_1_31_2020_To_1_31_2020_us-gaap_RelatedPartyTransactionAxis_anvs_RelatedPartyTransactionConversionOfPromissoryNotesToCommonStockMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_srt_DirectorMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_IfkwjFJuWk-TFaP8kqYr2g"
      decimals="0"
      id="Narr_9rpACz2JrE6chCKXwJvOfg"
      unitRef="Unit_Standard_shares__cOSbKjBTUyHt70_t1aAVw">71429</anvs:StockIssuedDuringPeriodSharesConversionOfConvertibleNotes>
    <us-gaap:SubsequentEventsTextBlock
      contextRef="Duration_1_1_2021_To_12_31_2021_uhkxAiZ6fUeekYGgaMhCqA"
      id="Tb_TG3YsRT2Jk-9qeZfYLiFcw">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;(14) Subsequent Events&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;On January 3, 2022, the Company granted options to purchase an aggregate of 188,294 shares of common stock at an exercise price of $19.78 per share to employees, members of the board of directors and consultants to the Company.&lt;/p&gt;</us-gaap:SubsequentEventsTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="Duration_1_3_2022_To_1_3_2022_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_rxWBqkfQFkesGFeOew63wA"
      decimals="INF"
      id="Narr_Ib0PuxjNg0eJWaK5suro4A"
      unitRef="Unit_Standard_shares__cOSbKjBTUyHt70_t1aAVw">188294</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="Duration_1_3_2022_To_1_3_2022_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_rxWBqkfQFkesGFeOew63wA"
      decimals="2"
      id="Narr_kssufqq9wkGIJPK1zlkssw"
      unitRef="Unit_Divide_USD_shares_ZtgwQidioUWlbMoOaTBzxg">19.78</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>75
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M?!^2!F.,6_0T7X\48JVFL:W&VC$,>8!8\PRA9CC?AT6:&C/5BZPYC0IO0=5
MY3_;U UH]@TT')$%7C&9MC:CY$X*/-S^[PVPPL2.X>V+OP%02P,$%     @
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M)C O9!9GX\GV2YO\6$S(A_<?+SH&FK-!'2^''F70[ @T9>2;C,U& ZXO_-<
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M/XN-4-GBWTXF^;Y;*XGAB#6]6$H]:R3U:8+(&!QH+56E8M3@W,BXS3U/  R
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MP@&'H'4(;* -F0WK@6N^F$EQ)-)8HYJYL+FQWAA-49MA?-82WQ;HIQ?/FFO
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M:#PQV,L<#W4@C0&^WPBA3S?F ]TQ<?$?4$L#!!0    ( (B!8E0J@UG<*P,
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M\C*<_($E)J<GD*"O2UD_&(NV0)K-UO""FZI_5W*0MS>TL,>FWF]X8VX"95$
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M.3,L;07,_8V4^NG$OD4_?9=9_ M02P,$%     @ B(%B5(OAQM5T!0  OQ(
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M'7LAP'GMD)'A112,_QZX_#]02P,$%     @ B(%B5"!V8D_1#0  V"4  !@
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M;BP9#I(B9>DTN[^%8K@/YP,7DDN-T/7!2F<2D7/Q#43!5)%)T;K-P;XD]L0
MYU-MAY[VO;/QHSP7QBAW.]P"*2@"(IV@;,%'293R)%4B.9 =2P%NQ8[;R'/A
M5HB[9(Q*'8I4#HB8*S325N[-]+4A;/)'X],L@ZI)$N@E.:^4]F@JTR4B")34
M2REM@"#JM9([2RZ_=(NA E+J:N7Y)V0G&FZD@M#":YVNR5VI'U7,;^@G76F
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M>6J\(*(3F?81.B1(N4P&ES,L=0@VC,6M=>O#$KDD!XR-T %LWL*H\11WW Q
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M&3@DC242DU:N%?N/*&FV0;\C5??1)N$,="MY(3*G'7']5<*Z4N;EM-X)SP/
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M8]I;5YM'V98;&*URG?@62>B"'(%X<W<M<D@GF);UYXL5?)1I,AZ)XVX,_CD
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MG'J\Z7_T\@@T&T$S#YK]K]"]C?$^24[@.1#\6B)<JJIF\@%*9JC\:Z4M%L!
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M@=&/'NT8TRVR46S0+X\!:6$D\#; ,4II,HC%R^[GAD-/KI4F@PK(1J)&64:
M.IP[7<EH,('(9'"&OY\4JE,-^$2NBT)956> /!XD>'8<#Z8G^/VL''S*%JP_
M5_<HQDM"7&16Y5#8>S(8X^UD,&.#3';WBDI>SA1 )0Z,Z5Y.3MD*NDW2-[BZ
M6LCZ5E& [V79A)<EQ0:!5N+X-!W,R)CC=#:8T,4'F,M5^1&!8H8D_-U #^=@
M;L<IJYC*M[7^#Q:9.:I:&HO>LH/$7/F54H%T\ :< :+2.06^,=Q:SI$-7JO
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MO8#GA3&^NZ$-^G]"7/P74$L#!!0    ( (B!8E1B9.P\H0(  .D%   9
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M[6@TA&5%LQB-=Z#SC:9Z=(:_H)_NB]]02P,$%     @ B(%B5)B,&\Q> @
M+P4  !D   !X;"]W;W)K<VAE971S+W-H965T,C$N>&ULI9113]LP$,>_RBG:
MPR:AIDG+**BM1(%IFX2&0-N>W>2:6,1V.%\H?/N=G38KVN!A>XE]]OU_OG/N
M/-\ZNO<U(L.3::Q?)#5S>Y:FOJC1*#]R+5K9V3@RBL6D*O4MH2JCR#1I/AY_
M3(W2-EG.X]H-+>>NXT9;O"'PG3&*GE?8N.TBR9+]PJVN:@X+Z7+>J@KOD+^W
M-R16.E!*;=!Z[2P0;A;)>7:VF@;_Z/!#X]8?S"%DLG;N/AA?RD4R#@%A@P4'
M@I+A$2^P:0)(PGC8,9/AR" \G._IGV+NDLM:>;QPS4]=<KU(9@F4N%%=P[=N
M^QEW^1P'7N$:'[^P[7TS<2XZS\[LQ!*!T;8?U=/N'@X$L_$K@GPGR&/<_4$Q
MRDO%:CDGMP4*WD(+DYAJ5$MPVH:?<L<DNUITO+SKUAX?.K0,5X_R]?.4!1LV
MTV*'6/6(_!5$EL.ULUQ[N+(EEB\!J<0S!)7O@UKE;Q(OL1C!)#N"?)QG;_ F
M0Y*3R)O\6Y(OF-.!.8W,Z?]<W-N(]]GT _S!@6\6OBK;28O )%Y!?@1<(UPX
MTRK[#!4IRUB":T-=>V ';4=%+;4)2NJ\J@@KQ0AN ]EL=I2?3L'7BM"'E<(9
M(]T@A57<@^*@P">D0HNZ)5U$V;OL='0R@Q:I5X8ST+2->T;T1V#0K)$B+@2V
M=HK*8)2:I-F<["A;RDG62V^HD)/H#U(8_>W^TX,B-DA5;%4OE,YR7\_#ZO :
MG/=-\-N]?TJN%55:;J;!C4C'HY/C!*AOS]Y@U\:66#N6!HO36EXTI. @^QOG
M>&^$ X8W<OD+4$L#!!0    ( (B!8E2O4%2@HPX  &LK   9    >&PO=V]R
M:W-H965T<R]S:&5E=#(R+GAM;*5:;6_;.!+^*T0..#A XL1NN^WV#<C+=F^!
MVT71;/8^TQ)M<RN)7E)*XOWU]\P,14FNK/1P7Q)+(H?#>7GFA7S_Z/S7L#6F
M5D]E484/)]NZWKV]N C9UI0ZS-W.5/BR=K[4-1[]YB+LO-$Y3RJ+B^7EY0\7
MI;;5R<?W_.ZS__C>-75A*_/9J]"4I?;[:U.XQP\GBY/VQ1>[V=;TXN+C^YW>
MF#M3W^\^>SQ=)"JY+4T5K*N4-^L/)U>+M]>+ES2!1_QAS6/H_5:TE95S7^GA
ME_S#R25Q9 J3U41"X]^#N3%%093 QU^1Z$E:DR;V?[?4/_'FL9F5#N;&%?^Q
M>;W]</+F1.5FK9NB_N(>_V7BAEX1O<P5@?^J1QG[ZN6)RII0NS).!@>EK>2_
M?HJ"Z$UX<WEDPC).6#+?LA!S>:MK_?&]=X_*TVA0HQ^\59X-YFQ%6KFK/;Y:
MS*L_WHDVE%NK.[NI[-IFNJK559:YIJIMM5&?76$S:X*:M;].WU_46)H(7&1Q
MF6M99GEDF<52_>JJ>AO43U5N\B&!"_"<&%^VC%\O)RG>FFRN7BS.U/)RN9B@
M]R()X@73>_%_"V)BL9=IL9>\V,LCBUWK8 ,M]=F;8*I:DX6.276:S$R?JE%2
MZO>M@<%GKMSI:D_,KVVEJ\SJ0@4,,?"K.JBM?C!J94REX-$[[4VN;*4R5Y&W
MVWH/6ZRW3">*8.<MB.P*6,/&5,;KHMC3=[.K96Z-=>\K2T]WM YS=E4:#VFJ
MV3__\6:YO'QW/[^;JY^OKC[S\^+=Z5Q=57OR<>--E9E(*!A5.2)1.Z5W.PA?
MKPJC-HW--8\*JC2D(WSGN?0CT58ZJ#7X3FSU- G6JES[/*@;E[.F66@M?U=W
M-RUG"@/'9][O<NRO-^<^S<&6:<%/2>2C!*X=_J7YGZ[NKI,X)BSL5;*P5Y.F
M<0_I@8^?0FU+TL.8<4U3F*U.U2$5MBNQ%1$9/HY:UH@9=9KQYJ_&PEJ!8Q60
MGV:0ZDK]U2B3EB+)ZX!HL:.58 5;72N]7@/.6;S@PGDR-%V2<-G2,-[4,K6P
M>F4+6\-AS\!.5C0YR3^W(2M<:#QO##R25HB!8U.UK,;*CHH=V_$9SSS&ES</
MIFKBILP30FK 0]YX8JF;Q"X&7W'Y7-TVAH1"'QM8NZ\186N&IS4BF?,!@=1[
M,O"61B<ZY]6?3;X1532A<\T#U4UL)JL;O(*2$-U(47M%I+UECW\@H%Q[5T8W
M32O/!]@)&"B)S=6?K#.'G]EV0L.B)>+2;; R.?XCNPKA6&%:K@GGM <EFI]#
MLH7;L0UA'JT$]A$VLZ_G%*USG@QYRZ:C[,_4QC.'%;X:)M0SA9[^Y^I34Y.Q
MD *C>6#/UBO#E@C>= 64 HJ2<'.;D>;9WI/.WC&">M)3L3_KPVDGBN@2HL<G
MXS,KGM>J<=['D&[:M&[#N'95MM78* %DA:PI[LQE6>//Z&7I:+]/9(@FXJS.
MF+V<O^L\M[0*B-I*\D):DZ+0BG9,IL^:9;:0/Q)3Q';U8+VK6%7"0IA"NA\2
MTOWP;"S->,5;6S0D_M^0S/XBFIW]VX5P2DZE[K8(<&,P.$U^EDF,_>XEXNC*
M)/.:%6E$X!$056[@324+JPFM!S]R#DGR>X#0H**J*5>8!77RQ""85980-YNX
M0IX=**(PM F<& W72"@2^9WD1MQ.U"5F#<0$F%:PUM;+U0ZA&.8'I7?VZ<EK
MP&J(-A<,;"CB)ONZ)LO.#0H)BMPRN+;T>\<1FS(.WLC9P4=7VA <4$8R !)]
MW+!@Q9EZW%HL\.B:(H\PU3H"9C:<(( C[,VSU9,'C(IPSC&-0**ID_/DSXL-
M*G3X0[[?XE:]-4<%(N%+V.6T2Z,B@3S/>2D4)E'R4Q[Q.GG$ZTF3O=%!P)%_
M_ 37?= %.?F8]4^2HIKP;=CIS'PXV1'N^@=S\G&6GZJC:[ X;R3Q)&D$FT,>
M"G%#;6'=B!Z%Q6B"K0< F2 2 Z;S=F,)50 HK=08R+PQ "6N'F!RA40&0MR,
MUC;=VD!)Q!D4C;"/NF.#\JK%ZW=!QJ]T0=8A0<T\9<9(W(:FO.&80-E!%[X1
M82FUI(0.IHR45]TB6 =+ ("1;&DWSB-^L_G,U80&WR0-OIG4X"^M"=^X !:N
MX L \11:2-S(!=I1HWJ=7."(7LVI^A]7[L9G/!ZNT/BNCJAB[<USQS1BA%[K
MLLFO46B@&K-%-*% #+!?>DHE^EY=F(TNSK@RH2AS!O,*'&XX!G5!<VTXF^.\
M;XU43^D-8E7@K(%L@) J,W#$_!!'!'X0L?R&3,7U ^!.V_R<]JIWMN: *&#)
M\"N .MPA87],9TP^:2L_)EOY<=)6/FED(W_HHF' ZXH.6&?MF_*8WT\3G:U/
MU7<0[CM[TFF7<]C>R!8DLQ8X#ITW948!4MUSP(@J](WILN9Y!SV'%%B[7?I=
M(U/&#AYH!X+RT##R,,H)M?=<%HN3<^GP/8M3G5G$ @2D._H(OFVZ;BE @(5S
M"O"J(BPS4ZB^N.Q:-9>32OG23WQON\1WM!TS36JV.57'R T_]!-L\7$=T\.*
MDD_=\WF6F#<#YRWQ$,1YX12!(*$X]Z9@2$EBE;(( JNDZ!A?/@U/*PHV0YF4
M3?9"2;VUJ*V1#@]S$<KQ/4J;;@GG-[JR?VLI0&(=0,F$3N&$?+CB#7!F=5BI
M#2(-;YB3 T8!O1>>2IVS=3 ! EN;<9+S8'/I6O3+M_RY^D?JQ:(=2B4/RI18
M%'*:48^&8-NV>6*ZV2_<!CE,EW7N(!C>@:F\*PK!QE"CE":QEA:QN'85*3#;
M6F@JES+8@0IR0\1PJA@3L^U&UR@:I"ZV^(?R(P?G[*$#EAXM<@9$^5X!V54N
M1XJ0E:%D#9\?M"W(C><4K8TDR$[ &?3Y:=TI"*0C&V**21516:'5UH&ZF45!
M%<X56;[(;9"FC$!'7PHA1LQ)9.@U<1>3[OPS5[-2D(RBP?3TV?94]4G(0R\B
M"K!F#K7]W^+T@_HY1KU>B0GAQL*/_4K$^K@U/' O$*(]53_0G4S>F8P:!\^7
M]SQ%T@01Y$:X):(H8^RFTAQ;XR:2DOOQG?*^P&P.-A)Y^G:[>5NMR/!H23&5
M5')^0OR.41M9;H2G,"I@^<[Q:&S-:?-9=N:SG-3_';=+KKE=<M-KEXR:TC2I
MF3U5Q\C%#R-M&7*%V,^-R;> F B!>V\R*PJA%W@C(&I"2E;!-Y*,'DAS-6S4
M:RJRSXEQ(DIMBX>8X',7!IF]Z4 Z8KR8F^VWO6D"53#]IMTGY]?&4L0/AT;$
M"?&WG:B#C+%S$>['S ?55!-B8+DN-.1XEVT==>*E)*:HFQ$OI<M-P8C&\B&(
MC2.T1!/92VK"<H=1NDT1::D:[?7E^NU3Z4_!50G)"KM.\F^7B/U-_B[M!>(+
MDG) /VJJ[65/_;Y?V\7*=)$UA32+OM5ROZ<7=P*TE4./7B<YI:$KZ.:@V8B2
MTQ4/)/.MX5JOZZQ:DYI[[6%#&V]':/?:<I@6^P_<-&F;LVVD LE>EYLUF-OU
M6I8?"/FYGB5>4O,  ;'7B>UH$2BNI5<ITIFK^QW/[KJ)!RV4?B2C^@2\Q=;&
MVGH(3WH_GGURW_9IJ#'4!E<F4<DXW=3(>MG45PU)EBE&(YC&J>Z(;O%BNBP6
M7/U=/XW7O,],G_UYJOHD!LX5 [Q$EPC@-8_J^G-\1C X(MB3L7B'](<2C1@C
M,.W(<4("!:Y"!I#6:I*2C96I'XVICO7GQ5"Q"!&8./=(!DUC?4SS8I\I(4T8
M+MTF]UE,5>CDP@=S9'>\F[S):#,0!3NK&"VL$\DK%[SKL^%.I<O);+>&I S)
M'J-A7Q((J ==V*^&@597W&?CW#:08BB_0N85L2<?88TSL]B8AP479)CLK9AS
MBZ#*&6Y[?,R"PH_+H4]L-9 &3@5*8QMK&PB$L",L#+';#@Y"I%\/@PL,@'1&
M>G>C7K\$ WT#[;HA)B";7I%^^J(Y)]&<BV@P!.&@RZ?&[":&HQ;8$OHQU]S3
M(G;F+3,J*U LK&T,$OUFRJ&/K/:)22ZKZ:J"+9MRL&3'),.BQ'HQZ+K&S :!
M]WO9/Z1 UC38!AZ^PL)!KF_.*Q/?VRJ.]P:86;&R"#I]:@06U'RF+!8 %QM_
M(,;<B)81$0^UO-72$4XN3B\[K*#-'1$Z93S?VB7&'[Z\G(32[@+"8OKJP!>0
M/;C>X%WEB+NC+:-G2,Z^4D]AFBS,N]O1\G+QHW@<G7ZK&#"N[N[5;V[.7\\7
MRZ%'J-GO;H<B =9Y^E;=6=3%=KUO\?EJ:*']B3'K !-Y.J&FE>(J*D12WV/I
M,#FX+CZVFJ3TOCVE%N>.:6+_P@3&)=ZET\#>M4^]RC*6J>8I=C#;FP[".YW5
MA7A[@.!$<)QR-0[]-B!]4GO4'/$L&DD-LH0R9I;2&.%DT_&Y8'_XRFQL53$C
M:TSJ-+1X=19QD=LJ&$WW/?(VXZ03K)IK+19N^YYAF0"OY39'24QNT1Y\0-;4
MA8GQX'C_L"LHYV0XOR%1CX:S7$P9SG)QO@#//U-B+^>-5X&:R S;T8+>O%C"
M@F[3=0#6[#7%>JK4?H+V)82N'+*944K'38K73V>ZNJKH+#WO+25448H@Q\O$
M<.2JC=IT*\F%!Y_,,1;+*\XY"K&;MA[UTMLB#)6[;LF I1R@294NW&;?&5/O
M*D1D==BI[?=5(L,TDQN:;>@=;*&[ 2&=CO[%(;H[M9=,GSKH\B6A?9_,.W[#
MY9E<(#A:;$>_[ )$)S'V#<E*#NEW-S7:$Y[>Y:*V23<6?A)+[^0\LG?3@5J]
MJ7V81T0?$5&_E*)#2!O/OP87$#+;PE7_JM-Q=W_6?1?/N.]9+%/V%![YLW06
MJ25#*V(2ED2@[+\:!KYT%KHR!34"1;Y' 8&S,T&#@1P[8*"D:A0(QJ+?1>_^
M8VG\AF]Y4ML4ZI6KD.EMNDEZ)?<GN^%R#?57[2',H JSQM3+^>M7)\K+S4YY
MJ-V.;U.N7%V[DG]NC49^0 /P?>U<W3[0 NE^[<?_ E!+ P04    " "(@6)4
M#<494H0"  #5!P  &0   'AL+W=O<FMS:&5E=',O<VAE970R,RYX;6S%56U/
MVS 0_BNG;)HVJ2(O34L%;24*0T,:$H*-?7:32V/AV,5V*/S[G9V7 :.%29/X
M$M]=[IY[SF?[IANE;TR):.&^$M+,@M+:]4$8FJS$BID]M49)?PJE*V9)U:O0
MK#6RW =5(DRB:!Q6C,M@/O6V"SV?JMH*+O%"@ZFKBNF'!0JUF05QT!DN^:JT
MSA#.IVNVPBNT/]<7FK2P1\EYA=)P)4%C,0N.XH-%ZOR]PS7'C7DD@ZMDJ=2-
M4\[R61 Y0B@PLPZ!T7*'QRB$ R(:MRUFT*=T@8_E#OW4UTZU+)G!8R5^\=R6
MLV 20(X%JX6]5)MOV-8S<GB9$L9_8=/Z1@%DM;&J:H.)0<5EL[+[=A_>$I"T
M 8GGW23R+$^89?.I5AO0SIO0G.!+]=%$CDO7E"NKZ2^G.#L_95S#-1,UPCDR
M4VND';<&/O]@2X'FRS2TE,7YAEF+N&@0DRV(<0+G2MK2P%>98_X4("1Z/<>D
MX[A(=B*>8+8'PW@ 293$._"&?<U#CS?\MYIW(*<]<NJ1TRW(5W1G\EH@J (R
MIO4#ERNX\YF8S*%PB1N5' HNF<PX$\",0=ISYR(X6W+!+4<#54,N!V:?A-)9
MION0U5H[>#J3W+S4IMU4/WV8)-'P$-Y[?;D9KN2W(M#QP&J)NC\B?WD<=ZUH
M\G3F[WB' N)G>O),'U*X*7US,B?@;<VI$?Z6=)X?(1T-QI/Q((K3UXQ.BI/#
M'9;W7O]_2Z+W:,ED$.VG@_%H\HIM:T->>A#"1T]MA7KE!XJ!3-72-J]N;^UG
MUE'S5/]Q;P;>.=,K+@T(+"@TVML?!:";(=(H5JW]P[U4EL: %TN:NZB= _TO
ME+*=XA+TDWS^&U!+ P04    " "(@6)4XY\^.(8"   B!@  &0   'AL+W=O
M<FMS:&5E=',O<VAE970R-"YX;6RM5=]OVR 0_E>05TV;9-4V)D[:)I&2ME/W
M4"UJ]N.9V)<8%8,'>&G_^P%V7&]I\[*]&.ZX^[[OCG"9[J5ZU"6 04\5%WH6
ME,;4EU&D\Q(JJL]E#<*>;*6JJ+&FVD6Z5D +GU3Q",=Q%E64B6 ^];Z5FD]E
M8S@3L%)(-U5%U?,2N-S/@B0X.![8KC3.$<VG-=W!&LRW>J6L%?4H!:M :"8%
M4K"=!8OD<DE<O _XSF"O!WOD*ME(^>B,S\4LB)T@X) ;AT#M\@NN@7,'9&7\
M[#"#GM(E#O<']$^^=EO+AFJXEOP'*TPY"R8!*F!+&VX>Y/X.NGI&#B^77/LO
MVK>Q(Q*@O-%&5EVR55 QT:[TJ>O#(&$2OY& NP3L=;=$7N4--70^57*/E(NV
M:&[C2_795AP3[E+61ME39O/,?*6@IJQ MT_VFC5H1$6!OI@2%+INE )AT$)K
M,!I]^$HW'/3':60LK\N.\HYCV7+@-S@2C.ZE,*5&MZ* XD^ R KN5>.#ZB4^
MB7@#^3E*DQ#A&"<G\-*^"ZG'2_^U"R>X2,]%/!=Y@VMMWU71<$!RB^J.%X:\
MTO/F'2]]A;=MT6F:]^\F.$ZOT/]:%]H)MHV':F/EN>;_'>(N8VC$Z-#7W*IC
M.>7(*&:_?;F'X#.$4QR.1WC@<;L$7_483.A&49'#,>]%F"3)L3L+1P3W^4>D
M) W':=:;21)F%S%:@^T\,\_V:==2,_,2?Q%.LE%O92$AY(CSS#9F%)*,##R$
MA-DX>^V7$PW>;05JYZ>31KELA&F?<._M!^"B??<OX>WTO*=J9SN$.&QM:GP^
M'@5(M1.I-8RL_1382&-GBM^6=HB#<@'V?"NE.1B.H/];F/\&4$L#!!0    (
M (B!8E2Z/KGR;P(  +4%   9    >&PO=V]R:W-H965T<R]S:&5E=#(U+GAM
M;*V4WV_:,!#'_Q4KJZ9-BIK$"9!V@ 1MI^VA$FKWX]DD%V+5L3/;#/K?[^Q
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MPM3X<C(*B.Z&1&=8U?K&7"N+;>ZW-<Y5T"X SRNE[-%P%_23>OX+4$L#!!0
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M%Y#& +_/A-#;@=F@_2LT^0]02P,$%     @ B(%B5)$P$.#> @  :0<  !D
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M\=%]V8#>^%<!UEYMI>VNSF%V>'A<=O?MP;Q[M7QA>L.E(0(J=$VB'&6NNY=
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MUPEJ?<68W 7Z +7W9?H+4$L#!!0    ( (B!8E2$0[<7  ,  *P)   9
M>&PO=V]R:W-H965T<R]S:&5E=#,Q+GAM;*V676^;,!2&_XJ%=M%*7<$$2%(E
MD9IF'[WH%#7J=NW  :P"SFR3=/]^MB$T:8D;:<M%P.:\KY]SL+$G.\:?10X@
MT4M95&+JY%)N;EQ7Q#F41%RS#53J2<IX2:1J\LP5&PXD,:*R<'W/B]R2T,J9
M34S?DL\FK)8%K6#)D:C+DO _<RC8;NI@9]_Q2+-<Z@YW-MF0#%8@GS9+KEIN
MYY+0$BI!684XI%/G%M\LL*\%)N(GA9TXN$<ZE35CS[IQGTP=3Q-! ;'4%D1=
MMG '1:&=%,?OUM3IQM3"P_N]^U>3O$IF303<L>(7360^=48.2B E=2$?V>X[
MM F%VB]FA3#_:-?$AH&#XEI(5K9B15#2JKF2E[80!P(<G1#XK<!_*S@UPJ 5
M#,X5!*T@,)5I4C%U6!!)9A/.=HCK:.6F;TPQC5JE3RO]WE>2JZ=4Z>3L&R>5
M1/=5S$I %PN0A!;B$GU&3ZL%NOAT.7&E&D7'NG'K.&\<_1..V$</K)*Y0%^J
M!))C U?A=8S^GG'N6QT7$%^C ;Y"ON?C'J"[\^5>CWQAEZ]@H^2>EN.Q)9M!
M5_&!\1N<47&+7=#9!<8NL-K1'KNFM(TZ-&K]$=C.!M$P#";N]K""[Z,P#H=!
M,.[BCN#"#BZTPCU5'&BYKKF Y I!03.Z+@#%3$BAF6O.(4&UFB<<R1Q0II/I
MRZ(9)CK@\]YD8(LX8H\Z]LC*_@AJN=$J0ZGB$XALU<H@BKX/+_H0SQ9QA#?L
M\(96O!_WWRVS9]2YC/['9!QW=F,[%),T!L12=+LC7+UR\T(1*5G=^UX7X_?S
M;NSI7W]QL/?Z6?/^:5FT\NB#==$39ET8^."[BZV 2\YB #6Q4LY*9'!%+R@^
M#_1]&!Z-_= /3H#ZKZ#^&97D$ /=GIK_K45H60#6D ;-/=C&2N"9.0X(];50
MDZ?9+;K>[LAQ:S;:-_US?'/7'!Q>;9ISS /A&:T$*B!5EM[U4/'PYFC0-"3;
MF,URS:3:>LUMKHY3P'6 >IXR)O<-/4!W0)O]!5!+ P04    " "(@6)4?+YZ
MYGP"  #Z!@  &0   'AL+W=O<FMS:&5E=',O<VAE970S,BYX;6RE55MOFS 4
M_BL6VD,K;>5F3%L1I#;9M#U,BYIU>W;@)%@%S&R3M/^^MJ$H"S2+M!?PY7R7
M8P['R9Z+)UD */1<E;6<.852S:WKRJR BLHKWD"M=S9<5%3IJ=BZLA% <PNJ
M2C?P/.)6E-5.FMBUI4@3WJJ2U; 42+951<7+/91\/W-\YVWA@6T+91;<-&GH
M%E:@'INET#-W8,E9!;5DO$8"-C/GSK^=QR;>!OQBL)<'8V0R67/^9";?\IGC
M&4-00J8, ]6O'<RA+ V1MO&GYW0&20,\'+^Q?[&YZUS65,*<E[]9KHJ9<^V@
M'#:T+=4#WW^%/I_(\&6\E/:)]ETL"1R4M5+QJ@=K!Q6KNS=][L_A .#C=P!!
M#PC.!80](+2)=LYL6@NJ:)H(OD?"1&LV,[!G8]$Z&U:;K[A20N\RC5/I4D!#
M68X^/^NZD" 1K7/T0Q4@T+P5 FJ%[J0$)='% A1EI;Q$G]#C:H$N/EPFKM(6
M#)&;]7+WG5SPCMP"LBL4^A]1X 7^!'Q^/MS[&^[JQ(?L@R'[P/*%_YO]":UP
MT JM%OZ'5J8W6$9+I 333^BEI\ZR(XPLH?D==VD0!G$4).YNP@@>C."SC+!:
MMH+6&4Q)=Q3D4/K&]_U!N?M:>&R01/@=?]'@+SK+WZF3B4;V<!B'Y,C>.,KW
MR8TW;8\,]LA)>RO(6L'4BVX6#9=,3=DC(^&;:Q(=N1L'$8SQM+EX,!>?-/>3
M*UU3S=$)VK+FMJRSOJSI1%EWWN/1-PW]"!-\Y'X<AC&)R9%]]Z SF5OA.Q5;
M77>HA(W&>5>Q)A!=I^TFBC>V6:VYTJW/#@M].8$P 7I_P[EZFYC^-UQWZ2M0
M2P,$%     @ B(%B5 AN6/!? @  +@8  !D   !X;"]W;W)K<VAE971S+W-H
M965T,S,N>&ULC57;CML@$/T59/5A5VIC&U_BK!Q+NTFK]J%2M.FVS\0>)VBQ
M<8'<_GX!.U8V-^4E9F#.X9P!)NF6BW>Y E!H5[%:CIV54LV3Z\I\!161 ]Y
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M_=@?)9=E1[WLZ"[9C.;FU%!#]KI]7"SO)#I3$"3!E;+%_?[QS?W_<&7JU*F
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M40+M G!_JY0]&2Y!_\P5+U!+ P04    " "(@6)4-R54X+D"  #]!P  &0
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M$1%.1?'=8O+>;7)%@\HD_,PD[6%RU=^D[S;GJ<14V4%5=I"QC]\F.PX$N$*
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MY0)7"G2>94P]7V(J#S.OZQT7;O@V,7;!GT]W;(NW:.YV*T4SOV*)>89"<RE
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M)XEBDG[\*4BM<DT%K-\?V&]U\#*8)>)X2I/?<2BBD=6W0(C7*$O$ ]U_P45
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M?@*OIGE[7='DW?X]8IM8OMH2O):43J<G=XGE#70^$'2K^[<E%;(;U+>1_.C
M3!G(YVM*Q6&@%B@_8\;_ 5!+ P04    " "(@6)42TXKX*,"   '"   &0
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M@./3VN0-1\U4:Q,;^AV)ANMBCKWK2L4MC+T+*F08->M'BU1/@.M6@?M[155
MKB>\*"$;5/P.*G7UQ_WE_Z/*<DM(@PN&V!N>]*?2D: _M<\=J=L%OJI?M-:;
M6YP(+]@%PZB+7=TQ\.BV(O0,YA)OHK[0-RVA[V][FJ(_061]!:GN%_B_-0P;
MD7?0\6B/0C]Z5*@B'V7%-9'X**'O?=<H7/<-_.\;QT>T^Y%')6WL7L^;U'V&
MN+WH#YN-@ U5@)@^4*8GJ1B]TG0/AGYQ39>(U^?2YD!I(CAKVAX)O%%'!I*Z
M19'^%G45/:ACWTH/7TO/.1EY,A ;.PE*%/-]KHJIH=JMILT'.V,U]N=Z"BUF
MQAJF&&&_4:&[K$0IK#6D.QQI6J*8"HN%XCL[6*VXTF.:?=SJ21J$$=#OUYRK
MX\(8J&;SV3]02P,$%     @ B(%B5"BR"L*1!0  ;1D  !D   !X;"]W;W)K
M<VAE971S+W-H965T-#,N>&ULM5E1<]HX$/XK&N8ZT\Y<P))LP!W"3$+:N3[T
MFDNN[;-B"]#$MJ@D(-S<CS])-I8)MDAZ- _!-MIO=S]IOY7%9,O%HUQ2JL!3
MGA7RLK=4:O5^,)#)DN9$]OF*%OJ;.1<Y4?I6+ 9R)2A)K5&>#5 0# <Y845O
M.K'/;L5TPM<J8P6]%4"N\YR(W37-^/:R!WO[!W=LL53FP6 Z69$%O:?JZ^I6
MZ+M!C9*RG!:2\0((.K_L7<'WLQ 9 SOB&Z-;V;@&)I4'SA_-S:?TLA>8B&A&
M$V4@B/[8T!G-,H.DX_A1@?9JG\:P>;U'_VB3U\D\$$EG//O.4K6\[(U[(*5S
MLL[4'=_^0:N$(H.7\$S:_V!;C0UZ(%E+Q?/*6$>0LZ+\)$\5$0T#%'48H,H
M/3. 88<!K@RP3;2,S*9U0Q293@3? F%&:S1S8;FQUCH;5IAIO%="?\NTG9K>
M*YX\7EQK(E(PX[E>'9)8?B_ 59HR<TDRD#*99%RN!97@[0U5A&7RG1[R]?X&
MO/WMW62@="@&<)!4;J]+MZC#+43@,R_44H(/14K30X"!SJ%.!.T3N49>Q!N:
M] &&OP,4(-@2T.SEYH$G'%SSBBT>?B6O'NBPA@XM=-@!?;58"+H@B@)6*,%T
M125@0[(U!7P.^,IXD8 ^49$P^9S:DLD2/[+XILXW4PCA$,?Q>#+8-#EK&1@/
MX]&P'G:00%0G$'D3^%+%N!"D4.T1E@##AN,(CX,X>A;?\; Q#/1?>WS#.KZA
M-[[OMO;UQ)$-%5K+RD!!:BB?$R9*MMO"+G''C7C0J _QLZA;1O5AW![SJ(YY
MY(WY:[&ATL:\)2*50"NV5*1(6;%H"W1T1%P'9^/:_]CK?Z8G5"NGYDD"[1:0
M=,,D%]*SWN,:.CYW*<' R5_@C?O/=?Y A:D<N21&WIB4:^U(<9"\**5*[0(/
MH>6LMPQ!4>=:A0T!AR=F7M"$+PKVCPX[:4HX?3+7K0NUPHQ.+P"(7"#HUY3-
MK )N5D38CV%'0$Z"(?8&]+%V:N?7+*-]>71+SZP"/1 ]A$91%S].MN$)W3YP
MK<7;]AKP+_BF*U=7;$'!CA(!YH+G#>Y\R]PI+HS.7D-.+J%?+[^5RE.UGE9.
MA\=ZWJW3T(D>]*N>30M\:7-\B.AD#([/3I03,AC_@E*-C]9C'&,\[*H/Y+0/
M^;5O7[ 7^X*MHK,1K:A@O+4WGT"%Y2K&("\W>'"LE_'.-SO(:1WR:]W?5.2F
MEFT5M\;FMX>!#:YUC?Z4Z6$>3BH1\JZR#U(Q_0JB5\'\0*-:2^C0AU,_Y%>_
M.R8?+^:"VFTBU:U- 7$D)Q5K?B38AZ,WK93Y[8(^'K_QY>*D$_FE\X,NC\30
ME;%Y>P9^^ZB<NQ.+LDKJ15"^M)PJ(_]&N$YKPS.M QE3N];D_"@0XGX0M$^0
MWW(<'!L>IN)Z /+W@#J5E&U82O5V:<=HUEZC?J26F*ID7FUWF(OK*N@5747W
MY];&#?47G_*<ILSL;TP+/-IJ'[IW+0B=O04AUX*0OP6=[-77%4"S5\,0XZYV
M@UV[P?[&\&):?WH_A%TCP?#<'&.G[MB_$3[-<05PP'$4H0AW<-PX=?!+[BLY
M5EM>*>,K2':JC<.SD^RT$_NUZP4D'Y\.6)*[%K+3.NQ7FE>2K._ICS7)P%]K
M(G0GSG;ZD7XYS[*<FG=+KG=?;B9\Y#@%PZ.S,^_T"?M?]5_ _/CX7"9$7=M]
M[,0+GQ8OK;*>O>D) '22X]#)67@&.?M?KW>AD[/P['(6.CD+3\N9E_79"8#R
MC: MED'CX#JG8F'/\Z5^-5H7JCSZK9_6OQE<V9/R9\^OX?M9>?+O8,H?(CX3
ML=#E!C(ZUY!!?Z15091G^^6-XBM[//[ E>*YO5Q2DE)A!NCOYYRK_8UQ4/_"
M,OT/4$L#!!0    ( (B!8E2/P]K(Q0(  #$(   9    >&PO=V]R:W-H965T
M<R]S:&5E=#0T+GAM;*U676_:,!3]*U:TAU9JR1<DH0*D ILV:9U04==G-[D0
MJXG-;%.Z?[]K)Z24AHQ)>R&V<\[Q/3>^OHQV0CZK'$"3U[+@:NSD6F]N7%>E
M.914]<0&.+Y9"5E2C5.Y=M5& LTLJ2S<P/,BMZ2,.Y.175O(R4AL=<$X+"11
MV[*D\O<4"K$;.[ZS7[AGZUR;!7<RVM U+$$_;!829VZCDK$2N&*"$PFKL7/K
MW\R&!F\!/QGLU,&8&"=/0CR;R;=L['@F("@@U4:!XN,%9E 41@C#^%5K.LV6
MAG@XWJM_L=[1RQ-5,!/%(\MT/G82AV2PHMM"WXO=5ZC]#(Q>*@IE?\FNPL8(
M3K=*B[(F8P0EX]63OM9Y."#XT0E"4!."8T+_!"&L":$U6D5F;<VIII.1%#LB
M#1K5S,#FQK+1#>/F*RZUQ+<,>7KR P_*=Z$468 DRYQ*(-=D2A5+">49R5BQ
MU9 1CK#"P#8(4Q9V,0=-6:$ND?"PG).+3Y<C5V-(1MA-Z^VGU?;!B>W]@-P)
MKG-%/O,,LO<"+GII# 5[0].@4W$.:8^$_A4)O,!O"6AV/MWK""=L\AM:O?!4
M?K<E2*J%[-#J-UI]J]7O^%;F([2EN6(.+--4[LODVN_WD]@/@Y'[<NB_!3GH
M1X'7CQO@N^@&372#3J=SX (/Z%^\1HU:U.GUT=8?9-?T!?.W!I**LL2RMV=/
M$;R/E,8#ROCZRI0Q2]N24FT1'5B-HR *XN0H)1]Q4>@EP\AOSTC<>(C_FX>Z
MT-I<Q&>Z^(CK=)$T+I*S3MU;Z7=DO))*WAW#WO HT!:0UTM.'+]A$^;PG\/L
M2.KPG$!;0"V!N@>W+Q;[VC8EA1][RW5U;S6K3=^[M=?]T?H4^V'5OMYDJF9Z
M1^6:<44*6*&DUXNQ%&75H*J)%AM[QS\)C1W##G/LZ2 - -^OA-#[B=F@^9<P
M^0-02P,$%     @ B(%B5-,JD[6- @  &0<  !D   !X;"]W;W)K<VAE971S
M+W-H965T-#4N>&ULQ55=;YLP%/TK%D^;M)6/4,(J@M2DFS9IW:)&6Y]=N 2K
MQF:V:;I_OVM#69HTJ ^3Q@/8YI[C<^Z%ZVPGU;VN 0QY;+C0"Z\VIKWP?5W4
MT%!])EL0^*:2JJ$&IVKKZU8!+1VHX7X4!(G?4":\/'-K:Y5GLC.<"5@KHKNF
MH>KW$KC<+;S0>UJX8=O:V 4_SUJZA0V8'^U:X<P?64K6@-!,"J*@6GB7X<4J
MM?$NX">#G=X;$^OD3LI[._E2+KS "@(.A;$,%!\/L +.+1'*^#5P>N.6%K@_
M?F+_Y+RCESNJ827Y+2M-O?!2CY10T8Z;&[G[#(.?<\M72*[=G>R&V, C1:>-
M; 8P*FB8Z)_T<<C#'B!,3@"B 1 = N(3@-D F#FCO3)GZXH:FF=*[HBRT<AF
M!RXW#HUNF+!5W!B%;QGB3/X-/Y2O4FNR!D4V-55 WI.U-" ,HYQHNZ()/!:\
M*Z$DE9(-*2@O.DY=&=Y<@:&,Z[<(ZX,SWZ NR^X7@X9EKR$ZH2&,R+44IM;D
MH\!-GA/X:&AT%3VY6D:3C%=0G)%9^(Y$012^(&CU>G@P(6<V)GGF^.(3?!LC
MBWORO;49TQ-\\<@7.[[9JXLV07H^DIY/BKS$BI>,=_:W(AJ*3C'#CFLOF[8S
M?>UE18 JP<16DQ:5Z&,E?;'ZC1.WL6TK#WD8IQ_F<9KY#_M5>2$.KSA)QKAG
MSI+163+I[)8J1869ROQ\I)K_N\RG(VGZOS*?'F4TBH/@(.W'06%@KX.L^WM=
MI@&U=<U7HZY.F/[7'%?'_G[IVMK!^A+[?M^F_]+TA\8U55LF-.%0(65P-L<O
M0O6-N)\8V;I>=B<-=D8WK/'L F4#\'TEL74-$[O!>!KF?P!02P,$%     @
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M6(&M*AO*UTT=HQQ;/*PNO0?\#-]@G-J(];4"RW/0],K:\F;0_MI-AEZR3W@
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M\0\ :#< WZ^4LON&FZ#]2S'_#U!+ P04    " "(@6)4DI 7G!(#  !H"@
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ME^7/27Q?U!>< _S]77P#4$L#!!0    ( (B!8E2 A/B=P $    >   3
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MU5__DVSN::6+^IC/VA^_TT]02P$"% ,4    " "(@6)4!T%-8H$   "Q
M$               @ $     9&]C4')O<',O87!P+GAM;%!+ 0(4 Q0    (
M (B!8E3_63&N[0   "L"   1              "  :\   !D;V-0<F]P<R]C
M;W)E+GAM;%!+ 0(4 Q0    ( (B!8E297)PC$ 8  )PG   3
M  "  <L!  !X;"]T:&5M92]T:&5M93$N>&UL4$L! A0#%     @ B(%B5#&6
M$]0S!@  IQH  !@              ("!# @  'AL+W=O<FMS:&5E=',O<VAE
M970Q+GAM;%!+ 0(4 Q0    ( (B!8E0+S(5,500  -D/   8
M  " @74.  !X;"]W;W)K<VAE971S+W-H965T,BYX;6Q02P$"% ,4    " "(
M@6)4BEMKY*("  !""0  &               @($ $P  >&PO=V]R:W-H965T
M<R]S:&5E=#,N>&UL4$L! A0#%     @ B(%B5+7\:]$.!   ,@X  !@
M         ("!V!4  'AL+W=O<FMS:&5E=',O<VAE970T+GAM;%!+ 0(4 Q0
M   ( (B!8E0J@UG<*P,  -P,   8              " @1P:  !X;"]W;W)K
M<VAE971S+W-H965T-2YX;6Q02P$"% ,4    " "(@6)4CTD8'[8%  "C&0
M&               @(%]'0  >&PO=V]R:W-H965T<R]S:&5E=#8N>&UL4$L!
M A0#%     @ B(%B5(OAQM5T!0  OQ(  !@              ("!:2,  'AL
M+W=O<FMS:&5E=',O<VAE970W+GAM;%!+ 0(4 Q0    ( (B!8E0@4.6(\@8
M "H0   8              " @1,I  !X;"]W;W)K<VAE971S+W-H965T."YX
M;6Q02P$"% ,4    " "(@6)4('9B3]$-  #8)0  &               @($[
M,   >&PO=V]R:W-H965T<R]S:&5E=#DN>&UL4$L! A0#%     @ B(%B5"6%
M13>$!   2 T  !D              ("!0CX  'AL+W=O<FMS:&5E=',O<VAE
M970Q,"YX;6Q02P$"% ,4    " "(@6)4ZWE3**\"  #K!0  &0
M    @(']0@  >&PO=V]R:W-H965T<R]S:&5E=#$Q+GAM;%!+ 0(4 Q0    (
M (B!8E3]J@%9BP(  (D&   9              " @>-%  !X;"]W;W)K<VAE
M971S+W-H965T,3(N>&UL4$L! A0#%     @ B(%B5/3',""1 @  *08  !D
M             ("!I4@  'AL+W=O<FMS:&5E=',O<VAE970Q,RYX;6Q02P$"
M% ,4    " "(@6)424;?*;8$  #-"@  &0              @(%M2P  >&PO
M=V]R:W-H965T<R]S:&5E=#$T+GAM;%!+ 0(4 Q0    ( (B!8E0]EY$2% <
M &(0   9              " @5I0  !X;"]W;W)K<VAE971S+W-H965T,34N
M>&UL4$L! A0#%     @ B(%B5'@S0W=P!0  $PX  !D              ("!
MI5<  'AL+W=O<FMS:&5E=',O<VAE970Q-BYX;6Q02P$"% ,4    " "(@6)4
M;15M!08)  #:&0  &0              @(%,70  >&PO=V]R:W-H965T<R]S
M:&5E=#$W+GAM;%!+ 0(4 Q0    ( (B!8E24IJ?LF0,  "T)   9
M      " @8EF  !X;"]W;W)K<VAE971S+W-H965T,3@N>&UL4$L! A0#%
M  @ B(%B5"(@2CLI"0  D!@  !D              ("!66H  'AL+W=O<FMS
M:&5E=',O<VAE970Q.2YX;6Q02P$"% ,4    " "(@6)48F3L/*$"  #I!0
M&0              @(&Y<P  >&PO=V]R:W-H965T<R]S:&5E=#(P+GAM;%!+
M 0(4 Q0    ( (B!8E28C!O,7@(  "\%   9              " @9%V  !X
M;"]W;W)K<VAE971S+W-H965T,C$N>&UL4$L! A0#%     @ B(%B5*]05*"C
M#@  :RL  !D              ("!)GD  'AL+W=O<FMS:&5E=',O<VAE970R
M,BYX;6Q02P$"% ,4    " "(@6)4#<494H0"  #5!P  &0
M@($ B   >&PO=V]R:W-H965T<R]S:&5E=#(S+GAM;%!+ 0(4 Q0    ( (B!
M8E3CGSXXA@(  "(&   9              " @;N*  !X;"]W;W)K<VAE971S
M+W-H965T,C0N>&UL4$L! A0#%     @ B(%B5+H^N?)O @  M04  !D
M         ("!>(T  'AL+W=O<FMS:&5E=',O<VAE970R-2YX;6Q02P$"% ,4
M    " "(@6)4][A$_7($   6#0  &0              @($>D   >&PO=V]R
M:W-H965T<R]S:&5E=#(V+GAM;%!+ 0(4 Q0    ( (B!8E21,!#@W@(  &D'
M   9              " @<>4  !X;"]W;W)K<VAE971S+W-H965T,C<N>&UL
M4$L! A0#%     @ B(%B5%[SC&W) P  F@D  !D              ("!W)<
M 'AL+W=O<FMS:&5E=',O<VAE970R."YX;6Q02P$"% ,4    " "(@6)4\DSF
M:3L$  !7$@  &0              @('<FP  >&PO=V]R:W-H965T<R]S:&5E
M=#(Y+GAM;%!+ 0(4 Q0    ( (B!8E0?[:-64 (  #L'   9
M  " @4Z@  !X;"]W;W)K<VAE971S+W-H965T,S N>&UL4$L! A0#%     @
MB(%B5(1#MQ<  P  K D  !D              ("!U:(  'AL+W=O<FMS:&5E
M=',O<VAE970S,2YX;6Q02P$"% ,4    " "(@6)4?+YZYGP"  #Z!@  &0
M            @($,I@  >&PO=V]R:W-H965T<R]S:&5E=#,R+GAM;%!+ 0(4
M Q0    ( (B!8E0(;ECP7P(  "X&   9              " @;^H  !X;"]W
M;W)K<VAE971S+W-H965T,S,N>&UL4$L! A0#%     @ B(%B5 L9QQ97 P
M'PP  !D              ("!5:L  'AL+W=O<FMS:&5E=',O<VAE970S-"YX
M;6Q02P$"% ,4    " "(@6)4 -3 #"8"  #R!   &0              @('C
MK@  >&PO=V]R:W-H965T<R]S:&5E=#,U+GAM;%!+ 0(4 Q0    ( (B!8E0W
M)53@N0(  /T'   9              " @4"Q  !X;"]W;W)K<VAE971S+W-H
M965T,S8N>&UL4$L! A0#%     @ B(%B5!KEU91M @  K 4  !D
M     ("!,+0  'AL+W=O<FMS:&5E=',O<VAE970S-RYX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( (B!8E34/P>'' 0  *</   9              "
M@2?%  !X;"]W;W)K<VAE971S+W-H965T-#(N>&UL4$L! A0#%     @ B(%B
M5"BR"L*1!0  ;1D  !D              ("!>LD  'AL+W=O<FMS:&5E=',O
M<VAE970T,RYX;6Q02P$"% ,4    " "(@6)4C\/:R,4"   Q"   &0
M        @(%"SP  >&PO=V]R:W-H965T<R]S:&5E=#0T+GAM;%!+ 0(4 Q0
M   ( (B!8E33*I.UC0(  !D'   9              " @3[2  !X;"]W;W)K
M<VAE971S+W-H965T-#4N>&UL4$L! A0#%     @ B(%B5%",D5&0 P  :@P
M !D              ("! M4  'AL+W=O<FMS:&5E=',O<VAE970T-BYX;6Q0
M2P$"% ,4    " "(@6)48$RB"-X"  !1"   &0              @(')V
M>&PO=V]R:W-H965T<R]S:&5E=#0W+GAM;%!+ 0(4 Q0    ( (B!8E2$T#?R
ME@,  %X,   9              " @=[;  !X;"]W;W)K<VAE971S+W-H965T
M-#@N>&UL4$L! A0#%     @ B(%B5)*0%YP2 P  : H  !D
M ("!J]\  'AL+W=O<FMS:&5E=',O<VAE970T.2YX;6Q02P$"% ,4    " "(
M@6)44N$R'U4"  #M!@  &0              @('TX@  >&PO=V]R:W-H965T
M<R]S:&5E=#4P+GAM;%!+ 0(4 Q0    ( (B!8E2)O B[$@,  #(1   -
M          "  8#E  !X;"]S='EL97,N>&UL4$L! A0#%     @ B(%B5)>*
MNQS     $P(   L              ( !O>@  %]R96QS+RYR96QS4$L! A0#
M%     @ B(%B5#(E4 I>!   ="$   \              ( !IND  'AL+W=O
M<FMB;V]K+GAM;%!+ 0(4 Q0    ( (B!8E0X@V\FQ $   T>   :
M      "  3'N  !X;"]?<F5L<R]W;W)K8F]O:RYX;6PN<F5L<U!+ 0(4 Q0
M   ( (B!8E2 A/B=P $    >   3              "  2WP  !;0V]N=&5N
B=%]4>7!E<UTN>&UL4$L%!@     Z #H S0\  ![R      $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>76
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>77
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>78
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.22.0.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>92</ContextCount>
  <ElementCount>318</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>36</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>8</UnitCount>
  <MyReports>
    <Report instance="anvs-20211231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>00090 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://annovisbio.com/role/DocumentDocumentAndEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="anvs-20211231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>00100 - Statement - Balance Sheets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://annovisbio.com/role/StatementBalanceSheets</Role>
      <ShortName>Balance Sheets</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="anvs-20211231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>00105 - Statement - Balance Sheets (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://annovisbio.com/role/StatementBalanceSheetsParenthetical</Role>
      <ShortName>Balance Sheets (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="anvs-20211231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>00200 - Statement - Statements of Operations</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://annovisbio.com/role/StatementStatementsOfOperations</Role>
      <ShortName>Statements of Operations</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="anvs-20211231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>00300 - Statement - Statements of Changes in Redeemable Convertible Preferred Stock</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://annovisbio.com/role/StatementStatementsOfChangesInRedeemableConvertiblePreferredStock</Role>
      <ShortName>Statements of Changes in Redeemable Convertible Preferred Stock</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="anvs-20211231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>00301 - Statement - Statements of Changes in Stockholders' Equity (Deficit)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://annovisbio.com/role/StatementStatementsOfChangesInStockholdersEquityDeficit</Role>
      <ShortName>Statements of Changes in Stockholders' Equity (Deficit)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="anvs-20211231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>00400 - Statement - Statements of Cash Flows</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://annovisbio.com/role/StatementStatementsOfCashFlows</Role>
      <ShortName>Statements of Cash Flows</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="anvs-20211231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>10101 - Disclosure - Nature of Business and Liquidity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://annovisbio.com/role/DisclosureNatureOfBusinessAndLiquidity</Role>
      <ShortName>Nature of Business and Liquidity</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="anvs-20211231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>10201 - Disclosure - Summary of Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://annovisbio.com/role/DisclosureSummaryOfSignificantAccountingPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="anvs-20211231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>10301 - Disclosure - Fair Value Measurements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://annovisbio.com/role/DisclosureFairValueMeasurements</Role>
      <ShortName>Fair Value Measurements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="anvs-20211231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>10401 - Disclosure - Grant Income</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://annovisbio.com/role/DisclosureGrantIncome</Role>
      <ShortName>Grant Income</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="anvs-20211231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>10501 - Disclosure - Prepaid Expenses and Other Current Assets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://annovisbio.com/role/DisclosurePrepaidExpensesAndOtherCurrentAssets</Role>
      <ShortName>Prepaid Expenses and Other Current Assets</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="anvs-20211231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>10601 - Disclosure - Accrued Expenses</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://annovisbio.com/role/DisclosureAccruedExpenses</Role>
      <ShortName>Accrued Expenses</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="anvs-20211231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>10701 - Disclosure - Convertible Promissory Notes</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://annovisbio.com/role/DisclosureConvertiblePromissoryNotes</Role>
      <ShortName>Convertible Promissory Notes</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="anvs-20211231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>10801 - Disclosure - Commitments and Contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://annovisbio.com/role/DisclosureCommitmentsAndContingencies</Role>
      <ShortName>Commitments and Contingencies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="anvs-20211231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>10901 - Disclosure - Redeemable Convertible Preferred Stock and Stockholders' Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://annovisbio.com/role/DisclosureRedeemableConvertiblePreferredStockAndStockholdersEquity</Role>
      <ShortName>Redeemable Convertible Preferred Stock and Stockholders' Equity</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="anvs-20211231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>11001 - Disclosure - Stock-Based Compensation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://annovisbio.com/role/DisclosureStockBasedCompensation</Role>
      <ShortName>Stock-Based Compensation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="anvs-20211231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>11101 - Disclosure - Net Loss Per Share</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://annovisbio.com/role/DisclosureNetLossPerShare</Role>
      <ShortName>Net Loss Per Share</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="anvs-20211231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>11201 - Disclosure - Income Taxes</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://annovisbio.com/role/DisclosureIncomeTaxes</Role>
      <ShortName>Income Taxes</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="anvs-20211231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>11301 - Disclosure - Related-Party Transactions</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://annovisbio.com/role/DisclosureRelatedPartyTransactions</Role>
      <ShortName>Related-Party Transactions</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="anvs-20211231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>11401 - Disclosure - Subsequent Events</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://annovisbio.com/role/DisclosureSubsequentEvents</Role>
      <ShortName>Subsequent Events</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>21</Position>
    </Report>
    <Report instance="anvs-20211231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>20202 - Disclosure - Summary of Significant Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://annovisbio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://annovisbio.com/role/DisclosureSummaryOfSignificantAccountingPolicies</ParentRole>
      <Position>22</Position>
    </Report>
    <Report instance="anvs-20211231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>30303 - Disclosure - Fair Value Measurements (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://annovisbio.com/role/DisclosureFairValueMeasurementsTables</Role>
      <ShortName>Fair Value Measurements (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://annovisbio.com/role/DisclosureFairValueMeasurements</ParentRole>
      <Position>23</Position>
    </Report>
    <Report instance="anvs-20211231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>30503 - Disclosure - Prepaid Expenses and Other Current Assets (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://annovisbio.com/role/DisclosurePrepaidExpensesAndOtherCurrentAssetsTables</Role>
      <ShortName>Prepaid Expenses and Other Current Assets (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://annovisbio.com/role/DisclosurePrepaidExpensesAndOtherCurrentAssets</ParentRole>
      <Position>24</Position>
    </Report>
    <Report instance="anvs-20211231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>30603 - Disclosure - Accrued Expenses (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://annovisbio.com/role/DisclosureAccruedExpensesTables</Role>
      <ShortName>Accrued Expenses (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://annovisbio.com/role/DisclosureAccruedExpenses</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="anvs-20211231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>31003 - Disclosure - Stock-Based Compensation (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://annovisbio.com/role/DisclosureStockBasedCompensationTables</Role>
      <ShortName>Stock-Based Compensation (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://annovisbio.com/role/DisclosureStockBasedCompensation</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="anvs-20211231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>31103 - Disclosure - Net Loss Per Share (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://annovisbio.com/role/DisclosureNetLossPerShareTables</Role>
      <ShortName>Net Loss Per Share (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://annovisbio.com/role/DisclosureNetLossPerShare</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="anvs-20211231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>31203 - Disclosure - Income Taxes (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://annovisbio.com/role/DisclosureIncomeTaxesTables</Role>
      <ShortName>Income Taxes (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://annovisbio.com/role/DisclosureIncomeTaxes</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="anvs-20211231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>40101 - Disclosure - Nature of Business and Liquidity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://annovisbio.com/role/DisclosureNatureOfBusinessAndLiquidityDetails</Role>
      <ShortName>Nature of Business and Liquidity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://annovisbio.com/role/DisclosureNatureOfBusinessAndLiquidity</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="anvs-20211231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>40301 - Disclosure - Fair Value Measurements (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://annovisbio.com/role/DisclosureFairValueMeasurementsDetails</Role>
      <ShortName>Fair Value Measurements (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://annovisbio.com/role/DisclosureFairValueMeasurementsTables</ParentRole>
      <Position>30</Position>
    </Report>
    <Report instance="anvs-20211231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>40401 - Disclosure - Grant Income (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://annovisbio.com/role/DisclosureGrantIncomeDetails</Role>
      <ShortName>Grant Income (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://annovisbio.com/role/DisclosureGrantIncome</ParentRole>
      <Position>31</Position>
    </Report>
    <Report instance="anvs-20211231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>40501 - Disclosure - Prepaid Expenses and Other Current Assets (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://annovisbio.com/role/DisclosurePrepaidExpensesAndOtherCurrentAssetsDetails</Role>
      <ShortName>Prepaid Expenses and Other Current Assets (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://annovisbio.com/role/DisclosurePrepaidExpensesAndOtherCurrentAssetsTables</ParentRole>
      <Position>32</Position>
    </Report>
    <Report instance="anvs-20211231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>40601 - Disclosure - Accrued Expenses (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://annovisbio.com/role/DisclosureAccruedExpensesDetails</Role>
      <ShortName>Accrued Expenses (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://annovisbio.com/role/DisclosureAccruedExpensesTables</ParentRole>
      <Position>33</Position>
    </Report>
    <Report instance="anvs-20211231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>40701 - Disclosure - Convertible Promissory Notes (Details)</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://annovisbio.com/role/DisclosureConvertiblePromissoryNotesDetails</Role>
      <ShortName>Convertible Promissory Notes (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://annovisbio.com/role/DisclosureConvertiblePromissoryNotes</ParentRole>
      <Position>34</Position>
    </Report>
    <Report instance="anvs-20211231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>40801 - Disclosure - Commitments and Contingencies - Leases (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://annovisbio.com/role/DisclosureCommitmentsAndContingenciesLeasesDetails</Role>
      <ShortName>Commitments and Contingencies - Leases (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>35</Position>
    </Report>
    <Report instance="anvs-20211231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>40802 - Disclosure - Commitments and Contingencies - License Agreement (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://annovisbio.com/role/DisclosureCommitmentsAndContingenciesLicenseAgreementDetails</Role>
      <ShortName>Commitments and Contingencies - License Agreement (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>36</Position>
    </Report>
    <Report instance="anvs-20211231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>40803 - Disclosure - Commitments and Contingencies - Employment Agreements (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://annovisbio.com/role/DisclosureCommitmentsAndContingenciesEmploymentAgreementsDetails</Role>
      <ShortName>Commitments and Contingencies - Employment Agreements (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>37</Position>
    </Report>
    <Report instance="anvs-20211231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>40901 - Disclosure - Redeemable Convertible Preferred Stock and Stockholders' Equity - Common and Preferred Stock (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://annovisbio.com/role/DisclosureRedeemableConvertiblePreferredStockAndStockholdersEquityCommonAndPreferredStockDetails</Role>
      <ShortName>Redeemable Convertible Preferred Stock and Stockholders' Equity - Common and Preferred Stock (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>38</Position>
    </Report>
    <Report instance="anvs-20211231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>40902 - Disclosure - Redeemable Convertible Preferred Stock and Stockholders' Equity - Warrants (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://annovisbio.com/role/DisclosureRedeemableConvertiblePreferredStockAndStockholdersEquityWarrantsDetails</Role>
      <ShortName>Redeemable Convertible Preferred Stock and Stockholders' Equity - Warrants (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://annovisbio.com/role/DisclosureRedeemableConvertiblePreferredStockAndStockholdersEquity</ParentRole>
      <Position>39</Position>
    </Report>
    <Report instance="anvs-20211231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>41001 - Disclosure - Stock-Based Compensation - Summary of plans (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://annovisbio.com/role/DisclosureStockBasedCompensationSummaryOfPlansDetails</Role>
      <ShortName>Stock-Based Compensation - Summary of plans (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>40</Position>
    </Report>
    <Report instance="anvs-20211231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>41002 - Disclosure - Stock-Based Compensation - Share-based compensation expense (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://annovisbio.com/role/DisclosureStockBasedCompensationShareBasedCompensationExpenseDetails</Role>
      <ShortName>Stock-Based Compensation - Share-based compensation expense (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>41</Position>
    </Report>
    <Report instance="anvs-20211231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>41003 - Disclosure - Stock-Based Compensation - Stock option activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://annovisbio.com/role/DisclosureStockBasedCompensationStockOptionActivityDetails</Role>
      <ShortName>Stock-Based Compensation - Stock option activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>42</Position>
    </Report>
    <Report instance="anvs-20211231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>41004 - Disclosure - Stock-Based Compensation - Additional disclosures (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://annovisbio.com/role/DisclosureStockBasedCompensationAdditionalDisclosuresDetails</Role>
      <ShortName>Stock-Based Compensation - Additional disclosures (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>43</Position>
    </Report>
    <Report instance="anvs-20211231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>41101 - Disclosure - Net Loss Per Share - Basic and diluted net loss per share (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://annovisbio.com/role/DisclosureNetLossPerShareBasicAndDilutedNetLossPerShareDetails</Role>
      <ShortName>Net Loss Per Share - Basic and diluted net loss per share (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>44</Position>
    </Report>
    <Report instance="anvs-20211231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>41102 - Disclosure - Net Loss Per Share - Potential shares excluded from calculation (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://annovisbio.com/role/DisclosureNetLossPerSharePotentialSharesExcludedFromCalculationDetails</Role>
      <ShortName>Net Loss Per Share - Potential shares excluded from calculation (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>45</Position>
    </Report>
    <Report instance="anvs-20211231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>41201 - Disclosure - Income Taxes - Reconciliation of income tax provision (benefit) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://annovisbio.com/role/DisclosureIncomeTaxesReconciliationOfIncomeTaxProvisionBenefitDetails</Role>
      <ShortName>Income Taxes - Reconciliation of income tax provision (benefit) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>46</Position>
    </Report>
    <Report instance="anvs-20211231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>41202 - Disclosure - Income Taxes - Deferred taxes (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://annovisbio.com/role/DisclosureIncomeTaxesDeferredTaxesDetails</Role>
      <ShortName>Income Taxes - Deferred taxes (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>47</Position>
    </Report>
    <Report instance="anvs-20211231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>41203 - Disclosure - Income Taxes - Additional disclosures (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://annovisbio.com/role/DisclosureIncomeTaxesAdditionalDisclosuresDetails</Role>
      <ShortName>Income Taxes - Additional disclosures (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>48</Position>
    </Report>
    <Report instance="anvs-20211231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>41301 - Disclosure - Related-Party Transactions (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://annovisbio.com/role/DisclosureRelatedPartyTransactionsDetails</Role>
      <ShortName>Related-Party Transactions (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://annovisbio.com/role/DisclosureRelatedPartyTransactions</ParentRole>
      <Position>49</Position>
    </Report>
    <Report instance="anvs-20211231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>41401 - Disclosure - Subsequent Events (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://annovisbio.com/role/DisclosureSubsequentEventsDetails</Role>
      <ShortName>Subsequent Events (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://annovisbio.com/role/DisclosureSubsequentEvents</ParentRole>
      <Position>50</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="10-K" original="anvs-20211231x10k.htm">anvs-20211231x10k.htm</File>
    <File>anvs-20211231.xsd</File>
    <File>anvs-20211231_cal.xml</File>
    <File>anvs-20211231_def.xml</File>
    <File>anvs-20211231_lab.xml</File>
    <File>anvs-20211231_pre.xml</File>
    <File>anvs-20211231xex23d1.htm</File>
    <File>anvs-20211231xex31d1.htm</File>
    <File>anvs-20211231xex31d2.htm</File>
    <File>anvs-20211231xex32d1.htm</File>
    <File>anvs-20211231xex32d2.htm</File>
  </InputFiles>
  <SupplementalFiles>
    <File>anvs-20211231x10k003.jpg</File>
    <File>anvs-20211231x10k004.jpg</File>
    <File>anvs-20211231x10k005.jpg</File>
    <File>anvs-20211231x10k006.jpg</File>
    <File>anvs-20211231x10k007.jpg</File>
    <File>anvs-20211231x10k008.jpg</File>
    <File>anvs-20211231x10k009.jpg</File>
    <File>anvs-20211231x10k010.jpg</File>
    <File>anvs-20211231x10k011.jpg</File>
    <File>anvs-20211231x10k012.jpg</File>
    <File>anvs-20211231x10k013.jpg</File>
    <File>anvs-20211231x10k014.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy items="343">http://fasb.org/us-gaap/2021-01-31</BaseTaxonomy>
    <BaseTaxonomy items="37">http://xbrl.sec.gov/dei/2021q4</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>81
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "anvs-20211231x10k.htm": {
   "axisCustom": 0,
   "axisStandard": 23,
   "contextCount": 92,
   "dts": {
    "calculationLink": {
     "local": [
      "anvs-20211231_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "anvs-20211231_def.xml"
     ]
    },
    "inline": {
     "local": [
      "anvs-20211231x10k.htm"
     ]
    },
    "labelLink": {
     "local": [
      "anvs-20211231_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "anvs-20211231_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "anvs-20211231.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/arcrole/esma-arcrole-2018-11-21.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-roles-2021-01-31.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-types-2021-01-31.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-roles-2021-01-31.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-types-2021-01-31.xsd",
      "https://xbrl.sec.gov/country/2021/country-2021.xsd",
      "https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd"
     ]
    }
   },
   "elementCount": 389,
   "entityCount": 1,
   "hidden": {
    "http://fasb.org/us-gaap/2021-01-31": 29,
    "http://xbrl.sec.gov/dei/2021q4": 4,
    "total": 33
   },
   "keyCustom": 38,
   "keyStandard": 280,
   "memberCustom": 17,
   "memberStandard": 18,
   "nsprefix": "anvs",
   "nsuri": "http://annovisbio.com/20211231",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "anvs-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_uhkxAiZ6fUeekYGgaMhCqA",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:EntityRegistrantName",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "00090 - Document - Document and Entity Information",
     "role": "http://annovisbio.com/role/DocumentDocumentAndEntityInformation",
     "shortName": "Document and Entity Information",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "anvs-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_uhkxAiZ6fUeekYGgaMhCqA",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:EntityRegistrantName",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R10": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "anvs-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_uhkxAiZ6fUeekYGgaMhCqA",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "10301 - Disclosure - Fair Value Measurements",
     "role": "http://annovisbio.com/role/DisclosureFairValueMeasurements",
     "shortName": "Fair Value Measurements",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "anvs-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_uhkxAiZ6fUeekYGgaMhCqA",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R11": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "anvs-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_uhkxAiZ6fUeekYGgaMhCqA",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "anvs:OtherNonoperatingIncomeGrantIncomeTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "10401 - Disclosure - Grant Income",
     "role": "http://annovisbio.com/role/DisclosureGrantIncome",
     "shortName": "Grant Income",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "anvs-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_uhkxAiZ6fUeekYGgaMhCqA",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "anvs:OtherNonoperatingIncomeGrantIncomeTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R12": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "anvs-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_uhkxAiZ6fUeekYGgaMhCqA",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "anvs:DeferredCostsCapitalizedPrepaidExpensesAndOtherAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "10501 - Disclosure - Prepaid Expenses and Other Current Assets",
     "role": "http://annovisbio.com/role/DisclosurePrepaidExpensesAndOtherCurrentAssets",
     "shortName": "Prepaid Expenses and Other Current Assets",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "anvs-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_uhkxAiZ6fUeekYGgaMhCqA",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "anvs:DeferredCostsCapitalizedPrepaidExpensesAndOtherAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R13": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "anvs-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_uhkxAiZ6fUeekYGgaMhCqA",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "10601 - Disclosure - Accrued Expenses",
     "role": "http://annovisbio.com/role/DisclosureAccruedExpenses",
     "shortName": "Accrued Expenses",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "anvs-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_uhkxAiZ6fUeekYGgaMhCqA",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R14": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "anvs-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_uhkxAiZ6fUeekYGgaMhCqA",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "10701 - Disclosure - Convertible Promissory Notes",
     "role": "http://annovisbio.com/role/DisclosureConvertiblePromissoryNotes",
     "shortName": "Convertible Promissory Notes",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "anvs-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_uhkxAiZ6fUeekYGgaMhCqA",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R15": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "anvs-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_uhkxAiZ6fUeekYGgaMhCqA",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "10801 - Disclosure - Commitments and Contingencies",
     "role": "http://annovisbio.com/role/DisclosureCommitmentsAndContingencies",
     "shortName": "Commitments and Contingencies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "anvs-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_uhkxAiZ6fUeekYGgaMhCqA",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R16": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "anvs-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_uhkxAiZ6fUeekYGgaMhCqA",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "10901 - Disclosure - Redeemable Convertible Preferred Stock and Stockholders' Equity",
     "role": "http://annovisbio.com/role/DisclosureRedeemableConvertiblePreferredStockAndStockholdersEquity",
     "shortName": "Redeemable Convertible Preferred Stock and Stockholders' Equity",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "anvs-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_uhkxAiZ6fUeekYGgaMhCqA",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R17": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "anvs-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_uhkxAiZ6fUeekYGgaMhCqA",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "11001 - Disclosure - Stock-Based Compensation",
     "role": "http://annovisbio.com/role/DisclosureStockBasedCompensation",
     "shortName": "Stock-Based Compensation",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "anvs-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_uhkxAiZ6fUeekYGgaMhCqA",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R18": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "anvs-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_uhkxAiZ6fUeekYGgaMhCqA",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "11101 - Disclosure - Net Loss Per Share",
     "role": "http://annovisbio.com/role/DisclosureNetLossPerShare",
     "shortName": "Net Loss Per Share",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "anvs-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_uhkxAiZ6fUeekYGgaMhCqA",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R19": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "anvs-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_uhkxAiZ6fUeekYGgaMhCqA",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "11201 - Disclosure - Income Taxes",
     "role": "http://annovisbio.com/role/DisclosureIncomeTaxes",
     "shortName": "Income Taxes",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "anvs-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_uhkxAiZ6fUeekYGgaMhCqA",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R2": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "anvs-20211231x10k.htm",
      "contextRef": "As_Of_12_31_2021_slf_IrTrZku1VVWbbttE4g",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unitRef": "Unit_Standard_USD_NFG_pVdyhEyJarLQmedkXA",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "00100 - Statement - Balance Sheets",
     "role": "http://annovisbio.com/role/StatementBalanceSheets",
     "shortName": "Balance Sheets",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "anvs-20211231x10k.htm",
      "contextRef": "As_Of_12_31_2021_slf_IrTrZku1VVWbbttE4g",
      "decimals": "0",
      "lang": null,
      "name": "us-gaap:AssetsCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_NFG_pVdyhEyJarLQmedkXA",
      "xsiNil": "false"
     }
    },
    "R20": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "anvs-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_uhkxAiZ6fUeekYGgaMhCqA",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "11301 - Disclosure - Related-Party Transactions",
     "role": "http://annovisbio.com/role/DisclosureRelatedPartyTransactions",
     "shortName": "Related-Party Transactions",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "anvs-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_uhkxAiZ6fUeekYGgaMhCqA",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R21": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "anvs-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_uhkxAiZ6fUeekYGgaMhCqA",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "11401 - Disclosure - Subsequent Events",
     "role": "http://annovisbio.com/role/DisclosureSubsequentEvents",
     "shortName": "Subsequent Events",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "anvs-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_uhkxAiZ6fUeekYGgaMhCqA",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R22": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "anvs-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_uhkxAiZ6fUeekYGgaMhCqA",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfAccounting",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "20202 - Disclosure - Summary of Significant Accounting Policies (Policies)",
     "role": "http://annovisbio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies",
     "shortName": "Summary of Significant Accounting Policies (Policies)",
     "subGroupType": "policies",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "anvs-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_uhkxAiZ6fUeekYGgaMhCqA",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfAccounting",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R23": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:FairValueDisclosuresTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "anvs-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_uhkxAiZ6fUeekYGgaMhCqA",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "30303 - Disclosure - Fair Value Measurements (Tables)",
     "role": "http://annovisbio.com/role/DisclosureFairValueMeasurementsTables",
     "shortName": "Fair Value Measurements (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:FairValueDisclosuresTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "anvs-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_uhkxAiZ6fUeekYGgaMhCqA",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R24": {
     "firstAnchor": {
      "ancestors": [
       "anvs:DeferredCostsCapitalizedPrepaidExpensesAndOtherAssetsDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "anvs-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_uhkxAiZ6fUeekYGgaMhCqA",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "30503 - Disclosure - Prepaid Expenses and Other Current Assets (Tables)",
     "role": "http://annovisbio.com/role/DisclosurePrepaidExpensesAndOtherCurrentAssetsTables",
     "shortName": "Prepaid Expenses and Other Current Assets (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "anvs:DeferredCostsCapitalizedPrepaidExpensesAndOtherAssetsDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "anvs-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_uhkxAiZ6fUeekYGgaMhCqA",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R25": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "anvs-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_uhkxAiZ6fUeekYGgaMhCqA",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "30603 - Disclosure - Accrued Expenses (Tables)",
     "role": "http://annovisbio.com/role/DisclosureAccruedExpensesTables",
     "shortName": "Accrued Expenses (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "anvs-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_uhkxAiZ6fUeekYGgaMhCqA",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R26": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "anvs-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_uhkxAiZ6fUeekYGgaMhCqA",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "31003 - Disclosure - Stock-Based Compensation (Tables)",
     "role": "http://annovisbio.com/role/DisclosureStockBasedCompensationTables",
     "shortName": "Stock-Based Compensation (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "anvs-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_uhkxAiZ6fUeekYGgaMhCqA",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R27": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "anvs-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_uhkxAiZ6fUeekYGgaMhCqA",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "31103 - Disclosure - Net Loss Per Share (Tables)",
     "role": "http://annovisbio.com/role/DisclosureNetLossPerShareTables",
     "shortName": "Net Loss Per Share (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "anvs-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_uhkxAiZ6fUeekYGgaMhCqA",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R28": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "anvs-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_uhkxAiZ6fUeekYGgaMhCqA",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "31203 - Disclosure - Income Taxes (Tables)",
     "role": "http://annovisbio.com/role/DisclosureIncomeTaxesTables",
     "shortName": "Income Taxes (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "anvs-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_uhkxAiZ6fUeekYGgaMhCqA",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R29": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "anvs-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_uhkxAiZ6fUeekYGgaMhCqA",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:ProceedsFromIssuanceOfCommonStock",
      "reportCount": 1,
      "unitRef": "Unit_Standard_USD_NFG_pVdyhEyJarLQmedkXA",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40101 - Disclosure - Nature of Business and Liquidity (Details)",
     "role": "http://annovisbio.com/role/DisclosureNatureOfBusinessAndLiquidityDetails",
     "shortName": "Nature of Business and Liquidity (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "anvs-20211231x10k.htm",
      "contextRef": "As_Of_1_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember_rLszk1iR-U-miS0THNh94A",
      "decimals": "2",
      "lang": null,
      "name": "us-gaap:SharePrice",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Divide_USD_shares_ZtgwQidioUWlbMoOaTBzxg",
      "xsiNil": "false"
     }
    },
    "R3": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:PreferredStockParOrStatedValuePerShare",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "anvs-20211231x10k.htm",
      "contextRef": "As_Of_12_31_2021_slf_IrTrZku1VVWbbttE4g",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:PreferredStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unitRef": "Unit_Divide_USD_shares_ZtgwQidioUWlbMoOaTBzxg",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "00105 - Statement - Balance Sheets (Parenthetical)",
     "role": "http://annovisbio.com/role/StatementBalanceSheetsParenthetical",
     "shortName": "Balance Sheets (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "anvs-20211231x10k.htm",
      "contextRef": "As_Of_12_31_2021_slf_IrTrZku1VVWbbttE4g",
      "decimals": "INF",
      "lang": null,
      "name": "us-gaap:CommonStockSharesIssued",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_shares__cOSbKjBTUyHt70_t1aAVw",
      "xsiNil": "false"
     }
    },
    "R30": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "anvs-20211231x10k.htm",
      "contextRef": "As_Of_12_31_2021_slf_IrTrZku1VVWbbttE4g",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unitRef": "Unit_Standard_USD_NFG_pVdyhEyJarLQmedkXA",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40301 - Disclosure - Fair Value Measurements (Details)",
     "role": "http://annovisbio.com/role/DisclosureFairValueMeasurementsDetails",
     "shortName": "Fair Value Measurements (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
       "us-gaap:FairValueDisclosuresTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "anvs-20211231x10k.htm",
      "contextRef": "As_Of_12_31_2021_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_4-P5H-hF4ESmAJ-kqpCyXw",
      "decimals": "0",
      "lang": null,
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_NFG_pVdyhEyJarLQmedkXA",
      "xsiNil": "false"
     }
    },
    "R31": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "anvs-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_uhkxAiZ6fUeekYGgaMhCqA",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "anvs:IncomeFromGrants",
      "reportCount": 1,
      "unitRef": "Unit_Standard_USD_NFG_pVdyhEyJarLQmedkXA",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40401 - Disclosure - Grant Income (Details)",
     "role": "http://annovisbio.com/role/DisclosureGrantIncomeDetails",
     "shortName": "Grant Income (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "anvs:UnreimbursedEligibleCostsIncurredDuringPeriod",
       "p",
       "anvs:OtherNonoperatingIncomeGrantIncomeTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "anvs-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_uhkxAiZ6fUeekYGgaMhCqA",
      "decimals": "0",
      "lang": null,
      "name": "anvs:UnreimbursedEligibleCostsIncurredDuringPeriod",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_NFG_pVdyhEyJarLQmedkXA",
      "xsiNil": "false"
     }
    },
    "R32": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock",
       "anvs:DeferredCostsCapitalizedPrepaidExpensesAndOtherAssetsDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "anvs-20211231x10k.htm",
      "contextRef": "As_Of_12_31_2021_slf_IrTrZku1VVWbbttE4g",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "anvs:PrepaidResearchAndDevelopmentExpenseCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_NFG_pVdyhEyJarLQmedkXA",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40501 - Disclosure - Prepaid Expenses and Other Current Assets (Details)",
     "role": "http://annovisbio.com/role/DisclosurePrepaidExpensesAndOtherCurrentAssetsDetails",
     "shortName": "Prepaid Expenses and Other Current Assets (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock",
       "anvs:DeferredCostsCapitalizedPrepaidExpensesAndOtherAssetsDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "anvs-20211231x10k.htm",
      "contextRef": "As_Of_12_31_2021_slf_IrTrZku1VVWbbttE4g",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "anvs:PrepaidResearchAndDevelopmentExpenseCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_NFG_pVdyhEyJarLQmedkXA",
      "xsiNil": "false"
     }
    },
    "R33": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "anvs-20211231x10k.htm",
      "contextRef": "As_Of_12_31_2021_slf_IrTrZku1VVWbbttE4g",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:EmployeeRelatedLiabilitiesCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_NFG_pVdyhEyJarLQmedkXA",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40601 - Disclosure - Accrued Expenses (Details)",
     "role": "http://annovisbio.com/role/DisclosureAccruedExpensesDetails",
     "shortName": "Accrued Expenses (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "anvs-20211231x10k.htm",
      "contextRef": "As_Of_12_31_2021_slf_IrTrZku1VVWbbttE4g",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:EmployeeRelatedLiabilitiesCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_NFG_pVdyhEyJarLQmedkXA",
      "xsiNil": "false"
     }
    },
    "R34": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "us-gaap:DebtDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "anvs-20211231x10k.htm",
      "contextRef": "As_Of_3_31_2019_oVmx4yeGk0q3UZkY6l4F-g",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:DebtInstrumentUnamortizedDiscount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_NFG_pVdyhEyJarLQmedkXA",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40701 - Disclosure - Convertible Promissory Notes (Details)",
     "role": "http://annovisbio.com/role/DisclosureConvertiblePromissoryNotesDetails",
     "shortName": "Convertible Promissory Notes (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "us-gaap:DebtDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "anvs-20211231x10k.htm",
      "contextRef": "As_Of_3_31_2019_oVmx4yeGk0q3UZkY6l4F-g",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:DebtInstrumentUnamortizedDiscount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_NFG_pVdyhEyJarLQmedkXA",
      "xsiNil": "false"
     }
    },
    "R35": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "anvs-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_uhkxAiZ6fUeekYGgaMhCqA",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:OperatingLeaseExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_NFG_pVdyhEyJarLQmedkXA",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40801 - Disclosure - Commitments and Contingencies - Leases (Details)",
     "role": "http://annovisbio.com/role/DisclosureCommitmentsAndContingenciesLeasesDetails",
     "shortName": "Commitments and Contingencies - Leases (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "anvs-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_uhkxAiZ6fUeekYGgaMhCqA",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:OperatingLeaseExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_NFG_pVdyhEyJarLQmedkXA",
      "xsiNil": "false"
     }
    },
    "R36": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "anvs-20211231x10k.htm",
      "contextRef": "As_Of_12_31_2020_K1oKCNbpv0CLR8EJWu1PSw",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "anvs:AccruedLicensePaymentsCurrent",
      "reportCount": 1,
      "unitRef": "Unit_Standard_USD_NFG_pVdyhEyJarLQmedkXA",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40802 - Disclosure - Commitments and Contingencies - License Agreement (Details)",
     "role": "http://annovisbio.com/role/DisclosureCommitmentsAndContingenciesLicenseAgreementDetails",
     "shortName": "Commitments and Contingencies - License Agreement (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "anvs-20211231x10k.htm",
      "contextRef": "Duration_5_1_2012_To_5_31_2012_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_anvs_LicenseAgreementTermsAmendedMay2012Member_P0aUOpgGN0mwPRsuYBHIew",
      "decimals": "0",
      "lang": null,
      "name": "anvs:LicenseAgreementMinimumAnnualCommitment",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_NFG_pVdyhEyJarLQmedkXA",
      "xsiNil": "false"
     }
    },
    "R37": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "anvs-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_uhkxAiZ6fUeekYGgaMhCqA",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:LossContingencyNewClaimsFiledNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_lawsuit_cWy34Dwcxk6mE22LYui79g",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40803 - Disclosure - Commitments and Contingencies - Employment Agreements (Details)",
     "role": "http://annovisbio.com/role/DisclosureCommitmentsAndContingenciesEmploymentAgreementsDetails",
     "shortName": "Commitments and Contingencies - Employment Agreements (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "anvs-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_uhkxAiZ6fUeekYGgaMhCqA",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:LossContingencyNewClaimsFiledNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_lawsuit_cWy34Dwcxk6mE22LYui79g",
      "xsiNil": "false"
     }
    },
    "R38": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "anvs-20211231x10k.htm",
      "contextRef": "As_Of_1_31_2020_kBrHfmPKTE-0UUCmwNXokA",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "anvs:NumberOfClassesOfStockDesignated",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_item_Y7Ur8tqCgUit9H-TWiK9OA",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40901 - Disclosure - Redeemable Convertible Preferred Stock and Stockholders' Equity - Common and Preferred Stock (Details)",
     "role": "http://annovisbio.com/role/DisclosureRedeemableConvertiblePreferredStockAndStockholdersEquityCommonAndPreferredStockDetails",
     "shortName": "Redeemable Convertible Preferred Stock and Stockholders' Equity - Common and Preferred Stock (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "anvs-20211231x10k.htm",
      "contextRef": "As_Of_1_31_2020_kBrHfmPKTE-0UUCmwNXokA",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "anvs:NumberOfClassesOfStockDesignated",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_item_Y7Ur8tqCgUit9H-TWiK9OA",
      "xsiNil": "false"
     }
    },
    "R39": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "anvs-20211231x10k.htm",
      "contextRef": "As_Of_1_31_2020_us-gaap_ClassOfWarrantOrRightAxis_anvs_UnderwritersWarrantsMember_p2Rmy9kgMES4LjCsl9nsqg",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights",
      "reportCount": 1,
      "unitRef": "Unit_Standard_shares__cOSbKjBTUyHt70_t1aAVw",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40902 - Disclosure - Redeemable Convertible Preferred Stock and Stockholders' Equity - Warrants (Details)",
     "role": "http://annovisbio.com/role/DisclosureRedeemableConvertiblePreferredStockAndStockholdersEquityWarrantsDetails",
     "shortName": "Redeemable Convertible Preferred Stock and Stockholders' Equity - Warrants (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "anvs-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_us-gaap_ClassOfWarrantOrRightAxis_anvs_UnderwritersWarrantsMember_lIkEDjt6I02rJoRPhXJAxw",
      "decimals": "INF",
      "lang": null,
      "name": "anvs:ConversionOfWarrantsNumberOfWarrantsConverted",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_shares__cOSbKjBTUyHt70_t1aAVw",
      "xsiNil": "false"
     }
    },
    "R4": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "anvs-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_uhkxAiZ6fUeekYGgaMhCqA",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:ResearchAndDevelopmentExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_NFG_pVdyhEyJarLQmedkXA",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "00200 - Statement - Statements of Operations",
     "role": "http://annovisbio.com/role/StatementStatementsOfOperations",
     "shortName": "Statements of Operations",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "anvs-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_uhkxAiZ6fUeekYGgaMhCqA",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:ResearchAndDevelopmentExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_NFG_pVdyhEyJarLQmedkXA",
      "xsiNil": "false"
     }
    },
    "R40": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "anvs-20211231x10k.htm",
      "contextRef": "As_Of_12_31_2021_slf_IrTrZku1VVWbbttE4g",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "reportCount": 1,
      "unitRef": "Unit_Standard_shares__cOSbKjBTUyHt70_t1aAVw",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "41001 - Disclosure - Stock-Based Compensation - Summary of plans (Details)",
     "role": "http://annovisbio.com/role/DisclosureStockBasedCompensationSummaryOfPlansDetails",
     "shortName": "Stock-Based Compensation - Summary of plans (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "anvs-20211231x10k.htm",
      "contextRef": "As_Of_6_1_2021_us-gaap_PlanNameAxis_anvs_EquityIncentivePlan2019Member__w3AH-0HNU6nl5M5tn5tng",
      "decimals": "INF",
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_shares__cOSbKjBTUyHt70_t1aAVw",
      "xsiNil": "false"
     }
    },
    "R41": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "anvs-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_uhkxAiZ6fUeekYGgaMhCqA",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensation",
      "reportCount": 1,
      "unitRef": "Unit_Standard_USD_NFG_pVdyhEyJarLQmedkXA",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "41002 - Disclosure - Stock-Based Compensation - Share-based compensation expense (Details)",
     "role": "http://annovisbio.com/role/DisclosureStockBasedCompensationShareBasedCompensationExpenseDetails",
     "shortName": "Stock-Based Compensation - Share-based compensation expense (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "anvs-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_PpS2s9PnUUSL1x-_RPEPIQ",
      "decimals": "0",
      "lang": null,
      "name": "us-gaap:ShareBasedCompensation",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_NFG_pVdyhEyJarLQmedkXA",
      "xsiNil": "false"
     }
    },
    "R42": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "anvs-20211231x10k.htm",
      "contextRef": "As_Of_12_31_2020_K1oKCNbpv0CLR8EJWu1PSw",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "reportCount": 1,
      "unitRef": "Unit_Standard_shares__cOSbKjBTUyHt70_t1aAVw",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "41003 - Disclosure - Stock-Based Compensation - Stock option activity (Details)",
     "role": "http://annovisbio.com/role/DisclosureStockBasedCompensationStockOptionActivityDetails",
     "shortName": "Stock-Based Compensation - Stock option activity (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "anvs-20211231x10k.htm",
      "contextRef": "Duration_1_1_2020_To_12_31_2020_3DdHOulAJk6Q0Zn4Vsxq5A",
      "decimals": "INF",
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_shares__cOSbKjBTUyHt70_t1aAVw",
      "xsiNil": "false"
     }
    },
    "R43": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "anvs-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_uhkxAiZ6fUeekYGgaMhCqA",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_NFG_pVdyhEyJarLQmedkXA",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "41004 - Disclosure - Stock-Based Compensation - Additional disclosures (Details)",
     "role": "http://annovisbio.com/role/DisclosureStockBasedCompensationAdditionalDisclosuresDetails",
     "shortName": "Stock-Based Compensation - Additional disclosures (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "anvs-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_uhkxAiZ6fUeekYGgaMhCqA",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_NFG_pVdyhEyJarLQmedkXA",
      "xsiNil": "false"
     }
    },
    "R44": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "anvs-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_uhkxAiZ6fUeekYGgaMhCqA",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "Unit_Standard_USD_NFG_pVdyhEyJarLQmedkXA",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "41101 - Disclosure - Net Loss Per Share - Basic and diluted net loss per share (Details)",
     "role": "http://annovisbio.com/role/DisclosureNetLossPerShareBasicAndDilutedNetLossPerShareDetails",
     "shortName": "Net Loss Per Share - Basic and diluted net loss per share (Details)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R45": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "anvs-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockOptionMember_ErimM70Lx0GlzbzdZjfaBQ",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_shares__cOSbKjBTUyHt70_t1aAVw",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "41102 - Disclosure - Net Loss Per Share - Potential shares excluded from calculation (Details)",
     "role": "http://annovisbio.com/role/DisclosureNetLossPerSharePotentialSharesExcludedFromCalculationDetails",
     "shortName": "Net Loss Per Share - Potential shares excluded from calculation (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "anvs-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockOptionMember_ErimM70Lx0GlzbzdZjfaBQ",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_shares__cOSbKjBTUyHt70_t1aAVw",
      "xsiNil": "false"
     }
    },
    "R46": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:StateAndLocalIncomeTaxExpenseBenefitContinuingOperations",
       "p",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "anvs-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_uhkxAiZ6fUeekYGgaMhCqA",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:StateAndLocalIncomeTaxExpenseBenefitContinuingOperations",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_NFG_pVdyhEyJarLQmedkXA",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "41201 - Disclosure - Income Taxes - Reconciliation of income tax provision (benefit) (Details)",
     "role": "http://annovisbio.com/role/DisclosureIncomeTaxesReconciliationOfIncomeTaxProvisionBenefitDetails",
     "shortName": "Income Taxes - Reconciliation of income tax provision (benefit) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:StateAndLocalIncomeTaxExpenseBenefitContinuingOperations",
       "p",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "anvs-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_uhkxAiZ6fUeekYGgaMhCqA",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:StateAndLocalIncomeTaxExpenseBenefitContinuingOperations",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_NFG_pVdyhEyJarLQmedkXA",
      "xsiNil": "false"
     }
    },
    "R47": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "anvs-20211231x10k.htm",
      "contextRef": "As_Of_12_31_2021_slf_IrTrZku1VVWbbttE4g",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_NFG_pVdyhEyJarLQmedkXA",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "41202 - Disclosure - Income Taxes - Deferred taxes (Details)",
     "role": "http://annovisbio.com/role/DisclosureIncomeTaxesDeferredTaxesDetails",
     "shortName": "Income Taxes - Deferred taxes (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "anvs-20211231x10k.htm",
      "contextRef": "As_Of_12_31_2021_slf_IrTrZku1VVWbbttE4g",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_NFG_pVdyhEyJarLQmedkXA",
      "xsiNil": "false"
     }
    },
    "R48": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "anvs-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_uhkxAiZ6fUeekYGgaMhCqA",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_NFG_pVdyhEyJarLQmedkXA",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "41203 - Disclosure - Income Taxes - Additional disclosures (Details)",
     "role": "http://annovisbio.com/role/DisclosureIncomeTaxesAdditionalDisclosuresDetails",
     "shortName": "Income Taxes - Additional disclosures (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "anvs-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_uhkxAiZ6fUeekYGgaMhCqA",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_NFG_pVdyhEyJarLQmedkXA",
      "xsiNil": "false"
     }
    },
    "R49": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "anvs-20211231x10k.htm",
      "contextRef": "Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_FOnigPlx6UaoZMNa-ktVRg",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "anvs:StockIssuedDuringPeriodSharesConversionOfConvertibleNotes",
      "reportCount": 1,
      "unitRef": "Unit_Standard_shares__cOSbKjBTUyHt70_t1aAVw",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "41301 - Disclosure - Related-Party Transactions (Details)",
     "role": "http://annovisbio.com/role/DisclosureRelatedPartyTransactionsDetails",
     "shortName": "Related-Party Transactions (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "anvs-20211231x10k.htm",
      "contextRef": "As_Of_3_31_2019_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember_us-gaap_RelatedPartyTransactionAxis_anvs_RelatedPartyTransactionIssuanceOfConvertiblePromissoryNotesMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_srt_DirectorMember_4brYU2SNtkC-xZaYEMvK_g",
      "decimals": "0",
      "lang": null,
      "name": "us-gaap:DebtInstrumentFaceAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_NFG_pVdyhEyJarLQmedkXA",
      "xsiNil": "false"
     }
    },
    "R5": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "anvs-20211231x10k.htm",
      "contextRef": "As_Of_12_31_2019_us-gaap_StatementClassOfStockAxis_anvs_SeriesaRedeemableConvertiblePreferredStockMember_odVgKOmG90OBa7U96NG4jw",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:TemporaryEquityCarryingAmountAttributableToParent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_NFG_pVdyhEyJarLQmedkXA",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "00300 - Statement - Statements of Changes in Redeemable Convertible Preferred Stock",
     "role": "http://annovisbio.com/role/StatementStatementsOfChangesInRedeemableConvertiblePreferredStock",
     "shortName": "Statements of Changes in Redeemable Convertible Preferred Stock",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "anvs-20211231x10k.htm",
      "contextRef": "As_Of_12_31_2019_us-gaap_StatementClassOfStockAxis_anvs_SeriesaRedeemableConvertiblePreferredStockMember_odVgKOmG90OBa7U96NG4jw",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:TemporaryEquityCarryingAmountAttributableToParent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_NFG_pVdyhEyJarLQmedkXA",
      "xsiNil": "false"
     }
    },
    "R50": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "anvs-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_uhkxAiZ6fUeekYGgaMhCqA",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
      "reportCount": 1,
      "unitRef": "Unit_Standard_shares__cOSbKjBTUyHt70_t1aAVw",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "41401 - Disclosure - Subsequent Events (Details)",
     "role": "http://annovisbio.com/role/DisclosureSubsequentEventsDetails",
     "shortName": "Subsequent Events (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "us-gaap:SubsequentEventsTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "anvs-20211231x10k.htm",
      "contextRef": "Duration_1_3_2022_To_1_3_2022_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_rxWBqkfQFkesGFeOew63wA",
      "decimals": "INF",
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_shares__cOSbKjBTUyHt70_t1aAVw",
      "xsiNil": "false"
     }
    },
    "R6": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "anvs-20211231x10k.htm",
      "contextRef": "As_Of_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_d1y_dVMmq02lOk2EI5_rBA",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:StockholdersEquity",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_NFG_pVdyhEyJarLQmedkXA",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "00301 - Statement - Statements of Changes in Stockholders' Equity (Deficit)",
     "role": "http://annovisbio.com/role/StatementStatementsOfChangesInStockholdersEquityDeficit",
     "shortName": "Statements of Changes in Stockholders' Equity (Deficit)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "anvs-20211231x10k.htm",
      "contextRef": "As_Of_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_d1y_dVMmq02lOk2EI5_rBA",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:StockholdersEquity",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_NFG_pVdyhEyJarLQmedkXA",
      "xsiNil": "false"
     }
    },
    "R7": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "anvs-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_uhkxAiZ6fUeekYGgaMhCqA",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:ProfitLoss",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_NFG_pVdyhEyJarLQmedkXA",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "00400 - Statement - Statements of Cash Flows",
     "role": "http://annovisbio.com/role/StatementStatementsOfCashFlows",
     "shortName": "Statements of Cash Flows",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "anvs-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_uhkxAiZ6fUeekYGgaMhCqA",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:ProfitLoss",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_NFG_pVdyhEyJarLQmedkXA",
      "xsiNil": "false"
     }
    },
    "R8": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "anvs-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_uhkxAiZ6fUeekYGgaMhCqA",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "10101 - Disclosure - Nature of Business and Liquidity",
     "role": "http://annovisbio.com/role/DisclosureNatureOfBusinessAndLiquidity",
     "shortName": "Nature of Business and Liquidity",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "anvs-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_uhkxAiZ6fUeekYGgaMhCqA",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R9": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "anvs-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_uhkxAiZ6fUeekYGgaMhCqA",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "10201 - Disclosure - Summary of Significant Accounting Policies",
     "role": "http://annovisbio.com/role/DisclosureSummaryOfSignificantAccountingPolicies",
     "shortName": "Summary of Significant Accounting Policies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "anvs-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_uhkxAiZ6fUeekYGgaMhCqA",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 36,
   "tag": {
    "anvs_AccruedLiabilitiesAndInterestAndEmployeeRelatedLiabilitiesCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://annovisbio.com/role/DisclosureAccruedExpensesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://annovisbio.com/role/StatementBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Includes accrued interest and obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits.",
        "label": "Accrued Liabilities and Interest, and Employee-Related Liabilities, Current",
        "terseLabel": "Accrued expenses",
        "totalLabel": "Total accrued expenses"
       }
      }
     },
     "localname": "AccruedLiabilitiesAndInterestAndEmployeeRelatedLiabilitiesCurrent",
     "nsuri": "http://annovisbio.com/20211231",
     "presentation": [
      "http://annovisbio.com/role/DisclosureAccruedExpensesDetails",
      "http://annovisbio.com/role/StatementBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "anvs_AccruedLicensePaymentsCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://annovisbio.com/role/DisclosureAccruedExpensesDetails": {
       "order": 3.0,
       "parentTag": "anvs_AccruedLiabilitiesAndInterestAndEmployeeRelatedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for accrued license payments.",
        "label": "Accrued License Payments, Current",
        "terseLabel": "Accrued license payments"
       }
      }
     },
     "localname": "AccruedLicensePaymentsCurrent",
     "nsuri": "http://annovisbio.com/20211231",
     "presentation": [
      "http://annovisbio.com/role/DisclosureAccruedExpensesDetails",
      "http://annovisbio.com/role/DisclosureCommitmentsAndContingenciesLicenseAgreementDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "anvs_AwardsGrantedIn2020Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to awards granted in 2020.",
        "label": "Awards granted in 2020"
       }
      }
     },
     "localname": "AwardsGrantedIn2020Member",
     "nsuri": "http://annovisbio.com/20211231",
     "presentation": [
      "http://annovisbio.com/role/DisclosureStockBasedCompensationAdditionalDisclosuresDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "anvs_AwardsGrantedIn2021Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to awards granted in 2021.",
        "label": "Awards granted in 2021"
       }
      }
     },
     "localname": "AwardsGrantedIn2021Member",
     "nsuri": "http://annovisbio.com/20211231",
     "presentation": [
      "http://annovisbio.com/role/DisclosureStockBasedCompensationAdditionalDisclosuresDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "anvs_CommonStockAndPreferredStockMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Pertaining to both common stock and preferred stock.",
        "label": "Common Stock And Preferred Stock [Member]"
       }
      }
     },
     "localname": "CommonStockAndPreferredStockMember",
     "nsuri": "http://annovisbio.com/20211231",
     "presentation": [
      "http://annovisbio.com/role/DisclosureRedeemableConvertiblePreferredStockAndStockholdersEquityCommonAndPreferredStockDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "anvs_CommonStockAndPreferredStockSharesAuthorized": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of shares permitted to be issued by an entity's charter and bylaws.",
        "label": "Common Stock And Preferred Stock, Shares Authorized",
        "terseLabel": "Number of common and preferred shares authorized"
       }
      }
     },
     "localname": "CommonStockAndPreferredStockSharesAuthorized",
     "nsuri": "http://annovisbio.com/20211231",
     "presentation": [
      "http://annovisbio.com/role/DisclosureRedeemableConvertiblePreferredStockAndStockholdersEquityCommonAndPreferredStockDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "anvs_ConversionOfConvertiblePromissoryNotesIncludingEmbeddedDerivativeToCommonStock": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the conversion of convertible promissory notes, including embedded derivative, to common stock",
        "label": "Conversion of Convertible Promissory Notes, Including Embedded Derivative, to Common Stock",
        "verboseLabel": "Conversion of convertible promissory notes, including embedded derivative, to common stock"
       }
      }
     },
     "localname": "ConversionOfConvertiblePromissoryNotesIncludingEmbeddedDerivativeToCommonStock",
     "nsuri": "http://annovisbio.com/20211231",
     "presentation": [
      "http://annovisbio.com/role/StatementStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "anvs_ConversionOfConvertibleSecuritiesConvertiblePromissoryNotesPercentageOfDiscountToInitialPublicOfferingPrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "In the conversion of promissory notes to common shares, the percentage discount to the initial offering price of shares issued in the IPO.",
        "label": "Conversion Of Convertible Securities, Convertible Promissory Notes, Percentage of Discount To Initial Public Offering Price",
        "terseLabel": "Percentage of discount to the initial offering price of shares issued in the IPO"
       }
      }
     },
     "localname": "ConversionOfConvertibleSecuritiesConvertiblePromissoryNotesPercentageOfDiscountToInitialPublicOfferingPrice",
     "nsuri": "http://annovisbio.com/20211231",
     "presentation": [
      "http://annovisbio.com/role/DisclosureConvertiblePromissoryNotesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "anvs_ConversionOfRedeemableConvertiblePreferredStockToCommonStock": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the conversion of redeemable convertible preferred stock to common stock.",
        "label": "Conversion of Redeemable Convertible Preferred Stock to Common Stock",
        "verboseLabel": "Conversion of redeemable convertible preferred stock to common stock"
       }
      }
     },
     "localname": "ConversionOfRedeemableConvertiblePreferredStockToCommonStock",
     "nsuri": "http://annovisbio.com/20211231",
     "presentation": [
      "http://annovisbio.com/role/StatementStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "anvs_ConversionOfWarrantsNumberOfWarrantsConverted": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of warrants converted in a noncash (or part noncash) transaction.",
        "label": "Conversion of Warrants, Number of Warrants Converted",
        "terseLabel": "Number of warrants converted in a non-cash transaction"
       }
      }
     },
     "localname": "ConversionOfWarrantsNumberOfWarrantsConverted",
     "nsuri": "http://annovisbio.com/20211231",
     "presentation": [
      "http://annovisbio.com/role/DisclosureRedeemableConvertiblePreferredStockAndStockholdersEquityWarrantsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "anvs_CumulativeNumberOfMilestonesAchieved": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative number of milestones achieved.",
        "label": "Cumulative Number of Milestones Achieved",
        "terseLabel": "Number of milestones achieved"
       }
      }
     },
     "localname": "CumulativeNumberOfMilestonesAchieved",
     "nsuri": "http://annovisbio.com/20211231",
     "presentation": [
      "http://annovisbio.com/role/DisclosureCommitmentsAndContingenciesLicenseAgreementDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "anvs_DeferredCostsCapitalizedPrepaidExpensesAndOtherAssetsDisclosureTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure of the amounts paid in advance for capitalized costs that will be expensed with the passage of time or the occurrence of a triggering event, and will be charged against earnings within one year or the normal operating cycle, if longer; the aggregate carrying amount of current assets, not separately presented elsewhere in the balance sheet; and other deferred costs.",
        "label": "Deferred Costs, Capitalized, Prepaid Expenses, and Other Assets Disclosure [Text Block]",
        "terseLabel": "Prepaid Expenses and Other Current Assets"
       }
      }
     },
     "localname": "DeferredCostsCapitalizedPrepaidExpensesAndOtherAssetsDisclosureTextBlock",
     "nsuri": "http://annovisbio.com/20211231",
     "presentation": [
      "http://annovisbio.com/role/DisclosurePrepaidExpensesAndOtherCurrentAssets"
     ],
     "xbrltype": "textBlockItemType"
    },
    "anvs_DeferredTaxAssetsTaxCreditCarryforwardsCapitalizedResearchAndDevelopment": {
     "auth_ref": [],
     "calculation": {
      "http://annovisbio.com/role/DisclosureIncomeTaxesDeferredTaxesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to capitalized research and development.",
        "label": "Deferred Tax Assets, Tax Credit Carryforwards, Capitalized Research and Development",
        "terseLabel": "Capitalized research and development"
       }
      }
     },
     "localname": "DeferredTaxAssetsTaxCreditCarryforwardsCapitalizedResearchAndDevelopment",
     "nsuri": "http://annovisbio.com/20211231",
     "presentation": [
      "http://annovisbio.com/role/DisclosureIncomeTaxesDeferredTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "anvs_EarningsPerShareBasicAndDilutedDenominatorAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "No definition available.",
        "label": "Earnings Per Share, Basic and Diluted, Denominator [Abstract]",
        "terseLabel": "Denominator"
       }
      }
     },
     "localname": "EarningsPerShareBasicAndDilutedDenominatorAbstract",
     "nsuri": "http://annovisbio.com/20211231",
     "presentation": [
      "http://annovisbio.com/role/DisclosureNetLossPerShareBasicAndDilutedNetLossPerShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "anvs_EarningsPerShareBasicAndDilutedNumeratorAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "No definition available.",
        "label": "Earnings Per Share, Basic and Diluted, Numerator [Abstract]",
        "terseLabel": "Numerator"
       }
      }
     },
     "localname": "EarningsPerShareBasicAndDilutedNumeratorAbstract",
     "nsuri": "http://annovisbio.com/20211231",
     "presentation": [
      "http://annovisbio.com/role/DisclosureNetLossPerShareBasicAndDilutedNetLossPerShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "anvs_EquityIncentivePlan2018Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Pertaining to the 2018 Equity Incentive Plan.",
        "label": "2018 Plan"
       }
      }
     },
     "localname": "EquityIncentivePlan2018Member",
     "nsuri": "http://annovisbio.com/20211231",
     "presentation": [
      "http://annovisbio.com/role/DisclosureStockBasedCompensationSummaryOfPlansDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "anvs_EquityIncentivePlan2019Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to the Company's 2019 Equity Incentive Plan.",
        "label": "2019 Plan"
       }
      }
     },
     "localname": "EquityIncentivePlan2019Member",
     "nsuri": "http://annovisbio.com/20211231",
     "presentation": [
      "http://annovisbio.com/role/DisclosureStockBasedCompensationSummaryOfPlansDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "anvs_GeneratedIn2017AndPriorMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to tax years 2017 and prior.",
        "label": "Generated in 2017 and prior"
       }
      }
     },
     "localname": "GeneratedIn2017AndPriorMember",
     "nsuri": "http://annovisbio.com/20211231",
     "presentation": [
      "http://annovisbio.com/role/DisclosureIncomeTaxesAdditionalDisclosuresDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "anvs_GrantAwardRemainingAmountAvailable": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The remining balance of funds available under a grant award.",
        "label": "Grant Award, Remaining Amount Available",
        "terseLabel": "Remining funds available"
       }
      }
     },
     "localname": "GrantAwardRemainingAmountAvailable",
     "nsuri": "http://annovisbio.com/20211231",
     "presentation": [
      "http://annovisbio.com/role/DisclosureGrantIncomeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "anvs_GrantIncomePolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for grant income.",
        "label": "Grant Income [Policy Text Block]",
        "terseLabel": "Grant Income"
       }
      }
     },
     "localname": "GrantIncomePolicyTextBlock",
     "nsuri": "http://annovisbio.com/20211231",
     "presentation": [
      "http://annovisbio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "anvs_GrantsReceivableNoticeOfAwardAmount": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of grant awarded.",
        "label": "Grants Receivable, Notice of Award Amount",
        "terseLabel": "Notice of Award, grant amount"
       }
      }
     },
     "localname": "GrantsReceivableNoticeOfAwardAmount",
     "nsuri": "http://annovisbio.com/20211231",
     "presentation": [
      "http://annovisbio.com/role/DisclosureGrantIncomeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "anvs_IncomeFromGrants": {
     "auth_ref": [],
     "calculation": {
      "http://annovisbio.com/role/StatementStatementsOfOperations": {
       "order": 3.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Income from non-repayable sum of money awarded to an entity to carry out a specific purpose as provided in grant agreements. Outside the scope of Topic 606.",
        "label": "Income from Grants",
        "terseLabel": "Grant income"
       }
      }
     },
     "localname": "IncomeFromGrants",
     "nsuri": "http://annovisbio.com/20211231",
     "presentation": [
      "http://annovisbio.com/role/DisclosureGrantIncomeDetails",
      "http://annovisbio.com/role/StatementStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "anvs_IncreaseDecreaseInGrantsReceivable": {
     "auth_ref": [],
     "calculation": {
      "http://annovisbio.com/role/StatementStatementsOfCashFlows": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in grants receivable.",
        "label": "Increase (Decrease) in Grants Receivable",
        "negatedLabel": "Grant receivable"
       }
      }
     },
     "localname": "IncreaseDecreaseInGrantsReceivable",
     "nsuri": "http://annovisbio.com/20211231",
     "presentation": [
      "http://annovisbio.com/role/StatementStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "anvs_InitialPublicOfferingAndOverAllotmentOptionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "First sale of stock by a private company to the public and right given to the underwriter to sell additional shares over the initial allotment.",
        "label": "IPO and Over-Allotment Option"
       }
      }
     },
     "localname": "InitialPublicOfferingAndOverAllotmentOptionMember",
     "nsuri": "http://annovisbio.com/20211231",
     "presentation": [
      "http://annovisbio.com/role/DisclosureNatureOfBusinessAndLiquidityDetails",
      "http://annovisbio.com/role/DisclosureRedeemableConvertiblePreferredStockAndStockholdersEquityCommonAndPreferredStockDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "anvs_IssuanceCostsAssociatedWithEquityIssuancesPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for issuance costs associated with equity issuances.",
        "label": "Issuance Costs Associated with Equity Issuances [Policy Text Block]",
        "terseLabel": "Issuance Costs Associated with Equity Issuances"
       }
      }
     },
     "localname": "IssuanceCostsAssociatedWithEquityIssuancesPolicyTextBlock",
     "nsuri": "http://annovisbio.com/20211231",
     "presentation": [
      "http://annovisbio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "anvs_LicenseAgreementMinimumAnnualCommitment": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The minimum amount of annual commitment under the terms of a license agreement.",
        "label": "License Agreement, Minimum Annual Commitment",
        "terseLabel": "Minimum annual commitment"
       }
      }
     },
     "localname": "LicenseAgreementMinimumAnnualCommitment",
     "nsuri": "http://annovisbio.com/20211231",
     "presentation": [
      "http://annovisbio.com/role/DisclosureCommitmentsAndContingenciesLicenseAgreementDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "anvs_LicenseAgreementPeriodOfAdvanceNoticeOfTermination": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The period of advance notice required to terminate the license agreement.",
        "label": "License Agreement, Period of Advance Notice of Termination",
        "terseLabel": "Period for advance notice of termination"
       }
      }
     },
     "localname": "LicenseAgreementPeriodOfAdvanceNoticeOfTermination",
     "nsuri": "http://annovisbio.com/20211231",
     "presentation": [
      "http://annovisbio.com/role/DisclosureCommitmentsAndContingenciesLicenseAgreementDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "anvs_LicenseAgreementTermsAmendedMay2012Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Terms of the license agreements, as amended May 2012, under research and development arrangements accounted for as a contract to perform research and development for others.",
        "label": "Amended License Agreement"
       }
      }
     },
     "localname": "LicenseAgreementTermsAmendedMay2012Member",
     "nsuri": "http://annovisbio.com/20211231",
     "presentation": [
      "http://annovisbio.com/role/DisclosureCommitmentsAndContingenciesLicenseAgreementDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "anvs_MaximumAggregateSeverancePayments": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum aggregate severance payments payable to executive officers under the terms of employment agreements.",
        "label": "Maximum Aggregate Severance Payments",
        "terseLabel": "Maximum aggregate severance payments"
       }
      }
     },
     "localname": "MaximumAggregateSeverancePayments",
     "nsuri": "http://annovisbio.com/20211231",
     "presentation": [
      "http://annovisbio.com/role/DisclosureCommitmentsAndContingenciesEmploymentAgreementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "anvs_NationalInstituteOnAgingOfNationalInstitutesOfHealthMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to the National Institute on Aging of the National Institutes of Health.",
        "label": "NIH"
       }
      }
     },
     "localname": "NationalInstituteOnAgingOfNationalInstitutesOfHealthMember",
     "nsuri": "http://annovisbio.com/20211231",
     "presentation": [
      "http://annovisbio.com/role/DisclosureGrantIncomeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "anvs_NatureOfBusinessAndLiquidityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "No definition available.",
        "label": "Nature of Business and Liquidity [Abstract]",
        "terseLabel": "Nature of Business and Liquidity"
       }
      }
     },
     "localname": "NatureOfBusinessAndLiquidityAbstract",
     "nsuri": "http://annovisbio.com/20211231",
     "presentation": [
      "http://annovisbio.com/role/DisclosureNatureOfBusinessAndLiquidityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "anvs_NonOperatingIncomeGrantIncomeAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "No definition available.",
        "label": "Grant Income"
       }
      }
     },
     "localname": "NonOperatingIncomeGrantIncomeAbstract",
     "nsuri": "http://annovisbio.com/20211231",
     "xbrltype": "stringItemType"
    },
    "anvs_NumberOfClassesOfStockDesignated": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of classes of stock designated.",
        "label": "Number of classes of stock designated",
        "terseLabel": "Number of classes of stock designated"
       }
      }
     },
     "localname": "NumberOfClassesOfStockDesignated",
     "nsuri": "http://annovisbio.com/20211231",
     "presentation": [
      "http://annovisbio.com/role/DisclosureRedeemableConvertiblePreferredStockAndStockholdersEquityCommonAndPreferredStockDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "anvs_NumberOfVotesForEachShareOfCommonStock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of vote for each share of common stock.",
        "label": "Number of Votes for Each Share of Common Stock",
        "terseLabel": "Number of vote for each share of common stock"
       }
      }
     },
     "localname": "NumberOfVotesForEachShareOfCommonStock",
     "nsuri": "http://annovisbio.com/20211231",
     "presentation": [
      "http://annovisbio.com/role/DisclosureRedeemableConvertiblePreferredStockAndStockholdersEquityCommonAndPreferredStockDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "anvs_OtherNonoperatingIncomeGrantIncomeTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the grant income classified as other non-operating income.",
        "label": "Other Nonoperating Income, Grant Income [Text Block]",
        "terseLabel": "Grant Income"
       }
      }
     },
     "localname": "OtherNonoperatingIncomeGrantIncomeTextBlock",
     "nsuri": "http://annovisbio.com/20211231",
     "presentation": [
      "http://annovisbio.com/role/DisclosureGrantIncome"
     ],
     "xbrltype": "textBlockItemType"
    },
    "anvs_PercentageOfExercisePriceToShareOfferingPrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of exercise price to the share offering price.",
        "label": "Percentage of Exercise Price to the Share Offering Price",
        "terseLabel": "Percentage of exercise price to the share offering price"
       }
      }
     },
     "localname": "PercentageOfExercisePriceToShareOfferingPrice",
     "nsuri": "http://annovisbio.com/20211231",
     "presentation": [
      "http://annovisbio.com/role/DisclosureNatureOfBusinessAndLiquidityDetails",
      "http://annovisbio.com/role/DisclosureRedeemableConvertiblePreferredStockAndStockholdersEquityWarrantsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "anvs_PrepaidExpenseSecurityDepositsAndOtherAssetsCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://annovisbio.com/role/DisclosurePrepaidExpensesAndOtherCurrentAssetsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://annovisbio.com/role/StatementBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer. Includes security deposits.",
        "label": "Prepaid Expense, Security Deposits, and Other Assets, Current",
        "terseLabel": "Prepaid expenses and other current assets",
        "totalLabel": "Total prepaid expenses and other current assets"
       }
      }
     },
     "localname": "PrepaidExpenseSecurityDepositsAndOtherAssetsCurrent",
     "nsuri": "http://annovisbio.com/20211231",
     "presentation": [
      "http://annovisbio.com/role/DisclosurePrepaidExpensesAndOtherCurrentAssetsDetails",
      "http://annovisbio.com/role/StatementBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "anvs_PrepaidResearchAndDevelopmentExpenseCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://annovisbio.com/role/DisclosurePrepaidExpensesAndOtherCurrentAssetsDetails": {
       "order": 1.0,
       "parentTag": "anvs_PrepaidExpenseSecurityDepositsAndOtherAssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for research and development expense that provides economic benefits within a future period of one year or the normal operating cycle, if longer.",
        "label": "Prepaid Research and Development Expense, Current",
        "terseLabel": "Prepaid clinical trial expenses"
       }
      }
     },
     "localname": "PrepaidResearchAndDevelopmentExpenseCurrent",
     "nsuri": "http://annovisbio.com/20211231",
     "presentation": [
      "http://annovisbio.com/role/DisclosurePrepaidExpensesAndOtherCurrentAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "anvs_ProceedsFromGrants": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from grants.",
        "label": "Proceeds from Grants"
       }
      }
     },
     "localname": "ProceedsFromGrants",
     "nsuri": "http://annovisbio.com/20211231",
     "presentation": [
      "http://annovisbio.com/role/DisclosureGrantIncomeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "anvs_RedeemableConvertiblePreferredStockConvertibleConversionPrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The price per share of the conversion price of redeemable convertible preferred stock.",
        "label": "Redeemable Convertible Preferred Stock, Convertible, Conversion Price",
        "terseLabel": "Conversion price"
       }
      }
     },
     "localname": "RedeemableConvertiblePreferredStockConvertibleConversionPrice",
     "nsuri": "http://annovisbio.com/20211231",
     "presentation": [
      "http://annovisbio.com/role/DisclosureRedeemableConvertiblePreferredStockAndStockholdersEquityCommonAndPreferredStockDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "anvs_RelatedPartyTransactionConversionOfPromissoryNotesToCommonStockMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to the conversion of promissory notes to common stock as a result of the Company's closing of an initial public offering.",
        "label": "Conversion of promissory notes to common stock"
       }
      }
     },
     "localname": "RelatedPartyTransactionConversionOfPromissoryNotesToCommonStockMember",
     "nsuri": "http://annovisbio.com/20211231",
     "presentation": [
      "http://annovisbio.com/role/DisclosureRelatedPartyTransactionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "anvs_RelatedPartyTransactionIssuanceOfConvertiblePromissoryNotesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to Convertible promissory notes issued by the Company and purchased by related parties.",
        "label": "Issuance of convertible promissory notes to related parties"
       }
      }
     },
     "localname": "RelatedPartyTransactionIssuanceOfConvertiblePromissoryNotesMember",
     "nsuri": "http://annovisbio.com/20211231",
     "presentation": [
      "http://annovisbio.com/role/DisclosureRelatedPartyTransactionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "anvs_RelatedPartyTransactionNumberOfCompanyDirectors": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of Company directors who purchased convertible promissory notes issued by the Company.",
        "label": "Related Party Transaction, Number Of Company Directors",
        "terseLabel": "Number of directors who purchased convertible promissory notes issued by the Company"
       }
      }
     },
     "localname": "RelatedPartyTransactionNumberOfCompanyDirectors",
     "nsuri": "http://annovisbio.com/20211231",
     "presentation": [
      "http://annovisbio.com/role/DisclosureRelatedPartyTransactionsDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "anvs_SecondaryPublicOfferingMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Secondary sale of stock.",
        "label": "Secondary Public Offering"
       }
      }
     },
     "localname": "SecondaryPublicOfferingMember",
     "nsuri": "http://annovisbio.com/20211231",
     "presentation": [
      "http://annovisbio.com/role/DisclosureNatureOfBusinessAndLiquidityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "anvs_Series1RedeemableConvertiblePreferredStockMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Series A-1 Redeemable convertible preferred stock.",
        "label": "Series A-1 Redeemable convertible preferred stock"
       }
      }
     },
     "localname": "Series1RedeemableConvertiblePreferredStockMember",
     "nsuri": "http://annovisbio.com/20211231",
     "presentation": [
      "http://annovisbio.com/role/DisclosureRedeemableConvertiblePreferredStockAndStockholdersEquityCommonAndPreferredStockDetails",
      "http://annovisbio.com/role/StatementStatementsOfChangesInRedeemableConvertiblePreferredStock"
     ],
     "xbrltype": "domainItemType"
    },
    "anvs_SeriesaRedeemableConvertiblePreferredStockMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Series A Redeemable convertible preferred stock.",
        "label": "Series A Redeemable convertible preferred stock"
       }
      }
     },
     "localname": "SeriesaRedeemableConvertiblePreferredStockMember",
     "nsuri": "http://annovisbio.com/20211231",
     "presentation": [
      "http://annovisbio.com/role/DisclosureRedeemableConvertiblePreferredStockAndStockholdersEquityCommonAndPreferredStockDetails",
      "http://annovisbio.com/role/StatementStatementsOfChangesInRedeemableConvertiblePreferredStock"
     ],
     "xbrltype": "domainItemType"
    },
    "anvs_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedInPeriodFairValue": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of share-based awards granted.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Granted in Period, Fair Value",
        "terseLabel": "Fair value of stock awards granted"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedInPeriodFairValue",
     "nsuri": "http://annovisbio.com/20211231",
     "presentation": [
      "http://annovisbio.com/role/DisclosureStockBasedCompensationAdditionalDisclosuresDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "anvs_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "No definition available.",
        "label": "Share-Based Compensation Arrangement By Share-Based Payment Award, Options, Weighted-Average Remaining Contractual Term [Abstract]",
        "terseLabel": "Weighted Average Remaining Contractual Term"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract",
     "nsuri": "http://annovisbio.com/20211231",
     "presentation": [
      "http://annovisbio.com/role/DisclosureStockBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "anvs_ShareBasedPaymentArrangementVestingPeriodEqualQuarterlyInstallmentsOverTwoYearsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Vesting period of equal quarterly installments over two years for award under share-based payment arrangement.",
        "label": "Vests in equal Quarterly installments over two years"
       }
      }
     },
     "localname": "ShareBasedPaymentArrangementVestingPeriodEqualQuarterlyInstallmentsOverTwoYearsMember",
     "nsuri": "http://annovisbio.com/20211231",
     "presentation": [
      "http://annovisbio.com/role/DisclosureStockBasedCompensationAdditionalDisclosuresDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "anvs_ShareBasedPaymentArrangementVestingPeriodImmediateVestingMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Immediate vesting of awards under share-based payment arrangement.",
        "label": "Immediate Vesting"
       }
      }
     },
     "localname": "ShareBasedPaymentArrangementVestingPeriodImmediateVestingMember",
     "nsuri": "http://annovisbio.com/20211231",
     "presentation": [
      "http://annovisbio.com/role/DisclosureStockBasedCompensationAdditionalDisclosuresDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "anvs_ShareBasedPaymentArrangementVestingPeriodOneYearMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "One year vesting period of award under share-based payment arrangement.",
        "label": "Vests one year from grant date"
       }
      }
     },
     "localname": "ShareBasedPaymentArrangementVestingPeriodOneYearMember",
     "nsuri": "http://annovisbio.com/20211231",
     "presentation": [
      "http://annovisbio.com/role/DisclosureStockBasedCompensationAdditionalDisclosuresDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "anvs_ShareBasedPaymentArrangementVestingPeriodTwoYearsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two year vesting period of award under share-based payment arrangement.",
        "label": "Vests two years from grant date"
       }
      }
     },
     "localname": "ShareBasedPaymentArrangementVestingPeriodTwoYearsMember",
     "nsuri": "http://annovisbio.com/20211231",
     "presentation": [
      "http://annovisbio.com/role/DisclosureStockBasedCompensationAdditionalDisclosuresDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "anvs_StockIssuedDuringPeriodSharesConversionOfConvertibleNotes": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued during the period as a result of the conversion of convertible notes.",
        "label": "Stock Issued During Period, Shares, Conversion of Convertible Notes",
        "terseLabel": "Conversion of convertible promissory notes, including embedded derivative, to common stock upon completion of initial public offering, shares",
        "verboseLabel": "Number of common shares issued upon conversion of notes"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesConversionOfConvertibleNotes",
     "nsuri": "http://annovisbio.com/20211231",
     "presentation": [
      "http://annovisbio.com/role/DisclosureConvertiblePromissoryNotesDetails",
      "http://annovisbio.com/role/DisclosureNatureOfBusinessAndLiquidityDetails",
      "http://annovisbio.com/role/DisclosureRelatedPartyTransactionsDetails",
      "http://annovisbio.com/role/StatementStatementsOfChangesInStockholdersEquityDeficit"
     ],
     "xbrltype": "sharesItemType"
    },
    "anvs_StockIssuedDuringPeriodSharesConversionOfConvertibleSecuritiesPreferredStock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued during the period as a result of the conversion of convertible preferred stock.",
        "label": "Stock Issued During Period, Shares, Conversion Of Convertible Securities, Preferred Stock",
        "terseLabel": "Conversion of redeemable convertible preferred stock to common stock upon completion of initial public offering, shares",
        "verboseLabel": "Number of shares issued for the conversion of redeemable convertible preferred stock"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesConversionOfConvertibleSecuritiesPreferredStock",
     "nsuri": "http://annovisbio.com/20211231",
     "presentation": [
      "http://annovisbio.com/role/DisclosureNatureOfBusinessAndLiquidityDetails",
      "http://annovisbio.com/role/DisclosureRedeemableConvertiblePreferredStockAndStockholdersEquityCommonAndPreferredStockDetails",
      "http://annovisbio.com/role/StatementStatementsOfChangesInStockholdersEquityDeficit"
     ],
     "xbrltype": "sharesItemType"
    },
    "anvs_StockIssuedDuringPeriodSharesWarrantsExercised": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Shares of stock issued as a result of the exercise of warrants.",
        "label": "Stock Issued During Period, Shares, Warrants Exercised",
        "terseLabel": "Cashless exercise of warrants, shares",
        "verboseLabel": "Shares issued upon exercise of warrants"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesWarrantsExercised",
     "nsuri": "http://annovisbio.com/20211231",
     "presentation": [
      "http://annovisbio.com/role/DisclosureRedeemableConvertiblePreferredStockAndStockholdersEquityWarrantsDetails",
      "http://annovisbio.com/role/StatementStatementsOfChangesInStockholdersEquityDeficit"
     ],
     "xbrltype": "sharesItemType"
    },
    "anvs_StockIssuedDuringPeriodValueConversionOfConvertibleSecuritiesConvertiblePromissoryNotes": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The value of stock issued during the period upon the conversion of convertible promissory notes.",
        "label": "Stock Issued During Period, Value, Conversion Of Convertible Securities, Convertible Promissory Notes",
        "terseLabel": "Conversion of convertible promissory notes, including embedded derivative, to common stock upon completion of initial public offering"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueConversionOfConvertibleSecuritiesConvertiblePromissoryNotes",
     "nsuri": "http://annovisbio.com/20211231",
     "presentation": [
      "http://annovisbio.com/role/StatementStatementsOfChangesInStockholdersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "anvs_StockIssuedDuringPeriodValueConversionOfConvertibleSecuritiesPreferredStock": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The value of stock issued during the period upon the conversion of convertible preferred stock.",
        "label": "Stock Issued During Period, Value, Conversion Of Convertible Securities, Preferred Stock",
        "terseLabel": "Conversion of redeemable convertible preferred stock to common stock upon completion of initial public offering"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueConversionOfConvertibleSecuritiesPreferredStock",
     "nsuri": "http://annovisbio.com/20211231",
     "presentation": [
      "http://annovisbio.com/role/StatementStatementsOfChangesInStockholdersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "anvs_StockIssuedDuringPeriodValueWarrantsExercised": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of stock issued as a result of the exercise of warrants.",
        "label": "Stock Issued During Period, Value, Warrants Exercised",
        "terseLabel": "Cashless exercise of warrants"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueWarrantsExercised",
     "nsuri": "http://annovisbio.com/20211231",
     "presentation": [
      "http://annovisbio.com/role/StatementStatementsOfChangesInStockholdersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "anvs_TemporaryEquityConversionOfPreferredStockToCommonStock": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Conversion of redeemable convertible preferred stock to common stock.",
        "label": "Temporary Equity, Conversion of Preferred Stock to Common Stock",
        "negatedLabel": "Conversion of redeemable convertible preferred stock to common stock upon completion of initial public offering"
       }
      }
     },
     "localname": "TemporaryEquityConversionOfPreferredStockToCommonStock",
     "nsuri": "http://annovisbio.com/20211231",
     "presentation": [
      "http://annovisbio.com/role/StatementStatementsOfChangesInRedeemableConvertiblePreferredStock"
     ],
     "xbrltype": "monetaryItemType"
    },
    "anvs_TemporaryEquitySharesConversionOfPreferredStockToCommonStock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Conversion of redeemable convertible preferred stock to common stock, shares.",
        "label": "Temporary Equity, Shares, Conversion of Preferred Stock to Common Stock",
        "negatedLabel": "Conversion of redeemable convertible preferred stock to common stock upon completion of initial public offering, shares",
        "verboseLabel": "Conversion of redeemable convertible preferred stock to common stock, shares"
       }
      }
     },
     "localname": "TemporaryEquitySharesConversionOfPreferredStockToCommonStock",
     "nsuri": "http://annovisbio.com/20211231",
     "presentation": [
      "http://annovisbio.com/role/DisclosureRedeemableConvertiblePreferredStockAndStockholdersEquityCommonAndPreferredStockDetails",
      "http://annovisbio.com/role/StatementStatementsOfChangesInRedeemableConvertiblePreferredStock"
     ],
     "xbrltype": "sharesItemType"
    },
    "anvs_UnderwritersWarrantsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to Underwriters warrants.",
        "label": "Underwriters warrants"
       }
      }
     },
     "localname": "UnderwritersWarrantsMember",
     "nsuri": "http://annovisbio.com/20211231",
     "presentation": [
      "http://annovisbio.com/role/DisclosureNatureOfBusinessAndLiquidityDetails",
      "http://annovisbio.com/role/DisclosureRedeemableConvertiblePreferredStockAndStockholdersEquityWarrantsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "anvs_UnreimbursedEligibleCostsIncurredDuringPeriod": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of unreimbursed eligible costs incurred during the period.",
        "label": "Unreimbursed Eligible Costs Incurred During the Period",
        "terseLabel": "Unreimbursed, eligible costs incurred under the grant"
       }
      }
     },
     "localname": "UnreimbursedEligibleCostsIncurredDuringPeriod",
     "nsuri": "http://annovisbio.com/20211231",
     "presentation": [
      "http://annovisbio.com/role/DisclosureGrantIncomeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://annovisbio.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_AuditorFirmId": {
     "auth_ref": [
      "r399",
      "r400",
      "r401"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "PCAOB issued Audit Firm Identifier",
        "label": "Auditor Firm ID"
       }
      }
     },
     "localname": "AuditorFirmId",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://annovisbio.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "nonemptySequenceNumberItemType"
    },
    "dei_AuditorLocation": {
     "auth_ref": [
      "r399",
      "r400",
      "r401"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Location"
       }
      }
     },
     "localname": "AuditorLocation",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://annovisbio.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "internationalNameItemType"
    },
    "dei_AuditorName": {
     "auth_ref": [
      "r399",
      "r400",
      "r401"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Name"
       }
      }
     },
     "localname": "AuditorName",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://annovisbio.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "internationalNameItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://annovisbio.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Document and Entity Information"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "xbrltype": "stringItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://annovisbio.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentAnnualReport": {
     "auth_ref": [
      "r399",
      "r400",
      "r401"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an annual report.",
        "label": "Document Annual Report"
       }
      }
     },
     "localname": "DocumentAnnualReport",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://annovisbio.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://annovisbio.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://annovisbio.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://annovisbio.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentTransitionReport": {
     "auth_ref": [
      "r402"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a transition report.",
        "label": "Document Transition Report"
       }
      }
     },
     "localname": "DocumentTransitionReport",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://annovisbio.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://annovisbio.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://annovisbio.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://annovisbio.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://annovisbio.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://annovisbio.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r397"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://annovisbio.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
        "label": "Entity Common Stock, Shares Outstanding"
       }
      }
     },
     "localname": "EntityCommonStockSharesOutstanding",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://annovisbio.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "sharesItemType"
    },
    "dei_EntityCurrentReportingStatus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Current Reporting Status"
       }
      }
     },
     "localname": "EntityCurrentReportingStatus",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://annovisbio.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r397"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://annovisbio.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityExTransitionPeriod": {
     "auth_ref": [
      "r406"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.",
        "label": "Entity Ex Transition Period"
       }
      }
     },
     "localname": "EntityExTransitionPeriod",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://annovisbio.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://annovisbio.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r397"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://annovisbio.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://annovisbio.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInteractiveDataCurrent": {
     "auth_ref": [
      "r404"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
        "label": "Entity Interactive Data Current"
       }
      }
     },
     "localname": "EntityInteractiveDataCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://annovisbio.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityPublicFloat": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.",
        "label": "Entity Public Float"
       }
      }
     },
     "localname": "EntityPublicFloat",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://annovisbio.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "monetaryItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r397"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://annovisbio.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityShellCompany": {
     "auth_ref": [
      "r397"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
        "label": "Entity Shell Company"
       }
      }
     },
     "localname": "EntityShellCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://annovisbio.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntitySmallBusiness": {
     "auth_ref": [
      "r397"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).",
        "label": "Entity Small Business"
       }
      }
     },
     "localname": "EntitySmallBusiness",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://annovisbio.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r397"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://annovisbio.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_EntityVoluntaryFilers": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.",
        "label": "Entity Voluntary Filers"
       }
      }
     },
     "localname": "EntityVoluntaryFilers",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://annovisbio.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "auth_ref": [
      "r405"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.",
        "label": "Entity Well Known Seasoned Issuer"
       }
      }
     },
     "localname": "EntityWellKnownSeasonedIssuer",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://annovisbio.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_IcfrAuditorAttestationFlag": {
     "auth_ref": [
      "r399",
      "r400",
      "r401"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "ICFR Auditor Attestation Flag"
       }
      }
     },
     "localname": "IcfrAuditorAttestationFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://annovisbio.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://annovisbio.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r396"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://annovisbio.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r398"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://annovisbio.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://annovisbio.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "srt_DirectorMember": {
     "auth_ref": [
      "r129"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Directors"
       }
      }
     },
     "localname": "DirectorMember",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://annovisbio.com/role/DisclosureRelatedPartyTransactionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ExecutiveOfficerMember": {
     "auth_ref": [
      "r129"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Executive Officers"
       }
      }
     },
     "localname": "ExecutiveOfficerMember",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://annovisbio.com/role/DisclosureCommitmentsAndContingenciesEmploymentAgreementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_TitleOfIndividualAxis": {
     "auth_ref": [
      "r129",
      "r346"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of Individual [Axis]"
       }
      }
     },
     "localname": "TitleOfIndividualAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://annovisbio.com/role/DisclosureCommitmentsAndContingenciesEmploymentAgreementsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_TitleOfIndividualWithRelationshipToEntityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of Individual [Domain]"
       }
      }
     },
     "localname": "TitleOfIndividualWithRelationshipToEntityDomain",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://annovisbio.com/role/DisclosureCommitmentsAndContingenciesEmploymentAgreementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccountingPoliciesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Summary of Significant Accounting Policies"
       }
      }
     },
     "localname": "AccountingPoliciesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock": {
     "auth_ref": [
      "r25"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period.",
        "label": "Accounts Payable and Accrued Liabilities Disclosure [Text Block]",
        "terseLabel": "Accrued Expenses"
       }
      }
     },
     "localname": "AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://annovisbio.com/role/DisclosureAccruedExpenses"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_AccountsPayableCurrent": {
     "auth_ref": [
      "r24",
      "r352"
     ],
     "calculation": {
      "http://annovisbio.com/role/StatementBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accounts Payable, Current",
        "terseLabel": "Accounts payable"
       }
      }
     },
     "localname": "AccountsPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://annovisbio.com/role/StatementBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accrued Expenses"
       }
      }
     },
     "localname": "AccruedLiabilitiesAndOtherLiabilitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccruedProfessionalFeesCurrent": {
     "auth_ref": [
      "r9",
      "r10",
      "r27"
     ],
     "calculation": {
      "http://annovisbio.com/role/DisclosureAccruedExpensesDetails": {
       "order": 2.0,
       "parentTag": "anvs_AccruedLiabilitiesAndInterestAndEmployeeRelatedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Professional Fees, Current",
        "terseLabel": "Accrued professional and clinical fees"
       }
      }
     },
     "localname": "AccruedProfessionalFeesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://annovisbio.com/role/DisclosureAccruedExpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapital": {
     "auth_ref": [
      "r16",
      "r268",
      "r352"
     ],
     "calculation": {
      "http://annovisbio.com/role/StatementBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.",
        "label": "Additional Paid in Capital",
        "terseLabel": "Additional paid-in capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapital",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://annovisbio.com/role/StatementBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "auth_ref": [
      "r74",
      "r75",
      "r76",
      "r265",
      "r266",
      "r267",
      "r314"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.",
        "label": "Additional Paid-In Capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://annovisbio.com/role/StatementStatementsOfChangesInStockholdersEquityDeficit"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments, Noncash Items, to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Adjustments to reconcile net loss to net cash used in operating activities:"
       }
      }
     },
     "localname": "AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://annovisbio.com/role/StatementStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for option under share-based payment arrangement.",
        "label": "APIC, Share-based Payment Arrangement, Option, Increase for Cost Recognition",
        "terseLabel": "Stock based compensation expense"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://annovisbio.com/role/StatementStatementsOfChangesInStockholdersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AmortizationOfDebtDiscountPremium": {
     "auth_ref": [
      "r50",
      "r58",
      "r181",
      "r335"
     ],
     "calculation": {
      "http://annovisbio.com/role/StatementStatementsOfCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncash expense included in interest expense to amortize debt discount and premium associated with the related debt instruments. Excludes amortization of financing costs. Alternate captions include noncash interest expense.",
        "label": "Amortization of Debt Discount (Premium)",
        "terseLabel": "Amortization of debt discount"
       }
      }
     },
     "localname": "AmortizationOfDebtDiscountPremium",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://annovisbio.com/role/StatementStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AmortizationOfFinancingCosts": {
     "auth_ref": [
      "r47",
      "r58",
      "r181",
      "r337"
     ],
     "calculation": {
      "http://annovisbio.com/role/StatementStatementsOfCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization expense attributable to debt issuance costs.",
        "label": "Amortization of Debt Issuance Costs",
        "terseLabel": "Amortization of deferred financing fees"
       }
      }
     },
     "localname": "AmortizationOfFinancingCosts",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://annovisbio.com/role/StatementStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "auth_ref": [
      "r96"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount",
        "terseLabel": "Antidilutive securities excluded from computation of earnings per share"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://annovisbio.com/role/DisclosureNetLossPerSharePotentialSharesExcludedFromCalculationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": {
     "auth_ref": [
      "r96"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of antidilutive security.",
        "label": "Antidilutive Securities [Axis]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://annovisbio.com/role/DisclosureNetLossPerSharePotentialSharesExcludedFromCalculationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]",
        "terseLabel": "Net Loss Per Share"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://annovisbio.com/role/DisclosureNetLossPerSharePotentialSharesExcludedFromCalculationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesNameDomain": {
     "auth_ref": [
      "r96"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented.",
        "label": "Antidilutive Securities, Name [Domain]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://annovisbio.com/role/DisclosureNetLossPerSharePotentialSharesExcludedFromCalculationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ArrangementsAndNonarrangementTransactionsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]"
       }
      }
     },
     "localname": "ArrangementsAndNonarrangementTransactionsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://annovisbio.com/role/DisclosureGrantIncomeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_Assets": {
     "auth_ref": [
      "r69",
      "r115",
      "r118",
      "r124",
      "r131",
      "r146",
      "r147",
      "r148",
      "r149",
      "r150",
      "r151",
      "r152",
      "r153",
      "r154",
      "r155",
      "r156",
      "r305",
      "r309",
      "r326",
      "r350",
      "r352",
      "r374",
      "r382"
     ],
     "calculation": {
      "http://annovisbio.com/role/StatementBalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets",
        "totalLabel": "Total assets"
       }
      }
     },
     "localname": "Assets",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://annovisbio.com/role/StatementBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets [Abstract]",
        "terseLabel": "Assets"
       }
      }
     },
     "localname": "AssetsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://annovisbio.com/role/StatementBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsCurrent": {
     "auth_ref": [
      "r6",
      "r8",
      "r36",
      "r69",
      "r131",
      "r146",
      "r147",
      "r148",
      "r149",
      "r150",
      "r151",
      "r152",
      "r153",
      "r154",
      "r155",
      "r156",
      "r305",
      "r309",
      "r326",
      "r350",
      "r352"
     ],
     "calculation": {
      "http://annovisbio.com/role/StatementBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Current",
        "totalLabel": "Total current assets"
       }
      }
     },
     "localname": "AssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://annovisbio.com/role/StatementBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Current [Abstract]",
        "terseLabel": "Current assets:"
       }
      }
     },
     "localname": "AssetsCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://annovisbio.com/role/StatementBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AwardDateAxis": {
     "auth_ref": [
      "r238",
      "r263"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by date or year award under share-based payment arrangement is granted.",
        "label": "Award Date [Axis]"
       }
      }
     },
     "localname": "AwardDateAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://annovisbio.com/role/DisclosureStockBasedCompensationAdditionalDisclosuresDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AwardDateDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Date or year award under share-based payment arrangement is granted.",
        "label": "Award Date [Domain]"
       }
      }
     },
     "localname": "AwardDateDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://annovisbio.com/role/DisclosureStockBasedCompensationAdditionalDisclosuresDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AwardTypeAxis": {
     "auth_ref": [
      "r238",
      "r263"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of award under share-based payment arrangement.",
        "label": "Award Type [Axis]"
       }
      }
     },
     "localname": "AwardTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://annovisbio.com/role/DisclosureStockBasedCompensationAdditionalDisclosuresDetails",
      "http://annovisbio.com/role/DisclosureStockBasedCompensationSummaryOfPlansDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BasisOfAccounting": {
     "auth_ref": [
      "r73"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).",
        "label": "Basis of Accounting [Text Block]",
        "terseLabel": "Basis of Presentation"
       }
      }
     },
     "localname": "BasisOfAccounting",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://annovisbio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "auth_ref": [
      "r3",
      "r21",
      "r60"
     ],
     "calculation": {
      "http://annovisbio.com/role/StatementBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.",
        "label": "Cash and Cash Equivalents, at Carrying Value",
        "terseLabel": "Cash and cash equivalents",
        "verboseLabel": "Cash and cash equivalents, Carrying Value"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://annovisbio.com/role/DisclosureFairValueMeasurementsDetails",
      "http://annovisbio.com/role/StatementBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsFairValueDisclosure": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash and Cash Equivalents, Fair Value Disclosure",
        "terseLabel": "Cash and cash equivalents, Fair Value"
       }
      }
     },
     "localname": "CashAndCashEquivalentsFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://annovisbio.com/role/DisclosureFairValueMeasurementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsPolicyTextBlock": {
     "auth_ref": [
      "r11",
      "r61"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.",
        "label": "Cash and Cash Equivalents, Policy [Policy Text Block]",
        "terseLabel": "Cash and Cash Equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://annovisbio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "auth_ref": [
      "r54",
      "r60",
      "r63"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents",
        "periodEndLabel": "Cash and cash equivalents, end of year",
        "periodStartLabel": "Cash and cash equivalents, beginning of year"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://annovisbio.com/role/StatementStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "auth_ref": [
      "r54",
      "r327"
     ],
     "calculation": {
      "http://annovisbio.com/role/StatementStatementsOfCashFlows": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect",
        "totalLabel": "Net increase in cash and cash equivalents"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://annovisbio.com/role/StatementStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ClassOfStockDomain": {
     "auth_ref": [
      "r66",
      "r69",
      "r89",
      "r90",
      "r91",
      "r93",
      "r95",
      "r103",
      "r104",
      "r105",
      "r131",
      "r146",
      "r150",
      "r151",
      "r152",
      "r155",
      "r156",
      "r195",
      "r196",
      "r200",
      "r204",
      "r326",
      "r403"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock.",
        "label": "Class of Stock [Domain]"
       }
      }
     },
     "localname": "ClassOfStockDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://annovisbio.com/role/DisclosureRedeemableConvertiblePreferredStockAndStockholdersEquityCommonAndPreferredStockDetails",
      "http://annovisbio.com/role/StatementStatementsOfChangesInRedeemableConvertiblePreferredStock"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ClassOfStockLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Class of Stock [Line Items]",
        "terseLabel": "Redeemable Convertible Preferred Stock and Stockholders' Equity"
       }
      }
     },
     "localname": "ClassOfStockLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://annovisbio.com/role/DisclosureNatureOfBusinessAndLiquidityDetails",
      "http://annovisbio.com/role/DisclosureRedeemableConvertiblePreferredStockAndStockholdersEquityCommonAndPreferredStockDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ClassOfWarrantOrRightAxis": {
     "auth_ref": [
      "r219",
      "r236"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of warrant or right issued.",
        "label": "Class of Warrant or Right [Axis]"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://annovisbio.com/role/DisclosureNatureOfBusinessAndLiquidityDetails",
      "http://annovisbio.com/role/DisclosureRedeemableConvertiblePreferredStockAndStockholdersEquityWarrantsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ClassOfWarrantOrRightDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the class or type of warrant or right outstanding. Warrants and rights represent derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months.",
        "label": "Class of Warrant or Right [Domain]"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://annovisbio.com/role/DisclosureNatureOfBusinessAndLiquidityDetails",
      "http://annovisbio.com/role/DisclosureRedeemableConvertiblePreferredStockAndStockholdersEquityWarrantsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1": {
     "auth_ref": [
      "r212"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Exercise price per share or per unit of warrants or rights outstanding.",
        "label": "Class of Warrant or Right, Exercise Price of Warrants or Rights",
        "verboseLabel": "Exercise price"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://annovisbio.com/role/DisclosureNatureOfBusinessAndLiquidityDetails",
      "http://annovisbio.com/role/DisclosureRedeemableConvertiblePreferredStockAndStockholdersEquityWarrantsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ClassOfWarrantOrRightLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Class of Warrant or Right [Line Items]",
        "terseLabel": "Warrants"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://annovisbio.com/role/DisclosureRedeemableConvertiblePreferredStockAndStockholdersEquityWarrantsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights": {
     "auth_ref": [
      "r212"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.",
        "label": "Class of Warrant or Right, Number of Securities Called by Warrants or Rights",
        "terseLabel": "Number of warrants issued"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://annovisbio.com/role/DisclosureNatureOfBusinessAndLiquidityDetails",
      "http://annovisbio.com/role/DisclosureRedeemableConvertiblePreferredStockAndStockholdersEquityWarrantsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ClassOfWarrantOrRightOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of warrants or rights outstanding.",
        "label": "Class of Warrant or Right, Outstanding",
        "terseLabel": "Warrants outstanding"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://annovisbio.com/role/DisclosureRedeemableConvertiblePreferredStockAndStockholdersEquityWarrantsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ClassOfWarrantOrRightTable": {
     "auth_ref": [
      "r219",
      "r236"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure for warrants or rights issued, which includes the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable.",
        "label": "Class of Warrant or Right [Table]"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://annovisbio.com/role/DisclosureRedeemableConvertiblePreferredStockAndStockholdersEquityWarrantsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]",
        "verboseLabel": "Grant Income"
       }
      }
     },
     "localname": "CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://annovisbio.com/role/DisclosureGrantIncomeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommitmentsAndContingencies": {
     "auth_ref": [
      "r31",
      "r142",
      "r376",
      "r385"
     ],
     "calculation": {
      "http://annovisbio.com/role/StatementBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.",
        "label": "Commitments and Contingencies.",
        "terseLabel": "Commitments and contingencies (Note 8)"
       }
      }
     },
     "localname": "CommitmentsAndContingencies",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://annovisbio.com/role/StatementBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "auth_ref": [
      "r139",
      "r140",
      "r141",
      "r144",
      "r394"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for commitments and contingencies.",
        "label": "Commitments and Contingencies Disclosure [Text Block]",
        "terseLabel": "Commitments and Contingencies"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://annovisbio.com/role/DisclosureCommitmentsAndContingencies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CommonStockMember": {
     "auth_ref": [
      "r74",
      "r75",
      "r314"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock that is subordinate to all other stock of the issuer.",
        "label": "Common Stock"
       }
      }
     },
     "localname": "CommonStockMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://annovisbio.com/role/DisclosureConvertiblePromissoryNotesDetails",
      "http://annovisbio.com/role/DisclosureIncomeTaxesAdditionalDisclosuresDetails",
      "http://annovisbio.com/role/DisclosureNatureOfBusinessAndLiquidityDetails",
      "http://annovisbio.com/role/DisclosureRedeemableConvertiblePreferredStockAndStockholdersEquityCommonAndPreferredStockDetails",
      "http://annovisbio.com/role/DisclosureRelatedPartyTransactionsDetails",
      "http://annovisbio.com/role/StatementStatementsOfChangesInStockholdersEquityDeficit"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r15"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of common stock.",
        "label": "Common Stock, Par or Stated Value Per Share",
        "terseLabel": "Common stock, par value (dollars per share)"
       }
      }
     },
     "localname": "CommonStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://annovisbio.com/role/DisclosureRedeemableConvertiblePreferredStockAndStockholdersEquityCommonAndPreferredStockDetails",
      "http://annovisbio.com/role/StatementBalanceSheetsParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "auth_ref": [
      "r15"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.",
        "label": "Common Stock, Shares Authorized",
        "terseLabel": "Common stock, shares authorized",
        "verboseLabel": "Number of common shares authorized"
       }
      }
     },
     "localname": "CommonStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://annovisbio.com/role/DisclosureRedeemableConvertiblePreferredStockAndStockholdersEquityCommonAndPreferredStockDetails",
      "http://annovisbio.com/role/StatementBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesIssued": {
     "auth_ref": [
      "r15"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.",
        "label": "Common Stock, Shares, Issued",
        "terseLabel": "Common stock, shares issued"
       }
      }
     },
     "localname": "CommonStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://annovisbio.com/role/StatementBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "auth_ref": [
      "r15",
      "r211"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.",
        "label": "Common Stock, Shares, Outstanding",
        "terseLabel": "Common stock, shares outstanding"
       }
      }
     },
     "localname": "CommonStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://annovisbio.com/role/StatementBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockValue": {
     "auth_ref": [
      "r15",
      "r352"
     ],
     "calculation": {
      "http://annovisbio.com/role/StatementBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Common Stock, Value, Issued",
        "verboseLabel": "Common stock - $0.0001 par value, 35,000,000 shares authorized and 8,100,570 and 6,891,608 shares issued and outstanding at December 31, 2021 and 2020, respectively"
       }
      }
     },
     "localname": "CommonStockValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://annovisbio.com/role/StatementBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ConvertibleDebtMember": {
     "auth_ref": [
      "r157",
      "r158",
      "r159",
      "r161",
      "r171",
      "r172",
      "r173",
      "r177",
      "r178",
      "r179",
      "r180",
      "r181",
      "r187",
      "r188",
      "r189",
      "r190"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Borrowing which can be exchanged for a specified number of another security at the option of the issuer or the holder, for example, but not limited to, the entity's common stock.",
        "label": "Convertible promissory notes"
       }
      }
     },
     "localname": "ConvertibleDebtMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://annovisbio.com/role/DisclosureConvertiblePromissoryNotesDetails",
      "http://annovisbio.com/role/DisclosureRelatedPartyTransactionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Convertible Promissory Notes."
       }
      }
     },
     "localname": "DebtDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtDisclosureTextBlock": {
     "auth_ref": [
      "r65",
      "r164",
      "r165",
      "r166",
      "r167",
      "r168",
      "r169",
      "r170",
      "r175",
      "r182",
      "r183",
      "r185",
      "r191"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.",
        "label": "Debt Disclosure [Text Block]",
        "terseLabel": "Convertible Promissory Notes"
       }
      }
     },
     "localname": "DebtDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://annovisbio.com/role/DisclosureConvertiblePromissoryNotes"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DebtInstrumentFaceAmount": {
     "auth_ref": [
      "r158",
      "r187",
      "r188",
      "r336",
      "r338",
      "r339"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face (par) amount of debt instrument at time of issuance.",
        "label": "Debt Instrument, Face Amount",
        "terseLabel": "Aggregate principal amount"
       }
      }
     },
     "localname": "DebtInstrumentFaceAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://annovisbio.com/role/DisclosureConvertiblePromissoryNotesDetails",
      "http://annovisbio.com/role/DisclosureRelatedPartyTransactionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentInterestRateEffectivePercentage": {
     "auth_ref": [
      "r29",
      "r186",
      "r336",
      "r338"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Effective interest rate for the funds borrowed under the debt agreement considering interest compounding and original issue discount or premium.",
        "label": "Debt Instrument, Interest Rate, Effective Percentage",
        "terseLabel": "Effective interest rate"
       }
      }
     },
     "localname": "DebtInstrumentInterestRateEffectivePercentage",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://annovisbio.com/role/DisclosureConvertiblePromissoryNotesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DebtInstrumentInterestRateStatedPercentage": {
     "auth_ref": [
      "r29",
      "r159"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contractual interest rate for funds borrowed, under the debt agreement.",
        "label": "Debt Instrument, Interest Rate, Stated Percentage",
        "terseLabel": "Stated interest rate"
       }
      }
     },
     "localname": "DebtInstrumentInterestRateStatedPercentage",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://annovisbio.com/role/DisclosureConvertiblePromissoryNotesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DebtInstrumentLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Debt Instrument [Line Items]",
        "terseLabel": "Convertible Promissory Notes"
       }
      }
     },
     "localname": "DebtInstrumentLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://annovisbio.com/role/DisclosureConvertiblePromissoryNotesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentTable": {
     "auth_ref": [
      "r30",
      "r68",
      "r72",
      "r158",
      "r159",
      "r160",
      "r161",
      "r162",
      "r163",
      "r165",
      "r171",
      "r172",
      "r173",
      "r174",
      "r176",
      "r177",
      "r178",
      "r179",
      "r180",
      "r181",
      "r184",
      "r187",
      "r188",
      "r189",
      "r190",
      "r212",
      "r215",
      "r216",
      "r217",
      "r335",
      "r336",
      "r338",
      "r339",
      "r381"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A table or schedule providing information pertaining to long-term debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.",
        "label": "Schedule of Long-term Debt Instruments [Table]"
       }
      }
     },
     "localname": "DebtInstrumentTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://annovisbio.com/role/DisclosureConvertiblePromissoryNotesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentUnamortizedDiscount": {
     "auth_ref": [
      "r171",
      "r335",
      "r339"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after accumulated amortization, of debt discount.",
        "label": "Debt Instrument, Unamortized Discount",
        "terseLabel": "Debt discount"
       }
      }
     },
     "localname": "DebtInstrumentUnamortizedDiscount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://annovisbio.com/role/DisclosureConvertiblePromissoryNotesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Deferred Compensation Arrangement with Individual, Excluding Share-based Payments and Postretirement Benefits [Line Items]"
       }
      }
     },
     "localname": "DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://annovisbio.com/role/DisclosureCommitmentsAndContingenciesEmploymentAgreementsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DeferredCompensationArrangementsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Compensation Arrangements [Abstract]",
        "terseLabel": "Employment Agreements"
       }
      }
     },
     "localname": "DeferredCompensationArrangementsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://annovisbio.com/role/DisclosureCommitmentsAndContingenciesEmploymentAgreementsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Prepaid Expenses and Other Current Assets"
       }
      }
     },
     "localname": "DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock": {
     "auth_ref": [
      "r23"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the amounts paid in advance for capitalized costs that will be expensed with the passage of time or the occurrence of a triggering event, and will be charged against earnings within one year or the normal operating cycle, if longer; the aggregate carrying amount of current assets, not separately presented elsewhere in the balance sheet; and other deferred costs.",
        "label": "Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Table Text Block]",
        "terseLabel": "Schedule of prepaid expenses and other current assets"
       }
      }
     },
     "localname": "DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://annovisbio.com/role/DisclosurePrepaidExpensesAndOtherCurrentAssetsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DeferredFinanceCostsGross": {
     "auth_ref": [
      "r337"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before accumulated amortization, of debt issuance costs. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs.",
        "label": "Debt Issuance Costs, Gross",
        "terseLabel": "Debt issuance costs incurred"
       }
      }
     },
     "localname": "DeferredFinanceCostsGross",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://annovisbio.com/role/DisclosureConvertiblePromissoryNotesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsGross": {
     "auth_ref": [
      "r284"
     ],
     "calculation": {
      "http://annovisbio.com/role/DisclosureIncomeTaxesDeferredTaxesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.",
        "label": "Deferred Tax Assets, Gross",
        "totalLabel": "Total deferred tax assets"
       }
      }
     },
     "localname": "DeferredTaxAssetsGross",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://annovisbio.com/role/DisclosureIncomeTaxesDeferredTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsNet": {
     "auth_ref": [
      "r286"
     ],
     "calculation": {
      "http://annovisbio.com/role/DisclosureIncomeTaxesDeferredTaxesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.",
        "label": "Deferred Tax Assets, Net of Valuation Allowance",
        "totalLabel": "Net deferred taxes"
       }
      }
     },
     "localname": "DeferredTaxAssetsNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://annovisbio.com/role/DisclosureIncomeTaxesDeferredTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsNetOfValuationAllowanceAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Assets, Net of Valuation Allowance [Abstract]",
        "terseLabel": "Deferred taxes"
       }
      }
     },
     "localname": "DeferredTaxAssetsNetOfValuationAllowanceAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://annovisbio.com/role/DisclosureIncomeTaxesDeferredTaxesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DeferredTaxAssetsOperatingLossCarryforwards": {
     "auth_ref": [
      "r291",
      "r292"
     ],
     "calculation": {
      "http://annovisbio.com/role/DisclosureIncomeTaxesDeferredTaxesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.",
        "label": "Deferred Tax Assets, Operating Loss Carryforwards",
        "terseLabel": "Net operating loss carryforwards"
       }
      }
     },
     "localname": "DeferredTaxAssetsOperatingLossCarryforwards",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://annovisbio.com/role/DisclosureIncomeTaxesDeferredTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch": {
     "auth_ref": [
      "r289",
      "r291",
      "r292"
     ],
     "calculation": {
      "http://annovisbio.com/role/DisclosureIncomeTaxesDeferredTaxesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible research tax credit carryforwards.",
        "label": "Deferred Tax Assets, Tax Credit Carryforwards, Research",
        "terseLabel": "Research and development tax credit carryforwards"
       }
      }
     },
     "localname": "DeferredTaxAssetsTaxCreditCarryforwardsResearch",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://annovisbio.com/role/DisclosureIncomeTaxesDeferredTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost": {
     "auth_ref": [
      "r291",
      "r292"
     ],
     "calculation": {
      "http://annovisbio.com/role/DisclosureIncomeTaxesDeferredTaxesDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation.",
        "label": "Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost",
        "terseLabel": "Share-based compensation"
       }
      }
     },
     "localname": "DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://annovisbio.com/role/DisclosureIncomeTaxesDeferredTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsValuationAllowance": {
     "auth_ref": [
      "r285"
     ],
     "calculation": {
      "http://annovisbio.com/role/DisclosureIncomeTaxesDeferredTaxesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.",
        "label": "Deferred Tax Assets, Valuation Allowance",
        "negatedLabel": "Less valuation allowance"
       }
      }
     },
     "localname": "DeferredTaxAssetsValuationAllowance",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://annovisbio.com/role/DisclosureIncomeTaxesDeferredTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": {
     "auth_ref": [
      "r271"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for share-based payment arrangement.",
        "label": "Share-based Payment Arrangement [Text Block]",
        "terseLabel": "Stock-Based Compensation"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://annovisbio.com/role/DisclosureStockBasedCompensation"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock-Based Compensation"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DomesticCountryMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Designated tax department of the government that is entitled to levy and collect income taxes from the entity in its country of domicile.",
        "label": "U.S. federal"
       }
      }
     },
     "localname": "DomesticCountryMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://annovisbio.com/role/DisclosureIncomeTaxesAdditionalDisclosuresDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EarningsPerShareAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Loss Per Share"
       }
      }
     },
     "localname": "EarningsPerShareAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareBasic": {
     "auth_ref": [
      "r45",
      "r79",
      "r80",
      "r81",
      "r82",
      "r83",
      "r87",
      "r89",
      "r93",
      "r94",
      "r95",
      "r99",
      "r100",
      "r315",
      "r316",
      "r379",
      "r387"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.",
        "label": "Earnings Per Share, Basic",
        "terseLabel": "Basic loss per common share",
        "verboseLabel": "Net loss per share, basic"
       }
      }
     },
     "localname": "EarningsPerShareBasic",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://annovisbio.com/role/DisclosureNetLossPerShareBasicAndDilutedNetLossPerShareDetails",
      "http://annovisbio.com/role/StatementStatementsOfOperations"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareDiluted": {
     "auth_ref": [
      "r45",
      "r79",
      "r80",
      "r81",
      "r82",
      "r83",
      "r89",
      "r93",
      "r94",
      "r95",
      "r99",
      "r100",
      "r315",
      "r316",
      "r379",
      "r387"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.",
        "label": "Earnings Per Share, Diluted",
        "terseLabel": "Diluted loss per common share",
        "verboseLabel": "Net loss per share, diluted"
       }
      }
     },
     "localname": "EarningsPerShareDiluted",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://annovisbio.com/role/DisclosureNetLossPerShareBasicAndDilutedNetLossPerShareDetails",
      "http://annovisbio.com/role/StatementStatementsOfOperations"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerSharePolicyTextBlock": {
     "auth_ref": [
      "r96",
      "r97"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.",
        "label": "Earnings Per Share, Policy [Policy Text Block]",
        "terseLabel": "Basic and Diluted Net Income (Loss) per Share"
       }
      }
     },
     "localname": "EarningsPerSharePolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://annovisbio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EarningsPerShareTextBlock": {
     "auth_ref": [
      "r96",
      "r97",
      "r98",
      "r101"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for earnings per share.",
        "label": "Earnings Per Share [Text Block]",
        "terseLabel": "Net Loss Per Share"
       }
      }
     },
     "localname": "EarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://annovisbio.com/role/DisclosureNetLossPerShare"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateContinuingOperations": {
     "auth_ref": [
      "r278"
     ],
     "calculation": {
      "http://annovisbio.com/role/DisclosureIncomeTaxesReconciliationOfIncomeTaxProvisionBenefitDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "Effective Income Tax Rate Reconciliation, Percent",
        "totalLabel": "Effective income tax rate"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateContinuingOperations",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://annovisbio.com/role/DisclosureIncomeTaxesReconciliationOfIncomeTaxProvisionBenefitDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective Income Tax Rate Reconciliation, Percent [Abstract]",
        "terseLabel": "Reconciliation of income tax benefit computed at the statutory federal income tax rate to income taxes as reflected in the financial statements"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://annovisbio.com/role/DisclosureIncomeTaxesReconciliationOfIncomeTaxProvisionBenefitDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate": {
     "auth_ref": [
      "r71",
      "r278",
      "r298"
     ],
     "calculation": {
      "http://annovisbio.com/role/DisclosureIncomeTaxesReconciliationOfIncomeTaxProvisionBenefitDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of domestic federal statutory tax rate applicable to pretax income (loss).",
        "label": "Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent",
        "terseLabel": "Federal income tax benefits at statutory rate"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://annovisbio.com/role/DisclosureIncomeTaxesReconciliationOfIncomeTaxProvisionBenefitDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance": {
     "auth_ref": [
      "r278",
      "r298"
     ],
     "calculation": {
      "http://annovisbio.com/role/DisclosureIncomeTaxesReconciliationOfIncomeTaxProvisionBenefitDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets.",
        "label": "Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent",
        "terseLabel": "Change in valuation allowance"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://annovisbio.com/role/DisclosureIncomeTaxesReconciliationOfIncomeTaxProvisionBenefitDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense": {
     "auth_ref": [
      "r278",
      "r298"
     ],
     "calculation": {
      "http://annovisbio.com/role/DisclosureIncomeTaxesReconciliationOfIncomeTaxProvisionBenefitDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to nondeductible expenses.",
        "label": "Effective Income Tax Rate Reconciliation, Nondeductible Expense, Percent",
        "terseLabel": "Permanent differences"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationNondeductibleExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://annovisbio.com/role/DisclosureIncomeTaxesReconciliationOfIncomeTaxProvisionBenefitDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment": {
     "auth_ref": [
      "r278",
      "r298"
     ],
     "calculation": {
      "http://annovisbio.com/role/DisclosureIncomeTaxesReconciliationOfIncomeTaxProvisionBenefitDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to research and development expense.",
        "label": "Effective Income Tax Rate Reconciliation, Nondeductible Expense, Research and Development, Percent",
        "terseLabel": "Research and development credit"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://annovisbio.com/role/DisclosureIncomeTaxesReconciliationOfIncomeTaxProvisionBenefitDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost": {
     "auth_ref": [
      "r278",
      "r298"
     ],
     "calculation": {
      "http://annovisbio.com/role/DisclosureIncomeTaxesReconciliationOfIncomeTaxProvisionBenefitDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to nondeductible expense for share-based payment arrangement.",
        "label": "Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-based Payment Arrangement, Percent",
        "terseLabel": "Stock-based compensation"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://annovisbio.com/role/DisclosureIncomeTaxesReconciliationOfIncomeTaxProvisionBenefitDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes": {
     "auth_ref": [
      "r278",
      "r298"
     ],
     "calculation": {
      "http://annovisbio.com/role/DisclosureIncomeTaxesReconciliationOfIncomeTaxProvisionBenefitDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit).",
        "label": "Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Percent",
        "terseLabel": "State and local tax, net of federal benefit"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://annovisbio.com/role/DisclosureIncomeTaxesReconciliationOfIncomeTaxProvisionBenefitDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EmployeeRelatedLiabilitiesCurrent": {
     "auth_ref": [
      "r27"
     ],
     "calculation": {
      "http://annovisbio.com/role/DisclosureAccruedExpensesDetails": {
       "order": 1.0,
       "parentTag": "anvs_AccruedLiabilitiesAndInterestAndEmployeeRelatedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Employee-related Liabilities, Current",
        "terseLabel": "Payroll and related benefits"
       }
      }
     },
     "localname": "EmployeeRelatedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://annovisbio.com/role/DisclosureAccruedExpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": {
     "auth_ref": [
      "r262"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition",
        "terseLabel": "Weighted-average recognition period"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://annovisbio.com/role/DisclosureStockBasedCompensationAdditionalDisclosuresDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions": {
     "auth_ref": [
      "r262"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cost to be recognized for option under share-based payment arrangement.",
        "label": "Share-based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount",
        "terseLabel": "Unrecognized compensation expense"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://annovisbio.com/role/DisclosureStockBasedCompensationAdditionalDisclosuresDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeStockOptionMember": {
     "auth_ref": [
      "r260"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time.",
        "label": "Stock Options"
       }
      }
     },
     "localname": "EmployeeStockOptionMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://annovisbio.com/role/DisclosureNetLossPerSharePotentialSharesExcludedFromCalculationDetails",
      "http://annovisbio.com/role/DisclosureStockBasedCompensationAdditionalDisclosuresDetails",
      "http://annovisbio.com/role/DisclosureStockBasedCompensationSummaryOfPlansDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquityComponentDomain": {
     "auth_ref": [
      "r0",
      "r40",
      "r41",
      "r42",
      "r74",
      "r75",
      "r76",
      "r78",
      "r84",
      "r86",
      "r102",
      "r132",
      "r211",
      "r218",
      "r265",
      "r266",
      "r267",
      "r294",
      "r295",
      "r314",
      "r328",
      "r329",
      "r330",
      "r331",
      "r332",
      "r333",
      "r389",
      "r390",
      "r391",
      "r407"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.",
        "label": "Equity Component [Domain]"
       }
      }
     },
     "localname": "EquityComponentDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://annovisbio.com/role/DisclosureConvertiblePromissoryNotesDetails",
      "http://annovisbio.com/role/DisclosureIncomeTaxesAdditionalDisclosuresDetails",
      "http://annovisbio.com/role/DisclosureNatureOfBusinessAndLiquidityDetails",
      "http://annovisbio.com/role/DisclosureRedeemableConvertiblePreferredStockAndStockholdersEquityCommonAndPreferredStockDetails",
      "http://annovisbio.com/role/DisclosureRelatedPartyTransactionsDetails",
      "http://annovisbio.com/role/StatementStatementsOfChangesInStockholdersEquityDeficit"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Fair Value Measurement Inputs and Valuation Techniques [Line Items]",
        "terseLabel": "Fair Value Measurements"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://annovisbio.com/role/DisclosureFairValueMeasurementsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable": {
     "auth_ref": [
      "r319"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about input and valuation technique used to measure fair value and change in valuation approach and technique for each separate class of asset and liability measured on recurring and nonrecurring basis.",
        "label": "Fair Value Measurement Inputs and Valuation Techniques [Table]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://annovisbio.com/role/DisclosureFairValueMeasurementsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "auth_ref": [
      "r173",
      "r187",
      "r188",
      "r225",
      "r226",
      "r227",
      "r228",
      "r229",
      "r230",
      "r231",
      "r233",
      "r318",
      "r356",
      "r357",
      "r358"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.",
        "label": "Fair Value Hierarchy and NAV [Axis]"
       }
      }
     },
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://annovisbio.com/role/DisclosureFairValueMeasurementsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByMeasurementFrequencyAxis": {
     "auth_ref": [
      "r317",
      "r318",
      "r320",
      "r321",
      "r323"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by measurement frequency.",
        "label": "Measurement Frequency [Axis]"
       }
      }
     },
     "localname": "FairValueByMeasurementFrequencyAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://annovisbio.com/role/DisclosureFairValueMeasurementsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Measurements"
       }
      }
     },
     "localname": "FairValueDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresTextBlock": {
     "auth_ref": [
      "r322"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.",
        "label": "Fair Value Disclosures [Text Block]",
        "terseLabel": "Fair Value Measurements"
       }
      }
     },
     "localname": "FairValueDisclosuresTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://annovisbio.com/role/DisclosureFairValueMeasurements"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueInputsLevel1Member": {
     "auth_ref": [
      "r173",
      "r225",
      "r226",
      "r231",
      "r233",
      "r318",
      "r356"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.",
        "label": "Level 1"
       }
      }
     },
     "localname": "FairValueInputsLevel1Member",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://annovisbio.com/role/DisclosureFairValueMeasurementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementFrequencyDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement frequency.",
        "label": "Measurement Frequency [Domain]"
       }
      }
     },
     "localname": "FairValueMeasurementFrequencyDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://annovisbio.com/role/DisclosureFairValueMeasurementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "auth_ref": [
      "r173",
      "r187",
      "r188",
      "r225",
      "r226",
      "r227",
      "r228",
      "r229",
      "r230",
      "r231",
      "r233",
      "r356",
      "r357",
      "r358"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.",
        "label": "Fair Value Hierarchy and NAV [Domain]"
       }
      }
     },
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://annovisbio.com/role/DisclosureFairValueMeasurementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementsRecurringMember": {
     "auth_ref": [
      "r322",
      "r323"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value.",
        "label": "Recurring"
       }
      }
     },
     "localname": "FairValueMeasurementsRecurringMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://annovisbio.com/role/DisclosureFairValueMeasurementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueOfFinancialInstrumentsPolicy": {
     "auth_ref": [
      "r324",
      "r325"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for determining the fair value of financial instruments.",
        "label": "Fair Value of Financial Instruments, Policy [Policy Text Block]",
        "terseLabel": "Fair Value of Financial Instruments"
       }
      }
     },
     "localname": "FairValueOfFinancialInstrumentsPolicy",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://annovisbio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperations": {
     "auth_ref": [
      "r70",
      "r277"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current and deferred federal income tax expense (benefit) attributable to income (loss) from continuing operations.",
        "label": "Federal Income Tax Expense (Benefit), Continuing Operations",
        "terseLabel": "Federal provision (benefit) for income taxes"
       }
      }
     },
     "localname": "FederalIncomeTaxExpenseBenefitContinuingOperations",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://annovisbio.com/role/DisclosureIncomeTaxesReconciliationOfIncomeTaxProvisionBenefitDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GeneralAndAdministrativeExpense": {
     "auth_ref": [
      "r48"
     ],
     "calculation": {
      "http://annovisbio.com/role/StatementStatementsOfOperations": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.",
        "label": "General and Administrative Expense",
        "terseLabel": "General and administrative"
       }
      }
     },
     "localname": "GeneralAndAdministrativeExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://annovisbio.com/role/StatementStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GeneralAndAdministrativeExpenseMember": {
     "auth_ref": [
      "r46"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing general and administrative expense.",
        "label": "General and administrative"
       }
      }
     },
     "localname": "GeneralAndAdministrativeExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://annovisbio.com/role/DisclosureStockBasedCompensationShareBasedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_GranteeStatusAxis": {
     "auth_ref": [
      "r234",
      "r235",
      "r260"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by status of recipient to whom award is granted.",
        "label": "Grantee Status [Axis]"
       }
      }
     },
     "localname": "GranteeStatusAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://annovisbio.com/role/DisclosureStockBasedCompensationAdditionalDisclosuresDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_GranteeStatusDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Status of recipient to whom award is granted.",
        "label": "Grantee Status [Domain]"
       }
      }
     },
     "localname": "GranteeStatusDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://annovisbio.com/role/DisclosureStockBasedCompensationAdditionalDisclosuresDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_GrantsReceivableCurrent": {
     "auth_ref": [
      "r34"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount as of the balance sheet date of amounts due under the terms of governmental, corporate, or foundation grants. For classified balance sheets, represents the current amount receivable, that is amounts expected to be collected within one year or the normal operating cycle, if longer.",
        "label": "Grants Receivable, Current",
        "terseLabel": "Grant receivable"
       }
      }
     },
     "localname": "GrantsReceivableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://annovisbio.com/role/DisclosureGrantIncomeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IPOMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "First sale of stock by a private company to the public.",
        "label": "IPO"
       }
      }
     },
     "localname": "IPOMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://annovisbio.com/role/DisclosureConvertiblePromissoryNotesDetails",
      "http://annovisbio.com/role/DisclosureNatureOfBusinessAndLiquidityDetails",
      "http://annovisbio.com/role/DisclosureRedeemableConvertiblePreferredStockAndStockholdersEquityCommonAndPreferredStockDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": {
     "auth_ref": [
      "r43",
      "r115",
      "r117",
      "r120",
      "r123",
      "r125",
      "r373",
      "r377",
      "r380",
      "r388"
     ],
     "calculation": {
      "http://annovisbio.com/role/StatementStatementsOfOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.",
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest",
        "totalLabel": "Loss before income taxes"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://annovisbio.com/role/StatementStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeStatementAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statements of Operations"
       }
      }
     },
     "localname": "IncomeStatementAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "auth_ref": [
      "r137",
      "r138"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by location in the income statement.",
        "label": "Income Statement Location [Axis]"
       }
      }
     },
     "localname": "IncomeStatementLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://annovisbio.com/role/DisclosureStockBasedCompensationShareBasedCompensationExpenseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "auth_ref": [
      "r138"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location in the income statement.",
        "label": "Income Statement Location [Domain]"
       }
      }
     },
     "localname": "IncomeStatementLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://annovisbio.com/role/DisclosureStockBasedCompensationShareBasedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeTaxAuthorityAxis": {
     "auth_ref": [
      "r281"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by tax jurisdiction.",
        "label": "Income Tax Authority [Axis]"
       }
      }
     },
     "localname": "IncomeTaxAuthorityAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://annovisbio.com/role/DisclosureIncomeTaxesAdditionalDisclosuresDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxAuthorityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Agency, division or body classification that levies income taxes, examines tax returns for compliance, or grants exemptions from or makes other decisions pertaining to income taxes.",
        "label": "Income Tax Authority [Domain]"
       }
      }
     },
     "localname": "IncomeTaxAuthorityDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://annovisbio.com/role/DisclosureIncomeTaxesAdditionalDisclosuresDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeTaxDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Taxes"
       }
      }
     },
     "localname": "IncomeTaxDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxDisclosureTextBlock": {
     "auth_ref": [
      "r71",
      "r279",
      "r282",
      "r288",
      "r296",
      "r299",
      "r300",
      "r301",
      "r302"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.",
        "label": "Income Tax Disclosure [Text Block]",
        "terseLabel": "Income Taxes"
       }
      }
     },
     "localname": "IncomeTaxDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://annovisbio.com/role/DisclosureIncomeTaxes"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued": {
     "auth_ref": [
      "r280"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of estimated penalties and interest accrued as of the balance sheet date arising from income tax examinations.",
        "label": "Income Tax Examination, Penalties and Interest Accrued",
        "terseLabel": "Accrued interest or penalties"
       }
      }
     },
     "localname": "IncomeTaxExaminationPenaltiesAndInterestAccrued",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://annovisbio.com/role/DisclosureIncomeTaxesAdditionalDisclosuresDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense": {
     "auth_ref": [
      "r280"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The sum of the amounts of estimated penalties and interest recognized in the period arising from income tax examinations.",
        "label": "Income Tax Examination, Penalties and Interest Expense",
        "terseLabel": "Recognized income tax interest and penalties"
       }
      }
     },
     "localname": "IncomeTaxExaminationPenaltiesAndInterestExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://annovisbio.com/role/DisclosureIncomeTaxesAdditionalDisclosuresDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxExpenseBenefitContinuingOperationsByJurisdictionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Federal and state provision (benefit) for income taxes"
       }
      }
     },
     "localname": "IncomeTaxExpenseBenefitContinuingOperationsByJurisdictionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://annovisbio.com/role/DisclosureIncomeTaxesReconciliationOfIncomeTaxProvisionBenefitDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxPolicyTextBlock": {
     "auth_ref": [
      "r39",
      "r275",
      "r276",
      "r282",
      "r283",
      "r287",
      "r293"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.",
        "label": "Income Tax, Policy [Policy Text Block]",
        "terseLabel": "Income Taxes"
       }
      }
     },
     "localname": "IncomeTaxPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://annovisbio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsPayable": {
     "auth_ref": [
      "r57"
     ],
     "calculation": {
      "http://annovisbio.com/role/StatementStatementsOfCashFlows": {
       "order": 8.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.",
        "label": "Increase (Decrease) in Accounts Payable",
        "terseLabel": "Accounts payable"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsPayable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://annovisbio.com/role/StatementStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccruedLiabilities": {
     "auth_ref": [
      "r57"
     ],
     "calculation": {
      "http://annovisbio.com/role/StatementStatementsOfCashFlows": {
       "order": 9.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.",
        "label": "Increase (Decrease) in Accrued Liabilities",
        "terseLabel": "Accrued expenses"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccruedLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://annovisbio.com/role/StatementStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Operating Capital [Abstract]",
        "terseLabel": "Changes in operating assets and liabilities:"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://annovisbio.com/role/StatementStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": {
     "auth_ref": [
      "r57"
     ],
     "calculation": {
      "http://annovisbio.com/role/StatementStatementsOfCashFlows": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other.",
        "label": "Increase (Decrease) in Prepaid Expense and Other Assets",
        "negatedLabel": "Prepaid expenses and other current assets"
       }
      }
     },
     "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://annovisbio.com/role/StatementStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]",
        "terseLabel": "Changes in Stockholders' Equity"
       }
      }
     },
     "localname": "IncreaseDecreaseInStockholdersEquityRollForward",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://annovisbio.com/role/StatementStatementsOfChangesInStockholdersEquityDeficit"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncreaseDecreaseInTemporaryEquityRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Increase (Decrease) in Temporary Equity [Roll Forward]",
        "terseLabel": "Changes in Redeemable Convertible Preferred Stock"
       }
      }
     },
     "localname": "IncreaseDecreaseInTemporaryEquityRollForward",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://annovisbio.com/role/StatementStatementsOfChangesInRedeemableConvertiblePreferredStock"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_InterestIncomeExpenseNonoperatingNet": {
     "auth_ref": [],
     "calculation": {
      "http://annovisbio.com/role/StatementStatementsOfOperations": {
       "order": 2.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net amount of nonoperating interest income (expense).",
        "label": "Interest Income (Expense), Nonoperating, Net",
        "terseLabel": "Interest income, net"
       }
      }
     },
     "localname": "InterestIncomeExpenseNonoperatingNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://annovisbio.com/role/StatementStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestPaidNet": {
     "auth_ref": [
      "r52",
      "r55",
      "r62"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.",
        "label": "Interest Paid, Excluding Capitalized Interest, Operating Activities",
        "terseLabel": "Cash payments for interest"
       }
      }
     },
     "localname": "InterestPaidNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://annovisbio.com/role/DisclosureConvertiblePromissoryNotesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LeaseCostAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lease, Cost [Abstract]",
        "terseLabel": "Leases"
       }
      }
     },
     "localname": "LeaseCostAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://annovisbio.com/role/DisclosureCommitmentsAndContingenciesLeasesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_Liabilities": {
     "auth_ref": [
      "r26",
      "r69",
      "r119",
      "r131",
      "r146",
      "r147",
      "r148",
      "r150",
      "r151",
      "r152",
      "r153",
      "r154",
      "r155",
      "r156",
      "r306",
      "r309",
      "r310",
      "r326",
      "r350",
      "r351"
     ],
     "calculation": {
      "http://annovisbio.com/role/StatementBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.",
        "label": "Liabilities",
        "totalLabel": "Total liabilities"
       }
      }
     },
     "localname": "Liabilities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://annovisbio.com/role/StatementBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "auth_ref": [
      "r20",
      "r69",
      "r131",
      "r326",
      "r352",
      "r375",
      "r384"
     ],
     "calculation": {
      "http://annovisbio.com/role/StatementBalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.",
        "label": "Liabilities and Equity",
        "totalLabel": "Total liabilities and stockholders' equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://annovisbio.com/role/StatementBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities and Equity [Abstract]",
        "terseLabel": "Liabilities, Redeemable Convertible Preferred Stock and Stockholders' Equity (Deficit)"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://annovisbio.com/role/StatementBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesCurrent": {
     "auth_ref": [
      "r28",
      "r69",
      "r131",
      "r146",
      "r147",
      "r148",
      "r150",
      "r151",
      "r152",
      "r153",
      "r154",
      "r155",
      "r156",
      "r306",
      "r309",
      "r310",
      "r326",
      "r350",
      "r351",
      "r352"
     ],
     "calculation": {
      "http://annovisbio.com/role/StatementBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.",
        "label": "Liabilities, Current",
        "totalLabel": "Total current liabilities"
       }
      }
     },
     "localname": "LiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://annovisbio.com/role/StatementBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Current [Abstract]",
        "terseLabel": "Current liabilities:"
       }
      }
     },
     "localname": "LiabilitiesCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://annovisbio.com/role/StatementBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LongtermDebtTypeAxis": {
     "auth_ref": [
      "r30"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of long-term debt.",
        "label": "Long-term Debt, Type [Axis]"
       }
      }
     },
     "localname": "LongtermDebtTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://annovisbio.com/role/DisclosureConvertiblePromissoryNotesDetails",
      "http://annovisbio.com/role/DisclosureRelatedPartyTransactionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LongtermDebtTypeDomain": {
     "auth_ref": [
      "r30",
      "r145"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Type of long-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.",
        "label": "Long-term Debt, Type [Domain]"
       }
      }
     },
     "localname": "LongtermDebtTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://annovisbio.com/role/DisclosureConvertiblePromissoryNotesDetails",
      "http://annovisbio.com/role/DisclosureRelatedPartyTransactionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LossContingencyInformationAboutLitigationMattersAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Loss Contingency, Information about Litigation Matters [Abstract]",
        "terseLabel": "Litigation"
       }
      }
     },
     "localname": "LossContingencyInformationAboutLitigationMattersAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://annovisbio.com/role/DisclosureCommitmentsAndContingenciesEmploymentAgreementsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LossContingencyNewClaimsFiledNumber": {
     "auth_ref": [
      "r143"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The total number of new claims filed pertaining to a loss contingency during the period.",
        "label": "Loss Contingency, New Claims Filed, Number",
        "terseLabel": "Number of new claims filed"
       }
      }
     },
     "localname": "LossContingencyNewClaimsFiledNumber",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://annovisbio.com/role/DisclosureCommitmentsAndContingenciesEmploymentAgreementsDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "auth_ref": [
      "r54"
     ],
     "calculation": {
      "http://annovisbio.com/role/StatementStatementsOfCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.",
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "totalLabel": "Net cash provided by financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://annovisbio.com/role/StatementStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]",
        "terseLabel": "Cash flows from financing activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://annovisbio.com/role/StatementStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "auth_ref": [
      "r54",
      "r56",
      "r59"
     ],
     "calculation": {
      "http://annovisbio.com/role/StatementStatementsOfCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.",
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "totalLabel": "Net cash used in operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://annovisbio.com/role/StatementStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Cash flows from operating activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://annovisbio.com/role/StatementStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetIncomeLoss": {
     "auth_ref": [
      "r1",
      "r37",
      "r38",
      "r42",
      "r44",
      "r59",
      "r69",
      "r77",
      "r79",
      "r80",
      "r81",
      "r82",
      "r85",
      "r86",
      "r92",
      "r115",
      "r117",
      "r120",
      "r123",
      "r125",
      "r131",
      "r146",
      "r147",
      "r148",
      "r150",
      "r151",
      "r152",
      "r153",
      "r154",
      "r155",
      "r156",
      "r316",
      "r326",
      "r378",
      "r386"
     ],
     "calculation": {
      "http://annovisbio.com/role/StatementStatementsOfOperations": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.",
        "label": "Net Income (Loss) Attributable to Parent",
        "terseLabel": "Net loss",
        "totalLabel": "Net loss"
       }
      }
     },
     "localname": "NetIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://annovisbio.com/role/DisclosureNetLossPerShareBasicAndDilutedNetLossPerShareDetails",
      "http://annovisbio.com/role/StatementStatementsOfChangesInStockholdersEquityDeficit",
      "http://annovisbio.com/role/StatementStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.",
        "label": "New Accounting Pronouncements, Policy [Policy Text Block]",
        "terseLabel": "Recent Accounting Pronouncements"
       }
      }
     },
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://annovisbio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_NonoperatingIncomeExpense": {
     "auth_ref": [
      "r49"
     ],
     "calculation": {
      "http://annovisbio.com/role/StatementStatementsOfOperations": {
       "order": 2.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).",
        "label": "Nonoperating Income (Expense)",
        "totalLabel": "Total other income (expense)"
       }
      }
     },
     "localname": "NonoperatingIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://annovisbio.com/role/StatementStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NonoperatingIncomeExpenseAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Nonoperating Income (Expense) [Abstract]",
        "terseLabel": "Other income (expense):"
       }
      }
     },
     "localname": "NonoperatingIncomeExpenseAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://annovisbio.com/role/StatementStatementsOfOperations"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingExpenses": {
     "auth_ref": [],
     "calculation": {
      "http://annovisbio.com/role/StatementStatementsOfOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.",
        "label": "Operating Expenses",
        "totalLabel": "Total operating expenses"
       }
      }
     },
     "localname": "OperatingExpenses",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://annovisbio.com/role/StatementStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingExpensesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Expenses [Abstract]",
        "terseLabel": "Operating expenses:"
       }
      }
     },
     "localname": "OperatingExpensesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://annovisbio.com/role/StatementStatementsOfOperations"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingIncomeLoss": {
     "auth_ref": [
      "r115",
      "r117",
      "r120",
      "r123",
      "r125"
     ],
     "calculation": {
      "http://annovisbio.com/role/StatementStatementsOfOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net result for the period of deducting operating expenses from operating revenues.",
        "label": "Operating Income (Loss)",
        "totalLabel": "Operating loss"
       }
      }
     },
     "localname": "OperatingIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://annovisbio.com/role/StatementStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseExpense": {
     "auth_ref": [
      "r340"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of operating lease expense. Excludes sublease income.",
        "label": "Operating Lease, Expense",
        "terseLabel": "Rental expense"
       }
      }
     },
     "localname": "OperatingLeaseExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://annovisbio.com/role/DisclosureCommitmentsAndContingenciesLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLossCarryforwards": {
     "auth_ref": [
      "r289"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.",
        "label": "Operating Loss Carryforwards",
        "terseLabel": "Net operating loss carryforwards"
       }
      }
     },
     "localname": "OperatingLossCarryforwards",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://annovisbio.com/role/DisclosureIncomeTaxesAdditionalDisclosuresDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLossCarryforwardsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Operating Loss Carryforwards [Line Items]",
        "terseLabel": "Income taxes"
       }
      }
     },
     "localname": "OperatingLossCarryforwardsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://annovisbio.com/role/DisclosureIncomeTaxesAdditionalDisclosuresDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingLossCarryforwardsTable": {
     "auth_ref": [
      "r290"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting pertinent information, such as tax authority, amounts, and expiration dates, of net operating loss carryforwards, including an assessment of the likelihood of utilization.",
        "label": "Operating Loss Carryforwards [Table]"
       }
      }
     },
     "localname": "OperatingLossCarryforwardsTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://annovisbio.com/role/DisclosureIncomeTaxesAdditionalDisclosuresDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Nature of Business and Liquidity"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock": {
     "auth_ref": [
      "r2",
      "r313"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.",
        "label": "Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]",
        "terseLabel": "Nature of Business and Liquidity"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://annovisbio.com/role/DisclosureNatureOfBusinessAndLiquidity"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_OtherCommitmentsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Other Commitments [Line Items]",
        "terseLabel": "Commitments and Contingencies"
       }
      }
     },
     "localname": "OtherCommitmentsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://annovisbio.com/role/DisclosureCommitmentsAndContingenciesLicenseAgreementDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherCommitmentsTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about obligations resulting from other commitments.",
        "label": "Other Commitments [Table]"
       }
      }
     },
     "localname": "OtherCommitmentsTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://annovisbio.com/role/DisclosureCommitmentsAndContingenciesLicenseAgreementDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherPrepaidExpenseCurrent": {
     "auth_ref": [
      "r4",
      "r7",
      "r134"
     ],
     "calculation": {
      "http://annovisbio.com/role/DisclosurePrepaidExpensesAndOtherCurrentAssetsDetails": {
       "order": 3.0,
       "parentTag": "anvs_PrepaidExpenseSecurityDepositsAndOtherAssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for other costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.",
        "label": "Other Prepaid Expense, Current",
        "terseLabel": "Prepaid expenses"
       }
      }
     },
     "localname": "OtherPrepaidExpenseCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://annovisbio.com/role/DisclosurePrepaidExpensesAndOtherCurrentAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PlanNameAxis": {
     "auth_ref": [
      "r238",
      "r263"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by plan name for share-based payment arrangement.",
        "label": "Plan Name [Axis]"
       }
      }
     },
     "localname": "PlanNameAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://annovisbio.com/role/DisclosureStockBasedCompensationSummaryOfPlansDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PlanNameDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Plan name for share-based payment arrangement.",
        "label": "Plan Name [Domain]"
       }
      }
     },
     "localname": "PlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://annovisbio.com/role/DisclosureStockBasedCompensationSummaryOfPlansDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PreferredStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r14",
      "r195"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.",
        "label": "Preferred Stock, Par or Stated Value Per Share",
        "terseLabel": "Preferred stock, par value (dollars per share)"
       }
      }
     },
     "localname": "PreferredStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://annovisbio.com/role/DisclosureRedeemableConvertiblePreferredStockAndStockholdersEquityCommonAndPreferredStockDetails",
      "http://annovisbio.com/role/StatementBalanceSheetsParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_PreferredStockSharesAuthorized": {
     "auth_ref": [
      "r14"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.",
        "label": "Preferred Stock, Shares Authorized",
        "terseLabel": "Preferred stock, shares authorized",
        "verboseLabel": "Number of preferred shares authorized"
       }
      }
     },
     "localname": "PreferredStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://annovisbio.com/role/DisclosureRedeemableConvertiblePreferredStockAndStockholdersEquityCommonAndPreferredStockDetails",
      "http://annovisbio.com/role/StatementBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesIssued": {
     "auth_ref": [
      "r14",
      "r195"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.",
        "label": "Preferred Stock, Shares Issued",
        "terseLabel": "Preferred stock, shares issued"
       }
      }
     },
     "localname": "PreferredStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://annovisbio.com/role/DisclosureRedeemableConvertiblePreferredStockAndStockholdersEquityCommonAndPreferredStockDetails",
      "http://annovisbio.com/role/StatementBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesOutstanding": {
     "auth_ref": [
      "r14"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.",
        "label": "Preferred Stock, Shares Outstanding",
        "terseLabel": "Preferred stock, shares outstanding"
       }
      }
     },
     "localname": "PreferredStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://annovisbio.com/role/DisclosureRedeemableConvertiblePreferredStockAndStockholdersEquityCommonAndPreferredStockDetails",
      "http://annovisbio.com/role/StatementBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockValue": {
     "auth_ref": [
      "r14",
      "r352"
     ],
     "calculation": {
      "http://annovisbio.com/role/StatementBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Preferred Stock, Value, Issued",
        "verboseLabel": "Preferred stock - $0.0001 par value, 2,000,000 shares authorized and 0 shares issued and outstanding"
       }
      }
     },
     "localname": "PreferredStockValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://annovisbio.com/role/StatementBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PrepaidInsurance": {
     "auth_ref": [
      "r5",
      "r7",
      "r133",
      "r134"
     ],
     "calculation": {
      "http://annovisbio.com/role/DisclosurePrepaidExpensesAndOtherCurrentAssetsDetails": {
       "order": 2.0,
       "parentTag": "anvs_PrepaidExpenseSecurityDepositsAndOtherAssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for insurance that provides economic benefits within a future period of one year or the normal operating cycle, if longer.",
        "label": "Prepaid Insurance",
        "verboseLabel": "Prepaid insurance"
       }
      }
     },
     "localname": "PrepaidInsurance",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://annovisbio.com/role/DisclosurePrepaidExpensesAndOtherCurrentAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfCommonStock": {
     "auth_ref": [
      "r51"
     ],
     "calculation": {
      "http://annovisbio.com/role/StatementStatementsOfCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from the additional capital contribution to the entity.",
        "label": "Proceeds from Issuance of Common Stock",
        "terseLabel": "Proceeds from issuance of common stock, net of issuance costs",
        "verboseLabel": "Gross proceeds from issuance of common shares"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://annovisbio.com/role/DisclosureNatureOfBusinessAndLiquidityDetails",
      "http://annovisbio.com/role/StatementStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromStockOptionsExercised": {
     "auth_ref": [
      "r51",
      "r264"
     ],
     "calculation": {
      "http://annovisbio.com/role/StatementStatementsOfCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement.",
        "label": "Proceeds from Stock Options Exercised",
        "terseLabel": "Proceeds from exercise of stock options"
       }
      }
     },
     "localname": "ProceedsFromStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://annovisbio.com/role/StatementStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProfitLoss": {
     "auth_ref": [
      "r1",
      "r37",
      "r38",
      "r42",
      "r53",
      "r69",
      "r77",
      "r85",
      "r86",
      "r115",
      "r117",
      "r120",
      "r123",
      "r125",
      "r131",
      "r146",
      "r147",
      "r148",
      "r150",
      "r151",
      "r152",
      "r153",
      "r154",
      "r155",
      "r156",
      "r304",
      "r307",
      "r308",
      "r311",
      "r312",
      "r316",
      "r326",
      "r380"
     ],
     "calculation": {
      "http://annovisbio.com/role/StatementStatementsOfCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.",
        "label": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest",
        "terseLabel": "Net loss"
       }
      }
     },
     "localname": "ProfitLoss",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://annovisbio.com/role/StatementStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RedeemableConvertiblePreferredStockMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of type or class of redeemable convertible preferred stock. Convertible redeemable preferred stock possess conversion and redemption features. The stock has redemption features that are outside the control of the issuer.",
        "label": "Redeemable convertible preferred stock"
       }
      }
     },
     "localname": "RedeemableConvertiblePreferredStockMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://annovisbio.com/role/StatementStatementsOfChangesInRedeemableConvertiblePreferredStock"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RelatedPartyDomain": {
     "auth_ref": [
      "r232",
      "r343",
      "r344"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Related parties include affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.",
        "label": "Related Party [Domain]"
       }
      }
     },
     "localname": "RelatedPartyDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://annovisbio.com/role/DisclosureRelatedPartyTransactionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RelatedPartyTransactionAxis": {
     "auth_ref": [
      "r232",
      "r343",
      "r344",
      "r347"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of related party transaction.",
        "label": "Related Party Transaction [Axis]"
       }
      }
     },
     "localname": "RelatedPartyTransactionAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://annovisbio.com/role/DisclosureRelatedPartyTransactionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionDomain": {
     "auth_ref": [
      "r232"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Transaction between related party.",
        "label": "Related Party Transaction [Domain]"
       }
      }
     },
     "localname": "RelatedPartyTransactionDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://annovisbio.com/role/DisclosureRelatedPartyTransactionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RelatedPartyTransactionLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Related Party Transaction [Line Items]",
        "terseLabel": "Related-Party Transactions"
       }
      }
     },
     "localname": "RelatedPartyTransactionLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://annovisbio.com/role/DisclosureRelatedPartyTransactionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related-Party Transactions"
       }
      }
     },
     "localname": "RelatedPartyTransactionsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": {
     "auth_ref": [
      "r232",
      "r343",
      "r347",
      "r361",
      "r362",
      "r363",
      "r364",
      "r365",
      "r366",
      "r367",
      "r368",
      "r369",
      "r370",
      "r371",
      "r372"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of related party. Related parties include, but not limited to, affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.",
        "label": "Related Party [Axis]"
       }
      }
     },
     "localname": "RelatedPartyTransactionsByRelatedPartyAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://annovisbio.com/role/DisclosureRelatedPartyTransactionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionsDisclosureTextBlock": {
     "auth_ref": [
      "r341",
      "r342",
      "r344",
      "r348",
      "r349"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.",
        "label": "Related Party Transactions Disclosure [Text Block]",
        "terseLabel": "Related-Party Transactions"
       }
      }
     },
     "localname": "RelatedPartyTransactionsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://annovisbio.com/role/DisclosureRelatedPartyTransactions"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis": {
     "auth_ref": [
      "r273",
      "r274"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by form of arrangement related to research and development.",
        "label": "Research and Development Arrangement, Contract to Perform for Others, Type [Axis]"
       }
      }
     },
     "localname": "ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://annovisbio.com/role/DisclosureCommitmentsAndContingenciesLicenseAgreementDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain": {
     "auth_ref": [
      "r273",
      "r274"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Listing of significant agreements under research and development arrangements accounted for as a contract to perform research and development for others.",
        "label": "Research and Development Arrangement, Contract to Perform for Others, Type [Domain]"
       }
      }
     },
     "localname": "ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://annovisbio.com/role/DisclosureCommitmentsAndContingenciesLicenseAgreementDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "auth_ref": [
      "r272",
      "r359",
      "r395"
     ],
     "calculation": {
      "http://annovisbio.com/role/StatementStatementsOfOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.",
        "label": "Research and Development Expense",
        "terseLabel": "Research and development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://annovisbio.com/role/StatementStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpenseMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included.",
        "label": "Research and development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://annovisbio.com/role/DisclosureStockBasedCompensationShareBasedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ResearchDevelopmentAndComputerSoftwarePolicyTextBlock": {
     "auth_ref": [
      "r22",
      "r135",
      "r136",
      "r395"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for its research and development and computer software activities including the accounting treatment for costs incurred for (1) research and development activities, (2) development of computer software for internal use, (3) computer software to be sold, leased or otherwise marketed as a separate product or as part of a product or process and (4) in-process research and development acquired in a purchase business combination.",
        "label": "Research, Development, and Computer Software, Policy [Policy Text Block]",
        "terseLabel": "Research and Development"
       }
      }
     },
     "localname": "ResearchDevelopmentAndComputerSoftwarePolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://annovisbio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ResearchMember": {
     "auth_ref": [
      "r290"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Research tax credit carryforwards arising from certain qualifying expenditures incurred to develop new products and processes.",
        "label": "Research Tax Credit Carryforward"
       }
      }
     },
     "localname": "ResearchMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://annovisbio.com/role/DisclosureIncomeTaxesAdditionalDisclosuresDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "auth_ref": [
      "r17",
      "r218",
      "r268",
      "r352",
      "r383",
      "r392",
      "r393"
     ],
     "calculation": {
      "http://annovisbio.com/role/StatementBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings (Accumulated Deficit)",
        "terseLabel": "Accumulated deficit"
       }
      }
     },
     "localname": "RetainedEarningsAccumulatedDeficit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://annovisbio.com/role/StatementBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsMember": {
     "auth_ref": [
      "r0",
      "r74",
      "r75",
      "r76",
      "r78",
      "r84",
      "r86",
      "r132",
      "r265",
      "r266",
      "r267",
      "r294",
      "r295",
      "r314",
      "r389",
      "r391"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Accumulated Deficit"
       }
      }
     },
     "localname": "RetainedEarningsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://annovisbio.com/role/StatementStatementsOfChangesInStockholdersEquityDeficit"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": {
     "auth_ref": [
      "r113",
      "r114",
      "r116",
      "r121",
      "r122",
      "r126",
      "r127",
      "r128",
      "r221",
      "r222",
      "r360"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.",
        "label": "Revenue from Contract with Customer, Excluding Assessed Tax",
        "terseLabel": "Revenue"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerExcludingAssessedTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://annovisbio.com/role/DisclosureNatureOfBusinessAndLiquidityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SaleOfStockConsiderationReceivedOnTransaction": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash received on stock transaction after deduction of issuance costs.",
        "label": "Sale of Stock, Consideration Received on Transaction",
        "terseLabel": "Net proceeds from issuance of common shares"
       }
      }
     },
     "localname": "SaleOfStockConsiderationReceivedOnTransaction",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://annovisbio.com/role/DisclosureNatureOfBusinessAndLiquidityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SaleOfStockNameOfTransactionDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement.",
        "label": "Sale of Stock [Domain]"
       }
      }
     },
     "localname": "SaleOfStockNameOfTransactionDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://annovisbio.com/role/DisclosureConvertiblePromissoryNotesDetails",
      "http://annovisbio.com/role/DisclosureNatureOfBusinessAndLiquidityDetails",
      "http://annovisbio.com/role/DisclosureRedeemableConvertiblePreferredStockAndStockholdersEquityCommonAndPreferredStockDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of accrued liabilities.",
        "label": "Schedule of Accrued Liabilities [Table Text Block]",
        "terseLabel": "Schedule of accrued expenses"
       }
      }
     },
     "localname": "ScheduleOfAccruedLiabilitiesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://annovisbio.com/role/DisclosureAccruedExpensesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": {
     "auth_ref": [
      "r96"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule for securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by Antidilutive Securities.",
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]"
       }
      }
     },
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://annovisbio.com/role/DisclosureNetLossPerSharePotentialSharesExcludedFromCalculationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": {
     "auth_ref": [
      "r96"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.",
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]",
        "terseLabel": "Schedule of shares excluded from the computation of diluted weighted-average shares outstanding"
       }
      }
     },
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://annovisbio.com/role/DisclosureNetLossPerShareTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable": {
     "auth_ref": [
      "r303"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Table]"
       }
      }
     },
     "localname": "ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://annovisbio.com/role/DisclosureGrantIncomeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfDeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTitleOfIndividualAndByTypeOfDeferredCompensationTable": {
     "auth_ref": [
      "r223",
      "r224"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule, table or text reflecting arrangements that are not equity-based payments, or pension and other postretirement benefits, with individual employees. The arrangements (for example, profit sharing, deferred bonuses or certain split-dollar life insurance arrangements) are generally based on employment contracts between the entity and one or more selected officers or key employees, and which contain a promise by the employer to pay certain amounts at designated future dates, sometimes including a period after retirement, upon compliance with stipulated requirements. This type of arrangement is distinguished from broader based employee benefit plans as it is usually tailored to the employee. Disclosure also typically includes the amount of related compensation expense recognized during the reporting period and the carrying amount as of the balance sheet date of the related liability.",
        "label": "Schedule of Deferred Compensation Arrangement with Individual, Excluding Share-based Payments and Postretirement Benefits, by Title of Individual and by Type of Deferred Compensation [Table]"
       }
      }
     },
     "localname": "ScheduleOfDeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTitleOfIndividualAndByTypeOfDeferredCompensationTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://annovisbio.com/role/DisclosureCommitmentsAndContingenciesEmploymentAgreementsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock": {
     "auth_ref": [
      "r286"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.",
        "label": "Schedule of Deferred Tax Assets and Liabilities [Table Text Block]",
        "terseLabel": "Schedule of significant components of deferred tax assets"
       }
      }
     },
     "localname": "ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://annovisbio.com/role/DisclosureIncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": {
     "auth_ref": [
      "r95"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.",
        "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]",
        "terseLabel": "Schedule of basic and diluted net loss per share"
       }
      }
     },
     "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://annovisbio.com/role/DisclosureNetLossPerShareTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock": {
     "auth_ref": [
      "r278"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.",
        "label": "Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]",
        "terseLabel": "Reconciliation of income tax provision (benefit) computed at the statutory federal income tax rate to income taxes as reflected in the financial statements"
       }
      }
     },
     "localname": "ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://annovisbio.com/role/DisclosureIncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": {
     "auth_ref": [
      "r237",
      "r261",
      "r270"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.",
        "label": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]",
        "terseLabel": "Schedule of stock-based compensation expense"
       }
      }
     },
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://annovisbio.com/role/DisclosureStockBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock": {
     "auth_ref": [
      "r317",
      "r318"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).",
        "label": "Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]",
        "terseLabel": "Schedule of carrying value and fair value of financial assets and liabilities measured at fair value on a recurring basis"
       }
      }
     },
     "localname": "ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://annovisbio.com/role/DisclosureFairValueMeasurementsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable": {
     "auth_ref": [
      "r345",
      "r347"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of quantitative and qualitative information pertaining to related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.",
        "label": "Schedule of Related Party Transactions, by Related Party [Table]"
       }
      }
     },
     "localname": "ScheduleOfRelatedPartyTransactionsByRelatedPartyTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://annovisbio.com/role/DisclosureRelatedPartyTransactionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "auth_ref": [
      "r238",
      "r263"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about share-based payment arrangement.",
        "label": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://annovisbio.com/role/DisclosureStockBasedCompensationAdditionalDisclosuresDetails",
      "http://annovisbio.com/role/DisclosureStockBasedCompensationShareBasedCompensationExpenseDetails",
      "http://annovisbio.com/role/DisclosureStockBasedCompensationSummaryOfPlansDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": {
     "auth_ref": [
      "r244",
      "r250",
      "r253"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.",
        "label": "Share-based Payment Arrangement, Option, Activity [Table Text Block]",
        "terseLabel": "Schedule of stock option activity"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://annovisbio.com/role/DisclosureStockBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": {
     "auth_ref": [
      "r255"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.",
        "label": "Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]",
        "terseLabel": "Schedule of weighted average assumptions used to determine fair value of options"
       }
      }
     },
     "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://annovisbio.com/role/DisclosureStockBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfStockByClassTable": {
     "auth_ref": [
      "r32",
      "r66",
      "r103",
      "r104",
      "r192",
      "r193",
      "r194",
      "r195",
      "r196",
      "r197",
      "r198",
      "r200",
      "r204",
      "r209",
      "r212",
      "r213",
      "r214",
      "r215",
      "r216",
      "r217",
      "r218"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule detailing information related to equity by class of stock. Class of stock includes common, convertible, and preferred stocks which are not redeemable or redeemable solely at the option of the issuer. It also includes preferred stock with redemption features that are solely within the control of the issuer and mandatorily redeemable stock if redemption is required to occur only upon liquidation or termination of the reporting entity.",
        "label": "Schedule of Stock by Class [Table]"
       }
      }
     },
     "localname": "ScheduleOfStockByClassTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://annovisbio.com/role/DisclosureNatureOfBusinessAndLiquidityDetails",
      "http://annovisbio.com/role/DisclosureRedeemableConvertiblePreferredStockAndStockholdersEquityCommonAndPreferredStockDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SecurityDeposit": {
     "auth_ref": [
      "r35"
     ],
     "calculation": {
      "http://annovisbio.com/role/DisclosurePrepaidExpensesAndOtherCurrentAssetsDetails": {
       "order": 4.0,
       "parentTag": "anvs_PrepaidExpenseSecurityDepositsAndOtherAssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of an asset, typically cash, provided to a counterparty to provide certain assurance of performance by the entity pursuant to the terms of a written or oral agreement, such as a lease.",
        "label": "Security Deposit",
        "terseLabel": "Security deposit"
       }
      }
     },
     "localname": "SecurityDeposit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://annovisbio.com/role/DisclosurePrepaidExpensesAndOtherCurrentAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensation": {
     "auth_ref": [
      "r57"
     ],
     "calculation": {
      "http://annovisbio.com/role/StatementStatementsOfCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncash expense for share-based payment arrangement.",
        "label": "Share-based Payment Arrangement, Noncash Expense",
        "terseLabel": "Stock-based compensation expense",
        "verboseLabel": "Stock-based compensation expense, including stock issued to consultants and advisors"
       }
      }
     },
     "localname": "ShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://annovisbio.com/role/DisclosureStockBasedCompensationShareBasedCompensationExpenseDetails",
      "http://annovisbio.com/role/StatementStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": {
     "auth_ref": [
      "r239"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period",
        "terseLabel": "Vesting period"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://annovisbio.com/role/DisclosureStockBasedCompensationAdditionalDisclosuresDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions and Methodology [Abstract]",
        "verboseLabel": "Estimated fair value of options"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://annovisbio.com/role/DisclosureStockBasedCompensationAdditionalDisclosuresDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": {
     "auth_ref": [
      "r258"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate",
        "terseLabel": "Expected dividend yield"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://annovisbio.com/role/DisclosureStockBasedCompensationAdditionalDisclosuresDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": {
     "auth_ref": [
      "r257"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate",
        "terseLabel": "Expected volatility"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://annovisbio.com/role/DisclosureStockBasedCompensationAdditionalDisclosuresDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": {
     "auth_ref": [
      "r259"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate",
        "terseLabel": "Risk-free interest rate"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://annovisbio.com/role/DisclosureStockBasedCompensationAdditionalDisclosuresDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]",
        "terseLabel": "Stock-Based Compensation"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://annovisbio.com/role/DisclosureStockBasedCompensationAdditionalDisclosuresDetails",
      "http://annovisbio.com/role/DisclosureStockBasedCompensationShareBasedCompensationExpenseDetails",
      "http://annovisbio.com/role/DisclosureStockBasedCompensationSummaryOfPlansDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized": {
     "auth_ref": [
      "r241"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares authorized for issuance under share-based payment arrangement.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized",
        "verboseLabel": "Shares authorized"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://annovisbio.com/role/DisclosureStockBasedCompensationSummaryOfPlansDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": {
     "auth_ref": [
      "r263"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant",
        "terseLabel": "Shares available for future grants"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://annovisbio.com/role/DisclosureStockBasedCompensationSummaryOfPlansDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": {
     "auth_ref": [
      "r247"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number",
        "terseLabel": "Exercisable at end of period"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://annovisbio.com/role/DisclosureStockBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": {
     "auth_ref": [
      "r247"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price",
        "terseLabel": "Exercisable at end of period (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://annovisbio.com/role/DisclosureStockBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue": {
     "auth_ref": [
      "r252"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value",
        "terseLabel": "Aggregate intrinsic value of options exercised"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://annovisbio.com/role/DisclosureStockBasedCompensationAdditionalDisclosuresDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": {
     "auth_ref": [
      "r249"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period",
        "negatedLabel": "Forfeited"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://annovisbio.com/role/DisclosureStockBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gross number of share options (or share units) granted during the period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross",
        "terseLabel": "Granted",
        "verboseLabel": "Options granted"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://annovisbio.com/role/DisclosureStockBasedCompensationAdditionalDisclosuresDetails",
      "http://annovisbio.com/role/DisclosureStockBasedCompensationStockOptionActivityDetails",
      "http://annovisbio.com/role/DisclosureSubsequentEventsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r251"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Weighted average grant date fair value"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://annovisbio.com/role/DisclosureStockBasedCompensationAdditionalDisclosuresDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": {
     "auth_ref": [
      "r263"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value",
        "terseLabel": "Aggregate intrinsic value of options outstanding"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://annovisbio.com/role/DisclosureStockBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "auth_ref": [
      "r246",
      "r263"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of options outstanding, including both vested and non-vested options.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number",
        "periodEndLabel": "Outstanding at end of the period",
        "periodStartLabel": "Outstanding at beginning of the period",
        "terseLabel": "Options outstanding"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://annovisbio.com/role/DisclosureStockBasedCompensationStockOptionActivityDetails",
      "http://annovisbio.com/role/DisclosureStockBasedCompensationSummaryOfPlansDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]",
        "terseLabel": "Number of Shares"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://annovisbio.com/role/DisclosureStockBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "auth_ref": [
      "r245"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price",
        "periodEndLabel": "Outstanding at end of the period (in dollars per share)",
        "periodStartLabel": "Outstanding at beginning of the period (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://annovisbio.com/role/DisclosureStockBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]",
        "terseLabel": "Weighted Average Exercise Price"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://annovisbio.com/role/DisclosureStockBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber": {
     "auth_ref": [
      "r254"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number",
        "terseLabel": "Vested options"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://annovisbio.com/role/DisclosureStockBasedCompensationAdditionalDisclosuresDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "auth_ref": [
      "r236",
      "r242"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Award under share-based payment arrangement.",
        "label": "Award Type [Domain]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://annovisbio.com/role/DisclosureStockBasedCompensationAdditionalDisclosuresDetails",
      "http://annovisbio.com/role/DisclosureStockBasedCompensationSummaryOfPlansDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares.",
        "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price",
        "terseLabel": "Exercised (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://annovisbio.com/role/DisclosureStockBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.",
        "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price",
        "terseLabel": "Forfeited (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://annovisbio.com/role/DisclosureStockBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.",
        "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price",
        "terseLabel": "Granted (in dollars per share)",
        "verboseLabel": "Exercise price"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://annovisbio.com/role/DisclosureStockBasedCompensationStockOptionActivityDetails",
      "http://annovisbio.com/role/DisclosureSubsequentEventsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": {
     "auth_ref": [
      "r238",
      "r243"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.",
        "label": "Share-based Payment Arrangement [Policy Text Block]",
        "terseLabel": "Stock-Based Compensation"
       }
      }
     },
     "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://annovisbio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ShareBasedPaymentArrangementNonemployeeMember": {
     "auth_ref": [
      "r234",
      "r260"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Recipient, of award granted under share-based payment arrangement, over whom grantor does not exercise nor has right to exercise sufficient control to establish employer-employee relationship based on law of pertinent jurisdiction. Excludes nonemployee director treated as employee when acting as member of board of directors, if elected by grantor's shareholders or appointed to board position to be filled by shareholder election when existing term expires.",
        "label": "Consultants and advisors"
       }
      }
     },
     "localname": "ShareBasedPaymentArrangementNonemployeeMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://annovisbio.com/role/DisclosureStockBasedCompensationAdditionalDisclosuresDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SharePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Price of a single share of a number of saleable stocks of a company.",
        "label": "Share Price",
        "terseLabel": "Share price"
       }
      }
     },
     "localname": "SharePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://annovisbio.com/role/DisclosureNatureOfBusinessAndLiquidityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod": {
     "auth_ref": [
      "r240"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period",
        "terseLabel": "Term of award"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://annovisbio.com/role/DisclosureStockBasedCompensationAdditionalDisclosuresDetails",
      "http://annovisbio.com/role/DisclosureStockBasedCompensationSummaryOfPlansDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": {
     "auth_ref": [
      "r256",
      "r269"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term",
        "terseLabel": "Expected life"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://annovisbio.com/role/DisclosureStockBasedCompensationAdditionalDisclosuresDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1": {
     "auth_ref": [
      "r263"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value",
        "terseLabel": "Aggregate intrinsic value of options exercisable"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://annovisbio.com/role/DisclosureStockBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": {
     "auth_ref": [
      "r263"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term",
        "terseLabel": "Exercisable at end of period (in years)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://annovisbio.com/role/DisclosureStockBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of non-vested options outstanding.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Nonvested, Number of Shares",
        "terseLabel": "Unvested awards outstanding"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://annovisbio.com/role/DisclosureStockBasedCompensationAdditionalDisclosuresDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": {
     "auth_ref": [
      "r254"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term",
        "terseLabel": "Outstanding at end of the period (in years)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://annovisbio.com/role/DisclosureStockBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharesIssued": {
     "auth_ref": [
      "r211"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of stock issued as of the balance sheet date, including shares that had been issued and were previously outstanding but which are now held in the treasury.",
        "label": "Shares, Issued",
        "periodEndLabel": "Balance, shares",
        "periodStartLabel": "Balance, shares"
       }
      }
     },
     "localname": "SharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://annovisbio.com/role/StatementStatementsOfChangesInStockholdersEquityDeficit"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_SignificantAccountingPoliciesTextBlock": {
     "auth_ref": [
      "r64",
      "r73"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for all significant accounting policies of the reporting entity.",
        "label": "Significant Accounting Policies [Text Block]",
        "terseLabel": "Summary of Significant Accounting Policies"
       }
      }
     },
     "localname": "SignificantAccountingPoliciesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://annovisbio.com/role/DisclosureSummaryOfSignificantAccountingPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_StateAndLocalIncomeTaxExpenseBenefitContinuingOperations": {
     "auth_ref": [
      "r70",
      "r277",
      "r297"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of state and local current and deferred income tax expense (benefit) attributable to continuing operations.",
        "label": "State and Local Income Tax Expense (Benefit), Continuing Operations",
        "terseLabel": "State provision (benefit) for income taxes"
       }
      }
     },
     "localname": "StateAndLocalIncomeTaxExpenseBenefitContinuingOperations",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://annovisbio.com/role/DisclosureIncomeTaxesReconciliationOfIncomeTaxProvisionBenefitDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StateAndLocalJurisdictionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Designated tax department of a state or local government entitled to levy and collect income taxes from the entity.",
        "label": "State"
       }
      }
     },
     "localname": "StateAndLocalJurisdictionMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://annovisbio.com/role/DisclosureIncomeTaxesAdditionalDisclosuresDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_StatementClassOfStockAxis": {
     "auth_ref": [
      "r13",
      "r14",
      "r15",
      "r66",
      "r69",
      "r89",
      "r90",
      "r91",
      "r93",
      "r95",
      "r103",
      "r104",
      "r105",
      "r131",
      "r146",
      "r150",
      "r151",
      "r152",
      "r155",
      "r156",
      "r195",
      "r196",
      "r200",
      "r204",
      "r211",
      "r326",
      "r403"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by the different classes of stock of the entity.",
        "label": "Class of Stock [Axis]"
       }
      }
     },
     "localname": "StatementClassOfStockAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://annovisbio.com/role/DisclosureRedeemableConvertiblePreferredStockAndStockholdersEquityCommonAndPreferredStockDetails",
      "http://annovisbio.com/role/StatementStatementsOfChangesInRedeemableConvertiblePreferredStock"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "auth_ref": [
      "r0",
      "r33",
      "r40",
      "r41",
      "r42",
      "r74",
      "r75",
      "r76",
      "r78",
      "r84",
      "r86",
      "r102",
      "r132",
      "r211",
      "r218",
      "r265",
      "r266",
      "r267",
      "r294",
      "r295",
      "r314",
      "r328",
      "r329",
      "r330",
      "r331",
      "r332",
      "r333",
      "r389",
      "r390",
      "r391",
      "r407"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by component of equity.",
        "label": "Equity Components [Axis]"
       }
      }
     },
     "localname": "StatementEquityComponentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://annovisbio.com/role/DisclosureConvertiblePromissoryNotesDetails",
      "http://annovisbio.com/role/DisclosureIncomeTaxesAdditionalDisclosuresDetails",
      "http://annovisbio.com/role/DisclosureNatureOfBusinessAndLiquidityDetails",
      "http://annovisbio.com/role/DisclosureRedeemableConvertiblePreferredStockAndStockholdersEquityCommonAndPreferredStockDetails",
      "http://annovisbio.com/role/DisclosureRelatedPartyTransactionsDetails",
      "http://annovisbio.com/role/StatementStatementsOfChangesInStockholdersEquityDeficit"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Statement [Line Items]"
       }
      }
     },
     "localname": "StatementLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://annovisbio.com/role/StatementStatementsOfChangesInRedeemableConvertiblePreferredStock",
      "http://annovisbio.com/role/StatementStatementsOfChangesInStockholdersEquityDeficit"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statements of Cash Flows"
       }
      }
     },
     "localname": "StatementOfCashFlowsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Balance Sheets"
       }
      }
     },
     "localname": "StatementOfFinancialPositionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statements of Redeemable Convertible Preferred Stock and Stockholders' Equity (Deficit)"
       }
      }
     },
     "localname": "StatementOfStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementTable": {
     "auth_ref": [
      "r74",
      "r75",
      "r76",
      "r102",
      "r360"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.",
        "label": "Statement [Table]"
       }
      }
     },
     "localname": "StatementTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://annovisbio.com/role/StatementStatementsOfChangesInRedeemableConvertiblePreferredStock",
      "http://annovisbio.com/role/StatementStatementsOfChangesInStockholdersEquityDeficit"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesIssuedForServices": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued in lieu of cash for services contributed to the entity. Number of shares includes, but is not limited to, shares issued for services contributed by vendors and founders.",
        "label": "Stock Issued During Period, Shares, Issued for Services",
        "terseLabel": "Issuance of common stock to consultants and advisors, shares",
        "verboseLabel": "Number of shares issued to consultants and advisors"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesIssuedForServices",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://annovisbio.com/role/DisclosureStockBasedCompensationAdditionalDisclosuresDetails",
      "http://annovisbio.com/role/StatementStatementsOfChangesInStockholdersEquityDeficit"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesNewIssues": {
     "auth_ref": [
      "r14",
      "r15",
      "r211",
      "r218"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of new stock issued during the period.",
        "label": "Stock Issued During Period, Shares, New Issues",
        "terseLabel": "Issuance of common stock, net of issuance costs (in shares)",
        "verboseLabel": "Issuance of common stock"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://annovisbio.com/role/DisclosureIncomeTaxesAdditionalDisclosuresDetails",
      "http://annovisbio.com/role/DisclosureNatureOfBusinessAndLiquidityDetails",
      "http://annovisbio.com/role/DisclosureRedeemableConvertiblePreferredStockAndStockholdersEquityCommonAndPreferredStockDetails",
      "http://annovisbio.com/role/StatementStatementsOfChangesInStockholdersEquityDeficit"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "auth_ref": [
      "r14",
      "r15",
      "r211",
      "r218",
      "r248"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of share options (or share units) exercised during the current period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period",
        "negatedLabel": "Exercised",
        "verboseLabel": "Exercise of stock options, shares"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://annovisbio.com/role/DisclosureStockBasedCompensationStockOptionActivityDetails",
      "http://annovisbio.com/role/StatementStatementsOfChangesInStockholdersEquityDeficit"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueIssuedForServices": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of stock issued in lieu of cash for services contributed to the entity. Value of the stock issued includes, but is not limited to, services contributed by vendors and founders.",
        "label": "Stock Issued During Period, Value, Issued for Services",
        "terseLabel": "Issuance of common stock to consultants and advisors"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueIssuedForServices",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://annovisbio.com/role/StatementStatementsOfChangesInStockholdersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueNewIssues": {
     "auth_ref": [
      "r14",
      "r15",
      "r211",
      "r218"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.",
        "label": "Stock Issued During Period, Value, New Issues",
        "terseLabel": "Issuance of common stock, net of issuance costs"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://annovisbio.com/role/StatementStatementsOfChangesInStockholdersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": {
     "auth_ref": [
      "r33",
      "r211",
      "r218"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of stock issued as a result of the exercise of stock options.",
        "label": "Stock Issued During Period, Value, Stock Options Exercised",
        "verboseLabel": "Exercise of stock options"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://annovisbio.com/role/StatementStatementsOfChangesInStockholdersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquity": {
     "auth_ref": [
      "r15",
      "r18",
      "r19",
      "r69",
      "r130",
      "r131",
      "r326",
      "r352"
     ],
     "calculation": {
      "http://annovisbio.com/role/StatementBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.",
        "label": "Stockholders' Equity Attributable to Parent",
        "periodEndLabel": "Balance",
        "periodStartLabel": "Balance",
        "totalLabel": "Total stockholders' equity"
       }
      }
     },
     "localname": "StockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://annovisbio.com/role/StatementBalanceSheets",
      "http://annovisbio.com/role/StatementStatementsOfChangesInStockholdersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders' Equity Attributable to Parent [Abstract]",
        "terseLabel": "Stockholders' equity (deficit):"
       }
      }
     },
     "localname": "StockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://annovisbio.com/role/StatementBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockholdersEquityNoteAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Redeemable Convertible Preferred Stock and Stockholders' Equity"
       }
      }
     },
     "localname": "StockholdersEquityNoteAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockholdersEquityNoteDisclosureTextBlock": {
     "auth_ref": [
      "r67",
      "r196",
      "r199",
      "r200",
      "r201",
      "r202",
      "r203",
      "r204",
      "r205",
      "r206",
      "r207",
      "r208",
      "r210",
      "r218",
      "r220"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.",
        "label": "Stockholders' Equity Note Disclosure [Text Block]",
        "terseLabel": "Redeemable Convertible Preferred Stock and Stockholders' Equity"
       }
      }
     },
     "localname": "StockholdersEquityNoteDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://annovisbio.com/role/DisclosureRedeemableConvertiblePreferredStockAndStockholdersEquity"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SubsequentEventLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.",
        "label": "Subsequent Event [Line Items]",
        "verboseLabel": "Subsequent Events"
       }
      }
     },
     "localname": "SubsequentEventLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://annovisbio.com/role/DisclosureSubsequentEventsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventMember": {
     "auth_ref": [
      "r334",
      "r354"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent events"
       }
      }
     },
     "localname": "SubsequentEventMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://annovisbio.com/role/DisclosureSubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SubsequentEventTable": {
     "auth_ref": [
      "r334",
      "r354"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Discloses pertinent information about one or more significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued.",
        "label": "Subsequent Event [Table]"
       }
      }
     },
     "localname": "SubsequentEventTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://annovisbio.com/role/DisclosureSubsequentEventsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventTypeAxis": {
     "auth_ref": [
      "r334",
      "r354"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event Type [Axis]"
       }
      }
     },
     "localname": "SubsequentEventTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://annovisbio.com/role/DisclosureSubsequentEventsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventTypeDomain": {
     "auth_ref": [
      "r334",
      "r354"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event Type [Domain]"
       }
      }
     },
     "localname": "SubsequentEventTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://annovisbio.com/role/DisclosureSubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SubsequentEventsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Events"
       }
      }
     },
     "localname": "SubsequentEventsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventsTextBlock": {
     "auth_ref": [
      "r353",
      "r355"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.",
        "label": "Subsequent Events [Text Block]",
        "verboseLabel": "Subsequent Events"
       }
      }
     },
     "localname": "SubsequentEventsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://annovisbio.com/role/DisclosureSubsequentEvents"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SubsidiarySaleOfStockAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of sale of the entity's stock.",
        "label": "Sale of Stock [Axis]"
       }
      }
     },
     "localname": "SubsidiarySaleOfStockAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://annovisbio.com/role/DisclosureConvertiblePromissoryNotesDetails",
      "http://annovisbio.com/role/DisclosureNatureOfBusinessAndLiquidityDetails",
      "http://annovisbio.com/role/DisclosureRedeemableConvertiblePreferredStockAndStockholdersEquityCommonAndPreferredStockDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SupplementalCashFlowElementsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Supplemental Cash Flow Elements [Abstract]",
        "terseLabel": "Supplemental disclosure of non-cash financing activities:"
       }
      }
     },
     "localname": "SupplementalCashFlowElementsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://annovisbio.com/role/StatementStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TaxCreditCarryforwardAmount": {
     "auth_ref": [
      "r289"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of the tax credit carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.",
        "label": "Tax Credit Carryforward, Amount",
        "terseLabel": "Tax credit carryforward"
       }
      }
     },
     "localname": "TaxCreditCarryforwardAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://annovisbio.com/role/DisclosureIncomeTaxesAdditionalDisclosuresDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TaxCreditCarryforwardAxis": {
     "auth_ref": [
      "r290"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by specific tax credit related to an unused tax credit.",
        "label": "Tax Credit Carryforward [Axis]"
       }
      }
     },
     "localname": "TaxCreditCarryforwardAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://annovisbio.com/role/DisclosureIncomeTaxesAdditionalDisclosuresDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TaxCreditCarryforwardNameDomain": {
     "auth_ref": [
      "r290"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The name of the tax credit carryforward.",
        "label": "Tax Credit Carryforward, Name [Domain]"
       }
      }
     },
     "localname": "TaxCreditCarryforwardNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://annovisbio.com/role/DisclosureIncomeTaxesAdditionalDisclosuresDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TaxPeriodAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information about the period subject to enacted tax laws.",
        "label": "Tax Period [Axis]"
       }
      }
     },
     "localname": "TaxPeriodAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://annovisbio.com/role/DisclosureIncomeTaxesAdditionalDisclosuresDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TaxPeriodDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identified tax period.",
        "label": "Tax Period [Domain]"
       }
      }
     },
     "localname": "TaxPeriodDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://annovisbio.com/role/DisclosureIncomeTaxesAdditionalDisclosuresDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TemporaryEquityCarryingAmountAttributableToParent": {
     "auth_ref": [
      "r146",
      "r150",
      "r151",
      "r152",
      "r155",
      "r156"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount, attributable to parent, of an entity's issued and outstanding stock which is not included within permanent equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. Includes stock with a put option held by an ESOP and stock redeemable by a holder only in the event of a change in control of the issuer.",
        "label": "Temporary Equity, Carrying Amount, Attributable to Parent",
        "periodEndLabel": "Balance",
        "periodStartLabel": "Balance"
       }
      }
     },
     "localname": "TemporaryEquityCarryingAmountAttributableToParent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://annovisbio.com/role/StatementStatementsOfChangesInRedeemableConvertiblePreferredStock"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TemporaryEquitySharesIssued": {
     "auth_ref": [
      "r12"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of securities classified as temporary equity that have been sold (or granted) to the entity's shareholders. Securities issued include securities outstanding and securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.",
        "label": "Temporary Equity, Shares Issued",
        "periodEndLabel": "Balance, shares",
        "periodStartLabel": "Balance, shares"
       }
      }
     },
     "localname": "TemporaryEquitySharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://annovisbio.com/role/StatementStatementsOfChangesInRedeemableConvertiblePreferredStock"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_TypeOfArrangementAxis": {
     "auth_ref": [
      "r303"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]"
       }
      }
     },
     "localname": "TypeOfArrangementAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://annovisbio.com/role/DisclosureGrantIncomeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_UnrealizedGainLossOnDerivatives": {
     "auth_ref": [
      "r58"
     ],
     "calculation": {
      "http://annovisbio.com/role/StatementStatementsOfCashFlows": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      },
      "http://annovisbio.com/role/StatementStatementsOfOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net change in the difference between the fair value and the carrying value, or in the comparative fair values, of derivative instruments, including options, swaps, futures, and forward contracts, held at each balance sheet date, that was included in earnings for the period.",
        "label": "Unrealized Gain (Loss) on Derivatives",
        "negatedLabel": "Change in fair value of derivative liability",
        "terseLabel": "Change in fair value of derivative liability"
       }
      }
     },
     "localname": "UnrealizedGainLossOnDerivatives",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://annovisbio.com/role/StatementStatementsOfCashFlows",
      "http://annovisbio.com/role/StatementStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UseOfEstimates": {
     "auth_ref": [
      "r106",
      "r107",
      "r108",
      "r109",
      "r110",
      "r111",
      "r112"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.",
        "label": "Use of Estimates, Policy [Policy Text Block]",
        "terseLabel": "Use of Estimates"
       }
      }
     },
     "localname": "UseOfEstimates",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://annovisbio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount": {
     "auth_ref": [
      "r286"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in the valuation allowance for a specified deferred tax asset.",
        "label": "Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount",
        "terseLabel": "Net change in valuation allowance"
       }
      }
     },
     "localname": "ValuationAllowanceDeferredTaxAssetChangeInAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://annovisbio.com/role/DisclosureIncomeTaxesAdditionalDisclosuresDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_VestingAxis": {
     "auth_ref": [
      "r263"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by vesting schedule of award under share-based payment arrangement.",
        "label": "Vesting [Axis]"
       }
      }
     },
     "localname": "VestingAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://annovisbio.com/role/DisclosureStockBasedCompensationAdditionalDisclosuresDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_VestingDomain": {
     "auth_ref": [
      "r263"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Vesting schedule of award under share-based payment arrangement.",
        "label": "Vesting [Domain]"
       }
      }
     },
     "localname": "VestingDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://annovisbio.com/role/DisclosureStockBasedCompensationAdditionalDisclosuresDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_WarrantMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Security that gives the holder the right to purchase shares of stock in accordance with the terms of the instrument, usually upon payment of a specified amount.",
        "label": "Warrants"
       }
      }
     },
     "localname": "WarrantMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://annovisbio.com/role/DisclosureNetLossPerSharePotentialSharesExcludedFromCalculationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_WarrantsAndRightsOutstandingTerm": {
     "auth_ref": [
      "r321"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period between issuance and expiration of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Warrants and Rights Outstanding, Term",
        "terseLabel": "Warrant term"
       }
      }
     },
     "localname": "WarrantsAndRightsOutstandingTerm",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://annovisbio.com/role/DisclosureRedeemableConvertiblePreferredStockAndStockholdersEquityWarrantsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "auth_ref": [
      "r88",
      "r95"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.",
        "label": "Weighted Average Number of Shares Outstanding, Diluted",
        "terseLabel": "Weighted average number of common shares outstanding, diluted",
        "verboseLabel": "Weighted-average common shares outstanding, diluted"
       }
      }
     },
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://annovisbio.com/role/DisclosureNetLossPerShareBasicAndDilutedNetLossPerShareDetails",
      "http://annovisbio.com/role/StatementStatementsOfOperations"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "auth_ref": [
      "r87",
      "r95"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.",
        "label": "Weighted Average Number of Shares Outstanding, Basic",
        "terseLabel": "Weighted average number of common shares outstanding, basic",
        "verboseLabel": "Weighted-average common shares outstanding, basic"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://annovisbio.com/role/DisclosureNetLossPerShareBasicAndDilutedNetLossPerShareDetails",
      "http://annovisbio.com/role/StatementStatementsOfOperations"
     ],
     "xbrltype": "sharesItemType"
    }
   },
   "unitCount": 8
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "105",
   "URI": "http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695"
  },
  "r1": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760"
  },
  "r10": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6935-107765"
  },
  "r100": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "52",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125512782&loc=d3e4984-109258"
  },
  "r101": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "260",
   "URI": "http://asc.fasb.org/topic&trid=2144383"
  },
  "r102": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=125520817&loc=d3e70191-108054"
  },
  "r103": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=125520817&loc=d3e70229-108054"
  },
  "r104": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=6373374&loc=d3e70434-108055"
  },
  "r105": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=6373374&loc=d3e70478-108055"
  },
  "r106": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r107": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r108": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592"
  },
  "r109": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592"
  },
  "r11": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r110": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592"
  },
  "r111": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592"
  },
  "r112": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592"
  },
  "r113": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r114": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r115": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r116": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599"
  },
  "r117": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599"
  },
  "r118": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599"
  },
  "r119": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599"
  },
  "r12": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(27)(b))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r120": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "31",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8924-108599"
  },
  "r121": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r122": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r123": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r124": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r125": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r126": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9031-108599"
  },
  "r127": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9038-108599"
  },
  "r128": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "42",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9054-108599"
  },
  "r129": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=124259787&loc=d3e4647-111522"
  },
  "r13": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(27))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r130": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 4.E)",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=122038336&loc=d3e74512-122707"
  },
  "r131": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571"
  },
  "r132": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437"
  },
  "r133": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "05",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "340",
   "URI": "http://asc.fasb.org/extlink&oid=123349782&loc=d3e5879-108316"
  },
  "r134": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "340",
   "URI": "http://asc.fasb.org/extlink&oid=6387103&loc=d3e6435-108320"
  },
  "r135": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "30",
   "SubTopic": "40",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=118172244&loc=d3e17916-109280"
  },
  "r136": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "50",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=16397303&loc=d3e19347-109286"
  },
  "r137": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230"
  },
  "r138": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869"
  },
  "r139": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "440",
   "URI": "http://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308"
  },
  "r14": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r140": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "440",
   "URI": "http://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308"
  },
  "r141": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "440",
   "URI": "http://asc.fasb.org/topic&trid=2144648"
  },
  "r142": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14326-108349"
  },
  "r143": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14435-108349"
  },
  "r144": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "450",
   "URI": "http://asc.fasb.org/topic&trid=2127136"
  },
  "r145": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123465755&loc=SL6230698-112601"
  },
  "r146": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r147": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r148": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r149": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r15": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r150": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r151": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r152": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r153": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r154": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r155": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r156": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r157": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466302&loc=d3e4852-112606"
  },
  "r158": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r159": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r16": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r160": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r161": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r162": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r163": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(f)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r164": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r165": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r166": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(i)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r167": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r168": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611"
  },
  "r169": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611"
  },
  "r17": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r170": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611"
  },
  "r171": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611"
  },
  "r172": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611"
  },
  "r173": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611"
  },
  "r174": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611"
  },
  "r175": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611"
  },
  "r176": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611"
  },
  "r177": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611"
  },
  "r178": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611"
  },
  "r179": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611"
  },
  "r18": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r180": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611"
  },
  "r181": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611"
  },
  "r182": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611"
  },
  "r183": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611"
  },
  "r184": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611"
  },
  "r185": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611"
  },
  "r186": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466204&loc=SL6036836-161870"
  },
  "r187": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69B",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495735-112612"
  },
  "r188": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69C",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495737-112612"
  },
  "r189": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69E",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495743-112612"
  },
  "r19": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(31))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r190": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495745-112612"
  },
  "r191": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "470",
   "URI": "http://asc.fasb.org/topic&trid=2208564"
  },
  "r192": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(CFRR 211.02)",
   "Topic": "480",
   "URI": "http://asc.fasb.org/extlink&oid=122040564&loc=d3e177068-122764"
  },
  "r193": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=65888546&loc=d3e21300-112643"
  },
  "r194": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21553-112644"
  },
  "r195": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r196": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r197": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r198": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r199": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r2": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "205",
   "URI": "http://asc.fasb.org/topic&trid=2122149"
  },
  "r20": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(32))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r200": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r201": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r202": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r203": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644"
  },
  "r204": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644"
  },
  "r205": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644"
  },
  "r206": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496180-112644"
  },
  "r207": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644"
  },
  "r208": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644"
  },
  "r209": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644"
  },
  "r21": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.1)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r210": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644"
  },
  "r211": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21463-112644"
  },
  "r212": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21475-112644"
  },
  "r213": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21484-112644"
  },
  "r214": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21488-112644"
  },
  "r215": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21506-112644"
  },
  "r216": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21521-112644"
  },
  "r217": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21538-112644"
  },
  "r218": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770"
  },
  "r219": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "50",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=6784392&loc=d3e188667-122775"
  },
  "r22": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.15)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r220": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "505",
   "URI": "http://asc.fasb.org/topic&trid=2208762"
  },
  "r221": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130543-203045"
  },
  "r222": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130545-203045"
  },
  "r223": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "10",
   "Topic": "710",
   "URI": "http://asc.fasb.org/extlink&oid=6409733&loc=d3e19524-108361"
  },
  "r224": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "30",
   "SubTopic": "10",
   "Topic": "710",
   "URI": "http://asc.fasb.org/extlink&oid=6409875&loc=d3e20015-108363"
  },
  "r225": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(ii)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r226": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(01)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r227": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r228": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(A)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r229": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(B)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r23": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.17)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r230": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(C)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r231": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(03)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r232": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(n)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r233": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123450688&loc=d3e4179-114921"
  },
  "r234": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=123468992&loc=SL116886442-113899"
  },
  "r235": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=123468992&loc=d3e4549-113899"
  },
  "r236": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r237": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r238": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r239": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r24": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r240": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r241": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r242": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a),(g)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r243": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b),(f)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r244": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r245": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r246": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)-(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r247": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r248": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r249": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(3)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r25": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a),20,24)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r250": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r251": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r252": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r253": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r254": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r255": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r256": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r257": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r258": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r259": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iv)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r26": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19-26)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r260": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r261": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r262": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r263": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r264": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=SL79508275-113901"
  },
  "r265": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r266": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r267": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r268": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(g)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r269": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.D.2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=122041274&loc=d3e301413-122809"
  },
  "r27": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.20)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r270": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.F)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=122041274&loc=d3e301413-122809"
  },
  "r271": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "718",
   "URI": "http://asc.fasb.org/topic&trid=2228938"
  },
  "r272": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "730",
   "URI": "http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373"
  },
  "r273": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "730",
   "URI": "http://asc.fasb.org/extlink&oid=6420387&loc=d3e23199-108380"
  },
  "r274": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "730",
   "URI": "http://asc.fasb.org/extlink&oid=6420387&loc=d3e23221-108380"
  },
  "r275": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123427490&loc=d3e32247-109318"
  },
  "r276": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123427490&loc=d3e32280-109318"
  },
  "r277": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32672-109319"
  },
  "r278": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32687-109319"
  },
  "r279": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32705-109319"
  },
  "r28": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.21)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r280": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32718-109319"
  },
  "r281": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32718-109319"
  },
  "r282": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32809-109319"
  },
  "r283": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32840-109319"
  },
  "r284": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319"
  },
  "r285": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319"
  },
  "r286": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319"
  },
  "r287": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32847-109319"
  },
  "r288": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32857-109319"
  },
  "r289": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32559-109319"
  },
  "r29": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22(a)(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r290": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32559-109319"
  },
  "r291": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32621-109319"
  },
  "r292": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32632-109319"
  },
  "r293": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319"
  },
  "r294": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277"
  },
  "r295": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(3)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277"
  },
  "r296": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.5.Q1)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
  },
  "r297": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.7)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
  },
  "r298": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.4)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
  },
  "r299": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.C)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330215-122817"
  },
  "r3": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r30": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r300": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "270",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=6424409&loc=d3e44925-109338"
  },
  "r301": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=6424122&loc=d3e41874-109331"
  },
  "r302": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "740",
   "URI": "http://asc.fasb.org/topic&trid=2144680"
  },
  "r303": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "808",
   "URI": "http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434"
  },
  "r304": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123454820&loc=SL4569616-111683"
  },
  "r305": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r306": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r307": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r308": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r309": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685"
  },
  "r31": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.25)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r310": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685"
  },
  "r311": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4J",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=120409616&loc=SL4591551-111686"
  },
  "r312": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4K",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=120409616&loc=SL4591552-111686"
  },
  "r313": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "810",
   "URI": "http://asc.fasb.org/topic&trid=2197479"
  },
  "r314": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(3)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r315": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(4)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r316": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r317": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r318": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r319": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r32": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.28,29)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r320": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(1)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r321": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(2)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r322": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r323": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=SL6742756-110258"
  },
  "r324": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "60",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=7493716&loc=d3e21868-110260"
  },
  "r325": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123594938&loc=d3e13279-108611"
  },
  "r326": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612"
  },
  "r327": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "230",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906"
  },
  "r328": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900"
  },
  "r329": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r33": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r330": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r331": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r332": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r333": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901"
  },
  "r334": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32618-110901"
  },
  "r335": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=124435984&loc=d3e28541-108399"
  },
  "r336": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=124435984&loc=d3e28551-108399"
  },
  "r337": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=124435984&loc=d3e28555-108399"
  },
  "r338": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=124429444&loc=SL124452920-239629"
  },
  "r339": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=114775985&loc=d3e28878-108400"
  },
  "r34": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.8)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r340": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918638-209977"
  },
  "r341": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r342": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r343": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r344": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r345": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r346": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39599-107864"
  },
  "r347": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39603-107864"
  },
  "r348": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39691-107864"
  },
  "r349": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "850",
   "URI": "http://asc.fasb.org/topic&trid=2122745"
  },
  "r35": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.8,17)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r350": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "852",
   "URI": "http://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765"
  },
  "r351": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "852",
   "URI": "http://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765"
  },
  "r352": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "852",
   "URI": "http://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766"
  },
  "r353": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "855",
   "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662"
  },
  "r354": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "855",
   "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662"
  },
  "r355": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "855",
   "URI": "http://asc.fasb.org/topic&trid=2122774"
  },
  "r356": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r357": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r358": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r359": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "730",
   "Topic": "912",
   "URI": "http://asc.fasb.org/extlink&oid=6472174&loc=d3e58812-109433"
  },
  "r36": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.9)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r360": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.L)",
   "Topic": "924",
   "URI": "http://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856"
  },
  "r361": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e61929-109447"
  },
  "r362": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e61929-109447"
  },
  "r363": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62059-109447"
  },
  "r364": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62059-109447"
  },
  "r365": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62395-109447"
  },
  "r366": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62395-109447"
  },
  "r367": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "33",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62479-109447"
  },
  "r368": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "33",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62479-109447"
  },
  "r369": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "35A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=SL6807758-109447"
  },
  "r37": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669619-108580"
  },
  "r370": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "35A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=SL6807758-109447"
  },
  "r371": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(c)(1)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e61872-109447"
  },
  "r372": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(c)(2)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e61872-109447"
  },
  "r373": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "20",
   "Topic": "940",
   "URI": "http://asc.fasb.org/extlink&oid=123384075&loc=d3e41242-110953"
  },
  "r374": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(11))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r375": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(23))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r376": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.17)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r377": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(15))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r378": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(22))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r379": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(27))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r38": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669625-108580"
  },
  "r380": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "235",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884"
  },
  "r381": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "470",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=123599511&loc=d3e64711-112823"
  },
  "r382": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r383": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r384": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r385": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.(a),19)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r386": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(18))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r387": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(23))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r388": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(8))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r389": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r39": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL116659661-227067"
  },
  "r390": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(1)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r391": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(2)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r392": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(i)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r393": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(h)(2)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r394": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "440",
   "Subparagraph": "(a)",
   "Topic": "954",
   "URI": "http://asc.fasb.org/extlink&oid=6491277&loc=d3e6429-115629"
  },
  "r395": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "985",
   "URI": "http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756"
  },
  "r396": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b"
  },
  "r397": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r398": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r399": {
   "Name": "Form 10-K",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "310"
  },
  "r4": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r40": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067"
  },
  "r400": {
   "Name": "Form 20-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "220",
   "Subsection": "f"
  },
  "r401": {
   "Name": "Form 40-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "240",
   "Subsection": "f"
  },
  "r402": {
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r403": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(a)",
   "Publisher": "SEC",
   "Section": "1402"
  },
  "r404": {
   "Name": "Regulation S-T",
   "Number": "232",
   "Publisher": "SEC",
   "Section": "405"
  },
  "r405": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "405"
  },
  "r406": {
   "Name": "Securities Act",
   "Number": "7A",
   "Publisher": "SEC",
   "Section": "B",
   "Subsection": "2"
  },
  "r407": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Topic": "848"
  },
  "r41": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067"
  },
  "r42": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067"
  },
  "r43": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(10))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r44": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(20))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r45": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(25))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r46": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(4))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r47": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(8))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r48": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.4)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r49": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.7)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r5": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(g)(1)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r50": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.8)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r51": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3255-108585"
  },
  "r52": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3367-108585"
  },
  "r53": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3000-108585"
  },
  "r54": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3521-108585"
  },
  "r55": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3536-108585"
  },
  "r56": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3536-108585"
  },
  "r57": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585"
  },
  "r58": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585"
  },
  "r59": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585"
  },
  "r6": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r60": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3044-108585"
  },
  "r61": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4273-108586"
  },
  "r62": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4297-108586"
  },
  "r63": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=SL98516268-108586"
  },
  "r64": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=123372394&loc=d3e18726-107790"
  },
  "r65": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(c))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r66": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(d))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r67": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(e)(1))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r68": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(f))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r69": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r7": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6787-107765"
  },
  "r70": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h)(1)(Note 1))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r71": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h)(2))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r72": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-04(a))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e24072-122690"
  },
  "r73": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "235",
   "URI": "http://asc.fasb.org/topic&trid=2122369"
  },
  "r74": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793"
  },
  "r75": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793"
  },
  "r76": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793"
  },
  "r77": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r78": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(3)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r79": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794"
  },
  "r8": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6801-107765"
  },
  "r80": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794"
  },
  "r81": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794"
  },
  "r82": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794"
  },
  "r83": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794"
  },
  "r84": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794"
  },
  "r85": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794"
  },
  "r86": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794"
  },
  "r87": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1448-109256"
  },
  "r88": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1505-109256"
  },
  "r89": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1252-109256"
  },
  "r9": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6911-107765"
  },
  "r90": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1278-109256"
  },
  "r91": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "55",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e2626-109256"
  },
  "r92": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=SL5780133-109256"
  },
  "r93": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=SL5780133-109256"
  },
  "r94": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1337-109256"
  },
  "r95": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257"
  },
  "r96": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257"
  },
  "r97": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257"
  },
  "r98": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=109243012&loc=SL65017193-207537"
  },
  "r99": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125512782&loc=d3e3842-109258"
  }
 },
 "version": "2.1"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>82
<FILENAME>0001558370-22-002668-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001558370-22-002668-xbrl.zip
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M3!VE4'\VYF1T6</NFP #VZU6>V'>SR\2"%<1=84=I?!E3(@4-:0T?GN^7YF
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M/JHZ@KC;BXMR/,'VJ;$@&_X,H?[?_@]02P,$%     @ B(%B5+<)YS4B)@
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M_-86UF"@"EP@85V\:AV0GY*[Z&$A>X+> GZ$A8$B:]5Q8:"A":R(; K<R5L
M60H8%<\HH3[7 #\G#/=G9JF(%(=5:E>F@X8PJUMH4.' =+0 L@9AV->&VV4*
MV/$NF&F1KZQ]=1YL^ MG"BO1Q4 G]S0E;*J4V8M=.P@K */ '.@!-_??H2>4
M9"A_U3@16/X:I8NSC*9XB4C^ZC%?:5+*B$+AS']1&%JKGD9?5KNH;_7F;0MJ
MP4G_]664GG0HX_W-)N48WI(H4!ZPE #&O&*VFWA*1( 3P2W! 4(AY0Z"ZXF?
M!(A?(U 5KW)H-^8=G9T$9D$;.#F6MO_,S].(,44D#]RA $5/*)PFI7B .3AK
MT\>8MRQV,T@W.L')6KI%NLDXOQA9V_M%;)&/PM/59F>T!G2*EKCT.F:"_D[Z
ML#/E^Z$AFP16,145/Q9D'+OHA;FO,1.[N]<&,[V]9W6S15W ]LC^ QN_@LX,
MBQ7&)GPK6T^UZ6#,!-]6 FQ#),BKLG^0:_J?NY+YZ[A__\IO3Q^-*6WKN]#]
MY%]>^A$1B>E?D<\_BRQ@M\3+#\W$2]ZK)[KUROWN3;YEP14>>TISX?OW42RL
M<DT16XO?<4M='R+?X(1L/I[Z-**\O5B[SU"P2)CN(&W"9K]#CK+4*T@Z796T
MX)(@AE@2Z%Y\MFH))_MS"'4IKP.MV -AL2_S+@6:VK-7JY9 SF =]%PJ11V)
M4*5("V76IO_8-85PN.N@JB8A-@D$)<735?'GWR)$&+<6JVOTA&([AZQM#">K
M=42?K.40*%4H*VT3:V<'K>D#GJNV, *CH:OI!27FJ^0Q2ZD@[]C.7<M:0/72
M1LV5BE%&(2BA=>NW&ED7PVP_KB&D"PW%4JF>]3+][&VM[#.?+ABI_#]^%^C)
MC\5%K'3SRIE@F2K:;]<60K[3&!IGR1YX!T)2O L.;N-*3FHA;0^A%# <U9"R
M:*PXY$_\T"J_D.X6??S8C#Z*OKR\L[T).6Y35<]PS%0<\X/_)S3AIWD/^3HG
M5X5 \7,I,<#R9GAW XWSR"0;83HO(:;9ORI@X800^Q-_Y1%*.1L@3 --2GTY
M<?KG@EQ[ ;(OU>IRI5:+*X%]'!/>^'EW5PEE?CA+T329/+#):3IO_$*G\[\A
M/TX7ZFL?N_0&84_:4G/+:>^MZ8=@N1TX+-/NM-LA1KRXT@.KY/==NIM%P%R3
M$<LZFF="^OG)N<AXFO 21_GSV#+W8M4,PJ:Q+^6PYT+O^27YFIPG+^?XR.35
MA(&P;>M5.$V2^T_9*R62JV4A@X+POD6OTI 1#2YJ4K?GLXP0U'" 1F@(SQ'T
M/2DJB>_=R'Y."(J6]QEA4^%%'#WP?*\S3%/*#)XC4<D2D]F?8P<0ZM#W:IJ.
M_.A=P$*UQ!1ZASB/>+Q.S*63)S^*)4$8ZU80BH_WOR Q,&&L8*3Z^1NWV.3W
MS=ADJ6MOV[<G.M^;6.4YND_YGI1DC7?::Q./%'*4"?,:)P\I(DN.$8^V:(*%
M<E XL4(-^\OSGIP,"(N7.F;:1!,5,)#(G4ZO=-* E"A2<DH</4-E22DLA$"<
M7JVJY26E1$"0Q>LHDZL(<5AZKK?RN&_E<=_*X[Z5QQW69RDB?[8^ZZTL[NB>
M#%19W#]6@55W/>NCJ&HO^]M&#$.[Q[V&<,YH(*#,>JE[V]O\TBHUEWZ I >#
M9G (!X*MI5@F!-S)1175*Z92!-'TCBU"Q4HTW)9)L!*:O@,(1X>MQ:@G#:!@
M\V(%EU'"RU*)N/Q/1/VPD@8>PAFCD]B4E "44IFLGQ-_B4D:_0N%/$QM[2JE
M[2 <)K8V-BE%P*57=A 7\SD*^$G,#OY3V@>$0\5.7*B4.G 2WF#,7]^[02IK
M;$!!."]TD%(#_[?2-GT(2O$XK86@^J]GLZ,\C<63U(>XY4)<&U\_P]+70905
MRP8='L([H[8Z,RACQDL06"ZC=),+P:M7,YQ0$D3\(A:C@:+) T%BF^R6,?#I
MZ*29,5",)5ZOK(S&?E\/Z!4C[DT:P31=(%(B3Y=(H( =J> [1?R:.1/].;\_
MCA_%C8UM!LRFG/D,,Y6>8[*\Q$000$]7AMR#COJ&DZR@%7*U''PGE$-8P^U
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M70  9RL& !4   !A;G9S+3(P,C$Q,C,Q7VQA8BYX;6SM??]SZS:VW^^=Z?^
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MP^_H1C(!8/<SWJH&"AN0SIXK:KED8MH7.=QV,D']U4.#CHBAM9O\=JKL/-*
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M+_3XT*,X9@FY9"3@HO$'LP0<B(,M^+=?.[U!=),+D6'%B:H0A@AIB!!G0;A
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M8?YR$P?A/@S8S+:Z2?<),M@_,&V#LNSW,@X>DBQ/:<[B!#[Y4#PN\N'P%.;
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M8K:9U@IBZIB\1<1LU=4A8A:R+>I9A2.6O!*O(%['P2B@.9JI)8K$RPF-@[)
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M\]_$GNJW:C'IVQ\HW/Z4_W](./D9'(P#_Q_\9XOX;^(BZ:B_3-OU4O)E&).
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MI:!H-A>OM+1B./5+]V]4GF_O'[>;[I*8;K91<J#-#_AUI8'<FWN91'V"9T
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MF&I>K.4\!_2=QORCS8W5;+'C\43:8P;FH\AO98(\TH]166Q?T7UKD'T5[L.
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M/:R3E+_09FJ[1@IS XYV<S1BAK[[G.#"0 NK2%'Q(\"0U#@B 8@13<)QLK)
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MJ_&.C^6U7573^U)!2Y#-;8IT\>)C]:]? "0E4B1N)" D:4='UY$E((',_)
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M^)5P(Z]"PTZVD/)5)-S!:J_EW8P-J8&S*HVT7\H)HE$0';0:XF<X!0;DI&I
M"C0'6Z*#G"ID8Y+GA)%<C-07MF(>RIT1#7]&:7##FZ^/XCA6X:B3XW2U<M-D
M(]A$X1%&-E[(5_#<G]8-U U1NLW8)0MYI'($(CV %6G8B0>4Z:-HN*L1 6<%
M&NFZ% +8GO\.V@R)P",L#7;J>(%!F50-RK;%G45 UN: -D9M3;'9OPPV#4,V
M.55)D26-,(<TOQ*0YP)(I^3MB73]\E Z/1X>6L\9+:-#_L,!*KQVT&Q0AIFI
M ?E&832LB0\@]+Y0@H,=BI!'^Y8'>F-UT^U[Y)%\+]3M1%/]D1XN\/91)@"J
M+5$[6PO93I\5.RW<@K2C"LZRZ,%+:4MC0$(=M$>WB.9COT,A95;2$-4%9J)X
M0"@-,*E!3@NR";IT0A\O5#>L"XP+N[@5L[';'9%!8)8'-]1%>BD.8C6N.C@\
MLR-?YUW6$S&JB2%,B0QR*I 'Y89?:3<#MX:M[%Z[/1*-3EX5< -40D<[N;K4
M>.O@,,T6#7=.&*\?0P<O)>8T>8;DF*V)!LPH?J$D!SLT(8]@EB@$PUA<S<I8
M9G5+?F@K4"B/ALEX,K;L&I3597&XM^6W@Z/_(7F*T)\))G+Y)A\#/*J))=Q2
M&FQ(01[LNYP+[S2SBENZG5WNCM QQRH/;N"*]%*^@ZW"E9&KLC NZ2A=UL&0
M&AXTOZPS^&O^Z6_ AWCW[^V<.9$;S9;;?C$Z7BD';EBKW<:1XZ<O#R[^&J'9
M\C**W943LU]!*17JN'XEF.E+MM!=/P\5SUK5Y[53J^/J;\*=@6SJUO(XD5B#
MG>QJ4JB0JMMQ;#3GT4""=#V/R&0);NFYS#2*@KE+MIF_N_%+>FZ<%Q"@H!VQ
MCL+" -.:LG19MR2;>XZ%Q 77/A9ALMH.&88ED:K;4<BTY]%ZBBYM+L (8>F^
M7* WY 6OA&T:YK9Z37#?'H)E_%UZ1=*(5L<1I(_G#%$GT.:FPN5,B<F'7;K$
M]&@XGAP<=T'13;C*5'G:=>-0_QQIFCH=HQP+!(O8?4-WGN/S)Y,&E#J*%]T<
M9UB:=!U+FX-2N;F$5;SCJ%!B*W=>#;NN^UOTO2"F,/#QQSDJ++'D,*%*IN-8
MT<)NCJ$NG3C6IAYZ)%<#Y$XO#H?X?Y()B 9_30E#/ZCH1R:BA_D+6B0>V6[E
MG4LOU]/TF9M+LYF"%C/_'LV3,,3XI^Y^JBKA.:;.-L"9$-5,1^:ET<&0!IDT
M+$KV9ERU-]+)6+IB@7J1E<6N+,17J]N1!6>M-"9N,2JC#MJPG9PM2N;JN&JN
M=C.W=,4J?904+MMYO-I;Q661B  X*](Z44M+WCMH'>HO8JH8B=&P:B18US&[
M8BP WLLD@#L8#X].3T?#P]')X6@RLFYA+E>O7K!&Z &%;^X<U7LRIQ[MC)L^
M4S(/GGTZ"]-WB2C/\@9)<WOE,3P:3R:V,]'H1PC/QNU#G'V)J]M*K5Y,Q;=B
MLS<\UXK3;5/"'QW&6N76EU#!.O%DDIY^=\)%43S$V9/B(XJ25?I=8^PV;^03
MQX9D:"S<<6_W\976HZ/J>K1Z*[\K*]%N7\\OK#5V.D:<QG.\.[MPO02/)45S
MHT0-G%U1N=JOD^?^K<6F?NPN"/_N&U[%SI.0[M0OW\F+<VAQA:6>!EAEZU?5
M;!'Z&^H)%HV*P]@2;"_Y*92FJH/J5%7,4M&524IKNHILW33&T_C)T7!T,CH]
ML&YGTE?H,=@W_29OTY/ML#]W/7?K,U.8PI1)@K,=JDKDSFYZQ-&_*2X_QL(2
MJ3N/5T2=$K5> ZZ])#HX3_$>H[U L>-Z<C/749,W:0=_S9J /IW-/E^G%?F4
MZ*G1^MQSHG2DB!U$NS7 &1>M6F=X>*2$P)G#\A>HK*V(<H;3JW)DD1_XE/]W
MEW79G%NG+("#\>3$=NY>1675J%N97\ *W^'A(E@YKL]0=&U9> I65D]5Q?*<
M,E5K+<]_=C+R#:V>4,C09*4<."W*:Z"J/3GN8&F.9"?"BR@G7#\X&^/$,[JL
M\B5>#X;VIUT-!E>)5\ZJW;:Q+73_UEGACX7$<5S+*ZX(3^U*2JM1>C.6-8UJ
M5G8&'^\='>\N>?+<^6R)-X&N_TQ"T-Y02.(HZ.L@Z5E>K?UM1@2>;IOI9JMD
MC7* 9<:O[V;<B7?S.QB=:E1%=1#SV34[5A^(:W&![4^9*_:XY%8 HR^]8U"=
M9\#3*UU8S):_.R&YI#\+[]WGEYBSAF*6AZ?LUFLH-5XY 24@E<Q=/'%J@%.T
MFIHDU6QMN?2KCZE_QWA!891U*6+;7W;I<M='Q\/A$*":Y*VN(J>PEC@9[]00
MW;@^NH[12F!ARV7!:5.;=97@DYEW3LN XQW_,,XMI.N!4YN\T'>&7V-N#1P^
M;R=46[<][M$;\A.4QO3XE'F2*^\\B>)@A<(TYH=L!Z((RXJ>IS)&>P-*8$#5
M#AA5BZ!+%D8A-[;Y<B1)PX@6%PG9;Z2W36CH6'2+OM.?V,=-,I5["ZP6[&N*
M9RCGM > )IH5.'3GS$/J38'^HH+/HH$+ O;U?A<&<X06$;&Q>4Y7>H\C/_QA
MP$%8K[<H:<:YIE3)++-Q9/\PAD2#N)C)[/+/'+EO) %.P:,F/I<1T^@MK-I+
MP4"69?OVJ=9)<)N0;3Z6UB:H_MSQ/+0X6^>.@*R@DM-2GFIO06A"+@92.P.%
MY>4["N=NE"XA-C]NI#-2 :.(UL>"8"-I:,H S9IR3S2YF_#6@^2N=9Y)?'^1
MS\> +DCSXZ2ZQ;DZ@=[A1I,(#.28;F&E6*>QO&TK7C5@J$8T]C;]'+M/7N'B
MV5W.2=VZ7CO]LI0/QI/320^ 9EQ"FO)3:]LG:$3B;5!]:ZL=L4^,B<6A*^LU
M"U&;9&9[3F"L=A&GYM%D9@;CCMR_T9S"F(!G?'@Z/L&<G9P.#TY*"P,KC$EF
MUL4%;@,_+"7:W>0 >43S%Q^/0L2]@6.R23!&JC$*JHOTO<L+\.6/C2S.U@4[
M<A729W+G:T[HE$1-N.#9E^8YX%,46Q<P5,<0-RY+HB9<#"DJD ,%1>YA!0/5
MKF\V(X@;"BU3%:[^%;4FIW\I]H$"X&R]^?B?+@JQ2%_6-^0I-+E9A%,9+@A
M3"2JD@,<P%T[)JK\*<\J3!IPH:6N5TD3HR0*H+;FVG]-XHB*8R0WQU1KP%5]
M8VUQ$"#)/U!]Z[6S-X*@9=/-PD4>@/ELGS(W&A5E[7Y,[9/HT_C<"<,U%A65
M,NLX5Z9N692'X\E1/^'+QT[-Z6]CX6F*\8468%4OD!H7GA(::^J7A7HTGAR/
M/A'96H &LI_58-+<T4OAI6:U Y>CZH$+I95G[C1^RL*ZW$,>#::A=?YSVI4"
MB]S;/3(5_[#_VLAYX.%N!Z2C;VA*XF2>L^1;='S,&3\7@@LE<Y7I:@B,X5%3
M<TT$YWY$HVFB\RSF[7S$+<R6!<XY[JW:LF PLV?=5T$G+YX>X*8J3J=>@EQ_
MAB(5<%B35WD5+CIXMPDD]I5=VH=K/\(KD"1&,W_ZC"WX;%GY)9HM_Q,Y7OS"
MOD/?G!HXK.C0]TYXDF;I], L:3#Y(G>:SB;*:A@?#P\M^QZL39[&I6KDLJ@6
MBTE7M5%ZN<A) PAI:#U]36FZ"A*_=A<D40T<O(QK><= -I41K,0(S.1]9"-$
M[CZF;-:!9+?,AT>$E$",NHITJ;]X^94-@&JI#P\!29%H.DWQH.1%V;6%YTE(
M-,-8Y3!*?V3P-!&-IKOF9BW)KWZ(W-53@MM87'KN,[G%0-^*Q,:2\%:Z^U!G
M9)0(?&0(:9*6T>OENE!%APE=:-TC$N)!SH7HBFOZYKA>C5];LM:'QT]#$1F]
M_#TR?_YU%Z)7QUU<OI-G;1$1[BQ^06%F?=.32;6#L7'U8"QK9)"W0A\$HNT,
MLH8&:4N=N9N4/QM%+<RY\^K&CD<?1$\YS<68R4_V.;S65#4M@6EK]QA:)):,
MO"U*(L*"5_I<1JK"^F6.:G5P1D>36@N+XG:RZ,L[=ID<KGTL+9).B('_W6)]
MQH<2SP#<;+H>52/R*4\Z_"T3N\)'0(<B]\:>>-]WM$>:46!]@5Z#R&5!8Z?4
M1\"##,L&=L<ZUQ49C'<XB<K2$*\O5,B4Q70\GDSZ@PRM,M&U!0XP/R7HF-O
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M"Q=F5R@7CP6UF\E@I*9CN)O"L62VJ\:ZZ50NIF2SLBC)BH3%9&@D\L_? X<
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MM6ZOG.M6NN(^UEK2,'TR(/12R]XEK^5DT8,(A\#N Z0TQ9:BV:BKXS4!(D4
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M9]/F*)G\=76O7_9W%4F6P^;;3^_Z4N"LQ(2U7[L2JL&;HV#=DBB2-H5\Z[I
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M5*XP,JQD1B P4JBZ 4UVH:CK!X^M0502<)8IIGUZ.#SH!80(D.L,3-Z*!Z9
M3$R=:+%$PW4M.#\2VX UFDU4:!4_NN#A4^!YU">*B$74Y*YKV:Q[!XNF'?%\
M9Y:!/S9U\@';/WP:LY$.;7G87+TD?:)"$V[?97T\%#1F?CW:SN= 4P>:"K/_
M(+A#P]*1TC,MY%7F%,0)+=!AW/%8GRVA/>\Y2*<FSQW!G7# D>WYN$>FH3F$
M5%@Q"<V8C6H_<:'<XSE3=$J"-R757.+J0!9$B5B;(<VBGG*+1UA5%QZCT6>-
MAI%F7E2:9<@0]1W.^[994 RRA P#6T?@?0$%#*1<Q'5RD$L'&@J=-&$@FK5
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M*_AV]67G#)B_!G5\,-['MILJ]A3[(#X4L>Y1OV_1PY!8@WMFZ7MDT2Q7\K5
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MLC@?&9DTWL'5/]_#M^RU?JYA,#D(5*UZA+$!OT6U%>A]1_YQ1!9^T@B>.^Q
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MVH9.4-  ^AX$ZKN01@F*'ZV5H(>1L.S[97*<Q;(#:<H]CNQ<7*H1^A*#'Z7
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M^9O5@6^/YCJ,BC^V.H3Y$>; V*,%<]/5YNDYA(71.E.LF! YX;,&&*WGN7X
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M$%/OE@5:]X_ZSGNON]>.$1E>UG&T4*+D?EHPM1\..>5&/01<1=O -7"C8[A
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MF$H$0+G<CM4]<WG">Q\7[RV,31I(,)4D7OFIB?L%*[NZIJ'<7 NUAN; ^BJ
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MCU?F?B 2_ATNPB+)7:''GD$I$'\6N#84',,E2V79%TV);MO,WPCXLE/5(FI
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MT!P>.K;H>'I%.ZW"C"OXRND\Z^;O\1IH1N< D59V*$LM%]/(R$,F]9&S6N\
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MXU\MB:97T.YR%-$H'7=W%8@]C6LGT5O)#&AX5;6.$C&1K4SC#ZTKOZJ7JYT
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MHS6%M+QZ7-6>T=.EXSXVY-Q-6_E(S*LF13*'2'LY6H0Z$*85L[8I%N]+\\T
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M1PFD?'H"4IZ E,<%4A[>  V_#(\]<&G6O#[&H]ICFR]28""-TYL56!@$LG
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M,=^7*',0:*Z4-HZ6LP.)3:4!#RPW6 GW^.5 @]NI/03'#HZV\$LPU2<<9R>
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MAT9A_#.2O"OV:#4@!WYTYRMS-%(^SL$DMP*5,F&UF]5NHMU@P+4TZDN6):>
M+C:F-#R+GNC<U2>J>FNPMYK4:E(>AQU3T5-+!0YJDU(FW7NAO<A&@I2R7%4<
M5SO*(&2N)_X3^==7BUHM:@K0YH$T\#-JV UW%/DE'65(EU! >J*(U;A6XW*1
M5*4<Z<+(MJ].5/G*5+!6]<35;A*[.;9<A9>AQH\-_/R#ZX+&+@&)43$5*_CI
M",Y&F-\=:P5(8U] I4Y,(E6PZJKZM"4H&Y1Y9!M!)DGHYVCI8G=,-">IT[%K
MFT8(^ZSYDX*_<H$";JB47>?OG1$8"QV0.40KI $8><2(87W>R6IP>Q/$O&@_
M=3-W1.#'"M#45#9">WPQ)HH#:02.C(BU>=6WJ^^K;=QUP<59]JU<H.I.O0"I
MRGWU7R/:\B>Z-X"T8B-K:=6 8"638TRO]K)F6H2^&TQOCQ4%0^+)]*)[*$P
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MG$%6@);CX +#?^$_* <(7I>C]B)]([JA^2!7DK&:#L:!(B.\^!>LS*ZU08(
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M+6/@E=D+T4?TE!$\+K;(KCU;ZB%94&(+9%SP"ZK!WE3\RX*GY/,+X^DAJP!
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MONY+TFBEVG)+'5,UU6K7-NT)2"!JXL'%^O[*0TG?"=_LVF#!)Z'7T"N,#97
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MN0-0#KV^LE@&9+9)HB./S. \%L2(*FJA1:3.WQOS\C2$RQN8YILH?D$*7%\
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M:Z5>HH OWA[EH1HN"WTJQ^$BN3N37.S9!'6WX3JNZD9I* U7S#FAY$Y\#HH
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M?VF'X!;#LV[(DV'R*Z0YX4"M:87+L:56E<I=A9W8#"U1[K4=1N910BF+S1;
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M#OLV.AM#/WLV2WE(0@A>2CY0X:]+%6L%QP8!J3K/$*V>CJ%::(R$E+#L6.\
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MR]7-_ 4)ZXP1JL%T:4"+*T2*JDU#2T[T#)!ZOE&1&O,N/((3:1QH!!$%,X9
M]X@0(,80WCR54Y@>F#H"QY(+UTIM$;]9+!Z7CW1-DV%"/%-8;]K"1['^$7-O
M-#P1[NJX^?1W,@457,I=+[4H;DBI(B,GW'B9T$)&))#P CR83C:)4DAJQZ\G
MV/K#785;HT2VZBI7#%6J8HG<>'"QYZR0HT",L.%L\0>+.XJ6S_E>V"$EA9[\
M,KJWT1X22(*<^/&>@NWUL'@Z<8ND6%'HP;QX=LM8AYQF0@J61)_JB.A]Y3Z5
M6_'ZG([/9,XZU,G%T""-"B0)-T);\X0I<D,CU 5Y2U/$],@+#<NN1;Z,V*C9
MV^@O:G%??_1F\\I)CD<)T.A:)2WPL,H,7R*ZO$\$&"!L$.X8?&7F%>$WV9&E
MJ!:?,\1"R?,=[[Z(9B&R8&N8&(JA#CPO.O1BY2VH1R?&S!/MWIP+RY1X8P)Q
MF>_,V92.I[<TK<MRND<ZW:*W;!?LLPA82VDR.'DM!)[&O\MF+M$:[J[J3G(7
MZ@BN3?#V0WM.]D*4[,LVQ7P6F(5CMC>^#1ZWQ;FO:RV-8"TJ4@F4R@4(CB9+
M6@@Y7? @/*M3QPJTMY88YNF<+$=E?$!PQ1#U^9L-UV_ORZ[&0*!5E=4(C,9.
M@A)IE?I?LQ;ICZ(6L PQFW*4S37>X]AQL.8F@L4XXF4*'WK"<"J#YDG.;LZC
M;*V_KN\E!BU/Y"S@9,)>C1-0FK<L3E2Z#(/@Z!6'$E37GKEK?:/ZV&0<(R?#
MFNF<P$@E!7^IWU)N2*0!0$\.2A3HOL3QD(,;[+/S[.IN_J<JA?S<T60W39SP
M=;C$7N?H52^66+Z$6Q3#="[0K[/RB ,(\3KR62M@*!$!DY^73&O/J+R'?JQ3
M;&!TW/X42[D',IJHC8.](4GVY9;,S+.HQN7H G7*<W2H8 [3DIL6\K,GISB3
MQB[_02>IE"1=F):!'XMX+@#6F;E[69E$5[.P0@&(6H_'I:4QC10R%8YU)27P
M-E.0G$"44:E98H#7;Z)?>MVL^%/.9F\V?[*L.JG@I4;;S=Q"A.;8VUR I/)/
MRT&?%1ADT-H=>\)SC#2J%Z[[A&Q9L0KN!G4?%!P='F@H%]EP+&CIU"OEL0K*
M!184XV.]^M386V8[[WC@C_D=)#-.(QCNC>DQ* #D.+8:-C$)UGB*MVRF_@#-
M5UE(.4;O*U?N$)'%^/#]$]=\*OUZ<16=NIG_\@NV?%YD?1?^#7R4C;-/U\;9
MVCA[WL;9<H!!7N?16JS?C(C]J]/YV%ZJ_8(/< X$4W2L+4N3L8R_(MQHV0QH
MM=]72KVL\7)+T[Q_5KH/JD$6Q*F$.H3XP:RSCUN^5I9AATC>S]H&R6%4,!95
M3XI#'1*VU).RAC1.7!=%)JC9[U&UHA"LU(04B^6H"D*\? ML;A?Y+KD(&GYB
MWQI5ID.@]V'E2TME>SY)M=3]Z/*CJJ@_N:]HI$,7<@,(2F>S39IIZ.T@7LO\
MN"QNR%OW6EP1$0$J>AW:'= R1RK.T"CO.U!N8>"TO8@.&$<FPZ!$<.%5<-#H
M7IZ<V[02 TU_T' 6\H?WM%9!G/*RMIV+4;I*;(@S1+!MZ."J/,U"Y#1#\,I1
M-[.?Y?'V]<AD$A0]VR3!'"-@9+0P#0M3N$^B1!_Z\ @*9"FR0 >,SL,+(%0U
M-:4W\[_K&:<KJ1(I^PT5LXE5P;G6_T>_.8F://<Q8.FE$B5:I(6*KNT- ^@D
M%>S8K 4#\[&N[BOWDB[I2]:,JZLLI Y^JQZ8^V]DE2.9&@L?][^DH/JPEPQ4
MUE>;5.XCFBO*2:[0*X- >C=[A?Y7N*(P!!H?;E8E,_6](UCQKXT)H!81J8[G
M^H\ NA,22^?J2DWHG<JWOX8FAL!(4$\@N4<I-:"Y7X$]A/SFOJ)R&"ZO?.A8
MD@QH0:WEU^Z5:_E.B:A<:97[3EJNUSO&;"A)(L9*GZNW)M4^5^.+I5I.CU'3
M-%%NRG;K26EW=CRK2TJ8T@Q^ZOY2F\/18W95)C9%TV=$AGW,%:8XLS!%*,N=
M^J$J]XQF3#O<4W$:P=E1XT-UHQ[?!K XB@(R*"%PJ))!@=#S%,F@7"<SR7XI
M79QI<D8L+F>PH_+Y_-RMHI,X>67BYVZ;N8TA^X([$?U/V1?)41[)L[EVQX;]
MX&@>1^5W7*);*@D\PU@5@5"H:H:_P)E9=^WK1J<?:;U3F0,X- 96.[]KB/XD
M1E RL>0JB+K,,?+SB3D3KA60&W[_*A J[[IJ[JB/L;<XK!95BUG1SVPWS)8'
MJ#9 ;VO*/:Z\4'X'30@RBREY7DJ81X<>J5!Y5K&IJGBKE,E3,X2'J/L<]L!_
MK(T[73BIX#9A;N60E71=66;FA-3.+A)31*7W;;#1R'$R^QTI0^[NVI;'A6C>
M$9?*.,'X[^/^,5)<9T ICHFIZ*.%VC<KWF$Q8*5?"W&",0CR!V/CT_<;-J 0
M(ZD==AMAJ?C1M86ML46\5>'.-R<P>P6.42THWI(*4J/#AU5:8278NCE0R:=P
MR3Z%G3Q2OIF9N:TBS[1S57/WZ\GZQ/56^_EZ?":A,Q]UP__O^%V?VCUAT7WC
M)/EDV_&Y1D.&/1.YG,6JD^%$3U;IUP]$ILDG$_HAZH?1#5A ,8,-:S&$?4MZ
M5>R3_/E[+1_(,'9.*$'GM+E(SC@W/G7HGC%*) [4Z(' 37 (ZU ;X,Z$HRHA
MCG3Z"CBV29Z)YCM9 89>75F;5T]WS;XF;<+$M4>F-Z'V+&5#)\DNHR-PQ2CJ
MYD[:X.[:P=BLHB)%RA&4*6(MSO5&*;2\1CT3?LDX 7S5"[7P;#+XI\_MR@4+
M"QNRUFSUI%;CL[+1,ZB%HH+P'NC\8+"=3[),BR/)FH:HL&TGI4WYP0<L[WWN
M U&XPCL!$08C*W%2N'S=^KM7HR ;W?&YX#P6H&X$:5>DMV _GK3;/(9A@O[6
MGFC;G(_E+MS)UQW/6?%\GWTW(G3-AY:-=6IHS$58.4]5-2@75T_(/.HAF>1;
MRHJ=$.(?B6".R$4!4A.,A?XE44P?Z2_:+0CKV%EV$ NJ<!;0)>DX3*#%Z!+S
M33X*?%<4'+EG>O="VFF2Z8XT(P79T#\CLS 4>$(X3^<(;<B2FD;'X!F,I8MC
M)TFGW/6YA:)C[NPYS)*=KEC?5YWA[=Q[)A.9/*W^S-3*B-4L.%5*?=@8?\SX
M#@0*)$;DF%N2]Q?1;]M(LZ8U! /3Q\D$%@H5M+P1MSV8;&_,,*A#!> <'_P/
M*'O.K!K)+[D-H6Y!#@P$!8K#U:7+5FYFAQ3Q8#A2P!>>AQAI!VF"<I6WNRO/
MV'/%%8*?9L&76,A^ HIPOC-\]81&:0#3<3FRUS<2#TGPE08#<F>#P#[CM[2
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M6^(1S7 6JLL+W*5'R.3]Q@7M'KGLY^ C;TK0"UD&T:\U1GY'A7NNA1<RU$&
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M0N"C=I8C!FY$@LY)0,HF_A5R!^?A(U)1D5350EYR@S.51A>"0OA40^^:#56
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M_#P.P5L]@\S!"-^T!Y">0)Q\FE:(=8"$C$@*(@% C!NN8GCX&VS!UR"\)E!
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M!3OS@=9JC\*O^LU+)E=$O&FV&XU^OU[M-MQ&JUOK5<UNVW*<;M6T^M5>CV^
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M2.1V\O=X$$3\_W;XS^I#_.?,LL,SZO_N\!5,^('F3Y8?I#^<?SV6'Q=CDK
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M%<B(M7\I_O2*+FE!A7!5S%R5@)/IA7^>;-@9YS>GY'U)0K,'E%/3R& @(@@
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M&T*QE8B/TR*4+5S]/\O5%WSAA:M?R/?&R_>R,OVRTBC77Q4BO371ZY'$SZ(
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MVE<AHT4#FT3S7K_TM<N&&"<L">Q<9JAD/\4FV4C XNM[!E](I3?5/VL2T^/
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MLG0SI0XY(5A*7O- BU,M+$YA<39(#3Q+BV.99>O_%<)6V)S[; [7T4^7%F2
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M=2CP,4M<6/)\U=]I;O)[ %?Y(189Q@-.F#+%-V92I]-Y=\][H??[R-ZO8-H
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M-J<![#::(P:ACZ XWG"Z_0Q5*6OYD6@4NF(K7;56(ND?B/MTY$[&\"C</P@
MW84P'PO^/*@T_[I!=59I)N;C8F;MZF6BW *I=&X:+U11.R4^3Y=XBI_!IKJT
M)]4#:.^A=27!R4H3$($4'4$;RQJ_,K.<B.6Y#K*?X72BD=%;XRP,+(7KOL^
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M.9&.O*KC#:^W2.=>*W)N+A=W3GOC%Y/RN;JI3AKZFA,D:UBM23'-[;9^UZ[
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MIL_<-!GU?T![<J-%$P_=KG'ZPWB2CE@??ZBBT[KD./4QSGEB]2R92T=LPY4
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M[,03S?XSLO<S(L@!-0UI'=NC68"C,1V,W>_!UW:?80Q\_M!R5"2IWVV@8QA
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M8P1$5^<"^&1(.J \/V!_GTYN;G].<MLJ.HY6A8PU1A2%4XOBN05TCTPAHX\
M,"%-)E!>_,M<]M 7;O]+3<=^:!%2#<L/Q$W5E?0HIB""9LF6_3)7!;&<-4>8
MO/>,5]N.7__*YHHY0(ZIZYAO_7\OX/^(J\K63J<36D;C4N6NRK6*:M]HOG4>
M_ARL?V[L09?JV;S#_XD$K(6RE=X(@H[I(MUOP\6;'O#% :T2?C&R 8@24Q7^
M34&\,U9=WW:<!\P)*0S?A,>K;@0.L_<>[]N&2,[>'#?_\G5,7*@^5/0^B&%0
M">+CB+%(O/-"=?P\IRB4/$]7($/ M<"E0/V#X5G"*EXU/;3A(\E1W^PB?!U<
M^PS(+H(/=VI!U+-5!XH?G((%M3.:/L8B-'J'T!$?H>=3"=)6!AX._SQ#-)XR
M(L0^5?%%B% -0A6)&-I^E^%VA) EA(5'B.$>P9YWN1=2#BT.X2D$'TP=68;Z
M8^SIT6?:*AX:$7P-KQ>.M4:(BA RT'#)WL!W3#R(*2A:+\W1.4A(="P[ "US
M]ZG/'^B1S^]$,7MTMA3&N*6*]O$I4C21+E-].-Z7:W^' 5*U\+%0NI>J;9EX
M-2CQ#H460CV0IR9T-R<^X7%3HP^$$(<AH@#X(@4@BN.OF?@%4'J6*EP-/NX:
M+A@8<]W:@(#3(9\X$"<E%%^(Y#P;X6+T*+''GF_H/'-B!.KR(Z_S*;W3_F^?
M L:0"UP<XT" !)ZI@1;D(].%@/<MRD$_$^HIM.^(<*;LV;9O?KA86P;T0WPN
MJ_-@YW:#]A85C(5J4=5]2\6%,\92C. B8$?5Q9R_PPY\/X<ZAML,"1L@4W"B
M.;K./& T^%<%F=GP\>C%<(UP_R'[O!6K@TV QIN!>-NQ/#LX'-TG_8MV07NW
M?WHZZGYPX3>@%K=]M7#Y74). U* +B*]BO%F[HUTJ,*M\=BW%_8-WF*C_FS/
M068M2:8'B?#*<R*B\ DV6C4&1M_*@GL#_1FXU? C1"-(C4\&BAV(E, 11;G>
M'I5GJ8ZP*;@\(;JDE.RNWHT5TWO!XN=? D=+?/::LGA#$"DL$]FAR;7J/(_:
MB^56L7_X\GT(SM O@0MO2SJHC_&85]^%9 J^X[1FV^PJ/2P2FZZV=H=:?[LB
M7I7W%FNY7RCPQ>]"AP(#!2X7;H_?M]W&5(+<@O]T4,E;DVQ;K)@<O>CFS+0&
M-LF%:[2:@U4]^>T'%:4)(DH<:<R.^,1_>_)_!*/V,[\\,PH4"9_1_^_CO<VH
MZ%0<G ((=G?H3E9-2%)+Z.FCJE67.JGM>G*T<OJBNVE7G*U&JJV8$#/4-M$I
MU*8)YE6V@?J5O42+;R"B'=TOD2]PR6ZL/Q;RC<Y F)52VZTV^?:#>SJV55"E
M^-N%301?RB8V<DGFNY.2X<Y@1;N&DW&AGO/%]B>;]2<9FQN2PAA[E@.ZN;W]
M7&CENM'R&CK!Z97):!1KK(LK*'\D_71801^!6D!_=AB1PMS?1H3(<'61%3+W
M7NWISV0OW,XC<OCR0A1W@]CD+[D%#5CH>BAULX.\8I^>1[<V0;3)13X]535.
MY]EF4NX+L<4*G=;U=$14@ZV-X#0&G#0R1!!^XMC/RO:=<=1U@*^(#XS3_3M6
M(G-)1>>(!N'7%W6.;6.X>[,@W.#['P&WO+:5)W!)R$-!GSV_&-C.&?3R>\B=
MUJ%_4A_W( 7A7.IV"WF=>,M1/E84]F85C'$"!IA3+6.3T";5;)NIS-*.GC"=
MQ>3WM>K1F=0\]"[(&,_V6AJZ(>@TM]UL@H''U6U=J9 *::4)@6H-UQVFI9=D
M!_'$>\IV%3P564W0@H*N"33M7S3PL\5VJ(F?3[^_C 8^YS[^BCX].H_=V<18
MSS[_\7GKR*-[Y[C M&4YW]#20GJ<T(04V1M J.:?V(]4;W1G[7Y:BN ^ ]'D
MW>0XKVNDMED,"FR-\M)"ZPIDZ#.TQY43T 9%*1EI @G\BMX="]LX]<!"?&WK
MQ*A]!.T-*D1>Z*K"AIC;C&P,-C/(?Q!!#P]"_>=.!;[GL6 Q>(H(\\"?1DY.
M< ;/,Q9:GHLB+'Y8[W,E^8&O_VX1H@_'P0@<5822_!,!QH8:FD/H#OT*<&.V
M^] 7>J>:YP7,7Y?C'H6!&-6)F;37882RTLDS\S*1H0J0*9DH2?)1(GYXP2_F
MD7 KOV0K<0;ZZ+XMF]E*I\93JVR[G',]CR@6X@("$S(>9?@C!Y#M!]3WJ^\@
M L1P_=VW'U$4*9T#%-*'9O93)%(W(U5I$Z$X/U_\VKH*PBJ2^6);095R %0H
M#!($UL_',ZQ(<<]9Z9=?SL\S6 -!@;/0W#<-O/:=*@@>,EVO-3 =U[1LKY?J
MMUV]D>3(RX1'Y)XZ: X<.9GMN=.F4*OI10UK(&2M_2P\@N)G1PRS+PV-7-G6
M=INZYU9E<:CUMN/*UETXL7CZMVV[G\1**#W5RV\4JR\ >EG(5\OJO,)"@XTE
M/@Z61'&TY#!.<C8O^K:%\0NB),/49B)Q36,I4-N5, 3+XF;17OD[^5O _1))
M>3>4\BRF1^(I 3Z'#/'G#/'G<9:-OG;;),F26CHV8=;KMEV/NTUT:\+3D0.$
M?X$YHG\>C(F\BL,<S1F]MOQM24'*PW=14*)G8-E:!),GLCMN=:\>R%5E#<'6
MQAA9^G.=4:W;#A(R\)UGJLS^9+G4LSBA=!KZP0%':[!QSE/%.CH:@9. ;B-.
MT8Z CA+RSDNN.LC(O7\>/'Z4XXW'JHP*B7#5MX>.%=M+L.*O^9DY&WW5#F:!
M@!^^1P>2X[_-A&N%"_*].+A/[M39*_V 4A>96ZC4%:]F:MEN#'*,\9+9=VWT
M%]5$A4SHK4>^$7GG&XW,4Z03S'TO[SG7)1-5(S1P*(CVQSO1R-1:[?*>+R8G
M3IF; "@?YH4_JI7 F=678TUV.7AI*:DZ=HY74V#B5^"Z(UPD(<M@[I=7H*4%
M&<U_ORJ5/'_E9/LETYN4L: BR\_2$5<XA_60R44UT6=R@Z9@=)/#AIOJT=UA
M8%*I)F3+I/O!.!$-(Z^@>I(*JB?;GH$ST5#Z]@@1>:%$9$>*+REC3:%2F?KX
MY?7/=!\UU2TK&Z5\UM"EK)>0-YP!5H=T/S[N6NC^7K4\$B]51ALC!1N#*8&V
M9;]Z]TLQ.DCVO^J/.0K)4VD)_*(%J!SGDNW7Q$&*(^6.BA;\0J87EH(.#7S(
M7(<S]0LN4(&.CP;^=Q$T(=,(_H9M&$R()&8ZZ;G.4WAJ/_FTRB>3C9>"SZ2)
MBH:@+0)P(9\9:)/GUAYHHD%:8]B9>*J"(0R2V@"(\8]"T,'OM]9,PX?--&$S
MS>\VTT#F#T#6K^S]4!'N@/87U"'U_CL^!/,S[<X>6B-;" $)0HW7:(.JW7%Y
M\ ZM]A3FSIUSX(XH6*'B)3V7P+?3KZK:CWY3F&,[^.4[PDOEE&\GOS3-''U
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MX%DF_]*?9^<7K:JHBP2%D#"'><X.:WV:(:9;0DZ#?&WBJBPD ^\4)^\7=@3
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M%'%;K^?88M,>C8E[PK;.7K[*<5Y]*1W $OZ*5JQ-4#$F6+C%EA-GP, YFOT
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M28S@#F!N M[]FU/7W-9T#II,[^Y)^>U5G]$HD$9$Z?B_0[Z_(42.P E']_F
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M$SDMEI(-PTA/A+X<L[5873'4=LV9R)(B4^%8[+E!4$' (A "9RR<6Q_SGJ3
M=>R9"TJ!U#3"MC;$4B+L(2=6VK5^J:H[ UXH.A&.4R^.>+EN4[._:VZ?B"_7
M-'?U_KY=]R;Z @ZI$T,-W1*Q=Y&"!!":V :Z<U@0+4Y60X 681,E=R96$SW9
MHWW]"XC'UG/MLD^QAU[:7+8>^IS*E[59+E58D-(=M,LFG7;9K*XAJ08%4LO0
MY[)IZL86X>*36F</MU;60G5XP0G>'T60Z3!"?%:? P+=AL .(?YYW\87NXUK
M<..A_\ ?0,*FB'_04=#?Y#]_A2P]M.(,6;?-D P>8%JZ ?_"I"5)AB@!40$>
M*&N\O("YQ#ELEX:5M?^ZBF2D,<&1:=8A*;:F:Q(087-(6KWM0F0VLNE]Z4,7
M_+Z.:GW9AW6G;(^9+M=O/M1;M<JF9,PV[?=&D.&#RYH)2!,R5@&H-08!X5!:
M-CC#8'/LUGRDBH+9+U*#QJ+=:_5R7/O7GSA-A(%R.Y*5T9 KH#U.YJS7*IT%
MX#%62UK,I*@JI+)=/I3B#<K.]COK&\*VW"B\&[HN,#J ZL Q@99JB0:L0.2D
MW<SS".4#^+R]BI6[-:*DB.O-<-*;YTIB%P#\.$C_;P"2^0*&5B"0-<WF5'4+
MQ2CX+V;P:*@'R![LVQD0"DE_S9F(&43.4&4@?0'E<Z&:O+1E :[)K^#U[T Z
MVPM'(*_!;RU1 P"9HWOB<:_[%,@?T3#QS^?<3$=O<+[4;<N$. 6FSDE6@VL<
MMH4R8,X)@#D!ZUM QH2X"0#9<9U["$AM.AIBCO8*#R2($UF#4 "B078D'WP)
M.K'S0BC#X8;PCD5#@H<W0H:H&Q*GR4](6[B+76&TEJTIV)J.%!5X&WCM/^ 5
M_G>8 (?P9Z8]AH>V9(0&B /G61P:LW+X9""3@&')3_T?H@AL\A\3B&2@9#P0
MK[60*IH0;4#YQXE_NX\2 2  &$P\W@68/0[LT'<0-O_  X+=NMOE@%:%P#MU
MU.AMM$%O#R0\M-N@[#<QP'Z03)Z(\.@%68/7(60A (J&;IHGA7)[0LR$:7W^
MJ$32Q8I0FX_-T1+*B'"".LZZ0U(#0-!$#$)$TA#Q4-'"E^UQ))3?(>BEP+5A
M*$W<9?M:VA!Y70)< YDN)  +"?$V('6=EU'ML/<:'Z-_ D;UP7P3VXI%A5C2
M_4?E(:'&"I%W5T7L"_,^^%('A  .G7-.?!(]G?DC'8\+.5X1!S7;;G:8[KS!
MX%LK3JA,K]P:V"YHC @G&\"(46V$&<#RD. $*.2!.)!7J#L0_&:B0H0"@8:$
MT)0S@(\J6I8JPJU"DPDZ Q# KB#?$X!MH"WDB0P>BDD.?!$-^0X(12JBR-#$
M_1Z56J'B*P& 98?T-=!PX"/!YN$A)L!6<XX!2.NLS'?V-.941(+F5 0R$NLK
ME\1V>T&B_-7[@3V6Z">0HT^\&B@)E\"!5I)=<\69ZQ*R31>HXF0"00R@[2V:
MB]94%_ ^3WQM('VC';X1J"@GK?*5[2#Z(E90WH7:2X90?)I+RH5.HIC/:FEE
M&AM/GI+5]:\_Z>@)4VB?<I!!<6%!<^!/ F#[_,F/@;YC;N5B9ZI-E<AJ(\0C
M7"2W+#TCLP"?\Q#\L''8%+5#V+O0;G&RT!!/BRB[^<2DZJ.:G(\4T[,ZV3#%
M+0V >UV@4<2>$TY\!&A"QDPRV6F_D:^FF7[N2<A5*[UG].\%@%8W+<E^'*6[
M_2K=-&V=K,@C$<AU33\1,CH4\CQG3KU@!HI_N%+C1I974PM5.. T&%M'-OEC
M2_Z8YP)H%A3UA%- D1U.[-L"4+$ P2R#<Y5;S6@(F1 \#P"-9+MG"4 ,FWL"
M.7SD+OBDYD(%3KSK1'HBUHD+X(_TD!O6>AW=(C5ILBS?[(ZKLTROORU928*U
M2(X9K,^2+NVCW2/215X=NJ(56>,0)KH&<7Q P_.YKG6A6>_0K_=[X#8 =P:@
MH<O!65YHS=YO 4R=WYB=V5-^G7TL$]N!LK$>E='3FEB_W5=%T57THC(*MH"S
M M@#@2SK0A>!"/,<M!^:$Q__(>R<Y(WD3,PRU30_5<24U+0W*6+ZT&G#&S92
MX5CRA-&#40&IP2,C!"/L^\"@ 7?QL,'7Q"GU6HR>05K7\P]]'^YB@0BG.V7<
MG+BV;4\O S #=[9ECU69;P+%C<C$D/DS*EM9+)2'3KPDY.>S+37:QN+Y?J(-
M6R9/!"\\>\TQ>V7\,D 1^#TP<H"=$X=4G,"@$\Q#DN8F,6&(=]E"<IS1! !3
M:(6+P"1]?K+BX_!IE7ML]P?Y[9)L=_I"<5/=.OI2UL#)&.N9=2Q<1MY!8#GE
M!98]*" ;? \.%]1H;]C;B3YH^/=OV0*^#@\WSSF;KXD<&AUYDY3(<>!#1=M!
M"A10/Z1ZX#PYJ:P0C.\9(<X)E8'W32.6'D%_A/2%""D:, MZ!+""=7#6$,Q]
M@?^X'@V,D%W:[WXO*[WSPB?WG AQSNC/DWJ(57*:-J,?NGTY94X?RMUBX2$E
M_?H3)\/)Q DU!$GWVK YM'KIG%!JVBI341)MXE&+#<S-,OX)L*D4*N)XPU"Z
M,GSL/ZDJKTNE.1#/,3*<((Z+O9"1"D0MIKRMR!EF2$3!9C<X&W+L01*!$1N&
M0%(OL(.G;D_G[/#4']]L(QX0KP&S[=-_]G.:-&25:PPW.CL.@(JYQ0(>HQ8B
M\"[@_9E%__/_]F8S>36.</2H;OQV,_^^@SDSH2A4!"")$3SZ"<5K?W/JFMN:
M;J5<.DJ[106_O>(!&DD/(DK'_QWR_0TA<@1..-;4![2]L:7.S_8GE[H?OC""
MRL&-I2]^4V0423?P3^=@,3*:C%\)6P="E-[AYK]<:&I EOO?7C-[7@%HD)?4
M/57B? 3D,!H@B\Q0- EVIQ4X_ZBJ<^2Z#^I3$ 34[ZAX''9_UAQPU/Q=*L^Q
MJSR=S#PC&2*RDN]&CP)/=053O^K6+1_ L4-$YB8T-'E@_G(P'CX5YZA]U$VA
M 5=4T?1U9*JOD3"#_J8*(ZPV6+0PH**UMMZ#IL ]F7/;T%@,F<!#0"3D2$L@
MQ8'HTQ<H"@O(:FJ# \,O@ <MVI;,FSA$RJ&$$?82X+J2;LA/@#QZOI7A4*N6
MW4MV8]CKAIOOAC%;P0EWNA43G(N7?2\=W2S,A0#/RG-[[B0,80SU&HD63P7&
M<;2,@BHP[@3+*,\-ZHBF"&L!@!V=VX&-,0P.6)+P3\B4<$L]'7@H4"46= /=
M76!FMEZ@"#H_K$.5'E'V8+"!F2.%5>>V\+6.Q]4BN'YS(14;Q'S=ZICV0Z94
M%M]7H73XTCH&+H-@N[.03VKC7B^CU%?51K$OCY-B05LRS;@$M7'B9&(=426T
MY R8]C-PNF#.*2+ J KK'+1=K0R.^7,6)'67#EW*WZU&*4) 8X:^Y51D:HXY
MR#'@IYIHH;PF\L\!]</8/AQX#KQ'.!9FBPAKP4%Y&7&S%PYOP&URH04,W>,<
M(Z0]$WF0B#IE#; <S%_P(A"0WL/<+"2*X[I4'@+8T$,2H ;+X60O-Q :V]N(
M;H.C+7!6"^52(7S$#?!E91/Q)(PBN'EE 04YCA(#'K? Q6!S0"^C! #.7/A@
M@HN3IC( VUF8'F0PIIQ/_B _%[Q8UF"2X.C5WCX!0"1Y!;?P$4_VE@R6RYKZ
MG'H</2ARMSI[ZB92JRG5/H[& HP<1&-/,A6.2S4GC+""\<2&#D2CV)ST'%@"
M*/BX:E!N,F2ZQ6V(;9%AZ)C=Z)<[,&M 8.4E $OKT"(-<?C)L+@(.E^ 6F=
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MA7M_!Z>#_A9G- T\F6L 3PC<.D0 )[$>6S5XBGJT9_ELDEC4N2Q;FPT9:/
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MF7EN7(H]Z<WB++-=?_X G$-"V1_O LGIM85$7[3?.!Z+$D'+\1WV'I'11"S
MR_WA)>@)NT^\!/QRKW@)T'*':$E%$X':OT.\!&+L/O&2BL:I "_WAY> 7^X4
M+T#O!PKF;F8GO.CF_\#VU9=$QT4:]M[=GG>^<>8B;9N?WDCRL8[X@$(^G4)>
M<-Q^H,!XR6<*>.:G\\Q+7L*]]8 /T;]$X6(BXP?C_D6+]SN)A\#\O']F^7H@
M"8S2@&X"4S4P5;\5)WUQ('TUDY8!Y^,D\:M8M%]/M 1V;F#G!BP4V+D!W01V
M[LTA$MBY=\-)7QQ(7\W.[8AS3M; !@-+-[!T TOW+N@E8*' T@WH9A\D%YF^
M?F51\\.SJM^!A[Z:^08O\X9-M#:G?BDR^5)$<7T#[M+!:TDR1(FSQ \-Y@]L
MLX [[L$VNS!S-&S4#:]/ H$9F%W?)/,76%V?2B(]T9A_*?KX4M3PY<RM,K#!
M9<V4^<#<"LRMSS&WOL_]86@&D!E(TT^TQ;X/\>0WHL'+IAAJ&3(?F&R?;K)]
M'TKZ#[PTV?SK2Y'0ER(8QZK[/A0SX%3[(@&V.YMMVK0M$PZC!"\-<5;HS!7(
M%$&F+\8H=P:!2X^0_R9W\9C(4F-9OMD=5V>97G];LI($:Y$<,UCO#R=E3+8Y
M\29#DFFVFYR-4KE>_"G?;'8Z1"96JD>XM7\::;E1^/ \4L8P.$U",^@SV]V2
M%K>%'S%K< IGKJ2/R'$\\,0H4VI(I6.S5KVL<*O8X[I$]5I&OLTF6>K7'SI.
MA:GKW"IQERQQD[GH=P>%BPD&7&]X[X+A7R](AIR\D@4132QV9,.C):W;LB#K
M_:$ZKNM-KI=YVD@?E@W4;22#FX!W(L*NLX%\C1/R@NZ6*",U[4>4K65L-G(_
M(O2F#) 7\5]_B"CYW/T17T]8O.ENU\^7'HY[<N=PN?!-QG>I.2YW.L>!^)(X
M_7JQX"(0F*CXZ!LXPQ<VZ.]*25_!>O_XU0*?:\PC4C7+6@M 4Q>*AFZ:)]0S
MMZFSQ93$)/)+\%Z]7>2X^63-IJ YGR*),$$0U]/0/]!V_Q8,_^F-01]F^/<9
MY1]G^8O:Z.:;./Z-=KJ:W+3G5E-C%?MQODW-B[.J\,0 00#L=#H:2WQ=*? E
MC/*[ L)5+/!O(?D^OVOI<VWK.W.37*%U.8/[S@[XO8/J1\<-_><;V.7P(J:R
M:=JB %X-X(G5+:[8\-_2Y!'O"6T;YZI/N<YPUN]3MO)H$ _I0BFW9M/0[(ZE
MPC$Z?J1O__JN/!!$T7]@%#VPUW<"XKTFNTDM^7%D7JL0W"">BIO+.E$HMX$0
M"4+K06@]"*T'H?4O%5HOZ,9$E(/@^KU5-O]0*_^#T7>'FFUCI]U/:'"E,*/I
M2"'QD!]V%XT'M5]6N$2;)0GH!U!A.D5>T0WX@3;_MY (0?3]+JWY$QS_1GM^
M2:[HY'0L;?)4@M8[A46ZTDQ*4!I@@SX6Q."#&/Q=HSF(P7^_&/QK*]\I(O H
MOV*0_O,KWX'NKI)Z-=L8+U9$MM9)Y2M#FVQU[[SR/3YOS!\KV<Y<L:6$G"_-
MS>IX#(QU$AKK9)@DR7 L<<4\^9UQ11"V#\+VUZA]?Y5T^!JU[XG'5+6]27/5
M?'>[G(FF06Z-WAI*#&#04]%X\EL)BR]AX]\[7(((?1"AO]<(?5#\'A2_.[$X
M<B\61[+V5-DP\F-BTA=%Y:$H<?5I=GGWQ>_;LKS8CI+Q;)]B'GKI9$$K+C)K
M>"Y@T<?I5)A(']?A? OR#^+O0?S]K?'WM_/\UZE^7RA;>E6+CR-*8IXH+8E5
MQ$JWD22 Y>]T-)GZNG+@2]CE=P6$(/8>Q-[OPE,*ZM^_=&C]Z+B?41ES==/\
M$O7OVPJE&HS:M_+R8%@9K192I<L ?4NC6'H\'4Z1=% !'X32@U#ZM[;9/UH!
MGRC4:^2&B4N*K9>D1G,Z,C8;)$90@#UU+$.^L@CY$H;\O<,E"+ ' ?9[#;"_
MNM2&#+S2EVKDZ<4F).CV6!7OHDC^!E4V)&NJ$[9L](Q'Q28'@^%X;%GYF'3?
M53;2>CO,;7(=)2^2!4I.2H5"O<BP9 Q7V<12Z7 R]H6C<?>ELX.H_%>S\-_!
MY%^C6(:H=XJ$E"BU^F*[R&24^(0ALHCQ@2U/TM%KSI6]*VOF)X;@CWAG#P@1
M4^0C\B:"(?"[A/[#YML/Z?Z@9M7[B8:];/5))9&92H>__="6\3_A@P#   >I
M>V/BG8\ HZ>B,0\;W^>6E^^4-7CS&%_/ (/RN5$HLHN!L)WFMQ7.J+7GHJ",
MF \+9N(V@MF[F0D-ZS\ABO5"IC0?/$@S)9M93P>5Q[94;[2A*$X#41P+TU0\
M3">?JU[\3MD7#OH0G^2.W1D$KI^>"9RV>W?:?%QPUFD;/24&-2.E/!#S![G3
MVA#-<<98LV3<:8T@XN%XXHI.VYVQ39#/"?(Y/\+;\\F&-WI[6U-*CTRA_9@O
MCI/E[J.>WJXS#)08P-N+1U-!:\1/S]R\QR6L/=:I<F.0LQ3Q:?PPS'1C9:K
MW,0E3$;35W()OZN8O\]DT_=P',<OR_CQRS)^WW$D3XCU;DMXV(RHI=!OII*Y
MJ5UOQNM/2*R_R7/\VX*O^^,N W8GP!M_473+&A 8UN]]ZCZ4%/@;;^P2!5:\
M4B!??J=TXI@1X8X<LNQ-@9,J288H<988DEU,A58052%]$M(Q.D.B6Y85$E#Y
M5L@"O]S">QY#(GB3X/FY(>#BAB!!A@!!PS^(T)HS0_^Z,/E_O&3E,\,H1Q4K
M/=WBU.<C*@W.,-AL[)'E\U-]I#0?$CF[5%)F"UT"3 '<HP0=3J>/W2,$]VN#
M^^U3=;X$N!=;I;N)E_1E?_E K 1R&N%[L38 =SH13B>/N_3#(6"2+T3PCY6H
M;J,AQH0\<\P*@%D,\2I\<*0&'!BR"!Z][4)D-K+I?9J?+U1]*XJ^BLLZVBM;
M5\I9(I%,F,2\8)CZTQ,UCC?7[\6@]Q[16 %3_C1"&[JV$DUH_<.]F@A)_N^S
MNFDU=.M!!$?E=4D# D[PEXJ>1&'^P;12]M.,)H:5R)@PG^+M69/Y]2<=3M-T
M.)$^GHT&4&!XSP? W6T 2#WXMPBPK +Y*(0L'2S&>W8E8S34FW(6^)EIA603
M_8)WEH[A#[T'Z\"P"7&AM>/Q1#CL\H06B$(AW;S"5!UW8CQE9V:1?+5F+G-6
M5RJTN9N8JN1A\@)K@^CGZ#&P@=Q;]5 8K84$QFE;@"M8BQPT/;ZFZ1$Q%EOG
M4C6AJS;[W:<\&:-+X[B4ELYW/"*X!R,=7PM>JE04RI,442#L;*\P,)C1JA!;
MG[].R94_ARJH#[C 0)0NP3<#Z\X0<54M/#/Z G&%"06I\Q"\%#SJ$P+5>_HI
M!Z0JTD^<MC+Q1Z;3+U[6X')'.;U7J;DK!D!D V&Q>]4QRG8(=19CA)7G0.O*
M8)O.I\Z#R1P1L9J9DJ04]0>R0V<ELRO?,-P^P'I4$_*._NGI\*,72Z<0Z3U0
MI86EJ?$Q41RD@7#LKH4R":V>&!VF3RE,H*L@';F^@:,091=4ZC:@I&-*:FKB
M ]!3SO-R\KR=7#+9>C_1FVS*M2*S;F9O.,KJ0P2D\"K?H)(&UQ?IX:HJBZW)
MJL[ EIQXF(H?E].?(J 0()(Z9_!35W%3 1$=$U%OK4,B,IT')B>RIB32TJR?
MK336HV5KS2R(]A>E(FT;J9ET@YGDN\:R-NQ'Z&5AL7:IZ'5BZ(B*Z"N9(5^=
MD/)+FU/;-F=8HJ%NRQK CZHB,Z$)_)(#,GML E]8US5"H9;MC#Z.Q(C,YJN2
MF:)PS7BF3G>(>63T.&9XX%//@;!*Q<+423OK!)7)P-6RQ_!EE@S@M@V)$)RA
MI0M/L& '4.SY_7<O*/DVC^$;DU:U]<AJC9Z142+Y7#+6;19K?+&]1TO0$_XM
MV,9:!T<5M8L1$_J?O9V3/C+)V(NNE12-Q[ZLYFMJMJ441Q0@$VNM8W_S*,SL
M]\#]Z8J%(490PN+7G]#$T.>(G 08;P6DA2SO:.B59CMQ([.=>!L-$E<RFN*1
MA&56XAV1Z,J=P;C>VR;;Y@U]NP_)(7-=S20ZVT>6:%*3RIJ<]*RV#M1=_)R_
M=]+HYB86%"Y.).;U,N;0;?X0?F]M3+.%::H][,L&(3[:DEDEAHTES]R!$+&?
MAN-.LY55B,0C44L)LZW6*TF_7B4K= T'MKPHVSO$#;1](-$8XIR3D80YH*(U
MC$N[I 06B[[B17OABIAHB%'5PY].N948XD(D$8&[# $RG ,Y]JG9K"^4>'-R
M;6[T-^1&?[&T1]I@PLG&<>+-B5/NLFXX<WZYU-NW:!G_R)0G]"44>06 @/.Y
MH?YL4^JF^^51OEMN;7I28I4@XNU??ZAD],34"1C6#R%XOB8?]RVNNO@$'%!Q
M1:%&M$P10T;H51M6D>STU[!I_]2]=:^1D!Z:#N.H(<BN/I:$G 3%_!PE@FS3
MS3UD5 X89-VIK@)1X=AE"R"@X?=S71!5YU%>8DB5)WL,?N[!I@STISR1P8=S
MT9KJ0C@$5OI3&%/P;U6>P]NO0E,96(8&K)L!O@?&*=R)I0-L@P/I"W \SM0U
M)-GQ7CC\?FZLVU9H8L,[2+PT?VC!64"BPZ\!]2YTTXJLL)(+B4BM0^Q&T<$,
MV50B$V"MA@PHQ>!Q4%$(=,7A;F5 L 9TFM#7"VZ+M@"^[$>[X EP6[:Q#0']
M#$2<)0,H<A;Z(0#)SD1&5C#G)LLLF'*339BL QLQ;?QFV9JB'^YR<$ G[:LM
M@(PB0##>&<(<^!H\UAZKP& "XEH1+<_@=N ,U069_ >_3=<<$QS@&"[3T<IR
MJQG>?[6WB ?Z55<!K*$.VH<.YU,'BX6A<_S4.9G&Z\9"AZ?"&'>Q"Q0%4$S^
M!SJG>W:K@*3 +IQ]>C;!L\\$Q">K0*OSZ+DRV@;8&-+Y8Q' #T,,_,XR.*B#
M]M#S'K3L\8B Y"'8Z%8650%B>M_"?<G360!:9K6DQ4R*JD(JV^5#*=Z@[&R_
M\\9LTGLMW!HS9[;&<%[I9^EEIU3N=IG9_/-%KR=-&6!%S-WB" SDG /C#D"2
M)VPCE$_:UK?"2%PFNB.EF\@,%H(RJI=@6/?:2'@V_O$&)*S4!F$EVT_5O-S(
M+.2'_*RRSGW^0/B/(<$LMC/3V:0Y)>1<HS@8,,M.G@,J[]A#//K@WX!5><XV
MQ2.MH>F63V, +EYP,G8 !%W$7V->]&0A+K4#+X"(DS6;<UX)./7/?\'_N'J6
M5X%A"HLVI__L6^,T-(*=DDV"^/=5RC!Y$>H:U^JF8F[AJ5?N5HC Z[ 6[K[1
M__[/__/O?U='&N%U53=^NQU%OH--<2D$A0I+)3$R!CI,B2!/_#>GKKFMZ1PT
MF8[2[H2)WUY3$HUJ\(@H'?]WR/<WA,@1..?<)N(#FE/'&E'%B?7;^9G[&:I!
M]3[431EBZ#>J7 $:#SY][[D(-Y:^^$V14>2J@'\Z!XN1T63\2M@Z*$6D=[CY
M+Q>:&E <_&^OF3U5T/)R34H/FQ830.N $("UZ;EXW!\?VL^1ZSZH3T&0<RM6
M^7%C&=\\E55E/BF9VS&391N/;19=ZH+>YJWLZ?QH6!W1 T(V)FVSP#UVQ],U
MBRYSV%])B=G>H-JLD7T[M<W0$]%*S6,,2QT_,Z(F.(-N119*-M.LTYGJL-!I
M2"QU_$Q>: _&-;*T)H9Z.25*G:E>E2669HG#E0UJ\/"DY\Q1GAMSM>94+)*1
M(0-6TH<KV63%7$VRZE 9#OEN.3OB'TF]#58F#E=6EQI;G5:-.B$V8DHZF:(?
M)B.)C1V_G6DE1'.]G*:(9:$3&RPL.C*7)#9^O%):%M:]VGJ5R-L;H3C*=XA(
M;MT&*X_V.7R4I_U4?Z4JV?1ZHI1;,=5*PV<>[5-(#S5KFA588OBXS0S3RTYY
M(S!LPGO[@=S#OQNSDY7>>\BP7(,8+E.Y;+66Z/0LB85+J2MP#*! ((Y%4Q01
MG3LF.S!!@5$-C"_/:((;M/9M0&RJ'T4?N)U& IX'S.%CRQBZ//BD/D=%PA%
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M2_F]5@S>>0DZLQ,67H8*BH/#G^DD&PEZ3QRHT%]&"5B*JT-_5<0'K0[*<[+
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MDT>(26%D?ET1$.K?]K\#9:Z1Y^"_/"_P?"Y?R?MD<_51OF(>7 )/21R#/^_
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M[-N=!,YQ$)7/HS 3SHRU7."A6LS[KH[*WC"MV7 GX$[*9#[B *ULD$2P,*(
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MT><(7^X%7E#)PY$IYII499-$?!47S?!F&WUYKYE;0:/E:TH\%#$,#3"49W9
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M** K_"Q'5; [0EEVS*8UK "3PM>3+?_G"M!S;F0\&L"R<T2^HV$YX_#*00/
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M>HM,)ZZSY^\68B2SM\/?E_W46Y21ZP7D_-1P-!,1BS(^]9\<C'?RO817+TL
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MP/>?ER!@8&!@8V&3X>"0\;VE>LOW_SA>?P (T!'QD,J1$.@!B 0(2 0(KP,
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M\\C+DKUKU_H+S2A7=1N/KOV/;?27T+1@F!^/.5N8/U=Z5 ^3T83,F79=U64
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MK9X3 J"?%CAOCP00G-_J=UEC-[(>K@T2,8U 9^S C/B#^XRCWZ8Q^QMN!73
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M) P @4ERC!4T[,P"BB)-;I$; K(?XOP=Y^'(,7(L4EO#:15'"2S_HJFG^N'
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MF77 O>$5 *("+\*;&>$"A\TW_#*.Y!]CR9Z/I:*/I&F"BCH-_2"?=3QMZX_
MU3544K?#XF@,+:<&>MO;N.U;8>^#VH+9-F!>@6JJ2D%\NHBH:G&DC^XSR1 [
MX:C/A[?N$J>IDCFL*2:AV3R\X=+DM4=65XI!HPBN'&'2PZ6;_K3&IU7<P!FG
MNQ,9E!D;:[&B3/[HQ&Z9:KU_<C;.ZA.]%)'MJAOY&6P$;1$>\KZ/GK^1O<+F
M&&%7ARMX!^[Z@'==?8;5?_]$I7V:"8J/33JJ979J*C@R3F7)?O-=9!5]$N"_
M&/$B[%ON%R":9MK=$KN;]L!KA75#DP&MMF\!DX9XJZH*.I>2V/F(VEG!TDZ
M8)I4,',&=9S*'!L_]82HJ.A?*'--66T-Q&1)/$HP#Y.$6L$>::*F^?F0<=X)
M:NIRYY5SB"\[(ANR])P @EPEY>%F;8&(FN.=,S(FU ]%?R/L@C?:+O] #J+3
M%-O'!QHB\%ZDDQ(DC@,Y1?I+F")WARZ1KW_M4K7]JRB?&T5W5ZJ9>OLUN7=H
M8>S?'L,%@B\3<\3#W;W9%#%Q(:V8"7X:>O-8BH4G=2#'8?IUOX&X@O.TD:H
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M+K201FN$U]:6!3-'.%O9#YPUQ?L?&W2+.EO%_S7]N=-6N.[LPKAY[7>D)?"
M/8#*XENX79;_5$K53>Y4K7^9$TOL5BPJ496[(.C:VH1NB]F-JF;6R[>V0NG*
MN^ >IAAPP#AK'1G_82!I,QF>6VEJ2(2QI23- ?2G=E2"1?DD(B"[K4EA#O*:
M $VR/V&&AK[KK'%0+I?''^/18TGR4"[W!6+>^Q JNZQ+YTLK'@H+$R>R1)V_
M#+5WB/W*.4^ZL]6XC14?ZDZQ%M]*ELH ]B[4;H&"V73]]/RF)Y3OJA+ LRXL
M%RYJ?[Y=<%83_MWFD2';Q!N"<I>L.'[MW^.P"@]/@'L/M;3ZS/8?^/M*^!+M
M2&9HU=ED*Q;8-A$[85BRD#\0%76"A=2(3S/GZ)+N?'KUO*<D,RR5G"+GUTLV
M1^E#W.<:(G/&!5)710B#$1M^&+L4($LY$9B8Q6+1=G2QOCBHF=U;D,POX"Q&
M&-3F?_@PF:]TO!%)\?%-'SF60Z:98>/-;6V$?)GA1Y-)Q$V$5 ^/P 7_NQJ.
MT0ZG47R1WY2I#L,Y6T3%-"Y6V0MG==XX,M:IO]*),7G:B)N*-X(R2>:9"1K9
M7AII$O6YH0R>3LG_S/*"#!.YOY3*WMOZMNY\!>U9.E'--5W]^.S2_"BN8[,C
MF&/*TIKS,ZOAWLH-JPAJ)UZD;]QG-0=7#M=]P!:&*-+> 7A3X++GL]LT1;;T
MLOC.UWZ80?&+6).J*ZD1$O,^XD>$E;V*TAHM;KY<+P^)GW&L=2:[__ZYPQ3"
M:6Z"9 :[:;&\2T]PM.A7P*[E_"O@I&.Q:L-H.-B&L[F8G7[GR,RJS$BY[/'G
M'%PK2C5$LAC>8\73]\RARS;L(/B0GXC9!<LU.Z*IG""RB4&"S4O.XKW<)_]]
M(J8^2Z>(+,EL?==#CDKNF;"8[_"78!9R=5]7UMV48\CYW6_G!HBIH0/OR;U)
M5G(HTNBFYUX(*6-GQZY"E$CT_W.?5NHHA0^!PA2<MQO5XN:(D7(#YE96ENUI
MA.>=;MDK:+ @P=#EWZ7RTN^%&PKQI OQ _2E8N_<BPYU5LO7Q/"XB,ZG5A$,
MS9#;>QM !7@@PM]9\$WUI.!$VK3?A/( GW8B0L"H"/$!>+^F\LA,PO\TI99C
M&XKG[?(^?7I=ZYB]'":(Y:SQ4]BWQ1/C;>I:MI%&ZTTA3LT8J;M%:ZWG(!]E
MC M1,U])B)L*C^!!0'U[<#2%&!)O$PYY]_7HJN7%A2EJ]-8:!=8(- ASJ[C%
M[W+VPW-QVLS7?Z[TR-@^?:M$.@@+T^UME QRH$$^T+Y#H6X'#S]/%XUW+$QB
M+N/'L(OC=/2 L4$BET WV[GR[;SKOC*E<K?%YWN))FGJ>;ZB3%M,-&UU-E:7
MLUH,_&FJ"&_,'XND*"7YH@M<M=QV&0) HX\\*PJ#'R;>-Q'  O6>+P!'G+A_
M.&G5NF2^E;5Z\ 0-NTM3:]%AIX4>.U0)?'1K_"X9&NG.8-R^((Y0!3E_H]F$
MY^K>FE#_EWNHTO@1^/.@G\=TG+>EX'1KXLA#CMVJSAAPR^(EDV6C=>ZN]F9@
M (&-, #PLYT;SX@EKHO<W'L@, S2TDD(^<&(*G)'G+TIA7/D05FU& G>AC_)
MQR8D^(3X74C3Q,H3&VCW1JO.NW#74A)(1ZY<GDF3-('YI\06\Q_YM1<XO;.B
MC:Q:#71\G? N \KVXG*&'L#0@C@OYMD5_HST9L8KM@3"9H1U;5?3SE:<XAZ_
MZDD&XY9%@3KH2BHN>JK0\VRK&RBYR4<*\T[6M*G#/6]8ZO-#(9[,FP_#6&QO
M3G\6F*CG;5*C7B@V9WS/%S5CLKR:^G% '0#K$'CX2WO%>GEVM[)N;/+!IC'?
MS-1]@>QA$. C8$=M7\MOT-&]Z'T_6UW*TT?Z=$"M4>.YS8N9H -=F>4Z[7 [
ML#-K&CB#VLBNAU:J[.Q?\@WC/JO^AN_Y8P^'@8KGOG>VSA<E/5EP;'Z>0%&C
M@$*XC.M;\\ZC1?K8!U?;C&0 7S'.P,8W&OBF:\<4DY-K55)IEM)C^;F+P67K
M7-\A@UZ]U[-\08EVT4-#W<HR[$!7R4C=HBUBKKWZL0!\]T-[[))-@H*/BPR;
M<%N8H.F$.N,.B\ :SK?'%5V4;Z&YB'X0;%\!A_&L;9^7H<-?HY^LO2<Y[/O,
MY+4#$ /F8P'67]%J_#N,:RMJ-X#'OJE]OIT/5)O!^1DS)YGSAGZ"A:E;^RD
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M >^^2<O']G]^A0FD_6/7E1W&'3!TN9_L*I"Y>$^17FS_Y];Z6@-"S.N1Z*W
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M[]B?B?W@R%K473SY__D=Q?_MO<6+Y!2TMKE1]@=##_\Z]SKZQ_'O:XY-1W/
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M:]]Z8<\T$?^KQ:@O*?V5JI7,MYT^]0F@AU0GNS/(:.4?;0'!.?C \9N"2#*
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MB9]Y<R97;#2_.SZ-UU\BX^LK_WT5%, ;XM5>9TAD=S&I<6"GH$:\<EX_]J&
M]68'97*Q)FYJUW% 3;'190),,59<.DL!^ANO7S9D,G%2:2)Y?%C,8^;-L,A4
MNF^@FK2VVW!7[CXW90M&^47@V:CPA79^>,^:O\)&0MC+L"I*[T*V<VFGO0^
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MG3?,*_C$:CK[]?0F?#07.O)4"<*PJH-0PU"L3SX<-_9H3HC:KY-1O/P+4$\
M9TJM#(1+BVT:\H_NH.+ID!P8VU'AQ/DW*R_9GM^OKT_/][%U6#'59CA//T#V
M+$Z?DL="]21;3<6G^M\TF'VB\(]^CY7A42"JL89E:.]P8BH<9:6M7*X7A=I%
M[I>MM$-[YM FT"W$QNZNG&8A'-2;\HIKZP[5,L9?UB/E-Y[A$7^7]MFKW-(Y
MX$<P6#$<L\!M\=.06<$_."_ #A*Y_W%Y@&)GH6?3Y?N-5Z>:D^S[EV$_>NN6
MA6?9*]T/TEN4WZO'-4=1=$D4^J"9[S6C^GBTE-E&\HCLHV%](.>8B&$U@[S[
M'^6ZYM]N_BS)_UU7XV:A^2]"FOHO0NJ/98+S(&7 /K,<]SGW(PQ9D+_34915
MO0U/53!:-6*^CZBF#&->,P;^JK#H<U P7R!D\X#Z8"Z%R33N;6WZZHZ$A3I8
MTKX1V-*.JS #U7-(.?<[@6M/UXU WQCATV9A(U[I'\".<J?!3*\LL4:=C;=_
M%L[MS3JKL;"B'?2"6FC<K>1JG=?QWKXE6Q3]2%G=<Q[!&XO>8^/9O!6KZ3.;
MD^FJH'9G?2>OIN+Z.?$X/V"E.3W989L=GN1Q$**. T2*L>;4)RSOBYWUG-\G
M]]IF%;J3?^G"K]BXB1'6YHZ/I,-@<$&S-MF+5R%*^80B!!.PPYXAV1&]4#%2
MH:6X9"**0]-NG'Q'7M)CTM1$BRC!T5&])<^(T8; 74CEC'O3B4>]H)$MKR,=
M^@1[;)>,N-A#[\"DWF<)9 PP?(O%>68S.2YM!VJ]%TKG(A$3*5+#3K:UQS@#
MQ#DVHQ!"H_NCH^4(_\$4.Q@A.Z$+U9M&>]U[/B=RU9EX5.=/* IWU#LHB,K]
MG+'UA=N..^#:]S%$G7VKJ$7K>9YQ-T#Y;8^3XH)T*>O^Q_U)0=,E[KA7KREL
M+5/.=_L>4NW[$AL"6<MJQF&'F"-.T@VYY+I#RY+DMK3?/]$6L0H0.OI*-2U=
MTHR[G>$4<7]<3(3\=F;YWYA[RZ XNK;?%P*!X!+<@P=WEP#!(1#<"<XPP=T#
M!'<($-R=P0>WX.X,,+B[#.[L//4^V^[:[ZEZSZXZ=3Y<U1^ZJ[NJ>ZU+?OV_
MUBI%H11X*OO1Q%2P324:;'XHU(//\<GQ>;<\LF4G?.;G'\U^K>W0B<'I5DAN
MPW!B^S-!-9LK,'4E/-'&S5AAJ*/M$;\Y-;Y@+Z>$#0+()]1ZC[)ICFSI9ST&
M&$X0K?C,06RZO7.3)')C/&^FQ2QO;V<20P3=U1U_4SS:W4XJ>R</1+3<TVV)
MH?)$H2"TGTUS[S;D0J/$F-A4O%K\@!'8<\IX% MR6.6#T9=ND>Y>V$6W)^#B
M+C?@Q?0^I/VZU]QK%8E8#+:IG*PUDJ>9/1'!V-"@%U:<:6ZG1\ZVF8"(<)98
M-Z<1/"K_IN1#'@5O?CUZ#Z5>6",VA3HD]'MYSU?Y<,/ <WU=DZX H]./\(^\
MLQFGE"L,[6J.R<DU?QB85VI83]U+/!9P#IEFW=E;XS#48/@_C<AAM/$#C#&D
ML:LRH)EE=0*UA6]>#QJ7 OL$RJ0*75'Q$?D5!G0-20[W>R8(JV&_:R_D*]W[
MW.]"A'E%$IN#;0I=7'>:K,+Z)+,SU_($(RW877%C"@<NJ]2L=/I7%@2J1,]/
M2ILAU(/W9O<3&X8'S#0^LQ03[^?40*B^B?[^3QR[S=&J.XWPD'H?3L9$PR [
MQY 7S:P/JEQE[ZZHP4\";XXXX (\[+(5 ,*'/CTU*QKNE+#35SB%A'_C,ZV?
M1"Y?I2U5_[G%T_\+^[=26/&KSG_@?J#U=RO6[@C&,MK_6Q[W3VI& ]ODIH,D
MQ<I4V55QWH'Q<'H GK0F*_"H[P;Q$II6!\( +2PISC_"OH@".Z:?V*WLWP'F
MG>.SO%#_>$<G QC%=..=0,1=8URB^JH<MKI0Z5.2,@C5?F'R.,2?Z9U&_--G
MK>0DX17!3[D.'E3:K':)RD1-S11=+I5UG]_P:M%0_#I643<2H$!^&\Z<!>:9
MCRC3H'@KS0O=+A7!O!XW7$.,#Y'7$C&-EQEJ8EFV;"%_TZ]X[^1$;=SF7^A,
M@A\-*?>+Z[GUJGG9OZU2]F2MQ^#\^FF0Z.M*-+JU[_.VEV]3!!7"%BJRS=YH
M16\=6>*85L*N8KB>KC[+ (]G$@'3=L+0Q6:M':W@%GWEZ),6ZUQ/[U(HE5N9
MG'+\^([&Z?8-?JPO2;V,].,P]\5<$$M"YO:YRDK%4?>-1]+6,MH;0M[/( 5Z
M^45%]M'F/Q1)6MY6#-F_MFA),HQE;ZKY3^15A#V'KLOC/LWPQ-<U])DB<&S'
MS/X*'.""B5UP7XUQ;KG9-B-F(?/6\ C361<H+PAHXRL 9<.2K2_:PT69?A3<
MJ.?VL'%*Z^.(K3LLB(:-X5,9P3!3K8I75Y7K?7.W!?KT,2$/+KB]G9T:0Q2K
M29A5/+*:+>&)HTE[@I8OV!^)=S)^B.G\\G/=4W!+&M\?6.'QFZ6MBZH>K>2.
M:2KN"QN_A<^("05;Z50#8KZL"]_@FVY:L._D[G.I%$HOM^\2- 2QG_V0&6#S
MV *;_##L.I0OM:-%7Y*U T_<A3P>C]ACF_*+W4 =')CS,FQ)K\4&WHZD[%3A
MV!IUYO&V'5 #J%.E/M*:A-H,V>+N6'+I$-,(CH^O!>O-N ICQT0HM<9<:Q.;
M''*K-,$D4ML:0G2ZT4V0Q,#ID>U3L,N20_EAKP9OT24E,21NF71Z@IS:XCKT
M^5C2WU6LW]+FSI<<8'\]=[OZAG_XU8F]7':/>Q0_5[7<6GGNH1BXVZ-\8S5W
M0W@/J)F@3V^V/1HA_\F;?QJ<T*+49SW*W,K(OB%KN2+DH%XD>P>I"N09"89]
MR61-S3X^<$",;][!]&4F("6]R6#&XN"$-^(51&I/WS@+*IY1.&KI^96$_1-Y
M9_#:1!WQS&3HV@(K:C_:O1C[D!:GFCE+;LSS.03L;AI R$6UM2O*+#NP2M,P
M[Z-GGHKN(/78ZAGZ8;Y)//H;_5TE*IP1S;BH.$E:>+,AR=>?1;/4E8M+.A[)
MJT#9!$F:)*%^[V?FWVTM"3<G>S[)9ETE[PP'3-=)9B<WZKWG^'$K=P1U)KRF
MA5A5:OYLE%KPD'N]PKU_J>A4SSE_26+-S,X8";<@IH&"1<I#_#SP3=X),#VY
ME?YAR"W;:88M9&C \ NUO&O;5)<#%<603?0IR-Q?U@)TOIET)ID/">?V.UZ5
MOQ U<=W%K#@OUG*>*/-D1K'<BA+\X_\ F*HG+X*9*["Y$\\#U";N:F9E_^TV
MQ3TX@LHA'VT^<0W:HK#5YF]68J.%HZ>W'UG2OTC].<6\X<(?[>-5T8^Y!AA*
M$PQ=2%%/1$T><)/8=M%YG#;2! ,OSVM+?9ZLY&56Y/_HZ%2)9^Z*DMTF;:&W
M>)>M "-(\A=+I_^;JWTCF.?*#P"''SK/ORFL#NU]P8DY4YRYLI@%6:3N-C3I
MOCE>&\(4C7[#:PJ;B[I<Q(L.!J^T)53$_M'Z4B(+4IM^H5FR@=JE.-O;^(P<
M%3=>U W;[HFG\ 97WJ%IBV'/K-<_GY:PC=;=6\%K25UN+6B"2+L:T[1[!=G4
M6*RKERPQ/2X5$$6\8"J?>*XF*(QLV-W9;S0 %G:UV?PG:$V_7N',0#KGC=';
M\V<?P*TS)$.GMAUSWY=Z4&C&N0>D#,8#-LI'>&:_97=+LQ?J1Z=EP9)7,MBX
MUPJ-[CPW2-=0UV3F"6@CRVFYE$Z:0=N4GF*A57CPDW>)?;767H59Z<"B(5]7
MAVBV/H=.QJ.H:[$YS*JMWR["0[9G( HNVV3O;RI<B4^49^AS*F%Z?J5E$OCM
MR>$WHV\F#?O8AFP+CQ>OBH%9%+.\O.=U*_J%*W,9P_-JL &R[/$X@M 8JJ ^
M+[> $HD;0)5MLKF3!^8*]N-<NCB!E%AXF4U"MVE,-X":1MP;,'"D*_0*]]-B
M_LG$G6<*#VPKBHL6YQGC2AO(_&:F.XLQO5L^=[DT$ B2*&QI(:*B$ER)N1<M
M0:B:$0%@%J]'=N+(?A^$E.PJNHD$ML=":D$O'U8G3%P&)"W: E?LGK)YY:Q5
M8%;ST)+BG]?/].RX@&ZMV1.P/O405TX4RU9TTRU^5:$'UY+,N>@<.#/<\,ON
MX #;[O+HW6.S:,DD\D&'8/)&O7_CP9J9H8(@O187$AK)*QS.PPP-;.QY^KFA
MIT<[14CF.6]'Q\[/L5F[%/_3G;9:,P5>8]I*@K"MF+YWX^#S# >5OU"V0C,L
M)+AX:3_>PT\XMN[E5'B*;V'8JI3<.>*;*S3SI*\HFO6D,+<IE>:2 '=)?DM@
MJ%),/$PHJH4U^'!?O&.63232VF?C\G$/['8K3PO]#CM!T@Y.02C:%/)SW6W,
M0IV]%G_G82^7M2HWRL]B%R&&KN!\:751\.,0U :PY0\Z!1^PKKZWF2"KYARZ
MQ%LO$;TO8HC>2.Q2N\MD3<?YR&[WY1U-227P!<?6[:R'1#;$K('DN]LM^CR_
M @)SL*!VOR>+9]'8!B7V@G4'W512NEK$/8$U ^I[+JM= [?K(F1UX):W\$:>
M/) X@56)7W"7*Y^6TLL^],GRX3C%R=]B!.,7TW$*W1^,NA*:FIN*M^>6A44>
M>_*S/'>W@%:1Q5P&-/0E#O\W-BT'% PO<W.G)SS&QU=-=<F".3$& ZX?-W1E
MS6*NX$&4O4?(YYIK86U!+[&"04,3+(M;5R#B)_NW[=LXO'4\3H!0U>5B6O@G
MWGZI\STUY2_3DSVO<+BIK(B-3'(#T#=;E"# _@-A&,LUJ]"I,J\AR"65-4*A
M!RBV!5:9_9I#<NYQ_0JW0=0,.:T/-PGG^UV]D:RZ(GARIEX5M1<SH)1UJ9
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M=ZDKC>64YR#YC%%2=P0B_%U;9]["JU7UVJ=>;*RO::L1K9PEQ^YAHX/$+5G
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M>;CKR+W(4?#$JN#!_=<2:S<*_/DJUT?!XO:9G%ISBW<UABBW;[@39!7&9]L
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MH$ZU8&;YR>R[$2 ;9@KT53B5NQPMIBX_.*TM(JP2$ MI2_+.K#*S1-G-=-#
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M@8[*@,]^ZQK]SO1!XP*H*0S=@\<. L&8N" 0XSU/<5_8D64_K_LUA]&SRGI
M:7O#;\M,V<8JDF$75>Q5C\<S';OB1]"[0("U&%O< V[ V/+:>@_6!GF].%&
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MMP]DAG9I]6.HKC8#D%E2K$4=\7&7:R</&JWBG>_8.H!;CSD Y@O+NYP?)AQ
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M^@UK_*X\(&1E'8PW/IPI>?2*K?TJ9:YV -$1#\1<61S+-Y@#<75]YX2DQ*#
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M78PQ&^AJ7&:Y._LJ.(]&WDN# QB\VV_SZU&IG]> KL5TRC3W$5KAMVM)N9Z
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M7KY\,9GD:;/0?%!/N70!T^@/<PX01MW8RU[+QCL3PF9#]@[!H'V?M:;=MW0
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M.'J,D>D4&XSC%!L[^VDN0>[39_DYV=EY1"_P"U^$P^$P[FL25R^)"UZ&7Z*
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M*>,?X<D%!,G B"U^ME,)A1F!-%65$MO)0*8*R9,$6U6)-\]%TNXVU')"&LC
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M=2CN5'U"A3-]=@'1.\29= _DV$BV'Y%@NY;6/S(V$ETQAW]BC]\554567*"
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M^/#JYPHQQ%3K!HG #64P><_SSD_ YO 9(E:%Q%L1U64:V3//4N)&,X.)@UQ
M>[T6W)AR@TP^1C$9L@J]VDO8,82L>D$QNC%0>#-YZ]M+0?9JR.I<J+U]%4W
M#O]JAZRVP)J1W&W!U5,(;,;:A&JTD7[FI.Y8!2-RV.T,-GTL:&>M"N+(#I!P
MQGGH&BFBMRC:!\P0?\IWWI:P\'B6&VSE^PDQC$<[=) XG8TUNSCSY5.*71B8
ME\]HJGE<.IC3O+@*HEDASP0;\1U[*^.*KAUYI4?(/JD3,SUFO<R^M:F%:.R5
MA9WXOF/)(6E76U6/+*HQ2"X;PB5V2:)I"&M!I!TFCVC&G0D8<9U7EZ\];XV
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MKCH-%:50SJ ,JG84?1B:'B+03!\' U7RD::Z]6.HF4G/3?N6VR+ML'W.K\C
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MAD:E4DP/;X/TZ"-^ZGGBERWKJKKE7]G"HOS\=X=*!+-@ Z$F_G>'0B@G1&G
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M7K-[Z^8\ZY>)";[C*D/,L?+%>3]>9!ZRWK@<1PG&94)8.762IQX)R^17"X5
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M+2Q ,O=BD'&4]:S<XAN*,NBR"7BQ%WL@!)FMP0*NRCX%E:!A ;J5UH$1ZUA
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M792ZUX0LY8/>/\B;$W'L><HQMU8#XW%K%\W@_?7=SE&5>ES21:L^[,<#0KA
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MG/_@[>T=S_V\__.^ZUO___UQL6:MN6;VS.P]>V;G=4!\0\P#-^6D9*4 E&L
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ML](Q E&Z4*Y?&YFT':D798C/87YM;_&\6D-,Z9!A;&I=4*"8IV%PUP.<VV&
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M18_-K0M[WB@U-W=65;C1I_C ^+.U9UN,TB>UI3WQ_><?)'JT"Z)2?QW',UK
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MP;+M3Z2P"_N6=F)LQFKE[DVK"8A*-%59E61K?YTS&:8+,^;D2NI(IV'%_V)
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M4C%<'E%7/B;ZB@!:Y<&PO?!#'LC/"N\RI( 4<@C'@X6EY(SOG%'R_A,4S^]
MOIN\%U[2"I+V$5#_1?.EX.X0F^<UW4L,57]@,?>F\VE'-C/[R8'E(6>^E$/"
MLT<C*@+5<!CDM!L!D''^ APS5M"Q"31-$-7(DZ<)9W-1HZG]J@/Q E\L(X!0
MXTTQ:J'0\13ZKH?E[$2B8++EST-)<AZ?9E<=#5?(:2,O=/MA,'D$X)D@-FZ/
M , $"&#.I!8,?40,A^!=7B" K4$$<-T' ?0O(( FR*7;@5=ZT [TPVS/QS[/
MHC6X%ST":.REMJQ! "F!D-TR76H8#19RG@#X)0(X1CIX;R0@:WO(29O@#=1*
M'4ZPAQ,JY NRF3'ND71A4-7/JXP-CKSA66;%F?6AE,V>\Z :(:/]0M9?^+N3
MR-EGRTJY)ZD,*Y4QI'WLZ#Q=0JZH"!T,#M]%WFF/E/VBJ.Z<'(II9F[KX-<I
MM9#/U7A036+(X0+>Y8EEFC]9H?L%KSM%7($C-EM#604L?GU$_0.2,UUU""#5
M WPZD0Z_+3EW"5JXHL/F,C$0KM]!D3(51[T&HSZC"I5T[8>Q!C>=8[1=[1%X
MP5@7 0R(45]L#_X&BG&RBG&& ##@TNE**CP7B<$[0I.[I[)KCTJM6@2Z^H1&
M/_PBQ;9\N$Q4IEN.6=Y$0?+A+_33B:GGPN%GX"69- N6N/W80/9ZEO1.KXB'
MMGJ.P0;T=A&=@FM#U?I0G:JY(\PJ)!,*X40-(KQ:D:M! T,\F?0.[CA$2W-[
M-39-Z[=L$ !$&\:$ /R^>"( \43(Q?G<@I:G7)-->[&!6.>G03U1!( 5<P%_
MS8< 3H^;6LMAHOL/3G7&=WC&A@L7B7%5JB/#!!BS1'/E,;3N5;Y9[V7Y=K3)
M3(&D@>,'#22_SM\*US]S(Q4SI\ R2<O=,B#8V*K\>#4-/I,"=Y4^'\.[I2#,
M9_UIE*Q6ZIC(][(.##L(/TZ_<(*<K5!OR6^IU(5O5KB3CZCAG6PC@,,>\%C1
MMUE%M[!FJ<0G0K<N+3[J?9ACU>3^*,#23<;SC_>@))"7")<=W$1]>0#YG#^G
MHZ.Y<<K_L,<(6X%A&O\#]E(APY"ZD6R5L5Y:_1;\-N\<#/KP-YX:(7G:_P9Y
M%(K!%^I8L#E?8010NJ__!9H^:%8LA-S,4&<$(';SZF:$0S7&?SM:9O#15@3
M/]]VP4$$:PH2O1UT6/RKT[(A9%K$XB*-W!OL@-PUAZ<=0^WZ$W7?UHK]\A_,
M#FJM!/W8T]_.A4QB)6SYUC9+QAKEOWAVS[=N%L+KLLU/<1@GJ.YE.JBSK')M
MW\!$I<!I7]K8>*HY.]TVGS@QIAYEJ5*CD6%?_2GTPSVZ8P'0UI/6FJ'5D'',
MG("!G</LF2<X??%T475R?<[^(:[UT;X!UE[)[TT.%1,FSW=EA[%[L2LCGPQ4
MM+UX&XL-NG40^SBLH;'\[,':"TG;L=J,6J/F*CN=+T11?;,ZKS .FE^6F#"N
MXJ>G.7>SC1--7[N.ZL"3\(G1SBRKC.@S4>*&PJ$B[ #2I4Q*3T2= %F+AC\(
MYT%N,"/,#Y"5E%Y-.4,2'9'>"SY$LN^N.(&2TEDVW!6\S/3;L*>H[U2\S)'*
M6O'LAL@P A!).2!$^3537I+:A(://JWOP;!LPYM)[=B<//#D6&,A\N@-7A9:
M;LZ=]HK).A&+N/]#!T74-L7^=[VT' 1@J75>=7DH?5)1G ^9XWDE_\F^L\8M
M*/TG(/7O [O96_JI5C:9Z5/<6 JL5?TE.CA^0R,C38X9_),HJI_( E%!X3^)
MDOX-RILN+?TWHI1^4IV*R90#^TF4ZV]47Y-CYKP+/NCM7)!$;L\_?&RK6;L+
M\V$X+X:_89'+V^0K=#7>8T%C"U,LZ7VUE-N3199QIVA:2]\NDY1I)-ASL&U0
M.V4O5!$!B"[!0JE_U;P\+X/#D2+:!BF*N6?.5ZA7[Z\7]D.ELI&X[\.EPO^H
M;>M 8!>0@+. <:08X7S_ @%0GR E^2@DKNA[S3<141Y^?!F3D#>V[8 [V7K^
M9K4[AC[.$XMR*Z=P?DHU(KH/E*U!3,4?!?XU#,>4BBX/ST0 ,^">>K*&5?UC
M#O@&7'5^]+OQE.+*>0I+>]W0&?RU)*%ZI<<G)4E"E!TW#%APK<VENS124 <-
M%NR X)(S_/"&=*0 EC0;_ZP*IVO0/+>FAMX_TH]0DB2*+UE# "3@926DC"P>
M00)1U3]H:%K"@ 4A9=WQ><HY:/RM>I4W'._K]S88<F?5S3^IRU]]_2-=R *O
M3;E$RT\HBD5J 5BXEOJE(_@<2\VQ*8!#ZC'\MB>AD)+XAJ3'Q*H?(=+K;LQ%
MLIBT,?WL1J[:L>+9]=YCZBY5N7UFF,W(2:X'U@!36I!/:Q4/Q_$S2#WXO<'8
MJA\\S^8TX* HA&-?J3\(?HMW/2WH.)R)V1^I-.]02L,;,I#8*NCGD:W!O!VI
MST^B$8 $;Y+^PI?!!&4XG:?2XCLE20_.TQ^G06\'*>.I]B'5X/<N"NX533#W
M#O@\7/7[<F+_RGGR;>=R,<A'>D(E?7&7OQ\D-.%+KG%EF8X>3L[*98?(R($E
M#.P,_$["3QN5,?L/"3E?^I-\-2<HF2@_[CD2%4J!:%5)$H.XQMO.7Z0]CM1^
M\2*\VX"V+)SCPM=.0,\-EUD7+%LV+-)F28X>C1*_;&J((1%#-V_Z6CTGV^DV
M-^,>/-X>]>87JYH[;)]L#)(Z64G65E$/)+I$MYX$W0.0[/V7HL["?WX&G@7W
MU>:MF"  ?<:+SK.Q(V<3WEKLM" 6^S_[X:#L<@00+@"9IN[)RK$"+_51GV(<
MY.8'?G=B\PEBRKC_#ZX[2JE,1/M0SV9D*NO73@!E.J%E=*VJNEQ7W)*KTS!/
M]7;W:W/Z?A):X?#GC0V6GN^XWC^_+G+3DOE"W/_@9':#_;M5,AH+B:_):+\R
MZ-Y:I2?3-:RZ&:G.EJQ-S_R<PM)= 1)-7'2[81_[#<VJX=D-XEL;>_K]3,E,
M<O*"N/O<CVD-!8Y>>KN@JC\X-U2T&!OGOS7]8"].UYCE< T:!IPUIKQ7U<?5
M(K%67G3/CTTB(M/,^)*7V^-W!_OY87+-5@+050L?K(@Y5:BJ::CV9ZB*CR=W
MV+H5@YOG?N!]/I_ L^,F8U(>KIJLZK* +Z#2Q74;);YK'I K<K-FV]!%"WM/
M^3;IS6&OR#(I8_QK^]>O!P#@J$,UNNTV@6><=;P:ZO6>XO8>$C'J,"^#9,Z1
M\P'T7LX5C?TZD?-[/.=,USC*.^%SEWN0UO#?*YEIWC07CR$[2'V( 6/Z56/6
M^G\F<'T5?IS^KN<P#&-X0X]8[Y#C/!8!(+4V\Y[%*9=5]L&EXOM%W0T/I#F%
M/(=38AI7/U\XL4)W0=X,6^%2MG0XZ')P1PML'G[9=#&/-!:>#8"7=8<A6Y/@
M2U2U4(\7^HORHRE92,'BBR=YAN^9!4:*TUU?..&O&A';E>Q*(3:1%:&W)G;R
MFDQ2"9]WVQ="]@8C@ ,F;00PO@E9Q].[JS<+@C(Z4<_?8$JK4_"I500^Z5-L
M/%JC,E_GAK'IS#@TX2& 9;>AIBVDA!K0*BN$";IQF>Z5K4O84X'#X5#P@OQ)
M' *80EIL>%"5]$RB0],$R3]:E/_ B)<0Y8L%*_G3N)#YR!&C3WD5-BI([14R
MIP3S4RDF*/Y\J6@1V]R E.DYK"RFDN^-@G0G+MK2HB=+\NT?((!G_!=M9^I2
MQ-"<M0X(9H+^KZVA_E63EW3K?/>GM55Q+!;Y!BH ?GLKQCWJ[RD6(_^9-%Q"
M:S><!3>=8NQ1*V:Z./ZS0$Q-^;6N*(70=]+.Z@ZAH'-0\U_3UEFUNU(ZD9$A
MOCY,U\+2^3(*";4<Z]DU" [ZEFE00K!Q904O<1Z:%F; R>'?$MB"(D7"@J8:
M5^U]IRELW?=5'$7)E?D^36@\-BTS,:DE5K>FBWAN /*CX] YW9D>\]6<UC4'
M3QQ.:6MWL-6UT;3<-2"AM? CEY(2B^MT*T0UJ0KD>$GCRBLO\*XA75?\DXRL
M #.V5>1IZ5;74O2&//@MQ]%Q355C585VA4Q&8)3409<K*H23EM;\3LI3\R@H
M1'EDT7@DJS(TO<S23.M:;PR];.1K$$4:K/YTM5AS(]9^\];L9K>%YDY':1L^
MN]\K^5O5V,M+(;88;CRWTWEZ77<GQ[@IY-:^'GX34[%RDIQT_\XL<X)>91DQ
M(L)H[XC] BTE85$U@N]!6YV95#BHP**:4BA9RK((!&"OS4972>2_ON/(8ZVO
M=#;057CZCCHGZTP):1KQPOSNADTWIA^FOSH/[TM<0:IQD7&DV?.S#Q"^:@[]
ML@D6LGE/#3O4[U+Z'038N6KEY\B!;32J0 Y[(7>E?X-X"JI"-JY?3?IK#:K?
M(,1QKUJ+M&R.#R#UD"0'N ID6K]+G9/_%OB_4"19Y08G J[4MLXGN5<S;V)I
M#$P^D+LGC&%C$=L3#G<M7F:YTBH!5\0-UGA*KRD<(,V/9$ND:8JT(M<2X \B
M.O]]GS?E5;/4RC%U$O]OLS']#@(X7;62QXYX.<PQ@\]6FR+2?T*@3 7DI$4\
M\DWC6)$$A'Y83LS^)7EMZ>:ELX\++J2[R2[77IJ"#L#>#-X<@RK?>9FL' )&
M3+!I9.J'B*.'!:BR*TRJWDY."K]O^A2#%1=))Z,Z^O7CE*&W-.E,RU$O8*.D
M@;,H:!BF83(\P8L:(Q SUXO*'Y^4 7YL.Q>9[V9=195C!7NK3R"Q)FAS9AKM
MC9=+QW]Y*$[V[K_QF3?7+^-NEPL!Y$).%0^*T8OM&28A'"-G>O2SL?U'R#O7
M4+:"5->I>)9_$9BF9M0'[!M-QSO4<!\6J4:NXGWZS?YA6P30$I &0\(7](:#
MH2T(@":TZ=(K&^Y]O$BT\Z]V7SW&GI?I'Y)2/P I2$7-]8^1_>ML.J/_5E)^
M' K"D&-9[>>YDO(K?UAW57F0+BF;'*0#HAZHON2572$_KX>T555N$]5\A.0E
M7B[ \G%_F7P.!I"@, _UO?ABI)59X"JAPMM_!FR"CW<8X3X6ET_'P<L@Y D9
M+T\YQRS81 "X>B%#L?NTF^&$R/.Y$%[]0QR=6D*@I\&7+;#\5LL9I#.R-,N!
M-'**G>EFD7NX5];P\? 2$XGCOT@Q9&$6#ERLJ(I:=+TMD*[\?=OEJ2!#/-HT
M,9_2K/0=O@,I>G41CPQ3D:-%;\:TTAT/R2S=C'[*%M4@#L&0G"YLR!RY=\]%
MV#W:_=OQ].6'@4EJ0.;H@J,'9VM$AO'R4?-J4EQ1J!;S^\9"4X?*7NRZQN&Z
M+^0R8([9KAW?EGXOYIV[5S8RVM_+JS)(<?3E$FPKKTCMYQ6UD78RTD[M84JK
MNO]G](7<%:&' 4C"\RS\A^$B2+UI"V%.J$Y>,_R&I/?A/WUN1,K%$U%+%TI>
M&D$I3J^8TT_4NSE+-5*4ZARNRBU76=H>S%M+V?&Z&Y7HADSK&J585JT;$PAW
M[4E][=[&T <09P6H?YXQCM/O#H$[GD6Z<]9F0D'9G*Q999DTH3PJ!Y/5=E0@
MKLP\R!MCU3(OS?O^W6&Z$=,1]@KYFX%"DF3:W/[/::<?$F0#*V'W73I>R"_L
M*#"4N3M\^TJ4V)-H.-5XO),2_\CH.<71*4.='!.0)6*P']5&/6-X[^@IJKZI
M_J[LC]A;7]-L-/R"EXT0A7AB_&((,F<27E9\FG$5DY*7!"1/'.%'*:<3Z=M;
MEQO@W3+E07%\SR1( ^/EB=F%$ )P4[S8'BG_OV\^]1BT@Y35Z.\I2V+O%QS_
MDSMO,O!<;0_^P5FVM]R3 FENJ87_G#9W_;^X_F\;?\.#YR>R%EHLW$;]8NSM
MMUK5EKE3CD8VVQ$ :#QPO KV' %$2LW!FYXA[3:W_1LG>]0MPI\0 -+5()I\
M233D@N;LLB:'FG*<_;%SK\+><0@&1@[8DD, 14A'6,*BKVIO9;T[I;7_HUA?
M]15B;?(_]RQ7^H=\"/ZY==(_\48:F()6L@\V";QE6RB?N-_(__>N8:6#1EL'
MNSQ>G(.AL!JOM9G^9A8"<($PK[<B "(*:/$"M_R_3-Y@U$/SBS/\:O@S6@K6
MNTR:2A$1:W?P@ZHD&:+5C!2R'>SF]HJ.YL[.:V'C/Z* SLB9^T?'5YL6=$.)
MNB]3_.&/'!& F2$DZ8,SC*6!'^Y5U,2+ &Z %W0WF@Z/'<^*H>I&DM034)ME
MB<N/@7"G/T_(DB>O\D@5CP$ [28D!TW&4+TGO^"UC!MM5RVT,=LUY/C]0(@2
MTLP3>&7S;+(8W?RS&Y;5N!/ZZ=JW)<:0X9Q47'WUJG&;NZ\92\L2"%D/VBB[
M4;HNO+_KB0L*'%\+YDU>:OYD7HP?=.+)&25P\,0VCE1@_D! K'%T1.G)8DGK
MYC4%I[G;?&6K4PI1@DJ+QF=?I![I+#$NVPR/E8O$P60+='0>GKPM5!L3:/_,
M%4)/<!;LW9943;I$L5B;=^\0+1S\SH),J\/1>!S4>^LZ:>HAF=HLJ:J_F#YO
M_+=D@1L"'<Y+=-@A9%KW^&WEVG0X/X^!]GKYC9L.!R!SX$NWJ*"'M!,<L"/J
MTWX$H!<:A=QB"02 =!".-^68KHG^Z7W]#["KA.C_;!#C[V\U\4WC8E>2TU&U
MIQ?>J'@:?EBX_OVKI0.I)*':ZI]=?0QIBU)R&;L[H.=P:HO$7XA;9<-<VZZ,
M8UX[T;Z.$JINR%HJDF&0\Z.7L7 WO(LUI )55I(Q=J='&BF^\+.KX'^I_MDZ
M>#<%WG"59OKU0OX'Q,A5MNG?#)"Z_>0[>#>!6>ZW Y!CS5ZX<U.T?;\U8YZ4
MA(EQ/_OK*I.>9&@&<\:;QR\:_%V*A)6Y+,3NOIT^<_,P:0G"6H]Z?!,!B*'O
M-/"M?5CT%A8),:6EJL#FCQG'Y_DT+4EG)F,BC8KMV%UDH9F@'T :!*9+O//8
MK'U1[$W(86A-9X72&%I$7>WM!_@&)Y8V%6<"F%7]E':=TS-0]Z<8AK5^B5KD
MF;5OIL)* ]$'H4>Y;P8)O&4RJGNP+Q<V12VCHI^$/QUU%#A:LBYY=%)FQ1*G
MI3H7T0PI*P-+J+ Z8O*8L_%EV'^.8+4K*U$>='W-37)L(EQR.>#C+7S.E"48
M8628[[92<LF$<J2B?15;,T?*421W<V; L$/%BUT$4"A.,*ADG0)WS;X\10!C
MZ4B7\[ 7O-L$KP#D)25K(6>K*:=S"$ K=!AY-GB0?$( YR,H;$2W-ZZL2\@<
MY-*"7Q%I, _#K[(T3U'+__==1^B/8%]4.5P>OB.V 0?;9+KHNL?S#9]Y9??L
MLQ\U0E*1LGDGA?7*@'37>XVT\+XG(D_](-)BHRFW9)0P#P@XVI9ZXYD@\@(!
M3%"-IO^!^M_41*!93M4?&"O] 5?&)Z 80GW -/6'1SVQ[]#C06_30(A7F2W5
MOP>N<$ER=\&;A_5M@YN1F#@EHOW-5JS)VQ !52.5QR2*F/FF'8Q-<PQ.T4#*
M#=4\TMB0?$#F <G_;3OD_X3?RT/9?X>3MV#O,_@#;D_I R+E0@OML(_L\RA=
M\Q0G1&KU<DWDQZ)Y^M>N%&?JI\)>K$N5N5V\%0W'LK1X5.5M2?#]S6\[1[_"
MBGPY_V8)I/*@3TO[@U%2?W 6B D*_H-1Y']F[#4M9K8_'XD_6)N*^6^)^<LZ
MBLH=7L]1CC!X@,V_>MIU!69]G3?2Z9);O2DE7Y%E93D6RGWN?VSO:+VO0/NV
MZ/'=>#F M/,K,#/@2.>47YGP9M"%P;W<-7EU$O.S:9N RRDV@<!+_)#3S^;?
MU(6860)&Z&H&=CHG.(KH+)-XEYUBGC%,@*1$6I)3MO! 81A$A@>3WX<.=N6'
M5^OBZ2J"7H7:/OX@!_)S$D2+%>VD#7FV@I7D1]0^N<6UL7M-_[)PJ?P6IXK5
M=KK3JS61MX,15$W<5-5%WVY*2<LI:-RJ5E(P80FAY1]*7.6''4"&8>;844'A
M7VVNPOO9T,&?C6;7Y)C!G$UKT?"4)>FXN:ND@.+^C^#_YZMDP3DDE,H(TL]X
M"?[\(T= #G<%;\!Y7$.O,@-'"( ,B*K1;!KOAN_#'8?_:%TU00 Z"&"7>DU[
M<"9N;)TKB*GPZY\#[+C)?UC,^5I=DAFT7^P/<%V.<CU^7_:'X*<GHOX=I_3?
M,1\B_:?6@:MDS$],PW_2\R-C\PLGD=]G!F0EI>@8X9K5L)S4*\\$8"8/EK=L
MQ[2W(>S)OFLLWDRM9V%Q]6$)!W_O0?37J3*GP:3&^*.3K(<O+&UN=:"5<TJ=
ML0:2/)W8BA :0=K&][6TM266)6P(GQY>E(OG]^NAX9B_W,'BK7]L@ !4Y$ K
M"*!N ZHR\@__G>3?%Q!242DC@.\I*WHX_V&DK^$O:8<QI[\+IB5F!$"@5W#)
MCP<C<>/H0H[Y^NT0 ?Q-S,SM^\(ER2'GEXJ7*%OM+%/-$(Q59P,X4BVRE']C
MR81"$ #MV'L$H*L(]QGM_5M>0FBN+3:= 8(E%D3)E.J0AI0F#ZZ8K?]'3"[?
M+1OVQN0\?)DYT^6]%_^FNTHCVCI2?$D8:"<0G^<VS5+W?-JZ"LVI_C4T=Z1T
M%8?[3UQZI1&'?"O%'O/'N:R/XE;\'X3%S\^'=0[%X#"/35XO7%#3=DDW@Q6V
MYZ-O55-E%S..G(].,E63\LV2#UM%&1\LOZ</[F+A*5@PA"\N[S5=VLBE/!EB
M*Q^+7.06*04*Z8;BR<WZB!D_=<,V+PF_MWY6Z S@V4ITN1LER-=1%\ER;:%/
MAY/:A1.(<!NKDF/*M/W''YW\2AN,J^H4S&TA#[ + A":#=O^7"7Q3DG2^OF?
MZ7$X2=E?P[OP/5,9Q?F+6725>_+_Q]^N]T'#M1,?UU2&LM^M#))9CNAE56#7
MM/.;S,#_$)UB,9= ETSL+RXG]/XY)@6UG<;0.I?6=)M=1B\%;B0/=EF^W(V8
MF0AG4\'3%AC3-=F*P.=[.:/&WIB]I=W+_EVSS<]-AQER=+;(DN,.)W42+8.S
MPABK'!X$URSC1[0Q>LL(?F?>7!=VX$QW/2N_/:MVV20&N]Q][-PA#J>N;2"^
MI3_[>=PZLA,[HJ/"Z-M%2PLCW2?2<T-OEIDMK;!D=BMVALI#PRB\HWZF-S++
MK/Q<:R7*0DN1SS;T[EI.L(ZMS%>:OK%1$^!@>44D<:3#B0!<+4Y2LG5:>&=6
MIO<5G&WSL@V))%4QS( HMRC%L3)K$:9AT3K/0OMRK!BS@SZ/EKLO!,]D#<)@
M1D/>0A9&/9%+[GEK64_N'1GQH!!/(F]K,E)Q>BJ=Q$'6\B!SJ@P8F214[U"H
M_S_3@UIU\XSC8N0B&]J0W[HUFP2BY: (<2A&.IQ^-OR7J,_@ERG[Q>JL[<KI
MO3N4Q38C9[!#-'V"C0N2V?%+W-M!WYL6M'N1/BDA F@RA9G]==2%- YL+GX>
M8F0$B=[77[4M5T?Z=S=F;<ZO9U]>@)>D82RN3>LT*:?;"""4>E+ 9A76=D%.
M#DL)0@#<A0.F@1[@;!#--;;T+L;+2"UJ\P"X6_;EL9+Y28KAL%6A/,;]]I(8
M$&GS9XL^C$R/#JD/4[K]=>G$9';!,W32/ZE4\<RB/MM,.1V5?;TAA9$I\7&M
MB?A%F"*F]AM'HY.1>>H3JOHG#4V+4%#K7].PF#,!4*3.*AI^7A3=S$K<*:1D
M"!PJ,EZ.%5G_+5SWAX'%5!- O?4,?IZ^<Q]IF"#%7V.>.+J0TNL-?3[7#,A/
M[*5_,4(ECNK=<[>G&!RY]ZT>&&;<E%GV1%/-=TOY=Z)2BZZDD[!N1GV54K'"
M<&SU#3?AE;FE2Z*_F)Y"!&,P_YW2W_=)^;D;<FV]DA7\RW_L$?]?WBY34%3W
MSD=4$GFLRO^60>4=$>**$J<EQ4#WYJQ_6*"0F?@HM/ C,6[/./_C1W;SIAB4
M_38?<ZUXB_G;0!K5WI_1ZIYTX;X"&&F_O8[<EE2M&3#U<1=.$I-,EH?<=W4^
MJ/<.P(HB6?;A.W=@',LL'S0)> CO?K_H8A+T(GZ8I;R&\7K3#/G;Y1,B+0VM
M=RGMZN<.' S9EIA<6KPC6""JU!S.$M&#K:[3Q9@UO1&'E9JJQK#A'7D*94D:
M[NNM]3[<=2*A&3Z>TIEX"SL/E0*'G]54H0OS5;Q.Q7:]2EVLOPKN%#W+']-Z
M,9WPYG2R>")9VEN;]>ERUM>H]N\443)+E<*#J15WAT7$3WO-R=\2A>T+^Y\]
MH8SD<]MEUG ':1]W6U 15-?Y<Q6:KPF\?S&;_=+@Q,]L3R@M%6LX=T/W.0E@
M*K K.Y4ZVI%..Y;051S:@RLJR=\=#'<M7I$QCJ<J-W8;\7JL?]@+81:):UI+
M@*N@,$@7DE)54$<3PP[U>\(9.,Y6F]X#LI%;4M*%TLL=/_(6Z;]-($Y@[#88
MN:5TQ@GIYX7E'!C^B/@_18TG^MUK+TK\#5+G:]LM,?!_%0I]" _XH:,FJ"JT
MQDAZ,^C^CW:N.ZRI;<L'D8X@79#>.X)T0F(#1,  TC'T%I ."E*B**(0"8(@
M-70!Z=)[%PB=4 2D2D<@A"(EP."]5^=[=^[,?&_>'^^;>?/'_L[.WNM;6>N<
ML\]>Y;=VVGS*^KKN[ZQ_2WB_DE)VZ-C-QO\NIN]O$SF443PC"*0)\O>_4?M=
MZ">\';MGZJ;_(9#.'U*GD/T%A^QSF@.:%S\I<I_H:1,N_SBS[</H87!!G#W?
MY'P7O22B1&YG%S1,M%$"L^+:ULS#Y7C?3K-W3F=^0)!(&>Y >".T<&_-,NNX
MIA?R\2#0-0$E:ZV __#6C LS7U$9-Q_)4*&-(TNSL<C:B"#M)"D7)#0(1;-S
M%1V)1DG&F2@P\@>G6HKO':7;7>US+''^8 )-<'>5B%MJM=-*.>XEAF0)L![U
M$Z'_P1I5X"G@S]@0O/E_'33\4XQP,?=/=EN2ZVS70!0X.%F%ZJVVHL[91RGU
M1S!&XE?NP"#S.+A[]&/'&]H,!"OR3N%QG._9,X LBK3GW'5QO9M5>#>#GK&.
MW$N_[UM7W\$<7%)MSW8)OP6.S=Z[]ZUKKV@CU/M7N@%\)+5]XI/<;5#PQEFL
MUH-,.X>7!GK)05U/*YU2<VZE-"Y3A=[PO>_3_]8J9F#%J+A2]$B'L3IDQGV>
M 2A&G5GX>N(RN12F@N(+E><N/Z&\=4YCWOZ) M#3P*(Z:'%8W#*:G02ZQHTB
MW>T!:*G8C3N-V^*Z^Z&?NLA]PR'H<W _5&Z[3ANO&=?@4BEJ17P4_8SXQO7S
M]EGG[5%3=3ECP3V*PADL24EH4^#5W+#$ Z,34>]#:];%_,&_K+KXE3'PUN_5
ML/>P\^#TH."8S<\N39#\D%!L$)K\S1"\W0PY6D06GWE'?63@S?CIN$NXC^3"
M\%\#H#;/LSO->[9C."Q>1W<(YIS\^\ 10Q\>&W5RD!Y'(L*9EO7KYT^VX3:L
M><MB/V$F'T0L#$;X+(,NGJ,>S"R0JQHI/WN;(IK_#'=Z\_V!<^QD^%6,=*DV
M,6..D[?G;.X6G*CVG<;Y]URD8D':3Q&(I:C!%-3-]XY[%=M-2HTC[*I6KQ)S
M7UP((N$!#U;?$21\>W2A'<_%,0:Z%U#Q#64?57H*\%.ZBE$NUM_ED#.L2=8N
M+:UTL @%Z,_9P,A[>6T!,XF"^-[?JEZ\2I&F#4,2#8/.ZULD;Z[<0-8KSQ=1
M*OKOSWOVV+:Q9V5VV>_);_ 8OP%FX_,/SET[[^*.PP<GHD!VH-@"7"A *!SQ
MN171H'EO.86T]D=4 !>8/*OV]A2P/07!_(ZQ$#H%+-4F9^WK+(#QWZ/.?$'R
MF%! &!I^L"FP<D+O^P-X-G\,_@UY@4L^\>L\A >SGRVL/E\P!)OC\"_'5F@2
M5F1^B[M&OQ+!UL3WVHAP+4AY-1G/?0@^)GQP"L R@D_XRP7?9XQT/[(#_^TP
M<E]E!WY(/'8*F!&%X[4>Z$!0T):XV+/9L.53P,Z%DE- H]$I8#\^DIIZ)08C
MVF\\H2+,FMON$MJR?"W_CN#2.[>:O](JAX;IIS*"/Z=_9(=^Z0+\J?2/!-$O
M99 _E=8KU3YO]I-=^A]*,_S($?U3V#X6TF^R:A_"9/_M2BS>2$W0'BRXIU]<
M 7U2ZO QCH"3E2X"+.YD%0J8YXI7!H$IIZ=LQ:PQW5I<)#0UO#;V&"XCO9@W
MM2CJZH_7K*MJ0S<T'(PLRZ]*FBFY=1V,&JKHMUD'#4%E:A[ WBB%.8O?7KSV
M_**&ZJU;<#_2+_#7#I=FM\1+W&42>\O78+0!J889N1*QZ20%7SR4MZ#.])Y$
M2%"D4P^?54UYQ!O.Y Y?2U$[Y]GRF0",2 E'6OYC .^3VTT[F6E1C\[GR0R'
MRY9/MTA/1L+[S/$/,](B.O;4SVX7?&M<]H]K9"@ :9.\/7H*8$O_XYHCF$+Z
MKT/6K#ZE>?;^.^3\>-Q";,T\2JS"B*AK%*I.J)%"<"E>,L#SO7FI.KTNH\_H
MHOP--[*5B7B7@I@&ZW(4SB^+_V*$29.(B(80\WEGSIA#K((TP<" $1-NE04>
M!,U,. 8IZ1OSL4:T RIF(^'DZ*'G\?I?#@.2AINO Z\PVD4GI8O)OXZEBR33
MA=/$ ]:E)%7<O\L^$GH$?V^4\"K?R@DV3J! I?>.*G1^WMXQT7YT)!U3%B>:
M6095*>"_<H/;_F:5WB;IH&1?S[8EP=)&\>8UMDSZ>VQC[N6RKJGT@$-A"9FS
M-?'LQ!KOL&U^X@->!'_Z$6']V4?^FCUG\O^D_T_Z/R)U5.%[QW<G^>:?RLH9
MPKS]X^O?>!_'!5I)!K'K:19=XGV*"IF.!XSW,'3)E\$I84R/HX?[WI87GRP*
M79+&28F#5K[TC!(JKPY!LF%39#&F+ZP#B#(B+RQYGB,0)MNXUBA01?]-).$@
M7:9YE=^9ZDO "]Q,V8^J!&!DR6R+*G @<69V(HM-6;AG(;JM;'TJ^GVG.Z^'
MB8K2K5%*H[G[\H;6T>)5;&H\92#MJL\#]Y4+"L7CL6*K4'6VV+A0GDUA0IMW
M"@?/'9;K<.IKH>M-Y\\ILOR(UY?>@^Y]7;#>H9^6.PXY<XU^H/1/ 9:G &'@
M]!X'[K>@_(].^A^C@/\K! B-Y!DX.O2L=_:5+'#^6E,6/VX[29^M\\D]0O6"
M=FV_Z*:+9>7#2G5+)%HU]*&F1!;)RH%!)CV!)BSF!!+%%6/4S<^H;B/*#+F_
ME/-]35ME]EA1Q.\EI83P%T%CRH]7BW7Z;1*?*%F5+J>0&YA RY[K9G!K#29V
M\G1 /W\E%/6=\<JVP9XD")6)_4"LHQD '@3:UPD::J4(ENI@ _\1(O3/:+*W
M1XQ0<LP&1+?WI%<%"?F76LJ9A&SRE]KW>'$SDG<[]"RH4@XI[?)OOF^A=&^O
M]Z6AB:)%]U7*0<?6]H?10I/!B%Q7JI7R'"E1RC51,W7:CM[S\"_,0(FBG)UC
M;HRFE$QUAYDFL:_-;_!X@:=1[75F:6%%Q>_ (:43L9POC(PR^(I?76*D]&AZ
M";YBW4F2[ZBCPOF?>ZT?BAT9MV\7IT?V]#M+#[I:RKYQ#&T=JH6FPEA"C<Q7
MM9O<)CSR?*#M%)4[]U%QGYS4=(;R=A*8)5P+:"E\MJJ^S% F$NP*('29'4.;
M2[?"G_F+=;,@-.VKCH3/D8)<Y!YPAE,1N\$J0-+8]:3:"B:6/)J;#&M&0(1;
MKB+B;5_VN2=RRWG'E^]C_*]GA:T+;RCE6K7)?7I\994Z-9_\[SK^722Q>G3#
MHB:>+YP[>^$ZYY[,P(C>.%'>=J<(,#4IC)5F&ELH(9V)R"'-X\W;S,&\B!:L
M6-<Q;$-QLK-AS5+SRH$=SF&J6?L9/*1@1NXJ\ NF\:07Z;D^IJ9#M@UUY4:N
MW"ACN7?J%UT AR)!8)85?]-9ABUH09RE<H<6:'Q#*2R6W'Z=/.EB(H)PJF0=
MQ H;ET-X'3^Z1@,K;J&,F#1I9^:>-<U2F DBP(L,OC[0_ZXP=<C.6WV\M,>8
M&GBXA"#.HM\F10F1E>BR!G^!6$[56;>=" VE8550R>_-5&2K MY?CG.9<8T4
MU%4>U"1=B<(5UOCIRX,8?6)&-:H'UFM=^F&&$*[(25'ZI(^T1BX"P/F1W5-
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MWFLM>5@V,T@?PF0*K17O.2)-0-7*UZ%YY8+O4+GZ'"';<ON@SLS9+M&HZNY
MAH6'?90\!MN:YE>ZVTR)3WC\HK%ZK<0VJ!(>.ZF2,)SN7%.Q7H77.^],-]-"
M<)6OS;@F;U)#6*'3H<L?EJ*TGC&>RV[[A1V(V&G5.7^&OF_K"WS%P&QF*A;
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M]36?)#GK9_7XIJ27PYRSV[<^>7^/^C*[=W2:TY1E0GODK.1$-/NH/IIAR8'
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M\<X,$^8\KBQE"M+GUK;OKZ4>M3FDI.63WW<F0S V)"/,U6Y6+!\DRU+KHDO
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MX3' 2;5ZQU1EO6AAPN4DS<<$Q50*?7SRN4+\<_IZYV* G^M8#R])7Q':";-
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MR.2;SSZ;#2>6:!"F6O>_VPK_G?Z=_A42Z';^?P!02P,$%     @ B(%B5,]
M$RT@40  E6L  !@   !A;G9S+3(P,C$Q,C,Q>#$P:S P."YJ<&?4NP=45,NV
M+KRPB9(D2D8%"0J2<V@$ 0$1$"0G1;)DD$P3!"0+""@Y!TFB-#EG1#(TDG/.
MN8&F^[7[[.W>^]Y]_A/NN?]XKQDUQEJUJF;5G%7SF]^LM4!]1\T!UQ3E%.0
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M>#PA2]_!&G.)PV&M?XX_E_Z2UB<W.SE1HD [XU.GZ6]A'\Q3Y5Y%]ZO'>%N
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M@U#8-RR<IRJ?)5]/V->W='S.[GRFZ"<X'^?\TIRI@"$MPEP?GM!.X^K/?TO
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MAY!_9?O\*_L2"*NUF+IO"\_)# 78?I2/HD'I)W;DJN/Z!KWW%+.U 8R1^.?
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MQ>YB)6J+4 OIA4[.&RQ.*"!QE\W;ZQ#>B[\C)NO[4Z36*4YE#J)GE\_Z]P.
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MPK<L:OV$Q>A6TS3Q_^:<KRCJ.7 GF4J&@VXG<)BDA_ "I*@3&'OGWMIP$)\
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M!<K& SCF_)\!U_]/Y6#X+U!+ P04    " "(@6)4LE/2!(4F  !4+0  &
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M&H/?1$<&PF-&/;DVB/P@.4ZW2N2P]9P_B1_/H#]57?6'+1PG;(-9?'PQR0C
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MKB-(DK!9YE0+@HW(AM$:;5D67S1>?3TBK7CC>B!;UKJ)YIB*,=1+E8B<;C'
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M4)M@@*YARQVBF4)&2P0R[&S>]&NAJ%BI)1511A&X:'PM,#L<8 <XANO!U1B
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M ('#"S' C\0J=,( I''D+Y@5:;3-\.;!M9W3G9B<YC)]?BE.KIN*]1ZD,P?
M>M("IM>5&*6R3NV03SY#J^G4I;JG$K.GN6ADUL_7 C>=,OX)S=K_^7WMNRPC
M?I_2QD<PP#3T^"ODUXUI9ACK4?FV@3H=91OWFZ#H'N/,4(_2J[=,GVF!(Y9P
M\L E5C0CL0H.OP/V2[(L#& QB %6\8+4(!U1[V3LP,QR/=+*#.4"0,."_PQC
M/L^WFM\Y22W#&7X=_.(#V!88>X.?X4L+@R[Q9\-J75 QY4RE2@2R5F2$],!1
M$?\%6+<IB%F/P)2T66[DAK0I2Z$Y7$1!/5=X**WC+=)XE=*5]QZ+^KT7 G1F
M>=-[BW1=_I7U\UL2"[T:\MO[.J'([3T];X9SXPRXYNFX'[>&1WG>,5-*.;RK
M:LZ96L>*H7;F'+^;>,F\QKX%A[ZO)WICR_QZ,.2&DU-0IL.6S7GX,H])A62D
MF-C]"CD>#-"*7]IO6^G+C&X& ;OD%2BAU(U.BF!X(*B.0'_LYF [C/2I#+N[
MGK:B=Y?LO^L[_6.V-NN)-)\ ZU"0:-$!]B(9*"-DUK(/5V8UU.97MQ!R ;F$
M ;Q@$LB8)M.PLT>P!FB*GZKV/X":K:\1.#=6-Z(9+3^A?)H ^<C#*5*P"#DA
M6H-LF\'8"Q\Y#;6!^<4TA$CL<F+H+#DK=3\REW-VKCC]K.Y19=0FO&!@_J7]
MP$P43YKT@4/2JV.?Y5K[/=Z7XWT,[2U^TP.!W7XJT-[:-*HNFZ(-:I..>8=*
MIV36%R+MGMBS=]@>O=T,'*.3&2_J([YQ5.<TF8)_RB(,B^$7MQ&\^Z@]$DP7
MAT[4[.[<D03)2%\0=&0#\H-1G,A%:N=*#I.Z?D"+R1O-W3%=1/17$-:64R[^
M*- [&X8VSH/2>R93W=]8.;0*)J^.B;4P1UF\7J[&ZNX&=<&+).<NQXO,91C@
MS%%C"*1Y8;!J^Q!:YX;U)',Q0*H#!O!+V\URPP#[/="=<O!@(4)+M@82>Q)L
MU@[%-0U%[6N>;F* 9X"&HD(=[&0Y[7@< Q!=U\0 4D/H4^B\++6VUG8:VCOW
M[ CV(>*O3_CZ3\50^'M8WH;&]:/S&:^'(+8)" PP)C/,T(_F]=/>MZ'YSE>_
MP(W\]V9:\G6@:Z$SD-ZFU#]7](_0TR[(M*//\AI4A6I^/W>["_$9+9^D?%H-
M[C9-T@0\#?7T(.KX/C3&@%YD?;[Y::1)&K78Q_3F>GAQR9&YE31K%PW;[1=F
M4\53+PBL(\D,V5+%BZ.4JQNJ@O4;OC97&+WG1NMTO;?._3Q2:TD!L]8H45U&
MV$KNQ<KA?EN*JE :I*#!^OK\' L/3#[D9FG#5^$M24UU(6=N[R<2JK6"1:BN
M^5N0"R@HZIITQ.;(3J _NA34$6"29\;7[CK!6B&/#<':B?M>.[JA:$9FZ/,-
M^\S0O=Z7/V'C;^T=PRPJP!V"/$K  +(B_GE.L#VL8=C&A.49T.^D@"@]5/YR
MH*UXW_\36 / =Y/YS?J^U7_63:9=.SSX +:U<U8!TO,7Q'MP;IQ(>.[O@%&*
MU"]JGA""Q3(%%@NU1=4%A,JW?+A0()RUPOG1PHRTZRFW0W:PL<[VV&M;KZ-7
M=UV?I )2^Z%K!]+7-P6FS-1]'A27L%/UN%9P^9)P:8D1X:M]@9..9.]+)\M$
M6>=6 37#3"IW%U-*WY!)N!J@^---[46I+A=-FA6UG8 $P'43%/L%+1"UO!+8
MG>L93:1N,@2G$\UG?OQ@6:P\ __;*/A.$V":Y>1UP$@CT]K=*T"D4=;Z_X4T
M75Y#:'F?/W*/)'3Z+[EWD?9W[FG('3A#.TSBNEXXQ\6X7!C+3<7AM;KV^BX3
M!=EF[$;2P*Y/^ZT"D:?D>-%\GRJ3!&D@#Q_8Z ZHNZ$<.%DN#:$4\S6L<XA/
MB4OX0A(]\K2_/O0(>L-?);%OZJ/?F^-.$Y'OD-FI>)M2L27A89=99)RVQ?'L
MT"%^J1?1JA3E<24,>6)Y1E,9B/L P;D#GL .#YJ15QP%+-ON:"Y(?.+*;"C/
M^R[5G+JC%Q^_6YJ[N\B18I0TG=,S_?0E7<,:Y&%X%\.<#Q[O(Z%U@<$J78^.
MZ8BQ%68A6;+,+)MDE\E+6&,T&&!CT#D-[<-YM@NJ\\N9F9-0U('FZ1RHYQGM
M0.QY 6H4"#R=T#ZOJ@\\DE"C$=!%)1!=5C)AL_@H>VP3;KYR$$]N@'A"CABH
M@IVLIAVW8@ &(#XT#*SS_0'H3A!:^"]/^,=J</H]1D39Q+CY?25)]^M3X>96
M=.MQ^D@(W'H]*@F495-GKWZI4M_?JO"W.#Y _UZ/(X>O)MT#9?0,B#BJ]F]9
M7]H]YO&YXW+F<)CXAV*^N,A_0N3P1X58\3AU0O9H?TH=NA)=4I2PJQXB<:4N
MOW^[P31_$I&L*Y"M3EG^=)HN2X]GG[HB*LW#YZA#<UZ3PH'"?%W"UV?JT01Q
M3F3K?<YI-ANE.<*EXL4G28U^KN_6);;.4J/?.I#PACL)C\[%>]A,70-Z@6TG
M7:72)J,E9XL^5=6@(,JRJ/#'V_2]]JK[YCAC(QWWO7AV0%8Y^,XJC+25<\V_
M6<4H;?Y]+IRM -0H7R3D?[8W_M;^BBY?D?\HP>6*_C<EMWH'!M@[_S-@1D66
MY\'9+7\J'&L+D78/5^EL'I$/&0+M.^\E/7#K_9P&TS& 1Z0WZN;^EG9%HJ_K
MNP@[RV2-&*X,TSL/'EXDI31[^46<EU&*)2!T74JP[G95#?KS",?PXLSUAFH9
M%X7(@*/"$T[XS6(+3?RU6RL%(GM4,*K*R@QFN?3D4P75RB'+AQ/Q^[Q/.B7>
M8(6Z()KG!*0CI RZ_D+./+0%<SN'$[_(67EW;![.]@[TJ%?B7X;P_WH8-3O2
M?BML1!&$%M9M]S.(VAT^--#@[_&*HK%*"Q4P-5-P,?$G!SFH\,?)+:<091#U
M%+JX:/Q3PJD:C:(9N2%4$J$@&.P_!"D!FS$YCW=.R$P-5**XK^<>/82:))56
M^K$LH\=C)/M>XW.7L?+$MJQ%OEDL,1G3D@^XI>DJ2ZQXHQ_/RK-;:$R$<[P+
M=1"+1J83YN7Y]T)7LM- C6T'V1_4/%W_T8X0 T$A!C:KY_<&UJ<*W7D')(6&
M;"ZB?51!D:)]Y )B!#N(!7G8CMR0\JB3-<ZS0^7?4[[[IR/@K\GTE4T"KC[+
M@PAJ(HYB$<WCP@P#_ZG4^#W%7[1Y]K N6[AR6F(DK,%5L[ O[$<+P9(&UNWT
MHX, ^<B=RKT# MO2]9^''D/:6>4Y)2I$(@M7!Y3&JJ(F>*$$H8Z6<4_[HY.C
M2>OY 08__'W**? E<4%$#X&GO _W?Y'VWQGM/ZFKDJ]^\N,EPAO)-K>+A#7I
M.-/9*<_LA;.''16;5K[0&&9C@ _IS2#/I52?[0[#/J3]NO]:+0C51,]\;EY9
M/TT[87%6]-%$73G% $C"2=@LJ?)?[P7)MS;KT?XEM1@@>GGXQY1I?S?EL"OK
MGQ.Z_LF9#2]D*&8+"F .DP]=CQD:/3*=A;YY)4!".NHL/IB--*(]P&"FG]S^
MKCT2X-=1P0=1R!7PX%-@5>25@%9(^J,GHV55[^!+T&E)31\J<*N#KNCJQ9H"
M?Y!JHAI_-1P,.DQV2U#^/[LR/!+-.$R>RNJ*-(:4[__KW[S_UK"^(/YL"FDM
MY,(OH$+<_EA<5H>'+H(R;#J\@R[7*ES_^7WNKF?-B\<FOVI(VRKG'UI$*!*7
M:>;+X G6MA7D#%S)'D4^SD!J1LF>>GM<V47Z=>4BL\*-Z<M7MV9P'T9_K/_R
M:8=36H5]UTE.[Q(N?0O=4C_VDG:TMDC#S8Y0; V(;0C:.Q1(N!0>&K;9#U*E
M@/)X!IBS5@&7N[,N99X*0_>_:!_9PU9>IQ,^XNK.:^HA1^W3^"5!3I:YL,U"
M!;GYRQ5 '=_Q_V">S-?1[-YCZ79%,@'BX[X&EX;M2AF4TO<5 EL(=O4.[L0O
M/1YJGN>*10?X)'R#8( +ANX1#-(Z[&ZP2WM,KZ_2W,W8)MC.K4%7ACBX[:E?
MSIF2)UZ%C72\"9242%WW@^'TN,E?BQGKJ>40W3[R,S1ZGWPJL3[!X[5,LK_9
MRGL!N!.546"4NS@1;O#NHS&5$(U52JB 8LM][K=I,)G8/$?%BL_U3VOBV)5#
M;*^QZ4L;L:1_W=2.<F1.*L?61*B!F)/.DG.BC $Z!B>\TLW72\%#T[@A_,M&
M0P+A4\L=4;HYF$1?34UB,55GIT@\4OLE^?0+6!,Z:#)?BFAVT.VU6X&'GC7O
M'O-0+P;P,3B4">IWPRY->FHP\>I-LC H/%KZ?RF0_]1XA(P&AO1>,$.Z&T(X
MB)_1<ST.E,S?AA8Y#&B(IO0GU7XT,6^(^>C@21&(A!R6VK%&]N;6I5FV[!O
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M8\\21T<@#!XGQ[!->$3$X/C'3!V7IK&T=33:>FI_%0MTQ*YT>V#\A=:/][#
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M:8:9N3/PU3_.=\X]Y]SG[GG6VK-ZO>NMW[MF4&.H.8!27>6."H"%#0!8Z ^
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M!MH;SX?[])T=.F=L.5MWH0"*/;Z-?;AX?E8M^&)8]D4GY&C.6>D."KAZBE!
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MJD]V6MEK<QJDI- A ^R%?B)*KIHN)JD TN-0/4'-"&(U)H77]QRD:2NPZ$]
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M0.]D6*^J5M)86-C%?=+_ZX0:_S]02P,$%     @ B(%B5 )013L;-@  GT0
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MRY?O.&V$5R2A@8N2.4A<EQ3$9:NUU51B4Q2IE]HIP88TG&84U$)BB0;N&;Q
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M*^-/FQALGA0)YKOV#*"KQ*?'I]^7:VSST1I>6H(*Z'!]-Q^^,5:(6[>TN+<
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MX&I^!N"KB27Y?RB/_(\*(_K;_P)02P,$%     @ B(%B5!8^SL*PJP  @[8
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MT/V@7FCHZ3$XC3;0R <RP^G_:>%V/UB"B#? +'LXGK6&?WP0TG(#:/_5_-?
MG[\YF-B4O 43)1;VM'WP?_L42( $$!QCG8$8SLA0\K$&S2J)'UHFM;#LR;&%
MXI,$)(33/S7]3_LOG\]&?HDF@!+PG#[SOUK6;[B<=[:1WA-J:W(>FF,(VN9I
MX?A<(&Q=G!Q4[/5:_]I-:+%BVEC)Q.I"UX$-':>'G5/RF4,VSI03M\T#=DMY
MX_#AFPB%L*(25G)KEN\=1+KOHA/7K[\A%2")3FR1LF\>$V>1GX5^\GC F^"^
MY^NH@"?KNK^@_L0A1\WL@JI>A!1"JT*Y:;.MHP=.9 MQ*O:5]!,I&W\[;E$;
M(^!LW["*7M:#%]^J%LK4NS_@TTM,5K>K:!T_7FCR]1<>HG!#N][;K((=#Y^S
M4&P:6VBB$O03%C@'+U>&6K2V9R-[W!>[V-AX?G!4SX!K@;93FX\0MUQGXONW
M29$&U25WY,W1)H&7E*V4 #MJ#KTJ"M?^9,#PLA,WF;^"P@#G^'2JJ)_DONF&
MEC.E!GULG.5"0[!)Y1BI9]'5 T7_BU-&&Q_F6)[M^EO?'J./.5 \>NVX-"3'
M53#3Z)' 94: -!8]TH]C Q<I@KB"]R%98Z5:-FJHHKK/= +W2,3$[<@?@8[7
M<UFZY>60SNWZS@<W2,\@S5?^4T UFU=\-3;:Y_"G) ,J*C5*9;6#4;]4D( 3
M+3II=!6%KV5<Q40\6I]3@F#-A_&LR31*[D4J@B ICB*PLZ#9AE9[:EJGX_;5
M!Q_RGY_Q+WX5["A@>O*% *'$&)E4F-@_?F^6&CPO=UB)PEISB/Y0K3%-/$5]
M7GAL2Q!GUM< C8/V4HKU0;X;=0W&R]ZIV:VY*"SK+[/T6@;C[F:IJLOQ1P(<
M8Z5D3'2=#RB3U0W%SO'[;\'GO#.]KJYT-^P8?=]J]@4$!(:(MYR-?L8&@B7.
M-A+)!+K48EMUK_C4OBI/9,86-_;W)WO'8<&>1Q!]]#>^>$'W3?B%<_%.?74O
M;U$BA?EGK_5>;6L% EQ,OU$24LLF(/HT'#& 8UO<8(E[$44^D4K.;9]-)6!>
MADM_!E%Y>N*X[H+UQ*"@&P7(/P>A[/@D?DNXF6%V,##,WLWOH(9Q?#/CJ&=<
MOHU,N&,:/DY[!.+IR.0V H1A*E>>/%^.]1\!*VM(D;:_5PN$:HS3D9G0\@_*
M(V#GZ1A?\.O*J5,0CW?V Z%'6$Z;U^4+?DO.1OOUN\R03P)T&R_&RDH.28=5
MR:M08#S+SR 6$]6\TK+G&!=)^"9!9L_S\XXQTKOK?4QA50 60)0W'-@0@J>F
M*"&%IXKP_V2Z-\5[D\-%O+'<4Y#CUZQS^:NN*3'L7+N]K8=Z^$BZ>B(=!CQ%
M+%QY":-$;:8M\W0E(OE($<-+MZ".'OL2<CFL0E=.CMB*O6BF!!KP+<+VMG2T
M.]/T/,PW)^_HO&BR0G;W$D[!9+7 H_$(()74DU$KUN@0O! <?>.H\ [WF3%S
M6LXG_CM&CRJH6^IKM+XY4,DSF4-^^*G/$7"C1NLV!=J]ZTY->FA25FE/.((M
MD[W>N4;6NDB(94:80A90Q4PYHX&@EM.UX%>)U^.?U5L<I%TF^GSX.#NOU_E:
M+N-[# 9X\/E+[\U2GWU'%I:#_:39#;3<P++7#"\Y4WR"NR1-4%)14VK0'?,\
M:$^<4SLJS5HFDSWCS'.LIU<;I0H5BHRV;R2JQO<_UC9\XTRV,N:1&;P6X0U@
ME_Z<<B0095XW_EH@]+!FT0ZN 3:%UL0$B812.W6K^!R2SQ*S4M=ZQ>=^8Y>A
MCD<EADTA)I/%%VEC"WL<,P^E#N*9;Y:*GK&(E:J<D$R C$ ;IC8<.9L1YTVR
M5"L(9$'L9/)1!ZZ+B6J/ $+1$.%NHM;K1H[I+BN>/R_1J70SF1_<2JBB)# %
M@ZX? 8]ZN#Z) KY[9770O+G+P9M(2DL1.9C&H9(?9[O^B#=M?,/\BPS%$<15
M1X_3J<CT0<@6V2-0NBL977.L7,V:6=9_@1]8S5>CB^QPVAF[\4[4:?F3MJ<K
M^!F-$?.DZ9A#Z4'43[ =4\2D[/X<49:1J=GIN7T@=#R%G"EKXD[$*=_&16\V
MISJ[6X ZW-F1J&/#[R0#)\C/5:NXRD]T=FBOT,)A/5[3_21T$CY&>4'VU580
M9!A<$&A3M)MN6U,]+@ISHJDQMD_]8D6PDX&"RA*D0"Y$CUHLX;02I64Q]M3G
M2K+ZF-%G<_8:WW-&@-J343(8S,X5MU#?D"HZ>#QRX&#R,^9E[OL7 3[@SY_X
M+_ 9@@A2Z3C>Q./]KC/Z0&J.M/5)C-%S\A&8,KZB^/1$M^3/RF.R_:VG9<A*
M7]5ITSCIWL9 ]%'^%-*5R-^-N$G'H[C#M;OP9MA^W0O"*UG0;U^8$/7!?XO+
M"J)@1?1 89_V^P6=<C7$F[*\)FR3IJ_WY;/3*=&Z_.4QMR@RY*-9W9DB>E79
M_/(OZB[2GS%7(#[SCX#Q6)DWV^[->/O$G8;K<X-D)-MFPS4/'/3Q\B1+I@:
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M@^^('F$K&!CP2X[?* \Y32YG=''RJ7H/$FV9 FV35BW0-3M0G0PY5&F_U)'
M^#$> '7U_:6=7E]'?'.^$O'36-Y!ZU+QA-<+I *>Q(_%P 1H8C!Q)MZ;B4Y,
M@4QM=$SNDVU"S2W)Y4\T#LA3RSBVU0RMRY5/8*_A73;NM0O=E"0EZ(#+S&J
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M#B;Q"*0E+E[^O5"L,>N5K%Y]C#!:#5>P5HSAZ>34%S"I0I05V/F$G2?_ZQ%
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M#)XHX7@$_%\WR?RGY@"N1H72G<GZM-^32=4YWP7-T>EK?DKPT42F0%SP[D?
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MVKO#&YK/49UX%WF27PLM&_LN;_'!9X'+>:9[%DWCWTXLQ4R,TIPEQ7ZS'LP
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M"0S,"67;@75*JX+B1#=$0% /&\QM(OV+X/F%[6V*NE?JYH7ZBVBV2GAJOE%
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M'WO>2B<XMW99B?NX^_#-")U*D'HG$;EG_,P,N\6YK/##93*.N(][.,X@ 6H
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M@F)0!L?LEVQ4,Y<8-L@XN(70;'/:#-#"1\L='>*L:9SVI<8LKNV_(%8T85?
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MCM1V;SO.MBY?5R(L8)2U'[;/)CI8T$> GDK80J;9DA%Y+\\P:D*#_?LS5CH
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M 1A@J!QKQ^$I#-BK*Z=*9K312S78IS4.AP%?O#9384!R,+0<!O1'0Z1_T,.
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M!;V,[&'=8<S\V:9V[6,M63O]J[8Y^-HUS/5Y6R':)=4ZA9+>Y"CI4J*OZ(Z
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M +1H4Y%QK]]NDV &E3!#\V^5%XR^R+2;C(C34-4UJU2FRUJK:IW!UR&+>6(
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M!FLMZ3YT00F2.G@Y]MO/'&C0'@3/3\U'KVV8O1DW?43D3<,_A,III51ULR;
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M_4<$WSOP'WTK9:W^1##C\UOB%G^BO$J8Y7?K5*%V5C6A=_N/O ;O]%U+AT?
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M4$C95Q%=]_?2,OW7<[/4VKLX!S2?2872>YSQB8\RCX!H^]F'=I[%&S85H+&
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MD*WN\)93M3L1-VR H_>,*!TUK\19Y?BCIE>F-BPEPOEVVDR0.LSK0(@<YL)
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MB&$V09NVE,?\L?6L5Y\E1+?^.[*,P534;?@<UA297ZE-P\ZLD;;VM*(#R_S
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M^M8D;LRYTR(X2O;7FO?Z#CV\1+8I-?%Y5DA6[K:#\8B@T=S<%_[.GH-[QG,
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M$PAU3U*_RUDNA%U>AI0A3T07H#;B.Y)(!!\"H(?A.XEAPG85Y,300^3Y8?B
MN,Q$?!4X.05I>KBJJKI,"%Z(OFH(X,V(6KE<",!:",V?HF^UKA (TT03&;X;
M1K)UN*9?P'\$E-0:W5 6%OS[1#9-N,B@A6=/C8E_-OXK%Q(KX*R0P4%Q55>O
M>K =:AWV?'8[3;X>#V74)D]% (D(/A4B0Y4(HYRCSPPQ0>N9Y-HMEEZ5Q[F6
M7D#O@BZ;F7 0*,T9.P?.@%V*0^@10O\K+Q@]Z@YURID5O]AZ1\CVG>+TN5M<
MVEN. GP\#C%B(;-C TQ\%K@=YTE#\OKZR<-#S67JFKJ: 'BX!(YN_4+R=_7*
M+<("Z[,>)E=69=.&.KKR#S+3.3[5C2(_+5TLK5 4 NR3A.5^$,S\$CLL'M0Y
M(S54WC,'?S.9<!M)R@7XV>OP!,/[^E^FQ/;HCW%X^*BE=3R?L=7=/E9\T848
MN5&9&":0],DN_6[6RWV(MN&&85$O:&TPH( 5EC]'5,S:U-O55:@L&("D@J@9
M]NHHNJVW^P.RK4+'C%"#O"'3GC;L:W.3V %;!C%#(P*UTP>@\7BUU,MJR.J@
M?U$:EL'V\ON6&5W+D+V^KM34""6W#0Z-D+5G$?XA@9OMR3DP9_>+M/+9F2'2
MZHHNQ/"O^[]"92'[(&C2:N0;YUE5,=#Q+SL6[OY4F\N]\FF]&685AF43U83H
M*5R(<A_G5K6T,.W#AK#73I^VDRO30*X]#>8^6LZ)TRAE>:3^C9:1%%Q-+J[G
MTFRO70XN=UTTUU;5[NM3(F:YM(4:I\N@I=]4 D8XG3UI%O;=K QZ\VQ-W!%J
MG,!,81D4O@PGQ0=,[R4:\'J)?W#HLUM7#&LMZ49NAAG9Z.8D,3OJ#%E:#'%*
M.7'27J/%&\*S?<=8A%F0H^]$;[D)V#1GEY=D7/1_MM;!5>&/-HE<%Z47E.%;
M<MDWB,=/\/=*63^(SE^<][&6NU!OJO63+<K0T>XAX6N+3K.7^PX -#E/"E%?
M6:\<8R;D6OV(;K->E[/7#H@>-J%.<8%;VR2+'U&5.;_W7G)^(#DZ&F6F %^Q
MI*GC*7!5=BJ8KYD,!%* G"-D;"([O3 /2L&D74UEKZ:++?3>49.QD@/X 2X:
M@\(#+G$JYT@9'=B(<WKE@;,_;O'A1^A-.'#,0V@7EB/XF#MO-A'X"B<_$;<T
MU#:E#05PHQ?>@C-2JAR+WGQ5'4Z+5\Z1VV,JS$R=_[VOPO6V!K*VUAR0?M;2
M),3)Y/W&R8!!G'1)893"_GZ5@NRS,9K?4(?7</U(P.R,-W3D0J_0KX)3N"-J
M%K0NS5[WL;F,?Y5@^I><%;9:VJ3+MWG-F_%,;6H%3]S5K_7S?K))Q.R!FF\P
MO.Z13$O]7[W>]J36[?T0H[\0I5-VJ=RILWI A2?27%B7Z3NW8M=$G3>KHZ]3
M-.R3O7VLXWG;RT8_OT& ^+$S8="C=S<,K4R(P<6TL9Q#FH75?B5^<^%-(%&[
M71"&4Y\I_Y;<CFU)9NIYZ_G<-VO3R,CVVEHY#"]_O6M+]82'==/HX#CG]5=*
M_FL_S@RO\_9<OC6_,."YU:HK#UR8FU-P?+#NF:%UQ/<3&T+,VYX$35I+O<P]
M/R&9?-J:ZH>N3.6@?=/9#=0B+OOV7ZG-WLH/<J:M4)1XLP&++8P\P'I-T!,>
M'FGT5&F&M?ALDT/[ -E($L<ZIAWGV%'^DL$0@3DLGOZ.AH&<?-KLC4&]+[PO
MU7_,FGJ"['P:!W$UO,LC-@H'EFRS*Y+I6:D37H^.M(]G?ZC#Z!R@_,YG@DTT
MR'YH,([O4GM^;T-J[SEG9!%K$,,)%],.WE*.1FKW]-,N\X52\7Y&PE\B\Z<Q
MY9ZP37:=R'*"H7S,<D!:&7*L8"=&R[5GX^^P$V[0[,(_+ /I?\(=P]M _3GQ
MX)+H3EC[]M#D=1C,!(W]A\KO4#HMT$4OG&<"NU824!\(!_Q:695]$QVODAX=
M ^A=I0O9LLJN N9WRJ1[!),H6U./KM^R[$W&6BRWU4<=H,A-N2WQ*CGY#A'E
MBRX3CDT(;J'K<C=W9Y'>4L7DJ,9;AAU_[TMQ'?3LX9[^)3%Z<_8(H,$VVIV\
MF^Y57!;\=GOL#.:RX"]-.-@@, TOSYG* GW@##1Q2I,?/EH/S(+-O&R>T^SL
M&QD2*N^3.S6X-(;/HD8\[69#%IS8_WWK_2-;[FGWW^Q9(%KSR?OC(:)^:X@0
M.NRJ?C_M+3AO859$;U;)]!TTB[H6/O:%)7G)EIO7?<B,(3)[X9?VF[!'0+CS
MXE$1%X9/8>)IR= #?FW@[:*MSQ6;C>BR@H?#@T]UZQVVC0G?T)7F"^#ER[LM
M40PN[ .%ZTG+1P":7H?/Z7WQ4W0/5OUGJ2T/(?01$&":[O/!:##JCGU8M/[5
MID'I'8,#EL_01>TCP'=?YI\%,9#1'1,ID'QG_6X7]JLJU.Z9D@*)6#L-35B$
M)W_A(^ (UL3["!"=67P 5I/_3P'C!01[Z"3K]"[_GU"-KMXND#P"TO8='@$(
M,Q TT2%YY7]51?Z[ _X#UXBCP OW)T"8CX"_$,G]QQR?); *@'_/AQ$ 6+,\
M@3V9Q;+<>OTP\81*.._?)3@4VD20<_(_P?SS.X"^B^Y?@\C\JR0&W+Q^N[I[
M_:<GT_YW?@6KP$66KDN+M,:3_Q]< JP&D*>M2SW5?/Q/#=V_7(WUVU^M3Q+\
M?[>_^E<[NK\T)MW_>:;0!\$/ZI]\XO];ER>,<K\__]T0>4C J1+<?,2XZ>]K
M[A&P>:OW"/A^D?V'3YL> 3T'U7^H(RY[!/3*'$%%-V&3#T&_$T<W'W#[WV-?
M!^FY/0)R_#)^B3S?\D(N1\ZWY<E@^0GWV<>JT1*]SCC%&_5NM]H,@Q]P8P'!
M=\&O^K]\@/3_IQ_RQ^G_!5!+ P04    " "(@6)4)8*J1],N  !L.   &
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MV7(D_-M+?_*.:ON>\PDXU63<6$G:<G4\GDI^0>[-L8K@Z:+NQ!FSZ1=A>S'
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M"\)* ^P88,F)=."R0UIX"6QN<R)5;/\X)UTS8:PYJYRK4\5=9J(M[5E:9OO
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M*:7V@,PV1#S1=/R),P<ZPKE0EG*X#DSLC QPB\RN26,8]_%EZW#::ZR45>@
M9=)NKE A?T4 RX%(?G[ ]GNIQ=NZ:'J9597O<J\_*TFJ=!-"^0)[;'KH:F*K
ML=LOOO4YJ_5!9G[ 4>U9@"(&,)OX:9A(]<IY\!;"XOTKY0AR%>XL1J-N%:U\
M_ZF((2EX>E4!%FZ<>!Q3EL:Y!@75+DM0Y*OBV;_R)X3EESOL^%"+OA6P'G++
M'TFF/[KY]+G:L4;(-S#]8C,#JL080;[::Q)FUJBMU-C4+M29J!X^756T]##
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MN RD,B[*/%QN2(<@Z=%L&.%+";K]#0/H-KPQGF0HHKW+T,)>ST1]:>[4 ;=
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MJH>]O]_J[JZ\T[>U7;WM_T/!_<O#X1]02P,$%     @ B(%B5$JI*(_R"
MVS$  !@   !A;G9S+3(P,C$Q,C,Q>&5X,S%D,BYH=&WM6_]3V[@2_U?TTKDK
MG8GS#7B/.I29-*17[EKH0#KO[D?%EK$&Q_))<D+>7_\^*SG!"7"%.VAI!V:
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M>^GT2F?BUT G."DS(80K=X4P8.:N'Q5;CC65+5=6"+E??RO9#DX.KB\7VGZ
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M   1              "  0    !A;G9S+3(P,C$Q,C,Q+GAS9%!+ 0(4 Q0
M   ( (B!8E2(?F7C#PH  $N#   5              "  8T0  !A;G9S+3(P
M,C$Q,C,Q7V-A;"YX;6Q02P$"% ,4    " "(@6)4MPGG-2(F   S80( %0
M            @ '/&@  86YV<RTR,#(Q,3(S,5]D968N>&UL4$L! A0#%
M  @ B(%B5%/Y*QR<70  9RL& !4              ( !)$$  &%N=G,M,C R
M,3$R,S%?;&%B+GAM;%!+ 0(4 Q0    ( (B!8E3ZO.6"VC\  *>2!  5
M          "  ?.>  !A;G9S+3(P,C$Q,C,Q7W!R92YX;6Q02P$"% ,4
M" "(@6)4G5H#,;F9 @ ;C!4 %0              @ $ WP  86YV<RTR,#(Q
M,3(S,7@Q,&LN:'1M4$L! A0#%     @ B(%B5)X0V2WN;@  ?(L  !@
M         ( !['@# &%N=G,M,C R,3$R,S%X,3!K,# S+FIP9U!+ 0(4 Q0
M   ( (B!8E3$IH@%C0T! !L: 0 8              "  1#H P!A;G9S+3(P
M,C$Q,C,Q>#$P:S P-"YJ<&=02P$"% ,4    " "(@6)4>&-=)[M?  #0<P
M&               @ '3]00 86YV<RTR,#(Q,3(S,7@Q,&LP,#4N:G!G4$L!
M A0#%     @ B(%B5"?FZ-G95P  4G   !@              ( !Q%4% &%N
M=G,M,C R,3$R,S%X,3!K,# V+FIP9U!+ 0(4 Q0    ( (B!8E3K?6K"Q%\
M (YV   8              "  =.M!0!A;G9S+3(P,C$Q,C,Q>#$P:S P-RYJ
M<&=02P$"% ,4    " "(@6)4ST 3+2!1  "5:P  &               @ '-
M#08 86YV<RTR,#(Q,3(S,7@Q,&LP,#@N:G!G4$L! A0#%     @ B(%B5+)3
MT@2%)@  5"T  !@              ( !(U\& &%N=G,M,C R,3$R,S%X,3!K
M,# Y+FIP9U!+ 0(4 Q0    ( (B!8E1F#)/2YB$  )\J   8
M  "  =Z%!@!A;G9S+3(P,C$Q,C,Q>#$P:S Q,"YJ<&=02P$"% ,4    " "(
M@6)4^RB4U>TI  "8,0  &               @ 'ZIP8 86YV<RTR,#(Q,3(S
M,7@Q,&LP,3$N:G!G4$L! A0#%     @ B(%B5 )013L;-@  GT0  !@
M         ( !'=(& &%N=G,M,C R,3$R,S%X,3!K,#$R+FIP9U!+ 0(4 Q0
M   ( (B!8E06/L["L*L  (.V   8              "  6X(!P!A;G9S+3(P
M,C$Q,C,Q>#$P:S Q,RYJ<&=02P$"% ,4    " "(@6)4)8*J1],N  !L.
M&               @ %4M < 86YV<RTR,#(Q,3(S,7@Q,&LP,30N:G!G4$L!
M A0#%     @ B(%B5 ,4I=\#!   E X  !@              ( !7>,' &%N
M=G,M,C R,3$R,S%X97@R,V0Q+FAT;5!+ 0(4 Q0    ( (B!8E0V3<]<!PD
M ,4Q   8              "  9;G!P!A;G9S+3(P,C$Q,C,Q>&5X,S%D,2YH
M=&U02P$"% ,4    " "(@6)42JDHC_((  #;,0  &               @ '3
M\ < 86YV<RTR,#(Q,3(S,7AE>#,Q9#(N:'1M4$L! A0#%     @ B(%B5,XL
MOLB7!0  QA@  !@              ( !^_D' &%N=G,M,C R,3$R,S%X97@S
M,F0Q+FAT;5!+ 0(4 Q0    ( (B!8E3AW=#DCP4  ,08   8
M  "  <C_!P!A;G9S+3(P,C$Q,C,Q>&5X,S)D,BYH=&U02P4&     !< %P T
)!@  C04(

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
